(dp1
S'ht3,antagonists'
p2
(F0
F0
I1
I1
I0
tp3
sS'controlled,and'
p4
(F1
F0.00014334862385321102
I0
I1
I-1
tp5
sS'of,percentage'
p6
(F1
F0.00043004587155963305
I3
I0
I3
tp7
sS'with,food'
p8
(F1
F0.00043004587155963305
I3
I0
I3
tp9
sS'atromid-s,may'
p10
(F1
F0.00014334862385321102
I1
I0
I1
tp11
sS'a,cyp2c19'
p12
(F1
F0.00014334862385321102
I1
I0
I1
tp13
sS'insulin-dependent,diabetic'
p14
(F1
F0.00014334862385321102
I0
I1
I-1
tp15
sS'fi,and'
p16
(F1
F0.00014334862385321102
I1
I0
I1
tp17
sS'when,has'
p18
(F1
F0.00014334862385321102
I1
I0
I1
tp19
sS'neurontin,mg'
p20
(F1
F0.00014334862385321102
I1
I0
I1
tp21
sS'not,indicate'
p22
(F1
F0.00028669724770642203
I2
I0
I2
tp23
sS'of,concentrations'
p24
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25
sS'by,use'
p26
(F1
F0.00014334862385321102
I0
I1
I-1
tp27
sS'and,brevibloc'
p28
(F1
F0.00028669724770642203
I2
I0
I2
tp29
sS'inhibitors,the'
p30
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31
sS'thereby,delaying'
p32
(F1
F0.00028669724770642203
I2
I0
I2
tp33
sS'were,on'
p34
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35
sS'been,occasional'
p36
(F1
F0.00014334862385321102
I1
I0
I1
tp37
sS'by,cerulein--an'
p38
(F1
F0.00014334862385321102
I0
I1
I-1
tp39
sS'additive,interaction'
p40
(F1
F0.00014334862385321102
I1
I0
I1
tp41
sS'midamor,may'
p42
(F1
F0.00014334862385321102
I1
I0
I1
tp43
sS'intravenous,adenocard'
p44
(F1
F0.00014334862385321102
I0
I1
I-1
tp45
sS'an,interleukin-1'
p46
(F1
F0.00028669724770642203
I2
I0
I2
tp47
sS'inhibitor,produced'
p48
(F1
F0.00014334862385321102
I1
I0
I1
tp49
sS'bio-rad,laboratories'
p50
(F1
F0.00014334862385321102
I0
I1
I-1
tp51
sS'this,pharmacological'
p52
(F1
F0.00014334862385321102
I1
I0
I1
tp53
sS'lower,serum'
p54
(F1
F0.00028669724770642203
I2
I0
I2
tp55
sS'monkeys,the'
p56
(F1
F0.00014334862385321102
I1
I0
I1
tp57
sS'reversal,of'
p58
(F1
F0.00014334862385321102
I1
I0
I1
tp59
sS'oral,placebo'
p60
(F1
F0.00014334862385321102
I0
I1
I-1
tp61
sS'timi-ii,isis-2'
p62
(F1
F0.00014334862385321102
I0
I1
I-1
tp63
sS'rare,instances'
p64
(F1
F0.00028669724770642203
I2
I0
I2
tp65
sS'in,mean'
p66
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp67
sS'vasopressors,thyroxine'
p68
(F1
F0.00014334862385321102
I1
I0
I1
tp69
sS'may,contribute'
p70
(F1
F0.00014334862385321102
I1
I0
I1
tp71
sS'one-third,to'
p72
(F0
F0
I1
I1
I0
tp73
sS'by,see'
p74
(F1
F0.00014334862385321102
I1
I0
I1
tp75
sS'since,bacteriostatic'
p76
(F1
F0.00028669724770642203
I2
I0
I2
tp77
sS'hypertension,was'
p78
(F1
F0.00014334862385321102
I1
I0
I1
tp79
sS'and,placebo'
p80
(F1
F0.00028669724770642203
I0
I2
I-2
tp81
sS'on,known'
p82
(F1
F0.00014334862385321102
I0
I1
I-1
tp83
sS'of,nor'
p84
(F1
F0.00014334862385321102
I0
I1
I-1
tp85
sS'another,botulinum'
p86
(F1
F0.00014334862385321102
I1
I0
I1
tp87
sS'of,didanosine-placebo'
p88
(F1
F0.00014334862385321102
I1
I0
I1
tp89
sS'vitro,from'
p90
(F1
F0.00014334862385321102
I1
I0
I1
tp91
sS'assess,the'
p92
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp93
sS'progesterone,preparations'
p94
(F1
F0.00014334862385321102
I1
I0
I1
tp95
sS'ii,may'
p96
(F1
F0.00014334862385321102
I1
I0
I1
tp97
sS'durations,of'
p98
(F1
F0.00014334862385321102
I1
I0
I1
tp99
sS'the,intensity'
p100
(F1
F0.00014334862385321102
I0
I1
I-1
tp101
sS'yeast,and'
p102
(F1
F0.00014334862385321102
I0
I1
I-1
tp103
sS'hydrochloride,on'
p104
(F1
F0.00014334862385321102
I1
I0
I1
tp105
sS'thalidomide,co-administration'
p106
(F1
F0.00014334862385321102
I0
I1
I-1
tp107
sS'containing,multivalent'
p108
(F1
F0.00014334862385321102
I1
I0
I1
tp109
sS'noted,at'
p110
(F1
F0.00014334862385321102
I0
I1
I-1
tp111
sS'samples,for'
p112
(F1
F0.00028669724770642203
I0
I2
I-2
tp113
sS'tests,vital'
p114
(F1
F0.00028669724770642203
I0
I2
I-2
tp115
sS'a,d'
p116
(F1
F0.00014334862385321102
I0
I1
I-1
tp117
sS'a,c'
p118
(F1
F0.00057339449541284407
I4
I0
I4
tp119
sS'certain,or'
p120
(F1
F0.00014334862385321102
I1
I0
I1
tp121
sS'maalox,reduced'
p122
(F1
F0.00014334862385321102
I1
I0
I1
tp123
sS'drugs,substances'
p124
(F1
F0.00014334862385321102
I0
I1
I-1
tp125
sS'a,u'
p126
(F1
F0.00014334862385321102
I0
I1
I-1
tp127
sS'parts,of'
p128
(F1
F0.00014334862385321102
I1
I0
I1
tp129
sS'ototoxicity,and'
p130
(F1
F0.00014334862385321102
I0
I1
I-1
tp131
sS'induce,cyp3a4'
p132
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp133
sS'patients,already'
p134
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp135
sS'alternate,sequence'
p136
(F1
F0.00014334862385321102
I1
I0
I1
tp137
sS'a,four-day'
p138
(F1
F0.00014334862385321102
I1
I0
I1
tp139
sS'to,play'
p140
(F1
F0.00014334862385321102
I0
I1
I-1
tp141
sS'sodium,plasma'
p142
(F1
F0.00028669724770642203
I2
I0
I2
tp143
sS'containing,or'
p144
(F0.83333333333333337
F0.0014334862385321102
I11
I1
I10
tp145
sS'as,poor'
p146
(F1
F0.00028669724770642203
I0
I2
I-2
tp147
sS'be,concomitantly'
p148
(F1
F0.00014334862385321102
I0
I1
I-1
tp149
sS'systolic,diastolic'
p150
(F1
F0.00014334862385321102
I1
I0
I1
tp151
sS'been,a'
p152
(F1
F0.00028669724770642203
I2
I0
I2
tp153
sS'the,serum'
p154
(F0.26315789473684209
F0.00071674311926605509
I12
I7
I5
tp155
sS'and,traumatic'
p156
(F1
F0.00014334862385321102
I1
I0
I1
tp157
sS'thiazide,use'
p158
(F1
F0.00014334862385321102
I1
I0
I1
tp159
sS'by,hours'
p160
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp161
sS'erection-supporting,medication'
p162
(F1
F0.00014334862385321102
I0
I1
I-1
tp163
sS'individuals,were'
p164
(F1
F0.00014334862385321102
I0
I1
I-1
tp165
sS'qd,for'
p166
(F0
F0
I1
I1
I0
tp167
sS'the,long'
p168
(F0
F0
I1
I1
I0
tp169
sS'and,n-acetyl'
p170
(F1
F0.00014334862385321102
I0
I1
I-1
tp171
sS'imuran,the'
p172
(F1
F0.00014334862385321102
I1
I0
I1
tp173
sS'following,elspar'
p174
(F1
F0.00014334862385321102
I1
I0
I1
tp175
sS'and,limited'
p176
(F1
F0.00014334862385321102
I0
I1
I-1
tp177
sS'with,treatment'
p178
(F1
F0.00014334862385321102
I0
I1
I-1
tp179
sS'the,leukopenic'
p180
(F1
F0.00014334862385321102
I1
I0
I1
tp181
sS'synthesis,of'
p182
(F0
F0
I2
I2
I0
tp183
sS'comparative,study'
p184
(F1
F0.00014334862385321102
I0
I1
I-1
tp185
sS'pharmacokinetic,dosing'
p186
(F1
F0.00014334862385321102
I0
I1
I-1
tp187
sS'synthesis,or'
p188
(F1
F0.00014334862385321102
I0
I1
I-1
tp189
sS'relaxants,nondepolarizing'
p190
(F1
F0.00043004587155963305
I0
I3
I-3
tp191
sS'pharmacodynamics,prothrombin'
p192
(F1
F0.00014334862385321102
I0
I1
I-1
tp193
sS'nonlethal,dose'
p194
(F0
F0
I1
I1
I0
tp195
sS'or,bind'
p196
(F1
F0.00014334862385321102
I1
I0
I1
tp197
sS'feso4,or'
p198
(F1
F0.00014334862385321102
I1
I0
I1
tp199
sS'hcl,with'
p200
(F1
F0.00014334862385321102
I1
I0
I1
tp201
sS'traumatic,edemas'
p202
(F1
F0.00014334862385321102
I1
I0
I1
tp203
sS'several,but'
p204
(F1
F0.00014334862385321102
I0
I1
I-1
tp205
sS'fluoride,and'
p206
(F1
F0.00014334862385321102
I1
I0
I1
tp207
sS'on,rare'
p208
(F1
F0.00028669724770642203
I2
I0
I2
tp209
sS'antagonized,the'
p210
(F1
F0.00028669724770642203
I2
I0
I2
tp211
sS'thereby,increasing'
p212
(F1
F0.00043004587155963305
I3
I0
I3
tp213
sS'auc,increased'
p214
(F1
F0.00057339449541284407
I4
I0
I4
tp215
sS'activity--such,as'
p216
(F1
F0.00014334862385321102
I1
I0
I1
tp217
sS'the,daily'
p218
(F0
F0
I2
I2
I0
tp219
sS'and,maximum'
p220
(F0
F0
I1
I1
I0
tp221
sS'and,essentially'
p222
(F1
F0.00014334862385321102
I0
I1
I-1
tp223
sS'primidone,population'
p224
(F1
F0.00014334862385321102
I1
I0
I1
tp225
sS'organisms,and'
p226
(F1
F0.00014334862385321102
I0
I1
I-1
tp227
sS'the,fed'
p228
(F1
F0.00014334862385321102
I1
I0
I1
tp229
sS'nnrti,based'
p230
(F1
F0.00014334862385321102
I0
I1
I-1
tp231
sS'of,per'
p232
(F0
F0
I2
I2
I0
tp233
sS'maximal,to'
p234
(F1
F0.00014334862385321102
I1
I0
I1
tp235
sS'all,muscle'
p236
(F1
F0.00014334862385321102
I1
I0
I1
tp237
sS'these,have'
p238
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp239
sS'an,adverse'
p240
(F1
F0.00014334862385321102
I0
I1
I-1
tp241
sS'containing,microgram'
p242
(F1
F0.00014334862385321102
I0
I1
I-1
tp243
sS'but,should'
p244
(F0.5
F0.00028669724770642203
I3
I1
I2
tp245
sS'typhoid,attenuation'
p246
(F1
F0.00014334862385321102
I1
I0
I1
tp247
sS'as,toxic'
p248
(F1
F0.00014334862385321102
I0
I1
I-1
tp249
sS'are,started'
p250
(F1
F0.00014334862385321102
I1
I0
I1
tp251
sS'adrenergic,agents'
p252
(F1
F0.00014334862385321102
I1
I0
I1
tp253
sS'increase,plasma'
p254
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp255
sS'with,coumarin-derivative'
p256
(F1
F0.00014334862385321102
I1
I0
I1
tp257
sS'has,had'
p258
(F1
F0.00014334862385321102
I1
I0
I1
tp259
sS'auc,ci'
p260
(F1
F0.00014334862385321102
I0
I1
I-1
tp261
sS'of,onto'
p262
(F1
F0.00014334862385321102
I1
I0
I1
tp263
sS'and,cold'
p264
(F0
F0
I1
I1
I0
tp265
sS'midamor,and'
p266
(F1
F0.00014334862385321102
I1
I0
I1
tp267
sS'behavioral,inhibition'
p268
(F1
F0.00014334862385321102
I0
I1
I-1
tp269
sS'studied,systematically'
p270
(F1
F0.00014334862385321102
I0
I1
I-1
tp271
sS'symptoms,have'
p272
(F1
F0.00014334862385321102
I1
I0
I1
tp273
sS'ophthalmic,solution'
p274
(F1
F0.00014334862385321102
I1
I0
I1
tp275
sS'benefit,from'
p276
(F1
F0.00014334862385321102
I1
I0
I1
tp277
sS'state,serum'
p278
(F1
F0.00014334862385321102
I0
I1
I-1
tp279
sS'ketoconazole,phenytoin'
p280
(F1
F0.00014334862385321102
I0
I1
I-1
tp281
sS'valid,in'
p282
(F1
F0.00014334862385321102
I0
I1
I-1
tp283
sS'corticotropin,may'
p284
(F1
F0.00028669724770642203
I2
I0
I2
tp285
sS'system,though'
p286
(F1
F0.00014334862385321102
I1
I0
I1
tp287
sS'of,daily'
p288
(F1
F0.00014334862385321102
I1
I0
I1
tp289
sS'these,effects'
p290
(F0
F0
I3
I3
I0
tp291
sS'inr,was'
p292
(F0
F0
I1
I1
I0
tp293
sS'theophylline,serum'
p294
(F1
F0.00014334862385321102
I1
I0
I1
tp295
sS'mediating,stimulus-induced'
p296
(F1
F0.00014334862385321102
I0
I1
I-1
tp297
sS'an,enhancement'
p298
(F1
F0.00028669724770642203
I2
I0
I2
tp299
sS'given,once'
p300
(F1
F0.00028669724770642203
I2
I0
I2
tp301
sS'aminoglutethimide,may'
p302
(F1
F0.00028669724770642203
I2
I0
I2
tp303
sS'that,meth'
p304
(F1
F0.00014334862385321102
I1
I0
I1
tp305
sS'healthy,white'
p306
(F1
F0.00014334862385321102
I0
I1
I-1
tp307
sS'mg,were'
p308
(F1
F0.00014334862385321102
I0
I1
I-1
tp309
sS'used,when'
p310
(F0.75
F0.0008600917431192661
I7
I1
I6
tp311
sS'metabolite,concentrations'
p312
(F1
F0.00014334862385321102
I1
I0
I1
tp313
sS'one,hour'
p314
(F1
F0.00043004587155963305
I3
I0
I3
tp315
sS'patients,there'
p316
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp317
sS'responding,in'
p318
(F0
F0
I1
I1
I0
tp319
sS'increased,prothrombin'
p320
(F1
F0.0008600917431192661
I6
I0
I6
tp321
sS'critical,role'
p322
(F1
F0.00014334862385321102
I0
I1
I-1
tp323
sS'kg,body'
p324
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp325
sS'when,trisenox'
p326
(F1
F0.00014334862385321102
I1
I0
I1
tp327
sS'sh,fa'
p328
(F1
F0.00014334862385321102
I0
I1
I-1
tp329
sS'subsequent,treatment'
p330
(F1
F0.00014334862385321102
I1
I0
I1
tp331
sS'effectiveness,of'
p332
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp333
sS'possible,toxicity'
p334
(F1
F0.00014334862385321102
I0
I1
I-1
tp335
sS'p-type,channel'
p336
(F1
F0.00014334862385321102
I0
I1
I-1
tp337
sS'induce,inhibit'
p338
(F1
F0.00014334862385321102
I1
I0
I1
tp339
sS'exposure,to'
p340
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp341
sS'closely,when'
p342
(F1
F0.00043004587155963305
I3
I0
I3
tp343
sS'a,cyp'
p344
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp345
sS'general,local'
p346
(F1
F0.00014334862385321102
I0
I1
I-1
tp347
sS'molt-4,cells'
p348
(F1
F0.00014334862385321102
I1
I0
I1
tp349
sS'additive,inotropic'
p350
(F1
F0.00014334862385321102
I0
I1
I-1
tp351
sS'an,levonorgestrol'
p352
(F1
F0.00014334862385321102
I0
I1
I-1
tp353
sS'may,potentially'
p354
(F1
F0.00028669724770642203
I0
I2
I-2
tp355
sS'acetaminophen,had'
p356
(F1
F0.00014334862385321102
I0
I1
I-1
tp357
sS'initiates,or'
p358
(F1
F0.00014334862385321102
I1
I0
I1
tp359
sS'bone,scintigraphy'
p360
(F1
F0.00014334862385321102
I0
I1
I-1
tp361
sS'dexfenfluramine,should'
p362
(F1
F0.00014334862385321102
I1
I0
I1
tp363
sS'treatment-experienced,patients'
p364
(F1
F0.00014334862385321102
I0
I1
I-1
tp365
sS'male,animals'
p366
(F1
F0.00014334862385321102
I0
I1
I-1
tp367
sS'dexamethasone,steady-state'
p368
(F1
F0.00014334862385321102
I1
I0
I1
tp369
sS'procedures,during'
p370
(F1
F0.00014334862385321102
I1
I0
I1
tp371
sS'increased,intracranial'
p372
(F1
F0.00014334862385321102
I1
I0
I1
tp373
sS'sole,indication'
p374
(F1
F0.00014334862385321102
I0
I1
I-1
tp375
sS'antiepileptic,aeds'
p376
(F1
F0.00014334862385321102
I1
I0
I1
tp377
sS'of,alternate-day'
p378
(F1
F0.00014334862385321102
I1
I0
I1
tp379
sS'relief,of'
p380
(F1
F0.00014334862385321102
I0
I1
I-1
tp381
sS'is,eliminated'
p382
(F0
F0
I1
I1
I0
tp383
sS'and,l-methionine'
p384
(F1
F0.00014334862385321102
I1
I0
I1
tp385
sS'mediated,transport'
p386
(F1
F0.00014334862385321102
I0
I1
I-1
tp387
sS'of,nonsedating'
p388
(F1
F0.00014334862385321102
I1
I0
I1
tp389
sS'induced,hypokalemia'
p390
(F1
F0.00014334862385321102
I1
I0
I1
tp391
sS'even,experienced'
p392
(F1
F0.00014334862385321102
I1
I0
I1
tp393
sS'with,showed'
p394
(F1
F0.00014334862385321102
I0
I1
I-1
tp395
sS'is,ordinarily'
p396
(F1
F0.00014334862385321102
I0
I1
I-1
tp397
sS'conjugated,system'
p398
(F1
F0.00014334862385321102
I0
I1
I-1
tp399
sS'nitrofurantoin,interferes'
p400
(F1
F0.00014334862385321102
I1
I0
I1
tp401
sS'of,induced'
p402
(F1
F0.00014334862385321102
I0
I1
I-1
tp403
sS'to,plasma'
p404
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp405
sS'known,inhibitor'
p406
(F1
F0.00043004587155963305
I3
I0
I3
tp407
sS'be,required'
p408
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp409
sS'findings,of'
p410
(F1
F0.00014334862385321102
I0
I1
I-1
tp411
sS's,determined'
p412
(F1
F0.00014334862385321102
I1
I0
I1
tp413
sS'the,have'
p414
(F1
F0.00043004587155963305
I3
I0
I3
tp415
sS'over,indinavir-based'
p416
(F1
F0.00014334862385321102
I0
I1
I-1
tp417
sS'increases,about'
p418
(F1
F0.00014334862385321102
I1
I0
I1
tp419
sS'inotropic,effects'
p420
(F1
F0.00028669724770642203
I2
I0
I2
tp421
sS'competition,for'
p422
(F1
F0.00014334862385321102
I1
I0
I1
tp423
sS'behavioral,or'
p424
(F1
F0.00014334862385321102
I0
I1
I-1
tp425
sS'nevertheless,caution'
p426
(F1
F0.00057339449541284407
I4
I0
I4
tp427
sS'normally,to'
p428
(F1
F0.00014334862385321102
I0
I1
I-1
tp429
sS'aerosol,and'
p430
(F1
F0.00014334862385321102
I0
I1
I-1
tp431
sS'suggested,the'
p432
(F1
F0.00014334862385321102
I0
I1
I-1
tp433
sS'with,coly-mycin'
p434
(F1
F0.00014334862385321102
I1
I0
I1
tp435
sS'systemically,administered'
p436
(F1
F0.00014334862385321102
I0
I1
I-1
tp437
sS'occurred,significantly'
p438
(F1
F0.00014334862385321102
I0
I1
I-1
tp439
sS'should,if'
p440
(F1
F0.00014334862385321102
I1
I0
I1
tp441
sS'in,standing'
p442
(F1
F0.00014334862385321102
I1
I0
I1
tp443
sS'gi,tract'
p444
(F1
F0.00014334862385321102
I1
I0
I1
tp445
sS'should,it'
p446
(F1
F0.00014334862385321102
I1
I0
I1
tp447
sS'the,ec50'
p448
(F1
F0.00014334862385321102
I0
I1
I-1
tp449
sS'enzyme,ace'
p450
(F1
F0.00028669724770642203
I0
I2
I-2
tp451
sS'calcium-channel,blockers'
p452
(F1
F0.00028669724770642203
I0
I2
I-2
tp453
sS'but,nearly'
p454
(F1
F0.00014334862385321102
I0
I1
I-1
tp455
sS'results,in'
p456
(F0.69230769230769229
F0.0012901376146788992
I11
I2
I9
tp457
sS'if,replacement'
p458
(F1
F0.00014334862385321102
I0
I1
I-1
tp459
sS'by,explain'
p460
(F1
F0.00014334862385321102
I1
I0
I1
tp461
sS'and,alone'
p462
(F1
F0.00014334862385321102
I0
I1
I-1
tp463
sS'may,develop'
p464
(F1
F0.00043004587155963305
I3
I0
I3
tp465
sS'v,remains'
p466
(F1
F0.00014334862385321102
I0
I1
I-1
tp467
sS'species,of'
p468
(F1
F0.00043004587155963305
I3
I0
I3
tp469
sS'or,either'
p470
(F1
F0.00014334862385321102
I1
I0
I1
tp471
sS'of,macrolide'
p472
(F1
F0.00014334862385321102
I1
I0
I1
tp473
sS'n,were'
p474
(F0
F0
I1
I1
I0
tp475
sS'serotype,o11'
p476
(F1
F0.00028669724770642203
I0
I2
I-2
tp477
sS'adsorption,of'
p478
(F1
F0.00014334862385321102
I1
I0
I1
tp479
sS'and,serial'
p480
(F1
F0.00014334862385321102
I1
I0
I1
tp481
sS'for,using'
p482
(F1
F0.00014334862385321102
I0
I1
I-1
tp483
sS'affect,pharmacokinetics'
p484
(F1
F0.00014334862385321102
I1
I0
I1
tp485
sS'coadministered,with'
p486
(F0.21951219512195122
F0.0012901376146788992
I25
I16
I9
tp487
sS'isozyme,including'
p488
(F0
F0
I1
I1
I0
tp489
sS'with,foscavir'
p490
(F1
F0.00014334862385321102
I1
I0
I1
tp491
sS'min,following'
p492
(F1
F0.00014334862385321102
I0
I1
I-1
tp493
sS'reported,as'
p494
(F1
F0.00014334862385321102
I1
I0
I1
tp495
sS'careful,observation'
p496
(F1
F0.00014334862385321102
I1
I0
I1
tp497
sS'changed,the'
p498
(F1
F0.00014334862385321102
I1
I0
I1
tp499
sS'in,ethinyl'
p500
(F1
F0.00014334862385321102
I1
I0
I1
tp501
sS'secreted,via'
p502
(F1
F0.00014334862385321102
I1
I0
I1
tp503
sS'levels,shown'
p504
(F1
F0.00014334862385321102
I0
I1
I-1
tp505
sS'the,steadystate'
p506
(F0
F0
I1
I1
I0
tp507
sS'management,of'
p508
(F0
F0
I2
I2
I0
tp509
sS'ketamine,when'
p510
(F1
F0.00014334862385321102
I1
I0
I1
tp511
sS'hiv-related,systemic'
p512
(F1
F0.00014334862385321102
I0
I1
I-1
tp513
sS'the,one-stage'
p514
(F1
F0.00014334862385321102
I0
I1
I-1
tp515
sS'multicenter,randomized'
p516
(F1
F0.00014334862385321102
I0
I1
I-1
tp517
sS'and,add'
p518
(F1
F0.0008600917431192661
I6
I0
I6
tp519
sS'of,relapses'
p520
(F1
F0.00014334862385321102
I0
I1
I-1
tp521
sS'concentration,due'
p522
(F1
F0.00014334862385321102
I1
I0
I1
tp523
sS'increased,over'
p524
(F1
F0.00014334862385321102
I1
I0
I1
tp525
sS'qd,by'
p526
(F1
F0.00014334862385321102
I1
I0
I1
tp527
sS'sodium,succinate'
p528
(F1
F0.00014334862385321102
I0
I1
I-1
tp529
sS'exjade,had'
p530
(F1
F0.00014334862385321102
I0
I1
I-1
tp531
sS'phenytoin,causes'
p532
(F1
F0.00014334862385321102
I1
I0
I1
tp533
sS'delayed,adverse'
p534
(F1
F0.00014334862385321102
I1
I0
I1
tp535
sS'subjects,demonstrated'
p536
(F1
F0.00014334862385321102
I1
I0
I1
tp537
sS'antagonist,with'
p538
(F1
F0.00014334862385321102
I1
I0
I1
tp539
sS'to,exhibit'
p540
(F1
F0.00014334862385321102
I0
I1
I-1
tp541
sS'the,volume'
p542
(F1
F0.00014334862385321102
I0
I1
I-1
tp543
sS'characterized,a'
p544
(F1
F0.00014334862385321102
I1
I0
I1
tp545
sS'the,adverse'
p546
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp547
sS'prophylactic,and'
p548
(F1
F0.00014334862385321102
I1
I0
I1
tp549
sS'captopril,s'
p550
(F1
F0.00014334862385321102
I1
I0
I1
tp551
sS'collected,through'
p552
(F1
F0.00014334862385321102
I0
I1
I-1
tp553
sS'in,any'
p554
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp555
sS'derive,from'
p556
(F1
F0.00014334862385321102
I1
I0
I1
tp557
sS'practice,has'
p558
(F1
F0.00014334862385321102
I1
I0
I1
tp559
sS'be,withdrawn'
p560
(F1
F0.00043004587155963305
I3
I0
I3
tp561
sS'second,day'
p562
(F1
F0.00014334862385321102
I1
I0
I1
tp563
sS'interactions,as'
p564
(F1
F0.00028669724770642203
I0
I2
I-2
tp565
sS'potentially,significant'
p566
(F1
F0.00014334862385321102
I1
I0
I1
tp567
sS'the,side'
p568
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp569
sS'of,cns'
p570
(F1
F0.00014334862385321102
I1
I0
I1
tp571
sS'enhancing,heparin'
p572
(F1
F0.00014334862385321102
I0
I1
I-1
tp573
sS'as,high'
p574
(F1
F0.00028669724770642203
I0
I2
I-2
tp575
sS'threshold,should'
p576
(F1
F0.00014334862385321102
I1
I0
I1
tp577
sS'presumably,by'
p578
(F1
F0.00014334862385321102
I1
I0
I1
tp579
sS'that,ingestion'
p580
(F1
F0.00014334862385321102
I1
I0
I1
tp581
sS'no,dosage'
p582
(F1
F0.00014334862385321102
I0
I1
I-1
tp583
sS'acid,a-blockers'
p584
(F1
F0.00014334862385321102
I0
I1
I-1
tp585
sS'diuretic,agents'
p586
(F1
F0.00043004587155963305
I3
I0
I3
tp587
sS'chronic,therapy'
p588
(F0
F0
I1
I1
I0
tp589
sS'thus,appeared'
p590
(F1
F0.00014334862385321102
I1
I0
I1
tp591
sS'mediated,by'
p592
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp593
sS'digoxin,when'
p594
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp595
sS'of,people'
p596
(F1
F0.00014334862385321102
I1
I0
I1
tp597
sS'small,quantities'
p598
(F1
F0.00014334862385321102
I0
I1
I-1
tp599
sS'were,receiving'
p600
(F1
F0.00014334862385321102
I0
I1
I-1
tp601
sS'studies,showed'
p602
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp603
sS'these,are'
p604
(F0.81818181818181823
F0.0012901376146788992
I1
I10
I-9
tp605
sS'noted,that'
p606
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp607
sS'accumulation,of'
p608
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp609
sS'developed,regarding'
p610
(F1
F0.00014334862385321102
I0
I1
I-1
tp611
sS'anti-anxiety,used'
p612
(F1
F0.00014334862385321102
I0
I1
I-1
tp613
sS'a,literature'
p614
(F1
F0.00014334862385321102
I1
I0
I1
tp615
sS'state,conditions'
p616
(F1
F0.00028669724770642203
I0
I2
I-2
tp617
sS'on,thiazide'
p618
(F1
F0.00028669724770642203
I2
I0
I2
tp619
sS'other,having'
p620
(F1
F0.00014334862385321102
I1
I0
I1
tp621
sS'mean,ratios'
p622
(F1
F0.00014334862385321102
I0
I1
I-1
tp623
sS'tikosyn,or'
p624
(F1
F0.00014334862385321102
I0
I1
I-1
tp625
sS'initial,clinical'
p626
(F1
F0.00014334862385321102
I0
I1
I-1
tp627
sS'decongestant,allergy'
p628
(F1
F0.00014334862385321102
I1
I0
I1
tp629
sS'piperacillin,sodium'
p630
(F1
F0.00014334862385321102
I1
I0
I1
tp631
sS'platelets,by'
p632
(F1
F0.00014334862385321102
I1
I0
I1
tp633
sS'produces,psychotomimetic'
p634
(F1
F0.00014334862385321102
I0
I1
I-1
tp635
sS'dosage,levels'
p636
(F1
F0.00014334862385321102
I1
I0
I1
tp637
sS'free,had'
p638
(F1
F0.00014334862385321102
I0
I1
I-1
tp639
sS'relaxants,and'
p640
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp641
sS'that,affect'
p642
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp643
sS'amiodarone,may'
p644
(F1
F0.00014334862385321102
I0
I1
I-1
tp645
sS'was,carried'
p646
(F1
F0.00014334862385321102
I0
I1
I-1
tp647
sS'or,basic'
p648
(F1
F0.00014334862385321102
I1
I0
I1
tp649
sS'fewer,extrapyramidal'
p650
(F1
F0.00014334862385321102
I0
I1
I-1
tp651
sS'as,not'
p652
(F1
F0.00014334862385321102
I1
I0
I1
tp653
sS'different,routes'
p654
(F1
F0.00014334862385321102
I1
I0
I1
tp655
sS'ulcerans,was'
p656
(F1
F0.00014334862385321102
I0
I1
I-1
tp657
sS'respiratory,depression'
p658
(F1
F0.00043004587155963305
I3
I0
I3
tp659
sS'in,vitro'
p660
(F0.095890410958904104
F0.0010034403669724771
I33
I40
I-7
tp661
sS'human,growth'
p662
(F1
F0.00014334862385321102
I1
I0
I1
tp663
sS'a,facilitates'
p664
(F1
F0.00014334862385321102
I0
I1
I-1
tp665
sS'study,male'
p666
(F1
F0.00014334862385321102
I0
I1
I-1
tp667
sS'betaseron,on'
p668
(F1
F0.00014334862385321102
I1
I0
I1
tp669
sS'but,are'
p670
(F1
F0.00028669724770642203
I0
I2
I-2
tp671
sS'if,it'
p672
(F1
F0.00014334862385321102
I1
I0
I1
tp673
sS'if,is'
p674
(F1
F0.0018635321100917432
I13
I0
I13
tp675
sS's,nor'
p676
(F1
F0.00014334862385321102
I0
I1
I-1
tp677
sS'was,higher'
p678
(F1
F0.00043004587155963305
I3
I0
I3
tp679
sS'schedule,was'
p680
(F1
F0.00014334862385321102
I1
I0
I1
tp681
sS'c,should'
p682
(F1
F0.00028669724770642203
I2
I0
I2
tp683
sS'in,a-chloralose'
p684
(F1
F0.00014334862385321102
I0
I1
I-1
tp685
sS'strong,central'
p686
(F1
F0.00014334862385321102
I0
I1
I-1
tp687
sS'dietary-obese,rats'
p688
(F1
F0.00043004587155963305
I0
I3
I-3
tp689
sS'particularly,if'
p690
(F1
F0.00014334862385321102
I1
I0
I1
tp691
sS'days,decreased'
p692
(F1
F0.00014334862385321102
I1
I0
I1
tp693
sS'to,administer'
p694
(F1
F0.00014334862385321102
I1
I0
I1
tp695
sS'particularly,in'
p696
(F0.5
F0.00028669724770642203
I3
I1
I2
tp697
sS'proleukin,and'
p698
(F1
F0.00028669724770642203
I2
I0
I2
tp699
sS'increased,possibility'
p700
(F1
F0.00028669724770642203
I2
I0
I2
tp701
sS'of,coma'
p702
(F1
F0.00014334862385321102
I1
I0
I1
tp703
sS'with,multivalent'
p704
(F1
F0.00014334862385321102
I1
I0
I1
tp705
sS'can,lead'
p706
(F1
F0.00043004587155963305
I3
I0
I3
tp707
sS'of,lexapro'
p708
(F1
F0.00014334862385321102
I0
I1
I-1
tp709
sS'had,treatment-emergent'
p710
(F1
F0.00014334862385321102
I0
I1
I-1
tp711
sS'of,innovar'
p712
(F0
F0
I1
I1
I0
tp713
sS'derivatives,niacin'
p714
(F1
F0.00014334862385321102
I0
I1
I-1
tp715
sS'k,the'
p716
(F1
F0.00014334862385321102
I1
I0
I1
tp717
sS'cmax,of'
p718
(F0.53846153846153844
F0.0010034403669724771
I10
I3
I7
tp719
sS'derivatives,nicotinic'
p720
(F1
F0.00014334862385321102
I0
I1
I-1
tp721
sS'glucocorticoid-induced,mouse'
p722
(F1
F0.00014334862385321102
I0
I1
I-1
tp723
sS'of,permits'
p724
(F1
F0.00014334862385321102
I1
I0
I1
tp725
sS'by,approximately'
p726
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp727
sS'a,a'
p728
(F1
F0.00014334862385321102
I1
I0
I1
tp729
sS'aspirin,animal'
p730
(F1
F0.00014334862385321102
I1
I0
I1
tp731
sS'pharmacokinetic,results'
p732
(F1
F0.00014334862385321102
I1
I0
I1
tp733
sS'achieve,exposures'
p734
(F1
F0.00028669724770642203
I2
I0
I2
tp735
sS'therapeutic,efficacy'
p736
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp737
sS'of,especially'
p738
(F1
F0.00028669724770642203
I2
I0
I2
tp739
sS'and,resulted'
p740
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp741
sS'smallest,effective'
p742
(F1
F0.00014334862385321102
I0
I1
I-1
tp743
sS'contractile,responses'
p744
(F1
F0.00014334862385321102
I1
I0
I1
tp745
sS'inhibitors,for'
p746
(F1
F0.00014334862385321102
I0
I1
I-1
tp747
sS'mild,but'
p748
(F1
F0.00014334862385321102
I0
I1
I-1
tp749
sS'arterial,thrombus'
p750
(F1
F0.00014334862385321102
I1
I0
I1
tp751
sS'the,placebo-controlled'
p752
(F1
F0.00014334862385321102
I0
I1
I-1
tp753
sS'indicated,and'
p754
(F1
F0.00014334862385321102
I1
I0
I1
tp755
sS'blocking,properties'
p756
(F1
F0.00028669724770642203
I2
I0
I2
tp757
sS'metabolite,are'
p758
(F1
F0.00014334862385321102
I0
I1
I-1
tp759
sS'celebrex,concomitantly'
p760
(F1
F0.00014334862385321102
I1
I0
I1
tp761
sS'condition,in'
p762
(F1
F0.00014334862385321102
I1
I0
I1
tp763
sS'altretamines,half-life'
p764
(F1
F0.00014334862385321102
I1
I0
I1
tp765
sS'maintain,concentrations'
p766
(F1
F0.00014334862385321102
I0
I1
I-1
tp767
sS'and,raise'
p768
(F1
F0.00014334862385321102
I1
I0
I1
tp769
sS'as,immediate-early'
p770
(F1
F0.00014334862385321102
I0
I1
I-1
tp771
sS'and,frequently'
p772
(F1
F0.00028669724770642203
I2
I0
I2
tp773
sS'hours,concurrently'
p774
(F1
F0.00014334862385321102
I0
I1
I-1
tp775
sS'and,discontinuing'
p776
(F1
F0.00057339449541284407
I4
I0
I4
tp777
sS'of,iopidine'
p778
(F1
F0.00014334862385321102
I1
I0
I1
tp779
sS'the,cardiotoxicity'
p780
(F1
F0.00014334862385321102
I0
I1
I-1
tp781
sS'rats,did'
p782
(F1
F0.00028669724770642203
I0
I2
I-2
tp783
sS'not,known'
p784
(F0
F0
I6
I6
I0
tp785
sS'but,also'
p786
(F0
F0
I1
I1
I0
tp787
sS'preclinical,or'
p788
(F1
F0.00014334862385321102
I0
I1
I-1
tp789
sS'individual,simulect'
p790
(F1
F0.00014334862385321102
I0
I1
I-1
tp791
sS'especially,neglect'
p792
(F1
F0.00014334862385321102
I0
I1
I-1
tp793
sS'or,potentiation'
p794
(F1
F0.00028669724770642203
I0
I2
I-2
tp795
sS'animals,indicate'
p796
(F1
F0.00014334862385321102
I1
I0
I1
tp797
sS'requiring,angioedema'
p798
(F1
F0.00014334862385321102
I0
I1
I-1
tp799
sS'and,inhibit'
p800
(F1
F0.0008600917431192661
I0
I6
I-6
tp801
sS'including,has'
p802
(F1
F0.00014334862385321102
I1
I0
I1
tp803
sS'demonstrated,a'
p804
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp805
sS'known,hence'
p806
(F1
F0.00014334862385321102
I1
I0
I1
tp807
sS'to,sensitize'
p808
(F0
F0
I1
I1
I0
tp809
sS'level,should'
p810
(F1
F0.00014334862385321102
I1
I0
I1
tp811
sS'hypercholesterolemic,noninsulin'
p812
(F1
F0.00014334862385321102
I0
I1
I-1
tp813
sS'c,eg'
p814
(F1
F0.00014334862385321102
I1
I0
I1
tp815
sS'of,equetrotm'
p816
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp817
sS'to,influence'
p818
(F1
F0.00028669724770642203
I2
I0
I2
tp819
sS'only,of'
p820
(F1
F0.00014334862385321102
I0
I1
I-1
tp821
sS'four-day,regimen'
p822
(F1
F0.00014334862385321102
I1
I0
I1
tp823
sS'of,n-desmethyldiazepam'
p824
(F1
F0.00014334862385321102
I0
I1
I-1
tp825
sS'glyburide,in'
p826
(F1
F0.00014334862385321102
I0
I1
I-1
tp827
sS'hypotension,and'
p828
(F1
F0.0008600917431192661
I6
I0
I6
tp829
sS'on,bar-press'
p830
(F1
F0.00014334862385321102
I0
I1
I-1
tp831
sS'remain,to'
p832
(F1
F0.00014334862385321102
I0
I1
I-1
tp833
sS'the,simultaneous'
p834
(F0
F0
I2
I2
I0
tp835
sS'subjects,taking'
p836
(F1
F0.00014334862385321102
I0
I1
I-1
tp837
sS'glyburide,is'
p838
(F1
F0.00014334862385321102
I0
I1
I-1
tp839
sS'n,ingestion'
p840
(F1
F0.00014334862385321102
I1
I0
I1
tp841
sS'valdecoxib,steady'
p842
(F1
F0.00014334862385321102
I0
I1
I-1
tp843
sS'metabolic,enzymes'
p844
(F1
F0.00028669724770642203
I0
I2
I-2
tp845
sS'of,edetate'
p846
(F1
F0.00014334862385321102
I1
I0
I1
tp847
sS'on,treatment'
p848
(F1
F0.00014334862385321102
I1
I0
I1
tp849
sS'clear,whether'
p850
(F1
F0.00014334862385321102
I0
I1
I-1
tp851
sS'eight,of'
p852
(F1
F0.00014334862385321102
I1
I0
I1
tp853
sS'a,non-steroidal'
p854
(F1
F0.00043004587155963305
I3
I0
I3
tp855
sS'tests,performed'
p856
(F1
F0.00014334862385321102
I0
I1
I-1
tp857
sS'neoplastic,disease'
p858
(F1
F0.00014334862385321102
I1
I0
I1
tp859
sS'volunteers,did'
p860
(F1
F0.00043004587155963305
I0
I3
I-3
tp861
sS'mouth,use'
p862
(F1
F0.00014334862385321102
I1
I0
I1
tp863
sS'guide,to'
p864
(F1
F0.00014334862385321102
I1
I0
I1
tp865
sS'subset,of'
p866
(F1
F0.00014334862385321102
I0
I1
I-1
tp867
sS'milk,products'
p868
(F1
F0.00014334862385321102
I1
I0
I1
tp869
sS'diuretics,studies'
p870
(F1
F0.00014334862385321102
I1
I0
I1
tp871
sS'selective,mao'
p872
(F1
F0.00014334862385321102
I1
I0
I1
tp873
sS'effective,than'
p874
(F1
F0.00014334862385321102
I0
I1
I-1
tp875
sS'a,theoretical'
p876
(F1
F0.00057339449541284407
I4
I0
I4
tp877
sS'valproate,available'
p878
(F1
F0.00014334862385321102
I0
I1
I-1
tp879
sS'relevant,interactions'
p880
(F1
F0.00014334862385321102
I0
I1
I-1
tp881
sS'excretion,is'
p882
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp883
sS'or,proton'
p884
(F1
F0.00043004587155963305
I3
I0
I3
tp885
sS'aprepitant,may'
p886
(F1
F0.00014334862385321102
I1
I0
I1
tp887
sS'deviation,to'
p888
(F1
F0.00014334862385321102
I1
I0
I1
tp889
sS'hydrodiuril,diuril'
p890
(F1
F0.00014334862385321102
I0
I1
I-1
tp891
sS'excretion,in'
p892
(F1
F0.00028669724770642203
I2
I0
I2
tp893
sS'recommended,daily'
p894
(F1
F0.00014334862385321102
I1
I0
I1
tp895
sS'elevations,less'
p896
(F1
F0.00014334862385321102
I1
I0
I1
tp897
sS'acetate,with'
p898
(F1
F0.00014334862385321102
I1
I0
I1
tp899
sS'which,require'
p900
(F1
F0.00014334862385321102
I1
I0
I1
tp901
sS'mac,was'
p902
(F0
F0
I1
I1
I0
tp903
sS'a,group'
p904
(F1
F0.00057339449541284407
I0
I4
I-4
tp905
sS'striking,and'
p906
(F1
F0.00028669724770642203
I2
I0
I2
tp907
sS'flurbiprofen,like'
p908
(F1
F0.00014334862385321102
I1
I0
I1
tp909
sS'racemic,was'
p910
(F1
F0.00014334862385321102
I0
I1
I-1
tp911
sS'the,positive'
p912
(F0
F0
I1
I1
I0
tp913
sS'as,these'
p914
(F1
F0.00028669724770642203
I2
I0
I2
tp915
sS'studies,other'
p916
(F1
F0.00014334862385321102
I0
I1
I-1
tp917
sS'be,gradual'
p918
(F1
F0.00014334862385321102
I1
I0
I1
tp919
sS'active,monohydroxy'
p920
(F1
F0.00014334862385321102
I0
I1
I-1
tp921
sS'strategies,during'
p922
(F1
F0.00014334862385321102
I0
I1
I-1
tp923
sS'syncope,or'
p924
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp925
sS'of,grams'
p926
(F1
F0.00014334862385321102
I1
I0
I1
tp927
sS'dietary,salt'
p928
(F1
F0.00014334862385321102
I1
I0
I1
tp929
sS'erythromycin,azole'
p930
(F1
F0.00014334862385321102
I0
I1
I-1
tp931
sS'switched,from'
p932
(F1
F0.00014334862385321102
I0
I1
I-1
tp933
sS'not,appreciably'
p934
(F1
F0.00028669724770642203
I0
I2
I-2
tp935
sS'had,no'
p936
(F0.73333333333333328
F0.0063073394495412848
I8
I52
I-44
tp937
sS'ingesting,the'
p938
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp939
sS'inhibitors,serious'
p940
(F1
F0.00014334862385321102
I0
I1
I-1
tp941
sS'a,because'
p942
(F1
F0.00014334862385321102
I1
I0
I1
tp943
sS'or,concomitant'
p944
(F1
F0.00014334862385321102
I1
I0
I1
tp945
sS'ecg,of'
p946
(F1
F0.00014334862385321102
I0
I1
I-1
tp947
sS'shortened,elimination'
p948
(F1
F0.00014334862385321102
I1
I0
I1
tp949
sS'without,co-administered'
p950
(F1
F0.00014334862385321102
I0
I1
I-1
tp951
sS'however,there'
p952
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp953
sS'number,of'
p954
(F0
F0
I7
I7
I0
tp955
sS'hctz,hydrodiuril'
p956
(F1
F0.00014334862385321102
I0
I1
I-1
tp957
sS'no,potentiation'
p958
(F1
F0.00014334862385321102
I0
I1
I-1
tp959
sS'to,this'
p960
(F0.5
F0.00028669724770642203
I3
I1
I2
tp961
sS'not,ordinarily'
p962
(F1
F0.00028669724770642203
I2
I0
I2
tp963
sS'will,need'
p964
(F1
F0.00014334862385321102
I1
I0
I1
tp965
sS'receiving,may'
p966
(F1
F0.00014334862385321102
I1
I0
I1
tp967
sS'uptake,inhibitors'
p968
(F1
F0.00014334862385321102
I1
I0
I1
tp969
sS'racemic,combined'
p970
(F0
F0
I1
I1
I0
tp971
sS'inhibitors,nnrtis'
p972
(F1
F0.00014334862385321102
I1
I0
I1
tp973
sS'msec,was'
p974
(F1
F0.00014334862385321102
I1
I0
I1
tp975
sS'coadministered,medicinal'
p976
(F1
F0.00014334862385321102
I1
I0
I1
tp977
sS'produce,any'
p978
(F0
F0
I1
I1
I0
tp979
sS'the,tablets'
p980
(F1
F0.00014334862385321102
I1
I0
I1
tp981
sS'weekly,or'
p982
(F1
F0.00014334862385321102
I0
I1
I-1
tp983
sS'about,when'
p984
(F1
F0.00057339449541284407
I4
I0
I4
tp985
sS'data,suggesting'
p986
(F1
F0.00014334862385321102
I1
I0
I1
tp987
sS'to,treat'
p988
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp989
sS'and,bone'
p990
(F0
F0
I1
I1
I0
tp991
sS'mp,aza'
p992
(F1
F0.00014334862385321102
I0
I1
I-1
tp993
sS'air,passages'
p994
(F1
F0.00014334862385321102
I1
I0
I1
tp995
sS'especially,cyclic'
p996
(F1
F0.00014334862385321102
I1
I0
I1
tp997
sS'itraconazole,with'
p998
(F1
F0.00028669724770642203
I2
I0
I2
tp999
sS'indicate,only'
p1000
(F1
F0.00014334862385321102
I1
I0
I1
tp1001
sS'with,labetalol'
p1002
(F1
F0.00014334862385321102
I1
I0
I1
tp1003
sS'after,weeks'
p1004
(F1
F0.00014334862385321102
I0
I1
I-1
tp1005
sS'ameliorate,increased'
p1006
(F1
F0.00014334862385321102
I1
I0
I1
tp1007
sS'sedation,times'
p1008
(F1
F0.00014334862385321102
I0
I1
I-1
tp1009
sS'range,mg'
p1010
(F1
F0.00014334862385321102
I1
I0
I1
tp1011
sS'overall,exposure'
p1012
(F1
F0.00014334862385321102
I1
I0
I1
tp1013
sS'been,titrated'
p1014
(F0
F0
I2
I2
I0
tp1015
sS'preliminary,animal'
p1016
(F1
F0.00014334862385321102
I0
I1
I-1
tp1017
sS'uninfected,volunteers'
p1018
(F1
F0.00014334862385321102
I1
I0
I1
tp1019
sS'anti-infectives,without'
p1020
(F1
F0.00014334862385321102
I0
I1
I-1
tp1021
sS'to,acth'
p1022
(F1
F0.00014334862385321102
I0
I1
I-1
tp1023
sS'seen,with'
p1024
(F0
F0
I3
I3
I0
tp1025
sS'phenobarbital,it'
p1026
(F1
F0.00014334862385321102
I1
I0
I1
tp1027
sS'or,recovery'
p1028
(F1
F0.00014334862385321102
I1
I0
I1
tp1029
sS'however,is'
p1030
(F0
F0
I1
I1
I0
tp1031
sS'and,confusion'
p1032
(F1
F0.00014334862385321102
I1
I0
I1
tp1033
sS'however,if'
p1034
(F1
F0.00014334862385321102
I0
I1
I-1
tp1035
sS'repeat,doses'
p1036
(F1
F0.00014334862385321102
I0
I1
I-1
tp1037
sS'produced,significant'
p1038
(F1
F0.00014334862385321102
I1
I0
I1
tp1039
sS'rats,suggest'
p1040
(F1
F0.00014334862385321102
I1
I0
I1
tp1041
sS'regularly,during'
p1042
(F1
F0.00014334862385321102
I0
I1
I-1
tp1043
sS'however,in'
p1044
(F0.27272727272727271
F0.00043004587155963305
I4
I7
I-3
tp1045
sS'and,suppressed'
p1046
(F1
F0.00014334862385321102
I0
I1
I-1
tp1047
sS'alone,because'
p1048
(F1
F0.00014334862385321102
I1
I0
I1
tp1049
sS'which,was'
p1050
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp1051
sS'mean,plasma'
p1052
(F1
F0.00028669724770642203
I2
I0
I2
tp1053
sS'may,mask'
p1054
(F1
F0.00014334862385321102
I0
I1
I-1
tp1055
sS'regarding,the'
p1056
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp1057
sS'antipsychotic,with'
p1058
(F1
F0.00014334862385321102
I0
I1
I-1
tp1059
sS'when,central'
p1060
(F1
F0.00014334862385321102
I1
I0
I1
tp1061
sS'careful,monitoring'
p1062
(F0.5
F0.00057339449541284407
I6
I2
I4
tp1063
sS'conclusion,cisapride'
p1064
(F1
F0.00014334862385321102
I0
I1
I-1
tp1065
sS'personality,characteristics'
p1066
(F1
F0.00014334862385321102
I0
I1
I-1
tp1067
sS'mental,status'
p1068
(F1
F0.00014334862385321102
I1
I0
I1
tp1069
sS'events,reported'
p1070
(F1
F0.00014334862385321102
I0
I1
I-1
tp1071
sS'kill,even'
p1072
(F1
F0.00014334862385321102
I1
I0
I1
tp1073
sS'nanm,nanm'
p1074
(F1
F0.00014334862385321102
I0
I1
I-1
tp1075
sS'pharmacist,of'
p1076
(F1
F0.00014334862385321102
I0
I1
I-1
tp1077
sS'or,potassium-containing'
p1078
(F0
F0
I1
I1
I0
tp1079
sS'indocin,relafen'
p1080
(F1
F0.00014334862385321102
I0
I1
I-1
tp1081
sS'possibly,increasing'
p1082
(F1
F0.00028669724770642203
I2
I0
I2
tp1083
sS'not,exceed'
p1084
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp1085
sS'any,oral'
p1086
(F1
F0.00014334862385321102
I1
I0
I1
tp1087
sS'positive,reaction'
p1088
(F1
F0.00014334862385321102
I0
I1
I-1
tp1089
sS'cmax,was'
p1090
(F1
F0.00014334862385321102
I0
I1
I-1
tp1091
sS'risks,of'
p1092
(F1
F0.00057339449541284407
I4
I0
I4
tp1093
sS'compromised,uptake-1'
p1094
(F1
F0.00014334862385321102
I0
I1
I-1
tp1095
sS'produce,aucs'
p1096
(F1
F0.00014334862385321102
I1
I0
I1
tp1097
sS'food,one'
p1098
(F1
F0.00014334862385321102
I1
I0
I1
tp1099
sS'adverse,interaction'
p1100
(F1
F0.00014334862385321102
I0
I1
I-1
tp1101
sS'a,day'
p1102
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp1103
sS'with,potentially'
p1104
(F1
F0.00014334862385321102
I1
I0
I1
tp1105
sS'nondepolarizing,used'
p1106
(F1
F0.00014334862385321102
I0
I1
I-1
tp1107
sS'withdrawn,from'
p1108
(F0.5
F0.00028669724770642203
I3
I1
I2
tp1109
sS'as,post-marketing'
p1110
(F1
F0.00043004587155963305
I3
I0
I3
tp1111
sS'hormonal,including'
p1112
(F1
F0.00014334862385321102
I1
I0
I1
tp1113
sS'and,antiparkinsonian'
p1114
(F1
F0.00014334862385321102
I1
I0
I1
tp1115
sS'on,high'
p1116
(F1
F0.00014334862385321102
I0
I1
I-1
tp1117
sS'contribution,to'
p1118
(F1
F0.00014334862385321102
I0
I1
I-1
tp1119
sS'maintained,between'
p1120
(F1
F0.00014334862385321102
I1
I0
I1
tp1121
sS'nimbex,include'
p1122
(F1
F0.00014334862385321102
I1
I0
I1
tp1123
sS'respectively,suggesting'
p1124
(F1
F0.00028669724770642203
I2
I0
I2
tp1125
sS'dose,proleukin'
p1126
(F1
F0.00014334862385321102
I1
I0
I1
tp1127
sS'lotensin,has'
p1128
(F1
F0.00014334862385321102
I0
I1
I-1
tp1129
sS'the,following'
p1130
(F0.14893617021276595
F0.0010034403669724771
I20
I27
I-7
tp1131
sS'l,did'
p1132
(F1
F0.00014334862385321102
I0
I1
I-1
tp1133
sS'seen,but'
p1134
(F1
F0.00014334862385321102
I1
I0
I1
tp1135
sS'methylthiadiazole,can'
p1136
(F1
F0.00014334862385321102
I0
I1
I-1
tp1137
sS'mhd,have'
p1138
(F1
F0.00014334862385321102
I0
I1
I-1
tp1139
sS'was,in'
p1140
(F1
F0.00014334862385321102
I0
I1
I-1
tp1141
sS'vitro,displacement'
p1142
(F1
F0.00014334862385321102
I0
I1
I-1
tp1143
sS'colistimethate,salts'
p1144
(F1
F0.00014334862385321102
I1
I0
I1
tp1145
sS'approximately,was'
p1146
(F1
F0.00014334862385321102
I1
I0
I1
tp1147
sS's,disease'
p1148
(F1
F0.00043004587155963305
I0
I3
I-3
tp1149
sS'of,stadol'
p1150
(F0
F0
I2
I2
I0
tp1151
sS'a,gas'
p1152
(F1
F0.00014334862385321102
I0
I1
I-1
tp1153
sS'following,precautions'
p1154
(F1
F0.00014334862385321102
I1
I0
I1
tp1155
sS'alternating,therapy'
p1156
(F1
F0.00014334862385321102
I0
I1
I-1
tp1157
sS'cautious,initiation'
p1158
(F1
F0.00014334862385321102
I1
I0
I1
tp1159
sS'similar,personality'
p1160
(F1
F0.00014334862385321102
I0
I1
I-1
tp1161
sS'with,reports'
p1162
(F1
F0.00014334862385321102
I0
I1
I-1
tp1163
sS'levels,considerably'
p1164
(F1
F0.00028669724770642203
I2
I0
I2
tp1165
sS'and,sustained'
p1166
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1167
sS'tcas,when'
p1168
(F1
F0.00071674311926605509
I0
I5
I-5
tp1169
sS'although,administered'
p1170
(F1
F0.00014334862385321102
I0
I1
I-1
tp1171
sS'occurred,more'
p1172
(F1
F0.00014334862385321102
I0
I1
I-1
tp1173
sS'oral,estrogens'
p1174
(F1
F0.00014334862385321102
I1
I0
I1
tp1175
sS'volunteers,under'
p1176
(F1
F0.00028669724770642203
I0
I2
I-2
tp1177
sS'for,signs'
p1178
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp1179
sS'includes,both'
p1180
(F1
F0.00014334862385321102
I1
I0
I1
tp1181
sS'any,intentional'
p1182
(F1
F0.00014334862385321102
I1
I0
I1
tp1183
sS'of,albendazole'
p1184
(F1
F0.00014334862385321102
I1
I0
I1
tp1185
sS'following,antibiotics'
p1186
(F1
F0.00014334862385321102
I0
I1
I-1
tp1187
sS'average,of'
p1188
(F1
F0.00071674311926605509
I5
I0
I5
tp1189
sS'the,week'
p1190
(F0
F0
I1
I1
I0
tp1191
sS'blood,mononuclear'
p1192
(F1
F0.00028669724770642203
I2
I0
I2
tp1193
sS'and,retinyl'
p1194
(F1
F0.00028669724770642203
I2
I0
I2
tp1195
sS'an,experimental'
p1196
(F1
F0.00014334862385321102
I1
I0
I1
tp1197
sS'pharmacology,studies'
p1198
(F1
F0.00043004587155963305
I0
I3
I-3
tp1199
sS'scales,and'
p1200
(F1
F0.00014334862385321102
I0
I1
I-1
tp1201
sS'of,mesenteric'
p1202
(F1
F0.00014334862385321102
I0
I1
I-1
tp1203
sS'hepatic,lipid'
p1204
(F1
F0.00014334862385321102
I1
I0
I1
tp1205
sS'enzyme,group'
p1206
(F1
F0.00014334862385321102
I0
I1
I-1
tp1207
sS'cns-active,drugs'
p1208
(F1
F0.00028669724770642203
I2
I0
I2
tp1209
sS'to,carbodiimide'
p1210
(F1
F0.00014334862385321102
I0
I1
I-1
tp1211
sS'blockade,produced'
p1212
(F1
F0.00028669724770642203
I2
I0
I2
tp1213
sS'experienced,users'
p1214
(F1
F0.00014334862385321102
I1
I0
I1
tp1215
sS'in,bile'
p1216
(F1
F0.00014334862385321102
I1
I0
I1
tp1217
sS'bromocriptine,mesylate'
p1218
(F1
F0.00043004587155963305
I3
I0
I3
tp1219
sS'to,maintain'
p1220
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp1221
sS'of,antagonists'
p1222
(F1
F0.00028669724770642203
I0
I2
I-2
tp1223
sS'micrograms,caused'
p1224
(F1
F0.00014334862385321102
I1
I0
I1
tp1225
sS'drugs,aliskiren'
p1226
(F1
F0.00014334862385321102
I0
I1
I-1
tp1227
sS'divalproex,sodium'
p1228
(F1
F0.00014334862385321102
I1
I0
I1
tp1229
sS'some,angiotensin'
p1230
(F1
F0.00014334862385321102
I1
I0
I1
tp1231
sS'by,n6-cyclopentyladenosine'
p1232
(F1
F0.00014334862385321102
I1
I0
I1
tp1233
sS'acute,intake'
p1234
(F1
F0.00014334862385321102
I1
I0
I1
tp1235
sS'of,nizoral'
p1236
(F1
F0.00014334862385321102
I1
I0
I1
tp1237
sS'of,cholesterol'
p1238
(F1
F0.00014334862385321102
I1
I0
I1
tp1239
sS'tissues,induced'
p1240
(F1
F0.00014334862385321102
I1
I0
I1
tp1241
sS'decreased,blood'
p1242
(F1
F0.00014334862385321102
I1
I0
I1
tp1243
sS'disorder,or'
p1244
(F1
F0.00014334862385321102
I1
I0
I1
tp1245
sS'carboxymethylcellulose,nacmc'
p1246
(F1
F0.00014334862385321102
I0
I1
I-1
tp1247
sS'increase,in'
p1248
(F0.68852459016393441
F0.012041284403669725
I103
I19
I84
tp1249
sS'of,vardenafil'
p1250
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp1251
sS'in,difluoro-2'
p1252
(F1
F0.00014334862385321102
I1
I0
I1
tp1253
sS'increase,is'
p1254
(F1
F0.00014334862385321102
I1
I0
I1
tp1255
sS'derivative,is'
p1256
(F1
F0.00014334862385321102
I0
I1
I-1
tp1257
sS'inducers,eg'
p1258
(F1
F0.00014334862385321102
I0
I1
I-1
tp1259
sS'zyvox,may'
p1260
(F1
F0.00014334862385321102
I1
I0
I1
tp1261
sS'peak,and'
p1262
(F1
F0.00014334862385321102
I0
I1
I-1
tp1263
sS'interval,must'
p1264
(F1
F0.00014334862385321102
I1
I0
I1
tp1265
sS'resistant,to'
p1266
(F0
F0
I1
I1
I0
tp1267
sS'be,administered'
p1268
(F0.61702127659574468
F0.0041571100917431195
I38
I9
I29
tp1269
sS'study,had'
p1270
(F1
F0.00014334862385321102
I0
I1
I-1
tp1271
sS'practices,in'
p1272
(F1
F0.00014334862385321102
I0
I1
I-1
tp1273
sS'in,this'
p1274
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp1275
sS'study,has'
p1276
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1277
sS'comparison,to'
p1278
(F1
F0.00014334862385321102
I1
I0
I1
tp1279
sS'tablets,reduces'
p1280
(F1
F0.00014334862385321102
I1
I0
I1
tp1281
sS'to,difluoroacetone'
p1282
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1283
sS'were,generated'
p1284
(F1
F0.00014334862385321102
I0
I1
I-1
tp1285
sS'has,no'
p1286
(F0.8571428571428571
F0.0017201834862385322
I1
I13
I-12
tp1287
sS'however,patients'
p1288
(F0
F0
I2
I2
I0
tp1289
sS'underlie,its'
p1290
(F1
F0.00014334862385321102
I0
I1
I-1
tp1291
sS'peroxidation,which'
p1292
(F1
F0.00014334862385321102
I1
I0
I1
tp1293
sS'proven,efficacy'
p1294
(F1
F0.00014334862385321102
I0
I1
I-1
tp1295
sS'gastrointestinal,events'
p1296
(F1
F0.00014334862385321102
I0
I1
I-1
tp1297
sS'hmg-coa,reductase'
p1298
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp1299
sS'neostgmine,can'
p1300
(F1
F0.00014334862385321102
I0
I1
I-1
tp1301
sS'capsule,within'
p1302
(F1
F0.00014334862385321102
I1
I0
I1
tp1303
sS'other,highly'
p1304
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1305
sS'step,in'
p1306
(F1
F0.00028669724770642203
I0
I2
I-2
tp1307
sS'on,valproic'
p1308
(F1
F0.00014334862385321102
I1
I0
I1
tp1309
sS'not,likely'
p1310
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1311
sS'acid,monoamine'
p1312
(F1
F0.00014334862385321102
I1
I0
I1
tp1313
sS'meth,has'
p1314
(F1
F0.00014334862385321102
I0
I1
I-1
tp1315
sS'change,to'
p1316
(F1
F0.00014334862385321102
I1
I0
I1
tp1317
sS'pharmacodynamic,interactions'
p1318
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp1319
sS'with,erectile'
p1320
(F1
F0.00014334862385321102
I0
I1
I-1
tp1321
sS'subjects,had'
p1322
(F1
F0.00014334862385321102
I0
I1
I-1
tp1323
sS'beta-blockers,in'
p1324
(F1
F0.00014334862385321102
I0
I1
I-1
tp1325
sS'acid,binding'
p1326
(F1
F0.00043004587155963305
I3
I0
I3
tp1327
sS'dosages,or'
p1328
(F1
F0.00014334862385321102
I1
I0
I1
tp1329
sS'previously,received'
p1330
(F1
F0.00028669724770642203
I2
I0
I2
tp1331
sS'ingestion,of'
p1332
(F1
F0.00057339449541284407
I4
I0
I4
tp1333
sS'and,subsequently'
p1334
(F1
F0.00014334862385321102
I1
I0
I1
tp1335
sS'system,mainly'
p1336
(F1
F0.00014334862385321102
I1
I0
I1
tp1337
sS'dosages,of'
p1338
(F1
F0.00014334862385321102
I0
I1
I-1
tp1339
sS'been,attributed'
p1340
(F1
F0.00014334862385321102
I1
I0
I1
tp1341
sS'long,and'
p1342
(F1
F0.00014334862385321102
I0
I1
I-1
tp1343
sS'on,long-term'
p1344
(F1
F0.00014334862385321102
I1
I0
I1
tp1345
sS'flupenthixol,and'
p1346
(F1
F0.00014334862385321102
I1
I0
I1
tp1347
sS'preliminary,clinical'
p1348
(F1
F0.00014334862385321102
I1
I0
I1
tp1349
sS'antagonism,in'
p1350
(F1
F0.00014334862385321102
I1
I0
I1
tp1351
sS'aerosol,of'
p1352
(F1
F0.00014334862385321102
I0
I1
I-1
tp1353
sS'doses,have'
p1354
(F1
F0.00014334862385321102
I0
I1
I-1
tp1355
sS'nerally,classified'
p1356
(F1
F0.00014334862385321102
I0
I1
I-1
tp1357
sS'slow-release,mg'
p1358
(F1
F0.00014334862385321102
I0
I1
I-1
tp1359
sS'cortisone-like,medicine'
p1360
(F1
F0.00014334862385321102
I1
I0
I1
tp1361
sS'with,pcp'
p1362
(F1
F0.00014334862385321102
I0
I1
I-1
tp1363
sS'few,patients'
p1364
(F1
F0.00028669724770642203
I2
I0
I2
tp1365
sS'the,basis'
p1366
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp1367
sS'b12,diagnostic'
p1368
(F1
F0.00014334862385321102
I0
I1
I-1
tp1369
sS'and,when'
p1370
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp1371
sS'electrophysiologic,interactions'
p1372
(F1
F0.00014334862385321102
I0
I1
I-1
tp1373
sS'fluothane,as'
p1374
(F1
F0.00014334862385321102
I1
I0
I1
tp1375
sS'day,ig'
p1376
(F1
F0.00014334862385321102
I1
I0
I1
tp1377
sS'dogs,unchanged'
p1378
(F1
F0.00014334862385321102
I0
I1
I-1
tp1379
sS'decreases,clearance'
p1380
(F1
F0.00028669724770642203
I2
I0
I2
tp1381
sS'relevant,elevation'
p1382
(F1
F0.00014334862385321102
I1
I0
I1
tp1383
sS'day,in'
p1384
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp1385
sS'its,toxicity'
p1386
(F1
F0.00014334862385321102
I1
I0
I1
tp1387
sS'iii,decreased'
p1388
(F1
F0.00014334862385321102
I0
I1
I-1
tp1389
sS'day,is'
p1390
(F1
F0.00014334862385321102
I0
I1
I-1
tp1391
sS'system,inhibitors'
p1392
(F1
F0.00014334862385321102
I0
I1
I-1
tp1393
sS'medication,must'
p1394
(F1
F0.00014334862385321102
I1
I0
I1
tp1395
sS'enhance,the'
p1396
(F0.83999999999999997
F0.0060206422018348627
I46
I4
I42
tp1397
sS'd,inhibited'
p1398
(F1
F0.00014334862385321102
I1
I0
I1
tp1399
sS'not,after'
p1400
(F1
F0.00014334862385321102
I1
I0
I1
tp1401
sS'active,s-isomer'
p1402
(F1
F0.00014334862385321102
I0
I1
I-1
tp1403
sS'with,cefamandole'
p1404
(F1
F0.00014334862385321102
I0
I1
I-1
tp1405
sS'concentrations,at'
p1406
(F1
F0.00014334862385321102
I0
I1
I-1
tp1407
sS'inhibitors,as'
p1408
(F0
F0
I1
I1
I0
tp1409
sS'n,pretreatment'
p1410
(F1
F0.00014334862385321102
I1
I0
I1
tp1411
sS'from,twitch'
p1412
(F1
F0.00014334862385321102
I1
I0
I1
tp1413
sS'bezalip,retard'
p1414
(F1
F0.00043004587155963305
I3
I0
I3
tp1415
sS'population,pharmacokinetic'
p1416
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp1417
sS'equetrotm,due'
p1418
(F1
F0.00014334862385321102
I1
I0
I1
tp1419
sS'are,the'
p1420
(F1
F0.00057339449541284407
I4
I0
I4
tp1421
sS'also,increase'
p1422
(F1
F0.00028669724770642203
I0
I2
I-2
tp1423
sS'mm,and'
p1424
(F1
F0.00014334862385321102
I0
I1
I-1
tp1425
sS'phenothiazines,tindal'
p1426
(F1
F0.00014334862385321102
I0
I1
I-1
tp1427
sS'variable,effects'
p1428
(F1
F0.00014334862385321102
I1
I0
I1
tp1429
sS'tdm,of'
p1430
(F1
F0.00014334862385321102
I0
I1
I-1
tp1431
sS'vioxx,is'
p1432
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1433
sS'clearance,leading'
p1434
(F1
F0.00028669724770642203
I0
I2
I-2
tp1435
sS'liquid,impinger'
p1436
(F1
F0.00014334862385321102
I0
I1
I-1
tp1437
sS'whenever,an'
p1438
(F1
F0.00014334862385321102
I0
I1
I-1
tp1439
sS'tablet,formulation'
p1440
(F1
F0.00043004587155963305
I3
I0
I3
tp1441
sS'injection,use'
p1442
(F1
F0.00014334862385321102
I0
I1
I-1
tp1443
sS'genes,iegs'
p1444
(F1
F0.00014334862385321102
I0
I1
I-1
tp1445
sS'and,resulting'
p1446
(F1
F0.00014334862385321102
I1
I0
I1
tp1447
sS'of,progestin-only'
p1448
(F0
F0
I1
I1
I0
tp1449
sS'injection,usp'
p1450
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp1451
sS'allergy,cold'
p1452
(F1
F0.00014334862385321102
I1
I0
I1
tp1453
sS'pediatric,use'
p1454
(F1
F0.00014334862385321102
I0
I1
I-1
tp1455
sS'chick,embryos'
p1456
(F1
F0.00014334862385321102
I1
I0
I1
tp1457
sS'of,hypoglycemia'
p1458
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1459
sS'of,hypoglycemic'
p1460
(F1
F0.00028669724770642203
I2
I0
I2
tp1461
sS'comedication,particularly'
p1462
(F1
F0.00014334862385321102
I1
I0
I1
tp1463
sS'of,desethylzaleplon'
p1464
(F1
F0.00014334862385321102
I0
I1
I-1
tp1465
sS'producing,medications'
p1466
(F1
F0.00014334862385321102
I0
I1
I-1
tp1467
sS'fortovase,may'
p1468
(F1
F0.00014334862385321102
I0
I1
I-1
tp1469
sS'with,renal'
p1470
(F1
F0.00057339449541284407
I4
I0
I4
tp1471
sS'achieve,mac'
p1472
(F1
F0.00014334862385321102
I1
I0
I1
tp1473
sS'reduced,and'
p1474
(F0
F0
I1
I1
I0
tp1475
sS'observe,the'
p1476
(F1
F0.00014334862385321102
I0
I1
I-1
tp1477
sS'warrant,alteration'
p1478
(F1
F0.00014334862385321102
I0
I1
I-1
tp1479
sS'extent,auc'
p1480
(F1
F0.00014334862385321102
I1
I0
I1
tp1481
sS'days,results'
p1482
(F1
F0.00014334862385321102
I1
I0
I1
tp1483
sS'the,sympathetic'
p1484
(F1
F0.00014334862385321102
I0
I1
I-1
tp1485
sS'nsaids,without'
p1486
(F1
F0.00014334862385321102
I0
I1
I-1
tp1487
sS'intracellular,exposure'
p1488
(F1
F0.00014334862385321102
I1
I0
I1
tp1489
sS'may,experience'
p1490
(F0.5
F0.00028669724770642203
I3
I1
I2
tp1491
sS'oral,product'
p1492
(F1
F0.00014334862385321102
I0
I1
I-1
tp1493
sS'meal,as'
p1494
(F1
F0.00014334862385321102
I1
I0
I1
tp1495
sS'very,weak'
p1496
(F1
F0.00014334862385321102
I1
I0
I1
tp1497
sS'three-,to'
p1498
(F1
F0.00014334862385321102
I0
I1
I-1
tp1499
sS'amphotericin,b'
p1500
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp1501
sS'amoxicillin,an'
p1502
(F1
F0.00014334862385321102
I1
I0
I1
tp1503
sS'fentanyl,is'
p1504
(F1
F0.00014334862385321102
I0
I1
I-1
tp1505
sS'mind,that'
p1506
(F1
F0.00014334862385321102
I1
I0
I1
tp1507
sS'produce,a'
p1508
(F0.5
F0.00028669724770642203
I3
I1
I2
tp1509
sS'with,nephrotoxic'
p1510
(F1
F0.00014334862385321102
I1
I0
I1
tp1511
sS'indinavir,and'
p1512
(F1
F0.00014334862385321102
I1
I0
I1
tp1513
sS'no,systematic'
p1514
(F1
F0.00014334862385321102
I0
I1
I-1
tp1515
sS'lethality,in'
p1516
(F1
F0.00014334862385321102
I0
I1
I-1
tp1517
sS'fr,schedule'
p1518
(F1
F0.00014334862385321102
I0
I1
I-1
tp1519
sS'systems,inhibition'
p1520
(F1
F0.00014334862385321102
I0
I1
I-1
tp1521
sS'oral,live'
p1522
(F1
F0.00014334862385321102
I1
I0
I1
tp1523
sS'concomitantly,should'
p1524
(F1
F0.00014334862385321102
I1
I0
I1
tp1525
sS'decreased,by'
p1526
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp1527
sS'interaction,were'
p1528
(F1
F0.00014334862385321102
I0
I1
I-1
tp1529
sS'substrate,given'
p1530
(F1
F0.00014334862385321102
I0
I1
I-1
tp1531
sS'of,nonsteroial'
p1532
(F1
F0.00014334862385321102
I1
I0
I1
tp1533
sS'not,demonstrate'
p1534
(F1
F0.00028669724770642203
I0
I2
I-2
tp1535
sS'significant,impact'
p1536
(F1
F0.00014334862385321102
I1
I0
I1
tp1537
sS'sudden,increase'
p1538
(F1
F0.00014334862385321102
I1
I0
I1
tp1539
sS'chop,chemotherapy'
p1540
(F1
F0.00014334862385321102
I0
I1
I-1
tp1541
sS'myocardial,infarction'
p1542
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1543
sS'volunteers,who'
p1544
(F0
F0
I1
I1
I0
tp1545
sS'note,dissolution'
p1546
(F1
F0.00014334862385321102
I0
I1
I-1
tp1547
sS'm,markedly'
p1548
(F1
F0.00014334862385321102
I1
I0
I1
tp1549
sS'dependence,on'
p1550
(F1
F0.00014334862385321102
I0
I1
I-1
tp1551
sS'when,you'
p1552
(F1
F0.00014334862385321102
I1
I0
I1
tp1553
sS'the,immune'
p1554
(F1
F0.00014334862385321102
I0
I1
I-1
tp1555
sS'similar,changes'
p1556
(F1
F0.00014334862385321102
I0
I1
I-1
tp1557
sS'any,hypokalemic'
p1558
(F1
F0.00014334862385321102
I1
I0
I1
tp1559
sS'maleate,or'
p1560
(F1
F0.00014334862385321102
I1
I0
I1
tp1561
sS'in,angina'
p1562
(F1
F0.00014334862385321102
I0
I1
I-1
tp1563
sS'digoxin,did'
p1564
(F1
F0.00014334862385321102
I0
I1
I-1
tp1565
sS'antipsychotic,agent'
p1566
(F1
F0.00014334862385321102
I0
I1
I-1
tp1567
sS'muscle,cell'
p1568
(F1
F0.00014334862385321102
I0
I1
I-1
tp1569
sS'profile,prothrombin'
p1570
(F1
F0.00014334862385321102
I0
I1
I-1
tp1571
sS'oxytocic,may'
p1572
(F0
F0
I2
I2
I0
tp1573
sS'have,received'
p1574
(F1
F0.00028669724770642203
I2
I0
I2
tp1575
sS'virologic,response'
p1576
(F1
F0.00028669724770642203
I0
I2
I-2
tp1577
sS'of,plendil'
p1578
(F1
F0.00014334862385321102
I0
I1
I-1
tp1579
sS'of,agents'
p1580
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp1581
sS'warfarin,anticoagulant'
p1582
(F1
F0.00014334862385321102
I1
I0
I1
tp1583
sS'of,individual'
p1584
(F1
F0.00014334862385321102
I0
I1
I-1
tp1585
sS'function,accompanied'
p1586
(F1
F0.00014334862385321102
I1
I0
I1
tp1587
sS'over,in'
p1588
(F1
F0.00014334862385321102
I0
I1
I-1
tp1589
sS'mothers,it'
p1590
(F1
F0.00014334862385321102
I0
I1
I-1
tp1591
sS'to,concurrent'
p1592
(F1
F0.00014334862385321102
I1
I0
I1
tp1593
sS'and,active'
p1594
(F1
F0.00028669724770642203
I2
I0
I2
tp1595
sS'azithromycin,had'
p1596
(F0
F0
I1
I1
I0
tp1597
sS'psychostimulant,effects'
p1598
(F1
F0.00014334862385321102
I0
I1
I-1
tp1599
sS'a,positive'
p1600
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1601
sS'increased,responsiveness'
p1602
(F1
F0.00028669724770642203
I0
I2
I-2
tp1603
sS'pcp,produced'
p1604
(F1
F0.00028669724770642203
I0
I2
I-2
tp1605
sS'against,two'
p1606
(F1
F0.00014334862385321102
I0
I1
I-1
tp1607
sS'cardiac,conduction'
p1608
(F1
F0.00014334862385321102
I1
I0
I1
tp1609
sS'users,develop'
p1610
(F1
F0.00014334862385321102
I0
I1
I-1
tp1611
sS'pcp,produces'
p1612
(F1
F0.00014334862385321102
I0
I1
I-1
tp1613
sS'relevant,effects'
p1614
(F1
F0.00014334862385321102
I0
I1
I-1
tp1615
sS'with,formulations'
p1616
(F1
F0.00014334862385321102
I1
I0
I1
tp1617
sS'additional,including'
p1618
(F1
F0.00014334862385321102
I1
I0
I1
tp1619
sS'sedatives,hypnotics'
p1620
(F0
F0
I1
I1
I0
tp1621
sS'this,sample'
p1622
(F1
F0.00014334862385321102
I0
I1
I-1
tp1623
sS'of,succinylcholine-induced'
p1624
(F1
F0.00014334862385321102
I0
I1
I-1
tp1625
sS'patient,being'
p1626
(F1
F0.00014334862385321102
I1
I0
I1
tp1627
sS'the,large'
p1628
(F1
F0.00014334862385321102
I0
I1
I-1
tp1629
sS'subjects,to'
p1630
(F1
F0.00043004587155963305
I0
I3
I-3
tp1631
sS'from,given'
p1632
(F1
F0.00014334862385321102
I1
I0
I1
tp1633
sS'd6,and'
p1634
(F1
F0.00028669724770642203
I0
I2
I-2
tp1635
sS'during,both'
p1636
(F1
F0.00014334862385321102
I0
I1
I-1
tp1637
sS'be,coadministered'
p1638
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1639
sS'normalizing,the'
p1640
(F1
F0.00014334862385321102
I0
I1
I-1
tp1641
sS'can,produce'
p1642
(F1
F0.00028669724770642203
I2
I0
I2
tp1643
sS'nonsteroidal,that'
p1644
(F1
F0.00014334862385321102
I1
I0
I1
tp1645
sS'intravenous,mg'
p1646
(F1
F0.00043004587155963305
I0
I3
I-3
tp1647
sS'the,smallest'
p1648
(F1
F0.00014334862385321102
I0
I1
I-1
tp1649
sS'or,substances'
p1650
(F1
F0.00014334862385321102
I1
I0
I1
tp1651
sS'renal,clearance'
p1652
(F0.66666666666666663
F0.0017201834862385322
I15
I3
I12
tp1653
sS'by,to'
p1654
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1655
sS'antifungal,agents'
p1656
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1657
sS'within,weeks'
p1658
(F1
F0.00014334862385321102
I1
I0
I1
tp1659
sS'amevive,on'
p1660
(F1
F0.00014334862385321102
I0
I1
I-1
tp1661
sS'terfenadine,in'
p1662
(F1
F0.00014334862385321102
I0
I1
I-1
tp1663
sS'of,supplementary'
p1664
(F1
F0.00014334862385321102
I0
I1
I-1
tp1665
sS'have,either'
p1666
(F1
F0.00014334862385321102
I0
I1
I-1
tp1667
sS'mc,has'
p1668
(F1
F0.00028669724770642203
I0
I2
I-2
tp1669
sS'potassium-sparing,diuretics'
p1670
(F1
F0.00028669724770642203
I2
I0
I2
tp1671
sS'and,progestogen'
p1672
(F1
F0.00014334862385321102
I0
I1
I-1
tp1673
sS'ulceration,and'
p1674
(F1
F0.00028669724770642203
I2
I0
I2
tp1675
sS'concurrently,subjects'
p1676
(F1
F0.00057339449541284407
I4
I0
I4
tp1677
sS'nimbex,is'
p1678
(F0
F0
I1
I1
I0
tp1679
sS'either,or'
p1680
(F0.33333333333333331
F0.00057339449541284407
I4
I8
I-4
tp1681
sS'v,did'
p1682
(F1
F0.00014334862385321102
I0
I1
I-1
tp1683
sS'nimbex,in'
p1684
(F1
F0.00014334862385321102
I1
I0
I1
tp1685
sS'corticosteroids,dexamethasone'
p1686
(F1
F0.00014334862385321102
I1
I0
I1
tp1687
sS'aeds,do'
p1688
(F1
F0.00014334862385321102
I0
I1
I-1
tp1689
sS'of,hydroxylated'
p1690
(F1
F0.00014334862385321102
I1
I0
I1
tp1691
sS'locomotion,and'
p1692
(F1
F0.00014334862385321102
I0
I1
I-1
tp1693
sS'arterial,pressure'
p1694
(F1
F0.00014334862385321102
I1
I0
I1
tp1695
sS'develop,a'
p1696
(F1
F0.00014334862385321102
I1
I0
I1
tp1697
sS'valproate,keppra'
p1698
(F1
F0.00014334862385321102
I0
I1
I-1
tp1699
sS'system,depression'
p1700
(F1
F0.00014334862385321102
I1
I0
I1
tp1701
sS'not,primarily'
p1702
(F1
F0.00014334862385321102
I1
I0
I1
tp1703
sS'vioxx,may'
p1704
(F1
F0.00014334862385321102
I1
I0
I1
tp1705
sS'lowers,serum'
p1706
(F1
F0.00014334862385321102
I0
I1
I-1
tp1707
sS'axert,within'
p1708
(F1
F0.00014334862385321102
I1
I0
I1
tp1709
sS'regimen,includes'
p1710
(F1
F0.00014334862385321102
I1
I0
I1
tp1711
sS'post,marketing'
p1712
(F1
F0.00014334862385321102
I1
I0
I1
tp1713
sS'based,regimens'
p1714
(F1
F0.00014334862385321102
I0
I1
I-1
tp1715
sS'cardiac,transplant'
p1716
(F1
F0.00014334862385321102
I1
I0
I1
tp1717
sS'two,combined'
p1718
(F1
F0.00014334862385321102
I0
I1
I-1
tp1719
sS'valproate,a'
p1720
(F1
F0.00014334862385321102
I1
I0
I1
tp1721
sS'peganone,is'
p1722
(F1
F0.00014334862385321102
I1
I0
I1
tp1723
sS'are,unlikely'
p1724
(F1
F0.00014334862385321102
I0
I1
I-1
tp1725
sS'p,although'
p1726
(F1
F0.00014334862385321102
I0
I1
I-1
tp1727
sS'seven,experiments'
p1728
(F1
F0.00014334862385321102
I0
I1
I-1
tp1729
sS'difference,between'
p1730
(F1
F0.00028669724770642203
I0
I2
I-2
tp1731
sS'conjunction,with'
p1732
(F0
F0
I5
I5
I0
tp1733
sS'peripheral,anitagonism'
p1734
(F1
F0.00014334862385321102
I1
I0
I1
tp1735
sS'of,endogenous'
p1736
(F1
F0.00028669724770642203
I2
I0
I2
tp1737
sS'mmol,day'
p1738
(F1
F0.00014334862385321102
I0
I1
I-1
tp1739
sS'of,clonazepam'
p1740
(F1
F0.00028669724770642203
I0
I2
I-2
tp1741
sS'didanosine,it'
p1742
(F1
F0.00014334862385321102
I0
I1
I-1
tp1743
sS'approach,in'
p1744
(F1
F0.00014334862385321102
I0
I1
I-1
tp1745
sS'treat,a'
p1746
(F1
F0.00014334862385321102
I0
I1
I-1
tp1747
sS'of,however'
p1748
(F1
F0.00014334862385321102
I1
I0
I1
tp1749
sS'triiodothyronine,levels'
p1750
(F1
F0.00014334862385321102
I0
I1
I-1
tp1751
sS'potential,of'
p1752
(F1
F0.0008600917431192661
I6
I0
I6
tp1753
sS'or,cns'
p1754
(F0
F0
I1
I1
I0
tp1755
sS'low,to'
p1756
(F1
F0.00014334862385321102
I0
I1
I-1
tp1757
sS'of,cerubidine'
p1758
(F1
F0.00014334862385321102
I1
I0
I1
tp1759
sS'in,ontario'
p1760
(F1
F0.00014334862385321102
I0
I1
I-1
tp1761
sS'with,hemodynamic'
p1762
(F1
F0.00014334862385321102
I1
I0
I1
tp1763
sS'nodal,conduction'
p1764
(F1
F0.00028669724770642203
I2
I0
I2
tp1765
sS'declining,to'
p1766
(F1
F0.00014334862385321102
I0
I1
I-1
tp1767
sS'therapy,had'
p1768
(F1
F0.00014334862385321102
I0
I1
I-1
tp1769
sS'propranolol,attenuated'
p1770
(F1
F0.00014334862385321102
I1
I0
I1
tp1771
sS'certain,antagonists'
p1772
(F1
F0.00014334862385321102
I1
I0
I1
tp1773
sS'ritonavir,significantly'
p1774
(F1
F0.00014334862385321102
I1
I0
I1
tp1775
sS'decrease,thyroidal'
p1776
(F1
F0.00014334862385321102
I1
I0
I1
tp1777
sS'to,oral'
p1778
(F1
F0.00014334862385321102
I0
I1
I-1
tp1779
sS'flavoridin,alone'
p1780
(F1
F0.00014334862385321102
I1
I0
I1
tp1781
sS'colestipol-concomitant,intake'
p1782
(F1
F0.00014334862385321102
I1
I0
I1
tp1783
sS'use,resulted'
p1784
(F1
F0.00014334862385321102
I0
I1
I-1
tp1785
sS'augment,the'
p1786
(F1
F0.00057339449541284407
I4
I0
I4
tp1787
sS'i131,a'
p1788
(F1
F0.00014334862385321102
I1
I0
I1
tp1789
sS'the,same'
p1790
(F0.375
F0.0008600917431192661
I5
I11
I-6
tp1791
sS'others,orudis'
p1792
(F1
F0.00014334862385321102
I0
I1
I-1
tp1793
sS'fluothane,augments'
p1794
(F1
F0.00014334862385321102
I1
I0
I1
tp1795
sS'regimen,containing'
p1796
(F1
F0.00014334862385321102
I0
I1
I-1
tp1797
sS'metabolism,and'
p1798
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp1799
sS'fa,were'
p1800
(F1
F0.00014334862385321102
I0
I1
I-1
tp1801
sS'maintenance,bolus'
p1802
(F1
F0.00014334862385321102
I0
I1
I-1
tp1803
sS'barbiturates,or'
p1804
(F1
F0.00014334862385321102
I1
I0
I1
tp1805
sS'while,under'
p1806
(F1
F0.00014334862385321102
I1
I0
I1
tp1807
sS'epinephrine,should'
p1808
(F1
F0.00014334862385321102
I1
I0
I1
tp1809
sS'anticholinesterases,concomitant'
p1810
(F1
F0.00014334862385321102
I1
I0
I1
tp1811
sS'clearance,ml'
p1812
(F1
F0.00014334862385321102
I0
I1
I-1
tp1813
sS'morphine-induced,tail-flick'
p1814
(F1
F0.00014334862385321102
I0
I1
I-1
tp1815
sS'probenecid,or'
p1816
(F1
F0.00014334862385321102
I1
I0
I1
tp1817
sS'experiencing,breakthrough'
p1818
(F1
F0.00014334862385321102
I0
I1
I-1
tp1819
sS'costs,despite'
p1820
(F1
F0.00014334862385321102
I0
I1
I-1
tp1821
sS'may,wear'
p1822
(F1
F0.00014334862385321102
I0
I1
I-1
tp1823
sS'p-glycoprotein,in'
p1824
(F1
F0.00014334862385321102
I1
I0
I1
tp1825
sS'a,sensitive'
p1826
(F1
F0.00014334862385321102
I1
I0
I1
tp1827
sS'interactions,amphetamines'
p1828
(F1
F0.00014334862385321102
I1
I0
I1
tp1829
sS'that,lodine'
p1830
(F1
F0.00014334862385321102
I1
I0
I1
tp1831
sS'and,thus'
p1832
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp1833
sS'monitored,frequently'
p1834
(F1
F0.00043004587155963305
I3
I0
I3
tp1835
sS'with,caution'
p1836
(F0.7931034482758621
F0.0032970183486238534
I26
I3
I23
tp1837
sS'on,prothrombin'
p1838
(F1
F0.00043004587155963305
I0
I3
I-3
tp1839
sS'thiazides,are'
p1840
(F1
F0.00043004587155963305
I0
I3
I-3
tp1841
sS'oxide,with'
p1842
(F1
F0.00014334862385321102
I0
I1
I-1
tp1843
sS'at,therapeutic'
p1844
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1845
sS'phase,days'
p1846
(F1
F0.00014334862385321102
I0
I1
I-1
tp1847
sS'therapy,a'
p1848
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp1849
sS'plasma,exposure'
p1850
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp1851
sS'potentiated,resulting'
p1852
(F1
F0.00014334862385321102
I1
I0
I1
tp1853
sS'and,copegus'
p1854
(F1
F0.00028669724770642203
I0
I2
I-2
tp1855
sS'the,modulation'
p1856
(F0
F0
I1
I1
I0
tp1857
sS'on,acth'
p1858
(F1
F0.00014334862385321102
I0
I1
I-1
tp1859
sS'combined,therapy'
p1860
(F1
F0.00057339449541284407
I4
I0
I4
tp1861
sS'are,begun'
p1862
(F1
F0.00014334862385321102
I1
I0
I1
tp1863
sS'a,controlled'
p1864
(F0
F0
I1
I1
I0
tp1865
sS'replaced,by'
p1866
(F1
F0.00014334862385321102
I0
I1
I-1
tp1867
sS'oral,twice'
p1868
(F1
F0.00014334862385321102
I1
I0
I1
tp1869
sS'receiving,comedication'
p1870
(F1
F0.00014334862385321102
I1
I0
I1
tp1871
sS'reports,in'
p1872
(F1
F0.00028669724770642203
I2
I0
I2
tp1873
sS'weekly,subcutaneous'
p1874
(F1
F0.00014334862385321102
I0
I1
I-1
tp1875
sS'of,include'
p1876
(F1
F0.00014334862385321102
I0
I1
I-1
tp1877
sS'creatinine,level'
p1878
(F1
F0.00014334862385321102
I1
I0
I1
tp1879
sS'of,hyperkalemia'
p1880
(F1
F0.00028669724770642203
I2
I0
I2
tp1881
sS'the,secretory'
p1882
(F1
F0.00014334862385321102
I1
I0
I1
tp1883
sS'antidepressant,single'
p1884
(F1
F0.00014334862385321102
I1
I0
I1
tp1885
sS'study,evaluated'
p1886
(F1
F0.00014334862385321102
I0
I1
I-1
tp1887
sS'inhibitors,studies'
p1888
(F1
F0.00014334862385321102
I1
I0
I1
tp1889
sS'significant,increases'
p1890
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp1891
sS'inter-patient,variation'
p1892
(F1
F0.00014334862385321102
I1
I0
I1
tp1893
sS'mefloquine,and'
p1894
(F1
F0.00014334862385321102
I1
I0
I1
tp1895
sS'antiepileptic,and'
p1896
(F1
F0.00014334862385321102
I1
I0
I1
tp1897
sS'with,chirocaine'
p1898
(F1
F0.00014334862385321102
I0
I1
I-1
tp1899
sS'aprepitant,increased'
p1900
(F1
F0.00028669724770642203
I2
I0
I2
tp1901
sS'agents,eg'
p1902
(F1
F0.00014334862385321102
I1
I0
I1
tp1903
sS'cns-depressant,effects'
p1904
(F1
F0.00014334862385321102
I1
I0
I1
tp1905
sS'cancidas,is'
p1906
(F1
F0.00014334862385321102
I1
I0
I1
tp1907
sS'ability,to'
p1908
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1909
sS'case,report'
p1910
(F1
F0.00028669724770642203
I2
I0
I2
tp1911
sS'values,for'
p1912
(F0
F0
I3
I3
I0
tp1913
sS'doses,above'
p1914
(F1
F0.00014334862385321102
I1
I0
I1
tp1915
sS'macrolide,or'
p1916
(F1
F0.00014334862385321102
I0
I1
I-1
tp1917
sS'pigeons,and'
p1918
(F1
F0.00014334862385321102
I0
I1
I-1
tp1919
sS'when,these'
p1920
(F0.16666666666666666
F0.00028669724770642203
I5
I7
I-2
tp1921
sS'either,was'
p1922
(F0
F0
I2
I2
I0
tp1923
sS'lithium,diclofenac'
p1924
(F1
F0.00014334862385321102
I1
I0
I1
tp1925
sS'dextromethorphan,dextromethorphan'
p1926
(F1
F0.00014334862385321102
I0
I1
I-1
tp1927
sS'effects,on'
p1928
(F0.35714285714285715
F0.0014334862385321102
I9
I19
I-10
tp1929
sS'together,as'
p1930
(F1
F0.00014334862385321102
I0
I1
I-1
tp1931
sS'with,produces'
p1932
(F1
F0.00014334862385321102
I1
I0
I1
tp1933
sS'effects,of'
p1934
(F0.1791907514450867
F0.0044438073394495415
I102
I71
I31
tp1935
sS'omeprazole,no'
p1936
(F1
F0.00014334862385321102
I0
I1
I-1
tp1937
sS'filtrated,to'
p1938
(F1
F0.00014334862385321102
I1
I0
I1
tp1939
sS'with,produced'
p1940
(F1
F0.00014334862385321102
I0
I1
I-1
tp1941
sS'effects,or'
p1942
(F1
F0.00014334862385321102
I0
I1
I-1
tp1943
sS'important,interaction'
p1944
(F1
F0.00014334862385321102
I0
I1
I-1
tp1945
sS'of,norpace'
p1946
(F1
F0.00014334862385321102
I1
I0
I1
tp1947
sS'red-orange,which'
p1948
(F1
F0.00014334862385321102
I0
I1
I-1
tp1949
sS'therapy,patients'
p1950
(F1
F0.00043004587155963305
I3
I0
I3
tp1951
sS'the,ld50'
p1952
(F1
F0.00014334862385321102
I1
I0
I1
tp1953
sS'during,can'
p1954
(F1
F0.00014334862385321102
I1
I0
I1
tp1955
sS'that,nonabsorbable'
p1956
(F1
F0.00014334862385321102
I1
I0
I1
tp1957
sS'with,alfenta'
p1958
(F1
F0.00014334862385321102
I1
I0
I1
tp1959
sS'whose,hypertension'
p1960
(F1
F0.00014334862385321102
I1
I0
I1
tp1961
sS'least,four'
p1962
(F1
F0.00014334862385321102
I0
I1
I-1
tp1963
sS'cimetidines,known'
p1964
(F1
F0.00014334862385321102
I1
I0
I1
tp1965
sS'taking,lexapro'
p1966
(F1
F0.00014334862385321102
I1
I0
I1
tp1967
sS'k,aquamephyton'
p1968
(F1
F0.00014334862385321102
I0
I1
I-1
tp1969
sS'which,concomitant'
p1970
(F1
F0.00014334862385321102
I1
I0
I1
tp1971
sS'receiving,velcade'
p1972
(F1
F0.00014334862385321102
I1
I0
I1
tp1973
sS'by,general'
p1974
(F1
F0.00014334862385321102
I0
I1
I-1
tp1975
sS'acute,renal'
p1976
(F1
F0.00014334862385321102
I1
I0
I1
tp1977
sS'activase,may'
p1978
(F1
F0.00014334862385321102
I0
I1
I-1
tp1979
sS'clozapine,may'
p1980
(F1
F0.00014334862385321102
I1
I0
I1
tp1981
sS'alcohol,alcohol'
p1982
(F1
F0.00014334862385321102
I0
I1
I-1
tp1983
sS'severe,structural'
p1984
(F1
F0.00014334862385321102
I0
I1
I-1
tp1985
sS'term,therapy'
p1986
(F1
F0.00014334862385321102
I1
I0
I1
tp1987
sS'mm,hg'
p1988
(F1
F0.00028669724770642203
I2
I0
I2
tp1989
sS'cime-tidine,therapy'
p1990
(F1
F0.00014334862385321102
I1
I0
I1
tp1991
sS'bextra,concomitantly'
p1992
(F1
F0.00014334862385321102
I1
I0
I1
tp1993
sS'receive,low-molecular'
p1994
(F1
F0.00014334862385321102
I0
I1
I-1
tp1995
sS'on,such'
p1996
(F1
F0.00014334862385321102
I1
I0
I1
tp1997
sS'with,administered'
p1998
(F1
F0.00014334862385321102
I1
I0
I1
tp1999
sS'mg,five'
p2000
(F1
F0.00014334862385321102
I0
I1
I-1
tp2001
sS'were,identified'
p2002
(F0
F0
I1
I1
I0
tp2003
sS'albendazole,sulfoxide'
p2004
(F1
F0.00014334862385321102
I1
I0
I1
tp2005
sS'synergism,was'
p2006
(F1
F0.00014334862385321102
I1
I0
I1
tp2007
sS'weight,loss'
p2008
(F1
F0.00014334862385321102
I1
I0
I1
tp2009
sS'trilafon,compazine'
p2010
(F1
F0.00014334862385321102
I0
I1
I-1
tp2011
sS'significant,interaction'
p2012
(F0
F0
I1
I1
I0
tp2013
sS'dsst,symbol'
p2014
(F1
F0.00014334862385321102
I1
I0
I1
tp2015
sS'and,area-under'
p2016
(F1
F0.00014334862385321102
I1
I0
I1
tp2017
sS'agents,affecting'
p2018
(F1
F0.00043004587155963305
I0
I3
I-3
tp2019
sS'and,monoamine'
p2020
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp2021
sS'alprazolam,when'
p2022
(F1
F0.00014334862385321102
I1
I0
I1
tp2023
sS'been,conducted'
p2024
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp2025
sS'agents,zyvox'
p2026
(F1
F0.00014334862385321102
I1
I0
I1
tp2027
sS'decreased,an'
p2028
(F1
F0.00028669724770642203
I2
I0
I2
tp2029
sS'high-estradiol,rats'
p2030
(F1
F0.00014334862385321102
I1
I0
I1
tp2031
sS'substudy,in'
p2032
(F1
F0.00014334862385321102
I1
I0
I1
tp2033
sS'be,reviewed'
p2034
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2035
sS'less,pronounced'
p2036
(F1
F0.00014334862385321102
I1
I0
I1
tp2037
sS'markedly,inhibit'
p2038
(F0.5
F0.00028669724770642203
I3
I1
I2
tp2039
sS'using,higher'
p2040
(F1
F0.00014334862385321102
I1
I0
I1
tp2041
sS'cyp2d6,cyp2c9'
p2042
(F1
F0.00014334862385321102
I0
I1
I-1
tp2043
sS'administering,with'
p2044
(F1
F0.00014334862385321102
I1
I0
I1
tp2045
sS'substances,the'
p2046
(F1
F0.00014334862385321102
I1
I0
I1
tp2047
sS'or,orthostatic'
p2048
(F1
F0.00014334862385321102
I1
I0
I1
tp2049
sS'medications,that'
p2050
(F0.5
F0.00028669724770642203
I3
I1
I2
tp2051
sS'cimetidine,treatment'
p2052
(F1
F0.00014334862385321102
I1
I0
I1
tp2053
sS'anti,platelet'
p2054
(F1
F0.00014334862385321102
I0
I1
I-1
tp2055
sS'one-third,as'
p2056
(F1
F0.00014334862385321102
I1
I0
I1
tp2057
sS'of,atropinization'
p2058
(F1
F0.00014334862385321102
I1
I0
I1
tp2059
sS'experience,to'
p2060
(F1
F0.00014334862385321102
I1
I0
I1
tp2061
sS'through,inhibition'
p2062
(F1
F0.00014334862385321102
I1
I0
I1
tp2063
sS'but,that'
p2064
(F1
F0.00014334862385321102
I0
I1
I-1
tp2065
sS'in,plasma'
p2066
(F0.76470588235294112
F0.0037270642201834864
I30
I4
I26
tp2067
sS'in,nonfailing'
p2068
(F1
F0.00014334862385321102
I1
I0
I1
tp2069
sS'as,methyltetrahydro-folate'
p2070
(F1
F0.00014334862385321102
I0
I1
I-1
tp2071
sS'of,oxypurines'
p2072
(F0
F0
I1
I1
I0
tp2073
sS'p-450,isoenzymes'
p2074
(F1
F0.00014334862385321102
I1
I0
I1
tp2075
sS'systemic,are'
p2076
(F1
F0.00014334862385321102
I0
I1
I-1
tp2077
sS'hypertensive,reactions'
p2078
(F1
F0.00014334862385321102
I1
I0
I1
tp2079
sS'healthy,volunteers'
p2080
(F0.081081081081081086
F0.00043004587155963305
I17
I20
I-3
tp2081
sS'a,bile'
p2082
(F1
F0.00028669724770642203
I2
I0
I2
tp2083
sS'with,fatal'
p2084
(F1
F0.00028669724770642203
I2
I0
I2
tp2085
sS'with,systemic'
p2086
(F1
F0.00014334862385321102
I0
I1
I-1
tp2087
sS'vitro,has'
p2088
(F1
F0.00014334862385321102
I1
I0
I1
tp2089
sS'analyses,of'
p2090
(F1
F0.00014334862385321102
I1
I0
I1
tp2091
sS'indicated,reduction'
p2092
(F1
F0.00014334862385321102
I1
I0
I1
tp2093
sS'with,anticoagulation'
p2094
(F1
F0.00014334862385321102
I1
I0
I1
tp2095
sS'cyp3a4,patients'
p2096
(F1
F0.00014334862385321102
I0
I1
I-1
tp2097
sS'oral,did'
p2098
(F1
F0.00014334862385321102
I0
I1
I-1
tp2099
sS'the,subjective'
p2100
(F1
F0.00028669724770642203
I0
I2
I-2
tp2101
sS'studies,also'
p2102
(F1
F0.00014334862385321102
I1
I0
I1
tp2103
sS'resulted,in'
p2104
(F0.66666666666666663
F0.008027522935779817
I70
I14
I56
tp2105
sS'a,main'
p2106
(F1
F0.00014334862385321102
I0
I1
I-1
tp2107
sS'cholestyramine-concomitant,intake'
p2108
(F1
F0.00014334862385321102
I1
I0
I1
tp2109
sS'hydroxides,and'
p2110
(F1
F0.00014334862385321102
I0
I1
I-1
tp2111
sS'agents,some'
p2112
(F1
F0.00043004587155963305
I3
I0
I3
tp2113
sS'reduces,the'
p2114
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp2115
sS'by,antihypertensive'
p2116
(F1
F0.00028669724770642203
I2
I0
I2
tp2117
sS'significantly,higher'
p2118
(F1
F0.00028669724770642203
I2
I0
I2
tp2119
sS'noted,above'
p2120
(F1
F0.00014334862385321102
I0
I1
I-1
tp2121
sS'responsiveness,of'
p2122
(F1
F0.00014334862385321102
I1
I0
I1
tp2123
sS'norpace,and'
p2124
(F1
F0.00014334862385321102
I1
I0
I1
tp2125
sS'us,a'
p2126
(F1
F0.00014334862385321102
I0
I1
I-1
tp2127
sS'including,immune'
p2128
(F1
F0.00014334862385321102
I0
I1
I-1
tp2129
sS'with,full'
p2130
(F1
F0.00014334862385321102
I0
I1
I-1
tp2131
sS'reduce,proleukin-induced'
p2132
(F1
F0.00014334862385321102
I1
I0
I1
tp2133
sS'avoided,by'
p2134
(F1
F0.00014334862385321102
I1
I0
I1
tp2135
sS'resulted,when'
p2136
(F1
F0.00014334862385321102
I1
I0
I1
tp2137
sS'as,because'
p2138
(F1
F0.00057339449541284407
I4
I0
I4
tp2139
sS'resin,or'
p2140
(F1
F0.00014334862385321102
I0
I1
I-1
tp2141
sS'rats,followed'
p2142
(F1
F0.00014334862385321102
I0
I1
I-1
tp2143
sS'and,dietary-obese'
p2144
(F1
F0.00014334862385321102
I0
I1
I-1
tp2145
sS'one-half,the'
p2146
(F1
F0.00014334862385321102
I1
I0
I1
tp2147
sS'as,are'
p2148
(F1
F0.00057339449541284407
I4
I0
I4
tp2149
sS'type,strains'
p2150
(F1
F0.00014334862385321102
I0
I1
I-1
tp2151
sS'acetazolamide,decreases'
p2152
(F1
F0.00014334862385321102
I1
I0
I1
tp2153
sS'eg,for'
p2154
(F1
F0.00014334862385321102
I1
I0
I1
tp2155
sS'daily,and'
p2156
(F0
F0
I2
I2
I0
tp2157
sS'of,additional'
p2158
(F1
F0.00043004587155963305
I0
I3
I-3
tp2159
sS'rifampicin,in'
p2160
(F1
F0.00014334862385321102
I1
I0
I1
tp2161
sS'dopamine-induced,ventricular'
p2162
(F1
F0.00014334862385321102
I1
I0
I1
tp2163
sS'mg,of'
p2164
(F0.25714285714285712
F0.0012901376146788992
I22
I13
I9
tp2165
sS'patient,who'
p2166
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2167
sS'in,volume'
p2168
(F1
F0.00014334862385321102
I1
I0
I1
tp2169
sS'mg,on'
p2170
(F0
F0
I4
I4
I0
tp2171
sS'anabolic,hormones'
p2172
(F0
F0
I1
I1
I0
tp2173
sS'mg,or'
p2174
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp2175
sS'intestinal,mucosa'
p2176
(F1
F0.00014334862385321102
I1
I0
I1
tp2177
sS'ssri-tcainteractions,may'
p2178
(F1
F0.00014334862385321102
I1
I0
I1
tp2179
sS'alter,gastrointestinal'
p2180
(F1
F0.00014334862385321102
I1
I0
I1
tp2181
sS'mean,minimum'
p2182
(F1
F0.00014334862385321102
I0
I1
I-1
tp2183
sS'similarly,in'
p2184
(F1
F0.00014334862385321102
I0
I1
I-1
tp2185
sS'but,were'
p2186
(F1
F0.00014334862385321102
I0
I1
I-1
tp2187
sS'in,situ'
p2188
(F0
F0
I1
I1
I0
tp2189
sS'study,adverse'
p2190
(F1
F0.00014334862385321102
I1
I0
I1
tp2191
sS'or,hypokalemia'
p2192
(F1
F0.00014334862385321102
I1
I0
I1
tp2193
sS'aed,induces'
p2194
(F1
F0.00014334862385321102
I0
I1
I-1
tp2195
sS'noted,even'
p2196
(F1
F0.00014334862385321102
I1
I0
I1
tp2197
sS'reported,in'
p2198
(F0.77142857142857146
F0.0038704128440366975
I31
I4
I27
tp2199
sS'key,pharmaceuticals'
p2200
(F1
F0.00014334862385321102
I1
I0
I1
tp2201
sS'cmc-cys7,from'
p2202
(F1
F0.00014334862385321102
I0
I1
I-1
tp2203
sS'parkinsons,disease'
p2204
(F0
F0
I1
I1
I0
tp2205
sS'occasional,literature'
p2206
(F1
F0.00014334862385321102
I1
I0
I1
tp2207
sS'and,ergot-type'
p2208
(F0
F0
I1
I1
I0
tp2209
sS'sodium,does'
p2210
(F1
F0.00014334862385321102
I0
I1
I-1
tp2211
sS'reactions,including'
p2212
(F1
F0.00028669724770642203
I2
I0
I2
tp2213
sS'maoi,as'
p2214
(F1
F0.00028669724770642203
I2
I0
I2
tp2215
sS'by,subsequent'
p2216
(F1
F0.00014334862385321102
I1
I0
I1
tp2217
sS'case,study'
p2218
(F1
F0.00014334862385321102
I1
I0
I1
tp2219
sS'rapidly,hydrolyzed'
p2220
(F1
F0.00014334862385321102
I0
I1
I-1
tp2221
sS'receiving,antihypertensive'
p2222
(F1
F0.00014334862385321102
I1
I0
I1
tp2223
sS'amiodarone,taken'
p2224
(F1
F0.00043004587155963305
I0
I3
I-3
tp2225
sS'is,added'
p2226
(F0.75
F0.0008600917431192661
I7
I1
I6
tp2227
sS'atorvastatin,increases'
p2228
(F1
F0.00014334862385321102
I1
I0
I1
tp2229
sS'tyrosine,phosphorylation'
p2230
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp2231
sS'ethyol,in'
p2232
(F1
F0.00014334862385321102
I1
I0
I1
tp2233
sS'and,return'
p2234
(F1
F0.00014334862385321102
I0
I1
I-1
tp2235
sS'b-induced,hypokalemia'
p2236
(F1
F0.00028669724770642203
I2
I0
I2
tp2237
sS'supplemental,folic'
p2238
(F1
F0.00014334862385321102
I0
I1
I-1
tp2239
sS'given,by'
p2240
(F1
F0.00014334862385321102
I0
I1
I-1
tp2241
sS'when,lotensin'
p2242
(F1
F0.00014334862385321102
I0
I1
I-1
tp2243
sS'cautiously,coadministered'
p2244
(F1
F0.00014334862385321102
I1
I0
I1
tp2245
sS'reactions,from'
p2246
(F1
F0.00014334862385321102
I0
I1
I-1
tp2247
sS'or,prolongation'
p2248
(F0
F0
I1
I1
I0
tp2249
sS'intravenous,pentamidine'
p2250
(F1
F0.00014334862385321102
I0
I1
I-1
tp2251
sS'administered,minutes'
p2252
(F0
F0
I1
I1
I0
tp2253
sS'although,neither'
p2254
(F1
F0.00014334862385321102
I1
I0
I1
tp2255
sS'the,first'
p2256
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp2257
sS'taking,concomitantly'
p2258
(F1
F0.00028669724770642203
I2
I0
I2
tp2259
sS'soon,after'
p2260
(F1
F0.00014334862385321102
I1
I0
I1
tp2261
sS'interactions,in'
p2262
(F1
F0.00028669724770642203
I0
I2
I-2
tp2263
sS'of,vasoconstricting'
p2264
(F1
F0.00014334862385321102
I1
I0
I1
tp2265
sS'the,data'
p2266
(F1
F0.00043004587155963305
I0
I3
I-3
tp2267
sS'erythromycin,in'
p2268
(F1
F0.00028669724770642203
I2
I0
I2
tp2269
sS'interactions,is'
p2270
(F1
F0.00014334862385321102
I0
I1
I-1
tp2271
sS'bid,with'
p2272
(F1
F0.00043004587155963305
I3
I0
I3
tp2273
sS'interactions,exists'
p2274
(F1
F0.00014334862385321102
I0
I1
I-1
tp2275
sS'the,approved'
p2276
(F1
F0.00014334862385321102
I0
I1
I-1
tp2277
sS'electrolyte,disturbances'
p2278
(F1
F0.00014334862385321102
I1
I0
I1
tp2279
sS'alter,glucose'
p2280
(F1
F0.00014334862385321102
I0
I1
I-1
tp2281
sS'antithrombin,iii'
p2282
(F0
F0
I1
I1
I0
tp2283
sS'hours,of'
p2284
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp2285
sS'inhibitors,that'
p2286
(F1
F0.00043004587155963305
I3
I0
I3
tp2287
sS'hyperprolactinaemia,as'
p2288
(F1
F0.00014334862385321102
I0
I1
I-1
tp2289
sS'useof,a'
p2290
(F1
F0.00014334862385321102
I1
I0
I1
tp2291
sS'pertechnetate,tc99m'
p2292
(F1
F0.00014334862385321102
I0
I1
I-1
tp2293
sS'inhibits,proliferation'
p2294
(F1
F0.00014334862385321102
I1
I0
I1
tp2295
sS'could,prolong'
p2296
(F1
F0.00014334862385321102
I1
I0
I1
tp2297
sS'may,occasionally'
p2298
(F1
F0.00071674311926605509
I5
I0
I5
tp2299
sS'or,might'
p2300
(F1
F0.00014334862385321102
I0
I1
I-1
tp2301
sS'undergoing,treatment'
p2302
(F1
F0.00043004587155963305
I3
I0
I3
tp2303
sS'that,include'
p2304
(F1
F0.00014334862385321102
I1
I0
I1
tp2305
sS'p-450,the'
p2306
(F0
F0
I1
I1
I0
tp2307
sS'testing,and'
p2308
(F1
F0.00014334862385321102
I1
I0
I1
tp2309
sS'similar,temporal'
p2310
(F1
F0.00014334862385321102
I0
I1
I-1
tp2311
sS'daily,increased'
p2312
(F1
F0.00014334862385321102
I1
I0
I1
tp2313
sS'in,comparative'
p2314
(F1
F0.00014334862385321102
I0
I1
I-1
tp2315
sS'inhibit,and'
p2316
(F1
F0.00014334862385321102
I1
I0
I1
tp2317
sS'that,alter'
p2318
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2319
sS'l-histidine,via'
p2320
(F1
F0.00014334862385321102
I1
I0
I1
tp2321
sS'demonstrated,superior'
p2322
(F1
F0.00014334862385321102
I0
I1
I-1
tp2323
sS'migraine,therapy'
p2324
(F1
F0.00014334862385321102
I1
I0
I1
tp2325
sS'were,administered'
p2326
(F0.69230769230769229
F0.0012901376146788992
I2
I11
I-9
tp2327
sS'the,regimen'
p2328
(F0
F0
I1
I1
I0
tp2329
sS'marketing,observations'
p2330
(F1
F0.00014334862385321102
I1
I0
I1
tp2331
sS'anorectic,and'
p2332
(F1
F0.00014334862385321102
I1
I0
I1
tp2333
sS'mice,after'
p2334
(F1
F0.00014334862385321102
I0
I1
I-1
tp2335
sS'these,reasons'
p2336
(F1
F0.00014334862385321102
I1
I0
I1
tp2337
sS'possibly,nicotinic'
p2338
(F1
F0.00014334862385321102
I0
I1
I-1
tp2339
sS'and,toxicity'
p2340
(F1
F0.00028669724770642203
I2
I0
I2
tp2341
sS'administered,together'
p2342
(F0
F0
I1
I1
I0
tp2343
sS'blood,level'
p2344
(F1
F0.00043004587155963305
I0
I3
I-3
tp2345
sS'used,with'
p2346
(F0.59999999999999998
F0.0021502293577981653
I20
I5
I15
tp2347
sS'a,short-acting'
p2348
(F0
F0
I1
I1
I0
tp2349
sS'symptom,onset'
p2350
(F1
F0.00014334862385321102
I0
I1
I-1
tp2351
sS'following,the'
p2352
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp2353
sS'with,glutathione'
p2354
(F1
F0.00014334862385321102
I1
I0
I1
tp2355
sS'with,does'
p2356
(F1
F0.00014334862385321102
I0
I1
I-1
tp2357
sS'affect,disease'
p2358
(F1
F0.00014334862385321102
I1
I0
I1
tp2359
sS'the,neuromuscular'
p2360
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp2361
sS'or,concentrations'
p2362
(F1
F0.00014334862385321102
I0
I1
I-1
tp2363
sS'fold,range'
p2364
(F1
F0.00014334862385321102
I0
I1
I-1
tp2365
sS'the,committed'
p2366
(F1
F0.00014334862385321102
I1
I0
I1
tp2367
sS'nor,is'
p2368
(F1
F0.00014334862385321102
I0
I1
I-1
tp2369
sS'of,ethyol'
p2370
(F1
F0.00014334862385321102
I1
I0
I1
tp2371
sS'of,those'
p2372
(F1
F0.00014334862385321102
I1
I0
I1
tp2373
sS'ecg,changes'
p2374
(F1
F0.00014334862385321102
I1
I0
I1
tp2375
sS'to,trace'
p2376
(F1
F0.00014334862385321102
I0
I1
I-1
tp2377
sS'open,air'
p2378
(F1
F0.00014334862385321102
I1
I0
I1
tp2379
sS'known,cytochrome'
p2380
(F1
F0.00014334862385321102
I0
I1
I-1
tp2381
sS'anticoagulants,increased'
p2382
(F1
F0.00014334862385321102
I1
I0
I1
tp2383
sS'etc,is'
p2384
(F1
F0.00014334862385321102
I1
I0
I1
tp2385
sS'vasoconstriction,after'
p2386
(F1
F0.00014334862385321102
I1
I0
I1
tp2387
sS'cholestyramine,binds'
p2388
(F1
F0.00014334862385321102
I1
I0
I1
tp2389
sS'histamine-induced,gastric'
p2390
(F1
F0.00014334862385321102
I0
I1
I-1
tp2391
sS'etc,in'
p2392
(F1
F0.00014334862385321102
I1
I0
I1
tp2393
sS'including,anti-arrhythmic'
p2394
(F1
F0.00014334862385321102
I0
I1
I-1
tp2395
sS'other,significantly'
p2396
(F1
F0.00014334862385321102
I1
I0
I1
tp2397
sS'denudation,indicating'
p2398
(F1
F0.00014334862385321102
I0
I1
I-1
tp2399
sS'particularly,at'
p2400
(F1
F0.00014334862385321102
I1
I0
I1
tp2401
sS'suitable,anticoagulation'
p2402
(F1
F0.00014334862385321102
I1
I0
I1
tp2403
sS'hormone,action'
p2404
(F1
F0.00014334862385321102
I0
I1
I-1
tp2405
sS'on,exjade'
p2406
(F1
F0.00014334862385321102
I0
I1
I-1
tp2407
sS'inhibit,prostaglandin'
p2408
(F1
F0.00014334862385321102
I1
I0
I1
tp2409
sS'of,their'
p2410
(F1
F0.00043004587155963305
I3
I0
I3
tp2411
sS'sinus,bradycardia'
p2412
(F1
F0.00014334862385321102
I0
I1
I-1
tp2413
sS'statistically,significant'
p2414
(F0
F0
I4
I4
I0
tp2415
sS'long,acting'
p2416
(F0
F0
I1
I1
I0
tp2417
sS'acid,temporarily'
p2418
(F1
F0.00014334862385321102
I1
I0
I1
tp2419
sS'is,displaced'
p2420
(F1
F0.00028669724770642203
I2
I0
I2
tp2421
sS'specific,sulfosalicylic'
p2422
(F1
F0.00014334862385321102
I0
I1
I-1
tp2423
sS'increasing,gastric'
p2424
(F1
F0.00014334862385321102
I1
I0
I1
tp2425
sS'data,lower'
p2426
(F1
F0.00014334862385321102
I1
I0
I1
tp2427
sS'significant,difference'
p2428
(F1
F0.00071674311926605509
I0
I5
I-5
tp2429
sS'whether,the'
p2430
(F0.5
F0.00028669724770642203
I3
I1
I2
tp2431
sS'cyp3a4,inducers'
p2432
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp2433
sS'we,compared'
p2434
(F1
F0.00014334862385321102
I0
I1
I-1
tp2435
sS'other,cause'
p2436
(F1
F0.00028669724770642203
I2
I0
I2
tp2437
sS'coma,and'
p2438
(F1
F0.00014334862385321102
I1
I0
I1
tp2439
sS'trecator,has'
p2440
(F1
F0.00014334862385321102
I1
I0
I1
tp2441
sS'of,different'
p2442
(F1
F0.00014334862385321102
I0
I1
I-1
tp2443
sS'anticholinesterase,effect'
p2444
(F1
F0.00014334862385321102
I1
I0
I1
tp2445
sS'in,nucleoside-experienced'
p2446
(F1
F0.00014334862385321102
I0
I1
I-1
tp2447
sS'changed,in'
p2448
(F1
F0.00014334862385321102
I1
I0
I1
tp2449
sS'of,injection'
p2450
(F0
F0
I1
I1
I0
tp2451
sS'decrease,the'
p2452
(F0.75
F0.0043004587155963305
I35
I5
I30
tp2453
sS'sodium,approximately'
p2454
(F1
F0.00028669724770642203
I2
I0
I2
tp2455
sS'max,by'
p2456
(F0
F0
I1
I1
I0
tp2457
sS'no,pharmacokinetic'
p2458
(F1
F0.0010034403669724771
I0
I7
I-7
tp2459
sS'n6-cyclopentyladenosine,cpa'
p2460
(F1
F0.00014334862385321102
I1
I0
I1
tp2461
sS'the,year'
p2462
(F1
F0.00028669724770642203
I0
I2
I-2
tp2463
sS'zebeta,may'
p2464
(F1
F0.00014334862385321102
I1
I0
I1
tp2465
sS'an,antiparkinsonian'
p2466
(F1
F0.00014334862385321102
I1
I0
I1
tp2467
sS'the,macrolide'
p2468
(F1
F0.00014334862385321102
I1
I0
I1
tp2469
sS'aluminum-,or'
p2470
(F1
F0.00014334862385321102
I1
I0
I1
tp2471
sS'and,antineoplastic'
p2472
(F1
F0.00014334862385321102
I1
I0
I1
tp2473
sS'whether,these'
p2474
(F1
F0.00014334862385321102
I1
I0
I1
tp2475
sS'a,safe'
p2476
(F1
F0.00014334862385321102
I1
I0
I1
tp2477
sS'reported,to'
p2478
(F0.74285714285714288
F0.0074541284403669729
I61
I9
I52
tp2479
sS'novo,renal'
p2480
(F1
F0.00014334862385321102
I0
I1
I-1
tp2481
sS'clearances,by'
p2482
(F1
F0.00014334862385321102
I1
I0
I1
tp2483
sS'decrease,first'
p2484
(F1
F0.00014334862385321102
I0
I1
I-1
tp2485
sS'several,species'
p2486
(F1
F0.00014334862385321102
I0
I1
I-1
tp2487
sS'different,before'
p2488
(F1
F0.00014334862385321102
I0
I1
I-1
tp2489
sS'and,special'
p2490
(F1
F0.00014334862385321102
I1
I0
I1
tp2491
sS'their,serum'
p2492
(F1
F0.00014334862385321102
I0
I1
I-1
tp2493
sS'to,use'
p2494
(F0.5
F0.00028669724770642203
I3
I1
I2
tp2495
sS'intravenously,over'
p2496
(F1
F0.00014334862385321102
I0
I1
I-1
tp2497
sS'not,change'
p2498
(F1
F0.00057339449541284407
I0
I4
I-4
tp2499
sS'pose,clinical'
p2500
(F1
F0.00071674311926605509
I5
I0
I5
tp2501
sS'temporarily,suspending'
p2502
(F1
F0.00014334862385321102
I1
I0
I1
tp2503
sS'enhance,in'
p2504
(F1
F0.00014334862385321102
I1
I0
I1
tp2505
sS'or,toxicologic'
p2506
(F1
F0.00014334862385321102
I0
I1
I-1
tp2507
sS'the,exposure'
p2508
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2509
sS'administering,insp'
p2510
(F1
F0.00014334862385321102
I1
I0
I1
tp2511
sS'pharmacology,coadministration'
p2512
(F1
F0.00014334862385321102
I1
I0
I1
tp2513
sS'other,substances'
p2514
(F0
F0
I1
I1
I0
tp2515
sS'of,videx'
p2516
(F1
F0.00028669724770642203
I2
I0
I2
tp2517
sS'ligated,duodenal'
p2518
(F1
F0.00014334862385321102
I0
I1
I-1
tp2519
sS'therapeutic,effect'
p2520
(F0
F0
I1
I1
I0
tp2521
sS'in,greater'
p2522
(F1
F0.00014334862385321102
I1
I0
I1
tp2523
sS'cause,tumors'
p2524
(F1
F0.00014334862385321102
I1
I0
I1
tp2525
sS'the,standard'
p2526
(F1
F0.00014334862385321102
I1
I0
I1
tp2527
sS'initial,doses'
p2528
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp2529
sS'with,enbrel'
p2530
(F1
F0.00014334862385321102
I1
I0
I1
tp2531
sS'advisable,to'
p2532
(F1
F0.00071674311926605509
I5
I0
I5
tp2533
sS'ca,concentration'
p2534
(F1
F0.00014334862385321102
I1
I0
I1
tp2535
sS'you,may'
p2536
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2537
sS'potassium-sparing,supplements'
p2538
(F1
F0.00014334862385321102
I0
I1
I-1
tp2539
sS'anticipated,with'
p2540
(F1
F0.00028669724770642203
I2
I0
I2
tp2541
sS'these,who'
p2542
(F1
F0.00014334862385321102
I0
I1
I-1
tp2543
sS'study,received'
p2544
(F1
F0.00014334862385321102
I0
I1
I-1
tp2545
sS'hypoglycemia,has'
p2546
(F1
F0.0008600917431192661
I6
I0
I6
tp2547
sS'disoproxil,fumarate'
p2548
(F1
F0.00014334862385321102
I0
I1
I-1
tp2549
sS'enough,to'
p2550
(F1
F0.00014334862385321102
I0
I1
I-1
tp2551
sS'is,probably'
p2552
(F1
F0.00014334862385321102
I1
I0
I1
tp2553
sS'spinal,naloxone-sensitive'
p2554
(F1
F0.00014334862385321102
I0
I1
I-1
tp2555
sS'that,itraconazole'
p2556
(F1
F0.00014334862385321102
I1
I0
I1
tp2557
sS'interaction,use'
p2558
(F1
F0.00014334862385321102
I1
I0
I1
tp2559
sS'capsule,was'
p2560
(F1
F0.00014334862385321102
I1
I0
I1
tp2561
sS'other,pharmacokinetics'
p2562
(F1
F0.00014334862385321102
I1
I0
I1
tp2563
sS'reduce,pulse'
p2564
(F1
F0.00014334862385321102
I1
I0
I1
tp2565
sS'incisive,by'
p2566
(F1
F0.00014334862385321102
I0
I1
I-1
tp2567
sS'bile,caution'
p2568
(F1
F0.00014334862385321102
I0
I1
I-1
tp2569
sS'inhaled,such'
p2570
(F1
F0.00014334862385321102
I0
I1
I-1
tp2571
sS'the,literature'
p2572
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2573
sS'with,are'
p2574
(F1
F0.00028669724770642203
I0
I2
I-2
tp2575
sS'when,coadminstered'
p2576
(F1
F0.00014334862385321102
I1
I0
I1
tp2577
sS'glyburide,an'
p2578
(F1
F0.00014334862385321102
I0
I1
I-1
tp2579
sS'in,unbound'
p2580
(F1
F0.00014334862385321102
I1
I0
I1
tp2581
sS'sectral,lopressor'
p2582
(F1
F0.00014334862385321102
I0
I1
I-1
tp2583
sS'for,interaction'
p2584
(F1
F0.00028669724770642203
I2
I0
I2
tp2585
sS'per,ml'
p2586
(F1
F0.00014334862385321102
I0
I1
I-1
tp2587
sS'supplements,are'
p2588
(F1
F0.00014334862385321102
I1
I0
I1
tp2589
sS'magnitude,and'
p2590
(F1
F0.00028669724770642203
I2
I0
I2
tp2591
sS'subjects,ages'
p2592
(F1
F0.00014334862385321102
I1
I0
I1
tp2593
sS'to,reduced'
p2594
(F1
F0.00014334862385321102
I0
I1
I-1
tp2595
sS'by,monoamine'
p2596
(F0.5
F0.00028669724770642203
I3
I1
I2
tp2597
sS'and,together'
p2598
(F1
F0.00014334862385321102
I1
I0
I1
tp2599
sS'subjects,aged'
p2600
(F0
F0
I1
I1
I0
tp2601
sS'show,clinically'
p2602
(F1
F0.00014334862385321102
I0
I1
I-1
tp2603
sS'plus,or'
p2604
(F1
F0.00014334862385321102
I1
I0
I1
tp2605
sS'very,potent'
p2606
(F1
F0.00014334862385321102
I1
I0
I1
tp2607
sS'binds,bile'
p2608
(F1
F0.00014334862385321102
I0
I1
I-1
tp2609
sS'impairment,of'
p2610
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp2611
sS'and,lunch'
p2612
(F1
F0.00014334862385321102
I0
I1
I-1
tp2613
sS'significant,in'
p2614
(F1
F0.00014334862385321102
I1
I0
I1
tp2615
sS'kg,once'
p2616
(F1
F0.00028669724770642203
I0
I2
I-2
tp2617
sS'is,of'
p2618
(F1
F0.00028669724770642203
I0
I2
I-2
tp2619
sS'reduces,urinary'
p2620
(F1
F0.00014334862385321102
I1
I0
I1
tp2621
sS'of,metabolism'
p2622
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp2623
sS'daily,mg'
p2624
(F1
F0.00014334862385321102
I0
I1
I-1
tp2625
sS'received,either'
p2626
(F1
F0.00014334862385321102
I0
I1
I-1
tp2627
sS'intravenous,administration'
p2628
(F1
F0.00043004587155963305
I0
I3
I-3
tp2629
sS'a,nasal'
p2630
(F1
F0.00014334862385321102
I0
I1
I-1
tp2631
sS'of,valproic'
p2632
(F1
F0.00014334862385321102
I0
I1
I-1
tp2633
sS'gabapentin,pharmacokinetic'
p2634
(F1
F0.00014334862385321102
I0
I1
I-1
tp2635
sS'plasma,tca'
p2636
(F1
F0.00014334862385321102
I1
I0
I1
tp2637
sS'and,general'
p2638
(F1
F0.00014334862385321102
I1
I0
I1
tp2639
sS'pharmacology,drug'
p2640
(F1
F0.00014334862385321102
I1
I0
I1
tp2641
sS'an,interval'
p2642
(F0
F0
I1
I1
I0
tp2643
sS'anions,antithyroid'
p2644
(F1
F0.00014334862385321102
I0
I1
I-1
tp2645
sS'damage,as'
p2646
(F1
F0.00014334862385321102
I1
I0
I1
tp2647
sS'sensitive,to'
p2648
(F1
F0.00028669724770642203
I0
I2
I-2
tp2649
sS'a,total'
p2650
(F1
F0.00014334862385321102
I0
I1
I-1
tp2651
sS'usp,is'
p2652
(F1
F0.00014334862385321102
I1
I0
I1
tp2653
sS'if,stadol'
p2654
(F1
F0.00014334862385321102
I1
I0
I1
tp2655
sS'intermediate,doses'
p2656
(F0
F0
I1
I1
I0
tp2657
sS'sodium,valproic'
p2658
(F1
F0.00014334862385321102
I1
I0
I1
tp2659
sS'net,change'
p2660
(F1
F0.00043004587155963305
I3
I0
I3
tp2661
sS'is,receiving'
p2662
(F1
F0.00043004587155963305
I3
I0
I3
tp2663
sS'guardians,of'
p2664
(F1
F0.00014334862385321102
I0
I1
I-1
tp2665
sS'probenecid,pretreatment'
p2666
(F1
F0.00014334862385321102
I1
I0
I1
tp2667
sS'increases,substantially'
p2668
(F1
F0.00014334862385321102
I1
I0
I1
tp2669
sS'depressants,including'
p2670
(F1
F0.0008600917431192661
I6
I0
I6
tp2671
sS'additive,vasodilator'
p2672
(F1
F0.00014334862385321102
I0
I1
I-1
tp2673
sS'other,pressor'
p2674
(F1
F0.00014334862385321102
I0
I1
I-1
tp2675
sS'of,sublingual'
p2676
(F1
F0.00014334862385321102
I1
I0
I1
tp2677
sS'another,known'
p2678
(F1
F0.00057339449541284407
I0
I4
I-4
tp2679
sS'apparently,through'
p2680
(F1
F0.00014334862385321102
I1
I0
I1
tp2681
sS'decreased,antihypertensive'
p2682
(F1
F0.00014334862385321102
I1
I0
I1
tp2683
sS'displacing,the'
p2684
(F1
F0.00014334862385321102
I1
I0
I1
tp2685
sS'suggest,no'
p2686
(F1
F0.00014334862385321102
I0
I1
I-1
tp2687
sS'enflurane,than'
p2688
(F1
F0.00014334862385321102
I0
I1
I-1
tp2689
sS'impairment,the'
p2690
(F1
F0.00014334862385321102
I1
I0
I1
tp2691
sS'a,slower'
p2692
(F1
F0.00043004587155963305
I3
I0
I3
tp2693
sS'taking,with'
p2694
(F1
F0.00043004587155963305
I3
I0
I3
tp2695
sS'other,cns-depressant'
p2696
(F1
F0.00014334862385321102
I1
I0
I1
tp2697
sS'primary,and'
p2698
(F0
F0
I1
I1
I0
tp2699
sS'non-significantly,reduced'
p2700
(F1
F0.00014334862385321102
I0
I1
I-1
tp2701
sS'a-v,node'
p2702
(F1
F0.00014334862385321102
I1
I0
I1
tp2703
sS'or,medications'
p2704
(F1
F0.00014334862385321102
I1
I0
I1
tp2705
sS'or,clotting'
p2706
(F1
F0.00014334862385321102
I0
I1
I-1
tp2707
sS'either,simultaneously'
p2708
(F1
F0.00014334862385321102
I1
I0
I1
tp2709
sS'overdosage,cns'
p2710
(F1
F0.00028669724770642203
I2
I0
I2
tp2711
sS'after,m-tco'
p2712
(F1
F0.00014334862385321102
I1
I0
I1
tp2713
sS'time,kill'
p2714
(F1
F0.00014334862385321102
I1
I0
I1
tp2715
sS'xanthine,and'
p2716
(F1
F0.00028669724770642203
I2
I0
I2
tp2717
sS'celebrex,should'
p2718
(F1
F0.00014334862385321102
I1
I0
I1
tp2719
sS'even,though'
p2720
(F1
F0.00043004587155963305
I0
I3
I-3
tp2721
sS'erythro-fluorocitrate,from'
p2722
(F1
F0.00014334862385321102
I0
I1
I-1
tp2723
sS'volunteers,significantly'
p2724
(F1
F0.00014334862385321102
I1
I0
I1
tp2725
sS'american,coffee'
p2726
(F1
F0.00014334862385321102
I0
I1
I-1
tp2727
sS'and,triazole'
p2728
(F1
F0.00014334862385321102
I0
I1
I-1
tp2729
sS'prevent,symptoms'
p2730
(F1
F0.00014334862385321102
I1
I0
I1
tp2731
sS'may,occur'
p2732
(F0.61904761904761907
F0.0018635321100917432
I17
I4
I13
tp2733
sS'other,complications'
p2734
(F1
F0.00028669724770642203
I2
I0
I2
tp2735
sS'inhibited,phosphorylation'
p2736
(F1
F0.00028669724770642203
I2
I0
I2
tp2737
sS'several,medicinal'
p2738
(F1
F0.00014334862385321102
I1
I0
I1
tp2739
sS'tests,may'
p2740
(F1
F0.00028669724770642203
I0
I2
I-2
tp2741
sS'of,tmp'
p2742
(F1
F0.00028669724770642203
I0
I2
I-2
tp2743
sS'creatinine,clearance'
p2744
(F0.5
F0.00028669724770642203
I3
I1
I2
tp2745
sS'severe,cardiovascular'
p2746
(F1
F0.00014334862385321102
I1
I0
I1
tp2747
sS'of,possible'
p2748
(F1
F0.00071674311926605509
I5
I0
I5
tp2749
sS'this,isozyme'
p2750
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2751
sS'ischemia,of'
p2752
(F1
F0.00014334862385321102
I0
I1
I-1
tp2753
sS'kg,mc'
p2754
(F1
F0.00014334862385321102
I0
I1
I-1
tp2755
sS'a,are'
p2756
(F1
F0.00014334862385321102
I0
I1
I-1
tp2757
sS'to,wshow'
p2758
(F1
F0.00028669724770642203
I0
I2
I-2
tp2759
sS'thus,may'
p2760
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp2761
sS'functional,classes'
p2762
(F1
F0.00028669724770642203
I0
I2
I-2
tp2763
sS'minor,metabolizing'
p2764
(F1
F0.00014334862385321102
I0
I1
I-1
tp2765
sS'mptp,administration'
p2766
(F1
F0.00014334862385321102
I0
I1
I-1
tp2767
sS'combination,of'
p2768
(F0.25
F0.00057339449541284407
I10
I6
I4
tp2769
sS'pectoris,additional'
p2770
(F1
F0.00014334862385321102
I1
I0
I1
tp2771
sS'trivalent,cations'
p2772
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2773
sS'in,humans'
p2774
(F0.27272727272727271
F0.00043004587155963305
I4
I7
I-3
tp2775
sS'in,prolongation'
p2776
(F1
F0.00071674311926605509
I5
I0
I5
tp2777
sS'groups,treated'
p2778
(F1
F0.00014334862385321102
I1
I0
I1
tp2779
sS'compounds,such'
p2780
(F1
F0.00014334862385321102
I1
I0
I1
tp2781
sS'important,effects'
p2782
(F1
F0.00028669724770642203
I0
I2
I-2
tp2783
sS'effects,may'
p2784
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp2785
sS'the,stadol'
p2786
(F1
F0.00014334862385321102
I1
I0
I1
tp2787
sS'the,nonfailing'
p2788
(F1
F0.00014334862385321102
I0
I1
I-1
tp2789
sS'buffer,should'
p2790
(F1
F0.00014334862385321102
I1
I0
I1
tp2791
sS'cisapride,should'
p2792
(F1
F0.00014334862385321102
I1
I0
I1
tp2793
sS'to,mechanisms'
p2794
(F1
F0.00014334862385321102
I1
I0
I1
tp2795
sS'various,containing'
p2796
(F1
F0.00014334862385321102
I1
I0
I1
tp2797
sS'for,day'
p2798
(F1
F0.00014334862385321102
I0
I1
I-1
tp2799
sS'given,at'
p2800
(F0
F0
I1
I1
I0
tp2801
sS'to,overlap'
p2802
(F1
F0.00014334862385321102
I0
I1
I-1
tp2803
sS'products,and'
p2804
(F1
F0.00043004587155963305
I3
I0
I3
tp2805
sS'prinivil,with'
p2806
(F1
F0.00014334862385321102
I1
I0
I1
tp2807
sS'pills,sleeping'
p2808
(F1
F0.00014334862385321102
I0
I1
I-1
tp2809
sS'additional,therapy'
p2810
(F1
F0.00014334862385321102
I0
I1
I-1
tp2811
sS'patient,for'
p2812
(F1
F0.00014334862385321102
I0
I1
I-1
tp2813
sS'ssris,and'
p2814
(F0
F0
I5
I5
I0
tp2815
sS'of,some'
p2816
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp2817
sS'in,glomerular'
p2818
(F1
F0.00014334862385321102
I0
I1
I-1
tp2819
sS'patients,predisposing'
p2820
(F1
F0.00014334862385321102
I1
I0
I1
tp2821
sS'beta-receptor,blockers'
p2822
(F1
F0.00028669724770642203
I0
I2
I-2
tp2823
sS'discontinuation,ordinarily'
p2824
(F1
F0.00014334862385321102
I0
I1
I-1
tp2825
sS'relative,risk'
p2826
(F1
F0.00014334862385321102
I0
I1
I-1
tp2827
sS'pulse,and'
p2828
(F1
F0.00014334862385321102
I1
I0
I1
tp2829
sS'pseudomonas,aeruginosa'
p2830
(F1
F0.00028669724770642203
I0
I2
I-2
tp2831
sS'patient,with'
p2832
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2833
sS'no,differential'
p2834
(F1
F0.00014334862385321102
I0
I1
I-1
tp2835
sS'with,increasing'
p2836
(F1
F0.00014334862385321102
I1
I0
I1
tp2837
sS'to,such'
p2838
(F1
F0.00028669724770642203
I0
I2
I-2
tp2839
sS'ketoconazole,tablets'
p2840
(F1
F0.00028669724770642203
I2
I0
I2
tp2841
sS'in,noradrenaline-precontracted'
p2842
(F1
F0.00014334862385321102
I0
I1
I-1
tp2843
sS'eg,channel'
p2844
(F1
F0.00014334862385321102
I1
I0
I1
tp2845
sS'including,medications'
p2846
(F1
F0.00014334862385321102
I1
I0
I1
tp2847
sS'increased,central'
p2848
(F1
F0.00014334862385321102
I1
I0
I1
tp2849
sS'rhabdomyolysis,appear'
p2850
(F1
F0.00014334862385321102
I1
I0
I1
tp2851
sS'citrate,may'
p2852
(F1
F0.00014334862385321102
I1
I0
I1
tp2853
sS'iatrogenic,alterations'
p2854
(F1
F0.00014334862385321102
I1
I0
I1
tp2855
sS'beta-adrenergic,antagonists'
p2856
(F1
F0.00028669724770642203
I2
I0
I2
tp2857
sS'maximum,recommended'
p2858
(F1
F0.00014334862385321102
I1
I0
I1
tp2859
sS'interaction,for'
p2860
(F1
F0.00014334862385321102
I1
I0
I1
tp2861
sS'by,different'
p2862
(F1
F0.00014334862385321102
I1
I0
I1
tp2863
sS'zebeta,be'
p2864
(F1
F0.00014334862385321102
I1
I0
I1
tp2865
sS'certain,thereby'
p2866
(F1
F0.00014334862385321102
I1
I0
I1
tp2867
sS'reflected,in'
p2868
(F1
F0.00014334862385321102
I1
I0
I1
tp2869
sS'studied,and'
p2870
(F0
F0
I1
I1
I0
tp2871
sS'tsh,levels'
p2872
(F1
F0.00014334862385321102
I0
I1
I-1
tp2873
sS'general,antianxiety'
p2874
(F1
F0.00014334862385321102
I0
I1
I-1
tp2875
sS'of,oxidative'
p2876
(F1
F0.00014334862385321102
I0
I1
I-1
tp2877
sS'bextra,mg'
p2878
(F1
F0.00014334862385321102
I0
I1
I-1
tp2879
sS'involvement,of'
p2880
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2881
sS'week,period'
p2882
(F1
F0.00014334862385321102
I1
I0
I1
tp2883
sS'wort,theo-dur'
p2884
(F1
F0.00014334862385321102
I1
I0
I1
tp2885
sS'intervals,or'
p2886
(F0
F0
I1
I1
I0
tp2887
sS'undergoing,concurrent'
p2888
(F1
F0.00014334862385321102
I1
I0
I1
tp2889
sS'of,vital'
p2890
(F1
F0.00014334862385321102
I1
I0
I1
tp2891
sS'diuretic,therapy'
p2892
(F1
F0.00043004587155963305
I3
I0
I3
tp2893
sS'other,antipsychotic'
p2894
(F1
F0.00014334862385321102
I1
I0
I1
tp2895
sS'a,sudden'
p2896
(F1
F0.00014334862385321102
I1
I0
I1
tp2897
sS'parameters,for'
p2898
(F1
F0.00014334862385321102
I0
I1
I-1
tp2899
sS'not,undergo'
p2900
(F1
F0.00014334862385321102
I0
I1
I-1
tp2901
sS'from,neuromuscular'
p2902
(F1
F0.00014334862385321102
I0
I1
I-1
tp2903
sS'block,the'
p2904
(F1
F0.00043004587155963305
I3
I0
I3
tp2905
sS'stimulus,response'
p2906
(F1
F0.00014334862385321102
I0
I1
I-1
tp2907
sS'four,doses'
p2908
(F1
F0.00014334862385321102
I0
I1
I-1
tp2909
sS'administered,alone'
p2910
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp2911
sS'resistance,to'
p2912
(F0
F0
I2
I2
I0
tp2913
sS'direct,causal'
p2914
(F1
F0.00014334862385321102
I1
I0
I1
tp2915
sS'rate,constant'
p2916
(F1
F0.00014334862385321102
I0
I1
I-1
tp2917
sS'known,side'
p2918
(F1
F0.00014334862385321102
I1
I0
I1
tp2919
sS'continued,need'
p2920
(F1
F0.00014334862385321102
I0
I1
I-1
tp2921
sS'aminoglutethimide,diminishes'
p2922
(F1
F0.00014334862385321102
I1
I0
I1
tp2923
sS'mg,produced'
p2924
(F1
F0.00071674311926605509
I5
I0
I5
tp2925
sS'main,meal'
p2926
(F1
F0.00014334862385321102
I0
I1
I-1
tp2927
sS'for,abilify'
p2928
(F1
F0.00014334862385321102
I0
I1
I-1
tp2929
sS'substrate,trough'
p2930
(F1
F0.00014334862385321102
I1
I0
I1
tp2931
sS'kerlone,and'
p2932
(F1
F0.00014334862385321102
I0
I1
I-1
tp2933
sS'of,bromocriptine'
p2934
(F1
F0.00014334862385321102
I1
I0
I1
tp2935
sS'cognitive,function'
p2936
(F1
F0.00014334862385321102
I0
I1
I-1
tp2937
sS'of,antiaddictive'
p2938
(F1
F0.00014334862385321102
I0
I1
I-1
tp2939
sS'as,initial'
p2940
(F1
F0.00014334862385321102
I0
I1
I-1
tp2941
sS'of,preparations'
p2942
(F0.5
F0.00028669724770642203
I3
I1
I2
tp2943
sS'injections,in'
p2944
(F1
F0.00014334862385321102
I0
I1
I-1
tp2945
sS'show,that'
p2946
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp2947
sS'class,of'
p2948
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp2949
sS'containing,alone'
p2950
(F1
F0.00014334862385321102
I1
I0
I1
tp2951
sS'usp,has'
p2952
(F1
F0.00014334862385321102
I0
I1
I-1
tp2953
sS'in,long'
p2954
(F1
F0.00014334862385321102
I1
I0
I1
tp2955
sS'intravenous,and'
p2956
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp2957
sS'in,horses'
p2958
(F1
F0.00014334862385321102
I0
I1
I-1
tp2959
sS'dose-time,effects'
p2960
(F1
F0.00014334862385321102
I0
I1
I-1
tp2961
sS'a4,or'
p2962
(F1
F0.00014334862385321102
I1
I0
I1
tp2963
sS'd,analogues'
p2964
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp2965
sS'antagonists,when'
p2966
(F1
F0.00014334862385321102
I1
I0
I1
tp2967
sS'the,period'
p2968
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2969
sS'sudden,death'
p2970
(F1
F0.00014334862385321102
I1
I0
I1
tp2971
sS'non-selective,mao'
p2972
(F1
F0.00028669724770642203
I2
I0
I2
tp2973
sS'about,three-fold'
p2974
(F1
F0.00014334862385321102
I0
I1
I-1
tp2975
sS'of,synthetic'
p2976
(F1
F0.00028669724770642203
I2
I0
I2
tp2977
sS'of,overdosage'
p2978
(F1
F0.00028669724770642203
I2
I0
I2
tp2979
sS'the,p-glycoprotein'
p2980
(F1
F0.00014334862385321102
I0
I1
I-1
tp2981
sS'reduce,lithiums'
p2982
(F1
F0.00014334862385321102
I1
I0
I1
tp2983
sS'overdose,recognized'
p2984
(F1
F0.00014334862385321102
I0
I1
I-1
tp2985
sS'flexeril,may'
p2986
(F1
F0.00028669724770642203
I2
I0
I2
tp2987
sS'the,sixth'
p2988
(F1
F0.00014334862385321102
I1
I0
I1
tp2989
sS'avoid,iatrogenic'
p2990
(F1
F0.00014334862385321102
I1
I0
I1
tp2991
sS'diminish,the'
p2992
(F1
F0.0011467889908256881
I8
I0
I8
tp2993
sS'however,other'
p2994
(F1
F0.00014334862385321102
I1
I0
I1
tp2995
sS'of,ergomar'
p2996
(F1
F0.00028669724770642203
I2
I0
I2
tp2997
sS'concentrations,peak'
p2998
(F1
F0.00014334862385321102
I1
I0
I1
tp2999
sS'mean,estimates'
p3000
(F1
F0.00014334862385321102
I0
I1
I-1
tp3001
sS'involving,adult'
p3002
(F1
F0.00014334862385321102
I0
I1
I-1
tp3003
sS'receptors,thus'
p3004
(F1
F0.00028669724770642203
I2
I0
I2
tp3005
sS'choice,of'
p3006
(F1
F0.00014334862385321102
I0
I1
I-1
tp3007
sS'well,concurent'
p3008
(F1
F0.00014334862385321102
I1
I0
I1
tp3009
sS'examples,of'
p3010
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp3011
sS'axert,and'
p3012
(F1
F0.00014334862385321102
I1
I0
I1
tp3013
sS'corresponding,increase'
p3014
(F1
F0.00028669724770642203
I2
I0
I2
tp3015
sS'insulin,or'
p3016
(F0
F0
I1
I1
I0
tp3017
sS'reuptake,of'
p3018
(F1
F0.00014334862385321102
I0
I1
I-1
tp3019
sS'or,collagen-stimulated'
p3020
(F1
F0.00014334862385321102
I0
I1
I-1
tp3021
sS'kg,injected'
p3022
(F1
F0.00014334862385321102
I1
I0
I1
tp3023
sS'voltaren,cataflam'
p3024
(F1
F0.00014334862385321102
I0
I1
I-1
tp3025
sS'hyperlipidemia,or'
p3026
(F1
F0.00014334862385321102
I1
I0
I1
tp3027
sS'elevations,in'
p3028
(F1
F0.00057339449541284407
I4
I0
I4
tp3029
sS'therefore,agents'
p3030
(F1
F0.00014334862385321102
I0
I1
I-1
tp3031
sS'fbs,followed'
p3032
(F1
F0.00014334862385321102
I1
I0
I1
tp3033
sS'treatment,did'
p3034
(F1
F0.00028669724770642203
I0
I2
I-2
tp3035
sS'of,further'
p3036
(F1
F0.00014334862385321102
I1
I0
I1
tp3037
sS'on,one'
p3038
(F1
F0.00014334862385321102
I1
I0
I1
tp3039
sS'mg,total'
p3040
(F1
F0.00014334862385321102
I0
I1
I-1
tp3041
sS'subjects,already'
p3042
(F1
F0.00014334862385321102
I1
I0
I1
tp3043
sS'with,sustiva'
p3044
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp3045
sS'not,mix'
p3046
(F1
F0.00014334862385321102
I0
I1
I-1
tp3047
sS'other,and'
p3048
(F0.5
F0.0008600917431192661
I3
I9
I-6
tp3049
sS'same,dose'
p3050
(F1
F0.00028669724770642203
I2
I0
I2
tp3051
sS'digestion,and'
p3052
(F1
F0.00014334862385321102
I0
I1
I-1
tp3053
sS'a,randomized'
p3054
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp3055
sS'oral,bioavailability'
p3056
(F1
F0.00028669724770642203
I2
I0
I2
tp3057
sS'colchicine,may'
p3058
(F1
F0.00014334862385321102
I1
I0
I1
tp3059
sS'day,qd'
p3060
(F1
F0.00014334862385321102
I0
I1
I-1
tp3061
sS'typical,side'
p3062
(F1
F0.00014334862385321102
I0
I1
I-1
tp3063
sS'thorazine,prolixin'
p3064
(F1
F0.00028669724770642203
I0
I2
I-2
tp3065
sS'vertigo,syncope'
p3066
(F0.5
F0.00028669724770642203
I3
I1
I2
tp3067
sS'prevents,gastrointestinal'
p3068
(F1
F0.00014334862385321102
I1
I0
I1
tp3069
sS'therefore,close'
p3070
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3071
sS'infections,an'
p3072
(F1
F0.00014334862385321102
I1
I0
I1
tp3073
sS'antibiotics,and'
p3074
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3075
sS'therapeutic,concentration'
p3076
(F1
F0.00014334862385321102
I1
I0
I1
tp3077
sS'inhalation,device'
p3078
(F1
F0.00014334862385321102
I0
I1
I-1
tp3079
sS'products,including'
p3080
(F1
F0.00014334862385321102
I1
I0
I1
tp3081
sS'of,active'
p3082
(F1
F0.00028669724770642203
I2
I0
I2
tp3083
sS'be,precipitated'
p3084
(F1
F0.00014334862385321102
I0
I1
I-1
tp3085
sS'unknown,neither'
p3086
(F1
F0.00014334862385321102
I1
I0
I1
tp3087
sS'small,but'
p3088
(F1
F0.00014334862385321102
I1
I0
I1
tp3089
sS'twice-daily,with'
p3090
(F1
F0.00014334862385321102
I1
I0
I1
tp3091
sS'ingesting,these'
p3092
(F1
F0.00014334862385321102
I1
I0
I1
tp3093
sS'reduced,as'
p3094
(F1
F0.00014334862385321102
I0
I1
I-1
tp3095
sS'with,salts'
p3096
(F1
F0.00014334862385321102
I0
I1
I-1
tp3097
sS'the,thioxanthene'
p3098
(F1
F0.00014334862385321102
I1
I0
I1
tp3099
sS'aluminum-containing,antacid'
p3100
(F1
F0.00014334862385321102
I0
I1
I-1
tp3101
sS'breakdown,products'
p3102
(F1
F0.00014334862385321102
I1
I0
I1
tp3103
sS'combine,to'
p3104
(F1
F0.00014334862385321102
I1
I0
I1
tp3105
sS'affect,hepatic'
p3106
(F0
F0
I1
I1
I0
tp3107
sS'selectively,bred'
p3108
(F1
F0.00014334862385321102
I0
I1
I-1
tp3109
sS'and,female'
p3110
(F0
F0
I1
I1
I0
tp3111
sS'of,both'
p3112
(F0.375
F0.0008600917431192661
I11
I5
I6
tp3113
sS'animal,source'
p3114
(F1
F0.00014334862385321102
I0
I1
I-1
tp3115
sS'intravenously,as'
p3116
(F1
F0.00014334862385321102
I1
I0
I1
tp3117
sS'was,to'
p3118
(F1
F0.0008600917431192661
I0
I6
I-6
tp3119
sS'if,such'
p3120
(F1
F0.00014334862385321102
I0
I1
I-1
tp3121
sS'brevibloc,should'
p3122
(F1
F0.00028669724770642203
I2
I0
I2
tp3123
sS'hiv-infected,subjects'
p3124
(F1
F0.00014334862385321102
I0
I1
I-1
tp3125
sS'and,tmax'
p3126
(F1
F0.00014334862385321102
I0
I1
I-1
tp3127
sS'the,disulfiram-ethanol'
p3128
(F1
F0.00028669724770642203
I0
I2
I-2
tp3129
sS'non-specific,cyp-450'
p3130
(F1
F0.00014334862385321102
I0
I1
I-1
tp3131
sS'concentration,by'
p3132
(F1
F0.00028669724770642203
I0
I2
I-2
tp3133
sS'at,clinically'
p3134
(F1
F0.00028669724770642203
I0
I2
I-2
tp3135
sS'videx,was'
p3136
(F1
F0.00014334862385321102
I1
I0
I1
tp3137
sS'referred,to'
p3138
(F1
F0.00043004587155963305
I0
I3
I-3
tp3139
sS'initiating,combination'
p3140
(F1
F0.00014334862385321102
I1
I0
I1
tp3141
sS'replication,of'
p3142
(F1
F0.00014334862385321102
I1
I0
I1
tp3143
sS'fulminant,pancreatitis'
p3144
(F1
F0.00014334862385321102
I1
I0
I1
tp3145
sS'maintain,twitch'
p3146
(F1
F0.00014334862385321102
I0
I1
I-1
tp3147
sS'induction,by'
p3148
(F1
F0.00014334862385321102
I0
I1
I-1
tp3149
sS'consider,xanax'
p3150
(F1
F0.00014334862385321102
I1
I0
I1
tp3151
sS'tikosyn,and'
p3152
(F0
F0
I1
I1
I0
tp3153
sS'as,antiemetic'
p3154
(F1
F0.00014334862385321102
I1
I0
I1
tp3155
sS'certain,weak'
p3156
(F1
F0.00014334862385321102
I1
I0
I1
tp3157
sS'other,oral'
p3158
(F1
F0.00043004587155963305
I3
I0
I3
tp3159
sS'which,enbrel'
p3160
(F1
F0.00014334862385321102
I1
I0
I1
tp3161
sS'if,high'
p3162
(F1
F0.00014334862385321102
I1
I0
I1
tp3163
sS'injectable,produces'
p3164
(F1
F0.00014334862385321102
I1
I0
I1
tp3165
sS'not,predispose'
p3166
(F1
F0.00014334862385321102
I0
I1
I-1
tp3167
sS'systemic,administration'
p3168
(F0
F0
I1
I1
I0
tp3169
sS'of,suggest'
p3170
(F1
F0.00014334862385321102
I1
I0
I1
tp3171
sS'interactive,effect'
p3172
(F1
F0.00028669724770642203
I0
I2
I-2
tp3173
sS'agents,coadministration'
p3174
(F1
F0.00028669724770642203
I0
I2
I-2
tp3175
sS'dosed,subjects'
p3176
(F1
F0.00014334862385321102
I0
I1
I-1
tp3177
sS'against,gram-negative'
p3178
(F1
F0.00014334862385321102
I0
I1
I-1
tp3179
sS'some,potential'
p3180
(F1
F0.00014334862385321102
I1
I0
I1
tp3181
sS'two,strains'
p3182
(F1
F0.00014334862385321102
I0
I1
I-1
tp3183
sS'state,therefore'
p3184
(F1
F0.00014334862385321102
I0
I1
I-1
tp3185
sS'its,cellular'
p3186
(F1
F0.00014334862385321102
I1
I0
I1
tp3187
sS'to,emerge'
p3188
(F1
F0.00014334862385321102
I1
I0
I1
tp3189
sS'or,marked'
p3190
(F0.5
F0.00028669724770642203
I3
I1
I2
tp3191
sS'or,did'
p3192
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp3193
sS'and,therapeutic'
p3194
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3195
sS'blockers,or'
p3196
(F1
F0.00071674311926605509
I5
I0
I5
tp3197
sS'association,between'
p3198
(F1
F0.00014334862385321102
I1
I0
I1
tp3199
sS'the,vehicle-controlled'
p3200
(F1
F0.00014334862385321102
I0
I1
I-1
tp3201
sS'work,involved'
p3202
(F1
F0.00014334862385321102
I0
I1
I-1
tp3203
sS'and,mc'
p3204
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp3205
sS'and,mg'
p3206
(F0.068965517241379309
F0.00057339449541284407
I31
I27
I4
tp3207
sS'model,peptide'
p3208
(F1
F0.00014334862385321102
I0
I1
I-1
tp3209
sS'basis,for'
p3210
(F0
F0
I1
I1
I0
tp3211
sS'and,loop'
p3212
(F1
F0.00014334862385321102
I0
I1
I-1
tp3213
sS'agents,reduce'
p3214
(F1
F0.00028669724770642203
I2
I0
I2
tp3215
sS'and,mu'
p3216
(F1
F0.00014334862385321102
I0
I1
I-1
tp3217
sS'receiving,revia'
p3218
(F1
F0.00014334862385321102
I1
I0
I1
tp3219
sS'clinically,effective'
p3220
(F1
F0.00028669724770642203
I2
I0
I2
tp3221
sS'quantities,of'
p3222
(F1
F0.00028669724770642203
I0
I2
I-2
tp3223
sS'be,avoided'
p3224
(F0.52941176470588236
F0.0012901376146788992
I13
I4
I9
tp3225
sS'microsomal,enzymes'
p3226
(F0
F0
I1
I1
I0
tp3227
sS'amevive,before'
p3228
(F1
F0.00014334862385321102
I0
I1
I-1
tp3229
sS'of,novolog'
p3230
(F1
F0.00028669724770642203
I0
I2
I-2
tp3231
sS'response,seen'
p3232
(F1
F0.00014334862385321102
I1
I0
I1
tp3233
sS'nuromax,before'
p3234
(F1
F0.00014334862385321102
I0
I1
I-1
tp3235
sS'the,duloxetine'
p3236
(F1
F0.00014334862385321102
I0
I1
I-1
tp3237
sS'with,enteric'
p3238
(F1
F0.00014334862385321102
I1
I0
I1
tp3239
sS'interval,for'
p3240
(F1
F0.00028669724770642203
I0
I2
I-2
tp3241
sS'administered,or'
p3242
(F0
F0
I1
I1
I0
tp3243
sS'addition,other'
p3244
(F1
F0.00014334862385321102
I1
I0
I1
tp3245
sS'emerge,with'
p3246
(F1
F0.00014334862385321102
I1
I0
I1
tp3247
sS'antiepileptic,effect'
p3248
(F1
F0.00014334862385321102
I1
I0
I1
tp3249
sS'serum,slightly'
p3250
(F1
F0.00014334862385321102
I1
I0
I1
tp3251
sS'a,catecholamine'
p3252
(F1
F0.00014334862385321102
I0
I1
I-1
tp3253
sS'cause,decreased'
p3254
(F1
F0.00014334862385321102
I1
I0
I1
tp3255
sS'of,aeds'
p3256
(F1
F0.00014334862385321102
I1
I0
I1
tp3257
sS'the,surface'
p3258
(F1
F0.00014334862385321102
I1
I0
I1
tp3259
sS'the,risks'
p3260
(F1
F0.00043004587155963305
I3
I0
I3
tp3261
sS'change,in'
p3262
(F0.16666666666666666
F0.00028669724770642203
I5
I7
I-2
tp3263
sS'diagnostic,or'
p3264
(F1
F0.00014334862385321102
I0
I1
I-1
tp3265
sS'erpf,and'
p3266
(F1
F0.00014334862385321102
I1
I0
I1
tp3267
sS'began,within'
p3268
(F1
F0.00014334862385321102
I0
I1
I-1
tp3269
sS'system,fentanyl'
p3270
(F1
F0.00014334862385321102
I0
I1
I-1
tp3271
sS'with,muscle'
p3272
(F1
F0.00014334862385321102
I0
I1
I-1
tp3273
sS'and,corticotropin'
p3274
(F1
F0.00014334862385321102
I1
I0
I1
tp3275
sS'arimidex,and'
p3276
(F1
F0.00014334862385321102
I0
I1
I-1
tp3277
sS'ten,patients'
p3278
(F1
F0.00014334862385321102
I0
I1
I-1
tp3279
sS'to,decrease'
p3280
(F0.6470588235294118
F0.0015768348623853212
I14
I3
I11
tp3281
sS'of,migraine'
p3282
(F1
F0.00014334862385321102
I0
I1
I-1
tp3283
sS'dilation,associated'
p3284
(F1
F0.00014334862385321102
I1
I0
I1
tp3285
sS'provides,considerable'
p3286
(F1
F0.00014334862385321102
I0
I1
I-1
tp3287
sS'impacted,by'
p3288
(F1
F0.00014334862385321102
I0
I1
I-1
tp3289
sS'recording,technique'
p3290
(F1
F0.00014334862385321102
I0
I1
I-1
tp3291
sS'in,and'
p3292
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp3293
sS'of,aed'
p3294
(F1
F0.00014334862385321102
I0
I1
I-1
tp3295
sS'steroidal,antiinflammatory'
p3296
(F1
F0.00014334862385321102
I1
I0
I1
tp3297
sS'not,mc'
p3298
(F1
F0.00014334862385321102
I0
I1
I-1
tp3299
sS'pharmacodynamic,interaction'
p3300
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp3301
sS'as,measured'
p3302
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp3303
sS'post-transplant,year'
p3304
(F1
F0.00014334862385321102
I0
I1
I-1
tp3305
sS'this,mechanism'
p3306
(F1
F0.00014334862385321102
I1
I0
I1
tp3307
sS'risk,that'
p3308
(F1
F0.00014334862385321102
I1
I0
I1
tp3309
sS'either,pharmacokinetics'
p3310
(F1
F0.00014334862385321102
I0
I1
I-1
tp3311
sS'that,prolongs'
p3312
(F1
F0.00014334862385321102
I1
I0
I1
tp3313
sS'mac,or'
p3314
(F1
F0.00014334862385321102
I0
I1
I-1
tp3315
sS'fixed-ratio,fi'
p3316
(F1
F0.00014334862385321102
I0
I1
I-1
tp3317
sS'and,complications'
p3318
(F1
F0.00014334862385321102
I1
I0
I1
tp3319
sS'this,indicates'
p3320
(F1
F0.00028669724770642203
I0
I2
I-2
tp3321
sS'perhexiline,hydrogen'
p3322
(F1
F0.00014334862385321102
I1
I0
I1
tp3323
sS'transdermal,and'
p3324
(F1
F0.00028669724770642203
I2
I0
I2
tp3325
sS'or,carbidopa-levodopa'
p3326
(F1
F0.00028669724770642203
I0
I2
I-2
tp3327
sS'bone,and'
p3328
(F1
F0.00014334862385321102
I1
I0
I1
tp3329
sS'methylglutaryl,coenzyme'
p3330
(F1
F0.00014334862385321102
I0
I1
I-1
tp3331
sS'nimbex,at'
p3332
(F1
F0.00014334862385321102
I1
I0
I1
tp3333
sS'medrol,others'
p3334
(F1
F0.00014334862385321102
I0
I1
I-1
tp3335
sS'after,initiating'
p3336
(F1
F0.00028669724770642203
I2
I0
I2
tp3337
sS'p-450,inducers'
p3338
(F1
F0.00014334862385321102
I1
I0
I1
tp3339
sS'additive,hypotensive'
p3340
(F1
F0.00014334862385321102
I1
I0
I1
tp3341
sS'ganciclovir,administration'
p3342
(F1
F0.00014334862385321102
I1
I0
I1
tp3343
sS'half-lives,to'
p3344
(F1
F0.00014334862385321102
I0
I1
I-1
tp3345
sS'wthionamide,trecator-sc'
p3346
(F1
F0.00014334862385321102
I0
I1
I-1
tp3347
sS'indinavir,may'
p3348
(F1
F0.00014334862385321102
I1
I0
I1
tp3349
sS'conversion,of'
p3350
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp3351
sS'rhabdomyolysis,has'
p3352
(F1
F0.00028669724770642203
I2
I0
I2
tp3353
sS'slightly,shorter'
p3354
(F1
F0.00014334862385321102
I1
I0
I1
tp3355
sS'the,contents'
p3356
(F1
F0.00028669724770642203
I0
I2
I-2
tp3357
sS'starting,and'
p3358
(F1
F0.00014334862385321102
I1
I0
I1
tp3359
sS'treatment,regimen'
p3360
(F1
F0.00014334862385321102
I1
I0
I1
tp3361
sS'with,plus'
p3362
(F0
F0
I1
I1
I0
tp3363
sS'auc,but'
p3364
(F1
F0.00014334862385321102
I1
I0
I1
tp3365
sS'particularly,those'
p3366
(F1
F0.00014334862385321102
I0
I1
I-1
tp3367
sS'experience,there'
p3368
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3369
sS'that,oral'
p3370
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp3371
sS'cognitive,and'
p3372
(F1
F0.00014334862385321102
I1
I0
I1
tp3373
sS'aczone,gel'
p3374
(F1
F0.00014334862385321102
I0
I1
I-1
tp3375
sS'therapeutic,response'
p3376
(F1
F0.00014334862385321102
I0
I1
I-1
tp3377
sS'about,fold'
p3378
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3379
sS'acetate,similarly'
p3380
(F1
F0.00014334862385321102
I1
I0
I1
tp3381
sS'that,there'
p3382
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp3383
sS'from,approximately'
p3384
(F1
F0.00014334862385321102
I1
I0
I1
tp3385
sS'increases,hydralazines'
p3386
(F1
F0.00014334862385321102
I1
I0
I1
tp3387
sS'termed,serotonin'
p3388
(F1
F0.00014334862385321102
I1
I0
I1
tp3389
sS'g,of'
p3390
(F1
F0.00014334862385321102
I1
I0
I1
tp3391
sS'as,deltasone'
p3392
(F1
F0.00014334862385321102
I0
I1
I-1
tp3393
sS'death,potentially'
p3394
(F1
F0.00014334862385321102
I1
I0
I1
tp3395
sS'comparable,to'
p3396
(F0
F0
I3
I3
I0
tp3397
sS'may,suppress'
p3398
(F1
F0.00014334862385321102
I0
I1
I-1
tp3399
sS'intraluminally,was'
p3400
(F1
F0.00014334862385321102
I0
I1
I-1
tp3401
sS'additional,effect'
p3402
(F1
F0.00028669724770642203
I2
I0
I2
tp3403
sS'does,it'
p3404
(F1
F0.00028669724770642203
I0
I2
I-2
tp3405
sS'indicated,that'
p3406
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp3407
sS'hearing,have'
p3408
(F1
F0.00014334862385321102
I1
I0
I1
tp3409
sS'benzodiazepines,were'
p3410
(F1
F0.00014334862385321102
I0
I1
I-1
tp3411
sS'produce,additive'
p3412
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3413
sS'a,dose'
p3414
(F0.66666666666666663
F0.0022935779816513763
I20
I4
I16
tp3415
sS'metabolized,nor'
p3416
(F1
F0.00014334862385321102
I0
I1
I-1
tp3417
sS'therapy,can'
p3418
(F1
F0.00014334862385321102
I0
I1
I-1
tp3419
sS'vivo,animal'
p3420
(F1
F0.00014334862385321102
I1
I0
I1
tp3421
sS'receiving,purinethol'
p3422
(F1
F0.00014334862385321102
I1
I0
I1
tp3423
sS'before,conducting'
p3424
(F1
F0.00014334862385321102
I1
I0
I1
tp3425
sS'serial,use'
p3426
(F1
F0.00014334862385321102
I0
I1
I-1
tp3427
sS'which,ssri-tca'
p3428
(F1
F0.00057339449541284407
I4
I0
I4
tp3429
sS'during,clinical'
p3430
(F1
F0.00014334862385321102
I0
I1
I-1
tp3431
sS'to,function'
p3432
(F1
F0.00014334862385321102
I0
I1
I-1
tp3433
sS'cyclosporine-induced,toxicity'
p3434
(F1
F0.00028669724770642203
I2
I0
I2
tp3435
sS'reduced,protein'
p3436
(F1
F0.00014334862385321102
I1
I0
I1
tp3437
sS'the,undesirable'
p3438
(F1
F0.00014334862385321102
I1
I0
I1
tp3439
sS'a,toxic'
p3440
(F1
F0.00014334862385321102
I1
I0
I1
tp3441
sS'induce,toxicity'
p3442
(F1
F0.00014334862385321102
I0
I1
I-1
tp3443
sS'reductions,in'
p3444
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3445
sS'not,display'
p3446
(F1
F0.00014334862385321102
I0
I1
I-1
tp3447
sS'and,crixivan'
p3448
(F1
F0.00014334862385321102
I1
I0
I1
tp3449
sS'vehicle-controlled,studies'
p3450
(F1
F0.00014334862385321102
I0
I1
I-1
tp3451
sS'diarrhea,was'
p3452
(F1
F0.00014334862385321102
I0
I1
I-1
tp3453
sS'by,simply'
p3454
(F1
F0.00014334862385321102
I0
I1
I-1
tp3455
sS'causal,mechanism'
p3456
(F1
F0.00014334862385321102
I1
I0
I1
tp3457
sS'acarbose,did'
p3458
(F1
F0.00014334862385321102
I0
I1
I-1
tp3459
sS'involving,concomitant'
p3460
(F1
F0.00014334862385321102
I0
I1
I-1
tp3461
sS'aspirin,in'
p3462
(F1
F0.00014334862385321102
I1
I0
I1
tp3463
sS'mao,inhibitor'
p3464
(F1
F0.00071674311926605509
I5
I0
I5
tp3465
sS'for,metabolism'
p3466
(F1
F0.00014334862385321102
I0
I1
I-1
tp3467
sS'aspirin,is'
p3468
(F1
F0.00014334862385321102
I1
I0
I1
tp3469
sS'and,heavy'
p3470
(F1
F0.00014334862385321102
I1
I0
I1
tp3471
sS'renal,clearances'
p3472
(F1
F0.00014334862385321102
I1
I0
I1
tp3473
sS'acquisition,of'
p3474
(F1
F0.00014334862385321102
I0
I1
I-1
tp3475
sS'subjects,should'
p3476
(F1
F0.00057339449541284407
I4
I0
I4
tp3477
sS'or,corrected'
p3478
(F1
F0.00014334862385321102
I0
I1
I-1
tp3479
sS'is,unaffected'
p3480
(F1
F0.00028669724770642203
I0
I2
I-2
tp3481
sS'angiomax,with'
p3482
(F1
F0.00014334862385321102
I1
I0
I1
tp3483
sS'the,impairment'
p3484
(F1
F0.00014334862385321102
I0
I1
I-1
tp3485
sS'be,prescribed'
p3486
(F1
F0.00014334862385321102
I1
I0
I1
tp3487
sS'n,compared'
p3488
(F1
F0.00043004587155963305
I3
I0
I3
tp3489
sS'induced,diarrhea'
p3490
(F0
F0
I1
I1
I0
tp3491
sS'a,dose-related'
p3492
(F1
F0.00028669724770642203
I2
I0
I2
tp3493
sS'effect,for'
p3494
(F0
F0
I1
I1
I0
tp3495
sS'level,of'
p3496
(F0.090909090909090912
F0.00014334862385321102
I5
I6
I-1
tp3497
sS'with,transient'
p3498
(F1
F0.00028669724770642203
I2
I0
I2
tp3499
sS'give,a'
p3500
(F1
F0.00014334862385321102
I0
I1
I-1
tp3501
sS'with,cyp2d6'
p3502
(F1
F0.00014334862385321102
I1
I0
I1
tp3503
sS'hcl,ascorbic'
p3504
(F1
F0.00014334862385321102
I1
I0
I1
tp3505
sS'adenocarcinomas,which'
p3506
(F1
F0.00014334862385321102
I1
I0
I1
tp3507
sS'years,total'
p3508
(F1
F0.00014334862385321102
I0
I1
I-1
tp3509
sS'cardiac,arrhythmias'
p3510
(F1
F0.00014334862385321102
I1
I0
I1
tp3511
sS'amphotericin,b-induced'
p3512
(F1
F0.00028669724770642203
I2
I0
I2
tp3513
sS'clonidine,concomitant'
p3514
(F1
F0.00014334862385321102
I1
I0
I1
tp3515
sS'effects,have'
p3516
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp3517
sS'that,be'
p3518
(F0
F0
I1
I1
I0
tp3519
sS'highly,bound'
p3520
(F0
F0
I1
I1
I0
tp3521
sS'agents,concomitant'
p3522
(F1
F0.00014334862385321102
I1
I0
I1
tp3523
sS'block,induced'
p3524
(F1
F0.00028669724770642203
I2
I0
I2
tp3525
sS'function,may'
p3526
(F1
F0.00014334862385321102
I0
I1
I-1
tp3527
sS'antiinflammatory,agent'
p3528
(F1
F0.00014334862385321102
I1
I0
I1
tp3529
sS'effect,after'
p3530
(F1
F0.00014334862385321102
I0
I1
I-1
tp3531
sS'using,red'
p3532
(F1
F0.00014334862385321102
I0
I1
I-1
tp3533
sS'to,date'
p3534
(F1
F0.00028669724770642203
I0
I2
I-2
tp3535
sS'twofold,from'
p3536
(F1
F0.00014334862385321102
I1
I0
I1
tp3537
sS'maintain,trough'
p3538
(F1
F0.00014334862385321102
I1
I0
I1
tp3539
sS'excretion,was'
p3540
(F1
F0.00028669724770642203
I0
I2
I-2
tp3541
sS'adenocard,has'
p3542
(F1
F0.00014334862385321102
I0
I1
I-1
tp3543
sS'except,leukemia'
p3544
(F1
F0.00014334862385321102
I1
I0
I1
tp3545
sS'a,spinal'
p3546
(F1
F0.00014334862385321102
I0
I1
I-1
tp3547
sS'nmda,and'
p3548
(F1
F0.00014334862385321102
I0
I1
I-1
tp3549
sS'sodium,perchlorate'
p3550
(F1
F0.00014334862385321102
I0
I1
I-1
tp3551
sS'growth,in'
p3552
(F1
F0.00014334862385321102
I1
I0
I1
tp3553
sS'or,cyp3a4'
p3554
(F1
F0.00014334862385321102
I0
I1
I-1
tp3555
sS'immediately,following'
p3556
(F1
F0.00028669724770642203
I2
I0
I2
tp3557
sS'characteristic,of'
p3558
(F1
F0.00014334862385321102
I0
I1
I-1
tp3559
sS'of,immunoreactive'
p3560
(F1
F0.00014334862385321102
I0
I1
I-1
tp3561
sS'combined,moieties'
p3562
(F1
F0.00014334862385321102
I0
I1
I-1
tp3563
sS'bioavailability,or'
p3564
(F1
F0.00014334862385321102
I0
I1
I-1
tp3565
sS'ms,contin'
p3566
(F1
F0.00014334862385321102
I1
I0
I1
tp3567
sS'interaction,between'
p3568
(F0.1111111111111111
F0.00071674311926605509
I20
I25
I-5
tp3569
sS'solution,the'
p3570
(F1
F0.00014334862385321102
I1
I0
I1
tp3571
sS'comparison,with'
p3572
(F0
F0
I1
I1
I0
tp3573
sS'of,blood'
p3574
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp3575
sS'using,human'
p3576
(F1
F0.00014334862385321102
I0
I1
I-1
tp3577
sS'with,cyp2c19'
p3578
(F1
F0.00014334862385321102
I0
I1
I-1
tp3579
sS'when,plasma'
p3580
(F1
F0.00028669724770642203
I2
I0
I2
tp3581
sS'antithrombotic,agent'
p3582
(F1
F0.00014334862385321102
I1
I0
I1
tp3583
sS'a,type'
p3584
(F0
F0
I1
I1
I0
tp3585
sS'for,include'
p3586
(F1
F0.00014334862385321102
I1
I0
I1
tp3587
sS'reduced,risk'
p3588
(F1
F0.00014334862385321102
I0
I1
I-1
tp3589
sS'either,due'
p3590
(F1
F0.00014334862385321102
I0
I1
I-1
tp3591
sS'an,and'
p3592
(F1
F0.00043004587155963305
I3
I0
I3
tp3593
sS'anticoagulants,ten'
p3594
(F1
F0.00014334862385321102
I0
I1
I-1
tp3595
sS'mg,elemental'
p3596
(F1
F0.00014334862385321102
I0
I1
I-1
tp3597
sS'or,nitrous'
p3598
(F1
F0.00014334862385321102
I0
I1
I-1
tp3599
sS'agent,administered'
p3600
(F1
F0.00028669724770642203
I0
I2
I-2
tp3601
sS'was,analyzed'
p3602
(F1
F0.00028669724770642203
I0
I2
I-2
tp3603
sS'bid,a'
p3604
(F1
F0.00028669724770642203
I2
I0
I2
tp3605
sS'with,more'
p3606
(F1
F0.00014334862385321102
I1
I0
I1
tp3607
sS'isoflurane,potentiates'
p3608
(F1
F0.00014334862385321102
I1
I0
I1
tp3609
sS'changes,that'
p3610
(F1
F0.00014334862385321102
I1
I0
I1
tp3611
sS'mg,both'
p3612
(F1
F0.00014334862385321102
I0
I1
I-1
tp3613
sS'of,channel'
p3614
(F1
F0.00014334862385321102
I0
I1
I-1
tp3615
sS'randomly,bred'
p3616
(F1
F0.00014334862385321102
I0
I1
I-1
tp3617
sS'compounds,taken'
p3618
(F1
F0.00014334862385321102
I1
I0
I1
tp3619
sS'itraconazole,macrolides'
p3620
(F1
F0.00014334862385321102
I0
I1
I-1
tp3621
sS'phenytoin,tiagabine'
p3622
(F1
F0.00014334862385321102
I0
I1
I-1
tp3623
sS'status,and'
p3624
(F1
F0.00014334862385321102
I0
I1
I-1
tp3625
sS'had,achieved'
p3626
(F1
F0.00014334862385321102
I0
I1
I-1
tp3627
sS'levulan,kerastick'
p3628
(F1
F0.00014334862385321102
I1
I0
I1
tp3629
sS'because,may'
p3630
(F1
F0.00057339449541284407
I4
I0
I4
tp3631
sS'would,seem'
p3632
(F1
F0.00014334862385321102
I1
I0
I1
tp3633
sS'is,expected'
p3634
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3635
sS'salts,and'
p3636
(F1
F0.00028669724770642203
I2
I0
I2
tp3637
sS'monitoring,is'
p3638
(F1
F0.00014334862385321102
I1
I0
I1
tp3639
sS'decrease,conduction'
p3640
(F1
F0.00014334862385321102
I1
I0
I1
tp3641
sS'ache,activity'
p3642
(F1
F0.00014334862385321102
I1
I0
I1
tp3643
sS'consequences,for'
p3644
(F1
F0.00014334862385321102
I1
I0
I1
tp3645
sS'therapy,urinary'
p3646
(F1
F0.00028669724770642203
I2
I0
I2
tp3647
sS'inflammatory,arthritis'
p3648
(F1
F0.00014334862385321102
I1
I0
I1
tp3649
sS'reciprocal,interactions'
p3650
(F1
F0.00014334862385321102
I1
I0
I1
tp3651
sS'lithium,nsaids'
p3652
(F1
F0.00043004587155963305
I3
I0
I3
tp3653
sS'steroidal,anti-'
p3654
(F1
F0.00014334862385321102
I1
I0
I1
tp3655
sS'auc,ss'
p3656
(F1
F0.00028669724770642203
I2
I0
I2
tp3657
sS'which,also'
p3658
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp3659
sS'smaller,alfenta'
p3660
(F1
F0.00014334862385321102
I0
I1
I-1
tp3661
sS'be,reduced'
p3662
(F0.15384615384615385
F0.00057339449541284407
I15
I11
I4
tp3663
sS'cyp3a,compounds'
p3664
(F1
F0.00014334862385321102
I1
I0
I1
tp3665
sS'infarction,or'
p3666
(F1
F0.00014334862385321102
I0
I1
I-1
tp3667
sS'on,performance'
p3668
(F1
F0.00014334862385321102
I0
I1
I-1
tp3669
sS'with,by'
p3670
(F1
F0.00014334862385321102
I0
I1
I-1
tp3671
sS'primarily,to'
p3672
(F1
F0.00014334862385321102
I1
I0
I1
tp3673
sS'severe,short'
p3674
(F1
F0.00014334862385321102
I1
I0
I1
tp3675
sS'reactive,species'
p3676
(F1
F0.00014334862385321102
I0
I1
I-1
tp3677
sS'of,antithrombotics'
p3678
(F1
F0.00014334862385321102
I0
I1
I-1
tp3679
sS'were,added'
p3680
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp3681
sS'ephesus,patients'
p3682
(F1
F0.00014334862385321102
I0
I1
I-1
tp3683
sS'hydrobromide,may'
p3684
(F1
F0.00014334862385321102
I1
I0
I1
tp3685
sS'magnitude,lower'
p3686
(F1
F0.00014334862385321102
I0
I1
I-1
tp3687
sS'the,rat'
p3688
(F0
F0
I1
I1
I0
tp3689
sS'peganone,to'
p3690
(F1
F0.00014334862385321102
I1
I0
I1
tp3691
sS'aureus,to'
p3692
(F1
F0.00014334862385321102
I0
I1
I-1
tp3693
sS'other,interactions'
p3694
(F1
F0.00028669724770642203
I0
I2
I-2
tp3695
sS'reviewed,in'
p3696
(F1
F0.00014334862385321102
I1
I0
I1
tp3697
sS'ethacrynic,acid'
p3698
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp3699
sS'avoid,giving'
p3700
(F1
F0.00014334862385321102
I1
I0
I1
tp3701
sS'decreased,in'
p3702
(F1
F0.00028669724770642203
I2
I0
I2
tp3703
sS'orencia,has'
p3704
(F1
F0.00014334862385321102
I1
I0
I1
tp3705
sS'with,concurrently'
p3706
(F1
F0.00014334862385321102
I1
I0
I1
tp3707
sS'several,days'
p3708
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp3709
sS'demonstrated,any'
p3710
(F1
F0.00014334862385321102
I0
I1
I-1
tp3711
sS'the,nonlinear'
p3712
(F1
F0.00014334862385321102
I0
I1
I-1
tp3713
sS'mean,value'
p3714
(F1
F0.00014334862385321102
I0
I1
I-1
tp3715
sS'reversible,acute'
p3716
(F1
F0.00014334862385321102
I1
I0
I1
tp3717
sS'the,analgesic'
p3718
(F1
F0.00028669724770642203
I2
I0
I2
tp3719
sS'significant,when'
p3720
(F1
F0.00014334862385321102
I0
I1
I-1
tp3721
sS'of,hyperlipidemia'
p3722
(F1
F0.00014334862385321102
I1
I0
I1
tp3723
sS'and,behavioral'
p3724
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp3725
sS'maintained,patients'
p3726
(F1
F0.00014334862385321102
I1
I0
I1
tp3727
sS'similar,effects'
p3728
(F1
F0.00057339449541284407
I0
I4
I-4
tp3729
sS'by,reducing'
p3730
(F1
F0.00014334862385321102
I1
I0
I1
tp3731
sS'pronestyl,sulfa'
p3732
(F1
F0.00014334862385321102
I1
I0
I1
tp3733
sS'im,has'
p3734
(F1
F0.00014334862385321102
I0
I1
I-1
tp3735
sS'acid,calcium'
p3736
(F1
F0.00014334862385321102
I0
I1
I-1
tp3737
sS'monitor,the'
p3738
(F1
F0.00014334862385321102
I0
I1
I-1
tp3739
sS'increase,toxicity'
p3740
(F0
F0
I1
I1
I0
tp3741
sS'induce,cytochrome'
p3742
(F0
F0
I1
I1
I0
tp3743
sS'injection,who'
p3744
(F1
F0.00014334862385321102
I0
I1
I-1
tp3745
sS'infinity,auc'
p3746
(F1
F0.00014334862385321102
I0
I1
I-1
tp3747
sS'pronounced,intersubject'
p3748
(F1
F0.00014334862385321102
I1
I0
I1
tp3749
sS'capsule,formulation'
p3750
(F0.5
F0.00028669724770642203
I3
I1
I2
tp3751
sS'vioxx,should'
p3752
(F1
F0.00014334862385321102
I0
I1
I-1
tp3753
sS'concomitantly,indicate'
p3754
(F1
F0.00014334862385321102
I1
I0
I1
tp3755
sS'but,this'
p3756
(F1
F0.00028669724770642203
I2
I0
I2
tp3757
sS'to,fulminant'
p3758
(F1
F0.00014334862385321102
I1
I0
I1
tp3759
sS'demonstrated,efficacy'
p3760
(F1
F0.00028669724770642203
I0
I2
I-2
tp3761
sS'by,when'
p3762
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3763
sS'serum,sex'
p3764
(F1
F0.00014334862385321102
I1
I0
I1
tp3765
sS'as,can'
p3766
(F1
F0.00014334862385321102
I1
I0
I1
tp3767
sS'two,controlled'
p3768
(F1
F0.00014334862385321102
I0
I1
I-1
tp3769
sS'following,cisplatin'
p3770
(F1
F0.00014334862385321102
I1
I0
I1
tp3771
sS'nonbenzodiazepine,agonists'
p3772
(F1
F0.00014334862385321102
I1
I0
I1
tp3773
sS'allow,sufficient'
p3774
(F1
F0.00014334862385321102
I0
I1
I-1
tp3775
sS'interactions,a'
p3776
(F1
F0.00043004587155963305
I0
I3
I-3
tp3777
sS'or,related'
p3778
(F1
F0.00014334862385321102
I0
I1
I-1
tp3779
sS'patients,want'
p3780
(F1
F0.00014334862385321102
I0
I1
I-1
tp3781
sS'confirmed,these'
p3782
(F1
F0.00014334862385321102
I0
I1
I-1
tp3783
sS'antagonists,increased'
p3784
(F1
F0.00014334862385321102
I1
I0
I1
tp3785
sS'been,too'
p3786
(F1
F0.00014334862385321102
I0
I1
I-1
tp3787
sS'cause,hypothyroidism'
p3788
(F1
F0.00014334862385321102
I0
I1
I-1
tp3789
sS'and,prevent'
p3790
(F1
F0.00014334862385321102
I0
I1
I-1
tp3791
sS'involving,inhibition'
p3792
(F1
F0.00014334862385321102
I1
I0
I1
tp3793
sS'disturbances,have'
p3794
(F0
F0
I1
I1
I0
tp3795
sS'modify,the'
p3796
(F0
F0
I1
I1
I0
tp3797
sS'indinavir,mg'
p3798
(F1
F0.00014334862385321102
I1
I0
I1
tp3799
sS'predominantly,cyp'
p3800
(F1
F0.00014334862385321102
I0
I1
I-1
tp3801
sS'cardiovascular,collapse'
p3802
(F1
F0.00014334862385321102
I0
I1
I-1
tp3803
sS'injection,concentrate'
p3804
(F1
F0.00014334862385321102
I1
I0
I1
tp3805
sS'absorbed,into'
p3806
(F1
F0.00028669724770642203
I2
I0
I2
tp3807
sS'corticosteroids,methylxanthines'
p3808
(F1
F0.00014334862385321102
I1
I0
I1
tp3809
sS'lower,seizure'
p3810
(F1
F0.00014334862385321102
I1
I0
I1
tp3811
sS'd-ala2,metenkephalinamide'
p3812
(F1
F0.00014334862385321102
I0
I1
I-1
tp3813
sS'agents,there'
p3814
(F1
F0.00028669724770642203
I2
I0
I2
tp3815
sS'complex,anions'
p3816
(F1
F0.00014334862385321102
I0
I1
I-1
tp3817
sS'a,do'
p3818
(F1
F0.00014334862385321102
I1
I0
I1
tp3819
sS'but,changes'
p3820
(F1
F0.00014334862385321102
I0
I1
I-1
tp3821
sS'binds,differently'
p3822
(F1
F0.00014334862385321102
I0
I1
I-1
tp3823
sS'possible,resistance'
p3824
(F1
F0.00028669724770642203
I0
I2
I-2
tp3825
sS'robinul,injection'
p3826
(F1
F0.00028669724770642203
I2
I0
I2
tp3827
sS'trileptal,the'
p3828
(F1
F0.00014334862385321102
I1
I0
I1
tp3829
sS'hand,the'
p3830
(F1
F0.00014334862385321102
I0
I1
I-1
tp3831
sS'increase,awareness'
p3832
(F1
F0.00014334862385321102
I1
I0
I1
tp3833
sS'with,indirect'
p3834
(F1
F0.00014334862385321102
I0
I1
I-1
tp3835
sS'hydroxytamoxifen,tam'
p3836
(F1
F0.00014334862385321102
I0
I1
I-1
tp3837
sS'electrocardiographic,abnormalities'
p3838
(F1
F0.00014334862385321102
I1
I0
I1
tp3839
sS'phase,and'
p3840
(F1
F0.00014334862385321102
I0
I1
I-1
tp3841
sS'indocin,with'
p3842
(F1
F0.00014334862385321102
I1
I0
I1
tp3843
sS'aspirin,celebrex'
p3844
(F1
F0.00014334862385321102
I1
I0
I1
tp3845
sS'components,p1'
p3846
(F1
F0.00014334862385321102
I1
I0
I1
tp3847
sS'components,p2'
p3848
(F1
F0.00014334862385321102
I1
I0
I1
tp3849
sS'tid,the'
p3850
(F1
F0.00014334862385321102
I1
I0
I1
tp3851
sS'antihypertensives,amphetamines'
p3852
(F1
F0.00028669724770642203
I2
I0
I2
tp3853
sS'from,treatment'
p3854
(F1
F0.00014334862385321102
I1
I0
I1
tp3855
sS'aliskiren,does'
p3856
(F1
F0.00014334862385321102
I0
I1
I-1
tp3857
sS'in,uptake'
p3858
(F1
F0.00014334862385321102
I1
I0
I1
tp3859
sS'is,further'
p3860
(F1
F0.00014334862385321102
I0
I1
I-1
tp3861
sS'cimetidine,reduces'
p3862
(F1
F0.00014334862385321102
I1
I0
I1
tp3863
sS'toxicity,possibly'
p3864
(F1
F0.00028669724770642203
I2
I0
I2
tp3865
sS'diabetics,with'
p3866
(F1
F0.00014334862385321102
I1
I0
I1
tp3867
sS'necessary,the'
p3868
(F1
F0.00014334862385321102
I1
I0
I1
tp3869
sS'cancer,cells'
p3870
(F0
F0
I1
I1
I0
tp3871
sS'and,epoxide'
p3872
(F1
F0.00028669724770642203
I0
I2
I-2
tp3873
sS'of,selective'
p3874
(F1
F0.00028669724770642203
I2
I0
I2
tp3875
sS'is,advised'
p3876
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp3877
sS'to,administration'
p3878
(F1
F0.00014334862385321102
I0
I1
I-1
tp3879
sS'recently,received'
p3880
(F1
F0.00014334862385321102
I1
I0
I1
tp3881
sS'baseline,values'
p3882
(F1
F0.00014334862385321102
I1
I0
I1
tp3883
sS'following,adrenocorticoids'
p3884
(F1
F0.00014334862385321102
I1
I0
I1
tp3885
sS'is,therefore'
p3886
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp3887
sS'using,their'
p3888
(F1
F0.00014334862385321102
I0
I1
I-1
tp3889
sS'of,r-warfarin'
p3890
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3891
sS'and,must'
p3892
(F1
F0.00014334862385321102
I0
I1
I-1
tp3893
sS'of,exjade'
p3894
(F1
F0.00043004587155963305
I0
I3
I-3
tp3895
sS'hepatic,metabolism'
p3896
(F1
F0.0012901376146788992
I9
I0
I9
tp3897
sS'volunteer,received'
p3898
(F1
F0.00014334862385321102
I0
I1
I-1
tp3899
sS'which,induce'
p3900
(F1
F0.00028669724770642203
I2
I0
I2
tp3901
sS'general,or'
p3902
(F1
F0.00028669724770642203
I2
I0
I2
tp3903
sS'reactions,atg'
p3904
(F1
F0.00014334862385321102
I0
I1
I-1
tp3905
sS'been,studied'
p3906
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp3907
sS'of,antistress'
p3908
(F1
F0.00014334862385321102
I0
I1
I-1
tp3909
sS'the,drug'
p3910
(F1
F0.00014334862385321102
I1
I0
I1
tp3911
sS'containing,to'
p3912
(F1
F0.00014334862385321102
I1
I0
I1
tp3913
sS'administered,did'
p3914
(F1
F0.00014334862385321102
I0
I1
I-1
tp3915
sS'those,produced'
p3916
(F1
F0.00014334862385321102
I1
I0
I1
tp3917
sS'increase,respectively'
p3918
(F1
F0.00014334862385321102
I1
I0
I1
tp3919
sS'hours,are'
p3920
(F1
F0.00014334862385321102
I1
I0
I1
tp3921
sS'days,systemic'
p3922
(F1
F0.00028669724770642203
I2
I0
I2
tp3923
sS'be,used'
p3924
(F0.62666666666666671
F0.0067373853211009178
I61
I14
I47
tp3925
sS'receiving,both'
p3926
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp3927
sS'system,by'
p3928
(F1
F0.00014334862385321102
I0
I1
I-1
tp3929
sS'possible,dose'
p3930
(F1
F0.00014334862385321102
I1
I0
I1
tp3931
sS'increased,the'
p3932
(F0.87878787878787878
F0.0041571100917431195
I31
I2
I29
tp3933
sS'levels,mcg'
p3934
(F1
F0.00014334862385321102
I1
I0
I1
tp3935
sS'on,other'
p3936
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp3937
sS'and,mycophenolate'
p3938
(F1
F0.00014334862385321102
I1
I0
I1
tp3939
sS't3,in'
p3940
(F1
F0.00014334862385321102
I1
I0
I1
tp3941
sS'they,reduce'
p3942
(F1
F0.00057339449541284407
I4
I0
I4
tp3943
sS'behaviors,most'
p3944
(F1
F0.00014334862385321102
I0
I1
I-1
tp3945
sS'antizol,by'
p3946
(F1
F0.00014334862385321102
I1
I0
I1
tp3947
sS'while,the'
p3948
(F0.5
F0.00028669724770642203
I3
I1
I2
tp3949
sS'the,auc0-120hr'
p3950
(F1
F0.00014334862385321102
I1
I0
I1
tp3951
sS'acarbose,in'
p3952
(F1
F0.00014334862385321102
I0
I1
I-1
tp3953
sS'morphine-induced,and'
p3954
(F1
F0.00014334862385321102
I1
I0
I1
tp3955
sS'by,activation'
p3956
(F1
F0.00014334862385321102
I0
I1
I-1
tp3957
sS'treated,subjects'
p3958
(F1
F0.00028669724770642203
I0
I2
I-2
tp3959
sS'platelet,effects'
p3960
(F1
F0.00028669724770642203
I0
I2
I-2
tp3961
sS'auc0-12,of'
p3962
(F0
F0
I1
I1
I0
tp3963
sS'resulting,in'
p3964
(F0.68000000000000005
F0.0048738532110091746
I42
I8
I34
tp3965
sS'and,protease'
p3966
(F1
F0.00014334862385321102
I0
I1
I-1
tp3967
sS'heart,can'
p3968
(F1
F0.00014334862385321102
I0
I1
I-1
tp3969
sS'control,of'
p3970
(F1
F0.00028669724770642203
I0
I2
I-2
tp3971
sS'than,two-fold'
p3972
(F1
F0.00028669724770642203
I2
I0
I2
tp3973
sS'usually,within'
p3974
(F1
F0.00014334862385321102
I1
I0
I1
tp3975
sS'of,chloride-induced'
p3976
(F1
F0.00014334862385321102
I1
I0
I1
tp3977
sS'fluoxetine,does'
p3978
(F1
F0.00014334862385321102
I0
I1
I-1
tp3979
sS'plasma,has'
p3980
(F1
F0.00014334862385321102
I1
I0
I1
tp3981
sS'state,mg'
p3982
(F1
F0.00014334862385321102
I1
I0
I1
tp3983
sS'including,ganglionic'
p3984
(F1
F0.00014334862385321102
I1
I0
I1
tp3985
sS'with,nevirapine-'
p3986
(F1
F0.00014334862385321102
I0
I1
I-1
tp3987
sS'is,coadministered'
p3988
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp3989
sS'affect,distribution'
p3990
(F1
F0.00014334862385321102
I0
I1
I-1
tp3991
sS'be,displaced'
p3992
(F1
F0.00014334862385321102
I1
I0
I1
tp3993
sS'mg,before'
p3994
(F1
F0.00014334862385321102
I0
I1
I-1
tp3995
sS'basis,appears'
p3996
(F1
F0.00014334862385321102
I1
I0
I1
tp3997
sS'antagonists,histamine'
p3998
(F1
F0.00014334862385321102
I0
I1
I-1
tp3999
sS'and,returned'
p4000
(F1
F0.00014334862385321102
I0
I1
I-1
tp4001
sS'decrease,glutathione'
p4002
(F1
F0.00014334862385321102
I1
I0
I1
tp4003
sS'sodium,enhances'
p4004
(F1
F0.00014334862385321102
I1
I0
I1
tp4005
sS'experience,an'
p4006
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4007
sS'epilepsy,ingesting'
p4008
(F1
F0.00043004587155963305
I0
I3
I-3
tp4009
sS'and,concomitant'
p4010
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp4011
sS'exacerbated,by'
p4012
(F1
F0.00028669724770642203
I2
I0
I2
tp4013
sS'a,change'
p4014
(F0
F0
I1
I1
I0
tp4015
sS'cmin,were'
p4016
(F1
F0.00057339449541284407
I4
I0
I4
tp4017
sS'single,agent'
p4018
(F1
F0.00014334862385321102
I0
I1
I-1
tp4019
sS'for,estimation'
p4020
(F1
F0.00014334862385321102
I0
I1
I-1
tp4021
sS'hot,weather'
p4022
(F1
F0.00014334862385321102
I1
I0
I1
tp4023
sS'estradiol,by'
p4024
(F1
F0.00043004587155963305
I3
I0
I3
tp4025
sS'implantable,forms'
p4026
(F1
F0.00014334862385321102
I1
I0
I1
tp4027
sS'coadministration,in'
p4028
(F1
F0.00014334862385321102
I0
I1
I-1
tp4029
sS'haca,titers'
p4030
(F1
F0.00014334862385321102
I0
I1
I-1
tp4031
sS'chemotherapy,plus'
p4032
(F1
F0.00028669724770642203
I0
I2
I-2
tp4033
sS'patients,treated'
p4034
(F0.39130434782608697
F0.0012901376146788992
I16
I7
I9
tp4035
sS'any,signs'
p4036
(F1
F0.00014334862385321102
I1
I0
I1
tp4037
sS'isocarboxazid,and'
p4038
(F1
F0.00014334862385321102
I1
I0
I1
tp4039
sS'or,hypersensitivity'
p4040
(F1
F0.00014334862385321102
I0
I1
I-1
tp4041
sS'contained,in'
p4042
(F1
F0.00028669724770642203
I2
I0
I2
tp4043
sS'greater,proportion'
p4044
(F1
F0.00014334862385321102
I1
I0
I1
tp4045
sS'of,were'
p4046
(F0.090909090909090912
F0.00028669724770642203
I10
I12
I-2
tp4047
sS'describes,a'
p4048
(F1
F0.00014334862385321102
I1
I0
I1
tp4049
sS'might,increase'
p4050
(F1
F0.00043004587155963305
I3
I0
I3
tp4051
sS'tests,the'
p4052
(F1
F0.00014334862385321102
I1
I0
I1
tp4053
sS'suggest,any'
p4054
(F1
F0.00014334862385321102
I0
I1
I-1
tp4055
sS'had,less'
p4056
(F1
F0.00014334862385321102
I1
I0
I1
tp4057
sS'collapse,in'
p4058
(F1
F0.00014334862385321102
I0
I1
I-1
tp4059
sS'more,convenient'
p4060
(F1
F0.00014334862385321102
I0
I1
I-1
tp4061
sS'it,significantly'
p4062
(F0
F0
I1
I1
I0
tp4063
sS'failure,in'
p4064
(F1
F0.00014334862385321102
I1
I0
I1
tp4065
sS'cautious,when'
p4066
(F1
F0.00028669724770642203
I2
I0
I2
tp4067
sS'biochemical,toxicology'
p4068
(F1
F0.00014334862385321102
I0
I1
I-1
tp4069
sS'that,are'
p4070
(F0.069767441860465115
F0.00043004587155963305
I23
I20
I3
tp4071
sS'phosphorylation,of'
p4072
(F0.5
F0.00028669724770642203
I3
I1
I2
tp4073
sS'kg,or'
p4074
(F1
F0.00057339449541284407
I0
I4
I-4
tp4075
sS'polystyrene,sulfonate'
p4076
(F1
F0.00014334862385321102
I1
I0
I1
tp4077
sS'a,fixed'
p4078
(F1
F0.00014334862385321102
I0
I1
I-1
tp4079
sS'warranted,in'
p4080
(F1
F0.00014334862385321102
I1
I0
I1
tp4081
sS'cardiac,enlargement'
p4082
(F1
F0.00014334862385321102
I1
I0
I1
tp4083
sS'kg,on'
p4084
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4085
sS'kg,of'
p4086
(F1
F0.00028669724770642203
I0
I2
I-2
tp4087
sS'in,young'
p4088
(F1
F0.00014334862385321102
I0
I1
I-1
tp4089
sS'ileus,may'
p4090
(F1
F0.00014334862385321102
I1
I0
I1
tp4091
sS'mild,to'
p4092
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4093
sS'block,caution'
p4094
(F1
F0.00014334862385321102
I1
I0
I1
tp4095
sS'were,nonsteroidal'
p4096
(F1
F0.00014334862385321102
I0
I1
I-1
tp4097
sS'reduced,when'
p4098
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4099
sS'be,additive'
p4100
(F1
F0.0011467889908256881
I8
I0
I8
tp4101
sS'on,this'
p4102
(F1
F0.00014334862385321102
I0
I1
I-1
tp4103
sS'of,strattera'
p4104
(F1
F0.00014334862385321102
I1
I0
I1
tp4105
sS'these,medicinal'
p4106
(F1
F0.00028669724770642203
I2
I0
I2
tp4107
sS'sedation,time'
p4108
(F1
F0.00014334862385321102
I0
I1
I-1
tp4109
sS'of,elimination'
p4110
(F1
F0.00043004587155963305
I3
I0
I3
tp4111
sS'cyp2a6,cyp2b6'
p4112
(F1
F0.00014334862385321102
I0
I1
I-1
tp4113
sS'vasculature,without'
p4114
(F1
F0.00014334862385321102
I0
I1
I-1
tp4115
sS'be,provided'
p4116
(F1
F0.00014334862385321102
I0
I1
I-1
tp4117
sS'receiving,prinivil'
p4118
(F1
F0.00014334862385321102
I1
I0
I1
tp4119
sS'acute,dosing'
p4120
(F1
F0.00028669724770642203
I0
I2
I-2
tp4121
sS'states,and'
p4122
(F1
F0.00014334862385321102
I0
I1
I-1
tp4123
sS'of,profound'
p4124
(F1
F0.00014334862385321102
I1
I0
I1
tp4125
sS'causing,bone'
p4126
(F1
F0.00014334862385321102
I1
I0
I1
tp4127
sS'agents,monoamine'
p4128
(F1
F0.00014334862385321102
I1
I0
I1
tp4129
sS'thiazides,may'
p4130
(F1
F0.00014334862385321102
I1
I0
I1
tp4131
sS'patients,steady-state'
p4132
(F1
F0.00014334862385321102
I1
I0
I1
tp4133
sS'effective,due'
p4134
(F0
F0
I1
I1
I0
tp4135
sS'inhaler,take'
p4136
(F1
F0.00014334862385321102
I1
I0
I1
tp4137
sS'complex,and'
p4138
(F1
F0.00014334862385321102
I1
I0
I1
tp4139
sS'three-period,randomized'
p4140
(F1
F0.00014334862385321102
I0
I1
I-1
tp4141
sS'performance,of'
p4142
(F1
F0.00014334862385321102
I0
I1
I-1
tp4143
sS'were,determined'
p4144
(F1
F0.00043004587155963305
I0
I3
I-3
tp4145
sS'or,extent'
p4146
(F1
F0.00043004587155963305
I0
I3
I-3
tp4147
sS'enzyme,eg'
p4148
(F1
F0.00014334862385321102
I1
I0
I1
tp4149
sS'mc,enhance'
p4150
(F1
F0.00014334862385321102
I0
I1
I-1
tp4151
sS'however,this'
p4152
(F1
F0.00014334862385321102
I0
I1
I-1
tp4153
sS'tubular,atrophy'
p4154
(F1
F0.00014334862385321102
I0
I1
I-1
tp4155
sS'concentrations,showing'
p4156
(F1
F0.00014334862385321102
I0
I1
I-1
tp4157
sS'of,protein'
p4158
(F1
F0.00014334862385321102
I0
I1
I-1
tp4159
sS'of,sites'
p4160
(F1
F0.00014334862385321102
I0
I1
I-1
tp4161
sS'beta-adrenergic,blockers'
p4162
(F1
F0.00028669724770642203
I2
I0
I2
tp4163
sS'laboratory,testing'
p4164
(F1
F0.00014334862385321102
I1
I0
I1
tp4165
sS'medicine,you'
p4166
(F1
F0.00014334862385321102
I1
I0
I1
tp4167
sS'with,humira'
p4168
(F1
F0.00014334862385321102
I0
I1
I-1
tp4169
sS'seriraline,and'
p4170
(F1
F0.00014334862385321102
I0
I1
I-1
tp4171
sS'trileptal,with'
p4172
(F1
F0.00028669724770642203
I2
I0
I2
tp4173
sS'tricor,there'
p4174
(F1
F0.00014334862385321102
I1
I0
I1
tp4175
sS'amitriptyline,hcl'
p4176
(F0
F0
I1
I1
I0
tp4177
sS'of,peptide'
p4178
(F1
F0.00014334862385321102
I0
I1
I-1
tp4179
sS'were,observed'
p4180
(F0.75
F0.0017201834862385322
I2
I14
I-12
tp4181
sS'the,anti-glaucoma'
p4182
(F1
F0.00014334862385321102
I1
I0
I1
tp4183
sS'in,eight'
p4184
(F1
F0.00043004587155963305
I3
I0
I3
tp4185
sS'and,mechanisms'
p4186
(F1
F0.00014334862385321102
I0
I1
I-1
tp4187
sS'angiotensln,converting'
p4188
(F1
F0.00014334862385321102
I1
I0
I1
tp4189
sS'qtc,values'
p4190
(F1
F0.00014334862385321102
I1
I0
I1
tp4191
sS'inhibitory,concentrations'
p4192
(F1
F0.00014334862385321102
I0
I1
I-1
tp4193
sS'end,of'
p4194
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp4195
sS'dose,to'
p4196
(F0.5
F0.00057339449541284407
I6
I2
I4
tp4197
sS'family,in'
p4198
(F1
F0.00014334862385321102
I1
I0
I1
tp4199
sS'elevated,levels'
p4200
(F0.5
F0.00028669724770642203
I3
I1
I2
tp4201
sS'warfarin,co-'
p4202
(F1
F0.00014334862385321102
I0
I1
I-1
tp4203
sS'increased,deet'
p4204
(F1
F0.00014334862385321102
I0
I1
I-1
tp4205
sS'structural,similarity'
p4206
(F1
F0.00014334862385321102
I1
I0
I1
tp4207
sS'we,investigated'
p4208
(F1
F0.00028669724770642203
I0
I2
I-2
tp4209
sS'with,cefizox'
p4210
(F1
F0.00014334862385321102
I1
I0
I1
tp4211
sS'administration,attenuates'
p4212
(F1
F0.00014334862385321102
I1
I0
I1
tp4213
sS'data,suggest'
p4214
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp4215
sS'zaleplons,maximal'
p4216
(F1
F0.00014334862385321102
I1
I0
I1
tp4217
sS'conclusions,olanzapine'
p4218
(F1
F0.00014334862385321102
I0
I1
I-1
tp4219
sS'and,low-dose'
p4220
(F1
F0.00014334862385321102
I1
I0
I1
tp4221
sS'with,changes'
p4222
(F1
F0.00014334862385321102
I0
I1
I-1
tp4223
sS'cyp450s,cyp1a2'
p4224
(F1
F0.00014334862385321102
I0
I1
I-1
tp4225
sS'interactions,among'
p4226
(F1
F0.00014334862385321102
I0
I1
I-1
tp4227
sS'to,triple-immunosuppression'
p4228
(F1
F0.00014334862385321102
I0
I1
I-1
tp4229
sS'and,collected'
p4230
(F1
F0.00014334862385321102
I0
I1
I-1
tp4231
sS'hypotension,cimetidine'
p4232
(F1
F0.00014334862385321102
I1
I0
I1
tp4233
sS'subjects,experienced'
p4234
(F1
F0.00028669724770642203
I2
I0
I2
tp4235
sS'unaltered,by'
p4236
(F1
F0.00014334862385321102
I0
I1
I-1
tp4237
sS'cephalothin,sodium'
p4238
(F1
F0.00014334862385321102
I0
I1
I-1
tp4239
sS'antihypertensive,therapy'
p4240
(F1
F0.00014334862385321102
I1
I0
I1
tp4241
sS'could,pose'
p4242
(F0
F0
I1
I1
I0
tp4243
sS'and,might'
p4244
(F1
F0.00028669724770642203
I2
I0
I2
tp4245
sS'and,increases'
p4246
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp4247
sS'copper,sulfate'
p4248
(F1
F0.00014334862385321102
I0
I1
I-1
tp4249
sS'volunteers,either'
p4250
(F1
F0.00014334862385321102
I1
I0
I1
tp4251
sS'ensure,that'
p4252
(F1
F0.00014334862385321102
I1
I0
I1
tp4253
sS'carbamazepine,overdose'
p4254
(F1
F0.00014334862385321102
I0
I1
I-1
tp4255
sS'to,potential'
p4256
(F1
F0.00057339449541284407
I0
I4
I-4
tp4257
sS'positive,readings'
p4258
(F1
F0.00014334862385321102
I0
I1
I-1
tp4259
sS'clozapine,plasma'
p4260
(F1
F0.00014334862385321102
I1
I0
I1
tp4261
sS'and,increased'
p4262
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp4263
sS'collected,by'
p4264
(F1
F0.00014334862385321102
I0
I1
I-1
tp4265
sS'narcotic,may'
p4266
(F1
F0.00014334862385321102
I1
I0
I1
tp4267
sS't,a'
p4268
(F1
F0.00014334862385321102
I1
I0
I1
tp4269
sS'patients,including'
p4270
(F1
F0.00014334862385321102
I0
I1
I-1
tp4271
sS't,i'
p4272
(F1
F0.00043004587155963305
I3
I0
I3
tp4273
sS'thus,decrease'
p4274
(F1
F0.00014334862385321102
I1
I0
I1
tp4275
sS'the,residual'
p4276
(F1
F0.00014334862385321102
I1
I0
I1
tp4277
sS'both,therapies'
p4278
(F1
F0.00014334862385321102
I0
I1
I-1
tp4279
sS'a,partially'
p4280
(F1
F0.00014334862385321102
I0
I1
I-1
tp4281
sS'of,metabolized'
p4282
(F1
F0.00028669724770642203
I0
I2
I-2
tp4283
sS'be,augmented'
p4284
(F1
F0.00014334862385321102
I1
I0
I1
tp4285
sS'by,cyp'
p4286
(F1
F0.00057339449541284407
I0
I4
I-4
tp4287
sS'with,concurrent'
p4288
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4289
sS'ra,were'
p4290
(F1
F0.00028669724770642203
I2
I0
I2
tp4291
sS'phenyl-1,tetrahydropyridine'
p4292
(F1
F0.00014334862385321102
I0
I1
I-1
tp4293
sS'and,vitamin'
p4294
(F0
F0
I2
I2
I0
tp4295
sS'few,systemic'
p4296
(F1
F0.00014334862385321102
I0
I1
I-1
tp4297
sS'in,older'
p4298
(F1
F0.00014334862385321102
I0
I1
I-1
tp4299
sS'due,to'
p4300
(F0.30232558139534882
F0.0018635321100917432
I28
I15
I13
tp4301
sS'been,definitively'
p4302
(F1
F0.00014334862385321102
I1
I0
I1
tp4303
sS'interactions,the'
p4304
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp4305
sS'required,for'
p4306
(F1
F0.00014334862385321102
I0
I1
I-1
tp4307
sS'either,tagamet'
p4308
(F1
F0.00014334862385321102
I1
I0
I1
tp4309
sS'multipledose,treatment'
p4310
(F1
F0.00014334862385321102
I0
I1
I-1
tp4311
sS'of,b6'
p4312
(F1
F0.00014334862385321102
I0
I1
I-1
tp4313
sS'inhibitors,oral'
p4314
(F1
F0.00014334862385321102
I0
I1
I-1
tp4315
sS'has,also'
p4316
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp4317
sS'cyp,c19'
p4318
(F1
F0.00014334862385321102
I0
I1
I-1
tp4319
sS'enzyme,inducer'
p4320
(F1
F0.00028669724770642203
I2
I0
I2
tp4321
sS'and,fermented'
p4322
(F1
F0.00014334862385321102
I0
I1
I-1
tp4323
sS'increases,auc'
p4324
(F1
F0.00014334862385321102
I1
I0
I1
tp4325
sS'vitro,upon'
p4326
(F1
F0.00014334862385321102
I1
I0
I1
tp4327
sS'of,be'
p4328
(F1
F0.00028669724770642203
I2
I0
I2
tp4329
sS'of,by'
p4330
(F0.82857142857142863
F0.0041571100917431195
I32
I3
I29
tp4331
sS'from,lean'
p4332
(F1
F0.00014334862385321102
I0
I1
I-1
tp4333
sS'until,a'
p4334
(F1
F0.00014334862385321102
I1
I0
I1
tp4335
sS'depressive,effects'
p4336
(F1
F0.00014334862385321102
I1
I0
I1
tp4337
sS'of,low-dose'
p4338
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4339
sS'as,with'
p4340
(F0.55555555555555558
F0.0014334862385321102
I14
I4
I10
tp4341
sS'regulation,of'
p4342
(F1
F0.00043004587155963305
I0
I3
I-3
tp4343
sS'coat-core,formulation'
p4344
(F1
F0.00014334862385321102
I1
I0
I1
tp4345
sS'two,other'
p4346
(F1
F0.00014334862385321102
I1
I0
I1
tp4347
sS'although,these'
p4348
(F1
F0.00014334862385321102
I1
I0
I1
tp4349
sS'either,diabetics'
p4350
(F1
F0.00014334862385321102
I0
I1
I-1
tp4351
sS'i,trial'
p4352
(F0
F0
I1
I1
I0
tp4353
sS'receiving,no'
p4354
(F1
F0.00014334862385321102
I0
I1
I-1
tp4355
sS'single,subject'
p4356
(F1
F0.00014334862385321102
I1
I0
I1
tp4357
sS'camptosar,than'
p4358
(F1
F0.00014334862385321102
I1
I0
I1
tp4359
sS'respond,differently'
p4360
(F1
F0.00014334862385321102
I0
I1
I-1
tp4361
sS'and,demonstrated'
p4362
(F1
F0.00014334862385321102
I0
I1
I-1
tp4363
sS'pharmacokinetic,study'
p4364
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp4365
sS'ethanolysis,of'
p4366
(F1
F0.00014334862385321102
I1
I0
I1
tp4367
sS'include,adrenocortical'
p4368
(F1
F0.00014334862385321102
I1
I0
I1
tp4369
sS'and,avastin'
p4370
(F1
F0.00014334862385321102
I0
I1
I-1
tp4371
sS'died,compared'
p4372
(F1
F0.00014334862385321102
I0
I1
I-1
tp4373
sS'on,sodium'
p4374
(F1
F0.00014334862385321102
I1
I0
I1
tp4375
sS'xigris,is'
p4376
(F1
F0.00014334862385321102
I0
I1
I-1
tp4377
sS'microsomal,enzyme'
p4378
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp4379
sS'controlled,clinical'
p4380
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp4381
sS'been,proposed'
p4382
(F1
F0.00014334862385321102
I1
I0
I1
tp4383
sS'with,coenzyme'
p4384
(F1
F0.00014334862385321102
I0
I1
I-1
tp4385
sS'slightly,from'
p4386
(F1
F0.00014334862385321102
I1
I0
I1
tp4387
sS'of,breast'
p4388
(F0
F0
I1
I1
I0
tp4389
sS'psychiatric,rating'
p4390
(F1
F0.00014334862385321102
I1
I0
I1
tp4391
sS'serum,enzymes'
p4392
(F1
F0.00014334862385321102
I1
I0
I1
tp4393
sS'erectile,dysfunction'
p4394
(F1
F0.00014334862385321102
I0
I1
I-1
tp4395
sS'cmax,by'
p4396
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4397
sS'prolonging,atrioventricular'
p4398
(F1
F0.00014334862385321102
I1
I0
I1
tp4399
sS'from,spontaneous'
p4400
(F1
F0.00014334862385321102
I0
I1
I-1
tp4401
sS'volunteers,treatment'
p4402
(F1
F0.00014334862385321102
I1
I0
I1
tp4403
sS'an,elevation'
p4404
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4405
sS'have,confirmed'
p4406
(F1
F0.00014334862385321102
I0
I1
I-1
tp4407
sS'generally,by'
p4408
(F1
F0.00014334862385321102
I0
I1
I-1
tp4409
sS'neuromuscular,blockers'
p4410
(F1
F0.00014334862385321102
I0
I1
I-1
tp4411
sS'mg,initial'
p4412
(F1
F0.00014334862385321102
I1
I0
I1
tp4413
sS'and,nose'
p4414
(F1
F0.00014334862385321102
I1
I0
I1
tp4415
sS'time,response'
p4416
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4417
sS'cyp2c19,substrate'
p4418
(F1
F0.00014334862385321102
I1
I0
I1
tp4419
sS'efficacy,has'
p4420
(F1
F0.00014334862385321102
I0
I1
I-1
tp4421
sS'including,humira'
p4422
(F1
F0.00014334862385321102
I1
I0
I1
tp4423
sS'absorbed,is'
p4424
(F1
F0.00014334862385321102
I0
I1
I-1
tp4425
sS'rats,results'
p4426
(F1
F0.00014334862385321102
I1
I0
I1
tp4427
sS'hormone,binding'
p4428
(F1
F0.00014334862385321102
I0
I1
I-1
tp4429
sS'formation,in'
p4430
(F1
F0.00014334862385321102
I1
I0
I1
tp4431
sS'sub-therapeutic,concentrations'
p4432
(F1
F0.00014334862385321102
I1
I0
I1
tp4433
sS'profound,hypotensive'
p4434
(F1
F0.00014334862385321102
I1
I0
I1
tp4435
sS'concomitant,therapy'
p4436
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp4437
sS'oxidation,of'
p4438
(F1
F0.00014334862385321102
I1
I0
I1
tp4439
sS'when,k'
p4440
(F1
F0.00014334862385321102
I1
I0
I1
tp4441
sS'metabotropic,glutamate'
p4442
(F1
F0.00014334862385321102
I0
I1
I-1
tp4443
sS'trisenox,is'
p4444
(F1
F0.00014334862385321102
I1
I0
I1
tp4445
sS'when,a'
p4446
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp4447
sS'is,minimally'
p4448
(F1
F0.00014334862385321102
I1
I0
I1
tp4449
sS'a,antidepressant'
p4450
(F1
F0.00014334862385321102
I1
I0
I1
tp4451
sS'for,information'
p4452
(F1
F0.00014334862385321102
I0
I1
I-1
tp4453
sS'possible,to'
p4454
(F1
F0.00014334862385321102
I0
I1
I-1
tp4455
sS'a,euthyroid'
p4456
(F1
F0.00014334862385321102
I0
I1
I-1
tp4457
sS'at,nacmc'
p4458
(F1
F0.00014334862385321102
I0
I1
I-1
tp4459
sS'area-under,the-curve'
p4460
(F1
F0.00014334862385321102
I1
I0
I1
tp4461
sS'treatment-naive,patients'
p4462
(F1
F0.00014334862385321102
I0
I1
I-1
tp4463
sS'an,omega-agatoxin'
p4464
(F1
F0.00014334862385321102
I0
I1
I-1
tp4465
sS'oral,hypoglycemics'
p4466
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp4467
sS'agents,including'
p4468
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp4469
sS'tagamet,is'
p4470
(F1
F0.00014334862385321102
I1
I0
I1
tp4471
sS'agonists,because'
p4472
(F1
F0.00014334862385321102
I1
I0
I1
tp4473
sS'sustained,increases'
p4474
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4475
sS'tablets,in'
p4476
(F1
F0.00028669724770642203
I2
I0
I2
tp4477
sS'given,lodine'
p4478
(F1
F0.00014334862385321102
I0
I1
I-1
tp4479
sS'decreased,when'
p4480
(F1
F0.00057339449541284407
I4
I0
I4
tp4481
sS'was,only'
p4482
(F0
F0
I1
I1
I0
tp4483
sS'play,an'
p4484
(F1
F0.00028669724770642203
I2
I0
I2
tp4485
sS'tablets,is'
p4486
(F1
F0.00014334862385321102
I1
I0
I1
tp4487
sS'metabolized,triazolo-benzodiazepines'
p4488
(F1
F0.00014334862385321102
I1
I0
I1
tp4489
sS'when,are'
p4490
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp4491
sS'rifabutin,did'
p4492
(F1
F0.00014334862385321102
I0
I1
I-1
tp4493
sS'an,ssri'
p4494
(F1
F0.00057339449541284407
I4
I0
I4
tp4495
sS'abolished,as'
p4496
(F1
F0.00014334862385321102
I1
I0
I1
tp4497
sS'lower,blood'
p4498
(F1
F0.00014334862385321102
I1
I0
I1
tp4499
sS'via,cytochrome'
p4500
(F1
F0.00028669724770642203
I0
I2
I-2
tp4501
sS'was,bioequivalent'
p4502
(F1
F0.00028669724770642203
I0
I2
I-2
tp4503
sS'studies,including'
p4504
(F1
F0.00014334862385321102
I0
I1
I-1
tp4505
sS'of,serotonin'
p4506
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4507
sS'thus,in'
p4508
(F1
F0.00014334862385321102
I1
I0
I1
tp4509
sS'within,a'
p4510
(F1
F0.00014334862385321102
I1
I0
I1
tp4511
sS'l,and'
p4512
(F0
F0
I1
I1
I0
tp4513
sS'bleeding,has'
p4514
(F1
F0.00057339449541284407
I4
I0
I4
tp4515
sS'strong,inhibitor'
p4516
(F1
F0.00014334862385321102
I1
I0
I1
tp4517
sS'nonsteroidal,agents'
p4518
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp4519
sS'a,clinical'
p4520
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp4521
sS'be,noted'
p4522
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4523
sS'of,proteus'
p4524
(F1
F0.00014334862385321102
I0
I1
I-1
tp4525
sS'titrated,with'
p4526
(F1
F0.00014334862385321102
I1
I0
I1
tp4527
sS'shortened,in'
p4528
(F1
F0.00014334862385321102
I1
I0
I1
tp4529
sS'decrease,hepatic'
p4530
(F1
F0.00014334862385321102
I1
I0
I1
tp4531
sS'of,total'
p4532
(F0
F0
I1
I1
I0
tp4533
sS'antagonists,congestive'
p4534
(F1
F0.00014334862385321102
I0
I1
I-1
tp4535
sS'sensitivity,and'
p4536
(F1
F0.00014334862385321102
I1
I0
I1
tp4537
sS'day,washout'
p4538
(F1
F0.00014334862385321102
I0
I1
I-1
tp4539
sS'when,any'
p4540
(F0
F0
I1
I1
I0
tp4541
sS'hemabate,may'
p4542
(F1
F0.00014334862385321102
I1
I0
I1
tp4543
sS'used,together'
p4544
(F1
F0.00043004587155963305
I3
I0
I3
tp4545
sS'five,normal'
p4546
(F1
F0.00014334862385321102
I1
I0
I1
tp4547
sS'effective,as'
p4548
(F1
F0.00014334862385321102
I0
I1
I-1
tp4549
sS'suspension,results'
p4550
(F1
F0.00014334862385321102
I1
I0
I1
tp4551
sS'increased,mean'
p4552
(F1
F0.00057339449541284407
I4
I0
I4
tp4553
sS'oral,such'
p4554
(F1
F0.00014334862385321102
I1
I0
I1
tp4555
sS'ritonavir,mg'
p4556
(F1
F0.00014334862385321102
I1
I0
I1
tp4557
sS'clinical,dose'
p4558
(F1
F0.00014334862385321102
I0
I1
I-1
tp4559
sS'analogues,vitamin'
p4560
(F1
F0.00043004587155963305
I3
I0
I3
tp4561
sS'in,several'
p4562
(F1
F0.00043004587155963305
I0
I3
I-3
tp4563
sS'of,flucoxacillin'
p4564
(F1
F0.00014334862385321102
I0
I1
I-1
tp4565
sS'may,ameliorate'
p4566
(F1
F0.00014334862385321102
I1
I0
I1
tp4567
sS'q12h,for'
p4568
(F0
F0
I1
I1
I0
tp4569
sS'oral,should'
p4570
(F1
F0.00014334862385321102
I0
I1
I-1
tp4571
sS'an,altered'
p4572
(F1
F0.00014334862385321102
I1
I0
I1
tp4573
sS'conducted,for'
p4574
(F1
F0.00014334862385321102
I0
I1
I-1
tp4575
sS'their,concomitant'
p4576
(F1
F0.00014334862385321102
I0
I1
I-1
tp4577
sS'many,angiotensin-converting'
p4578
(F1
F0.00014334862385321102
I1
I0
I1
tp4579
sS'when,therapeutic'
p4580
(F1
F0.00014334862385321102
I0
I1
I-1
tp4581
sS'oral,products'
p4582
(F1
F0.00014334862385321102
I0
I1
I-1
tp4583
sS'beta-glucuronidase,are'
p4584
(F1
F0.00014334862385321102
I0
I1
I-1
tp4585
sS'to,reduce'
p4586
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp4587
sS'passages,increasing'
p4588
(F1
F0.00014334862385321102
I1
I0
I1
tp4589
sS'considered,in'
p4590
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp4591
sS'can,in'
p4592
(F1
F0.00014334862385321102
I1
I0
I1
tp4593
sS'considered,if'
p4594
(F0
F0
I1
I1
I0
tp4595
sS'report,l-glutamine'
p4596
(F1
F0.00014334862385321102
I1
I0
I1
tp4597
sS'pressure,lowering'
p4598
(F1
F0.00014334862385321102
I1
I0
I1
tp4599
sS'cohort,then'
p4600
(F1
F0.00014334862385321102
I0
I1
I-1
tp4601
sS'been,rarely'
p4602
(F1
F0.00028669724770642203
I2
I0
I2
tp4603
sS'suggested,when'
p4604
(F1
F0.00014334862385321102
I1
I0
I1
tp4605
sS'each,administered'
p4606
(F1
F0.00014334862385321102
I1
I0
I1
tp4607
sS'both,with'
p4608
(F1
F0.00014334862385321102
I0
I1
I-1
tp4609
sS'peak,plasma'
p4610
(F1
F0.0012901376146788992
I9
I0
I9
tp4611
sS'g,h'
p4612
(F1
F0.00014334862385321102
I1
I0
I1
tp4613
sS'nsaids,suggests'
p4614
(F1
F0.00014334862385321102
I1
I0
I1
tp4615
sS'the,antimuscarinic'
p4616
(F1
F0.00014334862385321102
I1
I0
I1
tp4617
sS'alternative,hypoglycemic'
p4618
(F1
F0.00014334862385321102
I1
I0
I1
tp4619
sS'studies,where'
p4620
(F1
F0.00014334862385321102
I0
I1
I-1
tp4621
sS'approx,because'
p4622
(F1
F0.00014334862385321102
I1
I0
I1
tp4623
sS'with,gram'
p4624
(F1
F0.00014334862385321102
I1
I0
I1
tp4625
sS'depress,the'
p4626
(F1
F0.00014334862385321102
I1
I0
I1
tp4627
sS'unbound,by'
p4628
(F1
F0.00014334862385321102
I1
I0
I1
tp4629
sS'take,other'
p4630
(F1
F0.00014334862385321102
I0
I1
I-1
tp4631
sS'cancer,indicated'
p4632
(F1
F0.00014334862385321102
I1
I0
I1
tp4633
sS'antitumour,activity'
p4634
(F0
F0
I1
I1
I0
tp4635
sS'confusion,extrapyramidal'
p4636
(F1
F0.00014334862385321102
I1
I0
I1
tp4637
sS'rpmi1640,containing'
p4638
(F0
F0
I1
I1
I0
tp4639
sS'consideration,when'
p4640
(F1
F0.00014334862385321102
I1
I0
I1
tp4641
sS'is,believed'
p4642
(F1
F0.00014334862385321102
I1
I0
I1
tp4643
sS'urate,uricosuric'
p4644
(F1
F0.00014334862385321102
I1
I0
I1
tp4645
sS'completely,depressed'
p4646
(F1
F0.00014334862385321102
I1
I0
I1
tp4647
sS'to,alert'
p4648
(F1
F0.00014334862385321102
I1
I0
I1
tp4649
sS'patients,stabilized'
p4650
(F1
F0.00014334862385321102
I1
I0
I1
tp4651
sS'be,the'
p4652
(F0
F0
I2
I2
I0
tp4653
sS'acetate,and'
p4654
(F0
F0
I1
I1
I0
tp4655
sS'your,doctor'
p4656
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp4657
sS'caused,by'
p4658
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp4659
sS'dependent,oxidation'
p4660
(F0
F0
I1
I1
I0
tp4661
sS'separately,by'
p4662
(F1
F0.00014334862385321102
I1
I0
I1
tp4663
sS'm2,basis'
p4664
(F1
F0.00014334862385321102
I1
I0
I1
tp4665
sS'the,enhanced'
p4666
(F1
F0.00014334862385321102
I0
I1
I-1
tp4667
sS'period,when'
p4668
(F1
F0.00057339449541284407
I4
I0
I4
tp4669
sS'be,greater'
p4670
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4671
sS'different,in'
p4672
(F1
F0.00014334862385321102
I0
I1
I-1
tp4673
sS'refer,to'
p4674
(F0
F0
I2
I2
I0
tp4675
sS'certain,nonsteroidal'
p4676
(F1
F0.00014334862385321102
I1
I0
I1
tp4677
sS'potent,iiia4'
p4678
(F1
F0.00014334862385321102
I1
I0
I1
tp4679
sS'factor,vii'
p4680
(F1
F0.00014334862385321102
I0
I1
I-1
tp4681
sS'conclusion,that'
p4682
(F1
F0.00014334862385321102
I1
I0
I1
tp4683
sS'antacids,containing'
p4684
(F1
F0.00028669724770642203
I2
I0
I2
tp4685
sS'eg,valproic'
p4686
(F1
F0.00014334862385321102
I1
I0
I1
tp4687
sS'between,january'
p4688
(F1
F0.00014334862385321102
I0
I1
I-1
tp4689
sS'however,retinyl'
p4690
(F1
F0.00014334862385321102
I1
I0
I1
tp4691
sS'oral,antidiabetes'
p4692
(F1
F0.00014334862385321102
I0
I1
I-1
tp4693
sS'this,represents'
p4694
(F1
F0.00014334862385321102
I0
I1
I-1
tp4695
sS'drug-drug,interactions'
p4696
(F0.69230769230769229
F0.0012901376146788992
I2
I11
I-9
tp4697
sS'severe,reactions'
p4698
(F1
F0.00014334862385321102
I0
I1
I-1
tp4699
sS'to,m'
p4700
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4701
sS'to,l'
p4702
(F1
F0.00014334862385321102
I1
I0
I1
tp4703
sS'to,c'
p4704
(F1
F0.00014334862385321102
I0
I1
I-1
tp4705
sS'to,a'
p4706
(F0.23404255319148937
F0.0015768348623853212
I29
I18
I11
tp4707
sS'agents,such'
p4708
(F0.125
F0.00028669724770642203
I9
I7
I2
tp4709
sS'not,morphine-induced'
p4710
(F1
F0.00014334862385321102
I0
I1
I-1
tp4711
sS'we,conclude'
p4712
(F1
F0.00028669724770642203
I2
I0
I2
tp4713
sS'of,co'
p4714
(F1
F0.00014334862385321102
I0
I1
I-1
tp4715
sS'tool,with'
p4716
(F1
F0.00014334862385321102
I0
I1
I-1
tp4717
sS'coffee,was'
p4718
(F1
F0.00014334862385321102
I0
I1
I-1
tp4719
sS'can,inhibit'
p4720
(F0
F0
I5
I5
I0
tp4721
sS'when,macrolide'
p4722
(F1
F0.00014334862385321102
I0
I1
I-1
tp4723
sS'additionally,higher'
p4724
(F1
F0.00014334862385321102
I1
I0
I1
tp4725
sS'and,their'
p4726
(F0.5
F0.00028669724770642203
I3
I1
I2
tp4727
sS'on,pharmacokinetics'
p4728
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp4729
sS'showed,that'
p4730
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp4731
sS'currently,do'
p4732
(F1
F0.00014334862385321102
I0
I1
I-1
tp4733
sS'accelerated,when'
p4734
(F1
F0.00014334862385321102
I1
I0
I1
tp4735
sS'interactions,could'
p4736
(F1
F0.00014334862385321102
I0
I1
I-1
tp4737
sS'auc,for'
p4738
(F0
F0
I1
I1
I0
tp4739
sS'side-effects,in'
p4740
(F1
F0.00014334862385321102
I1
I0
I1
tp4741
sS'terfenadine,and'
p4742
(F1
F0.00014334862385321102
I1
I0
I1
tp4743
sS'or,and'
p4744
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp4745
sS'the,with'
p4746
(F1
F0.00014334862385321102
I1
I0
I1
tp4747
sS'pimozide,and'
p4748
(F1
F0.00014334862385321102
I1
I0
I1
tp4749
sS'rats,was'
p4750
(F1
F0.00028669724770642203
I0
I2
I-2
tp4751
sS'patients,chronically'
p4752
(F1
F0.00014334862385321102
I1
I0
I1
tp4753
sS'or,any'
p4754
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4755
sS'any,of'
p4756
(F0
F0
I7
I7
I0
tp4757
sS'cyp3a4,did'
p4758
(F1
F0.00014334862385321102
I0
I1
I-1
tp4759
sS'suggestive,of'
p4760
(F1
F0.00014334862385321102
I1
I0
I1
tp4761
sS'for,injection'
p4762
(F1
F0.00028669724770642203
I2
I0
I2
tp4763
sS'cisapride,was'
p4764
(F1
F0.00014334862385321102
I0
I1
I-1
tp4765
sS'cyp2c9,cyp2c19'
p4766
(F1
F0.00057339449541284407
I0
I4
I-4
tp4767
sS'reduced,if'
p4768
(F1
F0.00014334862385321102
I1
I0
I1
tp4769
sS'of,enhanced'
p4770
(F1
F0.00014334862385321102
I1
I0
I1
tp4771
sS'cause,adrenal'
p4772
(F1
F0.00014334862385321102
I1
I0
I1
tp4773
sS'dmpge2,given'
p4774
(F1
F0.00014334862385321102
I0
I1
I-1
tp4775
sS'reduced,in'
p4776
(F1
F0.00057339449541284407
I0
I4
I-4
tp4777
sS'usually,does'
p4778
(F1
F0.00014334862385321102
I1
I0
I1
tp4779
sS'in,no'
p4780
(F1
F0.00057339449541284407
I0
I4
I-4
tp4781
sS'mc,potentiates'
p4782
(F1
F0.00014334862385321102
I1
I0
I1
tp4783
sS'use,both'
p4784
(F1
F0.00014334862385321102
I0
I1
I-1
tp4785
sS'sex,hormone'
p4786
(F0
F0
I1
I1
I0
tp4787
sS'retention,of'
p4788
(F0
F0
I1
I1
I0
tp4789
sS'to,triple'
p4790
(F1
F0.00014334862385321102
I0
I1
I-1
tp4791
sS'this,protein'
p4792
(F1
F0.00014334862385321102
I1
I0
I1
tp4793
sS'spermatozoa,from'
p4794
(F1
F0.00014334862385321102
I0
I1
I-1
tp4795
sS'm,parenteral'
p4796
(F1
F0.00014334862385321102
I1
I0
I1
tp4797
sS'examine,some'
p4798
(F1
F0.00014334862385321102
I0
I1
I-1
tp4799
sS'altered,by'
p4800
(F0.55555555555555558
F0.00071674311926605509
I2
I7
I-5
tp4801
sS'reached,after'
p4802
(F1
F0.00014334862385321102
I1
I0
I1
tp4803
sS'metabolism,were'
p4804
(F1
F0.00014334862385321102
I0
I1
I-1
tp4805
sS'may,indicate'
p4806
(F1
F0.00014334862385321102
I1
I0
I1
tp4807
sS'the,availability'
p4808
(F0
F0
I1
I1
I0
tp4809
sS'oa,patients'
p4810
(F1
F0.00014334862385321102
I0
I1
I-1
tp4811
sS'intestinal,carcinogenesis'
p4812
(F1
F0.00014334862385321102
I0
I1
I-1
tp4813
sS'meal,hour'
p4814
(F1
F0.00014334862385321102
I0
I1
I-1
tp4815
sS'wellbutrin,on'
p4816
(F1
F0.00014334862385321102
I0
I1
I-1
tp4817
sS'have,carried'
p4818
(F1
F0.00014334862385321102
I0
I1
I-1
tp4819
sS'intravenous,prodrug'
p4820
(F1
F0.00014334862385321102
I0
I1
I-1
tp4821
sS'its,effects'
p4822
(F1
F0.00028669724770642203
I0
I2
I-2
tp4823
sS'evoked,hind'
p4824
(F1
F0.00014334862385321102
I0
I1
I-1
tp4825
sS'study,the'
p4826
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp4827
sS'haemodynamic,effects'
p4828
(F1
F0.00014334862385321102
I0
I1
I-1
tp4829
sS'large,initial'
p4830
(F1
F0.00014334862385321102
I0
I1
I-1
tp4831
sS'signs,and'
p4832
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp4833
sS'be,blunted'
p4834
(F1
F0.00028669724770642203
I2
I0
I2
tp4835
sS'amevive,who'
p4836
(F1
F0.00014334862385321102
I0
I1
I-1
tp4837
sS'and,foods'
p4838
(F1
F0.00014334862385321102
I1
I0
I1
tp4839
sS'and,liver'
p4840
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp4841
sS'i,these'
p4842
(F1
F0.00014334862385321102
I0
I1
I-1
tp4843
sS'intrinsic,effect'
p4844
(F1
F0.00014334862385321102
I1
I0
I1
tp4845
sS'pharmacological,effect'
p4846
(F1
F0.00014334862385321102
I1
I0
I1
tp4847
sS'captopril-digoxin,interaction'
p4848
(F1
F0.00014334862385321102
I0
I1
I-1
tp4849
sS'average,by'
p4850
(F1
F0.00014334862385321102
I1
I0
I1
tp4851
sS'may,predispose'
p4852
(F1
F0.00014334862385321102
I1
I0
I1
tp4853
sS'of,difluoroacetone'
p4854
(F1
F0.00043004587155963305
I0
I3
I-3
tp4855
sS'with,intravascular'
p4856
(F1
F0.00014334862385321102
I1
I0
I1
tp4857
sS'such,medicinal'
p4858
(F1
F0.00014334862385321102
I1
I0
I1
tp4859
sS'a,statistically'
p4860
(F0
F0
I2
I2
I0
tp4861
sS'if,hormonal'
p4862
(F1
F0.00014334862385321102
I0
I1
I-1
tp4863
sS'etc,lower'
p4864
(F1
F0.00014334862385321102
I1
I0
I1
tp4865
sS'tested,by'
p4866
(F1
F0.00014334862385321102
I0
I1
I-1
tp4867
sS'started,or'
p4868
(F1
F0.00014334862385321102
I1
I0
I1
tp4869
sS'observation,must'
p4870
(F1
F0.00014334862385321102
I0
I1
I-1
tp4871
sS'thin-layer,chromatographic'
p4872
(F1
F0.00014334862385321102
I0
I1
I-1
tp4873
sS'kinetics,and'
p4874
(F1
F0.00028669724770642203
I2
I0
I2
tp4875
sS'hour,then'
p4876
(F1
F0.00014334862385321102
I0
I1
I-1
tp4877
sS'general,conditions'
p4878
(F1
F0.00014334862385321102
I0
I1
I-1
tp4879
sS'a,medicine'
p4880
(F1
F0.00014334862385321102
I0
I1
I-1
tp4881
sS'diphenhydramine,is'
p4882
(F1
F0.00014334862385321102
I0
I1
I-1
tp4883
sS'have,led'
p4884
(F1
F0.00014334862385321102
I0
I1
I-1
tp4885
sS'days,after'
p4886
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp4887
sS'toxicity,with'
p4888
(F1
F0.00028669724770642203
I2
I0
I2
tp4889
sS'from,their'
p4890
(F1
F0.00028669724770642203
I2
I0
I2
tp4891
sS'when,amitriptyline'
p4892
(F0
F0
I1
I1
I0
tp4893
sS'not,detect'
p4894
(F1
F0.00014334862385321102
I0
I1
I-1
tp4895
sS'together,during'
p4896
(F1
F0.00014334862385321102
I1
I0
I1
tp4897
sS'diminished,binding'
p4898
(F1
F0.00014334862385321102
I1
I0
I1
tp4899
sS'by,nonbarbiturate'
p4900
(F1
F0.00014334862385321102
I1
I0
I1
tp4901
sS'historicalcontrol,group'
p4902
(F1
F0.00014334862385321102
I1
I0
I1
tp4903
sS'food,isrecommended'
p4904
(F1
F0.00014334862385321102
I1
I0
I1
tp4905
sS'cigarettes,and'
p4906
(F1
F0.00014334862385321102
I0
I1
I-1
tp4907
sS'vision,and'
p4908
(F1
F0.00028669724770642203
I2
I0
I2
tp4909
sS'curariform,effect'
p4910
(F1
F0.00014334862385321102
I1
I0
I1
tp4911
sS'additive,depressant'
p4912
(F1
F0.00014334862385321102
I0
I1
I-1
tp4913
sS'inhibits,the'
p4914
(F0.75
F0.0017201834862385322
I14
I2
I12
tp4915
sS'drugs,based'
p4916
(F1
F0.00014334862385321102
I0
I1
I-1
tp4917
sS'interference,by'
p4918
(F1
F0.00014334862385321102
I0
I1
I-1
tp4919
sS'failure,where'
p4920
(F1
F0.00014334862385321102
I0
I1
I-1
tp4921
sS'after,treatment'
p4922
(F1
F0.00014334862385321102
I0
I1
I-1
tp4923
sS'two,single'
p4924
(F1
F0.00014334862385321102
I0
I1
I-1
tp4925
sS'the,interference'
p4926
(F1
F0.00014334862385321102
I1
I0
I1
tp4927
sS'with,overdosage'
p4928
(F1
F0.00014334862385321102
I1
I0
I1
tp4929
sS'aripiprazole,dose'
p4930
(F1
F0.00014334862385321102
I1
I0
I1
tp4931
sS'cells,either'
p4932
(F1
F0.00014334862385321102
I0
I1
I-1
tp4933
sS'methyl-4,phenyl-1'
p4934
(F1
F0.00014334862385321102
I0
I1
I-1
tp4935
sS'study,cocaine-induced'
p4936
(F1
F0.00014334862385321102
I0
I1
I-1
tp4937
sS'comparison,of'
p4938
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp4939
sS'avoid,administration'
p4940
(F1
F0.00014334862385321102
I0
I1
I-1
tp4941
sS'dosing,recommendations'
p4942
(F1
F0.00014334862385321102
I0
I1
I-1
tp4943
sS'noted,to'
p4944
(F1
F0.00028669724770642203
I2
I0
I2
tp4945
sS'a,synergistic'
p4946
(F1
F0.00028669724770642203
I2
I0
I2
tp4947
sS'metabolism,via'
p4948
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp4949
sS'after,days'
p4950
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp4951
sS'mental,and'
p4952
(F1
F0.00014334862385321102
I0
I1
I-1
tp4953
sS'fluctuate,significantly'
p4954
(F1
F0.00014334862385321102
I1
I0
I1
tp4955
sS'to,cross'
p4956
(F1
F0.00014334862385321102
I1
I0
I1
tp4957
sS'release,of'
p4958
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp4959
sS'concentrations,following'
p4960
(F1
F0.00028669724770642203
I0
I2
I-2
tp4961
sS'with,erythromycin'
p4962
(F1
F0.00014334862385321102
I0
I1
I-1
tp4963
sS'male,rats'
p4964
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp4965
sS'reduction,at'
p4966
(F1
F0.00014334862385321102
I0
I1
I-1
tp4967
sS'mean,standard'
p4968
(F1
F0.00014334862385321102
I1
I0
I1
tp4969
sS'with,inomax'
p4970
(F1
F0.00014334862385321102
I1
I0
I1
tp4971
sS'obtained,with'
p4972
(F1
F0.00014334862385321102
I1
I0
I1
tp4973
sS'the,acute'
p4974
(F0
F0
I2
I2
I0
tp4975
sS'products,sharing'
p4976
(F1
F0.00014334862385321102
I1
I0
I1
tp4977
sS'way,the'
p4978
(F1
F0.00014334862385321102
I1
I0
I1
tp4979
sS'to,ng'
p4980
(F0
F0
I1
I1
I0
tp4981
sS'deaths,have'
p4982
(F1
F0.00014334862385321102
I1
I0
I1
tp4983
sS'of,but'
p4984
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp4985
sS'following,protease'
p4986
(F1
F0.00014334862385321102
I0
I1
I-1
tp4987
sS'taking,amyl'
p4988
(F1
F0.00014334862385321102
I1
I0
I1
tp4989
sS'gut,motility'
p4990
(F1
F0.00014334862385321102
I1
I0
I1
tp4991
sS'agent,that'
p4992
(F1
F0.00014334862385321102
I0
I1
I-1
tp4993
sS'anticipated,and'
p4994
(F1
F0.00014334862385321102
I1
I0
I1
tp4995
sS'nephrosis,acromegaly'
p4996
(F1
F0.00014334862385321102
I0
I1
I-1
tp4997
sS'cyp2d6,sensipar'
p4998
(F1
F0.00014334862385321102
I0
I1
I-1
tp4999
sS'elspar,therapy'
p5000
(F1
F0.00014334862385321102
I1
I0
I1
tp5001
sS'days,following'
p5002
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5003
sS'the,muscle'
p5004
(F1
F0.00057339449541284407
I4
I0
I4
tp5005
sS'also,there'
p5006
(F1
F0.00014334862385321102
I0
I1
I-1
tp5007
sS'if,intravenous'
p5008
(F1
F0.00014334862385321102
I1
I0
I1
tp5009
sS'oral,inhibits'
p5010
(F1
F0.00028669724770642203
I2
I0
I2
tp5011
sS'active,hydroxy'
p5012
(F1
F0.00014334862385321102
I1
I0
I1
tp5013
sS'levels,induced'
p5014
(F1
F0.00014334862385321102
I0
I1
I-1
tp5015
sS'bosentan,is'
p5016
(F1
F0.00028669724770642203
I2
I0
I2
tp5017
sS'second,experiment'
p5018
(F1
F0.00014334862385321102
I0
I1
I-1
tp5019
sS'significantly,prolonged'
p5020
(F1
F0.00014334862385321102
I1
I0
I1
tp5021
sS'effect,is'
p5022
(F0
F0
I2
I2
I0
tp5023
sS'other,ergot'
p5024
(F1
F0.00014334862385321102
I1
I0
I1
tp5025
sS'are,expected'
p5026
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp5027
sS'potent,in'
p5028
(F1
F0.00014334862385321102
I0
I1
I-1
tp5029
sS'baseline,to'
p5030
(F1
F0.00014334862385321102
I0
I1
I-1
tp5031
sS'rofecoxib,did'
p5032
(F1
F0.00043004587155963305
I0
I3
I-3
tp5033
sS'be,ineffective'
p5034
(F1
F0.00014334862385321102
I1
I0
I1
tp5035
sS'as,postmarketing'
p5036
(F1
F0.00014334862385321102
I1
I0
I1
tp5037
sS'abnormal,renal'
p5038
(F1
F0.00014334862385321102
I1
I0
I1
tp5039
sS'having,vasodilator'
p5040
(F0
F0
I1
I1
I0
tp5041
sS'although,not'
p5042
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp5043
sS'healthy,individuals'
p5044
(F1
F0.00014334862385321102
I1
I0
I1
tp5045
sS'antiepileptic,periodic'
p5046
(F1
F0.00014334862385321102
I1
I0
I1
tp5047
sS'i,d'
p5048
(F0.5
F0.0008600917431192661
I9
I3
I6
tp5049
sS'however,its'
p5050
(F1
F0.00014334862385321102
I0
I1
I-1
tp5051
sS'preparations,in'
p5052
(F1
F0.00014334862385321102
I1
I0
I1
tp5053
sS'i,n'
p5054
(F1
F0.00014334862385321102
I1
I0
I1
tp5055
sS'about,a'
p5056
(F1
F0.00043004587155963305
I3
I0
I3
tp5057
sS'co-administered,antiepilepsy'
p5058
(F1
F0.00014334862385321102
I0
I1
I-1
tp5059
sS'about,x'
p5060
(F1
F0.00014334862385321102
I1
I0
I1
tp5061
sS'short-acting,has'
p5062
(F1
F0.00014334862385321102
I0
I1
I-1
tp5063
sS'concentration,mean'
p5064
(F1
F0.00028669724770642203
I0
I2
I-2
tp5065
sS'septic,shock'
p5066
(F1
F0.00014334862385321102
I0
I1
I-1
tp5067
sS'drugs,which'
p5068
(F1
F0.0010034403669724771
I7
I0
I7
tp5069
sS'endoscopy,study'
p5070
(F1
F0.00014334862385321102
I0
I1
I-1
tp5071
sS'azoles,were'
p5072
(F1
F0.00014334862385321102
I0
I1
I-1
tp5073
sS'the,concentration'
p5074
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp5075
sS'may,temporarily'
p5076
(F1
F0.00014334862385321102
I1
I0
I1
tp5077
sS'or,agents'
p5078
(F1
F0.00028669724770642203
I2
I0
I2
tp5079
sS'important,potentiation'
p5080
(F1
F0.00014334862385321102
I0
I1
I-1
tp5081
sS'the,mptp-induced'
p5082
(F1
F0.00014334862385321102
I1
I0
I1
tp5083
sS'laceration,especially'
p5084
(F1
F0.00014334862385321102
I1
I0
I1
tp5085
sS'be,employed'
p5086
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5087
sS'relative,absorption'
p5088
(F1
F0.00014334862385321102
I0
I1
I-1
tp5089
sS'therapy,did'
p5090
(F1
F0.00028669724770642203
I0
I2
I-2
tp5091
sS'because,both'
p5092
(F1
F0.00043004587155963305
I3
I0
I3
tp5093
sS'tail-flick,response'
p5094
(F0
F0
I1
I1
I0
tp5095
sS'adenocard,in'
p5096
(F1
F0.00014334862385321102
I1
I0
I1
tp5097
sS'to,your'
p5098
(F1
F0.00014334862385321102
I0
I1
I-1
tp5099
sS'selective,ca'
p5100
(F1
F0.00014334862385321102
I0
I1
I-1
tp5101
sS'system,may'
p5102
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5103
sS'routine,administration'
p5104
(F1
F0.00014334862385321102
I1
I0
I1
tp5105
sS'nuromax,and'
p5106
(F1
F0.00014334862385321102
I0
I1
I-1
tp5107
sS'depressants,using'
p5108
(F1
F0.00014334862385321102
I1
I0
I1
tp5109
sS'cancer,patients'
p5110
(F1
F0.00014334862385321102
I1
I0
I1
tp5111
sS'anionic-binding,has'
p5112
(F1
F0.00014334862385321102
I1
I0
I1
tp5113
sS'cyp2c19,cyp2d6'
p5114
(F1
F0.00028669724770642203
I0
I2
I-2
tp5115
sS'with,haca'
p5116
(F1
F0.00014334862385321102
I0
I1
I-1
tp5117
sS'as,risk'
p5118
(F1
F0.00014334862385321102
I0
I1
I-1
tp5119
sS'viracept,and'
p5120
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp5121
sS'intravenously,to'
p5122
(F1
F0.00014334862385321102
I1
I0
I1
tp5123
sS'opioids,co-administration'
p5124
(F1
F0.00014334862385321102
I1
I0
I1
tp5125
sS'exposures,of'
p5126
(F1
F0.00057339449541284407
I4
I0
I4
tp5127
sS'prescription,dose'
p5128
(F1
F0.00028669724770642203
I2
I0
I2
tp5129
sS'cecum,and'
p5130
(F1
F0.00014334862385321102
I0
I1
I-1
tp5131
sS'anti-inflammatory,have'
p5132
(F1
F0.00014334862385321102
I1
I0
I1
tp5133
sS'immunosuppressive,drugs'
p5134
(F1
F0.00014334862385321102
I0
I1
I-1
tp5135
sS'enzymes,are'
p5136
(F1
F0.00014334862385321102
I1
I0
I1
tp5137
sS'schizophrenia,schizoaffective'
p5138
(F1
F0.00014334862385321102
I1
I0
I1
tp5139
sS'dinitrate,chloride'
p5140
(F1
F0.00014334862385321102
I0
I1
I-1
tp5141
sS'indicates,that'
p5142
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp5143
sS'significant,accuracy'
p5144
(F1
F0.00014334862385321102
I1
I0
I1
tp5145
sS'histologic,type'
p5146
(F1
F0.00014334862385321102
I0
I1
I-1
tp5147
sS'enzyme,would'
p5148
(F1
F0.00014334862385321102
I0
I1
I-1
tp5149
sS'contain,any'
p5150
(F1
F0.00014334862385321102
I1
I0
I1
tp5151
sS'itraconazole,co-administration'
p5152
(F1
F0.00014334862385321102
I0
I1
I-1
tp5153
sS'amiodarone-treated,patients'
p5154
(F1
F0.00014334862385321102
I0
I1
I-1
tp5155
sS'peroral,administration'
p5156
(F1
F0.00014334862385321102
I0
I1
I-1
tp5157
sS'sodium,may'
p5158
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5159
sS'accordingly,when'
p5160
(F1
F0.00014334862385321102
I1
I0
I1
tp5161
sS'decreased,respectively'
p5162
(F1
F0.00014334862385321102
I1
I0
I1
tp5163
sS'exceeded,when'
p5164
(F1
F0.00014334862385321102
I1
I0
I1
tp5165
sS'and,coly-mycin'
p5166
(F1
F0.00014334862385321102
I1
I0
I1
tp5167
sS'thyroxine,increases'
p5168
(F1
F0.00014334862385321102
I1
I0
I1
tp5169
sS'levels,could'
p5170
(F1
F0.00014334862385321102
I0
I1
I-1
tp5171
sS'using,concomitant'
p5172
(F1
F0.00014334862385321102
I0
I1
I-1
tp5173
sS'these,data'
p5174
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp5175
sS'additive,sedative'
p5176
(F1
F0.00014334862385321102
I1
I0
I1
tp5177
sS'consequent,possible'
p5178
(F1
F0.00014334862385321102
I1
I0
I1
tp5179
sS'selective,peripheral'
p5180
(F1
F0.00014334862385321102
I1
I0
I1
tp5181
sS'some,molecular'
p5182
(F1
F0.00014334862385321102
I0
I1
I-1
tp5183
sS'given,intravenously'
p5184
(F1
F0.00014334862385321102
I0
I1
I-1
tp5185
sS'if,you'
p5186
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp5187
sS'and,magnesium-containing'
p5188
(F1
F0.00014334862385321102
I0
I1
I-1
tp5189
sS'acromegaly,and'
p5190
(F1
F0.00014334862385321102
I0
I1
I-1
tp5191
sS'fifteen,to'
p5192
(F1
F0.00014334862385321102
I0
I1
I-1
tp5193
sS'from,midcycle'
p5194
(F1
F0.00014334862385321102
I0
I1
I-1
tp5195
sS'experience,enhanced'
p5196
(F1
F0.00014334862385321102
I1
I0
I1
tp5197
sS'metabolism,mediated'
p5198
(F1
F0.00014334862385321102
I0
I1
I-1
tp5199
sS'of,tablets'
p5200
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp5201
sS'patients,being'
p5202
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp5203
sS'though,reversible'
p5204
(F1
F0.00014334862385321102
I1
I0
I1
tp5205
sS'c9,substrates'
p5206
(F1
F0.00014334862385321102
I0
I1
I-1
tp5207
sS'as,inderal'
p5208
(F1
F0.00014334862385321102
I0
I1
I-1
tp5209
sS'since,does'
p5210
(F1
F0.00014334862385321102
I0
I1
I-1
tp5211
sS'endogenous,steroid'
p5212
(F1
F0.00014334862385321102
I1
I0
I1
tp5213
sS'instruct,the'
p5214
(F1
F0.00014334862385321102
I0
I1
I-1
tp5215
sS'undertaken,only'
p5216
(F1
F0.00014334862385321102
I1
I0
I1
tp5217
sS'following,initial'
p5218
(F1
F0.00014334862385321102
I0
I1
I-1
tp5219
sS'hydroxydesloratadine,pharmacokinetics'
p5220
(F1
F0.00014334862385321102
I0
I1
I-1
tp5221
sS'taking,mg'
p5222
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp5223
sS'aerosol,particles'
p5224
(F1
F0.00043004587155963305
I0
I3
I-3
tp5225
sS'and,achieve'
p5226
(F1
F0.00014334862385321102
I1
I0
I1
tp5227
sS'effective,there'
p5228
(F1
F0.00014334862385321102
I0
I1
I-1
tp5229
sS'hypotension,developed'
p5230
(F1
F0.00014334862385321102
I1
I0
I1
tp5231
sS'agent,and'
p5232
(F1
F0.00014334862385321102
I1
I0
I1
tp5233
sS'withdrawal,methadone'
p5234
(F1
F0.00014334862385321102
I1
I0
I1
tp5235
sS'occur,following'
p5236
(F1
F0.00014334862385321102
I0
I1
I-1
tp5237
sS'cold,remedies'
p5238
(F1
F0.00014334862385321102
I1
I0
I1
tp5239
sS'renal,impairment'
p5240
(F0.5
F0.00028669724770642203
I3
I1
I2
tp5241
sS'or,mycophenolate'
p5242
(F1
F0.00014334862385321102
I0
I1
I-1
tp5243
sS'its,rate'
p5244
(F1
F0.00014334862385321102
I0
I1
I-1
tp5245
sS'cas,but'
p5246
(F1
F0.00014334862385321102
I1
I0
I1
tp5247
sS'provide,close'
p5248
(F1
F0.00014334862385321102
I1
I0
I1
tp5249
sS'and,leading'
p5250
(F0
F0
I1
I1
I0
tp5251
sS'p,a'
p5252
(F1
F0.00014334862385321102
I1
I0
I1
tp5253
sS'p,o'
p5254
(F1
F0.00028669724770642203
I2
I0
I2
tp5255
sS'release,the'
p5256
(F1
F0.00014334862385321102
I1
I0
I1
tp5257
sS'patients,experiencing'
p5258
(F1
F0.00014334862385321102
I1
I0
I1
tp5259
sS'taking,should'
p5260
(F1
F0.00014334862385321102
I1
I0
I1
tp5261
sS'non-depolarising,muscle'
p5262
(F1
F0.00014334862385321102
I1
I0
I1
tp5263
sS'and,discontinuation'
p5264
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5265
sS'of,alone'
p5266
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp5267
sS'difference,in'
p5268
(F1
F0.00043004587155963305
I0
I3
I-3
tp5269
sS'olanzapine,is'
p5270
(F1
F0.00014334862385321102
I0
I1
I-1
tp5271
sS'evidence,suggests'
p5272
(F1
F0.00014334862385321102
I1
I0
I1
tp5273
sS'indicate,cyp3a4'
p5274
(F1
F0.00014334862385321102
I0
I1
I-1
tp5275
sS'with,resultant'
p5276
(F1
F0.00014334862385321102
I0
I1
I-1
tp5277
sS'phenyltheophylline,and'
p5278
(F1
F0.00014334862385321102
I0
I1
I-1
tp5279
sS'with,reduce'
p5280
(F1
F0.00014334862385321102
I1
I0
I1
tp5281
sS'included,as'
p5282
(F1
F0.00014334862385321102
I0
I1
I-1
tp5283
sS'peak,concentrations'
p5284
(F1
F0.00014334862385321102
I0
I1
I-1
tp5285
sS'prostatic,epithelium'
p5286
(F0
F0
I1
I1
I0
tp5287
sS'isoenzyme,family'
p5288
(F1
F0.00014334862385321102
I0
I1
I-1
tp5289
sS'aspirin,as'
p5290
(F1
F0.00014334862385321102
I1
I0
I1
tp5291
sS'thus,impairing'
p5292
(F1
F0.00014334862385321102
I1
I0
I1
tp5293
sS'trisilicate,when'
p5294
(F1
F0.00014334862385321102
I1
I0
I1
tp5295
sS'when,or'
p5296
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5297
sS'interaction,occurs'
p5298
(F1
F0.00014334862385321102
I0
I1
I-1
tp5299
sS'or,products'
p5300
(F1
F0.00014334862385321102
I1
I0
I1
tp5301
sS'of,arrhythmias'
p5302
(F1
F0.00028669724770642203
I0
I2
I-2
tp5303
sS'following,concurrent'
p5304
(F1
F0.00014334862385321102
I1
I0
I1
tp5305
sS'absorption,by'
p5306
(F1
F0.00014334862385321102
I1
I0
I1
tp5307
sS'of,diffusible'
p5308
(F1
F0.00014334862385321102
I0
I1
I-1
tp5309
sS'of,sular'
p5310
(F1
F0.00028669724770642203
I2
I0
I2
tp5311
sS'disease,medications'
p5312
(F1
F0.00014334862385321102
I0
I1
I-1
tp5313
sS'number,induced'
p5314
(F1
F0.00014334862385321102
I1
I0
I1
tp5315
sS'omega-conotoxin,gvia-sensitive'
p5316
(F1
F0.00014334862385321102
I0
I1
I-1
tp5317
sS'steady-state,pharmacokinetics'
p5318
(F1
F0.00071674311926605509
I0
I5
I-5
tp5319
sS'isis-2,currently'
p5320
(F1
F0.00014334862385321102
I0
I1
I-1
tp5321
sS'an,action'
p5322
(F1
F0.00014334862385321102
I0
I1
I-1
tp5323
sS'of,coadministration'
p5324
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp5325
sS'use,products'
p5326
(F1
F0.00014334862385321102
I1
I0
I1
tp5327
sS'orasone,others'
p5328
(F1
F0.00014334862385321102
I0
I1
I-1
tp5329
sS'dactinomycin,may'
p5330
(F1
F0.00014334862385321102
I0
I1
I-1
tp5331
sS'effective,dose'
p5332
(F0
F0
I1
I1
I0
tp5333
sS'stable,as'
p5334
(F1
F0.00014334862385321102
I0
I1
I-1
tp5335
sS'exposure,presumably'
p5336
(F1
F0.00014334862385321102
I1
I0
I1
tp5337
sS'uptake-1,were'
p5338
(F1
F0.00014334862385321102
I0
I1
I-1
tp5339
sS'and,l-ccg'
p5340
(F1
F0.00043004587155963305
I0
I3
I-3
tp5341
sS'atrovent,inhalation'
p5342
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5343
sS'p450iid6,cyp2d6'
p5344
(F1
F0.00014334862385321102
I0
I1
I-1
tp5345
sS'lower,auc'
p5346
(F1
F0.00014334862385321102
I0
I1
I-1
tp5347
sS'of,theophylline-related'
p5348
(F1
F0.00043004587155963305
I3
I0
I3
tp5349
sS'no,effect'
p5350
(F0.59375
F0.0054472477064220187
I13
I51
I-38
tp5351
sS'effects,resulting'
p5352
(F1
F0.00014334862385321102
I1
I0
I1
tp5353
sS'when,deet'
p5354
(F1
F0.00014334862385321102
I0
I1
I-1
tp5355
sS'pure,powders'
p5356
(F1
F0.00014334862385321102
I1
I0
I1
tp5357
sS'to,years'
p5358
(F0
F0
I1
I1
I0
tp5359
sS'or,infusions'
p5360
(F1
F0.00014334862385321102
I0
I1
I-1
tp5361
sS'in,chronic'
p5362
(F1
F0.00014334862385321102
I1
I0
I1
tp5363
sS'activity,persists'
p5364
(F1
F0.00014334862385321102
I1
I0
I1
tp5365
sS'time,spent'
p5366
(F1
F0.00014334862385321102
I1
I0
I1
tp5367
sS'analogues,which'
p5368
(F1
F0.00043004587155963305
I3
I0
I3
tp5369
sS'in,bioavailability'
p5370
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5371
sS'men,with'
p5372
(F1
F0.00028669724770642203
I0
I2
I-2
tp5373
sS'the,decreased'
p5374
(F1
F0.00014334862385321102
I0
I1
I-1
tp5375
sS'examined,the'
p5376
(F1
F0.00043004587155963305
I0
I3
I-3
tp5377
sS'when,meclofenamate'
p5378
(F1
F0.00014334862385321102
I1
I0
I1
tp5379
sS'clearance,from'
p5380
(F1
F0.00014334862385321102
I1
I0
I1
tp5381
sS'the,activity'
p5382
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp5383
sS'its,ability'
p5384
(F1
F0.00014334862385321102
I1
I0
I1
tp5385
sS'innovar,or'
p5386
(F1
F0.00014334862385321102
I1
I0
I1
tp5387
sS'patients,no'
p5388
(F1
F0.00028669724770642203
I0
I2
I-2
tp5389
sS'either,singly'
p5390
(F1
F0.00014334862385321102
I0
I1
I-1
tp5391
sS'chlorpropamides,plasma'
p5392
(F1
F0.00014334862385321102
I1
I0
I1
tp5393
sS'the,decreases'
p5394
(F1
F0.00014334862385321102
I1
I0
I1
tp5395
sS'juice,with'
p5396
(F1
F0.00028669724770642203
I0
I2
I-2
tp5397
sS'foods,fortified'
p5398
(F1
F0.00014334862385321102
I1
I0
I1
tp5399
sS'several,aed'
p5400
(F1
F0.00014334862385321102
I1
I0
I1
tp5401
sS'however,high'
p5402
(F1
F0.00014334862385321102
I1
I0
I1
tp5403
sS'steady-state,in'
p5404
(F1
F0.00014334862385321102
I0
I1
I-1
tp5405
sS'preparations,has'
p5406
(F1
F0.00014334862385321102
I0
I1
I-1
tp5407
sS'and,mesenteric'
p5408
(F0
F0
I1
I1
I0
tp5409
sS'molecule,naflu'
p5410
(F1
F0.00014334862385321102
I0
I1
I-1
tp5411
sS'auc,infinity'
p5412
(F1
F0.00014334862385321102
I0
I1
I-1
tp5413
sS'myelotoxic,chemotherapy'
p5414
(F1
F0.00014334862385321102
I1
I0
I1
tp5415
sS'irritability,and'
p5416
(F1
F0.00014334862385321102
I1
I0
I1
tp5417
sS'interresponse,times'
p5418
(F1
F0.00014334862385321102
I0
I1
I-1
tp5419
sS'and,initiation'
p5420
(F1
F0.00028669724770642203
I2
I0
I2
tp5421
sS'well,as'
p5422
(F0.30769230769230771
F0.0011467889908256881
I17
I9
I8
tp5423
sS'and,platelet'
p5424
(F1
F0.00014334862385321102
I1
I0
I1
tp5425
sS'curve,after'
p5426
(F1
F0.00014334862385321102
I1
I0
I1
tp5427
sS'resulting,from'
p5428
(F0
F0
I2
I2
I0
tp5429
sS'clearance,resulting'
p5430
(F1
F0.00014334862385321102
I0
I1
I-1
tp5431
sS'transmission,should'
p5432
(F1
F0.00014334862385321102
I0
I1
I-1
tp5433
sS'female,rats'
p5434
(F1
F0.00014334862385321102
I0
I1
I-1
tp5435
sS'one,report'
p5436
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp5437
sS'cyp1a2,which'
p5438
(F1
F0.00014334862385321102
I1
I0
I1
tp5439
sS'and,coronary'
p5440
(F1
F0.00014334862385321102
I0
I1
I-1
tp5441
sS'the,likelihood'
p5442
(F1
F0.00043004587155963305
I3
I0
I3
tp5443
sS'each,dose'
p5444
(F0
F0
I1
I1
I0
tp5445
sS'be,drawn'
p5446
(F1
F0.00028669724770642203
I0
I2
I-2
tp5447
sS'concomitant,at'
p5448
(F1
F0.00028669724770642203
I0
I2
I-2
tp5449
sS'de,pointes'
p5450
(F0
F0
I1
I1
I0
tp5451
sS'psychomotor,performance'
p5452
(F1
F0.00043004587155963305
I3
I0
I3
tp5453
sS'its,plasma'
p5454
(F0
F0
I1
I1
I0
tp5455
sS'may,not'
p5456
(F0
F0
I4
I4
I0
tp5457
sS'benzodiazepines,metabolized'
p5458
(F1
F0.00014334862385321102
I1
I0
I1
tp5459
sS'when,used'
p5460
(F0.44444444444444442
F0.0011467889908256881
I13
I5
I8
tp5461
sS'micrograms,completely'
p5462
(F1
F0.00014334862385321102
I1
I0
I1
tp5463
sS'during,transfer'
p5464
(F1
F0.00014334862385321102
I0
I1
I-1
tp5465
sS'comparable,cognitive'
p5466
(F1
F0.00014334862385321102
I0
I1
I-1
tp5467
sS'pharmacokinetic,parameter'
p5468
(F1
F0.00014334862385321102
I0
I1
I-1
tp5469
sS'delayed,elimination'
p5470
(F1
F0.00014334862385321102
I0
I1
I-1
tp5471
sS'or,therapy'
p5472
(F1
F0.00014334862385321102
I1
I0
I1
tp5473
sS'i,mg'
p5474
(F1
F0.00014334862385321102
I1
I0
I1
tp5475
sS'arthritis,concomitant'
p5476
(F1
F0.00014334862385321102
I0
I1
I-1
tp5477
sS'were,treated'
p5478
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp5479
sS'prospective,study'
p5480
(F1
F0.00014334862385321102
I0
I1
I-1
tp5481
sS'in,gastrointestinal'
p5482
(F1
F0.00014334862385321102
I1
I0
I1
tp5483
sS'kg,infused'
p5484
(F1
F0.00014334862385321102
I0
I1
I-1
tp5485
sS'who,developed'
p5486
(F1
F0.00014334862385321102
I1
I0
I1
tp5487
sS'at,or'
p5488
(F1
F0.00014334862385321102
I1
I0
I1
tp5489
sS'where,the'
p5490
(F1
F0.00014334862385321102
I0
I1
I-1
tp5491
sS'coma,have'
p5492
(F1
F0.00014334862385321102
I1
I0
I1
tp5493
sS'when,nsaids'
p5494
(F1
F0.00043004587155963305
I3
I0
I3
tp5495
sS'malignant,hyperthermia'
p5496
(F1
F0.00014334862385321102
I1
I0
I1
tp5497
sS'before,taking'
p5498
(F1
F0.00014334862385321102
I1
I0
I1
tp5499
sS'concentrations,cyp3a4'
p5500
(F1
F0.00028669724770642203
I0
I2
I-2
tp5501
sS'of,sprycel'
p5502
(F1
F0.00028669724770642203
I2
I0
I2
tp5503
sS'simvastatin,and'
p5504
(F1
F0.00014334862385321102
I1
I0
I1
tp5505
sS'study,did'
p5506
(F0
F0
I1
I1
I0
tp5507
sS'life,of'
p5508
(F1
F0.00014334862385321102
I1
I0
I1
tp5509
sS'longer,than'
p5510
(F1
F0.00014334862385321102
I1
I0
I1
tp5511
sS'increases,serum'
p5512
(F1
F0.00014334862385321102
I0
I1
I-1
tp5513
sS'meals,was'
p5514
(F1
F0.00028669724770642203
I0
I2
I-2
tp5515
sS'sustiva,and'
p5516
(F1
F0.00043004587155963305
I0
I3
I-3
tp5517
sS'altered,renal'
p5518
(F1
F0.00014334862385321102
I0
I1
I-1
tp5519
sS'at,of'
p5520
(F1
F0.00014334862385321102
I0
I1
I-1
tp5521
sS'and,produce'
p5522
(F1
F0.00028669724770642203
I0
I2
I-2
tp5523
sS'serum,i'
p5524
(F1
F0.00028669724770642203
I0
I2
I-2
tp5525
sS'hormone,replacement'
p5526
(F1
F0.00014334862385321102
I0
I1
I-1
tp5527
sS'interactions,would'
p5528
(F1
F0.00014334862385321102
I0
I1
I-1
tp5529
sS'urine,which'
p5530
(F1
F0.00014334862385321102
I0
I1
I-1
tp5531
sS'lithium,reversible'
p5532
(F1
F0.00014334862385321102
I1
I0
I1
tp5533
sS'is,approximately'
p5534
(F1
F0.00028669724770642203
I2
I0
I2
tp5535
sS'sustiva,is'
p5536
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp5537
sS'mixing,novolog'
p5538
(F1
F0.00028669724770642203
I0
I2
I-2
tp5539
sS'had,returned'
p5540
(F1
F0.00014334862385321102
I1
I0
I1
tp5541
sS'fluorescein,naflu'
p5542
(F1
F0.00014334862385321102
I0
I1
I-1
tp5543
sS'activity,thus'
p5544
(F1
F0.00014334862385321102
I1
I0
I1
tp5545
sS'alone,mg'
p5546
(F1
F0.00014334862385321102
I0
I1
I-1
tp5547
sS'its,congeners'
p5548
(F1
F0.00014334862385321102
I0
I1
I-1
tp5549
sS'sublingual,mg'
p5550
(F1
F0.00014334862385321102
I1
I0
I1
tp5551
sS'relationship,and'
p5552
(F1
F0.00014334862385321102
I1
I0
I1
tp5553
sS'colorectal,cancer'
p5554
(F1
F0.00014334862385321102
I0
I1
I-1
tp5555
sS'infants,a'
p5556
(F1
F0.00014334862385321102
I0
I1
I-1
tp5557
sS'thus,inhibiting'
p5558
(F1
F0.00057339449541284407
I4
I0
I4
tp5559
sS'slows,the'
p5560
(F1
F0.00014334862385321102
I0
I1
I-1
tp5561
sS'manifestation,of'
p5562
(F1
F0.00014334862385321102
I1
I0
I1
tp5563
sS'of,allergic'
p5564
(F1
F0.00014334862385321102
I1
I0
I1
tp5565
sS'a,rebound'
p5566
(F1
F0.00014334862385321102
I1
I0
I1
tp5567
sS'from,containing'
p5568
(F1
F0.00014334862385321102
I1
I0
I1
tp5569
sS'ketoconazole,may'
p5570
(F1
F0.00043004587155963305
I3
I0
I3
tp5571
sS'readings,were'
p5572
(F1
F0.00014334862385321102
I0
I1
I-1
tp5573
sS'more,in'
p5574
(F1
F0.00014334862385321102
I1
I0
I1
tp5575
sS'is,reduced'
p5576
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp5577
sS'has,proven'
p5578
(F1
F0.00014334862385321102
I0
I1
I-1
tp5579
sS'and,genetically'
p5580
(F1
F0.00014334862385321102
I0
I1
I-1
tp5581
sS'for,migraine'
p5582
(F1
F0.00014334862385321102
I1
I0
I1
tp5583
sS'synthetic,possibly'
p5584
(F1
F0.00014334862385321102
I1
I0
I1
tp5585
sS'to,report'
p5586
(F1
F0.00014334862385321102
I0
I1
I-1
tp5587
sS'interactions,flupenthixol'
p5588
(F1
F0.00014334862385321102
I1
I0
I1
tp5589
sS'pre-treatment,with'
p5590
(F1
F0.00014334862385321102
I1
I0
I1
tp5591
sS'the,blood'
p5592
(F0.2857142857142857
F0.00057339449541284407
I9
I5
I4
tp5593
sS'mechanism,under'
p5594
(F1
F0.00014334862385321102
I1
I0
I1
tp5595
sS'loss,compared'
p5596
(F1
F0.00014334862385321102
I1
I0
I1
tp5597
sS'relaxants,are'
p5598
(F1
F0.00014334862385321102
I0
I1
I-1
tp5599
sS'of,pharmacokinetics'
p5600
(F1
F0.00014334862385321102
I0
I1
I-1
tp5601
sS'no,first-pass'
p5602
(F1
F0.00014334862385321102
I0
I1
I-1
tp5603
sS'for,loss'
p5604
(F0
F0
I1
I1
I0
tp5605
sS'occur,physicians'
p5606
(F1
F0.00014334862385321102
I1
I0
I1
tp5607
sS'on,sgpt'
p5608
(F1
F0.00014334862385321102
I1
I0
I1
tp5609
sS'have,long'
p5610
(F1
F0.00014334862385321102
I0
I1
I-1
tp5611
sS'inhalational,such'
p5612
(F1
F0.00014334862385321102
I1
I0
I1
tp5613
sS'clinical,significance'
p5614
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp5615
sS'a,week'
p5616
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5617
sS'conclusions,to'
p5618
(F1
F0.00014334862385321102
I0
I1
I-1
tp5619
sS'pronounced,when'
p5620
(F1
F0.00014334862385321102
I1
I0
I1
tp5621
sS'kg,min'
p5622
(F1
F0.00014334862385321102
I0
I1
I-1
tp5623
sS'fashion,from'
p5624
(F1
F0.00014334862385321102
I0
I1
I-1
tp5625
sS'similar,study'
p5626
(F1
F0.00014334862385321102
I1
I0
I1
tp5627
sS'of,observed'
p5628
(F1
F0.00014334862385321102
I0
I1
I-1
tp5629
sS'of,welchol'
p5630
(F1
F0.00014334862385321102
I0
I1
I-1
tp5631
sS'strength,mg'
p5632
(F1
F0.00014334862385321102
I0
I1
I-1
tp5633
sS'agents,enhanced'
p5634
(F1
F0.00014334862385321102
I1
I0
I1
tp5635
sS'isoenzyme,system'
p5636
(F1
F0.00014334862385321102
I0
I1
I-1
tp5637
sS'maalox,decreased'
p5638
(F1
F0.00014334862385321102
I1
I0
I1
tp5639
sS'cyp-2c19,by'
p5640
(F1
F0.00014334862385321102
I0
I1
I-1
tp5641
sS'day,resulted'
p5642
(F1
F0.00014334862385321102
I1
I0
I1
tp5643
sS'indocin,resulted'
p5644
(F1
F0.00014334862385321102
I1
I0
I1
tp5645
sS'the,supraventricular'
p5646
(F1
F0.00014334862385321102
I1
I0
I1
tp5647
sS'epithelium,in'
p5648
(F1
F0.00014334862385321102
I1
I0
I1
tp5649
sS'in,common'
p5650
(F1
F0.00014334862385321102
I1
I0
I1
tp5651
sS'binding,in'
p5652
(F1
F0.00028669724770642203
I2
I0
I2
tp5653
sS'r,b'
p5654
(F1
F0.00014334862385321102
I0
I1
I-1
tp5655
sS'dose,studies'
p5656
(F1
F0.00014334862385321102
I1
I0
I1
tp5657
sS'binding,is'
p5658
(F1
F0.00014334862385321102
I1
I0
I1
tp5659
sS'dose-response,curves'
p5660
(F1
F0.00014334862385321102
I1
I0
I1
tp5661
sS'r,p'
p5662
(F1
F0.00014334862385321102
I0
I1
I-1
tp5663
sS'cause,synergistic'
p5664
(F1
F0.00014334862385321102
I1
I0
I1
tp5665
sS'hydrochloride,does'
p5666
(F1
F0.00014334862385321102
I0
I1
I-1
tp5667
sS'in,treatment-experienced'
p5668
(F1
F0.00014334862385321102
I0
I1
I-1
tp5669
sS'activity,potentiates'
p5670
(F1
F0.00014334862385321102
I1
I0
I1
tp5671
sS'fda,have'
p5672
(F1
F0.00014334862385321102
I0
I1
I-1
tp5673
sS'as,an'
p5674
(F0
F0
I1
I1
I0
tp5675
sS'min,p'
p5676
(F1
F0.00014334862385321102
I1
I0
I1
tp5677
sS'vitamin,k'
p5678
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp5679
sS'diabetic,nsaids'
p5680
(F1
F0.00014334862385321102
I1
I0
I1
tp5681
sS'sucralfate,and'
p5682
(F0
F0
I1
I1
I0
tp5683
sS'of,thiazide'
p5684
(F1
F0.00028669724770642203
I2
I0
I2
tp5685
sS'appears,to'
p5686
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp5687
sS'of,medline'
p5688
(F1
F0.00014334862385321102
I0
I1
I-1
tp5689
sS'drawn,into'
p5690
(F1
F0.00014334862385321102
I0
I1
I-1
tp5691
sS'placebo,day'
p5692
(F1
F0.00014334862385321102
I0
I1
I-1
tp5693
sS'of,cholecystokinin'
p5694
(F1
F0.00014334862385321102
I0
I1
I-1
tp5695
sS'the,pharmacodynamics'
p5696
(F1
F0.0012901376146788992
I0
I9
I-9
tp5697
sS'require,that'
p5698
(F1
F0.00014334862385321102
I1
I0
I1
tp5699
sS'giving,in'
p5700
(F1
F0.00014334862385321102
I1
I0
I1
tp5701
sS'the,divided'
p5702
(F1
F0.00014334862385321102
I1
I0
I1
tp5703
sS'absorption,has'
p5704
(F1
F0.00014334862385321102
I0
I1
I-1
tp5705
sS'or,tubular'
p5706
(F1
F0.00014334862385321102
I0
I1
I-1
tp5707
sS'advanced,or'
p5708
(F1
F0.00014334862385321102
I1
I0
I1
tp5709
sS'or,micrograms'
p5710
(F1
F0.00014334862385321102
I0
I1
I-1
tp5711
sS'blockers,beta'
p5712
(F1
F0.00014334862385321102
I0
I1
I-1
tp5713
sS'indinavir,steady-state'
p5714
(F1
F0.00014334862385321102
I1
I0
I1
tp5715
sS'cyclosporine,diclofenac'
p5716
(F1
F0.00014334862385321102
I0
I1
I-1
tp5717
sS'be,stopped'
p5718
(F1
F0.00014334862385321102
I1
I0
I1
tp5719
sS'during,videx'
p5720
(F1
F0.00014334862385321102
I0
I1
I-1
tp5721
sS'for,cyp2d6'
p5722
(F1
F0.00014334862385321102
I1
I0
I1
tp5723
sS'well,studied'
p5724
(F1
F0.00014334862385321102
I0
I1
I-1
tp5725
sS'compatibility,of'
p5726
(F1
F0.00014334862385321102
I0
I1
I-1
tp5727
sS'of,camptosar'
p5728
(F1
F0.00014334862385321102
I1
I0
I1
tp5729
sS'to,lower'
p5730
(F1
F0.00014334862385321102
I0
I1
I-1
tp5731
sS'and,respectively'
p5732
(F0.73333333333333328
F0.0015768348623853212
I13
I2
I11
tp5733
sS'naloxone-sensitive,endorphinergic'
p5734
(F1
F0.00014334862385321102
I0
I1
I-1
tp5735
sS'report,describes'
p5736
(F1
F0.00028669724770642203
I2
I0
I2
tp5737
sS'lower,meclofenamate'
p5738
(F1
F0.00014334862385321102
I1
I0
I1
tp5739
sS'chronically,had'
p5740
(F0
F0
I1
I1
I0
tp5741
sS'basic,as'
p5742
(F1
F0.00014334862385321102
I1
I0
I1
tp5743
sS'one,or'
p5744
(F0
F0
I2
I2
I0
tp5745
sS'glucose,when'
p5746
(F1
F0.00014334862385321102
I0
I1
I-1
tp5747
sS'elevation,in'
p5748
(F0.5
F0.00028669724770642203
I3
I1
I2
tp5749
sS'an,an'
p5750
(F1
F0.00014334862385321102
I0
I1
I-1
tp5751
sS'received,tended'
p5752
(F1
F0.00014334862385321102
I0
I1
I-1
tp5753
sS'for,comprehensive'
p5754
(F1
F0.00014334862385321102
I0
I1
I-1
tp5755
sS'conversely,may'
p5756
(F1
F0.00014334862385321102
I1
I0
I1
tp5757
sS'epinephrine,also'
p5758
(F1
F0.00014334862385321102
I1
I0
I1
tp5759
sS'following,are'
p5760
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp5761
sS'circulating,and'
p5762
(F1
F0.00028669724770642203
I0
I2
I-2
tp5763
sS'by,multiple-dose'
p5764
(F1
F0.00014334862385321102
I0
I1
I-1
tp5765
sS'for,to'
p5766
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5767
sS'nicotinic,receptors'
p5768
(F1
F0.00014334862385321102
I0
I1
I-1
tp5769
sS'n,and'
p5770
(F1
F0.00028669724770642203
I2
I0
I2
tp5771
sS'ibandronate,should'
p5772
(F1
F0.00014334862385321102
I1
I0
I1
tp5773
sS'in,nursing'
p5774
(F1
F0.00014334862385321102
I0
I1
I-1
tp5775
sS'congestive,heart'
p5776
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp5777
sS'products,absorption'
p5778
(F1
F0.00014334862385321102
I0
I1
I-1
tp5779
sS'amphetamines,may'
p5780
(F1
F0.0020068807339449542
I14
I0
I14
tp5781
sS'modest,increases'
p5782
(F1
F0.00028669724770642203
I2
I0
I2
tp5783
sS'of,racemic'
p5784
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp5785
sS'hormones,appear'
p5786
(F1
F0.00014334862385321102
I0
I1
I-1
tp5787
sS'and,terminal'
p5788
(F1
F0.00014334862385321102
I1
I0
I1
tp5789
sS'theoretical,potential'
p5790
(F1
F0.00014334862385321102
I1
I0
I1
tp5791
sS'sickness,medications'
p5792
(F1
F0.00014334862385321102
I0
I1
I-1
tp5793
sS'includes,such'
p5794
(F1
F0.00014334862385321102
I0
I1
I-1
tp5795
sS'antagonists,angiotensin'
p5796
(F1
F0.00014334862385321102
I0
I1
I-1
tp5797
sS'liver,alt'
p5798
(F1
F0.00014334862385321102
I1
I0
I1
tp5799
sS'relevant,concentrations'
p5800
(F1
F0.00014334862385321102
I0
I1
I-1
tp5801
sS'on,hormone'
p5802
(F1
F0.00028669724770642203
I0
I2
I-2
tp5803
sS'the,translocation'
p5804
(F1
F0.00014334862385321102
I0
I1
I-1
tp5805
sS'hydrochlorothiazide,hctz'
p5806
(F1
F0.00014334862385321102
I0
I1
I-1
tp5807
sS'administered,prior'
p5808
(F1
F0.00028669724770642203
I2
I0
I2
tp5809
sS'as,pure'
p5810
(F1
F0.00014334862385321102
I1
I0
I1
tp5811
sS'respiratory,and'
p5812
(F1
F0.00014334862385321102
I1
I0
I1
tp5813
sS'medications,may'
p5814
(F1
F0.00014334862385321102
I1
I0
I1
tp5815
sS'either,on'
p5816
(F1
F0.00014334862385321102
I0
I1
I-1
tp5817
sS'premedline,and'
p5818
(F1
F0.00014334862385321102
I0
I1
I-1
tp5819
sS'or,dihydroxyflavone'
p5820
(F1
F0.00014334862385321102
I0
I1
I-1
tp5821
sS'experience,in'
p5822
(F1
F0.00014334862385321102
I1
I0
I1
tp5823
sS'serum,by'
p5824
(F1
F0.00014334862385321102
I1
I0
I1
tp5825
sS'convulsions,in'
p5826
(F0
F0
I1
I1
I0
tp5827
sS'added,in'
p5828
(F1
F0.00014334862385321102
I0
I1
I-1
tp5829
sS'the,bioavailabillty'
p5830
(F1
F0.00014334862385321102
I1
I0
I1
tp5831
sS'of,precedex'
p5832
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5833
sS'general,skeletal'
p5834
(F1
F0.00028669724770642203
I2
I0
I2
tp5835
sS'eg,other'
p5836
(F1
F0.00014334862385321102
I1
I0
I1
tp5837
sS'with,dosage'
p5838
(F1
F0.00014334862385321102
I0
I1
I-1
tp5839
sS'bid,resulted'
p5840
(F1
F0.00014334862385321102
I1
I0
I1
tp5841
sS'are,to'
p5842
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp5843
sS'either,dose'
p5844
(F1
F0.00014334862385321102
I0
I1
I-1
tp5845
sS'transient,elevations'
p5846
(F1
F0.00028669724770642203
I2
I0
I2
tp5847
sS'metabolites,n-desmethylclozapine'
p5848
(F1
F0.00014334862385321102
I0
I1
I-1
tp5849
sS'this,may'
p5850
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp5851
sS'infant,has'
p5852
(F1
F0.00014334862385321102
I0
I1
I-1
tp5853
sS'with,alphagan'
p5854
(F1
F0.00028669724770642203
I2
I0
I2
tp5855
sS'old,participated'
p5856
(F1
F0.00014334862385321102
I0
I1
I-1
tp5857
sS'small,n'
p5858
(F1
F0.00014334862385321102
I1
I0
I1
tp5859
sS'on,positive'
p5860
(F1
F0.00014334862385321102
I0
I1
I-1
tp5861
sS'with,breast'
p5862
(F1
F0.00014334862385321102
I1
I0
I1
tp5863
sS'evidence,indicating'
p5864
(F1
F0.00014334862385321102
I0
I1
I-1
tp5865
sS'carbonate,mg'
p5866
(F1
F0.00014334862385321102
I0
I1
I-1
tp5867
sS'intestinal,adenocarcinomas'
p5868
(F0
F0
I1
I1
I0
tp5869
sS'cimetidine,can'
p5870
(F1
F0.00014334862385321102
I1
I0
I1
tp5871
sS'and,mhd'
p5872
(F1
F0.00043004587155963305
I0
I3
I-3
tp5873
sS'be,similar'
p5874
(F1
F0.00014334862385321102
I0
I1
I-1
tp5875
sS'should,therefore'
p5876
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp5877
sS'tab,ria'
p5878
(F1
F0.00014334862385321102
I0
I1
I-1
tp5879
sS'or,decrease'
p5880
(F1
F0.00028669724770642203
I2
I0
I2
tp5881
sS'anticoagulation,should'
p5882
(F1
F0.00014334862385321102
I0
I1
I-1
tp5883
sS'aldomet,use'
p5884
(F1
F0.00014334862385321102
I1
I0
I1
tp5885
sS'being,converted'
p5886
(F1
F0.00014334862385321102
I1
I0
I1
tp5887
sS'an,hmg-coa'
p5888
(F1
F0.00014334862385321102
I1
I0
I1
tp5889
sS'sustained-release,with'
p5890
(F1
F0.00014334862385321102
I0
I1
I-1
tp5891
sS'potentiate,renal'
p5892
(F1
F0.00014334862385321102
I1
I0
I1
tp5893
sS'direct,treatment'
p5894
(F1
F0.00014334862385321102
I0
I1
I-1
tp5895
sS'administration,twice'
p5896
(F1
F0.00014334862385321102
I0
I1
I-1
tp5897
sS'and,reduce'
p5898
(F0
F0
I1
I1
I0
tp5899
sS'vitamin,b12'
p5900
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5901
sS'recovery,time'
p5902
(F1
F0.00014334862385321102
I1
I0
I1
tp5903
sS'these,on'
p5904
(F1
F0.00028669724770642203
I0
I2
I-2
tp5905
sS'keppra,on'
p5906
(F1
F0.00014334862385321102
I0
I1
I-1
tp5907
sS'have,indicated'
p5908
(F1
F0.00014334862385321102
I0
I1
I-1
tp5909
sS'platelet,agents'
p5910
(F1
F0.00014334862385321102
I0
I1
I-1
tp5911
sS'to,hours'
p5912
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp5913
sS'with,fortovase'
p5914
(F1
F0.00014334862385321102
I0
I1
I-1
tp5915
sS'mg,dl'
p5916
(F0
F0
I1
I1
I0
tp5917
sS'romazicon,exerts'
p5918
(F1
F0.00014334862385321102
I1
I0
I1
tp5919
sS'to,competitively'
p5920
(F1
F0.00014334862385321102
I1
I0
I1
tp5921
sS'metabolites,with'
p5922
(F0
F0
I1
I1
I0
tp5923
sS'potentially,fatal'
p5924
(F1
F0.00014334862385321102
I1
I0
I1
tp5925
sS'of,n-allylnormetazocine'
p5926
(F1
F0.00014334862385321102
I0
I1
I-1
tp5927
sS'active,in'
p5928
(F1
F0.00014334862385321102
I1
I0
I1
tp5929
sS'diabetics,dosage'
p5930
(F1
F0.00014334862385321102
I1
I0
I1
tp5931
sS'bone,marrow'
p5932
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5933
sS'between,a'
p5934
(F0
F0
I1
I1
I0
tp5935
sS'subjects,decreases'
p5936
(F1
F0.00014334862385321102
I0
I1
I-1
tp5937
sS'prevent,the'
p5938
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp5939
sS'failure,as'
p5940
(F0
F0
I1
I1
I0
tp5941
sS'yields,a'
p5942
(F1
F0.00014334862385321102
I1
I0
I1
tp5943
sS'first,pass'
p5944
(F1
F0.00014334862385321102
I0
I1
I-1
tp5945
sS'a,tca'
p5946
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp5947
sS'oral,upon'
p5948
(F1
F0.00014334862385321102
I1
I0
I1
tp5949
sS'plasma,enzymes'
p5950
(F1
F0.00014334862385321102
I0
I1
I-1
tp5951
sS'explained,by'
p5952
(F1
F0.00014334862385321102
I1
I0
I1
tp5953
sS'including,or'
p5954
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp5955
sS'when,norpace'
p5956
(F1
F0.00014334862385321102
I0
I1
I-1
tp5957
sS'to,has'
p5958
(F1
F0.00014334862385321102
I1
I0
I1
tp5959
sS'relationship,physicians'
p5960
(F1
F0.00014334862385321102
I1
I0
I1
tp5961
sS'the,other'
p5962
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp5963
sS'antinonciceptive,effect'
p5964
(F1
F0.00014334862385321102
I0
I1
I-1
tp5965
sS'precedex,on'
p5966
(F1
F0.00014334862385321102
I1
I0
I1
tp5967
sS'of,class'
p5968
(F0
F0
I1
I1
I0
tp5969
sS'potentiated,when'
p5970
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp5971
sS'cyp1a2,c8'
p5972
(F1
F0.00014334862385321102
I0
I1
I-1
tp5973
sS'at,higher'
p5974
(F1
F0.00014334862385321102
I1
I0
I1
tp5975
sS'failure,were'
p5976
(F1
F0.00014334862385321102
I0
I1
I-1
tp5977
sS'by,similar'
p5978
(F1
F0.00028669724770642203
I0
I2
I-2
tp5979
sS'substitutes,may'
p5980
(F0
F0
I1
I1
I0
tp5981
sS'and,higher'
p5982
(F1
F0.00028669724770642203
I2
I0
I2
tp5983
sS'and,mean'
p5984
(F1
F0.00057339449541284407
I4
I0
I4
tp5985
sS'second,generation'
p5986
(F1
F0.00014334862385321102
I0
I1
I-1
tp5987
sS'cyp2d6,i'
p5988
(F1
F0.00014334862385321102
I1
I0
I1
tp5989
sS'for,dose'
p5990
(F1
F0.00028669724770642203
I0
I2
I-2
tp5991
sS'pharmacokinetics,have'
p5992
(F1
F0.00014334862385321102
I0
I1
I-1
tp5993
sS'capsule,n'
p5994
(F1
F0.00014334862385321102
I1
I0
I1
tp5995
sS'isocarboxazid,should'
p5996
(F1
F0.00014334862385321102
I1
I0
I1
tp5997
sS'other,monoamine'
p5998
(F1
F0.00014334862385321102
I1
I0
I1
tp5999
sS'concurrently,should'
p6000
(F1
F0.00014334862385321102
I1
I0
I1
tp6001
sS'kg,for'
p6002
(F1
F0.00028669724770642203
I2
I0
I2
tp6003
sS'blocks,receptors'
p6004
(F1
F0.00014334862385321102
I1
I0
I1
tp6005
sS'novolog,and'
p6006
(F1
F0.00014334862385321102
I0
I1
I-1
tp6007
sS'daily,acquisition'
p6008
(F1
F0.00014334862385321102
I0
I1
I-1
tp6009
sS'require,dose'
p6010
(F1
F0.00014334862385321102
I0
I1
I-1
tp6011
sS'that,obtained'
p6012
(F1
F0.00014334862385321102
I1
I0
I1
tp6013
sS'therapy,or'
p6014
(F1
F0.00014334862385321102
I0
I1
I-1
tp6015
sS'concurrently,it'
p6016
(F1
F0.00014334862385321102
I0
I1
I-1
tp6017
sS'nine,patients'
p6018
(F1
F0.00014334862385321102
I1
I0
I1
tp6019
sS'therapy,on'
p6020
(F1
F0.00014334862385321102
I1
I0
I1
tp6021
sS'microg,kg'
p6022
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp6023
sS'therapy,of'
p6024
(F1
F0.00028669724770642203
I2
I0
I2
tp6025
sS'be,acutely'
p6026
(F1
F0.00014334862385321102
I1
I0
I1
tp6027
sS'our,data'
p6028
(F1
F0.00014334862385321102
I1
I0
I1
tp6029
sS'general,population'
p6030
(F1
F0.00014334862385321102
I0
I1
I-1
tp6031
sS'with,first-episode'
p6032
(F1
F0.00014334862385321102
I0
I1
I-1
tp6033
sS'long,as'
p6034
(F1
F0.00014334862385321102
I1
I0
I1
tp6035
sS'not,experience'
p6036
(F1
F0.00014334862385321102
I0
I1
I-1
tp6037
sS'two,type'
p6038
(F1
F0.00014334862385321102
I0
I1
I-1
tp6039
sS'or,hepatic'
p6040
(F1
F0.00014334862385321102
I1
I0
I1
tp6041
sS'elevations,seen'
p6042
(F1
F0.00014334862385321102
I1
I0
I1
tp6043
sS'their,dosage'
p6044
(F1
F0.00043004587155963305
I3
I0
I3
tp6045
sS'adl,mg'
p6046
(F1
F0.00028669724770642203
I0
I2
I-2
tp6047
sS'femara,and'
p6048
(F1
F0.00014334862385321102
I1
I0
I1
tp6049
sS'dose,will'
p6050
(F1
F0.00014334862385321102
I1
I0
I1
tp6051
sS'hydroxy,acid'
p6052
(F1
F0.00014334862385321102
I1
I0
I1
tp6053
sS'nimbex,before'
p6054
(F1
F0.00014334862385321102
I0
I1
I-1
tp6055
sS'with,than'
p6056
(F0
F0
I1
I1
I0
tp6057
sS'except,for'
p6058
(F1
F0.00014334862385321102
I0
I1
I-1
tp6059
sS'as,hctz'
p6060
(F1
F0.00014334862385321102
I0
I1
I-1
tp6061
sS'relation,to'
p6062
(F1
F0.00014334862385321102
I0
I1
I-1
tp6063
sS'in,laboratory'
p6064
(F1
F0.00014334862385321102
I0
I1
I-1
tp6065
sS'with,that'
p6066
(F0.29999999999999999
F0.0008600917431192661
I7
I13
I-6
tp6067
sS'qd,mg'
p6068
(F1
F0.00014334862385321102
I1
I0
I1
tp6069
sS'to,obstetric'
p6070
(F0
F0
I1
I1
I0
tp6071
sS'significantly,reduced'
p6072
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp6073
sS'frequent,doses'
p6074
(F1
F0.00014334862385321102
I0
I1
I-1
tp6075
sS'effects,celebrex'
p6076
(F1
F0.00014334862385321102
I0
I1
I-1
tp6077
sS'compounds,attenuate'
p6078
(F1
F0.00014334862385321102
I0
I1
I-1
tp6079
sS'and,levo-dromoran'
p6080
(F1
F0.00014334862385321102
I1
I0
I1
tp6081
sS'significantly,reduces'
p6082
(F1
F0.00014334862385321102
I1
I0
I1
tp6083
sS'conjugation,through'
p6084
(F1
F0.00014334862385321102
I0
I1
I-1
tp6085
sS'and,cautioned'
p6086
(F1
F0.00014334862385321102
I0
I1
I-1
tp6087
sS'enzymes,responsible'
p6088
(F1
F0.00014334862385321102
I0
I1
I-1
tp6089
sS'disease,patients'
p6090
(F1
F0.00014334862385321102
I0
I1
I-1
tp6091
sS'well,controlled'
p6092
(F0
F0
I1
I1
I0
tp6093
sS'in,more'
p6094
(F1
F0.00014334862385321102
I0
I1
I-1
tp6095
sS'in,cortisol'
p6096
(F1
F0.00014334862385321102
I0
I1
I-1
tp6097
sS'as,narcotics'
p6098
(F1
F0.00014334862385321102
I1
I0
I1
tp6099
sS'a,course'
p6100
(F0.5
F0.00028669724770642203
I3
I1
I2
tp6101
sS'diminish,adrenal'
p6102
(F1
F0.00014334862385321102
I1
I0
I1
tp6103
sS'coelenterates,of'
p6104
(F1
F0.00014334862385321102
I0
I1
I-1
tp6105
sS'a,sub-'
p6106
(F1
F0.00014334862385321102
I0
I1
I-1
tp6107
sS'and,non-steroidal'
p6108
(F1
F0.00057339449541284407
I4
I0
I4
tp6109
sS'in,sheep'
p6110
(F1
F0.00014334862385321102
I0
I1
I-1
tp6111
sS'stomach,acidity'
p6112
(F1
F0.00014334862385321102
I0
I1
I-1
tp6113
sS'and,didanosine-placebo'
p6114
(F1
F0.00014334862385321102
I1
I0
I1
tp6115
sS'metabolite,at'
p6116
(F1
F0.00014334862385321102
I1
I0
I1
tp6117
sS'max,decreased'
p6118
(F1
F0.00014334862385321102
I1
I0
I1
tp6119
sS'on,diastolic'
p6120
(F1
F0.00014334862385321102
I0
I1
I-1
tp6121
sS'the,response'
p6122
(F0.5
F0.00028669724770642203
I3
I1
I2
tp6123
sS'test,should'
p6124
(F1
F0.00043004587155963305
I3
I0
I3
tp6125
sS'aeds,affects'
p6126
(F1
F0.00014334862385321102
I1
I0
I1
tp6127
sS'benzylpenicillin,and'
p6128
(F1
F0.00014334862385321102
I0
I1
I-1
tp6129
sS'use,with'
p6130
(F0.052631578947368418
F0.00014334862385321102
I10
I9
I1
tp6131
sS'potentiating,effects'
p6132
(F1
F0.00014334862385321102
I1
I0
I1
tp6133
sS'medicine,certain'
p6134
(F1
F0.00014334862385321102
I0
I1
I-1
tp6135
sS'in,epileptic'
p6136
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6137
sS'as,ophthalmic'
p6138
(F0
F0
I1
I1
I0
tp6139
sS'were,reduced'
p6140
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp6141
sS'potential,benefits'
p6142
(F1
F0.00028669724770642203
I2
I0
I2
tp6143
sS'cations,likely'
p6144
(F1
F0.00014334862385321102
I1
I0
I1
tp6145
sS'it,had'
p6146
(F0
F0
I1
I1
I0
tp6147
sS'and,plus'
p6148
(F1
F0.00014334862385321102
I1
I0
I1
tp6149
sS'which,sensitize'
p6150
(F1
F0.00014334862385321102
I1
I0
I1
tp6151
sS'to,ptx'
p6152
(F1
F0.00014334862385321102
I1
I0
I1
tp6153
sS'was,a'
p6154
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp6155
sS'agent,with'
p6156
(F1
F0.00014334862385321102
I1
I0
I1
tp6157
sS'a4,macrolide'
p6158
(F1
F0.00014334862385321102
I1
I0
I1
tp6159
sS'may,displace'
p6160
(F1
F0.00028669724770642203
I2
I0
I2
tp6161
sS'weeks,has'
p6162
(F1
F0.00014334862385321102
I1
I0
I1
tp6163
sS'the,steady-state'
p6164
(F0.043478260869565216
F0.00014334862385321102
I11
I12
I-1
tp6165
sS'and,cause'
p6166
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp6167
sS'convulsions,and'
p6168
(F1
F0.00014334862385321102
I1
I0
I1
tp6169
sS'as,cyp3a4'
p6170
(F1
F0.00014334862385321102
I1
I0
I1
tp6171
sS'dogs,but'
p6172
(F1
F0.00014334862385321102
I1
I0
I1
tp6173
sS'but,only'
p6174
(F1
F0.00014334862385321102
I0
I1
I-1
tp6175
sS'that,undergo'
p6176
(F1
F0.00014334862385321102
I1
I0
I1
tp6177
sS'last,subcutaneous'
p6178
(F1
F0.00014334862385321102
I1
I0
I1
tp6179
sS'clinical,conditions'
p6180
(F1
F0.00014334862385321102
I1
I0
I1
tp6181
sS'following,adverse'
p6182
(F1
F0.00014334862385321102
I1
I0
I1
tp6183
sS'im,was'
p6184
(F1
F0.00014334862385321102
I0
I1
I-1
tp6185
sS'or,were'
p6186
(F1
F0.00043004587155963305
I0
I3
I-3
tp6187
sS'reported,resulting'
p6188
(F1
F0.00014334862385321102
I1
I0
I1
tp6189
sS'ssris,weakness'
p6190
(F1
F0.00014334862385321102
I1
I0
I1
tp6191
sS'sprycel,is'
p6192
(F1
F0.00014334862385321102
I1
I0
I1
tp6193
sS'per,day'
p6194
(F0
F0
I5
I5
I0
tp6195
sS'to,one'
p6196
(F1
F0.00014334862385321102
I1
I0
I1
tp6197
sS'hcl,phenytoin'
p6198
(F1
F0.00028669724770642203
I2
I0
I2
tp6199
sS'inhibitors,aminosalicylic'
p6200
(F1
F0.00014334862385321102
I1
I0
I1
tp6201
sS'that,small'
p6202
(F1
F0.00014334862385321102
I0
I1
I-1
tp6203
sS'gel,should'
p6204
(F1
F0.00014334862385321102
I1
I0
I1
tp6205
sS'been,suggested'
p6206
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp6207
sS'taking,concurrent'
p6208
(F1
F0.00014334862385321102
I1
I0
I1
tp6209
sS'pharmacokinetic,profiles'
p6210
(F1
F0.00014334862385321102
I0
I1
I-1
tp6211
sS'greater,gastrointestinal'
p6212
(F1
F0.00014334862385321102
I1
I0
I1
tp6213
sS'hepatic,cyp'
p6214
(F1
F0.00014334862385321102
I0
I1
I-1
tp6215
sS'fluconazole,fluoxetine'
p6216
(F1
F0.00014334862385321102
I0
I1
I-1
tp6217
sS'no,difference'
p6218
(F1
F0.00028669724770642203
I0
I2
I-2
tp6219
sS'bioavailability,was'
p6220
(F1
F0.00028669724770642203
I2
I0
I2
tp6221
sS'analysis,of'
p6222
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp6223
sS'additional,adrenergic'
p6224
(F1
F0.00014334862385321102
I1
I0
I1
tp6225
sS'rifabutin,rifampin'
p6226
(F1
F0.00014334862385321102
I0
I1
I-1
tp6227
sS'to,outweigh'
p6228
(F1
F0.00014334862385321102
I1
I0
I1
tp6229
sS'taking,the'
p6230
(F1
F0.00014334862385321102
I1
I0
I1
tp6231
sS'of,extraneal'
p6232
(F1
F0.00014334862385321102
I0
I1
I-1
tp6233
sS'maintenance,of'
p6234
(F1
F0.00028669724770642203
I0
I2
I-2
tp6235
sS'accompanied,by'
p6236
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6237
sS'ketoconazole,increased'
p6238
(F1
F0.00014334862385321102
I1
I0
I1
tp6239
sS'member,of'
p6240
(F1
F0.00014334862385321102
I1
I0
I1
tp6241
sS'levels,by'
p6242
(F0
F0
I2
I2
I0
tp6243
sS'tablets,as'
p6244
(F1
F0.00014334862385321102
I1
I0
I1
tp6245
sS'an,nsaid'
p6246
(F0
F0
I1
I1
I0
tp6247
sS'enterococcus,faecium'
p6248
(F1
F0.00014334862385321102
I0
I1
I-1
tp6249
sS'colistemethate,salts'
p6250
(F1
F0.00014334862385321102
I1
I0
I1
tp6251
sS'including,protease'
p6252
(F1
F0.00014334862385321102
I0
I1
I-1
tp6253
sS'levels,be'
p6254
(F1
F0.0008600917431192661
I6
I0
I6
tp6255
sS'tablets,an'
p6256
(F1
F0.00014334862385321102
I1
I0
I1
tp6257
sS'selegiline,l-phenylalanine'
p6258
(F1
F0.00014334862385321102
I1
I0
I1
tp6259
sS'cordarone,administration'
p6260
(F1
F0.00014334862385321102
I0
I1
I-1
tp6261
sS'drugs,can'
p6262
(F1
F0.00014334862385321102
I1
I0
I1
tp6263
sS'epidural,may'
p6264
(F1
F0.00014334862385321102
I1
I0
I1
tp6265
sS'secretion,distribution'
p6266
(F1
F0.00014334862385321102
I0
I1
I-1
tp6267
sS'cyclosporine,cyp3a4'
p6268
(F1
F0.00014334862385321102
I0
I1
I-1
tp6269
sS'after,than'
p6270
(F1
F0.00014334862385321102
I1
I0
I1
tp6271
sS'general,have'
p6272
(F1
F0.00014334862385321102
I1
I0
I1
tp6273
sS'range,while'
p6274
(F1
F0.00014334862385321102
I0
I1
I-1
tp6275
sS'from,ml'
p6276
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6277
sS'of,see'
p6278
(F0
F0
I1
I1
I0
tp6279
sS'steady-state,conditions'
p6280
(F1
F0.00028669724770642203
I0
I2
I-2
tp6281
sS'two,studies'
p6282
(F0
F0
I1
I1
I0
tp6283
sS'and,caused'
p6284
(F1
F0.00014334862385321102
I0
I1
I-1
tp6285
sS'from,mg'
p6286
(F1
F0.00028669724770642203
I2
I0
I2
tp6287
sS'tumors,and'
p6288
(F1
F0.00014334862385321102
I1
I0
I1
tp6289
sS'volunteers,hydrochloride'
p6290
(F1
F0.00014334862385321102
I1
I0
I1
tp6291
sS'and,dpcpx-induced'
p6292
(F1
F0.00014334862385321102
I1
I0
I1
tp6293
sS'these,resulting'
p6294
(F1
F0.00014334862385321102
I1
I0
I1
tp6295
sS'with,prostatectomy'
p6296
(F1
F0.00014334862385321102
I0
I1
I-1
tp6297
sS'dietary,concentrations'
p6298
(F1
F0.00014334862385321102
I0
I1
I-1
tp6299
sS'each,may'
p6300
(F1
F0.00014334862385321102
I0
I1
I-1
tp6301
sS'when,patients'
p6302
(F0
F0
I1
I1
I0
tp6303
sS'interval,observed'
p6304
(F1
F0.00014334862385321102
I1
I0
I1
tp6305
sS'had,minimal'
p6306
(F1
F0.00014334862385321102
I0
I1
I-1
tp6307
sS'calcium,supplements'
p6308
(F1
F0.00043004587155963305
I0
I3
I-3
tp6309
sS'diabectics,than'
p6310
(F1
F0.00014334862385321102
I0
I1
I-1
tp6311
sS'and,stimulate'
p6312
(F1
F0.00014334862385321102
I1
I0
I1
tp6313
sS'cells,that'
p6314
(F1
F0.00014334862385321102
I1
I0
I1
tp6315
sS'of,acetate'
p6316
(F0
F0
I1
I1
I0
tp6317
sS'however,it'
p6318
(F0
F0
I2
I2
I0
tp6319
sS'are,negatively'
p6320
(F1
F0.00014334862385321102
I0
I1
I-1
tp6321
sS'inhibited,by'
p6322
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp6323
sS'behavior,has'
p6324
(F1
F0.00014334862385321102
I1
I0
I1
tp6325
sS'or,pharmacodynamic'
p6326
(F1
F0.00071674311926605509
I0
I5
I-5
tp6327
sS'interaction,involving'
p6328
(F1
F0.00014334862385321102
I1
I0
I1
tp6329
sS'but,definite'
p6330
(F1
F0.00014334862385321102
I0
I1
I-1
tp6331
sS'participated,in'
p6332
(F1
F0.00014334862385321102
I0
I1
I-1
tp6333
sS'effective,in'
p6334
(F1
F0.00028669724770642203
I2
I0
I2
tp6335
sS'interval,prolongation'
p6336
(F1
F0.00014334862385321102
I1
I0
I1
tp6337
sS'to,weeks'
p6338
(F1
F0.00028669724770642203
I2
I0
I2
tp6339
sS'n,the'
p6340
(F1
F0.00014334862385321102
I1
I0
I1
tp6341
sS'is,to'
p6342
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp6343
sS'taken,hour'
p6344
(F1
F0.00014334862385321102
I0
I1
I-1
tp6345
sS'or,glatiramer'
p6346
(F1
F0.00014334862385321102
I0
I1
I-1
tp6347
sS'bleeding,associated'
p6348
(F1
F0.00014334862385321102
I1
I0
I1
tp6349
sS'isoenzymes,cyp1a2'
p6350
(F1
F0.00014334862385321102
I0
I1
I-1
tp6351
sS'proteus,rettgeri'
p6352
(F1
F0.00014334862385321102
I0
I1
I-1
tp6353
sS'as,demonstrated'
p6354
(F1
F0.00014334862385321102
I0
I1
I-1
tp6355
sS'absolute,in'
p6356
(F1
F0.00014334862385321102
I0
I1
I-1
tp6357
sS'urine,was'
p6358
(F1
F0.00014334862385321102
I0
I1
I-1
tp6359
sS'that,also'
p6360
(F1
F0.00014334862385321102
I1
I0
I1
tp6361
sS'period,followed'
p6362
(F1
F0.00014334862385321102
I0
I1
I-1
tp6363
sS'the,ionized'
p6364
(F1
F0.00028669724770642203
I2
I0
I2
tp6365
sS'or,near'
p6366
(F1
F0.00014334862385321102
I1
I0
I1
tp6367
sS'binding,studies'
p6368
(F1
F0.00014334862385321102
I0
I1
I-1
tp6369
sS'to,several'
p6370
(F1
F0.00014334862385321102
I0
I1
I-1
tp6371
sS'of,parenterally'
p6372
(F1
F0.00014334862385321102
I1
I0
I1
tp6373
sS'arrhythmias,during'
p6374
(F1
F0.00014334862385321102
I1
I0
I1
tp6375
sS'patients,undergoing'
p6376
(F1
F0.00071674311926605509
I5
I0
I5
tp6377
sS'an,agent'
p6378
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp6379
sS'and,cyp3a4'
p6380
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp6381
sS'cardiovascular,agents'
p6382
(F1
F0.00014334862385321102
I0
I1
I-1
tp6383
sS'addition,neuromuscular'
p6384
(F1
F0.00014334862385321102
I0
I1
I-1
tp6385
sS'clarithromycin,exposure'
p6386
(F1
F0.00014334862385321102
I1
I0
I1
tp6387
sS'were,carried'
p6388
(F1
F0.00014334862385321102
I0
I1
I-1
tp6389
sS'tardive,dyskinesia'
p6390
(F1
F0.00014334862385321102
I1
I0
I1
tp6391
sS'nephrotoxicity,of'
p6392
(F1
F0.00014334862385321102
I1
I0
I1
tp6393
sS'possibility,of'
p6394
(F0.55555555555555558
F0.0014334862385321102
I14
I4
I10
tp6395
sS'acids,may'
p6396
(F1
F0.00014334862385321102
I0
I1
I-1
tp6397
sS'casodex,can'
p6398
(F1
F0.00014334862385321102
I1
I0
I1
tp6399
sS'zarontin,may'
p6400
(F1
F0.00014334862385321102
I1
I0
I1
tp6401
sS'ocs,macrolide'
p6402
(F1
F0.00014334862385321102
I0
I1
I-1
tp6403
sS'them,and'
p6404
(F1
F0.00014334862385321102
I0
I1
I-1
tp6405
sS'nonsteroidal,anti-inflammatory'
p6406
(F0.53846153846153844
F0.0010034403669724771
I10
I3
I7
tp6407
sS'binding,and'
p6408
(F0
F0
I1
I1
I0
tp6409
sS'potentiates,the'
p6410
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp6411
sS'conjugated,with'
p6412
(F1
F0.00014334862385321102
I0
I1
I-1
tp6413
sS'liver,function'
p6414
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp6415
sS'inhibitors,serotonin'
p6416
(F1
F0.00014334862385321102
I1
I0
I1
tp6417
sS'disease,have'
p6418
(F1
F0.00014334862385321102
I1
I0
I1
tp6419
sS'the,second'
p6420
(F0
F0
I2
I2
I0
tp6421
sS'of,affected'
p6422
(F1
F0.00028669724770642203
I0
I2
I-2
tp6423
sS'schizophrenia,and'
p6424
(F1
F0.00028669724770642203
I0
I2
I-2
tp6425
sS'chemotherapy,or'
p6426
(F1
F0.00028669724770642203
I0
I2
I-2
tp6427
sS'even,so'
p6428
(F1
F0.00014334862385321102
I1
I0
I1
tp6429
sS'not,potentiate'
p6430
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp6431
sS'fraction,of'
p6432
(F1
F0.00043004587155963305
I0
I3
I-3
tp6433
sS'flolan,was'
p6434
(F1
F0.00014334862385321102
I1
I0
I1
tp6435
sS'sodium,colistemethate'
p6436
(F1
F0.00014334862385321102
I1
I0
I1
tp6437
sS'less,frequent'
p6438
(F1
F0.00014334862385321102
I1
I0
I1
tp6439
sS'when,changing'
p6440
(F1
F0.00014334862385321102
I0
I1
I-1
tp6441
sS'sodium,can'
p6442
(F1
F0.00014334862385321102
I1
I0
I1
tp6443
sS'highly,effective'
p6444
(F1
F0.00014334862385321102
I0
I1
I-1
tp6445
sS'hypoparathyroid,patients'
p6446
(F1
F0.00028669724770642203
I2
I0
I2
tp6447
sS'in,t24'
p6448
(F1
F0.00014334862385321102
I1
I0
I1
tp6449
sS'antihistamines,amphetamines'
p6450
(F1
F0.00028669724770642203
I2
I0
I2
tp6451
sS'high,concentrations'
p6452
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp6453
sS'required,or'
p6454
(F1
F0.00014334862385321102
I1
I0
I1
tp6455
sS'chloride,sodium'
p6456
(F1
F0.00028669724770642203
I2
I0
I2
tp6457
sS'that,potentiate'
p6458
(F1
F0.00014334862385321102
I0
I1
I-1
tp6459
sS'injectable,implantable'
p6460
(F1
F0.00014334862385321102
I0
I1
I-1
tp6461
sS'the,cyp2c9'
p6462
(F1
F0.00028669724770642203
I2
I0
I2
tp6463
sS'prolixin,permitil'
p6464
(F1
F0.00014334862385321102
I0
I1
I-1
tp6465
sS'bioavailability,studies'
p6466
(F1
F0.00028669724770642203
I0
I2
I-2
tp6467
sS'when,edecrin'
p6468
(F1
F0.00014334862385321102
I1
I0
I1
tp6469
sS'of,enflurane'
p6470
(F1
F0.00014334862385321102
I0
I1
I-1
tp6471
sS'conducting,an'
p6472
(F1
F0.00014334862385321102
I1
I0
I1
tp6473
sS'with,kerlone'
p6474
(F1
F0.00014334862385321102
I0
I1
I-1
tp6475
sS'requirement,of'
p6476
(F1
F0.00014334862385321102
I1
I0
I1
tp6477
sS'and,high-estradiol'
p6478
(F1
F0.00014334862385321102
I1
I0
I1
tp6479
sS'neutralized,the'
p6480
(F1
F0.00028669724770642203
I0
I2
I-2
tp6481
sS'infarction,myocarditis'
p6482
(F1
F0.00014334862385321102
I1
I0
I1
tp6483
sS'is,derived'
p6484
(F1
F0.00014334862385321102
I1
I0
I1
tp6485
sS'methotrexate,there'
p6486
(F1
F0.00028669724770642203
I2
I0
I2
tp6487
sS'decreases,gastrointestinal'
p6488
(F1
F0.00014334862385321102
I1
I0
I1
tp6489
sS'antidiabetic,agents'
p6490
(F0
F0
I1
I1
I0
tp6491
sS'tca,is'
p6492
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp6493
sS'catecholamine,depletors'
p6494
(F1
F0.00014334862385321102
I1
I0
I1
tp6495
sS'established,on'
p6496
(F1
F0.00014334862385321102
I0
I1
I-1
tp6497
sS'gait,or'
p6498
(F1
F0.00014334862385321102
I1
I0
I1
tp6499
sS'iva,p-type'
p6500
(F1
F0.00014334862385321102
I0
I1
I-1
tp6501
sS'q24h,for'
p6502
(F0
F0
I1
I1
I0
tp6503
sS'all,prescription'
p6504
(F1
F0.00014334862385321102
I0
I1
I-1
tp6505
sS'usual,daily'
p6506
(F1
F0.00014334862385321102
I1
I0
I1
tp6507
sS'synergistic,elevation'
p6508
(F1
F0.00014334862385321102
I1
I0
I1
tp6509
sS'equipotent,inducers'
p6510
(F1
F0.00014334862385321102
I0
I1
I-1
tp6511
sS'drug,known'
p6512
(F1
F0.00014334862385321102
I0
I1
I-1
tp6513
sS'indanyl,sodium'
p6514
(F1
F0.00014334862385321102
I1
I0
I1
tp6515
sS'epoxide,metabolite'
p6516
(F1
F0.00014334862385321102
I0
I1
I-1
tp6517
sS'oral,regimen'
p6518
(F1
F0.00014334862385321102
I0
I1
I-1
tp6519
sS'sodium,the'
p6520
(F1
F0.00014334862385321102
I0
I1
I-1
tp6521
sS'rash,has'
p6522
(F1
F0.00014334862385321102
I1
I0
I1
tp6523
sS'sulfa-based,such'
p6524
(F1
F0.00014334862385321102
I0
I1
I-1
tp6525
sS'substrates,dasatinib'
p6526
(F1
F0.00014334862385321102
I0
I1
I-1
tp6527
sS'yet,statistically'
p6528
(F1
F0.00014334862385321102
I0
I1
I-1
tp6529
sS'therapeutic,margin'
p6530
(F1
F0.00014334862385321102
I0
I1
I-1
tp6531
sS'antagonism,of'
p6532
(F1
F0.00014334862385321102
I1
I0
I1
tp6533
sS'stimulating,the'
p6534
(F1
F0.00014334862385321102
I0
I1
I-1
tp6535
sS'considered,clinically'
p6536
(F1
F0.00014334862385321102
I0
I1
I-1
tp6537
sS'situation,when'
p6538
(F1
F0.00014334862385321102
I1
I0
I1
tp6539
sS'significantly,elevating'
p6540
(F1
F0.00014334862385321102
I1
I0
I1
tp6541
sS'damage,has'
p6542
(F1
F0.00014334862385321102
I1
I0
I1
tp6543
sS'patients,or'
p6544
(F1
F0.00028669724770642203
I0
I2
I-2
tp6545
sS'or,mao-inhibitors'
p6546
(F1
F0.00014334862385321102
I1
I0
I1
tp6547
sS'cerubidine,may'
p6548
(F1
F0.00014334862385321102
I1
I0
I1
tp6549
sS'patient,requires'
p6550
(F1
F0.00014334862385321102
I1
I0
I1
tp6551
sS'efficacy,compared'
p6552
(F1
F0.00014334862385321102
I0
I1
I-1
tp6553
sS'with,dynacirc'
p6554
(F1
F0.00014334862385321102
I0
I1
I-1
tp6555
sS'patients,on'
p6556
(F0.7142857142857143
F0.0035837155963302754
I30
I5
I25
tp6557
sS'results,indicate'
p6558
(F1
F0.00043004587155963305
I0
I3
I-3
tp6559
sS'or,initiating'
p6560
(F1
F0.00014334862385321102
I1
I0
I1
tp6561
sS'from,a'
p6562
(F0.25
F0.00028669724770642203
I5
I3
I2
tp6563
sS'liter,potentiated'
p6564
(F1
F0.00014334862385321102
I1
I0
I1
tp6565
sS'inhibiting,parts'
p6566
(F1
F0.00014334862385321102
I1
I0
I1
tp6567
sS'the,requirements'
p6568
(F1
F0.00014334862385321102
I1
I0
I1
tp6569
sS'blockade,associated'
p6570
(F1
F0.00014334862385321102
I0
I1
I-1
tp6571
sS'from,l'
p6572
(F1
F0.00014334862385321102
I1
I0
I1
tp6573
sS'from,m'
p6574
(F1
F0.00014334862385321102
I0
I1
I-1
tp6575
sS'ganoderma,lucidum'
p6576
(F1
F0.00014334862385321102
I0
I1
I-1
tp6577
sS'pain,medication'
p6578
(F1
F0.00014334862385321102
I0
I1
I-1
tp6579
sS'antacids,increase'
p6580
(F1
F0.00014334862385321102
I1
I0
I1
tp6581
sS'tdp,in'
p6582
(F1
F0.00014334862385321102
I0
I1
I-1
tp6583
sS'carbamazepine,concomitant'
p6584
(F1
F0.00014334862385321102
I1
I0
I1
tp6585
sS'effect,should'
p6586
(F1
F0.00028669724770642203
I2
I0
I2
tp6587
sS'a,substantial'
p6588
(F0
F0
I1
I1
I0
tp6589
sS'pharmacokinetics,has'
p6590
(F1
F0.00014334862385321102
I0
I1
I-1
tp6591
sS'sclerosis,patients'
p6592
(F1
F0.00014334862385321102
I0
I1
I-1
tp6593
sS'patients,although'
p6594
(F1
F0.00014334862385321102
I0
I1
I-1
tp6595
sS'should,elapse'
p6596
(F1
F0.00057339449541284407
I4
I0
I4
tp6597
sS'pressure,may'
p6598
(F1
F0.00014334862385321102
I1
I0
I1
tp6599
sS'morphine,a'
p6600
(F1
F0.00014334862385321102
I1
I0
I1
tp6601
sS'patient,s'
p6602
(F1
F0.00014334862385321102
I1
I0
I1
tp6603
sS'toxic,reactions'
p6604
(F1
F0.00014334862385321102
I0
I1
I-1
tp6605
sS'meaningful,reductions'
p6606
(F1
F0.00014334862385321102
I1
I0
I1
tp6607
sS'and,trivalent'
p6608
(F1
F0.00028669724770642203
I2
I0
I2
tp6609
sS'primary,cns'
p6610
(F1
F0.00043004587155963305
I3
I0
I3
tp6611
sS'relative,to'
p6612
(F0
F0
I2
I2
I0
tp6613
sS'levonorgestrol,oral'
p6614
(F1
F0.00014334862385321102
I0
I1
I-1
tp6615
sS'exposed,histidines'
p6616
(F1
F0.00014334862385321102
I0
I1
I-1
tp6617
sS'or,serial'
p6618
(F1
F0.00014334862385321102
I0
I1
I-1
tp6619
sS'system,development'
p6620
(F1
F0.00014334862385321102
I0
I1
I-1
tp6621
sS'is,prevented'
p6622
(F1
F0.00014334862385321102
I1
I0
I1
tp6623
sS'tnf,antagonist'
p6624
(F1
F0.00014334862385321102
I1
I0
I1
tp6625
sS'in,absorption'
p6626
(F0
F0
I1
I1
I0
tp6627
sS'relationship,of'
p6628
(F1
F0.00057339449541284407
I4
I0
I4
tp6629
sS'example,sparing'
p6630
(F1
F0.00014334862385321102
I0
I1
I-1
tp6631
sS'agents,used'
p6632
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6633
sS'monitoring,during'
p6634
(F1
F0.00014334862385321102
I0
I1
I-1
tp6635
sS'mg,mcg'
p6636
(F1
F0.00014334862385321102
I0
I1
I-1
tp6637
sS'nanm,in'
p6638
(F1
F0.00014334862385321102
I0
I1
I-1
tp6639
sS'or,not'
p6640
(F0
F0
I1
I1
I0
tp6641
sS'hydroxylation,catalyzed'
p6642
(F1
F0.00014334862385321102
I0
I1
I-1
tp6643
sS'plasma,asparagine'
p6644
(F1
F0.00028669724770642203
I2
I0
I2
tp6645
sS'still,valid'
p6646
(F1
F0.00014334862385321102
I0
I1
I-1
tp6647
sS'all,inclusive'
p6648
(F1
F0.00014334862385321102
I0
I1
I-1
tp6649
sS'been,extensively'
p6650
(F1
F0.00014334862385321102
I0
I1
I-1
tp6651
sS'orally,disintegrating'
p6652
(F1
F0.00014334862385321102
I1
I0
I1
tp6653
sS'and,anxiety'
p6654
(F1
F0.00014334862385321102
I0
I1
I-1
tp6655
sS'positive,inotropic'
p6656
(F1
F0.00014334862385321102
I1
I0
I1
tp6657
sS'ordinarily,recommended'
p6658
(F1
F0.00014334862385321102
I1
I0
I1
tp6659
sS'didrex,should'
p6660
(F1
F0.00014334862385321102
I1
I0
I1
tp6661
sS'acellular,live'
p6662
(F1
F0.00014334862385321102
I1
I0
I1
tp6663
sS'administered,immediately'
p6664
(F1
F0.00014334862385321102
I1
I0
I1
tp6665
sS'decreased,protein'
p6666
(F1
F0.00014334862385321102
I1
I0
I1
tp6667
sS'also,chronically'
p6668
(F1
F0.00014334862385321102
I0
I1
I-1
tp6669
sS'of,activated'
p6670
(F1
F0.00014334862385321102
I0
I1
I-1
tp6671
sS'by,causing'
p6672
(F1
F0.00014334862385321102
I1
I0
I1
tp6673
sS'all,nsaids'
p6674
(F1
F0.00014334862385321102
I1
I0
I1
tp6675
sS'coadministration,can'
p6676
(F1
F0.00014334862385321102
I1
I0
I1
tp6677
sS'quinidine,at'
p6678
(F1
F0.00014334862385321102
I1
I0
I1
tp6679
sS'coadministered,on'
p6680
(F1
F0.00014334862385321102
I1
I0
I1
tp6681
sS'interfere,with'
p6682
(F0.20000000000000001
F0.0017201834862385322
I36
I24
I12
tp6683
sS'in,altered'
p6684
(F1
F0.00014334862385321102
I0
I1
I-1
tp6685
sS'can,suppress'
p6686
(F1
F0.00014334862385321102
I1
I0
I1
tp6687
sS'have,involved'
p6688
(F1
F0.00014334862385321102
I0
I1
I-1
tp6689
sS'with,bezalip'
p6690
(F1
F0.00028669724770642203
I2
I0
I2
tp6691
sS'meal,resulted'
p6692
(F1
F0.00014334862385321102
I1
I0
I1
tp6693
sS'strong,and'
p6694
(F1
F0.00014334862385321102
I1
I0
I1
tp6695
sS'serious,and'
p6696
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp6697
sS'doses,increased'
p6698
(F1
F0.00014334862385321102
I1
I0
I1
tp6699
sS'behavioral,changes'
p6700
(F1
F0.00043004587155963305
I0
I3
I-3
tp6701
sS'needed,following'
p6702
(F1
F0.00014334862385321102
I1
I0
I1
tp6703
sS'either,stereoisomer'
p6704
(F1
F0.00014334862385321102
I1
I0
I1
tp6705
sS'organ,transplant'
p6706
(F1
F0.00014334862385321102
I1
I0
I1
tp6707
sS'm1,peak'
p6708
(F1
F0.00014334862385321102
I1
I0
I1
tp6709
sS'week,placebo'
p6710
(F1
F0.00014334862385321102
I0
I1
I-1
tp6711
sS'rise,resulting'
p6712
(F1
F0.00014334862385321102
I0
I1
I-1
tp6713
sS'warfarin,co-administration'
p6714
(F1
F0.00014334862385321102
I1
I0
I1
tp6715
sS'of,botox'
p6716
(F1
F0.00014334862385321102
I1
I0
I1
tp6717
sS'following,infusions'
p6718
(F1
F0.00014334862385321102
I0
I1
I-1
tp6719
sS'rats,are'
p6720
(F1
F0.00014334862385321102
I0
I1
I-1
tp6721
sS'psychiatric,disorder'
p6722
(F1
F0.00014334862385321102
I1
I0
I1
tp6723
sS'strength,of'
p6724
(F1
F0.00014334862385321102
I1
I0
I1
tp6725
sS'dimethyl-4,hydroxyphenyl'
p6726
(F1
F0.00014334862385321102
I1
I0
I1
tp6727
sS'inhibitors,during'
p6728
(F1
F0.00028669724770642203
I2
I0
I2
tp6729
sS'by,cardiac'
p6730
(F1
F0.00014334862385321102
I1
I0
I1
tp6731
sS'least,days'
p6732
(F1
F0.00014334862385321102
I1
I0
I1
tp6733
sS'allergic,or'
p6734
(F1
F0.00014334862385321102
I0
I1
I-1
tp6735
sS'fall,in'
p6736
(F1
F0.00014334862385321102
I1
I0
I1
tp6737
sS'relaxants,amphotericin'
p6738
(F1
F0.00014334862385321102
I1
I0
I1
tp6739
sS'shown,no'
p6740
(F1
F0.00043004587155963305
I0
I3
I-3
tp6741
sS'also,see'
p6742
(F1
F0.00014334862385321102
I1
I0
I1
tp6743
sS'of,saline'
p6744
(F1
F0.00014334862385321102
I0
I1
I-1
tp6745
sS'ketoconazole,coadministration'
p6746
(F1
F0.00028669724770642203
I2
I0
I2
tp6747
sS'both,s-warfarin'
p6748
(F1
F0.00014334862385321102
I1
I0
I1
tp6749
sS'reduction,is'
p6750
(F1
F0.00014334862385321102
I1
I0
I1
tp6751
sS'patients,whose'
p6752
(F0
F0
I1
I1
I0
tp6753
sS'using,preparations'
p6754
(F1
F0.00014334862385321102
I0
I1
I-1
tp6755
sS'dose,have'
p6756
(F1
F0.00014334862385321102
I0
I1
I-1
tp6757
sS'injury,including'
p6758
(F1
F0.00014334862385321102
I1
I0
I1
tp6759
sS'anticoagulants,while'
p6760
(F1
F0.00014334862385321102
I1
I0
I1
tp6761
sS'or,dosing'
p6762
(F1
F0.00014334862385321102
I0
I1
I-1
tp6763
sS'lowers,the'
p6764
(F1
F0.00014334862385321102
I1
I0
I1
tp6765
sS'gabapentin,is'
p6766
(F1
F0.00014334862385321102
I0
I1
I-1
tp6767
sS'myopathy,rhabdomyolysis'
p6768
(F1
F0.00043004587155963305
I3
I0
I3
tp6769
sS'used,successfully'
p6770
(F1
F0.00028669724770642203
I0
I2
I-2
tp6771
sS'some,of'
p6772
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp6773
sS'deferred,until'
p6774
(F1
F0.00014334862385321102
I1
I0
I1
tp6775
sS'approximately,the'
p6776
(F1
F0.00014334862385321102
I0
I1
I-1
tp6777
sS'antidiabetic,requirements'
p6778
(F1
F0.00014334862385321102
I0
I1
I-1
tp6779
sS'not,the'
p6780
(F1
F0.00028669724770642203
I2
I0
I2
tp6781
sS'pharmacodynamics,arecoline'
p6782
(F1
F0.00014334862385321102
I1
I0
I1
tp6783
sS'selective,toxicity'
p6784
(F1
F0.00014334862385321102
I0
I1
I-1
tp6785
sS'potent,a4'
p6786
(F1
F0.00014334862385321102
I1
I0
I1
tp6787
sS'carbamazepine,elevated'
p6788
(F1
F0.00014334862385321102
I1
I0
I1
tp6789
sS'myopathy,in'
p6790
(F1
F0.00014334862385321102
I0
I1
I-1
tp6791
sS'location,histologic'
p6792
(F1
F0.00014334862385321102
I0
I1
I-1
tp6793
sS'kg,x'
p6794
(F1
F0.00014334862385321102
I1
I0
I1
tp6795
sS'vardenafil,mg'
p6796
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp6797
sS'kg,w'
p6798
(F1
F0.00014334862385321102
I1
I0
I1
tp6799
sS'of,known'
p6800
(F1
F0.00014334862385321102
I1
I0
I1
tp6801
sS'levothyroxine,sodium'
p6802
(F1
F0.00014334862385321102
I1
I0
I1
tp6803
sS'kg,s'
p6804
(F1
F0.00028669724770642203
I2
I0
I2
tp6805
sS'kg,p'
p6806
(F1
F0.00014334862385321102
I1
I0
I1
tp6807
sS'avoid,this'
p6808
(F1
F0.00014334862385321102
I1
I0
I1
tp6809
sS'kg,h'
p6810
(F1
F0.00014334862385321102
I1
I0
I1
tp6811
sS'measure,plasma'
p6812
(F1
F0.00014334862385321102
I0
I1
I-1
tp6813
sS'and,hydroxy-1'
p6814
(F1
F0.00014334862385321102
I1
I0
I1
tp6815
sS'irritation,caution'
p6816
(F1
F0.00014334862385321102
I1
I0
I1
tp6817
sS'observed,but'
p6818
(F1
F0.00014334862385321102
I0
I1
I-1
tp6819
sS'in,tambocor'
p6820
(F1
F0.00014334862385321102
I0
I1
I-1
tp6821
sS'determinant,of'
p6822
(F1
F0.00028669724770642203
I2
I0
I2
tp6823
sS'probably,responsible'
p6824
(F1
F0.00014334862385321102
I0
I1
I-1
tp6825
sS'nsaids,have'
p6826
(F1
F0.00071674311926605509
I5
I0
I5
tp6827
sS'with,serotonin'
p6828
(F0
F0
I1
I1
I0
tp6829
sS'digestive,enzyme'
p6830
(F1
F0.00014334862385321102
I1
I0
I1
tp6831
sS'as,should'
p6832
(F1
F0.00028669724770642203
I0
I2
I-2
tp6833
sS'or,salt'
p6834
(F1
F0.00028669724770642203
I0
I2
I-2
tp6835
sS'the,diuretic'
p6836
(F1
F0.00014334862385321102
I1
I0
I1
tp6837
sS'inhibit,proliferation'
p6838
(F1
F0.00014334862385321102
I1
I0
I1
tp6839
sS'reaction,for'
p6840
(F1
F0.00071674311926605509
I0
I5
I-5
tp6841
sS'enhanced,as'
p6842
(F1
F0.00014334862385321102
I1
I0
I1
tp6843
sS'the,frequency'
p6844
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp6845
sS'acetazolamide,increases'
p6846
(F1
F0.00014334862385321102
I1
I0
I1
tp6847
sS'measurement,of'
p6848
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp6849
sS'l-glutamine,at'
p6850
(F1
F0.00028669724770642203
I2
I0
I2
tp6851
sS'the,antimicrobial'
p6852
(F0
F0
I1
I1
I0
tp6853
sS'other,general'
p6854
(F1
F0.00057339449541284407
I4
I0
I4
tp6855
sS'of,ergot-type'
p6856
(F1
F0.00014334862385321102
I0
I1
I-1
tp6857
sS'hour,period'
p6858
(F1
F0.0010034403669724771
I7
I0
I7
tp6859
sS'the,anti-inflammatory'
p6860
(F1
F0.00014334862385321102
I1
I0
I1
tp6861
sS'at,about'
p6862
(F1
F0.00014334862385321102
I1
I0
I1
tp6863
sS'generation,in'
p6864
(F1
F0.00014334862385321102
I0
I1
I-1
tp6865
sS'be,approximately'
p6866
(F1
F0.00014334862385321102
I0
I1
I-1
tp6867
sS'the,rate'
p6868
(F0.058823529411764705
F0.00014334862385321102
I9
I8
I1
tp6869
sS'physician,the'
p6870
(F1
F0.00014334862385321102
I1
I0
I1
tp6871
sS'although,clinical'
p6872
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6873
sS'a,daily'
p6874
(F0
F0
I1
I1
I0
tp6875
sS'taking,therapy'
p6876
(F1
F0.00014334862385321102
I1
I0
I1
tp6877
sS'in,susceptible'
p6878
(F1
F0.00028669724770642203
I2
I0
I2
tp6879
sS'age,the'
p6880
(F1
F0.00014334862385321102
I0
I1
I-1
tp6881
sS'coagulation,test'
p6882
(F1
F0.00028669724770642203
I2
I0
I2
tp6883
sS'and,volunteers'
p6884
(F1
F0.00014334862385321102
I1
I0
I1
tp6885
sS'added,cholesterol'
p6886
(F1
F0.00014334862385321102
I0
I1
I-1
tp6887
sS'be,anticipated'
p6888
(F1
F0.00057339449541284407
I4
I0
I4
tp6889
sS'substance,to'
p6890
(F1
F0.00014334862385321102
I1
I0
I1
tp6891
sS'intravenous,self-administration'
p6892
(F0
F0
I1
I1
I0
tp6893
sS'proportions,as'
p6894
(F1
F0.00014334862385321102
I0
I1
I-1
tp6895
sS'is,narrow'
p6896
(F1
F0.00014334862385321102
I0
I1
I-1
tp6897
sS'unchanged,alkaloids'
p6898
(F1
F0.00014334862385321102
I1
I0
I1
tp6899
sS'uptake-1,in'
p6900
(F1
F0.00014334862385321102
I0
I1
I-1
tp6901
sS'pneumonia,vs'
p6902
(F1
F0.00014334862385321102
I1
I0
I1
tp6903
sS'x,kg'
p6904
(F1
F0.00014334862385321102
I0
I1
I-1
tp6905
sS'together,may'
p6906
(F1
F0.00028669724770642203
I2
I0
I2
tp6907
sS'properties,if'
p6908
(F1
F0.00014334862385321102
I1
I0
I1
tp6909
sS'changes,were'
p6910
(F1
F0.00014334862385321102
I0
I1
I-1
tp6911
sS'may,necessitate'
p6912
(F1
F0.00014334862385321102
I1
I0
I1
tp6913
sS'block,angiotensin'
p6914
(F1
F0.00014334862385321102
I0
I1
I-1
tp6915
sS'pharmacologic,effect'
p6916
(F1
F0.00014334862385321102
I1
I0
I1
tp6917
sS'the,cyp1a2'
p6918
(F1
F0.00014334862385321102
I0
I1
I-1
tp6919
sS'dose,co-administered'
p6920
(F1
F0.00028669724770642203
I2
I0
I2
tp6921
sS'intake,prior'
p6922
(F1
F0.00057339449541284407
I4
I0
I4
tp6923
sS'lst,short'
p6924
(F1
F0.00014334862385321102
I0
I1
I-1
tp6925
sS'not,substantially'
p6926
(F1
F0.00014334862385321102
I1
I0
I1
tp6927
sS'of,tracrium'
p6928
(F1
F0.00014334862385321102
I1
I0
I1
tp6929
sS'extraneal,on'
p6930
(F1
F0.00014334862385321102
I0
I1
I-1
tp6931
sS'how,safe'
p6932
(F1
F0.00014334862385321102
I0
I1
I-1
tp6933
sS'clotibrate,and'
p6934
(F1
F0.00014334862385321102
I0
I1
I-1
tp6935
sS'likely,to'
p6936
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp6937
sS'in,metabolite'
p6938
(F1
F0.00014334862385321102
I0
I1
I-1
tp6939
sS'well-controlled,studies'
p6940
(F1
F0.00028669724770642203
I0
I2
I-2
tp6941
sS'the,mucocutaneous'
p6942
(F1
F0.00014334862385321102
I0
I1
I-1
tp6943
sS'coly-mycin,m'
p6944
(F1
F0.00014334862385321102
I1
I0
I1
tp6945
sS'significantly,superior'
p6946
(F1
F0.00014334862385321102
I0
I1
I-1
tp6947
sS'induced,responses'
p6948
(F0
F0
I1
I1
I0
tp6949
sS'serious,cardiac'
p6950
(F1
F0.00014334862385321102
I1
I0
I1
tp6951
sS'enhanced,possibility'
p6952
(F1
F0.00014334862385321102
I0
I1
I-1
tp6953
sS'the,development'
p6954
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp6955
sS'isomers,of'
p6956
(F1
F0.00014334862385321102
I0
I1
I-1
tp6957
sS'opioid-induced,gastrointestinal'
p6958
(F1
F0.00014334862385321102
I1
I0
I1
tp6959
sS'particular,importance'
p6960
(F1
F0.00014334862385321102
I1
I0
I1
tp6961
sS'levels,should'
p6962
(F0.066666666666666666
F0.00014334862385321102
I7
I8
I-1
tp6963
sS'the,normal'
p6964
(F1
F0.00014334862385321102
I1
I0
I1
tp6965
sS'days,received'
p6966
(F1
F0.00014334862385321102
I0
I1
I-1
tp6967
sS'concentrations,be'
p6968
(F1
F0.00014334862385321102
I1
I0
I1
tp6969
sS'concentrations,by'
p6970
(F1
F0.00014334862385321102
I1
I0
I1
tp6971
sS'of,intrathecal'
p6972
(F1
F0.00014334862385321102
I0
I1
I-1
tp6973
sS'ph,in'
p6974
(F1
F0.00014334862385321102
I0
I1
I-1
tp6975
sS'similarly,the'
p6976
(F1
F0.00014334862385321102
I1
I0
I1
tp6977
sS'by,jaffe'
p6978
(F1
F0.00014334862385321102
I0
I1
I-1
tp6979
sS'of,arachidonate-'
p6980
(F1
F0.00014334862385321102
I0
I1
I-1
tp6981
sS'since,they'
p6982
(F1
F0.00014334862385321102
I0
I1
I-1
tp6983
sS'pretreatment,on'
p6984
(F1
F0.00014334862385321102
I0
I1
I-1
tp6985
sS'the,us'
p6986
(F1
F0.00014334862385321102
I0
I1
I-1
tp6987
sS'ph,is'
p6988
(F1
F0.00028669724770642203
I2
I0
I2
tp6989
sS'pretreatment,of'
p6990
(F1
F0.00043004587155963305
I3
I0
I3
tp6991
sS'may,each'
p6992
(F1
F0.00014334862385321102
I1
I0
I1
tp6993
sS'weakness,associated'
p6994
(F1
F0.00014334862385321102
I0
I1
I-1
tp6995
sS'plasticity,ieg'
p6996
(F1
F0.00014334862385321102
I0
I1
I-1
tp6997
sS'between,doses'
p6998
(F1
F0.00014334862385321102
I1
I0
I1
tp6999
sS'the,urine'
p7000
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp7001
sS'first,hour'
p7002
(F1
F0.00014334862385321102
I1
I0
I1
tp7003
sS'thiazide,substrates'
p7004
(F1
F0.00014334862385321102
I0
I1
I-1
tp7005
sS'of,upon'
p7006
(F1
F0.00014334862385321102
I0
I1
I-1
tp7007
sS'vardenafil,dose'
p7008
(F1
F0.00057339449541284407
I4
I0
I4
tp7009
sS'cancidas,should'
p7010
(F1
F0.00014334862385321102
I1
I0
I1
tp7011
sS'tissues,of'
p7012
(F1
F0.00014334862385321102
I0
I1
I-1
tp7013
sS'several,hours'
p7014
(F0
F0
I1
I1
I0
tp7015
sS'cyp-450,inhibitor'
p7016
(F1
F0.00014334862385321102
I0
I1
I-1
tp7017
sS'long,lasting'
p7018
(F1
F0.00014334862385321102
I1
I0
I1
tp7019
sS'this,alteration'
p7020
(F1
F0.00014334862385321102
I0
I1
I-1
tp7021
sS'other,cns'
p7022
(F0.66666666666666663
F0.0017201834862385322
I15
I3
I12
tp7023
sS'f2alpha,and'
p7024
(F0
F0
I1
I1
I0
tp7025
sS'acid,derivatives'
p7026
(F1
F0.00028669724770642203
I0
I2
I-2
tp7027
sS'hormonal,birth'
p7028
(F1
F0.00014334862385321102
I0
I1
I-1
tp7029
sS'the,blood-glucose'
p7030
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp7031
sS'because,renal'
p7032
(F1
F0.00014334862385321102
I1
I0
I1
tp7033
sS'of,control'
p7034
(F1
F0.00014334862385321102
I1
I0
I1
tp7035
sS'labeling,index'
p7036
(F1
F0.00028669724770642203
I0
I2
I-2
tp7037
sS'n,or'
p7038
(F1
F0.00028669724770642203
I0
I2
I-2
tp7039
sS'that,rr'
p7040
(F1
F0.00014334862385321102
I0
I1
I-1
tp7041
sS'tiagabine,has'
p7042
(F1
F0.00014334862385321102
I0
I1
I-1
tp7043
sS'and,live'
p7044
(F1
F0.00014334862385321102
I1
I0
I1
tp7045
sS'n,of'
p7046
(F1
F0.00014334862385321102
I1
I0
I1
tp7047
sS'other,thyroid'
p7048
(F1
F0.00014334862385321102
I0
I1
I-1
tp7049
sS'was,again'
p7050
(F1
F0.00014334862385321102
I0
I1
I-1
tp7051
sS'can,potentiate'
p7052
(F1
F0.00014334862385321102
I1
I0
I1
tp7053
sS'l-type,omega-conotoxin'
p7054
(F1
F0.00014334862385321102
I0
I1
I-1
tp7055
sS'significant,protection'
p7056
(F1
F0.00014334862385321102
I1
I0
I1
tp7057
sS'they,do'
p7058
(F1
F0.00014334862385321102
I1
I0
I1
tp7059
sS'therefore,caution'
p7060
(F1
F0.00014334862385321102
I1
I0
I1
tp7061
sS'normal,volunteers'
p7062
(F0.36363636363636365
F0.0011467889908256881
I15
I7
I8
tp7063
sS'bile,and'
p7064
(F1
F0.00014334862385321102
I1
I0
I1
tp7065
sS'the,unbound'
p7066
(F1
F0.00014334862385321102
I1
I0
I1
tp7067
sS'precautions,should'
p7068
(F1
F0.00014334862385321102
I1
I0
I1
tp7069
sS'against,symptoms'
p7070
(F1
F0.00014334862385321102
I0
I1
I-1
tp7071
sS'an,alternative'
p7072
(F1
F0.00014334862385321102
I0
I1
I-1
tp7073
sS'diltiazem,in'
p7074
(F1
F0.00014334862385321102
I1
I0
I1
tp7075
sS'interaction,after'
p7076
(F1
F0.00014334862385321102
I0
I1
I-1
tp7077
sS'absorbed,when'
p7078
(F1
F0.00014334862385321102
I0
I1
I-1
tp7079
sS'response,of'
p7080
(F0
F0
I1
I1
I0
tp7081
sS'syndrome,has'
p7082
(F1
F0.00014334862385321102
I1
I0
I1
tp7083
sS'known,that'
p7084
(F1
F0.00028669724770642203
I2
I0
I2
tp7085
sS'citalopram,since'
p7086
(F1
F0.00014334862385321102
I1
I0
I1
tp7087
sS'mg,neurontin'
p7088
(F0
F0
I1
I1
I0
tp7089
sS'open,three-period'
p7090
(F1
F0.00014334862385321102
I0
I1
I-1
tp7091
sS'in,subcortical'
p7092
(F1
F0.00014334862385321102
I0
I1
I-1
tp7093
sS'phase,ii'
p7094
(F1
F0.00014334862385321102
I1
I0
I1
tp7095
sS'days,and'
p7096
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp7097
sS'doses,there'
p7098
(F1
F0.00014334862385321102
I0
I1
I-1
tp7099
sS'healthy,young'
p7100
(F1
F0.00014334862385321102
I0
I1
I-1
tp7101
sS'has,resulted'
p7102
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7103
sS'the,start'
p7104
(F1
F0.00028669724770642203
I2
I0
I2
tp7105
sS'epsilon,and'
p7106
(F1
F0.00014334862385321102
I0
I1
I-1
tp7107
sS'discontinuing,treatment'
p7108
(F1
F0.00014334862385321102
I1
I0
I1
tp7109
sS'additional,caution'
p7110
(F1
F0.00014334862385321102
I0
I1
I-1
tp7111
sS'and,coagulation'
p7112
(F1
F0.00014334862385321102
I0
I1
I-1
tp7113
sS'once,daily'
p7114
(F0.043478260869565216
F0.00014334862385321102
I11
I12
I-1
tp7115
sS'mechanism,of'
p7116
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7117
sS'approximately,minutes'
p7118
(F1
F0.00014334862385321102
I1
I0
I1
tp7119
sS'in,another'
p7120
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp7121
sS'this,reduction'
p7122
(F1
F0.00014334862385321102
I1
I0
I1
tp7123
sS'by,consulting'
p7124
(F1
F0.00014334862385321102
I0
I1
I-1
tp7125
sS'decrease,about'
p7126
(F1
F0.00014334862385321102
I1
I0
I1
tp7127
sS'study,tambocor'
p7128
(F1
F0.00014334862385321102
I0
I1
I-1
tp7129
sS'established,current'
p7130
(F1
F0.00014334862385321102
I1
I0
I1
tp7131
sS'as,impulsivity'
p7132
(F1
F0.00014334862385321102
I0
I1
I-1
tp7133
sS'oral,clearance'
p7134
(F1
F0.00043004587155963305
I3
I0
I3
tp7135
sS'temporal,patterns'
p7136
(F1
F0.00014334862385321102
I0
I1
I-1
tp7137
sS'or,elimination'
p7138
(F1
F0.00014334862385321102
I0
I1
I-1
tp7139
sS'when,gl'
p7140
(F1
F0.00014334862385321102
I1
I0
I1
tp7141
sS'coadminstered,with'
p7142
(F1
F0.00014334862385321102
I1
I0
I1
tp7143
sS'on,white'
p7144
(F1
F0.00014334862385321102
I0
I1
I-1
tp7145
sS'of,nimbex'
p7146
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp7147
sS'nursing,or'
p7148
(F1
F0.00014334862385321102
I0
I1
I-1
tp7149
sS'differential,actions'
p7150
(F1
F0.00014334862385321102
I0
I1
I-1
tp7151
sS'observations,on'
p7152
(F1
F0.00014334862385321102
I1
I0
I1
tp7153
sS'transport-related,effects'
p7154
(F1
F0.00014334862385321102
I1
I0
I1
tp7155
sS'qid,did'
p7156
(F1
F0.00014334862385321102
I0
I1
I-1
tp7157
sS'contraceptive,agents'
p7158
(F1
F0.00014334862385321102
I0
I1
I-1
tp7159
sS'with,rr'
p7160
(F1
F0.00014334862385321102
I1
I0
I1
tp7161
sS'arteries,from'
p7162
(F1
F0.00057339449541284407
I0
I4
I-4
tp7163
sS'cardiac,stimulants'
p7164
(F1
F0.00014334862385321102
I1
I0
I1
tp7165
sS'a,variety'
p7166
(F1
F0.00043004587155963305
I0
I3
I-3
tp7167
sS'with,only'
p7168
(F1
F0.00014334862385321102
I0
I1
I-1
tp7169
sS'likewise,pharmacokinetics'
p7170
(F1
F0.00014334862385321102
I0
I1
I-1
tp7171
sS'the,benzodiazepine'
p7172
(F1
F0.00014334862385321102
I1
I0
I1
tp7173
sS'triamterene,concomitant'
p7174
(F1
F0.00014334862385321102
I0
I1
I-1
tp7175
sS'the,retention'
p7176
(F0
F0
I1
I1
I0
tp7177
sS'mild,decrease'
p7178
(F1
F0.00014334862385321102
I1
I0
I1
tp7179
sS'while,left'
p7180
(F1
F0.00014334862385321102
I0
I1
I-1
tp7181
sS'tablets,with'
p7182
(F0.5
F0.00028669724770642203
I3
I1
I2
tp7183
sS'lymphoma,on'
p7184
(F1
F0.00014334862385321102
I0
I1
I-1
tp7185
sS'cholinesterase,activity'
p7186
(F1
F0.00014334862385321102
I1
I0
I1
tp7187
sS'concomitant,in'
p7188
(F1
F0.00014334862385321102
I0
I1
I-1
tp7189
sS'sprycel,should'
p7190
(F1
F0.00014334862385321102
I0
I1
I-1
tp7191
sS'and,concerns'
p7192
(F1
F0.00014334862385321102
I0
I1
I-1
tp7193
sS'with,nsaids'
p7194
(F1
F0.00014334862385321102
I1
I0
I1
tp7195
sS'antimycobacterial,agents'
p7196
(F0
F0
I1
I1
I0
tp7197
sS'was,conducted'
p7198
(F1
F0.00014334862385321102
I0
I1
I-1
tp7199
sS'wait,about'
p7200
(F1
F0.00014334862385321102
I1
I0
I1
tp7201
sS'oral,treatment'
p7202
(F1
F0.00014334862385321102
I1
I0
I1
tp7203
sS'with,did'
p7204
(F1
F0.00014334862385321102
I0
I1
I-1
tp7205
sS'other,agents'
p7206
(F0.076923076923076927
F0.00014334862385321102
I7
I6
I1
tp7207
sS'in,volunteers'
p7208
(F1
F0.00014334862385321102
I0
I1
I-1
tp7209
sS'anxiogenic,effects'
p7210
(F1
F0.00028669724770642203
I2
I0
I2
tp7211
sS'given,together'
p7212
(F1
F0.00014334862385321102
I0
I1
I-1
tp7213
sS'experiences,in'
p7214
(F0
F0
I1
I1
I0
tp7215
sS'preservation,of'
p7216
(F1
F0.00014334862385321102
I0
I1
I-1
tp7217
sS'only,clinically'
p7218
(F1
F0.00014334862385321102
I1
I0
I1
tp7219
sS'monitored,during'
p7220
(F1
F0.00014334862385321102
I1
I0
I1
tp7221
sS'pgf2alpha,upon'
p7222
(F1
F0.00014334862385321102
I1
I0
I1
tp7223
sS'the,aptt'
p7224
(F1
F0.00028669724770642203
I0
I2
I-2
tp7225
sS'severe,toxicity'
p7226
(F1
F0.00028669724770642203
I2
I0
I2
tp7227
sS'aeds,whether'
p7228
(F1
F0.00014334862385321102
I0
I1
I-1
tp7229
sS'dogs,have'
p7230
(F1
F0.00014334862385321102
I0
I1
I-1
tp7231
sS'doxil,may'
p7232
(F1
F0.00014334862385321102
I0
I1
I-1
tp7233
sS'and,tam'
p7234
(F1
F0.00014334862385321102
I1
I0
I1
tp7235
sS'should,also'
p7236
(F0
F0
I3
I3
I0
tp7237
sS'of,additive'
p7238
(F1
F0.00014334862385321102
I1
I0
I1
tp7239
sS'at,but'
p7240
(F1
F0.00014334862385321102
I0
I1
I-1
tp7241
sS'major,bleeding'
p7242
(F1
F0.00014334862385321102
I1
I0
I1
tp7243
sS'to,produce'
p7244
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp7245
sS'unclear,how'
p7246
(F1
F0.00014334862385321102
I1
I0
I1
tp7247
sS'to,humans'
p7248
(F1
F0.00014334862385321102
I1
I0
I1
tp7249
sS'contra-indication,overt'
p7250
(F1
F0.00014334862385321102
I0
I1
I-1
tp7251
sS'dose,administered'
p7252
(F1
F0.00014334862385321102
I0
I1
I-1
tp7253
sS'of,severe'
p7254
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp7255
sS'not,statistically'
p7256
(F1
F0.00014334862385321102
I1
I0
I1
tp7257
sS'inadequate,method'
p7258
(F1
F0.00014334862385321102
I1
I0
I1
tp7259
sS'cbg,sex'
p7260
(F1
F0.00028669724770642203
I0
I2
I-2
tp7261
sS'blurred,vision'
p7262
(F1
F0.00057339449541284407
I4
I0
I4
tp7263
sS'aminocaproic,acid'
p7264
(F1
F0.00014334862385321102
I0
I1
I-1
tp7265
sS'agonists,on'
p7266
(F1
F0.00014334862385321102
I1
I0
I1
tp7267
sS'stereotypic,effects'
p7268
(F1
F0.00014334862385321102
I0
I1
I-1
tp7269
sS'separated,by'
p7270
(F1
F0.00028669724770642203
I2
I0
I2
tp7271
sS'anticoagulants,coagulation'
p7272
(F1
F0.00014334862385321102
I0
I1
I-1
tp7273
sS'have,a'
p7274
(F0.20000000000000001
F0.00057339449541284407
I8
I12
I-4
tp7275
sS'phenytoin,etodolac'
p7276
(F1
F0.00014334862385321102
I0
I1
I-1
tp7277
sS'adequate,respiratory'
p7278
(F1
F0.00014334862385321102
I0
I1
I-1
tp7279
sS'concentration,mic'
p7280
(F1
F0.00014334862385321102
I0
I1
I-1
tp7281
sS'in,concurrent'
p7282
(F1
F0.00014334862385321102
I0
I1
I-1
tp7283
sS'b,was'
p7284
(F1
F0.00014334862385321102
I0
I1
I-1
tp7285
sS'prolonged,hot'
p7286
(F1
F0.00014334862385321102
I1
I0
I1
tp7287
sS'evaluated,using'
p7288
(F1
F0.00014334862385321102
I0
I1
I-1
tp7289
sS'additional,benefit'
p7290
(F1
F0.00028669724770642203
I2
I0
I2
tp7291
sS'not,with'
p7292
(F1
F0.00043004587155963305
I0
I3
I-3
tp7293
sS'precipitous,reduction'
p7294
(F1
F0.00014334862385321102
I1
I0
I1
tp7295
sS'some,limited'
p7296
(F1
F0.00014334862385321102
I1
I0
I1
tp7297
sS'adjusted,in'
p7298
(F1
F0.00014334862385321102
I1
I0
I1
tp7299
sS'steroids,chloral'
p7300
(F1
F0.00028669724770642203
I2
I0
I2
tp7301
sS'carbenicillin,indanyl'
p7302
(F1
F0.00014334862385321102
I1
I0
I1
tp7303
sS'not,markedly'
p7304
(F1
F0.00014334862385321102
I0
I1
I-1
tp7305
sS'non-infection,unwanted'
p7306
(F1
F0.00014334862385321102
I0
I1
I-1
tp7307
sS'proportion,of'
p7308
(F1
F0.00028669724770642203
I2
I0
I2
tp7309
sS'or,impairing'
p7310
(F1
F0.00014334862385321102
I1
I0
I1
tp7311
sS'of,transdermal'
p7312
(F1
F0.00014334862385321102
I1
I0
I1
tp7313
sS'hypoprothrombinemic,effect'
p7314
(F1
F0.00014334862385321102
I0
I1
I-1
tp7315
sS'glucose,and'
p7316
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp7317
sS'antipyrine,because'
p7318
(F1
F0.00014334862385321102
I0
I1
I-1
tp7319
sS'a,to'
p7320
(F1
F0.00057339449541284407
I4
I0
I4
tp7321
sS'pharmacodynamic,effects'
p7322
(F0
F0
I1
I1
I0
tp7323
sS'that,mc'
p7324
(F1
F0.00014334862385321102
I0
I1
I-1
tp7325
sS'that,mg'
p7326
(F1
F0.00014334862385321102
I1
I0
I1
tp7327
sS'or,angiotensin'
p7328
(F1
F0.00014334862385321102
I0
I1
I-1
tp7329
sS'high,threshold'
p7330
(F1
F0.00014334862385321102
I0
I1
I-1
tp7331
sS'mhd,did'
p7332
(F1
F0.00014334862385321102
I0
I1
I-1
tp7333
sS'instances,synergism'
p7334
(F1
F0.00014334862385321102
I1
I0
I1
tp7335
sS'enzyme,induction'
p7336
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7337
sS'uncontrolled,intake'
p7338
(F1
F0.00043004587155963305
I0
I3
I-3
tp7339
sS'wort,based'
p7340
(F1
F0.00014334862385321102
I0
I1
I-1
tp7341
sS'patient,monitoring'
p7342
(F1
F0.00014334862385321102
I1
I0
I1
tp7343
sS'by,mao'
p7344
(F1
F0.00014334862385321102
I1
I0
I1
tp7345
sS'aerolizertm,inhalation'
p7346
(F1
F0.00014334862385321102
I0
I1
I-1
tp7347
sS'or,inhibit'
p7348
(F1
F0.00014334862385321102
I1
I0
I1
tp7349
sS'bleeding,from'
p7350
(F1
F0.00014334862385321102
I0
I1
I-1
tp7351
sS'or,preparations'
p7352
(F1
F0.00014334862385321102
I0
I1
I-1
tp7353
sS'renal,transplant'
p7354
(F0
F0
I1
I1
I0
tp7355
sS'ineffective,if'
p7356
(F1
F0.00014334862385321102
I1
I0
I1
tp7357
sS'factive,with'
p7358
(F1
F0.00014334862385321102
I1
I0
I1
tp7359
sS'oral,concomitant'
p7360
(F1
F0.00014334862385321102
I1
I0
I1
tp7361
sS'of,sustiva'
p7362
(F1
F0.00014334862385321102
I0
I1
I-1
tp7363
sS'hiv-infected,patients'
p7364
(F1
F0.00014334862385321102
I1
I0
I1
tp7365
sS'plasma,expanders'
p7366
(F1
F0.00014334862385321102
I0
I1
I-1
tp7367
sS'following,may'
p7368
(F1
F0.00028669724770642203
I2
I0
I2
tp7369
sS'of,ganglionic'
p7370
(F1
F0.00014334862385321102
I1
I0
I1
tp7371
sS'experienced,tremor'
p7372
(F1
F0.00014334862385321102
I1
I0
I1
tp7373
sS'and,second'
p7374
(F1
F0.00014334862385321102
I1
I0
I1
tp7375
sS'for,longer'
p7376
(F1
F0.00014334862385321102
I1
I0
I1
tp7377
sS'acid,doses'
p7378
(F1
F0.00014334862385321102
I1
I0
I1
tp7379
sS'and,greater'
p7380
(F1
F0.00014334862385321102
I1
I0
I1
tp7381
sS'system,probably'
p7382
(F1
F0.00014334862385321102
I0
I1
I-1
tp7383
sS'supervision,and'
p7384
(F0
F0
I2
I2
I0
tp7385
sS'between,brevibloc'
p7386
(F1
F0.00014334862385321102
I0
I1
I-1
tp7387
sS'extreme,caution'
p7388
(F1
F0.00057339449541284407
I4
I0
I4
tp7389
sS'levels,whenever'
p7390
(F1
F0.00071674311926605509
I0
I5
I-5
tp7391
sS'as,is'
p7392
(F1
F0.00014334862385321102
I0
I1
I-1
tp7393
sS'as,it'
p7394
(F1
F0.00014334862385321102
I0
I1
I-1
tp7395
sS'a,complication'
p7396
(F1
F0.00014334862385321102
I0
I1
I-1
tp7397
sS'the,action'
p7398
(F1
F0.0027236238532110093
I19
I0
I19
tp7399
sS'with,without'
p7400
(F1
F0.00028669724770642203
I0
I2
I-2
tp7401
sS'zone,and'
p7402
(F1
F0.00014334862385321102
I1
I0
I1
tp7403
sS'treat,strongyloidiasis'
p7404
(F1
F0.00014334862385321102
I1
I0
I1
tp7405
sS'gliftor,difluoro-2'
p7406
(F1
F0.00014334862385321102
I0
I1
I-1
tp7407
sS'require,downward'
p7408
(F1
F0.00028669724770642203
I2
I0
I2
tp7409
sS'nucleoside-experienced,patients'
p7410
(F1
F0.00014334862385321102
I0
I1
I-1
tp7411
sS'drawn,regarding'
p7412
(F1
F0.00014334862385321102
I0
I1
I-1
tp7413
sS'of,glucocorticoid-induced'
p7414
(F1
F0.00014334862385321102
I0
I1
I-1
tp7415
sS'norpace,cr'
p7416
(F1
F0.00014334862385321102
I1
I0
I1
tp7417
sS'mouth,bodyweight'
p7418
(F1
F0.00014334862385321102
I0
I1
I-1
tp7419
sS'the,inhibition'
p7420
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp7421
sS'skin,rash'
p7422
(F1
F0.00014334862385321102
I1
I0
I1
tp7423
sS'oxidase,inhibitor'
p7424
(F1
F0.00014334862385321102
I0
I1
I-1
tp7425
sS'mean,scores'
p7426
(F1
F0.00014334862385321102
I1
I0
I1
tp7427
sS'other,psychotropic'
p7428
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp7429
sS'loss,between'
p7430
(F1
F0.00028669724770642203
I0
I2
I-2
tp7431
sS'thyroid,physiology'
p7432
(F1
F0.00014334862385321102
I0
I1
I-1
tp7433
sS'qd,resulted'
p7434
(F1
F0.00043004587155963305
I3
I0
I3
tp7435
sS'that,dopamine-induced'
p7436
(F1
F0.00014334862385321102
I1
I0
I1
tp7437
sS'magnesium-containing,meq'
p7438
(F1
F0.00014334862385321102
I0
I1
I-1
tp7439
sS'those,for'
p7440
(F1
F0.00014334862385321102
I0
I1
I-1
tp7441
sS'conjugated,and'
p7442
(F1
F0.00014334862385321102
I0
I1
I-1
tp7443
sS'were,assessed'
p7444
(F1
F0.00043004587155963305
I0
I3
I-3
tp7445
sS'total,concentrations'
p7446
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7447
sS'pupil,size'
p7448
(F1
F0.00014334862385321102
I1
I0
I1
tp7449
sS'isozymes,responsible'
p7450
(F1
F0.00028669724770642203
I2
I0
I2
tp7451
sS'pregnancy,category'
p7452
(F1
F0.00014334862385321102
I0
I1
I-1
tp7453
sS'as,bradycardia'
p7454
(F1
F0.00014334862385321102
I1
I0
I1
tp7455
sS'and,classes'
p7456
(F1
F0.00014334862385321102
I1
I0
I1
tp7457
sS'of,using'
p7458
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp7459
sS'duration,of'
p7460
(F0.076923076923076927
F0.00014334862385321102
I7
I6
I1
tp7461
sS'with,on'
p7462
(F0
F0
I1
I1
I0
tp7463
sS'and,digestive'
p7464
(F1
F0.00014334862385321102
I1
I0
I1
tp7465
sS'with,oh'
p7466
(F1
F0.00014334862385321102
I1
I0
I1
tp7467
sS'with,of'
p7468
(F0
F0
I3
I3
I0
tp7469
sS'oxytocin,or'
p7470
(F1
F0.00014334862385321102
I1
I0
I1
tp7471
sS'increase,following'
p7472
(F1
F0.00014334862385321102
I1
I0
I1
tp7473
sS'with,or'
p7474
(F0.42307692307692307
F0.0031536697247706424
I37
I15
I22
tp7475
sS'that,accompany'
p7476
(F1
F0.00014334862385321102
I1
I0
I1
tp7477
sS'the,class'
p7478
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7479
sS'or,ergot-type'
p7480
(F1
F0.00043004587155963305
I3
I0
I3
tp7481
sS'nephrotoxicity,has'
p7482
(F1
F0.0008600917431192661
I6
I0
I6
tp7483
sS'of,newly'
p7484
(F1
F0.00014334862385321102
I0
I1
I-1
tp7485
sS'prolonged,the'
p7486
(F1
F0.00028669724770642203
I2
I0
I2
tp7487
sS'oral,antagonist'
p7488
(F1
F0.00014334862385321102
I1
I0
I1
tp7489
sS'exercised,when'
p7490
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp7491
sS'no,alterations'
p7492
(F1
F0.00014334862385321102
I0
I1
I-1
tp7493
sS'a,thienobenzodiazepine'
p7494
(F1
F0.00014334862385321102
I0
I1
I-1
tp7495
sS'monitoring,tdm'
p7496
(F1
F0.00014334862385321102
I0
I1
I-1
tp7497
sS'given,only'
p7498
(F1
F0.00014334862385321102
I0
I1
I-1
tp7499
sS'agonists,hepatic'
p7500
(F1
F0.00014334862385321102
I0
I1
I-1
tp7501
sS'of,averaged'
p7502
(F1
F0.00014334862385321102
I1
I0
I1
tp7503
sS'pressure,below'
p7504
(F1
F0.00043004587155963305
I3
I0
I3
tp7505
sS'amiodarone,is'
p7506
(F0
F0
I1
I1
I0
tp7507
sS'or,than'
p7508
(F1
F0.00014334862385321102
I1
I0
I1
tp7509
sS'theophylline,twelve'
p7510
(F1
F0.00014334862385321102
I0
I1
I-1
tp7511
sS'or,that'
p7512
(F1
F0.00028669724770642203
I2
I0
I2
tp7513
sS'the,increase'
p7514
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp7515
sS'with,hereditary'
p7516
(F1
F0.00014334862385321102
I1
I0
I1
tp7517
sS'conducted,on'
p7518
(F1
F0.00014334862385321102
I0
I1
I-1
tp7519
sS'cholesterol,the'
p7520
(F1
F0.00014334862385321102
I0
I1
I-1
tp7521
sS'upon,discontinuation'
p7522
(F1
F0.00043004587155963305
I3
I0
I3
tp7523
sS'in,insulin-dependent'
p7524
(F1
F0.00014334862385321102
I0
I1
I-1
tp7525
sS'attempt,to'
p7526
(F1
F0.00014334862385321102
I1
I0
I1
tp7527
sS'is,primarily'
p7528
(F1
F0.00071674311926605509
I0
I5
I-5
tp7529
sS'high,intraperitoneal'
p7530
(F1
F0.00014334862385321102
I1
I0
I1
tp7531
sS'dual,effect'
p7532
(F1
F0.00014334862385321102
I0
I1
I-1
tp7533
sS'vs,serious'
p7534
(F1
F0.00014334862385321102
I1
I0
I1
tp7535
sS'known,cyp3a4'
p7536
(F1
F0.00043004587155963305
I3
I0
I3
tp7537
sS'reported,case'
p7538
(F1
F0.00014334862385321102
I1
I0
I1
tp7539
sS'eight,target'
p7540
(F1
F0.00014334862385321102
I0
I1
I-1
tp7541
sS'the,fischer-344'
p7542
(F1
F0.00014334862385321102
I0
I1
I-1
tp7543
sS'flupenthixol,increases'
p7544
(F1
F0.00014334862385321102
I1
I0
I1
tp7545
sS'secretion,and'
p7546
(F1
F0.00014334862385321102
I1
I0
I1
tp7547
sS'by,bezalip'
p7548
(F1
F0.00014334862385321102
I1
I0
I1
tp7549
sS'macrolide,and'
p7550
(F0
F0
I2
I2
I0
tp7551
sS'of,there'
p7552
(F0
F0
I1
I1
I0
tp7553
sS'in,bleeding'
p7554
(F1
F0.00014334862385321102
I0
I1
I-1
tp7555
sS'have,similar'
p7556
(F1
F0.00028669724770642203
I0
I2
I-2
tp7557
sS'culture,the'
p7558
(F1
F0.00014334862385321102
I1
I0
I1
tp7559
sS'would,be'
p7560
(F0.066666666666666666
F0.00014334862385321102
I8
I7
I1
tp7561
sS'and,carbonate'
p7562
(F1
F0.00014334862385321102
I1
I0
I1
tp7563
sS'chlorprothixene,may'
p7564
(F1
F0.00014334862385321102
I1
I0
I1
tp7565
sS'during,simultaneous'
p7566
(F1
F0.00014334862385321102
I0
I1
I-1
tp7567
sS'alternative,agents'
p7568
(F1
F0.00014334862385321102
I0
I1
I-1
tp7569
sS'renally,eliminated'
p7570
(F1
F0.00014334862385321102
I0
I1
I-1
tp7571
sS'hydroxides,be'
p7572
(F1
F0.00014334862385321102
I1
I0
I1
tp7573
sS'with,four'
p7574
(F0
F0
I1
I1
I0
tp7575
sS'cyp3a4,metabolized'
p7576
(F1
F0.00028669724770642203
I2
I0
I2
tp7577
sS'are,suggested'
p7578
(F1
F0.00014334862385321102
I1
I0
I1
tp7579
sS'from,co-administration'
p7580
(F1
F0.00014334862385321102
I1
I0
I1
tp7581
sS'the,enzymatic'
p7582
(F1
F0.00014334862385321102
I1
I0
I1
tp7583
sS'two,regimens'
p7584
(F1
F0.00014334862385321102
I0
I1
I-1
tp7585
sS'mimicked,by'
p7586
(F1
F0.00014334862385321102
I0
I1
I-1
tp7587
sS'insure,that'
p7588
(F1
F0.00014334862385321102
I1
I0
I1
tp7589
sS'if,tykerb'
p7590
(F1
F0.00014334862385321102
I0
I1
I-1
tp7591
sS'of,unbound'
p7592
(F1
F0.00028669724770642203
I0
I2
I-2
tp7593
sS'subjects,who'
p7594
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp7595
sS'and,hydrochloride'
p7596
(F1
F0.00014334862385321102
I0
I1
I-1
tp7597
sS'pressure,than'
p7598
(F1
F0.00014334862385321102
I1
I0
I1
tp7599
sS'as,much'
p7600
(F0
F0
I1
I1
I0
tp7601
sS'marker,of'
p7602
(F1
F0.00014334862385321102
I1
I0
I1
tp7603
sS'a,liquid'
p7604
(F1
F0.00014334862385321102
I0
I1
I-1
tp7605
sS'the,ames'
p7606
(F1
F0.00014334862385321102
I0
I1
I-1
tp7607
sS'of,incompatibility'
p7608
(F1
F0.00028669724770642203
I0
I2
I-2
tp7609
sS'clearance,rate'
p7610
(F1
F0.00014334862385321102
I1
I0
I1
tp7611
sS'attenuate,morphine-induced'
p7612
(F1
F0.00014334862385321102
I0
I1
I-1
tp7613
sS'distinct,from'
p7614
(F1
F0.00014334862385321102
I0
I1
I-1
tp7615
sS'adjunctive,therapy'
p7616
(F1
F0.00014334862385321102
I1
I0
I1
tp7617
sS'didanosine-placebo,tablets'
p7618
(F1
F0.00014334862385321102
I1
I0
I1
tp7619
sS'if,combination'
p7620
(F0
F0
I1
I1
I0
tp7621
sS'exposure,or'
p7622
(F1
F0.00028669724770642203
I0
I2
I-2
tp7623
sS'the,tnf'
p7624
(F1
F0.00014334862385321102
I1
I0
I1
tp7625
sS'the,mortality'
p7626
(F1
F0.00014334862385321102
I0
I1
I-1
tp7627
sS'administering,disulfiram'
p7628
(F1
F0.00014334862385321102
I1
I0
I1
tp7629
sS'exposure,of'
p7630
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp7631
sS'medications,the'
p7632
(F1
F0.00014334862385321102
I1
I0
I1
tp7633
sS'respond,normally'
p7634
(F1
F0.00014334862385321102
I0
I1
I-1
tp7635
sS'significant,reduction'
p7636
(F1
F0.00014334862385321102
I1
I0
I1
tp7637
sS'hydrochloride,including'
p7638
(F1
F0.00014334862385321102
I0
I1
I-1
tp7639
sS'cytadren,accelerates'
p7640
(F1
F0.00014334862385321102
I1
I0
I1
tp7641
sS'glycosides,amphotericin'
p7642
(F1
F0.00014334862385321102
I1
I0
I1
tp7643
sS'respectively,resulted'
p7644
(F1
F0.00014334862385321102
I1
I0
I1
tp7645
sS'be,prolonged'
p7646
(F1
F0.00043004587155963305
I3
I0
I3
tp7647
sS'and,kappa-selective'
p7648
(F1
F0.00014334862385321102
I0
I1
I-1
tp7649
sS'nafazodone,consider'
p7650
(F1
F0.00014334862385321102
I1
I0
I1
tp7651
sS'or,or'
p7652
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp7653
sS'humans,demonstrated'
p7654
(F1
F0.00014334862385321102
I0
I1
I-1
tp7655
sS'amiodarone,therapy'
p7656
(F1
F0.00014334862385321102
I0
I1
I-1
tp7657
sS'virus-positive,patients'
p7658
(F1
F0.00014334862385321102
I0
I1
I-1
tp7659
sS'caffeine,theobromine'
p7660
(F1
F0.00014334862385321102
I1
I0
I1
tp7661
sS'addition,steady'
p7662
(F1
F0.00014334862385321102
I0
I1
I-1
tp7663
sS'or,of'
p7664
(F1
F0.00028669724770642203
I0
I2
I-2
tp7665
sS'or,on'
p7666
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp7667
sS'receiving,another'
p7668
(F1
F0.00014334862385321102
I1
I0
I1
tp7669
sS'the,decrease'
p7670
(F1
F0.00014334862385321102
I0
I1
I-1
tp7671
sS'the,proposed'
p7672
(F1
F0.00014334862385321102
I0
I1
I-1
tp7673
sS'gabitril,carbamazepine'
p7674
(F1
F0.00014334862385321102
I1
I0
I1
tp7675
sS'be,warranted'
p7676
(F1
F0.00014334862385321102
I0
I1
I-1
tp7677
sS'primarily,iron-fortified'
p7678
(F1
F0.00014334862385321102
I0
I1
I-1
tp7679
sS'bioequivalent,when'
p7680
(F1
F0.00014334862385321102
I0
I1
I-1
tp7681
sS'amiodarone,amiodarone'
p7682
(F1
F0.00014334862385321102
I0
I1
I-1
tp7683
sS'excreted,by'
p7684
(F1
F0.00014334862385321102
I0
I1
I-1
tp7685
sS'fistulas,were'
p7686
(F1
F0.00014334862385321102
I0
I1
I-1
tp7687
sS'indicated,alternative'
p7688
(F1
F0.00014334862385321102
I0
I1
I-1
tp7689
sS'alteration,in'
p7690
(F0
F0
I1
I1
I0
tp7691
sS'addition,interfere'
p7692
(F1
F0.00014334862385321102
I1
I0
I1
tp7693
sS'concomitantly,receiving'
p7694
(F1
F0.00057339449541284407
I4
I0
I4
tp7695
sS'absence,of'
p7696
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp7697
sS'into,three'
p7698
(F0
F0
I1
I1
I0
tp7699
sS'is,necessary'
p7700
(F0
F0
I2
I2
I0
tp7701
sS'and,half-life'
p7702
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7703
sS'lodine,and'
p7704
(F1
F0.00014334862385321102
I1
I0
I1
tp7705
sS'etodolac-treated,patients'
p7706
(F1
F0.00014334862385321102
I1
I0
I1
tp7707
sS'diet,resulted'
p7708
(F1
F0.00014334862385321102
I1
I0
I1
tp7709
sS'increased,auc'
p7710
(F0
F0
I1
I1
I0
tp7711
sS'agents,decrease'
p7712
(F1
F0.00014334862385321102
I1
I0
I1
tp7713
sS'the,antitumor'
p7714
(F0
F0
I1
I1
I0
tp7715
sS'compared,directly'
p7716
(F1
F0.00014334862385321102
I0
I1
I-1
tp7717
sS'co,administered'
p7718
(F1
F0.00014334862385321102
I1
I0
I1
tp7719
sS'for,anions'
p7720
(F1
F0.00014334862385321102
I0
I1
I-1
tp7721
sS'physiological,behavioral'
p7722
(F1
F0.00014334862385321102
I0
I1
I-1
tp7723
sS'components,ee'
p7724
(F1
F0.00014334862385321102
I1
I0
I1
tp7725
sS'co-administration,enhances'
p7726
(F1
F0.00014334862385321102
I1
I0
I1
tp7727
sS'lithium,serum'
p7728
(F1
F0.00014334862385321102
I1
I0
I1
tp7729
sS'concentration,cmax'
p7730
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7731
sS'concomitantly,taking'
p7732
(F1
F0.00014334862385321102
I0
I1
I-1
tp7733
sS'the,strength'
p7734
(F1
F0.00014334862385321102
I1
I0
I1
tp7735
sS'sensory,and'
p7736
(F1
F0.00014334862385321102
I1
I0
I1
tp7737
sS'vs,cmax'
p7738
(F1
F0.00014334862385321102
I0
I1
I-1
tp7739
sS'levels,suggesting'
p7740
(F1
F0.00014334862385321102
I1
I0
I1
tp7741
sS'compensate,for'
p7742
(F1
F0.00028669724770642203
I2
I0
I2
tp7743
sS'background,the'
p7744
(F1
F0.00028669724770642203
I0
I2
I-2
tp7745
sS'quality,of'
p7746
(F1
F0.00014334862385321102
I0
I1
I-1
tp7747
sS'higher,as'
p7748
(F1
F0.00014334862385321102
I1
I0
I1
tp7749
sS'totally,atoxic'
p7750
(F1
F0.00014334862385321102
I0
I1
I-1
tp7751
sS'with,wshow'
p7752
(F1
F0.00014334862385321102
I0
I1
I-1
tp7753
sS'this,kind'
p7754
(F1
F0.00014334862385321102
I1
I0
I1
tp7755
sS'glucose,enzymatic'
p7756
(F1
F0.00014334862385321102
I0
I1
I-1
tp7757
sS'chemotherapy,cardiotoxic'
p7758
(F1
F0.00014334862385321102
I1
I0
I1
tp7759
sS'standard,cystic'
p7760
(F1
F0.00014334862385321102
I0
I1
I-1
tp7761
sS'vasodilating,effects'
p7762
(F1
F0.00043004587155963305
I3
I0
I3
tp7763
sS'total,cholesterol'
p7764
(F1
F0.00014334862385321102
I0
I1
I-1
tp7765
sS'greater,extent'
p7766
(F1
F0.00028669724770642203
I0
I2
I-2
tp7767
sS'and,dehydration'
p7768
(F1
F0.00014334862385321102
I1
I0
I1
tp7769
sS'mg,for'
p7770
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7771
sS'relaxants,sleeping'
p7772
(F1
F0.00014334862385321102
I0
I1
I-1
tp7773
sS'ordinarily,a'
p7774
(F1
F0.00014334862385321102
I0
I1
I-1
tp7775
sS'when,hydrochlorothiazide'
p7776
(F1
F0.00014334862385321102
I1
I0
I1
tp7777
sS'citrate,theoretically'
p7778
(F1
F0.00014334862385321102
I1
I0
I1
tp7779
sS'alcohol,has'
p7780
(F1
F0.00014334862385321102
I1
I0
I1
tp7781
sS'acth,may'
p7782
(F1
F0.00014334862385321102
I1
I0
I1
tp7783
sS'any,conclusions'
p7784
(F1
F0.00014334862385321102
I0
I1
I-1
tp7785
sS'neuron,blocking'
p7786
(F1
F0.00014334862385321102
I0
I1
I-1
tp7787
sS'cholesterol,mg'
p7788
(F1
F0.00014334862385321102
I0
I1
I-1
tp7789
sS'insert,labeling'
p7790
(F1
F0.00014334862385321102
I0
I1
I-1
tp7791
sS'cardiovascular,system'
p7792
(F1
F0.00043004587155963305
I3
I0
I3
tp7793
sS'statins,co-administration'
p7794
(F1
F0.00014334862385321102
I1
I0
I1
tp7795
sS'difluoroacetone,by'
p7796
(F1
F0.00014334862385321102
I0
I1
I-1
tp7797
sS'containing,are'
p7798
(F1
F0.00014334862385321102
I0
I1
I-1
tp7799
sS'pancreases,of'
p7800
(F1
F0.00014334862385321102
I0
I1
I-1
tp7801
sS'and,recurred'
p7802
(F1
F0.00014334862385321102
I0
I1
I-1
tp7803
sS'thyroidal,uptake'
p7804
(F1
F0.00014334862385321102
I1
I0
I1
tp7805
sS'by,severe'
p7806
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7807
sS'forevidence,of'
p7808
(F1
F0.00014334862385321102
I1
I0
I1
tp7809
sS'volunteers,the'
p7810
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp7811
sS'therapeutic,concentrations'
p7812
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp7813
sS'pulmozyme,can'
p7814
(F1
F0.00014334862385321102
I0
I1
I-1
tp7815
sS'the,levels'
p7816
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp7817
sS'solubility,of'
p7818
(F1
F0.00014334862385321102
I0
I1
I-1
tp7819
sS'hours,competes'
p7820
(F1
F0.00014334862385321102
I1
I0
I1
tp7821
sS'and,ketoconazole'
p7822
(F1
F0.00028669724770642203
I0
I2
I-2
tp7823
sS'given,mg'
p7824
(F0
F0
I1
I1
I0
tp7825
sS'rats,treated'
p7826
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7827
sS'volunteers,resulted'
p7828
(F0.5
F0.00028669724770642203
I3
I1
I2
tp7829
sS'their,additive'
p7830
(F1
F0.00014334862385321102
I1
I0
I1
tp7831
sS'fenfluramine,may'
p7832
(F1
F0.00014334862385321102
I1
I0
I1
tp7833
sS'contraction,and'
p7834
(F1
F0.00014334862385321102
I0
I1
I-1
tp7835
sS'hydrochloride,either'
p7836
(F1
F0.00014334862385321102
I1
I0
I1
tp7837
sS'high-dose,with'
p7838
(F1
F0.00014334862385321102
I1
I0
I1
tp7839
sS'theophylline,vioxx'
p7840
(F1
F0.00014334862385321102
I1
I0
I1
tp7841
sS'dose-dependent,fashion'
p7842
(F1
F0.00014334862385321102
I1
I0
I1
tp7843
sS'also,contribute'
p7844
(F1
F0.00014334862385321102
I1
I0
I1
tp7845
sS'metabolite,in'
p7846
(F1
F0.00014334862385321102
I0
I1
I-1
tp7847
sS'are,at'
p7848
(F0.5
F0.00028669724770642203
I3
I1
I2
tp7849
sS'was,delayed'
p7850
(F1
F0.00014334862385321102
I1
I0
I1
tp7851
sS'receiving,other'
p7852
(F1
F0.00043004587155963305
I3
I0
I3
tp7853
sS'another,serotonin'
p7854
(F1
F0.00014334862385321102
I1
I0
I1
tp7855
sS'decreases,of'
p7856
(F1
F0.00028669724770642203
I2
I0
I2
tp7857
sS'colestipol,plasma'
p7858
(F1
F0.00014334862385321102
I1
I0
I1
tp7859
sS'tindal,thorazine'
p7860
(F1
F0.00014334862385321102
I0
I1
I-1
tp7861
sS'suggested,that'
p7862
(F1
F0.00071674311926605509
I5
I0
I5
tp7863
sS'closely,after'
p7864
(F1
F0.00014334862385321102
I1
I0
I1
tp7865
sS'available,and'
p7866
(F1
F0.00014334862385321102
I0
I1
I-1
tp7867
sS'of,nsaids'
p7868
(F1
F0.00014334862385321102
I1
I0
I1
tp7869
sS'of,that'
p7870
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp7871
sS'following,use'
p7872
(F1
F0.00028669724770642203
I2
I0
I2
tp7873
sS'relafen,daypro'
p7874
(F1
F0.00014334862385321102
I0
I1
I-1
tp7875
sS'tricyclic,antidepressants'
p7876
(F1
F0.00028669724770642203
I2
I0
I2
tp7877
sS'in,elimination'
p7878
(F1
F0.00014334862385321102
I1
I0
I1
tp7879
sS'ototoxic,potential'
p7880
(F1
F0.00043004587155963305
I3
I0
I3
tp7881
sS'of,r-'
p7882
(F1
F0.00014334862385321102
I0
I1
I-1
tp7883
sS'pretreatment,did'
p7884
(F1
F0.00014334862385321102
I0
I1
I-1
tp7885
sS'of,than'
p7886
(F1
F0.00014334862385321102
I1
I0
I1
tp7887
sS'pharmacokinetics,data'
p7888
(F1
F0.00028669724770642203
I2
I0
I2
tp7889
sS'identified,in'
p7890
(F1
F0.00014334862385321102
I1
I0
I1
tp7891
sS'or,nsaid'
p7892
(F1
F0.00014334862385321102
I0
I1
I-1
tp7893
sS'penthrane,has'
p7894
(F1
F0.00014334862385321102
I1
I0
I1
tp7895
sS'the,mouth'
p7896
(F1
F0.00014334862385321102
I1
I0
I1
tp7897
sS'about,compared'
p7898
(F1
F0.00014334862385321102
I1
I0
I1
tp7899
sS'with,propranolols'
p7900
(F1
F0.00014334862385321102
I1
I0
I1
tp7901
sS'enzymes,is'
p7902
(F0
F0
I1
I1
I0
tp7903
sS'to,co-administration'
p7904
(F1
F0.00014334862385321102
I0
I1
I-1
tp7905
sS'limited,inhibitory'
p7906
(F1
F0.00014334862385321102
I1
I0
I1
tp7907
sS'of,within'
p7908
(F1
F0.00014334862385321102
I0
I1
I-1
tp7909
sS'be,performed'
p7910
(F1
F0.00043004587155963305
I3
I0
I3
tp7911
sS'abilify,is'
p7912
(F1
F0.00014334862385321102
I1
I0
I1
tp7913
sS'enhanced,effects'
p7914
(F1
F0.00014334862385321102
I0
I1
I-1
tp7915
sS'that,significantly'
p7916
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7917
sS'sodium,it'
p7918
(F1
F0.00014334862385321102
I1
I0
I1
tp7919
sS'sodium,is'
p7920
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp7921
sS'upon,beginning'
p7922
(F1
F0.00014334862385321102
I1
I0
I1
tp7923
sS'clearance,measurements'
p7924
(F1
F0.00014334862385321102
I1
I0
I1
tp7925
sS'and,hepatic'
p7926
(F1
F0.00028669724770642203
I2
I0
I2
tp7927
sS'agents,now'
p7928
(F1
F0.00014334862385321102
I0
I1
I-1
tp7929
sS'affinity,for'
p7930
(F0
F0
I1
I1
I0
tp7931
sS'interactions,toxicity'
p7932
(F1
F0.00014334862385321102
I1
I0
I1
tp7933
sS'the,curve'
p7934
(F1
F0.00043004587155963305
I3
I0
I3
tp7935
sS'impaired,when'
p7936
(F1
F0.00014334862385321102
I0
I1
I-1
tp7937
sS'metabolized,similarly'
p7938
(F1
F0.00014334862385321102
I1
I0
I1
tp7939
sS'levels,comparable'
p7940
(F1
F0.00014334862385321102
I0
I1
I-1
tp7941
sS'parnate,using'
p7942
(F1
F0.00014334862385321102
I0
I1
I-1
tp7943
sS'in,normovolemic'
p7944
(F1
F0.00014334862385321102
I1
I0
I1
tp7945
sS'and,profound'
p7946
(F1
F0.00014334862385321102
I1
I0
I1
tp7947
sS'significantly,potentiates'
p7948
(F1
F0.00014334862385321102
I1
I0
I1
tp7949
sS'other,bronchodilators'
p7950
(F1
F0.00014334862385321102
I1
I0
I1
tp7951
sS'bacillus,subtilis'
p7952
(F1
F0.00014334862385321102
I1
I0
I1
tp7953
sS'h,by'
p7954
(F1
F0.00014334862385321102
I0
I1
I-1
tp7955
sS'eg,should'
p7956
(F1
F0.00014334862385321102
I1
I0
I1
tp7957
sS'fell,by'
p7958
(F1
F0.00014334862385321102
I1
I0
I1
tp7959
sS'reportedly,resulted'
p7960
(F1
F0.00014334862385321102
I1
I0
I1
tp7961
sS'receiving,daily'
p7962
(F1
F0.00014334862385321102
I0
I1
I-1
tp7963
sS'generation,atypical'
p7964
(F1
F0.00014334862385321102
I0
I1
I-1
tp7965
sS'beta-blocking,agents'
p7966
(F1
F0.00028669724770642203
I0
I2
I-2
tp7967
sS'the,bile-acidsequestering'
p7968
(F1
F0.00014334862385321102
I0
I1
I-1
tp7969
sS'of,aerosol'
p7970
(F1
F0.00028669724770642203
I0
I2
I-2
tp7971
sS'acids,such'
p7972
(F1
F0.00014334862385321102
I1
I0
I1
tp7973
sS'produced,significantly'
p7974
(F1
F0.00014334862385321102
I1
I0
I1
tp7975
sS'cyp1a2,isoform'
p7976
(F1
F0.00014334862385321102
I0
I1
I-1
tp7977
sS'are,mediated'
p7978
(F1
F0.00014334862385321102
I0
I1
I-1
tp7979
sS'healthy,women'
p7980
(F1
F0.00014334862385321102
I0
I1
I-1
tp7981
sS'antagonists,of'
p7982
(F1
F0.00014334862385321102
I1
I0
I1
tp7983
sS'dose,or'
p7984
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp7985
sS'pressure,their'
p7986
(F1
F0.00014334862385321102
I1
I0
I1
tp7987
sS'administration,the'
p7988
(F1
F0.00014334862385321102
I0
I1
I-1
tp7989
sS'dose,of'
p7990
(F0.14285714285714285
F0.0022935779816513763
I64
I48
I16
tp7991
sS'prolonged,administration'
p7992
(F1
F0.00043004587155963305
I0
I3
I-3
tp7993
sS'sumatriptan,sumatriptan'
p7994
(F1
F0.00014334862385321102
I1
I0
I1
tp7995
sS'decreasing,heparin'
p7996
(F1
F0.00014334862385321102
I1
I0
I1
tp7997
sS'dialyzed,were'
p7998
(F1
F0.00014334862385321102
I0
I1
I-1
tp7999
sS'affinities,than'
p8000
(F1
F0.00014334862385321102
I0
I1
I-1
tp8001
sS'few,spontaneous'
p8002
(F1
F0.00014334862385321102
I1
I0
I1
tp8003
sS'package,insert'
p8004
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8005
sS'since,bile'
p8006
(F1
F0.00014334862385321102
I1
I0
I1
tp8007
sS'benzodiazepines,benzodiazepines'
p8008
(F1
F0.00014334862385321102
I1
I0
I1
tp8009
sS'by,while'
p8010
(F1
F0.00014334862385321102
I1
I0
I1
tp8011
sS'dark,test'
p8012
(F1
F0.00014334862385321102
I0
I1
I-1
tp8013
sS'and,bioavailability'
p8014
(F1
F0.00014334862385321102
I1
I0
I1
tp8015
sS'tca,may'
p8016
(F1
F0.00014334862385321102
I1
I0
I1
tp8017
sS'of,adrenocortical'
p8018
(F1
F0.00014334862385321102
I1
I0
I1
tp8019
sS'vecuronium,when'
p8020
(F1
F0.00014334862385321102
I1
I0
I1
tp8021
sS'auc,hrs'
p8022
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp8023
sS'the,administration'
p8024
(F0.45945945945945948
F0.0024369266055045873
I27
I10
I17
tp8025
sS'adrenocortical,steroids'
p8026
(F1
F0.00014334862385321102
I1
I0
I1
tp8027
sS'and,cmc-cys'
p8028
(F1
F0.00014334862385321102
I0
I1
I-1
tp8029
sS'low,for'
p8030
(F1
F0.00014334862385321102
I0
I1
I-1
tp8031
sS'antagonists,based'
p8032
(F1
F0.00014334862385321102
I1
I0
I1
tp8033
sS'sedation,if'
p8034
(F1
F0.00014334862385321102
I1
I0
I1
tp8035
sS'of,other'
p8036
(F0.28888888888888886
F0.0018635321100917432
I29
I16
I13
tp8037
sS'be,usedas'
p8038
(F1
F0.00014334862385321102
I1
I0
I1
tp8039
sS'cyp3a4,increased'
p8040
(F1
F0.00014334862385321102
I1
I0
I1
tp8041
sS'd,respectively'
p8042
(F1
F0.00014334862385321102
I1
I0
I1
tp8043
sS'apparent,effect'
p8044
(F1
F0.00014334862385321102
I0
I1
I-1
tp8045
sS'carcinogenesis,by'
p8046
(F1
F0.00014334862385321102
I0
I1
I-1
tp8047
sS'including,concomitantly'
p8048
(F1
F0.00028669724770642203
I2
I0
I2
tp8049
sS'warfarin,concomitant'
p8050
(F1
F0.00014334862385321102
I0
I1
I-1
tp8051
sS'commercially,available'
p8052
(F1
F0.00014334862385321102
I0
I1
I-1
tp8053
sS'tablets,inhibit'
p8054
(F1
F0.00014334862385321102
I1
I0
I1
tp8055
sS'result,from'
p8056
(F1
F0.00028669724770642203
I2
I0
I2
tp8057
sS'multivitamins,quinolones'
p8058
(F1
F0.00014334862385321102
I0
I1
I-1
tp8059
sS'or,inhibition'
p8060
(F1
F0.00014334862385321102
I0
I1
I-1
tp8061
sS'c129h223n3o54,isolated'
p8062
(F1
F0.00014334862385321102
I0
I1
I-1
tp8063
sS'brevibloc,concentrations'
p8064
(F1
F0.00014334862385321102
I1
I0
I1
tp8065
sS'a,bacteriostatic'
p8066
(F1
F0.00028669724770642203
I2
I0
I2
tp8067
sS'as,assessed'
p8068
(F1
F0.00043004587155963305
I0
I3
I-3
tp8069
sS'with,qt-interval'
p8070
(F1
F0.00014334862385321102
I0
I1
I-1
tp8071
sS'binding,displacement'
p8072
(F1
F0.00014334862385321102
I0
I1
I-1
tp8073
sS'of,fade'
p8074
(F1
F0.00014334862385321102
I1
I0
I1
tp8075
sS'affecting,cytochrome'
p8076
(F1
F0.00014334862385321102
I0
I1
I-1
tp8077
sS'plasma,level'
p8078
(F1
F0.00028669724770642203
I2
I0
I2
tp8079
sS'external,subcutaneous'
p8080
(F1
F0.00014334862385321102
I0
I1
I-1
tp8081
sS'to,regimens'
p8082
(F1
F0.00014334862385321102
I0
I1
I-1
tp8083
sS'any,efficacy'
p8084
(F1
F0.00014334862385321102
I0
I1
I-1
tp8085
sS'the,stimulant'
p8086
(F1
F0.00014334862385321102
I0
I1
I-1
tp8087
sS'ganciclovir,the'
p8088
(F1
F0.00014334862385321102
I0
I1
I-1
tp8089
sS'changing,therapy'
p8090
(F1
F0.00014334862385321102
I1
I0
I1
tp8091
sS'an,inhibitor'
p8092
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp8093
sS'by,single'
p8094
(F1
F0.00014334862385321102
I1
I0
I1
tp8095
sS'it,creates'
p8096
(F1
F0.00014334862385321102
I0
I1
I-1
tp8097
sS'arrythmias,ventricular'
p8098
(F1
F0.00014334862385321102
I1
I0
I1
tp8099
sS'neuromuscular,blocking'
p8100
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp8101
sS'of,liver'
p8102
(F1
F0.00014334862385321102
I1
I0
I1
tp8103
sS'produced,mean'
p8104
(F1
F0.00014334862385321102
I1
I0
I1
tp8105
sS'erythromycin,clarithromycin'
p8106
(F1
F0.00014334862385321102
I0
I1
I-1
tp8107
sS'in,general'
p8108
(F1
F0.00057339449541284407
I0
I4
I-4
tp8109
sS'encephalopathic,syndrome'
p8110
(F1
F0.00014334862385321102
I1
I0
I1
tp8111
sS'this,combination'
p8112
(F1
F0.00028669724770642203
I2
I0
I2
tp8113
sS'celexa,in'
p8114
(F1
F0.00014334862385321102
I1
I0
I1
tp8115
sS'sucralfate,should'
p8116
(F1
F0.00014334862385321102
I1
I0
I1
tp8117
sS'that,discontinuation'
p8118
(F1
F0.00014334862385321102
I1
I0
I1
tp8119
sS'modify,exposed'
p8120
(F1
F0.00014334862385321102
I0
I1
I-1
tp8121
sS'can,cause'
p8122
(F0
F0
I2
I2
I0
tp8123
sS'argatroban,with'
p8124
(F0
F0
I1
I1
I0
tp8125
sS'an,effect'
p8126
(F0
F0
I4
I4
I0
tp8127
sS'with,nonselective'
p8128
(F1
F0.00014334862385321102
I1
I0
I1
tp8129
sS'inhibit,pgp'
p8130
(F1
F0.00014334862385321102
I0
I1
I-1
tp8131
sS'in,additive'
p8132
(F1
F0.00057339449541284407
I4
I0
I4
tp8133
sS'or,ergot'
p8134
(F1
F0.00014334862385321102
I1
I0
I1
tp8135
sS'concomitantly,used'
p8136
(F1
F0.00014334862385321102
I0
I1
I-1
tp8137
sS'other,amphotericin'
p8138
(F1
F0.00014334862385321102
I1
I0
I1
tp8139
sS'increases,and'
p8140
(F1
F0.00014334862385321102
I1
I0
I1
tp8141
sS'with,iron'
p8142
(F1
F0.00014334862385321102
I1
I0
I1
tp8143
sS'may,cause'
p8144
(F0.40000000000000002
F0.0017201834862385322
I21
I9
I12
tp8145
sS'clostridium,three'
p8146
(F1
F0.00014334862385321102
I0
I1
I-1
tp8147
sS'therefore,you'
p8148
(F1
F0.00014334862385321102
I1
I0
I1
tp8149
sS'like,mptp'
p8150
(F1
F0.00014334862385321102
I1
I0
I1
tp8151
sS'presumably,to'
p8152
(F1
F0.00014334862385321102
I0
I1
I-1
tp8153
sS'with,auc'
p8154
(F1
F0.00014334862385321102
I0
I1
I-1
tp8155
sS'high-estradiol,treated'
p8156
(F1
F0.00014334862385321102
I1
I0
I1
tp8157
sS'and,caution'
p8158
(F1
F0.00028669724770642203
I0
I2
I-2
tp8159
sS'cells,this'
p8160
(F1
F0.00014334862385321102
I1
I0
I1
tp8161
sS'of,adenocarcinomas'
p8162
(F1
F0.00014334862385321102
I1
I0
I1
tp8163
sS'alcohol,in'
p8164
(F1
F0.00014334862385321102
I1
I0
I1
tp8165
sS'buffered,tablets'
p8166
(F1
F0.0011467889908256881
I8
I0
I8
tp8167
sS'to,might'
p8168
(F1
F0.00014334862385321102
I1
I0
I1
tp8169
sS'of,isocarboxazid'
p8170
(F0
F0
I1
I1
I0
tp8171
sS'course,of'
p8172
(F0.17647058823529413
F0.00043004587155963305
I10
I7
I3
tp8173
sS'histamine,h2'
p8174
(F1
F0.00014334862385321102
I1
I0
I1
tp8175
sS'alcohol,it'
p8176
(F1
F0.00014334862385321102
I1
I0
I1
tp8177
sS'may,become'
p8178
(F1
F0.00014334862385321102
I1
I0
I1
tp8179
sS'is,mildly'
p8180
(F1
F0.00014334862385321102
I1
I0
I1
tp8181
sS'functional,class'
p8182
(F0
F0
I1
I1
I0
tp8183
sS'optimal,pulmonary'
p8184
(F1
F0.00014334862385321102
I0
I1
I-1
tp8185
sS'iiia,inhibitors'
p8186
(F1
F0.00014334862385321102
I1
I0
I1
tp8187
sS'of,concurrent'
p8188
(F1
F0.00014334862385321102
I1
I0
I1
tp8189
sS'potential,must'
p8190
(F1
F0.00014334862385321102
I1
I0
I1
tp8191
sS'table,is'
p8192
(F1
F0.00014334862385321102
I0
I1
I-1
tp8193
sS'avoid,possible'
p8194
(F1
F0.00043004587155963305
I3
I0
I3
tp8195
sS'cross,toxicity'
p8196
(F1
F0.00014334862385321102
I1
I0
I1
tp8197
sS'drugs,cimetidine'
p8198
(F1
F0.00014334862385321102
I0
I1
I-1
tp8199
sS'another,tnf'
p8200
(F1
F0.00014334862385321102
I1
I0
I1
tp8201
sS'because,higher'
p8202
(F1
F0.00014334862385321102
I0
I1
I-1
tp8203
sS'taken,on'
p8204
(F1
F0.00014334862385321102
I1
I0
I1
tp8205
sS'bradycardia,sinus'
p8206
(F1
F0.00014334862385321102
I0
I1
I-1
tp8207
sS'reduce,its'
p8208
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp8209
sS'myocardial,depressants'
p8210
(F1
F0.00014334862385321102
I1
I0
I1
tp8211
sS'qt-interval,prolongation'
p8212
(F1
F0.00014334862385321102
I0
I1
I-1
tp8213
sS'and,administered'
p8214
(F1
F0.00014334862385321102
I0
I1
I-1
tp8215
sS'marked,interference'
p8216
(F1
F0.00014334862385321102
I1
I0
I1
tp8217
sS'via,this'
p8218
(F1
F0.00014334862385321102
I1
I0
I1
tp8219
sS'were,experienced'
p8220
(F1
F0.00014334862385321102
I1
I0
I1
tp8221
sS'results,for'
p8222
(F1
F0.00014334862385321102
I1
I0
I1
tp8223
sS'risk,of'
p8224
(F0.33333333333333331
F0.0028669724770642203
I40
I20
I20
tp8225
sS'careful,consideration'
p8226
(F1
F0.00014334862385321102
I1
I0
I1
tp8227
sS'volunteers,concomitant'
p8228
(F1
F0.00043004587155963305
I3
I0
I3
tp8229
sS'initial,therapy'
p8230
(F1
F0.00014334862385321102
I0
I1
I-1
tp8231
sS'or,camp-stimulated'
p8232
(F1
F0.00014334862385321102
I1
I0
I1
tp8233
sS'potentiated,by'
p8234
(F0.8571428571428571
F0.0017201834862385322
I13
I1
I12
tp8235
sS'three,strains'
p8236
(F1
F0.00014334862385321102
I0
I1
I-1
tp8237
sS'administered,separately'
p8238
(F1
F0.00014334862385321102
I1
I0
I1
tp8239
sS'by,cyp2d6'
p8240
(F0
F0
I2
I2
I0
tp8241
sS'sporanox,lipitor'
p8242
(F1
F0.00014334862385321102
I1
I0
I1
tp8243
sS'of,measured'
p8244
(F1
F0.00014334862385321102
I0
I1
I-1
tp8245
sS'of,the'
p8246
(F0.23131672597864769
F0.0093176605504587152
I173
I108
I65
tp8247
sS'coadministration,whereas'
p8248
(F1
F0.00014334862385321102
I1
I0
I1
tp8249
sS'phenytoin,felbatol'
p8250
(F1
F0.00014334862385321102
I1
I0
I1
tp8251
sS'to,one-half'
p8252
(F0.5
F0.00028669724770642203
I3
I1
I2
tp8253
sS'a,increase'
p8254
(F1
F0.0032970183486238534
I23
I0
I23
tp8255
sS'of,diethyl'
p8256
(F1
F0.00014334862385321102
I0
I1
I-1
tp8257
sS'concentrates,or'
p8258
(F1
F0.00014334862385321102
I0
I1
I-1
tp8259
sS'benefit,compared'
p8260
(F1
F0.00028669724770642203
I2
I0
I2
tp8261
sS'two,drugs'
p8262
(F1
F0.00014334862385321102
I1
I0
I1
tp8263
sS'peripheral,vasospasm'
p8264
(F0
F0
I2
I2
I0
tp8265
sS'of,products'
p8266
(F1
F0.00014334862385321102
I1
I0
I1
tp8267
sS'experiments,reactions'
p8268
(F1
F0.00014334862385321102
I0
I1
I-1
tp8269
sS'in,association'
p8270
(F0.5
F0.00028669724770642203
I3
I1
I2
tp8271
sS'all,central'
p8272
(F1
F0.00014334862385321102
I1
I0
I1
tp8273
sS'only,block'
p8274
(F1
F0.00014334862385321102
I1
I0
I1
tp8275
sS'the,homodimeric'
p8276
(F1
F0.00014334862385321102
I0
I1
I-1
tp8277
sS'cyclosporine,increased'
p8278
(F1
F0.00014334862385321102
I1
I0
I1
tp8279
sS'decreasing,its'
p8280
(F1
F0.00014334862385321102
I1
I0
I1
tp8281
sS'labelled,and'
p8282
(F1
F0.00014334862385321102
I0
I1
I-1
tp8283
sS'elc,should'
p8284
(F1
F0.00014334862385321102
I1
I0
I1
tp8285
sS'clozapine,and'
p8286
(F1
F0.00028669724770642203
I2
I0
I2
tp8287
sS'tablets,to'
p8288
(F1
F0.00014334862385321102
I1
I0
I1
tp8289
sS'an,aluminum'
p8290
(F1
F0.00014334862385321102
I0
I1
I-1
tp8291
sS'via,the'
p8292
(F1
F0.00057339449541284407
I0
I4
I-4
tp8293
sS'garlic,allium'
p8294
(F1
F0.00014334862385321102
I1
I0
I1
tp8295
sS'are,predominantly'
p8296
(F0
F0
I2
I2
I0
tp8297
sS'fluorouracil,is'
p8298
(F1
F0.00014334862385321102
I1
I0
I1
tp8299
sS'when,other'
p8300
(F1
F0.00028669724770642203
I2
I0
I2
tp8301
sS'both,cyp2d6'
p8302
(F1
F0.00014334862385321102
I0
I1
I-1
tp8303
sS'cmax,up'
p8304
(F1
F0.00014334862385321102
I1
I0
I1
tp8305
sS'risks,to'
p8306
(F1
F0.00014334862385321102
I1
I0
I1
tp8307
sS'regimens,may'
p8308
(F1
F0.00014334862385321102
I0
I1
I-1
tp8309
sS'see,clinical'
p8310
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp8311
sS'including,such'
p8312
(F1
F0.00028669724770642203
I2
I0
I2
tp8313
sS'enzymatic,oxidation'
p8314
(F1
F0.00014334862385321102
I1
I0
I1
tp8315
sS'or,acute'
p8316
(F1
F0.00014334862385321102
I0
I1
I-1
tp8317
sS'in,central'
p8318
(F1
F0.00014334862385321102
I1
I0
I1
tp8319
sS'levels,during'
p8320
(F1
F0.00014334862385321102
I1
I0
I1
tp8321
sS'not,suggest'
p8322
(F1
F0.00028669724770642203
I0
I2
I-2
tp8323
sS'cytochromes,p450'
p8324
(F1
F0.00014334862385321102
I0
I1
I-1
tp8325
sS'acid,may'
p8326
(F1
F0.00071674311926605509
I5
I0
I5
tp8327
sS'n,resulted'
p8328
(F1
F0.00014334862385321102
I1
I0
I1
tp8329
sS'increased,gastric'
p8330
(F1
F0.00014334862385321102
I0
I1
I-1
tp8331
sS'on,gabitril'
p8332
(F1
F0.00014334862385321102
I1
I0
I1
tp8333
sS'evaluate,the'
p8334
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp8335
sS'specific,interactions'
p8336
(F0
F0
I1
I1
I0
tp8337
sS'tachycardia,induced'
p8338
(F1
F0.00014334862385321102
I1
I0
I1
tp8339
sS'oral,carbonic'
p8340
(F1
F0.00028669724770642203
I2
I0
I2
tp8341
sS'observed,with'
p8342
(F0
F0
I4
I4
I0
tp8343
sS'during,therapy'
p8344
(F1
F0.0008600917431192661
I6
I0
I6
tp8345
sS'or,organophosphate'
p8346
(F1
F0.00014334862385321102
I1
I0
I1
tp8347
sS'theophylline,ethinyl'
p8348
(F1
F0.00014334862385321102
I1
I0
I1
tp8349
sS'concentrations,as'
p8350
(F1
F0.00014334862385321102
I0
I1
I-1
tp8351
sS'dynacirc,and'
p8352
(F1
F0.00028669724770642203
I0
I2
I-2
tp8353
sS'clinical,basis'
p8354
(F1
F0.00014334862385321102
I0
I1
I-1
tp8355
sS'of,therapeutic'
p8356
(F1
F0.00043004587155963305
I0
I3
I-3
tp8357
sS'published,reports'
p8358
(F1
F0.00014334862385321102
I1
I0
I1
tp8359
sS'when,xigris'
p8360
(F1
F0.00014334862385321102
I0
I1
I-1
tp8361
sS'from,smoking'
p8362
(F1
F0.00014334862385321102
I0
I1
I-1
tp8363
sS'equetrotm,are'
p8364
(F1
F0.00028669724770642203
I2
I0
I2
tp8365
sS'mean,serum'
p8366
(F1
F0.00028669724770642203
I2
I0
I2
tp8367
sS'or,severity'
p8368
(F1
F0.00028669724770642203
I2
I0
I2
tp8369
sS'these,with'
p8370
(F1
F0.00028669724770642203
I0
I2
I-2
tp8371
sS'desmopressin,tablets'
p8372
(F1
F0.00014334862385321102
I0
I1
I-1
tp8373
sS'needed,to'
p8374
(F1
F0.00014334862385321102
I1
I0
I1
tp8375
sS'theobromine,grepafloxacin'
p8376
(F1
F0.00014334862385321102
I1
I0
I1
tp8377
sS'prevent,absorption'
p8378
(F1
F0.00014334862385321102
I0
I1
I-1
tp8379
sS'inhibitors,administered'
p8380
(F1
F0.00014334862385321102
I1
I0
I1
tp8381
sS'against,cryptosporidium'
p8382
(F1
F0.00014334862385321102
I0
I1
I-1
tp8383
sS'oral,antagonists'
p8384
(F1
F0.00014334862385321102
I1
I0
I1
tp8385
sS'replacement,is'
p8386
(F1
F0.00014334862385321102
I0
I1
I-1
tp8387
sS'reactions,the'
p8388
(F1
F0.00014334862385321102
I1
I0
I1
tp8389
sS'isoenzyme,including'
p8390
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8391
sS'vasopressor,and'
p8392
(F1
F0.00014334862385321102
I0
I1
I-1
tp8393
sS'thought,to'
p8394
(F1
F0.00028669724770642203
I0
I2
I-2
tp8395
sS'by,measuring'
p8396
(F1
F0.00028669724770642203
I0
I2
I-2
tp8397
sS'or,over'
p8398
(F1
F0.00014334862385321102
I0
I1
I-1
tp8399
sS'different,times'
p8400
(F1
F0.00014334862385321102
I0
I1
I-1
tp8401
sS'metabolizers,have'
p8402
(F1
F0.00071674311926605509
I0
I5
I-5
tp8403
sS'with,itraconazole'
p8404
(F1
F0.00014334862385321102
I1
I0
I1
tp8405
sS'deaths,in'
p8406
(F0
F0
I1
I1
I0
tp8407
sS'has,previously'
p8408
(F1
F0.00014334862385321102
I1
I0
I1
tp8409
sS'direct,action'
p8410
(F0
F0
I1
I1
I0
tp8411
sS'temporarily,mask'
p8412
(F1
F0.00014334862385321102
I1
I0
I1
tp8413
sS'deaths,is'
p8414
(F1
F0.00014334862385321102
I0
I1
I-1
tp8415
sS'a,two-fold'
p8416
(F1
F0.00014334862385321102
I1
I0
I1
tp8417
sS'or,potentially'
p8418
(F1
F0.00014334862385321102
I1
I0
I1
tp8419
sS'and,monomeric'
p8420
(F1
F0.00014334862385321102
I0
I1
I-1
tp8421
sS'depressant,should'
p8422
(F1
F0.00028669724770642203
I2
I0
I2
tp8423
sS'further,metabolized'
p8424
(F1
F0.00014334862385321102
I0
I1
I-1
tp8425
sS'deet,n'
p8426
(F1
F0.00014334862385321102
I1
I0
I1
tp8427
sS'increases,should'
p8428
(F1
F0.00014334862385321102
I1
I0
I1
tp8429
sS'the,implication'
p8430
(F1
F0.00014334862385321102
I1
I0
I1
tp8431
sS'agents,has'
p8432
(F0
F0
I2
I2
I0
tp8433
sS'more,efficiently'
p8434
(F1
F0.00014334862385321102
I0
I1
I-1
tp8435
sS'cyp1a2,cyp2a6'
p8436
(F1
F0.00057339449541284407
I0
I4
I-4
tp8437
sS'n-demethylated,metabolite'
p8438
(F1
F0.00014334862385321102
I0
I1
I-1
tp8439
sS'cholino-,and'
p8440
(F1
F0.00014334862385321102
I0
I1
I-1
tp8441
sS'also,not'
p8442
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp8443
sS'do,if'
p8444
(F1
F0.00014334862385321102
I0
I1
I-1
tp8445
sS'oral,erection-supporting'
p8446
(F1
F0.00014334862385321102
I0
I1
I-1
tp8447
sS'hcl,in'
p8448
(F1
F0.00028669724770642203
I2
I0
I2
tp8449
sS'epoxide,steady-state'
p8450
(F1
F0.00014334862385321102
I0
I1
I-1
tp8451
sS'sonata,mg'
p8452
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp8453
sS'rate,of'
p8454
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp8455
sS'natrecor,in'
p8456
(F1
F0.00014334862385321102
I0
I1
I-1
tp8457
sS'for,hydroxy-iso'
p8458
(F1
F0.00014334862385321102
I1
I0
I1
tp8459
sS'novo,kidney'
p8460
(F1
F0.00014334862385321102
I0
I1
I-1
tp8461
sS'rate,or'
p8462
(F1
F0.00057339449541284407
I0
I4
I-4
tp8463
sS'doubling,the'
p8464
(F1
F0.00014334862385321102
I0
I1
I-1
tp8465
sS'hcl,is'
p8466
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp8467
sS'trial,has'
p8468
(F1
F0.00014334862385321102
I1
I0
I1
tp8469
sS'been,cases'
p8470
(F1
F0.00014334862385321102
I1
I0
I1
tp8471
sS'dose,baseline'
p8472
(F1
F0.00014334862385321102
I0
I1
I-1
tp8473
sS'following,blood'
p8474
(F1
F0.00014334862385321102
I0
I1
I-1
tp8475
sS'qid,n'
p8476
(F1
F0.00014334862385321102
I1
I0
I1
tp8477
sS'compared,retrospectively'
p8478
(F1
F0.00014334862385321102
I0
I1
I-1
tp8479
sS'than,reduction'
p8480
(F1
F0.00014334862385321102
I1
I0
I1
tp8481
sS'palythoa,tuberculosa'
p8482
(F1
F0.00014334862385321102
I0
I1
I-1
tp8483
sS'as,great'
p8484
(F1
F0.00014334862385321102
I0
I1
I-1
tp8485
sS'hypertensive,crises'
p8486
(F1
F0.00028669724770642203
I2
I0
I2
tp8487
sS'cyp,a'
p8488
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8489
sS'antizol,and'
p8490
(F1
F0.00014334862385321102
I1
I0
I1
tp8491
sS'of,initial'
p8492
(F0
F0
I1
I1
I0
tp8493
sS'significant,and'
p8494
(F1
F0.00014334862385321102
I0
I1
I-1
tp8495
sS'drugs,given'
p8496
(F1
F0.00014334862385321102
I0
I1
I-1
tp8497
sS'coadministered,orally'
p8498
(F1
F0.00014334862385321102
I1
I0
I1
tp8499
sS'microsomes,indicate'
p8500
(F1
F0.00014334862385321102
I0
I1
I-1
tp8501
sS'standard,dose'
p8502
(F1
F0.00014334862385321102
I1
I0
I1
tp8503
sS'normal,and'
p8504
(F1
F0.00028669724770642203
I0
I2
I-2
tp8505
sS'when,combined'
p8506
(F1
F0.00028669724770642203
I2
I0
I2
tp8507
sS'antihypertensive,effects'
p8508
(F1
F0.00071674311926605509
I5
I0
I5
tp8509
sS'red,rr'
p8510
(F1
F0.00014334862385321102
I0
I1
I-1
tp8511
sS'oral,supplementation'
p8512
(F1
F0.00028669724770642203
I0
I2
I-2
tp8513
sS'daily,had'
p8514
(F1
F0.00028669724770642203
I0
I2
I-2
tp8515
sS'daily,has'
p8516
(F1
F0.00014334862385321102
I0
I1
I-1
tp8517
sS'of,actions'
p8518
(F1
F0.00014334862385321102
I0
I1
I-1
tp8519
sS'analgesic,actions'
p8520
(F1
F0.00014334862385321102
I0
I1
I-1
tp8521
sS'even,ileus'
p8522
(F1
F0.00014334862385321102
I1
I0
I1
tp8523
sS'isoform,mediate'
p8524
(F1
F0.00014334862385321102
I0
I1
I-1
tp8525
sS'enhanced,if'
p8526
(F1
F0.00014334862385321102
I1
I0
I1
tp8527
sS'treated,for'
p8528
(F1
F0.00028669724770642203
I2
I0
I2
tp8529
sS'disturbances,were'
p8530
(F1
F0.00014334862385321102
I1
I0
I1
tp8531
sS'with,lodosyn'
p8532
(F1
F0.00028669724770642203
I0
I2
I-2
tp8533
sS'double-blind,placebo-controlled'
p8534
(F1
F0.00014334862385321102
I0
I1
I-1
tp8535
sS'showed,increased'
p8536
(F1
F0.00014334862385321102
I0
I1
I-1
tp8537
sS'require,increases'
p8538
(F1
F0.00014334862385321102
I1
I0
I1
tp8539
sS'and,addicts'
p8540
(F1
F0.00014334862385321102
I1
I0
I1
tp8541
sS'aprepitant,has'
p8542
(F1
F0.00014334862385321102
I1
I0
I1
tp8543
sS'prinivil,has'
p8544
(F1
F0.00014334862385321102
I0
I1
I-1
tp8545
sS'function,were'
p8546
(F1
F0.00014334862385321102
I0
I1
I-1
tp8547
sS'trimethoprim,alone'
p8548
(F1
F0.00014334862385321102
I0
I1
I-1
tp8549
sS'indinavir,concentrations'
p8550
(F1
F0.00014334862385321102
I1
I0
I1
tp8551
sS'hypothyroid,patient'
p8552
(F1
F0.00014334862385321102
I1
I0
I1
tp8553
sS'blockers,have'
p8554
(F1
F0.00014334862385321102
I0
I1
I-1
tp8555
sS'the,plasma'
p8556
(F0.35714285714285715
F0.0028669724770642203
I38
I18
I20
tp8557
sS'maintained,at'
p8558
(F1
F0.00014334862385321102
I0
I1
I-1
tp8559
sS'and,suggest'
p8560
(F0
F0
I1
I1
I0
tp8561
sS'to,prevent'
p8562
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp8563
sS'tegretol,tagamet'
p8564
(F1
F0.00014334862385321102
I0
I1
I-1
tp8565
sS'glycosides,inducers'
p8566
(F1
F0.00014334862385321102
I0
I1
I-1
tp8567
sS'central,syndrome'
p8568
(F1
F0.00014334862385321102
I1
I0
I1
tp8569
sS'including,most'
p8570
(F1
F0.00014334862385321102
I0
I1
I-1
tp8571
sS'during,photic'
p8572
(F1
F0.00014334862385321102
I0
I1
I-1
tp8573
sS'known,enzyme'
p8574
(F1
F0.00043004587155963305
I3
I0
I3
tp8575
sS'higher,when'
p8576
(F1
F0.00071674311926605509
I5
I0
I5
tp8577
sS'retard,and'
p8578
(F1
F0.00014334862385321102
I1
I0
I1
tp8579
sS'only,additive'
p8580
(F1
F0.00014334862385321102
I1
I0
I1
tp8581
sS'reduced,by'
p8582
(F0.59999999999999998
F0.0021502293577981653
I20
I5
I15
tp8583
sS'closely,and'
p8584
(F0
F0
I1
I1
I0
tp8585
sS'a,substantially'
p8586
(F1
F0.00014334862385321102
I0
I1
I-1
tp8587
sS'the,objective'
p8588
(F1
F0.00014334862385321102
I0
I1
I-1
tp8589
sS'mean,percentage'
p8590
(F1
F0.00014334862385321102
I1
I0
I1
tp8591
sS'average,increase'
p8592
(F1
F0.00014334862385321102
I1
I0
I1
tp8593
sS'other,hormonalmethods'
p8594
(F1
F0.00014334862385321102
I1
I0
I1
tp8595
sS'determine,if'
p8596
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp8597
sS'of,n-acetyltransferase'
p8598
(F1
F0.00014334862385321102
I1
I0
I1
tp8599
sS'are,adequate'
p8600
(F1
F0.00014334862385321102
I0
I1
I-1
tp8601
sS'and,invalidate'
p8602
(F1
F0.00014334862385321102
I0
I1
I-1
tp8603
sS'casodex,is'
p8604
(F1
F0.00014334862385321102
I1
I0
I1
tp8605
sS'norfloxacin,in'
p8606
(F1
F0.00014334862385321102
I1
I0
I1
tp8607
sS'cellular,basis'
p8608
(F1
F0.00014334862385321102
I0
I1
I-1
tp8609
sS'volunteers,suggests'
p8610
(F1
F0.00014334862385321102
I1
I0
I1
tp8611
sS'two,mg'
p8612
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp8613
sS'homocysteine,in'
p8614
(F1
F0.00014334862385321102
I0
I1
I-1
tp8615
sS'class,resulting'
p8616
(F1
F0.00014334862385321102
I1
I0
I1
tp8617
sS'diminish,its'
p8618
(F1
F0.00014334862385321102
I1
I0
I1
tp8619
sS'the,apparent'
p8620
(F0
F0
I1
I1
I0
tp8621
sS'the,patients'
p8622
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp8623
sS'not,require'
p8624
(F1
F0.00028669724770642203
I0
I2
I-2
tp8625
sS'folate,utilization'
p8626
(F1
F0.00014334862385321102
I1
I0
I1
tp8627
sS'or,unintentional'
p8628
(F1
F0.00014334862385321102
I1
I0
I1
tp8629
sS'white,female'
p8630
(F1
F0.00014334862385321102
I0
I1
I-1
tp8631
sS'a4,substrate'
p8632
(F1
F0.00014334862385321102
I0
I1
I-1
tp8633
sS'alphagan,p'
p8634
(F1
F0.00028669724770642203
I2
I0
I2
tp8635
sS'tested,up'
p8636
(F1
F0.00014334862385321102
I0
I1
I-1
tp8637
sS'by,cyp3a'
p8638
(F1
F0.00014334862385321102
I0
I1
I-1
tp8639
sS'particular,convulsions'
p8640
(F1
F0.00014334862385321102
I1
I0
I1
tp8641
sS'who,discontinue'
p8642
(F1
F0.00014334862385321102
I1
I0
I1
tp8643
sS'most,notably'
p8644
(F1
F0.00014334862385321102
I1
I0
I1
tp8645
sS'is,theoretically'
p8646
(F1
F0.00014334862385321102
I1
I0
I1
tp8647
sS'eye,drops'
p8648
(F1
F0.00014334862385321102
I0
I1
I-1
tp8649
sS'tcatreatment,in'
p8650
(F1
F0.00014334862385321102
I1
I0
I1
tp8651
sS'migraine,has'
p8652
(F1
F0.00014334862385321102
I0
I1
I-1
tp8653
sS'need,for'
p8654
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp8655
sS'n-desmethyldiazepam,to'
p8656
(F1
F0.00014334862385321102
I0
I1
I-1
tp8657
sS'cause,elimination'
p8658
(F1
F0.00028669724770642203
I2
I0
I2
tp8659
sS'received,or'
p8660
(F1
F0.00014334862385321102
I1
I0
I1
tp8661
sS'or,induces'
p8662
(F1
F0.00014334862385321102
I0
I1
I-1
tp8663
sS'antidepressants,or'
p8664
(F1
F0.00014334862385321102
I0
I1
I-1
tp8665
sS'efficacy,on'
p8666
(F1
F0.00014334862385321102
I0
I1
I-1
tp8667
sS'discontinuing,to'
p8668
(F1
F0.00028669724770642203
I2
I0
I2
tp8669
sS'delay,or'
p8670
(F1
F0.00014334862385321102
I1
I0
I1
tp8671
sS'efficacy,of'
p8672
(F0.125
F0.00028669724770642203
I9
I7
I2
tp8673
sS'this,observed'
p8674
(F1
F0.00014334862385321102
I1
I0
I1
tp8675
sS'the,are'
p8676
(F1
F0.00043004587155963305
I0
I3
I-3
tp8677
sS'for,protein'
p8678
(F1
F0.00014334862385321102
I0
I1
I-1
tp8679
sS'added,were'
p8680
(F1
F0.00014334862385321102
I1
I0
I1
tp8681
sS'to,approximately'
p8682
(F1
F0.00043004587155963305
I3
I0
I3
tp8683
sS'the,auc'
p8684
(F0.69999999999999996
F0.0040137614678899085
I34
I6
I28
tp8685
sS'help,to'
p8686
(F1
F0.00014334862385321102
I0
I1
I-1
tp8687
sS'in,elderly'
p8688
(F1
F0.00014334862385321102
I1
I0
I1
tp8689
sS'ns,were'
p8690
(F1
F0.00028669724770642203
I0
I2
I-2
tp8691
sS'cyp3a4,is'
p8692
(F1
F0.00043004587155963305
I0
I3
I-3
tp8693
sS'respectively,were'
p8694
(F1
F0.00014334862385321102
I1
I0
I1
tp8695
sS'serious,cardiovascular'
p8696
(F1
F0.00014334862385321102
I1
I0
I1
tp8697
sS'with,respectto'
p8698
(F1
F0.00014334862385321102
I0
I1
I-1
tp8699
sS'cyp2b6,cyp2c8'
p8700
(F1
F0.00014334862385321102
I0
I1
I-1
tp8701
sS'interaction,has'
p8702
(F0
F0
I2
I2
I0
tp8703
sS'abased,on'
p8704
(F1
F0.00014334862385321102
I1
I0
I1
tp8705
sS'contraction,of'
p8706
(F1
F0.00014334862385321102
I0
I1
I-1
tp8707
sS'highly,protein'
p8708
(F0.5
F0.00028669724770642203
I3
I1
I2
tp8709
sS'taking,coumarin-derivative'
p8710
(F1
F0.00014334862385321102
I1
I0
I1
tp8711
sS'strains,and'
p8712
(F0
F0
I1
I1
I0
tp8713
sS'for,detoxification'
p8714
(F1
F0.00014334862385321102
I1
I0
I1
tp8715
sS'administered,on'
p8716
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp8717
sS'if,a'
p8718
(F0.73333333333333328
F0.0015768348623853212
I13
I2
I11
tp8719
sS'acth,induced'
p8720
(F1
F0.00028669724770642203
I0
I2
I-2
tp8721
sS'digoxin,methotrexate'
p8722
(F0
F0
I1
I1
I0
tp8723
sS'potent,parental'
p8724
(F1
F0.00014334862385321102
I1
I0
I1
tp8725
sS'including,for'
p8726
(F1
F0.00014334862385321102
I1
I0
I1
tp8727
sS'tissues,from'
p8728
(F1
F0.00014334862385321102
I1
I0
I1
tp8729
sS'the,cross-reactivity'
p8730
(F1
F0.00014334862385321102
I1
I0
I1
tp8731
sS'toradol,therapy'
p8732
(F1
F0.00014334862385321102
I1
I0
I1
tp8733
sS'was,associated'
p8734
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp8735
sS'elicit,their'
p8736
(F1
F0.00014334862385321102
I0
I1
I-1
tp8737
sS'pain,without'
p8738
(F1
F0.00014334862385321102
I0
I1
I-1
tp8739
sS'incoordination,following'
p8740
(F1
F0.00014334862385321102
I1
I0
I1
tp8741
sS'enzymes,was'
p8742
(F1
F0.00014334862385321102
I1
I0
I1
tp8743
sS'sleeping,time'
p8744
(F1
F0.00014334862385321102
I1
I0
I1
tp8745
sS'antifungals,the'
p8746
(F1
F0.00014334862385321102
I0
I1
I-1
tp8747
sS'not,altered'
p8748
(F1
F0.0012901376146788992
I0
I9
I-9
tp8749
sS'great,an'
p8750
(F1
F0.00014334862385321102
I0
I1
I-1
tp8751
sS'that,modulates'
p8752
(F1
F0.00014334862385321102
I1
I0
I1
tp8753
sS'systems,for'
p8754
(F1
F0.00014334862385321102
I0
I1
I-1
tp8755
sS'different,type'
p8756
(F1
F0.00014334862385321102
I1
I0
I1
tp8757
sS'long-term,administration'
p8758
(F1
F0.00014334862385321102
I0
I1
I-1
tp8759
sS'and,human'
p8760
(F0
F0
I1
I1
I0
tp8761
sS'between,vitamin'
p8762
(F1
F0.00043004587155963305
I3
I0
I3
tp8763
sS'between,viracept'
p8764
(F1
F0.00014334862385321102
I0
I1
I-1
tp8765
sS'elapse,between'
p8766
(F1
F0.00043004587155963305
I3
I0
I3
tp8767
sS'substantially,decrease'
p8768
(F0
F0
I1
I1
I0
tp8769
sS'evidence,that'
p8770
(F1
F0.00014334862385321102
I0
I1
I-1
tp8771
sS'of,adverse'
p8772
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp8773
sS'with,xanthine'
p8774
(F1
F0.00014334862385321102
I1
I0
I1
tp8775
sS'selecting,an'
p8776
(F1
F0.00028669724770642203
I2
I0
I2
tp8777
sS'arterial,hypertension'
p8778
(F1
F0.00014334862385321102
I0
I1
I-1
tp8779
sS'parameters,pt'
p8780
(F1
F0.00014334862385321102
I1
I0
I1
tp8781
sS'acquainted,with'
p8782
(F1
F0.00014334862385321102
I0
I1
I-1
tp8783
sS'abilify,aripiprazole'
p8784
(F1
F0.00014334862385321102
I0
I1
I-1
tp8785
sS'ketoconazole,when'
p8786
(F0
F0
I1
I1
I0
tp8787
sS'concentration,monitoring'
p8788
(F1
F0.00014334862385321102
I1
I0
I1
tp8789
sS'vivo,resulting'
p8790
(F1
F0.00014334862385321102
I1
I0
I1
tp8791
sS'and,brovana'
p8792
(F1
F0.00014334862385321102
I1
I0
I1
tp8793
sS'eliminated,by'
p8794
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp8795
sS'male,n'
p8796
(F1
F0.00014334862385321102
I0
I1
I-1
tp8797
sS'triglycerides,mg'
p8798
(F1
F0.00014334862385321102
I0
I1
I-1
tp8799
sS'or,bezalip'
p8800
(F1
F0.00043004587155963305
I3
I0
I3
tp8801
sS'respectively,which'
p8802
(F1
F0.00014334862385321102
I0
I1
I-1
tp8803
sS'didanosine,chewable'
p8804
(F1
F0.00028669724770642203
I2
I0
I2
tp8805
sS'understand,how'
p8806
(F1
F0.00014334862385321102
I0
I1
I-1
tp8807
sS'effects,caused'
p8808
(F1
F0.00014334862385321102
I1
I0
I1
tp8809
sS'when,tagamet'
p8810
(F1
F0.00014334862385321102
I1
I0
I1
tp8811
sS'concentrations,substances'
p8812
(F1
F0.00014334862385321102
I0
I1
I-1
tp8813
sS'no,apparent'
p8814
(F1
F0.00071674311926605509
I0
I5
I-5
tp8815
sS'reduced,relative'
p8816
(F1
F0.00014334862385321102
I0
I1
I-1
tp8817
sS'compounds,which'
p8818
(F1
F0.00014334862385321102
I0
I1
I-1
tp8819
sS'and,superiority'
p8820
(F1
F0.00014334862385321102
I0
I1
I-1
tp8821
sS'a,pulmonary'
p8822
(F1
F0.00014334862385321102
I0
I1
I-1
tp8823
sS'norpace,was'
p8824
(F1
F0.00014334862385321102
I0
I1
I-1
tp8825
sS'produce,clinically'
p8826
(F1
F0.00028669724770642203
I2
I0
I2
tp8827
sS'diabetic,chinese'
p8828
(F1
F0.00028669724770642203
I0
I2
I-2
tp8829
sS'two,different'
p8830
(F1
F0.00014334862385321102
I0
I1
I-1
tp8831
sS'cleared,from'
p8832
(F1
F0.00014334862385321102
I0
I1
I-1
tp8833
sS'vitro,interferes'
p8834
(F1
F0.00014334862385321102
I1
I0
I1
tp8835
sS'with,normal'
p8836
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp8837
sS'aspirin,concomitant'
p8838
(F1
F0.00057339449541284407
I4
I0
I4
tp8839
sS'anafranil,should'
p8840
(F1
F0.00014334862385321102
I1
I0
I1
tp8841
sS'bid,as'
p8842
(F1
F0.00014334862385321102
I1
I0
I1
tp8843
sS'when,possible'
p8844
(F1
F0.00014334862385321102
I1
I0
I1
tp8845
sS'concentration,altered'
p8846
(F0
F0
I1
I1
I0
tp8847
sS'as,proof'
p8848
(F1
F0.00014334862385321102
I0
I1
I-1
tp8849
sS'or,increase'
p8850
(F1
F0.00014334862385321102
I1
I0
I1
tp8851
sS'qhs,after'
p8852
(F1
F0.00014334862385321102
I0
I1
I-1
tp8853
sS'bind,the'
p8854
(F1
F0.00014334862385321102
I1
I0
I1
tp8855
sS'of,where'
p8856
(F1
F0.00028669724770642203
I2
I0
I2
tp8857
sS'route,than'
p8858
(F1
F0.00014334862385321102
I0
I1
I-1
tp8859
sS'auranofin,should'
p8860
(F1
F0.00028669724770642203
I2
I0
I2
tp8861
sS'randomized,double-blind'
p8862
(F1
F0.00014334862385321102
I0
I1
I-1
tp8863
sS'or,those'
p8864
(F1
F0.00014334862385321102
I1
I0
I1
tp8865
sS'affect,renal'
p8866
(F1
F0.00057339449541284407
I0
I4
I-4
tp8867
sS'novolog,but'
p8868
(F1
F0.00014334862385321102
I0
I1
I-1
tp8869
sS'loop,potassium-'
p8870
(F1
F0.00014334862385321102
I1
I0
I1
tp8871
sS'anakinra,concurrent'
p8872
(F1
F0.00014334862385321102
I1
I0
I1
tp8873
sS'and,hydroxide-containing'
p8874
(F1
F0.00014334862385321102
I0
I1
I-1
tp8875
sS'a,therapeutic'
p8876
(F1
F0.00014334862385321102
I1
I0
I1
tp8877
sS'potentially,serious'
p8878
(F1
F0.00014334862385321102
I1
I0
I1
tp8879
sS'being,observed'
p8880
(F1
F0.00014334862385321102
I0
I1
I-1
tp8881
sS'episodes,permit'
p8882
(F1
F0.00014334862385321102
I0
I1
I-1
tp8883
sS'done,extremely'
p8884
(F1
F0.00014334862385321102
I1
I0
I1
tp8885
sS'of,hypotensive'
p8886
(F1
F0.00071674311926605509
I5
I0
I5
tp8887
sS'each,found'
p8888
(F1
F0.00014334862385321102
I0
I1
I-1
tp8889
sS'the,requirement'
p8890
(F1
F0.00014334862385321102
I1
I0
I1
tp8891
sS'beta-adrenergic,receptor'
p8892
(F1
F0.00014334862385321102
I0
I1
I-1
tp8893
sS'cyp2d6,are'
p8894
(F1
F0.00014334862385321102
I0
I1
I-1
tp8895
sS'by,beta-adrenergic'
p8896
(F1
F0.00014334862385321102
I1
I0
I1
tp8897
sS'hydroxide,cerivastatin'
p8898
(F1
F0.00014334862385321102
I0
I1
I-1
tp8899
sS'adverse,experience'
p8900
(F1
F0.00014334862385321102
I0
I1
I-1
tp8901
sS'on,steady-state'
p8902
(F1
F0.00014334862385321102
I0
I1
I-1
tp8903
sS'as,but'
p8904
(F1
F0.00014334862385321102
I1
I0
I1
tp8905
sS'para-aminobenzoic,acid'
p8906
(F1
F0.00014334862385321102
I1
I0
I1
tp8907
sS'effect,could'
p8908
(F1
F0.00028669724770642203
I2
I0
I2
tp8909
sS'require,empiric'
p8910
(F1
F0.00014334862385321102
I0
I1
I-1
tp8911
sS'drug,metabolism'
p8912
(F1
F0.00014334862385321102
I1
I0
I1
tp8913
sS'daily,should'
p8914
(F1
F0.00014334862385321102
I0
I1
I-1
tp8915
sS'agents,only'
p8916
(F1
F0.00014334862385321102
I0
I1
I-1
tp8917
sS'when,duloxetine'
p8918
(F1
F0.00014334862385321102
I0
I1
I-1
tp8919
sS'problem,associated'
p8920
(F1
F0.00014334862385321102
I1
I0
I1
tp8921
sS'lengthened,and'
p8922
(F1
F0.00014334862385321102
I1
I0
I1
tp8923
sS'should,generally'
p8924
(F1
F0.00028669724770642203
I2
I0
I2
tp8925
sS'affect,either'
p8926
(F1
F0.00014334862385321102
I0
I1
I-1
tp8927
sS'as,this'
p8928
(F1
F0.00043004587155963305
I0
I3
I-3
tp8929
sS'been,performed'
p8930
(F0
F0
I2
I2
I0
tp8931
sS'similar,conditions'
p8932
(F1
F0.00014334862385321102
I0
I1
I-1
tp8933
sS'additional,effects'
p8934
(F1
F0.00014334862385321102
I1
I0
I1
tp8935
sS'hydrochloride,may'
p8936
(F1
F0.00028669724770642203
I2
I0
I2
tp8937
sS'd3,calcitriol'
p8938
(F1
F0.00043004587155963305
I3
I0
I3
tp8939
sS'and,six'
p8940
(F1
F0.00014334862385321102
I0
I1
I-1
tp8941
sS'fentanyl,in'
p8942
(F1
F0.00014334862385321102
I1
I0
I1
tp8943
sS'probenecid,probenecid'
p8944
(F0
F0
I3
I3
I0
tp8945
sS'data,are'
p8946
(F1
F0.00043004587155963305
I0
I3
I-3
tp8947
sS'where,patients'
p8948
(F1
F0.00014334862385321102
I0
I1
I-1
tp8949
sS'p,app'
p8950
(F1
F0.00014334862385321102
I0
I1
I-1
tp8951
sS'h-triglyceride,fractional'
p8952
(F1
F0.00014334862385321102
I1
I0
I1
tp8953
sS'bacteriostatic,antibiotics'
p8954
(F1
F0.00014334862385321102
I1
I0
I1
tp8955
sS'besides,mtx'
p8956
(F1
F0.00014334862385321102
I0
I1
I-1
tp8957
sS'approved,for'
p8958
(F1
F0.00014334862385321102
I0
I1
I-1
tp8959
sS'rats,hydrochloride'
p8960
(F1
F0.00014334862385321102
I1
I0
I1
tp8961
sS'separating,the'
p8962
(F1
F0.00014334862385321102
I1
I0
I1
tp8963
sS'neurotoxic,effect'
p8964
(F1
F0.00014334862385321102
I1
I0
I1
tp8965
sS'apparent,oral'
p8966
(F1
F0.00043004587155963305
I3
I0
I3
tp8967
sS'by,resecting'
p8968
(F1
F0.00014334862385321102
I0
I1
I-1
tp8969
sS'the,net'
p8970
(F0
F0
I1
I1
I0
tp8971
sS'hydrogen-3,revealed'
p8972
(F1
F0.00014334862385321102
I0
I1
I-1
tp8973
sS'medications,agents'
p8974
(F1
F0.00014334862385321102
I0
I1
I-1
tp8975
sS'related,to'
p8976
(F0
F0
I4
I4
I0
tp8977
sS'interaction,fosinopril'
p8978
(F1
F0.00014334862385321102
I0
I1
I-1
tp8979
sS'a,dopa'
p8980
(F1
F0.00014334862385321102
I0
I1
I-1
tp8981
sS'studies,beta-receptor'
p8982
(F1
F0.00014334862385321102
I0
I1
I-1
tp8983
sS'decrease,by'
p8984
(F0
F0
I1
I1
I0
tp8985
sS'while,may'
p8986
(F1
F0.00014334862385321102
I1
I0
I1
tp8987
sS'by,such'
p8988
(F1
F0.00014334862385321102
I1
I0
I1
tp8989
sS'estradiol,following'
p8990
(F1
F0.00014334862385321102
I0
I1
I-1
tp8991
sS'decreasing,gut'
p8992
(F1
F0.00014334862385321102
I1
I0
I1
tp8993
sS'induce,metabolic'
p8994
(F1
F0.00014334862385321102
I0
I1
I-1
tp8995
sS'absorption,resulting'
p8996
(F1
F0.00043004587155963305
I3
I0
I3
tp8997
sS'with,hours'
p8998
(F1
F0.00014334862385321102
I1
I0
I1
tp8999
sS'azole,antifungals'
p9000
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp9001
sS'and,markedly'
p9002
(F1
F0.00028669724770642203
I2
I0
I2
tp9003
sS'are,added'
p9004
(F1
F0.00014334862385321102
I0
I1
I-1
tp9005
sS'antidepressant,or'
p9006
(F1
F0.00043004587155963305
I0
I3
I-3
tp9007
sS'gastric,secretion'
p9008
(F1
F0.00014334862385321102
I0
I1
I-1
tp9009
sS'r,and'
p9010
(F1
F0.00014334862385321102
I0
I1
I-1
tp9011
sS'be,enhanced'
p9012
(F1
F0.00071674311926605509
I5
I0
I5
tp9013
sS'pcp,were'
p9014
(F0
F0
I1
I1
I0
tp9015
sS'physicians,should'
p9016
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp9017
sS'may,significantly'
p9018
(F1
F0.00014334862385321102
I1
I0
I1
tp9019
sS'with,sodium'
p9020
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9021
sS'or,cimetidine'
p9022
(F1
F0.00014334862385321102
I1
I0
I1
tp9023
sS'daily,dosage'
p9024
(F1
F0.00014334862385321102
I0
I1
I-1
tp9025
sS'cyclosporine,a'
p9026
(F1
F0.00014334862385321102
I0
I1
I-1
tp9027
sS'be,kept'
p9028
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9029
sS'metabolism,increased'
p9030
(F1
F0.00014334862385321102
I1
I0
I1
tp9031
sS'to,toxic'
p9032
(F1
F0.00014334862385321102
I1
I0
I1
tp9033
sS'affect,any'
p9034
(F1
F0.00014334862385321102
I0
I1
I-1
tp9035
sS'antidepressant,agent'
p9036
(F1
F0.00014334862385321102
I0
I1
I-1
tp9037
sS'should,either'
p9038
(F1
F0.00014334862385321102
I1
I0
I1
tp9039
sS'depletions,of'
p9040
(F1
F0.00028669724770642203
I2
I0
I2
tp9041
sS'the,cautious'
p9042
(F1
F0.00014334862385321102
I1
I0
I1
tp9043
sS'displacing,effect'
p9044
(F1
F0.00014334862385321102
I0
I1
I-1
tp9045
sS'oral,during'
p9046
(F1
F0.00014334862385321102
I1
I0
I1
tp9047
sS'and,appears'
p9048
(F1
F0.00014334862385321102
I0
I1
I-1
tp9049
sS'was,coadministered'
p9050
(F0
F0
I6
I6
I0
tp9051
sS'to,inhibition'
p9052
(F1
F0.00028669724770642203
I2
I0
I2
tp9053
sS'polyene,showed'
p9054
(F1
F0.00014334862385321102
I0
I1
I-1
tp9055
sS'receiving,maintenance'
p9056
(F1
F0.00014334862385321102
I0
I1
I-1
tp9057
sS'acidifying,agents'
p9058
(F1
F0.0008600917431192661
I6
I0
I6
tp9059
sS'exaggerated,hypertensive'
p9060
(F1
F0.00014334862385321102
I1
I0
I1
tp9061
sS'significantly,affected'
p9062
(F1
F0.00028669724770642203
I0
I2
I-2
tp9063
sS'classes,ii'
p9064
(F1
F0.00028669724770642203
I0
I2
I-2
tp9065
sS'analyses,revealed'
p9066
(F1
F0.00014334862385321102
I0
I1
I-1
tp9067
sS'and,beta-adrenergic'
p9068
(F1
F0.00014334862385321102
I1
I0
I1
tp9069
sS'moieties,significantly'
p9070
(F1
F0.00014334862385321102
I0
I1
I-1
tp9071
sS'consisting,of'
p9072
(F0
F0
I1
I1
I0
tp9073
sS'sufficient,time'
p9074
(F0
F0
I1
I1
I0
tp9075
sS'dose,for'
p9076
(F1
F0.00028669724770642203
I0
I2
I-2
tp9077
sS'negative,and'
p9078
(F1
F0.00028669724770642203
I0
I2
I-2
tp9079
sS'by,but'
p9080
(F0.5
F0.00028669724770642203
I3
I1
I2
tp9081
sS'were,compared'
p9082
(F1
F0.00028669724770642203
I0
I2
I-2
tp9083
sS'fibrosis,therapies'
p9084
(F1
F0.00014334862385321102
I0
I1
I-1
tp9085
sS'sparing,pharmacological'
p9086
(F1
F0.00014334862385321102
I0
I1
I-1
tp9087
sS'and,reaction'
p9088
(F1
F0.00014334862385321102
I1
I0
I1
tp9089
sS'dipropylxanthine,dpcpx'
p9090
(F1
F0.00014334862385321102
I0
I1
I-1
tp9091
sS'indomethacin,was'
p9092
(F1
F0.00014334862385321102
I0
I1
I-1
tp9093
sS'for,urinary'
p9094
(F1
F0.00028669724770642203
I0
I2
I-2
tp9095
sS'of,theo-dur'
p9096
(F1
F0.00014334862385321102
I1
I0
I1
tp9097
sS'considerable,evidence'
p9098
(F1
F0.00014334862385321102
I0
I1
I-1
tp9099
sS'potential,terfenadine'
p9100
(F1
F0.00014334862385321102
I0
I1
I-1
tp9101
sS'conducted,concomitant'
p9102
(F1
F0.00014334862385321102
I1
I0
I1
tp9103
sS'derivatives,in'
p9104
(F1
F0.00014334862385321102
I1
I0
I1
tp9105
sS'the,pressor'
p9106
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp9107
sS'levo-dromoran,reported'
p9108
(F1
F0.00014334862385321102
I0
I1
I-1
tp9109
sS'not,expected'
p9110
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp9111
sS'of,before'
p9112
(F1
F0.00014334862385321102
I1
I0
I1
tp9113
sS'suggest,a'
p9114
(F1
F0.00057339449541284407
I4
I0
I4
tp9115
sS'new,class'
p9116
(F1
F0.00014334862385321102
I0
I1
I-1
tp9117
sS'less,active'
p9118
(F1
F0.00014334862385321102
I1
I0
I1
tp9119
sS'weakness,lethargy'
p9120
(F1
F0.00014334862385321102
I1
I0
I1
tp9121
sS'of,chronic'
p9122
(F0
F0
I2
I2
I0
tp9123
sS'fat,and'
p9124
(F1
F0.00014334862385321102
I0
I1
I-1
tp9125
sS'reactions,all'
p9126
(F1
F0.00014334862385321102
I0
I1
I-1
tp9127
sS'to,nonopioid'
p9128
(F1
F0.00014334862385321102
I0
I1
I-1
tp9129
sS'orally,because'
p9130
(F1
F0.00014334862385321102
I1
I0
I1
tp9131
sS'of,multipledose'
p9132
(F1
F0.00014334862385321102
I0
I1
I-1
tp9133
sS'capsules,garlic'
p9134
(F1
F0.00014334862385321102
I0
I1
I-1
tp9135
sS'one,of'
p9136
(F0
F0
I2
I2
I0
tp9137
sS'and,live-attenuated'
p9138
(F1
F0.00014334862385321102
I1
I0
I1
tp9139
sS'be,predictive'
p9140
(F1
F0.00014334862385321102
I0
I1
I-1
tp9141
sS'any,change'
p9142
(F1
F0.00014334862385321102
I0
I1
I-1
tp9143
sS'hypoglycemics,agents'
p9144
(F1
F0.00014334862385321102
I1
I0
I1
tp9145
sS'deet,was'
p9146
(F1
F0.00014334862385321102
I0
I1
I-1
tp9147
sS'maalox,tc'
p9148
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9149
sS'following,doses'
p9150
(F1
F0.00014334862385321102
I1
I0
I1
tp9151
sS'are,provided'
p9152
(F1
F0.00014334862385321102
I1
I0
I1
tp9153
sS'the,continued'
p9154
(F1
F0.00014334862385321102
I0
I1
I-1
tp9155
sS'pregnancy,from'
p9156
(F1
F0.00014334862385321102
I0
I1
I-1
tp9157
sS'diets,no'
p9158
(F1
F0.00014334862385321102
I0
I1
I-1
tp9159
sS'organisms,contained'
p9160
(F1
F0.00014334862385321102
I1
I0
I1
tp9161
sS'to,whom'
p9162
(F1
F0.00028669724770642203
I2
I0
I2
tp9163
sS'of,warfarin-type'
p9164
(F0
F0
I1
I1
I0
tp9165
sS'supplementation,mg'
p9166
(F1
F0.00014334862385321102
I0
I1
I-1
tp9167
sS'decrease,range'
p9168
(F1
F0.00014334862385321102
I1
I0
I1
tp9169
sS'activity,while'
p9170
(F1
F0.00014334862385321102
I1
I0
I1
tp9171
sS'curves,with'
p9172
(F1
F0.00014334862385321102
I1
I0
I1
tp9173
sS'parameters,including'
p9174
(F1
F0.00014334862385321102
I0
I1
I-1
tp9175
sS'placebo,n'
p9176
(F1
F0.00014334862385321102
I0
I1
I-1
tp9177
sS'stered,orally'
p9178
(F1
F0.00014334862385321102
I1
I0
I1
tp9179
sS'pharmacokinetic,effects'
p9180
(F1
F0.00014334862385321102
I1
I0
I1
tp9181
sS'carefully,monitored'
p9182
(F0.5
F0.00057339449541284407
I6
I2
I4
tp9183
sS'containing,may'
p9184
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9185
sS'chronic,or'
p9186
(F1
F0.00014334862385321102
I1
I0
I1
tp9187
sS'ssri-tca,interactions'
p9188
(F1
F0.00057339449541284407
I4
I0
I4
tp9189
sS'expression,that'
p9190
(F1
F0.00014334862385321102
I0
I1
I-1
tp9191
sS'elevated,with'
p9192
(F1
F0.00014334862385321102
I0
I1
I-1
tp9193
sS'tolerated,and'
p9194
(F1
F0.00014334862385321102
I1
I0
I1
tp9195
sS'plendil,with'
p9196
(F1
F0.00014334862385321102
I0
I1
I-1
tp9197
sS'quinidine,coadministration'
p9198
(F1
F0.00014334862385321102
I1
I0
I1
tp9199
sS'vessels,to'
p9200
(F1
F0.00014334862385321102
I1
I0
I1
tp9201
sS'with,tylenol'
p9202
(F1
F0.00014334862385321102
I1
I0
I1
tp9203
sS'has,little'
p9204
(F1
F0.00014334862385321102
I1
I0
I1
tp9205
sS'is,contraindicated'
p9206
(F0.5
F0.00028669724770642203
I3
I1
I2
tp9207
sS'is,advisable'
p9208
(F1
F0.00028669724770642203
I2
I0
I2
tp9209
sS'any,serious'
p9210
(F1
F0.00014334862385321102
I0
I1
I-1
tp9211
sS'organic,were'
p9212
(F1
F0.00028669724770642203
I2
I0
I2
tp9213
sS'currently,receiving'
p9214
(F1
F0.00043004587155963305
I3
I0
I3
tp9215
sS'days,mg'
p9216
(F1
F0.00028669724770642203
I0
I2
I-2
tp9217
sS'hypothyroid,patients'
p9218
(F1
F0.00043004587155963305
I0
I3
I-3
tp9219
sS'by,coadministration'
p9220
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp9221
sS'should,not'
p9222
(F0.73684210526315785
F0.008027522935779817
I66
I10
I56
tp9223
sS'secretion,chronic'
p9224
(F1
F0.00014334862385321102
I0
I1
I-1
tp9225
sS'bleeding,shortly'
p9226
(F1
F0.00014334862385321102
I0
I1
I-1
tp9227
sS'increased,nephrotoxicity'
p9228
(F1
F0.00028669724770642203
I2
I0
I2
tp9229
sS'glucose,including'
p9230
(F1
F0.00014334862385321102
I1
I0
I1
tp9231
sS'this,small'
p9232
(F1
F0.00014334862385321102
I1
I0
I1
tp9233
sS'reduce,endogenous'
p9234
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9235
sS'with,stable'
p9236
(F1
F0.00014334862385321102
I0
I1
I-1
tp9237
sS'omega-agatoxin,iva-sensitive'
p9238
(F1
F0.00014334862385321102
I0
I1
I-1
tp9239
sS'auc,vs'
p9240
(F1
F0.00014334862385321102
I0
I1
I-1
tp9241
sS'another,is'
p9242
(F1
F0.00014334862385321102
I0
I1
I-1
tp9243
sS'low-dose,combination'
p9244
(F1
F0.00014334862385321102
I0
I1
I-1
tp9245
sS'exert,additive'
p9246
(F1
F0.00028669724770642203
I0
I2
I-2
tp9247
sS'similarly,patients'
p9248
(F1
F0.00014334862385321102
I0
I1
I-1
tp9249
sS'de,novo'
p9250
(F1
F0.00028669724770642203
I0
I2
I-2
tp9251
sS'phosphatase,activity'
p9252
(F1
F0.00014334862385321102
I0
I1
I-1
tp9253
sS'with,occurs'
p9254
(F1
F0.00014334862385321102
I1
I0
I1
tp9255
sS'kg,was'
p9256
(F0
F0
I1
I1
I0
tp9257
sS'both,cyp1a2'
p9258
(F1
F0.00014334862385321102
I0
I1
I-1
tp9259
sS'taking,amevive'
p9260
(F1
F0.00014334862385321102
I0
I1
I-1
tp9261
sS'only,for'
p9262
(F1
F0.00014334862385321102
I0
I1
I-1
tp9263
sS'three,well-controlled'
p9264
(F1
F0.00014334862385321102
I0
I1
I-1
tp9265
sS'facilitates,acquisition'
p9266
(F1
F0.00014334862385321102
I0
I1
I-1
tp9267
sS'oxidation,responsible'
p9268
(F1
F0.00014334862385321102
I1
I0
I1
tp9269
sS'be,explained'
p9270
(F1
F0.00014334862385321102
I1
I0
I1
tp9271
sS'potential,to'
p9272
(F0.25
F0.00028669724770642203
I5
I3
I2
tp9273
sS'than,with'
p9274
(F0
F0
I1
I1
I0
tp9275
sS'receiving,either'
p9276
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9277
sS'enhanced,when'
p9278
(F0
F0
I1
I1
I0
tp9279
sS'two,cases'
p9280
(F1
F0.00014334862385321102
I1
I0
I1
tp9281
sS'of,rat'
p9282
(F1
F0.00014334862385321102
I0
I1
I-1
tp9283
sS'against,multidrug-resistant'
p9284
(F1
F0.00014334862385321102
I0
I1
I-1
tp9285
sS'study,regardless'
p9286
(F1
F0.00014334862385321102
I0
I1
I-1
tp9287
sS'vioxx,mg'
p9288
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9289
sS'with,one'
p9290
(F0
F0
I2
I2
I0
tp9291
sS'liver,injury'
p9292
(F1
F0.00014334862385321102
I0
I1
I-1
tp9293
sS'of,pointer'
p9294
(F1
F0.00014334862385321102
I0
I1
I-1
tp9295
sS'or,prothrombin'
p9296
(F1
F0.00028669724770642203
I0
I2
I-2
tp9297
sS'mg,was'
p9298
(F0
F0
I4
I4
I0
tp9299
sS'significant,additional'
p9300
(F1
F0.00014334862385321102
I1
I0
I1
tp9301
sS'phenothiazines,and'
p9302
(F1
F0.00028669724770642203
I2
I0
I2
tp9303
sS'efficacy,benefit'
p9304
(F1
F0.00014334862385321102
I0
I1
I-1
tp9305
sS'p450,cyp'
p9306
(F1
F0.00028669724770642203
I0
I2
I-2
tp9307
sS'was,and'
p9308
(F1
F0.00028669724770642203
I0
I2
I-2
tp9309
sS'orally,administered'
p9310
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9311
sS'a,kg'
p9312
(F1
F0.00014334862385321102
I0
I1
I-1
tp9313
sS'with,depen'
p9314
(F1
F0.00014334862385321102
I1
I0
I1
tp9315
sS'reduction,for'
p9316
(F1
F0.00014334862385321102
I0
I1
I-1
tp9317
sS'e2,dmpge2'
p9318
(F1
F0.00014334862385321102
I0
I1
I-1
tp9319
sS'acetazolamide,and'
p9320
(F1
F0.00014334862385321102
I1
I0
I1
tp9321
sS'was,prolonged'
p9322
(F1
F0.00014334862385321102
I1
I0
I1
tp9323
sS'oral,injectable'
p9324
(F1
F0.00028669724770642203
I2
I0
I2
tp9325
sS'mg,daily'
p9326
(F0.052631578947368418
F0.00014334862385321102
I9
I10
I-1
tp9327
sS'hormone,and'
p9328
(F1
F0.00014334862385321102
I0
I1
I-1
tp9329
sS'h,among'
p9330
(F1
F0.00014334862385321102
I1
I0
I1
tp9331
sS'of,akathisia'
p9332
(F1
F0.00014334862385321102
I1
I0
I1
tp9333
sS'or,systolic'
p9334
(F1
F0.00014334862385321102
I0
I1
I-1
tp9335
sS'masking,symptoms'
p9336
(F1
F0.00014334862385321102
I0
I1
I-1
tp9337
sS'arava,levels'
p9338
(F1
F0.00014334862385321102
I1
I0
I1
tp9339
sS'with,crohns'
p9340
(F1
F0.00014334862385321102
I1
I0
I1
tp9341
sS'then,careful'
p9342
(F1
F0.00014334862385321102
I1
I0
I1
tp9343
sS'mg,to'
p9344
(F1
F0.00028669724770642203
I2
I0
I2
tp9345
sS'dose,pharmacokinetic'
p9346
(F1
F0.00014334862385321102
I0
I1
I-1
tp9347
sS'myopathy,during'
p9348
(F1
F0.00014334862385321102
I0
I1
I-1
tp9349
sS'in,adults'
p9350
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9351
sS'the,antihypertensive'
p9352
(F1
F0.0015768348623853212
I11
I0
I11
tp9353
sS'blockers,did'
p9354
(F1
F0.00014334862385321102
I0
I1
I-1
tp9355
sS'as,hypercalcemia'
p9356
(F1
F0.00043004587155963305
I3
I0
I3
tp9357
sS'was,admini'
p9358
(F1
F0.00014334862385321102
I1
I0
I1
tp9359
sS'phenylbutazone,causes'
p9360
(F1
F0.00014334862385321102
I1
I0
I1
tp9361
sS'and,aspecific'
p9362
(F1
F0.00014334862385321102
I0
I1
I-1
tp9363
sS'identified,potentially'
p9364
(F1
F0.00014334862385321102
I1
I0
I1
tp9365
sS'v,cmc-cys7'
p9366
(F1
F0.00014334862385321102
I0
I1
I-1
tp9367
sS'establish,a'
p9368
(F1
F0.00014334862385321102
I1
I0
I1
tp9369
sS'elevate,serum'
p9370
(F1
F0.00014334862385321102
I1
I0
I1
tp9371
sS'i,sodium'
p9372
(F1
F0.00014334862385321102
I0
I1
I-1
tp9373
sS'chloromycetin,local'
p9374
(F1
F0.00014334862385321102
I1
I0
I1
tp9375
sS'sole,method'
p9376
(F1
F0.00014334862385321102
I1
I0
I1
tp9377
sS'exists,for'
p9378
(F1
F0.00014334862385321102
I1
I0
I1
tp9379
sS'very,low'
p9380
(F1
F0.00014334862385321102
I0
I1
I-1
tp9381
sS'concentration,has'
p9382
(F0
F0
I1
I1
I0
tp9383
sS'a,marked'
p9384
(F1
F0.00028669724770642203
I2
I0
I2
tp9385
sS'serum,exposure'
p9386
(F1
F0.00014334862385321102
I1
I0
I1
tp9387
sS'transferase,it'
p9388
(F1
F0.00014334862385321102
I0
I1
I-1
tp9389
sS'also,interact'
p9390
(F1
F0.00014334862385321102
I0
I1
I-1
tp9391
sS'is,mediated'
p9392
(F1
F0.00014334862385321102
I1
I0
I1
tp9393
sS'a,one'
p9394
(F1
F0.00014334862385321102
I1
I0
I1
tp9395
sS'were,fasted'
p9396
(F1
F0.00014334862385321102
I0
I1
I-1
tp9397
sS'warfarin,multiple'
p9398
(F1
F0.00014334862385321102
I0
I1
I-1
tp9399
sS'exacerbate,rebound'
p9400
(F1
F0.00014334862385321102
I1
I0
I1
tp9401
sS'dysrhythmias,some'
p9402
(F1
F0.00014334862385321102
I1
I0
I1
tp9403
sS'on,prolonging'
p9404
(F1
F0.00014334862385321102
I1
I0
I1
tp9405
sS'including,combined'
p9406
(F1
F0.00014334862385321102
I0
I1
I-1
tp9407
sS'taking,tell'
p9408
(F1
F0.00014334862385321102
I1
I0
I1
tp9409
sS'bombesin-enhanced,peritoneal'
p9410
(F1
F0.00014334862385321102
I1
I0
I1
tp9411
sS'with,phenurone'
p9412
(F1
F0.00014334862385321102
I1
I0
I1
tp9413
sS'which,contain'
p9414
(F1
F0.00014334862385321102
I1
I0
I1
tp9415
sS'less,suppression'
p9416
(F1
F0.00014334862385321102
I0
I1
I-1
tp9417
sS'a,hour'
p9418
(F1
F0.0010034403669724771
I7
I0
I7
tp9419
sS'alter,platelet'
p9420
(F1
F0.00014334862385321102
I1
I0
I1
tp9421
sS'response,suggest'
p9422
(F1
F0.00014334862385321102
I0
I1
I-1
tp9423
sS'enzyme,and'
p9424
(F1
F0.00014334862385321102
I0
I1
I-1
tp9425
sS'certain,actions'
p9426
(F1
F0.00014334862385321102
I0
I1
I-1
tp9427
sS'be,formed'
p9428
(F1
F0.00014334862385321102
I1
I0
I1
tp9429
sS'modifying,factors'
p9430
(F1
F0.00014334862385321102
I1
I0
I1
tp9431
sS'six,volunteers'
p9432
(F1
F0.00014334862385321102
I0
I1
I-1
tp9433
sS'failed,to'
p9434
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp9435
sS'day,was'
p9436
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp9437
sS'secretion,may'
p9438
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9439
sS'increase,cmax'
p9440
(F1
F0.00014334862385321102
I1
I0
I1
tp9441
sS'a,containing'
p9442
(F1
F0.00014334862385321102
I0
I1
I-1
tp9443
sS'dicumarol,and'
p9444
(F1
F0.00028669724770642203
I0
I2
I-2
tp9445
sS'acute,ergot'
p9446
(F1
F0.00014334862385321102
I0
I1
I-1
tp9447
sS'premedicated,with'
p9448
(F1
F0.00014334862385321102
I0
I1
I-1
tp9449
sS'lipid,levels'
p9450
(F0
F0
I1
I1
I0
tp9451
sS'higher,in'
p9452
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9453
sS'parameters,auc'
p9454
(F1
F0.00014334862385321102
I1
I0
I1
tp9455
sS'interactions,to'
p9456
(F1
F0.00014334862385321102
I0
I1
I-1
tp9457
sS'for,either'
p9458
(F1
F0.0010034403669724771
I0
I7
I-7
tp9459
sS'bicarbonate,etc'
p9460
(F1
F0.00014334862385321102
I1
I0
I1
tp9461
sS'a,sharp'
p9462
(F1
F0.00014334862385321102
I1
I0
I1
tp9463
sS'give,false'
p9464
(F1
F0.00014334862385321102
I1
I0
I1
tp9465
sS'if,therapy'
p9466
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp9467
sS'of,approximately'
p9468
(F0.75
F0.0008600917431192661
I7
I1
I6
tp9469
sS'pharmacodynamic,effect'
p9470
(F1
F0.00014334862385321102
I0
I1
I-1
tp9471
sS'clinical,interest'
p9472
(F1
F0.00014334862385321102
I0
I1
I-1
tp9473
sS'cause,hypermagnesemia'
p9474
(F1
F0.00043004587155963305
I3
I0
I3
tp9475
sS'a,severe'
p9476
(F1
F0.00014334862385321102
I1
I0
I1
tp9477
sS'status,which'
p9478
(F1
F0.00014334862385321102
I0
I1
I-1
tp9479
sS'metabolized,via'
p9480
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9481
sS'to,normal'
p9482
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp9483
sS'depen,cuprimine'
p9484
(F1
F0.00014334862385321102
I1
I0
I1
tp9485
sS'prophylaxis,may'
p9486
(F1
F0.00014334862385321102
I1
I0
I1
tp9487
sS'sst,and'
p9488
(F1
F0.00014334862385321102
I0
I1
I-1
tp9489
sS'of,taking'
p9490
(F1
F0.00014334862385321102
I1
I0
I1
tp9491
sS'or,fasting'
p9492
(F1
F0.00014334862385321102
I0
I1
I-1
tp9493
sS'recommended,levetiracetam'
p9494
(F1
F0.00014334862385321102
I0
I1
I-1
tp9495
sS'increases,anion'
p9496
(F1
F0.00014334862385321102
I1
I0
I1
tp9497
sS'cells,or'
p9498
(F1
F0.00014334862385321102
I1
I0
I1
tp9499
sS'enzyme,activity'
p9500
(F1
F0.00014334862385321102
I1
I0
I1
tp9501
sS'similar,agents'
p9502
(F1
F0.00028669724770642203
I2
I0
I2
tp9503
sS'micrograms,had'
p9504
(F1
F0.00014334862385321102
I1
I0
I1
tp9505
sS'often,administered'
p9506
(F1
F0.00014334862385321102
I0
I1
I-1
tp9507
sS'the,nasal'
p9508
(F1
F0.00014334862385321102
I1
I0
I1
tp9509
sS'volunteers,it'
p9510
(F1
F0.00014334862385321102
I1
I0
I1
tp9511
sS'of,peritoneal'
p9512
(F1
F0.00014334862385321102
I0
I1
I-1
tp9513
sS'and,life-threatening'
p9514
(F1
F0.00014334862385321102
I0
I1
I-1
tp9515
sS'of,conduction'
p9516
(F1
F0.00014334862385321102
I1
I0
I1
tp9517
sS'frequently,administered'
p9518
(F1
F0.00014334862385321102
I0
I1
I-1
tp9519
sS'adverse,experiences'
p9520
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9521
sS'volunteers,in'
p9522
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9523
sS'ureidopenicillins,including'
p9524
(F1
F0.00014334862385321102
I1
I0
I1
tp9525
sS'subgroup,of'
p9526
(F1
F0.00014334862385321102
I0
I1
I-1
tp9527
sS'taking,or'
p9528
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp9529
sS'received,angiomax'
p9530
(F1
F0.00014334862385321102
I0
I1
I-1
tp9531
sS'of,dosing'
p9532
(F0
F0
I1
I1
I0
tp9533
sS'with,hemostasis'
p9534
(F1
F0.00014334862385321102
I0
I1
I-1
tp9535
sS'fluvastatin,is'
p9536
(F1
F0.00014334862385321102
I0
I1
I-1
tp9537
sS'were,recorded'
p9538
(F1
F0.00014334862385321102
I0
I1
I-1
tp9539
sS'plasma,protein-bound'
p9540
(F1
F0.00014334862385321102
I1
I0
I1
tp9541
sS'mg,causing'
p9542
(F1
F0.00014334862385321102
I0
I1
I-1
tp9543
sS'i,severe'
p9544
(F1
F0.00014334862385321102
I1
I0
I1
tp9545
sS'about,minutes'
p9546
(F1
F0.00014334862385321102
I1
I0
I1
tp9547
sS'conductivity,and'
p9548
(F1
F0.00014334862385321102
I1
I0
I1
tp9549
sS'with,very'
p9550
(F1
F0.00014334862385321102
I0
I1
I-1
tp9551
sS'strong,likelihood'
p9552
(F1
F0.00014334862385321102
I1
I0
I1
tp9553
sS'hormone,levels'
p9554
(F1
F0.00028669724770642203
I0
I2
I-2
tp9555
sS'are,used'
p9556
(F0.33333333333333331
F0.0011467889908256881
I16
I8
I8
tp9557
sS'a,complete'
p9558
(F1
F0.00014334862385321102
I1
I0
I1
tp9559
sS'in,dosage'
p9560
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9561
sS'of,this'
p9562
(F0.40000000000000002
F0.0011467889908256881
I6
I14
I-8
tp9563
sS'mac,minimum'
p9564
(F1
F0.00028669724770642203
I2
I0
I2
tp9565
sS'cause,pancreatitis'
p9566
(F1
F0.00014334862385321102
I0
I1
I-1
tp9567
sS'significance,on'
p9568
(F1
F0.00014334862385321102
I1
I0
I1
tp9569
sS'vitamin,d'
p9570
(F0.35999999999999999
F0.0012901376146788992
I17
I8
I9
tp9571
sS'i,mac'
p9572
(F1
F0.00014334862385321102
I1
I0
I1
tp9573
sS'cardiopulmonary,arrest'
p9574
(F1
F0.00014334862385321102
I0
I1
I-1
tp9575
sS'recipients,during'
p9576
(F1
F0.00014334862385321102
I0
I1
I-1
tp9577
sS'i,may'
p9578
(F1
F0.00014334862385321102
I0
I1
I-1
tp9579
sS'and,hmg-coa'
p9580
(F1
F0.00014334862385321102
I1
I0
I1
tp9581
sS'association,though'
p9582
(F1
F0.00028669724770642203
I0
I2
I-2
tp9583
sS'growth,hormone'
p9584
(F1
F0.00014334862385321102
I1
I0
I1
tp9585
sS'orally,imidazole'
p9586
(F1
F0.00014334862385321102
I1
I0
I1
tp9587
sS'aprepitant,is'
p9588
(F1
F0.00014334862385321102
I0
I1
I-1
tp9589
sS'potentiation,occurs'
p9590
(F1
F0.00014334862385321102
I0
I1
I-1
tp9591
sS'patients,receiving'
p9592
(F0.34513274336283184
F0.0055905963302752297
I76
I37
I39
tp9593
sS'increase,with'
p9594
(F0
F0
I1
I1
I0
tp9595
sS'initiated,as'
p9596
(F1
F0.00014334862385321102
I1
I0
I1
tp9597
sS'wellbutrin,and'
p9598
(F1
F0.00028669724770642203
I2
I0
I2
tp9599
sS'initiated,at'
p9600
(F1
F0.00014334862385321102
I1
I0
I1
tp9601
sS'whole-cell,recording'
p9602
(F1
F0.00014334862385321102
I0
I1
I-1
tp9603
sS'beginning,therapy'
p9604
(F1
F0.00014334862385321102
I1
I0
I1
tp9605
sS'both,are'
p9606
(F1
F0.00028669724770642203
I2
I0
I2
tp9607
sS'acute,pretreatment'
p9608
(F1
F0.00014334862385321102
I0
I1
I-1
tp9609
sS'to,see'
p9610
(F1
F0.00028669724770642203
I2
I0
I2
tp9611
sS'sodium,an'
p9612
(F1
F0.00014334862385321102
I0
I1
I-1
tp9613
sS'glutathione,use'
p9614
(F1
F0.00014334862385321102
I1
I0
I1
tp9615
sS'atropine,either'
p9616
(F1
F0.00014334862385321102
I0
I1
I-1
tp9617
sS'receptor,antagonists'
p9618
(F0.5
F0.00028669724770642203
I3
I1
I2
tp9619
sS'anticoagulant,inhibition'
p9620
(F1
F0.00014334862385321102
I0
I1
I-1
tp9621
sS'system,such'
p9622
(F1
F0.00014334862385321102
I0
I1
I-1
tp9623
sS'with,proton'
p9624
(F1
F0.00014334862385321102
I1
I0
I1
tp9625
sS'several,advantages'
p9626
(F1
F0.00014334862385321102
I0
I1
I-1
tp9627
sS'tcas,with'
p9628
(F1
F0.00043004587155963305
I3
I0
I3
tp9629
sS'max,of'
p9630
(F1
F0.00014334862385321102
I1
I0
I1
tp9631
sS'absorption,can'
p9632
(F1
F0.00014334862385321102
I1
I0
I1
tp9633
sS'to,allow'
p9634
(F1
F0.00014334862385321102
I0
I1
I-1
tp9635
sS'beta2,agonists'
p9636
(F1
F0.00014334862385321102
I1
I0
I1
tp9637
sS'actions,via'
p9638
(F1
F0.00014334862385321102
I0
I1
I-1
tp9639
sS'colestid,tablets'
p9640
(F1
F0.00014334862385321102
I1
I0
I1
tp9641
sS'max,or'
p9642
(F1
F0.00028669724770642203
I0
I2
I-2
tp9643
sS'information,for'
p9644
(F1
F0.00043004587155963305
I0
I3
I-3
tp9645
sS'decreased,antithrombin'
p9646
(F1
F0.00014334862385321102
I0
I1
I-1
tp9647
sS'eliminated,from'
p9648
(F1
F0.00014334862385321102
I1
I0
I1
tp9649
sS'lodine,or'
p9650
(F1
F0.00014334862385321102
I0
I1
I-1
tp9651
sS'carbamazepine,coadministration'
p9652
(F1
F0.00014334862385321102
I1
I0
I1
tp9653
sS'analgesics,was'
p9654
(F1
F0.00014334862385321102
I0
I1
I-1
tp9655
sS'and,carbonic'
p9656
(F1
F0.00014334862385321102
I1
I0
I1
tp9657
sS's-warfarin,with'
p9658
(F1
F0.00014334862385321102
I0
I1
I-1
tp9659
sS'attenuation,in'
p9660
(F1
F0.00014334862385321102
I0
I1
I-1
tp9661
sS'given,simultaneously'
p9662
(F1
F0.00028669724770642203
I2
I0
I2
tp9663
sS'with,amprenavir'
p9664
(F1
F0.00014334862385321102
I1
I0
I1
tp9665
sS'morphine,combination'
p9666
(F1
F0.00014334862385321102
I1
I0
I1
tp9667
sS'drug,interaction'
p9668
(F0.40000000000000002
F0.00057339449541284407
I3
I7
I-4
tp9669
sS'all,should'
p9670
(F1
F0.00014334862385321102
I1
I0
I1
tp9671
sS'h2antagonists,reduced'
p9672
(F1
F0.00014334862385321102
I1
I0
I1
tp9673
sS'and,anti-depressants'
p9674
(F1
F0.00014334862385321102
I1
I0
I1
tp9675
sS'hiv-infected,individuals'
p9676
(F1
F0.00028669724770642203
I0
I2
I-2
tp9677
sS'and,sudden'
p9678
(F1
F0.00014334862385321102
I1
I0
I1
tp9679
sS'with,elemental'
p9680
(F1
F0.00014334862385321102
I0
I1
I-1
tp9681
sS'for,management'
p9682
(F1
F0.00014334862385321102
I1
I0
I1
tp9683
sS'reaction,at'
p9684
(F1
F0.00014334862385321102
I0
I1
I-1
tp9685
sS'ie,from'
p9686
(F1
F0.00014334862385321102
I0
I1
I-1
tp9687
sS'studies,fully'
p9688
(F1
F0.00014334862385321102
I0
I1
I-1
tp9689
sS'like,mg'
p9690
(F1
F0.00014334862385321102
I0
I1
I-1
tp9691
sS'barrier,contraception'
p9692
(F1
F0.00014334862385321102
I1
I0
I1
tp9693
sS'like,mc'
p9694
(F1
F0.00014334862385321102
I0
I1
I-1
tp9695
sS'in,insufficient'
p9696
(F1
F0.00014334862385321102
I1
I0
I1
tp9697
sS'nsaids,has'
p9698
(F1
F0.00028669724770642203
I2
I0
I2
tp9699
sS'administration,regimens'
p9700
(F1
F0.00014334862385321102
I0
I1
I-1
tp9701
sS'of,proleukin'
p9702
(F0
F0
I1
I1
I0
tp9703
sS'simulect,was'
p9704
(F1
F0.00014334862385321102
I1
I0
I1
tp9705
sS'lesions,in'
p9706
(F1
F0.00014334862385321102
I1
I0
I1
tp9707
sS'duration,suggesting'
p9708
(F1
F0.00014334862385321102
I1
I0
I1
tp9709
sS'that,physicians'
p9710
(F1
F0.00014334862385321102
I0
I1
I-1
tp9711
sS'with,further'
p9712
(F1
F0.00014334862385321102
I0
I1
I-1
tp9713
sS'quantitative,approach'
p9714
(F1
F0.00014334862385321102
I0
I1
I-1
tp9715
sS'increased,dosage'
p9716
(F1
F0.00014334862385321102
I1
I0
I1
tp9717
sS'the,pharmacodynamic'
p9718
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp9719
sS'mg,separated'
p9720
(F1
F0.00014334862385321102
I1
I0
I1
tp9721
sS'm,min'
p9722
(F1
F0.00014334862385321102
I1
I0
I1
tp9723
sS'discontinues,therapy'
p9724
(F1
F0.00014334862385321102
I1
I0
I1
tp9725
sS'overload,of'
p9726
(F1
F0.00014334862385321102
I0
I1
I-1
tp9727
sS'intrathecal,on'
p9728
(F1
F0.00028669724770642203
I0
I2
I-2
tp9729
sS'separate,controlled'
p9730
(F1
F0.00014334862385321102
I0
I1
I-1
tp9731
sS'further,antihypertensive'
p9732
(F1
F0.00014334862385321102
I1
I0
I1
tp9733
sS'pediatric,patients'
p9734
(F1
F0.00014334862385321102
I1
I0
I1
tp9735
sS'biologic,half-life'
p9736
(F1
F0.00014334862385321102
I1
I0
I1
tp9737
sS'oral,administration'
p9738
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp9739
sS'between,oral'
p9740
(F1
F0.00043004587155963305
I3
I0
I3
tp9741
sS'dilantin,use'
p9742
(F1
F0.00014334862385321102
I1
I0
I1
tp9743
sS'clinical,pharmacology-pharmacokinetics'
p9744
(F1
F0.00014334862385321102
I0
I1
I-1
tp9745
sS'despite,reduction'
p9746
(F1
F0.00014334862385321102
I0
I1
I-1
tp9747
sS'norethindrone,coadministration'
p9748
(F1
F0.00014334862385321102
I1
I0
I1
tp9749
sS'a,potent'
p9750
(F0.18181818181818182
F0.00057339449541284407
I13
I9
I4
tp9751
sS'oral,sulfate'
p9752
(F1
F0.00014334862385321102
I1
I0
I1
tp9753
sS'systemic,data'
p9754
(F1
F0.00014334862385321102
I0
I1
I-1
tp9755
sS'antiplatelet,agents'
p9756
(F1
F0.00028669724770642203
I2
I0
I2
tp9757
sS'digital,extensor'
p9758
(F1
F0.00014334862385321102
I0
I1
I-1
tp9759
sS'closely,observed'
p9760
(F0
F0
I1
I1
I0
tp9761
sS'however,plasma'
p9762
(F1
F0.00014334862385321102
I0
I1
I-1
tp9763
sS'mmol,l'
p9764
(F1
F0.00014334862385321102
I0
I1
I-1
tp9765
sS'be,maximal'
p9766
(F1
F0.00014334862385321102
I1
I0
I1
tp9767
sS'of,used'
p9768
(F1
F0.00014334862385321102
I0
I1
I-1
tp9769
sS'reduced,serum'
p9770
(F1
F0.00014334862385321102
I1
I0
I1
tp9771
sS'with,depressed'
p9772
(F1
F0.00014334862385321102
I1
I0
I1
tp9773
sS'mg,bid'
p9774
(F0.18518518518518517
F0.00071674311926605509
I16
I11
I5
tp9775
sS'anhydrase,inhibitors'
p9776
(F1
F0.00043004587155963305
I3
I0
I3
tp9777
sS'convenient,administration'
p9778
(F1
F0.00014334862385321102
I0
I1
I-1
tp9779
sS'than,mug'
p9780
(F1
F0.00014334862385321102
I0
I1
I-1
tp9781
sS'inhibitor,the'
p9782
(F1
F0.00028669724770642203
I2
I0
I2
tp9783
sS'to,discontinue'
p9784
(F0
F0
I1
I1
I0
tp9785
sS'blockers,antagonists'
p9786
(F1
F0.00014334862385321102
I0
I1
I-1
tp9787
sS'when,romazicon'
p9788
(F1
F0.00014334862385321102
I0
I1
I-1
tp9789
sS'ergomar,may'
p9790
(F1
F0.00014334862385321102
I1
I0
I1
tp9791
sS'xigris,have'
p9792
(F1
F0.00014334862385321102
I0
I1
I-1
tp9793
sS'paranoid,symptoms'
p9794
(F1
F0.00014334862385321102
I1
I0
I1
tp9795
sS'hydroxide-,and'
p9796
(F1
F0.00014334862385321102
I0
I1
I-1
tp9797
sS'elemental,oz'
p9798
(F1
F0.00014334862385321102
I0
I1
I-1
tp9799
sS'maximum,block'
p9800
(F1
F0.00014334862385321102
I1
I0
I1
tp9801
sS'dopaminergic,renal'
p9802
(F1
F0.00014334862385321102
I1
I0
I1
tp9803
sS'interfering,with'
p9804
(F1
F0.00043004587155963305
I3
I0
I3
tp9805
sS'between,epa'
p9806
(F1
F0.00014334862385321102
I1
I0
I1
tp9807
sS'cmin,plasma'
p9808
(F1
F0.00028669724770642203
I0
I2
I-2
tp9809
sS'also,used'
p9810
(F1
F0.00028669724770642203
I2
I0
I2
tp9811
sS'blunts,the'
p9812
(F1
F0.00028669724770642203
I2
I0
I2
tp9813
sS'and,sometimes'
p9814
(F1
F0.00014334862385321102
I1
I0
I1
tp9815
sS's,that'
p9816
(F1
F0.00014334862385321102
I1
I0
I1
tp9817
sS'ng,x'
p9818
(F1
F0.00014334862385321102
I1
I0
I1
tp9819
sS'examine,interactions'
p9820
(F1
F0.00014334862385321102
I0
I1
I-1
tp9821
sS'was,ineffective'
p9822
(F1
F0.00014334862385321102
I0
I1
I-1
tp9823
sS'antifibrinolytic,therapies'
p9824
(F1
F0.00014334862385321102
I0
I1
I-1
tp9825
sS'of,er'
p9826
(F1
F0.00014334862385321102
I0
I1
I-1
tp9827
sS'injection,with'
p9828
(F1
F0.00028669724770642203
I2
I0
I2
tp9829
sS'to,severe'
p9830
(F1
F0.00057339449541284407
I4
I0
I4
tp9831
sS'percentage,increase'
p9832
(F1
F0.00057339449541284407
I4
I0
I4
tp9833
sS'risk,for'
p9834
(F0
F0
I1
I1
I0
tp9835
sS'mean,eight-fold'
p9836
(F1
F0.00028669724770642203
I2
I0
I2
tp9837
sS'clarithromycin,is'
p9838
(F1
F0.00014334862385321102
I1
I0
I1
tp9839
sS'were,almost'
p9840
(F1
F0.00014334862385321102
I1
I0
I1
tp9841
sS'drugs,to'
p9842
(F1
F0.00028669724770642203
I0
I2
I-2
tp9843
sS'of,positive'
p9844
(F1
F0.00028669724770642203
I0
I2
I-2
tp9845
sS'mechanism,for'
p9846
(F1
F0.00028669724770642203
I2
I0
I2
tp9847
sS'prolonged,sodation'
p9848
(F1
F0.00014334862385321102
I1
I0
I1
tp9849
sS'basis,that'
p9850
(F1
F0.00028669724770642203
I2
I0
I2
tp9851
sS'not,sufficient'
p9852
(F0
F0
I1
I1
I0
tp9853
sS'mouse,tumour'
p9854
(F1
F0.00014334862385321102
I1
I0
I1
tp9855
sS'also,conducted'
p9856
(F1
F0.00014334862385321102
I0
I1
I-1
tp9857
sS'concomitant,medication'
p9858
(F1
F0.00014334862385321102
I0
I1
I-1
tp9859
sS'mononitrate,may'
p9860
(F1
F0.00014334862385321102
I1
I0
I1
tp9861
sS'clinical,isolates'
p9862
(F1
F0.00014334862385321102
I0
I1
I-1
tp9863
sS'for,as'
p9864
(F1
F0.00014334862385321102
I0
I1
I-1
tp9865
sS'and,creatinine'
p9866
(F1
F0.00028669724770642203
I2
I0
I2
tp9867
sS'sympatholytic,medicinal'
p9868
(F1
F0.00028669724770642203
I0
I2
I-2
tp9869
sS'and,ortho-novum'
p9870
(F1
F0.00014334862385321102
I1
I0
I1
tp9871
sS'might,also'
p9872
(F1
F0.00014334862385321102
I1
I0
I1
tp9873
sS'with,regard'
p9874
(F1
F0.00043004587155963305
I0
I3
I-3
tp9875
sS'currently,exist'
p9876
(F1
F0.00014334862385321102
I0
I1
I-1
tp9877
sS'nearly,normal'
p9878
(F1
F0.00014334862385321102
I0
I1
I-1
tp9879
sS'mean,sodium'
p9880
(F1
F0.00014334862385321102
I1
I0
I1
tp9881
sS'fluoxetine,and'
p9882
(F1
F0.00028669724770642203
I0
I2
I-2
tp9883
sS'where,gastric'
p9884
(F1
F0.00028669724770642203
I2
I0
I2
tp9885
sS'of,foscavir'
p9886
(F1
F0.00028669724770642203
I2
I0
I2
tp9887
sS'system,responsible'
p9888
(F1
F0.00028669724770642203
I2
I0
I2
tp9889
sS'physiological,changes'
p9890
(F1
F0.00014334862385321102
I0
I1
I-1
tp9891
sS'although,ipratropium'
p9892
(F1
F0.00014334862385321102
I1
I0
I1
tp9893
sS'compromised,in'
p9894
(F1
F0.00014334862385321102
I1
I0
I1
tp9895
sS'initiate,therapy'
p9896
(F1
F0.00014334862385321102
I1
I0
I1
tp9897
sS'diminished,the'
p9898
(F1
F0.00014334862385321102
I1
I0
I1
tp9899
sS'formulations,containing'
p9900
(F1
F0.00043004587155963305
I3
I0
I3
tp9901
sS'naflu,compared'
p9902
(F1
F0.00014334862385321102
I0
I1
I-1
tp9903
sS'furosemide,has'
p9904
(F1
F0.00014334862385321102
I1
I0
I1
tp9905
sS'diclofenac,and'
p9906
(F1
F0.00014334862385321102
I1
I0
I1
tp9907
sS'comparison,study'
p9908
(F1
F0.00014334862385321102
I0
I1
I-1
tp9909
sS'completely,inhibited'
p9910
(F1
F0.00014334862385321102
I1
I0
I1
tp9911
sS'antihypertensive,and'
p9912
(F1
F0.00014334862385321102
I1
I0
I1
tp9913
sS'safely,with'
p9914
(F1
F0.00014334862385321102
I0
I1
I-1
tp9915
sS'daily,produced'
p9916
(F1
F0.00014334862385321102
I1
I0
I1
tp9917
sS'tablets,the'
p9918
(F1
F0.00043004587155963305
I3
I0
I3
tp9919
sS'others,are'
p9920
(F1
F0.00014334862385321102
I1
I0
I1
tp9921
sS'anti-inflammatory,concomitantly'
p9922
(F1
F0.00014334862385321102
I1
I0
I1
tp9923
sS'prolonged,hypotension'
p9924
(F1
F0.00014334862385321102
I1
I0
I1
tp9925
sS'macrolide,have'
p9926
(F1
F0.00014334862385321102
I1
I0
I1
tp9927
sS'with,mao'
p9928
(F1
F0.00057339449541284407
I4
I0
I4
tp9929
sS'in,vitamin'
p9930
(F0
F0
I1
I1
I0
tp9931
sS'marked,changes'
p9932
(F1
F0.00014334862385321102
I1
I0
I1
tp9933
sS'ml,or'
p9934
(F1
F0.00014334862385321102
I0
I1
I-1
tp9935
sS'naproxen,and'
p9936
(F1
F0.00014334862385321102
I1
I0
I1
tp9937
sS'with,may'
p9938
(F0.48148148148148145
F0.0018635321100917432
I20
I7
I13
tp9939
sS'years,have'
p9940
(F1
F0.00014334862385321102
I0
I1
I-1
tp9941
sS'ml,of'
p9942
(F1
F0.00028669724770642203
I0
I2
I-2
tp9943
sS'oxaloacetate,and'
p9944
(F1
F0.00014334862385321102
I0
I1
I-1
tp9945
sS'salt,restriction'
p9946
(F1
F0.00014334862385321102
I1
I0
I1
tp9947
sS'supplements,may'
p9948
(F0
F0
I1
I1
I0
tp9949
sS'isozyme,which'
p9950
(F1
F0.00014334862385321102
I0
I1
I-1
tp9951
sS'diamox,modifies'
p9952
(F1
F0.00014334862385321102
I1
I0
I1
tp9953
sS'temporarily,discontinued'
p9954
(F1
F0.00014334862385321102
I1
I0
I1
tp9955
sS'inflammatory,agents'
p9956
(F1
F0.00014334862385321102
I1
I0
I1
tp9957
sS'although,in'
p9958
(F1
F0.00014334862385321102
I1
I0
I1
tp9959
sS'metabolic,interactions'
p9960
(F1
F0.00014334862385321102
I0
I1
I-1
tp9961
sS'possible,interaction'
p9962
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp9963
sS'side,effects'
p9964
(F0.23809523809523808
F0.00071674311926605509
I13
I8
I5
tp9965
sS'that,concomitan'
p9966
(F1
F0.00014334862385321102
I1
I0
I1
tp9967
sS'doses,is'
p9968
(F1
F0.00014334862385321102
I1
I0
I1
tp9969
sS'doses,in'
p9970
(F1
F0.00014334862385321102
I1
I0
I1
tp9971
sS'therefore,signs'
p9972
(F1
F0.00014334862385321102
I0
I1
I-1
tp9973
sS'mg,q24h'
p9974
(F1
F0.00028669724770642203
I0
I2
I-2
tp9975
sS'patients,reveiving'
p9976
(F1
F0.00014334862385321102
I1
I0
I1
tp9977
sS'although,is'
p9978
(F1
F0.00014334862385321102
I0
I1
I-1
tp9979
sS'intracellular,ca'
p9980
(F1
F0.00014334862385321102
I1
I0
I1
tp9981
sS'although,it'
p9982
(F1
F0.00057339449541284407
I4
I0
I4
tp9983
sS'nsaids,including'
p9984
(F0
F0
I1
I1
I0
tp9985
sS'inhibitors,dasatinib'
p9986
(F1
F0.00014334862385321102
I0
I1
I-1
tp9987
sS'caused,a'
p9988
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp9989
sS'the,fluoride'
p9990
(F1
F0.00014334862385321102
I1
I0
I1
tp9991
sS'infusions,myelosuppression'
p9992
(F1
F0.00014334862385321102
I1
I0
I1
tp9993
sS'analgesia,must'
p9994
(F1
F0.00014334862385321102
I1
I0
I1
tp9995
sS'acid,anabolic'
p9996
(F1
F0.00014334862385321102
I1
I0
I1
tp9997
sS'tablets,but'
p9998
(F1
F0.00014334862385321102
I0
I1
I-1
tp9999
sS'a,non-selective'
p10000
(F1
F0.00014334862385321102
I1
I0
I1
tp10001
sS'psychiatric,patients'
p10002
(F1
F0.00014334862385321102
I1
I0
I1
tp10003
sS'displacement,between'
p10004
(F1
F0.00014334862385321102
I0
I1
I-1
tp10005
sS'meal,and'
p10006
(F1
F0.00014334862385321102
I1
I0
I1
tp10007
sS'report,suggesting'
p10008
(F1
F0.00014334862385321102
I1
I0
I1
tp10009
sS'levels,is'
p10010
(F1
F0.00028669724770642203
I2
I0
I2
tp10011
sS'levels,it'
p10012
(F1
F0.00028669724770642203
I2
I0
I2
tp10013
sS'of,similar'
p10014
(F1
F0.00057339449541284407
I4
I0
I4
tp10015
sS'levels,in'
p10016
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp10017
sS'administering,concurrently'
p10018
(F1
F0.00014334862385321102
I1
I0
I1
tp10019
sS'of,circulating'
p10020
(F1
F0.00014334862385321102
I0
I1
I-1
tp10021
sS'was,responsible'
p10022
(F1
F0.00014334862385321102
I1
I0
I1
tp10023
sS'bid,the'
p10024
(F1
F0.00028669724770642203
I2
I0
I2
tp10025
sS'other,niacin'
p10026
(F1
F0.00014334862385321102
I0
I1
I-1
tp10027
sS'therefore,the'
p10028
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp10029
sS'half-life,the'
p10030
(F1
F0.00014334862385321102
I1
I0
I1
tp10031
sS'hand,intrathecal'
p10032
(F1
F0.00014334862385321102
I1
I0
I1
tp10033
sS'inhibitor,because'
p10034
(F1
F0.00014334862385321102
I0
I1
I-1
tp10035
sS'qd,and'
p10036
(F1
F0.00028669724770642203
I2
I0
I2
tp10037
sS'auc,from'
p10038
(F1
F0.00014334862385321102
I1
I0
I1
tp10039
sS'trace,pathways'
p10040
(F1
F0.00014334862385321102
I0
I1
I-1
tp10041
sS'therophylline,a'
p10042
(F1
F0.00014334862385321102
I1
I0
I1
tp10043
sS'manic-depressive,illness'
p10044
(F1
F0.00014334862385321102
I1
I0
I1
tp10045
sS'that,gets'
p10046
(F1
F0.00014334862385321102
I1
I0
I1
tp10047
sS'vasoconstrictors,d'
p10048
(F1
F0.00014334862385321102
I1
I0
I1
tp10049
sS'frova,within'
p10050
(F1
F0.00014334862385321102
I1
I0
I1
tp10051
sS'are,antagonized'
p10052
(F1
F0.00028669724770642203
I2
I0
I2
tp10053
sS'theoretically,coadministration'
p10054
(F1
F0.00014334862385321102
I1
I0
I1
tp10055
sS'interleukin-1,antagonist'
p10056
(F1
F0.00028669724770642203
I2
I0
I2
tp10057
sS'and,how'
p10058
(F1
F0.00014334862385321102
I0
I1
I-1
tp10059
sS'urinary,retention'
p10060
(F1
F0.00028669724770642203
I2
I0
I2
tp10061
sS'used,for'
p10062
(F0
F0
I1
I1
I0
tp10063
sS'ie,timi-ii'
p10064
(F1
F0.00014334862385321102
I0
I1
I-1
tp10065
sS'strong,in'
p10066
(F1
F0.00014334862385321102
I0
I1
I-1
tp10067
sS'plasma,half-life'
p10068
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10069
sS'or,large'
p10070
(F1
F0.00014334862385321102
I0
I1
I-1
tp10071
sS'the,pesticide'
p10072
(F1
F0.00028669724770642203
I0
I2
I-2
tp10073
sS'anti-hiv,protease'
p10074
(F1
F0.00014334862385321102
I0
I1
I-1
tp10075
sS'other,with'
p10076
(F1
F0.00014334862385321102
I1
I0
I1
tp10077
sS'nanm,but'
p10078
(F1
F0.00028669724770642203
I2
I0
I2
tp10079
sS'very,rarely'
p10080
(F1
F0.00014334862385321102
I1
I0
I1
tp10081
sS'with,mhd'
p10082
(F1
F0.00014334862385321102
I0
I1
I-1
tp10083
sS'those,obtained'
p10084
(F1
F0.00043004587155963305
I3
I0
I3
tp10085
sS'or,inr'
p10086
(F1
F0.00014334862385321102
I1
I0
I1
tp10087
sS'sn38,the'
p10088
(F1
F0.00014334862385321102
I0
I1
I-1
tp10089
sS'concentration,profile'
p10090
(F1
F0.00014334862385321102
I0
I1
I-1
tp10091
sS'cerubidine,in'
p10092
(F1
F0.00014334862385321102
I1
I0
I1
tp10093
sS'in,dose'
p10094
(F0.5
F0.00028669724770642203
I3
I1
I2
tp10095
sS'and,nicotine-induced'
p10096
(F1
F0.00014334862385321102
I1
I0
I1
tp10097
sS'of,observation'
p10098
(F1
F0.00014334862385321102
I0
I1
I-1
tp10099
sS'nph,human'
p10100
(F1
F0.00028669724770642203
I0
I2
I-2
tp10101
sS'of,morning'
p10102
(F1
F0.00014334862385321102
I0
I1
I-1
tp10103
sS'level,determinations'
p10104
(F1
F0.00014334862385321102
I1
I0
I1
tp10105
sS'have,shown'
p10106
(F0.040000000000000001
F0.00014334862385321102
I13
I12
I1
tp10107
sS'a,placebo-controlled'
p10108
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10109
sS'receiving,monoamine'
p10110
(F1
F0.00057339449541284407
I4
I0
I4
tp10111
sS'decreased,renal'
p10112
(F1
F0.00014334862385321102
I1
I0
I1
tp10113
sS'acidic,conditions'
p10114
(F1
F0.00014334862385321102
I1
I0
I1
tp10115
sS'beyond,the'
p10116
(F1
F0.00014334862385321102
I1
I0
I1
tp10117
sS'mesylate,injection'
p10118
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp10119
sS'diabetics,or'
p10120
(F1
F0.00014334862385321102
I1
I0
I1
tp10121
sS'advised,against'
p10122
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10123
sS'or,consider'
p10124
(F1
F0.00014334862385321102
I1
I0
I1
tp10125
sS'placebo-controlled,phase'
p10126
(F1
F0.00014334862385321102
I0
I1
I-1
tp10127
sS'initial,dose'
p10128
(F0
F0
I2
I2
I0
tp10129
sS'transporter,as'
p10130
(F1
F0.00014334862385321102
I0
I1
I-1
tp10131
sS'is,involved'
p10132
(F1
F0.00028669724770642203
I0
I2
I-2
tp10133
sS'neuromuscular,block'
p10134
(F0.5
F0.00028669724770642203
I3
I1
I2
tp10135
sS'or,the'
p10136
(F0
F0
I16
I16
I0
tp10137
sS'drug,laboratorytest'
p10138
(F1
F0.00014334862385321102
I0
I1
I-1
tp10139
sS'among,or'
p10140
(F1
F0.00014334862385321102
I0
I1
I-1
tp10141
sS'study,maximum'
p10142
(F1
F0.00014334862385321102
I1
I0
I1
tp10143
sS'femara,with'
p10144
(F1
F0.00014334862385321102
I0
I1
I-1
tp10145
sS'proleukin,in'
p10146
(F1
F0.00014334862385321102
I0
I1
I-1
tp10147
sS'acid,higher'
p10148
(F1
F0.00014334862385321102
I1
I0
I1
tp10149
sS'general,agents'
p10150
(F1
F0.00014334862385321102
I0
I1
I-1
tp10151
sS'without,affecting'
p10152
(F1
F0.00014334862385321102
I1
I0
I1
tp10153
sS'presyncope,or'
p10154
(F1
F0.00014334862385321102
I1
I0
I1
tp10155
sS'urticaria,require'
p10156
(F1
F0.00014334862385321102
I0
I1
I-1
tp10157
sS'resistant,strains'
p10158
(F1
F0.00014334862385321102
I0
I1
I-1
tp10159
sS'a,mcg'
p10160
(F1
F0.00014334862385321102
I0
I1
I-1
tp10161
sS'and,treatment'
p10162
(F1
F0.00028669724770642203
I0
I2
I-2
tp10163
sS'experimental,toxic'
p10164
(F1
F0.00014334862385321102
I1
I0
I1
tp10165
sS'romazicon,blocks'
p10166
(F1
F0.00014334862385321102
I1
I0
I1
tp10167
sS'n-acetyl,by'
p10168
(F1
F0.00014334862385321102
I0
I1
I-1
tp10169
sS'substrate,of'
p10170
(F1
F0.00028669724770642203
I0
I2
I-2
tp10171
sS'sufficient,numbers'
p10172
(F1
F0.00014334862385321102
I0
I1
I-1
tp10173
sS'who,may'
p10174
(F1
F0.00014334862385321102
I1
I0
I1
tp10175
sS'disturbing,the'
p10176
(F1
F0.00014334862385321102
I0
I1
I-1
tp10177
sS'microm,also'
p10178
(F1
F0.00014334862385321102
I1
I0
I1
tp10179
sS'mind,in'
p10180
(F1
F0.00014334862385321102
I1
I0
I1
tp10181
sS'drugs,ethanol'
p10182
(F1
F0.00028669724770642203
I2
I0
I2
tp10183
sS'manner,when'
p10184
(F1
F0.00014334862385321102
I1
I0
I1
tp10185
sS'dietary,deficiencies'
p10186
(F1
F0.00014334862385321102
I1
I0
I1
tp10187
sS'follow,dosing'
p10188
(F1
F0.00014334862385321102
I0
I1
I-1
tp10189
sS'congeners,and'
p10190
(F1
F0.00014334862385321102
I0
I1
I-1
tp10191
sS'dose,that'
p10192
(F1
F0.00014334862385321102
I0
I1
I-1
tp10193
sS'and,increase'
p10194
(F0.5
F0.0008600917431192661
I9
I3
I6
tp10195
sS'mg2,converted'
p10196
(F1
F0.00014334862385321102
I0
I1
I-1
tp10197
sS'retention,and'
p10198
(F1
F0.00014334862385321102
I1
I0
I1
tp10199
sS'warfarin,quinolones'
p10200
(F1
F0.00043004587155963305
I3
I0
I3
tp10201
sS'notably,nondepolarizing'
p10202
(F1
F0.00014334862385321102
I1
I0
I1
tp10203
sS'gallate,showed'
p10204
(F1
F0.00014334862385321102
I0
I1
I-1
tp10205
sS'ophthalmic,and'
p10206
(F0
F0
I1
I1
I0
tp10207
sS'certain,neurologic'
p10208
(F1
F0.00014334862385321102
I0
I1
I-1
tp10209
sS'believed,that'
p10210
(F1
F0.00014334862385321102
I1
I0
I1
tp10211
sS'test,monitoring'
p10212
(F1
F0.00014334862385321102
I0
I1
I-1
tp10213
sS'prolongation,in'
p10214
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp10215
sS'cryptosporidium,parvum'
p10216
(F0
F0
I1
I1
I0
tp10217
sS'longitudinal,assessment'
p10218
(F1
F0.00014334862385321102
I0
I1
I-1
tp10219
sS'succinylcholine-induced,neuromuscular'
p10220
(F1
F0.00014334862385321102
I0
I1
I-1
tp10221
sS'after,concomitant'
p10222
(F0
F0
I1
I1
I0
tp10223
sS'over,those'
p10224
(F1
F0.00014334862385321102
I1
I0
I1
tp10225
sS'reducing,effect'
p10226
(F1
F0.00014334862385321102
I1
I0
I1
tp10227
sS'exposure,compared'
p10228
(F1
F0.00014334862385321102
I1
I0
I1
tp10229
sS'chloride,folic'
p10230
(F1
F0.00014334862385321102
I0
I1
I-1
tp10231
sS'fondaparinux,the'
p10232
(F1
F0.00014334862385321102
I0
I1
I-1
tp10233
sS'systemic,vascular'
p10234
(F1
F0.00014334862385321102
I1
I0
I1
tp10235
sS'without,to'
p10236
(F1
F0.00014334862385321102
I1
I0
I1
tp10237
sS'that,at'
p10238
(F1
F0.00028669724770642203
I2
I0
I2
tp10239
sS'fi,responding'
p10240
(F0
F0
I1
I1
I0
tp10241
sS'or,hctz'
p10242
(F1
F0.00014334862385321102
I0
I1
I-1
tp10243
sS'performed,with'
p10244
(F0
F0
I2
I2
I0
tp10245
sS'peripheral,blood'
p10246
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10247
sS'maoi,there'
p10248
(F1
F0.00014334862385321102
I1
I0
I1
tp10249
sS'virus,vaccine'
p10250
(F1
F0.00014334862385321102
I1
I0
I1
tp10251
sS'brain,levels'
p10252
(F1
F0.00014334862385321102
I0
I1
I-1
tp10253
sS'values,in'
p10254
(F0
F0
I1
I1
I0
tp10255
sS'of,prinivil'
p10256
(F0
F0
I1
I1
I0
tp10257
sS'maximum,concentration'
p10258
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp10259
sS'addition,patients'
p10260
(F1
F0.00014334862385321102
I0
I1
I-1
tp10261
sS'or,acth'
p10262
(F1
F0.00014334862385321102
I0
I1
I-1
tp10263
sS'two,doses'
p10264
(F1
F0.00014334862385321102
I0
I1
I-1
tp10265
sS'qrs,complex'
p10266
(F1
F0.00014334862385321102
I1
I0
I1
tp10267
sS'exposure,with'
p10268
(F1
F0.00014334862385321102
I1
I0
I1
tp10269
sS'teratogenic,and'
p10270
(F1
F0.00014334862385321102
I0
I1
I-1
tp10271
sS'ns,was'
p10272
(F1
F0.00028669724770642203
I2
I0
I2
tp10273
sS'can,diminish'
p10274
(F1
F0.00014334862385321102
I1
I0
I1
tp10275
sS'i,coadministration'
p10276
(F1
F0.00014334862385321102
I1
I0
I1
tp10277
sS'about,higher'
p10278
(F1
F0.00014334862385321102
I1
I0
I1
tp10279
sS'hepatoxicity,of'
p10280
(F1
F0.00014334862385321102
I1
I0
I1
tp10281
sS'expected,lasma'
p10282
(F1
F0.00014334862385321102
I0
I1
I-1
tp10283
sS'between,coadministered'
p10284
(F1
F0.00014334862385321102
I0
I1
I-1
tp10285
sS'a4,by'
p10286
(F1
F0.00014334862385321102
I0
I1
I-1
tp10287
sS'limited,sampling'
p10288
(F1
F0.00014334862385321102
I0
I1
I-1
tp10289
sS'attenuated,by'
p10290
(F1
F0.00014334862385321102
I0
I1
I-1
tp10291
sS'nitroglycerin,dynacirc'
p10292
(F1
F0.00014334862385321102
I0
I1
I-1
tp10293
sS'dysfunction,by'
p10294
(F1
F0.00014334862385321102
I1
I0
I1
tp10295
sS'of,crohn'
p10296
(F1
F0.00014334862385321102
I0
I1
I-1
tp10297
sS'nsaid,such'
p10298
(F1
F0.00014334862385321102
I0
I1
I-1
tp10299
sS'synthetase,inhibitors'
p10300
(F1
F0.00014334862385321102
I0
I1
I-1
tp10301
sS'ssris,seriraline'
p10302
(F1
F0.00014334862385321102
I0
I1
I-1
tp10303
sS'streptozotocin-induced,diabetic'
p10304
(F1
F0.00014334862385321102
I0
I1
I-1
tp10305
sS'high,to'
p10306
(F1
F0.00014334862385321102
I1
I0
I1
tp10307
sS'type,revealed'
p10308
(F1
F0.00014334862385321102
I0
I1
I-1
tp10309
sS'for,that'
p10310
(F0
F0
I1
I1
I0
tp10311
sS'tambocor,unless'
p10312
(F1
F0.00014334862385321102
I1
I0
I1
tp10313
sS'complicated,or'
p10314
(F1
F0.00014334862385321102
I0
I1
I-1
tp10315
sS'metabolite,mhd'
p10316
(F1
F0.00014334862385321102
I0
I1
I-1
tp10317
sS'if,argatroban'
p10318
(F1
F0.00014334862385321102
I0
I1
I-1
tp10319
sS'although,concomitant'
p10320
(F1
F0.00014334862385321102
I1
I0
I1
tp10321
sS'diminished,effect'
p10322
(F1
F0.00014334862385321102
I0
I1
I-1
tp10323
sS'sudden,withdrawal'
p10324
(F1
F0.00014334862385321102
I1
I0
I1
tp10325
sS'listed,below'
p10326
(F1
F0.00014334862385321102
I1
I0
I1
tp10327
sS'least,hours'
p10328
(F1
F0.0015768348623853212
I11
I0
I11
tp10329
sS'inhibitor,therapy'
p10330
(F1
F0.00014334862385321102
I1
I0
I1
tp10331
sS'potent,of'
p10332
(F1
F0.00014334862385321102
I0
I1
I-1
tp10333
sS'both,free'
p10334
(F1
F0.00014334862385321102
I1
I0
I1
tp10335
sS'with,hcl'
p10336
(F1
F0.00014334862385321102
I1
I0
I1
tp10337
sS'can,directly'
p10338
(F1
F0.00014334862385321102
I1
I0
I1
tp10339
sS'discriminate,between'
p10340
(F1
F0.00014334862385321102
I0
I1
I-1
tp10341
sS'd,dosage'
p10342
(F1
F0.00057339449541284407
I4
I0
I4
tp10343
sS'active,therapy'
p10344
(F1
F0.00014334862385321102
I0
I1
I-1
tp10345
sS'in,ms'
p10346
(F0
F0
I1
I1
I0
tp10347
sS'adjustments,made'
p10348
(F1
F0.00028669724770642203
I0
I2
I-2
tp10349
sS'time,beyond'
p10350
(F1
F0.00014334862385321102
I1
I0
I1
tp10351
sS'regard,to'
p10352
(F1
F0.00043004587155963305
I0
I3
I-3
tp10353
sS'aed,s'
p10354
(F1
F0.00014334862385321102
I1
I0
I1
tp10355
sS'nonsteroidal,has'
p10356
(F1
F0.00014334862385321102
I1
I0
I1
tp10357
sS'that,nsaids'
p10358
(F1
F0.0015768348623853212
I11
I0
I11
tp10359
sS'hypokalemia,that'
p10360
(F1
F0.00014334862385321102
I1
I0
I1
tp10361
sS'because,false'
p10362
(F1
F0.00014334862385321102
I0
I1
I-1
tp10363
sS'considering,that'
p10364
(F1
F0.00014334862385321102
I0
I1
I-1
tp10365
sS'hours,subsequent'
p10366
(F1
F0.00014334862385321102
I0
I1
I-1
tp10367
sS'adjusting,or'
p10368
(F1
F0.00014334862385321102
I1
I0
I1
tp10369
sS'with,colorectal'
p10370
(F1
F0.00014334862385321102
I0
I1
I-1
tp10371
sS'cause,significant'
p10372
(F1
F0.00014334862385321102
I1
I0
I1
tp10373
sS'on,has'
p10374
(F1
F0.00014334862385321102
I1
I0
I1
tp10375
sS'are,being'
p10376
(F1
F0.00028669724770642203
I2
I0
I2
tp10377
sS'pressure,of'
p10378
(F1
F0.00043004587155963305
I3
I0
I3
tp10379
sS'time,ratio'
p10380
(F1
F0.00014334862385321102
I0
I1
I-1
tp10381
sS'displace,less'
p10382
(F1
F0.00014334862385321102
I1
I0
I1
tp10383
sS'a,relationship'
p10384
(F1
F0.00043004587155963305
I3
I0
I3
tp10385
sS'exposure,from'
p10386
(F1
F0.00014334862385321102
I0
I1
I-1
tp10387
sS'potassium,supplements'
p10388
(F1
F0.00028669724770642203
I2
I0
I2
tp10389
sS'an,attempt'
p10390
(F1
F0.00014334862385321102
I1
I0
I1
tp10391
sS'reuptake,thus'
p10392
(F1
F0.00028669724770642203
I2
I0
I2
tp10393
sS'and,dopa'
p10394
(F1
F0.00014334862385321102
I0
I1
I-1
tp10395
sS'confusion,and'
p10396
(F1
F0.00014334862385321102
I1
I0
I1
tp10397
sS'higher,concentrations'
p10398
(F1
F0.00028669724770642203
I2
I0
I2
tp10399
sS'human,immunodeficiency'
p10400
(F1
F0.00028669724770642203
I0
I2
I-2
tp10401
sS'lower,affinities'
p10402
(F1
F0.00014334862385321102
I0
I1
I-1
tp10403
sS'a,nonabsorbable'
p10404
(F1
F0.00014334862385321102
I1
I0
I1
tp10405
sS'anesthetized,with'
p10406
(F1
F0.00014334862385321102
I1
I0
I1
tp10407
sS'administered,once'
p10408
(F0
F0
I2
I2
I0
tp10409
sS'powder,for'
p10410
(F1
F0.0010034403669724771
I7
I0
I7
tp10411
sS'while,studies'
p10412
(F1
F0.00014334862385321102
I1
I0
I1
tp10413
sS'time,following'
p10414
(F1
F0.00028669724770642203
I0
I2
I-2
tp10415
sS'toxicity,associated'
p10416
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10417
sS'concomitant,and'
p10418
(F0
F0
I2
I2
I0
tp10419
sS'possibly,have'
p10420
(F1
F0.00014334862385321102
I0
I1
I-1
tp10421
sS'episodes,may'
p10422
(F1
F0.00014334862385321102
I1
I0
I1
tp10423
sS'the,amount'
p10424
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp10425
sS'stomach,may'
p10426
(F1
F0.00014334862385321102
I1
I0
I1
tp10427
sS'observed,when'
p10428
(F0.1111111111111111
F0.00028669724770642203
I10
I8
I2
tp10429
sS'potentially,result'
p10430
(F1
F0.00014334862385321102
I1
I0
I1
tp10431
sS'type,caution'
p10432
(F1
F0.00014334862385321102
I1
I0
I1
tp10433
sS'if,the'
p10434
(F0.52941176470588236
F0.0012901376146788992
I13
I4
I9
tp10435
sS'currently,available'
p10436
(F1
F0.00028669724770642203
I0
I2
I-2
tp10437
sS'in,anti-inflammatory'
p10438
(F1
F0.00014334862385321102
I1
I0
I1
tp10439
sS'and,cell'
p10440
(F1
F0.00014334862385321102
I0
I1
I-1
tp10441
sS'of,carbimazole'
p10442
(F1
F0.00014334862385321102
I1
I0
I1
tp10443
sS'the,chick'
p10444
(F1
F0.00014334862385321102
I0
I1
I-1
tp10445
sS'could,theoretically'
p10446
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10447
sS'n,under'
p10448
(F1
F0.00014334862385321102
I0
I1
I-1
tp10449
sS'aucs,m'
p10450
(F1
F0.00014334862385321102
I1
I0
I1
tp10451
sS'dosage,of'
p10452
(F0.25
F0.00057339449541284407
I10
I6
I4
tp10453
sS'dosage,on'
p10454
(F1
F0.00028669724770642203
I2
I0
I2
tp10455
sS'as,beta-adrenergic'
p10456
(F1
F0.00014334862385321102
I0
I1
I-1
tp10457
sS'dose,ranging'
p10458
(F1
F0.00014334862385321102
I1
I0
I1
tp10459
sS'supplements,containing'
p10460
(F1
F0.00014334862385321102
I1
I0
I1
tp10461
sS'evaluated,to'
p10462
(F1
F0.00014334862385321102
I0
I1
I-1
tp10463
sS'inr,days'
p10464
(F1
F0.00014334862385321102
I1
I0
I1
tp10465
sS'alert,for'
p10466
(F1
F0.00028669724770642203
I0
I2
I-2
tp10467
sS'oral,form'
p10468
(F1
F0.00014334862385321102
I1
I0
I1
tp10469
sS'should,consider'
p10470
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10471
sS'treatments,with'
p10472
(F1
F0.00014334862385321102
I0
I1
I-1
tp10473
sS'aluminum-containing,administered'
p10474
(F1
F0.00014334862385321102
I1
I0
I1
tp10475
sS'other,significant'
p10476
(F1
F0.00014334862385321102
I0
I1
I-1
tp10477
sS'in,advanced'
p10478
(F1
F0.00014334862385321102
I1
I0
I1
tp10479
sS'bretylium,tosylate'
p10480
(F1
F0.00014334862385321102
I0
I1
I-1
tp10481
sS'vitro,sodium'
p10482
(F1
F0.00014334862385321102
I0
I1
I-1
tp10483
sS'orally,as'
p10484
(F1
F0.00028669724770642203
I2
I0
I2
tp10485
sS'blocker,on'
p10486
(F1
F0.00014334862385321102
I0
I1
I-1
tp10487
sS'cyp3a4,therefore'
p10488
(F1
F0.00014334862385321102
I0
I1
I-1
tp10489
sS'blocker,of'
p10490
(F1
F0.00014334862385321102
I0
I1
I-1
tp10491
sS'angiotensin,ii'
p10492
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp10493
sS'and,h2'
p10494
(F0
F0
I1
I1
I0
tp10495
sS'and,charcoal'
p10496
(F1
F0.00014334862385321102
I1
I0
I1
tp10497
sS'and,viracept'
p10498
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10499
sS'the,orally'
p10500
(F1
F0.00014334862385321102
I1
I0
I1
tp10501
sS'when,hydrochloride'
p10502
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10503
sS'coadministration,of'
p10504
(F0.109375
F0.0020068807339449542
I71
I57
I14
tp10505
sS'initial,and'
p10506
(F1
F0.00014334862385321102
I1
I0
I1
tp10507
sS'with,n'
p10508
(F1
F0.00028669724770642203
I0
I2
I-2
tp10509
sS'desbutyl,levobupivacaine'
p10510
(F1
F0.00014334862385321102
I0
I1
I-1
tp10511
sS'with,c'
p10512
(F1
F0.00014334862385321102
I0
I1
I-1
tp10513
sS'with,a'
p10514
(F0.19354838709677419
F0.0017201834862385322
I37
I25
I12
tp10515
sS'antacid,when'
p10516
(F1
F0.00014334862385321102
I1
I0
I1
tp10517
sS'with,g'
p10518
(F1
F0.00014334862385321102
I0
I1
I-1
tp10519
sS'with,d'
p10520
(F1
F0.00014334862385321102
I1
I0
I1
tp10521
sS'decreases,effectiveness'
p10522
(F1
F0.00014334862385321102
I1
I0
I1
tp10523
sS'mucocutaneous,and'
p10524
(F1
F0.00014334862385321102
I0
I1
I-1
tp10525
sS'isocarboxazid,may'
p10526
(F1
F0.00014334862385321102
I0
I1
I-1
tp10527
sS'and,azoles'
p10528
(F1
F0.00014334862385321102
I0
I1
I-1
tp10529
sS'the,light'
p10530
(F1
F0.00014334862385321102
I1
I0
I1
tp10531
sS'very,high'
p10532
(F0
F0
I1
I1
I0
tp10533
sS'avoided,and'
p10534
(F1
F0.00014334862385321102
I1
I0
I1
tp10535
sS'and,increasing'
p10536
(F1
F0.00028669724770642203
I2
I0
I2
tp10537
sS'they,modify'
p10538
(F1
F0.00014334862385321102
I1
I0
I1
tp10539
sS'increase,metabolism'
p10540
(F1
F0.00014334862385321102
I0
I1
I-1
tp10541
sS'short-acting,adrenergic'
p10542
(F1
F0.00014334862385321102
I0
I1
I-1
tp10543
sS'review,was'
p10544
(F1
F0.00014334862385321102
I0
I1
I-1
tp10545
sS'ontario,the'
p10546
(F1
F0.00014334862385321102
I0
I1
I-1
tp10547
sS'potentially,toxic'
p10548
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp10549
sS'drugs,are'
p10550
(F1
F0.00014334862385321102
I0
I1
I-1
tp10551
sS'subsequently,treated'
p10552
(F1
F0.00014334862385321102
I1
I0
I1
tp10553
sS'hcl,to'
p10554
(F1
F0.00014334862385321102
I1
I0
I1
tp10555
sS'both,in'
p10556
(F1
F0.00043004587155963305
I0
I3
I-3
tp10557
sS'antitumor,effectiveness'
p10558
(F1
F0.00014334862385321102
I1
I0
I1
tp10559
sS'cause,hypercalcemia'
p10560
(F1
F0.00014334862385321102
I1
I0
I1
tp10561
sS'when,sustiva'
p10562
(F0
F0
I1
I1
I0
tp10563
sS'closely,monitored'
p10564
(F1
F0.0012901376146788992
I9
I0
I9
tp10565
sS'concomitantly,renal'
p10566
(F1
F0.00014334862385321102
I1
I0
I1
tp10567
sS'post-myocardial,infarction'
p10568
(F1
F0.00014334862385321102
I0
I1
I-1
tp10569
sS'broad-spectrum,augmentin'
p10570
(F1
F0.00014334862385321102
I1
I0
I1
tp10571
sS'their,dose'
p10572
(F0.5
F0.00028669724770642203
I3
I1
I2
tp10573
sS'a,together'
p10574
(F1
F0.00014334862385321102
I1
I0
I1
tp10575
sS'during,multiple-dose'
p10576
(F1
F0.00014334862385321102
I0
I1
I-1
tp10577
sS'the,hypotensive'
p10578
(F0.88235294117647056
F0.0021502293577981653
I16
I1
I15
tp10579
sS'of,actinic'
p10580
(F1
F0.00014334862385321102
I1
I0
I1
tp10581
sS'previously,effective'
p10582
(F1
F0.00014334862385321102
I1
I0
I1
tp10583
sS'of,any'
p10584
(F1
F0.00071674311926605509
I0
I5
I-5
tp10585
sS'affected,the'
p10586
(F1
F0.00014334862385321102
I1
I0
I1
tp10587
sS'microdosed,progestin-containing'
p10588
(F1
F0.00014334862385321102
I1
I0
I1
tp10589
sS'of,and'
p10590
(F0.36974789915966388
F0.01261467889908257
I163
I75
I88
tp10591
sS'rifampin,reduced'
p10592
(F1
F0.00014334862385321102
I1
I0
I1
tp10593
sS'single,mg'
p10594
(F0.071428571428571425
F0.00028669724770642203
I15
I13
I2
tp10595
sS'exhibit,an'
p10596
(F1
F0.00028669724770642203
I2
I0
I2
tp10597
sS'or,administered'
p10598
(F1
F0.00014334862385321102
I1
I0
I1
tp10599
sS'be,cautiously'
p10600
(F1
F0.00014334862385321102
I1
I0
I1
tp10601
sS'oil,interferes'
p10602
(F1
F0.00014334862385321102
I1
I0
I1
tp10603
sS'myocardium,may'
p10604
(F1
F0.00014334862385321102
I1
I0
I1
tp10605
sS'rats,that'
p10606
(F1
F0.00014334862385321102
I0
I1
I-1
tp10607
sS'absorption,mean'
p10608
(F1
F0.00014334862385321102
I1
I0
I1
tp10609
sS'spectrum,of'
p10610
(F1
F0.00028669724770642203
I0
I2
I-2
tp10611
sS'either,by'
p10612
(F1
F0.00014334862385321102
I0
I1
I-1
tp10613
sS'a,multiple-dose'
p10614
(F0
F0
I1
I1
I0
tp10615
sS'acid,with'
p10616
(F1
F0.00014334862385321102
I1
I0
I1
tp10617
sS'demonstrates,that'
p10618
(F1
F0.00014334862385321102
I1
I0
I1
tp10619
sS'may,still'
p10620
(F1
F0.00014334862385321102
I1
I0
I1
tp10621
sS'possibly,other'
p10622
(F1
F0.00057339449541284407
I4
I0
I4
tp10623
sS'rates,in'
p10624
(F1
F0.00014334862385321102
I0
I1
I-1
tp10625
sS'either,be'
p10626
(F1
F0.00014334862385321102
I1
I0
I1
tp10627
sS'was,performed'
p10628
(F1
F0.00028669724770642203
I0
I2
I-2
tp10629
sS'study,indicates'
p10630
(F1
F0.00014334862385321102
I0
I1
I-1
tp10631
sS'interaction,which'
p10632
(F1
F0.00014334862385321102
I1
I0
I1
tp10633
sS'symptoms,suggestive'
p10634
(F1
F0.00014334862385321102
I1
I0
I1
tp10635
sS'with,mefloquine'
p10636
(F1
F0.00014334862385321102
I1
I0
I1
tp10637
sS'bleeding,and'
p10638
(F1
F0.00028669724770642203
I2
I0
I2
tp10639
sS'tubular,excretion'
p10640
(F1
F0.00014334862385321102
I1
I0
I1
tp10641
sS'benign,prostatic'
p10642
(F1
F0.00014334862385321102
I0
I1
I-1
tp10643
sS'metabolism,produced'
p10644
(F1
F0.00014334862385321102
I1
I0
I1
tp10645
sS'sensitivity,to'
p10646
(F1
F0.00014334862385321102
I1
I0
I1
tp10647
sS'are,limited'
p10648
(F1
F0.00014334862385321102
I1
I0
I1
tp10649
sS'bid,in'
p10650
(F1
F0.00014334862385321102
I1
I0
I1
tp10651
sS'sequential,high'
p10652
(F1
F0.00014334862385321102
I1
I0
I1
tp10653
sS'coronary,artery'
p10654
(F0
F0
I1
I1
I0
tp10655
sS'naproxen,coadministration'
p10656
(F1
F0.00014334862385321102
I1
I0
I1
tp10657
sS'among,subjects'
p10658
(F1
F0.00014334862385321102
I0
I1
I-1
tp10659
sS'dry,mouth'
p10660
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp10661
sS'lymphoma,hiv-nhl'
p10662
(F1
F0.00014334862385321102
I0
I1
I-1
tp10663
sS'limited,therefore'
p10664
(F1
F0.00014334862385321102
I1
I0
I1
tp10665
sS'to,interfere'
p10666
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp10667
sS'steadystate,trough'
p10668
(F1
F0.00014334862385321102
I0
I1
I-1
tp10669
sS'tc,had'
p10670
(F1
F0.00014334862385321102
I0
I1
I-1
tp10671
sS'on,replacement'
p10672
(F1
F0.00014334862385321102
I1
I0
I1
tp10673
sS'inducer,mg'
p10674
(F1
F0.00014334862385321102
I1
I0
I1
tp10675
sS'an,emergency'
p10676
(F1
F0.00014334862385321102
I1
I0
I1
tp10677
sS'approximately,in'
p10678
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp10679
sS'on,that'
p10680
(F1
F0.00014334862385321102
I0
I1
I-1
tp10681
sS'of,isosorbide'
p10682
(F1
F0.00028669724770642203
I2
I0
I2
tp10683
sS'on,than'
p10684
(F1
F0.00014334862385321102
I1
I0
I1
tp10685
sS'a,previously'
p10686
(F1
F0.00043004587155963305
I3
I0
I3
tp10687
sS'ss,of'
p10688
(F1
F0.00028669724770642203
I2
I0
I2
tp10689
sS'cyp,a4'
p10690
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp10691
sS'corticosteroids,systemic'
p10692
(F1
F0.00014334862385321102
I0
I1
I-1
tp10693
sS'inhibitor,pi'
p10694
(F1
F0.00014334862385321102
I0
I1
I-1
tp10695
sS'nyha,class'
p10696
(F1
F0.00014334862385321102
I0
I1
I-1
tp10697
sS'hypotension,patients'
p10698
(F1
F0.00043004587155963305
I3
I0
I3
tp10699
sS'concentrations,greater'
p10700
(F1
F0.00014334862385321102
I0
I1
I-1
tp10701
sS'including,anafranil'
p10702
(F1
F0.00014334862385321102
I0
I1
I-1
tp10703
sS'racemic,celexa'
p10704
(F1
F0.00014334862385321102
I1
I0
I1
tp10705
sS'mononuclear,cells'
p10706
(F1
F0.00028669724770642203
I2
I0
I2
tp10707
sS'requires,maintaining'
p10708
(F1
F0.00014334862385321102
I0
I1
I-1
tp10709
sS'that,necessitated'
p10710
(F1
F0.00014334862385321102
I1
I0
I1
tp10711
sS'at,recovery'
p10712
(F1
F0.00014334862385321102
I1
I0
I1
tp10713
sS'a,pronounced'
p10714
(F1
F0.00014334862385321102
I1
I0
I1
tp10715
sS'sodium,are'
p10716
(F1
F0.00014334862385321102
I0
I1
I-1
tp10717
sS'urine,levels'
p10718
(F1
F0.00014334862385321102
I1
I0
I1
tp10719
sS'to,slow'
p10720
(F1
F0.00014334862385321102
I1
I0
I1
tp10721
sS'of,infection'
p10722
(F1
F0.00014334862385321102
I1
I0
I1
tp10723
sS'anti-inflammatory,agent'
p10724
(F1
F0.00028669724770642203
I2
I0
I2
tp10725
sS'secondary,to'
p10726
(F1
F0.00057339449541284407
I4
I0
I4
tp10727
sS'estradiol,concentrations'
p10728
(F1
F0.00014334862385321102
I0
I1
I-1
tp10729
sS'actions,certain'
p10730
(F1
F0.00014334862385321102
I1
I0
I1
tp10731
sS'by,equilibrium'
p10732
(F1
F0.00014334862385321102
I0
I1
I-1
tp10733
sS'any,antineoplastic'
p10734
(F1
F0.00014334862385321102
I0
I1
I-1
tp10735
sS'another,class'
p10736
(F1
F0.00014334862385321102
I1
I0
I1
tp10737
sS'time,must'
p10738
(F1
F0.00014334862385321102
I1
I0
I1
tp10739
sS'either,humira'
p10740
(F1
F0.00014334862385321102
I0
I1
I-1
tp10741
sS'including,ether'
p10742
(F1
F0.00014334862385321102
I1
I0
I1
tp10743
sS'effects,kemstro'
p10744
(F1
F0.00014334862385321102
I0
I1
I-1
tp10745
sS'serum,antidepressant'
p10746
(F1
F0.00014334862385321102
I1
I0
I1
tp10747
sS'may,diminish'
p10748
(F1
F0.0014334862385321102
I10
I0
I10
tp10749
sS'both,together'
p10750
(F1
F0.00028669724770642203
I2
I0
I2
tp10751
sS'the,changes'
p10752
(F1
F0.00043004587155963305
I0
I3
I-3
tp10753
sS'locomotor,activity'
p10754
(F1
F0.00014334862385321102
I0
I1
I-1
tp10755
sS'toxicity,bronchospasm'
p10756
(F1
F0.00014334862385321102
I1
I0
I1
tp10757
sS'activity,towards'
p10758
(F1
F0.00014334862385321102
I1
I0
I1
tp10759
sS'cyp2c9,substrate'
p10760
(F1
F0.00043004587155963305
I3
I0
I3
tp10761
sS'of,resulting'
p10762
(F0.81818181818181823
F0.0025802752293577983
I20
I2
I18
tp10763
sS'salicylate,and'
p10764
(F1
F0.00014334862385321102
I1
I0
I1
tp10765
sS'spinal,endorphinergic'
p10766
(F1
F0.00014334862385321102
I0
I1
I-1
tp10767
sS'early,as'
p10768
(F1
F0.00014334862385321102
I1
I0
I1
tp10769
sS'by,acidifying'
p10770
(F1
F0.00028669724770642203
I2
I0
I2
tp10771
sS'potentially,leading'
p10772
(F1
F0.00014334862385321102
I1
I0
I1
tp10773
sS'unchanged,the'
p10774
(F1
F0.00014334862385321102
I0
I1
I-1
tp10775
sS'for,bleeding'
p10776
(F1
F0.00014334862385321102
I0
I1
I-1
tp10777
sS'psychoactive,or'
p10778
(F1
F0.00014334862385321102
I1
I0
I1
tp10779
sS'grams,three'
p10780
(F1
F0.00014334862385321102
I1
I0
I1
tp10781
sS'decreased,even'
p10782
(F1
F0.00014334862385321102
I1
I0
I1
tp10783
sS'activity,and'
p10784
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp10785
sS'to,protein'
p10786
(F1
F0.00014334862385321102
I1
I0
I1
tp10787
sS'marrow,toxicity'
p10788
(F1
F0.00014334862385321102
I0
I1
I-1
tp10789
sS'oral,diabetes'
p10790
(F1
F0.00014334862385321102
I1
I0
I1
tp10791
sS'and,volume'
p10792
(F1
F0.00014334862385321102
I1
I0
I1
tp10793
sS'that,inhibit'
p10794
(F0.33333333333333331
F0.0008600917431192661
I6
I12
I-6
tp10795
sS'avoided,except'
p10796
(F1
F0.00014334862385321102
I1
I0
I1
tp10797
sS'well,tolerated'
p10798
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp10799
sS'hypotension,induced'
p10800
(F1
F0.00014334862385321102
I1
I0
I1
tp10801
sS'and,like'
p10802
(F1
F0.00014334862385321102
I0
I1
I-1
tp10803
sS'patient,has'
p10804
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp10805
sS'ethyl,mao'
p10806
(F1
F0.00014334862385321102
I1
I0
I1
tp10807
sS'lipid,peroxidation'
p10808
(F1
F0.00014334862385321102
I1
I0
I1
tp10809
sS'to,days'
p10810
(F0
F0
I3
I3
I0
tp10811
sS'humira,has'
p10812
(F1
F0.00028669724770642203
I0
I2
I-2
tp10813
sS'nondepolarizing,possible'
p10814
(F1
F0.00028669724770642203
I0
I2
I-2
tp10815
sS'were,dry'
p10816
(F1
F0.00014334862385321102
I0
I1
I-1
tp10817
sS'inositol,trisphosphate'
p10818
(F1
F0.00014334862385321102
I0
I1
I-1
tp10819
sS'discernible,changes'
p10820
(F1
F0.00014334862385321102
I0
I1
I-1
tp10821
sS'all,when'
p10822
(F1
F0.00014334862385321102
I1
I0
I1
tp10823
sS'resulting,increase'
p10824
(F1
F0.00014334862385321102
I0
I1
I-1
tp10825
sS'manufacturer,or'
p10826
(F1
F0.00014334862385321102
I0
I1
I-1
tp10827
sS'to,below'
p10828
(F1
F0.00014334862385321102
I1
I0
I1
tp10829
sS'brovana,has'
p10830
(F1
F0.00014334862385321102
I0
I1
I-1
tp10831
sS'temperature,and'
p10832
(F1
F0.00014334862385321102
I1
I0
I1
tp10833
sS'combined,use'
p10834
(F1
F0.0012901376146788992
I9
I0
I9
tp10835
sS'pathways,which'
p10836
(F1
F0.00014334862385321102
I0
I1
I-1
tp10837
sS'increased,from'
p10838
(F0
F0
I1
I1
I0
tp10839
sS'fortovase,as'
p10840
(F1
F0.00014334862385321102
I0
I1
I-1
tp10841
sS'tests,interactions'
p10842
(F1
F0.00014334862385321102
I0
I1
I-1
tp10843
sS'the,dosing'
p10844
(F1
F0.00014334862385321102
I1
I0
I1
tp10845
sS'in,their'
p10846
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp10847
sS'r-value,of'
p10848
(F1
F0.00028669724770642203
I0
I2
I-2
tp10849
sS'pharmacological,actions'
p10850
(F1
F0.00014334862385321102
I0
I1
I-1
tp10851
sS'volunteers,exjade'
p10852
(F1
F0.00014334862385321102
I0
I1
I-1
tp10853
sS'separate,studies'
p10854
(F1
F0.00028669724770642203
I0
I2
I-2
tp10855
sS'inhibition,inhibition'
p10856
(F1
F0.00014334862385321102
I0
I1
I-1
tp10857
sS'who,require'
p10858
(F1
F0.00028669724770642203
I0
I2
I-2
tp10859
sS'recently,instituted'
p10860
(F1
F0.00057339449541284407
I4
I0
I4
tp10861
sS'double,strength'
p10862
(F1
F0.00014334862385321102
I0
I1
I-1
tp10863
sS'zebeta,resulting'
p10864
(F1
F0.00014334862385321102
I1
I0
I1
tp10865
sS'a,decrease'
p10866
(F0.85185185185185186
F0.0032970183486238534
I25
I2
I23
tp10867
sS'rr,had'
p10868
(F1
F0.00014334862385321102
I0
I1
I-1
tp10869
sS'notably,systemic'
p10870
(F1
F0.00014334862385321102
I0
I1
I-1
tp10871
sS'which,suggests'
p10872
(F1
F0.00014334862385321102
I1
I0
I1
tp10873
sS'be,carefully'
p10874
(F0.5
F0.0008600917431192661
I9
I3
I6
tp10875
sS'novolog,should'
p10876
(F1
F0.00043004587155963305
I0
I3
I-3
tp10877
sS'of,cyp3a4'
p10878
(F0.052631578947368418
F0.00014334862385321102
I9
I10
I-1
tp10879
sS'maoi,such'
p10880
(F1
F0.00014334862385321102
I0
I1
I-1
tp10881
sS'of,rheumatoid'
p10882
(F1
F0.00014334862385321102
I0
I1
I-1
tp10883
sS'contains,a'
p10884
(F1
F0.00014334862385321102
I0
I1
I-1
tp10885
sS'racemic,mg'
p10886
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp10887
sS'in,those'
p10888
(F1
F0.00057339449541284407
I4
I0
I4
tp10889
sS'be,free'
p10890
(F1
F0.00014334862385321102
I0
I1
I-1
tp10891
sS'of,agranulocytosis'
p10892
(F1
F0.00014334862385321102
I0
I1
I-1
tp10893
sS'in,erythro-fluorocitrate'
p10894
(F1
F0.00014334862385321102
I0
I1
I-1
tp10895
sS'interaction,or'
p10896
(F1
F0.00014334862385321102
I1
I0
I1
tp10897
sS'interaction,of'
p10898
(F0
F0
I8
I8
I0
tp10899
sS'trials,and'
p10900
(F1
F0.00014334862385321102
I0
I1
I-1
tp10901
sS'bid,decreased'
p10902
(F1
F0.00014334862385321102
I1
I0
I1
tp10903
sS'interaction,on'
p10904
(F0
F0
I1
I1
I0
tp10905
sS'methods,toxi-lab'
p10906
(F1
F0.00014334862385321102
I0
I1
I-1
tp10907
sS'children,who'
p10908
(F1
F0.00014334862385321102
I0
I1
I-1
tp10909
sS'secretory,effect'
p10910
(F1
F0.00014334862385321102
I1
I0
I1
tp10911
sS'sprycel,dose'
p10912
(F1
F0.00014334862385321102
I0
I1
I-1
tp10913
sS'cns-depressant,should'
p10914
(F1
F0.00014334862385321102
I1
I0
I1
tp10915
sS'acid,depakene'
p10916
(F1
F0.00014334862385321102
I0
I1
I-1
tp10917
sS'be,more'
p10918
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10919
sS'days,with'
p10920
(F0
F0
I4
I4
I0
tp10921
sS'higher,absolute'
p10922
(F1
F0.00014334862385321102
I0
I1
I-1
tp10923
sS'regimens,consisted'
p10924
(F1
F0.00014334862385321102
I0
I1
I-1
tp10925
sS'therapeutic,index'
p10926
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp10927
sS'may,sterilize'
p10928
(F1
F0.00014334862385321102
I0
I1
I-1
tp10929
sS'naltrexone,trexan'
p10930
(F1
F0.00014334862385321102
I0
I1
I-1
tp10931
sS'any,statistically'
p10932
(F1
F0.00014334862385321102
I0
I1
I-1
tp10933
sS'on,plasma'
p10934
(F0.84615384615384615
F0.0015768348623853212
I1
I12
I-11
tp10935
sS'cgs,nor'
p10936
(F1
F0.00014334862385321102
I1
I0
I1
tp10937
sS'the,duodenum'
p10938
(F1
F0.00014334862385321102
I0
I1
I-1
tp10939
sS'concurrently,did'
p10940
(F1
F0.00014334862385321102
I0
I1
I-1
tp10941
sS'long-sedation,time'
p10942
(F1
F0.00014334862385321102
I0
I1
I-1
tp10943
sS'after,discontinuation'
p10944
(F1
F0.00014334862385321102
I0
I1
I-1
tp10945
sS'of,rats'
p10946
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10947
sS'x,ed95'
p10948
(F1
F0.00014334862385321102
I1
I0
I1
tp10949
sS'a,number'
p10950
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp10951
sS'inhibitor,mg'
p10952
(F1
F0.00028669724770642203
I2
I0
I2
tp10953
sS'in,functional'
p10954
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp10955
sS'capsules,is'
p10956
(F1
F0.00014334862385321102
I1
I0
I1
tp10957
sS'although,beta-adrenergic'
p10958
(F1
F0.00014334862385321102
I1
I0
I1
tp10959
sS'from,prefrontal'
p10960
(F1
F0.00014334862385321102
I0
I1
I-1
tp10961
sS'rats,prepared'
p10962
(F1
F0.00014334862385321102
I0
I1
I-1
tp10963
sS'fr,responding'
p10964
(F1
F0.00014334862385321102
I1
I0
I1
tp10965
sS'but,serious'
p10966
(F1
F0.00014334862385321102
I1
I0
I1
tp10967
sS'cyp,d6'
p10968
(F0
F0
I1
I1
I0
tp10969
sS'albendazole,mg'
p10970
(F1
F0.00014334862385321102
I1
I0
I1
tp10971
sS'cimetidine,co-administration'
p10972
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp10973
sS'increases,both'
p10974
(F1
F0.00014334862385321102
I1
I0
I1
tp10975
sS'tablets,injection'
p10976
(F1
F0.00014334862385321102
I1
I0
I1
tp10977
sS'for,characterization'
p10978
(F1
F0.00014334862385321102
I0
I1
I-1
tp10979
sS'after,stopping'
p10980
(F1
F0.00043004587155963305
I3
I0
I3
tp10981
sS'that,cyp1a2'
p10982
(F1
F0.00014334862385321102
I1
I0
I1
tp10983
sS'enbrel,and'
p10984
(F1
F0.00028669724770642203
I2
I0
I2
tp10985
sS'kidney,which'
p10986
(F1
F0.00014334862385321102
I0
I1
I-1
tp10987
sS'but,presumably'
p10988
(F1
F0.00014334862385321102
I0
I1
I-1
tp10989
sS'authors,examined'
p10990
(F1
F0.00014334862385321102
I0
I1
I-1
tp10991
sS'the,liver'
p10992
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp10993
sS'for,older'
p10994
(F1
F0.00014334862385321102
I0
I1
I-1
tp10995
sS'treated,patients'
p10996
(F1
F0.00014334862385321102
I0
I1
I-1
tp10997
sS'begins,a'
p10998
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10999
sS'the,actions'
p11000
(F1
F0.00014334862385321102
I1
I0
I1
tp11001
sS'aprepitant,was'
p11002
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp11003
sS'significant,inhibitors'
p11004
(F1
F0.00014334862385321102
I0
I1
I-1
tp11005
sS'auc,values'
p11006
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp11007
sS'agents,having'
p11008
(F0
F0
I1
I1
I0
tp11009
sS'antagonists,the'
p11010
(F0
F0
I1
I1
I0
tp11011
sS'of,fluorescence'
p11012
(F1
F0.00014334862385321102
I0
I1
I-1
tp11013
sS'separate,study'
p11014
(F1
F0.00014334862385321102
I0
I1
I-1
tp11015
sS'days,was'
p11016
(F1
F0.00028669724770642203
I2
I0
I2
tp11017
sS'maois,or'
p11018
(F1
F0.00014334862385321102
I1
I0
I1
tp11019
sS'dexamethasone,at'
p11020
(F1
F0.00014334862385321102
I1
I0
I1
tp11021
sS'toxicity,than'
p11022
(F1
F0.00014334862385321102
I1
I0
I1
tp11023
sS'deleterious,interactions'
p11024
(F1
F0.00014334862385321102
I0
I1
I-1
tp11025
sS'time,after'
p11026
(F1
F0.00014334862385321102
I1
I0
I1
tp11027
sS'edema,it'
p11028
(F1
F0.00014334862385321102
I1
I0
I1
tp11029
sS'antagonists,are'
p11030
(F1
F0.00014334862385321102
I1
I0
I1
tp11031
sS'close,medical'
p11032
(F1
F0.00014334862385321102
I1
I0
I1
tp11033
sS'ci,when'
p11034
(F1
F0.00014334862385321102
I1
I0
I1
tp11035
sS'erythromycin,use'
p11036
(F1
F0.00014334862385321102
I1
I0
I1
tp11037
sS'plenaxis,should'
p11038
(F1
F0.00014334862385321102
I0
I1
I-1
tp11039
sS'hcl,alternatives'
p11040
(F1
F0.00014334862385321102
I1
I0
I1
tp11041
sS'is,discontinued'
p11042
(F1
F0.00014334862385321102
I1
I0
I1
tp11043
sS'lovastatin,therapy'
p11044
(F1
F0.00014334862385321102
I0
I1
I-1
tp11045
sS'the,electrocardiographic'
p11046
(F1
F0.00028669724770642203
I0
I2
I-2
tp11047
sS'viracept,resulted'
p11048
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp11049
sS'sgpt,alt'
p11050
(F1
F0.00028669724770642203
I2
I0
I2
tp11051
sS'assessed,using'
p11052
(F1
F0.00014334862385321102
I1
I0
I1
tp11053
sS'concurrently,and'
p11054
(F0
F0
I1
I1
I0
tp11055
sS'alterations,in'
p11056
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp11057
sS'metabolized,in'
p11058
(F1
F0.00014334862385321102
I0
I1
I-1
tp11059
sS'of,enterococcus'
p11060
(F1
F0.00028669724770642203
I0
I2
I-2
tp11061
sS'of,exogenously'
p11062
(F1
F0.00014334862385321102
I0
I1
I-1
tp11063
sS'the,hydrophilic'
p11064
(F1
F0.00014334862385321102
I0
I1
I-1
tp11065
sS'mainly,via'
p11066
(F1
F0.00014334862385321102
I0
I1
I-1
tp11067
sS'multiple-dose,administration'
p11068
(F0
F0
I1
I1
I0
tp11069
sS'certain,that'
p11070
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp11071
sS'digoxin,a'
p11072
(F1
F0.00014334862385321102
I0
I1
I-1
tp11073
sS'suggest,the'
p11074
(F1
F0.00014334862385321102
I0
I1
I-1
tp11075
sS'unless,clinically'
p11076
(F1
F0.00014334862385321102
I1
I0
I1
tp11077
sS'the,antiedematous'
p11078
(F1
F0.00014334862385321102
I1
I0
I1
tp11079
sS'breakthrough,symptoms'
p11080
(F1
F0.00014334862385321102
I0
I1
I-1
tp11081
sS'products,such'
p11082
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp11083
sS'enzyme,prolongs'
p11084
(F1
F0.00014334862385321102
I0
I1
I-1
tp11085
sS'with,would'
p11086
(F0
F0
I1
I1
I0
tp11087
sS'accuracy,in'
p11088
(F1
F0.00014334862385321102
I1
I0
I1
tp11089
sS'considered,when'
p11090
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp11091
sS'cholinergic,blockade'
p11092
(F1
F0.00014334862385321102
I1
I0
I1
tp11093
sS'intoxication,prior'
p11094
(F1
F0.00014334862385321102
I1
I0
I1
tp11095
sS'mcg,im'
p11096
(F0
F0
I1
I1
I0
tp11097
sS'of,cyp2a6'
p11098
(F1
F0.00014334862385321102
I1
I0
I1
tp11099
sS'require,close'
p11100
(F1
F0.00014334862385321102
I1
I0
I1
tp11101
sS'in,etodolac-treated'
p11102
(F1
F0.00014334862385321102
I1
I0
I1
tp11103
sS'occurrence,has'
p11104
(F1
F0.00014334862385321102
I1
I0
I1
tp11105
sS'phenytoin,steady'
p11106
(F1
F0.00014334862385321102
I1
I0
I1
tp11107
sS'short-acting,because'
p11108
(F1
F0.00014334862385321102
I1
I0
I1
tp11109
sS'placebo-controlled,crossover'
p11110
(F1
F0.00014334862385321102
I1
I0
I1
tp11111
sS'augmented,by'
p11112
(F1
F0.00043004587155963305
I3
I0
I3
tp11113
sS'receiving,concurrent'
p11114
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp11115
sS'control,and'
p11116
(F0
F0
I1
I1
I0
tp11117
sS'reduced,cmax'
p11118
(F1
F0.00028669724770642203
I2
I0
I2
tp11119
sS'not,include'
p11120
(F1
F0.00014334862385321102
I0
I1
I-1
tp11121
sS'ml,for'
p11122
(F1
F0.00014334862385321102
I0
I1
I-1
tp11123
sS'exception,of'
p11124
(F1
F0.00028669724770642203
I0
I2
I-2
tp11125
sS'by,alpha-adrenergic'
p11126
(F1
F0.00014334862385321102
I1
I0
I1
tp11127
sS'combined,administration'
p11128
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp11129
sS'the,homocysteine'
p11130
(F1
F0.00014334862385321102
I0
I1
I-1
tp11131
sS'including,were'
p11132
(F0
F0
I1
I1
I0
tp11133
sS'of,sonata'
p11134
(F0
F0
I3
I3
I0
tp11135
sS'all,with'
p11136
(F1
F0.00014334862385321102
I1
I0
I1
tp11137
sS'ii,to'
p11138
(F1
F0.00028669724770642203
I0
I2
I-2
tp11139
sS'in,average'
p11140
(F1
F0.00014334862385321102
I1
I0
I1
tp11141
sS'to,insure'
p11142
(F1
F0.00014334862385321102
I1
I0
I1
tp11143
sS'of,deficit'
p11144
(F1
F0.00028669724770642203
I0
I2
I-2
tp11145
sS'mg,dose'
p11146
(F0.071428571428571425
F0.00028669724770642203
I15
I13
I2
tp11147
sS'be,necessary'
p11148
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp11149
sS'adefovir,dipivoxil'
p11150
(F1
F0.00014334862385321102
I0
I1
I-1
tp11151
sS'with,standard'
p11152
(F1
F0.00028669724770642203
I0
I2
I-2
tp11153
sS'were,reported'
p11154
(F0
F0
I2
I2
I0
tp11155
sS'that,produce'
p11156
(F1
F0.00043004587155963305
I3
I0
I3
tp11157
sS'other,nephrotoxic'
p11158
(F1
F0.00014334862385321102
I0
I1
I-1
tp11159
sS'oral,physiological'
p11160
(F1
F0.00014334862385321102
I0
I1
I-1
tp11161
sS'rats,with'
p11162
(F1
F0.00028669724770642203
I2
I0
I2
tp11163
sS'who,inactivate'
p11164
(F1
F0.00014334862385321102
I1
I0
I1
tp11165
sS'the,measurable'
p11166
(F1
F0.00014334862385321102
I1
I0
I1
tp11167
sS'imipramine,and'
p11168
(F1
F0.00014334862385321102
I0
I1
I-1
tp11169
sS'have,significant'
p11170
(F1
F0.00014334862385321102
I1
I0
I1
tp11171
sS'over,pi-based'
p11172
(F1
F0.00014334862385321102
I0
I1
I-1
tp11173
sS'is,likely'
p11174
(F1
F0.0010034403669724771
I7
I0
I7
tp11175
sS'affect,plasma'
p11176
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp11177
sS'acid,did'
p11178
(F1
F0.00014334862385321102
I0
I1
I-1
tp11179
sS'synthetic,analogue'
p11180
(F1
F0.00014334862385321102
I0
I1
I-1
tp11181
sS'cause,the'
p11182
(F1
F0.00014334862385321102
I1
I0
I1
tp11183
sS'sulfate,tests'
p11184
(F1
F0.00014334862385321102
I0
I1
I-1
tp11185
sS'avoided,unless'
p11186
(F1
F0.00028669724770642203
I2
I0
I2
tp11187
sS'protein,the'
p11188
(F1
F0.00014334862385321102
I1
I0
I1
tp11189
sS'example,when'
p11190
(F1
F0.00014334862385321102
I1
I0
I1
tp11191
sS'consuming,while'
p11192
(F1
F0.00014334862385321102
I1
I0
I1
tp11193
sS'before,starting'
p11194
(F1
F0.00043004587155963305
I3
I0
I3
tp11195
sS'aprepitant,with'
p11196
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp11197
sS'unchanged,accounts'
p11198
(F1
F0.00014334862385321102
I0
I1
I-1
tp11199
sS'for,these'
p11200
(F1
F0.00014334862385321102
I1
I0
I1
tp11201
sS'agonist,can'
p11202
(F1
F0.00014334862385321102
I1
I0
I1
tp11203
sS'precipitation,procedure'
p11204
(F1
F0.00014334862385321102
I0
I1
I-1
tp11205
sS'twitch,from'
p11206
(F1
F0.00014334862385321102
I1
I0
I1
tp11207
sS'gain,and'
p11208
(F0
F0
I1
I1
I0
tp11209
sS'the,vascular'
p11210
(F1
F0.00014334862385321102
I1
I0
I1
tp11211
sS'tysabri,clearance'
p11212
(F1
F0.00014334862385321102
I1
I0
I1
tp11213
sS'significant,decrease'
p11214
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp11215
sS'celebrex,did'
p11216
(F1
F0.00014334862385321102
I0
I1
I-1
tp11217
sS'as,three'
p11218
(F1
F0.00014334862385321102
I1
I0
I1
tp11219
sS'adl,and'
p11220
(F1
F0.00014334862385321102
I0
I1
I-1
tp11221
sS'unlikely,for'
p11222
(F1
F0.00014334862385321102
I0
I1
I-1
tp11223
sS'with,can'
p11224
(F1
F0.00028669724770642203
I2
I0
I2
tp11225
sS'two-second,increase'
p11226
(F1
F0.00014334862385321102
I1
I0
I1
tp11227
sS'analyzed,in'
p11228
(F1
F0.00014334862385321102
I0
I1
I-1
tp11229
sS'reduced,higher'
p11230
(F1
F0.00043004587155963305
I0
I3
I-3
tp11231
sS'taking,when'
p11232
(F0
F0
I1
I1
I0
tp11233
sS'nimbex,are'
p11234
(F1
F0.00014334862385321102
I1
I0
I1
tp11235
sS'supplements,can'
p11236
(F1
F0.00028669724770642203
I0
I2
I-2
tp11237
sS'reversed,by'
p11238
(F1
F0.00014334862385321102
I1
I0
I1
tp11239
sS'stopped,during'
p11240
(F1
F0.00014334862385321102
I1
I0
I1
tp11241
sS'serum,and'
p11242
(F0
F0
I3
I3
I0
tp11243
sS'neuronal,reuptake'
p11244
(F1
F0.00014334862385321102
I0
I1
I-1
tp11245
sS'immediately,before'
p11246
(F1
F0.00014334862385321102
I0
I1
I-1
tp11247
sS'primidone,no'
p11248
(F1
F0.00014334862385321102
I0
I1
I-1
tp11249
sS'medications,like'
p11250
(F1
F0.00043004587155963305
I3
I0
I3
tp11251
sS'specific,regulation'
p11252
(F1
F0.00014334862385321102
I0
I1
I-1
tp11253
sS'decreased,urinary'
p11254
(F1
F0.00014334862385321102
I0
I1
I-1
tp11255
sS'used,alone'
p11256
(F1
F0.00028669724770642203
I2
I0
I2
tp11257
sS'use,lowest'
p11258
(F1
F0.00014334862385321102
I1
I0
I1
tp11259
sS'literature,provides'
p11260
(F1
F0.00014334862385321102
I0
I1
I-1
tp11261
sS'specific,studies'
p11262
(F0
F0
I1
I1
I0
tp11263
sS'infections,caused'
p11264
(F1
F0.00014334862385321102
I0
I1
I-1
tp11265
sS'alter,plasma'
p11266
(F1
F0.00014334862385321102
I1
I0
I1
tp11267
sS'less,than'
p11268
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp11269
sS'antipsychotic,such'
p11270
(F1
F0.00014334862385321102
I0
I1
I-1
tp11271
sS'estrogens,including'
p11272
(F1
F0.00014334862385321102
I1
I0
I1
tp11273
sS'in,fat'
p11274
(F1
F0.00014334862385321102
I0
I1
I-1
tp11275
sS'worsened,by'
p11276
(F1
F0.00014334862385321102
I1
I0
I1
tp11277
sS'if,concomitant'
p11278
(F1
F0.00057339449541284407
I4
I0
I4
tp11279
sS'g,per'
p11280
(F1
F0.00014334862385321102
I0
I1
I-1
tp11281
sS'responsive,to'
p11282
(F1
F0.00014334862385321102
I0
I1
I-1
tp11283
sS'study,concomitant'
p11284
(F0
F0
I1
I1
I0
tp11285
sS'of,time'
p11286
(F0
F0
I1
I1
I0
tp11287
sS'implications,for'
p11288
(F1
F0.00014334862385321102
I0
I1
I-1
tp11289
sS'in,qtc'
p11290
(F1
F0.00014334862385321102
I1
I0
I1
tp11291
sS'will,affect'
p11292
(F1
F0.00014334862385321102
I1
I0
I1
tp11293
sS'to,elevate'
p11294
(F1
F0.00014334862385321102
I1
I0
I1
tp11295
sS'translocating,action'
p11296
(F1
F0.00014334862385321102
I0
I1
I-1
tp11297
sS'which,in'
p11298
(F1
F0.00014334862385321102
I1
I0
I1
tp11299
sS'large,well'
p11300
(F1
F0.00014334862385321102
I0
I1
I-1
tp11301
sS'lower,end'
p11302
(F1
F0.00014334862385321102
I1
I0
I1
tp11303
sS'tablets,administration'
p11304
(F1
F0.00014334862385321102
I1
I0
I1
tp11305
sS'ventricular,arrhythmias'
p11306
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp11307
sS'sodium,injection'
p11308
(F1
F0.00014334862385321102
I0
I1
I-1
tp11309
sS'sulfate,sulfate'
p11310
(F0
F0
I1
I1
I0
tp11311
sS'as,imitrex'
p11312
(F1
F0.00014334862385321102
I1
I0
I1
tp11313
sS'measures,have'
p11314
(F1
F0.00014334862385321102
I0
I1
I-1
tp11315
sS'which,is'
p11316
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp11317
sS'dexamethasone,and'
p11318
(F1
F0.00014334862385321102
I1
I0
I1
tp11319
sS'anticoagulation,levels'
p11320
(F1
F0.00014334862385321102
I1
I0
I1
tp11321
sS'with,orencia'
p11322
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp11323
sS'than,to'
p11324
(F1
F0.00014334862385321102
I0
I1
I-1
tp11325
sS'valproate,the'
p11326
(F1
F0.00014334862385321102
I1
I0
I1
tp11327
sS'as,early'
p11328
(F1
F0.00014334862385321102
I1
I0
I1
tp11329
sS'arachidonate-,or'
p11330
(F1
F0.00014334862385321102
I0
I1
I-1
tp11331
sS'cyp2d6,such'
p11332
(F0
F0
I1
I1
I0
tp11333
sS'mind,when'
p11334
(F1
F0.00028669724770642203
I0
I2
I-2
tp11335
sS'undesirable,involving'
p11336
(F1
F0.00028669724770642203
I0
I2
I-2
tp11337
sS'approximately,half'
p11338
(F1
F0.00028669724770642203
I0
I2
I-2
tp11339
sS'placental,vessels'
p11340
(F0
F0
I1
I1
I0
tp11341
sS'nephrotoxic,medications'
p11342
(F1
F0.00014334862385321102
I0
I1
I-1
tp11343
sS'psychopathology,rating'
p11344
(F1
F0.00014334862385321102
I0
I1
I-1
tp11345
sS'control,by'
p11346
(F1
F0.00028669724770642203
I2
I0
I2
tp11347
sS'use,short-acting'
p11348
(F1
F0.00014334862385321102
I1
I0
I1
tp11349
sS'hydatid,cyst'
p11350
(F1
F0.00014334862385321102
I1
I0
I1
tp11351
sS'the,sensitivity'
p11352
(F1
F0.00014334862385321102
I0
I1
I-1
tp11353
sS'inhibit,alfenta'
p11354
(F1
F0.00014334862385321102
I1
I0
I1
tp11355
sS'rifampin,significantly'
p11356
(F1
F0.00014334862385321102
I1
I0
I1
tp11357
sS'study,healthy'
p11358
(F1
F0.00028669724770642203
I0
I2
I-2
tp11359
sS'with,co-administration'
p11360
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp11361
sS'products,could'
p11362
(F1
F0.00014334862385321102
I1
I0
I1
tp11363
sS'lipolytic,activity'
p11364
(F1
F0.00014334862385321102
I1
I0
I1
tp11365
sS'initiated,in'
p11366
(F1
F0.00071674311926605509
I5
I0
I5
tp11367
sS'were,neither'
p11368
(F1
F0.00014334862385321102
I1
I0
I1
tp11369
sS'bleeding,parameters'
p11370
(F1
F0.00014334862385321102
I1
I0
I1
tp11371
sS'parenteral,forms'
p11372
(F1
F0.00014334862385321102
I0
I1
I-1
tp11373
sS'cimetidine,inhibits'
p11374
(F1
F0.00028669724770642203
I2
I0
I2
tp11375
sS'mixed,agonist'
p11376
(F0
F0
I1
I1
I0
tp11377
sS'be,minimized'
p11378
(F1
F0.0008600917431192661
I6
I0
I6
tp11379
sS'fetal,development'
p11380
(F1
F0.00014334862385321102
I0
I1
I-1
tp11381
sS'to,dictate'
p11382
(F1
F0.00014334862385321102
I1
I0
I1
tp11383
sS'under,a'
p11384
(F1
F0.00014334862385321102
I0
I1
I-1
tp11385
sS'and,produced'
p11386
(F0
F0
I1
I1
I0
tp11387
sS'load,constitutes'
p11388
(F1
F0.00014334862385321102
I0
I1
I-1
tp11389
sS'brevibloc,esmolol'
p11390
(F1
F0.00014334862385321102
I0
I1
I-1
tp11391
sS'with,amphotericin'
p11392
(F1
F0.00028669724770642203
I2
I0
I2
tp11393
sS'in,blood'
p11394
(F1
F0.00057339449541284407
I4
I0
I4
tp11395
sS'molecular,level'
p11396
(F1
F0.00014334862385321102
I0
I1
I-1
tp11397
sS'produced,transient'
p11398
(F1
F0.00014334862385321102
I0
I1
I-1
tp11399
sS'and,produces'
p11400
(F1
F0.00014334862385321102
I1
I0
I1
tp11401
sS'be,safely'
p11402
(F1
F0.00043004587155963305
I0
I3
I-3
tp11403
sS'possible,rapid'
p11404
(F1
F0.00014334862385321102
I1
I0
I1
tp11405
sS'following,medicines'
p11406
(F1
F0.00014334862385321102
I1
I0
I1
tp11407
sS'rate-decreasing,effects'
p11408
(F1
F0.00014334862385321102
I1
I0
I1
tp11409
sS'halved,for'
p11410
(F1
F0.00014334862385321102
I1
I0
I1
tp11411
sS'a,multi-day'
p11412
(F1
F0.00014334862385321102
I1
I0
I1
tp11413
sS'mediated,responses'
p11414
(F1
F0.00014334862385321102
I0
I1
I-1
tp11415
sS'of,uricosuric'
p11416
(F1
F0.00028669724770642203
I2
I0
I2
tp11417
sS'ssris,have'
p11418
(F0.5
F0.00028669724770642203
I3
I1
I2
tp11419
sS'poc,in'
p11420
(F1
F0.00014334862385321102
I0
I1
I-1
tp11421
sS'oral,dose'
p11422
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp11423
sS'or,by'
p11424
(F1
F0.00014334862385321102
I0
I1
I-1
tp11425
sS'and,formulations'
p11426
(F1
F0.00014334862385321102
I1
I0
I1
tp11427
sS'or,be'
p11428
(F1
F0.00014334862385321102
I0
I1
I-1
tp11429
sS'the,was'
p11430
(F1
F0.00014334862385321102
I0
I1
I-1
tp11431
sS'hydroalcoholic,solutions'
p11432
(F1
F0.00014334862385321102
I0
I1
I-1
tp11433
sS'be,monitored'
p11434
(F0.55000000000000004
F0.0031536697247706424
I31
I9
I22
tp11435
sS'v,oral'
p11436
(F1
F0.00014334862385321102
I1
I0
I1
tp11437
sS'instead,of'
p11438
(F1
F0.00014334862385321102
I1
I0
I1
tp11439
sS'required,infusion'
p11440
(F1
F0.00014334862385321102
I1
I0
I1
tp11441
sS'palytoxin-induced,contraction'
p11442
(F1
F0.00014334862385321102
I0
I1
I-1
tp11443
sS'oral,may'
p11444
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp11445
sS'therapy,compliance'
p11446
(F1
F0.00014334862385321102
I0
I1
I-1
tp11447
sS'first,year'
p11448
(F1
F0.00014334862385321102
I0
I1
I-1
tp11449
sS'with,similar'
p11450
(F0
F0
I1
I1
I0
tp11451
sS'including,nalidixic'
p11452
(F1
F0.00014334862385321102
I1
I0
I1
tp11453
sS'cyp3a4,activity'
p11454
(F0
F0
I5
I5
I0
tp11455
sS'adjustments,of'
p11456
(F0
F0
I2
I2
I0
tp11457
sS'toxicity,characterized'
p11458
(F0
F0
I2
I2
I0
tp11459
sS'in,combinations'
p11460
(F1
F0.00014334862385321102
I0
I1
I-1
tp11461
sS'cancidas,did'
p11462
(F1
F0.00014334862385321102
I0
I1
I-1
tp11463
sS'oral,containing'
p11464
(F0
F0
I2
I2
I0
tp11465
sS'not,extend'
p11466
(F1
F0.00014334862385321102
I0
I1
I-1
tp11467
sS'lesions,as'
p11468
(F1
F0.00014334862385321102
I1
I0
I1
tp11469
sS'beta-lactam,including'
p11470
(F1
F0.00014334862385321102
I1
I0
I1
tp11471
sS'hind,limb'
p11472
(F1
F0.00014334862385321102
I0
I1
I-1
tp11473
sS'the,toxic'
p11474
(F0.5
F0.00028669724770642203
I3
I1
I2
tp11475
sS'cyp3a,the'
p11476
(F1
F0.00014334862385321102
I0
I1
I-1
tp11477
sS'if,dosage'
p11478
(F1
F0.00014334862385321102
I1
I0
I1
tp11479
sS'hydroxylation,of'
p11480
(F1
F0.00014334862385321102
I1
I0
I1
tp11481
sS'serious,infections'
p11482
(F1
F0.00071674311926605509
I5
I0
I5
tp11483
sS'patients,before'
p11484
(F1
F0.00014334862385321102
I0
I1
I-1
tp11485
sS'results,of'
p11486
(F0.090909090909090912
F0.00014334862385321102
I5
I6
I-1
tp11487
sS'or,statistically'
p11488
(F1
F0.00014334862385321102
I0
I1
I-1
tp11489
sS'have,secondary'
p11490
(F1
F0.00014334862385321102
I1
I0
I1
tp11491
sS'tricyclic,in'
p11492
(F1
F0.00014334862385321102
I1
I0
I1
tp11493
sS'a,subset'
p11494
(F1
F0.00014334862385321102
I0
I1
I-1
tp11495
sS'mean,cmax'
p11496
(F1
F0.0011467889908256881
I8
I0
I8
tp11497
sS'repeated,oral'
p11498
(F1
F0.00014334862385321102
I0
I1
I-1
tp11499
sS'taking,while'
p11500
(F1
F0.00028669724770642203
I2
I0
I2
tp11501
sS'bepridil,and'
p11502
(F1
F0.00014334862385321102
I0
I1
I-1
tp11503
sS'the,permeation'
p11504
(F1
F0.00014334862385321102
I0
I1
I-1
tp11505
sS'suggested,with'
p11506
(F1
F0.00043004587155963305
I0
I3
I-3
tp11507
sS'that,iressa'
p11508
(F1
F0.00014334862385321102
I1
I0
I1
tp11509
sS'increased,levels'
p11510
(F0.5
F0.00028669724770642203
I3
I1
I2
tp11511
sS'b,were'
p11512
(F1
F0.00014334862385321102
I0
I1
I-1
tp11513
sS'organophosphate,and'
p11514
(F1
F0.00014334862385321102
I1
I0
I1
tp11515
sS'brief,psychiatric'
p11516
(F1
F0.00014334862385321102
I1
I0
I1
tp11517
sS'medicines,central'
p11518
(F1
F0.00014334862385321102
I1
I0
I1
tp11519
sS'a,tnf'
p11520
(F1
F0.00014334862385321102
I1
I0
I1
tp11521
sS'dyspnea,concomitant'
p11522
(F1
F0.00014334862385321102
I1
I0
I1
tp11523
sS'by,fold'
p11524
(F1
F0.0008600917431192661
I6
I0
I6
tp11525
sS'and,upon'
p11526
(F1
F0.00014334862385321102
I1
I0
I1
tp11527
sS'whom,aminoglycoside'
p11528
(F1
F0.00014334862385321102
I1
I0
I1
tp11529
sS'reaction,in'
p11530
(F1
F0.00014334862385321102
I0
I1
I-1
tp11531
sS'particularly,c-17'
p11532
(F1
F0.00014334862385321102
I0
I1
I-1
tp11533
sS'absorption,but'
p11534
(F1
F0.00014334862385321102
I0
I1
I-1
tp11535
sS'with,wthionamide'
p11536
(F1
F0.00014334862385321102
I0
I1
I-1
tp11537
sS'impairs,metabolism'
p11538
(F1
F0.00014334862385321102
I0
I1
I-1
tp11539
sS'or,azoles'
p11540
(F1
F0.00014334862385321102
I0
I1
I-1
tp11541
sS'those,seen'
p11542
(F1
F0.00043004587155963305
I3
I0
I3
tp11543
sS'forms,of'
p11544
(F1
F0.00028669724770642203
I0
I2
I-2
tp11545
sS'the,weekly'
p11546
(F1
F0.00014334862385321102
I1
I0
I1
tp11547
sS'agents,pharmacokinetic'
p11548
(F1
F0.00014334862385321102
I0
I1
I-1
tp11549
sS'tricyclic,have'
p11550
(F1
F0.00028669724770642203
I2
I0
I2
tp11551
sS'profound,sedation'
p11552
(F1
F0.00014334862385321102
I1
I0
I1
tp11553
sS'preferably,the'
p11554
(F1
F0.00014334862385321102
I0
I1
I-1
tp11555
sS'test,interactions'
p11556
(F0.77777777777777779
F0.0010034403669724771
I1
I8
I-7
tp11557
sS'kidney,function'
p11558
(F1
F0.00014334862385321102
I0
I1
I-1
tp11559
sS'rr,on'
p11560
(F1
F0.00014334862385321102
I0
I1
I-1
tp11561
sS'progestin-only,oral'
p11562
(F1
F0.00014334862385321102
I0
I1
I-1
tp11563
sS'may,be'
p11564
(F0.36764705882352944
F0.0071674311926605509
I93
I43
I50
tp11565
sS'others,or'
p11566
(F1
F0.00028669724770642203
I0
I2
I-2
tp11567
sS'diabetics,who'
p11568
(F1
F0.00014334862385321102
I0
I1
I-1
tp11569
sS'intensity,uniformity'
p11570
(F1
F0.00014334862385321102
I0
I1
I-1
tp11571
sS'been,demonstrated'
p11572
(F0.25
F0.00028669724770642203
I5
I3
I2
tp11573
sS'the,metabolite'
p11574
(F1
F0.00014334862385321102
I0
I1
I-1
tp11575
sS'daily,treatment'
p11576
(F1
F0.00014334862385321102
I0
I1
I-1
tp11577
sS'intraperitoneally,ip'
p11578
(F1
F0.00014334862385321102
I1
I0
I1
tp11579
sS'drug-induced,renal'
p11580
(F1
F0.00014334862385321102
I0
I1
I-1
tp11581
sS'on,renal'
p11582
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp11583
sS'unknown,and'
p11584
(F1
F0.00014334862385321102
I1
I0
I1
tp11585
sS'additionally,brevibloc'
p11586
(F1
F0.00014334862385321102
I1
I0
I1
tp11587
sS'digitalis,immediate'
p11588
(F1
F0.00014334862385321102
I1
I0
I1
tp11589
sS'were,considerably'
p11590
(F1
F0.00014334862385321102
I1
I0
I1
tp11591
sS'probable,benefits'
p11592
(F1
F0.00014334862385321102
I1
I0
I1
tp11593
sS'enhance,s'
p11594
(F1
F0.00014334862385321102
I0
I1
I-1
tp11595
sS'of,foscarnets'
p11596
(F1
F0.00014334862385321102
I1
I0
I1
tp11597
sS'the,mode'
p11598
(F1
F0.00014334862385321102
I0
I1
I-1
tp11599
sS'and,various'
p11600
(F1
F0.00014334862385321102
I0
I1
I-1
tp11601
sS'metabolite,by'
p11602
(F1
F0.00028669724770642203
I2
I0
I2
tp11603
sS'sexual,activity'
p11604
(F1
F0.00014334862385321102
I0
I1
I-1
tp11605
sS'intracranial,hypertension'
p11606
(F1
F0.00014334862385321102
I1
I0
I1
tp11607
sS'onset,of'
p11608
(F1
F0.00043004587155963305
I3
I0
I3
tp11609
sS'increase,catabolism'
p11610
(F1
F0.00014334862385321102
I0
I1
I-1
tp11611
sS'plasma,concentration'
p11612
(F0.15384615384615385
F0.00057339449541284407
I15
I11
I4
tp11613
sS'rats,decreased'
p11614
(F1
F0.00014334862385321102
I1
I0
I1
tp11615
sS'of,mm'
p11616
(F0
F0
I1
I1
I0
tp11617
sS'of,ml'
p11618
(F1
F0.00028669724770642203
I0
I2
I-2
tp11619
sS'inhaled,and'
p11620
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp11621
sS'of,mg'
p11622
(F0.16190476190476191
F0.0024369266055045873
I61
I44
I17
tp11623
sS'vitro,anti-cryptosporidial'
p11624
(F1
F0.00014334862385321102
I0
I1
I-1
tp11625
sS'increase,absorption'
p11626
(F1
F0.00014334862385321102
I1
I0
I1
tp11627
sS'effected,by'
p11628
(F1
F0.00014334862385321102
I0
I1
I-1
tp11629
sS'long,half-life'
p11630
(F1
F0.00014334862385321102
I1
I0
I1
tp11631
sS'physiological,supplementation'
p11632
(F1
F0.00014334862385321102
I0
I1
I-1
tp11633
sS'primary,effect'
p11634
(F1
F0.00014334862385321102
I1
I0
I1
tp11635
sS'of,m1'
p11636
(F1
F0.00014334862385321102
I1
I0
I1
tp11637
sS'half-life,and'
p11638
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp11639
sS'and,intensify'
p11640
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp11641
sS'octapeptide,was'
p11642
(F1
F0.00014334862385321102
I0
I1
I-1
tp11643
sS'administration,impairs'
p11644
(F1
F0.00014334862385321102
I0
I1
I-1
tp11645
sS'homozygous,for'
p11646
(F1
F0.00014334862385321102
I0
I1
I-1
tp11647
sS'catecholamine-depleting,drugs'
p11648
(F1
F0.00014334862385321102
I1
I0
I1
tp11649
sS'for,pharmacokinetic'
p11650
(F1
F0.00014334862385321102
I0
I1
I-1
tp11651
sS'mild,uncomplicated'
p11652
(F1
F0.00014334862385321102
I0
I1
I-1
tp11653
sS'concurrently,the'
p11654
(F1
F0.00043004587155963305
I3
I0
I3
tp11655
sS'the,variability'
p11656
(F1
F0.00014334862385321102
I1
I0
I1
tp11657
sS'twitch,to'
p11658
(F1
F0.00014334862385321102
I1
I0
I1
tp11659
sS'medicine,may'
p11660
(F1
F0.00014334862385321102
I1
I0
I1
tp11661
sS'whether,they'
p11662
(F1
F0.00014334862385321102
I0
I1
I-1
tp11663
sS'or,supplemented'
p11664
(F1
F0.00014334862385321102
I1
I0
I1
tp11665
sS'nonetheless,individual'
p11666
(F1
F0.00014334862385321102
I1
I0
I1
tp11667
sS'inhibitors,dipyridamole'
p11668
(F1
F0.00014334862385321102
I1
I0
I1
tp11669
sS'enzymes,carbamazepine'
p11670
(F1
F0.00014334862385321102
I0
I1
I-1
tp11671
sS'treatment,during'
p11672
(F1
F0.00014334862385321102
I0
I1
I-1
tp11673
sS'dogs,with'
p11674
(F1
F0.00014334862385321102
I0
I1
I-1
tp11675
sS'of,augmentin'
p11676
(F1
F0.00014334862385321102
I0
I1
I-1
tp11677
sS'nursing,mothers'
p11678
(F1
F0.00014334862385321102
I0
I1
I-1
tp11679
sS'also,bleeding'
p11680
(F1
F0.00014334862385321102
I1
I0
I1
tp11681
sS'single-dose,interaction'
p11682
(F1
F0.00014334862385321102
I0
I1
I-1
tp11683
sS'transport,ratio'
p11684
(F1
F0.00014334862385321102
I0
I1
I-1
tp11685
sS'etofibrate,elicited'
p11686
(F1
F0.00014334862385321102
I1
I0
I1
tp11687
sS'adequate,and'
p11688
(F1
F0.00014334862385321102
I0
I1
I-1
tp11689
sS'with,vaprisol'
p11690
(F1
F0.00014334862385321102
I1
I0
I1
tp11691
sS'or,withdrawn'
p11692
(F0
F0
I1
I1
I0
tp11693
sS'cumulative,urinary'
p11694
(F1
F0.00014334862385321102
I0
I1
I-1
tp11695
sS'the,pathway'
p11696
(F1
F0.00014334862385321102
I0
I1
I-1
tp11697
sS'to,broadly'
p11698
(F1
F0.00014334862385321102
I0
I1
I-1
tp11699
sS's-warfarin,a'
p11700
(F1
F0.00014334862385321102
I1
I0
I1
tp11701
sS'through,an'
p11702
(F1
F0.00014334862385321102
I1
I0
I1
tp11703
sS'vitro,against'
p11704
(F1
F0.00014334862385321102
I0
I1
I-1
tp11705
sS'but,a'
p11706
(F1
F0.00014334862385321102
I0
I1
I-1
tp11707
sS'would,affect'
p11708
(F1
F0.00014334862385321102
I0
I1
I-1
tp11709
sS'technique,in'
p11710
(F1
F0.00014334862385321102
I0
I1
I-1
tp11711
sS'with,bleeding'
p11712
(F1
F0.00014334862385321102
I0
I1
I-1
tp11713
sS'of,dcg-iv'
p11714
(F0
F0
I1
I1
I0
tp11715
sS'other,day'
p11716
(F1
F0.00014334862385321102
I0
I1
I-1
tp11717
sS'including,dry'
p11718
(F1
F0.00014334862385321102
I1
I0
I1
tp11719
sS'single,intravenous'
p11720
(F1
F0.00014334862385321102
I0
I1
I-1
tp11721
sS'subject,given'
p11722
(F1
F0.00014334862385321102
I1
I0
I1
tp11723
sS'antacids,sucralfate'
p11724
(F1
F0.00014334862385321102
I0
I1
I-1
tp11725
sS'amantadine,limited'
p11726
(F1
F0.00014334862385321102
I1
I0
I1
tp11727
sS'involved,in'
p11728
(F1
F0.00028669724770642203
I0
I2
I-2
tp11729
sS'demonstrated,similar'
p11730
(F1
F0.00014334862385321102
I0
I1
I-1
tp11731
sS'cmax,differences'
p11732
(F1
F0.00014334862385321102
I0
I1
I-1
tp11733
sS'on,anecdotal'
p11734
(F1
F0.00014334862385321102
I1
I0
I1
tp11735
sS'inhibitors,protease'
p11736
(F1
F0.00014334862385321102
I0
I1
I-1
tp11737
sS'drug-metabolizing,enzymes'
p11738
(F1
F0.00014334862385321102
I0
I1
I-1
tp11739
sS'in,separate'
p11740
(F1
F0.00057339449541284407
I0
I4
I-4
tp11741
sS'wide,variety'
p11742
(F1
F0.00014334862385321102
I0
I1
I-1
tp11743
sS'hypertension,the'
p11744
(F1
F0.00014334862385321102
I1
I0
I1
tp11745
sS'arrest,and'
p11746
(F1
F0.00014334862385321102
I0
I1
I-1
tp11747
sS'significant,elevation'
p11748
(F1
F0.00014334862385321102
I1
I0
I1
tp11749
sS'with,inhibitors'
p11750
(F1
F0.00043004587155963305
I3
I0
I3
tp11751
sS'a,meal'
p11752
(F1
F0.00014334862385321102
I1
I0
I1
tp11753
sS'international,literature'
p11754
(F1
F0.00014334862385321102
I0
I1
I-1
tp11755
sS'a,mean'
p11756
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp11757
sS'of,panretin'
p11758
(F1
F0.00014334862385321102
I0
I1
I-1
tp11759
sS'therapeutic,and'
p11760
(F1
F0.00014334862385321102
I0
I1
I-1
tp11761
sS'epithelium,proliferates'
p11762
(F1
F0.00014334862385321102
I0
I1
I-1
tp11763
sS'hour,before'
p11764
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp11765
sS'this,might'
p11766
(F1
F0.00014334862385321102
I1
I0
I1
tp11767
sS'a,rare'
p11768
(F1
F0.00014334862385321102
I1
I0
I1
tp11769
sS'antigout,oral'
p11770
(F1
F0.00014334862385321102
I0
I1
I-1
tp11771
sS'levels,at'
p11772
(F1
F0.00014334862385321102
I1
I0
I1
tp11773
sS'aggression,and'
p11774
(F1
F0.00014334862385321102
I0
I1
I-1
tp11775
sS'metabolizers,with'
p11776
(F1
F0.00028669724770642203
I0
I2
I-2
tp11777
sS'maintenance,dosing'
p11778
(F1
F0.00014334862385321102
I1
I0
I1
tp11779
sS'maois,may'
p11780
(F1
F0.00028669724770642203
I2
I0
I2
tp11781
sS'inhibitors,intravenous'
p11782
(F1
F0.00014334862385321102
I0
I1
I-1
tp11783
sS'rats,of'
p11784
(F1
F0.00014334862385321102
I0
I1
I-1
tp11785
sS'increase,when'
p11786
(F1
F0.00057339449541284407
I4
I0
I4
tp11787
sS'necessary,for'
p11788
(F0
F0
I1
I1
I0
tp11789
sS'that,were'
p11790
(F1
F0.00014334862385321102
I1
I0
I1
tp11791
sS'such,combined'
p11792
(F1
F0.00028669724770642203
I2
I0
I2
tp11793
sS'methods,to'
p11794
(F1
F0.00014334862385321102
I0
I1
I-1
tp11795
sS'when,arava'
p11796
(F1
F0.00028669724770642203
I2
I0
I2
tp11797
sS'will,have'
p11798
(F0
F0
I1
I1
I0
tp11799
sS'impairing,its'
p11800
(F1
F0.00014334862385321102
I1
I0
I1
tp11801
sS'limited,experience'
p11802
(F1
F0.00014334862385321102
I0
I1
I-1
tp11803
sS'inhibitor,hydrogen-3'
p11804
(F1
F0.00014334862385321102
I0
I1
I-1
tp11805
sS'natriuresis,is'
p11806
(F1
F0.00014334862385321102
I1
I0
I1
tp11807
sS'soluble,such'
p11808
(F1
F0.00014334862385321102
I0
I1
I-1
tp11809
sS'skeletal-muscle,relaxants'
p11810
(F1
F0.00014334862385321102
I0
I1
I-1
tp11811
sS'angina,attacks'
p11812
(F1
F0.00014334862385321102
I0
I1
I-1
tp11813
sS'ergot-type,medications'
p11814
(F1
F0.00043004587155963305
I3
I0
I3
tp11815
sS'and,axert'
p11816
(F1
F0.00014334862385321102
I1
I0
I1
tp11817
sS'monkeys,and'
p11818
(F1
F0.00014334862385321102
I0
I1
I-1
tp11819
sS'when,trileptal'
p11820
(F1
F0.00014334862385321102
I1
I0
I1
tp11821
sS'including,many'
p11822
(F1
F0.00028669724770642203
I0
I2
I-2
tp11823
sS'monurol,a'
p11824
(F1
F0.00014334862385321102
I1
I0
I1
tp11825
sS'conducted,the'
p11826
(F1
F0.00014334862385321102
I0
I1
I-1
tp11827
sS'mg,orally'
p11828
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp11829
sS'fully,characterized'
p11830
(F1
F0.00014334862385321102
I1
I0
I1
tp11831
sS'additive,effects'
p11832
(F0.68421052631578949
F0.0018635321100917432
I16
I3
I13
tp11833
sS'to,concomitant'
p11834
(F1
F0.00028669724770642203
I0
I2
I-2
tp11835
sS'test,in'
p11836
(F1
F0.00014334862385321102
I0
I1
I-1
tp11837
sS'calcium,channel'
p11838
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp11839
sS'mice,on'
p11840
(F1
F0.00014334862385321102
I0
I1
I-1
tp11841
sS'curariform,muscle'
p11842
(F1
F0.00014334862385321102
I1
I0
I1
tp11843
sS'be,increased'
p11844
(F1
F0.0015768348623853212
I11
I0
I11
tp11845
sS'information,to'
p11846
(F1
F0.00014334862385321102
I1
I0
I1
tp11847
sS'concurrent,or'
p11848
(F1
F0.00014334862385321102
I0
I1
I-1
tp11849
sS'synergistic,relationship'
p11850
(F1
F0.00014334862385321102
I1
I0
I1
tp11851
sS'contrast,to'
p11852
(F1
F0.00014334862385321102
I0
I1
I-1
tp11853
sS'fluvoxamine,tablets'
p11854
(F1
F0.00071674311926605509
I5
I0
I5
tp11855
sS'and,failed'
p11856
(F1
F0.00014334862385321102
I0
I1
I-1
tp11857
sS'effect,measured'
p11858
(F1
F0.00014334862385321102
I0
I1
I-1
tp11859
sS'about,equipotent'
p11860
(F1
F0.00014334862385321102
I0
I1
I-1
tp11861
sS'a,nondrug'
p11862
(F1
F0.00014334862385321102
I0
I1
I-1
tp11863
sS'with,microalbuminuria'
p11864
(F1
F0.00014334862385321102
I1
I0
I1
tp11865
sS'cyp3a4,the'
p11866
(F1
F0.00014334862385321102
I1
I0
I1
tp11867
sS'hydroxylamine,dha'
p11868
(F1
F0.00014334862385321102
I0
I1
I-1
tp11869
sS'and,somnolence'
p11870
(F1
F0.00014334862385321102
I1
I0
I1
tp11871
sS'tmax,vs'
p11872
(F1
F0.00014334862385321102
I0
I1
I-1
tp11873
sS'tolerated,in'
p11874
(F1
F0.00043004587155963305
I0
I3
I-3
tp11875
sS'systematically,alter'
p11876
(F1
F0.00014334862385321102
I0
I1
I-1
tp11877
sS'the,effects'
p11878
(F0.011764705882352941
F0.00014334862385321102
I43
I42
I1
tp11879
sS'especially,of'
p11880
(F1
F0.00014334862385321102
I0
I1
I-1
tp11881
sS'difference,p'
p11882
(F1
F0.00014334862385321102
I0
I1
I-1
tp11883
sS'higher,than'
p11884
(F0.066666666666666666
F0.00014334862385321102
I8
I7
I1
tp11885
sS'during,initiation'
p11886
(F1
F0.00014334862385321102
I0
I1
I-1
tp11887
sS'with,creatinine'
p11888
(F1
F0.00014334862385321102
I0
I1
I-1
tp11889
sS'not,systematically'
p11890
(F0
F0
I1
I1
I0
tp11891
sS'at,concentrations'
p11892
(F1
F0.00043004587155963305
I0
I3
I-3
tp11893
sS'dosage,adjustments'
p11894
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp11895
sS'and,histamine-induced'
p11896
(F1
F0.00014334862385321102
I0
I1
I-1
tp11897
sS'during,concurrent'
p11898
(F1
F0.00014334862385321102
I0
I1
I-1
tp11899
sS'pharmacodynamics,of'
p11900
(F1
F0.0010034403669724771
I0
I7
I-7
tp11901
sS'cyp3a4,cyp3a4'
p11902
(F1
F0.00014334862385321102
I0
I1
I-1
tp11903
sS'derivatives,hormones'
p11904
(F1
F0.00028669724770642203
I0
I2
I-2
tp11905
sS'with,early-phase'
p11906
(F1
F0.00014334862385321102
I0
I1
I-1
tp11907
sS'deoxy,to'
p11908
(F1
F0.00014334862385321102
I0
I1
I-1
tp11909
sS'of,pgf2alpha'
p11910
(F1
F0.00014334862385321102
I1
I0
I1
tp11911
sS'efficacy,against'
p11912
(F1
F0.00014334862385321102
I0
I1
I-1
tp11913
sS'plus,experienced'
p11914
(F1
F0.00014334862385321102
I1
I0
I1
tp11915
sS'smoking,cessation'
p11916
(F1
F0.00014334862385321102
I0
I1
I-1
tp11917
sS'approximate,doubling'
p11918
(F1
F0.00028669724770642203
I2
I0
I2
tp11919
sS'numbers,of'
p11920
(F1
F0.00014334862385321102
I0
I1
I-1
tp11921
sS'based,on'
p11922
(F0.052631578947368418
F0.00014334862385321102
I10
I9
I1
tp11923
sS'other,will'
p11924
(F1
F0.00014334862385321102
I0
I1
I-1
tp11925
sS'daily,trough'
p11926
(F1
F0.00014334862385321102
I0
I1
I-1
tp11927
sS'necessitating,a'
p11928
(F1
F0.00014334862385321102
I1
I0
I1
tp11929
sS'potentiate,or'
p11930
(F1
F0.00028669724770642203
I2
I0
I2
tp11931
sS'one,survey'
p11932
(F1
F0.00014334862385321102
I1
I0
I1
tp11933
sS'excretion,of'
p11934
(F0.63636363636363635
F0.0020068807339449542
I18
I4
I14
tp11935
sS'and,nonclinical'
p11936
(F1
F0.00014334862385321102
I0
I1
I-1
tp11937
sS'calcium-rich,foods'
p11938
(F1
F0.00014334862385321102
I1
I0
I1
tp11939
sS'by,gleevec'
p11940
(F1
F0.00014334862385321102
I1
I0
I1
tp11941
sS'given,exclusively'
p11942
(F1
F0.00014334862385321102
I0
I1
I-1
tp11943
sS'iron-fortified,breakfast'
p11944
(F1
F0.00014334862385321102
I0
I1
I-1
tp11945
sS'taken,orally'
p11946
(F1
F0.00014334862385321102
I1
I0
I1
tp11947
sS'co,and'
p11948
(F1
F0.00014334862385321102
I0
I1
I-1
tp11949
sS'when,both'
p11950
(F1
F0.00014334862385321102
I1
I0
I1
tp11951
sS'of,immunization'
p11952
(F1
F0.00014334862385321102
I1
I0
I1
tp11953
sS'exhibits,non-linear'
p11954
(F1
F0.00014334862385321102
I1
I0
I1
tp11955
sS'and,mmol'
p11956
(F1
F0.00014334862385321102
I0
I1
I-1
tp11957
sS'oculo-bulbar,myasthenia'
p11958
(F1
F0.00014334862385321102
I1
I0
I1
tp11959
sS'and,peak'
p11960
(F1
F0.00014334862385321102
I1
I0
I1
tp11961
sS'selective,survival'
p11962
(F1
F0.00014334862385321102
I0
I1
I-1
tp11963
sS'resulting,interference'
p11964
(F1
F0.00014334862385321102
I1
I0
I1
tp11965
sS'a,blocker'
p11966
(F1
F0.00014334862385321102
I0
I1
I-1
tp11967
sS'inhibitors,also'
p11968
(F1
F0.00014334862385321102
I0
I1
I-1
tp11969
sS'of,etc'
p11970
(F1
F0.00014334862385321102
I1
I0
I1
tp11971
sS'of,significantly'
p11972
(F1
F0.00014334862385321102
I1
I0
I1
tp11973
sS'and,videx'
p11974
(F1
F0.00014334862385321102
I1
I0
I1
tp11975
sS'of,palythoa'
p11976
(F1
F0.00014334862385321102
I0
I1
I-1
tp11977
sS'demonstrated,that'
p11978
(F0.076923076923076927
F0.00014334862385321102
I7
I6
I1
tp11979
sS'globulin,shbg'
p11980
(F1
F0.00028669724770642203
I0
I2
I-2
tp11981
sS'sodium,bicarbonate'
p11982
(F1
F0.00028669724770642203
I2
I0
I2
tp11983
sS'toxic,levels'
p11984
(F0
F0
I1
I1
I0
tp11985
sS'loads,treated'
p11986
(F1
F0.00014334862385321102
I0
I1
I-1
tp11987
sS'the,release'
p11988
(F1
F0.00028669724770642203
I0
I2
I-2
tp11989
sS'of,commonly'
p11990
(F1
F0.00014334862385321102
I0
I1
I-1
tp11991
sS'therapeutic,regimen'
p11992
(F1
F0.00014334862385321102
I0
I1
I-1
tp11993
sS'nonetheless,the'
p11994
(F1
F0.00014334862385321102
I0
I1
I-1
tp11995
sS'sulfate,multivitamin'
p11996
(F1
F0.00014334862385321102
I1
I0
I1
tp11997
sS'than,usually'
p11998
(F1
F0.0010034403669724771
I0
I7
I-7
tp11999
sS'cmax,leading'
p12000
(F1
F0.00014334862385321102
I1
I0
I1
tp12001
sS'the,phase'
p12002
(F1
F0.00014334862385321102
I0
I1
I-1
tp12003
sS'including,manic-depressive'
p12004
(F1
F0.00014334862385321102
I1
I0
I1
tp12005
sS'at,recommended'
p12006
(F1
F0.00014334862385321102
I1
I0
I1
tp12007
sS'populations,the'
p12008
(F1
F0.00014334862385321102
I1
I0
I1
tp12009
sS'peripheral,because'
p12010
(F1
F0.00014334862385321102
I1
I0
I1
tp12011
sS'emulsion,model'
p12012
(F1
F0.00014334862385321102
I0
I1
I-1
tp12013
sS'for,differential'
p12014
(F1
F0.00014334862385321102
I0
I1
I-1
tp12015
sS'first,double-blind'
p12016
(F1
F0.00014334862385321102
I0
I1
I-1
tp12017
sS'particularly,serotype'
p12018
(F1
F0.00014334862385321102
I0
I1
I-1
tp12019
sS'inducer,decreased'
p12020
(F1
F0.00014334862385321102
I1
I0
I1
tp12021
sS'rarely,toxicity'
p12022
(F1
F0.00014334862385321102
I1
I0
I1
tp12023
sS'or,efficacy'
p12024
(F1
F0.00043004587155963305
I0
I3
I-3
tp12025
sS'mean,neutrophil'
p12026
(F1
F0.00014334862385321102
I1
I0
I1
tp12027
sS'been,completely'
p12028
(F1
F0.00014334862385321102
I0
I1
I-1
tp12029
sS'a,cyp3a4'
p12030
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp12031
sS'inhibit,elimination'
p12032
(F1
F0.00014334862385321102
I1
I0
I1
tp12033
sS'descending,epsilon'
p12034
(F1
F0.00014334862385321102
I0
I1
I-1
tp12035
sS'proleukin,including'
p12036
(F1
F0.00014334862385321102
I1
I0
I1
tp12037
sS'using,escalating'
p12038
(F1
F0.00014334862385321102
I1
I0
I1
tp12039
sS'lacking,kidney'
p12040
(F1
F0.00014334862385321102
I0
I1
I-1
tp12041
sS'the,function'
p12042
(F0
F0
I1
I1
I0
tp12043
sS'can,completely'
p12044
(F1
F0.00014334862385321102
I1
I0
I1
tp12045
sS'with,intestinal'
p12046
(F1
F0.00014334862385321102
I1
I0
I1
tp12047
sS'inhibitors,and'
p12048
(F0.29032258064516131
F0.0012901376146788992
I20
I11
I9
tp12049
sS'produce,excessive'
p12050
(F1
F0.00014334862385321102
I1
I0
I1
tp12051
sS'oral,regular'
p12052
(F1
F0.00014334862385321102
I0
I1
I-1
tp12053
sS'safety,however'
p12054
(F1
F0.00014334862385321102
I0
I1
I-1
tp12055
sS'increased,severity'
p12056
(F1
F0.00014334862385321102
I1
I0
I1
tp12057
sS'as,retention'
p12058
(F1
F0.00014334862385321102
I0
I1
I-1
tp12059
sS'again,neutralized'
p12060
(F1
F0.00014334862385321102
I0
I1
I-1
tp12061
sS'volunteers,hormone'
p12062
(F1
F0.00014334862385321102
I0
I1
I-1
tp12063
sS'desired,and'
p12064
(F1
F0.00014334862385321102
I1
I0
I1
tp12065
sS'i,and'
p12066
(F1
F0.00043004587155963305
I0
I3
I-3
tp12067
sS'following,varying'
p12068
(F1
F0.00014334862385321102
I0
I1
I-1
tp12069
sS'observations,i'
p12070
(F1
F0.00014334862385321102
I0
I1
I-1
tp12071
sS'with,tablets'
p12072
(F1
F0.00057339449541284407
I4
I0
I4
tp12073
sS'pharmacokinetic,captopril-digoxin'
p12074
(F1
F0.00014334862385321102
I0
I1
I-1
tp12075
sS'tagamet,prozac'
p12076
(F1
F0.00014334862385321102
I0
I1
I-1
tp12077
sS'therefore,advised'
p12078
(F1
F0.00028669724770642203
I2
I0
I2
tp12079
sS'receiving,concurrently'
p12080
(F1
F0.00014334862385321102
I1
I0
I1
tp12081
sS'the,renal'
p12082
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp12083
sS'secretion,by'
p12084
(F0
F0
I1
I1
I0
tp12085
sS'generation,of'
p12086
(F1
F0.00014334862385321102
I0
I1
I-1
tp12087
sS'ci,kg'
p12088
(F1
F0.00014334862385321102
I0
I1
I-1
tp12089
sS'times,were'
p12090
(F1
F0.00028669724770642203
I0
I2
I-2
tp12091
sS'in,temperature'
p12092
(F1
F0.00014334862385321102
I0
I1
I-1
tp12093
sS'little,or'
p12094
(F0
F0
I3
I3
I0
tp12095
sS'wax,matrix'
p12096
(F1
F0.00014334862385321102
I1
I0
I1
tp12097
sS'cephalosporins,including'
p12098
(F1
F0.00014334862385321102
I0
I1
I-1
tp12099
sS'or,pharmacokinetics'
p12100
(F1
F0.00028669724770642203
I0
I2
I-2
tp12101
sS'one,patient'
p12102
(F1
F0.00014334862385321102
I1
I0
I1
tp12103
sS'edema,has'
p12104
(F1
F0.00014334862385321102
I1
I0
I1
tp12105
sS'enzyme,should'
p12106
(F1
F0.00014334862385321102
I1
I0
I1
tp12107
sS'a,double'
p12108
(F1
F0.00014334862385321102
I0
I1
I-1
tp12109
sS'tricyclic,flupenthixol'
p12110
(F1
F0.00014334862385321102
I1
I0
I1
tp12111
sS'tricyclic,when'
p12112
(F1
F0.00014334862385321102
I1
I0
I1
tp12113
sS'taken,closely'
p12114
(F1
F0.00014334862385321102
I1
I0
I1
tp12115
sS'formally,evaluated'
p12116
(F1
F0.00014334862385321102
I0
I1
I-1
tp12117
sS'contrast,media'
p12118
(F1
F0.00014334862385321102
I1
I0
I1
tp12119
sS'interactions,were'
p12120
(F1
F0.00071674311926605509
I0
I5
I-5
tp12121
sS'appeared,well'
p12122
(F1
F0.00014334862385321102
I0
I1
I-1
tp12123
sS'of,from'
p12124
(F0
F0
I2
I2
I0
tp12125
sS'nsaids,was'
p12126
(F1
F0.00014334862385321102
I0
I1
I-1
tp12127
sS'tuberculosa,caused'
p12128
(F1
F0.00014334862385321102
I0
I1
I-1
tp12129
sS'the,results'
p12130
(F0.23076923076923078
F0.00043004587155963305
I5
I8
I-3
tp12131
sS'placebo-controlled,within-subject'
p12132
(F1
F0.00014334862385321102
I0
I1
I-1
tp12133
sS'ingestion,may'
p12134
(F1
F0.00014334862385321102
I1
I0
I1
tp12135
sS'inhibitors,to'
p12136
(F1
F0.00014334862385321102
I1
I0
I1
tp12137
sS'other,studies'
p12138
(F1
F0.00014334862385321102
I0
I1
I-1
tp12139
sS'a,shortened'
p12140
(F1
F0.00014334862385321102
I1
I0
I1
tp12141
sS'toxoids,should'
p12142
(F1
F0.00014334862385321102
I1
I0
I1
tp12143
sS'little,published'
p12144
(F1
F0.00014334862385321102
I0
I1
I-1
tp12145
sS'and,slight'
p12146
(F1
F0.00014334862385321102
I1
I0
I1
tp12147
sS'antihypertensives,amiodarone'
p12148
(F1
F0.00014334862385321102
I0
I1
I-1
tp12149
sS'metabolism,may'
p12150
(F1
F0.00014334862385321102
I1
I0
I1
tp12151
sS'later,changed'
p12152
(F1
F0.00014334862385321102
I0
I1
I-1
tp12153
sS'impaired,by'
p12154
(F1
F0.00043004587155963305
I3
I0
I3
tp12155
sS'pancreatic,effects'
p12156
(F1
F0.00014334862385321102
I0
I1
I-1
tp12157
sS'of,clostridium'
p12158
(F1
F0.00014334862385321102
I0
I1
I-1
tp12159
sS'the,dose'
p12160
(F0.31818181818181818
F0.0020068807339449542
I29
I15
I14
tp12161
sS'in,em'
p12162
(F1
F0.00014334862385321102
I1
I0
I1
tp12163
sS'in,desloratadine'
p12164
(F1
F0.00014334862385321102
I0
I1
I-1
tp12165
sS'coadministration,leads'
p12166
(F1
F0.00028669724770642203
I2
I0
I2
tp12167
sS'tricyclic,may'
p12168
(F1
F0.00043004587155963305
I3
I0
I3
tp12169
sS'e1,and'
p12170
(F1
F0.00014334862385321102
I0
I1
I-1
tp12171
sS'of,rashes'
p12172
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12173
sS'activity,such'
p12174
(F1
F0.00028669724770642203
I2
I0
I2
tp12175
sS'dysregulation,of'
p12176
(F1
F0.00014334862385321102
I0
I1
I-1
tp12177
sS'but,there'
p12178
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12179
sS'to,doses'
p12180
(F1
F0.00014334862385321102
I0
I1
I-1
tp12181
sS'as,inhibitors'
p12182
(F1
F0.00014334862385321102
I0
I1
I-1
tp12183
sS'revia,the'
p12184
(F1
F0.00014334862385321102
I1
I0
I1
tp12185
sS'species,nanm'
p12186
(F1
F0.00014334862385321102
I1
I0
I1
tp12187
sS'or,since'
p12188
(F1
F0.00014334862385321102
I0
I1
I-1
tp12189
sS'cerebyx,dosage'
p12190
(F1
F0.00014334862385321102
I1
I0
I1
tp12191
sS'acid,or'
p12192
(F1
F0.00014334862385321102
I1
I0
I1
tp12193
sS'of,potentially'
p12194
(F1
F0.00014334862385321102
I1
I0
I1
tp12195
sS'and,result'
p12196
(F1
F0.00028669724770642203
I2
I0
I2
tp12197
sS'indicated,in'
p12198
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp12199
sS'n,did'
p12200
(F1
F0.00014334862385321102
I0
I1
I-1
tp12201
sS'maoi,maoi'
p12202
(F1
F0.00014334862385321102
I1
I0
I1
tp12203
sS'limited,comparative'
p12204
(F1
F0.00014334862385321102
I0
I1
I-1
tp12205
sS'usual,concentrations'
p12206
(F1
F0.00014334862385321102
I0
I1
I-1
tp12207
sS'one-half,and'
p12208
(F1
F0.00014334862385321102
I0
I1
I-1
tp12209
sS'hydoxide,hydrochloride'
p12210
(F1
F0.00014334862385321102
I1
I0
I1
tp12211
sS'of,prolongation'
p12212
(F1
F0.00014334862385321102
I1
I0
I1
tp12213
sS'of,flolan'
p12214
(F1
F0.00014334862385321102
I0
I1
I-1
tp12215
sS'differences,indicated'
p12216
(F1
F0.00014334862385321102
I0
I1
I-1
tp12217
sS'in,peripheral'
p12218
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12219
sS'higher-than,expected'
p12220
(F1
F0.00014334862385321102
I1
I0
I1
tp12221
sS'to,in'
p12222
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp12223
sS'digoxin,and'
p12224
(F1
F0.00014334862385321102
I1
I0
I1
tp12225
sS'patient,was'
p12226
(F1
F0.00043004587155963305
I0
I3
I-3
tp12227
sS'to,is'
p12228
(F0
F0
I1
I1
I0
tp12229
sS'the,elimination'
p12230
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp12231
sS'p450,c9'
p12232
(F1
F0.00028669724770642203
I2
I0
I2
tp12233
sS'a,lesser'
p12234
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12235
sS'in,higher'
p12236
(F0
F0
I1
I1
I0
tp12237
sS'studies,were'
p12238
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp12239
sS'of,starlix'
p12240
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12241
sS'cyp3a4,eg'
p12242
(F1
F0.00071674311926605509
I5
I0
I5
tp12243
sS'or,minus'
p12244
(F1
F0.00014334862385321102
I1
I0
I1
tp12245
sS'both,as'
p12246
(F1
F0.00014334862385321102
I1
I0
I1
tp12247
sS'occur,earlier'
p12248
(F1
F0.00014334862385321102
I1
I0
I1
tp12249
sS'the,ethanolysis'
p12250
(F1
F0.00014334862385321102
I1
I0
I1
tp12251
sS'extreme,agitation'
p12252
(F1
F0.00014334862385321102
I1
I0
I1
tp12253
sS'as,diphen-hydramine'
p12254
(F1
F0.00014334862385321102
I0
I1
I-1
tp12255
sS'methods,clinical'
p12256
(F1
F0.00014334862385321102
I0
I1
I-1
tp12257
sS'n,demonstrated'
p12258
(F1
F0.00014334862385321102
I0
I1
I-1
tp12259
sS'the,coagulation'
p12260
(F1
F0.00014334862385321102
I0
I1
I-1
tp12261
sS'use,foradil'
p12262
(F1
F0.00014334862385321102
I0
I1
I-1
tp12263
sS'within,hours'
p12264
(F1
F0.0015768348623853212
I11
I0
I11
tp12265
sS'significantly,more'
p12266
(F1
F0.00028669724770642203
I0
I2
I-2
tp12267
sS'shown,a'
p12268
(F1
F0.00071674311926605509
I5
I0
I5
tp12269
sS'deficiency,and'
p12270
(F1
F0.00014334862385321102
I0
I1
I-1
tp12271
sS'fixed-interval,fixed-ratio'
p12272
(F1
F0.00014334862385321102
I0
I1
I-1
tp12273
sS'neuropathy,has'
p12274
(F1
F0.00014334862385321102
I0
I1
I-1
tp12275
sS'of,carbamazepine'
p12276
(F0
F0
I1
I1
I0
tp12277
sS'glycosides,may'
p12278
(F1
F0.00014334862385321102
I0
I1
I-1
tp12279
sS'using,such'
p12280
(F1
F0.00014334862385321102
I1
I0
I1
tp12281
sS'either,these'
p12282
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp12283
sS'with,peripheral'
p12284
(F0
F0
I1
I1
I0
tp12285
sS'studies,wshow'
p12286
(F1
F0.00014334862385321102
I1
I0
I1
tp12287
sS'in,each'
p12288
(F1
F0.00057339449541284407
I0
I4
I-4
tp12289
sS'with,pegasys'
p12290
(F0
F0
I1
I1
I0
tp12291
sS'most,of'
p12292
(F0
F0
I1
I1
I0
tp12293
sS'd1,antagonist'
p12294
(F1
F0.00014334862385321102
I1
I0
I1
tp12295
sS'recipients,over'
p12296
(F1
F0.00014334862385321102
I0
I1
I-1
tp12297
sS'activity,in'
p12298
(F0
F0
I1
I1
I0
tp12299
sS'mesylate,has'
p12300
(F1
F0.00028669724770642203
I0
I2
I-2
tp12301
sS'alternatives,to'
p12302
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp12303
sS'by,means'
p12304
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp12305
sS'activity,is'
p12306
(F1
F0.00014334862385321102
I0
I1
I-1
tp12307
sS'metabolism,with'
p12308
(F1
F0.00014334862385321102
I1
I0
I1
tp12309
sS'at,and'
p12310
(F0
F0
I1
I1
I0
tp12311
sS'osteoporosis,treatment'
p12312
(F1
F0.00028669724770642203
I0
I2
I-2
tp12313
sS'and,chloride'
p12314
(F1
F0.00028669724770642203
I2
I0
I2
tp12315
sS'literature,reports'
p12316
(F0.5
F0.00028669724770642203
I3
I1
I2
tp12317
sS'ethanol,flupenthixol'
p12318
(F1
F0.00014334862385321102
I1
I0
I1
tp12319
sS'activate,the'
p12320
(F1
F0.00014334862385321102
I0
I1
I-1
tp12321
sS'acid,vitamin'
p12322
(F1
F0.00014334862385321102
I1
I0
I1
tp12323
sS'heart,function'
p12324
(F1
F0.00014334862385321102
I1
I0
I1
tp12325
sS'of,anafranil'
p12326
(F1
F0.00014334862385321102
I1
I0
I1
tp12327
sS'aminoglycosides,drugs'
p12328
(F1
F0.00014334862385321102
I1
I0
I1
tp12329
sS'felbamate,treatment'
p12330
(F1
F0.00014334862385321102
I1
I0
I1
tp12331
sS'and,cohort'
p12332
(F0
F0
I1
I1
I0
tp12333
sS'most,potent'
p12334
(F1
F0.00014334862385321102
I0
I1
I-1
tp12335
sS'antagonist,may'
p12336
(F1
F0.00014334862385321102
I0
I1
I-1
tp12337
sS'evaluate,possible'
p12338
(F1
F0.00014334862385321102
I0
I1
I-1
tp12339
sS'predominantly,in'
p12340
(F1
F0.00014334862385321102
I1
I0
I1
tp12341
sS'baseline,use'
p12342
(F1
F0.00014334862385321102
I0
I1
I-1
tp12343
sS'by,combination'
p12344
(F1
F0.00014334862385321102
I1
I0
I1
tp12345
sS'didanosine,fluconazole'
p12346
(F1
F0.00014334862385321102
I0
I1
I-1
tp12347
sS'will,require'
p12348
(F1
F0.00014334862385321102
I1
I0
I1
tp12349
sS'the,coadministration'
p12350
(F0.26315789473684209
F0.00071674311926605509
I7
I12
I-5
tp12351
sS'deficiency,can'
p12352
(F1
F0.00014334862385321102
I1
I0
I1
tp12353
sS'tranexamic,acid'
p12354
(F1
F0.00014334862385321102
I0
I1
I-1
tp12355
sS'agents,the'
p12356
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp12357
sS'hormonal,contraceptives'
p12358
(F0
F0
I1
I1
I0
tp12359
sS'steroidal,agent'
p12360
(F1
F0.00014334862385321102
I1
I0
I1
tp12361
sS'moreover,as'
p12362
(F1
F0.00014334862385321102
I1
I0
I1
tp12363
sS'subjects,on'
p12364
(F1
F0.00028669724770642203
I0
I2
I-2
tp12365
sS'drugs,phenytoin'
p12366
(F1
F0.00014334862385321102
I1
I0
I1
tp12367
sS'enterohepatic,elimination'
p12368
(F1
F0.00014334862385321102
I0
I1
I-1
tp12369
sS'cohort,or'
p12370
(F1
F0.00014334862385321102
I0
I1
I-1
tp12371
sS'appropriate,observation'
p12372
(F1
F0.00057339449541284407
I4
I0
I4
tp12373
sS'its,derivatives'
p12374
(F1
F0.00071674311926605509
I5
I0
I5
tp12375
sS'which,clearance'
p12376
(F1
F0.00014334862385321102
I1
I0
I1
tp12377
sS'd6,e1'
p12378
(F1
F0.00014334862385321102
I0
I1
I-1
tp12379
sS'both,thiazide-like'
p12380
(F1
F0.00014334862385321102
I0
I1
I-1
tp12381
sS'bowel,and'
p12382
(F1
F0.00014334862385321102
I0
I1
I-1
tp12383
sS'the,intravenous'
p12384
(F0
F0
I2
I2
I0
tp12385
sS'and,coreg'
p12386
(F1
F0.00014334862385321102
I1
I0
I1
tp12387
sS'neuroleptic,drugs'
p12388
(F1
F0.00014334862385321102
I1
I0
I1
tp12389
sS'administration,to'
p12390
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp12391
sS'followed,for'
p12392
(F1
F0.00014334862385321102
I0
I1
I-1
tp12393
sS'patient,initiates'
p12394
(F1
F0.00014334862385321102
I1
I0
I1
tp12395
sS'by,or'
p12396
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12397
sS'th,day'
p12398
(F1
F0.00028669724770642203
I2
I0
I2
tp12399
sS'intravenously,or'
p12400
(F1
F0.00014334862385321102
I0
I1
I-1
tp12401
sS'both,hyperthyroidism'
p12402
(F1
F0.00014334862385321102
I0
I1
I-1
tp12403
sS'by,of'
p12404
(F0
F0
I2
I2
I0
tp12405
sS'by,oh'
p12406
(F1
F0.00014334862385321102
I1
I0
I1
tp12407
sS'was,prepared'
p12408
(F1
F0.00014334862385321102
I0
I1
I-1
tp12409
sS'by,on'
p12410
(F1
F0.00028669724770642203
I2
I0
I2
tp12411
sS'is,enhanced'
p12412
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp12413
sS'plus,haart'
p12414
(F1
F0.00014334862385321102
I0
I1
I-1
tp12415
sS'other,cholinesterase'
p12416
(F1
F0.00014334862385321102
I1
I0
I1
tp12417
sS'numerous,interactions'
p12418
(F1
F0.00014334862385321102
I0
I1
I-1
tp12419
sS'the,ganglionic-blocking'
p12420
(F1
F0.00014334862385321102
I1
I0
I1
tp12421
sS'regimens,and'
p12422
(F1
F0.00014334862385321102
I0
I1
I-1
tp12423
sS'cmin,to'
p12424
(F1
F0.00028669724770642203
I2
I0
I2
tp12425
sS'greater,patients'
p12426
(F1
F0.00014334862385321102
I1
I0
I1
tp12427
sS'regimen,consisting'
p12428
(F1
F0.00014334862385321102
I1
I0
I1
tp12429
sS'and,vasoconstrictive'
p12430
(F1
F0.00014334862385321102
I1
I0
I1
tp12431
sS'vioxx,with'
p12432
(F1
F0.00028669724770642203
I2
I0
I2
tp12433
sS'nimbex,were'
p12434
(F1
F0.00014334862385321102
I1
I0
I1
tp12435
sS'fluoride,accumulation'
p12436
(F1
F0.00014334862385321102
I0
I1
I-1
tp12437
sS'a,significant'
p12438
(F0.10000000000000001
F0.00028669724770642203
I11
I9
I2
tp12439
sS'glycosides,in'
p12440
(F1
F0.00028669724770642203
I0
I2
I-2
tp12441
sS'any,that'
p12442
(F1
F0.00014334862385321102
I0
I1
I-1
tp12443
sS'preparations,by'
p12444
(F1
F0.00014334862385321102
I1
I0
I1
tp12445
sS'prolixin,serentil'
p12446
(F1
F0.00014334862385321102
I0
I1
I-1
tp12447
sS'be,no'
p12448
(F1
F0.00014334862385321102
I0
I1
I-1
tp12449
sS'systemic,circulation'
p12450
(F1
F0.00014334862385321102
I1
I0
I1
tp12451
sS'enhanced,by'
p12452
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp12453
sS'to,check'
p12454
(F1
F0.00014334862385321102
I1
I0
I1
tp12455
sS'about,absorption'
p12456
(F1
F0.00014334862385321102
I0
I1
I-1
tp12457
sS'of,sedation'
p12458
(F1
F0.00014334862385321102
I1
I0
I1
tp12459
sS'that,clearance'
p12460
(F1
F0.00043004587155963305
I3
I0
I3
tp12461
sS'when,baraclude'
p12462
(F1
F0.00014334862385321102
I0
I1
I-1
tp12463
sS'unrecognized,interaction'
p12464
(F1
F0.00014334862385321102
I1
I0
I1
tp12465
sS'non-steroidal,concomitantly'
p12466
(F1
F0.00014334862385321102
I1
I0
I1
tp12467
sS'and,extended'
p12468
(F1
F0.00028669724770642203
I2
I0
I2
tp12469
sS'i,tranexamic'
p12470
(F1
F0.00014334862385321102
I0
I1
I-1
tp12471
sS'dose,modifying'
p12472
(F1
F0.00014334862385321102
I1
I0
I1
tp12473
sS'and,imitrex'
p12474
(F1
F0.00014334862385321102
I0
I1
I-1
tp12475
sS'and,through'
p12476
(F1
F0.00014334862385321102
I0
I1
I-1
tp12477
sS'concentrations,or'
p12478
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12479
sS'iron,concomitant'
p12480
(F1
F0.00014334862385321102
I1
I0
I1
tp12481
sS'concentrations,of'
p12482
(F0.20833333333333334
F0.0028669724770642203
I58
I38
I20
tp12483
sS'active,vomiting'
p12484
(F1
F0.00014334862385321102
I1
I0
I1
tp12485
sS'mg,three'
p12486
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp12487
sS'whom,cyp3a4'
p12488
(F1
F0.00014334862385321102
I0
I1
I-1
tp12489
sS'iv,injection'
p12490
(F1
F0.00014334862385321102
I1
I0
I1
tp12491
sS'commonly,results'
p12492
(F1
F0.00014334862385321102
I1
I0
I1
tp12493
sS'than,fold'
p12494
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12495
sS'concentrates,has'
p12496
(F1
F0.00014334862385321102
I0
I1
I-1
tp12497
sS'including,crescentic'
p12498
(F1
F0.00014334862385321102
I1
I0
I1
tp12499
sS'invalidate,folic'
p12500
(F1
F0.00014334862385321102
I0
I1
I-1
tp12501
sS'acetate,because'
p12502
(F1
F0.00014334862385321102
I1
I0
I1
tp12503
sS'combined,with'
p12504
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp12505
sS'ketoconazole,at'
p12506
(F1
F0.00014334862385321102
I1
I0
I1
tp12507
sS'containing,vitamin'
p12508
(F1
F0.00014334862385321102
I1
I0
I1
tp12509
sS'also,produces'
p12510
(F1
F0.00014334862385321102
I1
I0
I1
tp12511
sS'conduction,disturbances'
p12512
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12513
sS'administration,decreased'
p12514
(F1
F0.00014334862385321102
I1
I0
I1
tp12515
sS'of,reduced'
p12516
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12517
sS'potential,especially'
p12518
(F1
F0.00014334862385321102
I1
I0
I1
tp12519
sS'increased,bun'
p12520
(F1
F0.00014334862385321102
I1
I0
I1
tp12521
sS'hydrate,and'
p12522
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp12523
sS'underlying,mechanism'
p12524
(F1
F0.00014334862385321102
I1
I0
I1
tp12525
sS'fischer-344,strain'
p12526
(F1
F0.00014334862385321102
I0
I1
I-1
tp12527
sS'stopping,before'
p12528
(F1
F0.00014334862385321102
I1
I0
I1
tp12529
sS'reported,both'
p12530
(F1
F0.00014334862385321102
I1
I0
I1
tp12531
sS'comparable,in'
p12532
(F1
F0.00014334862385321102
I0
I1
I-1
tp12533
sS'iib,iiia'
p12534
(F1
F0.00014334862385321102
I1
I0
I1
tp12535
sS'edecrin,and'
p12536
(F1
F0.00014334862385321102
I1
I0
I1
tp12537
sS'psychotic,disorders'
p12538
(F1
F0.00014334862385321102
I1
I0
I1
tp12539
sS'studies,no'
p12540
(F1
F0.00014334862385321102
I0
I1
I-1
tp12541
sS'subjects,mean'
p12542
(F1
F0.00014334862385321102
I1
I0
I1
tp12543
sS'pharmacokinetics,parameters'
p12544
(F1
F0.00014334862385321102
I1
I0
I1
tp12545
sS'treated,concurrently'
p12546
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp12547
sS'necessitate,reduction'
p12548
(F1
F0.00014334862385321102
I0
I1
I-1
tp12549
sS'problems,encountered'
p12550
(F1
F0.00014334862385321102
I0
I1
I-1
tp12551
sS'where,definitely'
p12552
(F1
F0.00014334862385321102
I1
I0
I1
tp12553
sS'to,half'
p12554
(F1
F0.00014334862385321102
I1
I0
I1
tp12555
sS'bid,for'
p12556
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp12557
sS'moderate,cyp1a2'
p12558
(F1
F0.00014334862385321102
I1
I0
I1
tp12559
sS'rhabdomyolysis,resulting'
p12560
(F1
F0.00014334862385321102
I0
I1
I-1
tp12561
sS'is,withdrawn'
p12562
(F1
F0.00014334862385321102
I1
I0
I1
tp12563
sS'falls,vs'
p12564
(F1
F0.00014334862385321102
I1
I0
I1
tp12565
sS'prolongs,the'
p12566
(F1
F0.00028669724770642203
I2
I0
I2
tp12567
sS'days,a'
p12568
(F1
F0.00028669724770642203
I2
I0
I2
tp12569
sS'in,vertigo'
p12570
(F1
F0.00014334862385321102
I0
I1
I-1
tp12571
sS'at,increased'
p12572
(F0
F0
I2
I2
I0
tp12573
sS'days,n'
p12574
(F1
F0.00014334862385321102
I0
I1
I-1
tp12575
sS'sharing,that'
p12576
(F1
F0.00014334862385321102
I1
I0
I1
tp12577
sS'female,n'
p12578
(F1
F0.00014334862385321102
I0
I1
I-1
tp12579
sS'intravenous,was'
p12580
(F1
F0.00014334862385321102
I1
I0
I1
tp12581
sS'vital,signs'
p12582
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12583
sS'produces,an'
p12584
(F1
F0.00028669724770642203
I2
I0
I2
tp12585
sS'while,mc'
p12586
(F1
F0.00014334862385321102
I0
I1
I-1
tp12587
sS'parenteral,enzyme'
p12588
(F1
F0.00014334862385321102
I0
I1
I-1
tp12589
sS'that,use'
p12590
(F1
F0.00014334862385321102
I1
I0
I1
tp12591
sS'when,flolan'
p12592
(F1
F0.00014334862385321102
I1
I0
I1
tp12593
sS'ventricular,fibrulation'
p12594
(F1
F0.00014334862385321102
I1
I0
I1
tp12595
sS'products,you'
p12596
(F1
F0.00014334862385321102
I0
I1
I-1
tp12597
sS'significant,pharmacokinetic'
p12598
(F1
F0.00057339449541284407
I0
I4
I-4
tp12599
sS'cns-depressive,effects'
p12600
(F1
F0.00014334862385321102
I1
I0
I1
tp12601
sS'controlled,on'
p12602
(F1
F0.00014334862385321102
I1
I0
I1
tp12603
sS'with,neuromuscular'
p12604
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12605
sS'following,cyclosporine'
p12606
(F1
F0.00014334862385321102
I0
I1
I-1
tp12607
sS'vs,myocardial'
p12608
(F1
F0.00014334862385321102
I1
I0
I1
tp12609
sS'dyskinesia,side'
p12610
(F1
F0.00014334862385321102
I1
I0
I1
tp12611
sS'h,receptor'
p12612
(F1
F0.00014334862385321102
I1
I0
I1
tp12613
sS'tid,was'
p12614
(F1
F0.00014334862385321102
I1
I0
I1
tp12615
sS'felodipine,may'
p12616
(F1
F0.00014334862385321102
I0
I1
I-1
tp12617
sS'isozymes,in'
p12618
(F1
F0.00014334862385321102
I0
I1
I-1
tp12619
sS'oxidation,elc'
p12620
(F1
F0.00014334862385321102
I1
I0
I1
tp12621
sS'reach,to10'
p12622
(F1
F0.00014334862385321102
I1
I0
I1
tp12623
sS'and,high'
p12624
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12625
sS'approximately,one'
p12626
(F1
F0.00014334862385321102
I1
I0
I1
tp12627
sS'increased,toxicity'
p12628
(F1
F0.00014334862385321102
I0
I1
I-1
tp12629
sS'determined,with'
p12630
(F1
F0.00043004587155963305
I3
I0
I3
tp12631
sS'acid,concentrations'
p12632
(F1
F0.00014334862385321102
I0
I1
I-1
tp12633
sS'or,urine'
p12634
(F1
F0.00014334862385321102
I0
I1
I-1
tp12635
sS'were,also'
p12636
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp12637
sS'plus,was'
p12638
(F0
F0
I1
I1
I0
tp12639
sS'anastrozole,did'
p12640
(F1
F0.00014334862385321102
I0
I1
I-1
tp12641
sS'videx,to'
p12642
(F1
F0.00014334862385321102
I1
I0
I1
tp12643
sS'purpose,of'
p12644
(F1
F0.00014334862385321102
I0
I1
I-1
tp12645
sS'the,dmpge2'
p12646
(F1
F0.00014334862385321102
I1
I0
I1
tp12647
sS'nd,female'
p12648
(F1
F0.00014334862385321102
I0
I1
I-1
tp12649
sS'triple-immunosuppression,regimens'
p12650
(F1
F0.00014334862385321102
I0
I1
I-1
tp12651
sS'stopping,an'
p12652
(F1
F0.00014334862385321102
I1
I0
I1
tp12653
sS'reveiving,phenytoin'
p12654
(F1
F0.00014334862385321102
I1
I0
I1
tp12655
sS'metabolizes,may'
p12656
(F1
F0.00014334862385321102
I0
I1
I-1
tp12657
sS'treatment-emergent,positive'
p12658
(F1
F0.00014334862385321102
I0
I1
I-1
tp12659
sS't,max'
p12660
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12661
sS'measurements,of'
p12662
(F1
F0.00014334862385321102
I1
I0
I1
tp12663
sS'the,loss'
p12664
(F1
F0.00014334862385321102
I1
I0
I1
tp12665
sS'bioavailability,by'
p12666
(F1
F0.00014334862385321102
I0
I1
I-1
tp12667
sS'volunteers,received'
p12668
(F1
F0.00014334862385321102
I0
I1
I-1
tp12669
sS'unbound,was'
p12670
(F1
F0.00014334862385321102
I0
I1
I-1
tp12671
sS'of,enhancement'
p12672
(F1
F0.00014334862385321102
I0
I1
I-1
tp12673
sS'solution,one'
p12674
(F1
F0.00014334862385321102
I1
I0
I1
tp12675
sS'ergot,toxicity'
p12676
(F1
F0.00014334862385321102
I0
I1
I-1
tp12677
sS'in,males'
p12678
(F1
F0.00014334862385321102
I1
I0
I1
tp12679
sS'disorder,including'
p12680
(F1
F0.00014334862385321102
I1
I0
I1
tp12681
sS'clinical,effects'
p12682
(F0
F0
I1
I1
I0
tp12683
sS'to,provide'
p12684
(F1
F0.00014334862385321102
I0
I1
I-1
tp12685
sS'product,erythro-fluorocitrate'
p12686
(F1
F0.00014334862385321102
I0
I1
I-1
tp12687
sS'in,significant'
p12688
(F1
F0.00014334862385321102
I1
I0
I1
tp12689
sS'between,these'
p12690
(F1
F0.00014334862385321102
I0
I1
I-1
tp12691
sS'clinical,bleeding'
p12692
(F1
F0.00028669724770642203
I2
I0
I2
tp12693
sS'decreased,hearing'
p12694
(F1
F0.00014334862385321102
I1
I0
I1
tp12695
sS'lower,and'
p12696
(F1
F0.00028669724770642203
I2
I0
I2
tp12697
sS'when,starlix'
p12698
(F1
F0.00028669724770642203
I0
I2
I-2
tp12699
sS'solutions,containing'
p12700
(F0.5
F0.00028669724770642203
I3
I1
I2
tp12701
sS'patient,receiving'
p12702
(F1
F0.00057339449541284407
I4
I0
I4
tp12703
sS'with,ribavirin'
p12704
(F1
F0.00028669724770642203
I0
I2
I-2
tp12705
sS'forms,may'
p12706
(F1
F0.00014334862385321102
I1
I0
I1
tp12707
sS'as,antineoplastic'
p12708
(F1
F0.00014334862385321102
I1
I0
I1
tp12709
sS'also,reported'
p12710
(F1
F0.00014334862385321102
I1
I0
I1
tp12711
sS'potassium-sparing,such'
p12712
(F1
F0.00014334862385321102
I0
I1
I-1
tp12713
sS'given,weekly'
p12714
(F1
F0.00014334862385321102
I0
I1
I-1
tp12715
sS'rbc,were'
p12716
(F1
F0.00014334862385321102
I0
I1
I-1
tp12717
sS'been,compared'
p12718
(F1
F0.00014334862385321102
I0
I1
I-1
tp12719
sS'similar,serum'
p12720
(F1
F0.00014334862385321102
I0
I1
I-1
tp12721
sS'paclitaxel,in'
p12722
(F1
F0.00014334862385321102
I1
I0
I1
tp12723
sS'also,be'
p12724
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp12725
sS'possible,complications'
p12726
(F1
F0.00014334862385321102
I1
I0
I1
tp12727
sS'the,excreted'
p12728
(F1
F0.00014334862385321102
I0
I1
I-1
tp12729
sS'clinical,studies'
p12730
(F0.12820512820512819
F0.00071674311926605509
I17
I22
I-5
tp12731
sS'immunoreactive,after'
p12732
(F1
F0.00014334862385321102
I0
I1
I-1
tp12733
sS'systemically-administered,oral'
p12734
(F1
F0.00014334862385321102
I1
I0
I1
tp12735
sS'elevated,creatinine'
p12736
(F1
F0.00014334862385321102
I0
I1
I-1
tp12737
sS'abstracts,using'
p12738
(F1
F0.00014334862385321102
I0
I1
I-1
tp12739
sS'antiarrhythmics,other'
p12740
(F1
F0.00014334862385321102
I0
I1
I-1
tp12741
sS'qtc,interval'
p12742
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12743
sS'with,modest'
p12744
(F1
F0.00014334862385321102
I1
I0
I1
tp12745
sS'either,alone'
p12746
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp12747
sS'the,minimum'
p12748
(F1
F0.00014334862385321102
I0
I1
I-1
tp12749
sS'administered,orally'
p12750
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12751
sS'use,during'
p12752
(F1
F0.00014334862385321102
I1
I0
I1
tp12753
sS'concomitant,useof'
p12754
(F1
F0.00014334862385321102
I1
I0
I1
tp12755
sS'concomitant,intake'
p12756
(F1
F0.00014334862385321102
I0
I1
I-1
tp12757
sS'when,hcl'
p12758
(F1
F0.00014334862385321102
I1
I0
I1
tp12759
sS'as,random'
p12760
(F1
F0.00014334862385321102
I1
I0
I1
tp12761
sS'system,can'
p12762
(F1
F0.00014334862385321102
I1
I0
I1
tp12763
sS'with,channel'
p12764
(F1
F0.00014334862385321102
I1
I0
I1
tp12765
sS'of,myobloc'
p12766
(F1
F0.00014334862385321102
I1
I0
I1
tp12767
sS'but,had'
p12768
(F0
F0
I1
I1
I0
tp12769
sS'vitamin,supplements'
p12770
(F1
F0.00014334862385321102
I1
I0
I1
tp12771
sS'is,completely'
p12772
(F1
F0.00014334862385321102
I0
I1
I-1
tp12773
sS'also,receiving'
p12774
(F1
F0.00014334862385321102
I0
I1
I-1
tp12775
sS'were,mp'
p12776
(F1
F0.00014334862385321102
I0
I1
I-1
tp12777
sS'potassium-depleting,and'
p12778
(F1
F0.00014334862385321102
I0
I1
I-1
tp12779
sS'or,subsequent'
p12780
(F1
F0.00014334862385321102
I1
I0
I1
tp12781
sS'appropriate,dose'
p12782
(F0
F0
I1
I1
I0
tp12783
sS'dialysis,may'
p12784
(F1
F0.00014334862385321102
I1
I0
I1
tp12785
sS'directly,on'
p12786
(F1
F0.00014334862385321102
I1
I0
I1
tp12787
sS'be,capable'
p12788
(F1
F0.00014334862385321102
I1
I0
I1
tp12789
sS'close,monitoring'
p12790
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp12791
sS'phenobarbital,tegretol'
p12792
(F1
F0.00014334862385321102
I1
I0
I1
tp12793
sS'pharmacology-pharmacokinetics,drug-drug'
p12794
(F1
F0.00014334862385321102
I0
I1
I-1
tp12795
sS'was,added'
p12796
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp12797
sS'cimetidine,atorvastatin'
p12798
(F1
F0.00014334862385321102
I0
I1
I-1
tp12799
sS'can,avoid'
p12800
(F1
F0.00014334862385321102
I1
I0
I1
tp12801
sS'tolerance,in'
p12802
(F1
F0.00028669724770642203
I2
I0
I2
tp12803
sS'concomitantly,with'
p12804
(F0.41176470588235292
F0.0050172018348623856
I60
I25
I35
tp12805
sS'near,mg'
p12806
(F1
F0.00014334862385321102
I1
I0
I1
tp12807
sS'antihypertensive,agents'
p12808
(F1
F0.00043004587155963305
I3
I0
I3
tp12809
sS'concomitant,agents'
p12810
(F1
F0.00014334862385321102
I0
I1
I-1
tp12811
sS'infusion,rate'
p12812
(F1
F0.00028669724770642203
I2
I0
I2
tp12813
sS'p,this'
p12814
(F1
F0.00014334862385321102
I1
I0
I1
tp12815
sS'systematically,investigated'
p12816
(F1
F0.00014334862385321102
I0
I1
I-1
tp12817
sS'extended,sodium'
p12818
(F1
F0.00014334862385321102
I0
I1
I-1
tp12819
sS'on,measures'
p12820
(F1
F0.00014334862385321102
I0
I1
I-1
tp12821
sS'an,analog'
p12822
(F1
F0.00014334862385321102
I0
I1
I-1
tp12823
sS'studies,used'
p12824
(F1
F0.00014334862385321102
I0
I1
I-1
tp12825
sS'demonstrated,to'
p12826
(F1
F0.00043004587155963305
I3
I0
I3
tp12827
sS'cyp,drug-metabolizing'
p12828
(F1
F0.00014334862385321102
I0
I1
I-1
tp12829
sS'importance,brevibloc'
p12830
(F1
F0.00014334862385321102
I1
I0
I1
tp12831
sS'crisis,until'
p12832
(F1
F0.00014334862385321102
I1
I0
I1
tp12833
sS'c,diethyl'
p12834
(F1
F0.00014334862385321102
I0
I1
I-1
tp12835
sS'conclusions,in'
p12836
(F1
F0.00014334862385321102
I0
I1
I-1
tp12837
sS'inhibiting,the'
p12838
(F1
F0.00057339449541284407
I4
I0
I4
tp12839
sS'or,has'
p12840
(F1
F0.00071674311926605509
I5
I0
I5
tp12841
sS'hydrochloride,mg'
p12842
(F1
F0.00028669724770642203
I0
I2
I-2
tp12843
sS'dispersible,buffered'
p12844
(F1
F0.00014334862385321102
I1
I0
I1
tp12845
sS'major,ingredient'
p12846
(F1
F0.00014334862385321102
I0
I1
I-1
tp12847
sS'acid,sympathomimet-ics'
p12848
(F1
F0.00014334862385321102
I0
I1
I-1
tp12849
sS'or,had'
p12850
(F0
F0
I1
I1
I0
tp12851
sS'their,metabolites'
p12852
(F1
F0.00014334862385321102
I0
I1
I-1
tp12853
sS'antimicrobial,activity'
p12854
(F1
F0.00014334862385321102
I0
I1
I-1
tp12855
sS'parental,such'
p12856
(F1
F0.00014334862385321102
I1
I0
I1
tp12857
sS'from,marketing'
p12858
(F1
F0.00014334862385321102
I1
I0
I1
tp12859
sS'aspirin-mediated,inhibition'
p12860
(F1
F0.00014334862385321102
I0
I1
I-1
tp12861
sS'used,cautiously'
p12862
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp12863
sS'using,four'
p12864
(F1
F0.00014334862385321102
I0
I1
I-1
tp12865
sS'have,produced'
p12866
(F1
F0.00043004587155963305
I3
I0
I3
tp12867
sS'transcriptase,inhibitor'
p12868
(F1
F0.00014334862385321102
I0
I1
I-1
tp12869
sS'with,busulfex'
p12870
(F1
F0.00014334862385321102
I1
I0
I1
tp12871
sS'a,possible'
p12872
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp12873
sS'patients,the'
p12874
(F0.5
F0.0011467889908256881
I12
I4
I8
tp12875
sS'maximal,plasma'
p12876
(F1
F0.00043004587155963305
I3
I0
I3
tp12877
sS'cytostatic,agent'
p12878
(F1
F0.00014334862385321102
I1
I0
I1
tp12879
sS'examining,the'
p12880
(F1
F0.00014334862385321102
I0
I1
I-1
tp12881
sS'costs,of'
p12882
(F1
F0.00014334862385321102
I0
I1
I-1
tp12883
sS'marrow,depression'
p12884
(F1
F0.00014334862385321102
I1
I0
I1
tp12885
sS'clinician,should'
p12886
(F1
F0.00014334862385321102
I1
I0
I1
tp12887
sS'm,failed'
p12888
(F1
F0.00014334862385321102
I1
I0
I1
tp12889
sS'the,complete'
p12890
(F1
F0.00014334862385321102
I0
I1
I-1
tp12891
sS'modest,degree'
p12892
(F1
F0.00014334862385321102
I0
I1
I-1
tp12893
sS'tam,which'
p12894
(F1
F0.00014334862385321102
I0
I1
I-1
tp12895
sS'fatal,adverse'
p12896
(F1
F0.00014334862385321102
I0
I1
I-1
tp12897
sS'minor,increase'
p12898
(F1
F0.00014334862385321102
I1
I0
I1
tp12899
sS'keppra,and'
p12900
(F1
F0.00028669724770642203
I0
I2
I-2
tp12901
sS'that,users'
p12902
(F1
F0.00028669724770642203
I2
I0
I2
tp12903
sS'to,blunt'
p12904
(F1
F0.00028669724770642203
I2
I0
I2
tp12905
sS'parvum,growth'
p12906
(F1
F0.00014334862385321102
I1
I0
I1
tp12907
sS'and,clinical'
p12908
(F0
F0
I1
I1
I0
tp12909
sS'persistently,elevated'
p12910
(F1
F0.00014334862385321102
I0
I1
I-1
tp12911
sS'cancidas,reduced'
p12912
(F1
F0.00014334862385321102
I1
I0
I1
tp12913
sS'atorvastatin,had'
p12914
(F1
F0.00014334862385321102
I0
I1
I-1
tp12915
sS'with,resulted'
p12916
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp12917
sS'approximately,increase'
p12918
(F1
F0.00014334862385321102
I1
I0
I1
tp12919
sS'medicine,blood'
p12920
(F1
F0.00014334862385321102
I1
I0
I1
tp12921
sS'inhibitors,rare'
p12922
(F1
F0.00014334862385321102
I1
I0
I1
tp12923
sS'known,it'
p12924
(F0
F0
I1
I1
I0
tp12925
sS'slight,decreases'
p12926
(F1
F0.00014334862385321102
I1
I0
I1
tp12927
sS'acid,should'
p12928
(F1
F0.00014334862385321102
I0
I1
I-1
tp12929
sS'mg,co-administered'
p12930
(F1
F0.00014334862385321102
I1
I0
I1
tp12931
sS'epithelium,by'
p12932
(F1
F0.00014334862385321102
I1
I0
I1
tp12933
sS'n,n-diethyl'
p12934
(F1
F0.00014334862385321102
I1
I0
I1
tp12935
sS'completely,block'
p12936
(F1
F0.00014334862385321102
I1
I0
I1
tp12937
sS'appears,that'
p12938
(F1
F0.00014334862385321102
I1
I0
I1
tp12939
sS'window,is'
p12940
(F1
F0.00014334862385321102
I1
I0
I1
tp12941
sS'oral,medication'
p12942
(F1
F0.00014334862385321102
I1
I0
I1
tp12943
sS'neglect,of'
p12944
(F1
F0.00014334862385321102
I0
I1
I-1
tp12945
sS'binding,to'
p12946
(F0
F0
I3
I3
I0
tp12947
sS'following,anti-anxiety'
p12948
(F1
F0.00014334862385321102
I0
I1
I-1
tp12949
sS'but,the'
p12950
(F0.5
F0.00028669724770642203
I3
I1
I2
tp12951
sS'carbonate,the'
p12952
(F1
F0.00028669724770642203
I2
I0
I2
tp12953
sS'in,healthy'
p12954
(F0
F0
I24
I24
I0
tp12955
sS'butyrophenone,classes'
p12956
(F1
F0.00014334862385321102
I1
I0
I1
tp12957
sS'acute,delirium'
p12958
(F1
F0.00014334862385321102
I1
I0
I1
tp12959
sS'digoxin,concomitant'
p12960
(F0
F0
I1
I1
I0
tp12961
sS'in,over'
p12962
(F1
F0.00014334862385321102
I1
I0
I1
tp12963
sS'w,and'
p12964
(F1
F0.00014334862385321102
I1
I0
I1
tp12965
sS'phenytoin,if'
p12966
(F1
F0.00014334862385321102
I1
I0
I1
tp12967
sS'not,observed'
p12968
(F0
F0
I1
I1
I0
tp12969
sS'estradiol,the'
p12970
(F1
F0.00014334862385321102
I0
I1
I-1
tp12971
sS'phenytoin,in'
p12972
(F0
F0
I1
I1
I0
tp12973
sS'imidazole,and'
p12974
(F0
F0
I1
I1
I0
tp12975
sS'blood,sugar'
p12976
(F1
F0.00028669724770642203
I2
I0
I2
tp12977
sS'contribute,to'
p12978
(F1
F0.00028669724770642203
I2
I0
I2
tp12979
sS'experience,with'
p12980
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp12981
sS'lymphatic,invasion'
p12982
(F1
F0.00014334862385321102
I1
I0
I1
tp12983
sS'administered,intraperitoneally'
p12984
(F1
F0.00014334862385321102
I0
I1
I-1
tp12985
sS'may,sensitize'
p12986
(F1
F0.00014334862385321102
I1
I0
I1
tp12987
sS'care,as'
p12988
(F1
F0.00014334862385321102
I1
I0
I1
tp12989
sS'antizol,mg'
p12990
(F1
F0.00014334862385321102
I1
I0
I1
tp12991
sS'minor,metabolic'
p12992
(F1
F0.00014334862385321102
I0
I1
I-1
tp12993
sS'when,eulexin'
p12994
(F1
F0.00014334862385321102
I1
I0
I1
tp12995
sS'undetectable,release'
p12996
(F1
F0.00014334862385321102
I0
I1
I-1
tp12997
sS'raptiva,should'
p12998
(F1
F0.00014334862385321102
I1
I0
I1
tp12999
sS'insp,together'
p13000
(F1
F0.00014334862385321102
I1
I0
I1
tp13001
sS'kineret,when'
p13002
(F1
F0.00014334862385321102
I0
I1
I-1
tp13003
sS'rhythm,following'
p13004
(F1
F0.00014334862385321102
I1
I0
I1
tp13005
sS'not,alter'
p13006
(F0.90909090909090906
F0.0028669724770642203
I1
I21
I-20
tp13007
sS'nad,dependent'
p13008
(F0
F0
I1
I1
I0
tp13009
sS'by,intrathecal'
p13010
(F1
F0.00014334862385321102
I0
I1
I-1
tp13011
sS'not,concurrently'
p13012
(F1
F0.00014334862385321102
I1
I0
I1
tp13013
sS'ranitidine,in'
p13014
(F1
F0.00014334862385321102
I1
I0
I1
tp13015
sS'and,s-warfarin'
p13016
(F1
F0.00014334862385321102
I1
I0
I1
tp13017
sS'prohibited,in'
p13018
(F1
F0.00014334862385321102
I0
I1
I-1
tp13019
sS'is,prolonged'
p13020
(F1
F0.00014334862385321102
I0
I1
I-1
tp13021
sS'be,observed'
p13022
(F0.55555555555555558
F0.0021502293577981653
I21
I6
I15
tp13023
sS'successive,application'
p13024
(F1
F0.00014334862385321102
I1
I0
I1
tp13025
sS'treatments,of'
p13026
(F1
F0.00014334862385321102
I0
I1
I-1
tp13027
sS'since,and'
p13028
(F1
F0.00028669724770642203
I2
I0
I2
tp13029
sS'alter,the'
p13030
(F0.51515151515151514
F0.0024369266055045873
I8
I25
I-17
tp13031
sS'infections,and'
p13032
(F1
F0.00028669724770642203
I2
I0
I2
tp13033
sS'elevated,in'
p13034
(F1
F0.00028669724770642203
I0
I2
I-2
tp13035
sS'also,lowers'
p13036
(F1
F0.00014334862385321102
I0
I1
I-1
tp13037
sS'exaggeration,of'
p13038
(F1
F0.00014334862385321102
I1
I0
I1
tp13039
sS'however,severe'
p13040
(F1
F0.00014334862385321102
I0
I1
I-1
tp13041
sS'including,remicade'
p13042
(F1
F0.00014334862385321102
I1
I0
I1
tp13043
sS'antianxiety,agents'
p13044
(F1
F0.00028669724770642203
I2
I0
I2
tp13045
sS'exhibit,monoamine'
p13046
(F1
F0.00014334862385321102
I1
I0
I1
tp13047
sS'dose-related,blockade'
p13048
(F1
F0.00014334862385321102
I1
I0
I1
tp13049
sS'to,higher'
p13050
(F1
F0.00014334862385321102
I1
I0
I1
tp13051
sS'hormonal,differ'
p13052
(F1
F0.00014334862385321102
I0
I1
I-1
tp13053
sS'enhances,the'
p13054
(F1
F0.00057339449541284407
I4
I0
I4
tp13055
sS'renal,toxicity'
p13056
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13057
sS'the,pharmacologic'
p13058
(F1
F0.00043004587155963305
I3
I0
I3
tp13059
sS'free,may'
p13060
(F1
F0.00014334862385321102
I1
I0
I1
tp13061
sS'importance,sufficient'
p13062
(F1
F0.00014334862385321102
I1
I0
I1
tp13063
sS'agents,interfering'
p13064
(F1
F0.00028669724770642203
I2
I0
I2
tp13065
sS'twice-a,day'
p13066
(F1
F0.00014334862385321102
I0
I1
I-1
tp13067
sS'the,introduction'
p13068
(F1
F0.00014334862385321102
I1
I0
I1
tp13069
sS'with,dopa'
p13070
(F1
F0.00014334862385321102
I0
I1
I-1
tp13071
sS'lexapro,and'
p13072
(F0
F0
I1
I1
I0
tp13073
sS'differ,in'
p13074
(F1
F0.00014334862385321102
I0
I1
I-1
tp13075
sS'cases,was'
p13076
(F1
F0.00014334862385321102
I0
I1
I-1
tp13077
sS'intake,of'
p13078
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp13079
sS'adversely,affect'
p13080
(F1
F0.00014334862385321102
I1
I0
I1
tp13081
sS'an,overactive'
p13082
(F1
F0.00014334862385321102
I0
I1
I-1
tp13083
sS'been,postmarketing'
p13084
(F1
F0.00014334862385321102
I1
I0
I1
tp13085
sS'was,noted'
p13086
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp13087
sS'interactions,and'
p13088
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp13089
sS'received,ace'
p13090
(F1
F0.00014334862385321102
I0
I1
I-1
tp13091
sS'medications,or'
p13092
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp13093
sS'cisplatin,hcl'
p13094
(F1
F0.00014334862385321102
I1
I0
I1
tp13095
sS'a,penicillin-type'
p13096
(F1
F0.00014334862385321102
I1
I0
I1
tp13097
sS'active,ra'
p13098
(F1
F0.00028669724770642203
I2
I0
I2
tp13099
sS'in,two'
p13100
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp13101
sS'magnesium-,and'
p13102
(F1
F0.00028669724770642203
I2
I0
I2
tp13103
sS'shown,consistent'
p13104
(F1
F0.00014334862385321102
I0
I1
I-1
tp13105
sS'average,steady-'
p13106
(F1
F0.00014334862385321102
I1
I0
I1
tp13107
sS'those,required'
p13108
(F1
F0.00014334862385321102
I1
I0
I1
tp13109
sS'and,more'
p13110
(F1
F0.00014334862385321102
I1
I0
I1
tp13111
sS'hcl,usually'
p13112
(F1
F0.00014334862385321102
I1
I0
I1
tp13113
sS'induced,with'
p13114
(F1
F0.00014334862385321102
I1
I0
I1
tp13115
sS'through,udp-glucuronyl'
p13116
(F1
F0.00014334862385321102
I0
I1
I-1
tp13117
sS'doses,vioxx'
p13118
(F1
F0.00014334862385321102
I1
I0
I1
tp13119
sS'some,cases'
p13120
(F1
F0.00014334862385321102
I0
I1
I-1
tp13121
sS'clotting,time'
p13122
(F1
F0.00028669724770642203
I0
I2
I-2
tp13123
sS'and,inhaled'
p13124
(F1
F0.00014334862385321102
I0
I1
I-1
tp13125
sS'also,the'
p13126
(F1
F0.00014334862385321102
I0
I1
I-1
tp13127
sS'recommended,unless'
p13128
(F1
F0.00014334862385321102
I1
I0
I1
tp13129
sS'liver,aminotransferases'
p13130
(F1
F0.00014334862385321102
I0
I1
I-1
tp13131
sS'and,for'
p13132
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp13133
sS'which,are'
p13134
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp13135
sS'provided,this'
p13136
(F1
F0.00014334862385321102
I1
I0
I1
tp13137
sS'overdosage,since'
p13138
(F1
F0.00014334862385321102
I1
I0
I1
tp13139
sS'xr,patients'
p13140
(F1
F0.00014334862385321102
I0
I1
I-1
tp13141
sS'the,group'
p13142
(F1
F0.00014334862385321102
I0
I1
I-1
tp13143
sS'reactions,compared'
p13144
(F1
F0.00014334862385321102
I0
I1
I-1
tp13145
sS'with,hepatic'
p13146
(F0
F0
I1
I1
I0
tp13147
sS'enzyme,responsible'
p13148
(F1
F0.00014334862385321102
I1
I0
I1
tp13149
sS'a,different'
p13150
(F0
F0
I1
I1
I0
tp13151
sS'norfluoxe-tine,have'
p13152
(F1
F0.00014334862385321102
I0
I1
I-1
tp13153
sS'of,neurons'
p13154
(F1
F0.00014334862385321102
I0
I1
I-1
tp13155
sS'and,abciximab'
p13156
(F1
F0.00014334862385321102
I1
I0
I1
tp13157
sS'carbonate,or'
p13158
(F1
F0.00014334862385321102
I1
I0
I1
tp13159
sS'reported,rarely'
p13160
(F0.5
F0.00028669724770642203
I3
I1
I2
tp13161
sS'including,based'
p13162
(F1
F0.00014334862385321102
I1
I0
I1
tp13163
sS'a,release'
p13164
(F1
F0.00014334862385321102
I0
I1
I-1
tp13165
sS'felbatol,gris-peg'
p13166
(F1
F0.00014334862385321102
I1
I0
I1
tp13167
sS'epoxide,concentrations'
p13168
(F1
F0.00014334862385321102
I0
I1
I-1
tp13169
sS'mg,as'
p13170
(F1
F0.00028669724770642203
I0
I2
I-2
tp13171
sS'mainly,responsible'
p13172
(F1
F0.00014334862385321102
I1
I0
I1
tp13173
sS'oral,route'
p13174
(F1
F0.00014334862385321102
I0
I1
I-1
tp13175
sS'usual,dose'
p13176
(F1
F0.00043004587155963305
I3
I0
I3
tp13177
sS'plasma,exposures'
p13178
(F1
F0.00014334862385321102
I1
I0
I1
tp13179
sS'vision,have'
p13180
(F1
F0.00028669724770642203
I2
I0
I2
tp13181
sS'supplied,aerolizertm'
p13182
(F1
F0.00014334862385321102
I0
I1
I-1
tp13183
sS'system,regardless'
p13184
(F1
F0.00014334862385321102
I1
I0
I1
tp13185
sS'or,increased'
p13186
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13187
sS'exposure,despite'
p13188
(F1
F0.00014334862385321102
I0
I1
I-1
tp13189
sS'immunoreactive,concentrations'
p13190
(F1
F0.00014334862385321102
I0
I1
I-1
tp13191
sS'diastolic,blood'
p13192
(F1
F0.00014334862385321102
I1
I0
I1
tp13193
sS'expected,plasma'
p13194
(F1
F0.00057339449541284407
I0
I4
I-4
tp13195
sS'mg,followed'
p13196
(F1
F0.00014334862385321102
I0
I1
I-1
tp13197
sS'inwomen,taking'
p13198
(F1
F0.00014334862385321102
I1
I0
I1
tp13199
sS'caution,in'
p13200
(F0.55555555555555558
F0.0014334862385321102
I14
I4
I10
tp13201
sS'hypertension,did'
p13202
(F1
F0.00014334862385321102
I0
I1
I-1
tp13203
sS'caution,if'
p13204
(F1
F0.00014334862385321102
I1
I0
I1
tp13205
sS'presented,here'
p13206
(F1
F0.00014334862385321102
I0
I1
I-1
tp13207
sS'agents,negative'
p13208
(F1
F0.00014334862385321102
I1
I0
I1
tp13209
sS'caution,is'
p13210
(F1
F0.0027236238532110093
I19
I0
I19
tp13211
sS'of,lanoxin'
p13212
(F1
F0.00014334862385321102
I1
I0
I1
tp13213
sS'least,partially'
p13214
(F1
F0.00014334862385321102
I1
I0
I1
tp13215
sS'received,both'
p13216
(F1
F0.00014334862385321102
I0
I1
I-1
tp13217
sS'multiple,dose'
p13218
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp13219
sS'antagonist,eg'
p13220
(F1
F0.00014334862385321102
I1
I0
I1
tp13221
sS'when,orudis'
p13222
(F1
F0.00014334862385321102
I0
I1
I-1
tp13223
sS'cytochrome,p-450'
p13224
(F0.75
F0.0008600917431192661
I7
I1
I6
tp13225
sS'sensipar,is'
p13226
(F1
F0.00043004587155963305
I0
I3
I-3
tp13227
sS'periodic,intervals'
p13228
(F1
F0.00014334862385321102
I1
I0
I1
tp13229
sS'to,indirect-acting'
p13230
(F1
F0.00014334862385321102
I1
I0
I1
tp13231
sS'meq,or'
p13232
(F1
F0.00014334862385321102
I0
I1
I-1
tp13233
sS'kinetic,characteristics'
p13234
(F1
F0.00014334862385321102
I0
I1
I-1
tp13235
sS'of,negative'
p13236
(F1
F0.00028669724770642203
I0
I2
I-2
tp13237
sS'm2,and'
p13238
(F1
F0.00014334862385321102
I1
I0
I1
tp13239
sS'interactions,of'
p13240
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp13241
sS'neurologic,disorders'
p13242
(F1
F0.00014334862385321102
I0
I1
I-1
tp13243
sS'supplementary,oral'
p13244
(F1
F0.00014334862385321102
I0
I1
I-1
tp13245
sS'potassium,prinivil'
p13246
(F1
F0.00014334862385321102
I1
I0
I1
tp13247
sS'causing,increased'
p13248
(F1
F0.00014334862385321102
I1
I0
I1
tp13249
sS'little,change'
p13250
(F1
F0.00014334862385321102
I1
I0
I1
tp13251
sS'blood,sampling'
p13252
(F1
F0.00014334862385321102
I0
I1
I-1
tp13253
sS'total,bioavailability'
p13254
(F1
F0.00014334862385321102
I0
I1
I-1
tp13255
sS'agents,without'
p13256
(F1
F0.00014334862385321102
I0
I1
I-1
tp13257
sS'usually,results'
p13258
(F1
F0.00014334862385321102
I1
I0
I1
tp13259
sS'trial,using'
p13260
(F1
F0.00014334862385321102
I1
I0
I1
tp13261
sS'narcotic,general'
p13262
(F1
F0.00014334862385321102
I1
I0
I1
tp13263
sS'seen,after'
p13264
(F1
F0.00014334862385321102
I1
I0
I1
tp13265
sS'trial,there'
p13266
(F1
F0.00014334862385321102
I0
I1
I-1
tp13267
sS'hydroxide-containing,maalox'
p13268
(F1
F0.00014334862385321102
I0
I1
I-1
tp13269
sS'indomethacin,indomethacin'
p13270
(F1
F0.00014334862385321102
I1
I0
I1
tp13271
sS'component,in'
p13272
(F1
F0.00014334862385321102
I0
I1
I-1
tp13273
sS'multiple-dose,study'
p13274
(F0
F0
I1
I1
I0
tp13275
sS'glycosides,concurrent'
p13276
(F1
F0.00014334862385321102
I0
I1
I-1
tp13277
sS'accumulation,in'
p13278
(F1
F0.00014334862385321102
I1
I0
I1
tp13279
sS'serotonin,releaser'
p13280
(F1
F0.00014334862385321102
I1
I0
I1
tp13281
sS'tml,or'
p13282
(F1
F0.00014334862385321102
I0
I1
I-1
tp13283
sS'performed,coadministration'
p13284
(F1
F0.00014334862385321102
I1
I0
I1
tp13285
sS'or,primidone'
p13286
(F1
F0.00014334862385321102
I0
I1
I-1
tp13287
sS'given,hour'
p13288
(F1
F0.00014334862385321102
I1
I0
I1
tp13289
sS'the,half-life'
p13290
(F1
F0.00071674311926605509
I5
I0
I5
tp13291
sS'systematically,studied'
p13292
(F1
F0.00014334862385321102
I1
I0
I1
tp13293
sS'cyclosporine,modest'
p13294
(F1
F0.00014334862385321102
I1
I0
I1
tp13295
sS'severe,weakness'
p13296
(F1
F0.00014334862385321102
I1
I0
I1
tp13297
sS'this,was'
p13298
(F0
F0
I1
I1
I0
tp13299
sS'theophylline,the'
p13300
(F1
F0.00028669724770642203
I0
I2
I-2
tp13301
sS'broadly,the'
p13302
(F1
F0.00014334862385321102
I0
I1
I-1
tp13303
sS'sulfosalicylic,acid'
p13304
(F1
F0.00014334862385321102
I0
I1
I-1
tp13305
sS'four,patients'
p13306
(F1
F0.00014334862385321102
I1
I0
I1
tp13307
sS'been,fully'
p13308
(F1
F0.00014334862385321102
I1
I0
I1
tp13309
sS'six-healthy,male'
p13310
(F1
F0.00014334862385321102
I0
I1
I-1
tp13311
sS'for,colazal'
p13312
(F1
F0.00014334862385321102
I0
I1
I-1
tp13313
sS'methods,from'
p13314
(F1
F0.00014334862385321102
I0
I1
I-1
tp13315
sS'two,clinical'
p13316
(F1
F0.00014334862385321102
I1
I0
I1
tp13317
sS'or,two'
p13318
(F1
F0.00014334862385321102
I1
I0
I1
tp13319
sS'useful,in'
p13320
(F1
F0.00014334862385321102
I1
I0
I1
tp13321
sS'of,up'
p13322
(F1
F0.00028669724770642203
I0
I2
I-2
tp13323
sS'profiles,in'
p13324
(F1
F0.00014334862385321102
I0
I1
I-1
tp13325
sS'metabolite,norfluoxe-tine'
p13326
(F1
F0.00014334862385321102
I0
I1
I-1
tp13327
sS'dosage,or'
p13328
(F1
F0.00014334862385321102
I0
I1
I-1
tp13329
sS'and,wide'
p13330
(F1
F0.00014334862385321102
I0
I1
I-1
tp13331
sS'infusion,of'
p13332
(F1
F0.00028669724770642203
I0
I2
I-2
tp13333
sS'one,reported'
p13334
(F1
F0.00014334862385321102
I1
I0
I1
tp13335
sS'can,enhance'
p13336
(F1
F0.00014334862385321102
I0
I1
I-1
tp13337
sS'this,has'
p13338
(F1
F0.00028669724770642203
I2
I0
I2
tp13339
sS'equetrotm,it'
p13340
(F1
F0.00014334862385321102
I1
I0
I1
tp13341
sS'equetrotm,is'
p13342
(F1
F0.00014334862385321102
I1
I0
I1
tp13343
sS'are,conflicting'
p13344
(F1
F0.00014334862385321102
I1
I0
I1
tp13345
sS'study,week'
p13346
(F1
F0.00014334862385321102
I0
I1
I-1
tp13347
sS'the,presence'
p13348
(F0.125
F0.00057339449541284407
I14
I18
I-4
tp13349
sS'using,for'
p13350
(F1
F0.00014334862385321102
I0
I1
I-1
tp13351
sS'etc,or'
p13352
(F1
F0.00014334862385321102
I1
I0
I1
tp13353
sS'than,for'
p13354
(F0.5
F0.00028669724770642203
I3
I1
I2
tp13355
sS'the,capsule'
p13356
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13357
sS'of,tambocor'
p13358
(F0
F0
I2
I2
I0
tp13359
sS'increased,amounts'
p13360
(F1
F0.00014334862385321102
I0
I1
I-1
tp13361
sS'or,prophylactic'
p13362
(F1
F0.00014334862385321102
I0
I1
I-1
tp13363
sS'and,anti'
p13364
(F1
F0.00014334862385321102
I0
I1
I-1
tp13365
sS'pulmonary,toxicity'
p13366
(F1
F0.00014334862385321102
I1
I0
I1
tp13367
sS'damage,produced'
p13368
(F1
F0.00014334862385321102
I1
I0
I1
tp13369
sS'decreases,the'
p13370
(F0.5
F0.00028669724770642203
I3
I1
I2
tp13371
sS'non-selective,monoamine'
p13372
(F1
F0.00014334862385321102
I0
I1
I-1
tp13373
sS'states,to'
p13374
(F1
F0.00014334862385321102
I1
I0
I1
tp13375
sS'the,hyperuricemic'
p13376
(F1
F0.00028669724770642203
I2
I0
I2
tp13377
sS'phase,i'
p13378
(F0
F0
I1
I1
I0
tp13379
sS'potassium-sparing,including'
p13380
(F1
F0.00014334862385321102
I1
I0
I1
tp13381
sS'life-,threatening'
p13382
(F1
F0.00014334862385321102
I1
I0
I1
tp13383
sS'antihypertensive,effect'
p13384
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp13385
sS'with,platelet-aggregation'
p13386
(F1
F0.00014334862385321102
I1
I0
I1
tp13387
sS'tightly,bound'
p13388
(F1
F0.00014334862385321102
I0
I1
I-1
tp13389
sS'by,chloral'
p13390
(F1
F0.00014334862385321102
I0
I1
I-1
tp13391
sS'to,compete'
p13392
(F1
F0.00014334862385321102
I0
I1
I-1
tp13393
sS'death,due'
p13394
(F1
F0.00014334862385321102
I1
I0
I1
tp13395
sS'produce,adverse'
p13396
(F1
F0.00014334862385321102
I0
I1
I-1
tp13397
sS'significantly,lowering'
p13398
(F1
F0.00014334862385321102
I0
I1
I-1
tp13399
sS'and,such'
p13400
(F1
F0.00043004587155963305
I3
I0
I3
tp13401
sS'mephenytoin,mesantoin'
p13402
(F1
F0.00014334862385321102
I0
I1
I-1
tp13403
sS'topical,dose'
p13404
(F1
F0.00014334862385321102
I0
I1
I-1
tp13405
sS'max,c'
p13406
(F1
F0.00014334862385321102
I0
I1
I-1
tp13407
sS'the,seizure'
p13408
(F1
F0.00014334862385321102
I1
I0
I1
tp13409
sS'rhabdomyolysis,is'
p13410
(F1
F0.00028669724770642203
I2
I0
I2
tp13411
sS'physician,should'
p13412
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp13413
sS'preliminary,results'
p13414
(F1
F0.00028669724770642203
I0
I2
I-2
tp13415
sS'state,levels'
p13416
(F1
F0.00014334862385321102
I0
I1
I-1
tp13417
sS'bid,otc'
p13418
(F1
F0.00014334862385321102
I1
I0
I1
tp13419
sS'with,crohn'
p13420
(F1
F0.00014334862385321102
I0
I1
I-1
tp13421
sS'other,enzyme-'
p13422
(F1
F0.00028669724770642203
I2
I0
I2
tp13423
sS'hyperuricemia,present'
p13424
(F1
F0.00014334862385321102
I1
I0
I1
tp13425
sS'study,demonstrated'
p13426
(F1
F0.00028669724770642203
I2
I0
I2
tp13427
sS'increased,half-life'
p13428
(F1
F0.00014334862385321102
I1
I0
I1
tp13429
sS'the,low'
p13430
(F1
F0.00014334862385321102
I0
I1
I-1
tp13431
sS'with,citrate'
p13432
(F1
F0.00014334862385321102
I1
I0
I1
tp13433
sS'approximate,reduction'
p13434
(F1
F0.00014334862385321102
I1
I0
I1
tp13435
sS'ribavirin,can'
p13436
(F1
F0.00014334862385321102
I1
I0
I1
tp13437
sS'that,precipitation'
p13438
(F1
F0.00014334862385321102
I0
I1
I-1
tp13439
sS'may,have'
p13440
(F0.2857142857142857
F0.0011467889908256881
I18
I10
I8
tp13441
sS'other,high'
p13442
(F1
F0.00014334862385321102
I0
I1
I-1
tp13443
sS'affect,protein'
p13444
(F1
F0.00014334862385321102
I0
I1
I-1
tp13445
sS'intake,for'
p13446
(F1
F0.00014334862385321102
I1
I0
I1
tp13447
sS'symptoms,leukocytosis'
p13448
(F1
F0.00014334862385321102
I1
I0
I1
tp13449
sS'oral,solution'
p13450
(F1
F0.0011467889908256881
I8
I0
I8
tp13451
sS'valium,is'
p13452
(F1
F0.00014334862385321102
I0
I1
I-1
tp13453
sS'drugs,alcohol'
p13454
(F1
F0.00014334862385321102
I0
I1
I-1
tp13455
sS'd,was'
p13456
(F1
F0.00014334862385321102
I1
I0
I1
tp13457
sS'patient,only'
p13458
(F1
F0.00014334862385321102
I1
I0
I1
tp13459
sS'using,a'
p13460
(F0
F0
I1
I1
I0
tp13461
sS'autoimmune,and'
p13462
(F1
F0.00014334862385321102
I1
I0
I1
tp13463
sS'seizure,associated'
p13464
(F1
F0.00014334862385321102
I0
I1
I-1
tp13465
sS'to,three'
p13466
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13467
sS'a,beta'
p13468
(F1
F0.00014334862385321102
I1
I0
I1
tp13469
sS'parameter,values'
p13470
(F1
F0.00014334862385321102
I0
I1
I-1
tp13471
sS'hypermagnesemia,and'
p13472
(F1
F0.00043004587155963305
I3
I0
I3
tp13473
sS'antibiotics,macrolide'
p13474
(F1
F0.00014334862385321102
I1
I0
I1
tp13475
sS'too,much'
p13476
(F0
F0
I1
I1
I0
tp13477
sS'changing,from'
p13478
(F1
F0.00014334862385321102
I0
I1
I-1
tp13479
sS'concomitant,oral'
p13480
(F1
F0.00028669724770642203
I2
I0
I2
tp13481
sS'not,bear'
p13482
(F1
F0.00014334862385321102
I1
I0
I1
tp13483
sS'when,abilify'
p13484
(F1
F0.00014334862385321102
I1
I0
I1
tp13485
sS'status,changes'
p13486
(F1
F0.00014334862385321102
I1
I0
I1
tp13487
sS'for,tubular'
p13488
(F1
F0.00014334862385321102
I1
I0
I1
tp13489
sS'lansoprazole,has'
p13490
(F1
F0.00014334862385321102
I0
I1
I-1
tp13491
sS'and,acetylsalicylic'
p13492
(F0
F0
I1
I1
I0
tp13493
sS'of,rejection'
p13494
(F1
F0.00014334862385321102
I0
I1
I-1
tp13495
sS'weight,heparins'
p13496
(F1
F0.00014334862385321102
I0
I1
I-1
tp13497
sS'either,nanm'
p13498
(F1
F0.00014334862385321102
I1
I0
I1
tp13499
sS'nitrous,oxide'
p13500
(F0
F0
I1
I1
I0
tp13501
sS'interactions,because'
p13502
(F1
F0.00014334862385321102
I0
I1
I-1
tp13503
sS'potentially,interact'
p13504
(F1
F0.00014334862385321102
I0
I1
I-1
tp13505
sS'dose,range'
p13506
(F1
F0.00028669724770642203
I2
I0
I2
tp13507
sS'to,significantly'
p13508
(F0
F0
I1
I1
I0
tp13509
sS'example,inhibitors'
p13510
(F1
F0.00014334862385321102
I0
I1
I-1
tp13511
sS'intracellular,phosphorylation'
p13512
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13513
sS'of,cmc-cys'
p13514
(F1
F0.00014334862385321102
I0
I1
I-1
tp13515
sS'faecium,to'
p13516
(F1
F0.00014334862385321102
I0
I1
I-1
tp13517
sS'responding,whereas'
p13518
(F1
F0.00014334862385321102
I0
I1
I-1
tp13519
sS'editorials,concerning'
p13520
(F1
F0.00014334862385321102
I0
I1
I-1
tp13521
sS'scores,on'
p13522
(F1
F0.00014334862385321102
I1
I0
I1
tp13523
sS'calcium-containing,preparations'
p13524
(F1
F0.00043004587155963305
I0
I3
I-3
tp13525
sS'biliary,excretion'
p13526
(F1
F0.00014334862385321102
I0
I1
I-1
tp13527
sS'iegs,are'
p13528
(F1
F0.00014334862385321102
I0
I1
I-1
tp13529
sS'high,doses'
p13530
(F0.53846153846153844
F0.0010034403669724771
I10
I3
I7
tp13531
sS'and,editorials'
p13532
(F1
F0.00014334862385321102
I0
I1
I-1
tp13533
sS'presumably,through'
p13534
(F1
F0.00014334862385321102
I1
I0
I1
tp13535
sS'fosinopril,sodium'
p13536
(F1
F0.00014334862385321102
I1
I0
I1
tp13537
sS'pivoxil,resulted'
p13538
(F1
F0.00014334862385321102
I1
I0
I1
tp13539
sS'one-fourth,of'
p13540
(F1
F0.00014334862385321102
I1
I0
I1
tp13541
sS'vivo,the'
p13542
(F1
F0.00028669724770642203
I2
I0
I2
tp13543
sS'provide,the'
p13544
(F1
F0.00014334862385321102
I0
I1
I-1
tp13545
sS'medications,containing'
p13546
(F1
F0.00014334862385321102
I1
I0
I1
tp13547
sS'strain,were'
p13548
(F1
F0.00014334862385321102
I0
I1
I-1
tp13549
sS'serum,concentration'
p13550
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp13551
sS'in,opioid-dependent'
p13552
(F1
F0.00014334862385321102
I0
I1
I-1
tp13553
sS'appreciably,metabolized'
p13554
(F1
F0.00014334862385321102
I0
I1
I-1
tp13555
sS'also,decrease'
p13556
(F1
F0.00043004587155963305
I3
I0
I3
tp13557
sS'where,endothelial'
p13558
(F1
F0.00014334862385321102
I0
I1
I-1
tp13559
sS'maalox,coadministration'
p13560
(F1
F0.00014334862385321102
I0
I1
I-1
tp13561
sS'to,withhold'
p13562
(F1
F0.00014334862385321102
I1
I0
I1
tp13563
sS'profile,seen'
p13564
(F1
F0.00014334862385321102
I0
I1
I-1
tp13565
sS'resins,an'
p13566
(F1
F0.00014334862385321102
I1
I0
I1
tp13567
sS'sixty,minutes'
p13568
(F1
F0.00014334862385321102
I1
I0
I1
tp13569
sS'inhibition,and'
p13570
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp13571
sS'of,one'
p13572
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13573
sS'from,regression'
p13574
(F1
F0.00014334862385321102
I1
I0
I1
tp13575
sS'the,clinical'
p13576
(F0.23076923076923078
F0.00043004587155963305
I5
I8
I-3
tp13577
sS'a,baseline'
p13578
(F1
F0.00014334862385321102
I1
I0
I1
tp13579
sS'therapy,may'
p13580
(F0.25
F0.00028669724770642203
I5
I3
I2
tp13581
sS'allows,to'
p13582
(F1
F0.00014334862385321102
I1
I0
I1
tp13583
sS'other,eg'
p13584
(F1
F0.00014334862385321102
I0
I1
I-1
tp13585
sS'suggests,the'
p13586
(F1
F0.00014334862385321102
I1
I0
I1
tp13587
sS'the,photosensitivity'
p13588
(F1
F0.00014334862385321102
I1
I0
I1
tp13589
sS'sequence,ie'
p13590
(F1
F0.00014334862385321102
I1
I0
I1
tp13591
sS'dosage,must'
p13592
(F1
F0.00043004587155963305
I3
I0
I3
tp13593
sS'griseofulvin,griseofulvin'
p13594
(F1
F0.00014334862385321102
I1
I0
I1
tp13595
sS'inhibitor,has'
p13596
(F1
F0.00014334862385321102
I1
I0
I1
tp13597
sS'aspirin,when'
p13598
(F1
F0.00014334862385321102
I1
I0
I1
tp13599
sS'a,patients'
p13600
(F1
F0.00014334862385321102
I1
I0
I1
tp13601
sS'in,male'
p13602
(F1
F0.00028669724770642203
I0
I2
I-2
tp13603
sS'ergocalcitriol,by'
p13604
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13605
sS'xr,was'
p13606
(F1
F0.00014334862385321102
I0
I1
I-1
tp13607
sS'patient,appeared'
p13608
(F1
F0.00014334862385321102
I1
I0
I1
tp13609
sS'affect,platelet'
p13610
(F0
F0
I1
I1
I0
tp13611
sS'chlorpromazine,chlorpromazine'
p13612
(F1
F0.00028669724770642203
I2
I0
I2
tp13613
sS'worsen,side'
p13614
(F1
F0.00014334862385321102
I1
I0
I1
tp13615
sS'and,oxo-desethylzaleplon'
p13616
(F1
F0.00014334862385321102
I0
I1
I-1
tp13617
sS'and,others'
p13618
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp13619
sS'within,two'
p13620
(F1
F0.00014334862385321102
I1
I0
I1
tp13621
sS'given,for'
p13622
(F1
F0.00014334862385321102
I0
I1
I-1
tp13623
sS'in,clinically'
p13624
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp13625
sS'dependent,hypertension'
p13626
(F1
F0.00014334862385321102
I1
I0
I1
tp13627
sS'superior,antipsychotic'
p13628
(F1
F0.00014334862385321102
I0
I1
I-1
tp13629
sS'mg,respectively'
p13630
(F0
F0
I2
I2
I0
tp13631
sS'otc,dose'
p13632
(F1
F0.00014334862385321102
I1
I0
I1
tp13633
sS'vivo,platelet'
p13634
(F1
F0.00014334862385321102
I0
I1
I-1
tp13635
sS'mediate,the'
p13636
(F1
F0.00014334862385321102
I0
I1
I-1
tp13637
sS'if,there'
p13638
(F1
F0.00057339449541284407
I0
I4
I-4
tp13639
sS'cyp1a2,activity'
p13640
(F1
F0.00014334862385321102
I0
I1
I-1
tp13641
sS'ovarian,cancer'
p13642
(F1
F0.00014334862385321102
I1
I0
I1
tp13643
sS'with,high'
p13644
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp13645
sS'demonstrated,renal'
p13646
(F1
F0.00014334862385321102
I0
I1
I-1
tp13647
sS'because,these'
p13648
(F1
F0.00014334862385321102
I1
I0
I1
tp13649
sS'taking,other'
p13650
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13651
sS'intravenous,misuse'
p13652
(F1
F0.00014334862385321102
I1
I0
I1
tp13653
sS'substrates,and'
p13654
(F1
F0.00028669724770642203
I0
I2
I-2
tp13655
sS'when,pletal'
p13656
(F1
F0.00014334862385321102
I1
I0
I1
tp13657
sS'increase,certain'
p13658
(F1
F0.00014334862385321102
I0
I1
I-1
tp13659
sS'on,concurrent'
p13660
(F1
F0.00014334862385321102
I0
I1
I-1
tp13661
sS'class,to'
p13662
(F1
F0.00057339449541284407
I4
I0
I4
tp13663
sS'triazolopyridazines,and'
p13664
(F1
F0.00014334862385321102
I1
I0
I1
tp13665
sS'to,initiation'
p13666
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp13667
sS'other,given'
p13668
(F1
F0.00014334862385321102
I1
I0
I1
tp13669
sS'indirect-acting,agents'
p13670
(F1
F0.00014334862385321102
I1
I0
I1
tp13671
sS'arrhythmia,and'
p13672
(F1
F0.00014334862385321102
I1
I0
I1
tp13673
sS'be,expected'
p13674
(F0.20000000000000001
F0.00057339449541284407
I12
I8
I4
tp13675
sS'rare,but'
p13676
(F1
F0.00014334862385321102
I1
I0
I1
tp13677
sS'argatroban,g'
p13678
(F1
F0.00014334862385321102
I0
I1
I-1
tp13679
sS'by,baseline'
p13680
(F1
F0.00014334862385321102
I0
I1
I-1
tp13681
sS'clinical,response'
p13682
(F1
F0.00014334862385321102
I0
I1
I-1
tp13683
sS'at,mg'
p13684
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp13685
sS'difluoro-2,propanol'
p13686
(F0
F0
I2
I2
I0
tp13687
sS'presumably,acts'
p13688
(F1
F0.00014334862385321102
I1
I0
I1
tp13689
sS'coadministered,the'
p13690
(F1
F0.00014334862385321102
I1
I0
I1
tp13691
sS'require,replacement'
p13692
(F1
F0.00014334862385321102
I1
I0
I1
tp13693
sS'enroll,patients'
p13694
(F1
F0.00014334862385321102
I0
I1
I-1
tp13695
sS'ibuprofen,ibuprofen'
p13696
(F1
F0.00014334862385321102
I0
I1
I-1
tp13697
sS'vivo,data'
p13698
(F1
F0.00043004587155963305
I3
I0
I3
tp13699
sS'of,radiolabeled'
p13700
(F1
F0.00014334862385321102
I0
I1
I-1
tp13701
sS'by,cyp2c9'
p13702
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13703
sS'in,steady-state'
p13704
(F1
F0.00057339449541284407
I4
I0
I4
tp13705
sS'depressed,in'
p13706
(F1
F0.00014334862385321102
I1
I0
I1
tp13707
sS'long-,term'
p13708
(F1
F0.00014334862385321102
I1
I0
I1
tp13709
sS'peptides,in'
p13710
(F1
F0.00014334862385321102
I0
I1
I-1
tp13711
sS'sulfonylureas,requirements'
p13712
(F1
F0.00014334862385321102
I0
I1
I-1
tp13713
sS'therapy,allow'
p13714
(F1
F0.00014334862385321102
I0
I1
I-1
tp13715
sS'equetrotm,may'
p13716
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp13717
sS'total,mucosal'
p13718
(F1
F0.00014334862385321102
I0
I1
I-1
tp13719
sS'derivatives,dihydroergotamine'
p13720
(F1
F0.00014334862385321102
I0
I1
I-1
tp13721
sS'sodium,colistimethate'
p13722
(F1
F0.00014334862385321102
I1
I0
I1
tp13723
sS'with,close'
p13724
(F1
F0.00014334862385321102
I1
I0
I1
tp13725
sS'clinitest,tablets'
p13726
(F1
F0.00014334862385321102
I0
I1
I-1
tp13727
sS'frequency,and'
p13728
(F1
F0.00028669724770642203
I2
I0
I2
tp13729
sS'taking,cyp3a4'
p13730
(F1
F0.00014334862385321102
I0
I1
I-1
tp13731
sS'identified,through'
p13732
(F1
F0.00014334862385321102
I0
I1
I-1
tp13733
sS'trial,showed'
p13734
(F1
F0.00014334862385321102
I0
I1
I-1
tp13735
sS'changes,induced'
p13736
(F1
F0.00014334862385321102
I0
I1
I-1
tp13737
sS'of,two'
p13738
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp13739
sS'either,concomitant'
p13740
(F1
F0.00014334862385321102
I0
I1
I-1
tp13741
sS'auc,approximately'
p13742
(F1
F0.00014334862385321102
I1
I0
I1
tp13743
sS'and,severity'
p13744
(F1
F0.00014334862385321102
I1
I0
I1
tp13745
sS'worse,and'
p13746
(F1
F0.00014334862385321102
I0
I1
I-1
tp13747
sS'clinical,trial'
p13748
(F0
F0
I3
I3
I0
tp13749
sS'cautiously,and'
p13750
(F1
F0.00014334862385321102
I1
I0
I1
tp13751
sS'between,clozapine'
p13752
(F1
F0.00014334862385321102
I1
I0
I1
tp13753
sS'amine,since'
p13754
(F1
F0.00014334862385321102
I1
I0
I1
tp13755
sS'chirocaine,that'
p13756
(F1
F0.00014334862385321102
I0
I1
I-1
tp13757
sS'haloperidol,blocks'
p13758
(F1
F0.00028669724770642203
I2
I0
I2
tp13759
sS'should,then'
p13760
(F1
F0.00014334862385321102
I1
I0
I1
tp13761
sS'pressure,after'
p13762
(F1
F0.00057339449541284407
I4
I0
I4
tp13763
sS'was,depressed'
p13764
(F1
F0.00014334862385321102
I1
I0
I1
tp13765
sS'and,one'
p13766
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp13767
sS'bentiromide,may'
p13768
(F1
F0.00014334862385321102
I1
I0
I1
tp13769
sS'depresses,activity'
p13770
(F1
F0.00014334862385321102
I1
I0
I1
tp13771
sS'the,has'
p13772
(F0.5
F0.00028669724770642203
I3
I1
I2
tp13773
sS'a,atp'
p13774
(F1
F0.00014334862385321102
I0
I1
I-1
tp13775
sS'of,various'
p13776
(F0
F0
I2
I2
I0
tp13777
sS'week,of'
p13778
(F1
F0.00014334862385321102
I0
I1
I-1
tp13779
sS'antipsychotic,medications'
p13780
(F1
F0.00014334862385321102
I0
I1
I-1
tp13781
sS'a,using'
p13782
(F1
F0.00014334862385321102
I0
I1
I-1
tp13783
sS'and,depletion'
p13784
(F1
F0.00014334862385321102
I0
I1
I-1
tp13785
sS'even,when'
p13786
(F0
F0
I3
I3
I0
tp13787
sS'combination,is'
p13788
(F1
F0.00014334862385321102
I1
I0
I1
tp13789
sS's-isomer,and'
p13790
(F1
F0.00014334862385321102
I0
I1
I-1
tp13791
sS'titration,to'
p13792
(F1
F0.00014334862385321102
I1
I0
I1
tp13793
sS'when,coadministering'
p13794
(F1
F0.00014334862385321102
I1
I0
I1
tp13795
sS'therapy,and'
p13796
(F0
F0
I3
I3
I0
tp13797
sS'c19,the'
p13798
(F1
F0.00014334862385321102
I0
I1
I-1
tp13799
sS'the,psychostimulant'
p13800
(F1
F0.00014334862385321102
I0
I1
I-1
tp13801
sS'concentrations,increased'
p13802
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp13803
sS'non-steroidal,and'
p13804
(F1
F0.00014334862385321102
I1
I0
I1
tp13805
sS'enzyme,abnormalities'
p13806
(F1
F0.00014334862385321102
I1
I0
I1
tp13807
sS'recommendations,for'
p13808
(F1
F0.00014334862385321102
I0
I1
I-1
tp13809
sS'potential,differences'
p13810
(F1
F0.00014334862385321102
I0
I1
I-1
tp13811
sS'ieg,response'
p13812
(F1
F0.00014334862385321102
I0
I1
I-1
tp13813
sS'decreasing,responding'
p13814
(F1
F0.00014334862385321102
I0
I1
I-1
tp13815
sS'back-up,methods'
p13816
(F1
F0.00014334862385321102
I1
I0
I1
tp13817
sS'infusion,pumps'
p13818
(F1
F0.00014334862385321102
I0
I1
I-1
tp13819
sS'mouse,model'
p13820
(F1
F0.00014334862385321102
I0
I1
I-1
tp13821
sS'of,gram'
p13822
(F1
F0.00014334862385321102
I1
I0
I1
tp13823
sS'especially,if'
p13824
(F1
F0.00014334862385321102
I0
I1
I-1
tp13825
sS'symptoms,occur'
p13826
(F1
F0.00014334862385321102
I1
I0
I1
tp13827
sS'by,one-third'
p13828
(F1
F0.00028669724770642203
I0
I2
I-2
tp13829
sS'especially,in'
p13830
(F1
F0.00071674311926605509
I5
I0
I5
tp13831
sS'medications,and'
p13832
(F1
F0.00028669724770642203
I2
I0
I2
tp13833
sS'cyp3a4,mg'
p13834
(F1
F0.00014334862385321102
I1
I0
I1
tp13835
sS'table,effects'
p13836
(F1
F0.00028669724770642203
I0
I2
I-2
tp13837
sS'carinii,pneumonia'
p13838
(F1
F0.00014334862385321102
I1
I0
I1
tp13839
sS'haart,on'
p13840
(F1
F0.00014334862385321102
I0
I1
I-1
tp13841
sS'objective,our'
p13842
(F1
F0.00028669724770642203
I0
I2
I-2
tp13843
sS'possible,adjustment'
p13844
(F1
F0.00014334862385321102
I0
I1
I-1
tp13845
sS'interferes,minimally'
p13846
(F1
F0.00014334862385321102
I1
I0
I1
tp13847
sS'cardiac,function'
p13848
(F1
F0.00014334862385321102
I1
I0
I1
tp13849
sS'administered,minute'
p13850
(F1
F0.00014334862385321102
I1
I0
I1
tp13851
sS'to,volunteers'
p13852
(F1
F0.00014334862385321102
I0
I1
I-1
tp13853
sS'trials,have'
p13854
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp13855
sS'been,identified'
p13856
(F0
F0
I1
I1
I0
tp13857
sS'aspirin,nonsteroidal'
p13858
(F1
F0.00014334862385321102
I0
I1
I-1
tp13859
sS'their,blood'
p13860
(F0
F0
I1
I1
I0
tp13861
sS'studies,the'
p13862
(F1
F0.00014334862385321102
I0
I1
I-1
tp13863
sS'studied,increased'
p13864
(F1
F0.00014334862385321102
I1
I0
I1
tp13865
sS'acth,intensified'
p13866
(F1
F0.00028669724770642203
I0
I2
I-2
tp13867
sS'impinger,for'
p13868
(F1
F0.00014334862385321102
I0
I1
I-1
tp13869
sS'twice,those'
p13870
(F1
F0.00014334862385321102
I1
I0
I1
tp13871
sS'disintegrin,was'
p13872
(F1
F0.00014334862385321102
I0
I1
I-1
tp13873
sS'of,functional'
p13874
(F1
F0.00043004587155963305
I3
I0
I3
tp13875
sS'of,habituation'
p13876
(F1
F0.00014334862385321102
I0
I1
I-1
tp13877
sS'substrate,by'
p13878
(F1
F0.00071674311926605509
I5
I0
I5
tp13879
sS'containing,side'
p13880
(F1
F0.00014334862385321102
I0
I1
I-1
tp13881
sS'agents,include'
p13882
(F1
F0.00014334862385321102
I0
I1
I-1
tp13883
sS'of,azole'
p13884
(F1
F0.00014334862385321102
I1
I0
I1
tp13885
sS'desloratadine,and'
p13886
(F1
F0.00014334862385321102
I0
I1
I-1
tp13887
sS'to,as'
p13888
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp13889
sS'to,an'
p13890
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp13891
sS'checkerboard,assay'
p13892
(F1
F0.00014334862385321102
I0
I1
I-1
tp13893
sS'heparin,effect'
p13894
(F0
F0
I1
I1
I0
tp13895
sS'for,days'
p13896
(F0
F0
I29
I29
I0
tp13897
sS'be,undertaken'
p13898
(F1
F0.00043004587155963305
I3
I0
I3
tp13899
sS'no,capacity'
p13900
(F1
F0.00014334862385321102
I0
I1
I-1
tp13901
sS'agents,a'
p13902
(F1
F0.00028669724770642203
I0
I2
I-2
tp13903
sS'made,whether'
p13904
(F1
F0.00014334862385321102
I0
I1
I-1
tp13905
sS'and,pharmacodynamics'
p13906
(F1
F0.00014334862385321102
I0
I1
I-1
tp13907
sS'manufacturers,have'
p13908
(F1
F0.00014334862385321102
I0
I1
I-1
tp13909
sS'antagonized,evidently'
p13910
(F1
F0.00014334862385321102
I1
I0
I1
tp13911
sS'than,additive'
p13912
(F1
F0.00014334862385321102
I1
I0
I1
tp13913
sS'therefore,plasma'
p13914
(F1
F0.00014334862385321102
I1
I0
I1
tp13915
sS'inhibitors,felodipine'
p13916
(F1
F0.00014334862385321102
I0
I1
I-1
tp13917
sS'involved,either'
p13918
(F1
F0.00014334862385321102
I0
I1
I-1
tp13919
sS'based,upon'
p13920
(F1
F0.00014334862385321102
I1
I0
I1
tp13921
sS'specific,methods'
p13922
(F1
F0.00014334862385321102
I0
I1
I-1
tp13923
sS'of,tyrosine'
p13924
(F1
F0.00014334862385321102
I0
I1
I-1
tp13925
sS'local,and'
p13926
(F0
F0
I1
I1
I0
tp13927
sS'injections,of'
p13928
(F1
F0.00043004587155963305
I0
I3
I-3
tp13929
sS'authors,compared'
p13930
(F1
F0.00014334862385321102
I0
I1
I-1
tp13931
sS'drugs,demonstrated'
p13932
(F1
F0.00014334862385321102
I1
I0
I1
tp13933
sS'levels,generally'
p13934
(F1
F0.00014334862385321102
I0
I1
I-1
tp13935
sS'release,capsules'
p13936
(F1
F0.00028669724770642203
I2
I0
I2
tp13937
sS'from,prospective'
p13938
(F1
F0.00014334862385321102
I0
I1
I-1
tp13939
sS'agents,simultaneous'
p13940
(F1
F0.00014334862385321102
I1
I0
I1
tp13941
sS'theo-dur,key'
p13942
(F1
F0.00014334862385321102
I1
I0
I1
tp13943
sS'excreted,levels'
p13944
(F1
F0.00014334862385321102
I0
I1
I-1
tp13945
sS'characterized,to'
p13946
(F1
F0.00014334862385321102
I0
I1
I-1
tp13947
sS'required,concentrations'
p13948
(F1
F0.00014334862385321102
I1
I0
I1
tp13949
sS'bind,and'
p13950
(F1
F0.00014334862385321102
I1
I0
I1
tp13951
sS'is,drawn'
p13952
(F1
F0.00014334862385321102
I1
I0
I1
tp13953
sS'mg,sustained-release'
p13954
(F1
F0.00014334862385321102
I0
I1
I-1
tp13955
sS'indices,as'
p13956
(F1
F0.00014334862385321102
I1
I0
I1
tp13957
sS'because,accutane'
p13958
(F1
F0.00014334862385321102
I1
I0
I1
tp13959
sS'when,taking'
p13960
(F0
F0
I2
I2
I0
tp13961
sS'lincomycin,has'
p13962
(F1
F0.00014334862385321102
I1
I0
I1
tp13963
sS'of,large'
p13964
(F1
F0.00014334862385321102
I0
I1
I-1
tp13965
sS'medications,used'
p13966
(F1
F0.00014334862385321102
I0
I1
I-1
tp13967
sS'vitro,does'
p13968
(F1
F0.00014334862385321102
I0
I1
I-1
tp13969
sS'were,less'
p13970
(F1
F0.00014334862385321102
I1
I0
I1
tp13971
sS'day-old,chick'
p13972
(F1
F0.00014334862385321102
I1
I0
I1
tp13973
sS'increased,about'
p13974
(F1
F0.00043004587155963305
I3
I0
I3
tp13975
sS'symptoms,but'
p13976
(F1
F0.00014334862385321102
I0
I1
I-1
tp13977
sS'glucose,was'
p13978
(F1
F0.00014334862385321102
I0
I1
I-1
tp13979
sS'on,no'
p13980
(F1
F0.00014334862385321102
I1
I0
I1
tp13981
sS'be,effectively'
p13982
(F1
F0.00014334862385321102
I0
I1
I-1
tp13983
sS'step,of'
p13984
(F0
F0
I1
I1
I0
tp13985
sS'aspirin,and'
p13986
(F1
F0.00014334862385321102
I0
I1
I-1
tp13987
sS'concentrations,c'
p13988
(F1
F0.00014334862385321102
I0
I1
I-1
tp13989
sS'of,mixed'
p13990
(F1
F0.00014334862385321102
I1
I0
I1
tp13991
sS'edetate,disodium'
p13992
(F1
F0.00014334862385321102
I1
I0
I1
tp13993
sS'compazine,phenergan'
p13994
(F1
F0.00014334862385321102
I0
I1
I-1
tp13995
sS'narrower,spectrum'
p13996
(F1
F0.00014334862385321102
I0
I1
I-1
tp13997
sS'men,n'
p13998
(F1
F0.00014334862385321102
I0
I1
I-1
tp13999
sS'inhibitors,has'
p14000
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14001
sS'example,and'
p14002
(F1
F0.00014334862385321102
I1
I0
I1
tp14003
sS'administered,twice'
p14004
(F1
F0.00014334862385321102
I0
I1
I-1
tp14005
sS'proves,to'
p14006
(F1
F0.00014334862385321102
I1
I0
I1
tp14007
sS'seizure,risk'
p14008
(F1
F0.00014334862385321102
I1
I0
I1
tp14009
sS'from,decrease'
p14010
(F1
F0.00028669724770642203
I2
I0
I2
tp14011
sS'during,and'
p14012
(F0.5
F0.00028669724770642203
I3
I1
I2
tp14013
sS'alkalinizing,agents'
p14014
(F1
F0.00028669724770642203
I2
I0
I2
tp14015
sS'of,between'
p14016
(F1
F0.00014334862385321102
I0
I1
I-1
tp14017
sS'which,cause'
p14018
(F1
F0.00043004587155963305
I3
I0
I3
tp14019
sS'i,with'
p14020
(F1
F0.00014334862385321102
I0
I1
I-1
tp14021
sS'when,healthy'
p14022
(F1
F0.00014334862385321102
I0
I1
I-1
tp14023
sS'extend,the'
p14024
(F1
F0.00014334862385321102
I1
I0
I1
tp14025
sS'alprazolam,caution'
p14026
(F1
F0.00014334862385321102
I1
I0
I1
tp14027
sS'appear,to'
p14028
(F0.5
F0.0008600917431192661
I3
I9
I-6
tp14029
sS'accutane,to'
p14030
(F1
F0.00014334862385321102
I1
I0
I1
tp14031
sS'established,steady-state'
p14032
(F1
F0.00014334862385321102
I1
I0
I1
tp14033
sS'that,can'
p14034
(F0
F0
I5
I5
I0
tp14035
sS'as,mhd'
p14036
(F1
F0.00014334862385321102
I0
I1
I-1
tp14037
sS'benign,intracranial'
p14038
(F1
F0.00014334862385321102
I1
I0
I1
tp14039
sS'controlled,study'
p14040
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp14041
sS'parameters,clinical'
p14042
(F1
F0.00014334862385321102
I0
I1
I-1
tp14043
sS'of,concomitantly'
p14044
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14045
sS'day,of'
p14046
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp14047
sS'the,clearance'
p14048
(F0.47058823529411764
F0.0022935779816513763
I25
I9
I16
tp14049
sS'urine,sampling'
p14050
(F1
F0.00014334862385321102
I0
I1
I-1
tp14051
sS'day,on'
p14052
(F0
F0
I3
I3
I0
tp14053
sS'day,or'
p14054
(F1
F0.00043004587155963305
I0
I3
I-3
tp14055
sS'and,does'
p14056
(F1
F0.00043004587155963305
I0
I3
I-3
tp14057
sS'research,is'
p14058
(F1
F0.00014334862385321102
I0
I1
I-1
tp14059
sS'groups,pd2'
p14060
(F1
F0.00014334862385321102
I1
I0
I1
tp14061
sS'relaxants,in'
p14062
(F1
F0.00014334862385321102
I0
I1
I-1
tp14063
sS'by,co-administration'
p14064
(F1
F0.00014334862385321102
I0
I1
I-1
tp14065
sS'and,muscle'
p14066
(F1
F0.00014334862385321102
I0
I1
I-1
tp14067
sS'and,electrophysiologic'
p14068
(F1
F0.00014334862385321102
I0
I1
I-1
tp14069
sS'or,taking'
p14070
(F1
F0.00014334862385321102
I1
I0
I1
tp14071
sS'or,toxoids'
p14072
(F1
F0.00014334862385321102
I1
I0
I1
tp14073
sS'to,share'
p14074
(F1
F0.00014334862385321102
I0
I1
I-1
tp14075
sS'range,from'
p14076
(F1
F0.00028669724770642203
I2
I0
I2
tp14077
sS'been,taking'
p14078
(F1
F0.00014334862385321102
I0
I1
I-1
tp14079
sS'receiving,beta'
p14080
(F1
F0.00014334862385321102
I0
I1
I-1
tp14081
sS'intestinal,adsorbents'
p14082
(F1
F0.00014334862385321102
I1
I0
I1
tp14083
sS'in,case'
p14084
(F1
F0.00014334862385321102
I1
I0
I1
tp14085
sS'to,prinivil'
p14086
(F1
F0.00014334862385321102
I0
I1
I-1
tp14087
sS'no,adjustment'
p14088
(F1
F0.00028669724770642203
I0
I2
I-2
tp14089
sS'creatinine,levels'
p14090
(F1
F0.00028669724770642203
I0
I2
I-2
tp14091
sS'provoke,toxicity'
p14092
(F1
F0.00014334862385321102
I0
I1
I-1
tp14093
sS'failure,channel'
p14094
(F1
F0.00014334862385321102
I1
I0
I1
tp14095
sS'co-administered,avonex'
p14096
(F1
F0.00014334862385321102
I0
I1
I-1
tp14097
sS'but,by'
p14098
(F1
F0.00014334862385321102
I1
I0
I1
tp14099
sS'tysabri,associated'
p14100
(F1
F0.00014334862385321102
I0
I1
I-1
tp14101
sS'sulfoxide,concentrations'
p14102
(F1
F0.00014334862385321102
I1
I0
I1
tp14103
sS'rifampin,coadministration'
p14104
(F1
F0.00028669724770642203
I2
I0
I2
tp14105
sS'been,implicated'
p14106
(F0
F0
I1
I1
I0
tp14107
sS'affect,behaviors'
p14108
(F1
F0.00014334862385321102
I0
I1
I-1
tp14109
sS'of,erythromycin'
p14110
(F1
F0.00014334862385321102
I0
I1
I-1
tp14111
sS'augments,the'
p14112
(F1
F0.00014334862385321102
I1
I0
I1
tp14113
sS'effects,with'
p14114
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp14115
sS'of,exposure'
p14116
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp14117
sS'with,have'
p14118
(F0
F0
I1
I1
I0
tp14119
sS'study,caused'
p14120
(F1
F0.00014334862385321102
I1
I0
I1
tp14121
sS'interact,pharmacologically'
p14122
(F1
F0.00014334862385321102
I1
I0
I1
tp14123
sS'mellaril,stelazine'
p14124
(F1
F0.00014334862385321102
I0
I1
I-1
tp14125
sS'orally,to'
p14126
(F1
F0.00014334862385321102
I0
I1
I-1
tp14127
sS'considered,prior'
p14128
(F1
F0.00014334862385321102
I1
I0
I1
tp14129
sS'the,biotransformation'
p14130
(F1
F0.00028669724770642203
I2
I0
I2
tp14131
sS'the,above'
p14132
(F0
F0
I1
I1
I0
tp14133
sS'the,currently'
p14134
(F1
F0.00014334862385321102
I0
I1
I-1
tp14135
sS'potentiate,vecuronium-induced'
p14136
(F1
F0.00014334862385321102
I1
I0
I1
tp14137
sS'blocking,hepatic'
p14138
(F1
F0.00014334862385321102
I1
I0
I1
tp14139
sS'with,beta-lactamtype'
p14140
(F1
F0.00014334862385321102
I1
I0
I1
tp14141
sS'those,prior'
p14142
(F1
F0.00014334862385321102
I0
I1
I-1
tp14143
sS'ml,when'
p14144
(F0
F0
I1
I1
I0
tp14145
sS'of,toxic'
p14146
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp14147
sS'of,inhibitor'
p14148
(F1
F0.00014334862385321102
I0
I1
I-1
tp14149
sS'increases,enterohepatic'
p14150
(F1
F0.00014334862385321102
I0
I1
I-1
tp14151
sS'repeated,exposure'
p14152
(F1
F0.00014334862385321102
I0
I1
I-1
tp14153
sS'inducers,iodinated'
p14154
(F1
F0.00014334862385321102
I0
I1
I-1
tp14155
sS'the,bile'
p14156
(F1
F0.00014334862385321102
I0
I1
I-1
tp14157
sS'upper,gastrointestinal'
p14158
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp14159
sS'the,pi'
p14160
(F1
F0.00014334862385321102
I0
I1
I-1
tp14161
sS'following,acetazolamide'
p14162
(F1
F0.00014334862385321102
I1
I0
I1
tp14163
sS'the,pk'
p14164
(F1
F0.00014334862385321102
I0
I1
I-1
tp14165
sS'causes,a'
p14166
(F1
F0.00043004587155963305
I3
I0
I3
tp14167
sS'cerivastatin,plasma'
p14168
(F1
F0.00043004587155963305
I0
I3
I-3
tp14169
sS'capsule,with'
p14170
(F1
F0.00014334862385321102
I1
I0
I1
tp14171
sS'inhibit,p-glycoprotein'
p14172
(F1
F0.00014334862385321102
I0
I1
I-1
tp14173
sS'events,associated'
p14174
(F1
F0.00014334862385321102
I1
I0
I1
tp14175
sS'the,pr'
p14176
(F1
F0.00014334862385321102
I1
I0
I1
tp14177
sS'with,zyvox'
p14178
(F1
F0.00014334862385321102
I1
I0
I1
tp14179
sS'on,day'
p14180
(F0.076923076923076927
F0.00014334862385321102
I7
I6
I1
tp14181
sS'after,cessation'
p14182
(F1
F0.00014334862385321102
I0
I1
I-1
tp14183
sS'food,cns'
p14184
(F1
F0.00014334862385321102
I1
I0
I1
tp14185
sS'ketoconazole,in'
p14186
(F1
F0.00014334862385321102
I1
I0
I1
tp14187
sS'including,decrease'
p14188
(F1
F0.00014334862385321102
I1
I0
I1
tp14189
sS'bleeding,time'
p14190
(F1
F0.00028669724770642203
I0
I2
I-2
tp14191
sS'of,ace'
p14192
(F0
F0
I1
I1
I0
tp14193
sS'hepatic,tissues'
p14194
(F1
F0.00014334862385321102
I1
I0
I1
tp14195
sS'lowering,their'
p14196
(F1
F0.00014334862385321102
I0
I1
I-1
tp14197
sS'dose-related,increase'
p14198
(F1
F0.00014334862385321102
I1
I0
I1
tp14199
sS'significantly,different'
p14200
(F1
F0.00028669724770642203
I0
I2
I-2
tp14201
sS'or,kcl'
p14202
(F1
F0.00014334862385321102
I0
I1
I-1
tp14203
sS'agents,disturbances'
p14204
(F1
F0.00014334862385321102
I1
I0
I1
tp14205
sS'photosensitizing,agents'
p14206
(F1
F0.00014334862385321102
I1
I0
I1
tp14207
sS'potent,cyp3a'
p14208
(F1
F0.00014334862385321102
I1
I0
I1
tp14209
sS'medications,with'
p14210
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp14211
sS'vasoconstriction,caused'
p14212
(F1
F0.00014334862385321102
I1
I0
I1
tp14213
sS'hypotension,or'
p14214
(F0
F0
I1
I1
I0
tp14215
sS'lithium,valdecoxib'
p14216
(F1
F0.00014334862385321102
I1
I0
I1
tp14217
sS'schizophrenia,were'
p14218
(F1
F0.00014334862385321102
I0
I1
I-1
tp14219
sS'usp,should'
p14220
(F1
F0.00028669724770642203
I2
I0
I2
tp14221
sS'usually,depresses'
p14222
(F1
F0.00014334862385321102
I1
I0
I1
tp14223
sS'immediate,discontinuation'
p14224
(F1
F0.00014334862385321102
I0
I1
I-1
tp14225
sS'on,cas'
p14226
(F1
F0.00014334862385321102
I1
I0
I1
tp14227
sS'some,normal'
p14228
(F1
F0.00014334862385321102
I1
I0
I1
tp14229
sS'introduced,atypical'
p14230
(F1
F0.00014334862385321102
I0
I1
I-1
tp14231
sS'by,mtc-methylene'
p14232
(F1
F0.00014334862385321102
I1
I0
I1
tp14233
sS'in,renally'
p14234
(F1
F0.00014334862385321102
I0
I1
I-1
tp14235
sS'and,showed'
p14236
(F1
F0.00028669724770642203
I0
I2
I-2
tp14237
sS'their,guardians'
p14238
(F1
F0.00014334862385321102
I0
I1
I-1
tp14239
sS'the,only'
p14240
(F1
F0.00014334862385321102
I1
I0
I1
tp14241
sS'relaxants,could'
p14242
(F1
F0.00014334862385321102
I1
I0
I1
tp14243
sS'nitrosamine,which'
p14244
(F1
F0.00014334862385321102
I1
I0
I1
tp14245
sS'unlikely,to'
p14246
(F1
F0.0012901376146788992
I0
I9
I-9
tp14247
sS'of,compared'
p14248
(F0
F0
I1
I1
I0
tp14249
sS'possible,that'
p14250
(F1
F0.00071674311926605509
I5
I0
I5
tp14251
sS'needed,should'
p14252
(F1
F0.00014334862385321102
I0
I1
I-1
tp14253
sS'treatpatients,co-infected'
p14254
(F1
F0.00014334862385321102
I0
I1
I-1
tp14255
sS'when,nimbex'
p14256
(F1
F0.00014334862385321102
I0
I1
I-1
tp14257
sS'show,a'
p14258
(F1
F0.00028669724770642203
I0
I2
I-2
tp14259
sS'one,strain'
p14260
(F1
F0.00014334862385321102
I0
I1
I-1
tp14261
sS'concentration,which'
p14262
(F1
F0.00014334862385321102
I0
I1
I-1
tp14263
sS'may,worsen'
p14264
(F1
F0.00014334862385321102
I1
I0
I1
tp14265
sS'response,by'
p14266
(F1
F0.00014334862385321102
I1
I0
I1
tp14267
sS'that,when'
p14268
(F1
F0.00028669724770642203
I2
I0
I2
tp14269
sS'addition,most'
p14270
(F1
F0.00014334862385321102
I1
I0
I1
tp14271
sS'potentiate,blood-pressure'
p14272
(F1
F0.00014334862385321102
I1
I0
I1
tp14273
sS'camptosar,such'
p14274
(F1
F0.00014334862385321102
I1
I0
I1
tp14275
sS'initiating,or'
p14276
(F1
F0.00028669724770642203
I2
I0
I2
tp14277
sS'measure,over'
p14278
(F1
F0.00014334862385321102
I0
I1
I-1
tp14279
sS'introduction,of'
p14280
(F1
F0.00028669724770642203
I2
I0
I2
tp14281
sS'ace,inhibitors'
p14282
(F0
F0
I10
I10
I0
tp14283
sS'occur,up'
p14284
(F1
F0.00014334862385321102
I1
I0
I1
tp14285
sS'of,neuromuscular'
p14286
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp14287
sS'spontaneous,reports'
p14288
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14289
sS'max,although'
p14290
(F1
F0.00014334862385321102
I0
I1
I-1
tp14291
sS'in,preclinical'
p14292
(F1
F0.00014334862385321102
I0
I1
I-1
tp14293
sS'balanced,technique'
p14294
(F1
F0.00014334862385321102
I0
I1
I-1
tp14295
sS'be,treated'
p14296
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14297
sS'is,extensively'
p14298
(F0
F0
I1
I1
I0
tp14299
sS'cause,renal'
p14300
(F0
F0
I1
I1
I0
tp14301
sS'has,led'
p14302
(F1
F0.00043004587155963305
I3
I0
I3
tp14303
sS'acutely,worsened'
p14304
(F1
F0.00014334862385321102
I1
I0
I1
tp14305
sS'either,mg'
p14306
(F1
F0.00028669724770642203
I0
I2
I-2
tp14307
sS'elderly,in'
p14308
(F1
F0.00014334862385321102
I1
I0
I1
tp14309
sS'actions,were'
p14310
(F1
F0.00014334862385321102
I1
I0
I1
tp14311
sS'an,endogenous'
p14312
(F1
F0.00014334862385321102
I1
I0
I1
tp14313
sS'delayed,and'
p14314
(F1
F0.00014334862385321102
I1
I0
I1
tp14315
sS'of,arimidex'
p14316
(F1
F0.00028669724770642203
I0
I2
I-2
tp14317
sS'reductions,of'
p14318
(F1
F0.00014334862385321102
I1
I0
I1
tp14319
sS'can,also'
p14320
(F1
F0.00014334862385321102
I1
I0
I1
tp14321
sS'mg,twice-daily'
p14322
(F1
F0.00014334862385321102
I1
I0
I1
tp14323
sS'agonists,within'
p14324
(F1
F0.00028669724770642203
I2
I0
I2
tp14325
sS'dosage,adjustment'
p14326
(F0.076923076923076927
F0.00014334862385321102
I6
I7
I-1
tp14327
sS'vitro,activity'
p14328
(F1
F0.00014334862385321102
I0
I1
I-1
tp14329
sS'decreased,levels'
p14330
(F1
F0.00028669724770642203
I0
I2
I-2
tp14331
sS'structurally,similar'
p14332
(F1
F0.00014334862385321102
I0
I1
I-1
tp14333
sS'interferences,dicumarol'
p14334
(F1
F0.00014334862385321102
I0
I1
I-1
tp14335
sS'potassium-,sparing'
p14336
(F1
F0.00014334862385321102
I1
I0
I1
tp14337
sS'increased,dramatically'
p14338
(F1
F0.00014334862385321102
I0
I1
I-1
tp14339
sS'with,neoplastic'
p14340
(F1
F0.00014334862385321102
I1
I0
I1
tp14341
sS'affect,the'
p14342
(F0.82222222222222219
F0.0053038990825688076
I4
I41
I-37
tp14343
sS'nsaid,while'
p14344
(F1
F0.00014334862385321102
I1
I0
I1
tp14345
sS'health,if'
p14346
(F0
F0
I1
I1
I0
tp14347
sS'or,concomitantly'
p14348
(F1
F0.00028669724770642203
I2
I0
I2
tp14349
sS'drugs,fibric'
p14350
(F1
F0.00014334862385321102
I0
I1
I-1
tp14351
sS'concomitantly,within14'
p14352
(F1
F0.00014334862385321102
I1
I0
I1
tp14353
sS'myasthenic,patient'
p14354
(F1
F0.00014334862385321102
I1
I0
I1
tp14355
sS'other,potent'
p14356
(F0.5
F0.00028669724770642203
I3
I1
I2
tp14357
sS'cardiovascular,effects'
p14358
(F1
F0.00014334862385321102
I1
I0
I1
tp14359
sS'from,combined'
p14360
(F1
F0.00028669724770642203
I2
I0
I2
tp14361
sS'decreased,with'
p14362
(F1
F0.00043004587155963305
I3
I0
I3
tp14363
sS'pth,and'
p14364
(F1
F0.00014334862385321102
I1
I0
I1
tp14365
sS'maximum,cumulative'
p14366
(F1
F0.00014334862385321102
I1
I0
I1
tp14367
sS'some,agents'
p14368
(F1
F0.00014334862385321102
I0
I1
I-1
tp14369
sS'no,important'
p14370
(F1
F0.00014334862385321102
I0
I1
I-1
tp14371
sS'decrease,of'
p14372
(F1
F0.00028669724770642203
I0
I2
I-2
tp14373
sS'or,moieties'
p14374
(F1
F0.00014334862385321102
I0
I1
I-1
tp14375
sS'chlorpropamide,chlorpropamides'
p14376
(F1
F0.00014334862385321102
I1
I0
I1
tp14377
sS'peak,levels'
p14378
(F0
F0
I1
I1
I0
tp14379
sS'clearance,secondary'
p14380
(F1
F0.00014334862385321102
I1
I0
I1
tp14381
sS'they,can'
p14382
(F0
F0
I1
I1
I0
tp14383
sS'concurrent,administration'
p14384
(F0.61290322580645162
F0.0027236238532110093
I25
I6
I19
tp14385
sS'reportedly,are'
p14386
(F1
F0.00014334862385321102
I1
I0
I1
tp14387
sS'dual,therapy'
p14388
(F1
F0.00014334862385321102
I0
I1
I-1
tp14389
sS'frequently,co-administered'
p14390
(F1
F0.00014334862385321102
I0
I1
I-1
tp14391
sS'strong,synergistic'
p14392
(F1
F0.00014334862385321102
I1
I0
I1
tp14393
sS'n-desmethylclozapine,and'
p14394
(F1
F0.00014334862385321102
I0
I1
I-1
tp14395
sS'receiving,there'
p14396
(F1
F0.00014334862385321102
I1
I0
I1
tp14397
sS'that,protects'
p14398
(F1
F0.00014334862385321102
I1
I0
I1
tp14399
sS'controlled,hypotensive'
p14400
(F1
F0.00014334862385321102
I1
I0
I1
tp14401
sS'cause,cardio'
p14402
(F1
F0.00014334862385321102
I0
I1
I-1
tp14403
sS'of,fluorouracil'
p14404
(F1
F0.00014334862385321102
I1
I0
I1
tp14405
sS'primarily,metabolized'
p14406
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp14407
sS'of,pulmonary'
p14408
(F1
F0.00014334862385321102
I1
I0
I1
tp14409
sS'and,c19'
p14410
(F1
F0.00014334862385321102
I0
I1
I-1
tp14411
sS'blood,or'
p14412
(F1
F0.00014334862385321102
I0
I1
I-1
tp14413
sS'double-blind,study'
p14414
(F1
F0.00014334862385321102
I0
I1
I-1
tp14415
sS'unaffected,given'
p14416
(F1
F0.00014334862385321102
I1
I0
I1
tp14417
sS'exert,particular'
p14418
(F1
F0.00014334862385321102
I1
I0
I1
tp14419
sS'required,may'
p14420
(F1
F0.00014334862385321102
I1
I0
I1
tp14421
sS'or,subjective'
p14422
(F1
F0.00014334862385321102
I0
I1
I-1
tp14423
sS'was,lower'
p14424
(F1
F0.00028669724770642203
I2
I0
I2
tp14425
sS'in,psoriatic'
p14426
(F1
F0.00014334862385321102
I0
I1
I-1
tp14427
sS'patients,prone'
p14428
(F1
F0.00014334862385321102
I1
I0
I1
tp14429
sS'recipients,suggest'
p14430
(F1
F0.00014334862385321102
I0
I1
I-1
tp14431
sS'and,clearance'
p14432
(F1
F0.00014334862385321102
I0
I1
I-1
tp14433
sS'endotoxin-induced,deaths'
p14434
(F1
F0.00014334862385321102
I1
I0
I1
tp14435
sS'a,satisfactory'
p14436
(F1
F0.00014334862385321102
I1
I0
I1
tp14437
sS'necessary,when'
p14438
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp14439
sS'decrease,established'
p14440
(F1
F0.00014334862385321102
I1
I0
I1
tp14441
sS'the,tricyclic'
p14442
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp14443
sS'th,generation'
p14444
(F1
F0.00014334862385321102
I0
I1
I-1
tp14445
sS'aid,sleep'
p14446
(F1
F0.00014334862385321102
I0
I1
I-1
tp14447
sS'actions,are'
p14448
(F1
F0.00014334862385321102
I0
I1
I-1
tp14449
sS'with,maxipime'
p14450
(F1
F0.00014334862385321102
I1
I0
I1
tp14451
sS'a,blockade'
p14452
(F1
F0.00014334862385321102
I1
I0
I1
tp14453
sS'min,compared'
p14454
(F1
F0.00014334862385321102
I0
I1
I-1
tp14455
sS'or,omega-agatoxin'
p14456
(F1
F0.00014334862385321102
I0
I1
I-1
tp14457
sS'prolong,and'
p14458
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp14459
sS'to,amide-type'
p14460
(F1
F0.00014334862385321102
I1
I0
I1
tp14461
sS'renal,failure'
p14462
(F0.5
F0.00028669724770642203
I3
I1
I2
tp14463
sS'nalidixic,acid'
p14464
(F1
F0.00028669724770642203
I2
I0
I2
tp14465
sS'mg,led'
p14466
(F1
F0.00014334862385321102
I1
I0
I1
tp14467
sS'cytotoxic,agents'
p14468
(F1
F0.00014334862385321102
I1
I0
I1
tp14469
sS'factors,when'
p14470
(F1
F0.00014334862385321102
I0
I1
I-1
tp14471
sS'st,johns'
p14472
(F0
F0
I1
I1
I0
tp14473
sS'receiving,high'
p14474
(F1
F0.00028669724770642203
I2
I0
I2
tp14475
sS'using,cyp3a4'
p14476
(F1
F0.00014334862385321102
I1
I0
I1
tp14477
sS'the,failing'
p14478
(F1
F0.00014334862385321102
I0
I1
I-1
tp14479
sS'the,pharmacokinetic'
p14480
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp14481
sS'baseline,for'
p14482
(F1
F0.00014334862385321102
I0
I1
I-1
tp14483
sS'metabolized,by'
p14484
(F0.33333333333333331
F0.0022935779816513763
I16
I32
I-16
tp14485
sS'escalating,doses'
p14486
(F0
F0
I1
I1
I0
tp14487
sS'levobupivacaine,and'
p14488
(F1
F0.00014334862385321102
I0
I1
I-1
tp14489
sS'interaction,to'
p14490
(F1
F0.00014334862385321102
I0
I1
I-1
tp14491
sS'effect,oral'
p14492
(F1
F0.00014334862385321102
I0
I1
I-1
tp14493
sS'may,delay'
p14494
(F1
F0.0010034403669724771
I7
I0
I7
tp14495
sS'and,hearing'
p14496
(F1
F0.00014334862385321102
I1
I0
I1
tp14497
sS'cimetidine,has'
p14498
(F1
F0.00043004587155963305
I3
I0
I3
tp14499
sS'zdv,has'
p14500
(F1
F0.00014334862385321102
I0
I1
I-1
tp14501
sS'm,enhance'
p14502
(F1
F0.00014334862385321102
I1
I0
I1
tp14503
sS'when,two'
p14504
(F1
F0.00014334862385321102
I0
I1
I-1
tp14505
sS'at,least'
p14506
(F0.73333333333333328
F0.0031536697247706424
I26
I4
I22
tp14507
sS'for,incombination'
p14508
(F1
F0.00014334862385321102
I0
I1
I-1
tp14509
sS'required,and'
p14510
(F0
F0
I1
I1
I0
tp14511
sS'electrolyte,depletion'
p14512
(F1
F0.00028669724770642203
I0
I2
I-2
tp14513
sS'illustrated,by'
p14514
(F1
F0.00014334862385321102
I0
I1
I-1
tp14515
sS'digoxin,interaction'
p14516
(F1
F0.00014334862385321102
I0
I1
I-1
tp14517
sS'confidence,interval'
p14518
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp14519
sS'adrenergic-blocking,agents'
p14520
(F1
F0.00014334862385321102
I0
I1
I-1
tp14521
sS'body,increase'
p14522
(F1
F0.00014334862385321102
I0
I1
I-1
tp14523
sS'dipyridamole,has'
p14524
(F1
F0.00014334862385321102
I1
I0
I1
tp14525
sS'inhibiting,cryptosporidium'
p14526
(F1
F0.00014334862385321102
I1
I0
I1
tp14527
sS'plus,catecholamine'
p14528
(F1
F0.00014334862385321102
I1
I0
I1
tp14529
sS'monotherapy,given'
p14530
(F1
F0.00014334862385321102
I0
I1
I-1
tp14531
sS'be,certain'
p14532
(F1
F0.00014334862385321102
I1
I0
I1
tp14533
sS'first-line,option'
p14534
(F1
F0.00014334862385321102
I0
I1
I-1
tp14535
sS'showed,higher'
p14536
(F1
F0.00014334862385321102
I1
I0
I1
tp14537
sS'methotrexate,mexate'
p14538
(F1
F0.00014334862385321102
I1
I0
I1
tp14539
sS'excessive,concurrent'
p14540
(F1
F0.00014334862385321102
I0
I1
I-1
tp14541
sS'white,male'
p14542
(F1
F0.00014334862385321102
I0
I1
I-1
tp14543
sS'or,frequency'
p14544
(F1
F0.00014334862385321102
I1
I0
I1
tp14545
sS'evidence,of'
p14546
(F0.80000000000000004
F0.0022935779816513763
I2
I18
I-16
tp14547
sS'in,breast'
p14548
(F1
F0.00014334862385321102
I0
I1
I-1
tp14549
sS'interval,decrease'
p14550
(F1
F0.00014334862385321102
I0
I1
I-1
tp14551
sS'g,and'
p14552
(F1
F0.00028669724770642203
I2
I0
I2
tp14553
sS'amounts,may'
p14554
(F0
F0
I1
I1
I0
tp14555
sS'difluoroacetone,to'
p14556
(F1
F0.00014334862385321102
I0
I1
I-1
tp14557
sS'of,displacement'
p14558
(F1
F0.00014334862385321102
I0
I1
I-1
tp14559
sS'metoprolol,administration'
p14560
(F1
F0.00014334862385321102
I1
I0
I1
tp14561
sS'concluded,that'
p14562
(F0
F0
I3
I3
I0
tp14563
sS'inhibitors,agenerase'
p14564
(F1
F0.00014334862385321102
I1
I0
I1
tp14565
sS'therefore,omnicef'
p14566
(F1
F0.00014334862385321102
I0
I1
I-1
tp14567
sS'being,given'
p14568
(F1
F0.00014334862385321102
I1
I0
I1
tp14569
sS'interactions,given'
p14570
(F1
F0.00014334862385321102
I1
I0
I1
tp14571
sS'el,eg'
p14572
(F1
F0.00014334862385321102
I1
I0
I1
tp14573
sS'and,nonprescription'
p14574
(F1
F0.00014334862385321102
I0
I1
I-1
tp14575
sS'tnfa-blocking,agents'
p14576
(F1
F0.00014334862385321102
I1
I0
I1
tp14577
sS'uroxatral,and'
p14578
(F1
F0.00014334862385321102
I0
I1
I-1
tp14579
sS'some,studies'
p14580
(F1
F0.00014334862385321102
I1
I0
I1
tp14581
sS'consider,the'
p14582
(F1
F0.00014334862385321102
I1
I0
I1
tp14583
sS'these,actions'
p14584
(F1
F0.00014334862385321102
I1
I0
I1
tp14585
sS'suggests,that'
p14586
(F1
F0.00043004587155963305
I3
I0
I3
tp14587
sS'the,they'
p14588
(F1
F0.00014334862385321102
I1
I0
I1
tp14589
sS'approximately,msec'
p14590
(F1
F0.00014334862385321102
I1
I0
I1
tp14591
sS'made,with'
p14592
(F1
F0.00014334862385321102
I1
I0
I1
tp14593
sS'infarction,in'
p14594
(F1
F0.00014334862385321102
I0
I1
I-1
tp14595
sS'increased,dose'
p14596
(F1
F0.00014334862385321102
I1
I0
I1
tp14597
sS'between,zdv'
p14598
(F1
F0.00014334862385321102
I0
I1
I-1
tp14599
sS'evoked,potentials'
p14600
(F1
F0.00014334862385321102
I0
I1
I-1
tp14601
sS'concentration,curve'
p14602
(F1
F0.00014334862385321102
I1
I0
I1
tp14603
sS'produce,significant'
p14604
(F1
F0.00014334862385321102
I1
I0
I1
tp14605
sS'mix,toradol'
p14606
(F1
F0.00014334862385321102
I0
I1
I-1
tp14607
sS'care,in'
p14608
(F1
F0.00043004587155963305
I3
I0
I3
tp14609
sS'doses,has'
p14610
(F1
F0.00014334862385321102
I1
I0
I1
tp14611
sS'includes,anafranil'
p14612
(F1
F0.00014334862385321102
I0
I1
I-1
tp14613
sS'clinical,and'
p14614
(F0
F0
I1
I1
I0
tp14615
sS'are,types'
p14616
(F1
F0.00014334862385321102
I0
I1
I-1
tp14617
sS'week,plasma'
p14618
(F1
F0.00014334862385321102
I1
I0
I1
tp14619
sS'doses,had'
p14620
(F1
F0.00014334862385321102
I1
I0
I1
tp14621
sS'dipstick,test'
p14622
(F1
F0.00014334862385321102
I0
I1
I-1
tp14623
sS'phenytoin,phenobarbitol'
p14624
(F1
F0.00014334862385321102
I0
I1
I-1
tp14625
sS'an,mao'
p14626
(F1
F0.00028669724770642203
I2
I0
I2
tp14627
sS'with,possible'
p14628
(F1
F0.00014334862385321102
I1
I0
I1
tp14629
sS'between,single'
p14630
(F1
F0.00014334862385321102
I1
I0
I1
tp14631
sS'an,may'
p14632
(F1
F0.00014334862385321102
I1
I0
I1
tp14633
sS'rats,given'
p14634
(F1
F0.00014334862385321102
I1
I0
I1
tp14635
sS'and,crystalline'
p14636
(F1
F0.00014334862385321102
I0
I1
I-1
tp14637
sS'attributed,to'
p14638
(F1
F0.00014334862385321102
I1
I0
I1
tp14639
sS'and,torsades'
p14640
(F0
F0
I1
I1
I0
tp14641
sS'only,a'
p14642
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14643
sS'taxol,a'
p14644
(F1
F0.00014334862385321102
I0
I1
I-1
tp14645
sS'objectives,to'
p14646
(F1
F0.00014334862385321102
I0
I1
I-1
tp14647
sS'a,cause-and'
p14648
(F1
F0.00028669724770642203
I2
I0
I2
tp14649
sS'severe,hypersensitivity'
p14650
(F0
F0
I1
I1
I0
tp14651
sS'fluconazole,and'
p14652
(F1
F0.00028669724770642203
I0
I2
I-2
tp14653
sS'pegasys,treatment'
p14654
(F1
F0.00014334862385321102
I0
I1
I-1
tp14655
sS'theoretically,may'
p14656
(F1
F0.00014334862385321102
I1
I0
I1
tp14657
sS'with,experienced'
p14658
(F1
F0.00014334862385321102
I1
I0
I1
tp14659
sS'on,without'
p14660
(F1
F0.00014334862385321102
I0
I1
I-1
tp14661
sS'as,tablets'
p14662
(F1
F0.00014334862385321102
I0
I1
I-1
tp14663
sS'the,benefit'
p14664
(F1
F0.00014334862385321102
I1
I0
I1
tp14665
sS'formal,pharmacokinetic'
p14666
(F1
F0.00014334862385321102
I0
I1
I-1
tp14667
sS'performed,both'
p14668
(F1
F0.00014334862385321102
I0
I1
I-1
tp14669
sS'population,of'
p14670
(F1
F0.00014334862385321102
I0
I1
I-1
tp14671
sS'central,nervous'
p14672
(F0.33333333333333331
F0.0010034403669724771
I14
I7
I7
tp14673
sS'clomipramine,hcl'
p14674
(F1
F0.00014334862385321102
I1
I0
I1
tp14675
sS'when,potent'
p14676
(F1
F0.00014334862385321102
I1
I0
I1
tp14677
sS'dha,was'
p14678
(F1
F0.00014334862385321102
I0
I1
I-1
tp14679
sS'of,causes'
p14680
(F1
F0.00014334862385321102
I1
I0
I1
tp14681
sS'also,with'
p14682
(F1
F0.00014334862385321102
I0
I1
I-1
tp14683
sS'other,antiretroviral'
p14684
(F0
F0
I1
I1
I0
tp14685
sS'low,molecular'
p14686
(F1
F0.00014334862385321102
I0
I1
I-1
tp14687
sS'a-blockers,angiotensin-converting'
p14688
(F1
F0.00014334862385321102
I0
I1
I-1
tp14689
sS'of,caused'
p14690
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14691
sS'm-tco,injection'
p14692
(F1
F0.00014334862385321102
I1
I0
I1
tp14693
sS'pressor,activity'
p14694
(F1
F0.00014334862385321102
I0
I1
I-1
tp14695
sS'systemic,eg'
p14696
(F1
F0.00014334862385321102
I0
I1
I-1
tp14697
sS'isoniazid,is'
p14698
(F1
F0.00028669724770642203
I2
I0
I2
tp14699
sS'two-fold,increases'
p14700
(F1
F0.00014334862385321102
I1
I0
I1
tp14701
sS'of,fludrocortisone'
p14702
(F1
F0.00014334862385321102
I1
I0
I1
tp14703
sS'toxicity,cns'
p14704
(F1
F0.00014334862385321102
I0
I1
I-1
tp14705
sS'demonstrated,in'
p14706
(F0
F0
I2
I2
I0
tp14707
sS'co-administration,concomitant'
p14708
(F1
F0.00014334862385321102
I1
I0
I1
tp14709
sS'different,concentrations'
p14710
(F1
F0.00014334862385321102
I0
I1
I-1
tp14711
sS'median,gastric'
p14712
(F1
F0.00014334862385321102
I1
I0
I1
tp14713
sS'cations,or'
p14714
(F1
F0.00014334862385321102
I1
I0
I1
tp14715
sS'the,tysabri'
p14716
(F1
F0.00014334862385321102
I0
I1
I-1
tp14717
sS'lower,tablet'
p14718
(F1
F0.00014334862385321102
I0
I1
I-1
tp14719
sS'prolonged,in'
p14720
(F1
F0.00014334862385321102
I1
I0
I1
tp14721
sS'cautiously,with'
p14722
(F1
F0.00028669724770642203
I2
I0
I2
tp14723
sS'change,was'
p14724
(F1
F0.00014334862385321102
I0
I1
I-1
tp14725
sS'given,one'
p14726
(F1
F0.00014334862385321102
I1
I0
I1
tp14727
sS'in,controlled'
p14728
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp14729
sS'depression,cns'
p14730
(F1
F0.00014334862385321102
I0
I1
I-1
tp14731
sS'may,either'
p14732
(F1
F0.00057339449541284407
I4
I0
I4
tp14733
sS'of,clearance'
p14734
(F1
F0.00028669724770642203
I2
I0
I2
tp14735
sS'shown,in'
p14736
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14737
sS'co-administered,particularly'
p14738
(F1
F0.00014334862385321102
I1
I0
I1
tp14739
sS'flucytosine,while'
p14740
(F1
F0.00014334862385321102
I1
I0
I1
tp14741
sS'protects,mouse'
p14742
(F1
F0.00014334862385321102
I1
I0
I1
tp14743
sS'potential,for'
p14744
(F0.15789473684210525
F0.0008600917431192661
I16
I22
I-6
tp14745
sS'm1,was'
p14746
(F1
F0.00028669724770642203
I0
I2
I-2
tp14747
sS'exhibited,similar'
p14748
(F1
F0.00014334862385321102
I0
I1
I-1
tp14749
sS'volunteers,taking'
p14750
(F1
F0.00014334862385321102
I1
I0
I1
tp14751
sS'warfarin,when'
p14752
(F0
F0
I1
I1
I0
tp14753
sS'insp,mediated'
p14754
(F1
F0.00014334862385321102
I0
I1
I-1
tp14755
sS'a,nd'
p14756
(F1
F0.00014334862385321102
I0
I1
I-1
tp14757
sS'result,if'
p14758
(F1
F0.00014334862385321102
I1
I0
I1
tp14759
sS'theoretically,affect'
p14760
(F1
F0.00014334862385321102
I1
I0
I1
tp14761
sS'g,day'
p14762
(F1
F0.00014334862385321102
I1
I0
I1
tp14763
sS'exposure,by'
p14764
(F1
F0.00014334862385321102
I1
I0
I1
tp14765
sS'elevated,plasma'
p14766
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp14767
sS'metabolite,beta-naltrexol'
p14768
(F1
F0.00014334862385321102
I0
I1
I-1
tp14769
sS'prelone,st'
p14770
(F1
F0.00014334862385321102
I1
I0
I1
tp14771
sS'another,tnf-blocking'
p14772
(F1
F0.00014334862385321102
I1
I0
I1
tp14773
sS'or,reverse'
p14774
(F1
F0.00028669724770642203
I2
I0
I2
tp14775
sS'already,accumulated'
p14776
(F1
F0.00014334862385321102
I1
I0
I1
tp14777
sS'indications,specific'
p14778
(F1
F0.00014334862385321102
I0
I1
I-1
tp14779
sS'weekly,reduced'
p14780
(F1
F0.00014334862385321102
I1
I0
I1
tp14781
sS'cyp2d6,substrate'
p14782
(F1
F0.00014334862385321102
I1
I0
I1
tp14783
sS'min,or'
p14784
(F1
F0.00014334862385321102
I0
I1
I-1
tp14785
sS'akathisia,in'
p14786
(F1
F0.00014334862385321102
I1
I0
I1
tp14787
sS'mg,if'
p14788
(F1
F0.00014334862385321102
I1
I0
I1
tp14789
sS'antimicrobial,is'
p14790
(F1
F0.00028669724770642203
I2
I0
I2
tp14791
sS'mg,in'
p14792
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp14793
sS'or,other'
p14794
(F0.51020408163265307
F0.0035837155963302754
I37
I12
I25
tp14795
sS'single,doses'
p14796
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp14797
sS'prelone,pediapred'
p14798
(F1
F0.00014334862385321102
I0
I1
I-1
tp14799
sS'of,side'
p14800
(F0.25
F0.00028669724770642203
I5
I3
I2
tp14801
sS'mg,iv'
p14802
(F1
F0.00014334862385321102
I0
I1
I-1
tp14803
sS'neither,metabolized'
p14804
(F1
F0.00014334862385321102
I0
I1
I-1
tp14805
sS'profile,in'
p14806
(F1
F0.00014334862385321102
I0
I1
I-1
tp14807
sS'in,men'
p14808
(F1
F0.00043004587155963305
I0
I3
I-3
tp14809
sS'stopping,since'
p14810
(F1
F0.00014334862385321102
I1
I0
I1
tp14811
sS'levonorgestrel-treated,rats'
p14812
(F1
F0.00014334862385321102
I0
I1
I-1
tp14813
sS'fortovase,invirase'
p14814
(F1
F0.00014334862385321102
I1
I0
I1
tp14815
sS'directed,and'
p14816
(F1
F0.00014334862385321102
I0
I1
I-1
tp14817
sS'hypnotics,opioids'
p14818
(F1
F0.00014334862385321102
I1
I0
I1
tp14819
sS'variability,and'
p14820
(F0
F0
I1
I1
I0
tp14821
sS'maximum,plasma'
p14822
(F1
F0.00071674311926605509
I5
I0
I5
tp14823
sS'supporting,the'
p14824
(F1
F0.00014334862385321102
I1
I0
I1
tp14825
sS'that,could'
p14826
(F0.5
F0.00028669724770642203
I3
I1
I2
tp14827
sS'hormones,and'
p14828
(F1
F0.00014334862385321102
I1
I0
I1
tp14829
sS'catecholamine-depleting,eg'
p14830
(F1
F0.00014334862385321102
I1
I0
I1
tp14831
sS'protein-bound,with'
p14832
(F1
F0.00014334862385321102
I1
I0
I1
tp14833
sS'discontinue,pegasys'
p14834
(F1
F0.00014334862385321102
I0
I1
I-1
tp14835
sS'avoided,see'
p14836
(F1
F0.00014334862385321102
I1
I0
I1
tp14837
sS'user,such'
p14838
(F1
F0.00014334862385321102
I0
I1
I-1
tp14839
sS'therefore,dose'
p14840
(F1
F0.00014334862385321102
I0
I1
I-1
tp14841
sS'sg,dipstick'
p14842
(F1
F0.00014334862385321102
I0
I1
I-1
tp14843
sS'fumarate,did'
p14844
(F1
F0.00014334862385321102
I0
I1
I-1
tp14845
sS'depressive,symptoms'
p14846
(F1
F0.00043004587155963305
I0
I3
I-3
tp14847
sS'caution,as'
p14848
(F1
F0.00028669724770642203
I2
I0
I2
tp14849
sS'racemic,for'
p14850
(F1
F0.00014334862385321102
I0
I1
I-1
tp14851
sS'acute,locomotor'
p14852
(F1
F0.00014334862385321102
I1
I0
I1
tp14853
sS'other,potassium-sparing'
p14854
(F1
F0.00014334862385321102
I1
I0
I1
tp14855
sS'crixivan,and'
p14856
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp14857
sS'be,induced'
p14858
(F1
F0.00014334862385321102
I0
I1
I-1
tp14859
sS'marked,has'
p14860
(F1
F0.00028669724770642203
I0
I2
I-2
tp14861
sS'period,will'
p14862
(F1
F0.00014334862385321102
I1
I0
I1
tp14863
sS'second,study'
p14864
(F1
F0.00014334862385321102
I1
I0
I1
tp14865
sS'at,three'
p14866
(F1
F0.00014334862385321102
I0
I1
I-1
tp14867
sS'no,reports'
p14868
(F1
F0.00014334862385321102
I0
I1
I-1
tp14869
sS'enzyme-inducing,properties'
p14870
(F1
F0.00014334862385321102
I1
I0
I1
tp14871
sS'levels,meq'
p14872
(F1
F0.00014334862385321102
I0
I1
I-1
tp14873
sS'optimal,pharmacokinetics'
p14874
(F1
F0.00014334862385321102
I0
I1
I-1
tp14875
sS'the,single'
p14876
(F1
F0.00014334862385321102
I0
I1
I-1
tp14877
sS'with,heart'
p14878
(F1
F0.00028669724770642203
I0
I2
I-2
tp14879
sS'not,however'
p14880
(F1
F0.00014334862385321102
I0
I1
I-1
tp14881
sS'alter,tromethamine'
p14882
(F1
F0.00014334862385321102
I0
I1
I-1
tp14883
sS'daily,was'
p14884
(F1
F0.00028669724770642203
I0
I2
I-2
tp14885
sS'may,effect'
p14886
(F1
F0.00014334862385321102
I1
I0
I1
tp14887
sS'inhibitors,monoamine'
p14888
(F1
F0.00014334862385321102
I0
I1
I-1
tp14889
sS'oral,response'
p14890
(F1
F0.00057339449541284407
I4
I0
I4
tp14891
sS'had,received'
p14892
(F0
F0
I1
I1
I0
tp14893
sS'could,lessen'
p14894
(F1
F0.00014334862385321102
I0
I1
I-1
tp14895
sS'of,antizol'
p14896
(F1
F0.00043004587155963305
I3
I0
I3
tp14897
sS'both,minimal'
p14898
(F1
F0.00014334862385321102
I0
I1
I-1
tp14899
sS'were,decreased'
p14900
(F1
F0.00057339449541284407
I4
I0
I4
tp14901
sS'neutropenia,and'
p14902
(F1
F0.00028669724770642203
I2
I0
I2
tp14903
sS'of,refludan'
p14904
(F1
F0.00014334862385321102
I0
I1
I-1
tp14905
sS'insufficiency,hyperbilirubinemia'
p14906
(F1
F0.00014334862385321102
I1
I0
I1
tp14907
sS'day,and'
p14908
(F0.058823529411764705
F0.00014334862385321102
I9
I8
I1
tp14909
sS'neutropenia,anc'
p14910
(F1
F0.00028669724770642203
I2
I0
I2
tp14911
sS'simulect,clearance'
p14912
(F1
F0.00014334862385321102
I0
I1
I-1
tp14913
sS'which,significantly'
p14914
(F1
F0.00014334862385321102
I1
I0
I1
tp14915
sS'less,alteration'
p14916
(F1
F0.00014334862385321102
I1
I0
I1
tp14917
sS'always,seen'
p14918
(F1
F0.00014334862385321102
I0
I1
I-1
tp14919
sS'higher,exposure'
p14920
(F1
F0.00014334862385321102
I1
I0
I1
tp14921
sS'blockers,proton'
p14922
(F1
F0.00014334862385321102
I1
I0
I1
tp14923
sS'as,belladonna'
p14924
(F1
F0.00014334862385321102
I1
I0
I1
tp14925
sS'difluoroacetone,mg'
p14926
(F1
F0.00028669724770642203
I0
I2
I-2
tp14927
sS'using,doses'
p14928
(F1
F0.00014334862385321102
I1
I0
I1
tp14929
sS'developed,increased'
p14930
(F1
F0.00014334862385321102
I1
I0
I1
tp14931
sS'the,inhibitory'
p14932
(F1
F0.00043004587155963305
I3
I0
I3
tp14933
sS'mixing,of'
p14934
(F1
F0.00028669724770642203
I2
I0
I2
tp14935
sS'st,john'
p14936
(F0
F0
I1
I1
I0
tp14937
sS'myocardium,p'
p14938
(F1
F0.00014334862385321102
I1
I0
I1
tp14939
sS'placebo-controlled,osteoporosis'
p14940
(F1
F0.00014334862385321102
I0
I1
I-1
tp14941
sS'c,inhibited'
p14942
(F1
F0.00014334862385321102
I1
I0
I1
tp14943
sS'those,with'
p14944
(F1
F0.00057339449541284407
I4
I0
I4
tp14945
sS'and,are'
p14946
(F0.46666666666666667
F0.0020068807339449542
I22
I8
I14
tp14947
sS'blood,which'
p14948
(F1
F0.00014334862385321102
I1
I0
I1
tp14949
sS'induce,cyp'
p14950
(F1
F0.00014334862385321102
I1
I0
I1
tp14951
sS'with,hiv-related'
p14952
(F1
F0.00014334862385321102
I0
I1
I-1
tp14953
sS'those,in'
p14954
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp14955
sS'cyp4a11,with'
p14956
(F1
F0.00014334862385321102
I0
I1
I-1
tp14957
sS'significantly,eliminated'
p14958
(F1
F0.00014334862385321102
I1
I0
I1
tp14959
sS'responses,have'
p14960
(F1
F0.00014334862385321102
I1
I0
I1
tp14961
sS'production,of'
p14962
(F0
F0
I2
I2
I0
tp14963
sS'standard,therapy'
p14964
(F1
F0.00014334862385321102
I0
I1
I-1
tp14965
sS'catabolic,enzymes'
p14966
(F1
F0.00043004587155963305
I3
I0
I3
tp14967
sS'v,to'
p14968
(F1
F0.00014334862385321102
I0
I1
I-1
tp14969
sS'systems,responsible'
p14970
(F1
F0.00014334862385321102
I0
I1
I-1
tp14971
sS'related,compounds'
p14972
(F1
F0.00014334862385321102
I1
I0
I1
tp14973
sS'garlic,capsules'
p14974
(F1
F0.00014334862385321102
I0
I1
I-1
tp14975
sS'and,will'
p14976
(F1
F0.00014334862385321102
I0
I1
I-1
tp14977
sS'pharmacokinetics,after'
p14978
(F1
F0.00014334862385321102
I0
I1
I-1
tp14979
sS'competes,for'
p14980
(F1
F0.00028669724770642203
I2
I0
I2
tp14981
sS'maleate,its'
p14982
(F1
F0.00014334862385321102
I1
I0
I1
tp14983
sS'the,anticoagulation'
p14984
(F1
F0.00014334862385321102
I1
I0
I1
tp14985
sS'celexa,the'
p14986
(F1
F0.00014334862385321102
I1
I0
I1
tp14987
sS'categories,result'
p14988
(F1
F0.00014334862385321102
I1
I0
I1
tp14989
sS'employed,when'
p14990
(F1
F0.00014334862385321102
I0
I1
I-1
tp14991
sS'protein,when'
p14992
(F1
F0.00014334862385321102
I0
I1
I-1
tp14993
sS'titrated,according'
p14994
(F1
F0.00014334862385321102
I1
I0
I1
tp14995
sS'blunting,of'
p14996
(F1
F0.00028669724770642203
I2
I0
I2
tp14997
sS'six,of'
p14998
(F1
F0.00014334862385321102
I1
I0
I1
tp14999
sS'or,alter'
p15000
(F1
F0.00014334862385321102
I1
I0
I1
tp15001
sS'from,women'
p15002
(F1
F0.00014334862385321102
I0
I1
I-1
tp15003
sS'be,mediated'
p15004
(F0
F0
I2
I2
I0
tp15005
sS'and,depressive'
p15006
(F1
F0.00028669724770642203
I0
I2
I-2
tp15007
sS'concerns,regarding'
p15008
(F1
F0.00014334862385321102
I0
I1
I-1
tp15009
sS'prothrombin,activity'
p15010
(F1
F0.00028669724770642203
I2
I0
I2
tp15011
sS'cyp2d6,eg'
p15012
(F1
F0.00014334862385321102
I1
I0
I1
tp15013
sS'with,extreme'
p15014
(F1
F0.00043004587155963305
I3
I0
I3
tp15015
sS'agonist,it'
p15016
(F1
F0.00014334862385321102
I1
I0
I1
tp15017
sS'and,small'
p15018
(F1
F0.00014334862385321102
I1
I0
I1
tp15019
sS'antagonists,drugs'
p15020
(F1
F0.00014334862385321102
I1
I0
I1
tp15021
sS'study,evoked'
p15022
(F1
F0.00014334862385321102
I0
I1
I-1
tp15023
sS'injection,clonidine'
p15024
(F1
F0.00014334862385321102
I1
I0
I1
tp15025
sS'antacid,maalox'
p15026
(F1
F0.00014334862385321102
I1
I0
I1
tp15027
sS'welchol,was'
p15028
(F1
F0.00014334862385321102
I0
I1
I-1
tp15029
sS'beginning,depletion'
p15030
(F1
F0.00014334862385321102
I1
I0
I1
tp15031
sS'and,clinically'
p15032
(F1
F0.00014334862385321102
I0
I1
I-1
tp15033
sS'metabolites,hydroxytolbutamide'
p15034
(F1
F0.00014334862385321102
I0
I1
I-1
tp15035
sS'function,have'
p15036
(F1
F0.00014334862385321102
I0
I1
I-1
tp15037
sS'significant,differences'
p15038
(F1
F0.00071674311926605509
I0
I5
I-5
tp15039
sS's,interresponse'
p15040
(F1
F0.00014334862385321102
I0
I1
I-1
tp15041
sS'intravenous,infusion'
p15042
(F1
F0.00028669724770642203
I0
I2
I-2
tp15043
sS'daily,doses'
p15044
(F0
F0
I2
I2
I0
tp15045
sS'less,firmly'
p15046
(F1
F0.00014334862385321102
I1
I0
I1
tp15047
sS'training,dose'
p15048
(F1
F0.00014334862385321102
I0
I1
I-1
tp15049
sS'echistatin,alone'
p15050
(F1
F0.00014334862385321102
I1
I0
I1
tp15051
sS'twice,daily'
p15052
(F0.35999999999999999
F0.0012901376146788992
I8
I17
I-9
tp15053
sS'heparin,the'
p15054
(F1
F0.00014334862385321102
I1
I0
I1
tp15055
sS'apart,so'
p15056
(F1
F0.00014334862385321102
I0
I1
I-1
tp15057
sS'of,buspirone'
p15058
(F1
F0.00028669724770642203
I2
I0
I2
tp15059
sS'mean,fold'
p15060
(F1
F0.00014334862385321102
I1
I0
I1
tp15061
sS'tromethamine,control'
p15062
(F1
F0.00014334862385321102
I1
I0
I1
tp15063
sS'of,cases'
p15064
(F1
F0.00014334862385321102
I1
I0
I1
tp15065
sS'chloride,excretion'
p15066
(F1
F0.00014334862385321102
I1
I0
I1
tp15067
sS'of,xigris'
p15068
(F1
F0.00014334862385321102
I0
I1
I-1
tp15069
sS'an,average'
p15070
(F1
F0.0010034403669724771
I7
I0
I7
tp15071
sS'be,needed'
p15072
(F1
F0.00014334862385321102
I1
I0
I1
tp15073
sS'either,erythro-fluorocitrate'
p15074
(F1
F0.00014334862385321102
I0
I1
I-1
tp15075
sS'as,most'
p15076
(F1
F0.00014334862385321102
I0
I1
I-1
tp15077
sS'nondepolarizing,agents'
p15078
(F1
F0.00028669724770642203
I2
I0
I2
tp15079
sS'tricyclic,with'
p15080
(F1
F0.00014334862385321102
I0
I1
I-1
tp15081
sS'monohydroxy,metabolite'
p15082
(F1
F0.00014334862385321102
I0
I1
I-1
tp15083
sS'of,levo-dromoran'
p15084
(F1
F0.00014334862385321102
I1
I0
I1
tp15085
sS'caffeine,two'
p15086
(F1
F0.00014334862385321102
I0
I1
I-1
tp15087
sS'ace-inhibitors,reports'
p15088
(F1
F0.00028669724770642203
I2
I0
I2
tp15089
sS'or,activity'
p15090
(F1
F0.00014334862385321102
I1
I0
I1
tp15091
sS'of,staphylococcus'
p15092
(F1
F0.00014334862385321102
I1
I0
I1
tp15093
sS'copegus,are'
p15094
(F1
F0.00014334862385321102
I0
I1
I-1
tp15095
sS'this,isoenzyme'
p15096
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp15097
sS'has,recently'
p15098
(F1
F0.00014334862385321102
I1
I0
I1
tp15099
sS'without,preventing'
p15100
(F1
F0.00014334862385321102
I1
I0
I1
tp15101
sS'received,under'
p15102
(F1
F0.00014334862385321102
I0
I1
I-1
tp15103
sS'potentiate,a'
p15104
(F1
F0.00014334862385321102
I1
I0
I1
tp15105
sS'gi,bleeding'
p15106
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15107
sS'agonist,antagonist'
p15108
(F0
F0
I1
I1
I0
tp15109
sS'a,precipitate'
p15110
(F1
F0.00014334862385321102
I0
I1
I-1
tp15111
sS'to,affect'
p15112
(F0.5714285714285714
F0.0011467889908256881
I3
I11
I-8
tp15113
sS'fentanyl,anesthesia'
p15114
(F1
F0.00014334862385321102
I1
I0
I1
tp15115
sS'interactions,general'
p15116
(F1
F0.00014334862385321102
I0
I1
I-1
tp15117
sS'uricosuric,medication'
p15118
(F1
F0.00014334862385321102
I1
I0
I1
tp15119
sS'take,lodine'
p15120
(F1
F0.00014334862385321102
I0
I1
I-1
tp15121
sS'of,based'
p15122
(F1
F0.00014334862385321102
I1
I0
I1
tp15123
sS'inhibitory,action'
p15124
(F1
F0.00014334862385321102
I0
I1
I-1
tp15125
sS'man,significantly'
p15126
(F1
F0.00028669724770642203
I2
I0
I2
tp15127
sS'a4,inhibitors'
p15128
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15129
sS'cefditoren,pivoxil'
p15130
(F0
F0
I2
I2
I0
tp15131
sS'markedly,with'
p15132
(F1
F0.00014334862385321102
I1
I0
I1
tp15133
sS'p-450,a'
p15134
(F1
F0.00014334862385321102
I1
I0
I1
tp15135
sS'i,corticosteroid'
p15136
(F1
F0.00014334862385321102
I0
I1
I-1
tp15137
sS'including,an'
p15138
(F1
F0.00014334862385321102
I0
I1
I-1
tp15139
sS'dosing,is'
p15140
(F1
F0.00014334862385321102
I0
I1
I-1
tp15141
sS'alt,and'
p15142
(F0
F0
I1
I1
I0
tp15143
sS'cyp450,enzyme'
p15144
(F1
F0.00028669724770642203
I0
I2
I-2
tp15145
sS'derivatives,prothrombin'
p15146
(F1
F0.00014334862385321102
I1
I0
I1
tp15147
sS'juice,co-administration'
p15148
(F1
F0.00014334862385321102
I0
I1
I-1
tp15149
sS'their,pharmacological'
p15150
(F1
F0.00014334862385321102
I0
I1
I-1
tp15151
sS'sedation,hallucinations'
p15152
(F1
F0.00014334862385321102
I1
I0
I1
tp15153
sS'and,k'
p15154
(F1
F0.00043004587155963305
I3
I0
I3
tp15155
sS'and,i'
p15156
(F1
F0.00028669724770642203
I0
I2
I-2
tp15157
sS'and,n'
p15158
(F1
F0.00014334862385321102
I1
I0
I1
tp15159
sS'and,m'
p15160
(F1
F0.00014334862385321102
I0
I1
I-1
tp15161
sS'and,b'
p15162
(F1
F0.00014334862385321102
I0
I1
I-1
tp15163
sS'and,a'
p15164
(F0.70909090909090911
F0.0055905963302752297
I47
I8
I39
tp15165
sS'and,g'
p15166
(F1
F0.00028669724770642203
I2
I0
I2
tp15167
sS'and,d'
p15168
(F0
F0
I1
I1
I0
tp15169
sS'and,s'
p15170
(F0
F0
I1
I1
I0
tp15171
sS'newly,diagnosed'
p15172
(F1
F0.00014334862385321102
I0
I1
I-1
tp15173
sS'reduce,plasma'
p15174
(F1
F0.00057339449541284407
I4
I0
I4
tp15175
sS'antipsychotic,action'
p15176
(F1
F0.00014334862385321102
I0
I1
I-1
tp15177
sS'was,greater'
p15178
(F1
F0.00028669724770642203
I2
I0
I2
tp15179
sS'subtilis,and'
p15180
(F1
F0.00014334862385321102
I1
I0
I1
tp15181
sS'injection,q12h'
p15182
(F1
F0.00014334862385321102
I0
I1
I-1
tp15183
sS'decrease,arterial'
p15184
(F1
F0.00043004587155963305
I3
I0
I3
tp15185
sS'time,may'
p15186
(F1
F0.00014334862385321102
I1
I0
I1
tp15187
sS'and,following'
p15188
(F1
F0.00071674311926605509
I0
I5
I-5
tp15189
sS'susceptibility,to'
p15190
(F1
F0.00028669724770642203
I0
I2
I-2
tp15191
sS'salicylic,acid'
p15192
(F0
F0
I2
I2
I0
tp15193
sS'oxidative,stress'
p15194
(F0
F0
I1
I1
I0
tp15195
sS'binding,sites'
p15196
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp15197
sS'treatment,dosage'
p15198
(F1
F0.00014334862385321102
I1
I0
I1
tp15199
sS'on,days'
p15200
(F0
F0
I3
I3
I0
tp15201
sS'or,resulted'
p15202
(F1
F0.00014334862385321102
I1
I0
I1
tp15203
sS'exhibiting,m'
p15204
(F1
F0.00014334862385321102
I0
I1
I-1
tp15205
sS'survey,of'
p15206
(F1
F0.00014334862385321102
I1
I0
I1
tp15207
sS'im,and'
p15208
(F1
F0.00014334862385321102
I0
I1
I-1
tp15209
sS'viracept,was'
p15210
(F1
F0.00014334862385321102
I0
I1
I-1
tp15211
sS'both,lower'
p15212
(F1
F0.00014334862385321102
I1
I0
I1
tp15213
sS'a4,enzymes'
p15214
(F1
F0.00014334862385321102
I0
I1
I-1
tp15215
sS'leads,to'
p15216
(F1
F0.00028669724770642203
I2
I0
I2
tp15217
sS'form,or'
p15218
(F1
F0.00014334862385321102
I1
I0
I1
tp15219
sS'cardiac,and'
p15220
(F1
F0.00043004587155963305
I0
I3
I-3
tp15221
sS'acidity,in'
p15222
(F1
F0.00014334862385321102
I1
I0
I1
tp15223
sS'form,of'
p15224
(F1
F0.00014334862385321102
I0
I1
I-1
tp15225
sS'or,uncomplicated'
p15226
(F1
F0.00014334862385321102
I0
I1
I-1
tp15227
sS'evening,meal'
p15228
(F0
F0
I1
I1
I0
tp15229
sS'with,dilaudid'
p15230
(F1
F0.00014334862385321102
I1
I0
I1
tp15231
sS'd,with'
p15232
(F1
F0.00014334862385321102
I1
I0
I1
tp15233
sS'regimen,did'
p15234
(F1
F0.00014334862385321102
I1
I0
I1
tp15235
sS'induction,the'
p15236
(F1
F0.00014334862385321102
I1
I0
I1
tp15237
sS'a,cytostatic'
p15238
(F1
F0.00014334862385321102
I1
I0
I1
tp15239
sS'inspra,mg'
p15240
(F1
F0.00028669724770642203
I2
I0
I2
tp15241
sS'and,fluoride'
p15242
(F1
F0.00014334862385321102
I0
I1
I-1
tp15243
sS'chance,of'
p15244
(F0
F0
I5
I5
I0
tp15245
sS'several,clinical'
p15246
(F1
F0.00014334862385321102
I0
I1
I-1
tp15247
sS'is,in'
p15248
(F1
F0.00014334862385321102
I0
I1
I-1
tp15249
sS'to10,m'
p15250
(F1
F0.00014334862385321102
I1
I0
I1
tp15251
sS'mg,sular'
p15252
(F1
F0.00014334862385321102
I1
I0
I1
tp15253
sS'ergotamine,concurrent'
p15254
(F1
F0.00014334862385321102
I1
I0
I1
tp15255
sS'increased,inr'
p15256
(F1
F0.00014334862385321102
I1
I0
I1
tp15257
sS'fulminant,rhabdomyolysis'
p15258
(F1
F0.00014334862385321102
I1
I0
I1
tp15259
sS'antagonize,the'
p15260
(F0.875
F0.0020068807339449542
I15
I1
I14
tp15261
sS'v,in'
p15262
(F1
F0.00014334862385321102
I0
I1
I-1
tp15263
sS'was,measured'
p15264
(F1
F0.00028669724770642203
I0
I2
I-2
tp15265
sS'these,include'
p15266
(F1
F0.00057339449541284407
I0
I4
I-4
tp15267
sS'general,most'
p15268
(F1
F0.00014334862385321102
I0
I1
I-1
tp15269
sS'occurrence,of'
p15270
(F0.5
F0.00028669724770642203
I3
I1
I2
tp15271
sS'theophylline,mg'
p15272
(F1
F0.00014334862385321102
I0
I1
I-1
tp15273
sS'cefotaxime,sodium'
p15274
(F1
F0.00014334862385321102
I0
I1
I-1
tp15275
sS'persistent,inhibition'
p15276
(F1
F0.00014334862385321102
I1
I0
I1
tp15277
sS'and,estrogen-containing'
p15278
(F0
F0
I1
I1
I0
tp15279
sS'ampicillin,in'
p15280
(F1
F0.00014334862385321102
I1
I0
I1
tp15281
sS'aspirin,acetaminophen'
p15282
(F1
F0.00014334862385321102
I0
I1
I-1
tp15283
sS'isoenzyme,macrolide'
p15284
(F1
F0.00014334862385321102
I1
I0
I1
tp15285
sS'serious,pneumonia'
p15286
(F1
F0.00014334862385321102
I1
I0
I1
tp15287
sS'a,methotrexate'
p15288
(F1
F0.00014334862385321102
I1
I0
I1
tp15289
sS'to,provoke'
p15290
(F1
F0.00014334862385321102
I0
I1
I-1
tp15291
sS'a,time-dependent'
p15292
(F1
F0.00014334862385321102
I0
I1
I-1
tp15293
sS'cancer,in'
p15294
(F1
F0.00014334862385321102
I1
I0
I1
tp15295
sS'effectively,administered'
p15296
(F1
F0.00014334862385321102
I0
I1
I-1
tp15297
sS'either,levels'
p15298
(F1
F0.00014334862385321102
I0
I1
I-1
tp15299
sS'chlorotrianisene,may'
p15300
(F1
F0.00014334862385321102
I1
I0
I1
tp15301
sS'the,intake'
p15302
(F0
F0
I1
I1
I0
tp15303
sS'exchange,it'
p15304
(F1
F0.00014334862385321102
I0
I1
I-1
tp15305
sS'flurbiprofen,pretreatment'
p15306
(F1
F0.00014334862385321102
I1
I0
I1
tp15307
sS'bid,have'
p15308
(F1
F0.00014334862385321102
I0
I1
I-1
tp15309
sS'diclofenac,decreases'
p15310
(F1
F0.00014334862385321102
I1
I0
I1
tp15311
sS'a,first'
p15312
(F1
F0.00014334862385321102
I0
I1
I-1
tp15313
sS'isoenzymes,may'
p15314
(F1
F0.00014334862385321102
I0
I1
I-1
tp15315
sS'slight,reduction'
p15316
(F1
F0.00014334862385321102
I1
I0
I1
tp15317
sS'any,excessive'
p15318
(F1
F0.00014334862385321102
I1
I0
I1
tp15319
sS'tarceva,with'
p15320
(F1
F0.00014334862385321102
I1
I0
I1
tp15321
sS'h,to'
p15322
(F0
F0
I1
I1
I0
tp15323
sS'an,increased'
p15324
(F0.5
F0.0014334862385321102
I15
I5
I10
tp15325
sS'normal,release'
p15326
(F1
F0.00014334862385321102
I0
I1
I-1
tp15327
sS'hours,experienced'
p15328
(F1
F0.00014334862385321102
I1
I0
I1
tp15329
sS'been,exploited'
p15330
(F1
F0.00014334862385321102
I0
I1
I-1
tp15331
sS'of,antihypertensive'
p15332
(F1
F0.00014334862385321102
I1
I0
I1
tp15333
sS'steady-state,cmin'
p15334
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15335
sS'tests,using'
p15336
(F1
F0.00028669724770642203
I0
I2
I-2
tp15337
sS'd-penicillamine,or'
p15338
(F1
F0.00014334862385321102
I0
I1
I-1
tp15339
sS'levels,to'
p15340
(F1
F0.00028669724770642203
I2
I0
I2
tp15341
sS'h-spiroperidol,and'
p15342
(F1
F0.00028669724770642203
I0
I2
I-2
tp15343
sS'avoid,intoxication'
p15344
(F1
F0.00028669724770642203
I0
I2
I-2
tp15345
sS'close,observation'
p15346
(F1
F0.00028669724770642203
I2
I0
I2
tp15347
sS'tablets,or'
p15348
(F1
F0.0011467889908256881
I8
I0
I8
tp15349
sS'alter,renal'
p15350
(F1
F0.00014334862385321102
I0
I1
I-1
tp15351
sS'fludara,for'
p15352
(F1
F0.00014334862385321102
I1
I0
I1
tp15353
sS'other,suitable'
p15354
(F1
F0.00043004587155963305
I3
I0
I3
tp15355
sS'has,occurred'
p15356
(F0
F0
I1
I1
I0
tp15357
sS'of,years'
p15358
(F1
F0.00014334862385321102
I0
I1
I-1
tp15359
sS'first,few'
p15360
(F1
F0.00043004587155963305
I3
I0
I3
tp15361
sS'diuretics,lotensin'
p15362
(F1
F0.00014334862385321102
I1
I0
I1
tp15363
sS'of,have'
p15364
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp15365
sS'sumatriptan,and'
p15366
(F1
F0.00014334862385321102
I1
I0
I1
tp15367
sS'bleeding,higher'
p15368
(F1
F0.00028669724770642203
I2
I0
I2
tp15369
sS'investigate,the'
p15370
(F1
F0.00043004587155963305
I0
I3
I-3
tp15371
sS'were,co-administered'
p15372
(F1
F0.00028669724770642203
I2
I0
I2
tp15373
sS'intestine,so'
p15374
(F1
F0.00014334862385321102
I1
I0
I1
tp15375
sS'major,metabolite'
p15376
(F1
F0.00028669724770642203
I0
I2
I-2
tp15377
sS'mg,enteric'
p15378
(F1
F0.00014334862385321102
I0
I1
I-1
tp15379
sS'almost,always'
p15380
(F1
F0.00014334862385321102
I0
I1
I-1
tp15381
sS'had,to'
p15382
(F1
F0.00014334862385321102
I0
I1
I-1
tp15383
sS'higher,doses'
p15384
(F0
F0
I5
I5
I0
tp15385
sS'health,care'
p15386
(F0
F0
I1
I1
I0
tp15387
sS'concurrently,being'
p15388
(F1
F0.00028669724770642203
I2
I0
I2
tp15389
sS'with,there'
p15390
(F1
F0.00014334862385321102
I1
I0
I1
tp15391
sS'as,decreasing'
p15392
(F1
F0.00014334862385321102
I1
I0
I1
tp15393
sS'and,there'
p15394
(F1
F0.00014334862385321102
I1
I0
I1
tp15395
sS'non-linear,pharmacokinetics'
p15396
(F1
F0.00014334862385321102
I1
I0
I1
tp15397
sS'arteries,preconstricted'
p15398
(F1
F0.00014334862385321102
I0
I1
I-1
tp15399
sS'midcycle,day'
p15400
(F1
F0.00014334862385321102
I0
I1
I-1
tp15401
sS'evidence,supporting'
p15402
(F1
F0.00014334862385321102
I1
I0
I1
tp15403
sS'antithyroid,b-adrenergic'
p15404
(F1
F0.00014334862385321102
I0
I1
I-1
tp15405
sS'have,some'
p15406
(F1
F0.00014334862385321102
I0
I1
I-1
tp15407
sS'vasodilators,the'
p15408
(F1
F0.00014334862385321102
I1
I0
I1
tp15409
sS'or,epoxide'
p15410
(F1
F0.00028669724770642203
I0
I2
I-2
tp15411
sS'such,a'
p15412
(F0
F0
I1
I1
I0
tp15413
sS'iodine-containing,products'
p15414
(F1
F0.00014334862385321102
I0
I1
I-1
tp15415
sS'because,cyp'
p15416
(F1
F0.00014334862385321102
I0
I1
I-1
tp15417
sS'replacement,therapy'
p15418
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp15419
sS'carbamazepine,causes'
p15420
(F1
F0.00014334862385321102
I1
I0
I1
tp15421
sS'beneficial,effects'
p15422
(F1
F0.00028669724770642203
I2
I0
I2
tp15423
sS'min,after'
p15424
(F0
F0
I1
I1
I0
tp15425
sS'are,using'
p15426
(F1
F0.00014334862385321102
I1
I0
I1
tp15427
sS'an,inadequate'
p15428
(F1
F0.00014334862385321102
I1
I0
I1
tp15429
sS'channel,antagonists'
p15430
(F1
F0.00043004587155963305
I0
I3
I-3
tp15431
sS'and,time'
p15432
(F0
F0
I1
I1
I0
tp15433
sS'fashion,and'
p15434
(F1
F0.00014334862385321102
I0
I1
I-1
tp15435
sS'methotrexate,lodine'
p15436
(F1
F0.00014334862385321102
I1
I0
I1
tp15437
sS'possible,index'
p15438
(F1
F0.00014334862385321102
I0
I1
I-1
tp15439
sS'with,hypertension'
p15440
(F1
F0.00014334862385321102
I1
I0
I1
tp15441
sS'since,these'
p15442
(F1
F0.00028669724770642203
I2
I0
I2
tp15443
sS'enzyme,based'
p15444
(F1
F0.00014334862385321102
I0
I1
I-1
tp15445
sS'bicarbonate,used'
p15446
(F1
F0.00014334862385321102
I1
I0
I1
tp15447
sS'ratio,when'
p15448
(F1
F0.00014334862385321102
I1
I0
I1
tp15449
sS'beta-blockers,not'
p15450
(F1
F0.00014334862385321102
I1
I0
I1
tp15451
sS'exist,comparing'
p15452
(F1
F0.00014334862385321102
I0
I1
I-1
tp15453
sS'hydrochlorothiazide,and'
p15454
(F1
F0.00014334862385321102
I1
I0
I1
tp15455
sS'on,separate'
p15456
(F1
F0.00014334862385321102
I1
I0
I1
tp15457
sS'special,care'
p15458
(F1
F0.00014334862385321102
I1
I0
I1
tp15459
sS'was,recently'
p15460
(F1
F0.00057339449541284407
I4
I0
I4
tp15461
sS'reasonable,to'
p15462
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15463
sS'anabolic,steroids'
p15464
(F1
F0.00014334862385321102
I1
I0
I1
tp15465
sS'probenecid,slows'
p15466
(F1
F0.00014334862385321102
I0
I1
I-1
tp15467
sS'inducers,such'
p15468
(F0.5
F0.00028669724770642203
I3
I1
I2
tp15469
sS'h2-receptor,antagonists'
p15470
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15471
sS'or,co-administration'
p15472
(F1
F0.00014334862385321102
I1
I0
I1
tp15473
sS'reviewed,for'
p15474
(F1
F0.00014334862385321102
I1
I0
I1
tp15475
sS'of,local'
p15476
(F1
F0.00043004587155963305
I3
I0
I3
tp15477
sS'depressasnts,such'
p15478
(F1
F0.00014334862385321102
I1
I0
I1
tp15479
sS'of,fat'
p15480
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15481
sS'and,brain'
p15482
(F1
F0.00028669724770642203
I2
I0
I2
tp15483
sS'by,evaluating'
p15484
(F1
F0.00014334862385321102
I0
I1
I-1
tp15485
sS'renal,vasodilator'
p15486
(F1
F0.00014334862385321102
I0
I1
I-1
tp15487
sS'pump,inhibitors'
p15488
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp15489
sS'on,administration'
p15490
(F1
F0.00014334862385321102
I1
I0
I1
tp15491
sS'breast,cancer'
p15492
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp15493
sS'fatal,prolongation'
p15494
(F1
F0.00014334862385321102
I1
I0
I1
tp15495
sS'ergot,alkaloids'
p15496
(F1
F0.00028669724770642203
I2
I0
I2
tp15497
sS'inhibitors,have'
p15498
(F1
F0.00014334862385321102
I1
I0
I1
tp15499
sS'blockade,will'
p15500
(F1
F0.00014334862385321102
I0
I1
I-1
tp15501
sS'cause,myopathy'
p15502
(F1
F0.00014334862385321102
I0
I1
I-1
tp15503
sS'drugs,include'
p15504
(F1
F0.00014334862385321102
I0
I1
I-1
tp15505
sS'anticholinergics,concurrent'
p15506
(F1
F0.00014334862385321102
I1
I0
I1
tp15507
sS'of,endotoxin-treated'
p15508
(F0
F0
I1
I1
I0
tp15509
sS'oxidase,and'
p15510
(F1
F0.00014334862385321102
I1
I0
I1
tp15511
sS'mixed--pharmacological,and'
p15512
(F1
F0.00014334862385321102
I0
I1
I-1
tp15513
sS'with,nonsteroidal'
p15514
(F1
F0.00043004587155963305
I3
I0
I3
tp15515
sS'of,prior'
p15516
(F1
F0.00014334862385321102
I1
I0
I1
tp15517
sS'requirements,for'
p15518
(F0
F0
I1
I1
I0
tp15519
sS'diazepam,the'
p15520
(F1
F0.00014334862385321102
I1
I0
I1
tp15521
sS'in,auc0-12'
p15522
(F1
F0.00014334862385321102
I1
I0
I1
tp15523
sS'or,too'
p15524
(F1
F0.00014334862385321102
I0
I1
I-1
tp15525
sS'gvia-sensitive,n-type'
p15526
(F1
F0.00014334862385321102
I0
I1
I-1
tp15527
sS'of,each'
p15528
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp15529
sS'with,metabolism'
p15530
(F1
F0.00014334862385321102
I0
I1
I-1
tp15531
sS'insertable,hormonal'
p15532
(F1
F0.00014334862385321102
I0
I1
I-1
tp15533
sS'mg,day'
p15534
(F0.023255813953488372
F0.00014334862385321102
I22
I21
I1
tp15535
sS'acid,using'
p15536
(F1
F0.00014334862385321102
I1
I0
I1
tp15537
sS'hepatitis,c'
p15538
(F1
F0.00014334862385321102
I0
I1
I-1
tp15539
sS'cereals,on'
p15540
(F1
F0.00014334862385321102
I0
I1
I-1
tp15541
sS'mm,fractional'
p15542
(F1
F0.00014334862385321102
I0
I1
I-1
tp15543
sS'propanol,derive'
p15544
(F1
F0.00014334862385321102
I1
I0
I1
tp15545
sS'been,reviewed'
p15546
(F1
F0.00014334862385321102
I1
I0
I1
tp15547
sS'without,additional'
p15548
(F1
F0.00014334862385321102
I0
I1
I-1
tp15549
sS'patients,addition'
p15550
(F1
F0.00014334862385321102
I0
I1
I-1
tp15551
sS'compared,to'
p15552
(F0.35135135135135137
F0.0018635321100917432
I25
I12
I13
tp15553
sS'minute,after'
p15554
(F1
F0.00014334862385321102
I1
I0
I1
tp15555
sS'the,manufacturer'
p15556
(F1
F0.00014334862385321102
I0
I1
I-1
tp15557
sS'survanta,also'
p15558
(F1
F0.00014334862385321102
I0
I1
I-1
tp15559
sS'a,limited'
p15560
(F1
F0.00014334862385321102
I0
I1
I-1
tp15561
sS'inducers,of'
p15562
(F0.16666666666666666
F0.00028669724770642203
I5
I7
I-2
tp15563
sS'recommended,when'
p15564
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp15565
sS'and,effect'
p15566
(F1
F0.00014334862385321102
I1
I0
I1
tp15567
sS'pharmacologically,predictable'
p15568
(F1
F0.00014334862385321102
I1
I0
I1
tp15569
sS'nsaids,and'
p15570
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp15571
sS'loop,diuretics'
p15572
(F1
F0.00014334862385321102
I0
I1
I-1
tp15573
sS'class,ia'
p15574
(F1
F0.00014334862385321102
I1
I0
I1
tp15575
sS'be,impaired'
p15576
(F1
F0.00014334862385321102
I0
I1
I-1
tp15577
sS'class,ii'
p15578
(F1
F0.00014334862385321102
I0
I1
I-1
tp15579
sS'class,iv'
p15580
(F1
F0.00014334862385321102
I0
I1
I-1
tp15581
sS'class,is'
p15582
(F1
F0.00014334862385321102
I0
I1
I-1
tp15583
sS'patients,taking'
p15584
(F0.42857142857142855
F0.0034403669724770644
I40
I16
I24
tp15585
sS'monitored,carefully'
p15586
(F1
F0.00028669724770642203
I2
I0
I2
tp15587
sS'histamine,h2-receptor'
p15588
(F1
F0.00014334862385321102
I0
I1
I-1
tp15589
sS'diabetics,and'
p15590
(F1
F0.00014334862385321102
I0
I1
I-1
tp15591
sS'included,beta-adrenergic'
p15592
(F1
F0.00014334862385321102
I0
I1
I-1
tp15593
sS'the,cecum'
p15594
(F1
F0.00014334862385321102
I0
I1
I-1
tp15595
sS'pregnancy,and'
p15596
(F1
F0.00028669724770642203
I0
I2
I-2
tp15597
sS'not,considered'
p15598
(F1
F0.00014334862385321102
I0
I1
I-1
tp15599
sS'clinical,laboratory'
p15600
(F1
F0.00028669724770642203
I0
I2
I-2
tp15601
sS'hyperthermia,crisis'
p15602
(F1
F0.00014334862385321102
I1
I0
I1
tp15603
sS'crixivan,or'
p15604
(F1
F0.00028669724770642203
I0
I2
I-2
tp15605
sS'prolong,adverse'
p15606
(F1
F0.00014334862385321102
I1
I0
I1
tp15607
sS'msec,compared'
p15608
(F1
F0.00014334862385321102
I1
I0
I1
tp15609
sS'copaxone,did'
p15610
(F1
F0.00014334862385321102
I0
I1
I-1
tp15611
sS'affinities,for'
p15612
(F1
F0.00014334862385321102
I0
I1
I-1
tp15613
sS'blockers,presumably'
p15614
(F1
F0.00014334862385321102
I1
I0
I1
tp15615
sS'p450,isoenzymes'
p15616
(F1
F0.00014334862385321102
I0
I1
I-1
tp15617
sS'for,reduction'
p15618
(F1
F0.00014334862385321102
I1
I0
I1
tp15619
sS'reduce,renal'
p15620
(F1
F0.00014334862385321102
I0
I1
I-1
tp15621
sS'phosphatase,activities'
p15622
(F1
F0.00014334862385321102
I1
I0
I1
tp15623
sS'i,such'
p15624
(F1
F0.00014334862385321102
I0
I1
I-1
tp15625
sS'clearance,does'
p15626
(F1
F0.00014334862385321102
I0
I1
I-1
tp15627
sS'with,persantine'
p15628
(F1
F0.00014334862385321102
I0
I1
I-1
tp15629
sS'on,antinociceptive'
p15630
(F1
F0.00014334862385321102
I0
I1
I-1
tp15631
sS'aminoglycosides,the'
p15632
(F1
F0.00014334862385321102
I1
I0
I1
tp15633
sS'reduced,extent'
p15634
(F1
F0.00014334862385321102
I1
I0
I1
tp15635
sS'various,combinations'
p15636
(F1
F0.00014334862385321102
I0
I1
I-1
tp15637
sS'mesantoin,use'
p15638
(F1
F0.00014334862385321102
I0
I1
I-1
tp15639
sS'antiarrhythmics,amiodarone'
p15640
(F1
F0.00014334862385321102
I0
I1
I-1
tp15641
sS'mao,inhibitors'
p15642
(F0.5
F0.0022935779816513763
I24
I8
I16
tp15643
sS'osteoarthritis,when'
p15644
(F1
F0.00014334862385321102
I0
I1
I-1
tp15645
sS'the,similarity'
p15646
(F1
F0.00014334862385321102
I0
I1
I-1
tp15647
sS'control,mechanisms'
p15648
(F1
F0.00014334862385321102
I0
I1
I-1
tp15649
sS'similarly,dialyzed'
p15650
(F1
F0.00014334862385321102
I0
I1
I-1
tp15651
sS'mg,oral'
p15652
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp15653
sS'or,skeletal-muscle'
p15654
(F1
F0.00014334862385321102
I0
I1
I-1
tp15655
sS'for,than'
p15656
(F1
F0.00014334862385321102
I1
I0
I1
tp15657
sS'pharmacokinetics,over'
p15658
(F1
F0.00014334862385321102
I1
I0
I1
tp15659
sS'produce,nephrotoxicity'
p15660
(F1
F0.00014334862385321102
I1
I0
I1
tp15661
sS'iodide,potentiates'
p15662
(F1
F0.00014334862385321102
I1
I0
I1
tp15663
sS'the,electrolyte'
p15664
(F1
F0.00028669724770642203
I2
I0
I2
tp15665
sS'simultaneous,dosing'
p15666
(F1
F0.00028669724770642203
I2
I0
I2
tp15667
sS'following,single'
p15668
(F1
F0.00014334862385321102
I0
I1
I-1
tp15669
sS'some,pronestyl'
p15670
(F1
F0.00014334862385321102
I1
I0
I1
tp15671
sS'even,be'
p15672
(F1
F0.00014334862385321102
I1
I0
I1
tp15673
sS't4,and'
p15674
(F1
F0.00014334862385321102
I1
I0
I1
tp15675
sS'of,alfenta'
p15676
(F1
F0.00014334862385321102
I0
I1
I-1
tp15677
sS'thiosulfate,is'
p15678
(F1
F0.00014334862385321102
I1
I0
I1
tp15679
sS'especially,those'
p15680
(F1
F0.00071674311926605509
I5
I0
I5
tp15681
sS'or,does'
p15682
(F1
F0.00028669724770642203
I0
I2
I-2
tp15683
sS'rehospitalisation,was'
p15684
(F1
F0.00014334862385321102
I0
I1
I-1
tp15685
sS'beginning,of'
p15686
(F1
F0.00014334862385321102
I0
I1
I-1
tp15687
sS'ml,h'
p15688
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15689
sS'imidazoles,etc'
p15690
(F1
F0.00014334862385321102
I1
I0
I1
tp15691
sS'beginning,or'
p15692
(F1
F0.00014334862385321102
I1
I0
I1
tp15693
sS'of,desmopressin'
p15694
(F1
F0.00014334862385321102
I0
I1
I-1
tp15695
sS'the,alkaloid'
p15696
(F1
F0.00014334862385321102
I1
I0
I1
tp15697
sS'these,agents'
p15698
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp15699
sS'endocrine,and'
p15700
(F1
F0.00028669724770642203
I0
I2
I-2
tp15701
sS'with,betagan'
p15702
(F1
F0.00014334862385321102
I1
I0
I1
tp15703
sS'behavioral,responses'
p15704
(F1
F0.00014334862385321102
I0
I1
I-1
tp15705
sS'oil,and'
p15706
(F1
F0.00014334862385321102
I1
I0
I1
tp15707
sS'be,diminished'
p15708
(F1
F0.00014334862385321102
I1
I0
I1
tp15709
sS'not,quantitatively'
p15710
(F1
F0.00014334862385321102
I0
I1
I-1
tp15711
sS'the,best'
p15712
(F1
F0.00028669724770642203
I0
I2
I-2
tp15713
sS'therapies,standard'
p15714
(F1
F0.00014334862385321102
I0
I1
I-1
tp15715
sS'orders,of'
p15716
(F1
F0.00014334862385321102
I0
I1
I-1
tp15717
sS'are,treated'
p15718
(F1
F0.00014334862385321102
I1
I0
I1
tp15719
sS'the,ht3'
p15720
(F0
F0
I1
I1
I0
tp15721
sS'the,colonic'
p15722
(F1
F0.00014334862385321102
I0
I1
I-1
tp15723
sS'nonopioid,tolerant'
p15724
(F1
F0.00014334862385321102
I0
I1
I-1
tp15725
sS'produced,distinctive'
p15726
(F1
F0.00014334862385321102
I0
I1
I-1
tp15727
sS'self-administration,of'
p15728
(F0
F0
I1
I1
I0
tp15729
sS'and,o-desacetylrifabutin'
p15730
(F1
F0.00014334862385321102
I1
I0
I1
tp15731
sS'and,streptozotocin-induced'
p15732
(F1
F0.00014334862385321102
I0
I1
I-1
tp15733
sS'also,blocked'
p15734
(F1
F0.00014334862385321102
I1
I0
I1
tp15735
sS'form,chelates'
p15736
(F1
F0.00028669724770642203
I0
I2
I-2
tp15737
sS'not,have'
p15738
(F1
F0.0018635321100917432
I0
I13
I-13
tp15739
sS'disturbances,of'
p15740
(F1
F0.00014334862385321102
I1
I0
I1
tp15741
sS'impaired,in'
p15742
(F1
F0.00014334862385321102
I1
I0
I1
tp15743
sS'reduced,or'
p15744
(F1
F0.00043004587155963305
I3
I0
I3
tp15745
sS'nacmc,with'
p15746
(F1
F0.00014334862385321102
I0
I1
I-1
tp15747
sS'combination,products'
p15748
(F1
F0.00014334862385321102
I0
I1
I-1
tp15749
sS'time,profiles'
p15750
(F1
F0.00014334862385321102
I0
I1
I-1
tp15751
sS'and,protein'
p15752
(F1
F0.00014334862385321102
I0
I1
I-1
tp15753
sS'drugs,such'
p15754
(F0.5
F0.00057339449541284407
I6
I2
I4
tp15755
sS'that,co-administration'
p15756
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15757
sS'and,dosage'
p15758
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp15759
sS'hypotension,has'
p15760
(F1
F0.00043004587155963305
I3
I0
I3
tp15761
sS'reviewed,after'
p15762
(F1
F0.00014334862385321102
I0
I1
I-1
tp15763
sS'be,reserved'
p15764
(F1
F0.00014334862385321102
I0
I1
I-1
tp15765
sS'nsaids,should'
p15766
(F1
F0.00028669724770642203
I2
I0
I2
tp15767
sS'chelates,with'
p15768
(F1
F0.00028669724770642203
I0
I2
I-2
tp15769
sS'media,experienced'
p15770
(F1
F0.00014334862385321102
I1
I0
I1
tp15771
sS'metabolism,inhibitors'
p15772
(F1
F0.00014334862385321102
I1
I0
I1
tp15773
sS'beta,adrenergic'
p15774
(F1
F0.00057339449541284407
I4
I0
I4
tp15775
sS'eulexin,capsules'
p15776
(F1
F0.00014334862385321102
I1
I0
I1
tp15777
sS'when,such'
p15778
(F1
F0.00014334862385321102
I0
I1
I-1
tp15779
sS'or,their'
p15780
(F1
F0.00028669724770642203
I0
I2
I-2
tp15781
sS'acid,by'
p15782
(F1
F0.00014334862385321102
I1
I0
I1
tp15783
sS'between,administration'
p15784
(F1
F0.00014334862385321102
I1
I0
I1
tp15785
sS'complexes,with'
p15786
(F1
F0.00014334862385321102
I1
I0
I1
tp15787
sS'on,arteries'
p15788
(F1
F0.00014334862385321102
I0
I1
I-1
tp15789
sS'severe,dry'
p15790
(F1
F0.00028669724770642203
I2
I0
I2
tp15791
sS'characteristics,in'
p15792
(F1
F0.00014334862385321102
I0
I1
I-1
tp15793
sS'reductase,may'
p15794
(F1
F0.00014334862385321102
I0
I1
I-1
tp15795
sS'weekly,for'
p15796
(F1
F0.00014334862385321102
I1
I0
I1
tp15797
sS'vitamin-d,mediated'
p15798
(F1
F0.00014334862385321102
I0
I1
I-1
tp15799
sS'accounts,for'
p15800
(F1
F0.00014334862385321102
I0
I1
I-1
tp15801
sS'than,one-tenth'
p15802
(F1
F0.00014334862385321102
I1
I0
I1
tp15803
sS'b,patients'
p15804
(F1
F0.00014334862385321102
I1
I0
I1
tp15805
sS'aeds,during'
p15806
(F1
F0.00014334862385321102
I0
I1
I-1
tp15807
sS'zinecard,does'
p15808
(F1
F0.00014334862385321102
I0
I1
I-1
tp15809
sS'amprenavir,significantly'
p15810
(F1
F0.00028669724770642203
I2
I0
I2
tp15811
sS'shock,can'
p15812
(F1
F0.00014334862385321102
I1
I0
I1
tp15813
sS'antiplatelet,and'
p15814
(F1
F0.00014334862385321102
I1
I0
I1
tp15815
sS'similarly,had'
p15816
(F1
F0.00014334862385321102
I0
I1
I-1
tp15817
sS'mg,every'
p15818
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp15819
sS'species,during'
p15820
(F1
F0.00014334862385321102
I1
I0
I1
tp15821
sS'in,symptoms'
p15822
(F1
F0.00014334862385321102
I1
I0
I1
tp15823
sS'ng,ml'
p15824
(F0
F0
I3
I3
I0
tp15825
sS'decreased,auc'
p15826
(F1
F0.00028669724770642203
I2
I0
I2
tp15827
sS'blockers,in'
p15828
(F1
F0.00028669724770642203
I0
I2
I-2
tp15829
sS'impairment,particularly'
p15830
(F1
F0.00014334862385321102
I0
I1
I-1
tp15831
sS'toradoliv,im'
p15832
(F1
F0.00043004587155963305
I0
I3
I-3
tp15833
sS'acid,have'
p15834
(F1
F0.00014334862385321102
I1
I0
I1
tp15835
sS'agents,and'
p15836
(F0.090909090909090912
F0.00028669724770642203
I10
I12
I-2
tp15837
sS'indinavir,coadministration'
p15838
(F1
F0.00014334862385321102
I1
I0
I1
tp15839
sS'by,glucuronidation'
p15840
(F1
F0.00014334862385321102
I0
I1
I-1
tp15841
sS'for,glucose'
p15842
(F1
F0.00028669724770642203
I0
I2
I-2
tp15843
sS'crixivan,fortovase'
p15844
(F1
F0.00014334862385321102
I1
I0
I1
tp15845
sS'qd,did'
p15846
(F1
F0.00014334862385321102
I0
I1
I-1
tp15847
sS'obstipation,even'
p15848
(F1
F0.00014334862385321102
I1
I0
I1
tp15849
sS'but,brevibloc'
p15850
(F1
F0.00014334862385321102
I1
I0
I1
tp15851
sS'containing,containing'
p15852
(F1
F0.00014334862385321102
I1
I0
I1
tp15853
sS'produced,in'
p15854
(F1
F0.00014334862385321102
I1
I0
I1
tp15855
sS'corticosteroids,acth'
p15856
(F1
F0.00028669724770642203
I0
I2
I-2
tp15857
sS'hypertension,or'
p15858
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15859
sS'inhibitors,psychotropic'
p15860
(F1
F0.00014334862385321102
I1
I0
I1
tp15861
sS'anticoagulants,thyroid'
p15862
(F1
F0.00014334862385321102
I0
I1
I-1
tp15863
sS'five,lacking'
p15864
(F1
F0.00014334862385321102
I0
I1
I-1
tp15865
sS'pill,such'
p15866
(F1
F0.00014334862385321102
I0
I1
I-1
tp15867
sS'be,antagonistic'
p15868
(F1
F0.00014334862385321102
I1
I0
I1
tp15869
sS'onset,were'
p15870
(F1
F0.00014334862385321102
I0
I1
I-1
tp15871
sS'or,maois'
p15872
(F1
F0.00014334862385321102
I0
I1
I-1
tp15873
sS'cardiac,glycosides'
p15874
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp15875
sS'administered,by'
p15876
(F0
F0
I1
I1
I0
tp15877
sS'inactivate,by'
p15878
(F1
F0.00014334862385321102
I1
I0
I1
tp15879
sS'patients,interaction'
p15880
(F1
F0.00014334862385321102
I0
I1
I-1
tp15881
sS'sprycel,and'
p15882
(F1
F0.00014334862385321102
I1
I0
I1
tp15883
sS'dilaudid,may'
p15884
(F1
F0.00014334862385321102
I1
I0
I1
tp15885
sS'depression,tricyclic'
p15886
(F1
F0.00014334862385321102
I1
I0
I1
tp15887
sS'l,kg'
p15888
(F1
F0.00014334862385321102
I1
I0
I1
tp15889
sS'alter,a'
p15890
(F1
F0.00014334862385321102
I1
I0
I1
tp15891
sS'to,to'
p15892
(F1
F0.00043004587155963305
I0
I3
I-3
tp15893
sS'august,were'
p15894
(F1
F0.00014334862385321102
I0
I1
I-1
tp15895
sS'motion,sickness'
p15896
(F1
F0.00014334862385321102
I0
I1
I-1
tp15897
sS'other,such'
p15898
(F0
F0
I2
I2
I0
tp15899
sS'methylpyrazole,mg'
p15900
(F0
F0
I1
I1
I0
tp15901
sS'by,increased'
p15902
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15903
sS'to,attenuate'
p15904
(F1
F0.00028669724770642203
I0
I2
I-2
tp15905
sS'by,since'
p15906
(F1
F0.00014334862385321102
I1
I0
I1
tp15907
sS'activity,the'
p15908
(F1
F0.00014334862385321102
I0
I1
I-1
tp15909
sS'other,cell'
p15910
(F1
F0.00014334862385321102
I1
I0
I1
tp15911
sS'a,trans-3'
p15912
(F1
F0.00014334862385321102
I1
I0
I1
tp15913
sS'particularly,have'
p15914
(F1
F0.00014334862385321102
I1
I0
I1
tp15915
sS'can,interact'
p15916
(F1
F0.00043004587155963305
I3
I0
I3
tp15917
sS'injected,with'
p15918
(F1
F0.00014334862385321102
I1
I0
I1
tp15919
sS'treatment,should'
p15920
(F1
F0.00043004587155963305
I3
I0
I3
tp15921
sS'fludrocortisone,acetate'
p15922
(F1
F0.00014334862385321102
I1
I0
I1
tp15923
sS'especially,when'
p15924
(F1
F0.00028669724770642203
I2
I0
I2
tp15925
sS'started,thus'
p15926
(F1
F0.00014334862385321102
I1
I0
I1
tp15927
sS'tbars,levels'
p15928
(F1
F0.00014334862385321102
I1
I0
I1
tp15929
sS'of,consciousness'
p15930
(F1
F0.00014334862385321102
I1
I0
I1
tp15931
sS'together,have'
p15932
(F1
F0.00028669724770642203
I2
I0
I2
tp15933
sS'receiving,without'
p15934
(F1
F0.00014334862385321102
I0
I1
I-1
tp15935
sS'elevated,cerebral'
p15936
(F1
F0.00014334862385321102
I1
I0
I1
tp15937
sS'skeletal,muscle'
p15938
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp15939
sS'for,coadministration'
p15940
(F1
F0.00028669724770642203
I0
I2
I-2
tp15941
sS'acute,atypical'
p15942
(F1
F0.00014334862385321102
I1
I0
I1
tp15943
sS'activity,with'
p15944
(F1
F0.00014334862385321102
I1
I0
I1
tp15945
sS'a,times'
p15946
(F1
F0.00014334862385321102
I1
I0
I1
tp15947
sS'contortrostatin-induced,phosphorylation'
p15948
(F1
F0.00014334862385321102
I1
I0
I1
tp15949
sS'on,receiving'
p15950
(F1
F0.00014334862385321102
I1
I0
I1
tp15951
sS'proleukin,may'
p15952
(F1
F0.00028669724770642203
I2
I0
I2
tp15953
sS'have,life-threatening'
p15954
(F1
F0.00014334862385321102
I1
I0
I1
tp15955
sS'or,should'
p15956
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp15957
sS'between,wellbutrin'
p15958
(F1
F0.00014334862385321102
I1
I0
I1
tp15959
sS'synergistic,activity'
p15960
(F1
F0.00028669724770642203
I2
I0
I2
tp15961
sS'if,inspra'
p15962
(F1
F0.00014334862385321102
I1
I0
I1
tp15963
sS'for,nmda'
p15964
(F1
F0.00014334862385321102
I0
I1
I-1
tp15965
sS'are,inducers'
p15966
(F1
F0.00014334862385321102
I0
I1
I-1
tp15967
sS'an,important'
p15968
(F1
F0.00057339449541284407
I4
I0
I4
tp15969
sS'major,membrane'
p15970
(F1
F0.00014334862385321102
I0
I1
I-1
tp15971
sS'acid,level'
p15972
(F1
F0.00014334862385321102
I1
I0
I1
tp15973
sS'which,have'
p15974
(F1
F0.00028669724770642203
I2
I0
I2
tp15975
sS'or,would'
p15976
(F1
F0.00014334862385321102
I0
I1
I-1
tp15977
sS'systolic,blood'
p15978
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp15979
sS'apart,was'
p15980
(F1
F0.00014334862385321102
I1
I0
I1
tp15981
sS'normal,metab-olizers'
p15982
(F1
F0.00014334862385321102
I0
I1
I-1
tp15983
sS'preparations,or'
p15984
(F1
F0.00014334862385321102
I0
I1
I-1
tp15985
sS'with,habituating'
p15986
(F1
F0.00014334862385321102
I0
I1
I-1
tp15987
sS'allium,sativum'
p15988
(F1
F0.00014334862385321102
I1
I0
I1
tp15989
sS'addition,there'
p15990
(F0
F0
I1
I1
I0
tp15991
sS'regimens,who'
p15992
(F1
F0.00014334862385321102
I1
I0
I1
tp15993
sS'confirm,that'
p15994
(F1
F0.00028669724770642203
I0
I2
I-2
tp15995
sS'blocking,the'
p15996
(F0
F0
I1
I1
I0
tp15997
sS'of,brevibloc'
p15998
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15999
sS'with,doses'
p16000
(F1
F0.00028669724770642203
I0
I2
I-2
tp16001
sS'h2,receptor'
p16002
(F1
F0.00014334862385321102
I1
I0
I1
tp16003
sS'sulfide,metabolite'
p16004
(F1
F0.00014334862385321102
I1
I0
I1
tp16005
sS'trial,should'
p16006
(F1
F0.00014334862385321102
I1
I0
I1
tp16007
sS'analogue,d-ala2'
p16008
(F1
F0.00014334862385321102
I0
I1
I-1
tp16009
sS'prolonged,from'
p16010
(F1
F0.00014334862385321102
I1
I0
I1
tp16011
sS'possible,drug'
p16012
(F1
F0.00043004587155963305
I3
I0
I3
tp16013
sS'hydrochloride,x'
p16014
(F1
F0.00014334862385321102
I1
I0
I1
tp16015
sS'clinical,experience'
p16016
(F0
F0
I1
I1
I0
tp16017
sS'however,because'
p16018
(F0.5
F0.00028669724770642203
I3
I1
I2
tp16019
sS'molecular,mechanisms'
p16020
(F1
F0.00014334862385321102
I0
I1
I-1
tp16021
sS'and,metabolite'
p16022
(F1
F0.00014334862385321102
I1
I0
I1
tp16023
sS'its,active'
p16024
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp16025
sS'hydrochloride,a'
p16026
(F1
F0.00014334862385321102
I0
I1
I-1
tp16027
sS'glaucoma,or'
p16028
(F1
F0.00014334862385321102
I1
I0
I1
tp16029
sS'definitively,demonstrated'
p16030
(F1
F0.00014334862385321102
I1
I0
I1
tp16031
sS'adult,data'
p16032
(F1
F0.00014334862385321102
I1
I0
I1
tp16033
sS'various,antihypertensive'
p16034
(F1
F0.00014334862385321102
I1
I0
I1
tp16035
sS'following,days'
p16036
(F1
F0.00014334862385321102
I0
I1
I-1
tp16037
sS'with,d2-antagonists'
p16038
(F1
F0.00014334862385321102
I1
I0
I1
tp16039
sS'via,its'
p16040
(F1
F0.00014334862385321102
I1
I0
I1
tp16041
sS'and,multiple'
p16042
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16043
sS'with,activity'
p16044
(F0
F0
I3
I3
I0
tp16045
sS'furosemide,should'
p16046
(F1
F0.00014334862385321102
I1
I0
I1
tp16047
sS'concentrations,include'
p16048
(F1
F0.00043004587155963305
I3
I0
I3
tp16049
sS'the,iatrogenic'
p16050
(F1
F0.00014334862385321102
I0
I1
I-1
tp16051
sS'these,interactions'
p16052
(F1
F0.00014334862385321102
I0
I1
I-1
tp16053
sS'further,the'
p16054
(F1
F0.00014334862385321102
I1
I0
I1
tp16055
sS'in,whom'
p16056
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp16057
sS'g,ml'
p16058
(F1
F0.00014334862385321102
I1
I0
I1
tp16059
sS'inhalation,aerosol'
p16060
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16061
sS'sub-,for'
p16062
(F1
F0.00014334862385321102
I0
I1
I-1
tp16063
sS'absorbed,from'
p16064
(F1
F0.00014334862385321102
I0
I1
I-1
tp16065
sS'without,a'
p16066
(F0
F0
I1
I1
I0
tp16067
sS'endogenous,plasma'
p16068
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16069
sS'as,alternatives'
p16070
(F1
F0.00014334862385321102
I1
I0
I1
tp16071
sS'hypoglycemic,effect'
p16072
(F1
F0.00014334862385321102
I1
I0
I1
tp16073
sS'g,m2'
p16074
(F1
F0.00014334862385321102
I0
I1
I-1
tp16075
sS'been,coadministered'
p16076
(F1
F0.00043004587155963305
I0
I3
I-3
tp16077
sS'also,higher'
p16078
(F1
F0.00014334862385321102
I1
I0
I1
tp16079
sS'antagonists,phenyltheophylline'
p16080
(F1
F0.00014334862385321102
I0
I1
I-1
tp16081
sS'with,micromol'
p16082
(F1
F0.00014334862385321102
I0
I1
I-1
tp16083
sS'revealed,that'
p16084
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16085
sS'inhibited,gastric'
p16086
(F1
F0.00014334862385321102
I0
I1
I-1
tp16087
sS'after,cholestyramine'
p16088
(F1
F0.00014334862385321102
I0
I1
I-1
tp16089
sS'meals,for'
p16090
(F1
F0.00028669724770642203
I0
I2
I-2
tp16091
sS'was,more'
p16092
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp16093
sS'aldehyde,oxidase'
p16094
(F0
F0
I1
I1
I0
tp16095
sS'cmax,when'
p16096
(F1
F0.00057339449541284407
I4
I0
I4
tp16097
sS'coumarin-type,the'
p16098
(F1
F0.00028669724770642203
I2
I0
I2
tp16099
sS'the,nursing'
p16100
(F1
F0.00014334862385321102
I0
I1
I-1
tp16101
sS'circulating,fluids'
p16102
(F1
F0.00014334862385321102
I0
I1
I-1
tp16103
sS'another,drug'
p16104
(F1
F0.00028669724770642203
I0
I2
I-2
tp16105
sS'rt-pa,or'
p16106
(F1
F0.00014334862385321102
I0
I1
I-1
tp16107
sS'thrombus,formation'
p16108
(F1
F0.00014334862385321102
I1
I0
I1
tp16109
sS'treatment,may'
p16110
(F1
F0.00014334862385321102
I1
I0
I1
tp16111
sS'monitored,regularly'
p16112
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16113
sS'if,additional'
p16114
(F1
F0.00014334862385321102
I1
I0
I1
tp16115
sS'nsaids,tnf'
p16116
(F1
F0.00014334862385321102
I0
I1
I-1
tp16117
sS'relevant,effect'
p16118
(F0
F0
I1
I1
I0
tp16119
sS'these,leading'
p16120
(F1
F0.00014334862385321102
I1
I0
I1
tp16121
sS'phenytoin,phenytoin'
p16122
(F1
F0.00014334862385321102
I1
I0
I1
tp16123
sS'extracellular,rr'
p16124
(F1
F0.00014334862385321102
I1
I0
I1
tp16125
sS'that,administration'
p16126
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16127
sS'desired,effect'
p16128
(F0.75
F0.0008600917431192661
I7
I1
I6
tp16129
sS'two,were'
p16130
(F1
F0.00014334862385321102
I1
I0
I1
tp16131
sS'ketoconazole,cyp3a4'
p16132
(F1
F0.00014334862385321102
I0
I1
I-1
tp16133
sS'insufficient,experience'
p16134
(F1
F0.00014334862385321102
I1
I0
I1
tp16135
sS'during,with'
p16136
(F1
F0.00014334862385321102
I1
I0
I1
tp16137
sS'study,toradoliv'
p16138
(F1
F0.00014334862385321102
I0
I1
I-1
tp16139
sS'therefore,consideration'
p16140
(F1
F0.00014334862385321102
I1
I0
I1
tp16141
sS'elimination,route'
p16142
(F1
F0.00014334862385321102
I1
I0
I1
tp16143
sS'acetazolamide,may'
p16144
(F1
F0.00043004587155963305
I3
I0
I3
tp16145
sS'between,copaxone'
p16146
(F1
F0.00014334862385321102
I0
I1
I-1
tp16147
sS'wedge,pressure'
p16148
(F1
F0.00014334862385321102
I1
I0
I1
tp16149
sS'cations,including'
p16150
(F1
F0.00014334862385321102
I1
I0
I1
tp16151
sS'hypotension,because'
p16152
(F1
F0.00014334862385321102
I0
I1
I-1
tp16153
sS'with,antihypertensive'
p16154
(F1
F0.00014334862385321102
I1
I0
I1
tp16155
sS'including,solganal'
p16156
(F1
F0.00014334862385321102
I1
I0
I1
tp16157
sS'enzymes,may'
p16158
(F0
F0
I1
I1
I0
tp16159
sS'of,vehicle'
p16160
(F1
F0.00014334862385321102
I0
I1
I-1
tp16161
sS'to,repeated'
p16162
(F1
F0.00014334862385321102
I0
I1
I-1
tp16163
sS'and,occurred'
p16164
(F1
F0.00014334862385321102
I1
I0
I1
tp16165
sS'rifampin,increases'
p16166
(F1
F0.00014334862385321102
I1
I0
I1
tp16167
sS'serial,pharmacokinetic'
p16168
(F1
F0.00014334862385321102
I0
I1
I-1
tp16169
sS'alone,was'
p16170
(F1
F0.00014334862385321102
I1
I0
I1
tp16171
sS'therapy,although'
p16172
(F1
F0.00028669724770642203
I0
I2
I-2
tp16173
sS'metabolism,is'
p16174
(F1
F0.00014334862385321102
I0
I1
I-1
tp16175
sS'also,expected'
p16176
(F1
F0.00028669724770642203
I2
I0
I2
tp16177
sS'metabolism,in'
p16178
(F0.5
F0.00028669724770642203
I3
I1
I2
tp16179
sS'single,and'
p16180
(F1
F0.00014334862385321102
I1
I0
I1
tp16181
sS'aeds,in'
p16182
(F1
F0.00014334862385321102
I1
I0
I1
tp16183
sS'agents,benzodiazepines'
p16184
(F1
F0.00014334862385321102
I1
I0
I1
tp16185
sS'toxic,that'
p16186
(F1
F0.00014334862385321102
I0
I1
I-1
tp16187
sS'b,non-steroidal'
p16188
(F1
F0.00014334862385321102
I0
I1
I-1
tp16189
sS'groups,receiving'
p16190
(F1
F0.00014334862385321102
I1
I0
I1
tp16191
sS'plasma,prothrombin'
p16192
(F1
F0.00028669724770642203
I2
I0
I2
tp16193
sS'ipratropium,bromide'
p16194
(F1
F0.00014334862385321102
I1
I0
I1
tp16195
sS'that,they'
p16196
(F1
F0.00014334862385321102
I1
I0
I1
tp16197
sS'diarrhea,in'
p16198
(F1
F0.00014334862385321102
I1
I0
I1
tp16199
sS'lithium,should'
p16200
(F1
F0.00014334862385321102
I1
I0
I1
tp16201
sS'in,markedly'
p16202
(F1
F0.00014334862385321102
I1
I0
I1
tp16203
sS'tacrolimus,felodipine'
p16204
(F1
F0.00014334862385321102
I0
I1
I-1
tp16205
sS'to,examine'
p16206
(F1
F0.00071674311926605509
I0
I5
I-5
tp16207
sS'a,comprehensive'
p16208
(F1
F0.00014334862385321102
I0
I1
I-1
tp16209
sS'tc99m,uptake'
p16210
(F1
F0.00014334862385321102
I0
I1
I-1
tp16211
sS'depress,plasma'
p16212
(F1
F0.00028669724770642203
I2
I0
I2
tp16213
sS'despite,persistent'
p16214
(F1
F0.00014334862385321102
I0
I1
I-1
tp16215
sS'for,maintenance'
p16216
(F1
F0.00014334862385321102
I0
I1
I-1
tp16217
sS'received,muscle'
p16218
(F1
F0.00014334862385321102
I1
I0
I1
tp16219
sS'acid,and'
p16220
(F0.33333333333333331
F0.00057339449541284407
I4
I8
I-4
tp16221
sS'with,but'
p16222
(F0
F0
I1
I1
I0
tp16223
sS'lodosyn,carbidopa'
p16224
(F1
F0.00014334862385321102
I0
I1
I-1
tp16225
sS'combination,oral'
p16226
(F1
F0.00028669724770642203
I0
I2
I-2
tp16227
sS'completely,evaluated'
p16228
(F1
F0.00014334862385321102
I0
I1
I-1
tp16229
sS'in,large'
p16230
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16231
sS'and,significant'
p16232
(F1
F0.00043004587155963305
I3
I0
I3
tp16233
sS'supplement,while'
p16234
(F1
F0.00014334862385321102
I1
I0
I1
tp16235
sS'isoenzymes,caution'
p16236
(F1
F0.00014334862385321102
I1
I0
I1
tp16237
sS'use,and'
p16238
(F1
F0.00014334862385321102
I0
I1
I-1
tp16239
sS'predict,the'
p16240
(F1
F0.00014334862385321102
I0
I1
I-1
tp16241
sS'same,study'
p16242
(F1
F0.00014334862385321102
I0
I1
I-1
tp16243
sS'when,vardenafil'
p16244
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16245
sS'is,frequently'
p16246
(F1
F0.00014334862385321102
I0
I1
I-1
tp16247
sS'studies,demonstrated'
p16248
(F1
F0.00028669724770642203
I0
I2
I-2
tp16249
sS'blockers,calcium'
p16250
(F1
F0.00014334862385321102
I0
I1
I-1
tp16251
sS'containing,higher'
p16252
(F1
F0.00014334862385321102
I0
I1
I-1
tp16253
sS'prolongation,cardiac'
p16254
(F1
F0.00014334862385321102
I1
I0
I1
tp16255
sS'ventricular,dysfunction'
p16256
(F1
F0.00014334862385321102
I0
I1
I-1
tp16257
sS'when,intravenous'
p16258
(F1
F0.00014334862385321102
I1
I0
I1
tp16259
sS'the,striatum'
p16260
(F1
F0.00014334862385321102
I1
I0
I1
tp16261
sS'rifampin,and'
p16262
(F1
F0.00014334862385321102
I1
I0
I1
tp16263
sS'endogenous,marker'
p16264
(F1
F0.00014334862385321102
I1
I0
I1
tp16265
sS'lack,of'
p16266
(F1
F0.0010034403669724771
I0
I7
I-7
tp16267
sS'undertaken,with'
p16268
(F1
F0.00028669724770642203
I2
I0
I2
tp16269
sS'ethanol,cause'
p16270
(F1
F0.00014334862385321102
I1
I0
I1
tp16271
sS'potentiate,any'
p16272
(F1
F0.00014334862385321102
I1
I0
I1
tp16273
sS'pharmacokinetic,substudy'
p16274
(F1
F0.00014334862385321102
I1
I0
I1
tp16275
sS'been,investigated'
p16276
(F0
F0
I1
I1
I0
tp16277
sS'generally,not'
p16278
(F1
F0.00028669724770642203
I2
I0
I2
tp16279
sS'p450iiia4,isozyme'
p16280
(F1
F0.00014334862385321102
I1
I0
I1
tp16281
sS'hydroxymethylglutaryl,coenzyme'
p16282
(F1
F0.00014334862385321102
I1
I0
I1
tp16283
sS'chemical,resemblance'
p16284
(F1
F0.00014334862385321102
I1
I0
I1
tp16285
sS'or,glycosides'
p16286
(F1
F0.00014334862385321102
I0
I1
I-1
tp16287
sS'monitoring,or'
p16288
(F1
F0.00014334862385321102
I1
I0
I1
tp16289
sS'least,months'
p16290
(F1
F0.00028669724770642203
I0
I2
I-2
tp16291
sS'the,pronounced'
p16292
(F1
F0.00014334862385321102
I1
I0
I1
tp16293
sS'impulsivity,and'
p16294
(F1
F0.00014334862385321102
I0
I1
I-1
tp16295
sS'monitoring,of'
p16296
(F0.25
F0.0008600917431192661
I15
I9
I6
tp16297
sS'of,containing'
p16298
(F1
F0.00014334862385321102
I1
I0
I1
tp16299
sS'renal,elimination'
p16300
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp16301
sS'unusually,high'
p16302
(F1
F0.00014334862385321102
I1
I0
I1
tp16303
sS'exaggerate,the'
p16304
(F1
F0.00028669724770642203
I2
I0
I2
tp16305
sS'urine,may'
p16306
(F1
F0.00043004587155963305
I0
I3
I-3
tp16307
sS'with,norpace'
p16308
(F1
F0.00014334862385321102
I1
I0
I1
tp16309
sS'co-,administration'
p16310
(F1
F0.00014334862385321102
I0
I1
I-1
tp16311
sS'antidepressant,levels'
p16312
(F1
F0.00028669724770642203
I2
I0
I2
tp16313
sS'preparations,glyceryl'
p16314
(F1
F0.00014334862385321102
I0
I1
I-1
tp16315
sS'its,nephrotoxicity'
p16316
(F1
F0.00014334862385321102
I1
I0
I1
tp16317
sS'maximum,of'
p16318
(F1
F0.00043004587155963305
I3
I0
I3
tp16319
sS'nicotine-induced,release'
p16320
(F1
F0.00014334862385321102
I1
I0
I1
tp16321
sS'medium,rpmi1640'
p16322
(F1
F0.00014334862385321102
I0
I1
I-1
tp16323
sS'vomiting,and'
p16324
(F1
F0.00014334862385321102
I1
I0
I1
tp16325
sS'also,in'
p16326
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp16327
sS'results,using'
p16328
(F1
F0.00014334862385321102
I0
I1
I-1
tp16329
sS'mean,confidence'
p16330
(F1
F0.00014334862385321102
I1
I0
I1
tp16331
sS'itraconazole,ketoconazole'
p16332
(F1
F0.00014334862385321102
I0
I1
I-1
tp16333
sS'or,changing'
p16334
(F1
F0.00043004587155963305
I3
I0
I3
tp16335
sS'inr,elevations'
p16336
(F1
F0.00014334862385321102
I1
I0
I1
tp16337
sS'of,h-triglyceride'
p16338
(F1
F0.00014334862385321102
I1
I0
I1
tp16339
sS'concentrations,similar'
p16340
(F1
F0.00014334862385321102
I1
I0
I1
tp16341
sS'medication,but'
p16342
(F1
F0.00014334862385321102
I0
I1
I-1
tp16343
sS'with,indicate'
p16344
(F1
F0.00014334862385321102
I1
I0
I1
tp16345
sS'b12,and'
p16346
(F1
F0.00014334862385321102
I1
I0
I1
tp16347
sS'possible,anticholinesterase'
p16348
(F1
F0.00014334862385321102
I1
I0
I1
tp16349
sS'accompany,high'
p16350
(F1
F0.00014334862385321102
I1
I0
I1
tp16351
sS'prostaglandins,may'
p16352
(F1
F0.00014334862385321102
I1
I0
I1
tp16353
sS'post-marketing,experience'
p16354
(F1
F0.00071674311926605509
I5
I0
I5
tp16355
sS'about,in'
p16356
(F1
F0.00043004587155963305
I3
I0
I3
tp16357
sS'oxo-desethylzaleplon,and'
p16358
(F1
F0.00014334862385321102
I0
I1
I-1
tp16359
sS'acid,sequestrants'
p16360
(F1
F0.00014334862385321102
I1
I0
I1
tp16361
sS'higher,daily'
p16362
(F1
F0.00014334862385321102
I0
I1
I-1
tp16363
sS'the,lower'
p16364
(F1
F0.00043004587155963305
I3
I0
I3
tp16365
sS'essentially,completely'
p16366
(F1
F0.00014334862385321102
I0
I1
I-1
tp16367
sS'with,topical'
p16368
(F1
F0.00014334862385321102
I1
I0
I1
tp16369
sS'locomotor,and'
p16370
(F1
F0.00014334862385321102
I0
I1
I-1
tp16371
sS'with,cyp1a2'
p16372
(F1
F0.00014334862385321102
I1
I0
I1
tp16373
sS'nimotop,was'
p16374
(F1
F0.00014334862385321102
I1
I0
I1
tp16375
sS'event,profile'
p16376
(F1
F0.00014334862385321102
I0
I1
I-1
tp16377
sS'insulin-induced,proliferation'
p16378
(F1
F0.00014334862385321102
I1
I0
I1
tp16379
sS'multiple-dose,crossover'
p16380
(F1
F0.00014334862385321102
I0
I1
I-1
tp16381
sS'immunodepressant--the,sandimmune--on'
p16382
(F1
F0.00014334862385321102
I0
I1
I-1
tp16383
sS'system,cns'
p16384
(F0
F0
I1
I1
I0
tp16385
sS'patterns,of'
p16386
(F1
F0.00014334862385321102
I0
I1
I-1
tp16387
sS'pre-existing,cardiac'
p16388
(F1
F0.00014334862385321102
I1
I0
I1
tp16389
sS'sc,or'
p16390
(F1
F0.00014334862385321102
I0
I1
I-1
tp16391
sS'higher,serum'
p16392
(F1
F0.00028669724770642203
I2
I0
I2
tp16393
sS'were,extensive'
p16394
(F1
F0.00014334862385321102
I1
I0
I1
tp16395
sS'those,elevations'
p16396
(F1
F0.00014334862385321102
I0
I1
I-1
tp16397
sS'follow-up,of'
p16398
(F1
F0.00014334862385321102
I0
I1
I-1
tp16399
sS'therefore,interactions'
p16400
(F1
F0.00014334862385321102
I0
I1
I-1
tp16401
sS'regarding,interactions'
p16402
(F1
F0.00028669724770642203
I0
I2
I-2
tp16403
sS'substitute,for'
p16404
(F1
F0.00057339449541284407
I0
I4
I-4
tp16405
sS'inhibited,insp'
p16406
(F1
F0.00028669724770642203
I2
I0
I2
tp16407
sS'pharmacokinetics,exposure'
p16408
(F1
F0.00014334862385321102
I0
I1
I-1
tp16409
sS'fatal,reactions'
p16410
(F1
F0.00014334862385321102
I1
I0
I1
tp16411
sS'with,neurontin'
p16412
(F1
F0.00014334862385321102
I1
I0
I1
tp16413
sS'and,azole'
p16414
(F1
F0.00014334862385321102
I0
I1
I-1
tp16415
sS'tail-flick,inhibition'
p16416
(F0
F0
I3
I3
I0
tp16417
sS'estazolam,interaction'
p16418
(F1
F0.00028669724770642203
I0
I2
I-2
tp16419
sS'bleeding,with'
p16420
(F1
F0.00014334862385321102
I0
I1
I-1
tp16421
sS'may,require'
p16422
(F0.066666666666666666
F0.00014334862385321102
I7
I8
I-1
tp16423
sS'detoxification,of'
p16424
(F1
F0.00014334862385321102
I1
I0
I1
tp16425
sS'and,from'
p16426
(F1
F0.00043004587155963305
I0
I3
I-3
tp16427
sS'regularly,results'
p16428
(F1
F0.00014334862385321102
I0
I1
I-1
tp16429
sS'antiinflammatory,agents'
p16430
(F1
F0.00028669724770642203
I2
I0
I2
tp16431
sS'patients,and'
p16432
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp16433
sS'lithium,coadministration'
p16434
(F1
F0.00014334862385321102
I0
I1
I-1
tp16435
sS'warfarin-type,certain'
p16436
(F1
F0.00014334862385321102
I1
I0
I1
tp16437
sS'the,channel'
p16438
(F1
F0.00014334862385321102
I0
I1
I-1
tp16439
sS'alkaloid,class'
p16440
(F1
F0.00014334862385321102
I1
I0
I1
tp16441
sS'inhibitors,should'
p16442
(F1
F0.0008600917431192661
I6
I0
I6
tp16443
sS'demonstrated,an'
p16444
(F1
F0.00014334862385321102
I1
I0
I1
tp16445
sS'rare,postmarketing'
p16446
(F1
F0.00014334862385321102
I1
I0
I1
tp16447
sS'mode,of'
p16448
(F1
F0.00014334862385321102
I0
I1
I-1
tp16449
sS'dosed,at'
p16450
(F1
F0.00014334862385321102
I0
I1
I-1
tp16451
sS'activity,against'
p16452
(F1
F0.00014334862385321102
I0
I1
I-1
tp16453
sS'milk,milk'
p16454
(F1
F0.00014334862385321102
I1
I0
I1
tp16455
sS'or,insulin-induced'
p16456
(F1
F0.00014334862385321102
I1
I0
I1
tp16457
sS'of,alcohol-related'
p16458
(F1
F0.00014334862385321102
I0
I1
I-1
tp16459
sS'chronic,dosing'
p16460
(F1
F0.00014334862385321102
I0
I1
I-1
tp16461
sS'with,cerubidine'
p16462
(F1
F0.00014334862385321102
I1
I0
I1
tp16463
sS'excretion,rate'
p16464
(F1
F0.00014334862385321102
I0
I1
I-1
tp16465
sS'there,any'
p16466
(F1
F0.00014334862385321102
I0
I1
I-1
tp16467
sS'eprosartan,has'
p16468
(F1
F0.00014334862385321102
I0
I1
I-1
tp16469
sS'changing,vioxx'
p16470
(F1
F0.00014334862385321102
I1
I0
I1
tp16471
sS'preparations,such'
p16472
(F1
F0.00014334862385321102
I1
I0
I1
tp16473
sS'diuretics,concomitant'
p16474
(F1
F0.00014334862385321102
I1
I0
I1
tp16475
sS'be,exceeded'
p16476
(F1
F0.00028669724770642203
I2
I0
I2
tp16477
sS'diuretics,patients'
p16478
(F1
F0.00028669724770642203
I2
I0
I2
tp16479
sS'fully,evaluating'
p16480
(F1
F0.00014334862385321102
I0
I1
I-1
tp16481
sS'that,has'
p16482
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16483
sS'treatment,study'
p16484
(F1
F0.00014334862385321102
I0
I1
I-1
tp16485
sS'all,animal'
p16486
(F1
F0.00014334862385321102
I0
I1
I-1
tp16487
sS'which,could'
p16488
(F0
F0
I2
I2
I0
tp16489
sS'that,had'
p16490
(F1
F0.00014334862385321102
I0
I1
I-1
tp16491
sS'psoriatic,arthritis'
p16492
(F1
F0.00014334862385321102
I0
I1
I-1
tp16493
sS'infusion,requirements'
p16494
(F1
F0.00014334862385321102
I1
I0
I1
tp16495
sS'effects,concerning'
p16496
(F1
F0.00014334862385321102
I1
I0
I1
tp16497
sS'metabolizers,resemble'
p16498
(F1
F0.00014334862385321102
I0
I1
I-1
tp16499
sS'more,of'
p16500
(F1
F0.00014334862385321102
I0
I1
I-1
tp16501
sS'been,tested'
p16502
(F1
F0.00014334862385321102
I0
I1
I-1
tp16503
sS'the,therapeutic'
p16504
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp16505
sS'are,relatively'
p16506
(F1
F0.00014334862385321102
I0
I1
I-1
tp16507
sS'of,stimulation'
p16508
(F1
F0.00014334862385321102
I0
I1
I-1
tp16509
sS'been,formally'
p16510
(F1
F0.00014334862385321102
I0
I1
I-1
tp16511
sS'more,or'
p16512
(F1
F0.00014334862385321102
I0
I1
I-1
tp16513
sS'group,of'
p16514
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp16515
sS'without,significantly'
p16516
(F1
F0.00014334862385321102
I0
I1
I-1
tp16517
sS'may,show'
p16518
(F1
F0.00014334862385321102
I1
I0
I1
tp16519
sS'against,an'
p16520
(F1
F0.00014334862385321102
I1
I0
I1
tp16521
sS'ie,decreased'
p16522
(F1
F0.00028669724770642203
I2
I0
I2
tp16523
sS'phenytoin,therapy'
p16524
(F1
F0.00014334862385321102
I1
I0
I1
tp16525
sS'received,days'
p16526
(F0
F0
I1
I1
I0
tp16527
sS'average,decreases'
p16528
(F1
F0.00014334862385321102
I1
I0
I1
tp16529
sS'the,early'
p16530
(F1
F0.00014334862385321102
I1
I0
I1
tp16531
sS'decreased,approximately'
p16532
(F1
F0.00028669724770642203
I2
I0
I2
tp16533
sS'not,recommended'
p16534
(F0.57894736842105265
F0.0015768348623853212
I15
I4
I11
tp16535
sS'this,class'
p16536
(F1
F0.00028669724770642203
I0
I2
I-2
tp16537
sS'of,l-tyrosine'
p16538
(F1
F0.00014334862385321102
I1
I0
I1
tp16539
sS'fibrillation,and'
p16540
(F1
F0.00014334862385321102
I0
I1
I-1
tp16541
sS'that,renal'
p16542
(F1
F0.00014334862385321102
I1
I0
I1
tp16543
sS'the,fertility'
p16544
(F1
F0.00014334862385321102
I0
I1
I-1
tp16545
sS'on,warfarin-type'
p16546
(F1
F0.00014334862385321102
I1
I0
I1
tp16547
sS'are,responsible'
p16548
(F1
F0.00014334862385321102
I0
I1
I-1
tp16549
sS'antagonists,appear'
p16550
(F1
F0.00014334862385321102
I0
I1
I-1
tp16551
sS'and,bezalip'
p16552
(F1
F0.00014334862385321102
I1
I0
I1
tp16553
sS'the,rate-limiting'
p16554
(F1
F0.00014334862385321102
I0
I1
I-1
tp16555
sS'cyp3a4,have'
p16556
(F1
F0.00014334862385321102
I0
I1
I-1
tp16557
sS'one-week,course'
p16558
(F1
F0.00014334862385321102
I1
I0
I1
tp16559
sS'doses,will'
p16560
(F1
F0.00014334862385321102
I0
I1
I-1
tp16561
sS'plasmaconcentration,of'
p16562
(F1
F0.00014334862385321102
I1
I0
I1
tp16563
sS'mg,qd'
p16564
(F0
F0
I8
I8
I0
tp16565
sS'of,either'
p16566
(F0.23809523809523808
F0.00071674311926605509
I8
I13
I-5
tp16567
sS'dihydropyridine,derivative'
p16568
(F1
F0.00014334862385321102
I0
I1
I-1
tp16569
sS'potential,pharmacokinetic'
p16570
(F1
F0.00014334862385321102
I0
I1
I-1
tp16571
sS'the,estimated'
p16572
(F1
F0.00014334862385321102
I0
I1
I-1
tp16573
sS'inhibitors,such'
p16574
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp16575
sS'with,male'
p16576
(F1
F0.00014334862385321102
I1
I0
I1
tp16577
sS'prolong,further'
p16578
(F1
F0.00014334862385321102
I1
I0
I1
tp16579
sS'blockers,could'
p16580
(F1
F0.00014334862385321102
I1
I0
I1
tp16581
sS'medicines,such'
p16582
(F1
F0.00014334862385321102
I1
I0
I1
tp16583
sS'for,hour'
p16584
(F1
F0.00014334862385321102
I1
I0
I1
tp16585
sS'fold,greater'
p16586
(F1
F0.00014334862385321102
I1
I0
I1
tp16587
sS'limited,to'
p16588
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16589
sS'botox,and'
p16590
(F1
F0.00014334862385321102
I1
I0
I1
tp16591
sS'with,angiotensln'
p16592
(F1
F0.00014334862385321102
I1
I0
I1
tp16593
sS'general,clinical'
p16594
(F1
F0.00014334862385321102
I1
I0
I1
tp16595
sS'activity,pra'
p16596
(F1
F0.00014334862385321102
I0
I1
I-1
tp16597
sS'were,variable'
p16598
(F1
F0.00014334862385321102
I0
I1
I-1
tp16599
sS'the,concomitant'
p16600
(F0.48051948051948051
F0.0053038990825688076
I57
I20
I37
tp16601
sS'binding,of'
p16602
(F0.125
F0.00028669724770642203
I9
I7
I2
tp16603
sS'as,marplan'
p16604
(F1
F0.00028669724770642203
I0
I2
I-2
tp16605
sS'low-dose,microg'
p16606
(F1
F0.00014334862385321102
I1
I0
I1
tp16607
sS'and,uroxatral'
p16608
(F1
F0.00014334862385321102
I1
I0
I1
tp16609
sS'as,plasma'
p16610
(F1
F0.00014334862385321102
I1
I0
I1
tp16611
sS'describes,two'
p16612
(F1
F0.00014334862385321102
I1
I0
I1
tp16613
sS'decreased,increased'
p16614
(F1
F0.00014334862385321102
I1
I0
I1
tp16615
sS'to,assess'
p16616
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp16617
sS'and,cerebyx'
p16618
(F0
F0
I1
I1
I0
tp16619
sS'the,distribution'
p16620
(F1
F0.00014334862385321102
I0
I1
I-1
tp16621
sS'in,lower'
p16622
(F1
F0.0008600917431192661
I6
I0
I6
tp16623
sS'by,a'
p16624
(F0.36363636363636365
F0.0011467889908256881
I15
I7
I8
tp16625
sS'highly,plasma'
p16626
(F1
F0.00014334862385321102
I1
I0
I1
tp16627
sS'by,m'
p16628
(F1
F0.00014334862385321102
I1
I0
I1
tp16629
sS'in,fdf'
p16630
(F1
F0.00043004587155963305
I3
I0
I3
tp16631
sS'proteins,and'
p16632
(F1
F0.00014334862385321102
I1
I0
I1
tp16633
sS'available,assay'
p16634
(F1
F0.00014334862385321102
I0
I1
I-1
tp16635
sS'complete,and'
p16636
(F1
F0.00014334862385321102
I1
I0
I1
tp16637
sS'fluothane,may'
p16638
(F1
F0.00014334862385321102
I1
I0
I1
tp16639
sS'pharmacology,clinical'
p16640
(F1
F0.00014334862385321102
I1
I0
I1
tp16641
sS'not,show'
p16642
(F1
F0.00057339449541284407
I0
I4
I-4
tp16643
sS'manifested,by'
p16644
(F1
F0.00014334862385321102
I0
I1
I-1
tp16645
sS'contractility,when'
p16646
(F1
F0.00014334862385321102
I1
I0
I1
tp16647
sS'trough,concentration'
p16648
(F1
F0.00014334862385321102
I1
I0
I1
tp16649
sS'inhibitors,result'
p16650
(F1
F0.00014334862385321102
I1
I0
I1
tp16651
sS'for,optimal'
p16652
(F1
F0.00014334862385321102
I0
I1
I-1
tp16653
sS'serum,valproic'
p16654
(F1
F0.00014334862385321102
I0
I1
I-1
tp16655
sS'used,such'
p16656
(F1
F0.00014334862385321102
I0
I1
I-1
tp16657
sS'gram-negative,organisms'
p16658
(F1
F0.00014334862385321102
I0
I1
I-1
tp16659
sS'micro-dosed,preparations'
p16660
(F1
F0.00014334862385321102
I1
I0
I1
tp16661
sS'much,lower'
p16662
(F1
F0.00014334862385321102
I0
I1
I-1
tp16663
sS'alone,suggesting'
p16664
(F1
F0.00014334862385321102
I1
I0
I1
tp16665
sS'isoform,also'
p16666
(F1
F0.00014334862385321102
I1
I0
I1
tp16667
sS'but,available'
p16668
(F1
F0.00014334862385321102
I0
I1
I-1
tp16669
sS'consequently,it'
p16670
(F1
F0.00028669724770642203
I2
I0
I2
tp16671
sS'a,inhibitors'
p16672
(F1
F0.00028669724770642203
I2
I0
I2
tp16673
sS'hormonal,and'
p16674
(F1
F0.00014334862385321102
I0
I1
I-1
tp16675
sS'other,psychoactive'
p16676
(F1
F0.00014334862385321102
I1
I0
I1
tp16677
sS'metenkephalinamide,or'
p16678
(F1
F0.00014334862385321102
I0
I1
I-1
tp16679
sS'attributed,at'
p16680
(F1
F0.00014334862385321102
I1
I0
I1
tp16681
sS'app,control'
p16682
(F1
F0.00014334862385321102
I0
I1
I-1
tp16683
sS'taken,if'
p16684
(F0
F0
I1
I1
I0
tp16685
sS'daily,increases'
p16686
(F1
F0.00014334862385321102
I1
I0
I1
tp16687
sS'high,viral'
p16688
(F1
F0.00014334862385321102
I0
I1
I-1
tp16689
sS'brovana,treated'
p16690
(F1
F0.00028669724770642203
I0
I2
I-2
tp16691
sS'depletion,related'
p16692
(F1
F0.00014334862385321102
I0
I1
I-1
tp16693
sS'out,to'
p16694
(F1
F0.00014334862385321102
I0
I1
I-1
tp16695
sS'significantly,influence'
p16696
(F1
F0.00014334862385321102
I0
I1
I-1
tp16697
sS'kg,increased'
p16698
(F1
F0.00014334862385321102
I1
I0
I1
tp16699
sS'tegretol,trileptal'
p16700
(F1
F0.00014334862385321102
I1
I0
I1
tp16701
sS'cells,rr'
p16702
(F1
F0.00014334862385321102
I0
I1
I-1
tp16703
sS'patients,have'
p16704
(F0
F0
I1
I1
I0
tp16705
sS'short-acting,such'
p16706
(F1
F0.00014334862385321102
I0
I1
I-1
tp16707
sS'including,certain'
p16708
(F1
F0.00028669724770642203
I2
I0
I2
tp16709
sS'liver,are'
p16710
(F1
F0.00014334862385321102
I0
I1
I-1
tp16711
sS'safety,profile'
p16712
(F1
F0.00043004587155963305
I0
I3
I-3
tp16713
sS'of,most'
p16714
(F1
F0.00028669724770642203
I2
I0
I2
tp16715
sS'was,investigated'
p16716
(F1
F0.00057339449541284407
I0
I4
I-4
tp16717
sS'somatrem,somatropin'
p16718
(F1
F0.00014334862385321102
I0
I1
I-1
tp16719
sS'phase,study'
p16720
(F1
F0.00014334862385321102
I0
I1
I-1
tp16721
sS'hypotensive,including'
p16722
(F1
F0.00014334862385321102
I1
I0
I1
tp16723
sS'non-opioid,analgesics'
p16724
(F1
F0.00014334862385321102
I0
I1
I-1
tp16725
sS'the,nrtis'
p16726
(F1
F0.00014334862385321102
I0
I1
I-1
tp16727
sS'and,with'
p16728
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp16729
sS'solution,fehlings'
p16730
(F1
F0.00014334862385321102
I0
I1
I-1
tp16731
sS'the,tail-flick'
p16732
(F0.25
F0.00028669724770642203
I5
I3
I2
tp16733
sS'single-dose,pharmacokinetic'
p16734
(F1
F0.00014334862385321102
I0
I1
I-1
tp16735
sS'iv,cannot'
p16736
(F1
F0.00014334862385321102
I0
I1
I-1
tp16737
sS'could,have'
p16738
(F1
F0.00014334862385321102
I0
I1
I-1
tp16739
sS'prescription,of'
p16740
(F1
F0.00014334862385321102
I1
I0
I1
tp16741
sS'in,gene'
p16742
(F1
F0.00014334862385321102
I0
I1
I-1
tp16743
sS'glomerulonephritis,oculo-bulbar'
p16744
(F1
F0.00014334862385321102
I1
I0
I1
tp16745
sS'involving,metabolized'
p16746
(F1
F0.00014334862385321102
I1
I0
I1
tp16747
sS'and,tricyclic'
p16748
(F1
F0.00014334862385321102
I1
I0
I1
tp16749
sS'on,oral'
p16750
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp16751
sS'overall,improvements'
p16752
(F1
F0.00014334862385321102
I0
I1
I-1
tp16753
sS'type,may'
p16754
(F1
F0.00014334862385321102
I0
I1
I-1
tp16755
sS'decreased,binding'
p16756
(F1
F0.00014334862385321102
I1
I0
I1
tp16757
sS'ibandronate,mg'
p16758
(F1
F0.00014334862385321102
I0
I1
I-1
tp16759
sS'haloperidol,reduced'
p16760
(F1
F0.00014334862385321102
I1
I0
I1
tp16761
sS'failure,of'
p16762
(F1
F0.00014334862385321102
I0
I1
I-1
tp16763
sS'kg,mg'
p16764
(F1
F0.00043004587155963305
I0
I3
I-3
tp16765
sS'prostate-specific,antigen'
p16766
(F1
F0.00014334862385321102
I0
I1
I-1
tp16767
sS'kg,ml'
p16768
(F1
F0.00014334862385321102
I0
I1
I-1
tp16769
sS'and,transition'
p16770
(F1
F0.00014334862385321102
I0
I1
I-1
tp16771
sS'co-administration,with'
p16772
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp16773
sS'acid-catalyzed,ethanolysis'
p16774
(F1
F0.00014334862385321102
I1
I0
I1
tp16775
sS'sedative,effects'
p16776
(F1
F0.00028669724770642203
I2
I0
I2
tp16777
sS'three,mg'
p16778
(F1
F0.00014334862385321102
I1
I0
I1
tp16779
sS'psychotropic,or'
p16780
(F1
F0.00014334862385321102
I0
I1
I-1
tp16781
sS'zofran,and'
p16782
(F1
F0.00014334862385321102
I0
I1
I-1
tp16783
sS'xa,and'
p16784
(F1
F0.00014334862385321102
I0
I1
I-1
tp16785
sS'and,elicit'
p16786
(F1
F0.00014334862385321102
I0
I1
I-1
tp16787
sS'other,cyp3a4'
p16788
(F0.5
F0.00028669724770642203
I3
I1
I2
tp16789
sS'dysrhythmias,of'
p16790
(F1
F0.00014334862385321102
I1
I0
I1
tp16791
sS'striatum,and'
p16792
(F1
F0.00014334862385321102
I1
I0
I1
tp16793
sS'homogenates,supplemented'
p16794
(F1
F0.00014334862385321102
I0
I1
I-1
tp16795
sS'administration,but'
p16796
(F1
F0.00014334862385321102
I0
I1
I-1
tp16797
sS'of,had'
p16798
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp16799
sS'unwanted,effects'
p16800
(F1
F0.00014334862385321102
I0
I1
I-1
tp16801
sS'of,has'
p16802
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp16803
sS'oral,markedly'
p16804
(F1
F0.00028669724770642203
I2
I0
I2
tp16805
sS'pharmacokinetic,changes'
p16806
(F1
F0.00014334862385321102
I1
I0
I1
tp16807
sS'too,low'
p16808
(F1
F0.00014334862385321102
I0
I1
I-1
tp16809
sS'multivalent,cation-containing'
p16810
(F1
F0.00014334862385321102
I1
I0
I1
tp16811
sS'and,use'
p16812
(F0
F0
I1
I1
I0
tp16813
sS'or,follow'
p16814
(F1
F0.00014334862385321102
I0
I1
I-1
tp16815
sS'sulfate,sodium'
p16816
(F1
F0.00014334862385321102
I1
I0
I1
tp16817
sS'dose-dependent,modification'
p16818
(F1
F0.00014334862385321102
I1
I0
I1
tp16819
sS'control,hypertension'
p16820
(F1
F0.00014334862385321102
I1
I0
I1
tp16821
sS'other,the'
p16822
(F0
F0
I1
I1
I0
tp16823
sS'after,starting'
p16824
(F1
F0.00028669724770642203
I0
I2
I-2
tp16825
sS'while,corresponding'
p16826
(F1
F0.00014334862385321102
I0
I1
I-1
tp16827
sS'adversely,influence'
p16828
(F1
F0.00014334862385321102
I1
I0
I1
tp16829
sS'and,fluvoxamine'
p16830
(F1
F0.00014334862385321102
I1
I0
I1
tp16831
sS'adsorbents,and'
p16832
(F1
F0.00014334862385321102
I1
I0
I1
tp16833
sS'hypothermia,as'
p16834
(F1
F0.00014334862385321102
I0
I1
I-1
tp16835
sS'phenytoin,serum'
p16836
(F1
F0.00028669724770642203
I2
I0
I2
tp16837
sS'intoxication,appropriate'
p16838
(F1
F0.00014334862385321102
I0
I1
I-1
tp16839
sS'the,central'
p16840
(F1
F0.0014334862385321102
I10
I0
I10
tp16841
sS'histidines,on'
p16842
(F1
F0.00014334862385321102
I0
I1
I-1
tp16843
sS'in,tbg'
p16844
(F1
F0.00014334862385321102
I0
I1
I-1
tp16845
sS'not,influence'
p16846
(F1
F0.0012901376146788992
I0
I9
I-9
tp16847
sS'healthy,males'
p16848
(F1
F0.00028669724770642203
I0
I2
I-2
tp16849
sS'for,four'
p16850
(F1
F0.00028669724770642203
I0
I2
I-2
tp16851
sS'weeks,plasma'
p16852
(F1
F0.00014334862385321102
I1
I0
I1
tp16853
sS'parenteral,may'
p16854
(F1
F0.00014334862385321102
I1
I0
I1
tp16855
sS'cyp3a5,responsible'
p16856
(F1
F0.00014334862385321102
I0
I1
I-1
tp16857
sS'studies,oral'
p16858
(F1
F0.00014334862385321102
I0
I1
I-1
tp16859
sS'pancreatic,acinar'
p16860
(F1
F0.00014334862385321102
I0
I1
I-1
tp16861
sS'and,b12'
p16862
(F1
F0.00014334862385321102
I0
I1
I-1
tp16863
sS'reports,suggest'
p16864
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp16865
sS'of,months'
p16866
(F1
F0.00014334862385321102
I0
I1
I-1
tp16867
sS'substrate,administered'
p16868
(F1
F0.00014334862385321102
I0
I1
I-1
tp16869
sS'significantly,improve'
p16870
(F1
F0.00014334862385321102
I0
I1
I-1
tp16871
sS'fentanyl,cyp3a4'
p16872
(F1
F0.00014334862385321102
I0
I1
I-1
tp16873
sS'caution,to'
p16874
(F1
F0.0008600917431192661
I6
I0
I6
tp16875
sS'of,co-administration'
p16876
(F1
F0.00028669724770642203
I0
I2
I-2
tp16877
sS'three,different'
p16878
(F1
F0.00014334862385321102
I0
I1
I-1
tp16879
sS'no,depressant'
p16880
(F1
F0.00014334862385321102
I0
I1
I-1
tp16881
sS'time,concomitant'
p16882
(F1
F0.00014334862385321102
I0
I1
I-1
tp16883
sS'two,times'
p16884
(F1
F0.00014334862385321102
I0
I1
I-1
tp16885
sS'release,was'
p16886
(F1
F0.00014334862385321102
I0
I1
I-1
tp16887
sS'by,through'
p16888
(F1
F0.00014334862385321102
I0
I1
I-1
tp16889
sS'and,potassium-depleting'
p16890
(F1
F0.00014334862385321102
I1
I0
I1
tp16891
sS'be,determined'
p16892
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp16893
sS'an,inhibition'
p16894
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16895
sS'at,five'
p16896
(F1
F0.00014334862385321102
I0
I1
I-1
tp16897
sS'the,myocardium'
p16898
(F1
F0.00057339449541284407
I4
I0
I4
tp16899
sS'monoamine,oxidase'
p16900
(F0.45945945945945948
F0.0024369266055045873
I27
I10
I17
tp16901
sS'immunodeficiency,virus-related'
p16902
(F1
F0.00014334862385321102
I0
I1
I-1
tp16903
sS'synthetic,hydroxy-3'
p16904
(F1
F0.00014334862385321102
I0
I1
I-1
tp16905
sS'prevents,morphine-induced'
p16906
(F1
F0.00014334862385321102
I1
I0
I1
tp16907
sS'observed,after'
p16908
(F1
F0.00028669724770642203
I0
I2
I-2
tp16909
sS'indocin,mg'
p16910
(F1
F0.00014334862385321102
I1
I0
I1
tp16911
sS'systemic,corticosteroids'
p16912
(F1
F0.00014334862385321102
I0
I1
I-1
tp16913
sS'without,an'
p16914
(F1
F0.00014334862385321102
I1
I0
I1
tp16915
sS'the,reddish'
p16916
(F1
F0.00014334862385321102
I1
I0
I1
tp16917
sS'be,subject'
p16918
(F1
F0.00014334862385321102
I0
I1
I-1
tp16919
sS'four,diets'
p16920
(F1
F0.00014334862385321102
I0
I1
I-1
tp16921
sS'nsaids,concomitant'
p16922
(F1
F0.00043004587155963305
I3
I0
I3
tp16923
sS'bismuth,bismuth'
p16924
(F1
F0.00014334862385321102
I1
I0
I1
tp16925
sS'the,non-ionized'
p16926
(F1
F0.00014334862385321102
I1
I0
I1
tp16927
sS'and,catabolic'
p16928
(F1
F0.00043004587155963305
I3
I0
I3
tp16929
sS'hydroxylamine,a'
p16930
(F1
F0.00014334862385321102
I0
I1
I-1
tp16931
sS'necessary,if'
p16932
(F1
F0.00043004587155963305
I0
I3
I-3
tp16933
sS'while,levels'
p16934
(F1
F0.00014334862385321102
I1
I0
I1
tp16935
sS'taking,either'
p16936
(F1
F0.00014334862385321102
I1
I0
I1
tp16937
sS'previous,studies'
p16938
(F1
F0.00014334862385321102
I1
I0
I1
tp16939
sS'excessive,neuromuscular'
p16940
(F1
F0.00014334862385321102
I1
I0
I1
tp16941
sS'lithium,increased'
p16942
(F1
F0.00043004587155963305
I3
I0
I3
tp16943
sS'reflecting,the'
p16944
(F1
F0.00014334862385321102
I0
I1
I-1
tp16945
sS'out,in'
p16946
(F1
F0.00014334862385321102
I0
I1
I-1
tp16947
sS'with,tambocor'
p16948
(F1
F0.00014334862385321102
I1
I0
I1
tp16949
sS'an,adequate'
p16950
(F1
F0.00043004587155963305
I0
I3
I-3
tp16951
sS'acid,secretion'
p16952
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16953
sS'from,normal'
p16954
(F1
F0.00014334862385321102
I0
I1
I-1
tp16955
sS'and,sgpt'
p16956
(F1
F0.00014334862385321102
I1
I0
I1
tp16957
sS'who,consume'
p16958
(F1
F0.00014334862385321102
I1
I0
I1
tp16959
sS'model,possibly'
p16960
(F1
F0.00014334862385321102
I1
I0
I1
tp16961
sS'ht1b,d'
p16962
(F1
F0.00014334862385321102
I1
I0
I1
tp16963
sS'patients,lowered'
p16964
(F1
F0.00014334862385321102
I1
I0
I1
tp16965
sS'dihydroergotamine,contraindicated'
p16966
(F1
F0.00014334862385321102
I0
I1
I-1
tp16967
sS'is,an'
p16968
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp16969
sS'outside,the'
p16970
(F1
F0.00014334862385321102
I0
I1
I-1
tp16971
sS'micrograms,g'
p16972
(F1
F0.00014334862385321102
I0
I1
I-1
tp16973
sS'either,added'
p16974
(F1
F0.00028669724770642203
I2
I0
I2
tp16975
sS'mg,once'
p16976
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp16977
sS'brovana,dose'
p16978
(F1
F0.00014334862385321102
I0
I1
I-1
tp16979
sS'frequently,with'
p16980
(F1
F0.00014334862385321102
I0
I1
I-1
tp16981
sS'fever,renal'
p16982
(F1
F0.00014334862385321102
I1
I0
I1
tp16983
sS'in,decreased'
p16984
(F0.5
F0.00057339449541284407
I6
I2
I4
tp16985
sS'syndrome,characterized'
p16986
(F1
F0.00014334862385321102
I1
I0
I1
tp16987
sS'pcp-induced,behavioral'
p16988
(F1
F0.00014334862385321102
I0
I1
I-1
tp16989
sS'placebo-controlled,study'
p16990
(F1
F0.00014334862385321102
I0
I1
I-1
tp16991
sS'in,decreases'
p16992
(F0
F0
I1
I1
I0
tp16993
sS'ec50,values'
p16994
(F1
F0.00014334862385321102
I0
I1
I-1
tp16995
sS'demonstrate,any'
p16996
(F1
F0.00028669724770642203
I0
I2
I-2
tp16997
sS'pcp,or'
p16998
(F1
F0.00014334862385321102
I1
I0
I1
tp16999
sS'pointer,dogs'
p17000
(F1
F0.00014334862385321102
I0
I1
I-1
tp17001
sS'permeation,of'
p17002
(F1
F0.00028669724770642203
I0
I2
I-2
tp17003
sS'supplements,uncontrolled'
p17004
(F1
F0.00043004587155963305
I0
I3
I-3
tp17005
sS'nefazodone,cyclosporine'
p17006
(F1
F0.00014334862385321102
I0
I1
I-1
tp17007
sS'of,adrenergic'
p17008
(F1
F0.00014334862385321102
I1
I0
I1
tp17009
sS'furosemide,toradol'
p17010
(F1
F0.00014334862385321102
I1
I0
I1
tp17011
sS'unique,biopharmaceutical'
p17012
(F1
F0.00014334862385321102
I0
I1
I-1
tp17013
sS'liver,but'
p17014
(F1
F0.00014334862385321102
I0
I1
I-1
tp17015
sS'particularly,during'
p17016
(F1
F0.00028669724770642203
I2
I0
I2
tp17017
sS'hypoglycemia,secondary'
p17018
(F1
F0.00014334862385321102
I1
I0
I1
tp17019
sS'and,similar'
p17020
(F1
F0.00014334862385321102
I0
I1
I-1
tp17021
sS'that,decreases'
p17022
(F1
F0.00014334862385321102
I0
I1
I-1
tp17023
sS'may,blunt'
p17024
(F1
F0.00014334862385321102
I0
I1
I-1
tp17025
sS'potent,than'
p17026
(F1
F0.00028669724770642203
I0
I2
I-2
tp17027
sS'steady-state,cmax'
p17028
(F1
F0.00043004587155963305
I3
I0
I3
tp17029
sS'basal,plasma'
p17030
(F1
F0.00014334862385321102
I0
I1
I-1
tp17031
sS'and,effectiveness'
p17032
(F1
F0.00028669724770642203
I0
I2
I-2
tp17033
sS'interval,as'
p17034
(F1
F0.00014334862385321102
I0
I1
I-1
tp17035
sS'cyp1a2,inhibitors'
p17036
(F0
F0
I1
I1
I0
tp17037
sS'substantially,interfere'
p17038
(F1
F0.00057339449541284407
I4
I0
I4
tp17039
sS'dicumarol,it'
p17040
(F1
F0.00014334862385321102
I1
I0
I1
tp17041
sS'elimination,or'
p17042
(F1
F0.00014334862385321102
I0
I1
I-1
tp17043
sS'an,oral'
p17044
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp17045
sS'were,there'
p17046
(F1
F0.00014334862385321102
I0
I1
I-1
tp17047
sS'urine,volume'
p17048
(F1
F0.00028669724770642203
I2
I0
I2
tp17049
sS'they,cause'
p17050
(F1
F0.00014334862385321102
I0
I1
I-1
tp17051
sS'azopt,ophthalmic'
p17052
(F1
F0.00014334862385321102
I0
I1
I-1
tp17053
sS'to,cause'
p17054
(F0.052631578947368418
F0.00014334862385321102
I10
I9
I1
tp17055
sS'in,postmenopausal'
p17056
(F1
F0.00014334862385321102
I1
I0
I1
tp17057
sS'with,pivoxil'
p17058
(F1
F0.00014334862385321102
I1
I0
I1
tp17059
sS'these,products'
p17060
(F1
F0.00014334862385321102
I1
I0
I1
tp17061
sS'acting,primarily'
p17062
(F1
F0.00014334862385321102
I1
I0
I1
tp17063
sS'oral,inhaled'
p17064
(F1
F0.00014334862385321102
I0
I1
I-1
tp17065
sS'inomax,has'
p17066
(F1
F0.00014334862385321102
I0
I1
I-1
tp17067
sS'this,table'
p17068
(F1
F0.00014334862385321102
I0
I1
I-1
tp17069
sS'ether,and'
p17070
(F1
F0.00014334862385321102
I1
I0
I1
tp17071
sS'two,appear'
p17072
(F1
F0.00014334862385321102
I1
I0
I1
tp17073
sS'when,compared'
p17074
(F0
F0
I4
I4
I0
tp17075
sS'prolonged,long'
p17076
(F1
F0.00014334862385321102
I1
I0
I1
tp17077
sS'as,or'
p17078
(F0.25
F0.0008600917431192661
I15
I9
I6
tp17079
sS'significantly,bound'
p17080
(F1
F0.00014334862385321102
I0
I1
I-1
tp17081
sS'myelosuppression,was'
p17082
(F1
F0.00014334862385321102
I1
I0
I1
tp17083
sS'downward,adjustment'
p17084
(F1
F0.00028669724770642203
I2
I0
I2
tp17085
sS'r,or'
p17086
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp17087
sS'hour,lag'
p17088
(F1
F0.00014334862385321102
I0
I1
I-1
tp17089
sS'evaluating,the'
p17090
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp17091
sS'caution,since'
p17092
(F1
F0.00014334862385321102
I0
I1
I-1
tp17093
sS'interactions,under'
p17094
(F1
F0.00014334862385321102
I0
I1
I-1
tp17095
sS'hydrocarbon,general'
p17096
(F1
F0.00014334862385321102
I1
I0
I1
tp17097
sS'severe,high'
p17098
(F1
F0.00014334862385321102
I1
I0
I1
tp17099
sS'to,adult'
p17100
(F1
F0.00014334862385321102
I0
I1
I-1
tp17101
sS'in,comparison'
p17102
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17103
sS'juice,given'
p17104
(F1
F0.00014334862385321102
I0
I1
I-1
tp17105
sS'abciximab,may'
p17106
(F1
F0.00014334862385321102
I1
I0
I1
tp17107
sS'occasionally,induce'
p17108
(F1
F0.00014334862385321102
I0
I1
I-1
tp17109
sS'in,patients'
p17110
(F0.40845070422535212
F0.012471330275229358
I150
I63
I87
tp17111
sS'anti-factor,xa'
p17112
(F1
F0.00014334862385321102
I0
I1
I-1
tp17113
sS'may,elevate'
p17114
(F1
F0.00014334862385321102
I1
I0
I1
tp17115
sS'juices,etc'
p17116
(F1
F0.00014334862385321102
I1
I0
I1
tp17117
sS'the,short-acting'
p17118
(F1
F0.00014334862385321102
I0
I1
I-1
tp17119
sS'anecdotal,reports'
p17120
(F1
F0.00014334862385321102
I1
I0
I1
tp17121
sS'from,one'
p17122
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp17123
sS'selected,for'
p17124
(F1
F0.00014334862385321102
I0
I1
I-1
tp17125
sS'glucose,alone'
p17126
(F1
F0.00014334862385321102
I0
I1
I-1
tp17127
sS'large,placebo-controlled'
p17128
(F1
F0.00014334862385321102
I0
I1
I-1
tp17129
sS'decreased,have'
p17130
(F1
F0.00014334862385321102
I1
I0
I1
tp17131
sS'oxidation,is'
p17132
(F1
F0.00014334862385321102
I0
I1
I-1
tp17133
sS'o-desacetyl,metabolites'
p17134
(F1
F0.00014334862385321102
I0
I1
I-1
tp17135
sS'period,has'
p17136
(F1
F0.00014334862385321102
I1
I0
I1
tp17137
sS'the,safety'
p17138
(F0.69230769230769229
F0.0012901376146788992
I2
I11
I-9
tp17139
sS'therefore,advisable'
p17140
(F1
F0.00014334862385321102
I1
I0
I1
tp17141
sS'been,concern'
p17142
(F1
F0.00014334862385321102
I1
I0
I1
tp17143
sS'subsalicylate,given'
p17144
(F1
F0.00014334862385321102
I1
I0
I1
tp17145
sS'prolonged,prothrombin'
p17146
(F1
F0.00028669724770642203
I2
I0
I2
tp17147
sS'fe,instead'
p17148
(F1
F0.00014334862385321102
I1
I0
I1
tp17149
sS'reduced,approximately'
p17150
(F0
F0
I1
I1
I0
tp17151
sS'study,examining'
p17152
(F1
F0.00014334862385321102
I1
I0
I1
tp17153
sS'doses,than'
p17154
(F1
F0.0010034403669724771
I0
I7
I-7
tp17155
sS'are,administered'
p17156
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp17157
sS'to,desbutyl'
p17158
(F1
F0.00014334862385321102
I0
I1
I-1
tp17159
sS'of,higher'
p17160
(F1
F0.00014334862385321102
I0
I1
I-1
tp17161
sS'cardiac,autonomic'
p17162
(F1
F0.00014334862385321102
I1
I0
I1
tp17163
sS'the,onset'
p17164
(F1
F0.00028669724770642203
I2
I0
I2
tp17165
sS'nursing,infants'
p17166
(F1
F0.00014334862385321102
I0
I1
I-1
tp17167
sS'exposure,were'
p17168
(F1
F0.00014334862385321102
I0
I1
I-1
tp17169
sS'pooled,human'
p17170
(F1
F0.00014334862385321102
I0
I1
I-1
tp17171
sS'revia,and'
p17172
(F0
F0
I1
I1
I0
tp17173
sS'dosing,with'
p17174
(F0
F0
I2
I2
I0
tp17175
sS'benefit,when'
p17176
(F1
F0.00014334862385321102
I0
I1
I-1
tp17177
sS'the,urinary'
p17178
(F0
F0
I2
I2
I0
tp17179
sS'antagonists,cyp1a2'
p17180
(F1
F0.00014334862385321102
I0
I1
I-1
tp17181
sS'for,this'
p17182
(F0.5
F0.00028669724770642203
I3
I1
I2
tp17183
sS'decided,to'
p17184
(F1
F0.00014334862385321102
I1
I0
I1
tp17185
sS'antiepileptic,potential'
p17186
(F1
F0.00014334862385321102
I0
I1
I-1
tp17187
sS'reported,when'
p17188
(F1
F0.0011467889908256881
I8
I0
I8
tp17189
sS'lorazepam,injection'
p17190
(F1
F0.00014334862385321102
I1
I0
I1
tp17191
sS'monitored,see'
p17192
(F1
F0.00014334862385321102
I0
I1
I-1
tp17193
sS'required,during'
p17194
(F1
F0.00028669724770642203
I2
I0
I2
tp17195
sS'cimetidine,mg'
p17196
(F1
F0.00014334862385321102
I0
I1
I-1
tp17197
sS'naflu,to'
p17198
(F1
F0.00014334862385321102
I0
I1
I-1
tp17199
sS'alone,at'
p17200
(F0
F0
I1
I1
I0
tp17201
sS'vasoconstrictive,action'
p17202
(F1
F0.00014334862385321102
I1
I0
I1
tp17203
sS'methotrexate,valdecoxib'
p17204
(F1
F0.00014334862385321102
I0
I1
I-1
tp17205
sS'medications,for'
p17206
(F1
F0.00014334862385321102
I0
I1
I-1
tp17207
sS'cyclosporin,reports'
p17208
(F1
F0.00014334862385321102
I1
I0
I1
tp17209
sS'infusion,rates'
p17210
(F1
F0.00014334862385321102
I1
I0
I1
tp17211
sS'therapy,have'
p17212
(F1
F0.00014334862385321102
I1
I0
I1
tp17213
sS'with,antagonists'
p17214
(F1
F0.00028669724770642203
I2
I0
I2
tp17215
sS'dcg-iv,were'
p17216
(F1
F0.00014334862385321102
I1
I0
I1
tp17217
sS'liver,which'
p17218
(F1
F0.00014334862385321102
I1
I0
I1
tp17219
sS'daily,mcg'
p17220
(F1
F0.00014334862385321102
I0
I1
I-1
tp17221
sS'to,delirium'
p17222
(F1
F0.00014334862385321102
I1
I0
I1
tp17223
sS'depletion,of'
p17224
(F1
F0.00014334862385321102
I1
I0
I1
tp17225
sS'of,fat-soluble'
p17226
(F0
F0
I1
I1
I0
tp17227
sS'of,decreased'
p17228
(F0.875
F0.0020068807339449542
I15
I1
I14
tp17229
sS'properties,and'
p17230
(F1
F0.00043004587155963305
I3
I0
I3
tp17231
sS'foscarnets,tendency'
p17232
(F1
F0.00014334862385321102
I1
I0
I1
tp17233
sS'dose,may'
p17234
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp17235
sS'render,oral'
p17236
(F1
F0.00028669724770642203
I2
I0
I2
tp17237
sS'of,decreases'
p17238
(F1
F0.00014334862385321102
I1
I0
I1
tp17239
sS'metabolizers,and'
p17240
(F1
F0.00014334862385321102
I0
I1
I-1
tp17241
sS'were,prohibited'
p17242
(F1
F0.00014334862385321102
I0
I1
I-1
tp17243
sS'prepared,by'
p17244
(F1
F0.00014334862385321102
I0
I1
I-1
tp17245
sS'both,ethynyl'
p17246
(F1
F0.00014334862385321102
I0
I1
I-1
tp17247
sS'other,no'
p17248
(F1
F0.00014334862385321102
I0
I1
I-1
tp17249
sS'contraceptives,rofecoxib'
p17250
(F1
F0.00014334862385321102
I0
I1
I-1
tp17251
sS'watched,very'
p17252
(F1
F0.00014334862385321102
I1
I0
I1
tp17253
sS'that,given'
p17254
(F1
F0.00014334862385321102
I1
I0
I1
tp17255
sS'form,chelation'
p17256
(F1
F0.00014334862385321102
I1
I0
I1
tp17257
sS'and,developed'
p17258
(F1
F0.00028669724770642203
I2
I0
I2
tp17259
sS'subsequently,found'
p17260
(F1
F0.00014334862385321102
I0
I1
I-1
tp17261
sS'suggesting,a'
p17262
(F0
F0
I1
I1
I0
tp17263
sS'of,natrecor'
p17264
(F1
F0.00014334862385321102
I0
I1
I-1
tp17265
sS'ischemic,response'
p17266
(F1
F0.00014334862385321102
I1
I0
I1
tp17267
sS'possible,be'
p17268
(F1
F0.00014334862385321102
I1
I0
I1
tp17269
sS'copaxone,and'
p17270
(F1
F0.00014334862385321102
I0
I1
I-1
tp17271
sS'reverse,the'
p17272
(F1
F0.00028669724770642203
I2
I0
I2
tp17273
sS'was,controlled'
p17274
(F1
F0.00014334862385321102
I1
I0
I1
tp17275
sS'these,or'
p17276
(F1
F0.00014334862385321102
I1
I0
I1
tp17277
sS'was,replaced'
p17278
(F1
F0.00014334862385321102
I0
I1
I-1
tp17279
sS'parvum,in'
p17280
(F1
F0.00014334862385321102
I0
I1
I-1
tp17281
sS'antifungals,grapefruit'
p17282
(F1
F0.00014334862385321102
I1
I0
I1
tp17283
sS'in,hydatid'
p17284
(F1
F0.00014334862385321102
I1
I0
I1
tp17285
sS'hypotension,requiring'
p17286
(F1
F0.00014334862385321102
I0
I1
I-1
tp17287
sS'baraclude,with'
p17288
(F1
F0.00028669724770642203
I0
I2
I-2
tp17289
sS'response,through'
p17290
(F1
F0.00014334862385321102
I1
I0
I1
tp17291
sS'cough,and'
p17292
(F0
F0
I1
I1
I0
tp17293
sS'groups,ie'
p17294
(F1
F0.00014334862385321102
I0
I1
I-1
tp17295
sS'prostaglandina,play'
p17296
(F1
F0.00014334862385321102
I1
I0
I1
tp17297
sS'methotrexate,cyclosporine'
p17298
(F1
F0.00014334862385321102
I0
I1
I-1
tp17299
sS'other,when'
p17300
(F1
F0.00028669724770642203
I2
I0
I2
tp17301
sS'scintigraphy,employing'
p17302
(F1
F0.00014334862385321102
I0
I1
I-1
tp17303
sS'benzthiazide,may'
p17304
(F1
F0.00014334862385321102
I1
I0
I1
tp17305
sS'cyclosporine,elevated'
p17306
(F1
F0.00028669724770642203
I2
I0
I2
tp17307
sS'avoided,because'
p17308
(F1
F0.00028669724770642203
I2
I0
I2
tp17309
sS'in,parkinsons'
p17310
(F1
F0.00014334862385321102
I1
I0
I1
tp17311
sS'mg,did'
p17312
(F1
F0.0014334862385321102
I0
I10
I-10
tp17313
sS'agents,ammonium'
p17314
(F1
F0.00028669724770642203
I2
I0
I2
tp17315
sS'is,initiated'
p17316
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp17317
sS'with,ace'
p17318
(F1
F0.00028669724770642203
I2
I0
I2
tp17319
sS'like,other'
p17320
(F0.75
F0.0008600917431192661
I7
I1
I6
tp17321
sS'toxic,epidermal'
p17322
(F1
F0.00014334862385321102
I0
I1
I-1
tp17323
sS'been,more'
p17324
(F1
F0.00014334862385321102
I0
I1
I-1
tp17325
sS'invirase,or'
p17326
(F1
F0.00014334862385321102
I0
I1
I-1
tp17327
sS'cause,serious'
p17328
(F1
F0.00014334862385321102
I1
I0
I1
tp17329
sS'are,applying'
p17330
(F1
F0.00014334862385321102
I1
I0
I1
tp17331
sS'or,hepatotoxic'
p17332
(F1
F0.00014334862385321102
I1
I0
I1
tp17333
sS'no,in'
p17334
(F1
F0.00014334862385321102
I1
I0
I1
tp17335
sS'the,ratios'
p17336
(F1
F0.00014334862385321102
I0
I1
I-1
tp17337
sS'displace,such'
p17338
(F1
F0.00014334862385321102
I1
I0
I1
tp17339
sS'kg,with'
p17340
(F1
F0.00014334862385321102
I1
I0
I1
tp17341
sS'hydrocodone,coadministration'
p17342
(F1
F0.00014334862385321102
I0
I1
I-1
tp17343
sS'shown,between'
p17344
(F1
F0.00014334862385321102
I1
I0
I1
tp17345
sS'the,alternate'
p17346
(F1
F0.00014334862385321102
I1
I0
I1
tp17347
sS'than,times'
p17348
(F1
F0.00014334862385321102
I1
I0
I1
tp17349
sS'reliable,method'
p17350
(F1
F0.00014334862385321102
I1
I0
I1
tp17351
sS'co-medications,that'
p17352
(F0
F0
I1
I1
I0
tp17353
sS'be,low'
p17354
(F1
F0.00014334862385321102
I0
I1
I-1
tp17355
sS'and,reducing'
p17356
(F1
F0.00014334862385321102
I1
I0
I1
tp17357
sS'at,ph'
p17358
(F1
F0.00014334862385321102
I0
I1
I-1
tp17359
sS'as,certain'
p17360
(F1
F0.00014334862385321102
I1
I0
I1
tp17361
sS'the,potentiating'
p17362
(F1
F0.00014334862385321102
I1
I0
I1
tp17363
sS'the,repeat'
p17364
(F1
F0.00014334862385321102
I0
I1
I-1
tp17365
sS'a,test'
p17366
(F1
F0.00014334862385321102
I0
I1
I-1
tp17367
sS'taken,as'
p17368
(F0
F0
I1
I1
I0
tp17369
sS'taken,at'
p17370
(F1
F0.0010034403669724771
I7
I0
I7
tp17371
sS'kappa,and'
p17372
(F1
F0.00014334862385321102
I0
I1
I-1
tp17373
sS'inflammatory,reactions'
p17374
(F1
F0.00014334862385321102
I1
I0
I1
tp17375
sS'concentrations,are'
p17376
(F0
F0
I1
I1
I0
tp17377
sS'also,increased'
p17378
(F0
F0
I1
I1
I0
tp17379
sS'anticonvulsants,increase'
p17380
(F1
F0.00014334862385321102
I1
I0
I1
tp17381
sS'bilirubin,elevations'
p17382
(F1
F0.00014334862385321102
I0
I1
I-1
tp17383
sS'toxicity,when'
p17384
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17385
sS'the,cyp450'
p17386
(F1
F0.00014334862385321102
I0
I1
I-1
tp17387
sS'by,minimally'
p17388
(F1
F0.00014334862385321102
I0
I1
I-1
tp17389
sS'a,far'
p17390
(F1
F0.00014334862385321102
I0
I1
I-1
tp17391
sS'formulation,of'
p17392
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp17393
sS'is,important'
p17394
(F1
F0.00028669724770642203
I0
I2
I-2
tp17395
sS'in,coma'
p17396
(F1
F0.00014334862385321102
I1
I0
I1
tp17397
sS'limited,number'
p17398
(F1
F0.00014334862385321102
I0
I1
I-1
tp17399
sS'most,like'
p17400
(F1
F0.00014334862385321102
I1
I0
I1
tp17401
sS'sites,for'
p17402
(F1
F0.00028669724770642203
I0
I2
I-2
tp17403
sS'ketoconazole,did'
p17404
(F1
F0.00014334862385321102
I0
I1
I-1
tp17405
sS'with,were'
p17406
(F0
F0
I1
I1
I0
tp17407
sS'the,r-value'
p17408
(F1
F0.00028669724770642203
I0
I2
I-2
tp17409
sS'antiaddictive,efficacy'
p17410
(F1
F0.00014334862385321102
I0
I1
I-1
tp17411
sS'that,interferes'
p17412
(F1
F0.00014334862385321102
I1
I0
I1
tp17413
sS'solution,should'
p17414
(F1
F0.00028669724770642203
I2
I0
I2
tp17415
sS'with,maximum'
p17416
(F1
F0.00014334862385321102
I0
I1
I-1
tp17417
sS'because,severe'
p17418
(F1
F0.00028669724770642203
I2
I0
I2
tp17419
sS'enter,the'
p17420
(F1
F0.00014334862385321102
I0
I1
I-1
tp17421
sS'without,bleeding'
p17422
(F1
F0.00014334862385321102
I1
I0
I1
tp17423
sS'of,trimethyl'
p17424
(F1
F0.00014334862385321102
I0
I1
I-1
tp17425
sS'unless,in'
p17426
(F1
F0.00014334862385321102
I1
I0
I1
tp17427
sS'sucralfate,administered'
p17428
(F1
F0.00014334862385321102
I1
I0
I1
tp17429
sS'to,high'
p17430
(F0
F0
I1
I1
I0
tp17431
sS'with,hexalen'
p17432
(F1
F0.00014334862385321102
I1
I0
I1
tp17433
sS'limit,adverse'
p17434
(F1
F0.00014334862385321102
I1
I0
I1
tp17435
sS'the,wild-type'
p17436
(F1
F0.00014334862385321102
I0
I1
I-1
tp17437
sS'hydrochloride,and'
p17438
(F1
F0.00043004587155963305
I0
I3
I-3
tp17439
sS'that,coadministration'
p17440
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp17441
sS'the,harmonic'
p17442
(F1
F0.00014334862385321102
I0
I1
I-1
tp17443
sS'animal,species'
p17444
(F1
F0.00014334862385321102
I0
I1
I-1
tp17445
sS'the,co-administration'
p17446
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp17447
sS'microdosed,minipill'
p17448
(F1
F0.00014334862385321102
I1
I0
I1
tp17449
sS'of,micrograms'
p17450
(F0
F0
I1
I1
I0
tp17451
sS'enzyme,inhibitors'
p17452
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp17453
sS'effect,caution'
p17454
(F1
F0.00014334862385321102
I1
I0
I1
tp17455
sS'that,plasma'
p17456
(F1
F0.00028669724770642203
I2
I0
I2
tp17457
sS'exhibited,strong'
p17458
(F1
F0.00014334862385321102
I1
I0
I1
tp17459
sS'interaction,may'
p17460
(F0
F0
I1
I1
I0
tp17461
sS'dopamine2-,and'
p17462
(F1
F0.00014334862385321102
I0
I1
I-1
tp17463
sS'furthermore,it'
p17464
(F1
F0.00014334862385321102
I1
I0
I1
tp17465
sS'were,studied'
p17466
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp17467
sS'observed,closely'
p17468
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp17469
sS'to,intravenous'
p17470
(F1
F0.00014334862385321102
I1
I0
I1
tp17471
sS'when,celebrex'
p17472
(F1
F0.00014334862385321102
I1
I0
I1
tp17473
sS'other,certain'
p17474
(F1
F0.00014334862385321102
I1
I0
I1
tp17475
sS'in,rat'
p17476
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp17477
sS'saquinavir,the'
p17478
(F1
F0.00014334862385321102
I0
I1
I-1
tp17479
sS'tracrium,should'
p17480
(F1
F0.00014334862385321102
I1
I0
I1
tp17481
sS'is,insufficient'
p17482
(F1
F0.00014334862385321102
I1
I0
I1
tp17483
sS'the,parent'
p17484
(F1
F0.00014334862385321102
I1
I0
I1
tp17485
sS'propranolol,in'
p17486
(F1
F0.00028669724770642203
I0
I2
I-2
tp17487
sS'reductase,resulting'
p17488
(F1
F0.00014334862385321102
I0
I1
I-1
tp17489
sS'inhibiting,yeast'
p17490
(F1
F0.00014334862385321102
I0
I1
I-1
tp17491
sS'nimodipine,and'
p17492
(F1
F0.00014334862385321102
I0
I1
I-1
tp17493
sS'reaction,time'
p17494
(F1
F0.00014334862385321102
I1
I0
I1
tp17495
sS'low-dose,has'
p17496
(F1
F0.00014334862385321102
I1
I0
I1
tp17497
sS'level,p'
p17498
(F1
F0.00014334862385321102
I0
I1
I-1
tp17499
sS'methotrexate,piperacillin'
p17500
(F1
F0.00014334862385321102
I1
I0
I1
tp17501
sS'the,commonly'
p17502
(F1
F0.00014334862385321102
I0
I1
I-1
tp17503
sS'hydroxy-iso,by'
p17504
(F1
F0.00014334862385321102
I1
I0
I1
tp17505
sS'altered,pharmacoktnetics'
p17506
(F1
F0.00014334862385321102
I0
I1
I-1
tp17507
sS'compounds,in'
p17508
(F1
F0.00014334862385321102
I1
I0
I1
tp17509
sS'as,nsaids'
p17510
(F1
F0.00014334862385321102
I0
I1
I-1
tp17511
sS'and,between'
p17512
(F1
F0.00014334862385321102
I0
I1
I-1
tp17513
sS'elevation,of'
p17514
(F1
F0.0010034403669724771
I7
I0
I7
tp17515
sS'of,nonbenzodiazepine'
p17516
(F1
F0.00014334862385321102
I1
I0
I1
tp17517
sS'hcl,was'
p17518
(F1
F0.00014334862385321102
I0
I1
I-1
tp17519
sS'achieve,the'
p17520
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17521
sS'documented,hypokalemia'
p17522
(F1
F0.00014334862385321102
I0
I1
I-1
tp17523
sS'cns,agents'
p17524
(F1
F0.00014334862385321102
I1
I0
I1
tp17525
sS'of,megakaryocytes'
p17526
(F1
F0.00014334862385321102
I1
I0
I1
tp17527
sS'ccnu,either'
p17528
(F1
F0.00014334862385321102
I0
I1
I-1
tp17529
sS'physiological,oral'
p17530
(F1
F0.00043004587155963305
I0
I3
I-3
tp17531
sS'medications,muscle'
p17532
(F1
F0.00014334862385321102
I0
I1
I-1
tp17533
sS'if,casodex'
p17534
(F1
F0.00014334862385321102
I1
I0
I1
tp17535
sS'reliable,when'
p17536
(F1
F0.00014334862385321102
I1
I0
I1
tp17537
sS'by,indicating'
p17538
(F1
F0.00014334862385321102
I0
I1
I-1
tp17539
sS'measurable,effect'
p17540
(F1
F0.00014334862385321102
I0
I1
I-1
tp17541
sS'events,compared'
p17542
(F1
F0.00014334862385321102
I1
I0
I1
tp17543
sS'to,took'
p17544
(F1
F0.00014334862385321102
I1
I0
I1
tp17545
sS'where,is'
p17546
(F1
F0.00014334862385321102
I0
I1
I-1
tp17547
sS'bioequivalent,to'
p17548
(F1
F0.00014334862385321102
I0
I1
I-1
tp17549
sS'when,enablex'
p17550
(F1
F0.00014334862385321102
I1
I0
I1
tp17551
sS'published,in'
p17552
(F1
F0.00014334862385321102
I0
I1
I-1
tp17553
sS'at,the'
p17554
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp17555
sS'maintenance,level'
p17556
(F0
F0
I1
I1
I0
tp17557
sS'agents,causing'
p17558
(F1
F0.00028669724770642203
I2
I0
I2
tp17559
sS'vitro,on'
p17560
(F1
F0.00014334862385321102
I0
I1
I-1
tp17561
sS'pharmacology,of'
p17562
(F1
F0.00014334862385321102
I1
I0
I1
tp17563
sS'of,apparent'
p17564
(F1
F0.00014334862385321102
I1
I0
I1
tp17565
sS'use,however'
p17566
(F1
F0.00014334862385321102
I0
I1
I-1
tp17567
sS'who,was'
p17568
(F1
F0.00014334862385321102
I0
I1
I-1
tp17569
sS'and,c9'
p17570
(F1
F0.00028669724770642203
I0
I2
I-2
tp17571
sS'is,genotoxic'
p17572
(F1
F0.00014334862385321102
I0
I1
I-1
tp17573
sS'sampling,the'
p17574
(F1
F0.00014334862385321102
I0
I1
I-1
tp17575
sS'the,heat'
p17576
(F1
F0.00014334862385321102
I0
I1
I-1
tp17577
sS'pharmacological,tool'
p17578
(F1
F0.00014334862385321102
I0
I1
I-1
tp17579
sS'produced,an'
p17580
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp17581
sS'stimulation,is'
p17582
(F1
F0.00028669724770642203
I2
I0
I2
tp17583
sS'inhibit,or'
p17584
(F0
F0
I1
I1
I0
tp17585
sS'toxicity,may'
p17586
(F1
F0.0008600917431192661
I6
I0
I6
tp17587
sS'antacids,enteric'
p17588
(F1
F0.00014334862385321102
I1
I0
I1
tp17589
sS'the,age'
p17590
(F1
F0.00014334862385321102
I0
I1
I-1
tp17591
sS'aprepitant,to'
p17592
(F1
F0.00028669724770642203
I2
I0
I2
tp17593
sS'components,may'
p17594
(F1
F0.00014334862385321102
I0
I1
I-1
tp17595
sS'and,enterococcus'
p17596
(F1
F0.00014334862385321102
I0
I1
I-1
tp17597
sS'the,commercially'
p17598
(F1
F0.00014334862385321102
I0
I1
I-1
tp17599
sS'provided,for'
p17600
(F1
F0.00014334862385321102
I0
I1
I-1
tp17601
sS'ml,min'
p17602
(F0
F0
I1
I1
I0
tp17603
sS'carefully,titrated'
p17604
(F1
F0.00014334862385321102
I1
I0
I1
tp17605
sS'although,increased'
p17606
(F1
F0.00028669724770642203
I0
I2
I-2
tp17607
sS'including,fever'
p17608
(F1
F0.00014334862385321102
I1
I0
I1
tp17609
sS'more,effective'
p17610
(F1
F0.00014334862385321102
I0
I1
I-1
tp17611
sS'amount,of'
p17612
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp17613
sS'probably,secondary'
p17614
(F1
F0.00014334862385321102
I1
I0
I1
tp17615
sS'to,both'
p17616
(F0
F0
I1
I1
I0
tp17617
sS'bactericidal,action'
p17618
(F1
F0.00028669724770642203
I2
I0
I2
tp17619
sS'p-glycoprotein,loop'
p17620
(F1
F0.00014334862385321102
I0
I1
I-1
tp17621
sS'during,coadministration'
p17622
(F1
F0.00043004587155963305
I3
I0
I3
tp17623
sS'is,lengthened'
p17624
(F1
F0.00014334862385321102
I1
I0
I1
tp17625
sS'be,potentiated'
p17626
(F0.52941176470588236
F0.0012901376146788992
I13
I4
I9
tp17627
sS'release,mg'
p17628
(F1
F0.00014334862385321102
I0
I1
I-1
tp17629
sS'continue,treatment'
p17630
(F1
F0.00014334862385321102
I1
I0
I1
tp17631
sS'reduction,of'
p17632
(F0.56521739130434778
F0.0018635321100917432
I18
I5
I13
tp17633
sS'of,inapsine'
p17634
(F1
F0.00014334862385321102
I1
I0
I1
tp17635
sS'fi,fr'
p17636
(F1
F0.00014334862385321102
I0
I1
I-1
tp17637
sS'liver,to'
p17638
(F1
F0.00014334862385321102
I0
I1
I-1
tp17639
sS'were,very'
p17640
(F1
F0.00014334862385321102
I1
I0
I1
tp17641
sS'interaction,should'
p17642
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp17643
sS'fall,of'
p17644
(F1
F0.00014334862385321102
I1
I0
I1
tp17645
sS'metabolized,and'
p17646
(F1
F0.00014334862385321102
I0
I1
I-1
tp17647
sS'hoof,twitch'
p17648
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17649
sS'levels,carbamazepine'
p17650
(F1
F0.00014334862385321102
I1
I0
I1
tp17651
sS'foods,highly'
p17652
(F1
F0.00014334862385321102
I0
I1
I-1
tp17653
sS'interactions,occurred'
p17654
(F1
F0.00028669724770642203
I0
I2
I-2
tp17655
sS'when,gleevec'
p17656
(F1
F0.00014334862385321102
I1
I0
I1
tp17657
sS'unreliable,prothrombin'
p17658
(F1
F0.00028669724770642203
I2
I0
I2
tp17659
sS'nacmc,conjugated'
p17660
(F1
F0.00014334862385321102
I0
I1
I-1
tp17661
sS'taxol,and'
p17662
(F1
F0.00014334862385321102
I0
I1
I-1
tp17663
sS'flolan,to'
p17664
(F1
F0.00014334862385321102
I1
I0
I1
tp17665
sS'prinivil,given'
p17666
(F1
F0.00014334862385321102
I0
I1
I-1
tp17667
sS'ortho-novum,produced'
p17668
(F1
F0.00014334862385321102
I1
I0
I1
tp17669
sS'that,inhibits'
p17670
(F0
F0
I2
I2
I0
tp17671
sS'transient,cardiac'
p17672
(F1
F0.00014334862385321102
I1
I0
I1
tp17673
sS'av,block'
p17674
(F1
F0.00014334862385321102
I1
I0
I1
tp17675
sS'on,established'
p17676
(F1
F0.00014334862385321102
I1
I0
I1
tp17677
sS'low,erpf'
p17678
(F1
F0.00014334862385321102
I1
I0
I1
tp17679
sS'subjects,by'
p17680
(F0
F0
I1
I1
I0
tp17681
sS'shifts,in'
p17682
(F1
F0.00014334862385321102
I0
I1
I-1
tp17683
sS'once,weekly'
p17684
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17685
sS'that,revlimid'
p17686
(F1
F0.00014334862385321102
I0
I1
I-1
tp17687
sS'their,combined'
p17688
(F1
F0.00028669724770642203
I2
I0
I2
tp17689
sS'baseline,vs'
p17690
(F1
F0.00014334862385321102
I0
I1
I-1
tp17691
sS'interval,because'
p17692
(F1
F0.00014334862385321102
I1
I0
I1
tp17693
sS'toxic,effects'
p17694
(F1
F0.00028669724770642203
I2
I0
I2
tp17695
sS'agonists,only'
p17696
(F1
F0.00014334862385321102
I1
I0
I1
tp17697
sS'expected,than'
p17698
(F1
F0.00014334862385321102
I1
I0
I1
tp17699
sS'cmax,but'
p17700
(F1
F0.00014334862385321102
I0
I1
I-1
tp17701
sS'nondepolarizing,neuromuscular'
p17702
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17703
sS'expected,that'
p17704
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17705
sS'mg,has'
p17706
(F1
F0.00014334862385321102
I0
I1
I-1
tp17707
sS'antipsychotic,eg'
p17708
(F1
F0.00014334862385321102
I1
I0
I1
tp17709
sS'time,reported'
p17710
(F1
F0.00014334862385321102
I1
I0
I1
tp17711
sS'with,steady'
p17712
(F1
F0.00014334862385321102
I1
I0
I1
tp17713
sS'enhancement,of'
p17714
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp17715
sS'toxicity,and'
p17716
(F0.40000000000000002
F0.00057339449541284407
I3
I7
I-4
tp17717
sS'with,compromised'
p17718
(F1
F0.00028669724770642203
I2
I0
I2
tp17719
sS'half-life,leading'
p17720
(F1
F0.00014334862385321102
I0
I1
I-1
tp17721
sS'a,closely'
p17722
(F1
F0.00014334862385321102
I1
I0
I1
tp17723
sS'on,these'
p17724
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp17725
sS'maois,selegiline'
p17726
(F1
F0.00014334862385321102
I1
I0
I1
tp17727
sS'great,extent'
p17728
(F1
F0.00014334862385321102
I0
I1
I-1
tp17729
sS'absorption,when'
p17730
(F1
F0.00014334862385321102
I1
I0
I1
tp17731
sS'via-resistant,presumptive'
p17732
(F1
F0.00014334862385321102
I0
I1
I-1
tp17733
sS'mu-,delta'
p17734
(F1
F0.00014334862385321102
I0
I1
I-1
tp17735
sS'some,further'
p17736
(F1
F0.00014334862385321102
I1
I0
I1
tp17737
sS'resolved,when'
p17738
(F1
F0.00014334862385321102
I0
I1
I-1
tp17739
sS'steady-,state'
p17740
(F1
F0.00014334862385321102
I1
I0
I1
tp17741
sS'of,pancreatic'
p17742
(F1
F0.00014334862385321102
I1
I0
I1
tp17743
sS'effects,vioxx'
p17744
(F1
F0.00014334862385321102
I0
I1
I-1
tp17745
sS'expected,based'
p17746
(F1
F0.00014334862385321102
I0
I1
I-1
tp17747
sS'rodent,studies'
p17748
(F1
F0.00014334862385321102
I0
I1
I-1
tp17749
sS'plasma,samples'
p17750
(F1
F0.00014334862385321102
I0
I1
I-1
tp17751
sS'ataxia,a'
p17752
(F1
F0.00014334862385321102
I0
I1
I-1
tp17753
sS'expected,with'
p17754
(F0
F0
I1
I1
I0
tp17755
sS'minutes,at'
p17756
(F1
F0.00014334862385321102
I0
I1
I-1
tp17757
sS'and,side-effects'
p17758
(F1
F0.00014334862385321102
I1
I0
I1
tp17759
sS'its,abrupt'
p17760
(F1
F0.00014334862385321102
I1
I0
I1
tp17761
sS'cumulative,doses'
p17762
(F1
F0.00014334862385321102
I1
I0
I1
tp17763
sS'then,titrated'
p17764
(F1
F0.00014334862385321102
I1
I0
I1
tp17765
sS'vitro,showed'
p17766
(F1
F0.00014334862385321102
I0
I1
I-1
tp17767
sS'be,followed'
p17768
(F1
F0.00014334862385321102
I0
I1
I-1
tp17769
sS'and,similarly'
p17770
(F1
F0.00014334862385321102
I1
I0
I1
tp17771
sS'eye,product'
p17772
(F1
F0.00014334862385321102
I1
I0
I1
tp17773
sS'sumatriptan,there'
p17774
(F1
F0.00014334862385321102
I1
I0
I1
tp17775
sS'volunteers,developed'
p17776
(F1
F0.00014334862385321102
I1
I0
I1
tp17777
sS'while,those'
p17778
(F0
F0
I1
I1
I0
tp17779
sS'following,eye'
p17780
(F1
F0.00014334862385321102
I1
I0
I1
tp17781
sS'or,exacerbation'
p17782
(F1
F0.00014334862385321102
I1
I0
I1
tp17783
sS'x,mg'
p17784
(F1
F0.00028669724770642203
I2
I0
I2
tp17785
sS'videx,didanosine'
p17786
(F1
F0.00028669724770642203
I2
I0
I2
tp17787
sS'in,s'
p17788
(F1
F0.00014334862385321102
I1
I0
I1
tp17789
sS'short-term,pharmacokinetic'
p17790
(F1
F0.00014334862385321102
I1
I0
I1
tp17791
sS'properties,relative'
p17792
(F1
F0.00014334862385321102
I0
I1
I-1
tp17793
sS'with,bextra'
p17794
(F1
F0.00028669724770642203
I2
I0
I2
tp17795
sS'the,post-marketing'
p17796
(F1
F0.00014334862385321102
I1
I0
I1
tp17797
sS'capsules,there'
p17798
(F1
F0.00014334862385321102
I1
I0
I1
tp17799
sS'in,a'
p17800
(F0.2988505747126437
F0.0074541284403669729
I113
I61
I52
tp17801
sS'concomitantly,serum'
p17802
(F1
F0.00014334862385321102
I1
I0
I1
tp17803
sS'depression,such'
p17804
(F1
F0.00014334862385321102
I1
I0
I1
tp17805
sS'fasted,and'
p17806
(F1
F0.00014334862385321102
I0
I1
I-1
tp17807
sS'indandione,derivatives'
p17808
(F1
F0.00014334862385321102
I1
I0
I1
tp17809
sS'cilexetil,given'
p17810
(F1
F0.00014334862385321102
I0
I1
I-1
tp17811
sS'for,the'
p17812
(F0.17391304347826086
F0.0011467889908256881
I19
I27
I-8
tp17813
sS'tachycardia,was'
p17814
(F1
F0.00014334862385321102
I1
I0
I1
tp17815
sS'and,sodium'
p17816
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp17817
sS'only,requires'
p17818
(F1
F0.00014334862385321102
I0
I1
I-1
tp17819
sS'simultaneous,ingestion'
p17820
(F1
F0.00014334862385321102
I1
I0
I1
tp17821
sS'interval,significantly'
p17822
(F1
F0.00014334862385321102
I1
I0
I1
tp17823
sS'administration,and'
p17824
(F0
F0
I1
I1
I0
tp17825
sS'to,study'
p17826
(F1
F0.00071674311926605509
I0
I5
I-5
tp17827
sS'could,potentially'
p17828
(F1
F0.00014334862385321102
I1
I0
I1
tp17829
sS'in,single'
p17830
(F0
F0
I1
I1
I0
tp17831
sS'with,based'
p17832
(F1
F0.00014334862385321102
I0
I1
I-1
tp17833
sS'a,chylomicron-like'
p17834
(F1
F0.00014334862385321102
I0
I1
I-1
tp17835
sS'studies,as'
p17836
(F1
F0.0008600917431192661
I6
I0
I6
tp17837
sS'studies,at'
p17838
(F1
F0.00014334862385321102
I0
I1
I-1
tp17839
sS'substantial,interaction'
p17840
(F1
F0.00014334862385321102
I1
I0
I1
tp17841
sS'compromise,their'
p17842
(F1
F0.00014334862385321102
I1
I0
I1
tp17843
sS'av,node'
p17844
(F1
F0.00014334862385321102
I1
I0
I1
tp17845
sS'of,breakthrough'
p17846
(F1
F0.00014334862385321102
I0
I1
I-1
tp17847
sS'inhibitors,because'
p17848
(F1
F0.00014334862385321102
I1
I0
I1
tp17849
sS'the,stable'
p17850
(F1
F0.00014334862385321102
I0
I1
I-1
tp17851
sS'toxi-lab,a'
p17852
(F1
F0.00014334862385321102
I0
I1
I-1
tp17853
sS'enkephalinergic,neurons'
p17854
(F1
F0.00014334862385321102
I1
I0
I1
tp17855
sS'obtained,should'
p17856
(F1
F0.00014334862385321102
I1
I0
I1
tp17857
sS'thus,concomitant'
p17858
(F0
F0
I1
I1
I0
tp17859
sS'both,lean'
p17860
(F1
F0.00028669724770642203
I0
I2
I-2
tp17861
sS'reported,interactions'
p17862
(F1
F0.00014334862385321102
I0
I1
I-1
tp17863
sS'hydrochloride,ferrous'
p17864
(F1
F0.00014334862385321102
I1
I0
I1
tp17865
sS'omnicef,therapy'
p17866
(F1
F0.00028669724770642203
I2
I0
I2
tp17867
sS'dogs,anesthetized'
p17868
(F1
F0.00014334862385321102
I1
I0
I1
tp17869
sS'sunscreens,and'
p17870
(F1
F0.00014334862385321102
I1
I0
I1
tp17871
sS'advised,and'
p17872
(F1
F0.00014334862385321102
I1
I0
I1
tp17873
sS'including,when'
p17874
(F1
F0.00014334862385321102
I1
I0
I1
tp17875
sS'acamprosate,concomitantly'
p17876
(F0
F0
I1
I1
I0
tp17877
sS'sodium,polystyrene'
p17878
(F1
F0.00014334862385321102
I1
I0
I1
tp17879
sS'benefits,outweigh'
p17880
(F1
F0.00043004587155963305
I3
I0
I3
tp17881
sS'accordingly,in'
p17882
(F1
F0.00028669724770642203
I2
I0
I2
tp17883
sS'of,liquid'
p17884
(F1
F0.00014334862385321102
I0
I1
I-1
tp17885
sS'been,administered'
p17886
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp17887
sS'there,have'
p17888
(F0.42105263157894735
F0.0022935779816513763
I27
I11
I16
tp17889
sS'taking,on'
p17890
(F1
F0.00014334862385321102
I0
I1
I-1
tp17891
sS'from,minutes'
p17892
(F1
F0.00014334862385321102
I1
I0
I1
tp17893
sS'left,ventricular'
p17894
(F0
F0
I2
I2
I0
tp17895
sS'omeprazole,is'
p17896
(F1
F0.00014334862385321102
I0
I1
I-1
tp17897
sS'small,study'
p17898
(F1
F0.00014334862385321102
I0
I1
I-1
tp17899
sS'body,by'
p17900
(F1
F0.00014334862385321102
I0
I1
I-1
tp17901
sS'demonstrates,some'
p17902
(F1
F0.00014334862385321102
I1
I0
I1
tp17903
sS'pharmacokinetics,except'
p17904
(F1
F0.00014334862385321102
I1
I0
I1
tp17905
sS'immediate-early,genes'
p17906
(F1
F0.00014334862385321102
I0
I1
I-1
tp17907
sS'slower,onset'
p17908
(F1
F0.00014334862385321102
I1
I0
I1
tp17909
sS'either,alpha-'
p17910
(F1
F0.00014334862385321102
I0
I1
I-1
tp17911
sS'dmpge2,in'
p17912
(F1
F0.00014334862385321102
I0
I1
I-1
tp17913
sS'actively,secreted'
p17914
(F1
F0.00014334862385321102
I1
I0
I1
tp17915
sS'already,on'
p17916
(F1
F0.00014334862385321102
I0
I1
I-1
tp17917
sS'ethosuximide,amphetamines'
p17918
(F1
F0.00028669724770642203
I2
I0
I2
tp17919
sS'cefditoren,with'
p17920
(F1
F0.00014334862385321102
I1
I0
I1
tp17921
sS'cell,lines'
p17922
(F1
F0.00014334862385321102
I1
I0
I1
tp17923
sS'volunteers,co-administration'
p17924
(F1
F0.00014334862385321102
I0
I1
I-1
tp17925
sS'lead,to'
p17926
(F0.26315789473684209
F0.00071674311926605509
I12
I7
I5
tp17927
sS'by,interfering'
p17928
(F1
F0.00014334862385321102
I1
I0
I1
tp17929
sS'magnesium,magnesium-containing'
p17930
(F1
F0.00043004587155963305
I3
I0
I3
tp17931
sS'circulation,there'
p17932
(F1
F0.00014334862385321102
I1
I0
I1
tp17933
sS'guardians,carefully'
p17934
(F1
F0.00014334862385321102
I0
I1
I-1
tp17935
sS'decreases,urinary'
p17936
(F1
F0.00014334862385321102
I1
I0
I1
tp17937
sS'other,schizophrenic'
p17938
(F1
F0.00014334862385321102
I1
I0
I1
tp17939
sS'as,selective'
p17940
(F1
F0.00014334862385321102
I1
I0
I1
tp17941
sS'maintenance,doses'
p17942
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17943
sS'demonstrated,moderate'
p17944
(F1
F0.00014334862385321102
I1
I0
I1
tp17945
sS'certain,intravenously'
p17946
(F1
F0.00014334862385321102
I1
I0
I1
tp17947
sS'ergot,derivatives'
p17948
(F1
F0.00014334862385321102
I0
I1
I-1
tp17949
sS'and,functional'
p17950
(F1
F0.00028669724770642203
I0
I2
I-2
tp17951
sS'is,mixed'
p17952
(F1
F0.00014334862385321102
I0
I1
I-1
tp17953
sS'usually,administered'
p17954
(F1
F0.00014334862385321102
I1
I0
I1
tp17955
sS'chronic,experiments'
p17956
(F1
F0.00014334862385321102
I0
I1
I-1
tp17957
sS'infusion,in'
p17958
(F1
F0.00014334862385321102
I0
I1
I-1
tp17959
sS'sublingual,may'
p17960
(F1
F0.00014334862385321102
I0
I1
I-1
tp17961
sS'same,metabolic'
p17962
(F1
F0.00014334862385321102
I0
I1
I-1
tp17963
sS'be,markedly'
p17964
(F1
F0.00014334862385321102
I1
I0
I1
tp17965
sS'supplemented,with'
p17966
(F0
F0
I1
I1
I0
tp17967
sS'regimens,lower'
p17968
(F1
F0.00014334862385321102
I0
I1
I-1
tp17969
sS'inhibits,or'
p17970
(F1
F0.00014334862385321102
I0
I1
I-1
tp17971
sS'when,is'
p17972
(F0.76470588235294112
F0.0037270642201834864
I30
I4
I26
tp17973
sS'when,it'
p17974
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp17975
sS'investigated,the'
p17976
(F1
F0.00043004587155963305
I0
I3
I-3
tp17977
sS'are,activated'
p17978
(F1
F0.00014334862385321102
I0
I1
I-1
tp17979
sS'may,partially'
p17980
(F1
F0.00028669724770642203
I2
I0
I2
tp17981
sS'possible,benefits'
p17982
(F1
F0.00014334862385321102
I1
I0
I1
tp17983
sS'bioavailability,eg'
p17984
(F1
F0.00014334862385321102
I1
I0
I1
tp17985
sS'discontinued,slowly'
p17986
(F1
F0.00014334862385321102
I1
I0
I1
tp17987
sS'occurred,when'
p17988
(F1
F0.00057339449541284407
I0
I4
I-4
tp17989
sS'response,is'
p17990
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp17991
sS'five-fold,increase'
p17992
(F1
F0.00014334862385321102
I1
I0
I1
tp17993
sS'response,in'
p17994
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp17995
sS'however,co'
p17996
(F1
F0.00014334862385321102
I1
I0
I1
tp17997
sS'response,ie'
p17998
(F1
F0.00057339449541284407
I4
I0
I4
tp17999
sS'b,antineoplastic'
p18000
(F1
F0.00014334862385321102
I1
I0
I1
tp18001
sS'consequently,should'
p18002
(F1
F0.00014334862385321102
I1
I0
I1
tp18003
sS'had,plasma'
p18004
(F1
F0.00014334862385321102
I1
I0
I1
tp18005
sS'blood,and'
p18006
(F1
F0.00014334862385321102
I1
I0
I1
tp18007
sS'different,types'
p18008
(F1
F0.00014334862385321102
I0
I1
I-1
tp18009
sS'hiv,classified'
p18010
(F1
F0.00014334862385321102
I1
I0
I1
tp18011
sS'with,sulfamethoxazole'
p18012
(F1
F0.00014334862385321102
I0
I1
I-1
tp18013
sS'expected,antidepressant'
p18014
(F1
F0.00014334862385321102
I1
I0
I1
tp18015
sS'with,known'
p18016
(F0
F0
I1
I1
I0
tp18017
sS'of,physiological'
p18018
(F1
F0.00014334862385321102
I0
I1
I-1
tp18019
sS'of,itraconazole'
p18020
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp18021
sS'cmax,values'
p18022
(F1
F0.00014334862385321102
I0
I1
I-1
tp18023
sS'the,antinociceptive'
p18024
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp18025
sS'pressure,or'
p18026
(F1
F0.00043004587155963305
I0
I3
I-3
tp18027
sS'the,supplied'
p18028
(F1
F0.00014334862385321102
I0
I1
I-1
tp18029
sS'by,and'
p18030
(F0.66666666666666663
F0.0028669724770642203
I25
I5
I20
tp18031
sS'function,there'
p18032
(F1
F0.00014334862385321102
I1
I0
I1
tp18033
sS'may,interact'
p18034
(F0.25
F0.0008600917431192661
I15
I9
I6
tp18035
sS'by,any'
p18036
(F1
F0.00028669724770642203
I2
I0
I2
tp18037
sS'or,low-dose'
p18038
(F1
F0.00014334862385321102
I1
I0
I1
tp18039
sS'about,and'
p18040
(F0.5
F0.00028669724770642203
I3
I1
I2
tp18041
sS'to,fluctuate'
p18042
(F1
F0.00014334862385321102
I1
I0
I1
tp18043
sS'swine,has'
p18044
(F1
F0.00014334862385321102
I0
I1
I-1
tp18045
sS'each,volunteer'
p18046
(F1
F0.00014334862385321102
I0
I1
I-1
tp18047
sS'the,ermbt'
p18048
(F1
F0.00028669724770642203
I0
I2
I-2
tp18049
sS'were,additive'
p18050
(F1
F0.00014334862385321102
I0
I1
I-1
tp18051
sS'particles,of'
p18052
(F1
F0.00043004587155963305
I0
I3
I-3
tp18053
sS'for,drug'
p18054
(F1
F0.00014334862385321102
I0
I1
I-1
tp18055
sS'of,epidural'
p18056
(F1
F0.00014334862385321102
I1
I0
I1
tp18057
sS'this,report'
p18058
(F1
F0.00028669724770642203
I2
I0
I2
tp18059
sS'be,accompanied'
p18060
(F1
F0.00014334862385321102
I0
I1
I-1
tp18061
sS'with,to'
p18062
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18063
sS'was,not'
p18064
(F0.73333333333333328
F0.0015768348623853212
I2
I13
I-11
tp18065
sS'bepridil,with'
p18066
(F1
F0.00014334862385321102
I0
I1
I-1
tp18067
sS'drug,is'
p18068
(F0
F0
I1
I1
I0
tp18069
sS'tremulousness,and'
p18070
(F1
F0.00014334862385321102
I1
I0
I1
tp18071
sS'mg,times'
p18072
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18073
sS'may,explain'
p18074
(F1
F0.00014334862385321102
I0
I1
I-1
tp18075
sS'discontinuation,of'
p18076
(F0.69230769230769229
F0.0012901376146788992
I11
I2
I9
tp18077
sS'l-ccg,was'
p18078
(F1
F0.00014334862385321102
I0
I1
I-1
tp18079
sS'or,pediatric'
p18080
(F1
F0.00028669724770642203
I2
I0
I2
tp18081
sS'supplement,containing'
p18082
(F1
F0.00014334862385321102
I1
I0
I1
tp18083
sS'on,equetrotm'
p18084
(F1
F0.00014334862385321102
I1
I0
I1
tp18085
sS'progressing,to'
p18086
(F1
F0.00014334862385321102
I1
I0
I1
tp18087
sS'cyp,at'
p18088
(F1
F0.00014334862385321102
I0
I1
I-1
tp18089
sS'amiodarone,contraindicated'
p18090
(F1
F0.00014334862385321102
I0
I1
I-1
tp18091
sS'decreased,effectiveness'
p18092
(F1
F0.00014334862385321102
I1
I0
I1
tp18093
sS'they,may'
p18094
(F0.59999999999999998
F0.0008600917431192661
I2
I8
I-6
tp18095
sS'possible,combined'
p18096
(F1
F0.00028669724770642203
I0
I2
I-2
tp18097
sS'sedation,when'
p18098
(F1
F0.00014334862385321102
I1
I0
I1
tp18099
sS'p,but'
p18100
(F1
F0.00014334862385321102
I1
I0
I1
tp18101
sS'micrograms,ml'
p18102
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp18103
sS'to,improve'
p18104
(F1
F0.00014334862385321102
I0
I1
I-1
tp18105
sS'plasma,albumin'
p18106
(F1
F0.00014334862385321102
I1
I0
I1
tp18107
sS'modest,elevations'
p18108
(F1
F0.00014334862385321102
I1
I0
I1
tp18109
sS'following,a'
p18110
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp18111
sS'kaletra,norvir'
p18112
(F1
F0.00014334862385321102
I1
I0
I1
tp18113
sS'properly,and'
p18114
(F1
F0.00014334862385321102
I0
I1
I-1
tp18115
sS'behavioral,response'
p18116
(F1
F0.00014334862385321102
I0
I1
I-1
tp18117
sS'in,cyp3a4'
p18118
(F1
F0.00014334862385321102
I0
I1
I-1
tp18119
sS'activities,similar'
p18120
(F1
F0.00014334862385321102
I0
I1
I-1
tp18121
sS'of,hoof'
p18122
(F1
F0.00014334862385321102
I1
I0
I1
tp18123
sS'prothrombin,times'
p18124
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp18125
sS'negative,inotropic'
p18126
(F1
F0.00043004587155963305
I3
I0
I3
tp18127
sS'recommended,during'
p18128
(F1
F0.00057339449541284407
I4
I0
I4
tp18129
sS'glycosides,patients'
p18130
(F1
F0.00014334862385321102
I0
I1
I-1
tp18131
sS'effect,may'
p18132
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp18133
sS'alert,clinicians'
p18134
(F1
F0.00014334862385321102
I1
I0
I1
tp18135
sS'ventricular,failure'
p18136
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18137
sS'hepatic,enzymes'
p18138
(F1
F0.00014334862385321102
I1
I0
I1
tp18139
sS'absorption,the'
p18140
(F1
F0.00014334862385321102
I1
I0
I1
tp18141
sS'of,status'
p18142
(F1
F0.00028669724770642203
I0
I2
I-2
tp18143
sS'function,and'
p18144
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18145
sS'if,novolog'
p18146
(F1
F0.00014334862385321102
I0
I1
I-1
tp18147
sS'of,bepridil'
p18148
(F1
F0.00028669724770642203
I0
I2
I-2
tp18149
sS'factive,had'
p18150
(F1
F0.00028669724770642203
I0
I2
I-2
tp18151
sS'hydroxylated,in'
p18152
(F1
F0.00014334862385321102
I1
I0
I1
tp18153
sS'antidepressants,amphetamines'
p18154
(F1
F0.00028669724770642203
I2
I0
I2
tp18155
sS'tikosyn,mcg'
p18156
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18157
sS'is,hydroxylation'
p18158
(F1
F0.00014334862385321102
I0
I1
I-1
tp18159
sS'warrant,dosage'
p18160
(F1
F0.00014334862385321102
I1
I0
I1
tp18161
sS'media,a'
p18162
(F1
F0.00014334862385321102
I1
I0
I1
tp18163
sS'agonists,at'
p18164
(F1
F0.00014334862385321102
I1
I0
I1
tp18165
sS'severe,prolonged'
p18166
(F1
F0.00014334862385321102
I1
I0
I1
tp18167
sS'divalent,and'
p18168
(F1
F0.00028669724770642203
I2
I0
I2
tp18169
sS'with,cancidas'
p18170
(F1
F0.00014334862385321102
I1
I0
I1
tp18171
sS'cells,revealed'
p18172
(F1
F0.00014334862385321102
I1
I0
I1
tp18173
sS'of,ewes'
p18174
(F1
F0.00014334862385321102
I1
I0
I1
tp18175
sS'are,decreased'
p18176
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18177
sS'heart,rate'
p18178
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp18179
sS'eg,commonly'
p18180
(F1
F0.00014334862385321102
I1
I0
I1
tp18181
sS'human,subjects'
p18182
(F1
F0.00014334862385321102
I1
I0
I1
tp18183
sS'antinociceptive,effect'
p18184
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp18185
sS'patient,taking'
p18186
(F1
F0.00014334862385321102
I1
I0
I1
tp18187
sS'trimethyl,lead'
p18188
(F1
F0.00014334862385321102
I0
I1
I-1
tp18189
sS'alone,or'
p18190
(F1
F0.0014334862385321102
I0
I10
I-10
tp18191
sS'produced,minor'
p18192
(F1
F0.00014334862385321102
I1
I0
I1
tp18193
sS'basal,medium'
p18194
(F1
F0.00014334862385321102
I0
I1
I-1
tp18195
sS'a,thin-layer'
p18196
(F1
F0.00014334862385321102
I0
I1
I-1
tp18197
sS'of,vitamin'
p18198
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp18199
sS'not,modify'
p18200
(F1
F0.00014334862385321102
I0
I1
I-1
tp18201
sS'suprax,is'
p18202
(F1
F0.00014334862385321102
I1
I0
I1
tp18203
sS'subsequent,to'
p18204
(F0
F0
I1
I1
I0
tp18205
sS'of,channels'
p18206
(F1
F0.00014334862385321102
I0
I1
I-1
tp18207
sS'hypertensive,response'
p18208
(F1
F0.00014334862385321102
I1
I0
I1
tp18209
sS'some,and'
p18210
(F1
F0.00028669724770642203
I2
I0
I2
tp18211
sS'while,taking'
p18212
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp18213
sS'thiazide,may'
p18214
(F1
F0.00043004587155963305
I3
I0
I3
tp18215
sS'too,frequent'
p18216
(F1
F0.00014334862385321102
I0
I1
I-1
tp18217
sS'the,luteinizing'
p18218
(F1
F0.00014334862385321102
I0
I1
I-1
tp18219
sS'eproxindine,ethanol'
p18220
(F1
F0.00014334862385321102
I1
I0
I1
tp18221
sS'serotonin2-receptors,underlies'
p18222
(F1
F0.00014334862385321102
I0
I1
I-1
tp18223
sS'mortality,rate'
p18224
(F1
F0.00014334862385321102
I0
I1
I-1
tp18225
sS'these,does'
p18226
(F1
F0.00014334862385321102
I0
I1
I-1
tp18227
sS'significantly,while'
p18228
(F1
F0.00014334862385321102
I0
I1
I-1
tp18229
sS'explain,in'
p18230
(F1
F0.00014334862385321102
I0
I1
I-1
tp18231
sS'to,identify'
p18232
(F1
F0.00014334862385321102
I0
I1
I-1
tp18233
sS'other,non-steroidal'
p18234
(F1
F0.00028669724770642203
I2
I0
I2
tp18235
sS'in,hemostasis'
p18236
(F1
F0.00028669724770642203
I2
I0
I2
tp18237
sS'urinary,bilirubin'
p18238
(F1
F0.00014334862385321102
I0
I1
I-1
tp18239
sS'bolus-ifl,alone'
p18240
(F1
F0.00014334862385321102
I0
I1
I-1
tp18241
sS'mice,treated'
p18242
(F1
F0.00014334862385321102
I0
I1
I-1
tp18243
sS'the,number'
p18244
(F0
F0
I2
I2
I0
tp18245
sS'tachycardia,produced'
p18246
(F1
F0.00014334862385321102
I1
I0
I1
tp18247
sS'maoi,within'
p18248
(F1
F0.00014334862385321102
I1
I0
I1
tp18249
sS'crixivan,may'
p18250
(F1
F0.00014334862385321102
I1
I0
I1
tp18251
sS'by,checkerboard'
p18252
(F1
F0.00014334862385321102
I0
I1
I-1
tp18253
sS'aeds,phenytoin'
p18254
(F1
F0.00028669724770642203
I0
I2
I-2
tp18255
sS'chlorthalidone,and'
p18256
(F1
F0.00028669724770642203
I2
I0
I2
tp18257
sS'loperamide,and'
p18258
(F0
F0
I1
I1
I0
tp18259
sS'method,of'
p18260
(F1
F0.00043004587155963305
I3
I0
I3
tp18261
sS'which,themselves'
p18262
(F1
F0.00014334862385321102
I1
I0
I1
tp18263
sS'be,allowed'
p18264
(F1
F0.00014334862385321102
I1
I0
I1
tp18265
sS'affect,strategies'
p18266
(F1
F0.00014334862385321102
I0
I1
I-1
tp18267
sS'we,show'
p18268
(F1
F0.00014334862385321102
I0
I1
I-1
tp18269
sS'romazicon,was'
p18270
(F1
F0.00014334862385321102
I0
I1
I-1
tp18271
sS'weight,gain'
p18272
(F1
F0.00028669724770642203
I2
I0
I2
tp18273
sS'constitutes,the'
p18274
(F1
F0.00014334862385321102
I0
I1
I-1
tp18275
sS'of,angiomax'
p18276
(F0
F0
I1
I1
I0
tp18277
sS'hydrogen,maleate'
p18278
(F1
F0.00014334862385321102
I1
I0
I1
tp18279
sS'cimetldine,cerivastatin'
p18280
(F1
F0.00014334862385321102
I0
I1
I-1
tp18281
sS'were,evaluated'
p18282
(F1
F0.00014334862385321102
I0
I1
I-1
tp18283
sS'stress,in'
p18284
(F1
F0.00014334862385321102
I1
I0
I1
tp18285
sS'of,antipsychotic'
p18286
(F1
F0.00014334862385321102
I1
I0
I1
tp18287
sS'that,intoxication'
p18288
(F1
F0.00028669724770642203
I2
I0
I2
tp18289
sS'new,agents'
p18290
(F1
F0.00014334862385321102
I0
I1
I-1
tp18291
sS'including,products'
p18292
(F1
F0.00014334862385321102
I1
I0
I1
tp18293
sS'protect,against'
p18294
(F1
F0.00014334862385321102
I1
I0
I1
tp18295
sS'arrhythmia,bradycardia'
p18296
(F1
F0.00014334862385321102
I1
I0
I1
tp18297
sS'to,antiepileptic'
p18298
(F1
F0.00014334862385321102
I1
I0
I1
tp18299
sS'other,beta2'
p18300
(F1
F0.00014334862385321102
I1
I0
I1
tp18301
sS'respectively,a'
p18302
(F1
F0.00028669724770642203
I2
I0
I2
tp18303
sS'patient,may'
p18304
(F1
F0.00014334862385321102
I1
I0
I1
tp18305
sS'be,advised'
p18306
(F0.5
F0.00028669724770642203
I3
I1
I2
tp18307
sS'acute,phase'
p18308
(F1
F0.00028669724770642203
I0
I2
I-2
tp18309
sS'to,which'
p18310
(F1
F0.0010034403669724771
I7
I0
I7
tp18311
sS'taking,revia'
p18312
(F1
F0.00014334862385321102
I1
I0
I1
tp18313
sS'tests,such'
p18314
(F1
F0.00014334862385321102
I0
I1
I-1
tp18315
sS'inhibitor,maoi'
p18316
(F1
F0.00014334862385321102
I0
I1
I-1
tp18317
sS'itraconazole,and'
p18318
(F1
F0.0008600917431192661
I6
I0
I6
tp18319
sS'to,inactivate'
p18320
(F1
F0.00014334862385321102
I1
I0
I1
tp18321
sS'and,nrtis'
p18322
(F1
F0.00014334862385321102
I0
I1
I-1
tp18323
sS'ions,may'
p18324
(F1
F0.00014334862385321102
I0
I1
I-1
tp18325
sS'increased,during'
p18326
(F1
F0.00014334862385321102
I1
I0
I1
tp18327
sS'in,increase'
p18328
(F1
F0.00014334862385321102
I1
I0
I1
tp18329
sS'and,coma'
p18330
(F1
F0.00014334862385321102
I1
I0
I1
tp18331
sS'with,fluvoxamine'
p18332
(F1
F0.00014334862385321102
I1
I0
I1
tp18333
sS'activity,acute'
p18334
(F1
F0.00014334862385321102
I0
I1
I-1
tp18335
sS'has,been'
p18336
(F0.41304347826086957
F0.010894495412844037
I130
I54
I76
tp18337
sS'the,should'
p18338
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp18339
sS'levetiracetam,had'
p18340
(F1
F0.00014334862385321102
I0
I1
I-1
tp18341
sS'ambulatory,patients'
p18342
(F1
F0.00014334862385321102
I0
I1
I-1
tp18343
sS'cuprimine,another'
p18344
(F1
F0.00014334862385321102
I1
I0
I1
tp18345
sS'or,minutes'
p18346
(F1
F0.00014334862385321102
I1
I0
I1
tp18347
sS'is,generally'
p18348
(F1
F0.00028669724770642203
I2
I0
I2
tp18349
sS'and,proquin'
p18350
(F1
F0.00014334862385321102
I0
I1
I-1
tp18351
sS'are,vasoconstrictive'
p18352
(F1
F0.00014334862385321102
I1
I0
I1
tp18353
sS'weeks,oral'
p18354
(F1
F0.00014334862385321102
I0
I1
I-1
tp18355
sS'other,manufacturers'
p18356
(F1
F0.00014334862385321102
I0
I1
I-1
tp18357
sS'of,repeat'
p18358
(F1
F0.00014334862385321102
I0
I1
I-1
tp18359
sS'bleeding,a'
p18360
(F1
F0.00014334862385321102
I0
I1
I-1
tp18361
sS'systematically,evaluated'
p18362
(F1
F0.00014334862385321102
I1
I0
I1
tp18363
sS'talk,to'
p18364
(F1
F0.00014334862385321102
I0
I1
I-1
tp18365
sS'may,represent'
p18366
(F1
F0.00014334862385321102
I0
I1
I-1
tp18367
sS'additional,reductions'
p18368
(F1
F0.00014334862385321102
I1
I0
I1
tp18369
sS'other,channel'
p18370
(F1
F0.00014334862385321102
I1
I0
I1
tp18371
sS'to,the'
p18372
(F0.050000000000000003
F0.00057339449541284407
I42
I38
I4
tp18373
sS'bullous,pemphigoid'
p18374
(F1
F0.00014334862385321102
I1
I0
I1
tp18375
sS'certain,antipsychotic'
p18376
(F1
F0.00014334862385321102
I0
I1
I-1
tp18377
sS'although,they'
p18378
(F1
F0.00014334862385321102
I1
I0
I1
tp18379
sS'prostaglandins,play'
p18380
(F1
F0.00014334862385321102
I1
I0
I1
tp18381
sS'the,digit'
p18382
(F1
F0.00014334862385321102
I1
I0
I1
tp18383
sS'receiving,proleukin'
p18384
(F1
F0.00014334862385321102
I1
I0
I1
tp18385
sS'reports,however'
p18386
(F1
F0.00014334862385321102
I1
I0
I1
tp18387
sS'increase,oral'
p18388
(F1
F0.00028669724770642203
I2
I0
I2
tp18389
sS'on,histamine-'
p18390
(F1
F0.00014334862385321102
I1
I0
I1
tp18391
sS'by,peripheral'
p18392
(F1
F0.00014334862385321102
I0
I1
I-1
tp18393
sS'oral,mg'
p18394
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18395
sS'acid,paba'
p18396
(F1
F0.00014334862385321102
I1
I0
I1
tp18397
sS'certainly,during'
p18398
(F1
F0.00014334862385321102
I1
I0
I1
tp18399
sS'and,have'
p18400
(F0.5
F0.0017201834862385322
I6
I18
I-12
tp18401
sS'adults,at'
p18402
(F1
F0.00014334862385321102
I1
I0
I1
tp18403
sS'effect,when'
p18404
(F0.75
F0.0008600917431192661
I7
I1
I6
tp18405
sS'receiving,concomitant'
p18406
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp18407
sS'the,digi-'
p18408
(F1
F0.00014334862385321102
I0
I1
I-1
tp18409
sS'phenytoin,no'
p18410
(F1
F0.00014334862385321102
I0
I1
I-1
tp18411
sS'donor,compounds'
p18412
(F1
F0.00014334862385321102
I1
I0
I1
tp18413
sS'including,derivatives'
p18414
(F1
F0.00014334862385321102
I1
I0
I1
tp18415
sS'and,day'
p18416
(F1
F0.00014334862385321102
I1
I0
I1
tp18417
sS'with,l-tryptophan'
p18418
(F1
F0.00014334862385321102
I0
I1
I-1
tp18419
sS'of,hydroxyzine'
p18420
(F1
F0.00014334862385321102
I1
I0
I1
tp18421
sS'rat,were'
p18422
(F1
F0.00014334862385321102
I0
I1
I-1
tp18423
sS'added,or'
p18424
(F1
F0.00028669724770642203
I2
I0
I2
tp18425
sS'l50,mg'
p18426
(F1
F0.00014334862385321102
I0
I1
I-1
tp18427
sS'in,fluoride'
p18428
(F1
F0.00014334862385321102
I0
I1
I-1
tp18429
sS'of,hydroxide'
p18430
(F0
F0
I1
I1
I0
tp18431
sS'added,of'
p18432
(F1
F0.00014334862385321102
I1
I0
I1
tp18433
sS'cyp3a4,cimetidine'
p18434
(F1
F0.00014334862385321102
I1
I0
I1
tp18435
sS'max,increased'
p18436
(F0
F0
I1
I1
I0
tp18437
sS'l,from'
p18438
(F0
F0
I1
I1
I0
tp18439
sS'heparin,other'
p18440
(F1
F0.00014334862385321102
I0
I1
I-1
tp18441
sS'defense,of'
p18442
(F1
F0.00014334862385321102
I1
I0
I1
tp18443
sS'receiving,hcl'
p18444
(F1
F0.00028669724770642203
I2
I0
I2
tp18445
sS'cyclophosphamide,treatment'
p18446
(F1
F0.00014334862385321102
I1
I0
I1
tp18447
sS'requires,oral'
p18448
(F1
F0.00014334862385321102
I0
I1
I-1
tp18449
sS'anaphylactic,shock'
p18450
(F1
F0.00014334862385321102
I1
I0
I1
tp18451
sS'of,vasopressor'
p18452
(F0
F0
I1
I1
I0
tp18453
sS'dasatinib,is'
p18454
(F1
F0.00028669724770642203
I0
I2
I-2
tp18455
sS'viracept,antiarrhythmics'
p18456
(F1
F0.00014334862385321102
I1
I0
I1
tp18457
sS'expected,and'
p18458
(F1
F0.00014334862385321102
I1
I0
I1
tp18459
sS'endothelium,from'
p18460
(F1
F0.00014334862385321102
I1
I0
I1
tp18461
sS'of,minutes'
p18462
(F1
F0.00014334862385321102
I0
I1
I-1
tp18463
sS'significant,drug-drug'
p18464
(F1
F0.00057339449541284407
I0
I4
I-4
tp18465
sS'ventricular,hypokinesia'
p18466
(F1
F0.00014334862385321102
I1
I0
I1
tp18467
sS'an,antipsychotic'
p18468
(F1
F0.00014334862385321102
I1
I0
I1
tp18469
sS'species,ros'
p18470
(F1
F0.00014334862385321102
I0
I1
I-1
tp18471
sS'of,clozapine'
p18472
(F1
F0.00043004587155963305
I3
I0
I3
tp18473
sS'when,inspra'
p18474
(F1
F0.00014334862385321102
I1
I0
I1
tp18475
sS'either,agent'
p18476
(F1
F0.00014334862385321102
I0
I1
I-1
tp18477
sS'mammalian,target'
p18478
(F1
F0.00014334862385321102
I0
I1
I-1
tp18479
sS'major,enzyme'
p18480
(F1
F0.00014334862385321102
I1
I0
I1
tp18481
sS'any,clinical'
p18482
(F0
F0
I1
I1
I0
tp18483
sS'either,s'
p18484
(F1
F0.00014334862385321102
I0
I1
I-1
tp18485
sS'avoided,in'
p18486
(F0.5
F0.00028669724770642203
I3
I1
I2
tp18487
sS'of,patient'
p18488
(F1
F0.00014334862385321102
I1
I0
I1
tp18489
sS'hepatic,microsomal'
p18490
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp18491
sS'which,has'
p18492
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18493
sS'day,a'
p18494
(F1
F0.00014334862385321102
I1
I0
I1
tp18495
sS'day,n'
p18496
(F0
F0
I1
I1
I0
tp18497
sS'antagonist,were'
p18498
(F1
F0.00014334862385321102
I0
I1
I-1
tp18499
sS'extensively,in'
p18500
(F1
F0.00014334862385321102
I0
I1
I-1
tp18501
sS'ketones,in'
p18502
(F1
F0.00028669724770642203
I0
I2
I-2
tp18503
sS'of,tikosyn'
p18504
(F1
F0.00014334862385321102
I1
I0
I1
tp18505
sS'betagan,and'
p18506
(F1
F0.00014334862385321102
I1
I0
I1
tp18507
sS'pancreatic,supplements'
p18508
(F1
F0.00014334862385321102
I1
I0
I1
tp18509
sS'on,sensipar'
p18510
(F1
F0.00014334862385321102
I0
I1
I-1
tp18511
sS'cell,number'
p18512
(F1
F0.00014334862385321102
I1
I0
I1
tp18513
sS'pegasys,should'
p18514
(F1
F0.00014334862385321102
I0
I1
I-1
tp18515
sS'rats,were'
p18516
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18517
sS'keppra,mg'
p18518
(F1
F0.00071674311926605509
I0
I5
I-5
tp18519
sS'to,compared'
p18520
(F1
F0.00014334862385321102
I1
I0
I1
tp18521
sS'extract,alone'
p18522
(F1
F0.00014334862385321102
I0
I1
I-1
tp18523
sS'h2-antagonists,and'
p18524
(F1
F0.00014334862385321102
I0
I1
I-1
tp18525
sS'for,for'
p18526
(F1
F0.00043004587155963305
I0
I3
I-3
tp18527
sS'the,type'
p18528
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp18529
sS'medications,tylenol'
p18530
(F1
F0.00014334862385321102
I1
I0
I1
tp18531
sS'following,multiple'
p18532
(F1
F0.00014334862385321102
I0
I1
I-1
tp18533
sS'the,consumption'
p18534
(F1
F0.00014334862385321102
I1
I0
I1
tp18535
sS'mg,fe'
p18536
(F1
F0.00014334862385321102
I1
I0
I1
tp18537
sS'adequate,methods'
p18538
(F1
F0.00014334862385321102
I0
I1
I-1
tp18539
sS'diminishes,the'
p18540
(F1
F0.00014334862385321102
I1
I0
I1
tp18541
sS'to,but'
p18542
(F0.5
F0.00028669724770642203
I3
I1
I2
tp18543
sS'pcp,discrimination'
p18544
(F1
F0.00014334862385321102
I0
I1
I-1
tp18545
sS'arrhythmias,due'
p18546
(F1
F0.00014334862385321102
I0
I1
I-1
tp18547
sS'taking,certain'
p18548
(F1
F0.00014334862385321102
I0
I1
I-1
tp18549
sS'antidepressants,foradil'
p18550
(F1
F0.00014334862385321102
I1
I0
I1
tp18551
sS'or,activase'
p18552
(F1
F0.00014334862385321102
I0
I1
I-1
tp18553
sS'omega-agatoxin,via-resistant'
p18554
(F1
F0.00014334862385321102
I0
I1
I-1
tp18555
sS'however,appropriate'
p18556
(F1
F0.00014334862385321102
I1
I0
I1
tp18557
sS'low,dose'
p18558
(F1
F0.00028669724770642203
I0
I2
I-2
tp18559
sS'six,subjects'
p18560
(F1
F0.00014334862385321102
I1
I0
I1
tp18561
sS'injection,like'
p18562
(F1
F0.00014334862385321102
I1
I0
I1
tp18563
sS'therapy,diabetes'
p18564
(F1
F0.00014334862385321102
I0
I1
I-1
tp18565
sS'itraconazole,plasma'
p18566
(F1
F0.00014334862385321102
I1
I0
I1
tp18567
sS'bound,like'
p18568
(F1
F0.00014334862385321102
I0
I1
I-1
tp18569
sS'as,potent'
p18570
(F1
F0.00014334862385321102
I0
I1
I-1
tp18571
sS'over,weeks'
p18572
(F1
F0.00014334862385321102
I0
I1
I-1
tp18573
sS'interaction,with'
p18574
(F0.36842105263157893
F0.0010034403669724771
I6
I13
I-7
tp18575
sS'm2,given'
p18576
(F1
F0.00014334862385321102
I1
I0
I1
tp18577
sS'altered,tsh'
p18578
(F1
F0.00014334862385321102
I0
I1
I-1
tp18579
sS'agents,glutamic'
p18580
(F1
F0.00014334862385321102
I1
I0
I1
tp18581
sS'clinically,significant'
p18582
(F0.80000000000000004
F0.0045871559633027525
I4
I36
I-32
tp18583
sS'inhibited,the'
p18584
(F1
F0.00043004587155963305
I3
I0
I3
tp18585
sS'reuptake,inhibitors'
p18586
(F0.14285714285714285
F0.00028669724770642203
I6
I8
I-2
tp18587
sS'seizures,in'
p18588
(F1
F0.00028669724770642203
I2
I0
I2
tp18589
sS'been,established'
p18590
(F0
F0
I4
I4
I0
tp18591
sS'be,due'
p18592
(F1
F0.00014334862385321102
I1
I0
I1
tp18593
sS'depressants,the'
p18594
(F1
F0.00014334862385321102
I1
I0
I1
tp18595
sS'duloxetine,to'
p18596
(F1
F0.00014334862385321102
I0
I1
I-1
tp18597
sS'in,escalating'
p18598
(F1
F0.00014334862385321102
I0
I1
I-1
tp18599
sS'have,cholesterol'
p18600
(F1
F0.00014334862385321102
I1
I0
I1
tp18601
sS'reaction,to'
p18602
(F1
F0.00014334862385321102
I1
I0
I1
tp18603
sS'effectiveness,against'
p18604
(F1
F0.00014334862385321102
I0
I1
I-1
tp18605
sS'succinate,and'
p18606
(F1
F0.00014334862385321102
I0
I1
I-1
tp18607
sS'rettgeri,were'
p18608
(F1
F0.00014334862385321102
I0
I1
I-1
tp18609
sS'for,arava'
p18610
(F1
F0.00014334862385321102
I1
I0
I1
tp18611
sS'cisapride,can'
p18612
(F1
F0.00014334862385321102
I0
I1
I-1
tp18613
sS'indocin,has'
p18614
(F1
F0.00028669724770642203
I2
I0
I2
tp18615
sS'test,interaction'
p18616
(F1
F0.00043004587155963305
I0
I3
I-3
tp18617
sS'the,diabetics'
p18618
(F1
F0.00014334862385321102
I0
I1
I-1
tp18619
sS'higher,end'
p18620
(F1
F0.00014334862385321102
I0
I1
I-1
tp18621
sS'by,high'
p18622
(F1
F0.00028669724770642203
I2
I0
I2
tp18623
sS'of,factive'
p18624
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18625
sS'clearance,values'
p18626
(F0
F0
I1
I1
I0
tp18627
sS'injection,should'
p18628
(F1
F0.00014334862385321102
I0
I1
I-1
tp18629
sS'are,sequestered'
p18630
(F1
F0.00014334862385321102
I0
I1
I-1
tp18631
sS'or,if'
p18632
(F0
F0
I1
I1
I0
tp18633
sS'and,interfere'
p18634
(F1
F0.00014334862385321102
I1
I0
I1
tp18635
sS'diffusible,treatment'
p18636
(F1
F0.00014334862385321102
I0
I1
I-1
tp18637
sS'of,krm-1648'
p18638
(F1
F0.00014334862385321102
I0
I1
I-1
tp18639
sS'color,is'
p18640
(F1
F0.00014334862385321102
I1
I0
I1
tp18641
sS'taken,when'
p18642
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18643
sS'of,cmi'
p18644
(F1
F0.00028669724770642203
I2
I0
I2
tp18645
sS'incoordination,when'
p18646
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18647
sS'by,contrast'
p18648
(F1
F0.00014334862385321102
I0
I1
I-1
tp18649
sS'blocking,action'
p18650
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp18651
sS'or,is'
p18652
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18653
sS'oleate,and'
p18654
(F1
F0.00014334862385321102
I0
I1
I-1
tp18655
sS'after,injection'
p18656
(F1
F0.00014334862385321102
I1
I0
I1
tp18657
sS'or,iv'
p18658
(F1
F0.00014334862385321102
I0
I1
I-1
tp18659
sS'cyp3a,channel'
p18660
(F1
F0.00014334862385321102
I0
I1
I-1
tp18661
sS'desirable,to'
p18662
(F1
F0.00071674311926605509
I0
I5
I-5
tp18663
sS'vardenafil,and'
p18664
(F1
F0.00014334862385321102
I1
I0
I1
tp18665
sS'acid,erythromycin'
p18666
(F1
F0.00014334862385321102
I0
I1
I-1
tp18667
sS'preanesthetic,or'
p18668
(F1
F0.00014334862385321102
I0
I1
I-1
tp18669
sS'mg,administered'
p18670
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18671
sS'but,significantly'
p18672
(F1
F0.00028669724770642203
I2
I0
I2
tp18673
sS'for,mg'
p18674
(F1
F0.00014334862385321102
I1
I0
I1
tp18675
sS'that,cefditoren'
p18676
(F0
F0
I1
I1
I0
tp18677
sS'this,article'
p18678
(F1
F0.00014334862385321102
I0
I1
I-1
tp18679
sS'from,week'
p18680
(F1
F0.00014334862385321102
I0
I1
I-1
tp18681
sS'cyclosporine,large'
p18682
(F1
F0.00014334862385321102
I0
I1
I-1
tp18683
sS'aquamephyton,synkayvite'
p18684
(F1
F0.00014334862385321102
I0
I1
I-1
tp18685
sS'after,multiple'
p18686
(F0
F0
I1
I1
I0
tp18687
sS'potent,loop'
p18688
(F1
F0.00014334862385321102
I1
I0
I1
tp18689
sS'proquin,xr'
p18690
(F1
F0.00028669724770642203
I0
I2
I-2
tp18691
sS'affecting,sympathetic'
p18692
(F1
F0.00028669724770642203
I0
I2
I-2
tp18693
sS'lower,rate'
p18694
(F1
F0.00014334862385321102
I1
I0
I1
tp18695
sS'parenterally,administered'
p18696
(F1
F0.00014334862385321102
I1
I0
I1
tp18697
sS'the,occurrence'
p18698
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18699
sS'ethynyl,and'
p18700
(F1
F0.00014334862385321102
I0
I1
I-1
tp18701
sS'thyroid,hormones'
p18702
(F1
F0.00014334862385321102
I0
I1
I-1
tp18703
sS'indicate,that'
p18704
(F0.25714285714285712
F0.0012901376146788992
I22
I13
I9
tp18705
sS'study,coadministration'
p18706
(F1
F0.00028669724770642203
I2
I0
I2
tp18707
sS'human,red'
p18708
(F1
F0.00014334862385321102
I0
I1
I-1
tp18709
sS'or,retinyl'
p18710
(F1
F0.00028669724770642203
I2
I0
I2
tp18711
sS'consistent,with'
p18712
(F1
F0.00014334862385321102
I0
I1
I-1
tp18713
sS'its,dosage'
p18714
(F1
F0.00014334862385321102
I1
I0
I1
tp18715
sS'antibiotics,videx'
p18716
(F1
F0.00014334862385321102
I1
I0
I1
tp18717
sS'the,lowest'
p18718
(F1
F0.00043004587155963305
I3
I0
I3
tp18719
sS'obtained,for'
p18720
(F1
F0.00014334862385321102
I0
I1
I-1
tp18721
sS'there,does'
p18722
(F1
F0.00014334862385321102
I0
I1
I-1
tp18723
sS'cyp2d6,resulted'
p18724
(F1
F0.00014334862385321102
I1
I0
I1
tp18725
sS'daily,brovana'
p18726
(F1
F0.00014334862385321102
I0
I1
I-1
tp18727
sS'women,of'
p18728
(F1
F0.00014334862385321102
I0
I1
I-1
tp18729
sS'digitalis,or'
p18730
(F1
F0.00014334862385321102
I1
I0
I1
tp18731
sS'brain,and'
p18732
(F1
F0.00014334862385321102
I1
I0
I1
tp18733
sS'rapidly,and'
p18734
(F1
F0.00014334862385321102
I0
I1
I-1
tp18735
sS'are,on'
p18736
(F1
F0.00057339449541284407
I4
I0
I4
tp18737
sS'intentional,or'
p18738
(F1
F0.00014334862385321102
I1
I0
I1
tp18739
sS'cyp2c19,the'
p18740
(F1
F0.00014334862385321102
I0
I1
I-1
tp18741
sS'contraindicated,due'
p18742
(F1
F0.00057339449541284407
I0
I4
I-4
tp18743
sS'before,using'
p18744
(F0
F0
I1
I1
I0
tp18745
sS'clinically,important'
p18746
(F1
F0.0024369266055045873
I0
I17
I-17
tp18747
sS'non-narcotic,analgesics'
p18748
(F1
F0.00014334862385321102
I1
I0
I1
tp18749
sS'and,require'
p18750
(F1
F0.00014334862385321102
I1
I0
I1
tp18751
sS'of,h1'
p18752
(F1
F0.00014334862385321102
I1
I0
I1
tp18753
sS'of,h2'
p18754
(F1
F0.00028669724770642203
I2
I0
I2
tp18755
sS'coadministered,intravenously'
p18756
(F1
F0.00014334862385321102
I1
I0
I1
tp18757
sS'mineral,oil'
p18758
(F1
F0.00028669724770642203
I2
I0
I2
tp18759
sS'the,abundance'
p18760
(F1
F0.00014334862385321102
I0
I1
I-1
tp18761
sS'additional,efficacy'
p18762
(F1
F0.00014334862385321102
I1
I0
I1
tp18763
sS'bovine,chromaffin'
p18764
(F1
F0.00028669724770642203
I0
I2
I-2
tp18765
sS'of,strong'
p18766
(F1
F0.00014334862385321102
I0
I1
I-1
tp18767
sS'occasionally,intensify'
p18768
(F1
F0.00014334862385321102
I1
I0
I1
tp18769
sS'in,response'
p18770
(F1
F0.00028669724770642203
I0
I2
I-2
tp18771
sS'starlix,mg'
p18772
(F1
F0.00057339449541284407
I0
I4
I-4
tp18773
sS'be,watched'
p18774
(F1
F0.00014334862385321102
I1
I0
I1
tp18775
sS'whether,injection'
p18776
(F1
F0.00014334862385321102
I0
I1
I-1
tp18777
sS'increase,for'
p18778
(F1
F0.00014334862385321102
I1
I0
I1
tp18779
sS'while,all'
p18780
(F1
F0.00071674311926605509
I0
I5
I-5
tp18781
sS'and,prolonged'
p18782
(F1
F0.00028669724770642203
I2
I0
I2
tp18783
sS'exists,between'
p18784
(F0.5
F0.00028669724770642203
I3
I1
I2
tp18785
sS'alg,mycophenolate'
p18786
(F1
F0.00014334862385321102
I0
I1
I-1
tp18787
sS'when,colestid'
p18788
(F1
F0.00014334862385321102
I1
I0
I1
tp18789
sS'nitrates,the'
p18790
(F0
F0
I1
I1
I0
tp18791
sS'the,influence'
p18792
(F1
F0.00071674311926605509
I0
I5
I-5
tp18793
sS'tablets,may'
p18794
(F1
F0.00043004587155963305
I3
I0
I3
tp18795
sS'gain,occurred'
p18796
(F1
F0.00014334862385321102
I0
I1
I-1
tp18797
sS'be,less'
p18798
(F1
F0.00014334862385321102
I1
I0
I1
tp18799
sS'with,two'
p18800
(F1
F0.00014334862385321102
I0
I1
I-1
tp18801
sS'discontinue,nursing'
p18802
(F1
F0.00014334862385321102
I0
I1
I-1
tp18803
sS'toxic,such'
p18804
(F1
F0.00014334862385321102
I1
I0
I1
tp18805
sS'diazepam,diazepam'
p18806
(F1
F0.00014334862385321102
I0
I1
I-1
tp18807
sS'inhibitors,with'
p18808
(F1
F0.00014334862385321102
I1
I0
I1
tp18809
sS'unchanged,after'
p18810
(F1
F0.00014334862385321102
I0
I1
I-1
tp18811
sS'failure,etc'
p18812
(F1
F0.00014334862385321102
I1
I0
I1
tp18813
sS'therefore,to'
p18814
(F0
F0
I1
I1
I0
tp18815
sS'other,hepatic'
p18816
(F1
F0.00014334862385321102
I1
I0
I1
tp18817
sS'coumarin-derivative,should'
p18818
(F1
F0.00014334862385321102
I0
I1
I-1
tp18819
sS'no,signs'
p18820
(F1
F0.00014334862385321102
I1
I0
I1
tp18821
sS'of,over'
p18822
(F1
F0.00028669724770642203
I0
I2
I-2
tp18823
sS'nevirapine,and'
p18824
(F1
F0.00028669724770642203
I2
I0
I2
tp18825
sS'to,lowered'
p18826
(F1
F0.00014334862385321102
I1
I0
I1
tp18827
sS'not,beadministered'
p18828
(F1
F0.00028669724770642203
I2
I0
I2
tp18829
sS'recommended,that'
p18830
(F0.63636363636363635
F0.0020068807339449542
I18
I4
I14
tp18831
sS'body,weight'
p18832
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp18833
sS'in,preventing'
p18834
(F1
F0.00014334862385321102
I0
I1
I-1
tp18835
sS'on,day9'
p18836
(F1
F0.00014334862385321102
I1
I0
I1
tp18837
sS'on,day5'
p18838
(F0
F0
I1
I1
I0
tp18839
sS'valdecoxib,did'
p18840
(F1
F0.00014334862385321102
I0
I1
I-1
tp18841
sS'isoforms,cyp3a4'
p18842
(F1
F0.00014334862385321102
I0
I1
I-1
tp18843
sS'minimally,absorbed'
p18844
(F1
F0.00014334862385321102
I1
I0
I1
tp18845
sS'stress,and'
p18846
(F1
F0.00014334862385321102
I0
I1
I-1
tp18847
sS'blockade,was'
p18848
(F0
F0
I1
I1
I0
tp18849
sS'the,vehicle'
p18850
(F1
F0.00014334862385321102
I1
I0
I1
tp18851
sS'when,channel'
p18852
(F1
F0.00028669724770642203
I2
I0
I2
tp18853
sS'hypertension,some'
p18854
(F1
F0.00014334862385321102
I1
I0
I1
tp18855
sS'antagonist,opioid'
p18856
(F1
F0.00014334862385321102
I1
I0
I1
tp18857
sS'fehlings,solution'
p18858
(F1
F0.00014334862385321102
I0
I1
I-1
tp18859
sS'on,tikosyn'
p18860
(F1
F0.00014334862385321102
I0
I1
I-1
tp18861
sS'when,they'
p18862
(F1
F0.00043004587155963305
I3
I0
I3
tp18863
sS'below,drugs'
p18864
(F1
F0.00014334862385321102
I1
I0
I1
tp18865
sS'disease,has'
p18866
(F1
F0.00014334862385321102
I1
I0
I1
tp18867
sS'juice,and'
p18868
(F1
F0.00014334862385321102
I1
I0
I1
tp18869
sS'with,suspension'
p18870
(F1
F0.00014334862385321102
I0
I1
I-1
tp18871
sS'hypertension,administration'
p18872
(F1
F0.00028669724770642203
I2
I0
I2
tp18873
sS'caution,using'
p18874
(F1
F0.00014334862385321102
I1
I0
I1
tp18875
sS'test,and'
p18876
(F1
F0.00014334862385321102
I1
I0
I1
tp18877
sS'induced,long'
p18878
(F1
F0.00014334862385321102
I1
I0
I1
tp18879
sS'further,fe'
p18880
(F1
F0.00014334862385321102
I0
I1
I-1
tp18881
sS'our,patient'
p18882
(F1
F0.00014334862385321102
I1
I0
I1
tp18883
sS'contraception,should'
p18884
(F1
F0.00028669724770642203
I2
I0
I2
tp18885
sS'eg,are'
p18886
(F1
F0.00014334862385321102
I0
I1
I-1
tp18887
sS'idv,exposure'
p18888
(F1
F0.00014334862385321102
I0
I1
I-1
tp18889
sS'agents,likely'
p18890
(F1
F0.00014334862385321102
I0
I1
I-1
tp18891
sS'time,was'
p18892
(F1
F0.00014334862385321102
I0
I1
I-1
tp18893
sS'combination,may'
p18894
(F1
F0.00043004587155963305
I3
I0
I3
tp18895
sS'nor,retinyl'
p18896
(F1
F0.00014334862385321102
I1
I0
I1
tp18897
sS'romazicon,in'
p18898
(F1
F0.00014334862385321102
I1
I0
I1
tp18899
sS'from,on'
p18900
(F1
F0.00014334862385321102
I1
I0
I1
tp18901
sS'onset,can'
p18902
(F1
F0.00014334862385321102
I1
I0
I1
tp18903
sS'nevirapine,may'
p18904
(F1
F0.00014334862385321102
I1
I0
I1
tp18905
sS'coadministered,plasma'
p18906
(F1
F0.00014334862385321102
I1
I0
I1
tp18907
sS'clinically,meaningful'
p18908
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18909
sS'because,the'
p18910
(F0.7142857142857143
F0.0014334862385321102
I12
I2
I10
tp18911
sS'revlimid,is'
p18912
(F1
F0.00014334862385321102
I0
I1
I-1
tp18913
sS'clozapine,potentially'
p18914
(F1
F0.00014334862385321102
I1
I0
I1
tp18915
sS'and,electrolyte'
p18916
(F1
F0.00014334862385321102
I1
I0
I1
tp18917
sS'the,small'
p18918
(F1
F0.00014334862385321102
I1
I0
I1
tp18919
sS'supervision,after'
p18920
(F1
F0.00014334862385321102
I1
I0
I1
tp18921
sS'in,survanta'
p18922
(F1
F0.00014334862385321102
I0
I1
I-1
tp18923
sS'atacand,so'
p18924
(F1
F0.00014334862385321102
I1
I0
I1
tp18925
sS'may,compete'
p18926
(F1
F0.00014334862385321102
I1
I0
I1
tp18927
sS'or,ototoxicity'
p18928
(F1
F0.00014334862385321102
I0
I1
I-1
tp18929
sS'developed,neutropenia'
p18930
(F1
F0.00028669724770642203
I2
I0
I2
tp18931
sS'are,tricky'
p18932
(F1
F0.00014334862385321102
I0
I1
I-1
tp18933
sS'antacids,in'
p18934
(F1
F0.00028669724770642203
I2
I0
I2
tp18935
sS'before,dosing'
p18936
(F1
F0.00014334862385321102
I1
I0
I1
tp18937
sS'of,withdrawal'
p18938
(F1
F0.00028669724770642203
I2
I0
I2
tp18939
sS'co-administered,has'
p18940
(F1
F0.00014334862385321102
I1
I0
I1
tp18941
sS'could,enhance'
p18942
(F1
F0.00014334862385321102
I1
I0
I1
tp18943
sS'effective,while'
p18944
(F1
F0.00014334862385321102
I1
I0
I1
tp18945
sS'given,supplemental'
p18946
(F1
F0.00014334862385321102
I1
I0
I1
tp18947
sS'cyp450,isoenzymes'
p18948
(F1
F0.00014334862385321102
I0
I1
I-1
tp18949
sS'for,novolog'
p18950
(F1
F0.00014334862385321102
I0
I1
I-1
tp18951
sS'observation,period'
p18952
(F1
F0.00014334862385321102
I0
I1
I-1
tp18953
sS'group,that'
p18954
(F1
F0.00014334862385321102
I0
I1
I-1
tp18955
sS'in,arteries'
p18956
(F1
F0.00014334862385321102
I0
I1
I-1
tp18957
sS'busulfex,were'
p18958
(F1
F0.00014334862385321102
I1
I0
I1
tp18959
sS'increases,excretion'
p18960
(F1
F0.00014334862385321102
I1
I0
I1
tp18961
sS'severe,obstipation'
p18962
(F1
F0.00014334862385321102
I1
I0
I1
tp18963
sS'orally,with'
p18964
(F1
F0.00014334862385321102
I1
I0
I1
tp18965
sS'induce,cyp1a2'
p18966
(F1
F0.00028669724770642203
I0
I2
I-2
tp18967
sS'monitored,after'
p18968
(F1
F0.00014334862385321102
I1
I0
I1
tp18969
sS'cause,changes'
p18970
(F1
F0.00028669724770642203
I2
I0
I2
tp18971
sS'the,potential'
p18972
(F0.30232558139534882
F0.0018635321100917432
I28
I15
I13
tp18973
sS'safety,profiles'
p18974
(F1
F0.00014334862385321102
I0
I1
I-1
tp18975
sS'control,inflammation'
p18976
(F1
F0.00014334862385321102
I1
I0
I1
tp18977
sS'some,have'
p18978
(F1
F0.00043004587155963305
I3
I0
I3
tp18979
sS'an,in'
p18980
(F0
F0
I2
I2
I0
tp18981
sS'days,showed'
p18982
(F1
F0.00014334862385321102
I0
I1
I-1
tp18983
sS'the,effect'
p18984
(F0.022222222222222223
F0.00028669724770642203
I46
I44
I2
tp18985
sS'gastrointestinal,adverse'
p18986
(F1
F0.00028669724770642203
I0
I2
I-2
tp18987
sS'receiving,single'
p18988
(F1
F0.00014334862385321102
I0
I1
I-1
tp18989
sS'sympathetic,activity'
p18990
(F1
F0.00028669724770642203
I0
I2
I-2
tp18991
sS'phosphohydrolase,from'
p18992
(F1
F0.00014334862385321102
I0
I1
I-1
tp18993
sS'fatal,convulsions'
p18994
(F1
F0.00028669724770642203
I2
I0
I2
tp18995
sS'chick,by'
p18996
(F1
F0.00014334862385321102
I0
I1
I-1
tp18997
sS'or,potentiating'
p18998
(F1
F0.00057339449541284407
I4
I0
I4
tp18999
sS'nervous,e-strain'
p19000
(F1
F0.00014334862385321102
I0
I1
I-1
tp19001
sS'of,norfloxacin'
p19002
(F1
F0.00014334862385321102
I1
I0
I1
tp19003
sS'antibiotics-broad,spectrum'
p19004
(F1
F0.00014334862385321102
I0
I1
I-1
tp19005
sS'plasmaconcentrations,may'
p19006
(F1
F0.00028669724770642203
I2
I0
I2
tp19007
sS'based,tests'
p19008
(F1
F0.00014334862385321102
I0
I1
I-1
tp19009
sS'until,the'
p19010
(F0
F0
I1
I1
I0
tp19011
sS'symptoms,i'
p19012
(F1
F0.00014334862385321102
I1
I0
I1
tp19013
sS'ed95,nimbex'
p19014
(F1
F0.00014334862385321102
I1
I0
I1
tp19015
sS'symptoms,p'
p19016
(F1
F0.00014334862385321102
I0
I1
I-1
tp19017
sS'it,appears'
p19018
(F1
F0.00014334862385321102
I1
I0
I1
tp19019
sS'conditions,to'
p19020
(F1
F0.00028669724770642203
I0
I2
I-2
tp19021
sS'rigidity,myoclonus'
p19022
(F1
F0.00014334862385321102
I1
I0
I1
tp19023
sS'the,initiation'
p19024
(F0
F0
I3
I3
I0
tp19025
sS'in,clozapine'
p19026
(F1
F0.00014334862385321102
I1
I0
I1
tp19027
sS'be,tested'
p19028
(F1
F0.00014334862385321102
I0
I1
I-1
tp19029
sS'that,mixing'
p19030
(F1
F0.00014334862385321102
I0
I1
I-1
tp19031
sS'and,aprepitant'
p19032
(F1
F0.00014334862385321102
I1
I0
I1
tp19033
sS'patients,who'
p19034
(F0.37142857142857144
F0.0018635321100917432
I24
I11
I13
tp19035
sS'cyp2c9,isoenzyme'
p19036
(F1
F0.00014334862385321102
I1
I0
I1
tp19037
sS'study,it'
p19038
(F1
F0.00014334862385321102
I0
I1
I-1
tp19039
sS'the,brovana'
p19040
(F1
F0.00014334862385321102
I0
I1
I-1
tp19041
sS'considered,for'
p19042
(F0
F0
I1
I1
I0
tp19043
sS'and,ldl-c'
p19044
(F1
F0.00014334862385321102
I0
I1
I-1
tp19045
sS'study,in'
p19046
(F0.125
F0.00057339449541284407
I18
I14
I4
tp19047
sS'hypoglycemic,action'
p19048
(F1
F0.00057339449541284407
I4
I0
I4
tp19049
sS'cytokines,cytokines'
p19050
(F1
F0.00014334862385321102
I0
I1
I-1
tp19051
sS'than,weeks'
p19052
(F1
F0.00014334862385321102
I1
I0
I1
tp19053
sS'and,antagonism'
p19054
(F1
F0.00014334862385321102
I1
I0
I1
tp19055
sS'hydroxide,with'
p19056
(F1
F0.00014334862385321102
I1
I0
I1
tp19057
sS'dosed,as'
p19058
(F1
F0.00014334862385321102
I0
I1
I-1
tp19059
sS'glyceryl,trinitrate'
p19060
(F1
F0.00014334862385321102
I0
I1
I-1
tp19061
sS'deficit,and'
p19062
(F1
F0.00014334862385321102
I0
I1
I-1
tp19063
sS'affected,prothrombin'
p19064
(F1
F0.00014334862385321102
I0
I1
I-1
tp19065
sS'several,dose'
p19066
(F1
F0.00014334862385321102
I0
I1
I-1
tp19067
sS'luteinizing,hormone'
p19068
(F1
F0.00014334862385321102
I0
I1
I-1
tp19069
sS'in,normal'
p19070
(F0.083333333333333329
F0.00028669724770642203
I13
I11
I2
tp19071
sS'tail-flick,and'
p19072
(F1
F0.00014334862385321102
I0
I1
I-1
tp19073
sS'more,pharmacologic'
p19074
(F1
F0.00014334862385321102
I0
I1
I-1
tp19075
sS'acting,nitrates'
p19076
(F1
F0.00014334862385321102
I0
I1
I-1
tp19077
sS'altered,serum'
p19078
(F1
F0.00014334862385321102
I1
I0
I1
tp19079
sS'alcohol,or'
p19080
(F1
F0.00028669724770642203
I0
I2
I-2
tp19081
sS'ht3,antagonist'
p19082
(F1
F0.00014334862385321102
I1
I0
I1
tp19083
sS'l-glutamine,for'
p19084
(F1
F0.00014334862385321102
I1
I0
I1
tp19085
sS'effective,duration'
p19086
(F1
F0.00014334862385321102
I1
I0
I1
tp19087
sS'enzymes,were'
p19088
(F1
F0.00014334862385321102
I0
I1
I-1
tp19089
sS'hours,is'
p19090
(F1
F0.00014334862385321102
I1
I0
I1
tp19091
sS'want,to'
p19092
(F1
F0.00014334862385321102
I0
I1
I-1
tp19093
sS'not,receiving'
p19094
(F1
F0.00043004587155963305
I3
I0
I3
tp19095
sS'cure,and'
p19096
(F0
F0
I1
I1
I0
tp19097
sS'taken,in'
p19098
(F0
F0
I2
I2
I0
tp19099
sS'taking,a'
p19100
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19101
sS'drugs,that'
p19102
(F0.085714285714285715
F0.00043004587155963305
I19
I16
I3
tp19103
sS'for,cyp3a4'
p19104
(F1
F0.00028669724770642203
I0
I2
I-2
tp19105
sS'reports,and'
p19106
(F1
F0.00014334862385321102
I0
I1
I-1
tp19107
sS'methyldopa,aldomet'
p19108
(F1
F0.00014334862385321102
I1
I0
I1
tp19109
sS'substituted,for'
p19110
(F1
F0.00014334862385321102
I0
I1
I-1
tp19111
sS'during,periods'
p19112
(F1
F0.00014334862385321102
I1
I0
I1
tp19113
sS'interactions,when'
p19114
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp19115
sS'levosimendan,does'
p19116
(F1
F0.00014334862385321102
I0
I1
I-1
tp19117
sS'antabuse-like,side'
p19118
(F1
F0.00014334862385321102
I1
I0
I1
tp19119
sS'kinds,of'
p19120
(F1
F0.00014334862385321102
I0
I1
I-1
tp19121
sS'optimal,dosing'
p19122
(F1
F0.00014334862385321102
I0
I1
I-1
tp19123
sS'impaired,renal'
p19124
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19125
sS'potential,danger'
p19126
(F1
F0.00014334862385321102
I1
I0
I1
tp19127
sS'when,mefloquine'
p19128
(F1
F0.00014334862385321102
I1
I0
I1
tp19129
sS'to,products'
p19130
(F1
F0.00014334862385321102
I1
I0
I1
tp19131
sS'emerge,if'
p19132
(F1
F0.00014334862385321102
I1
I0
I1
tp19133
sS'preparations,and'
p19134
(F1
F0.00014334862385321102
I0
I1
I-1
tp19135
sS'proposed,topical'
p19136
(F1
F0.00014334862385321102
I0
I1
I-1
tp19137
sS'atomoxetine,is'
p19138
(F1
F0.00014334862385321102
I0
I1
I-1
tp19139
sS'one,week'
p19140
(F1
F0.00043004587155963305
I3
I0
I3
tp19141
sS'also,received'
p19142
(F1
F0.00014334862385321102
I0
I1
I-1
tp19143
sS'care,providers'
p19144
(F1
F0.00014334862385321102
I0
I1
I-1
tp19145
sS'another,report'
p19146
(F1
F0.00014334862385321102
I1
I0
I1
tp19147
sS'of,heroin-related'
p19148
(F1
F0.00014334862385321102
I1
I0
I1
tp19149
sS'acetaminophen,may'
p19150
(F1
F0.00014334862385321102
I1
I0
I1
tp19151
sS'with,folate'
p19152
(F1
F0.00014334862385321102
I1
I0
I1
tp19153
sS'tract,infections'
p19154
(F1
F0.00014334862385321102
I0
I1
I-1
tp19155
sS'result,i'
p19156
(F1
F0.00014334862385321102
I1
I0
I1
tp19157
sS'videx,hours'
p19158
(F1
F0.00014334862385321102
I1
I0
I1
tp19159
sS'wshow,an'
p19160
(F1
F0.00014334862385321102
I0
I1
I-1
tp19161
sS'anticoagulants,several'
p19162
(F1
F0.00014334862385321102
I0
I1
I-1
tp19163
sS'this,medication'
p19164
(F1
F0.00014334862385321102
I0
I1
I-1
tp19165
sS'with,videx'
p19166
(F0
F0
I1
I1
I0
tp19167
sS'acts,as'
p19168
(F1
F0.00014334862385321102
I1
I0
I1
tp19169
sS'as,have'
p19170
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19171
sS'several-fold,higher'
p19172
(F1
F0.00014334862385321102
I0
I1
I-1
tp19173
sS'in,tumor'
p19174
(F1
F0.00014334862385321102
I0
I1
I-1
tp19175
sS'mptp,produced'
p19176
(F1
F0.00014334862385321102
I1
I0
I1
tp19177
sS'p-glycoprotein,mediated'
p19178
(F1
F0.00014334862385321102
I0
I1
I-1
tp19179
sS'available,for'
p19180
(F1
F0.00028669724770642203
I0
I2
I-2
tp19181
sS'acid,precipitation'
p19182
(F1
F0.00014334862385321102
I0
I1
I-1
tp19183
sS'only,observed'
p19184
(F0
F0
I1
I1
I0
tp19185
sS'dysfunction,or'
p19186
(F1
F0.00014334862385321102
I0
I1
I-1
tp19187
sS'cause,hypotension'
p19188
(F1
F0.00014334862385321102
I0
I1
I-1
tp19189
sS'of,such'
p19190
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp19191
sS'that,strongly'
p19192
(F1
F0.00014334862385321102
I1
I0
I1
tp19193
sS'for,hepatic'
p19194
(F1
F0.00014334862385321102
I0
I1
I-1
tp19195
sS'ns,absorbed'
p19196
(F1
F0.00014334862385321102
I0
I1
I-1
tp19197
sS'dried,and'
p19198
(F1
F0.00014334862385321102
I0
I1
I-1
tp19199
sS'high,as'
p19200
(F1
F0.00028669724770642203
I0
I2
I-2
tp19201
sS'a,highly'
p19202
(F1
F0.00014334862385321102
I1
I0
I1
tp19203
sS'stimulants,including'
p19204
(F1
F0.00014334862385321102
I1
I0
I1
tp19205
sS'as,formulations'
p19206
(F1
F0.00014334862385321102
I1
I0
I1
tp19207
sS'allowed,before'
p19208
(F1
F0.00014334862385321102
I1
I0
I1
tp19209
sS'by,with'
p19210
(F1
F0.00014334862385321102
I1
I0
I1
tp19211
sS'size,mydriasis'
p19212
(F1
F0.00014334862385321102
I1
I0
I1
tp19213
sS'agents,did'
p19214
(F1
F0.00043004587155963305
I0
I3
I-3
tp19215
sS'safety,of'
p19216
(F1
F0.00028669724770642203
I0
I2
I-2
tp19217
sS'by,non-steroidal'
p19218
(F1
F0.00014334862385321102
I1
I0
I1
tp19219
sS'pharmacodynamic,profile'
p19220
(F1
F0.00028669724770642203
I0
I2
I-2
tp19221
sS'safety,or'
p19222
(F1
F0.00043004587155963305
I0
I3
I-3
tp19223
sS'the,biogen'
p19224
(F1
F0.00014334862385321102
I0
I1
I-1
tp19225
sS'concomitantly,patients'
p19226
(F1
F0.00014334862385321102
I1
I0
I1
tp19227
sS'careful,patient'
p19228
(F1
F0.00014334862385321102
I1
I0
I1
tp19229
sS'been,case'
p19230
(F1
F0.00014334862385321102
I0
I1
I-1
tp19231
sS'fat,digestion'
p19232
(F1
F0.00014334862385321102
I0
I1
I-1
tp19233
sS'a,cascade'
p19234
(F1
F0.00014334862385321102
I0
I1
I-1
tp19235
sS'the,cns-depressive'
p19236
(F1
F0.00028669724770642203
I2
I0
I2
tp19237
sS'severe,hyperkalemia'
p19238
(F1
F0.00014334862385321102
I1
I0
I1
tp19239
sS'twelve,healthy'
p19240
(F1
F0.00014334862385321102
I0
I1
I-1
tp19241
sS'life-threatening,reactions'
p19242
(F1
F0.00028669724770642203
I0
I2
I-2
tp19243
sS'therapeutic,supplement'
p19244
(F1
F0.00014334862385321102
I1
I0
I1
tp19245
sS'when,coumarin'
p19246
(F1
F0.00014334862385321102
I1
I0
I1
tp19247
sS'metabolism,studies'
p19248
(F1
F0.00014334862385321102
I0
I1
I-1
tp19249
sS'in,amiodarone-treated'
p19250
(F1
F0.00014334862385321102
I0
I1
I-1
tp19251
sS'control,rbc'
p19252
(F1
F0.00014334862385321102
I0
I1
I-1
tp19253
sS'maintenance,schedule'
p19254
(F1
F0.00014334862385321102
I1
I0
I1
tp19255
sS'total,auc'
p19256
(F1
F0.00014334862385321102
I1
I0
I1
tp19257
sS'on,psychomotor'
p19258
(F1
F0.00014334862385321102
I1
I0
I1
tp19259
sS'therapy,is'
p19260
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp19261
sS'therapy,it'
p19262
(F1
F0.00014334862385321102
I1
I0
I1
tp19263
sS'implantable,contraceptives'
p19264
(F1
F0.00014334862385321102
I1
I0
I1
tp19265
sS'with,inhibition'
p19266
(F1
F0.00014334862385321102
I1
I0
I1
tp19267
sS'additional,titration'
p19268
(F1
F0.00014334862385321102
I1
I0
I1
tp19269
sS'with,intravenous'
p19270
(F1
F0.00014334862385321102
I0
I1
I-1
tp19271
sS'ast,when'
p19272
(F1
F0.00014334862385321102
I1
I0
I1
tp19273
sS'warranted,when'
p19274
(F0
F0
I1
I1
I0
tp19275
sS'a,false-positive'
p19276
(F1
F0.00071674311926605509
I0
I5
I-5
tp19277
sS'prolonged,because'
p19278
(F1
F0.00014334862385321102
I0
I1
I-1
tp19279
sS'and,orally'
p19280
(F1
F0.00014334862385321102
I1
I0
I1
tp19281
sS'an,insufficient'
p19282
(F1
F0.00014334862385321102
I0
I1
I-1
tp19283
sS'of,andtolbutamide'
p19284
(F1
F0.00014334862385321102
I0
I1
I-1
tp19285
sS'for,several'
p19286
(F1
F0.00057339449541284407
I4
I0
I4
tp19287
sS'cause,respiratory'
p19288
(F1
F0.00014334862385321102
I1
I0
I1
tp19289
sS'in,rheumatic'
p19290
(F1
F0.00014334862385321102
I1
I0
I1
tp19291
sS'responding,for'
p19292
(F1
F0.00014334862385321102
I0
I1
I-1
tp19293
sS'mean,renal'
p19294
(F1
F0.00014334862385321102
I1
I0
I1
tp19295
sS'to,about'
p19296
(F0
F0
I1
I1
I0
tp19297
sS'atp,oxaloacetate'
p19298
(F1
F0.00014334862385321102
I0
I1
I-1
tp19299
sS'reverse,transcriptase'
p19300
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp19301
sS'epidermal,necrolysis'
p19302
(F1
F0.00014334862385321102
I0
I1
I-1
tp19303
sS'blockers,of'
p19304
(F1
F0.00014334862385321102
I1
I0
I1
tp19305
sS'the,relationship'
p19306
(F0
F0
I1
I1
I0
tp19307
sS'to,displace'
p19308
(F1
F0.00014334862385321102
I1
I0
I1
tp19309
sS'sum,of'
p19310
(F1
F0.00014334862385321102
I0
I1
I-1
tp19311
sS'absorbed,while'
p19312
(F1
F0.00014334862385321102
I0
I1
I-1
tp19313
sS'preconstricted,with'
p19314
(F1
F0.00014334862385321102
I0
I1
I-1
tp19315
sS'oral,were'
p19316
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19317
sS'seizure,threshold'
p19318
(F1
F0.00014334862385321102
I1
I0
I1
tp19319
sS'allograft,recipients'
p19320
(F1
F0.00014334862385321102
I0
I1
I-1
tp19321
sS'half-life,was'
p19322
(F1
F0.00014334862385321102
I0
I1
I-1
tp19323
sS'leukemia,in'
p19324
(F1
F0.00014334862385321102
I1
I0
I1
tp19325
sS'wish,to'
p19326
(F1
F0.00014334862385321102
I1
I0
I1
tp19327
sS'the,biochemical'
p19328
(F1
F0.00014334862385321102
I0
I1
I-1
tp19329
sS'doses,because'
p19330
(F1
F0.00014334862385321102
I1
I0
I1
tp19331
sS'is,structurally'
p19332
(F1
F0.00028669724770642203
I0
I2
I-2
tp19333
sS'of,should'
p19334
(F0.20000000000000001
F0.00043004587155963305
I9
I6
I3
tp19335
sS'theoretically,l-arginine'
p19336
(F1
F0.00014334862385321102
I1
I0
I1
tp19337
sS'ml,may'
p19338
(F1
F0.00014334862385321102
I0
I1
I-1
tp19339
sS'during,the'
p19340
(F0.047619047619047616
F0.00014334862385321102
I10
I11
I-1
tp19341
sS'on,cyp'
p19342
(F1
F0.00014334862385321102
I0
I1
I-1
tp19343
sS'morphine,analgesia'
p19344
(F1
F0.00014334862385321102
I0
I1
I-1
tp19345
sS'dehydration,secondary'
p19346
(F1
F0.00014334862385321102
I1
I0
I1
tp19347
sS'nitrogen,mustard'
p19348
(F1
F0.00014334862385321102
I0
I1
I-1
tp19349
sS'pentamidine,treatment'
p19350
(F1
F0.00014334862385321102
I0
I1
I-1
tp19351
sS'is,too'
p19352
(F1
F0.00014334862385321102
I0
I1
I-1
tp19353
sS'a,frequent'
p19354
(F1
F0.00014334862385321102
I1
I0
I1
tp19355
sS'in,cardiac'
p19356
(F1
F0.00014334862385321102
I1
I0
I1
tp19357
sS'crixivan,to'
p19358
(F1
F0.00043004587155963305
I3
I0
I3
tp19359
sS'concomitantly,without'
p19360
(F1
F0.00014334862385321102
I0
I1
I-1
tp19361
sS'it,is'
p19362
(F0.3125
F0.0043004587155963305
I63
I33
I30
tp19363
sS'l-phenylalanine,and'
p19364
(F1
F0.00028669724770642203
I2
I0
I2
tp19365
sS'sporanox,nizoral'
p19366
(F1
F0.00014334862385321102
I0
I1
I-1
tp19367
sS'increasing,overall'
p19368
(F1
F0.00014334862385321102
I0
I1
I-1
tp19369
sS'to,do'
p19370
(F1
F0.00014334862385321102
I0
I1
I-1
tp19371
sS'salicylates-salicylates,in'
p19372
(F1
F0.00014334862385321102
I0
I1
I-1
tp19373
sS'either,had'
p19374
(F1
F0.00014334862385321102
I1
I0
I1
tp19375
sS'lamivudine,and'
p19376
(F1
F0.00014334862385321102
I1
I0
I1
tp19377
sS'either,protective'
p19378
(F1
F0.00014334862385321102
I0
I1
I-1
tp19379
sS'agonist,but'
p19380
(F1
F0.00014334862385321102
I1
I0
I1
tp19381
sS'significantly,fewer'
p19382
(F1
F0.00014334862385321102
I0
I1
I-1
tp19383
sS'hydrochlorothiazide,a'
p19384
(F1
F0.00014334862385321102
I0
I1
I-1
tp19385
sS'simultaneously,with'
p19386
(F1
F0.00028669724770642203
I2
I0
I2
tp19387
sS'pharmacokinetics,pharmacodynamics'
p19388
(F1
F0.00014334862385321102
I0
I1
I-1
tp19389
sS'may,raise'
p19390
(F1
F0.00028669724770642203
I2
I0
I2
tp19391
sS'studies,it'
p19392
(F1
F0.00028669724770642203
I0
I2
I-2
tp19393
sS'other,antiepilepsy'
p19394
(F0
F0
I1
I1
I0
tp19395
sS'viral,loads'
p19396
(F1
F0.00014334862385321102
I0
I1
I-1
tp19397
sS'as,appropriate'
p19398
(F1
F0.00014334862385321102
I0
I1
I-1
tp19399
sS'induces,or'
p19400
(F1
F0.00014334862385321102
I0
I1
I-1
tp19401
sS'oxypurines,hypoxanthine'
p19402
(F1
F0.00014334862385321102
I1
I0
I1
tp19403
sS'another,and'
p19404
(F1
F0.00014334862385321102
I1
I0
I1
tp19405
sS'release,formulation'
p19406
(F1
F0.00014334862385321102
I0
I1
I-1
tp19407
sS'serum,levels'
p19408
(F0.67441860465116277
F0.0041571100917431195
I36
I7
I29
tp19409
sS'of,dosage'
p19410
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp19411
sS'the,case-control'
p19412
(F1
F0.00014334862385321102
I1
I0
I1
tp19413
sS'administration,should'
p19414
(F1
F0.00014334862385321102
I1
I0
I1
tp19415
sS'for,an'
p19416
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19417
sS'fortified,with'
p19418
(F0
F0
I1
I1
I0
tp19419
sS'summarized,in'
p19420
(F1
F0.00028669724770642203
I0
I2
I-2
tp19421
sS'muscle,relaxants'
p19422
(F0
F0
I8
I8
I0
tp19423
sS'and,hydroxide'
p19424
(F0
F0
I1
I1
I0
tp19425
sS'some,resulting'
p19426
(F1
F0.00043004587155963305
I3
I0
I3
tp19427
sS'n,maintained'
p19428
(F1
F0.00014334862385321102
I0
I1
I-1
tp19429
sS'concurent,therapy'
p19430
(F1
F0.00014334862385321102
I1
I0
I1
tp19431
sS'and,mm'
p19432
(F1
F0.00014334862385321102
I0
I1
I-1
tp19433
sS'the,tmax'
p19434
(F1
F0.00014334862385321102
I1
I0
I1
tp19435
sS'oral,hormonal'
p19436
(F1
F0.00014334862385321102
I1
I0
I1
tp19437
sS'significant,decreases'
p19438
(F1
F0.00028669724770642203
I2
I0
I2
tp19439
sS'lithium,generally'
p19440
(F1
F0.00071674311926605509
I5
I0
I5
tp19441
sS'purinethol,or'
p19442
(F1
F0.00014334862385321102
I1
I0
I1
tp19443
sS'very,strong'
p19444
(F1
F0.00014334862385321102
I1
I0
I1
tp19445
sS'mg,qhs'
p19446
(F1
F0.00014334862385321102
I0
I1
I-1
tp19447
sS'aripiprazole,is'
p19448
(F1
F0.00028669724770642203
I0
I2
I-2
tp19449
sS'or,lead'
p19450
(F1
F0.00014334862385321102
I1
I0
I1
tp19451
sS'serum,protein'
p19452
(F0
F0
I1
I1
I0
tp19453
sS'thus,lower'
p19454
(F1
F0.00014334862385321102
I1
I0
I1
tp19455
sS'camptosar,would'
p19456
(F1
F0.00014334862385321102
I1
I0
I1
tp19457
sS'received,increases'
p19458
(F1
F0.00014334862385321102
I1
I0
I1
tp19459
sS'vasodilator,activity'
p19460
(F0
F0
I1
I1
I0
tp19461
sS'elevated,liver'
p19462
(F0
F0
I1
I1
I0
tp19463
sS'was,given'
p19464
(F0.14285714285714285
F0.00028669724770642203
I6
I8
I-2
tp19465
sS'ribavirin,see'
p19466
(F1
F0.00014334862385321102
I0
I1
I-1
tp19467
sS'administered,a'
p19468
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19469
sS'thiazide,can'
p19470
(F1
F0.00014334862385321102
I1
I0
I1
tp19471
sS'desmopressin,is'
p19472
(F1
F0.00014334862385321102
I0
I1
I-1
tp19473
sS'hereditary,antithrombin'
p19474
(F1
F0.00014334862385321102
I1
I0
I1
tp19475
sS'information,regarding'
p19476
(F1
F0.00014334862385321102
I0
I1
I-1
tp19477
sS'the,findings'
p19478
(F1
F0.00014334862385321102
I0
I1
I-1
tp19479
sS'nucleus,accumbens'
p19480
(F1
F0.00014334862385321102
I0
I1
I-1
tp19481
sS'years,who'
p19482
(F1
F0.00014334862385321102
I1
I0
I1
tp19483
sS'sheep,interactions'
p19484
(F1
F0.00014334862385321102
I0
I1
I-1
tp19485
sS'mc,decrease'
p19486
(F1
F0.00014334862385321102
I0
I1
I-1
tp19487
sS'of,mixed-function'
p19488
(F1
F0.00014334862385321102
I0
I1
I-1
tp19489
sS'preventing,erythro-fluorocitrate'
p19490
(F1
F0.00014334862385321102
I0
I1
I-1
tp19491
sS'exogenous,on'
p19492
(F1
F0.00014334862385321102
I0
I1
I-1
tp19493
sS'on,therapy'
p19494
(F1
F0.00057339449541284407
I4
I0
I4
tp19495
sS'used,because'
p19496
(F1
F0.00014334862385321102
I1
I0
I1
tp19497
sS'disulfiram,to'
p19498
(F1
F0.00014334862385321102
I1
I0
I1
tp19499
sS'already,receiving'
p19500
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19501
sS'no,effects'
p19502
(F1
F0.00028669724770642203
I0
I2
I-2
tp19503
sS'concurrent,with'
p19504
(F1
F0.00028669724770642203
I2
I0
I2
tp19505
sS'properties,of'
p19506
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp19507
sS'co-administered,with'
p19508
(F0.11764705882352941
F0.00057339449541284407
I19
I15
I4
tp19509
sS'properties,on'
p19510
(F1
F0.00014334862385321102
I0
I1
I-1
tp19511
sS'or,life-threatening'
p19512
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp19513
sS'theophylline,clearance'
p19514
(F1
F0.00014334862385321102
I0
I1
I-1
tp19515
sS'chloride-induced,gastrointestinal'
p19516
(F1
F0.00014334862385321102
I1
I0
I1
tp19517
sS'studies,nitrates'
p19518
(F1
F0.00014334862385321102
I1
I0
I1
tp19519
sS'that,reportedly'
p19520
(F1
F0.00028669724770642203
I2
I0
I2
tp19521
sS'the,mechanisms'
p19522
(F1
F0.00014334862385321102
I0
I1
I-1
tp19523
sS'studies,is'
p19524
(F1
F0.00014334862385321102
I0
I1
I-1
tp19525
sS'citrate,elevations'
p19526
(F1
F0.00014334862385321102
I1
I0
I1
tp19527
sS'clinistix,and'
p19528
(F1
F0.00014334862385321102
I0
I1
I-1
tp19529
sS'a,sprycel'
p19530
(F1
F0.00014334862385321102
I0
I1
I-1
tp19531
sS'positive,test'
p19532
(F1
F0.00028669724770642203
I0
I2
I-2
tp19533
sS'studies,ie'
p19534
(F1
F0.00014334862385321102
I0
I1
I-1
tp19535
sS'concentration,accompanied'
p19536
(F1
F0.00014334862385321102
I1
I0
I1
tp19537
sS'is,manifested'
p19538
(F1
F0.00014334862385321102
I0
I1
I-1
tp19539
sS'studies,in'
p19540
(F0.23076923076923078
F0.0008600917431192661
I10
I16
I-6
tp19541
sS'in,place'
p19542
(F1
F0.00014334862385321102
I1
I0
I1
tp19543
sS'hypotension,which'
p19544
(F1
F0.00014334862385321102
I1
I0
I1
tp19545
sS'with,metabolized'
p19546
(F1
F0.00014334862385321102
I0
I1
I-1
tp19547
sS'contraceptives,coadministration'
p19548
(F1
F0.00014334862385321102
I1
I0
I1
tp19549
sS'administered,h'
p19550
(F1
F0.00014334862385321102
I0
I1
I-1
tp19551
sS'serotonergic,agents'
p19552
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19553
sS'the,pharmacokinetits'
p19554
(F1
F0.00014334862385321102
I0
I1
I-1
tp19555
sS'were,pharmacokinetic'
p19556
(F1
F0.00014334862385321102
I0
I1
I-1
tp19557
sS'of,children'
p19558
(F1
F0.00014334862385321102
I0
I1
I-1
tp19559
sS'same,time'
p19560
(F1
F0.00014334862385321102
I1
I0
I1
tp19561
sS'hypercholesterolemic,patients'
p19562
(F1
F0.00014334862385321102
I1
I0
I1
tp19563
sS'levels,total'
p19564
(F1
F0.00014334862385321102
I1
I0
I1
tp19565
sS'of,usually'
p19566
(F1
F0.00014334862385321102
I1
I0
I1
tp19567
sS'in,creatinine'
p19568
(F1
F0.00014334862385321102
I1
I0
I1
tp19569
sS'assay,methods'
p19570
(F1
F0.00014334862385321102
I0
I1
I-1
tp19571
sS'the,reversal'
p19572
(F1
F0.00014334862385321102
I1
I0
I1
tp19573
sS'nephrotoxic,agents'
p19574
(F1
F0.00028669724770642203
I2
I0
I2
tp19575
sS'antiparkinsonian,drug'
p19576
(F1
F0.00014334862385321102
I1
I0
I1
tp19577
sS'experienced,acute'
p19578
(F1
F0.00014334862385321102
I1
I0
I1
tp19579
sS'several,short-term'
p19580
(F1
F0.00014334862385321102
I0
I1
I-1
tp19581
sS'chains,of'
p19582
(F1
F0.00014334862385321102
I0
I1
I-1
tp19583
sS'represent,the'
p19584
(F1
F0.00014334862385321102
I0
I1
I-1
tp19585
sS'the,molecule'
p19586
(F1
F0.00043004587155963305
I3
I0
I3
tp19587
sS'acetaminophen,tylenol'
p19588
(F1
F0.00014334862385321102
I1
I0
I1
tp19589
sS'be,reliable'
p19590
(F1
F0.00014334862385321102
I1
I0
I1
tp19591
sS'measures,of'
p19592
(F1
F0.00014334862385321102
I0
I1
I-1
tp19593
sS'omnicef,for'
p19594
(F1
F0.00014334862385321102
I0
I1
I-1
tp19595
sS'delay,in'
p19596
(F1
F0.00028669724770642203
I2
I0
I2
tp19597
sS'dysfunction,and'
p19598
(F1
F0.00014334862385321102
I0
I1
I-1
tp19599
sS'of,tbars'
p19600
(F1
F0.00014334862385321102
I1
I0
I1
tp19601
sS'pra,induced'
p19602
(F1
F0.00014334862385321102
I0
I1
I-1
tp19603
sS'standard,deviation'
p19604
(F1
F0.00014334862385321102
I1
I0
I1
tp19605
sS'and,reduces'
p19606
(F1
F0.00028669724770642203
I2
I0
I2
tp19607
sS'acetylsalicylic,acid'
p19608
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp19609
sS'treatment,potentiated'
p19610
(F1
F0.00014334862385321102
I1
I0
I1
tp19611
sS'assay,and'
p19612
(F1
F0.00014334862385321102
I0
I1
I-1
tp19613
sS'before,injection'
p19614
(F1
F0.00014334862385321102
I0
I1
I-1
tp19615
sS'and,reduced'
p19616
(F1
F0.00014334862385321102
I1
I0
I1
tp19617
sS'but,cases'
p19618
(F1
F0.00014334862385321102
I1
I0
I1
tp19619
sS'of,reports'
p19620
(F1
F0.00028669724770642203
I2
I0
I2
tp19621
sS'rat,kidney'
p19622
(F1
F0.00014334862385321102
I0
I1
I-1
tp19623
sS'other,coadministered'
p19624
(F0
F0
I1
I1
I0
tp19625
sS'with,kemstrotm'
p19626
(F1
F0.00014334862385321102
I0
I1
I-1
tp19627
sS'microsomal,drug'
p19628
(F1
F0.00014334862385321102
I1
I0
I1
tp19629
sS'make,normal'
p19630
(F1
F0.00028669724770642203
I0
I2
I-2
tp19631
sS'administered,in'
p19632
(F0.066666666666666666
F0.00014334862385321102
I7
I8
I-1
tp19633
sS'increase,slightly'
p19634
(F1
F0.00014334862385321102
I1
I0
I1
tp19635
sS'was,unaltered'
p19636
(F1
F0.00014334862385321102
I0
I1
I-1
tp19637
sS'cmax,a'
p19638
(F1
F0.00057339449541284407
I4
I0
I4
tp19639
sS'products,associated'
p19640
(F1
F0.00014334862385321102
I0
I1
I-1
tp19641
sS'receiving,preparations'
p19642
(F1
F0.00014334862385321102
I0
I1
I-1
tp19643
sS'experiment,rats'
p19644
(F1
F0.00014334862385321102
I0
I1
I-1
tp19645
sS'oral,users'
p19646
(F1
F0.00014334862385321102
I0
I1
I-1
tp19647
sS'double,the'
p19648
(F1
F0.00014334862385321102
I1
I0
I1
tp19649
sS'qd,days'
p19650
(F0
F0
I1
I1
I0
tp19651
sS'other,concurrent'
p19652
(F1
F0.00028669724770642203
I2
I0
I2
tp19653
sS'diphenoxylate,hcl'
p19654
(F1
F0.00014334862385321102
I1
I0
I1
tp19655
sS'therapy,administration'
p19656
(F1
F0.00014334862385321102
I0
I1
I-1
tp19657
sS'oral,phenytoin'
p19658
(F1
F0.00014334862385321102
I1
I0
I1
tp19659
sS'clozapine,caution'
p19660
(F1
F0.00014334862385321102
I1
I0
I1
tp19661
sS'valdecoxib,mg'
p19662
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp19663
sS'bromide,is'
p19664
(F1
F0.00014334862385321102
I1
I0
I1
tp19665
sS'ratio,inr'
p19666
(F1
F0.00014334862385321102
I1
I0
I1
tp19667
sS'structurally,related'
p19668
(F1
F0.00014334862385321102
I1
I0
I1
tp19669
sS'maximal,hypotension'
p19670
(F1
F0.00014334862385321102
I0
I1
I-1
tp19671
sS'gemfibrozil,other'
p19672
(F1
F0.00014334862385321102
I0
I1
I-1
tp19673
sS'rifabutin,coadministration'
p19674
(F1
F0.00014334862385321102
I1
I0
I1
tp19675
sS'properties,that'
p19676
(F1
F0.00028669724770642203
I2
I0
I2
tp19677
sS'function,eg'
p19678
(F1
F0.00014334862385321102
I1
I0
I1
tp19679
sS'that,concurrent'
p19680
(F1
F0.00028669724770642203
I2
I0
I2
tp19681
sS'metabolizers,suggesting'
p19682
(F1
F0.00014334862385321102
I1
I0
I1
tp19683
sS'containing,maalox'
p19684
(F1
F0.00014334862385321102
I1
I0
I1
tp19685
sS'that,indocin'
p19686
(F1
F0.00014334862385321102
I0
I1
I-1
tp19687
sS'dose,adjustments'
p19688
(F0
F0
I1
I1
I0
tp19689
sS'suggesting,no'
p19690
(F1
F0.00014334862385321102
I0
I1
I-1
tp19691
sS'simulect,with'
p19692
(F1
F0.00014334862385321102
I0
I1
I-1
tp19693
sS'twofold,increase'
p19694
(F1
F0.00028669724770642203
I2
I0
I2
tp19695
sS'vitamin,d2'
p19696
(F1
F0.00043004587155963305
I3
I0
I3
tp19697
sS'vitamin,d3'
p19698
(F1
F0.00057339449541284407
I4
I0
I4
tp19699
sS'minimized,by'
p19700
(F1
F0.00071674311926605509
I5
I0
I5
tp19701
sS'mhd,however'
p19702
(F1
F0.00014334862385321102
I0
I1
I-1
tp19703
sS'l-arginine,supplements'
p19704
(F1
F0.00028669724770642203
I2
I0
I2
tp19705
sS'in,previously'
p19706
(F1
F0.00014334862385321102
I1
I0
I1
tp19707
sS'cmc-cys7,a'
p19708
(F1
F0.00014334862385321102
I0
I1
I-1
tp19709
sS'united,kingdom'
p19710
(F1
F0.00014334862385321102
I1
I0
I1
tp19711
sS'schizophrenia,in'
p19712
(F1
F0.00014334862385321102
I0
I1
I-1
tp19713
sS'cause,heart'
p19714
(F1
F0.00014334862385321102
I1
I0
I1
tp19715
sS'or,methylthiadiazole'
p19716
(F1
F0.00014334862385321102
I0
I1
I-1
tp19717
sS'be,well'
p19718
(F0
F0
I1
I1
I0
tp19719
sS'inhibits,cyp3a4'
p19720
(F0
F0
I1
I1
I0
tp19721
sS'endotoxin-treated,rats'
p19722
(F0
F0
I1
I1
I0
tp19723
sS'to,experience'
p19724
(F1
F0.00014334862385321102
I0
I1
I-1
tp19725
sS'even,more'
p19726
(F1
F0.00014334862385321102
I1
I0
I1
tp19727
sS'without,clinical'
p19728
(F1
F0.00014334862385321102
I1
I0
I1
tp19729
sS'decreased,concentrations'
p19730
(F1
F0.00014334862385321102
I1
I0
I1
tp19731
sS'capsule,twice'
p19732
(F1
F0.00014334862385321102
I0
I1
I-1
tp19733
sS'during,controlled'
p19734
(F1
F0.00014334862385321102
I1
I0
I1
tp19735
sS'drugs,drugs'
p19736
(F1
F0.00028669724770642203
I0
I2
I-2
tp19737
sS'to,campath'
p19738
(F1
F0.00014334862385321102
I0
I1
I-1
tp19739
sS'hours,were'
p19740
(F1
F0.00014334862385321102
I1
I0
I1
tp19741
sS'acidity,does'
p19742
(F1
F0.00014334862385321102
I0
I1
I-1
tp19743
sS'loop,such'
p19744
(F1
F0.00014334862385321102
I1
I0
I1
tp19745
sS'studies,these'
p19746
(F1
F0.00014334862385321102
I0
I1
I-1
tp19747
sS'should,focus'
p19748
(F1
F0.00014334862385321102
I0
I1
I-1
tp19749
sS'relevant,changes'
p19750
(F1
F0.0008600917431192661
I0
I6
I-6
tp19751
sS'natriuresis,and'
p19752
(F1
F0.00014334862385321102
I1
I0
I1
tp19753
sS'has,suggested'
p19754
(F1
F0.00014334862385321102
I0
I1
I-1
tp19755
sS'when,at'
p19756
(F1
F0.00028669724770642203
I2
I0
I2
tp19757
sS'retinyl,acetate'
p19758
(F1
F0.0008600917431192661
I6
I0
I6
tp19759
sS'anti-inflammatory,activity'
p19760
(F1
F0.00028669724770642203
I2
I0
I2
tp19761
sS'for,use'
p19762
(F1
F0.00043004587155963305
I3
I0
I3
tp19763
sS'when,an'
p19764
(F0.5
F0.00028669724770642203
I3
I1
I2
tp19765
sS'changes,occurred'
p19766
(F1
F0.00014334862385321102
I0
I1
I-1
tp19767
sS'pulmonary,symptomatology'
p19768
(F1
F0.00014334862385321102
I1
I0
I1
tp19769
sS'disulfiram-ethanol,reaction'
p19770
(F1
F0.00014334862385321102
I0
I1
I-1
tp19771
sS'minutes,to'
p19772
(F1
F0.00014334862385321102
I0
I1
I-1
tp19773
sS'the,cardiovascular'
p19774
(F1
F0.00057339449541284407
I4
I0
I4
tp19775
sS'attenuates,loss'
p19776
(F1
F0.00014334862385321102
I1
I0
I1
tp19777
sS'concomitant,on'
p19778
(F1
F0.00014334862385321102
I0
I1
I-1
tp19779
sS'ethinyl,estradiol'
p19780
(F0.1111111111111111
F0.00028669724770642203
I10
I8
I2
tp19781
sS'seem,to'
p19782
(F0
F0
I1
I1
I0
tp19783
sS'exposed,to'
p19784
(F1
F0.00014334862385321102
I1
I0
I1
tp19785
sS'concomitant,or'
p19786
(F1
F0.00014334862385321102
I1
I0
I1
tp19787
sS'all,are'
p19788
(F1
F0.00014334862385321102
I0
I1
I-1
tp19789
sS'and,strong'
p19790
(F1
F0.00014334862385321102
I1
I0
I1
tp19791
sS'to,take'
p19792
(F1
F0.00028669724770642203
I2
I0
I2
tp19793
sS'by,up'
p19794
(F1
F0.00071674311926605509
I5
I0
I5
tp19795
sS'blocker,and'
p19796
(F1
F0.00014334862385321102
I1
I0
I1
tp19797
sS'time,in'
p19798
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp19799
sS'more,severe'
p19800
(F1
F0.00043004587155963305
I0
I3
I-3
tp19801
sS'time,is'
p19802
(F1
F0.00043004587155963305
I3
I0
I3
tp19803
sS'because,does'
p19804
(F1
F0.00014334862385321102
I0
I1
I-1
tp19805
sS'a,shift'
p19806
(F1
F0.00014334862385321102
I0
I1
I-1
tp19807
sS'c12hr,by'
p19808
(F1
F0.00014334862385321102
I1
I0
I1
tp19809
sS'remainder,no'
p19810
(F1
F0.00014334862385321102
I0
I1
I-1
tp19811
sS'rhabdomyolysis,have'
p19812
(F1
F0.00014334862385321102
I0
I1
I-1
tp19813
sS'subjects,nor'
p19814
(F1
F0.00014334862385321102
I0
I1
I-1
tp19815
sS'is,highly'
p19816
(F1
F0.00014334862385321102
I1
I0
I1
tp19817
sS'respectto,safety'
p19818
(F1
F0.00014334862385321102
I0
I1
I-1
tp19819
sS'still,kill'
p19820
(F1
F0.00014334862385321102
I1
I0
I1
tp19821
sS'studies,to'
p19822
(F1
F0.00043004587155963305
I0
I3
I-3
tp19823
sS'render,these'
p19824
(F1
F0.00014334862385321102
I1
I0
I1
tp19825
sS'experiences,of'
p19826
(F1
F0.00014334862385321102
I1
I0
I1
tp19827
sS'serotoninergic,agents'
p19828
(F1
F0.00014334862385321102
I1
I0
I1
tp19829
sS'of,busulfex'
p19830
(F1
F0.00014334862385321102
I1
I0
I1
tp19831
sS'which,were'
p19832
(F1
F0.00014334862385321102
I1
I0
I1
tp19833
sS'human,cells'
p19834
(F1
F0.00014334862385321102
I0
I1
I-1
tp19835
sS'pediapred,others'
p19836
(F1
F0.00014334862385321102
I0
I1
I-1
tp19837
sS'antagonist,has'
p19838
(F1
F0.00014334862385321102
I1
I0
I1
tp19839
sS'administered,agents'
p19840
(F0
F0
I1
I1
I0
tp19841
sS'pcp,induced'
p19842
(F1
F0.00014334862385321102
I0
I1
I-1
tp19843
sS'in,ventricular'
p19844
(F1
F0.00014334862385321102
I0
I1
I-1
tp19845
sS'by,several'
p19846
(F1
F0.00014334862385321102
I1
I0
I1
tp19847
sS'meclofenamate,sodium'
p19848
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp19849
sS'hc1,concomitant'
p19850
(F1
F0.00014334862385321102
I1
I0
I1
tp19851
sS'since,the'
p19852
(F0.14285714285714285
F0.00028669724770642203
I8
I6
I2
tp19853
sS'to,that'
p19854
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp19855
sS'agonists,in'
p19856
(F1
F0.00014334862385321102
I1
I0
I1
tp19857
sS'at,approximately'
p19858
(F1
F0.00014334862385321102
I1
I0
I1
tp19859
sS'chromatin,and'
p19860
(F1
F0.00014334862385321102
I1
I0
I1
tp19861
sS'degree,in'
p19862
(F1
F0.00014334862385321102
I0
I1
I-1
tp19863
sS'of,gemzar'
p19864
(F1
F0.00014334862385321102
I0
I1
I-1
tp19865
sS'nicotinic,acid'
p19866
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp19867
sS'and,commentaries'
p19868
(F1
F0.00014334862385321102
I0
I1
I-1
tp19869
sS'with,with'
p19870
(F0
F0
I2
I2
I0
tp19871
sS'pronounced,than'
p19872
(F1
F0.00014334862385321102
I0
I1
I-1
tp19873
sS'an,immune'
p19874
(F1
F0.00014334862385321102
I0
I1
I-1
tp19875
sS'b,has'
p19876
(F1
F0.00014334862385321102
I1
I0
I1
tp19877
sS'indomethacin,blunts'
p19878
(F1
F0.00014334862385321102
I1
I0
I1
tp19879
sS'until,therapy'
p19880
(F1
F0.00014334862385321102
I1
I0
I1
tp19881
sS'secretion,stimulated'
p19882
(F1
F0.00014334862385321102
I0
I1
I-1
tp19883
sS'medications,can'
p19884
(F1
F0.00014334862385321102
I1
I0
I1
tp19885
sS'pyrantel,antiminth'
p19886
(F1
F0.00014334862385321102
I1
I0
I1
tp19887
sS'vardenafil,experienced'
p19888
(F1
F0.00014334862385321102
I1
I0
I1
tp19889
sS'mesylate,was'
p19890
(F1
F0.00014334862385321102
I1
I0
I1
tp19891
sS'interaction,include'
p19892
(F1
F0.00028669724770642203
I0
I2
I-2
tp19893
sS'is,greater'
p19894
(F1
F0.00043004587155963305
I3
I0
I3
tp19895
sS'current,responses'
p19896
(F1
F0.00014334862385321102
I1
I0
I1
tp19897
sS'bile-acidsequestering,agent'
p19898
(F1
F0.00014334862385321102
I0
I1
I-1
tp19899
sS'and,prolongation'
p19900
(F1
F0.00071674311926605509
I5
I0
I5
tp19901
sS'expected,when'
p19902
(F1
F0.00014334862385321102
I1
I0
I1
tp19903
sS'including,and'
p19904
(F0
F0
I4
I4
I0
tp19905
sS'by,nor'
p19906
(F1
F0.00014334862385321102
I0
I1
I-1
tp19907
sS'gel,on'
p19908
(F1
F0.00014334862385321102
I0
I1
I-1
tp19909
sS'index,apoptotic'
p19910
(F1
F0.00014334862385321102
I0
I1
I-1
tp19911
sS'medicines,with'
p19912
(F0
F0
I1
I1
I0
tp19913
sS'have,used'
p19914
(F1
F0.00028669724770642203
I0
I2
I-2
tp19915
sS'contraceptives,an'
p19916
(F1
F0.00014334862385321102
I1
I0
I1
tp19917
sS'furthermore,caution'
p19918
(F1
F0.00014334862385321102
I0
I1
I-1
tp19919
sS'both,agents'
p19920
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp19921
sS'change,the'
p19922
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp19923
sS'clearance,and'
p19924
(F0.88235294117647056
F0.0021502293577981653
I16
I1
I15
tp19925
sS'fibrillation,when'
p19926
(F1
F0.00014334862385321102
I1
I0
I1
tp19927
sS'less,marked'
p19928
(F1
F0.00028669724770642203
I0
I2
I-2
tp19929
sS'agent,has'
p19930
(F1
F0.00043004587155963305
I3
I0
I3
tp19931
sS'permit,reductions'
p19932
(F1
F0.00014334862385321102
I0
I1
I-1
tp19933
sS'g,resulted'
p19934
(F1
F0.00014334862385321102
I1
I0
I1
tp19935
sS'two,metabolites'
p19936
(F1
F0.00014334862385321102
I0
I1
I-1
tp19937
sS'is,via'
p19938
(F1
F0.00014334862385321102
I0
I1
I-1
tp19939
sS'a,non-significantly'
p19940
(F1
F0.00014334862385321102
I0
I1
I-1
tp19941
sS'pregnancy,registry'
p19942
(F1
F0.00014334862385321102
I0
I1
I-1
tp19943
sS'euthyroid,state'
p19944
(F1
F0.00014334862385321102
I0
I1
I-1
tp19945
sS'severe,hypotension'
p19946
(F1
F0.00043004587155963305
I3
I0
I3
tp19947
sS'with,maois'
p19948
(F1
F0.00014334862385321102
I1
I0
I1
tp19949
sS'dose-dependent,inhibition'
p19950
(F1
F0.00014334862385321102
I1
I0
I1
tp19951
sS'suggested,to'
p19952
(F0
F0
I1
I1
I0
tp19953
sS'dehydrogenase,inhibition'
p19954
(F1
F0.00014334862385321102
I1
I0
I1
tp19955
sS'death,associated'
p19956
(F1
F0.00014334862385321102
I1
I0
I1
tp19957
sS'diamond,trials'
p19958
(F1
F0.00028669724770642203
I0
I2
I-2
tp19959
sS'nicotine,may'
p19960
(F1
F0.00014334862385321102
I1
I0
I1
tp19961
sS'two,percent'
p19962
(F1
F0.00028669724770642203
I2
I0
I2
tp19963
sS'may,change'
p19964
(F0
F0
I1
I1
I0
tp19965
sS'with,triamterene'
p19966
(F1
F0.00014334862385321102
I0
I1
I-1
tp19967
sS'mg,doses'
p19968
(F1
F0.00014334862385321102
I1
I0
I1
tp19969
sS'aprepitant,and'
p19970
(F0
F0
I1
I1
I0
tp19971
sS'the,primary'
p19972
(F1
F0.00071674311926605509
I5
I0
I5
tp19973
sS'onto,the'
p19974
(F1
F0.00014334862385321102
I1
I0
I1
tp19975
sS'all,been'
p19976
(F1
F0.00014334862385321102
I0
I1
I-1
tp19977
sS'indocin,should'
p19978
(F1
F0.00014334862385321102
I1
I0
I1
tp19979
sS'a,true'
p19980
(F1
F0.00014334862385321102
I1
I0
I1
tp19981
sS'amphetamines,inhibit'
p19982
(F1
F0.00028669724770642203
I2
I0
I2
tp19983
sS'solution,or'
p19984
(F1
F0.00014334862385321102
I0
I1
I-1
tp19985
sS'an,aed'
p19986
(F1
F0.00014334862385321102
I0
I1
I-1
tp19987
sS'psychoactive,medications'
p19988
(F1
F0.00014334862385321102
I1
I0
I1
tp19989
sS'neither,nor'
p19990
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19991
sS'phenytoin,dilantin'
p19992
(F1
F0.00014334862385321102
I1
I0
I1
tp19993
sS'only,minor'
p19994
(F1
F0.00014334862385321102
I1
I0
I1
tp19995
sS'a4,would'
p19996
(F1
F0.00014334862385321102
I1
I0
I1
tp19997
sS'solution,of'
p19998
(F1
F0.00014334862385321102
I0
I1
I-1
tp19999
sS'ephedrine,may'
p20000
(F1
F0.00014334862385321102
I1
I0
I1
tp20001
sS'hours,should'
p20002
(F1
F0.00043004587155963305
I3
I0
I3
tp20003
sS'bradycardia,has'
p20004
(F1
F0.00014334862385321102
I0
I1
I-1
tp20005
sS'carefully,and'
p20006
(F1
F0.00014334862385321102
I1
I0
I1
tp20007
sS'cyp3a4,pathway'
p20008
(F1
F0.00014334862385321102
I1
I0
I1
tp20009
sS'could,be'
p20010
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp20011
sS'deltasone,orasone'
p20012
(F1
F0.00014334862385321102
I0
I1
I-1
tp20013
sS'available,about'
p20014
(F1
F0.00028669724770642203
I0
I2
I-2
tp20015
sS'derivatives,or'
p20016
(F1
F0.00028669724770642203
I2
I0
I2
tp20017
sS'similarly,inhibit'
p20018
(F1
F0.00014334862385321102
I1
I0
I1
tp20019
sS'similarity,of'
p20020
(F1
F0.00014334862385321102
I0
I1
I-1
tp20021
sS'density,in'
p20022
(F1
F0.00014334862385321102
I0
I1
I-1
tp20023
sS'products,h2-antagonists'
p20024
(F1
F0.00014334862385321102
I0
I1
I-1
tp20025
sS'of,ganoderma'
p20026
(F1
F0.00014334862385321102
I0
I1
I-1
tp20027
sS'simultaneously,or'
p20028
(F0
F0
I1
I1
I0
tp20029
sS'n-multistix,sg'
p20030
(F1
F0.00014334862385321102
I0
I1
I-1
tp20031
sS'depressants,may'
p20032
(F0
F0
I4
I4
I0
tp20033
sS'positive,level'
p20034
(F1
F0.00014334862385321102
I1
I0
I1
tp20035
sS'vasodilation,is'
p20036
(F1
F0.00014334862385321102
I0
I1
I-1
tp20037
sS'surgery,or'
p20038
(F1
F0.00014334862385321102
I0
I1
I-1
tp20039
sS'digoxin,plasma'
p20040
(F1
F0.00014334862385321102
I0
I1
I-1
tp20041
sS'were,above'
p20042
(F1
F0.00014334862385321102
I1
I0
I1
tp20043
sS'defined,medium'
p20044
(F1
F0.00014334862385321102
I0
I1
I-1
tp20045
sS'hormonal,may'
p20046
(F1
F0.0012901376146788992
I9
I0
I9
tp20047
sS'by,nonsteroidal'
p20048
(F1
F0.00014334862385321102
I1
I0
I1
tp20049
sS'could,create'
p20050
(F1
F0.00043004587155963305
I0
I3
I-3
tp20051
sS'metoclopramide,when'
p20052
(F1
F0.00014334862385321102
I1
I0
I1
tp20053
sS'urinary,excretion'
p20054
(F0.5
F0.0008600917431192661
I9
I3
I6
tp20055
sS'racemic,were'
p20056
(F1
F0.00014334862385321102
I0
I1
I-1
tp20057
sS'shorter,durations'
p20058
(F1
F0.00014334862385321102
I1
I0
I1
tp20059
sS'and,efficacy'
p20060
(F0.25
F0.00028669724770642203
I5
I3
I2
tp20061
sS'of,upper'
p20062
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp20063
sS'inducers,can'
p20064
(F1
F0.00014334862385321102
I1
I0
I1
tp20065
sS'and,thereby'
p20066
(F1
F0.00014334862385321102
I1
I0
I1
tp20067
sS'of,felbatol'
p20068
(F0
F0
I4
I4
I0
tp20069
sS'to,dosing'
p20070
(F1
F0.00057339449541284407
I4
I0
I4
tp20071
sS'any,patient'
p20072
(F1
F0.00014334862385321102
I0
I1
I-1
tp20073
sS'interactions,benzodiazepines'
p20074
(F1
F0.00014334862385321102
I1
I0
I1
tp20075
sS'combination,outweigh'
p20076
(F1
F0.00014334862385321102
I1
I0
I1
tp20077
sS'above,ng'
p20078
(F1
F0.00014334862385321102
I1
I0
I1
tp20079
sS'a,potentiation'
p20080
(F1
F0.00014334862385321102
I1
I0
I1
tp20081
sS'over,minutes'
p20082
(F1
F0.00014334862385321102
I0
I1
I-1
tp20083
sS'use,should'
p20084
(F1
F0.00014334862385321102
I0
I1
I-1
tp20085
sS'increases,plasma'
p20086
(F1
F0.00014334862385321102
I0
I1
I-1
tp20087
sS'fo,the'
p20088
(F1
F0.00014334862385321102
I0
I1
I-1
tp20089
sS'median,of'
p20090
(F1
F0.00014334862385321102
I1
I0
I1
tp20091
sS'with,in'
p20092
(F0.058823529411764705
F0.00014334862385321102
I9
I8
I1
tp20093
sS'duloxetine,clinical'
p20094
(F1
F0.00014334862385321102
I0
I1
I-1
tp20095
sS'adjustment,required'
p20096
(F1
F0.00014334862385321102
I1
I0
I1
tp20097
sS'with,if'
p20098
(F1
F0.00014334862385321102
I1
I0
I1
tp20099
sS'have,little'
p20100
(F1
F0.00014334862385321102
I0
I1
I-1
tp20101
sS'skeletal,myopathy'
p20102
(F1
F0.00014334862385321102
I0
I1
I-1
tp20103
sS'mefloquine,on'
p20104
(F1
F0.00014334862385321102
I1
I0
I1
tp20105
sS'acute,increase'
p20106
(F1
F0.00014334862385321102
I0
I1
I-1
tp20107
sS'animal,experience'
p20108
(F1
F0.00014334862385321102
I1
I0
I1
tp20109
sS'with,is'
p20110
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp20111
sS'with,it'
p20112
(F1
F0.00028669724770642203
I0
I2
I-2
tp20113
sS'with,iv'
p20114
(F1
F0.00014334862385321102
I0
I1
I-1
tp20115
sS'a,non-'
p20116
(F1
F0.00014334862385321102
I1
I0
I1
tp20117
sS'rarely,reported'
p20118
(F1
F0.00028669724770642203
I2
I0
I2
tp20119
sS'normal,variability'
p20120
(F1
F0.00014334862385321102
I1
I0
I1
tp20121
sS'three,weeks'
p20122
(F1
F0.00028669724770642203
I2
I0
I2
tp20123
sS'by,stimulating'
p20124
(F1
F0.00014334862385321102
I0
I1
I-1
tp20125
sS'patients,under'
p20126
(F1
F0.00014334862385321102
I1
I0
I1
tp20127
sS'is,very'
p20128
(F1
F0.00014334862385321102
I0
I1
I-1
tp20129
sS'are,case'
p20130
(F1
F0.00014334862385321102
I1
I0
I1
tp20131
sS'clearance,has'
p20132
(F1
F0.00014334862385321102
I0
I1
I-1
tp20133
sS'nalfon,has'
p20134
(F1
F0.00014334862385321102
I1
I0
I1
tp20135
sS'significant,adverse'
p20136
(F1
F0.00014334862385321102
I0
I1
I-1
tp20137
sS'solution,was'
p20138
(F1
F0.00014334862385321102
I0
I1
I-1
tp20139
sS'activity,large'
p20140
(F1
F0.00014334862385321102
I0
I1
I-1
tp20141
sS'for,therapeutic'
p20142
(F1
F0.00014334862385321102
I0
I1
I-1
tp20143
sS'variable,and'
p20144
(F1
F0.00014334862385321102
I0
I1
I-1
tp20145
sS'the,required'
p20146
(F1
F0.00014334862385321102
I1
I0
I1
tp20147
sS'be,seen'
p20148
(F1
F0.00028669724770642203
I2
I0
I2
tp20149
sS'with,tikosyn'
p20150
(F0
F0
I3
I3
I0
tp20151
sS'excessive,release'
p20152
(F1
F0.00028669724770642203
I0
I2
I-2
tp20153
sS'elevated,by'
p20154
(F1
F0.00014334862385321102
I0
I1
I-1
tp20155
sS'ns,may'
p20156
(F1
F0.00014334862385321102
I1
I0
I1
tp20157
sS'concerning,have'
p20158
(F1
F0.00014334862385321102
I1
I0
I1
tp20159
sS'uptake,may'
p20160
(F1
F0.00014334862385321102
I1
I0
I1
tp20161
sS'colchicine,para-aminosalicylic'
p20162
(F1
F0.00014334862385321102
I1
I0
I1
tp20163
sS'cmax,cmin'
p20164
(F1
F0.00014334862385321102
I0
I1
I-1
tp20165
sS'period,with'
p20166
(F1
F0.00014334862385321102
I0
I1
I-1
tp20167
sS'and,including'
p20168
(F1
F0.00014334862385321102
I0
I1
I-1
tp20169
sS'vascularity,of'
p20170
(F1
F0.00014334862385321102
I0
I1
I-1
tp20171
sS'potentials,were'
p20172
(F1
F0.00014334862385321102
I0
I1
I-1
tp20173
sS'response,duration'
p20174
(F1
F0.00014334862385321102
I1
I0
I1
tp20175
sS'class,including'
p20176
(F0
F0
I1
I1
I0
tp20177
sS'least,minutes'
p20178
(F1
F0.00028669724770642203
I2
I0
I2
tp20179
sS'and,did'
p20180
(F0.81818181818181823
F0.0012901376146788992
I1
I10
I-9
tp20181
sS'four,resulted'
p20182
(F1
F0.00014334862385321102
I1
I0
I1
tp20183
sS'experimental,soft-gelatin'
p20184
(F1
F0.00014334862385321102
I1
I0
I1
tp20185
sS'prostatectomy,radiation'
p20186
(F1
F0.00014334862385321102
I0
I1
I-1
tp20187
sS'a,schedule'
p20188
(F1
F0.00014334862385321102
I1
I0
I1
tp20189
sS'cyp1a2,results'
p20190
(F1
F0.00014334862385321102
I1
I0
I1
tp20191
sS'metabolite,and'
p20192
(F1
F0.00014334862385321102
I0
I1
I-1
tp20193
sS'hazard,to'
p20194
(F0
F0
I1
I1
I0
tp20195
sS'are,advised'
p20196
(F1
F0.00014334862385321102
I1
I0
I1
tp20197
sS'from,marine'
p20198
(F1
F0.00014334862385321102
I0
I1
I-1
tp20199
sS'the,hepatoxicity'
p20200
(F1
F0.00014334862385321102
I1
I0
I1
tp20201
sS'mcg,once'
p20202
(F1
F0.00028669724770642203
I0
I2
I-2
tp20203
sS'the,aucs'
p20204
(F1
F0.00014334862385321102
I0
I1
I-1
tp20205
sS'of,compounds'
p20206
(F1
F0.00043004587155963305
I3
I0
I3
tp20207
sS'to,define'
p20208
(F1
F0.00014334862385321102
I0
I1
I-1
tp20209
sS'receive,oral'
p20210
(F1
F0.00014334862385321102
I0
I1
I-1
tp20211
sS'dosage,and'
p20212
(F1
F0.00028669724770642203
I0
I2
I-2
tp20213
sS'be,alerted'
p20214
(F1
F0.00014334862385321102
I0
I1
I-1
tp20215
sS'and,sigma-2'
p20216
(F1
F0.00014334862385321102
I0
I1
I-1
tp20217
sS'chelation,complexes'
p20218
(F1
F0.00014334862385321102
I1
I0
I1
tp20219
sS'with,respect'
p20220
(F1
F0.00014334862385321102
I0
I1
I-1
tp20221
sS'olanzapine,coadministration'
p20222
(F1
F0.00014334862385321102
I1
I0
I1
tp20223
sS'additionally,anti-malarial'
p20224
(F1
F0.00014334862385321102
I1
I0
I1
tp20225
sS'decrease,renal'
p20226
(F1
F0.00028669724770642203
I2
I0
I2
tp20227
sS'and,xanthine'
p20228
(F1
F0.00014334862385321102
I1
I0
I1
tp20229
sS'measuring,locomotor'
p20230
(F1
F0.00014334862385321102
I0
I1
I-1
tp20231
sS'quinidine,and'
p20232
(F0
F0
I1
I1
I0
tp20233
sS'is,known'
p20234
(F0.25
F0.00028669724770642203
I5
I3
I2
tp20235
sS'than,expected'
p20236
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp20237
sS'to,hypoglycemia'
p20238
(F1
F0.00028669724770642203
I0
I2
I-2
tp20239
sS'patients,mixed'
p20240
(F1
F0.00014334862385321102
I0
I1
I-1
tp20241
sS'initiated,to'
p20242
(F1
F0.00014334862385321102
I1
I0
I1
tp20243
sS'inc,demonstrated'
p20244
(F1
F0.00014334862385321102
I1
I0
I1
tp20245
sS'of,discontinuing'
p20246
(F1
F0.00014334862385321102
I1
I0
I1
tp20247
sS'the,label'
p20248
(F1
F0.00014334862385321102
I1
I0
I1
tp20249
sS'and,fbs'
p20250
(F1
F0.00014334862385321102
I1
I0
I1
tp20251
sS'avoided,as'
p20252
(F1
F0.00043004587155963305
I0
I3
I-3
tp20253
sS'a,mg'
p20254
(F0.14285714285714285
F0.00043004587155963305
I12
I9
I3
tp20255
sS'receiving,crixivan'
p20256
(F1
F0.00014334862385321102
I1
I0
I1
tp20257
sS'and,this'
p20258
(F0
F0
I1
I1
I0
tp20259
sS'meaningful,interactions'
p20260
(F1
F0.00014334862385321102
I0
I1
I-1
tp20261
sS'verapamil,concomitant'
p20262
(F1
F0.00014334862385321102
I0
I1
I-1
tp20263
sS'bid,were'
p20264
(F1
F0.00014334862385321102
I0
I1
I-1
tp20265
sS'of,enhancing'
p20266
(F1
F0.00014334862385321102
I1
I0
I1
tp20267
sS'received,one'
p20268
(F1
F0.00014334862385321102
I0
I1
I-1
tp20269
sS'failure,and'
p20270
(F0
F0
I1
I1
I0
tp20271
sS'hcl,should'
p20272
(F1
F0.00014334862385321102
I1
I0
I1
tp20273
sS'rifampin,cyp3a4'
p20274
(F1
F0.00014334862385321102
I0
I1
I-1
tp20275
sS'study,both'
p20276
(F1
F0.00014334862385321102
I0
I1
I-1
tp20277
sS'overlap,to'
p20278
(F1
F0.00014334862385321102
I0
I1
I-1
tp20279
sS'bound,such'
p20280
(F1
F0.00014334862385321102
I0
I1
I-1
tp20281
sS'at,different'
p20282
(F1
F0.00028669724770642203
I0
I2
I-2
tp20283
sS'including,yields'
p20284
(F1
F0.00014334862385321102
I1
I0
I1
tp20285
sS'coagulation,assays'
p20286
(F1
F0.00014334862385321102
I0
I1
I-1
tp20287
sS'a,five-fold'
p20288
(F1
F0.00014334862385321102
I1
I0
I1
tp20289
sS'calan,sr'
p20290
(F1
F0.00014334862385321102
I1
I0
I1
tp20291
sS'received,a'
p20292
(F1
F0.00014334862385321102
I0
I1
I-1
tp20293
sS'ritonavir,and'
p20294
(F1
F0.00014334862385321102
I1
I0
I1
tp20295
sS'tested,more'
p20296
(F1
F0.00014334862385321102
I0
I1
I-1
tp20297
sS'hours,following'
p20298
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp20299
sS'or,mg'
p20300
(F0.52000000000000002
F0.0018635321100917432
I6
I19
I-13
tp20301
sS'carbamazepine,steady-state'
p20302
(F1
F0.00014334862385321102
I0
I1
I-1
tp20303
sS'provide,information'
p20304
(F1
F0.00014334862385321102
I0
I1
I-1
tp20305
sS'individuals,are'
p20306
(F1
F0.00028669724770642203
I0
I2
I-2
tp20307
sS'of,deficiency'
p20308
(F1
F0.00014334862385321102
I0
I1
I-1
tp20309
sS'a,rapid'
p20310
(F1
F0.00028669724770642203
I2
I0
I2
tp20311
sS'not,metabolized'
p20312
(F1
F0.00028669724770642203
I0
I2
I-2
tp20313
sS'dysfunction,hyperpyrexia'
p20314
(F1
F0.00014334862385321102
I1
I0
I1
tp20315
sS'treatment,and'
p20316
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp20317
sS'dfur,fu'
p20318
(F1
F0.00014334862385321102
I0
I1
I-1
tp20319
sS'fecal,and'
p20320
(F1
F0.00014334862385321102
I0
I1
I-1
tp20321
sS'bronchodilators,has'
p20322
(F1
F0.00014334862385321102
I1
I0
I1
tp20323
sS'and,ulcerative'
p20324
(F1
F0.00014334862385321102
I1
I0
I1
tp20325
sS'and,potassium-sparing'
p20326
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp20327
sS'effect,relationship'
p20328
(F1
F0.00043004587155963305
I3
I0
I3
tp20329
sS'pgp,increased'
p20330
(F1
F0.00014334862385321102
I0
I1
I-1
tp20331
sS'hypotensive,effects'
p20332
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp20333
sS'reducing,the'
p20334
(F1
F0.00028669724770642203
I2
I0
I2
tp20335
sS'similar,length'
p20336
(F1
F0.00014334862385321102
I1
I0
I1
tp20337
sS'cases,a'
p20338
(F1
F0.00014334862385321102
I1
I0
I1
tp20339
sS'of,under'
p20340
(F1
F0.00014334862385321102
I1
I0
I1
tp20341
sS'chromatographic,assay'
p20342
(F1
F0.00014334862385321102
I0
I1
I-1
tp20343
sS'post-heparin,lipolytic'
p20344
(F1
F0.00014334862385321102
I1
I0
I1
tp20345
sS'pgf2alpha,produced'
p20346
(F1
F0.00014334862385321102
I1
I0
I1
tp20347
sS'alteration,of'
p20348
(F0
F0
I1
I1
I0
tp20349
sS'are,altered'
p20350
(F1
F0.00014334862385321102
I1
I0
I1
tp20351
sS'the,active'
p20352
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp20353
sS'cautiously,as'
p20354
(F1
F0.00014334862385321102
I0
I1
I-1
tp20355
sS'obtained,when'
p20356
(F1
F0.00028669724770642203
I2
I0
I2
tp20357
sS'of,hours'
p20358
(F1
F0.00014334862385321102
I1
I0
I1
tp20359
sS'severity,of'
p20360
(F1
F0.00057339449541284407
I4
I0
I4
tp20361
sS'plasma,concentrations'
p20362
(F0.2982456140350877
F0.0048738532110091746
I74
I40
I34
tp20363
sS'is,adsorption'
p20364
(F1
F0.00014334862385321102
I1
I0
I1
tp20365
sS'aerosol,with'
p20366
(F1
F0.00014334862385321102
I1
I0
I1
tp20367
sS'receiving,oral'
p20368
(F0
F0
I2
I2
I0
tp20369
sS'not,advisable'
p20370
(F1
F0.00014334862385321102
I1
I0
I1
tp20371
sS'tolerance,min'
p20372
(F1
F0.00014334862385321102
I0
I1
I-1
tp20373
sS'study,showed'
p20374
(F1
F0.00014334862385321102
I0
I1
I-1
tp20375
sS'regimen,particularly'
p20376
(F1
F0.00014334862385321102
I1
I0
I1
tp20377
sS'out,studies'
p20378
(F1
F0.00014334862385321102
I0
I1
I-1
tp20379
sS'when,extended'
p20380
(F1
F0.00014334862385321102
I0
I1
I-1
tp20381
sS'mg,each'
p20382
(F0
F0
I1
I1
I0
tp20383
sS'or,administration'
p20384
(F1
F0.00014334862385321102
I0
I1
I-1
tp20385
sS'and,epidural'
p20386
(F1
F0.00014334862385321102
I1
I0
I1
tp20387
sS'core,temperature'
p20388
(F0
F0
I1
I1
I0
tp20389
sS'while,additional'
p20390
(F1
F0.00014334862385321102
I0
I1
I-1
tp20391
sS'p,decreased'
p20392
(F1
F0.00014334862385321102
I1
I0
I1
tp20393
sS'free,is'
p20394
(F1
F0.00014334862385321102
I1
I0
I1
tp20395
sS'oral,the'
p20396
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp20397
sS'in,substantial'
p20398
(F1
F0.00028669724770642203
I2
I0
I2
tp20399
sS'for,additional'
p20400
(F1
F0.00014334862385321102
I1
I0
I1
tp20401
sS'reported,that'
p20402
(F0.75
F0.0008600917431192661
I7
I1
I6
tp20403
sS'rapid,contraction'
p20404
(F1
F0.00014334862385321102
I0
I1
I-1
tp20405
sS'ergosterol,the'
p20406
(F1
F0.00014334862385321102
I0
I1
I-1
tp20407
sS'therapy,eg'
p20408
(F0
F0
I1
I1
I0
tp20409
sS'contraceptives,multiple'
p20410
(F1
F0.00028669724770642203
I0
I2
I-2
tp20411
sS'most,patients'
p20412
(F1
F0.00014334862385321102
I0
I1
I-1
tp20413
sS'times,as'
p20414
(F1
F0.00028669724770642203
I0
I2
I-2
tp20415
sS'that,observed'
p20416
(F1
F0.00057339449541284407
I4
I0
I4
tp20417
sS'injury,or'
p20418
(F1
F0.00014334862385321102
I0
I1
I-1
tp20419
sS'no,significant'
p20420
(F0.80952380952380953
F0.0048738532110091746
I4
I38
I-34
tp20421
sS'and,blood'
p20422
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp20423
sS'that,mtx'
p20424
(F1
F0.00014334862385321102
I0
I1
I-1
tp20425
sS'plus,mg'
p20426
(F1
F0.00014334862385321102
I0
I1
I-1
tp20427
sS'significantly,greater'
p20428
(F1
F0.00014334862385321102
I0
I1
I-1
tp20429
sS'nitrates,nifedipine'
p20430
(F1
F0.00014334862385321102
I0
I1
I-1
tp20431
sS'self-injection,of'
p20432
(F1
F0.00014334862385321102
I0
I1
I-1
tp20433
sS'pharmacokinetics,and'
p20434
(F1
F0.0008600917431192661
I0
I6
I-6
tp20435
sS'for,volatile'
p20436
(F1
F0.00014334862385321102
I1
I0
I1
tp20437
sS'and,lethality'
p20438
(F1
F0.00014334862385321102
I0
I1
I-1
tp20439
sS'thiazides,thiazides'
p20440
(F1
F0.00043004587155963305
I0
I3
I-3
tp20441
sS'of,complicated'
p20442
(F1
F0.00014334862385321102
I0
I1
I-1
tp20443
sS'or,generalized'
p20444
(F1
F0.00014334862385321102
I0
I1
I-1
tp20445
sS'short-term,controlled'
p20446
(F1
F0.00028669724770642203
I0
I2
I-2
tp20447
sS'in,alcoholics'
p20448
(F1
F0.00014334862385321102
I0
I1
I-1
tp20449
sS'gastrointestinal,ulceration'
p20450
(F1
F0.00014334862385321102
I1
I0
I1
tp20451
sS'different,route'
p20452
(F1
F0.00014334862385321102
I0
I1
I-1
tp20453
sS'inhibitors,thereby'
p20454
(F1
F0.00014334862385321102
I1
I0
I1
tp20455
sS'homocysteine,excretion'
p20456
(F1
F0.00014334862385321102
I0
I1
I-1
tp20457
sS'be,made'
p20458
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp20459
sS'administered,starlix'
p20460
(F1
F0.00014334862385321102
I0
I1
I-1
tp20461
sS'mean,t'
p20462
(F1
F0.00014334862385321102
I1
I0
I1
tp20463
sS'the,diabetic'
p20464
(F1
F0.00014334862385321102
I0
I1
I-1
tp20465
sS'blockers,such'
p20466
(F0
F0
I1
I1
I0
tp20467
sS'mean,c'
p20468
(F0
F0
I1
I1
I0
tp20469
sS'inhibitors,inhibitors'
p20470
(F1
F0.00014334862385321102
I0
I1
I-1
tp20471
sS'day,followed'
p20472
(F1
F0.00014334862385321102
I1
I0
I1
tp20473
sS'maximum,levels'
p20474
(F1
F0.00014334862385321102
I0
I1
I-1
tp20475
sS'this,route'
p20476
(F1
F0.00014334862385321102
I1
I0
I1
tp20477
sS'non-hodgkin,lymphoma'
p20478
(F1
F0.00014334862385321102
I0
I1
I-1
tp20479
sS'first-episode,or'
p20480
(F1
F0.00014334862385321102
I0
I1
I-1
tp20481
sS'mhd,the'
p20482
(F1
F0.00014334862385321102
I0
I1
I-1
tp20483
sS'and,pth'
p20484
(F1
F0.00014334862385321102
I1
I0
I1
tp20485
sS'of,developing'
p20486
(F1
F0.00028669724770642203
I2
I0
I2
tp20487
sS'on,some'
p20488
(F1
F0.00014334862385321102
I0
I1
I-1
tp20489
sS'that,does'
p20490
(F1
F0.0011467889908256881
I0
I8
I-8
tp20491
sS'are,ge'
p20492
(F1
F0.00014334862385321102
I0
I1
I-1
tp20493
sS'blood,concentrations'
p20494
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp20495
sS'metabolite,or'
p20496
(F1
F0.00014334862385321102
I0
I1
I-1
tp20497
sS'block,following'
p20498
(F0
F0
I1
I1
I0
tp20499
sS'of,release'
p20500
(F1
F0.00014334862385321102
I0
I1
I-1
tp20501
sS'adverse,event'
p20502
(F1
F0.00014334862385321102
I0
I1
I-1
tp20503
sS'mechanisms,involving'
p20504
(F1
F0.00014334862385321102
I1
I0
I1
tp20505
sS'metabolite,of'
p20506
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp20507
sS'ectopic,pacemaker'
p20508
(F1
F0.00014334862385321102
I1
I0
I1
tp20509
sS'brevibloc,were'
p20510
(F1
F0.00028669724770642203
I2
I0
I2
tp20511
sS'random,observations'
p20512
(F1
F0.00014334862385321102
I1
I0
I1
tp20513
sS'antidiabetes,products'
p20514
(F1
F0.00014334862385321102
I0
I1
I-1
tp20515
sS'emphasize,that'
p20516
(F1
F0.00014334862385321102
I0
I1
I-1
tp20517
sS'how,to'
p20518
(F1
F0.00014334862385321102
I0
I1
I-1
tp20519
sS'neurontin,capsule'
p20520
(F1
F0.00014334862385321102
I1
I0
I1
tp20521
sS'cyp2c19,or'
p20522
(F1
F0.00014334862385321102
I0
I1
I-1
tp20523
sS'in,rare'
p20524
(F1
F0.00014334862385321102
I1
I0
I1
tp20525
sS'causal,relationship'
p20526
(F0
F0
I1
I1
I0
tp20527
sS'study,without'
p20528
(F1
F0.00014334862385321102
I0
I1
I-1
tp20529
sS'if,used'
p20530
(F1
F0.00014334862385321102
I1
I0
I1
tp20531
sS'enzymes,of'
p20532
(F1
F0.00043004587155963305
I3
I0
I3
tp20533
sS'occasionally,been'
p20534
(F1
F0.00028669724770642203
I0
I2
I-2
tp20535
sS'serious,gi'
p20536
(F1
F0.00028669724770642203
I2
I0
I2
tp20537
sS'enzymes,or'
p20538
(F1
F0.00014334862385321102
I0
I1
I-1
tp20539
sS'lowest,effective'
p20540
(F1
F0.00028669724770642203
I2
I0
I2
tp20541
sS'following,specific'
p20542
(F1
F0.00014334862385321102
I0
I1
I-1
tp20543
sS'markedly,inhibits'
p20544
(F1
F0.00028669724770642203
I2
I0
I2
tp20545
sS'reddish,color'
p20546
(F1
F0.00014334862385321102
I1
I0
I1
tp20547
sS'however,requirement'
p20548
(F1
F0.00014334862385321102
I1
I0
I1
tp20549
sS'anticholinergic,agents'
p20550
(F1
F0.00028669724770642203
I2
I0
I2
tp20551
sS'usual,and'
p20552
(F1
F0.00014334862385321102
I1
I0
I1
tp20553
sS'bismuth,subsalicylate'
p20554
(F1
F0.00014334862385321102
I1
I0
I1
tp20555
sS'toxicity,characteristics'
p20556
(F1
F0.00014334862385321102
I1
I0
I1
tp20557
sS'other,coumarin-derivative'
p20558
(F1
F0.00014334862385321102
I0
I1
I-1
tp20559
sS'lapatinib,on'
p20560
(F1
F0.00014334862385321102
I0
I1
I-1
tp20561
sS'cause-and,effect'
p20562
(F1
F0.00028669724770642203
I2
I0
I2
tp20563
sS'or,therapeutic'
p20564
(F1
F0.00014334862385321102
I0
I1
I-1
tp20565
sS'of,response'
p20566
(F1
F0.00014334862385321102
I1
I0
I1
tp20567
sS'equetrotm,increases'
p20568
(F1
F0.00014334862385321102
I1
I0
I1
tp20569
sS'relaxant,antagonists'
p20570
(F1
F0.00014334862385321102
I0
I1
I-1
tp20571
sS'beta,blockers'
p20572
(F0
F0
I5
I5
I0
tp20573
sS'sodium,kg'
p20574
(F1
F0.00014334862385321102
I1
I0
I1
tp20575
sS'diarrhea,but'
p20576
(F1
F0.00014334862385321102
I1
I0
I1
tp20577
sS'added,beta-adrenergic'
p20578
(F1
F0.00014334862385321102
I1
I0
I1
tp20579
sS'that,elspar'
p20580
(F1
F0.00014334862385321102
I1
I0
I1
tp20581
sS'urinary,and'
p20582
(F1
F0.00014334862385321102
I1
I0
I1
tp20583
sS'temperature,began'
p20584
(F1
F0.00014334862385321102
I0
I1
I-1
tp20585
sS'disturbances,left'
p20586
(F1
F0.00014334862385321102
I1
I0
I1
tp20587
sS'tuberculosis,andusing'
p20588
(F1
F0.00014334862385321102
I0
I1
I-1
tp20589
sS'block,morphine-induced'
p20590
(F1
F0.00014334862385321102
I1
I0
I1
tp20591
sS'antiretroviral,plasma'
p20592
(F1
F0.00014334862385321102
I0
I1
I-1
tp20593
sS'more,profound'
p20594
(F1
F0.00014334862385321102
I1
I0
I1
tp20595
sS'antiemetic,prophylaxis'
p20596
(F1
F0.00014334862385321102
I1
I0
I1
tp20597
sS'example,since'
p20598
(F1
F0.00014334862385321102
I1
I0
I1
tp20599
sS'above,effects'
p20600
(F1
F0.00014334862385321102
I1
I0
I1
tp20601
sS'macrolide,antibiotics'
p20602
(F0
F0
I2
I2
I0
tp20603
sS'cases,from'
p20604
(F1
F0.00014334862385321102
I0
I1
I-1
tp20605
sS'cause,striking'
p20606
(F1
F0.00028669724770642203
I2
I0
I2
tp20607
sS'guanethidine,or'
p20608
(F1
F0.00014334862385321102
I0
I1
I-1
tp20609
sS'activated,during'
p20610
(F1
F0.00014334862385321102
I0
I1
I-1
tp20611
sS'and,transport'
p20612
(F1
F0.00014334862385321102
I0
I1
I-1
tp20613
sS'in,tissue'
p20614
(F1
F0.00014334862385321102
I1
I0
I1
tp20615
sS'ponstel,with'
p20616
(F1
F0.00014334862385321102
I1
I0
I1
tp20617
sS'with,kineret'
p20618
(F1
F0.00014334862385321102
I1
I0
I1
tp20619
sS'a,median'
p20620
(F1
F0.00014334862385321102
I0
I1
I-1
tp20621
sS'in,cardioplegic'
p20622
(F1
F0.00014334862385321102
I0
I1
I-1
tp20623
sS'preparation,this'
p20624
(F1
F0.00014334862385321102
I1
I0
I1
tp20625
sS'in,rpmi1640'
p20626
(F1
F0.00014334862385321102
I1
I0
I1
tp20627
sS'adverse,events'
p20628
(F0.5714285714285714
F0.0011467889908256881
I3
I11
I-8
tp20629
sS'increased,and'
p20630
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp20631
sS'of,p-450iie1'
p20632
(F1
F0.00014334862385321102
I1
I0
I1
tp20633
sS'have,effects'
p20634
(F1
F0.00014334862385321102
I0
I1
I-1
tp20635
sS'morphine,prolonged'
p20636
(F1
F0.00014334862385321102
I1
I0
I1
tp20637
sS'single,daily'
p20638
(F1
F0.00014334862385321102
I0
I1
I-1
tp20639
sS'cmin,auc'
p20640
(F1
F0.00014334862385321102
I0
I1
I-1
tp20641
sS'inhibit,these'
p20642
(F1
F0.00014334862385321102
I0
I1
I-1
tp20643
sS'dose,mg'
p20644
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp20645
sS'further,no'
p20646
(F1
F0.00014334862385321102
I0
I1
I-1
tp20647
sS'a,dysregulation'
p20648
(F1
F0.00014334862385321102
I0
I1
I-1
tp20649
sS'inhibition,significantly'
p20650
(F1
F0.00014334862385321102
I1
I0
I1
tp20651
sS'results,with'
p20652
(F1
F0.00014334862385321102
I0
I1
I-1
tp20653
sS'eia,test'
p20654
(F1
F0.00014334862385321102
I0
I1
I-1
tp20655
sS'with,enzyme'
p20656
(F1
F0.00014334862385321102
I0
I1
I-1
tp20657
sS'and,either'
p20658
(F1
F0.00014334862385321102
I0
I1
I-1
tp20659
sS'frequency,of'
p20660
(F0
F0
I3
I3
I0
tp20661
sS'cases,reported'
p20662
(F1
F0.00014334862385321102
I1
I0
I1
tp20663
sS'include,aminosalicylic'
p20664
(F1
F0.00014334862385321102
I1
I0
I1
tp20665
sS'advantages,over'
p20666
(F1
F0.00014334862385321102
I0
I1
I-1
tp20667
sS'determinations,vitamin'
p20668
(F1
F0.00014334862385321102
I1
I0
I1
tp20669
sS'catalyzed,by'
p20670
(F1
F0.00028669724770642203
I0
I2
I-2
tp20671
sS'as,thiazide'
p20672
(F1
F0.00028669724770642203
I2
I0
I2
tp20673
sS'behavioral,responsiveness'
p20674
(F1
F0.00014334862385321102
I1
I0
I1
tp20675
sS'of,drugs'
p20676
(F1
F0.00014334862385321102
I1
I0
I1
tp20677
sS'decreased,alertness'
p20678
(F1
F0.00028669724770642203
I2
I0
I2
tp20679
sS'evidenced,by'
p20680
(F1
F0.00014334862385321102
I1
I0
I1
tp20681
sS'sedation,or'
p20682
(F0
F0
I1
I1
I0
tp20683
sS'pharmacokinetic,disposition'
p20684
(F1
F0.00014334862385321102
I0
I1
I-1
tp20685
sS'produces,depression'
p20686
(F1
F0.00014334862385321102
I1
I0
I1
tp20687
sS'and,exposure'
p20688
(F1
F0.00014334862385321102
I1
I0
I1
tp20689
sS'while,a'
p20690
(F1
F0.00014334862385321102
I1
I0
I1
tp20691
sS'and,fenofibric'
p20692
(F1
F0.00014334862385321102
I0
I1
I-1
tp20693
sS'of,candesartan'
p20694
(F1
F0.00014334862385321102
I0
I1
I-1
tp20695
sS'acid,has'
p20696
(F1
F0.00014334862385321102
I1
I0
I1
tp20697
sS'a,p-glycoprotein'
p20698
(F1
F0.00014334862385321102
I1
I0
I1
tp20699
sS'index,including'
p20700
(F1
F0.00014334862385321102
I1
I0
I1
tp20701
sS'products,containing'
p20702
(F1
F0.0010034403669724771
I7
I0
I7
tp20703
sS'therapy,plasma'
p20704
(F1
F0.00014334862385321102
I1
I0
I1
tp20705
sS'medication,iodine-containing'
p20706
(F1
F0.00014334862385321102
I0
I1
I-1
tp20707
sS'with,synthetic'
p20708
(F1
F0.00014334862385321102
I0
I1
I-1
tp20709
sS'related,presumably'
p20710
(F1
F0.00014334862385321102
I1
I0
I1
tp20711
sS'ninds,t-pa'
p20712
(F1
F0.00014334862385321102
I0
I1
I-1
tp20713
sS'evidence,was'
p20714
(F1
F0.00014334862385321102
I0
I1
I-1
tp20715
sS'subject,before'
p20716
(F1
F0.00014334862385321102
I0
I1
I-1
tp20717
sS'on,stimulated'
p20718
(F1
F0.00014334862385321102
I0
I1
I-1
tp20719
sS'depressants,eg'
p20720
(F1
F0.00014334862385321102
I1
I0
I1
tp20721
sS'phenurone,since'
p20722
(F1
F0.00014334862385321102
I1
I0
I1
tp20723
sS'while,it'
p20724
(F1
F0.00014334862385321102
I0
I1
I-1
tp20725
sS'another,such'
p20726
(F1
F0.00014334862385321102
I1
I0
I1
tp20727
sS'lower,in'
p20728
(F1
F0.00028669724770642203
I2
I0
I2
tp20729
sS'on,platelet'
p20730
(F1
F0.00028669724770642203
I2
I0
I2
tp20731
sS'are,cytochrome'
p20732
(F1
F0.00014334862385321102
I1
I0
I1
tp20733
sS'prevent,opioid-induced'
p20734
(F1
F0.00014334862385321102
I1
I0
I1
tp20735
sS'and,proton'
p20736
(F1
F0.00028669724770642203
I0
I2
I-2
tp20737
sS'enzymes,respectively'
p20738
(F1
F0.00014334862385321102
I1
I0
I1
tp20739
sS'adjustments,patients'
p20740
(F1
F0.00014334862385321102
I1
I0
I1
tp20741
sS'discontinue,therapy'
p20742
(F1
F0.00014334862385321102
I1
I0
I1
tp20743
sS'concerning,laboratory'
p20744
(F1
F0.00014334862385321102
I0
I1
I-1
tp20745
sS'vivo,resulted'
p20746
(F1
F0.00014334862385321102
I0
I1
I-1
tp20747
sS'on,aed'
p20748
(F1
F0.00014334862385321102
I0
I1
I-1
tp20749
sS'of,duloxetine'
p20750
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp20751
sS'since,nevirapinemay'
p20752
(F1
F0.00014334862385321102
I1
I0
I1
tp20753
sS'is,no'
p20754
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp20755
sS'of,resulted'
p20756
(F1
F0.00057339449541284407
I4
I0
I4
tp20757
sS'that,maximally'
p20758
(F1
F0.00014334862385321102
I0
I1
I-1
tp20759
sS'tricyclic,and'
p20760
(F1
F0.00028669724770642203
I2
I0
I2
tp20761
sS'obstetric,blocks'
p20762
(F0
F0
I1
I1
I0
tp20763
sS'hydrochlorothiazide,in'
p20764
(F1
F0.00014334862385321102
I1
I0
I1
tp20765
sS'add,a'
p20766
(F1
F0.0008600917431192661
I6
I0
I6
tp20767
sS'diagnosed,subjects'
p20768
(F1
F0.00014334862385321102
I0
I1
I-1
tp20769
sS'conduction,when'
p20770
(F1
F0.00014334862385321102
I1
I0
I1
tp20771
sS'concurrent,dosing'
p20772
(F1
F0.00014334862385321102
I0
I1
I-1
tp20773
sS'no,positive'
p20774
(F1
F0.00014334862385321102
I0
I1
I-1
tp20775
sS'study,co-administration'
p20776
(F0
F0
I1
I1
I0
tp20777
sS'established,a'
p20778
(F1
F0.00014334862385321102
I1
I0
I1
tp20779
sS'acute,pulmonary'
p20780
(F1
F0.00014334862385321102
I1
I0
I1
tp20781
sS'v,decreased'
p20782
(F1
F0.00014334862385321102
I0
I1
I-1
tp20783
sS'or,adrenergic'
p20784
(F1
F0.00014334862385321102
I0
I1
I-1
tp20785
sS'these,studies'
p20786
(F0
F0
I2
I2
I0
tp20787
sS'therefore,increased'
p20788
(F1
F0.00014334862385321102
I1
I0
I1
tp20789
sS'reported,among'
p20790
(F1
F0.00028669724770642203
I2
I0
I2
tp20791
sS'increased,plasma'
p20792
(F0.41666666666666669
F0.0014334862385321102
I17
I7
I10
tp20793
sS'the,absolute'
p20794
(F1
F0.00014334862385321102
I0
I1
I-1
tp20795
sS'other,b-lactam'
p20796
(F1
F0.00043004587155963305
I3
I0
I3
tp20797
sS'substances,are'
p20798
(F1
F0.00014334862385321102
I0
I1
I-1
tp20799
sS'studies,did'
p20800
(F1
F0.00014334862385321102
I0
I1
I-1
tp20801
sS'zidovudine,there'
p20802
(F1
F0.00014334862385321102
I0
I1
I-1
tp20803
sS'metabolism,which'
p20804
(F1
F0.00014334862385321102
I1
I0
I1
tp20805
sS'tumor,cells'
p20806
(F1
F0.00014334862385321102
I0
I1
I-1
tp20807
sS'discontinuance,of'
p20808
(F1
F0.00014334862385321102
I1
I0
I1
tp20809
sS'decrease,effectiveness'
p20810
(F1
F0.00014334862385321102
I0
I1
I-1
tp20811
sS'the,anti-platelet'
p20812
(F1
F0.00014334862385321102
I0
I1
I-1
tp20813
sS'selective,cyp3a4'
p20814
(F1
F0.00028669724770642203
I2
I0
I2
tp20815
sS'enablex,with'
p20816
(F1
F0.00014334862385321102
I1
I0
I1
tp20817
sS'standing,systolic'
p20818
(F1
F0.00071674311926605509
I5
I0
I5
tp20819
sS'pressure,effect'
p20820
(F1
F0.00014334862385321102
I1
I0
I1
tp20821
sS'because,changes'
p20822
(F1
F0.00014334862385321102
I1
I0
I1
tp20823
sS'medline,premedline'
p20824
(F1
F0.00014334862385321102
I0
I1
I-1
tp20825
sS'the,desired'
p20826
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp20827
sS'of,dependence'
p20828
(F1
F0.00014334862385321102
I0
I1
I-1
tp20829
sS'after,drinking'
p20830
(F1
F0.00014334862385321102
I1
I0
I1
tp20831
sS'probenecid,may'
p20832
(F1
F0.00028669724770642203
I2
I0
I2
tp20833
sS'of,neurontin'
p20834
(F1
F0.00043004587155963305
I0
I3
I-3
tp20835
sS'maybe,useful'
p20836
(F1
F0.00014334862385321102
I0
I1
I-1
tp20837
sS'methyltetrahydro-folate,and'
p20838
(F1
F0.00014334862385321102
I0
I1
I-1
tp20839
sS'to,co-administer'
p20840
(F1
F0.00014334862385321102
I1
I0
I1
tp20841
sS'serum,prostate-specific'
p20842
(F1
F0.00014334862385321102
I0
I1
I-1
tp20843
sS'tablets,a'
p20844
(F1
F0.00014334862385321102
I1
I0
I1
tp20845
sS'some,substances'
p20846
(F1
F0.00014334862385321102
I0
I1
I-1
tp20847
sS'therefore,potentially'
p20848
(F1
F0.00014334862385321102
I1
I0
I1
tp20849
sS'trials,were'
p20850
(F1
F0.00028669724770642203
I0
I2
I-2
tp20851
sS'increased,peak'
p20852
(F1
F0.00014334862385321102
I1
I0
I1
tp20853
sS'glucuronidation,is'
p20854
(F1
F0.00014334862385321102
I0
I1
I-1
tp20855
sS'antagonists,which'
p20856
(F1
F0.00014334862385321102
I1
I0
I1
tp20857
sS'sympathetic,nervous'
p20858
(F1
F0.00014334862385321102
I0
I1
I-1
tp20859
sS'or,its'
p20860
(F0
F0
I6
I6
I0
tp20861
sS'blocker,given'
p20862
(F1
F0.00014334862385321102
I1
I0
I1
tp20863
sS'gentamicin,is'
p20864
(F1
F0.00014334862385321102
I0
I1
I-1
tp20865
sS'interference,with'
p20866
(F1
F0.00043004587155963305
I3
I0
I3
tp20867
sS'prescribed,to'
p20868
(F1
F0.00014334862385321102
I1
I0
I1
tp20869
sS'this,interaction'
p20870
(F0.59999999999999998
F0.0012901376146788992
I12
I3
I9
tp20871
sS'on,alone'
p20872
(F1
F0.00014334862385321102
I0
I1
I-1
tp20873
sS'doses,of'
p20874
(F0.053763440860215055
F0.00071674311926605509
I49
I44
I5
tp20875
sS'tracrium,include'
p20876
(F1
F0.00014334862385321102
I1
I0
I1
tp20877
sS'with,suboxone'
p20878
(F1
F0.00014334862385321102
I1
I0
I1
tp20879
sS'were,the'
p20880
(F1
F0.00014334862385321102
I0
I1
I-1
tp20881
sS'on,especially'
p20882
(F1
F0.00028669724770642203
I2
I0
I2
tp20883
sS'doses,or'
p20884
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp20885
sS'markedly,decreased'
p20886
(F1
F0.00014334862385321102
I1
I0
I1
tp20887
sS'from,both'
p20888
(F1
F0.00028669724770642203
I0
I2
I-2
tp20889
sS'd6,many'
p20890
(F1
F0.00071674311926605509
I0
I5
I-5
tp20891
sS'dental,complications'
p20892
(F1
F0.00014334862385321102
I1
I0
I1
tp20893
sS'trials,no'
p20894
(F1
F0.00014334862385321102
I0
I1
I-1
tp20895
sS'is,comparable'
p20896
(F1
F0.00014334862385321102
I0
I1
I-1
tp20897
sS'when,maleate'
p20898
(F1
F0.00028669724770642203
I2
I0
I2
tp20899
sS'regression,analyses'
p20900
(F1
F0.00014334862385321102
I1
I0
I1
tp20901
sS'high,in'
p20902
(F1
F0.00014334862385321102
I1
I0
I1
tp20903
sS'other,compounds'
p20904
(F1
F0.00014334862385321102
I0
I1
I-1
tp20905
sS'busulfex,may'
p20906
(F1
F0.00014334862385321102
I1
I0
I1
tp20907
sS'also,verified'
p20908
(F1
F0.00014334862385321102
I0
I1
I-1
tp20909
sS'cyp1a2,in'
p20910
(F1
F0.00014334862385321102
I0
I1
I-1
tp20911
sS'tnf-blocking,agents'
p20912
(F1
F0.00014334862385321102
I1
I0
I1
tp20913
sS'that,should'
p20914
(F0.5
F0.00028669724770642203
I3
I1
I2
tp20915
sS'prescribed,with'
p20916
(F1
F0.00014334862385321102
I1
I0
I1
tp20917
sS'zebeta,should'
p20918
(F1
F0.00028669724770642203
I2
I0
I2
tp20919
sS'h,or'
p20920
(F1
F0.00014334862385321102
I0
I1
I-1
tp20921
sS'of,subutex'
p20922
(F1
F0.00014334862385321102
I0
I1
I-1
tp20923
sS'cancidas,has'
p20924
(F1
F0.00014334862385321102
I0
I1
I-1
tp20925
sS'morning,dose'
p20926
(F1
F0.00014334862385321102
I0
I1
I-1
tp20927
sS'of,sodium'
p20928
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp20929
sS'cyp1a2,cyp2c9'
p20930
(F1
F0.00014334862385321102
I0
I1
I-1
tp20931
sS'the,sleeping'
p20932
(F1
F0.00014334862385321102
I1
I0
I1
tp20933
sS'minutes,p'
p20934
(F1
F0.00014334862385321102
I1
I0
I1
tp20935
sS'propanol,to'
p20936
(F0
F0
I1
I1
I0
tp20937
sS'of,which'
p20938
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp20939
sS'extent,than'
p20940
(F1
F0.00028669724770642203
I0
I2
I-2
tp20941
sS'in,four'
p20942
(F1
F0.00028669724770642203
I0
I2
I-2
tp20943
sS'the,arrival'
p20944
(F1
F0.00014334862385321102
I0
I1
I-1
tp20945
sS'secretion,of'
p20946
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp20947
sS'rationalized,at'
p20948
(F1
F0.00014334862385321102
I0
I1
I-1
tp20949
sS'agents,sodium'
p20950
(F1
F0.00014334862385321102
I1
I0
I1
tp20951
sS'non-comparative,clinical'
p20952
(F1
F0.00014334862385321102
I1
I0
I1
tp20953
sS'potentiate,the'
p20954
(F0.65714285714285714
F0.0032970183486238534
I29
I6
I23
tp20955
sS'sustained-release,channel'
p20956
(F1
F0.00014334862385321102
I0
I1
I-1
tp20957
sS'start,of'
p20958
(F1
F0.00014334862385321102
I1
I0
I1
tp20959
sS'serum,creatinine'
p20960
(F1
F0.00071674311926605509
I5
I0
I5
tp20961
sS'treatment,practices'
p20962
(F1
F0.00014334862385321102
I0
I1
I-1
tp20963
sS'only,enhances'
p20964
(F1
F0.00014334862385321102
I1
I0
I1
tp20965
sS'and,particularly'
p20966
(F1
F0.00014334862385321102
I0
I1
I-1
tp20967
sS'and,has'
p20968
(F0.29999999999999999
F0.0008600917431192661
I13
I7
I6
tp20969
sS'affected,response'
p20970
(F1
F0.00014334862385321102
I1
I0
I1
tp20971
sS'volunteers,have'
p20972
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp20973
sS'as,well'
p20974
(F0.31034482758620691
F0.0012901376146788992
I19
I10
I9
tp20975
sS'microsomes,inhibition'
p20976
(F1
F0.00014334862385321102
I1
I0
I1
tp20977
sS'objective,to'
p20978
(F1
F0.00028669724770642203
I0
I2
I-2
tp20979
sS'four,chemotherapeutic'
p20980
(F1
F0.00014334862385321102
I0
I1
I-1
tp20981
sS'antidiabetics,oral'
p20982
(F1
F0.00014334862385321102
I1
I0
I1
tp20983
sS'when,lexapro'
p20984
(F1
F0.00014334862385321102
I1
I0
I1
tp20985
sS'on,low-dose'
p20986
(F1
F0.00014334862385321102
I0
I1
I-1
tp20987
sS'substrate,is'
p20988
(F1
F0.00014334862385321102
I0
I1
I-1
tp20989
sS'a,maximum'
p20990
(F1
F0.00043004587155963305
I3
I0
I3
tp20991
sS'prior,to'
p20992
(F0.51515151515151514
F0.0024369266055045873
I25
I8
I17
tp20993
sS'advised,when'
p20994
(F1
F0.00057339449541284407
I4
I0
I4
tp20995
sS'pharmaceutical,abstracts'
p20996
(F1
F0.00014334862385321102
I0
I1
I-1
tp20997
sS'anticoagulants,are'
p20998
(F1
F0.00014334862385321102
I1
I0
I1
tp20999
sS'substrate,in'
p21000
(F1
F0.00028669724770642203
I0
I2
I-2
tp21001
sS'of,efficacy'
p21002
(F1
F0.00014334862385321102
I0
I1
I-1
tp21003
sS'compounds,including'
p21004
(F1
F0.00014334862385321102
I1
I0
I1
tp21005
sS'generated,from'
p21006
(F1
F0.00014334862385321102
I0
I1
I-1
tp21007
sS'a,solution'
p21008
(F1
F0.00014334862385321102
I0
I1
I-1
tp21009
sS'added,concentration'
p21010
(F1
F0.00014334862385321102
I0
I1
I-1
tp21011
sS'twelve,strains'
p21012
(F1
F0.00014334862385321102
I1
I0
I1
tp21013
sS'neurochemical,and'
p21014
(F1
F0.00028669724770642203
I0
I2
I-2
tp21015
sS'doses,and'
p21016
(F1
F0.00014334862385321102
I1
I0
I1
tp21017
sS'combined,week'
p21018
(F1
F0.00014334862385321102
I0
I1
I-1
tp21019
sS'acid,diminished'
p21020
(F1
F0.00014334862385321102
I1
I0
I1
tp21021
sS'angiomax,in'
p21022
(F1
F0.00014334862385321102
I0
I1
I-1
tp21023
sS'for,initial'
p21024
(F1
F0.00014334862385321102
I0
I1
I-1
tp21025
sS'events,in'
p21026
(F1
F0.00043004587155963305
I0
I3
I-3
tp21027
sS'ast,and'
p21028
(F1
F0.00014334862385321102
I1
I0
I1
tp21029
sS'grapefruit,juice'
p21030
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp21031
sS'providers,are'
p21032
(F1
F0.00014334862385321102
I0
I1
I-1
tp21033
sS'stupor,and'
p21034
(F1
F0.00014334862385321102
I1
I0
I1
tp21035
sS'still,advisable'
p21036
(F1
F0.00014334862385321102
I1
I0
I1
tp21037
sS'dosing,lower'
p21038
(F1
F0.00014334862385321102
I1
I0
I1
tp21039
sS'date,levosimendan'
p21040
(F1
F0.00014334862385321102
I0
I1
I-1
tp21041
sS'toxoids,and'
p21042
(F1
F0.00014334862385321102
I1
I0
I1
tp21043
sS'of,colonic'
p21044
(F1
F0.00014334862385321102
I0
I1
I-1
tp21045
sS'lithiums,renal'
p21046
(F1
F0.00014334862385321102
I1
I0
I1
tp21047
sS'concurrent,kineret'
p21048
(F1
F0.00014334862385321102
I1
I0
I1
tp21049
sS'and,inhibition'
p21050
(F1
F0.00014334862385321102
I0
I1
I-1
tp21051
sS'coated,plus'
p21052
(F1
F0.00014334862385321102
I0
I1
I-1
tp21053
sS'using,labetalol'
p21054
(F1
F0.00014334862385321102
I1
I0
I1
tp21055
sS'disodium,in'
p21056
(F1
F0.00014334862385321102
I1
I0
I1
tp21057
sS'lodine,like'
p21058
(F1
F0.00014334862385321102
I1
I0
I1
tp21059
sS'actions,or'
p21060
(F1
F0.00014334862385321102
I0
I1
I-1
tp21061
sS'actions,of'
p21062
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp21063
sS'results,would'
p21064
(F1
F0.00014334862385321102
I1
I0
I1
tp21065
sS'parietal,cells'
p21066
(F1
F0.00014334862385321102
I0
I1
I-1
tp21067
sS'gabitril,is'
p21068
(F1
F0.00014334862385321102
I0
I1
I-1
tp21069
sS'and,hypoglycemic'
p21070
(F1
F0.00014334862385321102
I1
I0
I1
tp21071
sS'and,hypoglycemia'
p21072
(F0
F0
I1
I1
I0
tp21073
sS'was,the'
p21074
(F1
F0.00014334862385321102
I1
I0
I1
tp21075
sS'ulcers,in'
p21076
(F1
F0.00014334862385321102
I0
I1
I-1
tp21077
sS'synthetic,on'
p21078
(F1
F0.00014334862385321102
I0
I1
I-1
tp21079
sS'therapy,were'
p21080
(F1
F0.00028669724770642203
I0
I2
I-2
tp21081
sS'of,trileptal'
p21082
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp21083
sS'mofetil,respectively'
p21084
(F1
F0.00014334862385321102
I1
I0
I1
tp21085
sS'both,a'
p21086
(F1
F0.00014334862385321102
I0
I1
I-1
tp21087
sS'of,twice'
p21088
(F1
F0.00014334862385321102
I0
I1
I-1
tp21089
sS'been,inconsistent'
p21090
(F1
F0.00014334862385321102
I0
I1
I-1
tp21091
sS'the,hormone'
p21092
(F1
F0.00014334862385321102
I0
I1
I-1
tp21093
sS'are,reports'
p21094
(F1
F0.00014334862385321102
I1
I0
I1
tp21095
sS'tracleer,and'
p21096
(F1
F0.00014334862385321102
I1
I0
I1
tp21097
sS'reduced,thus'
p21098
(F1
F0.00014334862385321102
I1
I0
I1
tp21099
sS'blockers,adrenergic'
p21100
(F1
F0.00028669724770642203
I2
I0
I2
tp21101
sS'include,but'
p21102
(F1
F0.00014334862385321102
I0
I1
I-1
tp21103
sS'prolongation,of'
p21104
(F0.80000000000000004
F0.0022935779816513763
I18
I2
I16
tp21105
sS'intravascular,volume'
p21106
(F1
F0.00014334862385321102
I1
I0
I1
tp21107
sS's,isomers'
p21108
(F1
F0.00014334862385321102
I0
I1
I-1
tp21109
sS'carbamazepine,felbatol'
p21110
(F1
F0.00014334862385321102
I1
I0
I1
tp21111
sS'pah,cannot'
p21112
(F1
F0.00014334862385321102
I1
I0
I1
tp21113
sS'as,nimbex'
p21114
(F1
F0.00014334862385321102
I1
I0
I1
tp21115
sS'low,hepatic'
p21116
(F1
F0.00014334862385321102
I0
I1
I-1
tp21117
sS'cardiovascular,action'
p21118
(F1
F0.00014334862385321102
I1
I0
I1
tp21119
sS'be,borne'
p21120
(F0
F0
I1
I1
I0
tp21121
sS'begun,in'
p21122
(F1
F0.00014334862385321102
I1
I0
I1
tp21123
sS'which,metabolizes'
p21124
(F1
F0.00014334862385321102
I0
I1
I-1
tp21125
sS'warfarin-type,cyp2c9'
p21126
(F1
F0.00014334862385321102
I0
I1
I-1
tp21127
sS'which,involved'
p21128
(F1
F0.00014334862385321102
I1
I0
I1
tp21129
sS'distribution,in'
p21130
(F1
F0.00014334862385321102
I1
I0
I1
tp21131
sS'constipation,blurred'
p21132
(F1
F0.00014334862385321102
I1
I0
I1
tp21133
sS'to,vomiting'
p21134
(F1
F0.00014334862385321102
I1
I0
I1
tp21135
sS'daily,taken'
p21136
(F1
F0.00014334862385321102
I1
I0
I1
tp21137
sS'values,of'
p21138
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21139
sS'cimetidine,albendazole'
p21140
(F1
F0.00014334862385321102
I1
I0
I1
tp21141
sS'itraconazole,mg'
p21142
(F1
F0.00014334862385321102
I0
I1
I-1
tp21143
sS'nitrite,after'
p21144
(F1
F0.00014334862385321102
I1
I0
I1
tp21145
sS'hybridization,we'
p21146
(F1
F0.00014334862385321102
I1
I0
I1
tp21147
sS'xr,may'
p21148
(F1
F0.00014334862385321102
I1
I0
I1
tp21149
sS'levels,possibly'
p21150
(F1
F0.00014334862385321102
I1
I0
I1
tp21151
sS'hydrogen,breath'
p21152
(F1
F0.00014334862385321102
I0
I1
I-1
tp21153
sS'hydrate,dietary'
p21154
(F1
F0.00014334862385321102
I1
I0
I1
tp21155
sS'borne,in'
p21156
(F0
F0
I1
I1
I0
tp21157
sS'and,supplemental'
p21158
(F1
F0.00014334862385321102
I1
I0
I1
tp21159
sS'because,their'
p21160
(F1
F0.00014334862385321102
I1
I0
I1
tp21161
sS'determined,before'
p21162
(F1
F0.00014334862385321102
I1
I0
I1
tp21163
sS'genetically,nervous'
p21164
(F1
F0.00014334862385321102
I0
I1
I-1
tp21165
sS'one,controlled'
p21166
(F1
F0.00014334862385321102
I1
I0
I1
tp21167
sS'gentamicin,methionine'
p21168
(F1
F0.00014334862385321102
I1
I0
I1
tp21169
sS'botulinum,prior'
p21170
(F1
F0.00014334862385321102
I1
I0
I1
tp21171
sS'describe,modest'
p21172
(F1
F0.00014334862385321102
I1
I0
I1
tp21173
sS'be,an'
p21174
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp21175
sS'andtolbutamide,did'
p21176
(F1
F0.00014334862385321102
I0
I1
I-1
tp21177
sS'sodium,acid'
p21178
(F1
F0.00028669724770642203
I2
I0
I2
tp21179
sS'alkaloids,is'
p21180
(F1
F0.00014334862385321102
I1
I0
I1
tp21181
sS'the,optimal'
p21182
(F1
F0.00043004587155963305
I0
I3
I-3
tp21183
sS'with,reduced'
p21184
(F1
F0.00028669724770642203
I2
I0
I2
tp21185
sS'or,potassium-depleting'
p21186
(F1
F0.00014334862385321102
I0
I1
I-1
tp21187
sS'their,prothrombin'
p21188
(F1
F0.00028669724770642203
I2
I0
I2
tp21189
sS'for,alone'
p21190
(F0.5
F0.00028669724770642203
I3
I1
I2
tp21191
sS'with,reduces'
p21192
(F1
F0.00014334862385321102
I1
I0
I1
tp21193
sS'prinivil,was'
p21194
(F1
F0.00014334862385321102
I0
I1
I-1
tp21195
sS'conservatively,adjusted'
p21196
(F1
F0.00014334862385321102
I1
I0
I1
tp21197
sS'label,should'
p21198
(F1
F0.00014334862385321102
I1
I0
I1
tp21199
sS'has,much'
p21200
(F1
F0.00014334862385321102
I0
I1
I-1
tp21201
sS'sustained,elevation'
p21202
(F1
F0.00014334862385321102
I1
I0
I1
tp21203
sS'adequate,monitoring'
p21204
(F1
F0.00014334862385321102
I1
I0
I1
tp21205
sS'with,who'
p21206
(F1
F0.00014334862385321102
I0
I1
I-1
tp21207
sS'cefotan,and'
p21208
(F1
F0.00014334862385321102
I1
I0
I1
tp21209
sS'aluminum-containing,preparations'
p21210
(F1
F0.00014334862385321102
I0
I1
I-1
tp21211
sS'on,in'
p21212
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21213
sS'were,found'
p21214
(F1
F0.00028669724770642203
I0
I2
I-2
tp21215
sS'days,because'
p21216
(F1
F0.00014334862385321102
I1
I0
I1
tp21217
sS'ca,subtypes'
p21218
(F1
F0.00014334862385321102
I0
I1
I-1
tp21219
sS'this,oral'
p21220
(F1
F0.00014334862385321102
I0
I1
I-1
tp21221
sS'since,paranoid'
p21222
(F1
F0.00014334862385321102
I1
I0
I1
tp21223
sS'inhibitors,nefazodone'
p21224
(F1
F0.00014334862385321102
I0
I1
I-1
tp21225
sS'the,vasoconstrictive'
p21226
(F1
F0.00014334862385321102
I1
I0
I1
tp21227
sS'such,reduction'
p21228
(F1
F0.00014334862385321102
I1
I0
I1
tp21229
sS'are,observed'
p21230
(F1
F0.00014334862385321102
I0
I1
I-1
tp21231
sS'of,regular'
p21232
(F1
F0.00014334862385321102
I0
I1
I-1
tp21233
sS'since,may'
p21234
(F1
F0.00071674311926605509
I5
I0
I5
tp21235
sS'with,beta-blockers'
p21236
(F1
F0.00014334862385321102
I1
I0
I1
tp21237
sS'were,given'
p21238
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp21239
sS'approximately,to'
p21240
(F1
F0.00043004587155963305
I3
I0
I3
tp21241
sS'isoenzyme,in'
p21242
(F1
F0.00014334862385321102
I1
I0
I1
tp21243
sS'however,another'
p21244
(F1
F0.00014334862385321102
I1
I0
I1
tp21245
sS'enrolled,in'
p21246
(F1
F0.00014334862385321102
I0
I1
I-1
tp21247
sS'males,and'
p21248
(F1
F0.00014334862385321102
I1
I0
I1
tp21249
sS'the,neutropenic'
p21250
(F1
F0.00014334862385321102
I1
I0
I1
tp21251
sS'disodium,interferes'
p21252
(F1
F0.00014334862385321102
I1
I0
I1
tp21253
sS'is,one'
p21254
(F0.5
F0.00028669724770642203
I3
I1
I2
tp21255
sS'wshow,no'
p21256
(F1
F0.00014334862385321102
I0
I1
I-1
tp21257
sS'have,enhanced'
p21258
(F1
F0.00014334862385321102
I1
I0
I1
tp21259
sS'with,brain'
p21260
(F1
F0.00014334862385321102
I0
I1
I-1
tp21261
sS'interaction,effects'
p21262
(F1
F0.00014334862385321102
I0
I1
I-1
tp21263
sS'dependent,diabetic'
p21264
(F1
F0.00014334862385321102
I0
I1
I-1
tp21265
sS'we,have'
p21266
(F1
F0.00028669724770642203
I0
I2
I-2
tp21267
sS'blood,coagulation'
p21268
(F0
F0
I1
I1
I0
tp21269
sS'bosentan-,and'
p21270
(F1
F0.00014334862385321102
I0
I1
I-1
tp21271
sS'same,evening'
p21272
(F1
F0.00014334862385321102
I1
I0
I1
tp21273
sS'by,alterations'
p21274
(F1
F0.00014334862385321102
I0
I1
I-1
tp21275
sS'initiated,after'
p21276
(F1
F0.00014334862385321102
I0
I1
I-1
tp21277
sS'this,defect'
p21278
(F1
F0.00014334862385321102
I0
I1
I-1
tp21279
sS'when,screening'
p21280
(F1
F0.00014334862385321102
I0
I1
I-1
tp21281
sS'topical,glaucoma'
p21282
(F1
F0.00014334862385321102
I1
I0
I1
tp21283
sS'angiotensin-converting,enzyme'
p21284
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21285
sS'n,mean'
p21286
(F1
F0.00014334862385321102
I1
I0
I1
tp21287
sS'absorption,as'
p21288
(F1
F0.00014334862385321102
I0
I1
I-1
tp21289
sS'an,isoform'
p21290
(F1
F0.00014334862385321102
I1
I0
I1
tp21291
sS'properties,such'
p21292
(F1
F0.00014334862385321102
I1
I0
I1
tp21293
sS'were,inconclusive'
p21294
(F1
F0.00014334862385321102
I0
I1
I-1
tp21295
sS'the,maximal'
p21296
(F1
F0.00014334862385321102
I0
I1
I-1
tp21297
sS'study,administration'
p21298
(F1
F0.00014334862385321102
I1
I0
I1
tp21299
sS'alone,auc'
p21300
(F1
F0.00014334862385321102
I1
I0
I1
tp21301
sS'but,it'
p21302
(F0
F0
I1
I1
I0
tp21303
sS'but,is'
p21304
(F1
F0.00014334862385321102
I1
I0
I1
tp21305
sS'can,combine'
p21306
(F1
F0.00014334862385321102
I1
I0
I1
tp21307
sS'other,antianxiety'
p21308
(F1
F0.00014334862385321102
I1
I0
I1
tp21309
sS'but,in'
p21310
(F1
F0.00014334862385321102
I0
I1
I-1
tp21311
sS'toxicity,was'
p21312
(F1
F0.00028669724770642203
I2
I0
I2
tp21313
sS'uptake,and'
p21314
(F1
F0.00014334862385321102
I1
I0
I1
tp21315
sS'mixed,overdosage'
p21316
(F1
F0.00014334862385321102
I1
I0
I1
tp21317
sS'antidepressants,in'
p21318
(F1
F0.00014334862385321102
I1
I0
I1
tp21319
sS'during,this'
p21320
(F1
F0.00014334862385321102
I0
I1
I-1
tp21321
sS'in,using'
p21322
(F0
F0
I2
I2
I0
tp21323
sS'mg,all'
p21324
(F1
F0.00014334862385321102
I0
I1
I-1
tp21325
sS'therefore,be'
p21326
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21327
sS'of,pregnancy'
p21328
(F1
F0.00014334862385321102
I0
I1
I-1
tp21329
sS'uterine,rupture'
p21330
(F1
F0.00014334862385321102
I1
I0
I1
tp21331
sS'and,ng'
p21332
(F1
F0.00014334862385321102
I1
I0
I1
tp21333
sS'inhibition,of'
p21334
(F0.12820512820512819
F0.00071674311926605509
I22
I17
I5
tp21335
sS'heparins,as'
p21336
(F1
F0.00014334862385321102
I0
I1
I-1
tp21337
sS'and,no'
p21338
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp21339
sS'recipients,a'
p21340
(F1
F0.00014334862385321102
I1
I0
I1
tp21341
sS'because,xigris'
p21342
(F1
F0.00014334862385321102
I0
I1
I-1
tp21343
sS'of,onset'
p21344
(F1
F0.00014334862385321102
I1
I0
I1
tp21345
sS'consider,starting'
p21346
(F1
F0.00014334862385321102
I0
I1
I-1
tp21347
sS'oral,ethinyl'
p21348
(F1
F0.00014334862385321102
I0
I1
I-1
tp21349
sS'in,hiv-infected'
p21350
(F1
F0.00028669724770642203
I0
I2
I-2
tp21351
sS'and,n1'
p21352
(F1
F0.00014334862385321102
I1
I0
I1
tp21353
sS'human,pharmacokinetics'
p21354
(F1
F0.00028669724770642203
I2
I0
I2
tp21355
sS'concentration,ca'
p21356
(F1
F0.00014334862385321102
I1
I0
I1
tp21357
sS'extent,and'
p21358
(F1
F0.00014334862385321102
I0
I1
I-1
tp21359
sS'from,masking'
p21360
(F1
F0.00014334862385321102
I0
I1
I-1
tp21361
sS'angiotensin,and'
p21362
(F1
F0.00014334862385321102
I0
I1
I-1
tp21363
sS'administered,at'
p21364
(F0.5
F0.00057339449541284407
I6
I2
I4
tp21365
sS'administered,as'
p21366
(F1
F0.00028669724770642203
I0
I2
I-2
tp21367
sS'receiving,prothrombin'
p21368
(F1
F0.00014334862385321102
I1
I0
I1
tp21369
sS'ns,mg'
p21370
(F1
F0.00014334862385321102
I0
I1
I-1
tp21371
sS'converted,difluoroacetone'
p21372
(F1
F0.00014334862385321102
I0
I1
I-1
tp21373
sS'experience,when'
p21374
(F1
F0.00014334862385321102
I1
I0
I1
tp21375
sS'kg,enhanced'
p21376
(F1
F0.00014334862385321102
I1
I0
I1
tp21377
sS'specific,effects'
p21378
(F1
F0.00014334862385321102
I1
I0
I1
tp21379
sS'reported,from'
p21380
(F1
F0.00014334862385321102
I1
I0
I1
tp21381
sS'of,cyp2c19'
p21382
(F0
F0
I1
I1
I0
tp21383
sS'a,similar'
p21384
(F0
F0
I5
I5
I0
tp21385
sS'require,immediate'
p21386
(F1
F0.00014334862385321102
I0
I1
I-1
tp21387
sS'of,cytochrome'
p21388
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp21389
sS'addition,the'
p21390
(F1
F0.00014334862385321102
I1
I0
I1
tp21391
sS'and,within'
p21392
(F1
F0.00014334862385321102
I1
I0
I1
tp21393
sS'strong,inducers'
p21394
(F1
F0.00014334862385321102
I0
I1
I-1
tp21395
sS'for,duloxetine'
p21396
(F1
F0.00014334862385321102
I0
I1
I-1
tp21397
sS'known,whether'
p21398
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp21399
sS'isolated,single'
p21400
(F1
F0.00014334862385321102
I0
I1
I-1
tp21401
sS'tremor,as'
p21402
(F1
F0.00014334862385321102
I1
I0
I1
tp21403
sS'sprycel,with'
p21404
(F1
F0.00014334862385321102
I1
I0
I1
tp21405
sS'comparative,analysis'
p21406
(F1
F0.00014334862385321102
I0
I1
I-1
tp21407
sS'system,when'
p21408
(F1
F0.00014334862385321102
I1
I0
I1
tp21409
sS'ml,maalox'
p21410
(F1
F0.00014334862385321102
I1
I0
I1
tp21411
sS'day,there'
p21412
(F0
F0
I1
I1
I0
tp21413
sS'the,inhibits'
p21414
(F1
F0.00014334862385321102
I0
I1
I-1
tp21415
sS'concurrently,patients'
p21416
(F1
F0.00014334862385321102
I1
I0
I1
tp21417
sS'concurrently,plasma'
p21418
(F1
F0.00014334862385321102
I1
I0
I1
tp21419
sS'aerosol,has'
p21420
(F1
F0.00014334862385321102
I0
I1
I-1
tp21421
sS'incompletely,responsive'
p21422
(F1
F0.00014334862385321102
I0
I1
I-1
tp21423
sS'may,interfere'
p21424
(F0.33333333333333331
F0.0011467889908256881
I16
I8
I8
tp21425
sS'd3,administration'
p21426
(F1
F0.00014334862385321102
I1
I0
I1
tp21427
sS'inhibit,adrenal'
p21428
(F1
F0.00014334862385321102
I1
I0
I1
tp21429
sS'of,antacids'
p21430
(F1
F0.00014334862385321102
I0
I1
I-1
tp21431
sS'for,deoxycytidine'
p21432
(F1
F0.00014334862385321102
I0
I1
I-1
tp21433
sS'the,discontinuance'
p21434
(F1
F0.00014334862385321102
I1
I0
I1
tp21435
sS'trial,of'
p21436
(F1
F0.00014334862385321102
I1
I0
I1
tp21437
sS'after,initiation'
p21438
(F0.75
F0.0008600917431192661
I7
I1
I6
tp21439
sS'vistide,and'
p21440
(F1
F0.00014334862385321102
I1
I0
I1
tp21441
sS'treatment,costs'
p21442
(F1
F0.00028669724770642203
I0
I2
I-2
tp21443
sS'plasma,substrate'
p21444
(F1
F0.00014334862385321102
I0
I1
I-1
tp21445
sS'i,suggesting'
p21446
(F1
F0.00014334862385321102
I0
I1
I-1
tp21447
sS'digi-,tab'
p21448
(F1
F0.00014334862385321102
I0
I1
I-1
tp21449
sS'similar,responses'
p21450
(F1
F0.00014334862385321102
I0
I1
I-1
tp21451
sS'concomitantly,may'
p21452
(F1
F0.00028669724770642203
I2
I0
I2
tp21453
sS'inhibit,metabolism'
p21454
(F1
F0.00014334862385321102
I0
I1
I-1
tp21455
sS'grepafloxacin,like'
p21456
(F1
F0.00014334862385321102
I1
I0
I1
tp21457
sS'system,depressants'
p21458
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp21459
sS'or,tmax'
p21460
(F1
F0.00014334862385321102
I0
I1
I-1
tp21461
sS'clearance,accelerated'
p21462
(F1
F0.00014334862385321102
I1
I0
I1
tp21463
sS'mg,resulted'
p21464
(F1
F0.00028669724770642203
I2
I0
I2
tp21465
sS'azole,antifungal'
p21466
(F1
F0.00014334862385321102
I1
I0
I1
tp21467
sS'of,ethinyl'
p21468
(F0
F0
I3
I3
I0
tp21469
sS'extensively,metabolized'
p21470
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21471
sS'toxicology,of'
p21472
(F1
F0.00014334862385321102
I0
I1
I-1
tp21473
sS'alcohol,there'
p21474
(F1
F0.00014334862385321102
I0
I1
I-1
tp21475
sS'drug,interactions'
p21476
(F0
F0
I7
I7
I0
tp21477
sS'with,gastric'
p21478
(F1
F0.00014334862385321102
I0
I1
I-1
tp21479
sS'approximately,of'
p21480
(F0
F0
I1
I1
I0
tp21481
sS'is,still'
p21482
(F0
F0
I1
I1
I0
tp21483
sS'particularly,with'
p21484
(F1
F0.00014334862385321102
I1
I0
I1
tp21485
sS'severe,bronchospasm'
p21486
(F1
F0.00014334862385321102
I1
I0
I1
tp21487
sS'inotropic,such'
p21488
(F1
F0.00014334862385321102
I1
I0
I1
tp21489
sS'mtx,in'
p21490
(F1
F0.00014334862385321102
I0
I1
I-1
tp21491
sS'antiprothrombinemic,effect'
p21492
(F1
F0.00014334862385321102
I0
I1
I-1
tp21493
sS'any,procedure'
p21494
(F1
F0.00014334862385321102
I0
I1
I-1
tp21495
sS'and,variable'
p21496
(F1
F0.00014334862385321102
I0
I1
I-1
tp21497
sS'transit-enhancing,effect'
p21498
(F1
F0.00014334862385321102
I0
I1
I-1
tp21499
sS'morphine,pharmacokinetic'
p21500
(F1
F0.00014334862385321102
I0
I1
I-1
tp21501
sS'appetite,and'
p21502
(F1
F0.00014334862385321102
I0
I1
I-1
tp21503
sS'as,has'
p21504
(F0
F0
I1
I1
I0
tp21505
sS'time,as'
p21506
(F1
F0.00014334862385321102
I1
I0
I1
tp21507
sS'strong,inhibitors'
p21508
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp21509
sS'iva-sensitive,p-type'
p21510
(F1
F0.00014334862385321102
I0
I1
I-1
tp21511
sS'taking,vioxx'
p21512
(F1
F0.00014334862385321102
I1
I0
I1
tp21513
sS'little,has'
p21514
(F1
F0.00014334862385321102
I0
I1
I-1
tp21515
sS'vary,in'
p21516
(F1
F0.00071674311926605509
I0
I5
I-5
tp21517
sS'two,to'
p21518
(F1
F0.00014334862385321102
I1
I0
I1
tp21519
sS'by,confidence'
p21520
(F1
F0.00014334862385321102
I0
I1
I-1
tp21521
sS'their,need'
p21522
(F1
F0.00014334862385321102
I0
I1
I-1
tp21523
sS'free,and'
p21524
(F1
F0.00014334862385321102
I1
I0
I1
tp21525
sS'and,cyp3a5'
p21526
(F1
F0.00014334862385321102
I0
I1
I-1
tp21527
sS'toxicokinetic,studies'
p21528
(F1
F0.00014334862385321102
I0
I1
I-1
tp21529
sS'the,degree'
p21530
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp21531
sS'combination,study'
p21532
(F1
F0.00014334862385321102
I1
I0
I1
tp21533
sS'the,production'
p21534
(F0
F0
I2
I2
I0
tp21535
sS'absorption,and'
p21536
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp21537
sS'safely,tolerated'
p21538
(F1
F0.00014334862385321102
I0
I1
I-1
tp21539
sS'supplemental,l-glutamine'
p21540
(F1
F0.00028669724770642203
I2
I0
I2
tp21541
sS'each,to'
p21542
(F1
F0.00014334862385321102
I1
I0
I1
tp21543
sS'observations,from'
p21544
(F1
F0.00014334862385321102
I0
I1
I-1
tp21545
sS'n,hypotension'
p21546
(F1
F0.00014334862385321102
I1
I0
I1
tp21547
sS'efficacy,toxicity'
p21548
(F1
F0.00014334862385321102
I0
I1
I-1
tp21549
sS'prevention,studies'
p21550
(F1
F0.00014334862385321102
I0
I1
I-1
tp21551
sS'celebrex,mg'
p21552
(F1
F0.00014334862385321102
I1
I0
I1
tp21553
sS'ketoconazole,and'
p21554
(F0
F0
I1
I1
I0
tp21555
sS'creatinine,despite'
p21556
(F1
F0.00014334862385321102
I0
I1
I-1
tp21557
sS'probably,reduces'
p21558
(F1
F0.00014334862385321102
I1
I0
I1
tp21559
sS'be,significantly'
p21560
(F1
F0.00014334862385321102
I0
I1
I-1
tp21561
sS'accutane,has'
p21562
(F1
F0.00014334862385321102
I0
I1
I-1
tp21563
sS'a,clinically'
p21564
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp21565
sS'taking,to'
p21566
(F1
F0.00014334862385321102
I1
I0
I1
tp21567
sS'delta,and'
p21568
(F1
F0.00014334862385321102
I0
I1
I-1
tp21569
sS'dose,decrease'
p21570
(F1
F0.00014334862385321102
I1
I0
I1
tp21571
sS'dopa,decarboxylase'
p21572
(F1
F0.00028669724770642203
I0
I2
I-2
tp21573
sS'p,and'
p21574
(F1
F0.00014334862385321102
I1
I0
I1
tp21575
sS'are,co-administered'
p21576
(F1
F0.00014334862385321102
I1
I0
I1
tp21577
sS'removes,the'
p21578
(F1
F0.00014334862385321102
I1
I0
I1
tp21579
sS'daily,for'
p21580
(F0
F0
I11
I11
I0
tp21581
sS'report,that'
p21582
(F1
F0.00014334862385321102
I1
I0
I1
tp21583
sS'be,terminated'
p21584
(F1
F0.00014334862385321102
I1
I0
I1
tp21585
sS'intramuscularly,injected'
p21586
(F1
F0.00014334862385321102
I0
I1
I-1
tp21587
sS'dose,during'
p21588
(F1
F0.00014334862385321102
I0
I1
I-1
tp21589
sS'of,crude'
p21590
(F1
F0.00014334862385321102
I0
I1
I-1
tp21591
sS'and,loss'
p21592
(F1
F0.00014334862385321102
I1
I0
I1
tp21593
sS'bioavailability,of'
p21594
(F0.17647058823529413
F0.00043004587155963305
I7
I10
I-3
tp21595
sS'neuronal,damage'
p21596
(F1
F0.00014334862385321102
I1
I0
I1
tp21597
sS'of,torsade'
p21598
(F1
F0.00028669724770642203
I2
I0
I2
tp21599
sS'increased,both'
p21600
(F1
F0.00014334862385321102
I0
I1
I-1
tp21601
sS'the,therapy'
p21602
(F1
F0.00014334862385321102
I1
I0
I1
tp21603
sS'in,approximately'
p21604
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp21605
sS'is,rapidly'
p21606
(F1
F0.00014334862385321102
I0
I1
I-1
tp21607
sS'promote,absorption'
p21608
(F1
F0.00043004587155963305
I3
I0
I3
tp21609
sS'both,alone'
p21610
(F1
F0.00014334862385321102
I0
I1
I-1
tp21611
sS'c,antiarrhythrnics'
p21612
(F1
F0.00014334862385321102
I0
I1
I-1
tp21613
sS'blood-glucose,lowering'
p21614
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp21615
sS'administration,for'
p21616
(F1
F0.00028669724770642203
I0
I2
I-2
tp21617
sS'glucose,in'
p21618
(F1
F0.00028669724770642203
I0
I2
I-2
tp21619
sS'the,mechanism'
p21620
(F0.5
F0.00028669724770642203
I3
I1
I2
tp21621
sS'that,interfere'
p21622
(F0
F0
I2
I2
I0
tp21623
sS'serious,clinical'
p21624
(F1
F0.00014334862385321102
I1
I0
I1
tp21625
sS'including,midamor'
p21626
(F1
F0.00014334862385321102
I1
I0
I1
tp21627
sS'the,polyene'
p21628
(F1
F0.00014334862385321102
I0
I1
I-1
tp21629
sS'insufficient,to'
p21630
(F1
F0.00014334862385321102
I1
I0
I1
tp21631
sS'with,multiple'
p21632
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp21633
sS'and,downward'
p21634
(F1
F0.00014334862385321102
I1
I0
I1
tp21635
sS'complications,blurred'
p21636
(F1
F0.00014334862385321102
I1
I0
I1
tp21637
sS'days,however'
p21638
(F1
F0.00014334862385321102
I1
I0
I1
tp21639
sS'felbatol,the'
p21640
(F1
F0.00028669724770642203
I0
I2
I-2
tp21641
sS'channel,an'
p21642
(F1
F0.00014334862385321102
I0
I1
I-1
tp21643
sS'auc,was'
p21644
(F1
F0.00014334862385321102
I0
I1
I-1
tp21645
sS'longer,intervals'
p21646
(F1
F0.00014334862385321102
I1
I0
I1
tp21647
sS'compazine,sparine'
p21648
(F1
F0.00014334862385321102
I0
I1
I-1
tp21649
sS'those,receiving'
p21650
(F1
F0.00014334862385321102
I1
I0
I1
tp21651
sS'day,decreases'
p21652
(F1
F0.00014334862385321102
I1
I0
I1
tp21653
sS'agents,folic'
p21654
(F1
F0.00028669724770642203
I0
I2
I-2
tp21655
sS'after,prolonged'
p21656
(F1
F0.00014334862385321102
I0
I1
I-1
tp21657
sS'rofecoxib,mg'
p21658
(F1
F0.00014334862385321102
I0
I1
I-1
tp21659
sS'n,had'
p21660
(F1
F0.00014334862385321102
I0
I1
I-1
tp21661
sS'as,motrin'
p21662
(F1
F0.00014334862385321102
I0
I1
I-1
tp21663
sS'blockers,certain'
p21664
(F1
F0.00014334862385321102
I1
I0
I1
tp21665
sS'of,hepatic'
p21666
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp21667
sS'conduction,such'
p21668
(F1
F0.00014334862385321102
I1
I0
I1
tp21669
sS'without,alterations'
p21670
(F1
F0.00014334862385321102
I0
I1
I-1
tp21671
sS'in,conjunction'
p21672
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp21673
sS'an,active'
p21674
(F1
F0.00014334862385321102
I0
I1
I-1
tp21675
sS'endogenous,prostaglandin'
p21676
(F1
F0.00014334862385321102
I1
I0
I1
tp21677
sS'the,tarceva'
p21678
(F1
F0.00014334862385321102
I1
I0
I1
tp21679
sS'the,intracellular'
p21680
(F0.5
F0.00028669724770642203
I3
I1
I2
tp21681
sS'phenothiazines,taking'
p21682
(F1
F0.00014334862385321102
I1
I0
I1
tp21683
sS'over,three'
p21684
(F1
F0.00014334862385321102
I0
I1
I-1
tp21685
sS'or,innovar'
p21686
(F1
F0.00014334862385321102
I1
I0
I1
tp21687
sS'is,concluded'
p21688
(F0
F0
I2
I2
I0
tp21689
sS'n-oxide,were'
p21690
(F1
F0.00014334862385321102
I0
I1
I-1
tp21691
sS'in,these'
p21692
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp21693
sS'given,injections'
p21694
(F1
F0.00014334862385321102
I0
I1
I-1
tp21695
sS'four-session,placebo-controlled'
p21696
(F1
F0.00014334862385321102
I0
I1
I-1
tp21697
sS'yielded,similar'
p21698
(F1
F0.00014334862385321102
I0
I1
I-1
tp21699
sS'considered,and'
p21700
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp21701
sS'pronounced,effect'
p21702
(F1
F0.00014334862385321102
I1
I0
I1
tp21703
sS'tablets,should'
p21704
(F0
F0
I1
I1
I0
tp21705
sS'of,combined'
p21706
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21707
sS'of,grapefruit'
p21708
(F1
F0.00028669724770642203
I0
I2
I-2
tp21709
sS'capsules,are'
p21710
(F1
F0.00014334862385321102
I1
I0
I1
tp21711
sS'agents,but'
p21712
(F1
F0.00014334862385321102
I1
I0
I1
tp21713
sS'metabolism,to'
p21714
(F1
F0.00014334862385321102
I1
I0
I1
tp21715
sS'or,was'
p21716
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp21717
sS'the,last'
p21718
(F0
F0
I1
I1
I0
tp21719
sS'of,stress'
p21720
(F1
F0.00014334862385321102
I0
I1
I-1
tp21721
sS'patients,concomitantly'
p21722
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp21723
sS'interactions,following'
p21724
(F1
F0.00014334862385321102
I0
I1
I-1
tp21725
sS'a,slight'
p21726
(F1
F0.0008600917431192661
I6
I0
I6
tp21727
sS'nonsteroidal,antiinflammatory'
p21728
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21729
sS'in,but'
p21730
(F1
F0.00014334862385321102
I1
I0
I1
tp21731
sS'minipill,preparations'
p21732
(F1
F0.00014334862385321102
I1
I0
I1
tp21733
sS'prothrombin,time'
p21734
(F0.2857142857142857
F0.0017201834862385322
I27
I15
I12
tp21735
sS'thus,agents'
p21736
(F1
F0.00014334862385321102
I0
I1
I-1
tp21737
sS'aspergillus,eia'
p21738
(F1
F0.00014334862385321102
I0
I1
I-1
tp21739
sS'been,done'
p21740
(F0
F0
I1
I1
I0
tp21741
sS'danger,of'
p21742
(F1
F0.00043004587155963305
I3
I0
I3
tp21743
sS'concomitant,single'
p21744
(F1
F0.00014334862385321102
I1
I0
I1
tp21745
sS'nabilone,should'
p21746
(F1
F0.00014334862385321102
I1
I0
I1
tp21747
sS'showed,comparable'
p21748
(F1
F0.00014334862385321102
I0
I1
I-1
tp21749
sS'simulect,is'
p21750
(F1
F0.00014334862385321102
I0
I1
I-1
tp21751
sS'a2-selective,agonist'
p21752
(F1
F0.00014334862385321102
I1
I0
I1
tp21753
sS'single,oral'
p21754
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp21755
sS'closely,watched'
p21756
(F1
F0.00014334862385321102
I0
I1
I-1
tp21757
sS'inhibit,cyp'
p21758
(F1
F0.00014334862385321102
I1
I0
I1
tp21759
sS'employed,because'
p21760
(F1
F0.00014334862385321102
I1
I0
I1
tp21761
sS'buspirone,hydrochloride'
p21762
(F1
F0.00014334862385321102
I1
I0
I1
tp21763
sS'are,also'
p21764
(F1
F0.00071674311926605509
I5
I0
I5
tp21765
sS'single-dose,administration'
p21766
(F1
F0.00014334862385321102
I0
I1
I-1
tp21767
sS'susceptible,patients'
p21768
(F1
F0.00014334862385321102
I1
I0
I1
tp21769
sS'acarbose,has'
p21770
(F0
F0
I1
I1
I0
tp21771
sS'by,following'
p21772
(F1
F0.00014334862385321102
I1
I0
I1
tp21773
sS'exacerbation,or'
p21774
(F1
F0.00014334862385321102
I1
I0
I1
tp21775
sS'with,an'
p21776
(F0.56521739130434778
F0.0018635321100917432
I18
I5
I13
tp21777
sS'with,as'
p21778
(F1
F0.00057339449541284407
I4
I0
I4
tp21779
sS'with,at'
p21780
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp21781
sS'significant,teratogenic'
p21782
(F1
F0.00014334862385321102
I0
I1
I-1
tp21783
sS'in,binding'
p21784
(F1
F0.00014334862385321102
I1
I0
I1
tp21785
sS'or,even'
p21786
(F1
F0.00014334862385321102
I0
I1
I-1
tp21787
sS'or,salicylic'
p21788
(F1
F0.00028669724770642203
I0
I2
I-2
tp21789
sS'dihydroxycholecalciferol,d3'
p21790
(F1
F0.00014334862385321102
I0
I1
I-1
tp21791
sS'other,strong'
p21792
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21793
sS'of,nondepolarizing'
p21794
(F0.5
F0.00028669724770642203
I3
I1
I2
tp21795
sS'of,systemically'
p21796
(F1
F0.00014334862385321102
I0
I1
I-1
tp21797
sS'ability,of'
p21798
(F0
F0
I1
I1
I0
tp21799
sS'and,minimizes'
p21800
(F1
F0.00014334862385321102
I1
I0
I1
tp21801
sS'n,vs'
p21802
(F1
F0.00014334862385321102
I0
I1
I-1
tp21803
sS'fold,elevations'
p21804
(F1
F0.00014334862385321102
I1
I0
I1
tp21805
sS'orally,inhaled'
p21806
(F0
F0
I1
I1
I0
tp21807
sS'concomitant,agent'
p21808
(F1
F0.00014334862385321102
I1
I0
I1
tp21809
sS'the,groups'
p21810
(F0
F0
I1
I1
I0
tp21811
sS'is,small'
p21812
(F0
F0
I1
I1
I0
tp21813
sS'six,healthy'
p21814
(F1
F0.00014334862385321102
I1
I0
I1
tp21815
sS'was,combined'
p21816
(F0
F0
I1
I1
I0
tp21817
sS'with,appropriate'
p21818
(F1
F0.00014334862385321102
I0
I1
I-1
tp21819
sS'etopophos,with'
p21820
(F1
F0.00014334862385321102
I1
I0
I1
tp21821
sS'translocation,when'
p21822
(F1
F0.00014334862385321102
I0
I1
I-1
tp21823
sS'a,modest'
p21824
(F1
F0.00043004587155963305
I3
I0
I3
tp21825
sS'oral,unreliable'
p21826
(F1
F0.00014334862385321102
I1
I0
I1
tp21827
sS'days,or'
p21828
(F1
F0.00014334862385321102
I0
I1
I-1
tp21829
sS'potentiating,action'
p21830
(F1
F0.00014334862385321102
I1
I0
I1
tp21831
sS'with,rheumatoid'
p21832
(F1
F0.00014334862385321102
I0
I1
I-1
tp21833
sS'taking,fortovase'
p21834
(F1
F0.00014334862385321102
I0
I1
I-1
tp21835
sS'days,of'
p21836
(F0.5
F0.0008600917431192661
I3
I9
I-6
tp21837
sS'relevant,interaction'
p21838
(F1
F0.00014334862385321102
I1
I0
I1
tp21839
sS'if,replacing'
p21840
(F1
F0.00014334862385321102
I1
I0
I1
tp21841
sS'an,open'
p21842
(F1
F0.00014334862385321102
I0
I1
I-1
tp21843
sS'vasoconstrictive,and'
p21844
(F1
F0.00014334862385321102
I1
I0
I1
tp21845
sS'and,undetectable'
p21846
(F1
F0.00014334862385321102
I0
I1
I-1
tp21847
sS'highly,active'
p21848
(F1
F0.00014334862385321102
I0
I1
I-1
tp21849
sS'one-third,when'
p21850
(F1
F0.00014334862385321102
I0
I1
I-1
tp21851
sS'its,breakdown'
p21852
(F1
F0.00014334862385321102
I1
I0
I1
tp21853
sS'effects,due'
p21854
(F1
F0.00014334862385321102
I1
I0
I1
tp21855
sS'high,risk'
p21856
(F1
F0.0008600917431192661
I6
I0
I6
tp21857
sS'free,cmin'
p21858
(F1
F0.00014334862385321102
I0
I1
I-1
tp21859
sS'duloxetine-treated,patients'
p21860
(F1
F0.00014334862385321102
I0
I1
I-1
tp21861
sS'instances,of'
p21862
(F1
F0.00028669724770642203
I2
I0
I2
tp21863
sS'cystic,fluid'
p21864
(F1
F0.00014334862385321102
I1
I0
I1
tp21865
sS'also,to'
p21866
(F1
F0.00014334862385321102
I1
I0
I1
tp21867
sS'because,anafranil'
p21868
(F1
F0.00014334862385321102
I1
I0
I1
tp21869
sS'n-allylnormetazocine,nanm'
p21870
(F1
F0.00014334862385321102
I0
I1
I-1
tp21871
sS'completely,cleared'
p21872
(F1
F0.00014334862385321102
I0
I1
I-1
tp21873
sS'aeruginosa,serotype'
p21874
(F1
F0.00014334862385321102
I0
I1
I-1
tp21875
sS'objective,was'
p21876
(F1
F0.00028669724770642203
I0
I2
I-2
tp21877
sS'required,when'
p21878
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp21879
sS'demonstrated,by'
p21880
(F1
F0.00014334862385321102
I0
I1
I-1
tp21881
sS'toxic,product'
p21882
(F1
F0.00014334862385321102
I0
I1
I-1
tp21883
sS'this,inhibitory'
p21884
(F1
F0.00014334862385321102
I0
I1
I-1
tp21885
sS'and,acamprosate'
p21886
(F1
F0.00014334862385321102
I0
I1
I-1
tp21887
sS'to,after'
p21888
(F1
F0.00014334862385321102
I1
I0
I1
tp21889
sS'pharmacodynamics,or'
p21890
(F1
F0.00014334862385321102
I0
I1
I-1
tp21891
sS'the,combined'
p21892
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp21893
sS'been,co-administered'
p21894
(F0
F0
I1
I1
I0
tp21895
sS'serum,meq'
p21896
(F1
F0.00014334862385321102
I1
I0
I1
tp21897
sS'the,insp'
p21898
(F1
F0.00014334862385321102
I0
I1
I-1
tp21899
sS'levels,but'
p21900
(F1
F0.00014334862385321102
I0
I1
I-1
tp21901
sS'delaying,elimination'
p21902
(F1
F0.00028669724770642203
I2
I0
I2
tp21903
sS'are,usually'
p21904
(F1
F0.00014334862385321102
I1
I0
I1
tp21905
sS'warfarin,digoxin'
p21906
(F1
F0.00014334862385321102
I1
I0
I1
tp21907
sS'symptoms,severe'
p21908
(F1
F0.00014334862385321102
I1
I0
I1
tp21909
sS'be,refractory'
p21910
(F1
F0.00014334862385321102
I1
I0
I1
tp21911
sS'toxicity,occur'
p21912
(F1
F0.00014334862385321102
I1
I0
I1
tp21913
sS'so,plasma'
p21914
(F1
F0.00014334862385321102
I1
I0
I1
tp21915
sS'examining,mg'
p21916
(F1
F0.00014334862385321102
I1
I0
I1
tp21917
sS'neither,influenced'
p21918
(F1
F0.00014334862385321102
I0
I1
I-1
tp21919
sS'or,t'
p21920
(F1
F0.00028669724770642203
I0
I2
I-2
tp21921
sS'or,s'
p21922
(F0
F0
I1
I1
I0
tp21923
sS'general,such'
p21924
(F1
F0.00028669724770642203
I2
I0
I2
tp21925
sS'antidiuretic,activity'
p21926
(F1
F0.00014334862385321102
I0
I1
I-1
tp21927
sS'or,a'
p21928
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp21929
sS'or,n'
p21930
(F1
F0.00014334862385321102
I1
I0
I1
tp21931
sS'or,h'
p21932
(F0
F0
I1
I1
I0
tp21933
sS'and,that'
p21934
(F0.16666666666666666
F0.00028669724770642203
I5
I7
I-2
tp21935
sS'with,equetrotm'
p21936
(F1
F0.00014334862385321102
I1
I0
I1
tp21937
sS'agents,these'
p21938
(F0
F0
I1
I1
I0
tp21939
sS'multiple-dose,suggesting'
p21940
(F1
F0.00014334862385321102
I0
I1
I-1
tp21941
sS'are,increased'
p21942
(F1
F0.00043004587155963305
I3
I0
I3
tp21943
sS'urinary,protein'
p21944
(F1
F0.00014334862385321102
I0
I1
I-1
tp21945
sS'pulmonary,function'
p21946
(F1
F0.00014334862385321102
I0
I1
I-1
tp21947
sS'the,anti-coagulant'
p21948
(F1
F0.00014334862385321102
I0
I1
I-1
tp21949
sS'available,in'
p21950
(F1
F0.00014334862385321102
I0
I1
I-1
tp21951
sS'this,the'
p21952
(F1
F0.00014334862385321102
I0
I1
I-1
tp21953
sS'l-tyrosine,and'
p21954
(F1
F0.00014334862385321102
I1
I0
I1
tp21955
sS'dose,adjustment'
p21956
(F0.058823529411764705
F0.00014334862385321102
I8
I9
I-1
tp21957
sS'when,was'
p21958
(F0.41935483870967744
F0.0018635321100917432
I22
I9
I13
tp21959
sS'medicine,such'
p21960
(F1
F0.00014334862385321102
I0
I1
I-1
tp21961
sS'to,vehicle-'
p21962
(F1
F0.00014334862385321102
I1
I0
I1
tp21963
sS'mcg,of'
p21964
(F0
F0
I1
I1
I0
tp21965
sS'substantial,increases'
p21966
(F1
F0.00014334862385321102
I1
I0
I1
tp21967
sS'of,cefditoren'
p21968
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21969
sS'was,reduced'
p21970
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp21971
sS'necessitating,an'
p21972
(F1
F0.00014334862385321102
I1
I0
I1
tp21973
sS'plasma,kinetics'
p21974
(F1
F0.00014334862385321102
I0
I1
I-1
tp21975
sS'enzyme,inhibitor'
p21976
(F1
F0.00014334862385321102
I1
I0
I1
tp21977
sS'linear,logarithmic'
p21978
(F1
F0.00014334862385321102
I0
I1
I-1
tp21979
sS'play,a'
p21980
(F1
F0.00014334862385321102
I0
I1
I-1
tp21981
sS'beginning,discontinuing'
p21982
(F1
F0.00014334862385321102
I1
I0
I1
tp21983
sS'and,current'
p21984
(F1
F0.00014334862385321102
I1
I0
I1
tp21985
sS'improved,permeation'
p21986
(F1
F0.00014334862385321102
I0
I1
I-1
tp21987
sS'data,where'
p21988
(F1
F0.00014334862385321102
I1
I0
I1
tp21989
sS'between,trileptal'
p21990
(F1
F0.00014334862385321102
I0
I1
I-1
tp21991
sS'before,intramuscular'
p21992
(F1
F0.00014334862385321102
I1
I0
I1
tp21993
sS'prescribing,information'
p21994
(F1
F0.00043004587155963305
I0
I3
I-3
tp21995
sS'toxicity,should'
p21996
(F1
F0.00028669724770642203
I2
I0
I2
tp21997
sS'but,physicians'
p21998
(F1
F0.00028669724770642203
I2
I0
I2
tp21999
sS'of,plasma'
p22000
(F0.2857142857142857
F0.00057339449541284407
I9
I5
I4
tp22001
sS'reuptake,and'
p22002
(F1
F0.00014334862385321102
I1
I0
I1
tp22003
sS'therapy,indicate'
p22004
(F1
F0.00014334862385321102
I0
I1
I-1
tp22005
sS'patients,currently'
p22006
(F0
F0
I1
I1
I0
tp22007
sS'subjects,when'
p22008
(F1
F0.00014334862385321102
I1
I0
I1
tp22009
sS'mcg,bid'
p22010
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp22011
sS'whereas,b'
p22012
(F1
F0.00014334862385321102
I0
I1
I-1
tp22013
sS'concentrations,may'
p22014
(F1
F0.00028669724770642203
I2
I0
I2
tp22015
sS'it,concomitantly'
p22016
(F1
F0.00014334862385321102
I1
I0
I1
tp22017
sS'channel-blockers,ace'
p22018
(F1
F0.00014334862385321102
I0
I1
I-1
tp22019
sS'drug-drug,pharmacokinetic'
p22020
(F1
F0.00028669724770642203
I0
I2
I-2
tp22021
sS'intravenous,placebo'
p22022
(F1
F0.00014334862385321102
I0
I1
I-1
tp22023
sS'existing,clinical'
p22024
(F1
F0.00014334862385321102
I0
I1
I-1
tp22025
sS'selegiline,combination'
p22026
(F1
F0.00014334862385321102
I1
I0
I1
tp22027
sS'with,hypercholesterolemia'
p22028
(F1
F0.00014334862385321102
I0
I1
I-1
tp22029
sS'tikosyn,does'
p22030
(F1
F0.00028669724770642203
I0
I2
I-2
tp22031
sS'however,since'
p22032
(F0
F0
I1
I1
I0
tp22033
sS'on,glycosides'
p22034
(F1
F0.00014334862385321102
I0
I1
I-1
tp22035
sS'vasoactive,resulting'
p22036
(F1
F0.00014334862385321102
I1
I0
I1
tp22037
sS'mg,capsule'
p22038
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp22039
sS'degree,when'
p22040
(F1
F0.00014334862385321102
I0
I1
I-1
tp22041
sS'same,enzyme'
p22042
(F1
F0.00014334862385321102
I0
I1
I-1
tp22043
sS'closely,related'
p22044
(F1
F0.00028669724770642203
I2
I0
I2
tp22045
sS'involving,levo-dromoran'
p22046
(F1
F0.00014334862385321102
I0
I1
I-1
tp22047
sS'mg,single'
p22048
(F0
F0
I2
I2
I0
tp22049
sS'considerably,enhance'
p22050
(F1
F0.00014334862385321102
I0
I1
I-1
tp22051
sS'cardioselective,could'
p22052
(F1
F0.00014334862385321102
I0
I1
I-1
tp22053
sS'since,nsaids'
p22054
(F1
F0.00014334862385321102
I1
I0
I1
tp22055
sS'temperature,in'
p22056
(F1
F0.00014334862385321102
I0
I1
I-1
tp22057
sS'proleukin-induced,side'
p22058
(F1
F0.00014334862385321102
I1
I0
I1
tp22059
sS'with,emtriva'
p22060
(F1
F0.00014334862385321102
I0
I1
I-1
tp22061
sS'p,in'
p22062
(F0
F0
I1
I1
I0
tp22063
sS'predisposing,to'
p22064
(F1
F0.00014334862385321102
I1
I0
I1
tp22065
sS'eight,healthy'
p22066
(F1
F0.00014334862385321102
I1
I0
I1
tp22067
sS'elapse,before'
p22068
(F1
F0.00028669724770642203
I2
I0
I2
tp22069
sS'drugs,aeds'
p22070
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22071
sS'for,which'
p22072
(F1
F0.00043004587155963305
I0
I3
I-3
tp22073
sS'apoptosis,can'
p22074
(F1
F0.00014334862385321102
I0
I1
I-1
tp22075
sS'central,stimulant'
p22076
(F1
F0.00057339449541284407
I4
I0
I4
tp22077
sS'and,hour'
p22078
(F1
F0.00014334862385321102
I1
I0
I1
tp22079
sS'beta-blockers,salts'
p22080
(F1
F0.00028669724770642203
I2
I0
I2
tp22081
sS'mg,increased'
p22082
(F1
F0.00043004587155963305
I3
I0
I3
tp22083
sS'be,mixed'
p22084
(F1
F0.00043004587155963305
I0
I3
I-3
tp22085
sS'brevibloc,on'
p22086
(F1
F0.00014334862385321102
I0
I1
I-1
tp22087
sS'withdrawn,at'
p22088
(F1
F0.00028669724770642203
I2
I0
I2
tp22089
sS'nonsteroidal,probably'
p22090
(F1
F0.00014334862385321102
I1
I0
I1
tp22091
sS'preparations,produced'
p22092
(F1
F0.00014334862385321102
I0
I1
I-1
tp22093
sS'receiving,thiazide'
p22094
(F1
F0.00014334862385321102
I0
I1
I-1
tp22095
sS'cautiously,in'
p22096
(F1
F0.0008600917431192661
I6
I0
I6
tp22097
sS'cautiously,if'
p22098
(F1
F0.00014334862385321102
I0
I1
I-1
tp22099
sS'many,of'
p22100
(F1
F0.00014334862385321102
I0
I1
I-1
tp22101
sS'as,prolonged'
p22102
(F1
F0.00014334862385321102
I0
I1
I-1
tp22103
sS'rupture,or'
p22104
(F1
F0.00014334862385321102
I1
I0
I1
tp22105
sS'crescentic,iga'
p22106
(F1
F0.00014334862385321102
I1
I0
I1
tp22107
sS'of,single'
p22108
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp22109
sS'cyp3a4,rifampin'
p22110
(F1
F0.00014334862385321102
I0
I1
I-1
tp22111
sS'not,exhibit'
p22112
(F1
F0.00014334862385321102
I1
I0
I1
tp22113
sS'drugs,enhancing'
p22114
(F1
F0.00014334862385321102
I0
I1
I-1
tp22115
sS'data,showed'
p22116
(F1
F0.00014334862385321102
I0
I1
I-1
tp22117
sS'with,derivatives'
p22118
(F1
F0.00014334862385321102
I0
I1
I-1
tp22119
sS'preparations,should'
p22120
(F1
F0.00043004587155963305
I0
I3
I-3
tp22121
sS'to,steady'
p22122
(F1
F0.00014334862385321102
I1
I0
I1
tp22123
sS'restricted,antagonist'
p22124
(F1
F0.00014334862385321102
I1
I0
I1
tp22125
sS'agents,which'
p22126
(F1
F0.00028669724770642203
I2
I0
I2
tp22127
sS'is,different'
p22128
(F1
F0.00014334862385321102
I1
I0
I1
tp22129
sS'probenecid,the'
p22130
(F1
F0.00014334862385321102
I1
I0
I1
tp22131
sS'warfarin,the'
p22132
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp22133
sS'control,atrial'
p22134
(F1
F0.00014334862385321102
I1
I0
I1
tp22135
sS'acebutolol,and'
p22136
(F1
F0.00014334862385321102
I0
I1
I-1
tp22137
sS'egf-,or'
p22138
(F1
F0.00014334862385321102
I1
I0
I1
tp22139
sS'metabolism,was'
p22140
(F1
F0.00014334862385321102
I0
I1
I-1
tp22141
sS'and,paraclinical'
p22142
(F1
F0.00014334862385321102
I0
I1
I-1
tp22143
sS'auc,of'
p22144
(F1
F0.0057339449541284407
I40
I0
I40
tp22145
sS'enoxacin,does'
p22146
(F1
F0.00014334862385321102
I0
I1
I-1
tp22147
sS'many,that'
p22148
(F1
F0.00071674311926605509
I0
I5
I-5
tp22149
sS'auc,or'
p22150
(F1
F0.00028669724770642203
I0
I2
I-2
tp22151
sS'of,serious'
p22152
(F0.83333333333333337
F0.0014334862385321102
I11
I1
I10
tp22153
sS'neural,pathways'
p22154
(F1
F0.00014334862385321102
I0
I1
I-1
tp22155
sS'agranulocytosis,as'
p22156
(F1
F0.00014334862385321102
I0
I1
I-1
tp22157
sS'coadministered,than'
p22158
(F1
F0.00014334862385321102
I1
I0
I1
tp22159
sS'receiving,nonselective'
p22160
(F1
F0.00014334862385321102
I1
I0
I1
tp22161
sS'regularly,for'
p22162
(F0
F0
I1
I1
I0
tp22163
sS'n,for'
p22164
(F1
F0.00014334862385321102
I0
I1
I-1
tp22165
sS'either,medicine'
p22166
(F1
F0.00014334862385321102
I1
I0
I1
tp22167
sS'regimens,has'
p22168
(F1
F0.00014334862385321102
I0
I1
I-1
tp22169
sS'an,unsatisfactory'
p22170
(F1
F0.00014334862385321102
I1
I0
I1
tp22171
sS'several-,fold'
p22172
(F1
F0.00014334862385321102
I0
I1
I-1
tp22173
sS'dipyridamole,may'
p22174
(F1
F0.00014334862385321102
I1
I0
I1
tp22175
sS'anagrelide,alone'
p22176
(F1
F0.00014334862385321102
I1
I0
I1
tp22177
sS'interactions,observed'
p22178
(F1
F0.00014334862385321102
I1
I0
I1
tp22179
sS'coingestion,of'
p22180
(F1
F0.00014334862385321102
I1
I0
I1
tp22181
sS'competitive,inhibitor'
p22182
(F1
F0.00014334862385321102
I1
I0
I1
tp22183
sS'asparagine,levels'
p22184
(F1
F0.00028669724770642203
I2
I0
I2
tp22185
sS'pain,or'
p22186
(F1
F0.00014334862385321102
I0
I1
I-1
tp22187
sS'that,serum'
p22188
(F1
F0.00028669724770642203
I2
I0
I2
tp22189
sS'diuretics,fosinopril'
p22190
(F1
F0.00014334862385321102
I1
I0
I1
tp22191
sS'tablets,results'
p22192
(F1
F0.00028669724770642203
I2
I0
I2
tp22193
sS'propranolol,increases'
p22194
(F1
F0.00014334862385321102
I1
I0
I1
tp22195
sS'no,greater'
p22196
(F1
F0.00014334862385321102
I1
I0
I1
tp22197
sS'rna,from'
p22198
(F1
F0.00014334862385321102
I0
I1
I-1
tp22199
sS'effect,will'
p22200
(F1
F0.00014334862385321102
I1
I0
I1
tp22201
sS'and,during'
p22202
(F1
F0.00043004587155963305
I0
I3
I-3
tp22203
sS'controlled,parallel'
p22204
(F1
F0.00014334862385321102
I0
I1
I-1
tp22205
sS'subjects,administered'
p22206
(F1
F0.00014334862385321102
I1
I0
I1
tp22207
sS'of,blocking'
p22208
(F1
F0.00028669724770642203
I2
I0
I2
tp22209
sS'rise,to'
p22210
(F1
F0.00014334862385321102
I1
I0
I1
tp22211
sS'the,major'
p22212
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp22213
sS'potential,components'
p22214
(F1
F0.00014334862385321102
I0
I1
I-1
tp22215
sS'conditions,similar'
p22216
(F1
F0.00014334862385321102
I1
I0
I1
tp22217
sS'most,closely'
p22218
(F1
F0.00014334862385321102
I0
I1
I-1
tp22219
sS'present,a'
p22220
(F1
F0.00014334862385321102
I1
I0
I1
tp22221
sS'consequently,with'
p22222
(F1
F0.00014334862385321102
I0
I1
I-1
tp22223
sS'arginine,in'
p22224
(F1
F0.00028669724770642203
I0
I2
I-2
tp22225
sS'doxazosin,mesylate'
p22226
(F1
F0.00014334862385321102
I0
I1
I-1
tp22227
sS'and,cmin'
p22228
(F1
F0.00057339449541284407
I4
I0
I4
tp22229
sS'motor,effects'
p22230
(F1
F0.00014334862385321102
I1
I0
I1
tp22231
sS'established,if'
p22232
(F1
F0.00014334862385321102
I0
I1
I-1
tp22233
sS'were,elevated'
p22234
(F1
F0.00014334862385321102
I0
I1
I-1
tp22235
sS'or,compounds'
p22236
(F1
F0.00014334862385321102
I0
I1
I-1
tp22237
sS'its,absorption'
p22238
(F1
F0.00014334862385321102
I1
I0
I1
tp22239
sS'anesthetics,general'
p22240
(F1
F0.00014334862385321102
I1
I0
I1
tp22241
sS'main,hemostatic'
p22242
(F1
F0.00014334862385321102
I1
I0
I1
tp22243
sS'false,low'
p22244
(F1
F0.00014334862385321102
I0
I1
I-1
tp22245
sS'levels,has'
p22246
(F1
F0.00014334862385321102
I1
I0
I1
tp22247
sS'such,preparations'
p22248
(F1
F0.00014334862385321102
I1
I0
I1
tp22249
sS'strong,cyp3a4'
p22250
(F1
F0.00071674311926605509
I5
I0
I5
tp22251
sS'which,competes'
p22252
(F1
F0.00014334862385321102
I1
I0
I1
tp22253
sS'and,potentiates'
p22254
(F1
F0.00014334862385321102
I0
I1
I-1
tp22255
sS'habituating,potential'
p22256
(F1
F0.00014334862385321102
I0
I1
I-1
tp22257
sS'fold,lower'
p22258
(F1
F0.00014334862385321102
I1
I0
I1
tp22259
sS'and,neither'
p22260
(F1
F0.00014334862385321102
I0
I1
I-1
tp22261
sS'on,in-vitro'
p22262
(F1
F0.00014334862385321102
I0
I1
I-1
tp22263
sS'period,particularly'
p22264
(F1
F0.00014334862385321102
I1
I0
I1
tp22265
sS'established,in'
p22266
(F1
F0.00014334862385321102
I0
I1
I-1
tp22267
sS'taken,by'
p22268
(F1
F0.00028669724770642203
I0
I2
I-2
tp22269
sS'resulting,respiratory'
p22270
(F1
F0.00014334862385321102
I1
I0
I1
tp22271
sS'binds,both'
p22272
(F1
F0.00014334862385321102
I1
I0
I1
tp22273
sS'at,some'
p22274
(F1
F0.00014334862385321102
I1
I0
I1
tp22275
sS'infused,over'
p22276
(F1
F0.00014334862385321102
I0
I1
I-1
tp22277
sS'not,significantly'
p22278
(F0.81818181818181823
F0.0025802752293577983
I2
I20
I-18
tp22279
sS'of,mental'
p22280
(F1
F0.00014334862385321102
I0
I1
I-1
tp22281
sS'the,blockade'
p22282
(F1
F0.00014334862385321102
I0
I1
I-1
tp22283
sS'plus,vioxx'
p22284
(F1
F0.00014334862385321102
I0
I1
I-1
tp22285
sS'breath,test'
p22286
(F1
F0.00014334862385321102
I0
I1
I-1
tp22287
sS'concentrations,were'
p22288
(F0.38461538461538464
F0.00071674311926605509
I4
I9
I-5
tp22289
sS'at,microm'
p22290
(F0
F0
I1
I1
I0
tp22291
sS'with,fluoxetine'
p22292
(F1
F0.00014334862385321102
I0
I1
I-1
tp22293
sS'both,first'
p22294
(F1
F0.00014334862385321102
I1
I0
I1
tp22295
sS'lodine,is'
p22296
(F1
F0.00014334862385321102
I1
I0
I1
tp22297
sS'sympathomimet-ics,channel'
p22298
(F1
F0.00014334862385321102
I0
I1
I-1
tp22299
sS'on,overall'
p22300
(F1
F0.00014334862385321102
I0
I1
I-1
tp22301
sS'separated,from'
p22302
(F1
F0.00014334862385321102
I1
I0
I1
tp22303
sS'excessive,widening'
p22304
(F1
F0.00014334862385321102
I1
I0
I1
tp22305
sS'by,electrocardiographic'
p22306
(F1
F0.00028669724770642203
I0
I2
I-2
tp22307
sS'cyp2a6,cyp2c9'
p22308
(F1
F0.00043004587155963305
I0
I3
I-3
tp22309
sS'determination,of'
p22310
(F1
F0.00043004587155963305
I0
I3
I-3
tp22311
sS'mellitus,certain'
p22312
(F1
F0.00014334862385321102
I0
I1
I-1
tp22313
sS'accumulated,in'
p22314
(F1
F0.00014334862385321102
I1
I0
I1
tp22315
sS'gabitril,with'
p22316
(F1
F0.00028669724770642203
I0
I2
I-2
tp22317
sS'receiving,to'
p22318
(F1
F0.00014334862385321102
I1
I0
I1
tp22319
sS'administering,etopophos'
p22320
(F1
F0.00014334862385321102
I1
I0
I1
tp22321
sS'is,potentially'
p22322
(F1
F0.00014334862385321102
I0
I1
I-1
tp22323
sS'serious,or'
p22324
(F1
F0.00028669724770642203
I0
I2
I-2
tp22325
sS'prostaglandin,synthetase'
p22326
(F1
F0.00014334862385321102
I0
I1
I-1
tp22327
sS'dosing,by'
p22328
(F1
F0.00014334862385321102
I0
I1
I-1
tp22329
sS'cyp1a2,and'
p22330
(F1
F0.00014334862385321102
I0
I1
I-1
tp22331
sS'pharmacokinetics,exposure-response'
p22332
(F1
F0.00014334862385321102
I0
I1
I-1
tp22333
sS'enhancing,the'
p22334
(F1
F0.00014334862385321102
I1
I0
I1
tp22335
sS'increased,metabolic'
p22336
(F1
F0.00014334862385321102
I1
I0
I1
tp22337
sS'than,has'
p22338
(F1
F0.00014334862385321102
I0
I1
I-1
tp22339
sS'ulcerative,colitis'
p22340
(F1
F0.00014334862385321102
I1
I0
I1
tp22341
sS'with,axert'
p22342
(F1
F0.00028669724770642203
I2
I0
I2
tp22343
sS'like,or'
p22344
(F1
F0.00043004587155963305
I3
I0
I3
tp22345
sS'compromise,the'
p22346
(F1
F0.00014334862385321102
I1
I0
I1
tp22347
sS'sodium,absorption'
p22348
(F1
F0.00014334862385321102
I1
I0
I1
tp22349
sS'causing,uterine'
p22350
(F1
F0.00014334862385321102
I1
I0
I1
tp22351
sS'be,associated'
p22352
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp22353
sS'triazole,have'
p22354
(F1
F0.00014334862385321102
I0
I1
I-1
tp22355
sS'antiviral,activity'
p22356
(F1
F0.00014334862385321102
I1
I0
I1
tp22357
sS'member,have'
p22358
(F1
F0.00014334862385321102
I1
I0
I1
tp22359
sS'similar,among'
p22360
(F1
F0.00014334862385321102
I0
I1
I-1
tp22361
sS'in,diabetic'
p22362
(F0
F0
I3
I3
I0
tp22363
sS'therapies,i'
p22364
(F1
F0.00014334862385321102
I0
I1
I-1
tp22365
sS'from,several'
p22366
(F1
F0.00014334862385321102
I0
I1
I-1
tp22367
sS'observed,following'
p22368
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp22369
sS'parameters,and'
p22370
(F1
F0.00014334862385321102
I1
I0
I1
tp22371
sS'circulation,the'
p22372
(F1
F0.00014334862385321102
I1
I0
I1
tp22373
sS'human,cytochrome'
p22374
(F1
F0.00028669724770642203
I0
I2
I-2
tp22375
sS'flolan,which'
p22376
(F1
F0.00014334862385321102
I1
I0
I1
tp22377
sS'similar,efficacy'
p22378
(F1
F0.00014334862385321102
I0
I1
I-1
tp22379
sS'with,less'
p22380
(F1
F0.00014334862385321102
I0
I1
I-1
tp22381
sS'of,neutropenia'
p22382
(F1
F0.00028669724770642203
I2
I0
I2
tp22383
sS'lower,doses'
p22384
(F0.59999999999999998
F0.0008600917431192661
I2
I8
I-6
tp22385
sS'oral,produced'
p22386
(F1
F0.00014334862385321102
I1
I0
I1
tp22387
sS'considered,during'
p22388
(F1
F0.00014334862385321102
I1
I0
I1
tp22389
sS'patients,is'
p22390
(F0
F0
I1
I1
I0
tp22391
sS'sulfoxide,by'
p22392
(F1
F0.00014334862385321102
I1
I0
I1
tp22393
sS'is,especially'
p22394
(F1
F0.00014334862385321102
I1
I0
I1
tp22395
sS'that,received'
p22396
(F1
F0.00014334862385321102
I0
I1
I-1
tp22397
sS'capsules,should'
p22398
(F1
F0.00014334862385321102
I0
I1
I-1
tp22399
sS'vardenafil,should'
p22400
(F1
F0.00028669724770642203
I2
I0
I2
tp22401
sS'r-warfarin,and'
p22402
(F1
F0.00014334862385321102
I1
I0
I1
tp22403
sS'orudis,doses'
p22404
(F1
F0.00014334862385321102
I0
I1
I-1
tp22405
sS'contraceptives,valdecoxib'
p22406
(F1
F0.00014334862385321102
I0
I1
I-1
tp22407
sS'flushing,mydriasis'
p22408
(F1
F0.00014334862385321102
I1
I0
I1
tp22409
sS'weaken,the'
p22410
(F1
F0.00028669724770642203
I2
I0
I2
tp22411
sS'a,history'
p22412
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp22413
sS'cases,where'
p22414
(F1
F0.00014334862385321102
I0
I1
I-1
tp22415
sS'too,little'
p22416
(F1
F0.00014334862385321102
I0
I1
I-1
tp22417
sS'therapy,which'
p22418
(F1
F0.00014334862385321102
I0
I1
I-1
tp22419
sS'and,under'
p22420
(F0
F0
I1
I1
I0
tp22421
sS'in,pharmacological'
p22422
(F1
F0.00014334862385321102
I1
I0
I1
tp22423
sS'either,secobarbitone'
p22424
(F1
F0.00014334862385321102
I1
I0
I1
tp22425
sS'chinese,hamster'
p22426
(F1
F0.00014334862385321102
I0
I1
I-1
tp22427
sS'hivid,with'
p22428
(F1
F0.00014334862385321102
I1
I0
I1
tp22429
sS'hormonal,increasing'
p22430
(F1
F0.00014334862385321102
I1
I0
I1
tp22431
sS'therapeutic,range'
p22432
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22433
sS'heparin,no'
p22434
(F1
F0.00014334862385321102
I0
I1
I-1
tp22435
sS'studies,and'
p22436
(F0
F0
I2
I2
I0
tp22437
sS'rr,is'
p22438
(F1
F0.00014334862385321102
I0
I1
I-1
tp22439
sS'azole,agents'
p22440
(F1
F0.00028669724770642203
I2
I0
I2
tp22441
sS'of,ketoconazole'
p22442
(F1
F0.00014334862385321102
I1
I0
I1
tp22443
sS'underlies,the'
p22444
(F1
F0.00014334862385321102
I0
I1
I-1
tp22445
sS'drugs,has'
p22446
(F1
F0.00014334862385321102
I1
I0
I1
tp22447
sS'a,member'
p22448
(F1
F0.00014334862385321102
I1
I0
I1
tp22449
sS'potassium-sparing,each'
p22450
(F1
F0.00014334862385321102
I0
I1
I-1
tp22451
sS'cmax,auc'
p22452
(F1
F0.00014334862385321102
I1
I0
I1
tp22453
sS'diabetes,used'
p22454
(F1
F0.00014334862385321102
I1
I0
I1
tp22455
sS'starting,the'
p22456
(F1
F0.00014334862385321102
I0
I1
I-1
tp22457
sS'and,titration'
p22458
(F1
F0.00014334862385321102
I1
I0
I1
tp22459
sS'increased,steady-state'
p22460
(F1
F0.00014334862385321102
I0
I1
I-1
tp22461
sS'excessive,fall'
p22462
(F1
F0.00014334862385321102
I1
I0
I1
tp22463
sS'animals,treated'
p22464
(F1
F0.00014334862385321102
I1
I0
I1
tp22465
sS'gastric,fistulas'
p22466
(F1
F0.00014334862385321102
I0
I1
I-1
tp22467
sS'to,treatment'
p22468
(F1
F0.00014334862385321102
I0
I1
I-1
tp22469
sS'of,ci'
p22470
(F0
F0
I1
I1
I0
tp22471
sS'to,minutes'
p22472
(F0
F0
I1
I1
I0
tp22473
sS'foscarnet,and'
p22474
(F1
F0.00014334862385321102
I1
I0
I1
tp22475
sS'clinically,necessary'
p22476
(F1
F0.00014334862385321102
I1
I0
I1
tp22477
sS'ssris,ssris'
p22478
(F1
F0.00014334862385321102
I1
I0
I1
tp22479
sS'probenecid,increases'
p22480
(F1
F0.00014334862385321102
I1
I0
I1
tp22481
sS'month,controlled'
p22482
(F1
F0.00014334862385321102
I0
I1
I-1
tp22483
sS'these,increased'
p22484
(F1
F0.00014334862385321102
I1
I0
I1
tp22485
sS'almost,fold'
p22486
(F1
F0.00014334862385321102
I1
I0
I1
tp22487
sS'zidovudine,ribavirin'
p22488
(F1
F0.00014334862385321102
I1
I0
I1
tp22489
sS'these,increases'
p22490
(F1
F0.00014334862385321102
I1
I0
I1
tp22491
sS'containing,hydroxide'
p22492
(F1
F0.00014334862385321102
I1
I0
I1
tp22493
sS'with,increased'
p22494
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp22495
sS'occur,when'
p22496
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp22497
sS'concentration,during'
p22498
(F1
F0.00014334862385321102
I1
I0
I1
tp22499
sS'b-,induced'
p22500
(F1
F0.00014334862385321102
I1
I0
I1
tp22501
sS'prostaglandin,synthesis'
p22502
(F1
F0.00043004587155963305
I3
I0
I3
tp22503
sS'the,antidepressant'
p22504
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp22505
sS'cypermethrin-induced,oxidative'
p22506
(F1
F0.00014334862385321102
I1
I0
I1
tp22507
sS'how,it'
p22508
(F1
F0.00028669724770642203
I0
I2
I-2
tp22509
sS'trials,the'
p22510
(F1
F0.00043004587155963305
I0
I3
I-3
tp22511
sS'population,chronically'
p22512
(F1
F0.00014334862385321102
I0
I1
I-1
tp22513
sS'depressants,causing'
p22514
(F1
F0.00028669724770642203
I2
I0
I2
tp22515
sS'the,combination'
p22516
(F0.55555555555555558
F0.0014334862385321102
I14
I4
I10
tp22517
sS'administered,hours'
p22518
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp22519
sS'with,camptosar'
p22520
(F1
F0.00028669724770642203
I2
I0
I2
tp22521
sS'a4,had'
p22522
(F1
F0.00014334862385321102
I0
I1
I-1
tp22523
sS'pharmacologically,active'
p22524
(F1
F0.00014334862385321102
I0
I1
I-1
tp22525
sS'lying,the'
p22526
(F1
F0.00014334862385321102
I1
I0
I1
tp22527
sS'beta-blockers,serum'
p22528
(F1
F0.00014334862385321102
I0
I1
I-1
tp22529
sS'bleeding,reduced'
p22530
(F1
F0.00014334862385321102
I1
I0
I1
tp22531
sS'a4,has'
p22532
(F1
F0.00014334862385321102
I0
I1
I-1
tp22533
sS'prinivil,an'
p22534
(F1
F0.00014334862385321102
I1
I0
I1
tp22535
sS'tcaplasma,levels'
p22536
(F1
F0.00014334862385321102
I0
I1
I-1
tp22537
sS'normal,tissues'
p22538
(F1
F0.00014334862385321102
I1
I0
I1
tp22539
sS'type,depth'
p22540
(F1
F0.00014334862385321102
I0
I1
I-1
tp22541
sS'o-desacetylrifabutin,and'
p22542
(F1
F0.00014334862385321102
I1
I0
I1
tp22543
sS'affected,during'
p22544
(F1
F0.00028669724770642203
I0
I2
I-2
tp22545
sS'and,severe'
p22546
(F1
F0.00014334862385321102
I1
I0
I1
tp22547
sS'mouth,constipation'
p22548
(F1
F0.00014334862385321102
I1
I0
I1
tp22549
sS'clinically,compatible'
p22550
(F1
F0.00014334862385321102
I0
I1
I-1
tp22551
sS'the,numerous'
p22552
(F1
F0.00014334862385321102
I0
I1
I-1
tp22553
sS'situ,hybridization'
p22554
(F1
F0.00014334862385321102
I1
I0
I1
tp22555
sS'blockers,are'
p22556
(F1
F0.00028669724770642203
I2
I0
I2
tp22557
sS'therefore,mao'
p22558
(F1
F0.00014334862385321102
I1
I0
I1
tp22559
sS'practically,only'
p22560
(F1
F0.00014334862385321102
I0
I1
I-1
tp22561
sS'is,shortened'
p22562
(F1
F0.00014334862385321102
I1
I0
I1
tp22563
sS'rats,at'
p22564
(F0
F0
I1
I1
I0
tp22565
sS'therefore,may'
p22566
(F1
F0.00014334862385321102
I1
I0
I1
tp22567
sS'included,mtx'
p22568
(F1
F0.00014334862385321102
I0
I1
I-1
tp22569
sS'hrs,of'
p22570
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp22571
sS'antihistamines,antimigraine'
p22572
(F1
F0.00014334862385321102
I1
I0
I1
tp22573
sS'or,diarrhea'
p22574
(F1
F0.00014334862385321102
I1
I0
I1
tp22575
sS'affect,sinus'
p22576
(F1
F0.00014334862385321102
I1
I0
I1
tp22577
sS'given,single'
p22578
(F1
F0.00014334862385321102
I1
I0
I1
tp22579
sS'threshold,concurrent'
p22580
(F1
F0.00014334862385321102
I1
I0
I1
tp22581
sS'given,singly'
p22582
(F1
F0.00014334862385321102
I0
I1
I-1
tp22583
sS'metabolite,i'
p22584
(F1
F0.00028669724770642203
I0
I2
I-2
tp22585
sS'which,resulted'
p22586
(F1
F0.00014334862385321102
I1
I0
I1
tp22587
sS'd,e'
p22588
(F1
F0.00014334862385321102
I0
I1
I-1
tp22589
sS'for,adverse'
p22590
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22591
sS'd,h'
p22592
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp22593
sS'necessary,because'
p22594
(F1
F0.00014334862385321102
I1
I0
I1
tp22595
sS'least,one'
p22596
(F1
F0.00014334862385321102
I1
I0
I1
tp22597
sS'were,already'
p22598
(F1
F0.00014334862385321102
I0
I1
I-1
tp22599
sS'sleep,drowsiness-causing'
p22600
(F1
F0.00014334862385321102
I0
I1
I-1
tp22601
sS'close,supervision'
p22602
(F0
F0
I2
I2
I0
tp22603
sS'again,given'
p22604
(F1
F0.00014334862385321102
I0
I1
I-1
tp22605
sS'added,drug'
p22606
(F1
F0.00014334862385321102
I0
I1
I-1
tp22607
sS'combination,to'
p22608
(F1
F0.00014334862385321102
I1
I0
I1
tp22609
sS'a,rate'
p22610
(F1
F0.00028669724770642203
I2
I0
I2
tp22611
sS'with,higher'
p22612
(F1
F0.00028669724770642203
I2
I0
I2
tp22613
sS'at,hours'
p22614
(F1
F0.00014334862385321102
I1
I0
I1
tp22615
sS'of,maximum'
p22616
(F1
F0.00014334862385321102
I1
I0
I1
tp22617
sS'concentration,for'
p22618
(F1
F0.00014334862385321102
I0
I1
I-1
tp22619
sS'mean,half-life'
p22620
(F1
F0.00014334862385321102
I1
I0
I1
tp22621
sS'taking,acamprosate'
p22622
(F1
F0.00014334862385321102
I1
I0
I1
tp22623
sS'antacids,kaolin-pectin'
p22624
(F1
F0.00014334862385321102
I1
I0
I1
tp22625
sS'humans,show'
p22626
(F1
F0.00014334862385321102
I1
I0
I1
tp22627
sS'as,systemic'
p22628
(F1
F0.00014334862385321102
I0
I1
I-1
tp22629
sS'drugs,the'
p22630
(F1
F0.00028669724770642203
I2
I0
I2
tp22631
sS'have,caused'
p22632
(F1
F0.00014334862385321102
I1
I0
I1
tp22633
sS'subutex,and'
p22634
(F1
F0.00014334862385321102
I1
I0
I1
tp22635
sS'increased,renal'
p22636
(F1
F0.00014334862385321102
I0
I1
I-1
tp22637
sS'agents,demonstrated'
p22638
(F1
F0.00014334862385321102
I0
I1
I-1
tp22639
sS'and,subcutaneous'
p22640
(F1
F0.00014334862385321102
I0
I1
I-1
tp22641
sS'one,day'
p22642
(F1
F0.00014334862385321102
I0
I1
I-1
tp22643
sS'an,aluminum-containing'
p22644
(F1
F0.00014334862385321102
I0
I1
I-1
tp22645
sS'anticoagulants,there'
p22646
(F1
F0.00028669724770642203
I2
I0
I2
tp22647
sS'micromol,l'
p22648
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22649
sS'death,have'
p22650
(F0
F0
I1
I1
I0
tp22651
sS'performance,for'
p22652
(F1
F0.00028669724770642203
I2
I0
I2
tp22653
sS'motor,skills'
p22654
(F1
F0.00028669724770642203
I0
I2
I-2
tp22655
sS'this,paper'
p22656
(F1
F0.00014334862385321102
I0
I1
I-1
tp22657
sS'hormone-binding,globulin'
p22658
(F1
F0.00014334862385321102
I0
I1
I-1
tp22659
sS'least,two'
p22660
(F1
F0.00014334862385321102
I1
I0
I1
tp22661
sS'trileptal,and'
p22662
(F1
F0.00014334862385321102
I0
I1
I-1
tp22663
sS'option,in'
p22664
(F1
F0.00014334862385321102
I0
I1
I-1
tp22665
sS'arava,was'
p22666
(F1
F0.00014334862385321102
I1
I0
I1
tp22667
sS'as,platelet'
p22668
(F1
F0.00014334862385321102
I0
I1
I-1
tp22669
sS'staphylococcus,aureus'
p22670
(F1
F0.00014334862385321102
I1
I0
I1
tp22671
sS'the,levulan'
p22672
(F1
F0.00014334862385321102
I1
I0
I1
tp22673
sS'and,hiv'
p22674
(F1
F0.00014334862385321102
I0
I1
I-1
tp22675
sS'time,from'
p22676
(F1
F0.00014334862385321102
I1
I0
I1
tp22677
sS'such,patients'
p22678
(F1
F0.00043004587155963305
I3
I0
I3
tp22679
sS'or,cervical'
p22680
(F1
F0.00014334862385321102
I1
I0
I1
tp22681
sS'a,decreased'
p22682
(F1
F0.00057339449541284407
I4
I0
I4
tp22683
sS'for,additive'
p22684
(F1
F0.00028669724770642203
I2
I0
I2
tp22685
sS'start,and'
p22686
(F1
F0.00014334862385321102
I1
I0
I1
tp22687
sS'the,patch-clamp'
p22688
(F1
F0.00014334862385321102
I0
I1
I-1
tp22689
sS'alone,versus'
p22690
(F1
F0.00014334862385321102
I0
I1
I-1
tp22691
sS'of,followed'
p22692
(F1
F0.00014334862385321102
I1
I0
I1
tp22693
sS'complex,fashion'
p22694
(F1
F0.00014334862385321102
I0
I1
I-1
tp22695
sS'analog,of'
p22696
(F1
F0.00028669724770642203
I0
I2
I-2
tp22697
sS'duloxetine,with'
p22698
(F0
F0
I1
I1
I0
tp22699
sS'not,antagonize'
p22700
(F1
F0.00014334862385321102
I1
I0
I1
tp22701
sS'trilisate,disalcid'
p22702
(F1
F0.00014334862385321102
I1
I0
I1
tp22703
sS'release,from'
p22704
(F1
F0.00014334862385321102
I1
I0
I1
tp22705
sS'cns,stimulation'
p22706
(F1
F0.00043004587155963305
I3
I0
I3
tp22707
sS'tract,to'
p22708
(F1
F0.00014334862385321102
I1
I0
I1
tp22709
sS'salt,or'
p22710
(F1
F0.00014334862385321102
I0
I1
I-1
tp22711
sS'mug,ml'
p22712
(F1
F0.00014334862385321102
I0
I1
I-1
tp22713
sS'medicines,during'
p22714
(F1
F0.00014334862385321102
I1
I0
I1
tp22715
sS'a,standing'
p22716
(F1
F0.00057339449541284407
I4
I0
I4
tp22717
sS'implications,of'
p22718
(F1
F0.00014334862385321102
I1
I0
I1
tp22719
sS'microm,preferentially'
p22720
(F1
F0.00014334862385321102
I1
I0
I1
tp22721
sS'with,enhances'
p22722
(F1
F0.00014334862385321102
I1
I0
I1
tp22723
sS'mean,terminal'
p22724
(F1
F0.00028669724770642203
I2
I0
I2
tp22725
sS'were,supersensitive'
p22726
(F1
F0.00028669724770642203
I2
I0
I2
tp22727
sS'during,early'
p22728
(F1
F0.00014334862385321102
I1
I0
I1
tp22729
sS'following,coadministration'
p22730
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22731
sS'ocular,and'
p22732
(F1
F0.00014334862385321102
I0
I1
I-1
tp22733
sS'individuals,plasma'
p22734
(F1
F0.00014334862385321102
I1
I0
I1
tp22735
sS'diuretics,etodolac'
p22736
(F1
F0.00014334862385321102
I0
I1
I-1
tp22737
sS'some,patients'
p22738
(F0.73913043478260865
F0.0024369266055045873
I20
I3
I17
tp22739
sS'substrate,agent'
p22740
(F1
F0.00014334862385321102
I0
I1
I-1
tp22741
sS'and,lead'
p22742
(F1
F0.00014334862385321102
I1
I0
I1
tp22743
sS'after,inhalational'
p22744
(F1
F0.00014334862385321102
I0
I1
I-1
tp22745
sS'photosensitivity,reaction'
p22746
(F1
F0.00014334862385321102
I1
I0
I1
tp22747
sS'this,product'
p22748
(F1
F0.00014334862385321102
I0
I1
I-1
tp22749
sS'anion,plasma'
p22750
(F1
F0.00014334862385321102
I1
I0
I1
tp22751
sS'for,aerobic'
p22752
(F1
F0.00014334862385321102
I0
I1
I-1
tp22753
sS'phenobarbitol,rifabutin'
p22754
(F1
F0.00014334862385321102
I0
I1
I-1
tp22755
sS'some,blockers'
p22756
(F1
F0.00014334862385321102
I1
I0
I1
tp22757
sS'unpredictable,potentiation'
p22758
(F1
F0.00014334862385321102
I1
I0
I1
tp22759
sS'be,rationalized'
p22760
(F1
F0.00014334862385321102
I0
I1
I-1
tp22761
sS'activity,data'
p22762
(F1
F0.00014334862385321102
I0
I1
I-1
tp22763
sS'herbal,supplement'
p22764
(F1
F0.00014334862385321102
I0
I1
I-1
tp22765
sS'a,fold'
p22766
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp22767
sS'chromaffin,cell'
p22768
(F1
F0.00028669724770642203
I0
I2
I-2
tp22769
sS'in,simultaneous'
p22770
(F1
F0.00014334862385321102
I1
I0
I1
tp22771
sS'cells,u937'
p22772
(F1
F0.00014334862385321102
I1
I0
I1
tp22773
sS'antacids,administration'
p22774
(F0
F0
I1
I1
I0
tp22775
sS'both,t4'
p22776
(F1
F0.00014334862385321102
I1
I0
I1
tp22777
sS'following,simultaneous'
p22778
(F1
F0.00014334862385321102
I1
I0
I1
tp22779
sS'hcl,and'
p22780
(F0.5
F0.00028669724770642203
I3
I1
I2
tp22781
sS'increased,concentrations'
p22782
(F1
F0.00043004587155963305
I0
I3
I-3
tp22783
sS'interactions,posed'
p22784
(F1
F0.00014334862385321102
I0
I1
I-1
tp22785
sS'weeks,with'
p22786
(F1
F0.00028669724770642203
I2
I0
I2
tp22787
sS'to,its'
p22788
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp22789
sS'rat,brain'
p22790
(F1
F0.00014334862385321102
I1
I0
I1
tp22791
sS'vasopressor,for'
p22792
(F1
F0.00014334862385321102
I1
I0
I1
tp22793
sS'increased,its'
p22794
(F1
F0.00014334862385321102
I0
I1
I-1
tp22795
sS'of,fell'
p22796
(F1
F0.00014334862385321102
I1
I0
I1
tp22797
sS'three,separate'
p22798
(F1
F0.00014334862385321102
I0
I1
I-1
tp22799
sS'estrogens,may'
p22800
(F1
F0.00014334862385321102
I1
I0
I1
tp22801
sS'etc,increase'
p22802
(F1
F0.00043004587155963305
I3
I0
I3
tp22803
sS'for,renal'
p22804
(F1
F0.00014334862385321102
I1
I0
I1
tp22805
sS'placebo,controlled'
p22806
(F1
F0.00014334862385321102
I0
I1
I-1
tp22807
sS'sn38,levels'
p22808
(F1
F0.00014334862385321102
I0
I1
I-1
tp22809
sS'phenobarbital,estimates'
p22810
(F1
F0.00014334862385321102
I0
I1
I-1
tp22811
sS'lodine,indocin'
p22812
(F1
F0.00014334862385321102
I0
I1
I-1
tp22813
sS'other,aeds'
p22814
(F1
F0.00043004587155963305
I0
I3
I-3
tp22815
sS'no,studies'
p22816
(F1
F0.00014334862385321102
I1
I0
I1
tp22817
sS'significantly,improved'
p22818
(F1
F0.00028669724770642203
I0
I2
I-2
tp22819
sS'of,loop'
p22820
(F1
F0.0008600917431192661
I6
I0
I6
tp22821
sS'significantly,improves'
p22822
(F1
F0.00014334862385321102
I0
I1
I-1
tp22823
sS'the,enzymes'
p22824
(F1
F0.00014334862385321102
I0
I1
I-1
tp22825
sS'a,supersensitivity'
p22826
(F1
F0.00014334862385321102
I1
I0
I1
tp22827
sS'mg,twice'
p22828
(F0.36842105263157893
F0.0010034403669724771
I6
I13
I-7
tp22829
sS'inhibitors,was'
p22830
(F1
F0.00028669724770642203
I2
I0
I2
tp22831
sS'epinephrine,may'
p22832
(F1
F0.00014334862385321102
I1
I0
I1
tp22833
sS'instances,a'
p22834
(F1
F0.00014334862385321102
I1
I0
I1
tp22835
sS'this,is'
p22836
(F0
F0
I1
I1
I0
tp22837
sS'unchanged,following'
p22838
(F1
F0.00028669724770642203
I0
I2
I-2
tp22839
sS'may,prevent'
p22840
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp22841
sS'as,camptosar'
p22842
(F1
F0.00014334862385321102
I1
I0
I1
tp22843
sS'and,indicated'
p22844
(F1
F0.00014334862385321102
I0
I1
I-1
tp22845
sS'anavar,anadrol'
p22846
(F1
F0.00014334862385321102
I0
I1
I-1
tp22847
sS'promethazine,coadministration'
p22848
(F1
F0.00014334862385321102
I1
I0
I1
tp22849
sS'light,meal'
p22850
(F0
F0
I1
I1
I0
tp22851
sS'hours,prior'
p22852
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp22853
sS'a,combination'
p22854
(F1
F0.00028669724770642203
I0
I2
I-2
tp22855
sS'therapies,commonly'
p22856
(F1
F0.00014334862385321102
I0
I1
I-1
tp22857
sS'cyp1a2,substrate'
p22858
(F1
F0.00014334862385321102
I0
I1
I-1
tp22859
sS'warfarin-type,therapy'
p22860
(F1
F0.00014334862385321102
I1
I0
I1
tp22861
sS'hours,apart'
p22862
(F0
F0
I1
I1
I0
tp22863
sS'of,high'
p22864
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp22865
sS'and,squirrel'
p22866
(F1
F0.00014334862385321102
I0
I1
I-1
tp22867
sS'consider,additive'
p22868
(F1
F0.00014334862385321102
I1
I0
I1
tp22869
sS'iopidine,ophthalmic'
p22870
(F1
F0.00014334862385321102
I1
I0
I1
tp22871
sS'shortly,after'
p22872
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22873
sS'on,an'
p22874
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22875
sS'itraconazole,was'
p22876
(F1
F0.00014334862385321102
I1
I0
I1
tp22877
sS'disruptive,effects'
p22878
(F1
F0.00014334862385321102
I1
I0
I1
tp22879
sS'second,contractile'
p22880
(F1
F0.00014334862385321102
I1
I0
I1
tp22881
sS'lasma,concentrations'
p22882
(F1
F0.00014334862385321102
I0
I1
I-1
tp22883
sS'on,av'
p22884
(F1
F0.00014334862385321102
I1
I0
I1
tp22885
sS'a,non-specific'
p22886
(F1
F0.00014334862385321102
I0
I1
I-1
tp22887
sS'a,resulting'
p22888
(F1
F0.00014334862385321102
I1
I0
I1
tp22889
sS'inclusive,viracept'
p22890
(F1
F0.00014334862385321102
I0
I1
I-1
tp22891
sS'and,antacids'
p22892
(F1
F0.00014334862385321102
I1
I0
I1
tp22893
sS'enterocolitis,diarrhea'
p22894
(F1
F0.00014334862385321102
I1
I0
I1
tp22895
sS'week,prior'
p22896
(F1
F0.00014334862385321102
I1
I0
I1
tp22897
sS'the,range'
p22898
(F1
F0.00057339449541284407
I0
I4
I-4
tp22899
sS'the,antipsychotic'
p22900
(F1
F0.00014334862385321102
I0
I1
I-1
tp22901
sS'interaction,during'
p22902
(F1
F0.00014334862385321102
I0
I1
I-1
tp22903
sS'fewer,interactions'
p22904
(F1
F0.00014334862385321102
I0
I1
I-1
tp22905
sS'and,impaired'
p22906
(F1
F0.00028669724770642203
I2
I0
I2
tp22907
sS'or,placebo'
p22908
(F1
F0.00043004587155963305
I0
I3
I-3
tp22909
sS'the,trans-diol'
p22910
(F1
F0.00014334862385321102
I0
I1
I-1
tp22911
sS'felt,that'
p22912
(F1
F0.00014334862385321102
I1
I0
I1
tp22913
sS'for,drugs'
p22914
(F1
F0.00014334862385321102
I1
I0
I1
tp22915
sS'a,cyp2c9'
p22916
(F1
F0.00043004587155963305
I3
I0
I3
tp22917
sS'following,nicotinic'
p22918
(F1
F0.00014334862385321102
I0
I1
I-1
tp22919
sS'dosing,and'
p22920
(F1
F0.00014334862385321102
I0
I1
I-1
tp22921
sS'application,of'
p22922
(F1
F0.00014334862385321102
I1
I0
I1
tp22923
sS'rate,cmax'
p22924
(F1
F0.00014334862385321102
I1
I0
I1
tp22925
sS'contain,an'
p22926
(F1
F0.00014334862385321102
I1
I0
I1
tp22927
sS'precipitate,seizures'
p22928
(F1
F0.00014334862385321102
I1
I0
I1
tp22929
sS'with,blood'
p22930
(F1
F0.00028669724770642203
I2
I0
I2
tp22931
sS'model,in'
p22932
(F1
F0.00014334862385321102
I0
I1
I-1
tp22933
sS'elspar,can'
p22934
(F1
F0.00014334862385321102
I1
I0
I1
tp22935
sS'test,results'
p22936
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22937
sS'significant,effect'
p22938
(F0.9285714285714286
F0.0037270642201834864
I1
I27
I-26
tp22939
sS'methotrexate,renal'
p22940
(F1
F0.00014334862385321102
I1
I0
I1
tp22941
sS'carbamazepine,due'
p22942
(F1
F0.00014334862385321102
I0
I1
I-1
tp22943
sS'phenobarbital,or'
p22944
(F1
F0.00014334862385321102
I0
I1
I-1
tp22945
sS'controlled,studies'
p22946
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22947
sS'with,failed'
p22948
(F1
F0.00014334862385321102
I0
I1
I-1
tp22949
sS'risk,factors'
p22950
(F1
F0.00014334862385321102
I1
I0
I1
tp22951
sS'precipitated,by'
p22952
(F1
F0.00014334862385321102
I0
I1
I-1
tp22953
sS'little,if'
p22954
(F1
F0.00014334862385321102
I0
I1
I-1
tp22955
sS'krm-1648,exhibited'
p22956
(F1
F0.00014334862385321102
I1
I0
I1
tp22957
sS'that,from'
p22958
(F1
F0.00014334862385321102
I0
I1
I-1
tp22959
sS'of,free'
p22960
(F0
F0
I1
I1
I0
tp22961
sS'concentrations,which'
p22962
(F1
F0.00014334862385321102
I1
I0
I1
tp22963
sS'to,confirm'
p22964
(F1
F0.00014334862385321102
I0
I1
I-1
tp22965
sS'are,very'
p22966
(F1
F0.00014334862385321102
I1
I0
I1
tp22967
sS'elements,ethacrynic'
p22968
(F1
F0.00014334862385321102
I1
I0
I1
tp22969
sS'and,bound'
p22970
(F1
F0.00014334862385321102
I1
I0
I1
tp22971
sS'volunteers,ingesting'
p22972
(F1
F0.00014334862385321102
I1
I0
I1
tp22973
sS'bred,control'
p22974
(F1
F0.00014334862385321102
I0
I1
I-1
tp22975
sS'thereafter,and'
p22976
(F1
F0.00014334862385321102
I1
I0
I1
tp22977
sS'this,should'
p22978
(F1
F0.00014334862385321102
I0
I1
I-1
tp22979
sS'of,angiotensin'
p22980
(F0.5
F0.00028669724770642203
I3
I1
I2
tp22981
sS'or,type'
p22982
(F1
F0.00014334862385321102
I1
I0
I1
tp22983
sS'by,cytochrome'
p22984
(F0.38461538461538464
F0.00071674311926605509
I4
I9
I-5
tp22985
sS'in,altering'
p22986
(F1
F0.00014334862385321102
I0
I1
I-1
tp22987
sS'was,necessary'
p22988
(F1
F0.00028669724770642203
I2
I0
I2
tp22989
sS'response,induced'
p22990
(F0
F0
I1
I1
I0
tp22991
sS'a,macrolide'
p22992
(F1
F0.00014334862385321102
I0
I1
I-1
tp22993
sS'in,of'
p22994
(F1
F0.00028669724770642203
I2
I0
I2
tp22995
sS'product,with'
p22996
(F1
F0.00014334862385321102
I0
I1
I-1
tp22997
sS'in,oa'
p22998
(F1
F0.00014334862385321102
I0
I1
I-1
tp22999
sS'in,doses'
p23000
(F1
F0.00014334862385321102
I1
I0
I1
tp23001
sS'indication,of'
p23002
(F1
F0.00014334862385321102
I0
I1
I-1
tp23003
sS'in,or'
p23004
(F1
F0.00057339449541284407
I0
I4
I-4
tp23005
sS'stelazine,vesprin'
p23006
(F1
F0.00014334862385321102
I0
I1
I-1
tp23007
sS'established,therapy'
p23008
(F1
F0.00014334862385321102
I1
I0
I1
tp23009
sS'weight,and'
p23010
(F1
F0.00014334862385321102
I0
I1
I-1
tp23011
sS'lotensin,was'
p23012
(F1
F0.00014334862385321102
I0
I1
I-1
tp23013
sS'a,report'
p23014
(F1
F0.00014334862385321102
I1
I0
I1
tp23015
sS'low-molecular,weight'
p23016
(F1
F0.00014334862385321102
I0
I1
I-1
tp23017
sS'minimum,concentration'
p23018
(F1
F0.00014334862385321102
I0
I1
I-1
tp23019
sS'levels,are'
p23020
(F0
F0
I1
I1
I0
tp23021
sS'evidence,has'
p23022
(F1
F0.00014334862385321102
I1
I0
I1
tp23023
sS'dose,did'
p23024
(F1
F0.00014334862385321102
I0
I1
I-1
tp23025
sS'plasma,clearance'
p23026
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23027
sS'a,large'
p23028
(F0
F0
I1
I1
I0
tp23029
sS'another,hmg-coa'
p23030
(F1
F0.00014334862385321102
I1
I0
I1
tp23031
sS'window,such'
p23032
(F1
F0.00014334862385321102
I1
I0
I1
tp23033
sS'trials,with'
p23034
(F0
F0
I1
I1
I0
tp23035
sS'hydrochloride,could'
p23036
(F1
F0.00014334862385321102
I0
I1
I-1
tp23037
sS'with,concomitant'
p23038
(F0.17647058823529413
F0.00043004587155963305
I10
I7
I3
tp23039
sS'interaction,studies'
p23040
(F0.88571428571428568
F0.0044438073394495415
I2
I33
I-31
tp23041
sS'to,marked'
p23042
(F1
F0.00014334862385321102
I1
I0
I1
tp23043
sS'and,do'
p23044
(F1
F0.00028669724770642203
I0
I2
I-2
tp23045
sS'plasma,indicate'
p23046
(F1
F0.00014334862385321102
I0
I1
I-1
tp23047
sS'to,or'
p23048
(F1
F0.0012901376146788992
I9
I0
I9
tp23049
sS'dosage,range'
p23050
(F1
F0.00014334862385321102
I1
I0
I1
tp23051
sS'myelosuppression,and'
p23052
(F1
F0.00014334862385321102
I1
I0
I1
tp23053
sS'other,local'
p23054
(F1
F0.00014334862385321102
I1
I0
I1
tp23055
sS'the,growth'
p23056
(F1
F0.00043004587155963305
I0
I3
I-3
tp23057
sS'to,of'
p23058
(F1
F0.00014334862385321102
I0
I1
I-1
tp23059
sS'study,objective'
p23060
(F1
F0.00014334862385321102
I0
I1
I-1
tp23061
sS'beverages,is'
p23062
(F1
F0.00014334862385321102
I1
I0
I1
tp23063
sS'time,scale'
p23064
(F1
F0.00014334862385321102
I0
I1
I-1
tp23065
sS'coagulation,time'
p23066
(F1
F0.00014334862385321102
I1
I0
I1
tp23067
sS'adequate,period'
p23068
(F1
F0.00014334862385321102
I0
I1
I-1
tp23069
sS'received,maoi'
p23070
(F1
F0.00014334862385321102
I1
I0
I1
tp23071
sS'atoxic,since'
p23072
(F1
F0.00014334862385321102
I0
I1
I-1
tp23073
sS'the,soluble'
p23074
(F1
F0.00014334862385321102
I0
I1
I-1
tp23075
sS'a,control'
p23076
(F1
F0.00014334862385321102
I1
I0
I1
tp23077
sS'light,dark'
p23078
(F1
F0.00014334862385321102
I0
I1
I-1
tp23079
sS'experiments,on'
p23080
(F1
F0.00028669724770642203
I0
I2
I-2
tp23081
sS'transferring,the'
p23082
(F1
F0.00014334862385321102
I0
I1
I-1
tp23083
sS'cyp3a4,or'
p23084
(F1
F0.00014334862385321102
I0
I1
I-1
tp23085
sS'maximal,effects'
p23086
(F1
F0.00014334862385321102
I0
I1
I-1
tp23087
sS'the,gi'
p23088
(F1
F0.00014334862385321102
I1
I0
I1
tp23089
sS'expected,because'
p23090
(F1
F0.00014334862385321102
I0
I1
I-1
tp23091
sS'addition,of'
p23092
(F0.20000000000000001
F0.00043004587155963305
I9
I6
I3
tp23093
sS'two,consecutive'
p23094
(F1
F0.00014334862385321102
I0
I1
I-1
tp23095
sS'addition,or'
p23096
(F1
F0.00014334862385321102
I0
I1
I-1
tp23097
sS'pcp,dcg-iv'
p23098
(F1
F0.00014334862385321102
I0
I1
I-1
tp23099
sS'increase,cyp'
p23100
(F1
F0.00014334862385321102
I1
I0
I1
tp23101
sS'single,or'
p23102
(F1
F0.00028669724770642203
I0
I2
I-2
tp23103
sS'concomitantly,to'
p23104
(F1
F0.00014334862385321102
I1
I0
I1
tp23105
sS'of,all'
p23106
(F0
F0
I1
I1
I0
tp23107
sS'administered,antiepileptic'
p23108
(F1
F0.00014334862385321102
I1
I0
I1
tp23109
sS'vitro,binding'
p23110
(F0
F0
I1
I1
I0
tp23111
sS'arimidex,with'
p23112
(F1
F0.00014334862385321102
I0
I1
I-1
tp23113
sS'agents,chloral'
p23114
(F1
F0.00014334862385321102
I0
I1
I-1
tp23115
sS'some,leading'
p23116
(F1
F0.00014334862385321102
I1
I0
I1
tp23117
sS'an,equivalent'
p23118
(F1
F0.00014334862385321102
I0
I1
I-1
tp23119
sS'b12,supplement'
p23120
(F1
F0.00014334862385321102
I1
I0
I1
tp23121
sS'permeation,was'
p23122
(F1
F0.00014334862385321102
I0
I1
I-1
tp23123
sS'during,toradol'
p23124
(F1
F0.00014334862385321102
I1
I0
I1
tp23125
sS'serious,falls'
p23126
(F1
F0.00014334862385321102
I1
I0
I1
tp23127
sS'valdecoxib,caused'
p23128
(F1
F0.00014334862385321102
I1
I0
I1
tp23129
sS'completion,of'
p23130
(F1
F0.00014334862385321102
I1
I0
I1
tp23131
sS'its,effectiveness'
p23132
(F1
F0.00014334862385321102
I0
I1
I-1
tp23133
sS'then,with'
p23134
(F1
F0.00014334862385321102
I0
I1
I-1
tp23135
sS'of,fludara'
p23136
(F1
F0.00014334862385321102
I1
I0
I1
tp23137
sS'the,fractional'
p23138
(F1
F0.00014334862385321102
I0
I1
I-1
tp23139
sS'is,totally'
p23140
(F1
F0.00014334862385321102
I0
I1
I-1
tp23141
sS'bleeding,or'
p23142
(F1
F0.00014334862385321102
I0
I1
I-1
tp23143
sS'of,psychiatric'
p23144
(F1
F0.00014334862385321102
I1
I0
I1
tp23145
sS'induce,hypercalcemia'
p23146
(F1
F0.00043004587155963305
I0
I3
I-3
tp23147
sS'in,unexpectedly'
p23148
(F1
F0.00014334862385321102
I1
I0
I1
tp23149
sS'p450,pathway'
p23150
(F1
F0.00014334862385321102
I0
I1
I-1
tp23151
sS'when,bezalip'
p23152
(F1
F0.00028669724770642203
I2
I0
I2
tp23153
sS'boric,acid'
p23154
(F1
F0.00014334862385321102
I1
I0
I1
tp23155
sS'known,metabolite'
p23156
(F1
F0.00014334862385321102
I0
I1
I-1
tp23157
sS'provoke,vasoconstriction'
p23158
(F1
F0.00014334862385321102
I1
I0
I1
tp23159
sS'cerulein--an,analog'
p23160
(F1
F0.00014334862385321102
I0
I1
I-1
tp23161
sS'five,times'
p23162
(F1
F0.00014334862385321102
I0
I1
I-1
tp23163
sS'formed,with'
p23164
(F1
F0.00014334862385321102
I1
I0
I1
tp23165
sS'northern,blot'
p23166
(F1
F0.00014334862385321102
I0
I1
I-1
tp23167
sS'nondepolarizing,muscle'
p23168
(F0
F0
I1
I1
I0
tp23169
sS'increased,appetite'
p23170
(F1
F0.00014334862385321102
I0
I1
I-1
tp23171
sS'lodine,can'
p23172
(F0
F0
I1
I1
I0
tp23173
sS'first,day'
p23174
(F1
F0.00014334862385321102
I0
I1
I-1
tp23175
sS'induce,hepatic'
p23176
(F1
F0.00014334862385321102
I1
I0
I1
tp23177
sS'of,lamprene'
p23178
(F1
F0.00014334862385321102
I1
I0
I1
tp23179
sS'revealed,concentration'
p23180
(F1
F0.00014334862385321102
I0
I1
I-1
tp23181
sS'inhibits,c9'
p23182
(F1
F0.00014334862385321102
I0
I1
I-1
tp23183
sS'for,ototoxicity'
p23184
(F1
F0.00014334862385321102
I1
I0
I1
tp23185
sS'oral,doses'
p23186
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp23187
sS'nursing,infant'
p23188
(F1
F0.00014334862385321102
I0
I1
I-1
tp23189
sS'node,conduction'
p23190
(F1
F0.00014334862385321102
I1
I0
I1
tp23191
sS'the,neuron'
p23192
(F1
F0.00014334862385321102
I1
I0
I1
tp23193
sS'possible,pharmacokinetic'
p23194
(F1
F0.00014334862385321102
I1
I0
I1
tp23195
sS'agents,calcium-channel'
p23196
(F1
F0.00014334862385321102
I0
I1
I-1
tp23197
sS'residues,on'
p23198
(F1
F0.00014334862385321102
I0
I1
I-1
tp23199
sS'by,ex'
p23200
(F1
F0.00014334862385321102
I0
I1
I-1
tp23201
sS'rebound,hypertension'
p23202
(F1
F0.00028669724770642203
I2
I0
I2
tp23203
sS'initial,oral'
p23204
(F1
F0.00014334862385321102
I1
I0
I1
tp23205
sS'via,conjugation'
p23206
(F1
F0.00014334862385321102
I1
I0
I1
tp23207
sS'ptca,pci'
p23208
(F1
F0.00014334862385321102
I1
I0
I1
tp23209
sS'enbrel,was'
p23210
(F0
F0
I1
I1
I0
tp23211
sS'replacement,may'
p23212
(F1
F0.00014334862385321102
I0
I1
I-1
tp23213
sS'possible,when'
p23214
(F1
F0.00014334862385321102
I0
I1
I-1
tp23215
sS'were,within'
p23216
(F1
F0.00014334862385321102
I1
I0
I1
tp23217
sS'when,videx'
p23218
(F1
F0.00014334862385321102
I1
I0
I1
tp23219
sS'activity,appeared'
p23220
(F1
F0.00014334862385321102
I1
I0
I1
tp23221
sS'however,appear'
p23222
(F1
F0.00014334862385321102
I0
I1
I-1
tp23223
sS'to,know'
p23224
(F1
F0.00014334862385321102
I0
I1
I-1
tp23225
sS'of,l-phenylalanine'
p23226
(F1
F0.00014334862385321102
I1
I0
I1
tp23227
sS'the,non-renal'
p23228
(F1
F0.00014334862385321102
I1
I0
I1
tp23229
sS'patients,understand'
p23230
(F1
F0.00014334862385321102
I0
I1
I-1
tp23231
sS'relationships,between'
p23232
(F1
F0.00014334862385321102
I0
I1
I-1
tp23233
sS'or,aluminum-containing'
p23234
(F1
F0.00014334862385321102
I1
I0
I1
tp23235
sS'of,was'
p23236
(F0.090909090909090912
F0.00043004587155963305
I15
I18
I-3
tp23237
sS'concomitantly,including'
p23238
(F1
F0.00014334862385321102
I0
I1
I-1
tp23239
sS'the,spinal'
p23240
(F1
F0.00014334862385321102
I0
I1
I-1
tp23241
sS'false,positive'
p23242
(F1
F0.00028669724770642203
I0
I2
I-2
tp23243
sS'contrast,in'
p23244
(F1
F0.00014334862385321102
I0
I1
I-1
tp23245
sS'bumetanide-induced,increase'
p23246
(F1
F0.00014334862385321102
I1
I0
I1
tp23247
sS'fraction,fdf'
p23248
(F1
F0.00014334862385321102
I1
I0
I1
tp23249
sS'cell,growth'
p23250
(F1
F0.00014334862385321102
I0
I1
I-1
tp23251
sS'natrecor,with'
p23252
(F1
F0.00014334862385321102
I0
I1
I-1
tp23253
sS'inr,were'
p23254
(F1
F0.00014334862385321102
I0
I1
I-1
tp23255
sS'nonfunctioning,gland'
p23256
(F1
F0.00014334862385321102
I1
I0
I1
tp23257
sS'for,commonly'
p23258
(F1
F0.00014334862385321102
I0
I1
I-1
tp23259
sS'when,parenteral'
p23260
(F1
F0.00014334862385321102
I0
I1
I-1
tp23261
sS'subcutaneous,dose'
p23262
(F1
F0.00014334862385321102
I1
I0
I1
tp23263
sS'urinary,antiseptic'
p23264
(F1
F0.00014334862385321102
I1
I0
I1
tp23265
sS'with,concentrations'
p23266
(F1
F0.00014334862385321102
I0
I1
I-1
tp23267
sS'toxicologic,profile'
p23268
(F1
F0.00014334862385321102
I0
I1
I-1
tp23269
sS'a,tendency'
p23270
(F1
F0.00014334862385321102
I1
I0
I1
tp23271
sS'these,polyene'
p23272
(F1
F0.00014334862385321102
I0
I1
I-1
tp23273
sS'alteration,caused'
p23274
(F1
F0.00014334862385321102
I0
I1
I-1
tp23275
sS'methotrexate,an'
p23276
(F1
F0.00014334862385321102
I1
I0
I1
tp23277
sS'b-adrenergic,blocking'
p23278
(F1
F0.00028669724770642203
I0
I2
I-2
tp23279
sS'competitive,renal'
p23280
(F1
F0.00014334862385321102
I1
I0
I1
tp23281
sS'at,micromol'
p23282
(F1
F0.00014334862385321102
I1
I0
I1
tp23283
sS'of,responses'
p23284
(F1
F0.00014334862385321102
I0
I1
I-1
tp23285
sS'reaction,and'
p23286
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp23287
sS'hepatotoxic,potential'
p23288
(F1
F0.00014334862385321102
I1
I0
I1
tp23289
sS'stopping,fluvoxamine'
p23290
(F1
F0.00014334862385321102
I1
I0
I1
tp23291
sS'the,incidence'
p23292
(F0.16666666666666666
F0.00028669724770642203
I7
I5
I2
tp23293
sS'tikosyn,had'
p23294
(F1
F0.00014334862385321102
I0
I1
I-1
tp23295
sS'compounds,like'
p23296
(F1
F0.00014334862385321102
I1
I0
I1
tp23297
sS'occasions,resulted'
p23298
(F1
F0.00028669724770642203
I2
I0
I2
tp23299
sS'agents,may'
p23300
(F0.45454545454545453
F0.0014334862385321102
I16
I6
I10
tp23301
sS'or,maintenance'
p23302
(F1
F0.00014334862385321102
I0
I1
I-1
tp23303
sS'other,coumarin-like'
p23304
(F1
F0.00014334862385321102
I1
I0
I1
tp23305
sS'taking,placebo'
p23306
(F1
F0.00028669724770642203
I0
I2
I-2
tp23307
sS'with,vardenafil'
p23308
(F1
F0.0010034403669724771
I7
I0
I7
tp23309
sS'clearance,prolongation'
p23310
(F1
F0.00014334862385321102
I0
I1
I-1
tp23311
sS'omeprazole,omeprazole'
p23312
(F1
F0.00014334862385321102
I0
I1
I-1
tp23313
sS'individuals,receiving'
p23314
(F1
F0.00014334862385321102
I1
I0
I1
tp23315
sS'caffeine,enoxacin'
p23316
(F1
F0.00014334862385321102
I1
I0
I1
tp23317
sS'in,induction'
p23318
(F1
F0.00028669724770642203
I2
I0
I2
tp23319
sS'pregnancy,has'
p23320
(F1
F0.00014334862385321102
I0
I1
I-1
tp23321
sS'concurrently,increases'
p23322
(F1
F0.00028669724770642203
I2
I0
I2
tp23323
sS'these,larger'
p23324
(F1
F0.00014334862385321102
I1
I0
I1
tp23325
sS'and,minimal'
p23326
(F1
F0.00014334862385321102
I0
I1
I-1
tp23327
sS'kg,removes'
p23328
(F1
F0.00014334862385321102
I1
I0
I1
tp23329
sS'pressure,medications'
p23330
(F1
F0.00014334862385321102
I0
I1
I-1
tp23331
sS'compromise,have'
p23332
(F1
F0.00014334862385321102
I1
I0
I1
tp23333
sS'important,interactions'
p23334
(F1
F0.00043004587155963305
I0
I3
I-3
tp23335
sS'studies,do'
p23336
(F1
F0.00014334862385321102
I1
I0
I1
tp23337
sS'doctor,or'
p23338
(F1
F0.00014334862385321102
I0
I1
I-1
tp23339
sS'alert,to'
p23340
(F1
F0.00028669724770642203
I2
I0
I2
tp23341
sS'marine,coelenterates'
p23342
(F1
F0.00014334862385321102
I0
I1
I-1
tp23343
sS'powder,or'
p23344
(F1
F0.00014334862385321102
I1
I0
I1
tp23345
sS'are,equipotent'
p23346
(F1
F0.00014334862385321102
I0
I1
I-1
tp23347
sS'be,continued'
p23348
(F1
F0.00014334862385321102
I1
I0
I1
tp23349
sS'two,weeks'
p23350
(F1
F0.00028669724770642203
I2
I0
I2
tp23351
sS'international,normalized'
p23352
(F1
F0.00057339449541284407
I4
I0
I4
tp23353
sS'clearance,based'
p23354
(F1
F0.00014334862385321102
I1
I0
I1
tp23355
sS'nor,appears'
p23356
(F1
F0.00014334862385321102
I0
I1
I-1
tp23357
sS'exposure,was'
p23358
(F1
F0.00028669724770642203
I2
I0
I2
tp23359
sS'to,rats'
p23360
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp23361
sS'cortex,that'
p23362
(F1
F0.00014334862385321102
I1
I0
I1
tp23363
sS'any,interaction'
p23364
(F1
F0.00028669724770642203
I0
I2
I-2
tp23365
sS'vivo,and'
p23366
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp23367
sS'vs,for'
p23368
(F1
F0.00014334862385321102
I0
I1
I-1
tp23369
sS'significant,hyperprolactinaemia'
p23370
(F1
F0.00014334862385321102
I0
I1
I-1
tp23371
sS'of,l-glutamine'
p23372
(F1
F0.00028669724770642203
I2
I0
I2
tp23373
sS'metabolic,pathway'
p23374
(F1
F0.00028669724770642203
I0
I2
I-2
tp23375
sS'prostaglandin,f2alpha'
p23376
(F0
F0
I1
I1
I0
tp23377
sS'the,bactericidal'
p23378
(F1
F0.00057339449541284407
I4
I0
I4
tp23379
sS'fat-soluble,including'
p23380
(F1
F0.00014334862385321102
I1
I0
I1
tp23381
sS'results,together'
p23382
(F1
F0.00014334862385321102
I0
I1
I-1
tp23383
sS'racemic,titrated'
p23384
(F1
F0.00014334862385321102
I0
I1
I-1
tp23385
sS'slow-channel,blockers'
p23386
(F1
F0.00014334862385321102
I0
I1
I-1
tp23387
sS'blockers,including'
p23388
(F1
F0.00014334862385321102
I0
I1
I-1
tp23389
sS'by,the'
p23390
(F0.30769230769230771
F0.0022935779816513763
I18
I34
I-16
tp23391
sS'have,been'
p23392
(F0.3707865168539326
F0.0094610091743119271
I122
I56
I66
tp23393
sS'whose,efficacy'
p23394
(F1
F0.00014334862385321102
I1
I0
I1
tp23395
sS'altering,activity'
p23396
(F1
F0.00014334862385321102
I0
I1
I-1
tp23397
sS'response,to'
p23398
(F0.052631578947368418
F0.00014334862385321102
I10
I9
I1
tp23399
sS'of,zdv'
p23400
(F1
F0.00014334862385321102
I1
I0
I1
tp23401
sS'efficacy,in'
p23402
(F1
F0.00014334862385321102
I0
I1
I-1
tp23403
sS'inhaled,with'
p23404
(F1
F0.00014334862385321102
I0
I1
I-1
tp23405
sS'the,physician'
p23406
(F0
F0
I4
I4
I0
tp23407
sS'increased,interaction'
p23408
(F1
F0.00028669724770642203
I0
I2
I-2
tp23409
sS'metabolites,oxo-desethylzaleplon'
p23410
(F1
F0.00014334862385321102
I0
I1
I-1
tp23411
sS'paper,was'
p23412
(F1
F0.00014334862385321102
I0
I1
I-1
tp23413
sS'hypertension,were'
p23414
(F1
F0.00014334862385321102
I0
I1
I-1
tp23415
sS'relationship,have'
p23416
(F1
F0.00014334862385321102
I1
I0
I1
tp23417
sS'all,in'
p23418
(F1
F0.00014334862385321102
I0
I1
I-1
tp23419
sS'who,increase'
p23420
(F1
F0.00014334862385321102
I1
I0
I1
tp23421
sS'particularly,since'
p23422
(F1
F0.00014334862385321102
I1
I0
I1
tp23423
sS'toxic,concentrations'
p23424
(F1
F0.00014334862385321102
I1
I0
I1
tp23425
sS'inhibit,both'
p23426
(F1
F0.00057339449541284407
I4
I0
I4
tp23427
sS'min,for'
p23428
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23429
sS'additive,central'
p23430
(F1
F0.00014334862385321102
I1
I0
I1
tp23431
sS'blocking,add'
p23432
(F1
F0.00014334862385321102
I1
I0
I1
tp23433
sS'are,incompatible'
p23434
(F0
F0
I1
I1
I0
tp23435
sS'especially,at'
p23436
(F1
F0.00014334862385321102
I0
I1
I-1
tp23437
sS'five,days'
p23438
(F1
F0.00028669724770642203
I0
I2
I-2
tp23439
sS'midazolam,used'
p23440
(F1
F0.00014334862385321102
I1
I0
I1
tp23441
sS'thereby,decreasing'
p23442
(F1
F0.00028669724770642203
I2
I0
I2
tp23443
sS'noncardioselective,porpranolol'
p23444
(F1
F0.00014334862385321102
I1
I0
I1
tp23445
sS'nicotine,nicotine'
p23446
(F1
F0.00014334862385321102
I1
I0
I1
tp23447
sS'observed,by'
p23448
(F1
F0.00014334862385321102
I0
I1
I-1
tp23449
sS'beta-blockers,concomitant'
p23450
(F1
F0.00014334862385321102
I1
I0
I1
tp23451
sS'beta-1a,avonex'
p23452
(F0
F0
I1
I1
I0
tp23453
sS'intramuscular,injection'
p23454
(F1
F0.00014334862385321102
I1
I0
I1
tp23455
sS'immediate,and'
p23456
(F1
F0.00014334862385321102
I1
I0
I1
tp23457
sS'than,in'
p23458
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp23459
sS'interaction,is'
p23460
(F1
F0.00028669724770642203
I2
I0
I2
tp23461
sS'of,iressa'
p23462
(F1
F0.00014334862385321102
I1
I0
I1
tp23463
sS'system,cyp3a4'
p23464
(F1
F0.00014334862385321102
I0
I1
I-1
tp23465
sS'arrhythmias,have'
p23466
(F1
F0.00014334862385321102
I1
I0
I1
tp23467
sS'b12,which'
p23468
(F1
F0.00014334862385321102
I1
I0
I1
tp23469
sS'concentrations,prior'
p23470
(F1
F0.00014334862385321102
I0
I1
I-1
tp23471
sS'to,decreased'
p23472
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp23473
sS'whom,died'
p23474
(F1
F0.00014334862385321102
I0
I1
I-1
tp23475
sS'concentrations,just'
p23476
(F1
F0.00014334862385321102
I0
I1
I-1
tp23477
sS'clofibric,acid'
p23478
(F1
F0.00014334862385321102
I1
I0
I1
tp23479
sS'substantive,effect'
p23480
(F1
F0.00014334862385321102
I0
I1
I-1
tp23481
sS'analgesic,effect'
p23482
(F1
F0.00014334862385321102
I1
I0
I1
tp23483
sS'w,in'
p23484
(F1
F0.00014334862385321102
I1
I0
I1
tp23485
sS'normal,dose'
p23486
(F1
F0.00014334862385321102
I1
I0
I1
tp23487
sS'with,see'
p23488
(F1
F0.00014334862385321102
I1
I0
I1
tp23489
sS'nonbarbiturate,antianxiety'
p23490
(F1
F0.00014334862385321102
I1
I0
I1
tp23491
sS'have,synergistic'
p23492
(F1
F0.00014334862385321102
I1
I0
I1
tp23493
sS'adenocarcinomas,induced'
p23494
(F0
F0
I1
I1
I0
tp23495
sS'kg,weight'
p23496
(F1
F0.00014334862385321102
I1
I0
I1
tp23497
sS'time,to'
p23498
(F0
F0
I1
I1
I0
tp23499
sS'increased,gleevec'
p23500
(F1
F0.00014334862385321102
I1
I0
I1
tp23501
sS'including,cefotaxime'
p23502
(F1
F0.00014334862385321102
I0
I1
I-1
tp23503
sS'cgs21680,was'
p23504
(F1
F0.00014334862385321102
I1
I0
I1
tp23505
sS'eg,grapefruit'
p23506
(F1
F0.00014334862385321102
I0
I1
I-1
tp23507
sS'reported,significantly'
p23508
(F1
F0.00014334862385321102
I0
I1
I-1
tp23509
sS'potent,inhalational'
p23510
(F1
F0.00014334862385321102
I1
I0
I1
tp23511
sS'of,pra'
p23512
(F1
F0.00014334862385321102
I0
I1
I-1
tp23513
sS'assays,based'
p23514
(F1
F0.00014334862385321102
I0
I1
I-1
tp23515
sS'c,treated'
p23516
(F1
F0.00014334862385321102
I0
I1
I-1
tp23517
sS'pressure,by'
p23518
(F1
F0.00014334862385321102
I1
I0
I1
tp23519
sS'v,concentrations'
p23520
(F1
F0.00028669724770642203
I0
I2
I-2
tp23521
sS'imipramine,coadministration'
p23522
(F1
F0.00014334862385321102
I1
I0
I1
tp23523
sS'thiazide,acidic'
p23524
(F1
F0.00014334862385321102
I1
I0
I1
tp23525
sS'substrates,of'
p23526
(F0
F0
I1
I1
I0
tp23527
sS'as,v'
p23528
(F1
F0.00057339449541284407
I0
I4
I-4
tp23529
sS'as,a'
p23530
(F0
F0
I12
I12
I0
tp23531
sS'as,g'
p23532
(F1
F0.00014334862385321102
I1
I0
I1
tp23533
sS'as,k'
p23534
(F1
F0.00014334862385321102
I0
I1
I-1
tp23535
sS'have,increased'
p23536
(F1
F0.00014334862385321102
I1
I0
I1
tp23537
sS'were,more'
p23538
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23539
sS'cyp2c9,cyp2d6'
p23540
(F1
F0.00028669724770642203
I0
I2
I-2
tp23541
sS'its,metabolites'
p23542
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23543
sS'estrogens,tend'
p23544
(F1
F0.00014334862385321102
I0
I1
I-1
tp23545
sS'positive,urine'
p23546
(F1
F0.00014334862385321102
I0
I1
I-1
tp23547
sS'alter,cardiac'
p23548
(F1
F0.00014334862385321102
I1
I0
I1
tp23549
sS'for,relief'
p23550
(F1
F0.00014334862385321102
I0
I1
I-1
tp23551
sS'and,systemic'
p23552
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23553
sS'with,prior'
p23554
(F1
F0.00014334862385321102
I1
I0
I1
tp23555
sS'as,cns'
p23556
(F1
F0.00014334862385321102
I0
I1
I-1
tp23557
sS'the,transport'
p23558
(F1
F0.00014334862385321102
I0
I1
I-1
tp23559
sS'with,beta-receptor'
p23560
(F1
F0.00014334862385321102
I0
I1
I-1
tp23561
sS'mg,experienced'
p23562
(F1
F0.00014334862385321102
I1
I0
I1
tp23563
sS'mefloquine,may'
p23564
(F1
F0.00014334862385321102
I1
I0
I1
tp23565
sS'cause,abnormal'
p23566
(F1
F0.00014334862385321102
I1
I0
I1
tp23567
sS'cation-containing,products'
p23568
(F1
F0.00014334862385321102
I1
I0
I1
tp23569
sS'mixed,signalled-unsignalled'
p23570
(F1
F0.00014334862385321102
I0
I1
I-1
tp23571
sS'with,medication'
p23572
(F1
F0.00014334862385321102
I0
I1
I-1
tp23573
sS'channel,blocking'
p23574
(F1
F0.00028669724770642203
I0
I2
I-2
tp23575
sS'phenytoin,intoxication'
p23576
(F1
F0.00014334862385321102
I1
I0
I1
tp23577
sS'nonsedating,and'
p23578
(F1
F0.00014334862385321102
I1
I0
I1
tp23579
sS'that,like'
p23580
(F1
F0.00014334862385321102
I1
I0
I1
tp23581
sS'enhanced,secretion'
p23582
(F1
F0.00014334862385321102
I0
I1
I-1
tp23583
sS'therapy,was'
p23584
(F1
F0.00057339449541284407
I4
I0
I4
tp23585
sS'hyperglycemia,and'
p23586
(F1
F0.00014334862385321102
I1
I0
I1
tp23587
sS'omnicef,should'
p23588
(F1
F0.00028669724770642203
I2
I0
I2
tp23589
sS'alterations,of'
p23590
(F0
F0
I1
I1
I0
tp23591
sS'being,treated'
p23592
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp23593
sS'a,stable'
p23594
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23595
sS'and,angiotensin'
p23596
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp23597
sS'study,conducted'
p23598
(F0
F0
I1
I1
I0
tp23599
sS'once,a'
p23600
(F1
F0.00014334862385321102
I0
I1
I-1
tp23601
sS'information,digoxin'
p23602
(F1
F0.00014334862385321102
I0
I1
I-1
tp23603
sS'leading,to'
p23604
(F0.45454545454545453
F0.0014334862385321102
I16
I6
I10
tp23605
sS'concentrations,from'
p23606
(F1
F0.00014334862385321102
I1
I0
I1
tp23607
sS'may,render'
p23608
(F1
F0.00043004587155963305
I3
I0
I3
tp23609
sS'hydrolase,inhibitors'
p23610
(F1
F0.00014334862385321102
I0
I1
I-1
tp23611
sS'induced,by'
p23612
(F0.058823529411764705
F0.00014334862385321102
I9
I8
I1
tp23613
sS'parent,and'
p23614
(F1
F0.00014334862385321102
I1
I0
I1
tp23615
sS'to,obtain'
p23616
(F1
F0.00014334862385321102
I1
I0
I1
tp23617
sS'receiving,intravenous'
p23618
(F1
F0.00014334862385321102
I1
I0
I1
tp23619
sS'including,cyp1a2'
p23620
(F1
F0.00014334862385321102
I0
I1
I-1
tp23621
sS'mg,four'
p23622
(F1
F0.00014334862385321102
I0
I1
I-1
tp23623
sS'the,chance'
p23624
(F0
F0
I5
I5
I0
tp23625
sS'the,b-blocking'
p23626
(F1
F0.00014334862385321102
I1
I0
I1
tp23627
sS'the,hypoglycemic'
p23628
(F1
F0.0008600917431192661
I6
I0
I6
tp23629
sS'presence,of'
p23630
(F0.066666666666666666
F0.00028669724770642203
I14
I16
I-2
tp23631
sS'presence,or'
p23632
(F1
F0.00014334862385321102
I0
I1
I-1
tp23633
sS'in,pediatric'
p23634
(F1
F0.00014334862385321102
I1
I0
I1
tp23635
sS'renal,insufficiency'
p23636
(F1
F0.00014334862385321102
I1
I0
I1
tp23637
sS'additive,cns'
p23638
(F1
F0.0008600917431192661
I6
I0
I6
tp23639
sS'gastrointestinal,irritation'
p23640
(F1
F0.00014334862385321102
I1
I0
I1
tp23641
sS'of,lymphatic'
p23642
(F1
F0.00014334862385321102
I1
I0
I1
tp23643
sS'to,investigate'
p23644
(F1
F0.00043004587155963305
I0
I3
I-3
tp23645
sS'physiology,the'
p23646
(F1
F0.00014334862385321102
I0
I1
I-1
tp23647
sS'steroid,hormones'
p23648
(F1
F0.00014334862385321102
I1
I0
I1
tp23649
sS'disease,may'
p23650
(F1
F0.00014334862385321102
I1
I0
I1
tp23651
sS'study,involving'
p23652
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp23653
sS'on,hepatic'
p23654
(F1
F0.00014334862385321102
I0
I1
I-1
tp23655
sS'by,two'
p23656
(F1
F0.00014334862385321102
I0
I1
I-1
tp23657
sS'frequent,involvement'
p23658
(F1
F0.00014334862385321102
I1
I0
I1
tp23659
sS'action,is'
p23660
(F1
F0.00014334862385321102
I0
I1
I-1
tp23661
sS'action,it'
p23662
(F1
F0.00014334862385321102
I1
I0
I1
tp23663
sS'monitor,tca'
p23664
(F1
F0.00057339449541284407
I0
I4
I-4
tp23665
sS'half-life,by'
p23666
(F1
F0.00028669724770642203
I2
I0
I2
tp23667
sS'among,bosentan-'
p23668
(F1
F0.00014334862385321102
I0
I1
I-1
tp23669
sS'development,including'
p23670
(F1
F0.00014334862385321102
I0
I1
I-1
tp23671
sS'sinus,medicines'
p23672
(F1
F0.00014334862385321102
I1
I0
I1
tp23673
sS'suppress,the'
p23674
(F1
F0.00014334862385321102
I1
I0
I1
tp23675
sS'and,levels'
p23676
(F0
F0
I1
I1
I0
tp23677
sS'preparations,micro-dosed'
p23678
(F1
F0.00014334862385321102
I1
I0
I1
tp23679
sS'expected,steady-state'
p23680
(F1
F0.00014334862385321102
I1
I0
I1
tp23681
sS'endothelium-intact,aortic'
p23682
(F1
F0.00014334862385321102
I1
I0
I1
tp23683
sS'cyclopentyl-1,dipropylxanthine'
p23684
(F1
F0.00014334862385321102
I0
I1
I-1
tp23685
sS'undergo,renal'
p23686
(F1
F0.00014334862385321102
I0
I1
I-1
tp23687
sS'nonsteroial,anti-inflammatory'
p23688
(F1
F0.00014334862385321102
I1
I0
I1
tp23689
sS'or,neurotoxic'
p23690
(F1
F0.00014334862385321102
I0
I1
I-1
tp23691
sS'bezalip,or'
p23692
(F1
F0.00071674311926605509
I5
I0
I5
tp23693
sS'searches,of'
p23694
(F1
F0.00014334862385321102
I0
I1
I-1
tp23695
sS'nonabsorbable,given'
p23696
(F1
F0.00014334862385321102
I1
I0
I1
tp23697
sS'could,occur'
p23698
(F1
F0.00014334862385321102
I0
I1
I-1
tp23699
sS'in,zollinger-ellison'
p23700
(F1
F0.00014334862385321102
I0
I1
I-1
tp23701
sS'in,lysing'
p23702
(F1
F0.00014334862385321102
I0
I1
I-1
tp23703
sS'are,cyp3a4'
p23704
(F1
F0.00014334862385321102
I1
I0
I1
tp23705
sS'if,they'
p23706
(F1
F0.00014334862385321102
I0
I1
I-1
tp23707
sS'be,longer'
p23708
(F1
F0.00014334862385321102
I0
I1
I-1
tp23709
sS'an,excessive'
p23710
(F1
F0.00057339449541284407
I4
I0
I4
tp23711
sS'hypoglycemic,agents'
p23712
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp23713
sS'taking,ace'
p23714
(F1
F0.00014334862385321102
I0
I1
I-1
tp23715
sS'and,penthrane'
p23716
(F1
F0.00014334862385321102
I1
I0
I1
tp23717
sS'additive,effect'
p23718
(F1
F0.0011467889908256881
I8
I0
I8
tp23719
sS'inhibitory,effect'
p23720
(F1
F0.00043004587155963305
I3
I0
I3
tp23721
sS'hydrochloride,with'
p23722
(F1
F0.00028669724770642203
I2
I0
I2
tp23723
sS'consequences,of'
p23724
(F1
F0.00014334862385321102
I0
I1
I-1
tp23725
sS'experienced,severe'
p23726
(F1
F0.00014334862385321102
I1
I0
I1
tp23727
sS'also,involved'
p23728
(F1
F0.00014334862385321102
I1
I0
I1
tp23729
sS'iv,is'
p23730
(F1
F0.00014334862385321102
I1
I0
I1
tp23731
sS'iv,im'
p23732
(F1
F0.00014334862385321102
I1
I0
I1
tp23733
sS'days,did'
p23734
(F1
F0.0010034403669724771
I0
I7
I-7
tp23735
sS'negative,symptoms'
p23736
(F1
F0.00043004587155963305
I0
I3
I-3
tp23737
sS'or,pharmacist'
p23738
(F1
F0.00014334862385321102
I0
I1
I-1
tp23739
sS'any,amine'
p23740
(F1
F0.00014334862385321102
I1
I0
I1
tp23741
sS'as,ace'
p23742
(F1
F0.00014334862385321102
I0
I1
I-1
tp23743
sS'sulfapyridine,may'
p23744
(F1
F0.00014334862385321102
I1
I0
I1
tp23745
sS'trileptal,on'
p23746
(F1
F0.00014334862385321102
I0
I1
I-1
tp23747
sS'containing,for'
p23748
(F1
F0.00014334862385321102
I1
I0
I1
tp23749
sS'system,leading'
p23750
(F1
F0.00028669724770642203
I0
I2
I-2
tp23751
sS'h1,and'
p23752
(F1
F0.00014334862385321102
I1
I0
I1
tp23753
sS'loop,sparing'
p23754
(F1
F0.00014334862385321102
I0
I1
I-1
tp23755
sS'in,prothrombin'
p23756
(F0.40000000000000002
F0.00057339449541284407
I3
I7
I-4
tp23757
sS'and,adverse'
p23758
(F1
F0.00014334862385321102
I0
I1
I-1
tp23759
sS'trileptal,was'
p23760
(F1
F0.00014334862385321102
I1
I0
I1
tp23761
sS'withdrawn,in'
p23762
(F1
F0.00014334862385321102
I0
I1
I-1
tp23763
sS'reported,following'
p23764
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp23765
sS'or,ml'
p23766
(F1
F0.00014334862385321102
I1
I0
I1
tp23767
sS'high,concentration'
p23768
(F1
F0.00014334862385321102
I1
I0
I1
tp23769
sS'important,determinant'
p23770
(F1
F0.00028669724770642203
I2
I0
I2
tp23771
sS'days,does'
p23772
(F1
F0.00014334862385321102
I0
I1
I-1
tp23773
sS'showed,differential'
p23774
(F1
F0.00014334862385321102
I0
I1
I-1
tp23775
sS'contents,of'
p23776
(F1
F0.00028669724770642203
I0
I2
I-2
tp23777
sS'enzymes,i'
p23778
(F1
F0.00014334862385321102
I0
I1
I-1
tp23779
sS'udp-glucuronyl,transferase'
p23780
(F1
F0.00014334862385321102
I0
I1
I-1
tp23781
sS'hypoglycemia,oral'
p23782
(F1
F0.00028669724770642203
I0
I2
I-2
tp23783
sS'incidence,or'
p23784
(F1
F0.00014334862385321102
I1
I0
I1
tp23785
sS'broad,spectrum'
p23786
(F1
F0.00014334862385321102
I0
I1
I-1
tp23787
sS'moderate,hypertension'
p23788
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23789
sS'incidence,of'
p23790
(F0.066666666666666666
F0.00014334862385321102
I8
I7
I1
tp23791
sS'limited,in'
p23792
(F1
F0.00014334862385321102
I1
I0
I1
tp23793
sS'and,heart-rate'
p23794
(F1
F0.00014334862385321102
I1
I0
I1
tp23795
sS'receiving,camptosar'
p23796
(F1
F0.00014334862385321102
I1
I0
I1
tp23797
sS'regular,users'
p23798
(F1
F0.00028669724770642203
I0
I2
I-2
tp23799
sS'other,hivid-associated'
p23800
(F1
F0.00014334862385321102
I1
I0
I1
tp23801
sS'clearance,a'
p23802
(F1
F0.00014334862385321102
I1
I0
I1
tp23803
sS'with,resulting'
p23804
(F1
F0.00014334862385321102
I1
I0
I1
tp23805
sS'foscavir,and'
p23806
(F1
F0.00028669724770642203
I2
I0
I2
tp23807
sS'increased,total'
p23808
(F1
F0.00028669724770642203
I0
I2
I-2
tp23809
sS'oxo-desethylzaleplon,glucuronide'
p23810
(F1
F0.00014334862385321102
I0
I1
I-1
tp23811
sS'such,agents'
p23812
(F1
F0.00014334862385321102
I0
I1
I-1
tp23813
sS'av,nodal'
p23814
(F1
F0.00028669724770642203
I2
I0
I2
tp23815
sS'gemzar,and'
p23816
(F1
F0.00014334862385321102
I0
I1
I-1
tp23817
sS'is,combined'
p23818
(F1
F0.00028669724770642203
I2
I0
I2
tp23819
sS'of,metabotropic'
p23820
(F1
F0.00014334862385321102
I0
I1
I-1
tp23821
sS'during,studies'
p23822
(F1
F0.00014334862385321102
I1
I0
I1
tp23823
sS'was,determined'
p23824
(F1
F0.00028669724770642203
I0
I2
I-2
tp23825
sS'one,should'
p23826
(F1
F0.00014334862385321102
I0
I1
I-1
tp23827
sS'metabolites,were'
p23828
(F1
F0.00028669724770642203
I0
I2
I-2
tp23829
sS'advised,to'
p23830
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23831
sS'roles,of'
p23832
(F1
F0.00014334862385321102
I0
I1
I-1
tp23833
sS'in,auc'
p23834
(F0.5
F0.0011467889908256881
I12
I4
I8
tp23835
sS'with,prolonged'
p23836
(F1
F0.00014334862385321102
I0
I1
I-1
tp23837
sS'other,hydroxymethylglutaryl'
p23838
(F1
F0.00014334862385321102
I1
I0
I1
tp23839
sS'approximate,increase'
p23840
(F1
F0.00057339449541284407
I4
I0
I4
tp23841
sS'threefold,from'
p23842
(F1
F0.00014334862385321102
I1
I0
I1
tp23843
sS'of,salicylic'
p23844
(F1
F0.00014334862385321102
I1
I0
I1
tp23845
sS'cyclophosphamide,used'
p23846
(F1
F0.00014334862385321102
I1
I0
I1
tp23847
sS'furosemide,may'
p23848
(F1
F0.00043004587155963305
I3
I0
I3
tp23849
sS'decreased,symptoms'
p23850
(F1
F0.00014334862385321102
I1
I0
I1
tp23851
sS'in,effects'
p23852
(F0
F0
I1
I1
I0
tp23853
sS'is,given'
p23854
(F0.21739130434782608
F0.00071674311926605509
I14
I9
I5
tp23855
sS'endorphinergic,system'
p23856
(F1
F0.00028669724770642203
I0
I2
I-2
tp23857
sS'lumen,at'
p23858
(F1
F0.00014334862385321102
I0
I1
I-1
tp23859
sS'nervous,system'
p23860
(F0.33333333333333331
F0.0010034403669724771
I14
I7
I7
tp23861
sS'nifedipine,may'
p23862
(F1
F0.00014334862385321102
I0
I1
I-1
tp23863
sS'hypothyroidism,may'
p23864
(F1
F0.00014334862385321102
I0
I1
I-1
tp23865
sS'are,all'
p23866
(F1
F0.00028669724770642203
I2
I0
I2
tp23867
sS'as,was'
p23868
(F1
F0.00014334862385321102
I1
I0
I1
tp23869
sS'person,and'
p23870
(F1
F0.00014334862385321102
I0
I1
I-1
tp23871
sS'induced,hypotension'
p23872
(F1
F0.00014334862385321102
I0
I1
I-1
tp23873
sS'tcas,such'
p23874
(F1
F0.00014334862385321102
I1
I0
I1
tp23875
sS'interaction,will'
p23876
(F1
F0.00014334862385321102
I1
I0
I1
tp23877
sS'for,up'
p23878
(F0.5
F0.00028669724770642203
I3
I1
I2
tp23879
sS'terfenadine,astemizole'
p23880
(F1
F0.00014334862385321102
I0
I1
I-1
tp23881
sS'affect,safety'
p23882
(F1
F0.00014334862385321102
I0
I1
I-1
tp23883
sS'oral,ccnu'
p23884
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23885
sS'emptying,may'
p23886
(F1
F0.00014334862385321102
I1
I0
I1
tp23887
sS'glutathione,levels'
p23888
(F1
F0.00014334862385321102
I1
I0
I1
tp23889
sS'and,coexisting'
p23890
(F1
F0.00014334862385321102
I0
I1
I-1
tp23891
sS'preferentially,blocked'
p23892
(F1
F0.00014334862385321102
I1
I0
I1
tp23893
sS'could,exaggerate'
p23894
(F1
F0.00028669724770642203
I2
I0
I2
tp23895
sS'patients,below'
p23896
(F1
F0.00014334862385321102
I0
I1
I-1
tp23897
sS'study,was'
p23898
(F1
F0.0012901376146788992
I0
I9
I-9
tp23899
sS'reactions,of'
p23900
(F0
F0
I1
I1
I0
tp23901
sS'b,i'
p23902
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp23903
sS's-warfarin,and'
p23904
(F1
F0.00014334862385321102
I1
I0
I1
tp23905
sS'combined,effects'
p23906
(F1
F0.00014334862385321102
I1
I0
I1
tp23907
sS'include,nucleoside'
p23908
(F1
F0.00014334862385321102
I0
I1
I-1
tp23909
sS'antagonists,hypertension'
p23910
(F1
F0.00014334862385321102
I1
I0
I1
tp23911
sS'suggest,that'
p23912
(F0.5
F0.0025802752293577983
I27
I9
I18
tp23913
sS'and,cmax'
p23914
(F0.125
F0.00028669724770642203
I7
I9
I-2
tp23915
sS'other,statins'
p23916
(F1
F0.00014334862385321102
I1
I0
I1
tp23917
sS'in,significantly'
p23918
(F1
F0.00028669724770642203
I2
I0
I2
tp23919
sS'deficiencies,affecting'
p23920
(F1
F0.00014334862385321102
I1
I0
I1
tp23921
sS'also,suggest'
p23922
(F1
F0.00014334862385321102
I1
I0
I1
tp23923
sS'or,inducers'
p23924
(F1
F0.00014334862385321102
I0
I1
I-1
tp23925
sS'normal,subjects'
p23926
(F0
F0
I3
I3
I0
tp23927
sS'hormone,therapy'
p23928
(F1
F0.00014334862385321102
I0
I1
I-1
tp23929
sS'daily,a'
p23930
(F1
F0.00014334862385321102
I1
I0
I1
tp23931
sS'nsaids,aspirin'
p23932
(F1
F0.00014334862385321102
I0
I1
I-1
tp23933
sS'exists,not'
p23934
(F1
F0.00014334862385321102
I0
I1
I-1
tp23935
sS'as,protease'
p23936
(F1
F0.00028669724770642203
I2
I0
I2
tp23937
sS'phe-nothiazines,products'
p23938
(F1
F0.00014334862385321102
I0
I1
I-1
tp23939
sS'serum,at'
p23940
(F1
F0.00014334862385321102
I0
I1
I-1
tp23941
sS'inducers,drugs'
p23942
(F1
F0.00014334862385321102
I0
I1
I-1
tp23943
sS'dimenhydrinate,may'
p23944
(F1
F0.00014334862385321102
I1
I0
I1
tp23945
sS'inhibitory,effects'
p23946
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23947
sS'with,monoamine'
p23948
(F1
F0.00057339449541284407
I4
I0
I4
tp23949
sS'data,have'
p23950
(F1
F0.00014334862385321102
I0
I1
I-1
tp23951
sS'group,interaction'
p23952
(F1
F0.00014334862385321102
I0
I1
I-1
tp23953
sS'blockers,should'
p23954
(F1
F0.00028669724770642203
I2
I0
I2
tp23955
sS'been,one'
p23956
(F1
F0.00014334862385321102
I1
I0
I1
tp23957
sS'lodine,as'
p23958
(F1
F0.00014334862385321102
I0
I1
I-1
tp23959
sS'prostaglandin,synthase'
p23960
(F1
F0.00014334862385321102
I1
I0
I1
tp23961
sS'half-life,may'
p23962
(F1
F0.00014334862385321102
I1
I0
I1
tp23963
sS'dosed,with'
p23964
(F0
F0
I1
I1
I0
tp23965
sS'by,therapeutic'
p23966
(F1
F0.00014334862385321102
I0
I1
I-1
tp23967
sS'weight,to'
p23968
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23969
sS'loss,associated'
p23970
(F1
F0.00028669724770642203
I2
I0
I2
tp23971
sS'excreted,in'
p23972
(F1
F0.00014334862385321102
I0
I1
I-1
tp23973
sS'these,results'
p23974
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp23975
sS'ii,or'
p23976
(F1
F0.00014334862385321102
I0
I1
I-1
tp23977
sS'quinolones,may'
p23978
(F1
F0.00014334862385321102
I1
I0
I1
tp23979
sS'alpha-adrenergic,stimulants'
p23980
(F1
F0.00014334862385321102
I1
I0
I1
tp23981
sS'minutes,were'
p23982
(F1
F0.00014334862385321102
I0
I1
I-1
tp23983
sS'cytochrome,p450iid6'
p23984
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23985
sS'corrected,qt'
p23986
(F1
F0.00043004587155963305
I0
I3
I-3
tp23987
sS'modest,effect'
p23988
(F1
F0.00028669724770642203
I2
I0
I2
tp23989
sS'initiated,or'
p23990
(F0
F0
I1
I1
I0
tp23991
sS'use,has'
p23992
(F1
F0.00014334862385321102
I1
I0
I1
tp23993
sS'the,mediation'
p23994
(F1
F0.00014334862385321102
I0
I1
I-1
tp23995
sS'pegasys,alone'
p23996
(F1
F0.00028669724770642203
I0
I2
I-2
tp23997
sS'found,or'
p23998
(F1
F0.00043004587155963305
I3
I0
I3
tp23999
sS'divergently,selected'
p24000
(F1
F0.00014334862385321102
I0
I1
I-1
tp24001
sS'value,of'
p24002
(F1
F0.00028669724770642203
I0
I2
I-2
tp24003
sS'of,lodine'
p24004
(F1
F0.00014334862385321102
I1
I0
I1
tp24005
sS'subjects,with'
p24006
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp24007
sS'acquisition,cost'
p24008
(F1
F0.00014334862385321102
I0
I1
I-1
tp24009
sS'the,mg'
p24010
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24011
sS'those,contained'
p24012
(F1
F0.00014334862385321102
I1
I0
I1
tp24013
sS'long-term,high-dose'
p24014
(F0
F0
I1
I1
I0
tp24015
sS'both,at'
p24016
(F1
F0.00014334862385321102
I0
I1
I-1
tp24017
sS'of,among'
p24018
(F1
F0.00014334862385321102
I1
I0
I1
tp24019
sS'monitored,particularly'
p24020
(F1
F0.00028669724770642203
I2
I0
I2
tp24021
sS'if,peganone'
p24022
(F1
F0.00014334862385321102
I1
I0
I1
tp24023
sS'to,modify'
p24024
(F1
F0.00014334862385321102
I0
I1
I-1
tp24025
sS'insulins,ability'
p24026
(F1
F0.00014334862385321102
I0
I1
I-1
tp24027
sS'not,interact'
p24028
(F1
F0.00028669724770642203
I0
I2
I-2
tp24029
sS'blockers,derivatives'
p24030
(F1
F0.00014334862385321102
I1
I0
I1
tp24031
sS'events,involving'
p24032
(F1
F0.00014334862385321102
I0
I1
I-1
tp24033
sS'competitive,interaction'
p24034
(F1
F0.00014334862385321102
I1
I0
I1
tp24035
sS'because,oral'
p24036
(F1
F0.00014334862385321102
I1
I0
I1
tp24037
sS'unaltered,in'
p24038
(F1
F0.00014334862385321102
I0
I1
I-1
tp24039
sS'therapy,should'
p24040
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp24041
sS'be,unaffected'
p24042
(F1
F0.00014334862385321102
I0
I1
I-1
tp24043
sS'introduced,at'
p24044
(F1
F0.00014334862385321102
I1
I0
I1
tp24045
sS'same,day'
p24046
(F1
F0.00014334862385321102
I1
I0
I1
tp24047
sS'not,affected'
p24048
(F1
F0.0028669724770642203
I0
I20
I-20
tp24049
sS'that,may'
p24050
(F0.23076923076923078
F0.0012901376146788992
I24
I15
I9
tp24051
sS'however,prudent'
p24052
(F1
F0.00014334862385321102
I1
I0
I1
tp24053
sS'doses,higher'
p24054
(F1
F0.00028669724770642203
I0
I2
I-2
tp24055
sS'major,psychotic'
p24056
(F1
F0.00014334862385321102
I1
I0
I1
tp24057
sS'amount,absorbed'
p24058
(F1
F0.00014334862385321102
I0
I1
I-1
tp24059
sS'a,delay'
p24060
(F1
F0.00014334862385321102
I1
I0
I1
tp24061
sS'and,intestinal'
p24062
(F1
F0.00014334862385321102
I0
I1
I-1
tp24063
sS'increased,by'
p24064
(F0.77777777777777779
F0.0020068807339449542
I16
I2
I14
tp24065
sS'information,is'
p24066
(F1
F0.00028669724770642203
I0
I2
I-2
tp24067
sS'the,bumetanide-induced'
p24068
(F1
F0.00014334862385321102
I1
I0
I1
tp24069
sS'parenteral,should'
p24070
(F1
F0.00014334862385321102
I1
I0
I1
tp24071
sS'are,substrates'
p24072
(F1
F0.0011467889908256881
I0
I8
I-8
tp24073
sS'meal,of'
p24074
(F1
F0.00014334862385321102
I0
I1
I-1
tp24075
sS'formulation,with'
p24076
(F1
F0.00028669724770642203
I2
I0
I2
tp24077
sS'patients,this'
p24078
(F1
F0.00014334862385321102
I0
I1
I-1
tp24079
sS'anti-inflammatory,drugs'
p24080
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp24081
sS'significant,effects'
p24082
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp24083
sS'trials,concomitant'
p24084
(F1
F0.00014334862385321102
I0
I1
I-1
tp24085
sS'heroin-related,deaths'
p24086
(F1
F0.00014334862385321102
I1
I0
I1
tp24087
sS'sulfoxide,were'
p24088
(F1
F0.00014334862385321102
I1
I0
I1
tp24089
sS'on,auc'
p24090
(F1
F0.00014334862385321102
I0
I1
I-1
tp24091
sS'receiving,a'
p24092
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24093
sS'local,which'
p24094
(F1
F0.00014334862385321102
I1
I0
I1
tp24095
sS'corticosteroids,and'
p24096
(F1
F0.00014334862385321102
I1
I0
I1
tp24097
sS'approximately,threefold'
p24098
(F1
F0.00014334862385321102
I1
I0
I1
tp24099
sS'm2,plus'
p24100
(F1
F0.00014334862385321102
I0
I1
I-1
tp24101
sS'should,only'
p24102
(F1
F0.00028669724770642203
I2
I0
I2
tp24103
sS'after,coadministration'
p24104
(F1
F0.00014334862385321102
I0
I1
I-1
tp24105
sS'heparinized,patients'
p24106
(F1
F0.00014334862385321102
I1
I0
I1
tp24107
sS'of,therapy'
p24108
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp24109
sS'topical,injectable'
p24110
(F1
F0.00014334862385321102
I0
I1
I-1
tp24111
sS'cns,depressive'
p24112
(F1
F0.00014334862385321102
I1
I0
I1
tp24113
sS'vasospastic,reactions'
p24114
(F1
F0.00014334862385321102
I1
I0
I1
tp24115
sS'could,decrease'
p24116
(F1
F0.00014334862385321102
I0
I1
I-1
tp24117
sS'weight,approximately'
p24118
(F1
F0.00014334862385321102
I0
I1
I-1
tp24119
sS'recorded,at'
p24120
(F1
F0.00014334862385321102
I0
I1
I-1
tp24121
sS'an,intravenous'
p24122
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24123
sS'via,a'
p24124
(F1
F0.00014334862385321102
I0
I1
I-1
tp24125
sS'often,used'
p24126
(F1
F0.00014334862385321102
I0
I1
I-1
tp24127
sS'bioavailability,parameters'
p24128
(F1
F0.00014334862385321102
I0
I1
I-1
tp24129
sS'oral,channel'
p24130
(F1
F0.00014334862385321102
I0
I1
I-1
tp24131
sS'copegus,pegasys'
p24132
(F1
F0.00014334862385321102
I0
I1
I-1
tp24133
sS'for,alterations'
p24134
(F1
F0.00028669724770642203
I2
I0
I2
tp24135
sS'known,caution'
p24136
(F1
F0.00014334862385321102
I1
I0
I1
tp24137
sS'or,complete'
p24138
(F1
F0.00014334862385321102
I1
I0
I1
tp24139
sS'hemodynamic,compromise'
p24140
(F1
F0.00014334862385321102
I1
I0
I1
tp24141
sS'lower,the'
p24142
(F1
F0.00028669724770642203
I2
I0
I2
tp24143
sS'cholesterol,and'
p24144
(F1
F0.00014334862385321102
I1
I0
I1
tp24145
sS'effects,particularly'
p24146
(F1
F0.00014334862385321102
I1
I0
I1
tp24147
sS'cohort,design'
p24148
(F1
F0.00014334862385321102
I1
I0
I1
tp24149
sS'with,highly'
p24150
(F1
F0.00028669724770642203
I0
I2
I-2
tp24151
sS'month,toxicology'
p24152
(F1
F0.00014334862385321102
I0
I1
I-1
tp24153
sS'a,such'
p24154
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24155
sS'depressant,effect'
p24156
(F0
F0
I2
I2
I0
tp24157
sS'anti-peptic,agents'
p24158
(F1
F0.00014334862385321102
I0
I1
I-1
tp24159
sS'two,hours'
p24160
(F1
F0.00014334862385321102
I0
I1
I-1
tp24161
sS'min,interval'
p24162
(F1
F0.00014334862385321102
I1
I0
I1
tp24163
sS'a,reliable'
p24164
(F1
F0.00014334862385321102
I1
I0
I1
tp24165
sS'with,antithrombin'
p24166
(F1
F0.00028669724770642203
I2
I0
I2
tp24167
sS'and,against'
p24168
(F1
F0.00014334862385321102
I0
I1
I-1
tp24169
sS'initiated,adjusted'
p24170
(F1
F0.00014334862385321102
I1
I0
I1
tp24171
sS'regimens,where'
p24172
(F1
F0.00014334862385321102
I0
I1
I-1
tp24173
sS'years,of'
p24174
(F1
F0.00014334862385321102
I0
I1
I-1
tp24175
sS'these,and'
p24176
(F1
F0.00014334862385321102
I0
I1
I-1
tp24177
sS'recent,study'
p24178
(F1
F0.00014334862385321102
I1
I0
I1
tp24179
sS'while,plasma'
p24180
(F1
F0.00014334862385321102
I1
I0
I1
tp24181
sS'angiotensin,converting'
p24182
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp24183
sS'protection,against'
p24184
(F1
F0.00014334862385321102
I1
I0
I1
tp24185
sS'dosages,may'
p24186
(F1
F0.00014334862385321102
I1
I0
I1
tp24187
sS'inducers,are'
p24188
(F1
F0.00014334862385321102
I1
I0
I1
tp24189
sS'later,also'
p24190
(F1
F0.00014334862385321102
I1
I0
I1
tp24191
sS'and,substrates'
p24192
(F1
F0.00014334862385321102
I1
I0
I1
tp24193
sS'made,on'
p24194
(F1
F0.00014334862385321102
I0
I1
I-1
tp24195
sS'propranolol,may'
p24196
(F1
F0.00014334862385321102
I1
I0
I1
tp24197
sS'toradol,and'
p24198
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24199
sS'derivatives,k'
p24200
(F1
F0.00014334862385321102
I0
I1
I-1
tp24201
sS'with,small'
p24202
(F1
F0.00014334862385321102
I1
I0
I1
tp24203
sS'in,u937'
p24204
(F1
F0.00014334862385321102
I1
I0
I1
tp24205
sS'effects,when'
p24206
(F1
F0.0010034403669724771
I7
I0
I7
tp24207
sS'receiving,replacement'
p24208
(F1
F0.00014334862385321102
I1
I0
I1
tp24209
sS'given,consideration'
p24210
(F1
F0.0010034403669724771
I7
I0
I7
tp24211
sS'tumour,and'
p24212
(F1
F0.00014334862385321102
I1
I0
I1
tp24213
sS'determine,the'
p24214
(F1
F0.00028669724770642203
I0
I2
I-2
tp24215
sS'reduced,although'
p24216
(F1
F0.00014334862385321102
I1
I0
I1
tp24217
sS'activity,if'
p24218
(F1
F0.00014334862385321102
I1
I0
I1
tp24219
sS'noted,below'
p24220
(F1
F0.00014334862385321102
I0
I1
I-1
tp24221
sS'a,non-enzyme'
p24222
(F1
F0.00014334862385321102
I0
I1
I-1
tp24223
sS'automaticity,as'
p24224
(F1
F0.00014334862385321102
I1
I0
I1
tp24225
sS'anticonvulsants,in'
p24226
(F1
F0.00014334862385321102
I1
I0
I1
tp24227
sS'and,provide'
p24228
(F1
F0.00014334862385321102
I1
I0
I1
tp24229
sS'decarboxylase,inhibitor'
p24230
(F1
F0.00014334862385321102
I0
I1
I-1
tp24231
sS'of,kg'
p24232
(F0
F0
I1
I1
I0
tp24233
sS'acarbose,was'
p24234
(F1
F0.00014334862385321102
I0
I1
I-1
tp24235
sS'at,min'
p24236
(F1
F0.00014334862385321102
I0
I1
I-1
tp24237
sS'in,most'
p24238
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24239
sS'as,normal'
p24240
(F1
F0.00014334862385321102
I0
I1
I-1
tp24241
sS'breakfast,cereals'
p24242
(F1
F0.00014334862385321102
I0
I1
I-1
tp24243
sS'if,sprycel'
p24244
(F1
F0.00014334862385321102
I0
I1
I-1
tp24245
sS'the,steady'
p24246
(F0
F0
I1
I1
I0
tp24247
sS'the,principal'
p24248
(F0
F0
I1
I1
I0
tp24249
sS'either,prophylactic'
p24250
(F1
F0.00014334862385321102
I0
I1
I-1
tp24251
sS'metabolism,hormone'
p24252
(F1
F0.00014334862385321102
I0
I1
I-1
tp24253
sS'methotrexate,ketoprofen'
p24254
(F1
F0.00014334862385321102
I1
I0
I1
tp24255
sS'considerable,effect'
p24256
(F1
F0.00014334862385321102
I1
I0
I1
tp24257
sS'related,psychoses'
p24258
(F1
F0.00028669724770642203
I0
I2
I-2
tp24259
sS'with,angiotensin-'
p24260
(F1
F0.00014334862385321102
I0
I1
I-1
tp24261
sS'relaxants,most'
p24262
(F1
F0.00014334862385321102
I1
I0
I1
tp24263
sS'h,in'
p24264
(F1
F0.00014334862385321102
I0
I1
I-1
tp24265
sS'anticoagulants,in'
p24266
(F0
F0
I1
I1
I0
tp24267
sS'that,and'
p24268
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp24269
sS'pharmacokinetics,if'
p24270
(F1
F0.00014334862385321102
I0
I1
I-1
tp24271
sS'doses,did'
p24272
(F1
F0.00014334862385321102
I0
I1
I-1
tp24273
sS'on,may'
p24274
(F1
F0.00028669724770642203
I2
I0
I2
tp24275
sS'citrate,potentiate'
p24276
(F1
F0.00014334862385321102
I1
I0
I1
tp24277
sS'aim,of'
p24278
(F1
F0.00028669724770642203
I0
I2
I-2
tp24279
sS'receiving,in'
p24280
(F1
F0.00014334862385321102
I1
I0
I1
tp24281
sS'the,ccnu'
p24282
(F1
F0.00014334862385321102
I0
I1
I-1
tp24283
sS'property,of'
p24284
(F1
F0.00014334862385321102
I1
I0
I1
tp24285
sS'or,reduce'
p24286
(F1
F0.00014334862385321102
I1
I0
I1
tp24287
sS'as,part'
p24288
(F1
F0.00014334862385321102
I0
I1
I-1
tp24289
sS'patient,population'
p24290
(F1
F0.00014334862385321102
I0
I1
I-1
tp24291
sS'cyclooxygenase-2,cox-2'
p24292
(F1
F0.00014334862385321102
I0
I1
I-1
tp24293
sS'pharmacokinetics,in'
p24294
(F1
F0.00043004587155963305
I0
I3
I-3
tp24295
sS'with,ototoxic'
p24296
(F1
F0.00014334862385321102
I1
I0
I1
tp24297
sS'products,should'
p24298
(F1
F0.00014334862385321102
I0
I1
I-1
tp24299
sS'distribution,of'
p24300
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp24301
sS'qt,c'
p24302
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24303
sS'trough,serum'
p24304
(F1
F0.00028669724770642203
I0
I2
I-2
tp24305
sS'by,range'
p24306
(F1
F0.00014334862385321102
I1
I0
I1
tp24307
sS'distribution,or'
p24308
(F1
F0.00014334862385321102
I0
I1
I-1
tp24309
sS'or,cardiac'
p24310
(F1
F0.00028669724770642203
I0
I2
I-2
tp24311
sS'in,rodent'
p24312
(F1
F0.00014334862385321102
I0
I1
I-1
tp24313
sS'k,antagonists'
p24314
(F0
F0
I2
I2
I0
tp24315
sS'exposed,histidine'
p24316
(F1
F0.00014334862385321102
I0
I1
I-1
tp24317
sS'assessed,by'
p24318
(F1
F0.00057339449541284407
I0
I4
I-4
tp24319
sS'of,chloral'
p24320
(F1
F0.00014334862385321102
I0
I1
I-1
tp24321
sS'along,with'
p24322
(F1
F0.00014334862385321102
I1
I0
I1
tp24323
sS'affect,gastrointestinal'
p24324
(F1
F0.00014334862385321102
I1
I0
I1
tp24325
sS'starting,st'
p24326
(F1
F0.00014334862385321102
I0
I1
I-1
tp24327
sS'a,rapidly'
p24328
(F1
F0.00028669724770642203
I0
I2
I-2
tp24329
sS'serotonin,reuptake'
p24330
(F0
F0
I9
I9
I0
tp24331
sS'nonsteroidal,anti'
p24332
(F1
F0.00014334862385321102
I1
I0
I1
tp24333
sS'incombination,with'
p24334
(F1
F0.00014334862385321102
I0
I1
I-1
tp24335
sS'patients,consuming'
p24336
(F1
F0.00014334862385321102
I1
I0
I1
tp24337
sS'with,antacids'
p24338
(F1
F0.00014334862385321102
I1
I0
I1
tp24339
sS'concentrations,during'
p24340
(F1
F0.00014334862385321102
I1
I0
I1
tp24341
sS'anti-platelet,effect'
p24342
(F1
F0.00014334862385321102
I0
I1
I-1
tp24343
sS'initial,or'
p24344
(F1
F0.00028669724770642203
I0
I2
I-2
tp24345
sS'likely,viracept'
p24346
(F1
F0.00014334862385321102
I1
I0
I1
tp24347
sS'differential,regulation'
p24348
(F1
F0.00014334862385321102
I0
I1
I-1
tp24349
sS'abnormalities,such'
p24350
(F1
F0.00014334862385321102
I1
I0
I1
tp24351
sS'when,doses'
p24352
(F1
F0.00014334862385321102
I1
I0
I1
tp24353
sS'with,left'
p24354
(F1
F0.00014334862385321102
I0
I1
I-1
tp24355
sS'was,covalently'
p24356
(F1
F0.00014334862385321102
I0
I1
I-1
tp24357
sS'treatment,following'
p24358
(F1
F0.00014334862385321102
I1
I0
I1
tp24359
sS'except,in'
p24360
(F1
F0.00014334862385321102
I1
I0
I1
tp24361
sS'role,of'
p24362
(F1
F0.00014334862385321102
I0
I1
I-1
tp24363
sS'well-controlled,study'
p24364
(F1
F0.00014334862385321102
I0
I1
I-1
tp24365
sS'taking,these'
p24366
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24367
sS'acid,the'
p24368
(F1
F0.00014334862385321102
I0
I1
I-1
tp24369
sS'however,a'
p24370
(F1
F0.00014334862385321102
I1
I0
I1
tp24371
sS'by,bacterial'
p24372
(F1
F0.00014334862385321102
I1
I0
I1
tp24373
sS'one,class'
p24374
(F1
F0.00057339449541284407
I4
I0
I4
tp24375
sS'kg,decreased'
p24376
(F1
F0.00014334862385321102
I1
I0
I1
tp24377
sS'absorption,acting'
p24378
(F1
F0.00014334862385321102
I1
I0
I1
tp24379
sS'by,gram-negative'
p24380
(F1
F0.00014334862385321102
I0
I1
I-1
tp24381
sS'kg,decreases'
p24382
(F1
F0.00014334862385321102
I0
I1
I-1
tp24383
sS'blocking,agents'
p24384
(F0.090909090909090912
F0.00043004587155963305
I18
I15
I3
tp24385
sS'soluble,to'
p24386
(F1
F0.00014334862385321102
I0
I1
I-1
tp24387
sS'bar-press,behavior'
p24388
(F1
F0.00014334862385321102
I0
I1
I-1
tp24389
sS'other,especially'
p24390
(F1
F0.00014334862385321102
I0
I1
I-1
tp24391
sS'are,actively'
p24392
(F1
F0.00014334862385321102
I1
I0
I1
tp24393
sS'unfractionated,up'
p24394
(F1
F0.00014334862385321102
I0
I1
I-1
tp24395
sS'mean,arterial'
p24396
(F1
F0.00014334862385321102
I1
I0
I1
tp24397
sS'has,reduced'
p24398
(F1
F0.00014334862385321102
I1
I0
I1
tp24399
sS'on,and'
p24400
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24401
sS'cerebri,benign'
p24402
(F1
F0.00014334862385321102
I1
I0
I1
tp24403
sS'cephalosporins-cephalosporins,containing'
p24404
(F1
F0.00014334862385321102
I0
I1
I-1
tp24405
sS'several,well-controlled'
p24406
(F1
F0.00014334862385321102
I0
I1
I-1
tp24407
sS'vet,or'
p24408
(F1
F0.00014334862385321102
I1
I0
I1
tp24409
sS'volunteers,when'
p24410
(F1
F0.00014334862385321102
I0
I1
I-1
tp24411
sS'after,co-treatment'
p24412
(F1
F0.00014334862385321102
I1
I0
I1
tp24413
sS'cyp3a4,may'
p24414
(F1
F0.00028669724770642203
I0
I2
I-2
tp24415
sS'inducer,should'
p24416
(F1
F0.00028669724770642203
I2
I0
I2
tp24417
sS'an,decrease'
p24418
(F1
F0.00028669724770642203
I2
I0
I2
tp24419
sS'that,although'
p24420
(F1
F0.00014334862385321102
I1
I0
I1
tp24421
sS'prolong,both'
p24422
(F1
F0.00014334862385321102
I0
I1
I-1
tp24423
sS'affect,abilify'
p24424
(F1
F0.00014334862385321102
I0
I1
I-1
tp24425
sS'necessary,during'
p24426
(F1
F0.00014334862385321102
I1
I0
I1
tp24427
sS'and,lethal'
p24428
(F1
F0.00014334862385321102
I0
I1
I-1
tp24429
sS'human,volunteers'
p24430
(F1
F0.00014334862385321102
I0
I1
I-1
tp24431
sS'were,between'
p24432
(F1
F0.00014334862385321102
I0
I1
I-1
tp24433
sS'regarding,protease'
p24434
(F1
F0.00014334862385321102
I0
I1
I-1
tp24435
sS'produced,only'
p24436
(F1
F0.00014334862385321102
I1
I0
I1
tp24437
sS'dehydration,have'
p24438
(F1
F0.00014334862385321102
I1
I0
I1
tp24439
sS'argatroban,is'
p24440
(F1
F0.00014334862385321102
I0
I1
I-1
tp24441
sS'hence,is'
p24442
(F1
F0.00014334862385321102
I1
I0
I1
tp24443
sS'contrary,and'
p24444
(F1
F0.00014334862385321102
I1
I0
I1
tp24445
sS'with,any'
p24446
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp24447
sS'no,interaction'
p24448
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp24449
sS'with,and'
p24450
(F0.018181818181818181
F0.00014334862385321102
I28
I27
I1
tp24451
sS'possible,extrarenal'
p24452
(F1
F0.00014334862385321102
I0
I1
I-1
tp24453
sS'intake,which'
p24454
(F1
F0.00014334862385321102
I0
I1
I-1
tp24455
sS'aspirin,should'
p24456
(F1
F0.00043004587155963305
I3
I0
I3
tp24457
sS'are,associated'
p24458
(F1
F0.00028669724770642203
I0
I2
I-2
tp24459
sS'supplements,and'
p24460
(F1
F0.00071674311926605509
I5
I0
I5
tp24461
sS'disease,requires'
p24462
(F1
F0.00014334862385321102
I0
I1
I-1
tp24463
sS'medical,practice'
p24464
(F1
F0.00014334862385321102
I1
I0
I1
tp24465
sS'supplements,or'
p24466
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24467
sS'dihydroxyflavone,with'
p24468
(F1
F0.00014334862385321102
I0
I1
I-1
tp24469
sS'of,depressive'
p24470
(F1
F0.00014334862385321102
I0
I1
I-1
tp24471
sS'clonazepam,does'
p24472
(F1
F0.00014334862385321102
I0
I1
I-1
tp24473
sS'of,humorsol'
p24474
(F1
F0.00014334862385321102
I1
I0
I1
tp24475
sS'a,functioning'
p24476
(F1
F0.00014334862385321102
I1
I0
I1
tp24477
sS'agents,contraindicated'
p24478
(F1
F0.00014334862385321102
I0
I1
I-1
tp24479
sS'h-2,antagonists'
p24480
(F1
F0.00014334862385321102
I0
I1
I-1
tp24481
sS'with,ventricular'
p24482
(F1
F0.00014334862385321102
I1
I0
I1
tp24483
sS'three,doses'
p24484
(F1
F0.00014334862385321102
I1
I0
I1
tp24485
sS'cause,too'
p24486
(F1
F0.00014334862385321102
I0
I1
I-1
tp24487
sS'medication,including'
p24488
(F1
F0.00014334862385321102
I1
I0
I1
tp24489
sS'agents,since'
p24490
(F1
F0.00028669724770642203
I2
I0
I2
tp24491
sS'in,nine'
p24492
(F1
F0.00014334862385321102
I0
I1
I-1
tp24493
sS'to,electrolyte'
p24494
(F1
F0.00014334862385321102
I1
I0
I1
tp24495
sS'concurrently,use'
p24496
(F1
F0.00014334862385321102
I1
I0
I1
tp24497
sS'channel,subtypes'
p24498
(F1
F0.00014334862385321102
I0
I1
I-1
tp24499
sS'of,histidine'
p24500
(F1
F0.00014334862385321102
I0
I1
I-1
tp24501
sS'whether,other'
p24502
(F1
F0.00014334862385321102
I0
I1
I-1
tp24503
sS'can,result'
p24504
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp24505
sS'cannot,be'
p24506
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24507
sS'nonsteroidal,nsaid'
p24508
(F1
F0.00014334862385321102
I0
I1
I-1
tp24509
sS'asa,and'
p24510
(F1
F0.00014334862385321102
I0
I1
I-1
tp24511
sS'adverse,interactions'
p24512
(F1
F0.00014334862385321102
I0
I1
I-1
tp24513
sS'glycoprotein,iib'
p24514
(F1
F0.00014334862385321102
I1
I0
I1
tp24515
sS'counts,in'
p24516
(F1
F0.00014334862385321102
I1
I0
I1
tp24517
sS'of,glucose'
p24518
(F1
F0.00014334862385321102
I0
I1
I-1
tp24519
sS'and,symptoms'
p24520
(F1
F0.0008600917431192661
I6
I0
I6
tp24521
sS'methenamine,therapy'
p24522
(F1
F0.00028669724770642203
I2
I0
I2
tp24523
sS'receiving,cautious'
p24524
(F1
F0.00014334862385321102
I1
I0
I1
tp24525
sS'oral,formulations'
p24526
(F1
F0.00014334862385321102
I1
I0
I1
tp24527
sS'adult,volunteers'
p24528
(F1
F0.00014334862385321102
I0
I1
I-1
tp24529
sS'protein,tyrosine'
p24530
(F1
F0.00014334862385321102
I0
I1
I-1
tp24531
sS'mesylate,may'
p24532
(F1
F0.00014334862385321102
I1
I0
I1
tp24533
sS'propanol,mg'
p24534
(F1
F0.00014334862385321102
I1
I0
I1
tp24535
sS'among,co-administered'
p24536
(F1
F0.00014334862385321102
I0
I1
I-1
tp24537
sS'large,number'
p24538
(F1
F0.00014334862385321102
I0
I1
I-1
tp24539
sS'table,aed'
p24540
(F1
F0.00014334862385321102
I0
I1
I-1
tp24541
sS'singly,or'
p24542
(F1
F0.00014334862385321102
I0
I1
I-1
tp24543
sS'of,could'
p24544
(F1
F0.00014334862385321102
I1
I0
I1
tp24545
sS'clinical,practice'
p24546
(F1
F0.00014334862385321102
I1
I0
I1
tp24547
sS'steady-state,levels'
p24548
(F1
F0.00014334862385321102
I0
I1
I-1
tp24549
sS'a,short-term'
p24550
(F1
F0.00014334862385321102
I0
I1
I-1
tp24551
sS'drugs,nsaids'
p24552
(F0
F0
I1
I1
I0
tp24553
sS'trials,similar'
p24554
(F1
F0.00014334862385321102
I0
I1
I-1
tp24555
sS'following,acetaminophen'
p24556
(F1
F0.00028669724770642203
I2
I0
I2
tp24557
sS'rating,scale'
p24558
(F1
F0.00014334862385321102
I1
I0
I1
tp24559
sS'placebo,and'
p24560
(F1
F0.00028669724770642203
I0
I2
I-2
tp24561
sS'beta,to'
p24562
(F1
F0.00014334862385321102
I0
I1
I-1
tp24563
sS'albumin,binding'
p24564
(F1
F0.00014334862385321102
I1
I0
I1
tp24565
sS'no,documentation'
p24566
(F1
F0.00014334862385321102
I0
I1
I-1
tp24567
sS'inducers,indicate'
p24568
(F1
F0.00014334862385321102
I1
I0
I1
tp24569
sS'blockers,sustained-release'
p24570
(F1
F0.00014334862385321102
I0
I1
I-1
tp24571
sS'pharmacodynamics,ecg'
p24572
(F1
F0.00014334862385321102
I0
I1
I-1
tp24573
sS'anti-asthma,medications'
p24574
(F1
F0.00014334862385321102
I0
I1
I-1
tp24575
sS'be,deferred'
p24576
(F1
F0.00014334862385321102
I1
I0
I1
tp24577
sS'or,enantiomer'
p24578
(F1
F0.00014334862385321102
I0
I1
I-1
tp24579
sS'addition,does'
p24580
(F1
F0.00014334862385321102
I0
I1
I-1
tp24581
sS'imipramine,mg'
p24582
(F1
F0.00014334862385321102
I0
I1
I-1
tp24583
sS'metabolic,clearance'
p24584
(F1
F0.0008600917431192661
I6
I0
I6
tp24585
sS'been,effectively'
p24586
(F1
F0.00014334862385321102
I0
I1
I-1
tp24587
sS'compounds,and'
p24588
(F1
F0.00014334862385321102
I1
I0
I1
tp24589
sS'serum,level'
p24590
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp24591
sS'range,in'
p24592
(F1
F0.00014334862385321102
I1
I0
I1
tp24593
sS'led,to'
p24594
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp24595
sS'to,subjects'
p24596
(F1
F0.00057339449541284407
I4
I0
I4
tp24597
sS'by,cimetidines'
p24598
(F1
F0.00014334862385321102
I1
I0
I1
tp24599
sS'praziquantel,in'
p24600
(F1
F0.00014334862385321102
I1
I0
I1
tp24601
sS'a,potentially'
p24602
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24603
sS'have,previously'
p24604
(F0
F0
I1
I1
I0
tp24605
sS'however,mg'
p24606
(F1
F0.00014334862385321102
I1
I0
I1
tp24607
sS'of,p-glycoprotein'
p24608
(F1
F0.00014334862385321102
I0
I1
I-1
tp24609
sS'their,plasma'
p24610
(F0
F0
I1
I1
I0
tp24611
sS'mg,capsules'
p24612
(F1
F0.00043004587155963305
I3
I0
I3
tp24613
sS'both,the'
p24614
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp24615
sS'clinicians,should'
p24616
(F1
F0.00014334862385321102
I1
I0
I1
tp24617
sS'camp,whereas'
p24618
(F1
F0.00014334862385321102
I1
I0
I1
tp24619
sS'agent,for'
p24620
(F0
F0
I1
I1
I0
tp24621
sS'carbonic,anhydrase'
p24622
(F1
F0.00043004587155963305
I3
I0
I3
tp24623
sS'to,increased'
p24624
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp24625
sS'and,absorption'
p24626
(F0
F0
I1
I1
I0
tp24627
sS'barbiturates,and'
p24628
(F1
F0.00028669724770642203
I2
I0
I2
tp24629
sS'regimen,reduces'
p24630
(F1
F0.00014334862385321102
I0
I1
I-1
tp24631
sS'to,increases'
p24632
(F1
F0.00028669724770642203
I0
I2
I-2
tp24633
sS'and,aluminum-containing'
p24634
(F0
F0
I1
I1
I0
tp24635
sS'principal,pathway'
p24636
(F1
F0.00014334862385321102
I1
I0
I1
tp24637
sS'of,anti-factor'
p24638
(F1
F0.00014334862385321102
I0
I1
I-1
tp24639
sS'doubled,in'
p24640
(F1
F0.00014334862385321102
I0
I1
I-1
tp24641
sS'eg,or'
p24642
(F1
F0.00043004587155963305
I3
I0
I3
tp24643
sS'heparin-induced,thrombocytopenia'
p24644
(F1
F0.00014334862385321102
I0
I1
I-1
tp24645
sS'including,other'
p24646
(F1
F0.00014334862385321102
I1
I0
I1
tp24647
sS'by,without'
p24648
(F1
F0.00028669724770642203
I2
I0
I2
tp24649
sS'and,diuretics'
p24650
(F1
F0.00014334862385321102
I1
I0
I1
tp24651
sS'a,and'
p24652
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24653
sS'there,may'
p24654
(F1
F0.00028669724770642203
I2
I0
I2
tp24655
sS'relaxants,that'
p24656
(F1
F0.00014334862385321102
I0
I1
I-1
tp24657
sS'aprepitant,when'
p24658
(F1
F0.00057339449541284407
I4
I0
I4
tp24659
sS'in,isolated'
p24660
(F0
F0
I1
I1
I0
tp24661
sS'imitrex,nasal'
p24662
(F1
F0.00014334862385321102
I0
I1
I-1
tp24663
sS'patients,n'
p24664
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24665
sS'successfully,concurrently'
p24666
(F1
F0.00028669724770642203
I0
I2
I-2
tp24667
sS'may,accelerate'
p24668
(F1
F0.00014334862385321102
I0
I1
I-1
tp24669
sS'patients,a'
p24670
(F1
F0.00014334862385321102
I0
I1
I-1
tp24671
sS'carbamazepine,isoniazid'
p24672
(F1
F0.00014334862385321102
I1
I0
I1
tp24673
sS'vitro,therefore'
p24674
(F1
F0.00014334862385321102
I0
I1
I-1
tp24675
sS'steady-state,blood'
p24676
(F0
F0
I1
I1
I0
tp24677
sS'by,tromethamine'
p24678
(F1
F0.00014334862385321102
I1
I0
I1
tp24679
sS'when,co-administered'
p24680
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp24681
sS'check,coagulation'
p24682
(F1
F0.00014334862385321102
I1
I0
I1
tp24683
sS'undergo,enterohepatic'
p24684
(F1
F0.00014334862385321102
I1
I0
I1
tp24685
sS'during,concomitant'
p24686
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp24687
sS'experiments,demonstrated'
p24688
(F1
F0.00014334862385321102
I0
I1
I-1
tp24689
sS'higher,and'
p24690
(F1
F0.00028669724770642203
I0
I2
I-2
tp24691
sS'of,uptake'
p24692
(F1
F0.00014334862385321102
I0
I1
I-1
tp24693
sS'adrenoreceptors,on'
p24694
(F1
F0.00014334862385321102
I0
I1
I-1
tp24695
sS'discontinuing,or'
p24696
(F1
F0.00014334862385321102
I1
I0
I1
tp24697
sS'hepatic,cytochrome'
p24698
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24699
sS'due,not'
p24700
(F1
F0.00014334862385321102
I1
I0
I1
tp24701
sS'therefore,cyp3a4'
p24702
(F1
F0.00014334862385321102
I1
I0
I1
tp24703
sS'medicines,since'
p24704
(F1
F0.00014334862385321102
I1
I0
I1
tp24705
sS'breast,milk'
p24706
(F1
F0.00014334862385321102
I0
I1
I-1
tp24707
sS'therapeutic,superiority'
p24708
(F1
F0.00014334862385321102
I0
I1
I-1
tp24709
sS'creatinine,an'
p24710
(F1
F0.00014334862385321102
I1
I0
I1
tp24711
sS'hydrochloride,alone'
p24712
(F1
F0.00014334862385321102
I0
I1
I-1
tp24713
sS'levamisole,hydrochloride'
p24714
(F1
F0.00014334862385321102
I1
I0
I1
tp24715
sS'strattera,may'
p24716
(F1
F0.00014334862385321102
I1
I0
I1
tp24717
sS'vaiproic,acid'
p24718
(F1
F0.00014334862385321102
I1
I0
I1
tp24719
sS'retrospectively,a'
p24720
(F1
F0.00014334862385321102
I0
I1
I-1
tp24721
sS'an,can'
p24722
(F1
F0.00014334862385321102
I1
I0
I1
tp24723
sS'in,pigeons'
p24724
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp24725
sS'completed,with'
p24726
(F1
F0.00014334862385321102
I0
I1
I-1
tp24727
sS'er,extended'
p24728
(F1
F0.00014334862385321102
I0
I1
I-1
tp24729
sS'may,lead'
p24730
(F0.40000000000000002
F0.00057339449541284407
I3
I7
I-4
tp24731
sS'sole,protease'
p24732
(F1
F0.00028669724770642203
I0
I2
I-2
tp24733
sS'reported,during'
p24734
(F1
F0.0008600917431192661
I6
I0
I6
tp24735
sS'that,you'
p24736
(F1
F0.00028669724770642203
I2
I0
I2
tp24737
sS'groups,and'
p24738
(F1
F0.00014334862385321102
I0
I1
I-1
tp24739
sS'the,addition'
p24740
(F0.25
F0.00057339449541284407
I10
I6
I4
tp24741
sS'the,free'
p24742
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24743
sS'indinavir,has'
p24744
(F1
F0.00014334862385321102
I1
I0
I1
tp24745
sS'cholestyramine,and'
p24746
(F1
F0.00043004587155963305
I3
I0
I3
tp24747
sS'blockers,nonsteroidal'
p24748
(F1
F0.00014334862385321102
I0
I1
I-1
tp24749
sS'p450,a4'
p24750
(F0
F0
I7
I7
I0
tp24751
sS'p450,a2'
p24752
(F1
F0.00028669724770642203
I2
I0
I2
tp24753
sS'digoxin,rofecoxib'
p24754
(F1
F0.00014334862385321102
I0
I1
I-1
tp24755
sS'following,dosing'
p24756
(F1
F0.00014334862385321102
I0
I1
I-1
tp24757
sS'efavirenz,has'
p24758
(F1
F0.00014334862385321102
I0
I1
I-1
tp24759
sS'while,they'
p24760
(F1
F0.00014334862385321102
I0
I1
I-1
tp24761
sS'thus,when'
p24762
(F1
F0.00057339449541284407
I4
I0
I4
tp24763
sS'rashes,in'
p24764
(F1
F0.00014334862385321102
I1
I0
I1
tp24765
sS'occur,with'
p24766
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp24767
sS'concentrations,tested'
p24768
(F1
F0.00014334862385321102
I0
I1
I-1
tp24769
sS'im,reduced'
p24770
(F1
F0.00014334862385321102
I1
I0
I1
tp24771
sS'both,ca'
p24772
(F1
F0.00014334862385321102
I1
I0
I1
tp24773
sS'the,or'
p24774
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp24775
sS'in,systemic'
p24776
(F1
F0.00043004587155963305
I3
I0
I3
tp24777
sS'rashes,is'
p24778
(F1
F0.00014334862385321102
I1
I0
I1
tp24779
sS'employed,since'
p24780
(F1
F0.00014334862385321102
I1
I0
I1
tp24781
sS'if,supplements'
p24782
(F1
F0.00014334862385321102
I1
I0
I1
tp24783
sS'orencia,administered'
p24784
(F1
F0.00014334862385321102
I1
I0
I1
tp24785
sS'the,potent'
p24786
(F1
F0.00057339449541284407
I4
I0
I4
tp24787
sS'the,mao-b'
p24788
(F1
F0.00014334862385321102
I0
I1
I-1
tp24789
sS'relative,bioavailability'
p24790
(F1
F0.00014334862385321102
I0
I1
I-1
tp24791
sS'or,monitoring'
p24792
(F1
F0.00014334862385321102
I0
I1
I-1
tp24793
sS'months,received'
p24794
(F1
F0.00014334862385321102
I0
I1
I-1
tp24795
sS'by,other'
p24796
(F0
F0
I1
I1
I0
tp24797
sS'effects,including'
p24798
(F1
F0.00028669724770642203
I2
I0
I2
tp24799
sS'addition,we'
p24800
(F1
F0.00014334862385321102
I0
I1
I-1
tp24801
sS'oxypurines,in'
p24802
(F1
F0.00014334862385321102
I0
I1
I-1
tp24803
sS'm,g'
p24804
(F1
F0.00028669724770642203
I2
I0
I2
tp24805
sS'edecrin,may'
p24806
(F1
F0.00014334862385321102
I1
I0
I1
tp24807
sS'm,i'
p24808
(F1
F0.00014334862385321102
I1
I0
I1
tp24809
sS'm,m'
p24810
(F0
F0
I1
I1
I0
tp24811
sS'this,procedure'
p24812
(F1
F0.00014334862385321102
I0
I1
I-1
tp24813
sS'neuropathy,include'
p24814
(F1
F0.00014334862385321102
I0
I1
I-1
tp24815
sS'm,v'
p24816
(F1
F0.00057339449541284407
I0
I4
I-4
tp24817
sS'n-methyllevallorphan,mg'
p24818
(F1
F0.00014334862385321102
I1
I0
I1
tp24819
sS'activity,of'
p24820
(F0.040000000000000001
F0.00014334862385321102
I12
I13
I-1
tp24821
sS'of,monoamine'
p24822
(F1
F0.00014334862385321102
I1
I0
I1
tp24823
sS'also,adversely'
p24824
(F1
F0.00014334862385321102
I1
I0
I1
tp24825
sS'metabolite,concentration'
p24826
(F1
F0.00014334862385321102
I1
I0
I1
tp24827
sS'at,all'
p24828
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24829
sS'become,subtherapeutic'
p24830
(F1
F0.00014334862385321102
I1
I0
I1
tp24831
sS'become,pregnant'
p24832
(F1
F0.00014334862385321102
I0
I1
I-1
tp24833
sS'between,b12'
p24834
(F1
F0.00014334862385321102
I1
I0
I1
tp24835
sS'and,can'
p24836
(F0.5
F0.0011467889908256881
I12
I4
I8
tp24837
sS'a,channel'
p24838
(F1
F0.00014334862385321102
I0
I1
I-1
tp24839
sS'potent,cytochrome'
p24840
(F1
F0.00014334862385321102
I1
I0
I1
tp24841
sS'alfenta,my'
p24842
(F1
F0.00014334862385321102
I0
I1
I-1
tp24843
sS'of,pt'
p24844
(F1
F0.00014334862385321102
I0
I1
I-1
tp24845
sS'levels,the'
p24846
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24847
sS'enzymes,bun'
p24848
(F1
F0.00014334862385321102
I1
I0
I1
tp24849
sS'far,more'
p24850
(F1
F0.00014334862385321102
I0
I1
I-1
tp24851
sS'have,also'
p24852
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp24853
sS'iv,has'
p24854
(F1
F0.00014334862385321102
I0
I1
I-1
tp24855
sS'warfarin,increased'
p24856
(F1
F0.00014334862385321102
I1
I0
I1
tp24857
sS'against,the'
p24858
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp24859
sS'mg,vardenafil'
p24860
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24861
sS'homocysteine,following'
p24862
(F1
F0.00014334862385321102
I0
I1
I-1
tp24863
sS'or,are'
p24864
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp24865
sS'depressive,and'
p24866
(F1
F0.00014334862385321102
I0
I1
I-1
tp24867
sS'procedures,for'
p24868
(F1
F0.00014334862385321102
I0
I1
I-1
tp24869
sS'with,injectable'
p24870
(F1
F0.00014334862385321102
I1
I0
I1
tp24871
sS'flolan,is'
p24872
(F1
F0.00014334862385321102
I1
I0
I1
tp24873
sS'significantly,inhibited'
p24874
(F1
F0.00028669724770642203
I2
I0
I2
tp24875
sS'potential,interactions'
p24876
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp24877
sS'flolan,in'
p24878
(F1
F0.00014334862385321102
I0
I1
I-1
tp24879
sS'myocardial,injury'
p24880
(F1
F0.00014334862385321102
I1
I0
I1
tp24881
sS'into,consideration'
p24882
(F1
F0.00014334862385321102
I1
I0
I1
tp24883
sS'aminoglutethimide,aminoglutethimide'
p24884
(F1
F0.00014334862385321102
I1
I0
I1
tp24885
sS'thyroiditis,bullous'
p24886
(F1
F0.00014334862385321102
I1
I0
I1
tp24887
sS'continue,the'
p24888
(F1
F0.00014334862385321102
I1
I0
I1
tp24889
sS'of,ranging'
p24890
(F1
F0.00014334862385321102
I1
I0
I1
tp24891
sS'plasma-level,of'
p24892
(F1
F0.00014334862385321102
I1
I0
I1
tp24893
sS'enoxacin,may'
p24894
(F1
F0.00014334862385321102
I1
I0
I1
tp24895
sS'of,bombesin-enhanced'
p24896
(F1
F0.00014334862385321102
I1
I0
I1
tp24897
sS'is,felt'
p24898
(F1
F0.00014334862385321102
I1
I0
I1
tp24899
sS'by,mg'
p24900
(F0
F0
I1
I1
I0
tp24901
sS'prefrontal,cortical'
p24902
(F1
F0.00014334862385321102
I0
I1
I-1
tp24903
sS'like,due'
p24904
(F1
F0.00014334862385321102
I1
I0
I1
tp24905
sS'different,than'
p24906
(F1
F0.00014334862385321102
I1
I0
I1
tp24907
sS'route,in'
p24908
(F1
F0.00014334862385321102
I0
I1
I-1
tp24909
sS'and,what'
p24910
(F1
F0.00014334862385321102
I0
I1
I-1
tp24911
sS'other,traditional'
p24912
(F1
F0.00014334862385321102
I0
I1
I-1
tp24913
sS'cholestyramine,an'
p24914
(F1
F0.00014334862385321102
I1
I0
I1
tp24915
sS'short-acting,and'
p24916
(F1
F0.00014334862385321102
I1
I0
I1
tp24917
sS'or,dose'
p24918
(F1
F0.00014334862385321102
I0
I1
I-1
tp24919
sS'product,containing'
p24920
(F1
F0.00014334862385321102
I1
I0
I1
tp24921
sS'incoordination,have'
p24922
(F1
F0.00014334862385321102
I1
I0
I1
tp24923
sS'cyp2c9,such'
p24924
(F1
F0.00014334862385321102
I1
I0
I1
tp24925
sS'blood,thinners'
p24926
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24927
sS'morphological,markers'
p24928
(F1
F0.00014334862385321102
I1
I0
I1
tp24929
sS'vs,when'
p24930
(F1
F0.00014334862385321102
I1
I0
I1
tp24931
sS'members,of'
p24932
(F1
F0.00028669724770642203
I2
I0
I2
tp24933
sS'mtx,were'
p24934
(F1
F0.00014334862385321102
I0
I1
I-1
tp24935
sS'possibly,due'
p24936
(F1
F0.00043004587155963305
I3
I0
I3
tp24937
sS'the,protective'
p24938
(F1
F0.00014334862385321102
I1
I0
I1
tp24939
sS'inhibitors,mg'
p24940
(F1
F0.00014334862385321102
I1
I0
I1
tp24941
sS'be,rarely'
p24942
(F1
F0.00028669724770642203
I2
I0
I2
tp24943
sS'benzodiazepines,gi'
p24944
(F0
F0
I1
I1
I0
tp24945
sS'be,further'
p24946
(F1
F0.00014334862385321102
I0
I1
I-1
tp24947
sS'the,hour'
p24948
(F1
F0.00028669724770642203
I0
I2
I-2
tp24949
sS'mhd,concentration'
p24950
(F1
F0.00014334862385321102
I0
I1
I-1
tp24951
sS'felbatol,given'
p24952
(F1
F0.00028669724770642203
I2
I0
I2
tp24953
sS'fever,tremulousness'
p24954
(F1
F0.00014334862385321102
I1
I0
I1
tp24955
sS'concentrations,mg'
p24956
(F1
F0.00014334862385321102
I0
I1
I-1
tp24957
sS'methotrexate,in'
p24958
(F1
F0.00014334862385321102
I0
I1
I-1
tp24959
sS'cautious,titration'
p24960
(F1
F0.00014334862385321102
I1
I0
I1
tp24961
sS'toradol,to'
p24962
(F1
F0.00014334862385321102
I1
I0
I1
tp24963
sS'in,about'
p24964
(F0
F0
I1
I1
I0
tp24965
sS'the,guinea-pig'
p24966
(F1
F0.00014334862385321102
I0
I1
I-1
tp24967
sS'not,demonstrated'
p24968
(F1
F0.00028669724770642203
I0
I2
I-2
tp24969
sS'with,proleukin'
p24970
(F1
F0.00028669724770642203
I2
I0
I2
tp24971
sS'glomerular,filtration'
p24972
(F1
F0.00014334862385321102
I0
I1
I-1
tp24973
sS'of,non-potassium'
p24974
(F1
F0.00014334862385321102
I1
I0
I1
tp24975
sS'associated,with'
p24976
(F0.31147540983606559
F0.0027236238532110093
I40
I21
I19
tp24977
sS'dissolution,rate'
p24978
(F1
F0.00014334862385321102
I0
I1
I-1
tp24979
sS'for,clinically'
p24980
(F1
F0.00014334862385321102
I0
I1
I-1
tp24981
sS'caution,should'
p24982
(F0.48837209302325579
F0.0030103211009174314
I32
I11
I21
tp24983
sS'covalently,linked'
p24984
(F1
F0.00014334862385321102
I0
I1
I-1
tp24985
sS'diabetes,mellitus'
p24986
(F1
F0.00028669724770642203
I0
I2
I-2
tp24987
sS'acinar,cells'
p24988
(F1
F0.00014334862385321102
I0
I1
I-1
tp24989
sS'orudis,orudis'
p24990
(F1
F0.00014334862385321102
I0
I1
I-1
tp24991
sS'plasma,in'
p24992
(F1
F0.00014334862385321102
I0
I1
I-1
tp24993
sS'two-fold,or'
p24994
(F1
F0.00014334862385321102
I1
I0
I1
tp24995
sS'doubling,in'
p24996
(F1
F0.00014334862385321102
I1
I0
I1
tp24997
sS'plasma,is'
p24998
(F1
F0.00014334862385321102
I0
I1
I-1
tp24999
sS'two-fold,of'
p25000
(F1
F0.00014334862385321102
I1
I0
I1
tp25001
sS'substantial,number'
p25002
(F1
F0.00014334862385321102
I1
I0
I1
tp25003
sS'rheumatoid,arthritis'
p25004
(F1
F0.00057339449541284407
I0
I4
I-4
tp25005
sS'of,autoimmune'
p25006
(F1
F0.00014334862385321102
I1
I0
I1
tp25007
sS'x,use'
p25008
(F1
F0.00014334862385321102
I0
I1
I-1
tp25009
sS'catabloism,of'
p25010
(F1
F0.00014334862385321102
I0
I1
I-1
tp25011
sS'rats,and'
p25012
(F1
F0.00043004587155963305
I0
I3
I-3
tp25013
sS'decrease,to'
p25014
(F1
F0.00028669724770642203
I2
I0
I2
tp25015
sS'shbg,leading'
p25016
(F1
F0.00028669724770642203
I0
I2
I-2
tp25017
sS'tolazamide,a'
p25018
(F1
F0.00014334862385321102
I1
I0
I1
tp25019
sS'loop,and'
p25020
(F1
F0.00014334862385321102
I0
I1
I-1
tp25021
sS'coadministration,loratadine'
p25022
(F1
F0.00014334862385321102
I0
I1
I-1
tp25023
sS'in,metabolism'
p25024
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25025
sS'in,cmax'
p25026
(F1
F0.0021502293577981653
I15
I0
I15
tp25027
sS'unlike,mc'
p25028
(F1
F0.00014334862385321102
I0
I1
I-1
tp25029
sS'before,or'
p25030
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp25031
sS'of,studies'
p25032
(F0
F0
I1
I1
I0
tp25033
sS'system,depressant'
p25034
(F1
F0.00014334862385321102
I0
I1
I-1
tp25035
sS'growth,both'
p25036
(F1
F0.00014334862385321102
I0
I1
I-1
tp25037
sS'of,while'
p25038
(F1
F0.00028669724770642203
I2
I0
I2
tp25039
sS'studies,coadministration'
p25040
(F1
F0.00014334862385321102
I0
I1
I-1
tp25041
sS'implants,and'
p25042
(F1
F0.00014334862385321102
I0
I1
I-1
tp25043
sS'to,enroll'
p25044
(F1
F0.00014334862385321102
I0
I1
I-1
tp25045
sS'using,but'
p25046
(F1
F0.00028669724770642203
I0
I2
I-2
tp25047
sS'on,phenytoin'
p25048
(F1
F0.00014334862385321102
I1
I0
I1
tp25049
sS'enoxacin,interferes'
p25050
(F1
F0.00014334862385321102
I1
I0
I1
tp25051
sS'present,as'
p25052
(F1
F0.00014334862385321102
I1
I0
I1
tp25053
sS'injection,produced'
p25054
(F1
F0.00014334862385321102
I0
I1
I-1
tp25055
sS'effects,such'
p25056
(F1
F0.00043004587155963305
I3
I0
I3
tp25057
sS'compared,pharmacokinetics'
p25058
(F1
F0.00014334862385321102
I0
I1
I-1
tp25059
sS'secretion,blocking'
p25060
(F1
F0.00014334862385321102
I0
I1
I-1
tp25061
sS'vivo,drug-drug'
p25062
(F1
F0.00014334862385321102
I1
I0
I1
tp25063
sS'significantly,affect'
p25064
(F0.80000000000000004
F0.0011467889908256881
I1
I9
I-8
tp25065
sS'a,wax'
p25066
(F1
F0.00014334862385321102
I1
I0
I1
tp25067
sS'however,serum'
p25068
(F1
F0.00014334862385321102
I1
I0
I1
tp25069
sS'for,evidence'
p25070
(F0
F0
I1
I1
I0
tp25071
sS'the,management'
p25072
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25073
sS'after,concurrent'
p25074
(F0
F0
I1
I1
I0
tp25075
sS'with,ethacrynic'
p25076
(F1
F0.00014334862385321102
I1
I0
I1
tp25077
sS'produce,cns-depressant'
p25078
(F1
F0.00014334862385321102
I1
I0
I1
tp25079
sS'of,aldehyde'
p25080
(F1
F0.00014334862385321102
I0
I1
I-1
tp25081
sS'sodium,thiosulfate'
p25082
(F1
F0.00014334862385321102
I1
I0
I1
tp25083
sS'hcl,blunts'
p25084
(F1
F0.00014334862385321102
I1
I0
I1
tp25085
sS'and,phase'
p25086
(F1
F0.00014334862385321102
I0
I1
I-1
tp25087
sS'it,palliates'
p25088
(F1
F0.00014334862385321102
I0
I1
I-1
tp25089
sS'the,mitogenic'
p25090
(F1
F0.00028669724770642203
I2
I0
I2
tp25091
sS'not,benefit'
p25092
(F1
F0.00014334862385321102
I1
I0
I1
tp25093
sS'an,appropriate'
p25094
(F1
F0.00014334862385321102
I1
I0
I1
tp25095
sS'the,lack'
p25096
(F1
F0.00014334862385321102
I0
I1
I-1
tp25097
sS'chewable,dispersible'
p25098
(F1
F0.00028669724770642203
I2
I0
I2
tp25099
sS'in,exposure'
p25100
(F1
F0.00028669724770642203
I2
I0
I2
tp25101
sS'toward,normal'
p25102
(F1
F0.00014334862385321102
I0
I1
I-1
tp25103
sS'no,increase'
p25104
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25105
sS'previously,administered'
p25106
(F0
F0
I1
I1
I0
tp25107
sS'products,oral'
p25108
(F1
F0.00057339449541284407
I0
I4
I-4
tp25109
sS'a,narrow'
p25110
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp25111
sS'time,have'
p25112
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25113
sS'including,sulfate'
p25114
(F0
F0
I1
I1
I0
tp25115
sS'trazodone,hydrochloride'
p25116
(F1
F0.00014334862385321102
I1
I0
I1
tp25117
sS'to,micrograms'
p25118
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25119
sS'of,unchanged'
p25120
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25121
sS'organic,l-arginine'
p25122
(F1
F0.00014334862385321102
I1
I0
I1
tp25123
sS'recommended,dosages'
p25124
(F1
F0.00014334862385321102
I1
I0
I1
tp25125
sS'carrier,density'
p25126
(F1
F0.00014334862385321102
I0
I1
I-1
tp25127
sS'moderately,reduced'
p25128
(F1
F0.00014334862385321102
I0
I1
I-1
tp25129
sS'then,received'
p25130
(F1
F0.00014334862385321102
I0
I1
I-1
tp25131
sS'binding,after'
p25132
(F1
F0.00014334862385321102
I0
I1
I-1
tp25133
sS'interaction,as'
p25134
(F1
F0.00014334862385321102
I0
I1
I-1
tp25135
sS'interaction,at'
p25136
(F1
F0.00014334862385321102
I1
I0
I1
tp25137
sS'nicardipine,hcl'
p25138
(F1
F0.00014334862385321102
I1
I0
I1
tp25139
sS'in,accordance'
p25140
(F1
F0.00014334862385321102
I0
I1
I-1
tp25141
sS'frontal,cortex'
p25142
(F1
F0.00014334862385321102
I0
I1
I-1
tp25143
sS'and,cyp1a2'
p25144
(F1
F0.00043004587155963305
I0
I3
I-3
tp25145
sS'warfarin,atorvastatin'
p25146
(F1
F0.00014334862385321102
I0
I1
I-1
tp25147
sS'clinical,evidence'
p25148
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25149
sS'compromised,renal'
p25150
(F1
F0.00028669724770642203
I2
I0
I2
tp25151
sS'without,coadministration'
p25152
(F1
F0.00014334862385321102
I0
I1
I-1
tp25153
sS'of,insect'
p25154
(F1
F0.00014334862385321102
I1
I0
I1
tp25155
sS'schedule,of'
p25156
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25157
sS'of,multiple'
p25158
(F0
F0
I1
I1
I0
tp25159
sS'intravenous,iv'
p25160
(F1
F0.00014334862385321102
I1
I0
I1
tp25161
sS'intravenous,is'
p25162
(F1
F0.00014334862385321102
I1
I0
I1
tp25163
sS'gastrointestinal,absorption'
p25164
(F1
F0.00071674311926605509
I5
I0
I5
tp25165
sS'displaces,from'
p25166
(F1
F0.00014334862385321102
I1
I0
I1
tp25167
sS'thus,if'
p25168
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25169
sS'normal,healthy'
p25170
(F1
F0.00057339449541284407
I0
I4
I-4
tp25171
sS'atypical,antipsychotic'
p25172
(F1
F0.00043004587155963305
I0
I3
I-3
tp25173
sS'oxide,donor'
p25174
(F1
F0.00014334862385321102
I1
I0
I1
tp25175
sS'after,to'
p25176
(F1
F0.00014334862385321102
I0
I1
I-1
tp25177
sS'for,when'
p25178
(F0
F0
I1
I1
I0
tp25179
sS'concurrent,ingestion'
p25180
(F1
F0.00014334862385321102
I1
I0
I1
tp25181
sS'with,precedex'
p25182
(F1
F0.00014334862385321102
I1
I0
I1
tp25183
sS'of,probenecid'
p25184
(F1
F0.00014334862385321102
I0
I1
I-1
tp25185
sS'tambocor,to'
p25186
(F1
F0.00014334862385321102
I1
I0
I1
tp25187
sS'etc,should'
p25188
(F1
F0.00014334862385321102
I0
I1
I-1
tp25189
sS'individuals,with'
p25190
(F1
F0.00014334862385321102
I0
I1
I-1
tp25191
sS'and,antihypertensive'
p25192
(F1
F0.00043004587155963305
I3
I0
I3
tp25193
sS'been,characterized'
p25194
(F1
F0.00014334862385321102
I0
I1
I-1
tp25195
sS'experience,profile'
p25196
(F1
F0.00014334862385321102
I0
I1
I-1
tp25197
sS'lag,phase'
p25198
(F1
F0.00014334862385321102
I0
I1
I-1
tp25199
sS'minimally,or'
p25200
(F1
F0.00014334862385321102
I1
I0
I1
tp25201
sS'the,case'
p25202
(F1
F0.00028669724770642203
I2
I0
I2
tp25203
sS'interval,and'
p25204
(F1
F0.00014334862385321102
I0
I1
I-1
tp25205
sS'have,included'
p25206
(F1
F0.00014334862385321102
I0
I1
I-1
tp25207
sS'showing,a'
p25208
(F1
F0.00014334862385321102
I0
I1
I-1
tp25209
sS'nutrient,absorption'
p25210
(F1
F0.00014334862385321102
I1
I0
I1
tp25211
sS'both,compounds'
p25212
(F1
F0.00014334862385321102
I0
I1
I-1
tp25213
sS'renal,and'
p25214
(F0
F0
I3
I3
I0
tp25215
sS'sparing,thiazide'
p25216
(F1
F0.00014334862385321102
I0
I1
I-1
tp25217
sS'significantly,increase'
p25218
(F1
F0.00014334862385321102
I0
I1
I-1
tp25219
sS'fat-soluble,should'
p25220
(F1
F0.00014334862385321102
I0
I1
I-1
tp25221
sS'are,known'
p25222
(F0.69230769230769229
F0.0012901376146788992
I2
I11
I-9
tp25223
sS'convulsions,have'
p25224
(F1
F0.00014334862385321102
I1
I0
I1
tp25225
sS'atac,trial'
p25226
(F1
F0.00014334862385321102
I1
I0
I1
tp25227
sS'unlikely,that'
p25228
(F1
F0.00043004587155963305
I0
I3
I-3
tp25229
sS'citrate,and'
p25230
(F1
F0.00014334862385321102
I0
I1
I-1
tp25231
sS'd2,antagonists'
p25232
(F1
F0.00014334862385321102
I1
I0
I1
tp25233
sS'of,inhibition'
p25234
(F0.75
F0.0008600917431192661
I7
I1
I6
tp25235
sS'effect,in'
p25236
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp25237
sS'rifampicin,racemic'
p25238
(F1
F0.00014334862385321102
I1
I0
I1
tp25239
sS'noninsulin,dependent'
p25240
(F1
F0.00014334862385321102
I0
I1
I-1
tp25241
sS'particularly,important'
p25242
(F1
F0.00014334862385321102
I0
I1
I-1
tp25243
sS'serum,thyroxine-binding'
p25244
(F1
F0.00014334862385321102
I0
I1
I-1
tp25245
sS'therefore,viracept'
p25246
(F1
F0.00014334862385321102
I1
I0
I1
tp25247
sS'iv,dose'
p25248
(F1
F0.00014334862385321102
I1
I0
I1
tp25249
sS'seminiferous,tubular'
p25250
(F1
F0.00014334862385321102
I0
I1
I-1
tp25251
sS'subcutaneous,infusion'
p25252
(F1
F0.00014334862385321102
I0
I1
I-1
tp25253
sS'thiazide,diuretics'
p25254
(F1
F0.00014334862385321102
I1
I0
I1
tp25255
sS'when,anafranil'
p25256
(F1
F0.00014334862385321102
I1
I0
I1
tp25257
sS'lithium-a,interaction'
p25258
(F1
F0.00014334862385321102
I0
I1
I-1
tp25259
sS'were,potentiated'
p25260
(F1
F0.00028669724770642203
I2
I0
I2
tp25261
sS'additional,interaction'
p25262
(F1
F0.00028669724770642203
I0
I2
I-2
tp25263
sS'different,descending'
p25264
(F1
F0.00014334862385321102
I0
I1
I-1
tp25265
sS'marketing,experiences'
p25266
(F1
F0.00014334862385321102
I1
I0
I1
tp25267
sS'been,received'
p25268
(F1
F0.00014334862385321102
I0
I1
I-1
tp25269
sS'monitored,by'
p25270
(F1
F0.00014334862385321102
I0
I1
I-1
tp25271
sS'decrease,in'
p25272
(F0.80392156862745101
F0.0058772935779816517
I46
I5
I41
tp25273
sS'severe,adverse'
p25274
(F1
F0.00014334862385321102
I0
I1
I-1
tp25275
sS'impairment,clcr'
p25276
(F1
F0.00014334862385321102
I1
I0
I1
tp25277
sS'not,result'
p25278
(F0.81818181818181823
F0.0012901376146788992
I1
I10
I-9
tp25279
sS'tablets,and'
p25280
(F1
F0.00043004587155963305
I3
I0
I3
tp25281
sS'disturbances,and'
p25282
(F1
F0.00014334862385321102
I1
I0
I1
tp25283
sS'of,organic'
p25284
(F1
F0.00014334862385321102
I1
I0
I1
tp25285
sS'phenytoin,keppra'
p25286
(F1
F0.00014334862385321102
I0
I1
I-1
tp25287
sS'the,pediatric'
p25288
(F1
F0.0008600917431192661
I6
I0
I6
tp25289
sS'either,procedure'
p25290
(F1
F0.00014334862385321102
I0
I1
I-1
tp25291
sS'avonex,indicates'
p25292
(F1
F0.00014334862385321102
I0
I1
I-1
tp25293
sS'viracept,may'
p25294
(F1
F0.00014334862385321102
I0
I1
I-1
tp25295
sS'in,type'
p25296
(F1
F0.00014334862385321102
I1
I0
I1
tp25297
sS'the,enzyme-inducing'
p25298
(F1
F0.00014334862385321102
I1
I0
I1
tp25299
sS'procedure,is'
p25300
(F1
F0.00014334862385321102
I0
I1
I-1
tp25301
sS'the,antinonciceptive'
p25302
(F1
F0.00014334862385321102
I0
I1
I-1
tp25303
sS'the,plasma-level'
p25304
(F1
F0.00014334862385321102
I1
I0
I1
tp25305
sS'fruit,juices'
p25306
(F1
F0.00014334862385321102
I1
I0
I1
tp25307
sS'procedure,it'
p25308
(F1
F0.00014334862385321102
I0
I1
I-1
tp25309
sS'procedure,in'
p25310
(F1
F0.00014334862385321102
I0
I1
I-1
tp25311
sS'preliminary,studies'
p25312
(F1
F0.00028669724770642203
I2
I0
I2
tp25313
sS'exercised,during'
p25314
(F1
F0.00014334862385321102
I1
I0
I1
tp25315
sS'routes,a'
p25316
(F1
F0.00014334862385321102
I1
I0
I1
tp25317
sS'of,lower'
p25318
(F1
F0.00014334862385321102
I0
I1
I-1
tp25319
sS'if,treatment'
p25320
(F1
F0.00014334862385321102
I1
I0
I1
tp25321
sS'the,duration'
p25322
(F0.090909090909090912
F0.00014334862385321102
I5
I6
I-1
tp25323
sS'antimigraine,derivatives'
p25324
(F1
F0.00014334862385321102
I1
I0
I1
tp25325
sS'the,clinician'
p25326
(F1
F0.00014334862385321102
I1
I0
I1
tp25327
sS'or,ibuprofen'
p25328
(F1
F0.00014334862385321102
I1
I0
I1
tp25329
sS'then,begins'
p25330
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25331
sS'agents,known'
p25332
(F1
F0.00014334862385321102
I1
I0
I1
tp25333
sS'felbatol,at'
p25334
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25335
sS'theophylline-related,adverse'
p25336
(F1
F0.00014334862385321102
I1
I0
I1
tp25337
sS'felbatol,as'
p25338
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25339
sS'and,very'
p25340
(F1
F0.00014334862385321102
I1
I0
I1
tp25341
sS'other,currently'
p25342
(F1
F0.00014334862385321102
I0
I1
I-1
tp25343
sS'by,six'
p25344
(F1
F0.00014334862385321102
I0
I1
I-1
tp25345
sS'the,need'
p25346
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp25347
sS'with,simultaneous'
p25348
(F1
F0.00028669724770642203
I2
I0
I2
tp25349
sS'secretion,via'
p25350
(F1
F0.00014334862385321102
I1
I0
I1
tp25351
sS'metabolizers,of'
p25352
(F0
F0
I2
I2
I0
tp25353
sS'enantiomer,pharmacokinetics'
p25354
(F1
F0.00014334862385321102
I0
I1
I-1
tp25355
sS'done,to'
p25356
(F1
F0.00014334862385321102
I1
I0
I1
tp25357
sS'increase,exposure'
p25358
(F1
F0.00014334862385321102
I1
I0
I1
tp25359
sS'efficacy,over'
p25360
(F1
F0.00014334862385321102
I1
I0
I1
tp25361
sS'in,uninfected'
p25362
(F1
F0.00014334862385321102
I1
I0
I1
tp25363
sS'following,treatment'
p25364
(F1
F0.00028669724770642203
I0
I2
I-2
tp25365
sS'display,the'
p25366
(F1
F0.00014334862385321102
I0
I1
I-1
tp25367
sS'fe,over'
p25368
(F1
F0.00014334862385321102
I0
I1
I-1
tp25369
sS'animal,studies'
p25370
(F1
F0.0008600917431192661
I6
I0
I6
tp25371
sS'theophylline,combined'
p25372
(F1
F0.00014334862385321102
I0
I1
I-1
tp25373
sS'caution,because'
p25374
(F1
F0.00043004587155963305
I3
I0
I3
tp25375
sS'intact,endothelium'
p25376
(F1
F0.00014334862385321102
I1
I0
I1
tp25377
sS'control,period'
p25378
(F1
F0.00014334862385321102
I1
I0
I1
tp25379
sS'and,some'
p25380
(F0
F0
I4
I4
I0
tp25381
sS'multiple,effects'
p25382
(F1
F0.00014334862385321102
I1
I0
I1
tp25383
sS'any,pharmacokinetic'
p25384
(F1
F0.00014334862385321102
I0
I1
I-1
tp25385
sS'involved,the'
p25386
(F1
F0.00014334862385321102
I0
I1
I-1
tp25387
sS'locomotion,in'
p25388
(F1
F0.00014334862385321102
I0
I1
I-1
tp25389
sS'administering,peganone'
p25390
(F1
F0.00014334862385321102
I1
I0
I1
tp25391
sS'and,ethacrynic'
p25392
(F1
F0.00014334862385321102
I1
I0
I1
tp25393
sS'alpha-blockers,when'
p25394
(F1
F0.00014334862385321102
I1
I0
I1
tp25395
sS'antistress,effects'
p25396
(F1
F0.00014334862385321102
I0
I1
I-1
tp25397
sS'catabolism,of'
p25398
(F1
F0.00014334862385321102
I0
I1
I-1
tp25399
sS'a,phase'
p25400
(F1
F0.00014334862385321102
I1
I0
I1
tp25401
sS'and,micrograms'
p25402
(F1
F0.00043004587155963305
I0
I3
I-3
tp25403
sS'catecholamine-depleting,such'
p25404
(F1
F0.00043004587155963305
I3
I0
I3
tp25405
sS'that,no'
p25406
(F1
F0.00028669724770642203
I2
I0
I2
tp25407
sS'eg,flu-like'
p25408
(F1
F0.00014334862385321102
I0
I1
I-1
tp25409
sS'sodium,given'
p25410
(F1
F0.00014334862385321102
I0
I1
I-1
tp25411
sS'have,no'
p25412
(F0.55555555555555558
F0.00071674311926605509
I2
I7
I-5
tp25413
sS'd3,and'
p25414
(F0
F0
I1
I1
I0
tp25415
sS'interval,were'
p25416
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25417
sS'the,hmg-coa'
p25418
(F0
F0
I1
I1
I0
tp25419
sS'mg,given'
p25420
(F1
F0.00014334862385321102
I1
I0
I1
tp25421
sS'uroxatral,should'
p25422
(F1
F0.00014334862385321102
I1
I0
I1
tp25423
sS'cyp3a4,mediated'
p25424
(F1
F0.00014334862385321102
I0
I1
I-1
tp25425
sS'reduced,upon'
p25426
(F1
F0.00014334862385321102
I1
I0
I1
tp25427
sS'medications,besides'
p25428
(F1
F0.00014334862385321102
I0
I1
I-1
tp25429
sS'deletion,of'
p25430
(F1
F0.00014334862385321102
I0
I1
I-1
tp25431
sS'bepridil,has'
p25432
(F1
F0.00014334862385321102
I0
I1
I-1
tp25433
sS'thiazide,agents'
p25434
(F1
F0.00014334862385321102
I0
I1
I-1
tp25435
sS'of,depletion'
p25436
(F1
F0.00014334862385321102
I0
I1
I-1
tp25437
sS'of,block'
p25438
(F1
F0.00014334862385321102
I1
I0
I1
tp25439
sS'plasma,proteins'
p25440
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25441
sS'alfenta,clearance'
p25442
(F1
F0.00014334862385321102
I1
I0
I1
tp25443
sS'valid,prothrombin'
p25444
(F1
F0.00014334862385321102
I1
I0
I1
tp25445
sS'and,hydroxy'
p25446
(F1
F0.00014334862385321102
I0
I1
I-1
tp25447
sS'pointes,have'
p25448
(F1
F0.00014334862385321102
I0
I1
I-1
tp25449
sS'with,parasite'
p25450
(F1
F0.00014334862385321102
I0
I1
I-1
tp25451
sS'can,occur'
p25452
(F1
F0.00028669724770642203
I2
I0
I2
tp25453
sS'studies,one'
p25454
(F1
F0.00014334862385321102
I1
I0
I1
tp25455
sS'in,reduced'
p25456
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25457
sS'basis,to'
p25458
(F1
F0.00014334862385321102
I1
I0
I1
tp25459
sS'under,lying'
p25460
(F1
F0.00014334862385321102
I1
I0
I1
tp25461
sS'elimination,half-life'
p25462
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp25463
sS'medicinal,products'
p25464
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp25465
sS'more,prolonged'
p25466
(F1
F0.00014334862385321102
I1
I0
I1
tp25467
sS'under,similar'
p25468
(F1
F0.00014334862385321102
I0
I1
I-1
tp25469
sS'toradol,was'
p25470
(F1
F0.00014334862385321102
I1
I0
I1
tp25471
sS'psa,decreased'
p25472
(F1
F0.00014334862385321102
I0
I1
I-1
tp25473
sS'discontinuing,hydrochloride'
p25474
(F0
F0
I1
I1
I0
tp25475
sS'indicating,that'
p25476
(F1
F0.00028669724770642203
I0
I2
I-2
tp25477
sS'agents,it'
p25478
(F1
F0.00014334862385321102
I1
I0
I1
tp25479
sS'general,cognitive'
p25480
(F1
F0.00014334862385321102
I0
I1
I-1
tp25481
sS'agents,is'
p25482
(F1
F0.00028669724770642203
I2
I0
I2
tp25483
sS'agents,in'
p25484
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp25485
sS'pretreatment,attenuated'
p25486
(F1
F0.00014334862385321102
I1
I0
I1
tp25487
sS'of,pah'
p25488
(F1
F0.00014334862385321102
I1
I0
I1
tp25489
sS'while,not'
p25490
(F1
F0.00014334862385321102
I1
I0
I1
tp25491
sS'of,triazo'
p25492
(F1
F0.00014334862385321102
I0
I1
I-1
tp25493
sS'of,mcg'
p25494
(F1
F0.00028669724770642203
I0
I2
I-2
tp25495
sS'depletion,are'
p25496
(F1
F0.00014334862385321102
I0
I1
I-1
tp25497
sS'the,successive'
p25498
(F1
F0.00014334862385321102
I1
I0
I1
tp25499
sS'caffeine-related,adverse'
p25500
(F1
F0.00014334862385321102
I1
I0
I1
tp25501
sS'were,about'
p25502
(F1
F0.00014334862385321102
I1
I0
I1
tp25503
sS'mydriasis,resulting'
p25504
(F1
F0.00014334862385321102
I1
I0
I1
tp25505
sS'with,pulmonary'
p25506
(F1
F0.00014334862385321102
I0
I1
I-1
tp25507
sS'performed,when'
p25508
(F1
F0.00014334862385321102
I1
I0
I1
tp25509
sS'mptp-induced,neuronal'
p25510
(F1
F0.00014334862385321102
I1
I0
I1
tp25511
sS'eg,could'
p25512
(F1
F0.00014334862385321102
I1
I0
I1
tp25513
sS'are,recommended'
p25514
(F1
F0.00014334862385321102
I1
I0
I1
tp25515
sS'with,antiplatelet'
p25516
(F1
F0.00028669724770642203
I2
I0
I2
tp25517
sS'propanol,was'
p25518
(F1
F0.00014334862385321102
I0
I1
I-1
tp25519
sS'patient,is'
p25520
(F1
F0.00043004587155963305
I3
I0
I3
tp25521
sS'to,characterize'
p25522
(F1
F0.00014334862385321102
I0
I1
I-1
tp25523
sS'dictates,careful'
p25524
(F1
F0.00014334862385321102
I1
I0
I1
tp25525
sS'patient,in'
p25526
(F1
F0.00028669724770642203
I0
I2
I-2
tp25527
sS'exceed,micrograms'
p25528
(F1
F0.00014334862385321102
I0
I1
I-1
tp25529
sS'estradiol,should'
p25530
(F1
F0.00014334862385321102
I1
I0
I1
tp25531
sS'another,oral'
p25532
(F1
F0.00014334862385321102
I1
I0
I1
tp25533
sS'theoretical,risk'
p25534
(F1
F0.00014334862385321102
I1
I0
I1
tp25535
sS'system,decreased'
p25536
(F1
F0.00014334862385321102
I0
I1
I-1
tp25537
sS'substances,that'
p25538
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp25539
sS'ci,of'
p25540
(F1
F0.00014334862385321102
I0
I1
I-1
tp25541
sS'hepatitis,has'
p25542
(F1
F0.00014334862385321102
I1
I0
I1
tp25543
sS'ibandronate,osteoporosis'
p25544
(F1
F0.00014334862385321102
I0
I1
I-1
tp25545
sS'with,no'
p25546
(F1
F0.00057339449541284407
I0
I4
I-4
tp25547
sS'or,discontinued'
p25548
(F1
F0.00014334862385321102
I1
I0
I1
tp25549
sS'people,use'
p25550
(F1
F0.00014334862385321102
I0
I1
I-1
tp25551
sS'be,titrated'
p25552
(F1
F0.00014334862385321102
I1
I0
I1
tp25553
sS'or,discontinues'
p25554
(F1
F0.00014334862385321102
I1
I0
I1
tp25555
sS'anorexia,tachypnea'
p25556
(F1
F0.00014334862385321102
I1
I0
I1
tp25557
sS'concentrations,above'
p25558
(F1
F0.00014334862385321102
I1
I0
I1
tp25559
sS'safe,sexual'
p25560
(F1
F0.00014334862385321102
I0
I1
I-1
tp25561
sS'bacterial,metabolism'
p25562
(F1
F0.00014334862385321102
I1
I0
I1
tp25563
sS'impairing,absorption'
p25564
(F1
F0.00014334862385321102
I1
I0
I1
tp25565
sS'urine,red-orange'
p25566
(F1
F0.00014334862385321102
I0
I1
I-1
tp25567
sS'medroxyprogesterone,acetate'
p25568
(F1
F0.00014334862385321102
I1
I0
I1
tp25569
sS'users,of'
p25570
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25571
sS'in,inhibiting'
p25572
(F0
F0
I1
I1
I0
tp25573
sS'with,co-administered'
p25574
(F0
F0
I1
I1
I0
tp25575
sS'with,because'
p25576
(F1
F0.00071674311926605509
I5
I0
I5
tp25577
sS'associated,in'
p25578
(F1
F0.00028669724770642203
I2
I0
I2
tp25579
sS'systemic,antiretroviral'
p25580
(F1
F0.00014334862385321102
I0
I1
I-1
tp25581
sS'and,serotonergic'
p25582
(F0
F0
I1
I1
I0
tp25583
sS'did,indeed'
p25584
(F1
F0.00014334862385321102
I1
I0
I1
tp25585
sS'include,certain'
p25586
(F1
F0.00043004587155963305
I3
I0
I3
tp25587
sS'could,result'
p25588
(F1
F0.00014334862385321102
I0
I1
I-1
tp25589
sS'patients,using'
p25590
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25591
sS'disposition,of'
p25592
(F1
F0.00057339449541284407
I0
I4
I-4
tp25593
sS'in,treatment-naive'
p25594
(F1
F0.00014334862385321102
I0
I1
I-1
tp25595
sS'steadystate,cmin'
p25596
(F1
F0.00014334862385321102
I1
I0
I1
tp25597
sS'it,substituted'
p25598
(F1
F0.00014334862385321102
I0
I1
I-1
tp25599
sS'interactions,between'
p25600
(F0.77777777777777779
F0.0020068807339449542
I2
I16
I-14
tp25601
sS'contraindicated,in'
p25602
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25603
sS'is,unknown'
p25604
(F0
F0
I1
I1
I0
tp25605
sS'system,notably'
p25606
(F1
F0.00014334862385321102
I1
I0
I1
tp25607
sS'nsaids,a'
p25608
(F1
F0.00014334862385321102
I0
I1
I-1
tp25609
sS'result,of'
p25610
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25611
sS'fluvoxamine,inhibits'
p25612
(F1
F0.00014334862385321102
I1
I0
I1
tp25613
sS'physician,or'
p25614
(F1
F0.00014334862385321102
I1
I0
I1
tp25615
sS'test,period'
p25616
(F1
F0.00014334862385321102
I1
I0
I1
tp25617
sS'to,measure'
p25618
(F1
F0.00028669724770642203
I0
I2
I-2
tp25619
sS'corn,oil'
p25620
(F1
F0.00014334862385321102
I0
I1
I-1
tp25621
sS'prostaglandins,and'
p25622
(F1
F0.00014334862385321102
I0
I1
I-1
tp25623
sS'certain,such'
p25624
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25625
sS'ineffective,in'
p25626
(F1
F0.00028669724770642203
I0
I2
I-2
tp25627
sS'ketoconazole,ketoconazole'
p25628
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp25629
sS'an,regimen'
p25630
(F1
F0.00014334862385321102
I0
I1
I-1
tp25631
sS'systemic,and'
p25632
(F0
F0
I1
I1
I0
tp25633
sS'acetate,affected'
p25634
(F1
F0.00014334862385321102
I1
I0
I1
tp25635
sS'may,exacerbate'
p25636
(F1
F0.00057339449541284407
I4
I0
I4
tp25637
sS'care,when'
p25638
(F1
F0.00014334862385321102
I1
I0
I1
tp25639
sS'causing,a'
p25640
(F1
F0.00014334862385321102
I1
I0
I1
tp25641
sS'medications,is'
p25642
(F1
F0.00014334862385321102
I1
I0
I1
tp25643
sS'gleevec,gleevec'
p25644
(F1
F0.00014334862385321102
I1
I0
I1
tp25645
sS'akineton,are'
p25646
(F1
F0.00014334862385321102
I1
I0
I1
tp25647
sS'will,result'
p25648
(F1
F0.00014334862385321102
I0
I1
I-1
tp25649
sS'receiving,infusions'
p25650
(F1
F0.00014334862385321102
I0
I1
I-1
tp25651
sS'a,physician'
p25652
(F1
F0.00014334862385321102
I1
I0
I1
tp25653
sS'of,interaction'
p25654
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp25655
sS'medications,in'
p25656
(F1
F0.00014334862385321102
I0
I1
I-1
tp25657
sS'tricor,with'
p25658
(F1
F0.00043004587155963305
I3
I0
I3
tp25659
sS'included,brovana'
p25660
(F1
F0.00014334862385321102
I0
I1
I-1
tp25661
sS'cyp,enzymes'
p25662
(F1
F0.00014334862385321102
I1
I0
I1
tp25663
sS'twitch,for'
p25664
(F1
F0.00014334862385321102
I0
I1
I-1
tp25665
sS'metabolite,n-desmethyldiazepam'
p25666
(F1
F0.00014334862385321102
I1
I0
I1
tp25667
sS'inhibitors,somatostatin'
p25668
(F1
F0.00028669724770642203
I0
I2
I-2
tp25669
sS'active,isomer'
p25670
(F1
F0.00028669724770642203
I2
I0
I2
tp25671
sS'of,levels'
p25672
(F0
F0
I1
I1
I0
tp25673
sS'cell,including'
p25674
(F1
F0.00014334862385321102
I0
I1
I-1
tp25675
sS'to,units'
p25676
(F1
F0.00014334862385321102
I0
I1
I-1
tp25677
sS'whose,pulmonary'
p25678
(F1
F0.00014334862385321102
I0
I1
I-1
tp25679
sS'and,nsaids'
p25680
(F1
F0.00057339449541284407
I4
I0
I4
tp25681
sS'cns,depressants'
p25682
(F0.57894736842105265
F0.0015768348623853212
I15
I4
I11
tp25683
sS'agents,have'
p25684
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp25685
sS'supraventricular,arrhythmias'
p25686
(F1
F0.00014334862385321102
I0
I1
I-1
tp25687
sS'view,of'
p25688
(F0
F0
I1
I1
I0
tp25689
sS'strongly,support'
p25690
(F1
F0.00014334862385321102
I0
I1
I-1
tp25691
sS'produce,an'
p25692
(F1
F0.00014334862385321102
I1
I0
I1
tp25693
sS'by,irreversible'
p25694
(F1
F0.00014334862385321102
I1
I0
I1
tp25695
sS'serum,proteins'
p25696
(F0
F0
I1
I1
I0
tp25697
sS'thereby,raising'
p25698
(F1
F0.00014334862385321102
I1
I0
I1
tp25699
sS'when,hypothyroid'
p25700
(F1
F0.00014334862385321102
I0
I1
I-1
tp25701
sS'of,neuropathy'
p25702
(F1
F0.00014334862385321102
I0
I1
I-1
tp25703
sS'between,folic'
p25704
(F1
F0.00014334862385321102
I0
I1
I-1
tp25705
sS'or,potentiated'
p25706
(F1
F0.00014334862385321102
I1
I0
I1
tp25707
sS'an,approximately'
p25708
(F1
F0.00028669724770642203
I2
I0
I2
tp25709
sS'enterococcus,faecalis'
p25710
(F1
F0.00014334862385321102
I0
I1
I-1
tp25711
sS'index,and'
p25712
(F1
F0.00014334862385321102
I0
I1
I-1
tp25713
sS'the,seminiferous'
p25714
(F1
F0.00014334862385321102
I0
I1
I-1
tp25715
sS'consider,hmg-coa'
p25716
(F1
F0.00014334862385321102
I1
I0
I1
tp25717
sS'min,in'
p25718
(F1
F0.00014334862385321102
I1
I0
I1
tp25719
sS'intestinal,permeability'
p25720
(F1
F0.00014334862385321102
I1
I0
I1
tp25721
sS'surgical,procedures'
p25722
(F1
F0.00014334862385321102
I1
I0
I1
tp25723
sS'produced,some'
p25724
(F1
F0.00014334862385321102
I0
I1
I-1
tp25725
sS'hctz,mg'
p25726
(F1
F0.00014334862385321102
I0
I1
I-1
tp25727
sS'infection,in'
p25728
(F1
F0.00014334862385321102
I1
I0
I1
tp25729
sS'muscle,pain'
p25730
(F1
F0.00014334862385321102
I0
I1
I-1
tp25731
sS'versus,mg'
p25732
(F1
F0.00014334862385321102
I0
I1
I-1
tp25733
sS'our,objective'
p25734
(F1
F0.00028669724770642203
I0
I2
I-2
tp25735
sS'alternative,therapy'
p25736
(F1
F0.00014334862385321102
I1
I0
I1
tp25737
sS'to,erythro-fluorocitrate'
p25738
(F0
F0
I1
I1
I0
tp25739
sS'administered,safely'
p25740
(F1
F0.00043004587155963305
I0
I3
I-3
tp25741
sS'most,likely'
p25742
(F1
F0.00014334862385321102
I1
I0
I1
tp25743
sS'synergism,with'
p25744
(F1
F0.00014334862385321102
I1
I0
I1
tp25745
sS'ingested,simultaneously'
p25746
(F1
F0.00014334862385321102
I1
I0
I1
tp25747
sS'asthma,or'
p25748
(F1
F0.00014334862385321102
I0
I1
I-1
tp25749
sS'are,excreted'
p25750
(F1
F0.00028669724770642203
I0
I2
I-2
tp25751
sS'if,labetalol'
p25752
(F1
F0.00014334862385321102
I1
I0
I1
tp25753
sS'in,water'
p25754
(F1
F0.00014334862385321102
I0
I1
I-1
tp25755
sS'be,deeper'
p25756
(F1
F0.00014334862385321102
I1
I0
I1
tp25757
sS'mustard,etc'
p25758
(F1
F0.00014334862385321102
I0
I1
I-1
tp25759
sS'drugs,on'
p25760
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25761
sS'association,with'
p25762
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25763
sS'noted,with'
p25764
(F0
F0
I1
I1
I0
tp25765
sS'tissue,culture'
p25766
(F1
F0.00028669724770642203
I2
I0
I2
tp25767
sS'or,fortovase'
p25768
(F1
F0.00014334862385321102
I0
I1
I-1
tp25769
sS'higher,increases'
p25770
(F1
F0.00014334862385321102
I1
I0
I1
tp25771
sS'previous,reports'
p25772
(F1
F0.00014334862385321102
I1
I0
I1
tp25773
sS'to,hydrochloride'
p25774
(F1
F0.00014334862385321102
I0
I1
I-1
tp25775
sS'addition,higher-than'
p25776
(F1
F0.00014334862385321102
I1
I0
I1
tp25777
sS'the,secretion'
p25778
(F1
F0.00014334862385321102
I0
I1
I-1
tp25779
sS'extended,release'
p25780
(F0
F0
I2
I2
I0
tp25781
sS'sensipar,on'
p25782
(F1
F0.00014334862385321102
I0
I1
I-1
tp25783
sS'inhibitor,may'
p25784
(F1
F0.00014334862385321102
I1
I0
I1
tp25785
sS'functional,consequences'
p25786
(F1
F0.00028669724770642203
I0
I2
I-2
tp25787
sS'other,drug'
p25788
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp25789
sS'studies,sodium'
p25790
(F1
F0.00014334862385321102
I0
I1
I-1
tp25791
sS'detect,an'
p25792
(F1
F0.00014334862385321102
I0
I1
I-1
tp25793
sS'by,rats'
p25794
(F1
F0.00014334862385321102
I0
I1
I-1
tp25795
sS'with,ovcon-35'
p25796
(F1
F0.00014334862385321102
I1
I0
I1
tp25797
sS'not,attenuated'
p25798
(F1
F0.00014334862385321102
I0
I1
I-1
tp25799
sS'nizoral,tablets'
p25800
(F1
F0.00028669724770642203
I2
I0
I2
tp25801
sS'erythromycin,mg'
p25802
(F1
F0.00014334862385321102
I1
I0
I1
tp25803
sS'diet,for'
p25804
(F1
F0.00014334862385321102
I1
I0
I1
tp25805
sS'anti-inflammatory,may'
p25806
(F1
F0.00014334862385321102
I1
I0
I1
tp25807
sS'been,shown'
p25808
(F0.5714285714285714
F0.0034403669724770644
I33
I9
I24
tp25809
sS'prodrug,form'
p25810
(F1
F0.00014334862385321102
I0
I1
I-1
tp25811
sS'containing,ferrous'
p25812
(F1
F0.00014334862385321102
I1
I0
I1
tp25813
sS'ewes,given'
p25814
(F1
F0.00014334862385321102
I1
I0
I1
tp25815
sS'age,and'
p25816
(F1
F0.00014334862385321102
I0
I1
I-1
tp25817
sS'by,decreasing'
p25818
(F1
F0.00043004587155963305
I3
I0
I3
tp25819
sS'intravenous,dose'
p25820
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25821
sS'and,amphotericin'
p25822
(F1
F0.00014334862385321102
I1
I0
I1
tp25823
sS'monitoring,and'
p25824
(F1
F0.00014334862385321102
I1
I0
I1
tp25825
sS'most,commonly'
p25826
(F1
F0.00014334862385321102
I1
I0
I1
tp25827
sS'total,rna'
p25828
(F1
F0.00014334862385321102
I0
I1
I-1
tp25829
sS'but,not'
p25830
(F0.12
F0.00043004587155963305
I14
I11
I3
tp25831
sS'goal-directed,behavior'
p25832
(F1
F0.00014334862385321102
I0
I1
I-1
tp25833
sS'different,and'
p25834
(F1
F0.00014334862385321102
I0
I1
I-1
tp25835
sS'application,mode'
p25836
(F1
F0.00014334862385321102
I0
I1
I-1
tp25837
sS'severity,and'
p25838
(F1
F0.00014334862385321102
I1
I0
I1
tp25839
sS'glyburide,etodolac'
p25840
(F1
F0.00014334862385321102
I0
I1
I-1
tp25841
sS'an,nad'
p25842
(F1
F0.00014334862385321102
I0
I1
I-1
tp25843
sS'however,coadministration'
p25844
(F1
F0.00014334862385321102
I0
I1
I-1
tp25845
sS'protein-bound,such'
p25846
(F1
F0.00014334862385321102
I0
I1
I-1
tp25847
sS'of,adjusted'
p25848
(F1
F0.00043004587155963305
I0
I3
I-3
tp25849
sS'steady-state,with'
p25850
(F0
F0
I1
I1
I0
tp25851
sS'inotropic,properties'
p25852
(F1
F0.00014334862385321102
I1
I0
I1
tp25853
sS'acetate,were'
p25854
(F1
F0.00014334862385321102
I0
I1
I-1
tp25855
sS'of,impaired'
p25856
(F1
F0.00028669724770642203
I2
I0
I2
tp25857
sS'in,clinically-'
p25858
(F1
F0.00014334862385321102
I0
I1
I-1
tp25859
sS'constriction,were'
p25860
(F1
F0.00014334862385321102
I0
I1
I-1
tp25861
sS'necessary,to'
p25862
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25863
sS'glutamate,mglur'
p25864
(F1
F0.00014334862385321102
I0
I1
I-1
tp25865
sS'inhibits,platelet'
p25866
(F1
F0.00014334862385321102
I1
I0
I1
tp25867
sS'most,are'
p25868
(F1
F0.00014334862385321102
I1
I0
I1
tp25869
sS'ibuprofen,as'
p25870
(F1
F0.00014334862385321102
I1
I0
I1
tp25871
sS'interaction,this'
p25872
(F1
F0.00014334862385321102
I1
I0
I1
tp25873
sS'that,clorazepate'
p25874
(F1
F0.00014334862385321102
I1
I0
I1
tp25875
sS'no,discernible'
p25876
(F1
F0.00014334862385321102
I0
I1
I-1
tp25877
sS'oral,and'
p25878
(F0.33333333333333331
F0.0011467889908256881
I16
I8
I8
tp25879
sS'by,multiple'
p25880
(F1
F0.00028669724770642203
I0
I2
I-2
tp25881
sS'may,induce'
p25882
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp25883
sS'those,of'
p25884
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp25885
sS'patients,that'
p25886
(F1
F0.00014334862385321102
I1
I0
I1
tp25887
sS'those,on'
p25888
(F1
F0.00014334862385321102
I1
I0
I1
tp25889
sS'estradiol,mg'
p25890
(F1
F0.00014334862385321102
I0
I1
I-1
tp25891
sS'through,the'
p25892
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25893
sS'warranted,appropriate'
p25894
(F1
F0.00057339449541284407
I4
I0
I4
tp25895
sS'include,the'
p25896
(F1
F0.0010034403669724771
I0
I7
I-7
tp25897
sS'cases,in'
p25898
(F1
F0.00014334862385321102
I1
I0
I1
tp25899
sS'although,have'
p25900
(F1
F0.00014334862385321102
I1
I0
I1
tp25901
sS'similarly,decreased'
p25902
(F1
F0.00028669724770642203
I2
I0
I2
tp25903
sS'when,prinivil'
p25904
(F1
F0.00014334862385321102
I0
I1
I-1
tp25905
sS'either,one'
p25906
(F1
F0.00014334862385321102
I1
I0
I1
tp25907
sS'effect,between'
p25908
(F1
F0.00014334862385321102
I1
I0
I1
tp25909
sS'been,found'
p25910
(F0.25
F0.00028669724770642203
I5
I3
I2
tp25911
sS'against,taking'
p25912
(F1
F0.00014334862385321102
I1
I0
I1
tp25913
sS'foradil,fumarate'
p25914
(F1
F0.00014334862385321102
I0
I1
I-1
tp25915
sS'orally,given'
p25916
(F1
F0.00014334862385321102
I0
I1
I-1
tp25917
sS'tract,hydoxide'
p25918
(F1
F0.00014334862385321102
I1
I0
I1
tp25919
sS'in,dietary-obese'
p25920
(F1
F0.00014334862385321102
I0
I1
I-1
tp25921
sS'neutralizing,agent'
p25922
(F1
F0.00014334862385321102
I1
I0
I1
tp25923
sS'mcg,per'
p25924
(F1
F0.00014334862385321102
I0
I1
I-1
tp25925
sS'jaffe,reaction'
p25926
(F1
F0.00014334862385321102
I0
I1
I-1
tp25927
sS'of,st'
p25928
(F1
F0.00014334862385321102
I0
I1
I-1
tp25929
sS'sular,tablets'
p25930
(F1
F0.00014334862385321102
I1
I0
I1
tp25931
sS'of,hexalen'
p25932
(F1
F0.00028669724770642203
I2
I0
I2
tp25933
sS'erroneously,low'
p25934
(F1
F0.00014334862385321102
I1
I0
I1
tp25935
sS'with,cardiac'
p25936
(F1
F0.00014334862385321102
I0
I1
I-1
tp25937
sS'to,human'
p25938
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25939
sS'in,area'
p25940
(F1
F0.00014334862385321102
I1
I0
I1
tp25941
sS'venlafaxine,coadministration'
p25942
(F1
F0.00014334862385321102
I0
I1
I-1
tp25943
sS'rarely,when'
p25944
(F1
F0.00014334862385321102
I1
I0
I1
tp25945
sS'administered,one'
p25946
(F0
F0
I1
I1
I0
tp25947
sS'severe,myopathy'
p25948
(F1
F0.00014334862385321102
I1
I0
I1
tp25949
sS'major,cytochrome'
p25950
(F1
F0.00014334862385321102
I0
I1
I-1
tp25951
sS'and,urinary'
p25952
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp25953
sS'apparent,volume'
p25954
(F1
F0.00014334862385321102
I0
I1
I-1
tp25955
sS'antiinflammatories,and'
p25956
(F1
F0.00014334862385321102
I0
I1
I-1
tp25957
sS'azlocillin,should'
p25958
(F1
F0.00014334862385321102
I1
I0
I1
tp25959
sS'and,about'
p25960
(F0
F0
I1
I1
I0
tp25961
sS'in,slight'
p25962
(F1
F0.00014334862385321102
I1
I0
I1
tp25963
sS'findings,to'
p25964
(F1
F0.00014334862385321102
I1
I0
I1
tp25965
sS'assigned,to'
p25966
(F1
F0.00014334862385321102
I0
I1
I-1
tp25967
sS'equal,groups'
p25968
(F1
F0.00014334862385321102
I0
I1
I-1
tp25969
sS'adl,a'
p25970
(F1
F0.00014334862385321102
I1
I0
I1
tp25971
sS'with,low'
p25972
(F1
F0.00014334862385321102
I1
I0
I1
tp25973
sS'propantheline,and'
p25974
(F1
F0.00014334862385321102
I1
I0
I1
tp25975
sS'qt,intervals'
p25976
(F1
F0.00028669724770642203
I0
I2
I-2
tp25977
sS'in,respect'
p25978
(F1
F0.00014334862385321102
I0
I1
I-1
tp25979
sS'supersensitivity,to'
p25980
(F1
F0.00014334862385321102
I1
I0
I1
tp25981
sS'concomitant,therapies'
p25982
(F1
F0.00014334862385321102
I0
I1
I-1
tp25983
sS'instituted,as'
p25984
(F1
F0.00014334862385321102
I1
I0
I1
tp25985
sS'ethanol,nutrition'
p25986
(F1
F0.00014334862385321102
I1
I0
I1
tp25987
sS'concentration,dependent'
p25988
(F1
F0.00014334862385321102
I0
I1
I-1
tp25989
sS'or,s-'
p25990
(F1
F0.00014334862385321102
I0
I1
I-1
tp25991
sS'initiating,extraneal'
p25992
(F1
F0.00014334862385321102
I1
I0
I1
tp25993
sS'the,less'
p25994
(F1
F0.00014334862385321102
I1
I0
I1
tp25995
sS'the,atypical'
p25996
(F1
F0.00014334862385321102
I0
I1
I-1
tp25997
sS'nsaid,users'
p25998
(F1
F0.00014334862385321102
I0
I1
I-1
tp25999
sS'with,adefovir'
p26000
(F1
F0.00014334862385321102
I0
I1
I-1
tp26001
sS'for,less'
p26002
(F1
F0.00028669724770642203
I0
I2
I-2
tp26003
sS'and,cardiovascular'
p26004
(F0
F0
I2
I2
I0
tp26005
sS'before,any'
p26006
(F1
F0.00014334862385321102
I1
I0
I1
tp26007
sS'and,pharmacological'
p26008
(F1
F0.00014334862385321102
I0
I1
I-1
tp26009
sS'daily,dose'
p26010
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp26011
sS'development,is'
p26012
(F1
F0.00014334862385321102
I0
I1
I-1
tp26013
sS'before,and'
p26014
(F1
F0.00028669724770642203
I0
I2
I-2
tp26015
sS'and,indanedione'
p26016
(F1
F0.00014334862385321102
I0
I1
I-1
tp26017
sS'inhibit,k'
p26018
(F1
F0.00014334862385321102
I0
I1
I-1
tp26019
sS'single,high'
p26020
(F1
F0.00014334862385321102
I1
I0
I1
tp26021
sS'felodipine,is'
p26022
(F1
F0.00014334862385321102
I0
I1
I-1
tp26023
sS'or,st'
p26024
(F1
F0.00014334862385321102
I1
I0
I1
tp26025
sS'not,necessitate'
p26026
(F1
F0.00028669724770642203
I0
I2
I-2
tp26027
sS'particularly,the'
p26028
(F1
F0.00014334862385321102
I1
I0
I1
tp26029
sS'an,encephalopathic'
p26030
(F1
F0.00014334862385321102
I1
I0
I1
tp26031
sS'demonstrated,effectiveness'
p26032
(F1
F0.00014334862385321102
I0
I1
I-1
tp26033
sS'cholestytamine,and'
p26034
(F1
F0.00014334862385321102
I1
I0
I1
tp26035
sS'biological,and'
p26036
(F1
F0.00014334862385321102
I1
I0
I1
tp26037
sS'currently,taking'
p26038
(F1
F0.00014334862385321102
I0
I1
I-1
tp26039
sS'beta,blocker'
p26040
(F1
F0.00028669724770642203
I2
I0
I2
tp26041
sS'erythro-fluorocitrate,synthesis'
p26042
(F1
F0.00043004587155963305
I0
I3
I-3
tp26043
sS'receiving,mg'
p26044
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26045
sS'know,if'
p26046
(F1
F0.00014334862385321102
I1
I0
I1
tp26047
sS'pharmacokinetic,screening'
p26048
(F1
F0.00014334862385321102
I0
I1
I-1
tp26049
sS'proton,pump'
p26050
(F0.5
F0.00057339449541284407
I6
I2
I4
tp26051
sS'activity,would'
p26052
(F1
F0.00014334862385321102
I0
I1
I-1
tp26053
sS'depressant,and'
p26054
(F0
F0
I1
I1
I0
tp26055
sS'optimal,dose'
p26056
(F1
F0.00028669724770642203
I0
I2
I-2
tp26057
sS'soft-gelatin,capsule'
p26058
(F1
F0.00014334862385321102
I1
I0
I1
tp26059
sS'with,acetylsalicylic'
p26060
(F1
F0.00014334862385321102
I0
I1
I-1
tp26061
sS'pressor,response'
p26062
(F1
F0.00014334862385321102
I1
I0
I1
tp26063
sS'while,only'
p26064
(F1
F0.00014334862385321102
I1
I0
I1
tp26065
sS'propecia,mg'
p26066
(F1
F0.00014334862385321102
I0
I1
I-1
tp26067
sS'xigris,present'
p26068
(F1
F0.00014334862385321102
I0
I1
I-1
tp26069
sS'using,romazicon'
p26070
(F1
F0.00014334862385321102
I1
I0
I1
tp26071
sS'in,regimens'
p26072
(F1
F0.00014334862385321102
I0
I1
I-1
tp26073
sS'gain,when'
p26074
(F1
F0.00014334862385321102
I1
I0
I1
tp26075
sS'affect,bioavailabillty'
p26076
(F1
F0.00014334862385321102
I0
I1
I-1
tp26077
sS'a,marketed'
p26078
(F1
F0.00014334862385321102
I1
I0
I1
tp26079
sS'syncope,presyncope'
p26080
(F1
F0.00014334862385321102
I1
I0
I1
tp26081
sS'cns-impairing,effects'
p26082
(F1
F0.00014334862385321102
I1
I0
I1
tp26083
sS'activation,of'
p26084
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26085
sS'a,mouse'
p26086
(F1
F0.00014334862385321102
I0
I1
I-1
tp26087
sS'and,subcortical'
p26088
(F1
F0.00014334862385321102
I0
I1
I-1
tp26089
sS'intersubject,variability'
p26090
(F1
F0.00014334862385321102
I1
I0
I1
tp26091
sS'vehicle-,progesterone-'
p26092
(F1
F0.00014334862385321102
I1
I0
I1
tp26093
sS'other,inducers'
p26094
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26095
sS'from,to'
p26096
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp26097
sS'daily,oral'
p26098
(F1
F0.00014334862385321102
I0
I1
I-1
tp26099
sS'fold,of'
p26100
(F1
F0.00014334862385321102
I1
I0
I1
tp26101
sS'interactions,for'
p26102
(F1
F0.00071674311926605509
I5
I0
I5
tp26103
sS'initial,release'
p26104
(F1
F0.00014334862385321102
I1
I0
I1
tp26105
sS'fold,on'
p26106
(F1
F0.00043004587155963305
I3
I0
I3
tp26107
sS'using,bromocriptine'
p26108
(F1
F0.00014334862385321102
I1
I0
I1
tp26109
sS'following,have'
p26110
(F1
F0.00014334862385321102
I0
I1
I-1
tp26111
sS'including,acetylsalicylic'
p26112
(F1
F0.00014334862385321102
I0
I1
I-1
tp26113
sS'administered,following'
p26114
(F0
F0
I1
I1
I0
tp26115
sS'prolong,the'
p26116
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp26117
sS'be,mimicked'
p26118
(F1
F0.00014334862385321102
I0
I1
I-1
tp26119
sS'part,to'
p26120
(F1
F0.00014334862385321102
I1
I0
I1
tp26121
sS'weeks,as'
p26122
(F1
F0.00014334862385321102
I0
I1
I-1
tp26123
sS'tachycardia,ventricular'
p26124
(F1
F0.00014334862385321102
I1
I0
I1
tp26125
sS'therapy,resulted'
p26126
(F1
F0.00014334862385321102
I0
I1
I-1
tp26127
sS'survival,in'
p26128
(F1
F0.00014334862385321102
I0
I1
I-1
tp26129
sS'every,hours'
p26130
(F0.14285714285714285
F0.00028669724770642203
I8
I6
I2
tp26131
sS'discontinue,after'
p26132
(F1
F0.00014334862385321102
I1
I0
I1
tp26133
sS'common,component'
p26134
(F1
F0.00014334862385321102
I1
I0
I1
tp26135
sS'of,septic'
p26136
(F1
F0.00014334862385321102
I0
I1
I-1
tp26137
sS'of,robinul'
p26138
(F1
F0.00028669724770642203
I2
I0
I2
tp26139
sS'not,generally'
p26140
(F1
F0.00028669724770642203
I2
I0
I2
tp26141
sS'diclofenac,like'
p26142
(F1
F0.00014334862385321102
I0
I1
I-1
tp26143
sS'active,metabolites'
p26144
(F1
F0.00014334862385321102
I0
I1
I-1
tp26145
sS'with,life-threatening'
p26146
(F1
F0.00014334862385321102
I0
I1
I-1
tp26147
sS'antiretroviral,drugs'
p26148
(F1
F0.00014334862385321102
I1
I0
I1
tp26149
sS'show,elevations'
p26150
(F1
F0.00014334862385321102
I1
I0
I1
tp26151
sS'sgot,ast'
p26152
(F1
F0.00014334862385321102
I1
I0
I1
tp26153
sS'combined,actions'
p26154
(F1
F0.00028669724770642203
I0
I2
I-2
tp26155
sS'into,the'
p26156
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp26157
sS'physiological,tolerance'
p26158
(F1
F0.00014334862385321102
I0
I1
I-1
tp26159
sS'metabolic,profiles'
p26160
(F1
F0.00014334862385321102
I0
I1
I-1
tp26161
sS'two,are'
p26162
(F1
F0.00028669724770642203
I2
I0
I2
tp26163
sS'daily,as'
p26164
(F0
F0
I2
I2
I0
tp26165
sS'salts,with'
p26166
(F1
F0.00014334862385321102
I0
I1
I-1
tp26167
sS'including,preparations'
p26168
(F1
F0.00014334862385321102
I0
I1
I-1
tp26169
sS'conflicting,results'
p26170
(F1
F0.00028669724770642203
I2
I0
I2
tp26171
sS'bactericidal,effect'
p26172
(F1
F0.00014334862385321102
I1
I0
I1
tp26173
sS'the,properties'
p26174
(F1
F0.00014334862385321102
I0
I1
I-1
tp26175
sS'under,steady'
p26176
(F1
F0.00028669724770642203
I0
I2
I-2
tp26177
sS'chylomicron,metabolism'
p26178
(F1
F0.00014334862385321102
I0
I1
I-1
tp26179
sS'in,meclofenamate'
p26180
(F1
F0.00014334862385321102
I0
I1
I-1
tp26181
sS'in,hypertensive'
p26182
(F1
F0.00014334862385321102
I0
I1
I-1
tp26183
sS'although,romazicon'
p26184
(F1
F0.00014334862385321102
I1
I0
I1
tp26185
sS'and,inotropic'
p26186
(F1
F0.00014334862385321102
I1
I0
I1
tp26187
sS'and,mixed--pharmacological'
p26188
(F1
F0.00014334862385321102
I0
I1
I-1
tp26189
sS'rash,while'
p26190
(F1
F0.00014334862385321102
I1
I0
I1
tp26191
sS'the,ssris'
p26192
(F1
F0.00057339449541284407
I4
I0
I4
tp26193
sS'as,sequential'
p26194
(F1
F0.00014334862385321102
I1
I0
I1
tp26195
sS'antacid,the'
p26196
(F1
F0.00014334862385321102
I0
I1
I-1
tp26197
sS'pharmacokinetics,during'
p26198
(F1
F0.00014334862385321102
I0
I1
I-1
tp26199
sS'receiving,hmg-coa'
p26200
(F1
F0.00014334862385321102
I1
I0
I1
tp26201
sS'of,thereby'
p26202
(F1
F0.00028669724770642203
I2
I0
I2
tp26203
sS'nonsmoking,healthy'
p26204
(F1
F0.00014334862385321102
I0
I1
I-1
tp26205
sS'fluconazole,concomitant'
p26206
(F1
F0.00014334862385321102
I1
I0
I1
tp26207
sS'predispose,the'
p26208
(F1
F0.00014334862385321102
I1
I0
I1
tp26209
sS'by,cyp3a4'
p26210
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp26211
sS'tolerated,when'
p26212
(F1
F0.00014334862385321102
I0
I1
I-1
tp26213
sS'the,blood-sugar'
p26214
(F1
F0.00014334862385321102
I1
I0
I1
tp26215
sS'adjustment,of'
p26216
(F0.1875
F0.0008600917431192661
I19
I13
I6
tp26217
sS'young,healthy'
p26218
(F1
F0.00014334862385321102
I0
I1
I-1
tp26219
sS'anticoagulants,flurbiprofen'
p26220
(F1
F0.00014334862385321102
I1
I0
I1
tp26221
sS'volume,in'
p26222
(F1
F0.00014334862385321102
I1
I0
I1
tp26223
sS'patient,populations'
p26224
(F1
F0.00014334862385321102
I1
I0
I1
tp26225
sS'dose,reduction'
p26226
(F0.5
F0.00057339449541284407
I6
I2
I4
tp26227
sS'taking,bextra'
p26228
(F1
F0.00014334862385321102
I1
I0
I1
tp26229
sS'ephedrine,ephedrine'
p26230
(F1
F0.00014334862385321102
I1
I0
I1
tp26231
sS'diminished,effects'
p26232
(F1
F0.00014334862385321102
I1
I0
I1
tp26233
sS'observed,between'
p26234
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp26235
sS'some,nsaids'
p26236
(F1
F0.00014334862385321102
I1
I0
I1
tp26237
sS'interval,on'
p26238
(F1
F0.0010034403669724771
I7
I0
I7
tp26239
sS'interval,of'
p26240
(F1
F0.00014334862385321102
I1
I0
I1
tp26241
sS'the,lipid-lowering'
p26242
(F1
F0.00014334862385321102
I0
I1
I-1
tp26243
sS'is,warranted'
p26244
(F1
F0.00043004587155963305
I3
I0
I3
tp26245
sS'experiments,using'
p26246
(F1
F0.00014334862385321102
I0
I1
I-1
tp26247
sS'suppression,of'
p26248
(F0
F0
I2
I2
I0
tp26249
sS'affect,pharmacodynamics'
p26250
(F1
F0.00014334862385321102
I1
I0
I1
tp26251
sS'however,from'
p26252
(F1
F0.00014334862385321102
I1
I0
I1
tp26253
sS'pseudotumor,cerebri'
p26254
(F1
F0.00014334862385321102
I1
I0
I1
tp26255
sS'study,evaluating'
p26256
(F1
F0.00028669724770642203
I2
I0
I2
tp26257
sS'humans,may'
p26258
(F1
F0.00014334862385321102
I1
I0
I1
tp26259
sS'balance,were'
p26260
(F1
F0.00014334862385321102
I0
I1
I-1
tp26261
sS'not,outweigh'
p26262
(F1
F0.00014334862385321102
I1
I0
I1
tp26263
sS'interactions,cimetidine'
p26264
(F1
F0.00028669724770642203
I0
I2
I-2
tp26265
sS'acid-base,and'
p26266
(F1
F0.00014334862385321102
I1
I0
I1
tp26267
sS'cancidas,are'
p26268
(F1
F0.00014334862385321102
I0
I1
I-1
tp26269
sS'the,cyp2d6'
p26270
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26271
sS'cmax,vs'
p26272
(F1
F0.00014334862385321102
I0
I1
I-1
tp26273
sS'their,o-desacetyl'
p26274
(F1
F0.00014334862385321102
I0
I1
I-1
tp26275
sS'bleeding,events'
p26276
(F1
F0.00043004587155963305
I3
I0
I3
tp26277
sS'below,the'
p26278
(F0
F0
I1
I1
I0
tp26279
sS'labetalol,hcl'
p26280
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp26281
sS'with,alkaline'
p26282
(F1
F0.00014334862385321102
I0
I1
I-1
tp26283
sS'combining,these'
p26284
(F1
F0.00014334862385321102
I0
I1
I-1
tp26285
sS'accordingly,careful'
p26286
(F1
F0.00014334862385321102
I1
I0
I1
tp26287
sS'to,p450-based'
p26288
(F1
F0.00014334862385321102
I0
I1
I-1
tp26289
sS'cytochrome,p450-mediated'
p26290
(F1
F0.00014334862385321102
I0
I1
I-1
tp26291
sS'half,life'
p26292
(F1
F0.00014334862385321102
I1
I0
I1
tp26293
sS'with,epilepsy'
p26294
(F1
F0.00057339449541284407
I0
I4
I-4
tp26295
sS'leprosy-associated,inflammatory'
p26296
(F1
F0.00014334862385321102
I1
I0
I1
tp26297
sS'gastrointestinal,transit'
p26298
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26299
sS'm-toluamide,a'
p26300
(F1
F0.00014334862385321102
I1
I0
I1
tp26301
sS'similar,in'
p26302
(F1
F0.00028669724770642203
I0
I2
I-2
tp26303
sS'concentration,were'
p26304
(F1
F0.00014334862385321102
I0
I1
I-1
tp26305
sS'in,mediating'
p26306
(F1
F0.00014334862385321102
I0
I1
I-1
tp26307
sS'syndrome,in'
p26308
(F0
F0
I1
I1
I0
tp26309
sS'be,given'
p26310
(F0.80000000000000004
F0.0022935779816513763
I18
I2
I16
tp26311
sS'hiv,protease'
p26312
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp26313
sS'the,ed50'
p26314
(F1
F0.00014334862385321102
I1
I0
I1
tp26315
sS'in,vivo'
p26316
(F0
F0
I12
I12
I0
tp26317
sS'receiving,catecholamine-depleting'
p26318
(F1
F0.00043004587155963305
I3
I0
I3
tp26319
sS'or,triazolam'
p26320
(F1
F0.00014334862385321102
I0
I1
I-1
tp26321
sS'or,supplements'
p26322
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp26323
sS'exposure,following'
p26324
(F1
F0.00014334862385321102
I1
I0
I1
tp26325
sS'fatal,when'
p26326
(F1
F0.00014334862385321102
I1
I0
I1
tp26327
sS'a,single'
p26328
(F0.014925373134328358
F0.00014334862385321102
I33
I34
I-1
tp26329
sS'trials,in'
p26330
(F0
F0
I1
I1
I0
tp26331
sS'system,and'
p26332
(F1
F0.00028669724770642203
I2
I0
I2
tp26333
sS'prophylactic,low'
p26334
(F1
F0.00028669724770642203
I0
I2
I-2
tp26335
sS'a4,enzyme'
p26336
(F1
F0.00028669724770642203
I2
I0
I2
tp26337
sS'diclofenac,does'
p26338
(F1
F0.00014334862385321102
I0
I1
I-1
tp26339
sS'of,subjects'
p26340
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp26341
sS'tricyclic,antidepressant'
p26342
(F1
F0.00043004587155963305
I0
I3
I-3
tp26343
sS'activase,in'
p26344
(F1
F0.00014334862385321102
I0
I1
I-1
tp26345
sS'especially,central'
p26346
(F1
F0.00014334862385321102
I0
I1
I-1
tp26347
sS'eg,selective'
p26348
(F1
F0.00014334862385321102
I0
I1
I-1
tp26349
sS'especially,or'
p26350
(F1
F0.00014334862385321102
I0
I1
I-1
tp26351
sS'changes,in'
p26352
(F0.52631578947368418
F0.0028669724770642203
I9
I29
I-20
tp26353
sS'information,should'
p26354
(F1
F0.00014334862385321102
I0
I1
I-1
tp26355
sS'both,angiotensins'
p26356
(F1
F0.00014334862385321102
I0
I1
I-1
tp26357
sS'of,o-desacetylrifabutin'
p26358
(F1
F0.00014334862385321102
I1
I0
I1
tp26359
sS'sodium,was'
p26360
(F1
F0.00028669724770642203
I0
I2
I-2
tp26361
sS'potentially,nephrotoxic'
p26362
(F1
F0.00028669724770642203
I2
I0
I2
tp26363
sS'administered,simultaneously'
p26364
(F1
F0.00014334862385321102
I1
I0
I1
tp26365
sS'in,relation'
p26366
(F1
F0.00014334862385321102
I0
I1
I-1
tp26367
sS'that,results'
p26368
(F1
F0.00028669724770642203
I2
I0
I2
tp26369
sS'method,for'
p26370
(F1
F0.00014334862385321102
I0
I1
I-1
tp26371
sS'cyp2d6,because'
p26372
(F1
F0.00014334862385321102
I0
I1
I-1
tp26373
sS'for,five'
p26374
(F1
F0.00014334862385321102
I0
I1
I-1
tp26375
sS'of,fluvoxamine'
p26376
(F1
F0.00014334862385321102
I1
I0
I1
tp26377
sS'enzyme,systems'
p26378
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26379
sS'mcg,ml'
p26380
(F1
F0.00014334862385321102
I0
I1
I-1
tp26381
sS'depletion,may'
p26382
(F1
F0.00014334862385321102
I1
I0
I1
tp26383
sS'ns,and'
p26384
(F1
F0.00014334862385321102
I0
I1
I-1
tp26385
sS'injection,and'
p26386
(F1
F0.00071674311926605509
I5
I0
I5
tp26387
sS'subjects,concurrent'
p26388
(F1
F0.00014334862385321102
I1
I0
I1
tp26389
sS'synthetic,by'
p26390
(F1
F0.00014334862385321102
I1
I0
I1
tp26391
sS'bun,and'
p26392
(F1
F0.00014334862385321102
I1
I0
I1
tp26393
sS'was,too'
p26394
(F1
F0.00014334862385321102
I0
I1
I-1
tp26395
sS'intake,and'
p26396
(F1
F0.00014334862385321102
I0
I1
I-1
tp26397
sS'renal,uptake'
p26398
(F1
F0.00014334862385321102
I1
I0
I1
tp26399
sS'creatinine,in'
p26400
(F1
F0.00028669724770642203
I2
I0
I2
tp26401
sS'avoided,also'
p26402
(F1
F0.00014334862385321102
I1
I0
I1
tp26403
sS'two,multiple-dose'
p26404
(F1
F0.00014334862385321102
I0
I1
I-1
tp26405
sS'documentation,of'
p26406
(F1
F0.00014334862385321102
I0
I1
I-1
tp26407
sS'in,renal'
p26408
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp26409
sS'niddm,subjects'
p26410
(F1
F0.00014334862385321102
I0
I1
I-1
tp26411
sS'awareness,of'
p26412
(F1
F0.00014334862385321102
I1
I0
I1
tp26413
sS'others,that'
p26414
(F1
F0.00014334862385321102
I1
I0
I1
tp26415
sS'balance,testing'
p26416
(F1
F0.00014334862385321102
I1
I0
I1
tp26417
sS'conclusions,single-dose'
p26418
(F1
F0.00014334862385321102
I1
I0
I1
tp26419
sS'a,crossover'
p26420
(F1
F0.00014334862385321102
I1
I0
I1
tp26421
sS'have,one'
p26422
(F1
F0.00014334862385321102
I0
I1
I-1
tp26423
sS'metabolism,of'
p26424
(F0.62264150943396224
F0.0047305045871559636
I43
I10
I33
tp26425
sS'bextra,in'
p26426
(F1
F0.00028669724770642203
I2
I0
I2
tp26427
sS'are,often'
p26428
(F1
F0.00028669724770642203
I0
I2
I-2
tp26429
sS'saquinavir,steady-state'
p26430
(F1
F0.00014334862385321102
I1
I0
I1
tp26431
sS'receiving,treatment'
p26432
(F1
F0.00014334862385321102
I0
I1
I-1
tp26433
sS'agents,were'
p26434
(F1
F0.00028669724770642203
I0
I2
I-2
tp26435
sS'dexamethasone,aprepitant'
p26436
(F1
F0.00014334862385321102
I1
I0
I1
tp26437
sS'the,long-term'
p26438
(F1
F0.00014334862385321102
I0
I1
I-1
tp26439
sS'consideration,in'
p26440
(F1
F0.0010034403669724771
I7
I0
I7
tp26441
sS'a,considerable'
p26442
(F1
F0.00014334862385321102
I1
I0
I1
tp26443
sS'of,tricor'
p26444
(F1
F0.00014334862385321102
I1
I0
I1
tp26445
sS'other,tnf-blocking'
p26446
(F1
F0.00014334862385321102
I1
I0
I1
tp26447
sS'nonselective,inhibitor'
p26448
(F1
F0.00014334862385321102
I1
I0
I1
tp26449
sS'period,in'
p26450
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp26451
sS'to,iii'
p26452
(F1
F0.00028669724770642203
I0
I2
I-2
tp26453
sS'velcade,treatment'
p26454
(F1
F0.00014334862385321102
I1
I0
I1
tp26455
sS'palytoxin,ptx'
p26456
(F1
F0.00014334862385321102
I0
I1
I-1
tp26457
sS'because,binds'
p26458
(F1
F0.00014334862385321102
I0
I1
I-1
tp26459
sS'racemic,nor'
p26460
(F1
F0.00014334862385321102
I0
I1
I-1
tp26461
sS'maintenance,dose'
p26462
(F1
F0.00057339449541284407
I4
I0
I4
tp26463
sS'pharmacokinetic,interaction'
p26464
(F0.77777777777777779
F0.0020068807339449542
I2
I16
I-14
tp26465
sS'and,extent'
p26466
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp26467
sS'a,further'
p26468
(F1
F0.00028669724770642203
I2
I0
I2
tp26469
sS'been,filtrated'
p26470
(F1
F0.00014334862385321102
I1
I0
I1
tp26471
sS'delirium,has'
p26472
(F1
F0.00014334862385321102
I1
I0
I1
tp26473
sS'overall,treatment'
p26474
(F1
F0.00014334862385321102
I0
I1
I-1
tp26475
sS'on,protein'
p26476
(F1
F0.00014334862385321102
I0
I1
I-1
tp26477
sS'the,octapeptide'
p26478
(F1
F0.00014334862385321102
I0
I1
I-1
tp26479
sS'pharmaceuticals,inc'
p26480
(F1
F0.00014334862385321102
I1
I0
I1
tp26481
sS'separate,randomized'
p26482
(F1
F0.00014334862385321102
I0
I1
I-1
tp26483
sS'quinolones,have'
p26484
(F1
F0.00043004587155963305
I3
I0
I3
tp26485
sS'or,nsaids'
p26486
(F0
F0
I1
I1
I0
tp26487
sS'motility,lowers'
p26488
(F1
F0.00014334862385321102
I1
I0
I1
tp26489
sS'monitoring,can'
p26490
(F1
F0.00014334862385321102
I1
I0
I1
tp26491
sS'via,p450'
p26492
(F1
F0.00014334862385321102
I1
I0
I1
tp26493
sS'tell,your'
p26494
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26495
sS'pressure,reductions'
p26496
(F1
F0.00014334862385321102
I1
I0
I1
tp26497
sS'one-stage,coagulation'
p26498
(F1
F0.00014334862385321102
I0
I1
I-1
tp26499
sS'superiority,compared'
p26500
(F1
F0.00014334862385321102
I0
I1
I-1
tp26501
sS'and,appropriate'
p26502
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp26503
sS'was,about'
p26504
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26505
sS'the,pharmacokinetics'
p26506
(F0.80582524271844658
F0.011897935779816514
I10
I93
I-83
tp26507
sS'inducers,it'
p26508
(F1
F0.00014334862385321102
I1
I0
I1
tp26509
sS'oxide,to'
p26510
(F1
F0.00014334862385321102
I1
I0
I1
tp26511
sS'prednisolone,ethinyl'
p26512
(F1
F0.00014334862385321102
I1
I0
I1
tp26513
sS'periods,with'
p26514
(F1
F0.00014334862385321102
I0
I1
I-1
tp26515
sS'human,novolog'
p26516
(F1
F0.00014334862385321102
I0
I1
I-1
tp26517
sS'actions,desirable'
p26518
(F1
F0.00028669724770642203
I0
I2
I-2
tp26519
sS'is,bound'
p26520
(F1
F0.00014334862385321102
I0
I1
I-1
tp26521
sS'the,systemic'
p26522
(F1
F0.00057339449541284407
I4
I0
I4
tp26523
sS'dose,level'
p26524
(F1
F0.00014334862385321102
I0
I1
I-1
tp26525
sS'in,control'
p26526
(F1
F0.00014334862385321102
I0
I1
I-1
tp26527
sS'for,most'
p26528
(F1
F0.00014334862385321102
I0
I1
I-1
tp26529
sS'until,blood'
p26530
(F1
F0.00014334862385321102
I1
I0
I1
tp26531
sS'short-acting,aerosol'
p26532
(F1
F0.00014334862385321102
I0
I1
I-1
tp26533
sS'l,induced'
p26534
(F1
F0.00014334862385321102
I0
I1
I-1
tp26535
sS'indanavir,ketoconazole'
p26536
(F1
F0.00014334862385321102
I0
I1
I-1
tp26537
sS'and,diamond'
p26538
(F1
F0.00014334862385321102
I1
I0
I1
tp26539
sS'known,if'
p26540
(F0
F0
I1
I1
I0
tp26541
sS'butalbital,and'
p26542
(F1
F0.00014334862385321102
I1
I0
I1
tp26543
sS'had,only'
p26544
(F1
F0.00014334862385321102
I1
I0
I1
tp26545
sS'instances,and'
p26546
(F1
F0.00014334862385321102
I1
I0
I1
tp26547
sS'sali-cylates,nsaids'
p26548
(F1
F0.00014334862385321102
I0
I1
I-1
tp26549
sS'may,underlie'
p26550
(F1
F0.00014334862385321102
I0
I1
I-1
tp26551
sS'birth,control'
p26552
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26553
sS'anesthetized,swine'
p26554
(F1
F0.00014334862385321102
I0
I1
I-1
tp26555
sS'enzymes,lapatinib'
p26556
(F1
F0.00014334862385321102
I0
I1
I-1
tp26557
sS'washout,period'
p26558
(F1
F0.00014334862385321102
I0
I1
I-1
tp26559
sS'groups,sh'
p26560
(F1
F0.00014334862385321102
I0
I1
I-1
tp26561
sS'these,pharmacokinetic'
p26562
(F1
F0.00028669724770642203
I2
I0
I2
tp26563
sS'to,dose-related'
p26564
(F1
F0.00014334862385321102
I1
I0
I1
tp26565
sS'r-warfarin,a'
p26566
(F1
F0.00014334862385321102
I1
I0
I1
tp26567
sS'on,its'
p26568
(F1
F0.00014334862385321102
I0
I1
I-1
tp26569
sS'hepatotoxicity,concomitant'
p26570
(F1
F0.00014334862385321102
I1
I0
I1
tp26571
sS'with,diethyl'
p26572
(F1
F0.00014334862385321102
I0
I1
I-1
tp26573
sS'and,kytril'
p26574
(F1
F0.00014334862385321102
I0
I1
I-1
tp26575
sS'solution,dried'
p26576
(F1
F0.00014334862385321102
I0
I1
I-1
tp26577
sS'inflammatory,disorders'
p26578
(F1
F0.00014334862385321102
I1
I0
I1
tp26579
sS'and,but'
p26580
(F1
F0.00014334862385321102
I1
I0
I1
tp26581
sS'other,tegretol'
p26582
(F1
F0.00014334862385321102
I0
I1
I-1
tp26583
sS'therefore,smaller'
p26584
(F1
F0.00014334862385321102
I0
I1
I-1
tp26585
sS'ssris,may'
p26586
(F1
F0.00014334862385321102
I1
I0
I1
tp26587
sS'for,preparations'
p26588
(F1
F0.00028669724770642203
I2
I0
I2
tp26589
sS'of,pcp-induced'
p26590
(F1
F0.00014334862385321102
I0
I1
I-1
tp26591
sS'underlying,the'
p26592
(F1
F0.00014334862385321102
I0
I1
I-1
tp26593
sS'results,confirm'
p26594
(F1
F0.00014334862385321102
I0
I1
I-1
tp26595
sS'like,and'
p26596
(F1
F0.00014334862385321102
I0
I1
I-1
tp26597
sS'all,associated'
p26598
(F1
F0.00014334862385321102
I1
I0
I1
tp26599
sS'we,propose'
p26600
(F1
F0.00014334862385321102
I1
I0
I1
tp26601
sS'performed,examining'
p26602
(F1
F0.00014334862385321102
I0
I1
I-1
tp26603
sS'consider,doubling'
p26604
(F1
F0.00014334862385321102
I0
I1
I-1
tp26605
sS'though,such'
p26606
(F1
F0.00014334862385321102
I0
I1
I-1
tp26607
sS'similar,to'
p26608
(F0.076923076923076927
F0.00014334862385321102
I6
I7
I-1
tp26609
sS'between,h-spiroperidol'
p26610
(F1
F0.00028669724770642203
I0
I2
I-2
tp26611
sS'therapeutic,levels'
p26612
(F1
F0.00014334862385321102
I0
I1
I-1
tp26613
sS'carbamazepine,is'
p26614
(F1
F0.00028669724770642203
I0
I2
I-2
tp26615
sS'or,during'
p26616
(F0
F0
I1
I1
I0
tp26617
sS'some,gram-positive'
p26618
(F1
F0.00014334862385321102
I0
I1
I-1
tp26619
sS'duloxetine,did'
p26620
(F1
F0.00014334862385321102
I0
I1
I-1
tp26621
sS'for,one'
p26622
(F0
F0
I1
I1
I0
tp26623
sS'blocking,agent'
p26624
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26625
sS'carbamazepine,in'
p26626
(F1
F0.00014334862385321102
I1
I0
I1
tp26627
sS'racemic,citalopram'
p26628
(F1
F0.00014334862385321102
I1
I0
I1
tp26629
sS'b3,niacin'
p26630
(F1
F0.00014334862385321102
I1
I0
I1
tp26631
sS'nnrtis,nevirapine'
p26632
(F1
F0.00014334862385321102
I1
I0
I1
tp26633
sS'studies,demonstrate'
p26634
(F1
F0.00014334862385321102
I0
I1
I-1
tp26635
sS'and,l-lysine'
p26636
(F1
F0.00014334862385321102
I1
I0
I1
tp26637
sS'bactercidal,effect'
p26638
(F1
F0.00014334862385321102
I1
I0
I1
tp26639
sS'vitro,interaction'
p26640
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26641
sS'therefore,and'
p26642
(F1
F0.00028669724770642203
I2
I0
I2
tp26643
sS'live,typhoid'
p26644
(F1
F0.00014334862385321102
I1
I0
I1
tp26645
sS'tended,to'
p26646
(F0
F0
I1
I1
I0
tp26647
sS'e2,may'
p26648
(F1
F0.00014334862385321102
I1
I0
I1
tp26649
sS'kerlone,with'
p26650
(F1
F0.00014334862385321102
I0
I1
I-1
tp26651
sS'the,gaba-ergic'
p26652
(F1
F0.00014334862385321102
I1
I0
I1
tp26653
sS'you,need'
p26654
(F1
F0.00014334862385321102
I1
I0
I1
tp26655
sS'a,krm-1648'
p26656
(F1
F0.00014334862385321102
I0
I1
I-1
tp26657
sS'antidiabetic,oral'
p26658
(F1
F0.00057339449541284407
I0
I4
I-4
tp26659
sS'changes,to'
p26660
(F0
F0
I1
I1
I0
tp26661
sS'clinical,implications'
p26662
(F1
F0.00014334862385321102
I1
I0
I1
tp26663
sS'hydroxy-3,methylglutaryl'
p26664
(F1
F0.00014334862385321102
I0
I1
I-1
tp26665
sS'each,subject'
p26666
(F1
F0.00014334862385321102
I0
I1
I-1
tp26667
sS'less,effective'
p26668
(F1
F0.00014334862385321102
I1
I0
I1
tp26669
sS'diet,or'
p26670
(F1
F0.00014334862385321102
I0
I1
I-1
tp26671
sS'made,when'
p26672
(F1
F0.00028669724770642203
I0
I2
I-2
tp26673
sS'hours,and'
p26674
(F1
F0.00014334862385321102
I1
I0
I1
tp26675
sS'inhibition,induced'
p26676
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp26677
sS'in,ra'
p26678
(F1
F0.00014334862385321102
I0
I1
I-1
tp26679
sS'products,concurrent'
p26680
(F1
F0.00014334862385321102
I1
I0
I1
tp26681
sS'the,course'
p26682
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp26683
sS'treatment,of'
p26684
(F0.41666666666666669
F0.0014334862385321102
I7
I17
I-10
tp26685
sS'recommended,twice'
p26686
(F1
F0.00014334862385321102
I0
I1
I-1
tp26687
sS'digoxin,salicylate'
p26688
(F1
F0.00014334862385321102
I1
I0
I1
tp26689
sS'satisfactory,hypotensive'
p26690
(F1
F0.00014334862385321102
I1
I0
I1
tp26691
sS'diamox,may'
p26692
(F1
F0.00014334862385321102
I1
I0
I1
tp26693
sS'sodium,iodide'
p26694
(F0
F0
I1
I1
I0
tp26695
sS'isolated,reports'
p26696
(F1
F0.00043004587155963305
I3
I0
I3
tp26697
sS'week,intraperitoneal'
p26698
(F1
F0.00014334862385321102
I0
I1
I-1
tp26699
sS'like,does'
p26700
(F1
F0.00014334862385321102
I0
I1
I-1
tp26701
sS'septra,gantrisin'
p26702
(F1
F0.00014334862385321102
I0
I1
I-1
tp26703
sS'a,nonfunctioning'
p26704
(F1
F0.00014334862385321102
I1
I0
I1
tp26705
sS'likely,that'
p26706
(F1
F0.00014334862385321102
I1
I0
I1
tp26707
sS'ischemic,heart'
p26708
(F1
F0.00028669724770642203
I2
I0
I2
tp26709
sS'undesirable,effects'
p26710
(F1
F0.00014334862385321102
I1
I0
I1
tp26711
sS'ml,day'
p26712
(F1
F0.00014334862385321102
I0
I1
I-1
tp26713
sS'may,protect'
p26714
(F1
F0.00014334862385321102
I1
I0
I1
tp26715
sS'equally,antagonized'
p26716
(F1
F0.00014334862385321102
I1
I0
I1
tp26717
sS'the,qrs'
p26718
(F1
F0.00014334862385321102
I1
I0
I1
tp26719
sS'syndrome,cognitive'
p26720
(F1
F0.00014334862385321102
I1
I0
I1
tp26721
sS'uptake,to'
p26722
(F1
F0.00014334862385321102
I1
I0
I1
tp26723
sS'involving,alprazolam'
p26724
(F1
F0.00014334862385321102
I1
I0
I1
tp26725
sS'and,release'
p26726
(F1
F0.00028669724770642203
I0
I2
I-2
tp26727
sS'at,periodic'
p26728
(F1
F0.00014334862385321102
I1
I0
I1
tp26729
sS'enough,during'
p26730
(F1
F0.00014334862385321102
I1
I0
I1
tp26731
sS'a,subgroup'
p26732
(F1
F0.00014334862385321102
I0
I1
I-1
tp26733
sS'or,eliminated'
p26734
(F1
F0.00014334862385321102
I1
I0
I1
tp26735
sS'inducers,include'
p26736
(F1
F0.00014334862385321102
I0
I1
I-1
tp26737
sS'no,controlled'
p26738
(F1
F0.00014334862385321102
I0
I1
I-1
tp26739
sS'administering,to'
p26740
(F1
F0.00028669724770642203
I2
I0
I2
tp26741
sS'reduced,creatinine'
p26742
(F1
F0.00014334862385321102
I1
I0
I1
tp26743
sS'inhibitors,eg'
p26744
(F0
F0
I1
I1
I0
tp26745
sS'inhibitors,coadministration'
p26746
(F1
F0.00014334862385321102
I1
I0
I1
tp26747
sS'the,oral'
p26748
(F0.55555555555555558
F0.0014334862385321102
I14
I4
I10
tp26749
sS'independent,of'
p26750
(F1
F0.00014334862385321102
I0
I1
I-1
tp26751
sS'like,cannot'
p26752
(F1
F0.00014334862385321102
I0
I1
I-1
tp26753
sS'major,contributing'
p26754
(F1
F0.00014334862385321102
I1
I0
I1
tp26755
sS'in,clearance'
p26756
(F0.75
F0.0008600917431192661
I7
I1
I6
tp26757
sS'or,back-up'
p26758
(F1
F0.00014334862385321102
I1
I0
I1
tp26759
sS'present,in'
p26760
(F0
F0
I1
I1
I0
tp26761
sS'estrogen-containing,oral'
p26762
(F0
F0
I1
I1
I0
tp26763
sS'since,cholestyramine'
p26764
(F1
F0.00014334862385321102
I0
I1
I-1
tp26765
sS'therefore,or'
p26766
(F1
F0.00014334862385321102
I1
I0
I1
tp26767
sS'inherent,in'
p26768
(F1
F0.00014334862385321102
I1
I0
I1
tp26769
sS'can,form'
p26770
(F1
F0.00014334862385321102
I1
I0
I1
tp26771
sS'main,non-infection'
p26772
(F1
F0.00014334862385321102
I0
I1
I-1
tp26773
sS'significant,deterioration'
p26774
(F1
F0.00014334862385321102
I0
I1
I-1
tp26775
sS'sterilize,the'
p26776
(F1
F0.00014334862385321102
I0
I1
I-1
tp26777
sS'from,plasma'
p26778
(F1
F0.00014334862385321102
I1
I0
I1
tp26779
sS'by,cgs21680'
p26780
(F1
F0.00014334862385321102
I1
I0
I1
tp26781
sS'clidinium,may'
p26782
(F1
F0.00014334862385321102
I1
I0
I1
tp26783
sS'when,using'
p26784
(F0.5
F0.00028669724770642203
I3
I1
I2
tp26785
sS'when,suprax'
p26786
(F1
F0.00014334862385321102
I1
I0
I1
tp26787
sS'combined,oral'
p26788
(F1
F0.00014334862385321102
I0
I1
I-1
tp26789
sS'in,total'
p26790
(F1
F0.00014334862385321102
I1
I0
I1
tp26791
sS'these,components'
p26792
(F1
F0.00014334862385321102
I0
I1
I-1
tp26793
sS'time,monitored'
p26794
(F1
F0.00014334862385321102
I1
I0
I1
tp26795
sS'up,to'
p26796
(F0.26315789473684209
F0.00071674311926605509
I12
I7
I5
tp26797
sS'data,on'
p26798
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp26799
sS'patient,should'
p26800
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp26801
sS'nonetheless,since'
p26802
(F1
F0.00014334862385321102
I1
I0
I1
tp26803
sS'and,differed'
p26804
(F1
F0.00014334862385321102
I0
I1
I-1
tp26805
sS'caverject,the'
p26806
(F1
F0.00014334862385321102
I0
I1
I-1
tp26807
sS'prozac,sporanox'
p26808
(F1
F0.00014334862385321102
I0
I1
I-1
tp26809
sS'eldepryl,and'
p26810
(F1
F0.00014334862385321102
I0
I1
I-1
tp26811
sS'thus,leading'
p26812
(F1
F0.00014334862385321102
I1
I0
I1
tp26813
sS'tilade,has'
p26814
(F1
F0.00014334862385321102
I0
I1
I-1
tp26815
sS'known,relationships'
p26816
(F1
F0.00014334862385321102
I0
I1
I-1
tp26817
sS'to,existing'
p26818
(F1
F0.00014334862385321102
I0
I1
I-1
tp26819
sS'were,investigated'
p26820
(F1
F0.00028669724770642203
I0
I2
I-2
tp26821
sS'as,clinistix'
p26822
(F1
F0.00014334862385321102
I0
I1
I-1
tp26823
sS'test,dsst'
p26824
(F1
F0.00014334862385321102
I1
I0
I1
tp26825
sS'therefore,proton'
p26826
(F1
F0.00014334862385321102
I1
I0
I1
tp26827
sS'electrocardiographic,qt'
p26828
(F1
F0.00014334862385321102
I0
I1
I-1
tp26829
sS'opposite,way'
p26830
(F1
F0.00014334862385321102
I1
I0
I1
tp26831
sS'ethoxzolamide,may'
p26832
(F1
F0.00014334862385321102
I1
I0
I1
tp26833
sS'to,release'
p26834
(F1
F0.00014334862385321102
I1
I0
I1
tp26835
sS'potentially,arise'
p26836
(F1
F0.00014334862385321102
I1
I0
I1
tp26837
sS'of,major'
p26838
(F1
F0.00028669724770642203
I2
I0
I2
tp26839
sS'related,ethacrynic'
p26840
(F1
F0.00014334862385321102
I0
I1
I-1
tp26841
sS'delirium,associated'
p26842
(F1
F0.00014334862385321102
I1
I0
I1
tp26843
sS'directed,to'
p26844
(F1
F0.00014334862385321102
I1
I0
I1
tp26845
sS'curves,derived'
p26846
(F1
F0.00014334862385321102
I1
I0
I1
tp26847
sS'allopurinol,the'
p26848
(F1
F0.00028669724770642203
I2
I0
I2
tp26849
sS'in,cyp'
p26850
(F1
F0.00014334862385321102
I1
I0
I1
tp26851
sS'drug,laboratory'
p26852
(F0.8571428571428571
F0.0017201834862385322
I1
I13
I-12
tp26853
sS'its,activity'
p26854
(F1
F0.00028669724770642203
I0
I2
I-2
tp26855
sS'thus,an'
p26856
(F1
F0.00014334862385321102
I1
I0
I1
tp26857
sS'approximately,with'
p26858
(F1
F0.00014334862385321102
I1
I0
I1
tp26859
sS'to,significant'
p26860
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26861
sS'noradrenaline-precontracted,arteries'
p26862
(F1
F0.00014334862385321102
I0
I1
I-1
tp26863
sS'not,an'
p26864
(F1
F0.00014334862385321102
I0
I1
I-1
tp26865
sS'not,at'
p26866
(F0
F0
I1
I1
I0
tp26867
sS'weakness,hyperreflexia'
p26868
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp26869
sS'and,hours'
p26870
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26871
sS'artery,vasospasm'
p26872
(F1
F0.00014334862385321102
I1
I0
I1
tp26873
sS'be,modified'
p26874
(F1
F0.00014334862385321102
I1
I0
I1
tp26875
sS'severe,in'
p26876
(F1
F0.00014334862385321102
I0
I1
I-1
tp26877
sS'of,during'
p26878
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26879
sS'received,concomitant'
p26880
(F1
F0.00043004587155963305
I0
I3
I-3
tp26881
sS'enzymes,and'
p26882
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26883
sS'is,introduced'
p26884
(F1
F0.00014334862385321102
I1
I0
I1
tp26885
sS'carefully,observed'
p26886
(F0
F0
I1
I1
I0
tp26887
sS'or,changed'
p26888
(F1
F0.00014334862385321102
I1
I0
I1
tp26889
sS'at,six'
p26890
(F1
F0.00014334862385321102
I1
I0
I1
tp26891
sS'index,fici'
p26892
(F1
F0.00014334862385321102
I0
I1
I-1
tp26893
sS'and,many'
p26894
(F1
F0.00071674311926605509
I0
I5
I-5
tp26895
sS'with,preparations'
p26896
(F1
F0.00028669724770642203
I2
I0
I2
tp26897
sS'aucs,of'
p26898
(F1
F0.00014334862385321102
I0
I1
I-1
tp26899
sS'short,sedation'
p26900
(F1
F0.00014334862385321102
I0
I1
I-1
tp26901
sS'and,gastric'
p26902
(F1
F0.00014334862385321102
I0
I1
I-1
tp26903
sS'studies,adjuvant'
p26904
(F1
F0.00014334862385321102
I1
I0
I1
tp26905
sS'and,could'
p26906
(F1
F0.00014334862385321102
I0
I1
I-1
tp26907
sS'mean,sd'
p26908
(F1
F0.00014334862385321102
I0
I1
I-1
tp26909
sS'blockers,concurrently'
p26910
(F1
F0.00014334862385321102
I0
I1
I-1
tp26911
sS'arthralgia,adverse'
p26912
(F1
F0.00014334862385321102
I1
I0
I1
tp26913
sS'avoid,the'
p26914
(F0.5
F0.00028669724770642203
I3
I1
I2
tp26915
sS'the,highest'
p26916
(F1
F0.00014334862385321102
I0
I1
I-1
tp26917
sS'with,heparin-induced'
p26918
(F1
F0.00014334862385321102
I0
I1
I-1
tp26919
sS'its,antidiuretic'
p26920
(F1
F0.00014334862385321102
I0
I1
I-1
tp26921
sS'enteric,coating'
p26922
(F1
F0.00014334862385321102
I1
I0
I1
tp26923
sS'was,potentiated'
p26924
(F1
F0.00014334862385321102
I0
I1
I-1
tp26925
sS'ergamisol,levamisole'
p26926
(F1
F0.00014334862385321102
I1
I0
I1
tp26927
sS'of,difluoro-2'
p26928
(F0
F0
I1
I1
I0
tp26929
sS'relationship,with'
p26930
(F1
F0.00014334862385321102
I1
I0
I1
tp26931
sS'with,isosorbide'
p26932
(F1
F0.00014334862385321102
I0
I1
I-1
tp26933
sS'if,signs'
p26934
(F1
F0.00014334862385321102
I1
I0
I1
tp26935
sS'possible,hypokalemic'
p26936
(F1
F0.00014334862385321102
I1
I0
I1
tp26937
sS'reactions,have'
p26938
(F1
F0.00028669724770642203
I2
I0
I2
tp26939
sS'objective,of'
p26940
(F1
F0.00014334862385321102
I0
I1
I-1
tp26941
sS'no,measurable'
p26942
(F1
F0.00014334862385321102
I0
I1
I-1
tp26943
sS'starting,a'
p26944
(F1
F0.00014334862385321102
I1
I0
I1
tp26945
sS'during,dosing'
p26946
(F1
F0.00014334862385321102
I1
I0
I1
tp26947
sS'and,ethanol'
p26948
(F1
F0.00014334862385321102
I1
I0
I1
tp26949
sS'the,displacing'
p26950
(F1
F0.00014334862385321102
I0
I1
I-1
tp26951
sS'tetracyclines,concomitant'
p26952
(F1
F0.00014334862385321102
I1
I0
I1
tp26953
sS'macrolide,azole'
p26954
(F1
F0.00014334862385321102
I1
I0
I1
tp26955
sS'a,lack'
p26956
(F1
F0.00014334862385321102
I0
I1
I-1
tp26957
sS'neutrophil,counts'
p26958
(F1
F0.00014334862385321102
I1
I0
I1
tp26959
sS'of,schizophrenia'
p26960
(F1
F0.00028669724770642203
I0
I2
I-2
tp26961
sS'of,schizophrenic'
p26962
(F0
F0
I1
I1
I0
tp26963
sS'patients,with'
p26964
(F0.083333333333333329
F0.0008600917431192661
I33
I39
I-6
tp26965
sS'may,present'
p26966
(F1
F0.00028669724770642203
I2
I0
I2
tp26967
sS'persist,for'
p26968
(F1
F0.00014334862385321102
I0
I1
I-1
tp26969
sS'brovana,doses'
p26970
(F1
F0.00014334862385321102
I0
I1
I-1
tp26971
sS'were,concomitantly'
p26972
(F0
F0
I2
I2
I0
tp26973
sS'suggested,may'
p26974
(F1
F0.00014334862385321102
I0
I1
I-1
tp26975
sS'g,kg'
p26976
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp26977
sS'psychoactive,drugs'
p26978
(F1
F0.00014334862385321102
I1
I0
I1
tp26979
sS'after,sudden'
p26980
(F1
F0.00014334862385321102
I1
I0
I1
tp26981
sS'mechanism,and'
p26982
(F1
F0.00014334862385321102
I1
I0
I1
tp26983
sS'might,decrease'
p26984
(F1
F0.00014334862385321102
I1
I0
I1
tp26985
sS'within,days'
p26986
(F1
F0.00028669724770642203
I2
I0
I2
tp26987
sS'chemotherapy,agents'
p26988
(F1
F0.00028669724770642203
I0
I2
I-2
tp26989
sS'with,beta'
p26990
(F0
F0
I1
I1
I0
tp26991
sS'agents,anesthetics'
p26992
(F1
F0.00014334862385321102
I1
I0
I1
tp26993
sS'presumably,because'
p26994
(F1
F0.00014334862385321102
I1
I0
I1
tp26995
sS'labelling,of'
p26996
(F1
F0.00014334862385321102
I0
I1
I-1
tp26997
sS'therefore,co-administration'
p26998
(F1
F0.00057339449541284407
I4
I0
I4
tp26999
sS'vitro,metabolism'
p27000
(F1
F0.00014334862385321102
I0
I1
I-1
tp27001
sS'an,association'
p27002
(F1
F0.00014334862385321102
I1
I0
I1
tp27003
sS'theoretical,basis'
p27004
(F1
F0.00028669724770642203
I2
I0
I2
tp27005
sS'to,eliminate'
p27006
(F1
F0.00014334862385321102
I1
I0
I1
tp27007
sS'and,anaprox'
p27008
(F1
F0.00014334862385321102
I0
I1
I-1
tp27009
sS'using,tricor'
p27010
(F1
F0.00014334862385321102
I1
I0
I1
tp27011
sS'motility,of'
p27012
(F1
F0.00014334862385321102
I1
I0
I1
tp27013
sS'otherwise,healthy'
p27014
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp27015
sS'and,every'
p27016
(F1
F0.00014334862385321102
I0
I1
I-1
tp27017
sS'glycosides,therapeutic'
p27018
(F1
F0.00014334862385321102
I0
I1
I-1
tp27019
sS'injury,should'
p27020
(F1
F0.00014334862385321102
I0
I1
I-1
tp27021
sS'the,immediate'
p27022
(F1
F0.00014334862385321102
I1
I0
I1
tp27023
sS'agents,for'
p27024
(F0
F0
I1
I1
I0
tp27025
sS'but,quickens'
p27026
(F1
F0.00014334862385321102
I1
I0
I1
tp27027
sS'motility,agents'
p27028
(F1
F0.00014334862385321102
I0
I1
I-1
tp27029
sS'involvement,labeling'
p27030
(F1
F0.00014334862385321102
I0
I1
I-1
tp27031
sS'related,may'
p27032
(F1
F0.00028669724770642203
I2
I0
I2
tp27033
sS'a,broad'
p27034
(F1
F0.00014334862385321102
I0
I1
I-1
tp27035
sS'avoid,impeding'
p27036
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27037
sS'after,a'
p27038
(F0.5
F0.0008600917431192661
I9
I3
I6
tp27039
sS'as,in'
p27040
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27041
sS'replacing,by'
p27042
(F1
F0.00014334862385321102
I1
I0
I1
tp27043
sS'or,deletion'
p27044
(F1
F0.00014334862385321102
I0
I1
I-1
tp27045
sS'the,prophylactic'
p27046
(F1
F0.00014334862385321102
I1
I0
I1
tp27047
sS'gravis,inflammatory'
p27048
(F1
F0.00014334862385321102
I1
I0
I1
tp27049
sS'stimulate,egf-'
p27050
(F1
F0.00014334862385321102
I1
I0
I1
tp27051
sS'blood,is'
p27052
(F1
F0.00014334862385321102
I1
I0
I1
tp27053
sS'whenever,a'
p27054
(F1
F0.00057339449541284407
I0
I4
I-4
tp27055
sS'nsaids,the'
p27056
(F1
F0.00014334862385321102
I1
I0
I1
tp27057
sS'day,preferably'
p27058
(F1
F0.00014334862385321102
I0
I1
I-1
tp27059
sS'enzymes,including'
p27060
(F1
F0.00014334862385321102
I0
I1
I-1
tp27061
sS'even,death'
p27062
(F1
F0.00014334862385321102
I0
I1
I-1
tp27063
sS'malabsorption,of'
p27064
(F1
F0.00014334862385321102
I1
I0
I1
tp27065
sS'sulfamethoxazole,concomitant'
p27066
(F1
F0.00014334862385321102
I0
I1
I-1
tp27067
sS'anticipated,if'
p27068
(F1
F0.00014334862385321102
I1
I0
I1
tp27069
sS'averaged,s'
p27070
(F1
F0.00014334862385321102
I1
I0
I1
tp27071
sS'induction,and'
p27072
(F1
F0.00014334862385321102
I1
I0
I1
tp27073
sS'one,gram'
p27074
(F1
F0.00014334862385321102
I1
I0
I1
tp27075
sS'apparent,total'
p27076
(F1
F0.00014334862385321102
I1
I0
I1
tp27077
sS'day,regimen'
p27078
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp27079
sS'complex,between'
p27080
(F1
F0.00014334862385321102
I1
I0
I1
tp27081
sS'they,respond'
p27082
(F1
F0.00014334862385321102
I0
I1
I-1
tp27083
sS'acute,angina'
p27084
(F1
F0.00014334862385321102
I0
I1
I-1
tp27085
sS'were,examined'
p27086
(F1
F0.00014334862385321102
I0
I1
I-1
tp27087
sS'risk,in'
p27088
(F1
F0.00014334862385321102
I1
I0
I1
tp27089
sS'drugs,administered'
p27090
(F1
F0.00014334862385321102
I0
I1
I-1
tp27091
sS'ionized,species'
p27092
(F1
F0.00028669724770642203
I2
I0
I2
tp27093
sS'clearance,is'
p27094
(F1
F0.00057339449541284407
I4
I0
I4
tp27095
sS'observation,is'
p27096
(F1
F0.00014334862385321102
I1
I0
I1
tp27097
sS'clearance,in'
p27098
(F1
F0.00043004587155963305
I3
I0
I3
tp27099
sS'not,impaired'
p27100
(F1
F0.00014334862385321102
I0
I1
I-1
tp27101
sS'john,s'
p27102
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27103
sS'atrophy,and'
p27104
(F1
F0.00014334862385321102
I0
I1
I-1
tp27105
sS'with,which'
p27106
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27107
sS'blocked,the'
p27108
(F1
F0.00028669724770642203
I2
I0
I2
tp27109
sS'category,x'
p27110
(F1
F0.00014334862385321102
I0
I1
I-1
tp27111
sS'anagrelide,demonstrates'
p27112
(F1
F0.00014334862385321102
I1
I0
I1
tp27113
sS'however,neither'
p27114
(F1
F0.00014334862385321102
I0
I1
I-1
tp27115
sS'shown,to'
p27116
(F0.51111111111111107
F0.0032970183486238534
I34
I11
I23
tp27117
sS'arthritis,n'
p27118
(F1
F0.00014334862385321102
I0
I1
I-1
tp27119
sS'administered,daily'
p27120
(F1
F0.00014334862385321102
I0
I1
I-1
tp27121
sS'receptors,mc'
p27122
(F1
F0.00014334862385321102
I0
I1
I-1
tp27123
sS'changing,the'
p27124
(F1
F0.00014334862385321102
I1
I0
I1
tp27125
sS'of,endoscopic'
p27126
(F1
F0.00014334862385321102
I0
I1
I-1
tp27127
sS'interferons,such'
p27128
(F1
F0.00014334862385321102
I0
I1
I-1
tp27129
sS'symbol,copying'
p27130
(F1
F0.00014334862385321102
I1
I0
I1
tp27131
sS'may,impair'
p27132
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27133
sS'in,metabolic'
p27134
(F1
F0.00014334862385321102
I1
I0
I1
tp27135
sS'slight,intrinsic'
p27136
(F1
F0.00014334862385321102
I1
I0
I1
tp27137
sS'injectable,transdermal'
p27138
(F1
F0.00028669724770642203
I2
I0
I2
tp27139
sS'ortho-novum,increased'
p27140
(F1
F0.00014334862385321102
I1
I0
I1
tp27141
sS'reported,cases'
p27142
(F1
F0.00014334862385321102
I0
I1
I-1
tp27143
sS'one,ng'
p27144
(F1
F0.00014334862385321102
I0
I1
I-1
tp27145
sS'chronic,weeks'
p27146
(F1
F0.00014334862385321102
I0
I1
I-1
tp27147
sS'among,the'
p27148
(F0
F0
I2
I2
I0
tp27149
sS'to,sinus'
p27150
(F1
F0.00014334862385321102
I1
I0
I1
tp27151
sS'eg,would'
p27152
(F1
F0.00014334862385321102
I1
I0
I1
tp27153
sS'amprenavir,and'
p27154
(F1
F0.00043004587155963305
I3
I0
I3
tp27155
sS'agent,which'
p27156
(F1
F0.00014334862385321102
I0
I1
I-1
tp27157
sS'occurred,in'
p27158
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp27159
sS'traditional,agents'
p27160
(F1
F0.00014334862385321102
I0
I1
I-1
tp27161
sS'the,efficacy'
p27162
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp27163
sS'intestinal,permeation'
p27164
(F1
F0.00028669724770642203
I0
I2
I-2
tp27165
sS'n,with'
p27166
(F1
F0.00014334862385321102
I0
I1
I-1
tp27167
sS'in,three'
p27168
(F1
F0.00043004587155963305
I0
I3
I-3
tp27169
sS'effects,are'
p27170
(F1
F0.00028669724770642203
I2
I0
I2
tp27171
sS'adenosine,dipyridamole'
p27172
(F1
F0.00014334862385321102
I1
I0
I1
tp27173
sS'bear,directly'
p27174
(F1
F0.00014334862385321102
I1
I0
I1
tp27175
sS'dipivoxil,or'
p27176
(F1
F0.00014334862385321102
I0
I1
I-1
tp27177
sS'male,and'
p27178
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp27179
sS'further,data'
p27180
(F1
F0.00014334862385321102
I0
I1
I-1
tp27181
sS'a,prolongation'
p27182
(F1
F0.00043004587155963305
I3
I0
I3
tp27183
sS'an,eight-fold'
p27184
(F1
F0.00028669724770642203
I2
I0
I2
tp27185
sS'hormonal,ortho-novum'
p27186
(F1
F0.00014334862385321102
I1
I0
I1
tp27187
sS'a,nonsteroidal'
p27188
(F0
F0
I1
I1
I0
tp27189
sS'although,may'
p27190
(F1
F0.00014334862385321102
I1
I0
I1
tp27191
sS'which,affect'
p27192
(F1
F0.00014334862385321102
I0
I1
I-1
tp27193
sS'taken,and'
p27194
(F1
F0.00014334862385321102
I1
I0
I1
tp27195
sS'and,butyrophenone'
p27196
(F1
F0.00014334862385321102
I1
I0
I1
tp27197
sS'significant,fluctuations'
p27198
(F1
F0.00014334862385321102
I1
I0
I1
tp27199
sS'cancidas,mg'
p27200
(F1
F0.00014334862385321102
I1
I0
I1
tp27201
sS'which,erbitux'
p27202
(F1
F0.00014334862385321102
I0
I1
I-1
tp27203
sS'therapies,including'
p27204
(F1
F0.00014334862385321102
I0
I1
I-1
tp27205
sS'local,including'
p27206
(F1
F0.00014334862385321102
I1
I0
I1
tp27207
sS'causing,renin'
p27208
(F1
F0.00028669724770642203
I2
I0
I2
tp27209
sS'control,blood'
p27210
(F0
F0
I1
I1
I0
tp27211
sS'other,chemotherapy'
p27212
(F1
F0.00014334862385321102
I0
I1
I-1
tp27213
sS'for,altering'
p27214
(F1
F0.00014334862385321102
I0
I1
I-1
tp27215
sS'phosphorylated,which'
p27216
(F1
F0.00014334862385321102
I1
I0
I1
tp27217
sS'whereas,it'
p27218
(F1
F0.00014334862385321102
I1
I0
I1
tp27219
sS'interaction,information'
p27220
(F1
F0.00014334862385321102
I0
I1
I-1
tp27221
sS'whereas,in'
p27222
(F1
F0.00014334862385321102
I0
I1
I-1
tp27223
sS'is,augmented'
p27224
(F1
F0.00028669724770642203
I2
I0
I2
tp27225
sS'on,bone'
p27226
(F1
F0.00028669724770642203
I0
I2
I-2
tp27227
sS'with,sprycel'
p27228
(F0
F0
I1
I1
I0
tp27229
sS'iron,salts'
p27230
(F1
F0.00014334862385321102
I1
I0
I1
tp27231
sS'acid,decrease'
p27232
(F1
F0.00014334862385321102
I1
I0
I1
tp27233
sS'observed,on'
p27234
(F1
F0.00014334862385321102
I1
I0
I1
tp27235
sS'contraceptive,based'
p27236
(F1
F0.00014334862385321102
I0
I1
I-1
tp27237
sS'increase,blood'
p27238
(F1
F0.00028669724770642203
I2
I0
I2
tp27239
sS'steady-state,auc'
p27240
(F1
F0.00057339449541284407
I4
I0
I4
tp27241
sS'diclofenac,administration'
p27242
(F1
F0.00014334862385321102
I0
I1
I-1
tp27243
sS'stimulation,and'
p27244
(F1
F0.00014334862385321102
I0
I1
I-1
tp27245
sS'levsin,is'
p27246
(F1
F0.00014334862385321102
I1
I0
I1
tp27247
sS'the,elevation'
p27248
(F1
F0.00014334862385321102
I1
I0
I1
tp27249
sS'potentially,may'
p27250
(F1
F0.00014334862385321102
I1
I0
I1
tp27251
sS'given,intraluminally'
p27252
(F1
F0.00014334862385321102
I0
I1
I-1
tp27253
sS'group,were'
p27254
(F1
F0.00014334862385321102
I1
I0
I1
tp27255
sS'with,copper'
p27256
(F1
F0.00014334862385321102
I0
I1
I-1
tp27257
sS'during,adjunctive'
p27258
(F1
F0.00014334862385321102
I1
I0
I1
tp27259
sS'sucralfate,metal'
p27260
(F1
F0.00014334862385321102
I0
I1
I-1
tp27261
sS'with,altered'
p27262
(F0
F0
I1
I1
I0
tp27263
sS'by,auc0-24hr'
p27264
(F0
F0
I1
I1
I0
tp27265
sS'of,microsomal'
p27266
(F0
F0
I1
I1
I0
tp27267
sS'agenerase,crixivan'
p27268
(F1
F0.00014334862385321102
I1
I0
I1
tp27269
sS'whose,absorption'
p27270
(F0
F0
I1
I1
I0
tp27271
sS'to,mac'
p27272
(F1
F0.00014334862385321102
I0
I1
I-1
tp27273
sS'facultative,and'
p27274
(F1
F0.00014334862385321102
I0
I1
I-1
tp27275
sS'following,subcutaneous'
p27276
(F1
F0.00014334862385321102
I0
I1
I-1
tp27277
sS'to,two'
p27278
(F1
F0.00028669724770642203
I2
I0
I2
tp27279
sS'kg,days'
p27280
(F1
F0.00014334862385321102
I0
I1
I-1
tp27281
sS'of,skin'
p27282
(F1
F0.00014334862385321102
I1
I0
I1
tp27283
sS'phenytoin,phenobarbital'
p27284
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27285
sS'to,may'
p27286
(F1
F0.00014334862385321102
I1
I0
I1
tp27287
sS'in,ovarian'
p27288
(F1
F0.00014334862385321102
I1
I0
I1
tp27289
sS'effect,with'
p27290
(F1
F0.00057339449541284407
I4
I0
I4
tp27291
sS'erythromycin,has'
p27292
(F1
F0.00043004587155963305
I3
I0
I3
tp27293
sS'be,checked'
p27294
(F1
F0.00014334862385321102
I1
I0
I1
tp27295
sS'aeruginosa,particularly'
p27296
(F1
F0.00014334862385321102
I0
I1
I-1
tp27297
sS'the,gastrointestinal'
p27298
(F1
F0.0008600917431192661
I6
I0
I6
tp27299
sS'auc,cmax'
p27300
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27301
sS'a,with'
p27302
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp27303
sS'methods,hydrocortisone'
p27304
(F1
F0.00014334862385321102
I0
I1
I-1
tp27305
sS'glucose,should'
p27306
(F1
F0.00014334862385321102
I1
I0
I1
tp27307
sS'measured,by'
p27308
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp27309
sS'mg,starlix'
p27310
(F1
F0.00014334862385321102
I0
I1
I-1
tp27311
sS'cyp2d6,and'
p27312
(F0
F0
I1
I1
I0
tp27313
sS'crossover,study'
p27314
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp27315
sS'methods,such'
p27316
(F1
F0.00014334862385321102
I0
I1
I-1
tp27317
sS'in,sub-therapeutic'
p27318
(F1
F0.00014334862385321102
I1
I0
I1
tp27319
sS'they,might'
p27320
(F1
F0.00014334862385321102
I1
I0
I1
tp27321
sS'inhibiting,may'
p27322
(F1
F0.00014334862385321102
I1
I0
I1
tp27323
sS'anion,exchange'
p27324
(F1
F0.00014334862385321102
I0
I1
I-1
tp27325
sS'adults,to'
p27326
(F1
F0.00014334862385321102
I0
I1
I-1
tp27327
sS'following,initiation'
p27328
(F1
F0.00028669724770642203
I2
I0
I2
tp27329
sS'blockers,although'
p27330
(F1
F0.00028669724770642203
I2
I0
I2
tp27331
sS'a,molecular'
p27332
(F1
F0.00014334862385321102
I1
I0
I1
tp27333
sS'acamprosate,does'
p27334
(F1
F0.00014334862385321102
I0
I1
I-1
tp27335
sS'clearance,with'
p27336
(F1
F0.00014334862385321102
I1
I0
I1
tp27337
sS'broad-spectrum,antibiotics-broad'
p27338
(F1
F0.00014334862385321102
I0
I1
I-1
tp27339
sS'also,significantly'
p27340
(F1
F0.00014334862385321102
I1
I0
I1
tp27341
sS'the,two'
p27342
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp27343
sS'prednisolone,sodium'
p27344
(F1
F0.00014334862385321102
I0
I1
I-1
tp27345
sS'variability,component'
p27346
(F1
F0.00014334862385321102
I1
I0
I1
tp27347
sS'alkaloid,while'
p27348
(F1
F0.00014334862385321102
I1
I0
I1
tp27349
sS'antidotal,properties'
p27350
(F1
F0.00014334862385321102
I1
I0
I1
tp27351
sS'structural,heart'
p27352
(F1
F0.00014334862385321102
I0
I1
I-1
tp27353
sS'medications,they'
p27354
(F1
F0.00014334862385321102
I0
I1
I-1
tp27355
sS'myobloc,and'
p27356
(F1
F0.00014334862385321102
I1
I0
I1
tp27357
sS'urobilin,due'
p27358
(F1
F0.00014334862385321102
I0
I1
I-1
tp27359
sS'or,some'
p27360
(F1
F0.00014334862385321102
I1
I0
I1
tp27361
sS'high,trileptal'
p27362
(F1
F0.00014334862385321102
I1
I0
I1
tp27363
sS'action,by'
p27364
(F1
F0.00014334862385321102
I1
I0
I1
tp27365
sS'abolished,both'
p27366
(F1
F0.00014334862385321102
I0
I1
I-1
tp27367
sS'from,patients'
p27368
(F1
F0.00014334862385321102
I0
I1
I-1
tp27369
sS'nine,otherwise'
p27370
(F1
F0.00014334862385321102
I0
I1
I-1
tp27371
sS'other,progestational'
p27372
(F1
F0.00014334862385321102
I0
I1
I-1
tp27373
sS'free,radical-mediated'
p27374
(F1
F0.00014334862385321102
I1
I0
I1
tp27375
sS'and,range'
p27376
(F1
F0.00014334862385321102
I1
I0
I1
tp27377
sS'with,significantly'
p27378
(F0
F0
I1
I1
I0
tp27379
sS'cardiac,abnormalities'
p27380
(F1
F0.00014334862385321102
I1
I0
I1
tp27381
sS'minimizes,this'
p27382
(F1
F0.00014334862385321102
I1
I0
I1
tp27383
sS'induce,metabolism'
p27384
(F1
F0.00014334862385321102
I1
I0
I1
tp27385
sS'focus,on'
p27386
(F1
F0.00014334862385321102
I0
I1
I-1
tp27387
sS'approximately,mean'
p27388
(F1
F0.00014334862385321102
I1
I0
I1
tp27389
sS'vitro,study'
p27390
(F1
F0.00014334862385321102
I1
I0
I1
tp27391
sS'as,triple'
p27392
(F1
F0.00014334862385321102
I0
I1
I-1
tp27393
sS'the,higher'
p27394
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27395
sS'of,concomitant'
p27396
(F0.17647058823529413
F0.00043004587155963305
I7
I10
I-3
tp27397
sS'the,united'
p27398
(F0
F0
I1
I1
I0
tp27399
sS'can,not'
p27400
(F1
F0.00014334862385321102
I1
I0
I1
tp27401
sS'significant,increase'
p27402
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp27403
sS'used,while'
p27404
(F1
F0.00014334862385321102
I0
I1
I-1
tp27405
sS'hypercholesterolemia,concomitant'
p27406
(F1
F0.00014334862385321102
I0
I1
I-1
tp27407
sS'with,fentanyl'
p27408
(F1
F0.00014334862385321102
I0
I1
I-1
tp27409
sS'nephrotoxic,myelotoxic'
p27410
(F1
F0.00014334862385321102
I1
I0
I1
tp27411
sS'comparisons,to'
p27412
(F1
F0.00014334862385321102
I0
I1
I-1
tp27413
sS'administered,within'
p27414
(F1
F0.00014334862385321102
I1
I0
I1
tp27415
sS'p-glycoprotein,substrate'
p27416
(F1
F0.00014334862385321102
I1
I0
I1
tp27417
sS'a,pure'
p27418
(F1
F0.00014334862385321102
I1
I0
I1
tp27419
sS'gastric,acid'
p27420
(F0
F0
I1
I1
I0
tp27421
sS'shown,on'
p27422
(F1
F0.00014334862385321102
I0
I1
I-1
tp27423
sS'preanesthetic,and'
p27424
(F1
F0.00014334862385321102
I0
I1
I-1
tp27425
sS'cardiovasculars,cardiac'
p27426
(F1
F0.00014334862385321102
I0
I1
I-1
tp27427
sS'subnormal,release'
p27428
(F1
F0.00014334862385321102
I0
I1
I-1
tp27429
sS'of,infections'
p27430
(F1
F0.00014334862385321102
I0
I1
I-1
tp27431
sS'the,herbal'
p27432
(F1
F0.00014334862385321102
I0
I1
I-1
tp27433
sS'pharmacokinetic,profile'
p27434
(F1
F0.00028669724770642203
I2
I0
I2
tp27435
sS'thus,careful'
p27436
(F1
F0.00014334862385321102
I1
I0
I1
tp27437
sS'lower,when'
p27438
(F1
F0.00014334862385321102
I1
I0
I1
tp27439
sS'ed50,of'
p27440
(F1
F0.00014334862385321102
I1
I0
I1
tp27441
sS'without,evidence'
p27442
(F1
F0.0011467889908256881
I0
I8
I-8
tp27443
sS'by,displacing'
p27444
(F1
F0.00014334862385321102
I1
I0
I1
tp27445
sS'cardiac,h2'
p27446
(F1
F0.00014334862385321102
I0
I1
I-1
tp27447
sS'obtained,after'
p27448
(F1
F0.00014334862385321102
I1
I0
I1
tp27449
sS'endoscopic,gastroduodenal'
p27450
(F1
F0.00014334862385321102
I0
I1
I-1
tp27451
sS'as,and'
p27452
(F0.33333333333333331
F0.0017201834862385322
I24
I12
I12
tp27453
sS'last,two'
p27454
(F1
F0.00014334862385321102
I0
I1
I-1
tp27455
sS'auc,were'
p27456
(F1
F0.00014334862385321102
I0
I1
I-1
tp27457
sS'and,micromol'
p27458
(F1
F0.00014334862385321102
I0
I1
I-1
tp27459
sS'cyp3a,may'
p27460
(F1
F0.00028669724770642203
I0
I2
I-2
tp27461
sS'kg,hours'
p27462
(F1
F0.00014334862385321102
I1
I0
I1
tp27463
sS'concurrently,with'
p27464
(F0.20000000000000001
F0.0010034403669724771
I21
I14
I7
tp27465
sS'enoxaparin,dosed'
p27466
(F1
F0.00014334862385321102
I0
I1
I-1
tp27467
sS'mg,kg'
p27468
(F0.047619047619047616
F0.00028669724770642203
I20
I22
I-2
tp27469
sS'copying,test'
p27470
(F1
F0.00014334862385321102
I1
I0
I1
tp27471
sS'seizure,control'
p27472
(F1
F0.00014334862385321102
I1
I0
I1
tp27473
sS'profile,of'
p27474
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp27475
sS'vitro,may'
p27476
(F1
F0.00014334862385321102
I1
I0
I1
tp27477
sS'half-life,or'
p27478
(F1
F0.00014334862385321102
I1
I0
I1
tp27479
sS'reexacerbation,of'
p27480
(F1
F0.00014334862385321102
I1
I0
I1
tp27481
sS'trials,however'
p27482
(F1
F0.00014334862385321102
I0
I1
I-1
tp27483
sS'profile,or'
p27484
(F1
F0.00014334862385321102
I0
I1
I-1
tp27485
sS'in,glycemia'
p27486
(F1
F0.00014334862385321102
I0
I1
I-1
tp27487
sS'other,vasoconstrictor'
p27488
(F1
F0.00014334862385321102
I1
I0
I1
tp27489
sS'half-life,of'
p27490
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp27491
sS'cyp3a4,isoform'
p27492
(F1
F0.00014334862385321102
I0
I1
I-1
tp27493
sS'high,fever'
p27494
(F1
F0.00014334862385321102
I1
I0
I1
tp27495
sS'therefore,serum'
p27496
(F1
F0.00028669724770642203
I0
I2
I-2
tp27497
sS'digoxin,studies'
p27498
(F1
F0.00028669724770642203
I0
I2
I-2
tp27499
sS'of,day-old'
p27500
(F1
F0.00014334862385321102
I1
I0
I1
tp27501
sS'not,report'
p27502
(F1
F0.00014334862385321102
I0
I1
I-1
tp27503
sS'mrna,level'
p27504
(F1
F0.00014334862385321102
I1
I0
I1
tp27505
sS'diuretic,natriuretic'
p27506
(F1
F0.00014334862385321102
I1
I0
I1
tp27507
sS'controlled,with'
p27508
(F1
F0.00014334862385321102
I1
I0
I1
tp27509
sS'reports,describe'
p27510
(F1
F0.00014334862385321102
I1
I0
I1
tp27511
sS'or,more'
p27512
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp27513
sS'as,monotherapy'
p27514
(F1
F0.00014334862385321102
I0
I1
I-1
tp27515
sS'with,cns'
p27516
(F1
F0.00028669724770642203
I2
I0
I2
tp27517
sS'on,dogs'
p27518
(F1
F0.00014334862385321102
I0
I1
I-1
tp27519
sS'inhibitors,simvastatin'
p27520
(F1
F0.00014334862385321102
I0
I1
I-1
tp27521
sS'coadministered,prescribers'
p27522
(F1
F0.00014334862385321102
I0
I1
I-1
tp27523
sS'in,myocardium'
p27524
(F1
F0.00014334862385321102
I0
I1
I-1
tp27525
sS'to,any'
p27526
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27527
sS'anafranil,with'
p27528
(F1
F0.00014334862385321102
I0
I1
I-1
tp27529
sS'infant,formula'
p27530
(F1
F0.00014334862385321102
I0
I1
I-1
tp27531
sS'embryocidal,effects'
p27532
(F1
F0.00014334862385321102
I0
I1
I-1
tp27533
sS'to,and'
p27534
(F0.27272727272727271
F0.00043004587155963305
I4
I7
I-3
tp27535
sS'enzymes,such'
p27536
(F1
F0.00014334862385321102
I1
I0
I1
tp27537
sS'lethargy,and'
p27538
(F1
F0.00028669724770642203
I2
I0
I2
tp27539
sS'certain,cyp450'
p27540
(F1
F0.00014334862385321102
I0
I1
I-1
tp27541
sS'cyp,inducers'
p27542
(F1
F0.00014334862385321102
I1
I0
I1
tp27543
sS'and,agonists'
p27544
(F1
F0.00014334862385321102
I0
I1
I-1
tp27545
sS'certain,tetracyclic'
p27546
(F1
F0.00014334862385321102
I0
I1
I-1
tp27547
sS'ca,channel'
p27548
(F1
F0.00014334862385321102
I0
I1
I-1
tp27549
sS'of,systemic'
p27550
(F1
F0.00028669724770642203
I2
I0
I2
tp27551
sS'and,individual'
p27552
(F1
F0.00014334862385321102
I1
I0
I1
tp27553
sS'sampling,were'
p27554
(F1
F0.00014334862385321102
I0
I1
I-1
tp27555
sS'oral,platelet'
p27556
(F1
F0.00014334862385321102
I0
I1
I-1
tp27557
sS'volunteers,no'
p27558
(F1
F0.00028669724770642203
I0
I2
I-2
tp27559
sS'hydrochloride,concomitantly'
p27560
(F1
F0.00014334862385321102
I1
I0
I1
tp27561
sS'vasoconstrictor,can'
p27562
(F1
F0.00014334862385321102
I1
I0
I1
tp27563
sS'antithrombotics,aspirin'
p27564
(F1
F0.00014334862385321102
I0
I1
I-1
tp27565
sS'your,condition'
p27566
(F1
F0.00014334862385321102
I0
I1
I-1
tp27567
sS'probenecid,interferes'
p27568
(F1
F0.00014334862385321102
I1
I0
I1
tp27569
sS'daily,with'
p27570
(F0
F0
I1
I1
I0
tp27571
sS'insp,induced'
p27572
(F0
F0
I1
I1
I0
tp27573
sS'amounts,of'
p27574
(F1
F0.00014334862385321102
I0
I1
I-1
tp27575
sS'steady-state,concentrations'
p27576
(F0
F0
I1
I1
I0
tp27577
sS'furosemide,in'
p27578
(F1
F0.00014334862385321102
I0
I1
I-1
tp27579
sS'acid,were'
p27580
(F1
F0.00028669724770642203
I0
I2
I-2
tp27581
sS'ie,increased'
p27582
(F1
F0.00028669724770642203
I2
I0
I2
tp27583
sS'properties,may'
p27584
(F1
F0.00028669724770642203
I2
I0
I2
tp27585
sS'all,strains'
p27586
(F1
F0.00014334862385321102
I0
I1
I-1
tp27587
sS'activity,was'
p27588
(F1
F0.00014334862385321102
I0
I1
I-1
tp27589
sS'wear,off'
p27590
(F1
F0.00014334862385321102
I0
I1
I-1
tp27591
sS'aortic,rings'
p27592
(F1
F0.00028669724770642203
I2
I0
I2
tp27593
sS'evaluated,but'
p27594
(F1
F0.00043004587155963305
I3
I0
I3
tp27595
sS'mouth,and'
p27596
(F1
F0.00028669724770642203
I2
I0
I2
tp27597
sS'also,ineffective'
p27598
(F1
F0.00014334862385321102
I0
I1
I-1
tp27599
sS'effectiveness,when'
p27600
(F1
F0.00014334862385321102
I0
I1
I-1
tp27601
sS'conduction,disturbance'
p27602
(F1
F0.00014334862385321102
I1
I0
I1
tp27603
sS'auc,and'
p27604
(F0.33333333333333331
F0.0015768348623853212
I22
I11
I11
tp27605
sS'weight,every'
p27606
(F1
F0.00014334862385321102
I0
I1
I-1
tp27607
sS'similar,association'
p27608
(F1
F0.00028669724770642203
I0
I2
I-2
tp27609
sS'are,analgesic'
p27610
(F1
F0.00014334862385321102
I0
I1
I-1
tp27611
sS'methotrexate-related,toxicity'
p27612
(F1
F0.00028669724770642203
I2
I0
I2
tp27613
sS'physicians,are'
p27614
(F1
F0.00028669724770642203
I2
I0
I2
tp27615
sS'clonazepam,on'
p27616
(F1
F0.00014334862385321102
I0
I1
I-1
tp27617
sS'if,higher'
p27618
(F1
F0.00014334862385321102
I0
I1
I-1
tp27619
sS'reactions,to'
p27620
(F0
F0
I2
I2
I0
tp27621
sS'oz,has'
p27622
(F1
F0.00014334862385321102
I0
I1
I-1
tp27623
sS'and,zdv'
p27624
(F1
F0.00014334862385321102
I0
I1
I-1
tp27625
sS'adults,on'
p27626
(F1
F0.00014334862385321102
I1
I0
I1
tp27627
sS'supine,systolic'
p27628
(F1
F0.00014334862385321102
I1
I0
I1
tp27629
sS'depth,of'
p27630
(F0
F0
I1
I1
I0
tp27631
sS'given,fu'
p27632
(F1
F0.00014334862385321102
I0
I1
I-1
tp27633
sS'complication,of'
p27634
(F1
F0.00014334862385321102
I0
I1
I-1
tp27635
sS'without,any'
p27636
(F1
F0.00043004587155963305
I0
I3
I-3
tp27637
sS'oral,overload'
p27638
(F1
F0.00014334862385321102
I0
I1
I-1
tp27639
sS'natriuretic,and'
p27640
(F1
F0.0011467889908256881
I8
I0
I8
tp27641
sS'potential,inhibitor'
p27642
(F1
F0.00014334862385321102
I1
I0
I1
tp27643
sS'without,and'
p27644
(F1
F0.00028669724770642203
I0
I2
I-2
tp27645
sS'mc,does'
p27646
(F1
F0.00014334862385321102
I0
I1
I-1
tp27647
sS'and,preparations'
p27648
(F1
F0.00014334862385321102
I1
I0
I1
tp27649
sS'be,introduced'
p27650
(F1
F0.00014334862385321102
I1
I0
I1
tp27651
sS'chronic,hepatitis'
p27652
(F1
F0.00014334862385321102
I0
I1
I-1
tp27653
sS'deficiency,due'
p27654
(F1
F0.00014334862385321102
I0
I1
I-1
tp27655
sS'because,plasma'
p27656
(F1
F0.00014334862385321102
I1
I0
I1
tp27657
sS'other,metabolized'
p27658
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp27659
sS'cardiac,effects'
p27660
(F1
F0.00014334862385321102
I1
I0
I1
tp27661
sS'd,by'
p27662
(F1
F0.00043004587155963305
I3
I0
I3
tp27663
sS'placebo-controlled,clinical'
p27664
(F1
F0.00014334862385321102
I0
I1
I-1
tp27665
sS'two,hundred'
p27666
(F1
F0.00014334862385321102
I0
I1
I-1
tp27667
sS'dysfunction,associated'
p27668
(F1
F0.00014334862385321102
I0
I1
I-1
tp27669
sS'increase,their'
p27670
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27671
sS'admini,stered'
p27672
(F1
F0.00014334862385321102
I1
I0
I1
tp27673
sS'with,central'
p27674
(F0.5
F0.00028669724770642203
I3
I1
I2
tp27675
sS'one,mg'
p27676
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27677
sS'remicade,used'
p27678
(F1
F0.00014334862385321102
I1
I0
I1
tp27679
sS'or,side'
p27680
(F1
F0.00014334862385321102
I0
I1
I-1
tp27681
sS'as,increasing'
p27682
(F1
F0.00014334862385321102
I0
I1
I-1
tp27683
sS'on,insp'
p27684
(F1
F0.00014334862385321102
I0
I1
I-1
tp27685
sS'laboratory,test'
p27686
(F0.8571428571428571
F0.0017201834862385322
I1
I13
I-12
tp27687
sS'brovana,at'
p27688
(F1
F0.00014334862385321102
I0
I1
I-1
tp27689
sS'capable,of'
p27690
(F1
F0.00014334862385321102
I1
I0
I1
tp27691
sS'brovana,as'
p27692
(F1
F0.00014334862385321102
I1
I0
I1
tp27693
sS'studies,when'
p27694
(F1
F0.00014334862385321102
I0
I1
I-1
tp27695
sS'on,stable'
p27696
(F1
F0.00028669724770642203
I0
I2
I-2
tp27697
sS'of,tubular'
p27698
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27699
sS'skills,or'
p27700
(F1
F0.00014334862385321102
I0
I1
I-1
tp27701
sS'was,decreased'
p27702
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp27703
sS'disease,in'
p27704
(F1
F0.00028669724770642203
I0
I2
I-2
tp27705
sS'from,existing'
p27706
(F1
F0.00014334862385321102
I0
I1
I-1
tp27707
sS'poorly,tolerated'
p27708
(F1
F0.00014334862385321102
I1
I0
I1
tp27709
sS'taking,tysabri'
p27710
(F1
F0.00014334862385321102
I0
I1
I-1
tp27711
sS'of,cholino-'
p27712
(F1
F0.00014334862385321102
I0
I1
I-1
tp27713
sS'sandimmune--on,hepatic'
p27714
(F1
F0.00014334862385321102
I0
I1
I-1
tp27715
sS'videx,chewable'
p27716
(F1
F0.0008600917431192661
I6
I0
I6
tp27717
sS'cream,cream'
p27718
(F1
F0.00014334862385321102
I0
I1
I-1
tp27719
sS'the,may'
p27720
(F0.5
F0.00057339449541284407
I6
I2
I4
tp27721
sS'one,with'
p27722
(F1
F0.00014334862385321102
I0
I1
I-1
tp27723
sS'changes,northern'
p27724
(F1
F0.00014334862385321102
I0
I1
I-1
tp27725
sS'the,mao'
p27726
(F1
F0.00014334862385321102
I1
I0
I1
tp27727
sS'lapatinib,undergoes'
p27728
(F1
F0.00014334862385321102
I0
I1
I-1
tp27729
sS'thyroid,products'
p27730
(F1
F0.00014334862385321102
I0
I1
I-1
tp27731
sS'last,intravenous'
p27732
(F1
F0.00014334862385321102
I1
I0
I1
tp27733
sS'be,evaluated'
p27734
(F1
F0.00014334862385321102
I1
I0
I1
tp27735
sS'labeling,of'
p27736
(F1
F0.00014334862385321102
I0
I1
I-1
tp27737
sS'for,preservation'
p27738
(F1
F0.00014334862385321102
I0
I1
I-1
tp27739
sS'other,folic'
p27740
(F1
F0.00014334862385321102
I1
I0
I1
tp27741
sS'possible,and'
p27742
(F1
F0.00014334862385321102
I1
I0
I1
tp27743
sS'medications,motion'
p27744
(F1
F0.00014334862385321102
I0
I1
I-1
tp27745
sS'should,take'
p27746
(F1
F0.00014334862385321102
I1
I0
I1
tp27747
sS'lipitor,atromid-s'
p27748
(F1
F0.00014334862385321102
I1
I0
I1
tp27749
sS'thus,patients'
p27750
(F1
F0.00014334862385321102
I1
I0
I1
tp27751
sS'dryness,of'
p27752
(F1
F0.00014334862385321102
I1
I0
I1
tp27753
sS'potentially,associated'
p27754
(F1
F0.00014334862385321102
I1
I0
I1
tp27755
sS'conjugation,at'
p27756
(F1
F0.00014334862385321102
I0
I1
I-1
tp27757
sS'in,lipid'
p27758
(F1
F0.00014334862385321102
I1
I0
I1
tp27759
sS'enzyme,supplements'
p27760
(F1
F0.00014334862385321102
I0
I1
I-1
tp27761
sS'amiodarone,should'
p27762
(F1
F0.00014334862385321102
I0
I1
I-1
tp27763
sS'are,illustrated'
p27764
(F1
F0.00014334862385321102
I0
I1
I-1
tp27765
sS'potent,inducer'
p27766
(F0.5
F0.00028669724770642203
I3
I1
I2
tp27767
sS'following,medications'
p27768
(F0
F0
I1
I1
I0
tp27769
sS'overactive,pain'
p27770
(F1
F0.00014334862385321102
I0
I1
I-1
tp27771
sS'and,adjustment'
p27772
(F1
F0.00071674311926605509
I5
I0
I5
tp27773
sS'is,co-administered'
p27774
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp27775
sS'mice,selectively'
p27776
(F1
F0.00014334862385321102
I0
I1
I-1
tp27777
sS'ethanolysis,reaction'
p27778
(F1
F0.00014334862385321102
I1
I0
I1
tp27779
sS'dosing,of'
p27780
(F0
F0
I3
I3
I0
tp27781
sS'without,coadministered'
p27782
(F1
F0.00014334862385321102
I0
I1
I-1
tp27783
sS'human,in'
p27784
(F0
F0
I1
I1
I0
tp27785
sS'but,statistically'
p27786
(F1
F0.00014334862385321102
I1
I0
I1
tp27787
sS'day,groups'
p27788
(F1
F0.00014334862385321102
I1
I0
I1
tp27789
sS'a,selective'
p27790
(F1
F0.00014334862385321102
I1
I0
I1
tp27791
sS'ph,may'
p27792
(F1
F0.00014334862385321102
I0
I1
I-1
tp27793
sS'exemestane,is'
p27794
(F1
F0.00014334862385321102
I0
I1
I-1
tp27795
sS'after,their'
p27796
(F1
F0.00014334862385321102
I0
I1
I-1
tp27797
sS'coagulation,have'
p27798
(F1
F0.00014334862385321102
I1
I0
I1
tp27799
sS'or,pcp'
p27800
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27801
sS'adjusted,upward'
p27802
(F1
F0.00014334862385321102
I1
I0
I1
tp27803
sS'daily,inhalation'
p27804
(F1
F0.00014334862385321102
I1
I0
I1
tp27805
sS'principal,given'
p27806
(F1
F0.00014334862385321102
I0
I1
I-1
tp27807
sS'via,organic'
p27808
(F1
F0.00014334862385321102
I1
I0
I1
tp27809
sS'taking,another'
p27810
(F1
F0.00014334862385321102
I1
I0
I1
tp27811
sS'the,end'
p27812
(F1
F0.00014334862385321102
I0
I1
I-1
tp27813
sS'with,various'
p27814
(F1
F0.00014334862385321102
I1
I0
I1
tp27815
sS'no,human'
p27816
(F1
F0.00028669724770642203
I0
I2
I-2
tp27817
sS'taking,acarbose'
p27818
(F0
F0
I1
I1
I0
tp27819
sS'of,congestive'
p27820
(F1
F0.00014334862385321102
I1
I0
I1
tp27821
sS'hyperthermia,rigidity'
p27822
(F1
F0.00014334862385321102
I1
I0
I1
tp27823
sS'a,six-day'
p27824
(F1
F0.00014334862385321102
I1
I0
I1
tp27825
sS'measured,from'
p27826
(F1
F0.00014334862385321102
I0
I1
I-1
tp27827
sS'starlix,and'
p27828
(F1
F0.00028669724770642203
I2
I0
I2
tp27829
sS'is,catalyzed'
p27830
(F1
F0.00028669724770642203
I0
I2
I-2
tp27831
sS'modulates,in'
p27832
(F1
F0.00014334862385321102
I1
I0
I1
tp27833
sS'blood,pressure'
p27834
(F0.53846153846153844
F0.0020068807339449542
I20
I6
I14
tp27835
sS'thus,should'
p27836
(F1
F0.00028669724770642203
I2
I0
I2
tp27837
sS'compared,with'
p27838
(F0.066666666666666666
F0.00014334862385321102
I7
I8
I-1
tp27839
sS'this,neurotoxic'
p27840
(F1
F0.00014334862385321102
I1
I0
I1
tp27841
sS'its,capacity'
p27842
(F1
F0.00014334862385321102
I1
I0
I1
tp27843
sS'stabilized,on'
p27844
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp27845
sS'week,controlled'
p27846
(F1
F0.00014334862385321102
I0
I1
I-1
tp27847
sS'increased,with'
p27848
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27849
sS'decrease,plasma'
p27850
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp27851
sS'drinking,during'
p27852
(F1
F0.00014334862385321102
I1
I0
I1
tp27853
sS'a,guide'
p27854
(F1
F0.00014334862385321102
I1
I0
I1
tp27855
sS'and,minutes'
p27856
(F1
F0.00014334862385321102
I0
I1
I-1
tp27857
sS'drugs,sporadic'
p27858
(F1
F0.00014334862385321102
I1
I0
I1
tp27859
sS'lean,and'
p27860
(F1
F0.00043004587155963305
I0
I3
I-3
tp27861
sS'any,route'
p27862
(F1
F0.00014334862385321102
I1
I0
I1
tp27863
sS'events,when'
p27864
(F1
F0.00028669724770642203
I0
I2
I-2
tp27865
sS'clarithromycin,telithromycin'
p27866
(F1
F0.00014334862385321102
I0
I1
I-1
tp27867
sS'of,mean'
p27868
(F1
F0.00014334862385321102
I1
I0
I1
tp27869
sS'significant,respiratory'
p27870
(F1
F0.00014334862385321102
I1
I0
I1
tp27871
sS'day,microg'
p27872
(F1
F0.00014334862385321102
I0
I1
I-1
tp27873
sS'arava,with'
p27874
(F1
F0.00014334862385321102
I1
I0
I1
tp27875
sS'reduced,tysabri'
p27876
(F1
F0.00014334862385321102
I1
I0
I1
tp27877
sS'protein,binding'
p27878
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp27879
sS'control,supraventricular'
p27880
(F1
F0.00014334862385321102
I1
I0
I1
tp27881
sS'was,partially'
p27882
(F1
F0.00014334862385321102
I1
I0
I1
tp27883
sS'eight,hiv-infected'
p27884
(F0
F0
I1
I1
I0
tp27885
sS'the,compatibility'
p27886
(F1
F0.00014334862385321102
I0
I1
I-1
tp27887
sS'organic,cationic'
p27888
(F1
F0.00014334862385321102
I1
I0
I1
tp27889
sS'potassium,levels'
p27890
(F1
F0.00014334862385321102
I1
I0
I1
tp27891
sS'd6,they'
p27892
(F1
F0.00071674311926605509
I0
I5
I-5
tp27893
sS'methylpyrazole,seen'
p27894
(F1
F0.00014334862385321102
I1
I0
I1
tp27895
sS'reduced,accordingly'
p27896
(F1
F0.00014334862385321102
I1
I0
I1
tp27897
sS'the,involvement'
p27898
(F0
F0
I1
I1
I0
tp27899
sS'are,reported'
p27900
(F1
F0.00028669724770642203
I2
I0
I2
tp27901
sS'patients,concurrently'
p27902
(F1
F0.00014334862385321102
I1
I0
I1
tp27903
sS'by,inhibiting'
p27904
(F1
F0.00057339449541284407
I4
I0
I4
tp27905
sS'from,bovine'
p27906
(F1
F0.00014334862385321102
I0
I1
I-1
tp27907
sS'induction,of'
p27908
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp27909
sS'or,verapamil'
p27910
(F1
F0.00014334862385321102
I1
I0
I1
tp27911
sS'stimulants,and'
p27912
(F1
F0.00014334862385321102
I1
I0
I1
tp27913
sS'nevertheless,plasma'
p27914
(F1
F0.00014334862385321102
I0
I1
I-1
tp27915
sS'to,discriminate'
p27916
(F1
F0.00014334862385321102
I0
I1
I-1
tp27917
sS'electrolyte,abnormalities'
p27918
(F1
F0.00014334862385321102
I1
I0
I1
tp27919
sS'have,erroneously'
p27920
(F1
F0.00014334862385321102
I1
I0
I1
tp27921
sS'iiia4,inhibitor'
p27922
(F1
F0.00014334862385321102
I1
I0
I1
tp27923
sS'of,fe'
p27924
(F0
F0
I1
I1
I0
tp27925
sS'digoxin,the'
p27926
(F1
F0.00014334862385321102
I0
I1
I-1
tp27927
sS'including,complete'
p27928
(F1
F0.00014334862385321102
I0
I1
I-1
tp27929
sS'and,agents'
p27930
(F0.5
F0.00057339449541284407
I6
I2
I4
tp27931
sS'vardenafil,with'
p27932
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27933
sS'weeks,in'
p27934
(F1
F0.00014334862385321102
I1
I0
I1
tp27935
sS'subjects,the'
p27936
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27937
sS'attacks,during'
p27938
(F1
F0.00014334862385321102
I0
I1
I-1
tp27939
sS'or,from'
p27940
(F0
F0
I1
I1
I0
tp27941
sS'and,had'
p27942
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp27943
sS'or,hypotension'
p27944
(F1
F0.00028669724770642203
I2
I0
I2
tp27945
sS'interactions,with'
p27946
(F0.14285714285714285
F0.00043004587155963305
I9
I12
I-3
tp27947
sS'invirase,kaletra'
p27948
(F1
F0.00014334862385321102
I1
I0
I1
tp27949
sS'one,to'
p27950
(F1
F0.00014334862385321102
I0
I1
I-1
tp27951
sS'inactivate,the'
p27952
(F1
F0.00014334862385321102
I1
I0
I1
tp27953
sS'methods,healthy'
p27954
(F1
F0.00014334862385321102
I0
I1
I-1
tp27955
sS'determinations,of'
p27956
(F1
F0.00014334862385321102
I1
I0
I1
tp27957
sS'further,enhanced'
p27958
(F1
F0.00014334862385321102
I0
I1
I-1
tp27959
sS'not,all'
p27960
(F1
F0.00028669724770642203
I0
I2
I-2
tp27961
sS'agents,insulin'
p27962
(F1
F0.00014334862385321102
I0
I1
I-1
tp27963
sS'increasing,blood'
p27964
(F1
F0.00014334862385321102
I1
I0
I1
tp27965
sS'frequently,enough'
p27966
(F1
F0.00014334862385321102
I1
I0
I1
tp27967
sS'statistically,or'
p27968
(F1
F0.00014334862385321102
I0
I1
I-1
tp27969
sS'influence,through'
p27970
(F1
F0.00014334862385321102
I0
I1
I-1
tp27971
sS'chloramphenicol,has'
p27972
(F1
F0.00014334862385321102
I1
I0
I1
tp27973
sS'ermbt,after'
p27974
(F1
F0.00014334862385321102
I0
I1
I-1
tp27975
sS'antigen,psa'
p27976
(F1
F0.00014334862385321102
I0
I1
I-1
tp27977
sS'literature,between'
p27978
(F1
F0.00014334862385321102
I0
I1
I-1
tp27979
sS'to,substantially'
p27980
(F1
F0.00014334862385321102
I0
I1
I-1
tp27981
sS'of,preliminary'
p27982
(F1
F0.00014334862385321102
I1
I0
I1
tp27983
sS'auc,exhibited'
p27984
(F1
F0.00014334862385321102
I0
I1
I-1
tp27985
sS'nitric,oxide'
p27986
(F1
F0.00014334862385321102
I1
I0
I1
tp27987
sS'additive,coadministration'
p27988
(F1
F0.00014334862385321102
I1
I0
I1
tp27989
sS'proved,to'
p27990
(F1
F0.00014334862385321102
I0
I1
I-1
tp27991
sS'indicate,a'
p27992
(F1
F0.00028669724770642203
I2
I0
I2
tp27993
sS'exploited,in'
p27994
(F1
F0.00014334862385321102
I0
I1
I-1
tp27995
sS'and,oral'
p27996
(F0.36842105263157893
F0.0010034403669724771
I13
I6
I7
tp27997
sS'ketoconazole,itraconazole'
p27998
(F1
F0.00014334862385321102
I0
I1
I-1
tp27999
sS'approximately,decrease'
p28000
(F1
F0.00028669724770642203
I2
I0
I2
tp28001
sS'anticoagulants,blood'
p28002
(F1
F0.00014334862385321102
I0
I1
I-1
tp28003
sS'increases,ranging'
p28004
(F1
F0.00028669724770642203
I0
I2
I-2
tp28005
sS'as,nonsteroidal'
p28006
(F0
F0
I1
I1
I0
tp28007
sS'and,enhance'
p28008
(F1
F0.00028669724770642203
I2
I0
I2
tp28009
sS'cns-depressant,action'
p28010
(F1
F0.00014334862385321102
I1
I0
I1
tp28011
sS'the,iop'
p28012
(F1
F0.00014334862385321102
I1
I0
I1
tp28013
sS'ca,i'
p28014
(F1
F0.00014334862385321102
I1
I0
I1
tp28015
sS'that,reduce'
p28016
(F0
F0
I1
I1
I0
tp28017
sS'shock,in'
p28018
(F1
F0.00014334862385321102
I0
I1
I-1
tp28019
sS'assessed,in'
p28020
(F1
F0.00043004587155963305
I0
I3
I-3
tp28021
sS'c,interval'
p28022
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28023
sS'group,resulted'
p28024
(F1
F0.00014334862385321102
I1
I0
I1
tp28025
sS'modifies,metabolism'
p28026
(F1
F0.00014334862385321102
I1
I0
I1
tp28027
sS'atg,alg'
p28028
(F1
F0.00014334862385321102
I0
I1
I-1
tp28029
sS'normal,metabolizers'
p28030
(F1
F0.00014334862385321102
I0
I1
I-1
tp28031
sS'considerable,caution'
p28032
(F1
F0.00014334862385321102
I1
I0
I1
tp28033
sS'interaction,observed'
p28034
(F1
F0.00014334862385321102
I1
I0
I1
tp28035
sS'not,increase'
p28036
(F1
F0.00057339449541284407
I0
I4
I-4
tp28037
sS'alprazolam,metabolism'
p28038
(F1
F0.00014334862385321102
I0
I1
I-1
tp28039
sS'ingested,being'
p28040
(F1
F0.00014334862385321102
I1
I0
I1
tp28041
sS'heparins,effect'
p28042
(F1
F0.00014334862385321102
I0
I1
I-1
tp28043
sS'systemic,concentrations'
p28044
(F1
F0.00014334862385321102
I1
I0
I1
tp28045
sS'with,thiazide'
p28046
(F1
F0.00014334862385321102
I1
I0
I1
tp28047
sS'should,refer'
p28048
(F1
F0.00014334862385321102
I0
I1
I-1
tp28049
sS'there,appears'
p28050
(F1
F0.00014334862385321102
I0
I1
I-1
tp28051
sS'or,slightly'
p28052
(F1
F0.00014334862385321102
I1
I0
I1
tp28053
sS'depression,hypotension'
p28054
(F1
F0.00014334862385321102
I1
I0
I1
tp28055
sS'oral,an'
p28056
(F0
F0
I1
I1
I0
tp28057
sS'the,anticholinesterase'
p28058
(F1
F0.00014334862385321102
I1
I0
I1
tp28059
sS'to,during'
p28060
(F1
F0.00014334862385321102
I1
I0
I1
tp28061
sS'observed,carefully'
p28062
(F1
F0.00057339449541284407
I4
I0
I4
tp28063
sS'when,itraconazole'
p28064
(F1
F0.00043004587155963305
I3
I0
I3
tp28065
sS'oral,poc'
p28066
(F1
F0.00014334862385321102
I0
I1
I-1
tp28067
sS'd6,may'
p28068
(F1
F0.0008600917431192661
I0
I6
I-6
tp28069
sS'welchol,decreased'
p28070
(F1
F0.00014334862385321102
I1
I0
I1
tp28071
sS'also,additive'
p28072
(F1
F0.00014334862385321102
I1
I0
I1
tp28073
sS'in,time'
p28074
(F1
F0.00014334862385321102
I1
I0
I1
tp28075
sS'hyperplasia,bph'
p28076
(F1
F0.00014334862385321102
I0
I1
I-1
tp28077
sS'minutes,post'
p28078
(F1
F0.00014334862385321102
I0
I1
I-1
tp28079
sS'including,with'
p28080
(F1
F0.00028669724770642203
I2
I0
I2
tp28081
sS'using,or'
p28082
(F1
F0.00014334862385321102
I1
I0
I1
tp28083
sS'tagamet,mg'
p28084
(F1
F0.00014334862385321102
I1
I0
I1
tp28085
sS'blockers,cardiac'
p28086
(F1
F0.00028669724770642203
I0
I2
I-2
tp28087
sS'a,second'
p28088
(F1
F0.00028669724770642203
I0
I2
I-2
tp28089
sS'block,is'
p28090
(F1
F0.00014334862385321102
I1
I0
I1
tp28091
sS'these,is'
p28092
(F0
F0
I1
I1
I0
tp28093
sS'highly,potent'
p28094
(F1
F0.00014334862385321102
I1
I0
I1
tp28095
sS'is,concurrently'
p28096
(F1
F0.00014334862385321102
I0
I1
I-1
tp28097
sS'separate,single'
p28098
(F1
F0.00014334862385321102
I0
I1
I-1
tp28099
sS'other,published'
p28100
(F1
F0.00014334862385321102
I1
I0
I1
tp28101
sS'returned,to'
p28102
(F0
F0
I1
I1
I0
tp28103
sS'these,in'
p28104
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp28105
sS'a4,cyp'
p28106
(F1
F0.00014334862385321102
I1
I0
I1
tp28107
sS'and,ethinyl'
p28108
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp28109
sS'and,total'
p28110
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28111
sS'clinical,importance'
p28112
(F1
F0.00014334862385321102
I1
I0
I1
tp28113
sS'mucosal,accumulation'
p28114
(F1
F0.00014334862385321102
I0
I1
I-1
tp28115
sS'increased,sedation'
p28116
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28117
sS'to,interact'
p28118
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp28119
sS'precedex,with'
p28120
(F1
F0.00014334862385321102
I1
I0
I1
tp28121
sS'astemizole,and'
p28122
(F1
F0.00014334862385321102
I0
I1
I-1
tp28123
sS'under,treatment'
p28124
(F1
F0.00014334862385321102
I1
I0
I1
tp28125
sS'altered,hypo-prothrombinemic'
p28126
(F1
F0.00014334862385321102
I0
I1
I-1
tp28127
sS'substrate,the'
p28128
(F1
F0.00014334862385321102
I1
I0
I1
tp28129
sS'given,later'
p28130
(F1
F0.00014334862385321102
I1
I0
I1
tp28131
sS'return,toward'
p28132
(F1
F0.00014334862385321102
I0
I1
I-1
tp28133
sS'co-treatment,with'
p28134
(F1
F0.00014334862385321102
I1
I0
I1
tp28135
sS'with,increases'
p28136
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp28137
sS'harmonic,mean'
p28138
(F1
F0.00014334862385321102
I0
I1
I-1
tp28139
sS'calcium-blocking,agents'
p28140
(F1
F0.00014334862385321102
I0
I1
I-1
tp28141
sS'with,evidence'
p28142
(F1
F0.00014334862385321102
I0
I1
I-1
tp28143
sS'may,potentiate'
p28144
(F0.8666666666666667
F0.0037270642201834864
I28
I2
I26
tp28145
sS'concurrent,use'
p28146
(F0.4358974358974359
F0.0024369266055045873
I28
I11
I17
tp28147
sS'inhibit,p450'
p28148
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp28149
sS'deaths,due'
p28150
(F1
F0.00014334862385321102
I0
I1
I-1
tp28151
sS'auc,to'
p28152
(F1
F0.00043004587155963305
I3
I0
I3
tp28153
sS'no,study'
p28154
(F1
F0.00014334862385321102
I1
I0
I1
tp28155
sS'the,geometric'
p28156
(F0
F0
I1
I1
I0
tp28157
sS'be,exacerbated'
p28158
(F1
F0.00028669724770642203
I2
I0
I2
tp28159
sS'lodine,capsules'
p28160
(F1
F0.00014334862385321102
I1
I0
I1
tp28161
sS'inhibitors,prolong'
p28162
(F1
F0.00071674311926605509
I5
I0
I5
tp28163
sS'was,longer'
p28164
(F1
F0.00014334862385321102
I1
I0
I1
tp28165
sS'occurred,with'
p28166
(F1
F0.00014334862385321102
I1
I0
I1
tp28167
sS'desethylzaleplon,formed'
p28168
(F1
F0.00014334862385321102
I0
I1
I-1
tp28169
sS'interferes,with'
p28170
(F1
F0.0010034403669724771
I7
I0
I7
tp28171
sS'tablets,containing'
p28172
(F1
F0.00014334862385321102
I0
I1
I-1
tp28173
sS'transcriptase,inhibitors'
p28174
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28175
sS'diminish,oral'
p28176
(F1
F0.00028669724770642203
I2
I0
I2
tp28177
sS'tracleer,is'
p28178
(F1
F0.00014334862385321102
I1
I0
I1
tp28179
sS'hcl,no'
p28180
(F1
F0.00014334862385321102
I1
I0
I1
tp28181
sS'general,and'
p28182
(F1
F0.00028669724770642203
I0
I2
I-2
tp28183
sS'require,a'
p28184
(F1
F0.00028669724770642203
I2
I0
I2
tp28185
sS'pupil,constriction'
p28186
(F1
F0.00014334862385321102
I0
I1
I-1
tp28187
sS'or,h1-blocking'
p28188
(F1
F0.00014334862385321102
I1
I0
I1
tp28189
sS'include,hypotension'
p28190
(F1
F0.00014334862385321102
I1
I0
I1
tp28191
sS'revia,may'
p28192
(F1
F0.00014334862385321102
I1
I0
I1
tp28193
sS'recovered,from'
p28194
(F1
F0.00014334862385321102
I1
I0
I1
tp28195
sS'targretin,capsules'
p28196
(F1
F0.00028669724770642203
I2
I0
I2
tp28197
sS'reported,predominantly'
p28198
(F1
F0.00014334862385321102
I1
I0
I1
tp28199
sS'chlorpromazine,blocks'
p28200
(F1
F0.00028669724770642203
I2
I0
I2
tp28201
sS'decreased,slightly'
p28202
(F1
F0.00014334862385321102
I1
I0
I1
tp28203
sS'and,left'
p28204
(F1
F0.00014334862385321102
I1
I0
I1
tp28205
sS'and,related'
p28206
(F0
F0
I3
I3
I0
tp28207
sS'in,gastric'
p28208
(F1
F0.00014334862385321102
I1
I0
I1
tp28209
sS'methionine,may'
p28210
(F1
F0.00014334862385321102
I1
I0
I1
tp28211
sS'individuals,treated'
p28212
(F1
F0.00014334862385321102
I1
I0
I1
tp28213
sS'human,immediately'
p28214
(F1
F0.00014334862385321102
I0
I1
I-1
tp28215
sS'microm,inhibited'
p28216
(F1
F0.00014334862385321102
I1
I0
I1
tp28217
sS'of,prostate'
p28218
(F1
F0.00014334862385321102
I1
I0
I1
tp28219
sS'most,ssris'
p28220
(F1
F0.00014334862385321102
I0
I1
I-1
tp28221
sS'or,given'
p28222
(F1
F0.00014334862385321102
I0
I1
I-1
tp28223
sS'sulfacetamide,preparations'
p28224
(F1
F0.00014334862385321102
I1
I0
I1
tp28225
sS'mean,distribution'
p28226
(F1
F0.00014334862385321102
I0
I1
I-1
tp28227
sS'digoxin,digoxin'
p28228
(F1
F0.00014334862385321102
I1
I0
I1
tp28229
sS'phenytoin,population'
p28230
(F1
F0.00014334862385321102
I1
I0
I1
tp28231
sS'for,possible'
p28232
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp28233
sS'may,exhibit'
p28234
(F1
F0.00043004587155963305
I3
I0
I3
tp28235
sS'common,distilled'
p28236
(F1
F0.00014334862385321102
I0
I1
I-1
tp28237
sS'antagonists,after'
p28238
(F1
F0.00014334862385321102
I1
I0
I1
tp28239
sS'between,treatments'
p28240
(F1
F0.00014334862385321102
I0
I1
I-1
tp28241
sS'can,reduce'
p28242
(F1
F0.0021502293577981653
I15
I0
I15
tp28243
sS'the,co-administered'
p28244
(F1
F0.00014334862385321102
I0
I1
I-1
tp28245
sS'total,were'
p28246
(F1
F0.00014334862385321102
I0
I1
I-1
tp28247
sS'vardenafil,when'
p28248
(F1
F0.00014334862385321102
I0
I1
I-1
tp28249
sS'the,steroidal'
p28250
(F1
F0.00014334862385321102
I1
I0
I1
tp28251
sS'dopamine,antagonists'
p28252
(F1
F0.00014334862385321102
I1
I0
I1
tp28253
sS'mg,decreased'
p28254
(F1
F0.00014334862385321102
I1
I0
I1
tp28255
sS'have,demonstrated'
p28256
(F0
F0
I5
I5
I0
tp28257
sS'hormonalmethods,of'
p28258
(F1
F0.00014334862385321102
I1
I0
I1
tp28259
sS'patients,were'
p28260
(F1
F0.00057339449541284407
I0
I4
I-4
tp28261
sS'been,reported'
p28262
(F0.7290322580645161
F0.016198394495412844
I134
I21
I113
tp28263
sS'in,interactions'
p28264
(F1
F0.00014334862385321102
I1
I0
I1
tp28265
sS'formal,studies'
p28266
(F1
F0.00014334862385321102
I0
I1
I-1
tp28267
sS'vascular,resistance'
p28268
(F1
F0.00014334862385321102
I1
I0
I1
tp28269
sS'dl,submitted'
p28270
(F1
F0.00014334862385321102
I0
I1
I-1
tp28271
sS'however,has'
p28272
(F1
F0.00014334862385321102
I1
I0
I1
tp28273
sS'pressure,response'
p28274
(F1
F0.00014334862385321102
I0
I1
I-1
tp28275
sS'pulmonary,wedge'
p28276
(F1
F0.00014334862385321102
I1
I0
I1
tp28277
sS'possible,interactions'
p28278
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28279
sS'many,selective'
p28280
(F1
F0.00028669724770642203
I0
I2
I-2
tp28281
sS'these,categories'
p28282
(F1
F0.00014334862385321102
I1
I0
I1
tp28283
sS'nimbex,may'
p28284
(F1
F0.00014334862385321102
I1
I0
I1
tp28285
sS'action,independent'
p28286
(F1
F0.00014334862385321102
I0
I1
I-1
tp28287
sS'increased,fold'
p28288
(F1
F0.00028669724770642203
I2
I0
I2
tp28289
sS'preparations,containing'
p28290
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28291
sS'dynacirc,an'
p28292
(F1
F0.00014334862385321102
I0
I1
I-1
tp28293
sS'are,unknown'
p28294
(F1
F0.00028669724770642203
I2
I0
I2
tp28295
sS'and,st'
p28296
(F1
F0.00014334862385321102
I0
I1
I-1
tp28297
sS'in,females'
p28298
(F1
F0.00014334862385321102
I1
I0
I1
tp28299
sS'other,phe-nothiazines'
p28300
(F1
F0.00014334862385321102
I0
I1
I-1
tp28301
sS'enzyme-inducer,did'
p28302
(F1
F0.00014334862385321102
I1
I0
I1
tp28303
sS'therapeutic,monitoring'
p28304
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28305
sS'antiretroviral,regimens'
p28306
(F1
F0.00014334862385321102
I0
I1
I-1
tp28307
sS'decrease,elimination'
p28308
(F1
F0.00014334862385321102
I1
I0
I1
tp28309
sS'sildenafil,dose'
p28310
(F1
F0.00014334862385321102
I1
I0
I1
tp28311
sS'receiving,careful'
p28312
(F1
F0.00014334862385321102
I1
I0
I1
tp28313
sS'hypokalemic,effect'
p28314
(F1
F0.00014334862385321102
I1
I0
I1
tp28315
sS'though,less'
p28316
(F1
F0.00028669724770642203
I0
I2
I-2
tp28317
sS'and,dose'
p28318
(F1
F0.00028669724770642203
I2
I0
I2
tp28319
sS'be,adjusted'
p28320
(F0.5
F0.00028669724770642203
I3
I1
I2
tp28321
sS'prolongation,and'
p28322
(F1
F0.00043004587155963305
I0
I3
I-3
tp28323
sS'would,worsen'
p28324
(F1
F0.00014334862385321102
I1
I0
I1
tp28325
sS'tc,suspension'
p28326
(F1
F0.00028669724770642203
I2
I0
I2
tp28327
sS'prevent,folic'
p28328
(F1
F0.00014334862385321102
I0
I1
I-1
tp28329
sS'blood-pressure,and'
p28330
(F1
F0.00014334862385321102
I1
I0
I1
tp28331
sS'monthly,comparison'
p28332
(F1
F0.00014334862385321102
I0
I1
I-1
tp28333
sS'metabolic,responses'
p28334
(F1
F0.00014334862385321102
I0
I1
I-1
tp28335
sS'treatment,resulted'
p28336
(F1
F0.00014334862385321102
I1
I0
I1
tp28337
sS'as,directed'
p28338
(F1
F0.00014334862385321102
I0
I1
I-1
tp28339
sS'concomitant,administration'
p28340
(F0.45333333333333331
F0.0097477064220183492
I109
I41
I68
tp28341
sS'loop,potassium-sparing'
p28342
(F1
F0.00028669724770642203
I2
I0
I2
tp28343
sS'however,due'
p28344
(F1
F0.00014334862385321102
I1
I0
I1
tp28345
sS'lomefloxacin,is'
p28346
(F1
F0.00014334862385321102
I0
I1
I-1
tp28347
sS'haldol,has'
p28348
(F1
F0.00014334862385321102
I0
I1
I-1
tp28349
sS'a,mild'
p28350
(F0
F0
I1
I1
I0
tp28351
sS'instituted,may'
p28352
(F1
F0.00043004587155963305
I3
I0
I3
tp28353
sS'are,inhibitors'
p28354
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28355
sS'this,formal'
p28356
(F1
F0.00014334862385321102
I0
I1
I-1
tp28357
sS'and,interact'
p28358
(F1
F0.00014334862385321102
I1
I0
I1
tp28359
sS'of,increasing'
p28360
(F1
F0.00014334862385321102
I1
I0
I1
tp28361
sS'rapid,equilibration'
p28362
(F1
F0.00014334862385321102
I0
I1
I-1
tp28363
sS'or,embryocidal'
p28364
(F1
F0.00014334862385321102
I0
I1
I-1
tp28365
sS'when,tested'
p28366
(F1
F0.00014334862385321102
I0
I1
I-1
tp28367
sS'discontinued,or'
p28368
(F1
F0.00014334862385321102
I1
I0
I1
tp28369
sS'nsaids,may'
p28370
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp28371
sS'hydroxy-1,on'
p28372
(F1
F0.00014334862385321102
I1
I0
I1
tp28373
sS'as,long'
p28374
(F1
F0.00014334862385321102
I1
I0
I1
tp28375
sS'vitro,was'
p28376
(F1
F0.00014334862385321102
I0
I1
I-1
tp28377
sS'in,lowered'
p28378
(F0
F0
I1
I1
I0
tp28379
sS'thus,smaller'
p28380
(F1
F0.00014334862385321102
I1
I0
I1
tp28381
sS'of,crixivan'
p28382
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp28383
sS'time,for'
p28384
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28385
sS'metabolized,mainly'
p28386
(F1
F0.00028669724770642203
I0
I2
I-2
tp28387
sS'aluminum,hydroxide-'
p28388
(F1
F0.00014334862385321102
I0
I1
I-1
tp28389
sS'been,observed'
p28390
(F0.066666666666666666
F0.00014334862385321102
I8
I7
I1
tp28391
sS'n1,while'
p28392
(F1
F0.00014334862385321102
I1
I0
I1
tp28393
sS'or,altered'
p28394
(F1
F0.00014334862385321102
I0
I1
I-1
tp28395
sS'indicated,by'
p28396
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28397
sS'such,the'
p28398
(F1
F0.00014334862385321102
I0
I1
I-1
tp28399
sS'for,eight'
p28400
(F1
F0.00014334862385321102
I1
I0
I1
tp28401
sS'trinitrate,isosorbide'
p28402
(F1
F0.00014334862385321102
I0
I1
I-1
tp28403
sS'exjade,should'
p28404
(F1
F0.00014334862385321102
I1
I0
I1
tp28405
sS'agonists,has'
p28406
(F1
F0.00014334862385321102
I0
I1
I-1
tp28407
sS'although,a'
p28408
(F1
F0.00043004587155963305
I3
I0
I3
tp28409
sS'although,c'
p28410
(F1
F0.00014334862385321102
I0
I1
I-1
tp28411
sS'h,s'
p28412
(F1
F0.00014334862385321102
I1
I0
I1
tp28413
sS'autonomic,instability'
p28414
(F1
F0.00014334862385321102
I1
I0
I1
tp28415
sS'systemic,clearance'
p28416
(F1
F0.00014334862385321102
I1
I0
I1
tp28417
sS'h,e'
p28418
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp28419
sS'far,greater'
p28420
(F1
F0.00028669724770642203
I0
I2
I-2
tp28421
sS'cns,effects'
p28422
(F1
F0.00057339449541284407
I4
I0
I4
tp28423
sS'psychoses,to'
p28424
(F1
F0.00028669724770642203
I0
I2
I-2
tp28425
sS'subjects,did'
p28426
(F1
F0.00014334862385321102
I0
I1
I-1
tp28427
sS'weight,w'
p28428
(F1
F0.00014334862385321102
I1
I0
I1
tp28429
sS'peak,serum'
p28430
(F1
F0.00028669724770642203
I2
I0
I2
tp28431
sS'the,genetically'
p28432
(F1
F0.00014334862385321102
I0
I1
I-1
tp28433
sS'nuclear,matrix'
p28434
(F1
F0.00014334862385321102
I1
I0
I1
tp28435
sS'are,encouraged'
p28436
(F1
F0.00014334862385321102
I0
I1
I-1
tp28437
sS'benazepril,like'
p28438
(F1
F0.00014334862385321102
I1
I0
I1
tp28439
sS'as,used'
p28440
(F1
F0.00014334862385321102
I1
I0
I1
tp28441
sS'cyclosporin,after'
p28442
(F1
F0.00014334862385321102
I1
I0
I1
tp28443
sS'inhibitors,beta'
p28444
(F1
F0.00014334862385321102
I0
I1
I-1
tp28445
sS'thioxanthene,and'
p28446
(F1
F0.00014334862385321102
I1
I0
I1
tp28447
sS'or,due'
p28448
(F1
F0.00028669724770642203
I0
I2
I-2
tp28449
sS'sporadic,cases'
p28450
(F1
F0.00014334862385321102
I1
I0
I1
tp28451
sS'switching,from'
p28452
(F1
F0.00057339449541284407
I4
I0
I4
tp28453
sS'analyses,indicate'
p28454
(F0.5
F0.00028669724770642203
I3
I1
I2
tp28455
sS'on,reports'
p28456
(F1
F0.00028669724770642203
I2
I0
I2
tp28457
sS'respectively,have'
p28458
(F1
F0.00014334862385321102
I0
I1
I-1
tp28459
sS'enterohepatic,circulation'
p28460
(F1
F0.00014334862385321102
I1
I0
I1
tp28461
sS'and,it'
p28462
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp28463
sS'of,already'
p28464
(F1
F0.00014334862385321102
I1
I0
I1
tp28465
sS'and,iv'
p28466
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp28467
sS'use,of'
p28468
(F0.38547486033519551
F0.0098910550458715593
I124
I55
I69
tp28469
sS'and,is'
p28470
(F0.76923076923076927
F0.0028669724770642203
I23
I3
I20
tp28471
sS'hypertension,in'
p28472
(F1
F0.00028669724770642203
I2
I0
I2
tp28473
sS'cyp3a4,and'
p28474
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp28475
sS'and,if'
p28476
(F0
F0
I1
I1
I0
tp28477
sS'the,aim'
p28478
(F1
F0.00028669724770642203
I0
I2
I-2
tp28479
sS'tubular,secretion'
p28480
(F0.5
F0.0011467889908256881
I12
I4
I8
tp28481
sS'and,in'
p28482
(F0.094339622641509441
F0.00071674311926605509
I29
I24
I5
tp28483
sS'and,ii'
p28484
(F1
F0.00014334862385321102
I0
I1
I-1
tp28485
sS'intensify,the'
p28486
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp28487
sS'given,after'
p28488
(F0
F0
I1
I1
I0
tp28489
sS'respect,of'
p28490
(F1
F0.00014334862385321102
I0
I1
I-1
tp28491
sS'such,medications'
p28492
(F1
F0.00014334862385321102
I1
I0
I1
tp28493
sS'symptoms,and'
p28494
(F1
F0.00014334862385321102
I0
I1
I-1
tp28495
sS'ponstel,and'
p28496
(F1
F0.00014334862385321102
I1
I0
I1
tp28497
sS'benzodiazepine,class'
p28498
(F1
F0.00014334862385321102
I1
I0
I1
tp28499
sS'herbs,such'
p28500
(F1
F0.00014334862385321102
I1
I0
I1
tp28501
sS'hypotension,av'
p28502
(F1
F0.00014334862385321102
I1
I0
I1
tp28503
sS'taking,tricyclic'
p28504
(F1
F0.00014334862385321102
I1
I0
I1
tp28505
sS'relaxants,may'
p28506
(F1
F0.00014334862385321102
I1
I0
I1
tp28507
sS'such,that'
p28508
(F1
F0.00028669724770642203
I2
I0
I2
tp28509
sS'produce,malabsorption'
p28510
(F1
F0.00014334862385321102
I1
I0
I1
tp28511
sS'received,among'
p28512
(F1
F0.00014334862385321102
I0
I1
I-1
tp28513
sS'modulation,of'
p28514
(F0
F0
I1
I1
I0
tp28515
sS'of,apoptosis'
p28516
(F0
F0
I1
I1
I0
tp28517
sS'reports,have'
p28518
(F1
F0.00043004587155963305
I3
I0
I3
tp28519
sS'known,to'
p28520
(F0.3125
F0.0014334862385321102
I11
I21
I-10
tp28521
sS'oral,absorption'
p28522
(F1
F0.00043004587155963305
I3
I0
I3
tp28523
sS'exercised,because'
p28524
(F1
F0.00014334862385321102
I1
I0
I1
tp28525
sS'esmolol,hcl'
p28526
(F1
F0.00014334862385321102
I0
I1
I-1
tp28527
sS'cross-reactivity,of'
p28528
(F1
F0.00014334862385321102
I1
I0
I1
tp28529
sS'mg,reduced'
p28530
(F1
F0.00014334862385321102
I1
I0
I1
tp28531
sS'of,copegus'
p28532
(F1
F0.00014334862385321102
I1
I0
I1
tp28533
sS'had,an'
p28534
(F0
F0
I1
I1
I0
tp28535
sS'phenergan,mellaril'
p28536
(F1
F0.00014334862385321102
I0
I1
I-1
tp28537
sS'had,liver'
p28538
(F1
F0.00014334862385321102
I0
I1
I-1
tp28539
sS'initiating,and'
p28540
(F1
F0.00014334862385321102
I1
I0
I1
tp28541
sS'was,superior'
p28542
(F1
F0.00014334862385321102
I0
I1
I-1
tp28543
sS'palliates,deficiencies'
p28544
(F1
F0.00014334862385321102
I0
I1
I-1
tp28545
sS'working,properly'
p28546
(F1
F0.00014334862385321102
I0
I1
I-1
tp28547
sS'than,when'
p28548
(F0.75
F0.0008600917431192661
I7
I1
I6
tp28549
sS'arava,and'
p28550
(F1
F0.00014334862385321102
I1
I0
I1
tp28551
sS'n-desmethyldiazepam,there'
p28552
(F1
F0.00014334862385321102
I1
I0
I1
tp28553
sS'corneal,lesions'
p28554
(F1
F0.00014334862385321102
I1
I0
I1
tp28555
sS'concentrations,dosage'
p28556
(F1
F0.00014334862385321102
I1
I0
I1
tp28557
sS'avoid,them'
p28558
(F1
F0.00014334862385321102
I0
I1
I-1
tp28559
sS'previously,stable'
p28560
(F1
F0.00028669724770642203
I2
I0
I2
tp28561
sS'when,concomitant'
p28562
(F1
F0.00057339449541284407
I4
I0
I4
tp28563
sS'and,molecular'
p28564
(F1
F0.00014334862385321102
I0
I1
I-1
tp28565
sS'substitutes,containing'
p28566
(F1
F0.00014334862385321102
I0
I1
I-1
tp28567
sS'mixed,with'
p28568
(F1
F0.00057339449541284407
I0
I4
I-4
tp28569
sS'minimized,or'
p28570
(F1
F0.00014334862385321102
I1
I0
I1
tp28571
sS'investigated,using'
p28572
(F1
F0.00014334862385321102
I1
I0
I1
tp28573
sS'on,dosing'
p28574
(F1
F0.00014334862385321102
I0
I1
I-1
tp28575
sS'with,transdermal'
p28576
(F1
F0.00014334862385321102
I1
I0
I1
tp28577
sS'anti-,inflammatory'
p28578
(F1
F0.00014334862385321102
I1
I0
I1
tp28579
sS'corticosteroids,concomitant'
p28580
(F1
F0.00014334862385321102
I1
I0
I1
tp28581
sS'l-lysine,may'
p28582
(F1
F0.00014334862385321102
I1
I0
I1
tp28583
sS'as,factor'
p28584
(F1
F0.00014334862385321102
I0
I1
I-1
tp28585
sS'not,in'
p28586
(F0.5
F0.00028669724770642203
I3
I1
I2
tp28587
sS'concomitantly,in'
p28588
(F1
F0.00014334862385321102
I1
I0
I1
tp28589
sS'rebound,in'
p28590
(F1
F0.00014334862385321102
I1
I0
I1
tp28591
sS'induces,the'
p28592
(F1
F0.00014334862385321102
I0
I1
I-1
tp28593
sS'cyp4a9,and'
p28594
(F1
F0.00014334862385321102
I0
I1
I-1
tp28595
sS'd,agonists'
p28596
(F1
F0.00014334862385321102
I1
I0
I1
tp28597
sS'the,terms'
p28598
(F1
F0.00014334862385321102
I0
I1
I-1
tp28599
sS'or,within'
p28600
(F1
F0.00057339449541284407
I4
I0
I4
tp28601
sS'fortovase,and'
p28602
(F1
F0.00014334862385321102
I0
I1
I-1
tp28603
sS'reaching,a'
p28604
(F1
F0.00014334862385321102
I0
I1
I-1
tp28605
sS'injectables,are'
p28606
(F1
F0.00014334862385321102
I0
I1
I-1
tp28607
sS'choline,arthropan'
p28608
(F1
F0.00014334862385321102
I1
I0
I1
tp28609
sS'duration,but'
p28610
(F1
F0.00014334862385321102
I1
I0
I1
tp28611
sS'characterize,the'
p28612
(F1
F0.00014334862385321102
I0
I1
I-1
tp28613
sS'and,heparin'
p28614
(F1
F0.00014334862385321102
I1
I0
I1
tp28615
sS'or,increasing'
p28616
(F1
F0.00071674311926605509
I5
I0
I5
tp28617
sS'than,changes'
p28618
(F1
F0.00014334862385321102
I0
I1
I-1
tp28619
sS'comparative,data'
p28620
(F1
F0.00028669724770642203
I0
I2
I-2
tp28621
sS'affect,idv'
p28622
(F1
F0.00014334862385321102
I0
I1
I-1
tp28623
sS'and,area'
p28624
(F0
F0
I1
I1
I0
tp28625
sS'triclofos,sodium'
p28626
(F1
F0.00014334862385321102
I1
I0
I1
tp28627
sS'the,predominant'
p28628
(F1
F0.00014334862385321102
I0
I1
I-1
tp28629
sS'accordingly,and'
p28630
(F1
F0.00014334862385321102
I1
I0
I1
tp28631
sS'given,alone'
p28632
(F1
F0.00014334862385321102
I0
I1
I-1
tp28633
sS'it,was'
p28634
(F0
F0
I7
I7
I0
tp28635
sS'nonlethal,and'
p28636
(F1
F0.00014334862385321102
I0
I1
I-1
tp28637
sS'users,particularly'
p28638
(F1
F0.00014334862385321102
I1
I0
I1
tp28639
sS'epoxide,reductase'
p28640
(F1
F0.00014334862385321102
I0
I1
I-1
tp28641
sS'be,cautious'
p28642
(F1
F0.00028669724770642203
I2
I0
I2
tp28643
sS'a,three-'
p28644
(F1
F0.00014334862385321102
I0
I1
I-1
tp28645
sS'day,did'
p28646
(F1
F0.00014334862385321102
I0
I1
I-1
tp28647
sS'the,selective'
p28648
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp28649
sS'take,by'
p28650
(F1
F0.00014334862385321102
I1
I0
I1
tp28651
sS'physiologic,activity'
p28652
(F1
F0.00014334862385321102
I1
I0
I1
tp28653
sS'volume,depletion'
p28654
(F1
F0.00014334862385321102
I1
I0
I1
tp28655
sS'an,containing'
p28656
(F1
F0.00014334862385321102
I1
I0
I1
tp28657
sS'moderate,cyp3a4'
p28658
(F1
F0.00014334862385321102
I1
I0
I1
tp28659
sS'state,vioxx'
p28660
(F1
F0.00014334862385321102
I0
I1
I-1
tp28661
sS'same,degree'
p28662
(F1
F0.00014334862385321102
I0
I1
I-1
tp28663
sS'time,within'
p28664
(F1
F0.00014334862385321102
I1
I0
I1
tp28665
sS'coreg,is'
p28666
(F1
F0.00028669724770642203
I2
I0
I2
tp28667
sS'latter,agents'
p28668
(F1
F0.00014334862385321102
I1
I0
I1
tp28669
sS'agent,orally'
p28670
(F1
F0.00014334862385321102
I1
I0
I1
tp28671
sS'the,clinically'
p28672
(F1
F0.00014334862385321102
I1
I0
I1
tp28673
sS'with,oral'
p28674
(F0.47368421052631576
F0.0012901376146788992
I14
I5
I9
tp28675
sS'with,non-steroidal'
p28676
(F1
F0.00014334862385321102
I1
I0
I1
tp28677
sS'cytochrome,p-'
p28678
(F1
F0.00014334862385321102
I0
I1
I-1
tp28679
sS'of,iiia4'
p28680
(F1
F0.00014334862385321102
I1
I0
I1
tp28681
sS'usedas,the'
p28682
(F1
F0.00014334862385321102
I1
I0
I1
tp28683
sS'p-450iie1,in'
p28684
(F1
F0.00014334862385321102
I1
I0
I1
tp28685
sS'or,used'
p28686
(F1
F0.00014334862385321102
I0
I1
I-1
tp28687
sS'crossover,clinical'
p28688
(F1
F0.00014334862385321102
I0
I1
I-1
tp28689
sS'any,reduction'
p28690
(F1
F0.00014334862385321102
I1
I0
I1
tp28691
sS'reverse,triiodothyronine'
p28692
(F1
F0.00014334862385321102
I0
I1
I-1
tp28693
sS'is,required'
p28694
(F0.5
F0.00028669724770642203
I3
I1
I2
tp28695
sS'the,vitamin'
p28696
(F1
F0.00043004587155963305
I0
I3
I-3
tp28697
sS'treatment,improves'
p28698
(F1
F0.00014334862385321102
I0
I1
I-1
tp28699
sS'is,significantly'
p28700
(F0
F0
I1
I1
I0
tp28701
sS'ratio,r'
p28702
(F1
F0.00014334862385321102
I0
I1
I-1
tp28703
sS'marrow,megakaryocytes'
p28704
(F1
F0.00014334862385321102
I0
I1
I-1
tp28705
sS'about,to'
p28706
(F1
F0.00014334862385321102
I1
I0
I1
tp28707
sS'hour,apart'
p28708
(F1
F0.00014334862385321102
I1
I0
I1
tp28709
sS'developing,peripheral'
p28710
(F1
F0.00014334862385321102
I1
I0
I1
tp28711
sS'ca,and'
p28712
(F1
F0.00014334862385321102
I1
I0
I1
tp28713
sS'water,pill'
p28714
(F1
F0.00014334862385321102
I0
I1
I-1
tp28715
sS'dispersible,tablet'
p28716
(F1
F0.00014334862385321102
I1
I0
I1
tp28717
sS'offered,by'
p28718
(F1
F0.00014334862385321102
I0
I1
I-1
tp28719
sS'including,ketorolac'
p28720
(F1
F0.00014334862385321102
I0
I1
I-1
tp28721
sS'because,have'
p28722
(F1
F0.00014334862385321102
I1
I0
I1
tp28723
sS'by,high-performance'
p28724
(F1
F0.00014334862385321102
I0
I1
I-1
tp28725
sS'studied,the'
p28726
(F1
F0.00014334862385321102
I1
I0
I1
tp28727
sS'of,non-steroidal'
p28728
(F1
F0.00014334862385321102
I1
I0
I1
tp28729
sS'transient,delirium'
p28730
(F1
F0.00014334862385321102
I1
I0
I1
tp28731
sS'and,tnf'
p28732
(F0
F0
I1
I1
I0
tp28733
sS'intensified,electrolyte'
p28734
(F1
F0.00028669724770642203
I0
I2
I-2
tp28735
sS'uncomplicated,urinary'
p28736
(F1
F0.00014334862385321102
I0
I1
I-1
tp28737
sS'compliance,especially'
p28738
(F1
F0.00014334862385321102
I0
I1
I-1
tp28739
sS'their,vasospastic'
p28740
(F1
F0.00014334862385321102
I1
I0
I1
tp28741
sS'href,frova_od'
p28742
(F1
F0.00014334862385321102
I1
I0
I1
tp28743
sS'each,of'
p28744
(F1
F0.00014334862385321102
I0
I1
I-1
tp28745
sS'who,begin'
p28746
(F1
F0.00014334862385321102
I1
I0
I1
tp28747
sS'have,negative'
p28748
(F0
F0
I1
I1
I0
tp28749
sS'could,cause'
p28750
(F0.5
F0.00028669724770642203
I3
I1
I2
tp28751
sS'of,antifibrinolytic'
p28752
(F1
F0.00014334862385321102
I0
I1
I-1
tp28753
sS'their,similar'
p28754
(F1
F0.00014334862385321102
I1
I0
I1
tp28755
sS'taken,with'
p28756
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp28757
sS'with,vioxx'
p28758
(F1
F0.00028669724770642203
I2
I0
I2
tp28759
sS'tablets,was'
p28760
(F1
F0.00014334862385321102
I0
I1
I-1
tp28761
sS'selective,serotonin'
p28762
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp28763
sS'occurred,following'
p28764
(F1
F0.00014334862385321102
I1
I0
I1
tp28765
sS'tissue,damage'
p28766
(F1
F0.00014334862385321102
I1
I0
I1
tp28767
sS'bleeding,complications'
p28768
(F1
F0.00028669724770642203
I0
I2
I-2
tp28769
sS'reduce,both'
p28770
(F1
F0.00014334862385321102
I1
I0
I1
tp28771
sS'of,marked'
p28772
(F1
F0.00014334862385321102
I1
I0
I1
tp28773
sS'sertraline,neutralized'
p28774
(F1
F0.00014334862385321102
I0
I1
I-1
tp28775
sS'in,cardiovascular'
p28776
(F1
F0.00014334862385321102
I0
I1
I-1
tp28777
sS'improves,quality'
p28778
(F1
F0.00014334862385321102
I0
I1
I-1
tp28779
sS'clinical,signs'
p28780
(F1
F0.00014334862385321102
I1
I0
I1
tp28781
sS'history,of'
p28782
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp28783
sS'are,taken'
p28784
(F1
F0.00028669724770642203
I2
I0
I2
tp28785
sS'most,common'
p28786
(F1
F0.00043004587155963305
I0
I3
I-3
tp28787
sS'wild-type,alleles'
p28788
(F1
F0.00014334862385321102
I0
I1
I-1
tp28789
sS'slow,the'
p28790
(F1
F0.00014334862385321102
I1
I0
I1
tp28791
sS'specific,and'
p28792
(F1
F0.00014334862385321102
I0
I1
I-1
tp28793
sS'selectively,prevent'
p28794
(F1
F0.00014334862385321102
I1
I0
I1
tp28795
sS'and,because'
p28796
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp28797
sS'postdose,a'
p28798
(F1
F0.00014334862385321102
I1
I0
I1
tp28799
sS'reported,concomitant'
p28800
(F1
F0.00014334862385321102
I1
I0
I1
tp28801
sS'pharmacokinetic,or'
p28802
(F1
F0.0008600917431192661
I0
I6
I-6
tp28803
sS'transplant,patients'
p28804
(F1
F0.00028669724770642203
I2
I0
I2
tp28805
sS'sch-23390,but'
p28806
(F1
F0.00014334862385321102
I1
I0
I1
tp28807
sS'that,the'
p28808
(F0.44186046511627908
F0.0027236238532110093
I31
I12
I19
tp28809
sS'or,similar'
p28810
(F1
F0.00028669724770642203
I2
I0
I2
tp28811
sS'or,alternatively'
p28812
(F1
F0.00014334862385321102
I0
I1
I-1
tp28813
sS'olanzapine,a'
p28814
(F1
F0.00014334862385321102
I0
I1
I-1
tp28815
sS'their,increased'
p28816
(F1
F0.00014334862385321102
I0
I1
I-1
tp28817
sS'as,liver'
p28818
(F1
F0.00014334862385321102
I1
I0
I1
tp28819
sS'clearance,at'
p28820
(F1
F0.00014334862385321102
I0
I1
I-1
tp28821
sS'general,although'
p28822
(F1
F0.00014334862385321102
I0
I1
I-1
tp28823
sS'placebo,coadministered'
p28824
(F1
F0.00014334862385321102
I0
I1
I-1
tp28825
sS'or,substantially'
p28826
(F1
F0.00014334862385321102
I1
I0
I1
tp28827
sS'metabolism,or'
p28828
(F0
F0
I1
I1
I0
tp28829
sS'marplan,nardil'
p28830
(F1
F0.00014334862385321102
I0
I1
I-1
tp28831
sS'profound,when'
p28832
(F1
F0.00014334862385321102
I1
I0
I1
tp28833
sS'taking,any'
p28834
(F0
F0
I1
I1
I0
tp28835
sS'size,is'
p28836
(F1
F0.00014334862385321102
I0
I1
I-1
tp28837
sS'administering,gleevec'
p28838
(F1
F0.00028669724770642203
I2
I0
I2
tp28839
sS'be,especially'
p28840
(F1
F0.00014334862385321102
I0
I1
I-1
tp28841
sS'using,long-acting'
p28842
(F1
F0.00014334862385321102
I1
I0
I1
tp28843
sS's,effect'
p28844
(F1
F0.00014334862385321102
I1
I0
I1
tp28845
sS'additional,that'
p28846
(F0
F0
I1
I1
I0
tp28847
sS'h2,antagonists'
p28848
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28849
sS'blockade,may'
p28850
(F1
F0.00014334862385321102
I1
I0
I1
tp28851
sS'as,etc'
p28852
(F1
F0.00014334862385321102
I1
I0
I1
tp28853
sS'in,nephrosis'
p28854
(F1
F0.00014334862385321102
I0
I1
I-1
tp28855
sS'therapeutic,action'
p28856
(F1
F0.00014334862385321102
I1
I0
I1
tp28857
sS'these,potentially'
p28858
(F1
F0.00014334862385321102
I1
I0
I1
tp28859
sS'and,safety'
p28860
(F1
F0.00014334862385321102
I0
I1
I-1
tp28861
sS'to,change'
p28862
(F0
F0
I2
I2
I0
tp28863
sS'proposed,that'
p28864
(F1
F0.00014334862385321102
I1
I0
I1
tp28865
sS'niacin,antihypertensive'
p28866
(F1
F0.00014334862385321102
I1
I0
I1
tp28867
sS'studies,was'
p28868
(F1
F0.00014334862385321102
I0
I1
I-1
tp28869
sS'pharmacokinetic,interactions'
p28870
(F0.84615384615384615
F0.0015768348623853212
I1
I12
I-11
tp28871
sS'inhibit,alprazolam'
p28872
(F1
F0.00014334862385321102
I0
I1
I-1
tp28873
sS'to,leading'
p28874
(F1
F0.00014334862385321102
I1
I0
I1
tp28875
sS'warfarin,meclofenamate'
p28876
(F1
F0.00014334862385321102
I1
I0
I1
tp28877
sS'spectrophotometrically,determined'
p28878
(F1
F0.00014334862385321102
I0
I1
I-1
tp28879
sS'healthy,male'
p28880
(F0.5
F0.0008600917431192661
I3
I9
I-6
tp28881
sS'a,hazard'
p28882
(F0
F0
I1
I1
I0
tp28883
sS'caused,excessive'
p28884
(F1
F0.00028669724770642203
I0
I2
I-2
tp28885
sS'conduction,eg'
p28886
(F1
F0.00014334862385321102
I1
I0
I1
tp28887
sS'bosentan,has'
p28888
(F1
F0.00014334862385321102
I0
I1
I-1
tp28889
sS'pyrazolone,derivatives'
p28890
(F1
F0.00014334862385321102
I1
I0
I1
tp28891
sS'thyroid,preparations'
p28892
(F1
F0.00014334862385321102
I1
I0
I1
tp28893
sS'occurred,at'
p28894
(F1
F0.00014334862385321102
I1
I0
I1
tp28895
sS'complications,considerably'
p28896
(F1
F0.00014334862385321102
I0
I1
I-1
tp28897
sS'of,aprepitant'
p28898
(F0.33333333333333331
F0.0008600917431192661
I12
I6
I6
tp28899
sS'nuromax,is'
p28900
(F1
F0.00014334862385321102
I1
I0
I1
tp28901
sS'of,hepatitis'
p28902
(F1
F0.00014334862385321102
I1
I0
I1
tp28903
sS'mucosa,caused'
p28904
(F1
F0.00014334862385321102
I1
I0
I1
tp28905
sS'spent,in'
p28906
(F1
F0.00014334862385321102
I1
I0
I1
tp28907
sS'fold,during'
p28908
(F1
F0.00014334862385321102
I1
I0
I1
tp28909
sS'not,to'
p28910
(F0.5
F0.00028669724770642203
I3
I1
I2
tp28911
sS'of,are'
p28912
(F0.46666666666666667
F0.0010034403669724771
I11
I4
I7
tp28913
sS'assay,xigris'
p28914
(F1
F0.00014334862385321102
I0
I1
I-1
tp28915
sS'agents,although'
p28916
(F1
F0.00014334862385321102
I1
I0
I1
tp28917
sS'clotting,factor'
p28918
(F1
F0.00014334862385321102
I0
I1
I-1
tp28919
sS'increase,serum'
p28920
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp28921
sS'an,are'
p28922
(F1
F0.00014334862385321102
I1
I0
I1
tp28923
sS'interactions,cephalosporins'
p28924
(F1
F0.00014334862385321102
I0
I1
I-1
tp28925
sS'brain,edema'
p28926
(F1
F0.00014334862385321102
I1
I0
I1
tp28927
sS'for,measurement'
p28928
(F1
F0.00014334862385321102
I0
I1
I-1
tp28929
sS'of,potassium-sparing'
p28930
(F1
F0.00014334862385321102
I0
I1
I-1
tp28931
sS'nor,should'
p28932
(F1
F0.00014334862385321102
I1
I0
I1
tp28933
sS'rats,simultaneous'
p28934
(F1
F0.00014334862385321102
I1
I0
I1
tp28935
sS'and,single'
p28936
(F1
F0.00014334862385321102
I0
I1
I-1
tp28937
sS'supraventricular,arrhythmia'
p28938
(F1
F0.00014334862385321102
I1
I0
I1
tp28939
sS'dose,until'
p28940
(F1
F0.00014334862385321102
I1
I0
I1
tp28941
sS'and,vasoactive'
p28942
(F1
F0.00014334862385321102
I1
I0
I1
tp28943
sS'pharmacologic,activities'
p28944
(F1
F0.00014334862385321102
I0
I1
I-1
tp28945
sS'and,maximal'
p28946
(F1
F0.00014334862385321102
I1
I0
I1
tp28947
sS'd6,cyp2d6'
p28948
(F1
F0.00014334862385321102
I0
I1
I-1
tp28949
sS'min,over'
p28950
(F1
F0.00014334862385321102
I0
I1
I-1
tp28951
sS'as,post'
p28952
(F1
F0.00014334862385321102
I1
I0
I1
tp28953
sS'medication,patients'
p28954
(F1
F0.00014334862385321102
I0
I1
I-1
tp28955
sS'multiple,sclerosis'
p28956
(F1
F0.00014334862385321102
I0
I1
I-1
tp28957
sS'following,beta-adrenergic'
p28958
(F1
F0.00014334862385321102
I0
I1
I-1
tp28959
sS'levels,monitored'
p28960
(F1
F0.00014334862385321102
I1
I0
I1
tp28961
sS'were,performed'
p28962
(F1
F0.00014334862385321102
I0
I1
I-1
tp28963
sS'by,adl'
p28964
(F1
F0.00014334862385321102
I0
I1
I-1
tp28965
sS'therapy,free'
p28966
(F1
F0.00014334862385321102
I1
I0
I1
tp28967
sS'monitored,especially'
p28968
(F0
F0
I1
I1
I0
tp28969
sS'can,follow'
p28970
(F1
F0.00014334862385321102
I1
I0
I1
tp28971
sS'reduce,hepatic'
p28972
(F1
F0.00014334862385321102
I1
I0
I1
tp28973
sS'l,were'
p28974
(F1
F0.00014334862385321102
I0
I1
I-1
tp28975
sS'd2-antagonists,such'
p28976
(F1
F0.00014334862385321102
I1
I0
I1
tp28977
sS'matrix,may'
p28978
(F1
F0.00014334862385321102
I1
I0
I1
tp28979
sS'to,increase'
p28980
(F0.68421052631578949
F0.0037270642201834864
I32
I6
I26
tp28981
sS'but,its'
p28982
(F1
F0.00014334862385321102
I0
I1
I-1
tp28983
sS'antacids,aluminum-'
p28984
(F1
F0.00014334862385321102
I1
I0
I1
tp28985
sS'reactions,thought'
p28986
(F1
F0.00014334862385321102
I0
I1
I-1
tp28987
sS'misonidazole,reduced'
p28988
(F1
F0.00014334862385321102
I1
I0
I1
tp28989
sS'hypotensive,using'
p28990
(F1
F0.00014334862385321102
I1
I0
I1
tp28991
sS'progestational,such'
p28992
(F1
F0.00014334862385321102
I0
I1
I-1
tp28993
sS'single,enzyme'
p28994
(F1
F0.00014334862385321102
I0
I1
I-1
tp28995
sS'greater,ischemic'
p28996
(F1
F0.00014334862385321102
I1
I0
I1
tp28997
sS'with,potent'
p28998
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp28999
sS'volunteers,administration'
p29000
(F1
F0.00014334862385321102
I0
I1
I-1
tp29001
sS'of,prolonged'
p29002
(F1
F0.00043004587155963305
I3
I0
I3
tp29003
sS'which,includes'
p29004
(F1
F0.00014334862385321102
I0
I1
I-1
tp29005
sS'in,uterine'
p29006
(F1
F0.00014334862385321102
I1
I0
I1
tp29007
sS'modified,by'
p29008
(F1
F0.00014334862385321102
I1
I0
I1
tp29009
sS'propranolols,hypotensive'
p29010
(F1
F0.00014334862385321102
I1
I0
I1
tp29011
sS'for,decreased'
p29012
(F1
F0.00014334862385321102
I0
I1
I-1
tp29013
sS'about,of'
p29014
(F1
F0.00028669724770642203
I0
I2
I-2
tp29015
sS'weakness,in'
p29016
(F1
F0.00014334862385321102
I1
I0
I1
tp29017
sS'acth,treatment'
p29018
(F1
F0.00014334862385321102
I0
I1
I-1
tp29019
sS'when,known'
p29020
(F1
F0.00014334862385321102
I0
I1
I-1
tp29021
sS'to,min'
p29022
(F1
F0.00014334862385321102
I0
I1
I-1
tp29023
sS'clorazepate,dipotassium'
p29024
(F1
F0.00014334862385321102
I1
I0
I1
tp29025
sS'ra,clinical'
p29026
(F1
F0.00014334862385321102
I0
I1
I-1
tp29027
sS'on,the'
p29028
(F0.43859649122807015
F0.010751146788990825
I48
I123
I-75
tp29029
sS'and,organic'
p29030
(F1
F0.00028669724770642203
I2
I0
I2
tp29031
sS'recommended,since'
p29032
(F1
F0.00014334862385321102
I1
I0
I1
tp29033
sS'administered,and'
p29034
(F1
F0.00014334862385321102
I1
I0
I1
tp29035
sS'theoretically,possible'
p29036
(F1
F0.00014334862385321102
I1
I0
I1
tp29037
sS'of,nephrolithiasis'
p29038
(F1
F0.00014334862385321102
I1
I0
I1
tp29039
sS'are,thought'
p29040
(F1
F0.00014334862385321102
I0
I1
I-1
tp29041
sS'determined,on'
p29042
(F1
F0.00014334862385321102
I1
I0
I1
tp29043
sS'varying,degrees'
p29044
(F1
F0.00014334862385321102
I0
I1
I-1
tp29045
sS'a,stimulator'
p29046
(F1
F0.00014334862385321102
I1
I0
I1
tp29047
sS'adrenergic,agonists'
p29048
(F1
F0.00014334862385321102
I1
I0
I1
tp29049
sS'hydrolase,carbamazepine'
p29050
(F1
F0.00014334862385321102
I0
I1
I-1
tp29051
sS'generally,converted'
p29052
(F1
F0.00014334862385321102
I1
I0
I1
tp29053
sS'affinity,binding'
p29054
(F1
F0.00028669724770642203
I0
I2
I-2
tp29055
sS'arc,mrna'
p29056
(F1
F0.00014334862385321102
I1
I0
I1
tp29057
sS'not,limited'
p29058
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29059
sS'urine,creatinine'
p29060
(F1
F0.00028669724770642203
I0
I2
I-2
tp29061
sS'the,immunodepressant--the'
p29062
(F1
F0.00014334862385321102
I0
I1
I-1
tp29063
sS'on,application'
p29064
(F1
F0.00014334862385321102
I0
I1
I-1
tp29065
sS'lofexidine,may'
p29066
(F1
F0.00028669724770642203
I2
I0
I2
tp29067
sS'psychotropic,agents'
p29068
(F1
F0.00028669724770642203
I2
I0
I2
tp29069
sS'multiple-dose,interaction'
p29070
(F1
F0.00014334862385321102
I0
I1
I-1
tp29071
sS'effect,beyond'
p29072
(F1
F0.00014334862385321102
I1
I0
I1
tp29073
sS'given,hours'
p29074
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29075
sS'felbatol,to'
p29076
(F1
F0.00014334862385321102
I1
I0
I1
tp29077
sS'levodopa,and'
p29078
(F1
F0.00014334862385321102
I1
I0
I1
tp29079
sS'mean,daily'
p29080
(F1
F0.00014334862385321102
I0
I1
I-1
tp29081
sS'to,therapy'
p29082
(F1
F0.00043004587155963305
I3
I0
I3
tp29083
sS'phosphatases,in'
p29084
(F1
F0.00014334862385321102
I0
I1
I-1
tp29085
sS'by,mu-'
p29086
(F1
F0.00014334862385321102
I0
I1
I-1
tp29087
sS'and,concurrent'
p29088
(F1
F0.00028669724770642203
I2
I0
I2
tp29089
sS'ibogaine,attenuates'
p29090
(F1
F0.00014334862385321102
I1
I0
I1
tp29091
sS'in,switching'
p29092
(F1
F0.00057339449541284407
I4
I0
I4
tp29093
sS'with,targretin'
p29094
(F1
F0.00014334862385321102
I1
I0
I1
tp29095
sS'with,since'
p29096
(F1
F0.00043004587155963305
I3
I0
I3
tp29097
sS'aggregation,inhibitors'
p29098
(F1
F0.00014334862385321102
I1
I0
I1
tp29099
sS'or,when'
p29100
(F1
F0.00028669724770642203
I0
I2
I-2
tp29101
sS'sustiva,mg'
p29102
(F0
F0
I1
I1
I0
tp29103
sS'elevated,blood'
p29104
(F1
F0.00014334862385321102
I0
I1
I-1
tp29105
sS'coadministration,n'
p29106
(F1
F0.00014334862385321102
I1
I0
I1
tp29107
sS'physician,may'
p29108
(F1
F0.00014334862385321102
I1
I0
I1
tp29109
sS'involving,renal'
p29110
(F1
F0.00014334862385321102
I1
I0
I1
tp29111
sS'muscle,in'
p29112
(F1
F0.00014334862385321102
I1
I0
I1
tp29113
sS'comprehensive,information'
p29114
(F1
F0.00014334862385321102
I0
I1
I-1
tp29115
sS'oxc,and'
p29116
(F1
F0.00028669724770642203
I0
I2
I-2
tp29117
sS'neoral,sandimmune'
p29118
(F1
F0.00014334862385321102
I1
I0
I1
tp29119
sS'on,drug'
p29120
(F1
F0.00014334862385321102
I0
I1
I-1
tp29121
sS'useful,pharmacological'
p29122
(F1
F0.00014334862385321102
I0
I1
I-1
tp29123
sS'of,anaphylactic'
p29124
(F1
F0.00014334862385321102
I1
I0
I1
tp29125
sS'is,particularly'
p29126
(F1
F0.00014334862385321102
I0
I1
I-1
tp29127
sS'and,you'
p29128
(F1
F0.00014334862385321102
I1
I0
I1
tp29129
sS'seroquel,is'
p29130
(F1
F0.00014334862385321102
I0
I1
I-1
tp29131
sS'tachycardia,dryness'
p29132
(F1
F0.00014334862385321102
I1
I0
I1
tp29133
sS'animals,edetate'
p29134
(F1
F0.00014334862385321102
I1
I0
I1
tp29135
sS'pi,related'
p29136
(F1
F0.00014334862385321102
I0
I1
I-1
tp29137
sS'brevibloc,and'
p29138
(F0
F0
I1
I1
I0
tp29139
sS'wort,may'
p29140
(F0
F0
I1
I1
I0
tp29141
sS'with,laboratory'
p29142
(F1
F0.00014334862385321102
I0
I1
I-1
tp29143
sS'and,certain'
p29144
(F1
F0.00028669724770642203
I2
I0
I2
tp29145
sS'lesser,extent'
p29146
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29147
sS'depressant,cns'
p29148
(F1
F0.00014334862385321102
I0
I1
I-1
tp29149
sS'sometimes,fatal'
p29150
(F1
F0.00014334862385321102
I1
I0
I1
tp29151
sS'inhibitor,nnrti'
p29152
(F1
F0.00014334862385321102
I0
I1
I-1
tp29153
sS'with,available'
p29154
(F1
F0.00014334862385321102
I1
I0
I1
tp29155
sS'apoptotic,index'
p29156
(F1
F0.00014334862385321102
I0
I1
I-1
tp29157
sS'on,coumarin-type'
p29158
(F1
F0.00014334862385321102
I1
I0
I1
tp29159
sS'strattera,should'
p29160
(F1
F0.00014334862385321102
I1
I0
I1
tp29161
sS'the,cmax'
p29162
(F0.69230769230769229
F0.0012901376146788992
I11
I2
I9
tp29163
sS'total,formation'
p29164
(F1
F0.00014334862385321102
I1
I0
I1
tp29165
sS'or,corticosteroids'
p29166
(F1
F0.00014334862385321102
I0
I1
I-1
tp29167
sS'd,for'
p29168
(F1
F0.00028669724770642203
I2
I0
I2
tp29169
sS'intravenous,amphotericin'
p29170
(F1
F0.00014334862385321102
I1
I0
I1
tp29171
sS'be,at'
p29172
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29173
sS'benefits,and'
p29174
(F1
F0.00014334862385321102
I1
I0
I1
tp29175
sS'mc,block'
p29176
(F1
F0.00014334862385321102
I1
I0
I1
tp29177
sS'containing,either'
p29178
(F1
F0.00014334862385321102
I0
I1
I-1
tp29179
sS'rings,with'
p29180
(F1
F0.00014334862385321102
I1
I0
I1
tp29181
sS'with,natrecor'
p29182
(F1
F0.00014334862385321102
I0
I1
I-1
tp29183
sS'a,weak'
p29184
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29185
sS'that,concomitant'
p29186
(F0.25
F0.00028669724770642203
I5
I3
I2
tp29187
sS'receiving,combination'
p29188
(F1
F0.00014334862385321102
I1
I0
I1
tp29189
sS'can,displace'
p29190
(F1
F0.00014334862385321102
I1
I0
I1
tp29191
sS'lastly,local'
p29192
(F1
F0.00014334862385321102
I0
I1
I-1
tp29193
sS'aerobic,facultative'
p29194
(F1
F0.00014334862385321102
I0
I1
I-1
tp29195
sS'or,prolong'
p29196
(F0
F0
I1
I1
I0
tp29197
sS'spectrum,may'
p29198
(F1
F0.00014334862385321102
I0
I1
I-1
tp29199
sS'inhalation,are'
p29200
(F1
F0.00014334862385321102
I1
I0
I1
tp29201
sS'withhold,during'
p29202
(F1
F0.00014334862385321102
I1
I0
I1
tp29203
sS'or,h2antagonists'
p29204
(F1
F0.00014334862385321102
I1
I0
I1
tp29205
sS'experience,fewer'
p29206
(F1
F0.00014334862385321102
I0
I1
I-1
tp29207
sS'addicts,were'
p29208
(F1
F0.00014334862385321102
I1
I0
I1
tp29209
sS'were,each'
p29210
(F1
F0.00014334862385321102
I0
I1
I-1
tp29211
sS'weak,effect'
p29212
(F1
F0.00014334862385321102
I1
I0
I1
tp29213
sS'similar,interaction'
p29214
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29215
sS'wide,interindividual'
p29216
(F1
F0.00014334862385321102
I1
I0
I1
tp29217
sS'weighed,against'
p29218
(F1
F0.00014334862385321102
I1
I0
I1
tp29219
sS'as,noted'
p29220
(F0
F0
I1
I1
I0
tp29221
sS'male,volunteers'
p29222
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp29223
sS'with,bioavailability'
p29224
(F1
F0.00014334862385321102
I0
I1
I-1
tp29225
sS'pulmonary,extract'
p29226
(F1
F0.00014334862385321102
I0
I1
I-1
tp29227
sS'when,eye'
p29228
(F1
F0.00014334862385321102
I0
I1
I-1
tp29229
sS'and,beta-blocking'
p29230
(F1
F0.00014334862385321102
I0
I1
I-1
tp29231
sS'taking,and'
p29232
(F1
F0.0008600917431192661
I6
I0
I6
tp29233
sS'heavy,intake'
p29234
(F1
F0.00014334862385321102
I1
I0
I1
tp29235
sS'minimally,elevated'
p29236
(F1
F0.00014334862385321102
I0
I1
I-1
tp29237
sS'animal,toxicology'
p29238
(F1
F0.00014334862385321102
I0
I1
I-1
tp29239
sS'norpace,or'
p29240
(F1
F0.00014334862385321102
I1
I0
I1
tp29241
sS'did,occur'
p29242
(F1
F0.00014334862385321102
I0
I1
I-1
tp29243
sS'as,determined'
p29244
(F1
F0.00014334862385321102
I0
I1
I-1
tp29245
sS'weeks,should'
p29246
(F1
F0.00028669724770642203
I2
I0
I2
tp29247
sS'in,arc'
p29248
(F1
F0.00014334862385321102
I1
I0
I1
tp29249
sS'antifungals,protease'
p29250
(F1
F0.00014334862385321102
I0
I1
I-1
tp29251
sS'starlix,three'
p29252
(F1
F0.00014334862385321102
I0
I1
I-1
tp29253
sS'should,receive'
p29254
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29255
sS'thus,the'
p29256
(F0.5
F0.00028669724770642203
I3
I1
I2
tp29257
sS'the,prescribing'
p29258
(F1
F0.00028669724770642203
I0
I2
I-2
tp29259
sS'preparations,which'
p29260
(F1
F0.00014334862385321102
I0
I1
I-1
tp29261
sS'glucose,metabolism'
p29262
(F1
F0.00014334862385321102
I0
I1
I-1
tp29263
sS'chloral,hydrate'
p29264
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp29265
sS'before,initiating'
p29266
(F1
F0.00014334862385321102
I1
I0
I1
tp29267
sS'to,occasionally'
p29268
(F0
F0
I1
I1
I0
tp29269
sS'cimetidine,cimetidine'
p29270
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp29271
sS'fu,bolus-ifl'
p29272
(F1
F0.00014334862385321102
I0
I1
I-1
tp29273
sS'given,did'
p29274
(F1
F0.00014334862385321102
I0
I1
I-1
tp29275
sS'may,wish'
p29276
(F1
F0.00014334862385321102
I1
I0
I1
tp29277
sS'infarction,vs'
p29278
(F1
F0.00014334862385321102
I1
I0
I1
tp29279
sS'data,which'
p29280
(F1
F0.00014334862385321102
I1
I0
I1
tp29281
sS'fluorescence,labelled'
p29282
(F1
F0.00014334862385321102
I0
I1
I-1
tp29283
sS'is,little'
p29284
(F1
F0.00028669724770642203
I0
I2
I-2
tp29285
sS'anhydrous,and'
p29286
(F1
F0.00014334862385321102
I1
I0
I1
tp29287
sS'adrenergic,antagonism'
p29288
(F1
F0.00014334862385321102
I1
I0
I1
tp29289
sS'dynacirc,has'
p29290
(F1
F0.00014334862385321102
I0
I1
I-1
tp29291
sS'c19,d6'
p29292
(F1
F0.00014334862385321102
I0
I1
I-1
tp29293
sS'trace,elements'
p29294
(F1
F0.00014334862385321102
I0
I1
I-1
tp29295
sS'studies,should'
p29296
(F1
F0.00014334862385321102
I0
I1
I-1
tp29297
sS'membrane,sterol'
p29298
(F1
F0.00014334862385321102
I0
I1
I-1
tp29299
sS'and,chop'
p29300
(F1
F0.00014334862385321102
I0
I1
I-1
tp29301
sS'representations,of'
p29302
(F1
F0.00014334862385321102
I0
I1
I-1
tp29303
sS'pharmacokinetic,and'
p29304
(F1
F0.00014334862385321102
I0
I1
I-1
tp29305
sS'carefully,for'
p29306
(F1
F0.00057339449541284407
I4
I0
I4
tp29307
sS'with,compared'
p29308
(F1
F0.00028669724770642203
I2
I0
I2
tp29309
sS'be,approved'
p29310
(F1
F0.00014334862385321102
I0
I1
I-1
tp29311
sS'suspension,were'
p29312
(F1
F0.00014334862385321102
I1
I0
I1
tp29313
sS'distribution,metabolism'
p29314
(F1
F0.00014334862385321102
I0
I1
I-1
tp29315
sS'ms,patients'
p29316
(F0
F0
I1
I1
I0
tp29317
sS'of,sulfoxide'
p29318
(F1
F0.00028669724770642203
I2
I0
I2
tp29319
sS'mesenteric,arteries'
p29320
(F1
F0.00014334862385321102
I0
I1
I-1
tp29321
sS'acid,sali-cylates'
p29322
(F1
F0.00014334862385321102
I0
I1
I-1
tp29323
sS'beta-blockers,and'
p29324
(F1
F0.00014334862385321102
I1
I0
I1
tp29325
sS'phosphorylated,concentration'
p29326
(F1
F0.00014334862385321102
I0
I1
I-1
tp29327
sS'of,bezalip'
p29328
(F1
F0.00014334862385321102
I1
I0
I1
tp29329
sS'with,containing'
p29330
(F1
F0.00028669724770642203
I2
I0
I2
tp29331
sS'ganglionic,or'
p29332
(F1
F0.00014334862385321102
I0
I1
I-1
tp29333
sS'administration,systemic'
p29334
(F1
F0.00014334862385321102
I1
I0
I1
tp29335
sS'has,received'
p29336
(F1
F0.00014334862385321102
I1
I0
I1
tp29337
sS'was,poorly'
p29338
(F1
F0.00014334862385321102
I1
I0
I1
tp29339
sS'increased,dosages'
p29340
(F1
F0.00014334862385321102
I1
I0
I1
tp29341
sS'with,products'
p29342
(F1
F0.00014334862385321102
I1
I0
I1
tp29343
sS'day9,of'
p29344
(F1
F0.00014334862385321102
I1
I0
I1
tp29345
sS'emergency,situation'
p29346
(F1
F0.00014334862385321102
I1
I0
I1
tp29347
sS'enhanced,side'
p29348
(F1
F0.00014334862385321102
I1
I0
I1
tp29349
sS'compounds,meclofenamic'
p29350
(F1
F0.00014334862385321102
I1
I0
I1
tp29351
sS'single-dose,crossover'
p29352
(F1
F0.00014334862385321102
I1
I0
I1
tp29353
sS'normal,male'
p29354
(F1
F0.00014334862385321102
I1
I0
I1
tp29355
sS'steady-state,peak'
p29356
(F1
F0.00014334862385321102
I1
I0
I1
tp29357
sS'for,diagnosis'
p29358
(F1
F0.00014334862385321102
I0
I1
I-1
tp29359
sS'oral,cough'
p29360
(F1
F0.00014334862385321102
I0
I1
I-1
tp29361
sS'verapamil,also'
p29362
(F1
F0.00014334862385321102
I1
I0
I1
tp29363
sS'requiring,increased'
p29364
(F1
F0.00014334862385321102
I1
I0
I1
tp29365
sS'who,take'
p29366
(F1
F0.00014334862385321102
I0
I1
I-1
tp29367
sS'coronary,oral'
p29368
(F1
F0.00014334862385321102
I0
I1
I-1
tp29369
sS'mm,had'
p29370
(F1
F0.00014334862385321102
I0
I1
I-1
tp29371
sS'tea,polyphenols'
p29372
(F1
F0.00014334862385321102
I0
I1
I-1
tp29373
sS'and,inhibits'
p29374
(F1
F0.00014334862385321102
I1
I0
I1
tp29375
sS'affect,responding'
p29376
(F1
F0.00014334862385321102
I0
I1
I-1
tp29377
sS'isolates,of'
p29378
(F1
F0.00014334862385321102
I0
I1
I-1
tp29379
sS'uterine,hypertonus'
p29380
(F1
F0.00014334862385321102
I1
I0
I1
tp29381
sS'is,due'
p29382
(F0.5
F0.00028669724770642203
I3
I1
I2
tp29383
sS'affects,the'
p29384
(F1
F0.00014334862385321102
I1
I0
I1
tp29385
sS'cox-2,inhibitor'
p29386
(F1
F0.00014334862385321102
I0
I1
I-1
tp29387
sS'to,baseline'
p29388
(F1
F0.00014334862385321102
I1
I0
I1
tp29389
sS'depletor,should'
p29390
(F1
F0.00014334862385321102
I0
I1
I-1
tp29391
sS'produce,severe'
p29392
(F1
F0.00071674311926605509
I5
I0
I5
tp29393
sS'performed,on'
p29394
(F1
F0.00014334862385321102
I0
I1
I-1
tp29395
sS's,d'
p29396
(F1
F0.00014334862385321102
I1
I0
I1
tp29397
sS's,a'
p29398
(F1
F0.00014334862385321102
I1
I0
I1
tp29399
sS'and,permit'
p29400
(F1
F0.00014334862385321102
I0
I1
I-1
tp29401
sS's,c'
p29402
(F1
F0.00028669724770642203
I2
I0
I2
tp29403
sS'the,general'
p29404
(F1
F0.00043004587155963305
I0
I3
I-3
tp29405
sS'interval,clinical'
p29406
(F1
F0.00014334862385321102
I0
I1
I-1
tp29407
sS'vitro,aspirin-mediated'
p29408
(F1
F0.00014334862385321102
I0
I1
I-1
tp29409
sS'inhibitors,macrolide'
p29410
(F1
F0.00014334862385321102
I0
I1
I-1
tp29411
sS'usage,of'
p29412
(F1
F0.00014334862385321102
I0
I1
I-1
tp29413
sS'substrate,with'
p29414
(F1
F0.00014334862385321102
I1
I0
I1
tp29415
sS'cholestyramine,resin'
p29416
(F1
F0.00014334862385321102
I0
I1
I-1
tp29417
sS'of,hcl'
p29418
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29419
sS'include,acute'
p29420
(F1
F0.00014334862385321102
I1
I0
I1
tp29421
sS'females,and'
p29422
(F1
F0.00014334862385321102
I1
I0
I1
tp29423
sS'may,regulate'
p29424
(F1
F0.00014334862385321102
I1
I0
I1
tp29425
sS'fivefold,increase'
p29426
(F1
F0.00014334862385321102
I0
I1
I-1
tp29427
sS'no,substantive'
p29428
(F1
F0.00014334862385321102
I0
I1
I-1
tp29429
sS'because,reduces'
p29430
(F1
F0.00014334862385321102
I1
I0
I1
tp29431
sS'well,after'
p29432
(F1
F0.00014334862385321102
I0
I1
I-1
tp29433
sS'transplant,recipients'
p29434
(F0
F0
I1
I1
I0
tp29435
sS'r-warfarin,or'
p29436
(F1
F0.00014334862385321102
I0
I1
I-1
tp29437
sS'others,prelone'
p29438
(F1
F0.00014334862385321102
I0
I1
I-1
tp29439
sS'significant,change'
p29440
(F1
F0.00028669724770642203
I0
I2
I-2
tp29441
sS'using,morphological'
p29442
(F1
F0.00014334862385321102
I1
I0
I1
tp29443
sS'concentrates,should'
p29444
(F1
F0.00014334862385321102
I0
I1
I-1
tp29445
sS'mtc-methylene,diphosphonate'
p29446
(F1
F0.00014334862385321102
I1
I0
I1
tp29447
sS'drugs,clonazepam'
p29448
(F1
F0.00014334862385321102
I0
I1
I-1
tp29449
sS'active,tubular'
p29450
(F0
F0
I1
I1
I0
tp29451
sS'iron,supplements'
p29452
(F1
F0.00014334862385321102
I1
I0
I1
tp29453
sS'prospective,long-term'
p29454
(F1
F0.00014334862385321102
I0
I1
I-1
tp29455
sS'many,and'
p29456
(F1
F0.00014334862385321102
I0
I1
I-1
tp29457
sS'lower,with'
p29458
(F1
F0.00014334862385321102
I0
I1
I-1
tp29459
sS'fexofenadine,has'
p29460
(F1
F0.00014334862385321102
I0
I1
I-1
tp29461
sS'in,order'
p29462
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp29463
sS'or,intravenous'
p29464
(F1
F0.00028669724770642203
I2
I0
I2
tp29465
sS'and,given'
p29466
(F1
F0.00014334862385321102
I0
I1
I-1
tp29467
sS'are,potentiated'
p29468
(F1
F0.00014334862385321102
I1
I0
I1
tp29469
sS'fexofenadine,had'
p29470
(F1
F0.00014334862385321102
I0
I1
I-1
tp29471
sS'by,either'
p29472
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp29473
sS'query,patients'
p29474
(F1
F0.00014334862385321102
I0
I1
I-1
tp29475
sS'individual,glucose'
p29476
(F1
F0.00014334862385321102
I1
I0
I1
tp29477
sS'decrease,blood'
p29478
(F1
F0.00043004587155963305
I3
I0
I3
tp29479
sS'thereby,potentially'
p29480
(F1
F0.00014334862385321102
I1
I0
I1
tp29481
sS'example,complications'
p29482
(F1
F0.00014334862385321102
I0
I1
I-1
tp29483
sS'the,initial'
p29484
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp29485
sS'additive,or'
p29486
(F1
F0.00057339449541284407
I4
I0
I4
tp29487
sS'inhibitor,increased'
p29488
(F1
F0.00014334862385321102
I1
I0
I1
tp29489
sS'high,blood'
p29490
(F1
F0.00028669724770642203
I2
I0
I2
tp29491
sS'cell,could'
p29492
(F1
F0.00014334862385321102
I0
I1
I-1
tp29493
sS'inhibitor,increases'
p29494
(F1
F0.00014334862385321102
I1
I0
I1
tp29495
sS'ml,with'
p29496
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29497
sS'mineral,oil-concomitant'
p29498
(F1
F0.00014334862385321102
I1
I0
I1
tp29499
sS'reflects,an'
p29500
(F1
F0.00014334862385321102
I1
I0
I1
tp29501
sS'capsules,since'
p29502
(F1
F0.00014334862385321102
I1
I0
I1
tp29503
sS'each,study'
p29504
(F1
F0.00028669724770642203
I0
I2
I-2
tp29505
sS'future,studies'
p29506
(F1
F0.00014334862385321102
I0
I1
I-1
tp29507
sS'of,antidepressant'
p29508
(F1
F0.00014334862385321102
I1
I0
I1
tp29509
sS'other,antituberculous'
p29510
(F1
F0.00014334862385321102
I1
I0
I1
tp29511
sS'needed,when'
p29512
(F0
F0
I1
I1
I0
tp29513
sS'is,available'
p29514
(F1
F0.00028669724770642203
I0
I2
I-2
tp29515
sS'the,induction'
p29516
(F1
F0.00028669724770642203
I2
I0
I2
tp29517
sS'homodimeric,disintegrin'
p29518
(F1
F0.00028669724770642203
I0
I2
I-2
tp29519
sS'the,r'
p29520
(F0
F0
I1
I1
I0
tp29521
sS'the,v'
p29522
(F1
F0.00014334862385321102
I0
I1
I-1
tp29523
sS'vitro,studies'
p29524
(F0.20000000000000001
F0.00071674311926605509
I10
I15
I-5
tp29525
sS'the,c'
p29526
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29527
sS'lower,affinity'
p29528
(F1
F0.00014334862385321102
I1
I0
I1
tp29529
sS'isoproterenol,hydrochloride'
p29530
(F1
F0.00014334862385321102
I1
I0
I1
tp29531
sS'the,k'
p29532
(F1
F0.00014334862385321102
I0
I1
I-1
tp29533
sS'the,kidneys'
p29534
(F1
F0.00014334862385321102
I0
I1
I-1
tp29535
sS'antimicrobial,and'
p29536
(F1
F0.00014334862385321102
I1
I0
I1
tp29537
sS'ml,administered'
p29538
(F1
F0.00014334862385321102
I1
I0
I1
tp29539
sS'over,patients'
p29540
(F0
F0
I1
I1
I0
tp29541
sS'demonstrated,the'
p29542
(F1
F0.00014334862385321102
I0
I1
I-1
tp29543
sS'been,used'
p29544
(F0.69230769230769229
F0.0012901376146788992
I2
I11
I-9
tp29545
sS'of,gleevec'
p29546
(F1
F0.00014334862385321102
I1
I0
I1
tp29547
sS'potentially,resulting'
p29548
(F1
F0.00028669724770642203
I2
I0
I2
tp29549
sS'possibly,causing'
p29550
(F1
F0.00014334862385321102
I1
I0
I1
tp29551
sS'propoxyphene,the'
p29552
(F1
F0.00014334862385321102
I0
I1
I-1
tp29553
sS'injury,as'
p29554
(F1
F0.00014334862385321102
I0
I1
I-1
tp29555
sS'resistance,arteries'
p29556
(F1
F0.00014334862385321102
I0
I1
I-1
tp29557
sS'symptoms,resolved'
p29558
(F1
F0.00014334862385321102
I0
I1
I-1
tp29559
sS'serious,interactions'
p29560
(F1
F0.00014334862385321102
I1
I0
I1
tp29561
sS'and,secondary'
p29562
(F0
F0
I1
I1
I0
tp29563
sS'containing,buffer'
p29564
(F1
F0.00014334862385321102
I1
I0
I1
tp29565
sS'activity,enough'
p29566
(F1
F0.00014334862385321102
I0
I1
I-1
tp29567
sS'minimal,inhibitory'
p29568
(F1
F0.00028669724770642203
I0
I2
I-2
tp29569
sS'they,should'
p29570
(F1
F0.00028669724770642203
I2
I0
I2
tp29571
sS'of,cyp1a2'
p29572
(F1
F0.00014334862385321102
I1
I0
I1
tp29573
sS'of,cyp1a1'
p29574
(F1
F0.00014334862385321102
I0
I1
I-1
tp29575
sS'higher,incidence'
p29576
(F1
F0.00014334862385321102
I1
I0
I1
tp29577
sS'large,reduction'
p29578
(F1
F0.00014334862385321102
I1
I0
I1
tp29579
sS'the,possible'
p29580
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp29581
sS'sustiva,in'
p29582
(F1
F0.00014334862385321102
I0
I1
I-1
tp29583
sS'qd,is'
p29584
(F1
F0.00014334862385321102
I1
I0
I1
tp29585
sS'transferred,to'
p29586
(F1
F0.00014334862385321102
I0
I1
I-1
tp29587
sS'the,history'
p29588
(F1
F0.00014334862385321102
I0
I1
I-1
tp29589
sS'antiepilepsy,aeds'
p29590
(F1
F0.00014334862385321102
I0
I1
I-1
tp29591
sS'than,two'
p29592
(F1
F0.00014334862385321102
I1
I0
I1
tp29593
sS'rat,liver'
p29594
(F1
F0.00014334862385321102
I0
I1
I-1
tp29595
sS'qd,in'
p29596
(F1
F0.00014334862385321102
I0
I1
I-1
tp29597
sS'substantial,accumulation'
p29598
(F1
F0.00014334862385321102
I1
I0
I1
tp29599
sS'and,enhanced'
p29600
(F1
F0.00014334862385321102
I0
I1
I-1
tp29601
sS'pcp,in'
p29602
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp29603
sS'anti-glaucoma,action'
p29604
(F1
F0.00014334862385321102
I1
I0
I1
tp29605
sS'other,cns-active'
p29606
(F1
F0.00014334862385321102
I1
I0
I1
tp29607
sS'day,relative'
p29608
(F1
F0.00014334862385321102
I1
I0
I1
tp29609
sS'decreases,heart'
p29610
(F1
F0.00014334862385321102
I0
I1
I-1
tp29611
sS'blood,area'
p29612
(F1
F0.00014334862385321102
I1
I0
I1
tp29613
sS'in,seven'
p29614
(F1
F0.00028669724770642203
I0
I2
I-2
tp29615
sS'syndrome,associated'
p29616
(F1
F0.00014334862385321102
I1
I0
I1
tp29617
sS'antagonists,particularly'
p29618
(F1
F0.00014334862385321102
I1
I0
I1
tp29619
sS'pressure,without'
p29620
(F1
F0.00014334862385321102
I1
I0
I1
tp29621
sS'no,deleterious'
p29622
(F1
F0.00014334862385321102
I0
I1
I-1
tp29623
sS'or,delayed'
p29624
(F1
F0.00014334862385321102
I1
I0
I1
tp29625
sS'less,specific'
p29626
(F1
F0.00014334862385321102
I0
I1
I-1
tp29627
sS'carbachol-stimulated,intracellular'
p29628
(F1
F0.00014334862385321102
I1
I0
I1
tp29629
sS'against,bacillus'
p29630
(F1
F0.00014334862385321102
I1
I0
I1
tp29631
sS'for,and'
p29632
(F0.5
F0.0008600917431192661
I3
I9
I-6
tp29633
sS'myopathy,and'
p29634
(F1
F0.00014334862385321102
I0
I1
I-1
tp29635
sS'was,enhanced'
p29636
(F1
F0.00028669724770642203
I0
I2
I-2
tp29637
sS'in,small'
p29638
(F1
F0.00014334862385321102
I0
I1
I-1
tp29639
sS'cyclosporine,l-arginine'
p29640
(F1
F0.00014334862385321102
I1
I0
I1
tp29641
sS'racemic,did'
p29642
(F1
F0.00014334862385321102
I0
I1
I-1
tp29643
sS'acetate,at'
p29644
(F1
F0.00014334862385321102
I1
I0
I1
tp29645
sS'the,enkephalinergic'
p29646
(F1
F0.00014334862385321102
I1
I0
I1
tp29647
sS'kg,doses'
p29648
(F1
F0.00014334862385321102
I1
I0
I1
tp29649
sS'using,cardiac'
p29650
(F1
F0.00014334862385321102
I0
I1
I-1
tp29651
sS'concomitantly,careful'
p29652
(F1
F0.00014334862385321102
I0
I1
I-1
tp29653
sS'for,any'
p29654
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp29655
sS'nuromax,include'
p29656
(F1
F0.00014334862385321102
I1
I0
I1
tp29657
sS'chelation,and'
p29658
(F1
F0.00014334862385321102
I0
I1
I-1
tp29659
sS'metabolite,may'
p29660
(F1
F0.00014334862385321102
I1
I0
I1
tp29661
sS'of,cancidas'
p29662
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29663
sS'p450iid6,such'
p29664
(F1
F0.00014334862385321102
I1
I0
I1
tp29665
sS'exposure,auc0-12'
p29666
(F1
F0.00014334862385321102
I0
I1
I-1
tp29667
sS'cgs,an'
p29668
(F1
F0.00014334862385321102
I1
I0
I1
tp29669
sS'may,lower'
p29670
(F1
F0.00014334862385321102
I1
I0
I1
tp29671
sS'diuretics,diclofenac'
p29672
(F1
F0.00014334862385321102
I1
I0
I1
tp29673
sS'oxidase,in'
p29674
(F0
F0
I1
I1
I0
tp29675
sS'and,inr'
p29676
(F1
F0.00014334862385321102
I0
I1
I-1
tp29677
sS'transport,of'
p29678
(F0
F0
I1
I1
I0
tp29679
sS'altering,cyp1a2-mediated'
p29680
(F1
F0.00014334862385321102
I0
I1
I-1
tp29681
sS'if,necessary'
p29682
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29683
sS'an,inducer'
p29684
(F0
F0
I1
I1
I0
tp29685
sS'data,presented'
p29686
(F1
F0.00014334862385321102
I0
I1
I-1
tp29687
sS'serum,hormone'
p29688
(F1
F0.00014334862385321102
I0
I1
I-1
tp29689
sS'depression,when'
p29690
(F1
F0.00014334862385321102
I1
I0
I1
tp29691
sS'day,days'
p29692
(F0
F0
I1
I1
I0
tp29693
sS'and,inn'
p29694
(F1
F0.00014334862385321102
I0
I1
I-1
tp29695
sS'interval,certain'
p29696
(F1
F0.00028669724770642203
I2
I0
I2
tp29697
sS'renally,impaired'
p29698
(F1
F0.00014334862385321102
I0
I1
I-1
tp29699
sS'induce,fungal'
p29700
(F1
F0.00014334862385321102
I1
I0
I1
tp29701
sS'or,non-opioid'
p29702
(F1
F0.00014334862385321102
I0
I1
I-1
tp29703
sS'may,block'
p29704
(F1
F0.00014334862385321102
I1
I0
I1
tp29705
sS'intervals,during'
p29706
(F1
F0.00014334862385321102
I0
I1
I-1
tp29707
sS'a4,isozyme'
p29708
(F1
F0.00014334862385321102
I0
I1
I-1
tp29709
sS'hepatic,oxidation'
p29710
(F1
F0.00014334862385321102
I1
I0
I1
tp29711
sS'bind,other'
p29712
(F0
F0
I1
I1
I0
tp29713
sS'furosemide,when'
p29714
(F1
F0.00014334862385321102
I1
I0
I1
tp29715
sS'of,future'
p29716
(F1
F0.00014334862385321102
I0
I1
I-1
tp29717
sS'and,longer'
p29718
(F1
F0.00014334862385321102
I1
I0
I1
tp29719
sS'be,considered'
p29720
(F0
F0
I11
I11
I0
tp29721
sS'volunteers,increased'
p29722
(F1
F0.00014334862385321102
I0
I1
I-1
tp29723
sS'appropriate,laboratory'
p29724
(F1
F0.00014334862385321102
I1
I0
I1
tp29725
sS'tetracycline,a'
p29726
(F1
F0.00028669724770642203
I2
I0
I2
tp29727
sS'lexapro,did'
p29728
(F1
F0.00014334862385321102
I1
I0
I1
tp29729
sS'extensive,cyp2d6'
p29730
(F1
F0.00014334862385321102
I0
I1
I-1
tp29731
sS'or,sodium'
p29732
(F1
F0.00014334862385321102
I1
I0
I1
tp29733
sS'acid,nsaids'
p29734
(F1
F0.00014334862385321102
I0
I1
I-1
tp29735
sS'inhalation,dose'
p29736
(F1
F0.00014334862385321102
I1
I0
I1
tp29737
sS'anti-inflammatory,but'
p29738
(F1
F0.00014334862385321102
I0
I1
I-1
tp29739
sS'clcr,and'
p29740
(F1
F0.00014334862385321102
I1
I0
I1
tp29741
sS'the,excretion'
p29742
(F1
F0.00028669724770642203
I2
I0
I2
tp29743
sS'to,alpha'
p29744
(F1
F0.00014334862385321102
I0
I1
I-1
tp29745
sS'which,can'
p29746
(F1
F0.0008600917431192661
I6
I0
I6
tp29747
sS'hydrocortisone,mg'
p29748
(F1
F0.00014334862385321102
I0
I1
I-1
tp29749
sS'or,discontinue'
p29750
(F1
F0.00014334862385321102
I0
I1
I-1
tp29751
sS'mean,template'
p29752
(F1
F0.00014334862385321102
I0
I1
I-1
tp29753
sS'other,known'
p29754
(F1
F0.00043004587155963305
I3
I0
I3
tp29755
sS'lodosyn,and'
p29756
(F1
F0.00014334862385321102
I0
I1
I-1
tp29757
sS'to,monitor'
p29758
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp29759
sS'and,ast'
p29760
(F1
F0.00014334862385321102
I1
I0
I1
tp29761
sS'avoid,bleeding'
p29762
(F1
F0.00014334862385321102
I1
I0
I1
tp29763
sS'extent,of'
p29764
(F0.59999999999999998
F0.0012901376146788992
I3
I12
I-9
tp29765
sS'months,had'
p29766
(F1
F0.00014334862385321102
I0
I1
I-1
tp29767
sS'rejection,episodes'
p29768
(F1
F0.00014334862385321102
I0
I1
I-1
tp29769
sS'uptake-1,carrier'
p29770
(F1
F0.00014334862385321102
I0
I1
I-1
tp29771
sS'either,long-acting'
p29772
(F1
F0.00014334862385321102
I0
I1
I-1
tp29773
sS'beyond,that'
p29774
(F1
F0.00014334862385321102
I1
I0
I1
tp29775
sS'cyp3a4,cyp2d6'
p29776
(F1
F0.00028669724770642203
I0
I2
I-2
tp29777
sS'of,hctz'
p29778
(F1
F0.00014334862385321102
I0
I1
I-1
tp29779
sS'mitogenic,activity'
p29780
(F1
F0.00014334862385321102
I1
I0
I1
tp29781
sS'competitively,inhibit'
p29782
(F1
F0.00014334862385321102
I1
I0
I1
tp29783
sS'using,the'
p29784
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp29785
sS'suppresses,gastric'
p29786
(F1
F0.00014334862385321102
I0
I1
I-1
tp29787
sS'the,problems'
p29788
(F1
F0.00014334862385321102
I0
I1
I-1
tp29789
sS'stress,induction'
p29790
(F1
F0.00014334862385321102
I0
I1
I-1
tp29791
sS'from,an'
p29792
(F1
F0.00043004587155963305
I0
I3
I-3
tp29793
sS'myalgia,and'
p29794
(F1
F0.00014334862385321102
I1
I0
I1
tp29795
sS'ht3,zofran'
p29796
(F1
F0.00014334862385321102
I0
I1
I-1
tp29797
sS'addition,results'
p29798
(F1
F0.00014334862385321102
I1
I0
I1
tp29799
sS'if,diminished'
p29800
(F1
F0.00014334862385321102
I1
I0
I1
tp29801
sS'vitro,appears'
p29802
(F1
F0.00014334862385321102
I1
I0
I1
tp29803
sS'proliferates,in'
p29804
(F1
F0.00014334862385321102
I0
I1
I-1
tp29805
sS'if,are'
p29806
(F1
F0.00014334862385321102
I1
I0
I1
tp29807
sS'trexan,with'
p29808
(F1
F0.00014334862385321102
I0
I1
I-1
tp29809
sS'was,co-administered'
p29810
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp29811
sS'produced,average'
p29812
(F1
F0.00014334862385321102
I1
I0
I1
tp29813
sS'daily,may'
p29814
(F1
F0.00014334862385321102
I1
I0
I1
tp29815
sS'coexisting,in'
p29816
(F1
F0.00014334862385321102
I0
I1
I-1
tp29817
sS'then,wait'
p29818
(F1
F0.00014334862385321102
I1
I0
I1
tp29819
sS'of,dissolution'
p29820
(F1
F0.00028669724770642203
I0
I2
I-2
tp29821
sS'channel,and'
p29822
(F1
F0.00014334862385321102
I0
I1
I-1
tp29823
sS'fold,increase'
p29824
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp29825
sS'otthostatic,hypotension'
p29826
(F1
F0.00014334862385321102
I0
I1
I-1
tp29827
sS'cns,cardiac'
p29828
(F1
F0.00014334862385321102
I0
I1
I-1
tp29829
sS'may,give'
p29830
(F1
F0.00014334862385321102
I1
I0
I1
tp29831
sS'of,for'
p29832
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29833
sS'of,our'
p29834
(F1
F0.00014334862385321102
I1
I0
I1
tp29835
sS'minutes,after'
p29836
(F0
F0
I1
I1
I0
tp29837
sS'between,intravenous'
p29838
(F1
F0.00014334862385321102
I0
I1
I-1
tp29839
sS'a,defined'
p29840
(F1
F0.00014334862385321102
I0
I1
I-1
tp29841
sS'is,considered'
p29842
(F1
F0.00028669724770642203
I0
I2
I-2
tp29843
sS'bile,acid'
p29844
(F1
F0.00043004587155963305
I3
I0
I3
tp29845
sS'oxidase,inhibitors'
p29846
(F0.90000000000000002
F0.0025802752293577983
I19
I1
I18
tp29847
sS'theophylline,enoxacin'
p29848
(F1
F0.00014334862385321102
I1
I0
I1
tp29849
sS'oxidase,inhibitory'
p29850
(F1
F0.00014334862385321102
I0
I1
I-1
tp29851
sS'coadministration,with'
p29852
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp29853
sS'vasospastic,effects'
p29854
(F1
F0.00014334862385321102
I1
I0
I1
tp29855
sS'water-miscible,or'
p29856
(F1
F0.00014334862385321102
I0
I1
I-1
tp29857
sS'hydrate,may'
p29858
(F1
F0.00014334862385321102
I1
I0
I1
tp29859
sS'an,with'
p29860
(F1
F0.00014334862385321102
I1
I0
I1
tp29861
sS'mainly,metabolized'
p29862
(F1
F0.00014334862385321102
I1
I0
I1
tp29863
sS'which,a'
p29864
(F1
F0.00014334862385321102
I1
I0
I1
tp29865
sS'which,d'
p29866
(F1
F0.00014334862385321102
I1
I0
I1
tp29867
sS'thyroid,administration'
p29868
(F1
F0.00014334862385321102
I1
I0
I1
tp29869
sS'toxic,effect'
p29870
(F1
F0.00014334862385321102
I1
I0
I1
tp29871
sS'best,approach'
p29872
(F1
F0.00014334862385321102
I0
I1
I-1
tp29873
sS'the,rate-decreasing'
p29874
(F1
F0.00014334862385321102
I1
I0
I1
tp29875
sS'months,the'
p29876
(F1
F0.00014334862385321102
I0
I1
I-1
tp29877
sS'the,during'
p29878
(F1
F0.00014334862385321102
I1
I0
I1
tp29879
sS'the,bad'
p29880
(F1
F0.00014334862385321102
I1
I0
I1
tp29881
sS'with,lowered'
p29882
(F1
F0.00028669724770642203
I2
I0
I2
tp29883
sS'increasing,serum'
p29884
(F1
F0.00028669724770642203
I2
I0
I2
tp29885
sS'days,increased'
p29886
(F1
F0.00043004587155963305
I3
I0
I3
tp29887
sS'dexamethasone,had'
p29888
(F1
F0.00014334862385321102
I0
I1
I-1
tp29889
sS'lower,respectively'
p29890
(F1
F0.00014334862385321102
I0
I1
I-1
tp29891
sS'men,who'
p29892
(F1
F0.00014334862385321102
I0
I1
I-1
tp29893
sS'days,increases'
p29894
(F1
F0.00014334862385321102
I0
I1
I-1
tp29895
sS'which,increases'
p29896
(F1
F0.00014334862385321102
I1
I0
I1
tp29897
sS'concomitant,supplementation'
p29898
(F1
F0.00014334862385321102
I0
I1
I-1
tp29899
sS'other,asthma'
p29900
(F1
F0.00014334862385321102
I0
I1
I-1
tp29901
sS'invirase,is'
p29902
(F1
F0.00014334862385321102
I1
I0
I1
tp29903
sS'l-ccg,on'
p29904
(F1
F0.00014334862385321102
I0
I1
I-1
tp29905
sS'valproate,tiagabine'
p29906
(F1
F0.00014334862385321102
I1
I0
I1
tp29907
sS'increased,risk'
p29908
(F0.33333333333333331
F0.0008600917431192661
I12
I6
I6
tp29909
sS'therapeutic,actions'
p29910
(F1
F0.00014334862385321102
I1
I0
I1
tp29911
sS'auc,decreased'
p29912
(F1
F0.00014334862385321102
I1
I0
I1
tp29913
sS'a,useful'
p29914
(F1
F0.00014334862385321102
I0
I1
I-1
tp29915
sS'with,plendil'
p29916
(F1
F0.00014334862385321102
I0
I1
I-1
tp29917
sS'characterized,by'
p29918
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp29919
sS'and,cyp'
p29920
(F1
F0.00057339449541284407
I0
I4
I-4
tp29921
sS'initiating,adjusting'
p29922
(F1
F0.00057339449541284407
I4
I0
I4
tp29923
sS'to,occur'
p29924
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29925
sS'ii,clinical'
p29926
(F1
F0.00014334862385321102
I1
I0
I1
tp29927
sS'positive,and'
p29928
(F1
F0.00043004587155963305
I0
I3
I-3
tp29929
sS'laboratory,tests'
p29930
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp29931
sS'ex,vivo'
p29932
(F1
F0.00014334862385321102
I0
I1
I-1
tp29933
sS'each,other'
p29934
(F1
F0.00071674311926605509
I5
I0
I5
tp29935
sS'liver,is'
p29936
(F1
F0.00014334862385321102
I1
I0
I1
tp29937
sS'suppression,by'
p29938
(F1
F0.00028669724770642203
I2
I0
I2
tp29939
sS'with,therapeutic'
p29940
(F0
F0
I1
I1
I0
tp29941
sS'clinical,trials'
p29942
(F0.66666666666666663
F0.0022935779816513763
I4
I20
I-16
tp29943
sS'fashion,as'
p29944
(F1
F0.00014334862385321102
I1
I0
I1
tp29945
sS'experience,toxicity'
p29946
(F1
F0.00014334862385321102
I1
I0
I1
tp29947
sS'these,drugs'
p29948
(F1
F0.00043004587155963305
I0
I3
I-3
tp29949
sS'amphetamines,potentiate'
p29950
(F1
F0.00028669724770642203
I2
I0
I2
tp29951
sS'of,k-dependent'
p29952
(F1
F0.00028669724770642203
I0
I2
I-2
tp29953
sS'patients,should'
p29954
(F0.53846153846153844
F0.0010034403669724771
I10
I3
I7
tp29955
sS'meq,l'
p29956
(F0
F0
I1
I1
I0
tp29957
sS'volume,fewer'
p29958
(F1
F0.00014334862385321102
I0
I1
I-1
tp29959
sS'with,sustained-release'
p29960
(F1
F0.00014334862385321102
I0
I1
I-1
tp29961
sS'c9,c19'
p29962
(F1
F0.00028669724770642203
I0
I2
I-2
tp29963
sS'potentially,aggravating'
p29964
(F1
F0.00014334862385321102
I1
I0
I1
tp29965
sS'week,for'
p29966
(F1
F0.00014334862385321102
I1
I0
I1
tp29967
sS'nerve,transmission'
p29968
(F1
F0.00014334862385321102
I0
I1
I-1
tp29969
sS'first,rapid'
p29970
(F1
F0.00014334862385321102
I0
I1
I-1
tp29971
sS'infusions,of'
p29972
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29973
sS'rate,and'
p29974
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp29975
sS'the,monoamine'
p29976
(F1
F0.00014334862385321102
I0
I1
I-1
tp29977
sS'is,summarized'
p29978
(F1
F0.00014334862385321102
I0
I1
I-1
tp29979
sS'by,brevibloc'
p29980
(F1
F0.00014334862385321102
I1
I0
I1
tp29981
sS'the,antianginal'
p29982
(F1
F0.00014334862385321102
I0
I1
I-1
tp29983
sS'after,administration'
p29984
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp29985
sS'condition,worse'
p29986
(F1
F0.00014334862385321102
I0
I1
I-1
tp29987
sS'tumor,virus'
p29988
(F1
F0.00014334862385321102
I0
I1
I-1
tp29989
sS'antihypertensive,action'
p29990
(F1
F0.00014334862385321102
I1
I0
I1
tp29991
sS'major,circulating'
p29992
(F1
F0.00014334862385321102
I0
I1
I-1
tp29993
sS'chronic,treatment'
p29994
(F1
F0.00014334862385321102
I1
I0
I1
tp29995
sS'maxipime,because'
p29996
(F1
F0.00014334862385321102
I1
I0
I1
tp29997
sS'produced,no'
p29998
(F1
F0.00014334862385321102
I0
I1
I-1
tp29999
sS'and,local'
p30000
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp30001
sS'react,with'
p30002
(F1
F0.00014334862385321102
I1
I0
I1
tp30003
sS'function,the'
p30004
(F1
F0.00014334862385321102
I1
I0
I1
tp30005
sS'hypoglycemics,bepridil'
p30006
(F1
F0.00014334862385321102
I0
I1
I-1
tp30007
sS'hiv-nhl,the'
p30008
(F1
F0.00014334862385321102
I0
I1
I-1
tp30009
sS'poisoning,although'
p30010
(F1
F0.00014334862385321102
I1
I0
I1
tp30011
sS'with,its'
p30012
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30013
sS'urinary,acidifying'
p30014
(F1
F0.00043004587155963305
I3
I0
I3
tp30015
sS'the,cns'
p30016
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp30017
sS'studies,designed'
p30018
(F1
F0.00014334862385321102
I0
I1
I-1
tp30019
sS'oral,aprepitant'
p30020
(F1
F0.00014334862385321102
I1
I0
I1
tp30021
sS'adversely,affected'
p30022
(F1
F0.00014334862385321102
I1
I0
I1
tp30023
sS'administered,over'
p30024
(F1
F0.00014334862385321102
I0
I1
I-1
tp30025
sS'inducer,a'
p30026
(F1
F0.00014334862385321102
I0
I1
I-1
tp30027
sS'logarithmic,fashion'
p30028
(F1
F0.00014334862385321102
I0
I1
I-1
tp30029
sS'strains,of'
p30030
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp30031
sS'discrimination,and'
p30032
(F1
F0.00043004587155963305
I0
I3
I-3
tp30033
sS'and,bretylium'
p30034
(F1
F0.00014334862385321102
I0
I1
I-1
tp30035
sS'plasma,levels'
p30036
(F0.49450549450549453
F0.0064506880733944958
I68
I23
I45
tp30037
sS'that,produced'
p30038
(F1
F0.00014334862385321102
I0
I1
I-1
tp30039
sS'its,two'
p30040
(F1
F0.00014334862385321102
I0
I1
I-1
tp30041
sS'serum,potassium'
p30042
(F1
F0.00043004587155963305
I3
I0
I3
tp30043
sS'extent,to'
p30044
(F1
F0.00071674311926605509
I5
I0
I5
tp30045
sS'lethargy,fever'
p30046
(F1
F0.00014334862385321102
I1
I0
I1
tp30047
sS'dose-dependent,increase'
p30048
(F1
F0.00014334862385321102
I1
I0
I1
tp30049
sS'tenormin,sectral'
p30050
(F1
F0.00014334862385321102
I0
I1
I-1
tp30051
sS'b,the'
p30052
(F1
F0.00028669724770642203
I0
I2
I-2
tp30053
sS'variable,half-life'
p30054
(F1
F0.00014334862385321102
I0
I1
I-1
tp30055
sS'in,diabetics'
p30056
(F1
F0.00014334862385321102
I1
I0
I1
tp30057
sS'second,hour'
p30058
(F1
F0.00014334862385321102
I0
I1
I-1
tp30059
sS'ml,nor'
p30060
(F1
F0.00014334862385321102
I0
I1
I-1
tp30061
sS'other,multivalent'
p30062
(F1
F0.00028669724770642203
I2
I0
I2
tp30063
sS'are,developed'
p30064
(F1
F0.00014334862385321102
I0
I1
I-1
tp30065
sS'antagonistic,effect'
p30066
(F1
F0.00014334862385321102
I1
I0
I1
tp30067
sS'the,trials'
p30068
(F1
F0.00028669724770642203
I0
I2
I-2
tp30069
sS'age,of'
p30070
(F1
F0.00014334862385321102
I0
I1
I-1
tp30071
sS'recommended,dose'
p30072
(F0.5
F0.00028669724770642203
I3
I1
I2
tp30073
sS'niacin,nicotinic'
p30074
(F1
F0.00028669724770642203
I0
I2
I-2
tp30075
sS'aluminum-containing,products'
p30076
(F1
F0.00014334862385321102
I1
I0
I1
tp30077
sS'a,that'
p30078
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp30079
sS'an,adjustment'
p30080
(F1
F0.00028669724770642203
I0
I2
I-2
tp30081
sS'in,by'
p30082
(F1
F0.00014334862385321102
I1
I0
I1
tp30083
sS'trial,a'
p30084
(F1
F0.00014334862385321102
I0
I1
I-1
tp30085
sS'of,cardiopulmonary'
p30086
(F1
F0.00014334862385321102
I0
I1
I-1
tp30087
sS'therefore,has'
p30088
(F0
F0
I1
I1
I0
tp30089
sS'quinidine,immediate'
p30090
(F1
F0.00014334862385321102
I1
I0
I1
tp30091
sS'more,than'
p30092
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp30093
sS'may,possibly'
p30094
(F1
F0.00014334862385321102
I0
I1
I-1
tp30095
sS'except,that'
p30096
(F1
F0.00014334862385321102
I1
I0
I1
tp30097
sS'however,no'
p30098
(F1
F0.00028669724770642203
I0
I2
I-2
tp30099
sS'it,would'
p30100
(F0
F0
I1
I1
I0
tp30101
sS'digitalized,hypothyroid'
p30102
(F1
F0.00014334862385321102
I1
I0
I1
tp30103
sS'a,significantly'
p30104
(F1
F0.00014334862385321102
I0
I1
I-1
tp30105
sS'mediated,metabolism'
p30106
(F1
F0.00014334862385321102
I0
I1
I-1
tp30107
sS'in,either'
p30108
(F1
F0.00057339449541284407
I0
I4
I-4
tp30109
sS'human,interaction'
p30110
(F1
F0.00028669724770642203
I0
I2
I-2
tp30111
sS'schizoaffective,disorder'
p30112
(F1
F0.00014334862385321102
I1
I0
I1
tp30113
sS'a,which'
p30114
(F1
F0.00014334862385321102
I1
I0
I1
tp30115
sS'other,central'
p30116
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp30117
sS'low-dose,hcl'
p30118
(F1
F0.00014334862385321102
I1
I0
I1
tp30119
sS'micro-dosed,progesterone'
p30120
(F1
F0.00014334862385321102
I1
I0
I1
tp30121
sS'inhibits,metabolism'
p30122
(F1
F0.00014334862385321102
I1
I0
I1
tp30123
sS'any,medication'
p30124
(F1
F0.00014334862385321102
I1
I0
I1
tp30125
sS'others,medrol'
p30126
(F1
F0.00014334862385321102
I0
I1
I-1
tp30127
sS'smx,such'
p30128
(F1
F0.00014334862385321102
I0
I1
I-1
tp30129
sS'class,may'
p30130
(F1
F0.00014334862385321102
I1
I0
I1
tp30131
sS'were,equivocally'
p30132
(F1
F0.00014334862385321102
I1
I0
I1
tp30133
sS'a,nitrosamine'
p30134
(F1
F0.00014334862385321102
I1
I0
I1
tp30135
sS'and,descarboethoxyloratadine'
p30136
(F1
F0.00014334862385321102
I0
I1
I-1
tp30137
sS'l-name,and'
p30138
(F1
F0.00014334862385321102
I0
I1
I-1
tp30139
sS'rats,increased'
p30140
(F1
F0.00014334862385321102
I1
I0
I1
tp30141
sS'steady-state,plasma'
p30142
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp30143
sS'amines,may'
p30144
(F1
F0.00014334862385321102
I1
I0
I1
tp30145
sS'the,palytoxin-induced'
p30146
(F1
F0.00014334862385321102
I0
I1
I-1
tp30147
sS'ages,to'
p30148
(F1
F0.00014334862385321102
I1
I0
I1
tp30149
sS'of,toradol'
p30150
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp30151
sS'taxol,was'
p30152
(F1
F0.00028669724770642203
I2
I0
I2
tp30153
sS'the,hepatic'
p30154
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp30155
sS'blunted,by'
p30156
(F1
F0.00028669724770642203
I2
I0
I2
tp30157
sS'with,celebrex'
p30158
(F1
F0.00028669724770642203
I2
I0
I2
tp30159
sS'vitro,in'
p30160
(F1
F0.00014334862385321102
I1
I0
I1
tp30161
sS'concentrations,up'
p30162
(F1
F0.00014334862385321102
I0
I1
I-1
tp30163
sS'for,drug-induced'
p30164
(F1
F0.00014334862385321102
I0
I1
I-1
tp30165
sS'hypertension,which'
p30166
(F1
F0.00014334862385321102
I1
I0
I1
tp30167
sS'elemental,primarily'
p30168
(F1
F0.00014334862385321102
I0
I1
I-1
tp30169
sS'in,high'
p30170
(F1
F0.00014334862385321102
I1
I0
I1
tp30171
sS'therefore,concurrent'
p30172
(F1
F0.00028669724770642203
I2
I0
I2
tp30173
sS'and,a4'
p30174
(F1
F0.00014334862385321102
I0
I1
I-1
tp30175
sS'in,treatment'
p30176
(F1
F0.00014334862385321102
I0
I1
I-1
tp30177
sS'of,required'
p30178
(F1
F0.00028669724770642203
I2
I0
I2
tp30179
sS'nonsteroidal,can'
p30180
(F1
F0.00014334862385321102
I1
I0
I1
tp30181
sS'the,overall'
p30182
(F0
F0
I1
I1
I0
tp30183
sS'bumetanide,may'
p30184
(F1
F0.00014334862385321102
I1
I0
I1
tp30185
sS'before,idv'
p30186
(F1
F0.00014334862385321102
I0
I1
I-1
tp30187
sS'acetohydroxamic,acid'
p30188
(F1
F0.00014334862385321102
I0
I1
I-1
tp30189
sS'respectively,on'
p30190
(F1
F0.00014334862385321102
I1
I0
I1
tp30191
sS'respectively,of'
p30192
(F0
F0
I1
I1
I0
tp30193
sS'antacids,concomitant'
p30194
(F0
F0
I2
I2
I0
tp30195
sS'carbidopa-levodopa,combination'
p30196
(F1
F0.00014334862385321102
I0
I1
I-1
tp30197
sS'and,an'
p30198
(F0.76470588235294112
F0.0018635321100917432
I15
I2
I13
tp30199
sS'aminotransferases,was'
p30200
(F1
F0.00014334862385321102
I0
I1
I-1
tp30201
sS'systemic,levels'
p30202
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp30203
sS'and,maois'
p30204
(F1
F0.00028669724770642203
I2
I0
I2
tp30205
sS'with,taxol'
p30206
(F1
F0.00014334862385321102
I0
I1
I-1
tp30207
sS'and,at'
p30208
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp30209
sS'and,av'
p30210
(F0
F0
I1
I1
I0
tp30211
sS'and,as'
p30212
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30213
sS'with,hydrochloride'
p30214
(F1
F0.00014334862385321102
I0
I1
I-1
tp30215
sS'p450,d6'
p30216
(F1
F0.0025802752293577983
I0
I18
I-18
tp30217
sS'a,typical'
p30218
(F1
F0.00014334862385321102
I0
I1
I-1
tp30219
sS'divided,into'
p30220
(F0
F0
I1
I1
I0
tp30221
sS'fluoride,or'
p30222
(F1
F0.00014334862385321102
I0
I1
I-1
tp30223
sS'lipid,response'
p30224
(F1
F0.00014334862385321102
I1
I0
I1
tp30225
sS'gvia,omega-agatoxin'
p30226
(F1
F0.00014334862385321102
I0
I1
I-1
tp30227
sS'four,subjects'
p30228
(F1
F0.00014334862385321102
I0
I1
I-1
tp30229
sS'from,healthy'
p30230
(F1
F0.00014334862385321102
I0
I1
I-1
tp30231
sS'in,bovine'
p30232
(F1
F0.00043004587155963305
I0
I3
I-3
tp30233
sS'to,have'
p30234
(F0.14285714285714285
F0.00043004587155963305
I9
I12
I-3
tp30235
sS'administering,hcl'
p30236
(F1
F0.00014334862385321102
I1
I0
I1
tp30237
sS'drugs,significant'
p30238
(F1
F0.00014334862385321102
I1
I0
I1
tp30239
sS'test,interferences'
p30240
(F1
F0.00014334862385321102
I0
I1
I-1
tp30241
sS'variation,in'
p30242
(F1
F0.00014334862385321102
I1
I0
I1
tp30243
sS'tubular,transport'
p30244
(F1
F0.00014334862385321102
I1
I0
I1
tp30245
sS'antagonists,since'
p30246
(F1
F0.00014334862385321102
I1
I0
I1
tp30247
sS'including,oral'
p30248
(F0.5
F0.00028669724770642203
I3
I1
I2
tp30249
sS'was,included'
p30250
(F1
F0.00014334862385321102
I0
I1
I-1
tp30251
sS'by,concomitant'
p30252
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp30253
sS'change,fasting'
p30254
(F1
F0.00014334862385321102
I0
I1
I-1
tp30255
sS'or,another'
p30256
(F1
F0.00014334862385321102
I1
I0
I1
tp30257
sS'qd,was'
p30258
(F1
F0.00014334862385321102
I0
I1
I-1
tp30259
sS'kadian,ms'
p30260
(F1
F0.00014334862385321102
I1
I0
I1
tp30261
sS'vardenafil,in'
p30262
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30263
sS'pivoxil,administered'
p30264
(F1
F0.00014334862385321102
I1
I0
I1
tp30265
sS'selective,regulation'
p30266
(F1
F0.00014334862385321102
I0
I1
I-1
tp30267
sS'ip,or'
p30268
(F1
F0.00014334862385321102
I1
I0
I1
tp30269
sS'its,major'
p30270
(F1
F0.00028669724770642203
I0
I2
I-2
tp30271
sS'administration,may'
p30272
(F1
F0.00028669724770642203
I2
I0
I2
tp30273
sS'disulfiram,should'
p30274
(F1
F0.00014334862385321102
I1
I0
I1
tp30275
sS'a,false'
p30276
(F1
F0.00028669724770642203
I0
I2
I-2
tp30277
sS'through,searches'
p30278
(F1
F0.00014334862385321102
I0
I1
I-1
tp30279
sS'improvements,in'
p30280
(F1
F0.00028669724770642203
I0
I2
I-2
tp30281
sS'contractility,conductivity'
p30282
(F1
F0.00014334862385321102
I1
I0
I1
tp30283
sS'addition,to'
p30284
(F0.5
F0.00028669724770642203
I3
I1
I2
tp30285
sS'with,causes'
p30286
(F1
F0.00014334862385321102
I1
I0
I1
tp30287
sS'natriuretic,effect'
p30288
(F1
F0.0008600917431192661
I6
I0
I6
tp30289
sS'depressants,are'
p30290
(F1
F0.00014334862385321102
I1
I0
I1
tp30291
sS'conjugation,with'
p30292
(F1
F0.00014334862385321102
I1
I0
I1
tp30293
sS'coincide,duloxetine'
p30294
(F1
F0.00014334862385321102
I0
I1
I-1
tp30295
sS'of,oxidized'
p30296
(F1
F0.00014334862385321102
I0
I1
I-1
tp30297
sS'parameters,of'
p30298
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp30299
sS'and,omega-conotoxin'
p30300
(F1
F0.00014334862385321102
I0
I1
I-1
tp30301
sS'aggregation,in'
p30302
(F1
F0.00014334862385321102
I0
I1
I-1
tp30303
sS'any,significant'
p30304
(F0
F0
I1
I1
I0
tp30305
sS'when,midamor'
p30306
(F1
F0.00014334862385321102
I1
I0
I1
tp30307
sS'two,at'
p30308
(F1
F0.00014334862385321102
I0
I1
I-1
tp30309
sS'withdrawal,of'
p30310
(F0
F0
I1
I1
I0
tp30311
sS'be,of'
p30312
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30313
sS'as,triazolopyridazines'
p30314
(F1
F0.00014334862385321102
I1
I0
I1
tp30315
sS'phenytoin,increases'
p30316
(F1
F0.00014334862385321102
I1
I0
I1
tp30317
sS'capsules,with'
p30318
(F0
F0
I1
I1
I0
tp30319
sS'long-acting,is'
p30320
(F1
F0.00014334862385321102
I0
I1
I-1
tp30321
sS'preparations,eg'
p30322
(F1
F0.00043004587155963305
I3
I0
I3
tp30323
sS'sodium,citrate'
p30324
(F1
F0.00014334862385321102
I1
I0
I1
tp30325
sS'a,toxicology'
p30326
(F1
F0.00014334862385321102
I1
I0
I1
tp30327
sS'or,because'
p30328
(F1
F0.00014334862385321102
I1
I0
I1
tp30329
sS'over,a'
p30330
(F0
F0
I1
I1
I0
tp30331
sS'therapy,omnicef'
p30332
(F1
F0.00028669724770642203
I2
I0
I2
tp30333
sS'that,requirements'
p30334
(F1
F0.00014334862385321102
I1
I0
I1
tp30335
sS'system,with'
p30336
(F1
F0.00014334862385321102
I1
I0
I1
tp30337
sS'and,cyp4a11'
p30338
(F1
F0.00014334862385321102
I0
I1
I-1
tp30339
sS'in,low'
p30340
(F1
F0.00028669724770642203
I2
I0
I2
tp30341
sS'minutes,of'
p30342
(F0
F0
I1
I1
I0
tp30343
sS'by,h2'
p30344
(F1
F0.00014334862385321102
I1
I0
I1
tp30345
sS'normovolemic,healthy'
p30346
(F1
F0.00014334862385321102
I1
I0
I1
tp30347
sS'l-phenylalanine,may'
p30348
(F1
F0.00014334862385321102
I1
I0
I1
tp30349
sS'perioperative,period'
p30350
(F1
F0.00014334862385321102
I1
I0
I1
tp30351
sS'cyp3a4,inhibitor'
p30352
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp30353
sS'conclude,that'
p30354
(F1
F0.00028669724770642203
I2
I0
I2
tp30355
sS'approximately,by'
p30356
(F1
F0.00014334862385321102
I1
I0
I1
tp30357
sS'or,dosage'
p30358
(F1
F0.00014334862385321102
I0
I1
I-1
tp30359
sS'by,added'
p30360
(F1
F0.00014334862385321102
I0
I1
I-1
tp30361
sS'pulmonary,disease'
p30362
(F1
F0.00014334862385321102
I0
I1
I-1
tp30363
sS'been,well'
p30364
(F1
F0.00028669724770642203
I0
I2
I-2
tp30365
sS'omeprazole,should'
p30366
(F1
F0.00014334862385321102
I0
I1
I-1
tp30367
sS'a,decline'
p30368
(F1
F0.00014334862385321102
I0
I1
I-1
tp30369
sS'other,systemic'
p30370
(F1
F0.00014334862385321102
I1
I0
I1
tp30371
sS'therefore,coadministration'
p30372
(F0
F0
I1
I1
I0
tp30373
sS'gastric,ph'
p30374
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp30375
sS'are,examples'
p30376
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp30377
sS'extent,enhanced'
p30378
(F1
F0.00014334862385321102
I0
I1
I-1
tp30379
sS'given,prior'
p30380
(F0
F0
I1
I1
I0
tp30381
sS'anaphylactic,reaction'
p30382
(F1
F0.00014334862385321102
I1
I0
I1
tp30383
sS'carbamazepine,tiagabine'
p30384
(F1
F0.00014334862385321102
I0
I1
I-1
tp30385
sS'platelet,function'
p30386
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp30387
sS'active,epoxide'
p30388
(F1
F0.00014334862385321102
I0
I1
I-1
tp30389
sS'colchicine,is'
p30390
(F1
F0.00014334862385321102
I1
I0
I1
tp30391
sS'similar,with'
p30392
(F1
F0.00014334862385321102
I0
I1
I-1
tp30393
sS'markedly,reduced'
p30394
(F1
F0.00014334862385321102
I1
I0
I1
tp30395
sS'of,binding'
p30396
(F1
F0.00014334862385321102
I1
I0
I1
tp30397
sS'frova_od,htm'
p30398
(F1
F0.00014334862385321102
I1
I0
I1
tp30399
sS'studies,of'
p30400
(F0.125
F0.00028669724770642203
I7
I9
I-2
tp30401
sS'a,chop-like'
p30402
(F1
F0.00014334862385321102
I0
I1
I-1
tp30403
sS'mumol,liter'
p30404
(F1
F0.00014334862385321102
I1
I0
I1
tp30405
sS'studies,on'
p30406
(F1
F0.00043004587155963305
I0
I3
I-3
tp30407
sS'blunt,the'
p30408
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30409
sS'parameters,without'
p30410
(F1
F0.00014334862385321102
I0
I1
I-1
tp30411
sS'in,decreasing'
p30412
(F1
F0.00014334862385321102
I0
I1
I-1
tp30413
sS'ibuprofen,is'
p30414
(F1
F0.00014334862385321102
I0
I1
I-1
tp30415
sS'two-way,interaction'
p30416
(F1
F0.00014334862385321102
I1
I0
I1
tp30417
sS'three,lines'
p30418
(F1
F0.00014334862385321102
I0
I1
I-1
tp30419
sS'levo-dromoran,with'
p30420
(F1
F0.00014334862385321102
I1
I0
I1
tp30421
sS'of,dosages'
p30422
(F1
F0.00014334862385321102
I0
I1
I-1
tp30423
sS'inflammatory,with'
p30424
(F1
F0.00014334862385321102
I1
I0
I1
tp30425
sS'of,suggesting'
p30426
(F1
F0.00014334862385321102
I0
I1
I-1
tp30427
sS'therapy,when'
p30428
(F1
F0.00014334862385321102
I1
I0
I1
tp30429
sS'sulfonate,soybean'
p30430
(F1
F0.00014334862385321102
I1
I0
I1
tp30431
sS'received,in'
p30432
(F1
F0.00014334862385321102
I0
I1
I-1
tp30433
sS'of,mice'
p30434
(F1
F0.00014334862385321102
I0
I1
I-1
tp30435
sS'rifampin,has'
p30436
(F1
F0.00014334862385321102
I1
I0
I1
tp30437
sS'depressants,such'
p30438
(F1
F0.00043004587155963305
I3
I0
I3
tp30439
sS'either,increase'
p30440
(F1
F0.00014334862385321102
I1
I0
I1
tp30441
sS'than,suggest'
p30442
(F1
F0.00028669724770642203
I2
I0
I2
tp30443
sS'arava,to'
p30444
(F1
F0.00014334862385321102
I1
I0
I1
tp30445
sS'not,diminish'
p30446
(F1
F0.00014334862385321102
I0
I1
I-1
tp30447
sS'in,excretion'
p30448
(F1
F0.00014334862385321102
I1
I0
I1
tp30449
sS'compounds,that'
p30450
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp30451
sS'adrenal,synthesis'
p30452
(F1
F0.00014334862385321102
I1
I0
I1
tp30453
sS'to,evaluate'
p30454
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp30455
sS'has,recovered'
p30456
(F1
F0.00014334862385321102
I1
I0
I1
tp30457
sS'evidence,in'
p30458
(F1
F0.00014334862385321102
I0
I1
I-1
tp30459
sS'rats,have'
p30460
(F1
F0.00014334862385321102
I1
I0
I1
tp30461
sS'coumarin,anticoagulants'
p30462
(F0.5
F0.00028669724770642203
I3
I1
I2
tp30463
sS'while,no'
p30464
(F1
F0.00014334862385321102
I1
I0
I1
tp30465
sS'of,aczone'
p30466
(F1
F0.00014334862385321102
I0
I1
I-1
tp30467
sS'estrogen-containing,compounds'
p30468
(F1
F0.00014334862385321102
I1
I0
I1
tp30469
sS'hypertension,where'
p30470
(F1
F0.00014334862385321102
I0
I1
I-1
tp30471
sS'only,increases'
p30472
(F1
F0.00014334862385321102
I0
I1
I-1
tp30473
sS'aprepitant,on'
p30474
(F1
F0.00028669724770642203
I2
I0
I2
tp30475
sS'half-life,decreased'
p30476
(F1
F0.00014334862385321102
I1
I0
I1
tp30477
sS'not,nanm'
p30478
(F1
F0.00028669724770642203
I2
I0
I2
tp30479
sS'pacemaker,activity'
p30480
(F1
F0.00014334862385321102
I1
I0
I1
tp30481
sS'to,potentiate'
p30482
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30483
sS'under,acidic'
p30484
(F1
F0.00014334862385321102
I1
I0
I1
tp30485
sS'hemodynamic,and'
p30486
(F1
F0.00014334862385321102
I0
I1
I-1
tp30487
sS'between,study'
p30488
(F1
F0.00014334862385321102
I0
I1
I-1
tp30489
sS'net,decrease'
p30490
(F1
F0.00014334862385321102
I1
I0
I1
tp30491
sS'neuron,blockade'
p30492
(F1
F0.00014334862385321102
I1
I0
I1
tp30493
sS'subjects,were'
p30494
(F1
F0.00028669724770642203
I0
I2
I-2
tp30495
sS'since,invirase'
p30496
(F1
F0.00014334862385321102
I1
I0
I1
tp30497
sS'hypotension,vs'
p30498
(F1
F0.00014334862385321102
I1
I0
I1
tp30499
sS'a,reduction'
p30500
(F0.78947368421052633
F0.0021502293577981653
I17
I2
I15
tp30501
sS'azole,inhibits'
p30502
(F1
F0.00014334862385321102
I1
I0
I1
tp30503
sS'peptide,in'
p30504
(F1
F0.00014334862385321102
I0
I1
I-1
tp30505
sS'oil-concomitant,intake'
p30506
(F1
F0.00014334862385321102
I1
I0
I1
tp30507
sS'of,zyvox'
p30508
(F1
F0.00014334862385321102
I1
I0
I1
tp30509
sS'd,but'
p30510
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30511
sS'deleted,from'
p30512
(F1
F0.00028669724770642203
I2
I0
I2
tp30513
sS'metastasis,of'
p30514
(F0
F0
I1
I1
I0
tp30515
sS'be,compromised'
p30516
(F1
F0.00014334862385321102
I1
I0
I1
tp30517
sS'limited,data'
p30518
(F1
F0.00014334862385321102
I1
I0
I1
tp30519
sS'increased,cns'
p30520
(F1
F0.00014334862385321102
I1
I0
I1
tp30521
sS'anti-arrhythmics,and'
p30522
(F1
F0.00014334862385321102
I1
I0
I1
tp30523
sS'terminated,the'
p30524
(F1
F0.00014334862385321102
I1
I0
I1
tp30525
sS'concurrently,concentrations'
p30526
(F1
F0.00014334862385321102
I1
I0
I1
tp30527
sS'relevant,pharmacokinetic'
p30528
(F1
F0.00028669724770642203
I0
I2
I-2
tp30529
sS'when,equetrotm'
p30530
(F1
F0.00014334862385321102
I1
I0
I1
tp30531
sS'studied,following'
p30532
(F1
F0.00014334862385321102
I0
I1
I-1
tp30533
sS'effect,the'
p30534
(F1
F0.00014334862385321102
I1
I0
I1
tp30535
sS'metabolized,to'
p30536
(F1
F0.00057339449541284407
I0
I4
I-4
tp30537
sS'function,or'
p30538
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp30539
sS'enzyme,preparations'
p30540
(F1
F0.00014334862385321102
I1
I0
I1
tp30541
sS'the,adrenergic'
p30542
(F0
F0
I1
I1
I0
tp30543
sS'function,of'
p30544
(F1
F0.00014334862385321102
I1
I0
I1
tp30545
sS'doxorubicin,caused'
p30546
(F1
F0.00014334862385321102
I1
I0
I1
tp30547
sS'prepared,in'
p30548
(F1
F0.00014334862385321102
I0
I1
I-1
tp30549
sS'so,careful'
p30550
(F1
F0.00014334862385321102
I1
I0
I1
tp30551
sS'kemstrotm,was'
p30552
(F1
F0.00014334862385321102
I0
I1
I-1
tp30553
sS'the,sole'
p30554
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp30555
sS'this,information'
p30556
(F0
F0
I1
I1
I0
tp30557
sS'gvia,n-type'
p30558
(F1
F0.00014334862385321102
I0
I1
I-1
tp30559
sS'patients,had'
p30560
(F1
F0.00014334862385321102
I0
I1
I-1
tp30561
sS'inhibitors,hypertensive'
p30562
(F1
F0.00014334862385321102
I1
I0
I1
tp30563
sS'l-histidine,was'
p30564
(F1
F0.00014334862385321102
I1
I0
I1
tp30565
sS'arrhythmias,and'
p30566
(F1
F0.00014334862385321102
I1
I0
I1
tp30567
sS'taxol,should'
p30568
(F1
F0.00014334862385321102
I0
I1
I-1
tp30569
sS'over,hours'
p30570
(F1
F0.00014334862385321102
I0
I1
I-1
tp30571
sS'is,far'
p30572
(F1
F0.00014334862385321102
I0
I1
I-1
tp30573
sS'excess,may'
p30574
(F1
F0.00014334862385321102
I1
I0
I1
tp30575
sS'trial,as'
p30576
(F1
F0.00014334862385321102
I1
I0
I1
tp30577
sS'pressure,in'
p30578
(F1
F0.00014334862385321102
I0
I1
I-1
tp30579
sS'as,diminished'
p30580
(F1
F0.00014334862385321102
I1
I0
I1
tp30581
sS'see,a'
p30582
(F1
F0.00028669724770642203
I2
I0
I2
tp30583
sS'a,stimulating'
p30584
(F1
F0.00014334862385321102
I1
I0
I1
tp30585
sS'the,context'
p30586
(F1
F0.00014334862385321102
I0
I1
I-1
tp30587
sS'lowered,the'
p30588
(F1
F0.00028669724770642203
I2
I0
I2
tp30589
sS'following,or'
p30590
(F0
F0
I1
I1
I0
tp30591
sS'depressants,but'
p30592
(F1
F0.00014334862385321102
I0
I1
I-1
tp30593
sS'efficient,substrate'
p30594
(F1
F0.00014334862385321102
I0
I1
I-1
tp30595
sS'observed,there'
p30596
(F1
F0.00014334862385321102
I0
I1
I-1
tp30597
sS'upon,the'
p30598
(F1
F0.00028669724770642203
I2
I0
I2
tp30599
sS'myocardium,to'
p30600
(F1
F0.00043004587155963305
I3
I0
I3
tp30601
sS'medication,used'
p30602
(F1
F0.00014334862385321102
I0
I1
I-1
tp30603
sS'urinary,uric'
p30604
(F1
F0.00014334862385321102
I1
I0
I1
tp30605
sS'ultracentrifugation,indicated'
p30606
(F1
F0.00014334862385321102
I0
I1
I-1
tp30607
sS'cyp3a,inducers'
p30608
(F1
F0.00014334862385321102
I1
I0
I1
tp30609
sS'cyp,c9'
p30610
(F1
F0.00028669724770642203
I0
I2
I-2
tp30611
sS'net,effects'
p30612
(F1
F0.00014334862385321102
I1
I0
I1
tp30613
sS'a,linear'
p30614
(F1
F0.00014334862385321102
I0
I1
I-1
tp30615
sS'of,nonsmoking'
p30616
(F1
F0.00014334862385321102
I0
I1
I-1
tp30617
sS'cells,by'
p30618
(F1
F0.00014334862385321102
I0
I1
I-1
tp30619
sS'decrease,vascular'
p30620
(F1
F0.00014334862385321102
I1
I0
I1
tp30621
sS'its,inhibitory'
p30622
(F0
F0
I1
I1
I0
tp30623
sS'live,and'
p30624
(F1
F0.00014334862385321102
I1
I0
I1
tp30625
sS'midazolam,aprepitant'
p30626
(F1
F0.00014334862385321102
I1
I0
I1
tp30627
sS'produced,depletions'
p30628
(F1
F0.00014334862385321102
I1
I0
I1
tp30629
sS'acute,pharmacological'
p30630
(F1
F0.00014334862385321102
I0
I1
I-1
tp30631
sS'therefore,a'
p30632
(F0
F0
I1
I1
I0
tp30633
sS'other,caution'
p30634
(F1
F0.00028669724770642203
I2
I0
I2
tp30635
sS'commonly,reported'
p30636
(F1
F0.00014334862385321102
I1
I0
I1
tp30637
sS'hepatotoxic,influenza'
p30638
(F1
F0.00014334862385321102
I1
I0
I1
tp30639
sS'k,may'
p30640
(F1
F0.00043004587155963305
I3
I0
I3
tp30641
sS'time,or'
p30642
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp30643
sS'produces,a'
p30644
(F1
F0.00028669724770642203
I2
I0
I2
tp30645
sS'time,of'
p30646
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp30647
sS'interaction,study'
p30648
(F0.55555555555555558
F0.0014334862385321102
I4
I14
I-10
tp30649
sS'appropriate,in'
p30650
(F1
F0.00014334862385321102
I0
I1
I-1
tp30651
sS'compete,for'
p30652
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp30653
sS'hypotension,with'
p30654
(F1
F0.00014334862385321102
I1
I0
I1
tp30655
sS'potassium-sparing,and'
p30656
(F1
F0.00028669724770642203
I0
I2
I-2
tp30657
sS'because,of'
p30658
(F0.47619047619047616
F0.0028669724770642203
I31
I11
I20
tp30659
sS'evidently,the'
p30660
(F1
F0.00014334862385321102
I1
I0
I1
tp30661
sS'by,nuromax'
p30662
(F1
F0.00014334862385321102
I1
I0
I1
tp30663
sS'placebo,were'
p30664
(F1
F0.00014334862385321102
I0
I1
I-1
tp30665
sS'or,orally'
p30666
(F1
F0.00014334862385321102
I0
I1
I-1
tp30667
sS'upon,pcp'
p30668
(F1
F0.00014334862385321102
I0
I1
I-1
tp30669
sS'a,wide'
p30670
(F1
F0.00014334862385321102
I0
I1
I-1
tp30671
sS'any,known'
p30672
(F1
F0.00028669724770642203
I2
I0
I2
tp30673
sS'because,or'
p30674
(F1
F0.00014334862385321102
I0
I1
I-1
tp30675
sS'q,i'
p30676
(F1
F0.00014334862385321102
I1
I0
I1
tp30677
sS'q,d'
p30678
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30679
sS'receiving,therapy'
p30680
(F0.5
F0.00028669724770642203
I3
I1
I2
tp30681
sS'on,total'
p30682
(F0
F0
I1
I1
I0
tp30683
sS'the,vasodilating'
p30684
(F1
F0.00057339449541284407
I4
I0
I4
tp30685
sS'acid,prolonged'
p30686
(F1
F0.00014334862385321102
I1
I0
I1
tp30687
sS'hypercalcemia,too'
p30688
(F1
F0.00014334862385321102
I1
I0
I1
tp30689
sS'were,no'
p30690
(F0.83333333333333337
F0.0014334862385321102
I1
I11
I-10
tp30691
sS'that,have'
p30692
(F0.5
F0.0008600917431192661
I9
I3
I6
tp30693
sS'tendency,produced'
p30694
(F1
F0.00014334862385321102
I1
I0
I1
tp30695
sS'toxicity,in'
p30696
(F1
F0.00071674311926605509
I5
I0
I5
tp30697
sS'alkaloids,amphetamines'
p30698
(F1
F0.00028669724770642203
I2
I0
I2
tp30699
sS'viagra,and'
p30700
(F1
F0.00014334862385321102
I0
I1
I-1
tp30701
sS'phasic,contraction'
p30702
(F1
F0.00014334862385321102
I0
I1
I-1
tp30703
sS'be,co-administered'
p30704
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp30705
sS'patients,when'
p30706
(F1
F0.00043004587155963305
I3
I0
I3
tp30707
sS'secretion,has'
p30708
(F1
F0.00014334862385321102
I1
I0
I1
tp30709
sS'by,endothelial'
p30710
(F1
F0.00028669724770642203
I0
I2
I-2
tp30711
sS'antiinflammatory,including'
p30712
(F1
F0.00014334862385321102
I1
I0
I1
tp30713
sS'sustiva,has'
p30714
(F1
F0.00014334862385321102
I1
I0
I1
tp30715
sS'aeds,on'
p30716
(F1
F0.00014334862385321102
I1
I0
I1
tp30717
sS'v,has'
p30718
(F1
F0.00014334862385321102
I0
I1
I-1
tp30719
sS'isoform,and'
p30720
(F1
F0.00014334862385321102
I0
I1
I-1
tp30721
sS'wellbutrin,should'
p30722
(F1
F0.00014334862385321102
I1
I0
I1
tp30723
sS'such,individuals'
p30724
(F1
F0.00028669724770642203
I0
I2
I-2
tp30725
sS'felbatol,therapy'
p30726
(F1
F0.00014334862385321102
I0
I1
I-1
tp30727
sS'adrenocorticoids,cortisone-like'
p30728
(F1
F0.00014334862385321102
I1
I0
I1
tp30729
sS'data,demonstrate'
p30730
(F1
F0.00014334862385321102
I0
I1
I-1
tp30731
sS'in,clotting'
p30732
(F1
F0.00028669724770642203
I0
I2
I-2
tp30733
sS'antihypertensives,bumetanide'
p30734
(F1
F0.00014334862385321102
I1
I0
I1
tp30735
sS'given,and'
p30736
(F0
F0
I1
I1
I0
tp30737
sS'these,isoenzymes'
p30738
(F1
F0.00014334862385321102
I0
I1
I-1
tp30739
sS'nacmc,m'
p30740
(F1
F0.00028669724770642203
I0
I2
I-2
tp30741
sS'equilibration,of'
p30742
(F1
F0.00014334862385321102
I0
I1
I-1
tp30743
sS'these,imidazole'
p30744
(F1
F0.00014334862385321102
I0
I1
I-1
tp30745
sS'and,see'
p30746
(F1
F0.00014334862385321102
I1
I0
I1
tp30747
sS'initial,step'
p30748
(F1
F0.00014334862385321102
I0
I1
I-1
tp30749
sS'd3,the'
p30750
(F1
F0.00014334862385321102
I0
I1
I-1
tp30751
sS'hypokinesia,and'
p30752
(F1
F0.00014334862385321102
I1
I0
I1
tp30753
sS'the,bioavailability'
p30754
(F0.125
F0.00028669724770642203
I7
I9
I-2
tp30755
sS'of,skeletal'
p30756
(F0
F0
I1
I1
I0
tp30757
sS'the,coat-core'
p30758
(F1
F0.00014334862385321102
I1
I0
I1
tp30759
sS'reduce,or'
p30760
(F1
F0.00028669724770642203
I2
I0
I2
tp30761
sS'monitored,at'
p30762
(F1
F0.00014334862385321102
I1
I0
I1
tp30763
sS'iv,attenuate'
p30764
(F1
F0.00014334862385321102
I1
I0
I1
tp30765
sS'gel,in'
p30766
(F1
F0.00014334862385321102
I0
I1
I-1
tp30767
sS'enantiomers,or'
p30768
(F1
F0.00014334862385321102
I0
I1
I-1
tp30769
sS'nsaids,on'
p30770
(F1
F0.00028669724770642203
I2
I0
I2
tp30771
sS'hydroxytolbutamide,and'
p30772
(F1
F0.00028669724770642203
I0
I2
I-2
tp30773
sS'full,recovery'
p30774
(F1
F0.00014334862385321102
I0
I1
I-1
tp30775
sS'reaction,may'
p30776
(F0
F0
I1
I1
I0
tp30777
sS'and,haldol'
p30778
(F1
F0.00014334862385321102
I0
I1
I-1
tp30779
sS'required,with'
p30780
(F1
F0.00014334862385321102
I0
I1
I-1
tp30781
sS'glycosides,heart'
p30782
(F1
F0.00014334862385321102
I1
I0
I1
tp30783
sS'not,due'
p30784
(F0
F0
I1
I1
I0
tp30785
sS'of,spermatozoa'
p30786
(F1
F0.00014334862385321102
I0
I1
I-1
tp30787
sS'with,other'
p30788
(F0.20000000000000001
F0.0025802752293577983
I54
I36
I18
tp30789
sS'in,liver'
p30790
(F1
F0.00028669724770642203
I2
I0
I2
tp30791
sS'dose,in'
p30792
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp30793
sS'the,gradual'
p30794
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30795
sS'safely,co-administered'
p30796
(F1
F0.00014334862385321102
I0
I1
I-1
tp30797
sS'of,probably'
p30798
(F1
F0.00014334862385321102
I1
I0
I1
tp30799
sS'monomeric,disintegrins'
p30800
(F1
F0.00014334862385321102
I0
I1
I-1
tp30801
sS'study,dosed'
p30802
(F1
F0.00014334862385321102
I0
I1
I-1
tp30803
sS'on,insulins'
p30804
(F1
F0.00014334862385321102
I0
I1
I-1
tp30805
sS'uncontrolled,domestic'
p30806
(F1
F0.00014334862385321102
I0
I1
I-1
tp30807
sS'reported,with'
p30808
(F0.52380952380952384
F0.0015768348623853212
I16
I5
I11
tp30809
sS'the,peripheral'
p30810
(F1
F0.00014334862385321102
I1
I0
I1
tp30811
sS'long-term,studies'
p30812
(F1
F0.00014334862385321102
I0
I1
I-1
tp30813
sS'and,unexpected'
p30814
(F1
F0.00014334862385321102
I0
I1
I-1
tp30815
sS'dpcpx-induced,anxiogenic'
p30816
(F1
F0.00014334862385321102
I1
I0
I1
tp30817
sS'rarely,with'
p30818
(F1
F0.00028669724770642203
I2
I0
I2
tp30819
sS'ii,alone'
p30820
(F1
F0.00028669724770642203
I0
I2
I-2
tp30821
sS'function,seen'
p30822
(F1
F0.00014334862385321102
I0
I1
I-1
tp30823
sS'are,possible'
p30824
(F1
F0.00014334862385321102
I0
I1
I-1
tp30825
sS'these,cases'
p30826
(F1
F0.00014334862385321102
I0
I1
I-1
tp30827
sS'fluoroquinolones,macrolide'
p30828
(F1
F0.00014334862385321102
I0
I1
I-1
tp30829
sS'spray,during'
p30830
(F1
F0.00014334862385321102
I0
I1
I-1
tp30831
sS'clinical,differences'
p30832
(F1
F0.00014334862385321102
I0
I1
I-1
tp30833
sS'antibiotics,chloramphenicol'
p30834
(F1
F0.00014334862385321102
I1
I0
I1
tp30835
sS'though,this'
p30836
(F1
F0.00014334862385321102
I1
I0
I1
tp30837
sS'precedex,a'
p30838
(F1
F0.00014334862385321102
I1
I0
I1
tp30839
sS'clinical,problems'
p30840
(F1
F0.00071674311926605509
I5
I0
I5
tp30841
sS'solutions,and'
p30842
(F1
F0.00014334862385321102
I0
I1
I-1
tp30843
sS'slower,gastrointestinal'
p30844
(F1
F0.00014334862385321102
I1
I0
I1
tp30845
sS'nsaids,concomitantly'
p30846
(F1
F0.00057339449541284407
I4
I0
I4
tp30847
sS'cessation,with'
p30848
(F1
F0.00014334862385321102
I0
I1
I-1
tp30849
sS'small,decrease'
p30850
(F1
F0.00043004587155963305
I3
I0
I3
tp30851
sS'and,fatal'
p30852
(F1
F0.00028669724770642203
I2
I0
I2
tp30853
sS'kg,produced'
p30854
(F1
F0.00014334862385321102
I1
I0
I1
tp30855
sS'you,take'
p30856
(F1
F0.00014334862385321102
I1
I0
I1
tp30857
sS'a,microdilution'
p30858
(F1
F0.00014334862385321102
I0
I1
I-1
tp30859
sS'pills,is'
p30860
(F1
F0.00014334862385321102
I1
I0
I1
tp30861
sS'medication,tell'
p30862
(F1
F0.00014334862385321102
I0
I1
I-1
tp30863
sS'increased,hepatotoxicity'
p30864
(F1
F0.00014334862385321102
I1
I0
I1
tp30865
sS'similar,proportion'
p30866
(F1
F0.00014334862385321102
I1
I0
I1
tp30867
sS'addition,under'
p30868
(F1
F0.00028669724770642203
I0
I2
I-2
tp30869
sS'as,mg'
p30870
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp30871
sS'clinical,pharmacology'
p30872
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp30873
sS'administered,radiographic'
p30874
(F1
F0.00014334862385321102
I1
I0
I1
tp30875
sS'the,fda'
p30876
(F1
F0.00014334862385321102
I0
I1
I-1
tp30877
sS'which,the'
p30878
(F0
F0
I1
I1
I0
tp30879
sS'that,variable'
p30880
(F1
F0.00014334862385321102
I1
I0
I1
tp30881
sS'ensure,clinically'
p30882
(F1
F0.00014334862385321102
I1
I0
I1
tp30883
sS'activity,should'
p30884
(F1
F0.00028669724770642203
I2
I0
I2
tp30885
sS'including,may'
p30886
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30887
sS'the,chemical'
p30888
(F1
F0.00014334862385321102
I1
I0
I1
tp30889
sS'coreg,slow'
p30890
(F1
F0.00014334862385321102
I1
I0
I1
tp30891
sS'imipramine,hydrochloride'
p30892
(F1
F0.00014334862385321102
I1
I0
I1
tp30893
sS'blood,cells'
p30894
(F1
F0.00014334862385321102
I0
I1
I-1
tp30895
sS'and,synthetic'
p30896
(F1
F0.00014334862385321102
I0
I1
I-1
tp30897
sS'the,antiprothrombinemic'
p30898
(F1
F0.00014334862385321102
I0
I1
I-1
tp30899
sS'displacement,of'
p30900
(F0
F0
I1
I1
I0
tp30901
sS'characteristics,for'
p30902
(F1
F0.00014334862385321102
I0
I1
I-1
tp30903
sS'a,direct'
p30904
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp30905
sS'effectiveness,and'
p30906
(F1
F0.00014334862385321102
I1
I0
I1
tp30907
sS'inotropic,agents'
p30908
(F1
F0.00014334862385321102
I1
I0
I1
tp30909
sS'about,the'
p30910
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp30911
sS'the,estrogenic'
p30912
(F1
F0.00014334862385321102
I0
I1
I-1
tp30913
sS'an,used'
p30914
(F1
F0.00014334862385321102
I0
I1
I-1
tp30915
sS'placebo,with'
p30916
(F1
F0.00014334862385321102
I0
I1
I-1
tp30917
sS'mean,apparent'
p30918
(F1
F0.00014334862385321102
I1
I0
I1
tp30919
sS'and,fentanyl'
p30920
(F1
F0.00014334862385321102
I1
I0
I1
tp30921
sS'tid,study'
p30922
(F1
F0.00014334862385321102
I0
I1
I-1
tp30923
sS'of,when'
p30924
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp30925
sS'proliferation,in'
p30926
(F1
F0.00014334862385321102
I1
I0
I1
tp30927
sS'cortex,and'
p30928
(F1
F0.00014334862385321102
I0
I1
I-1
tp30929
sS'of,having'
p30930
(F1
F0.00014334862385321102
I0
I1
I-1
tp30931
sS'for,other'
p30932
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp30933
sS'adenosine,effects'
p30934
(F1
F0.00014334862385321102
I1
I0
I1
tp30935
sS'alfenta,induction'
p30936
(F1
F0.00014334862385321102
I1
I0
I1
tp30937
sS'a,single-dose'
p30938
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp30939
sS'tolbutamide,in'
p30940
(F1
F0.00028669724770642203
I0
I2
I-2
tp30941
sS'after,tracleer'
p30942
(F1
F0.00014334862385321102
I1
I0
I1
tp30943
sS'males,who'
p30944
(F1
F0.00014334862385321102
I0
I1
I-1
tp30945
sS'may,persist'
p30946
(F1
F0.00014334862385321102
I0
I1
I-1
tp30947
sS'etc,but'
p30948
(F1
F0.00014334862385321102
I1
I0
I1
tp30949
sS'with,concomitantly'
p30950
(F1
F0.00014334862385321102
I1
I0
I1
tp30951
sS'emerging,roles'
p30952
(F1
F0.00014334862385321102
I0
I1
I-1
tp30953
sS'nephrolithiasis,is'
p30954
(F1
F0.00014334862385321102
I1
I0
I1
tp30955
sS'converted,to'
p30956
(F1
F0.00028669724770642203
I2
I0
I2
tp30957
sS'antagonist,and'
p30958
(F1
F0.00014334862385321102
I1
I0
I1
tp30959
sS'a,substrate'
p30960
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp30961
sS'in-vitro,studies'
p30962
(F1
F0.00014334862385321102
I0
I1
I-1
tp30963
sS'intravenous,antagonists'
p30964
(F1
F0.00014334862385321102
I1
I0
I1
tp30965
sS'in,alcoholic'
p30966
(F1
F0.00014334862385321102
I1
I0
I1
tp30967
sS'class,antimicrobial'
p30968
(F1
F0.00014334862385321102
I1
I0
I1
tp30969
sS'the,dosage'
p30970
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp30971
sS'and,another'
p30972
(F1
F0.00014334862385321102
I1
I0
I1
tp30973
sS'be,premedicated'
p30974
(F1
F0.00014334862385321102
I0
I1
I-1
tp30975
sS'hyperkalemia,serum'
p30976
(F1
F0.00014334862385321102
I1
I0
I1
tp30977
sS'studies,evaluating'
p30978
(F1
F0.00014334862385321102
I0
I1
I-1
tp30979
sS'on,two'
p30980
(F1
F0.00014334862385321102
I0
I1
I-1
tp30981
sS'require,anticoagulation'
p30982
(F1
F0.00014334862385321102
I0
I1
I-1
tp30983
sS'oral,on'
p30984
(F1
F0.00028669724770642203
I0
I2
I-2
tp30985
sS'cerubidine,should'
p30986
(F1
F0.00014334862385321102
I1
I0
I1
tp30987
sS'and,also'
p30988
(F1
F0.00071674311926605509
I5
I0
I5
tp30989
sS'unless,the'
p30990
(F1
F0.00043004587155963305
I3
I0
I3
tp30991
sS'oral,or'
p30992
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp30993
sS'also,inhibited'
p30994
(F1
F0.00014334862385321102
I1
I0
I1
tp30995
sS'photic,stimulation'
p30996
(F1
F0.00014334862385321102
I0
I1
I-1
tp30997
sS'in,lowering'
p30998
(F1
F0.00028669724770642203
I2
I0
I2
tp30999
sS'approached,with'
p31000
(F1
F0.00028669724770642203
I2
I0
I2
tp31001
sS'nifedipine,did'
p31002
(F1
F0.00014334862385321102
I0
I1
I-1
tp31003
sS'usually,reversible'
p31004
(F1
F0.00014334862385321102
I1
I0
I1
tp31005
sS'of,intravenously'
p31006
(F0
F0
I1
I1
I0
tp31007
sS'absorption,decreases'
p31008
(F1
F0.00014334862385321102
I1
I0
I1
tp31009
sS'function,tests'
p31010
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31011
sS'daily,under'
p31012
(F1
F0.00014334862385321102
I0
I1
I-1
tp31013
sS'protocol,for'
p31014
(F1
F0.00014334862385321102
I0
I1
I-1
tp31015
sS'take,and'
p31016
(F1
F0.00014334862385321102
I1
I0
I1
tp31017
sS'see,drug'
p31018
(F1
F0.00014334862385321102
I0
I1
I-1
tp31019
sS'investigated,as'
p31020
(F1
F0.00014334862385321102
I0
I1
I-1
tp31021
sS'rauwolfia,alkaloid'
p31022
(F1
F0.00014334862385321102
I1
I0
I1
tp31023
sS'i,cigarettes'
p31024
(F1
F0.00014334862385321102
I0
I1
I-1
tp31025
sS'metabolite,which'
p31026
(F1
F0.00028669724770642203
I2
I0
I2
tp31027
sS'following,synthetic'
p31028
(F1
F0.00014334862385321102
I0
I1
I-1
tp31029
sS'identify,any'
p31030
(F1
F0.00014334862385321102
I0
I1
I-1
tp31031
sS'are,a'
p31032
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31033
sS'oral,medications'
p31034
(F1
F0.00014334862385321102
I1
I0
I1
tp31035
sS'of,tricyclic'
p31036
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31037
sS'in,well-controlled'
p31038
(F1
F0.00028669724770642203
I2
I0
I2
tp31039
sS'supplements,theoretically'
p31040
(F1
F0.00014334862385321102
I1
I0
I1
tp31041
sS'agents,calcium-blocking'
p31042
(F1
F0.00014334862385321102
I0
I1
I-1
tp31043
sS'that,lower'
p31044
(F1
F0.00014334862385321102
I1
I0
I1
tp31045
sS'reports,that'
p31046
(F1
F0.00028669724770642203
I2
I0
I2
tp31047
sS'the,monomeric'
p31048
(F1
F0.00014334862385321102
I0
I1
I-1
tp31049
sS'adrenergic,blockers'
p31050
(F1
F0.00028669724770642203
I2
I0
I2
tp31051
sS'a,carbonic'
p31052
(F1
F0.00014334862385321102
I0
I1
I-1
tp31053
sS'transient,dose-dependent'
p31054
(F1
F0.00014334862385321102
I1
I0
I1
tp31055
sS'with,double'
p31056
(F1
F0.00014334862385321102
I0
I1
I-1
tp31057
sS'and,sustiva'
p31058
(F1
F0.00014334862385321102
I0
I1
I-1
tp31059
sS'kidney,homogenates'
p31060
(F1
F0.00014334862385321102
I0
I1
I-1
tp31061
sS'albuterol,strattera'
p31062
(F1
F0.00014334862385321102
I1
I0
I1
tp31063
sS'cortical,tissues'
p31064
(F1
F0.00014334862385321102
I0
I1
I-1
tp31065
sS'decreased,measured'
p31066
(F1
F0.00014334862385321102
I1
I0
I1
tp31067
sS'cyp2c9,and'
p31068
(F1
F0.00057339449541284407
I0
I4
I-4
tp31069
sS'arise,from'
p31070
(F1
F0.00014334862385321102
I1
I0
I1
tp31071
sS'steady-state,l50'
p31072
(F1
F0.00014334862385321102
I0
I1
I-1
tp31073
sS'dextromethorphan,is'
p31074
(F1
F0.00028669724770642203
I0
I2
I-2
tp31075
sS'muscle,to'
p31076
(F1
F0.00014334862385321102
I1
I0
I1
tp31077
sS'characterization,or'
p31078
(F1
F0.00014334862385321102
I0
I1
I-1
tp31079
sS'lithium,ibuprofen'
p31080
(F1
F0.00014334862385321102
I1
I0
I1
tp31081
sS'agonist,such'
p31082
(F1
F0.00014334862385321102
I1
I0
I1
tp31083
sS'concentration,increased'
p31084
(F0
F0
I1
I1
I0
tp31085
sS'through,increased'
p31086
(F1
F0.00028669724770642203
I2
I0
I2
tp31087
sS'of,nanm'
p31088
(F0
F0
I2
I2
I0
tp31089
sS'neither,were'
p31090
(F1
F0.00014334862385321102
I0
I1
I-1
tp31091
sS'and,alpha-adrenergic'
p31092
(F1
F0.00014334862385321102
I1
I0
I1
tp31093
sS'consequently,concomitant'
p31094
(F1
F0.00014334862385321102
I1
I0
I1
tp31095
sS'between,taxol'
p31096
(F1
F0.00014334862385321102
I0
I1
I-1
tp31097
sS'ratios,of'
p31098
(F1
F0.00014334862385321102
I0
I1
I-1
tp31099
sS'cns,depressant'
p31100
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp31101
sS'authors,investigated'
p31102
(F1
F0.00014334862385321102
I0
I1
I-1
tp31103
sS'affecting,the'
p31104
(F1
F0.00057339449541284407
I4
I0
I4
tp31105
sS'can,increase'
p31106
(F0
F0
I2
I2
I0
tp31107
sS'channels,and'
p31108
(F1
F0.00014334862385321102
I0
I1
I-1
tp31109
sS'report,any'
p31110
(F1
F0.00014334862385321102
I0
I1
I-1
tp31111
sS'only,with'
p31112
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp31113
sS'much,more'
p31114
(F1
F0.00014334862385321102
I0
I1
I-1
tp31115
sS'more,frequently'
p31116
(F1
F0.00043004587155963305
I0
I3
I-3
tp31117
sS'pi-based,therapy'
p31118
(F1
F0.00014334862385321102
I0
I1
I-1
tp31119
sS'hemostasis,and'
p31120
(F1
F0.00028669724770642203
I2
I0
I2
tp31121
sS'therefore,intake'
p31122
(F1
F0.00014334862385321102
I0
I1
I-1
tp31123
sS'and,induce'
p31124
(F1
F0.00014334862385321102
I1
I0
I1
tp31125
sS'who,were'
p31126
(F0.23076923076923078
F0.00043004587155963305
I5
I8
I-3
tp31127
sS'or,weaken'
p31128
(F1
F0.00028669724770642203
I2
I0
I2
tp31129
sS'either,potentiate'
p31130
(F1
F0.00028669724770642203
I2
I0
I2
tp31131
sS'a,lower'
p31132
(F0
F0
I2
I2
I0
tp31133
sS'clearance,when'
p31134
(F1
F0.00014334862385321102
I1
I0
I1
tp31135
sS'in,the'
p31136
(F0.011583011583011582
F0.00043004587155963305
I131
I128
I3
tp31137
sS'sr,by'
p31138
(F1
F0.00014334862385321102
I1
I0
I1
tp31139
sS'so,that'
p31140
(F0
F0
I1
I1
I0
tp31141
sS'survanta,and'
p31142
(F1
F0.00014334862385321102
I0
I1
I-1
tp31143
sS'a,cyp3a'
p31144
(F1
F0.00014334862385321102
I0
I1
I-1
tp31145
sS'not,compensate'
p31146
(F1
F0.00028669724770642203
I2
I0
I2
tp31147
sS'and,most'
p31148
(F1
F0.00014334862385321102
I0
I1
I-1
tp31149
sS'and,concentrations'
p31150
(F0
F0
I1
I1
I0
tp31151
sS'recommended,because'
p31152
(F1
F0.00071674311926605509
I5
I0
I5
tp31153
sS'gastrointestinal,acidifying'
p31154
(F1
F0.00014334862385321102
I1
I0
I1
tp31155
sS'interactions,food'
p31156
(F1
F0.00014334862385321102
I1
I0
I1
tp31157
sS'since,blood'
p31158
(F1
F0.00043004587155963305
I0
I3
I-3
tp31159
sS'following,co-administration'
p31160
(F1
F0.00028669724770642203
I0
I2
I-2
tp31161
sS'was,misused'
p31162
(F1
F0.00014334862385321102
I0
I1
I-1
tp31163
sS'volunteers,receiving'
p31164
(F1
F0.00043004587155963305
I3
I0
I3
tp31165
sS'or,s-warfarin'
p31166
(F1
F0.00014334862385321102
I0
I1
I-1
tp31167
sS'microm,which'
p31168
(F1
F0.00014334862385321102
I0
I1
I-1
tp31169
sS'mammary,tumor'
p31170
(F1
F0.00014334862385321102
I0
I1
I-1
tp31171
sS'to,serum'
p31172
(F1
F0.00028669724770642203
I2
I0
I2
tp31173
sS'the,hyperuricemia'
p31174
(F1
F0.00014334862385321102
I1
I0
I1
tp31175
sS'nimbex,and'
p31176
(F0
F0
I1
I1
I0
tp31177
sS'mean,qt'
p31178
(F1
F0.00014334862385321102
I1
I0
I1
tp31179
sS'and,requiring'
p31180
(F1
F0.00014334862385321102
I1
I0
I1
tp31181
sS'co-administration,of'
p31182
(F0.27536231884057971
F0.0027236238532110093
I44
I25
I19
tp31183
sS'to,develop'
p31184
(F1
F0.00014334862385321102
I1
I0
I1
tp31185
sS'intervals,between'
p31186
(F1
F0.00014334862385321102
I1
I0
I1
tp31187
sS'calcium-containing,medicines'
p31188
(F1
F0.00014334862385321102
I0
I1
I-1
tp31189
sS'or,kineret'
p31190
(F1
F0.00014334862385321102
I0
I1
I-1
tp31191
sS'with,thrombolytic'
p31192
(F1
F0.00014334862385321102
I0
I1
I-1
tp31193
sS'tadalafil,dose'
p31194
(F1
F0.00014334862385321102
I1
I0
I1
tp31195
sS'fed,state'
p31196
(F1
F0.00014334862385321102
I1
I0
I1
tp31197
sS'of,loratadine'
p31198
(F1
F0.00014334862385321102
I0
I1
I-1
tp31199
sS'a,monoamine'
p31200
(F1
F0.00014334862385321102
I0
I1
I-1
tp31201
sS'potential,interaction'
p31202
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp31203
sS'antagonists,administered'
p31204
(F1
F0.00014334862385321102
I0
I1
I-1
tp31205
sS'controlled,trials'
p31206
(F1
F0.00028669724770642203
I0
I2
I-2
tp31207
sS'free,of'
p31208
(F1
F0.00014334862385321102
I0
I1
I-1
tp31209
sS'regarding,asthma'
p31210
(F1
F0.00014334862385321102
I0
I1
I-1
tp31211
sS'followed,by'
p31212
(F0
F0
I6
I6
I0
tp31213
sS'metabolites,may'
p31214
(F1
F0.00014334862385321102
I0
I1
I-1
tp31215
sS'respiration,and'
p31216
(F1
F0.00014334862385321102
I0
I1
I-1
tp31217
sS'indocin,does'
p31218
(F1
F0.00014334862385321102
I0
I1
I-1
tp31219
sS'exjade,pharmacokinetics'
p31220
(F1
F0.00014334862385321102
I0
I1
I-1
tp31221
sS'formal,interaction'
p31222
(F1
F0.00043004587155963305
I0
I3
I-3
tp31223
sS'salts,may'
p31224
(F1
F0.00014334862385321102
I1
I0
I1
tp31225
sS'frequent,maintenance'
p31226
(F1
F0.00014334862385321102
I1
I0
I1
tp31227
sS'in,ewes'
p31228
(F1
F0.00014334862385321102
I1
I0
I1
tp31229
sS'and,randomly'
p31230
(F1
F0.00014334862385321102
I0
I1
I-1
tp31231
sS'a,should'
p31232
(F1
F0.00014334862385321102
I1
I0
I1
tp31233
sS'slight,increases'
p31234
(F1
F0.00014334862385321102
I1
I0
I1
tp31235
sS'were,followed'
p31236
(F1
F0.00014334862385321102
I0
I1
I-1
tp31237
sS'kinetics,of'
p31238
(F1
F0.00014334862385321102
I0
I1
I-1
tp31239
sS'active,dose'
p31240
(F1
F0.00014334862385321102
I0
I1
I-1
tp31241
sS'k,epoxide'
p31242
(F1
F0.00014334862385321102
I0
I1
I-1
tp31243
sS'monkeys,nanm'
p31244
(F1
F0.00014334862385321102
I0
I1
I-1
tp31245
sS'techniques,confirmation'
p31246
(F1
F0.00014334862385321102
I0
I1
I-1
tp31247
sS'for,or'
p31248
(F1
F0.00043004587155963305
I0
I3
I-3
tp31249
sS'type,of'
p31250
(F1
F0.00014334862385321102
I1
I0
I1
tp31251
sS'for,of'
p31252
(F1
F0.00014334862385321102
I1
I0
I1
tp31253
sS'crohn,s'
p31254
(F1
F0.00043004587155963305
I0
I3
I-3
tp31255
sS'for,on'
p31256
(F1
F0.00014334862385321102
I0
I1
I-1
tp31257
sS'if,systemic'
p31258
(F1
F0.00014334862385321102
I0
I1
I-1
tp31259
sS'subjects,single-dose'
p31260
(F1
F0.00014334862385321102
I0
I1
I-1
tp31261
sS'to,phenytoin'
p31262
(F1
F0.00014334862385321102
I1
I0
I1
tp31263
sS'marplan,parnate'
p31264
(F1
F0.00014334862385321102
I0
I1
I-1
tp31265
sS'similar,events'
p31266
(F1
F0.00014334862385321102
I0
I1
I-1
tp31267
sS'but,does'
p31268
(F1
F0.00014334862385321102
I1
I0
I1
tp31269
sS'reduction,was'
p31270
(F1
F0.00014334862385321102
I1
I0
I1
tp31271
sS'given,in'
p31272
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp31273
sS'inhibits,cyp2d6'
p31274
(F1
F0.00014334862385321102
I0
I1
I-1
tp31275
sS'calcium-channel,blocking'
p31276
(F1
F0.00014334862385321102
I0
I1
I-1
tp31277
sS'antipsychotic,agents'
p31278
(F1
F0.00028669724770642203
I2
I0
I2
tp31279
sS'nasal,spray'
p31280
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31281
sS'possible,additive'
p31282
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp31283
sS'andusing,a'
p31284
(F1
F0.00014334862385321102
I0
I1
I-1
tp31285
sS'receptor,blockers'
p31286
(F1
F0.00014334862385321102
I0
I1
I-1
tp31287
sS'of,neural'
p31288
(F1
F0.00014334862385321102
I0
I1
I-1
tp31289
sS'with,aprepitant'
p31290
(F1
F0.00043004587155963305
I3
I0
I3
tp31291
sS'this,period'
p31292
(F1
F0.00014334862385321102
I0
I1
I-1
tp31293
sS'that,exposure'
p31294
(F1
F0.00028669724770642203
I2
I0
I2
tp31295
sS'be,even'
p31296
(F1
F0.00014334862385321102
I1
I0
I1
tp31297
sS'profiles,clinically'
p31298
(F1
F0.00014334862385321102
I0
I1
I-1
tp31299
sS'in,effect'
p31300
(F1
F0.00014334862385321102
I1
I0
I1
tp31301
sS'metabolism,very'
p31302
(F1
F0.00014334862385321102
I0
I1
I-1
tp31303
sS'provided,significant'
p31304
(F1
F0.00014334862385321102
I1
I0
I1
tp31305
sS'levo-dromoran,has'
p31306
(F1
F0.00014334862385321102
I1
I0
I1
tp31307
sS'with,propecia'
p31308
(F1
F0.00014334862385321102
I0
I1
I-1
tp31309
sS'cyp1a2,concomitant'
p31310
(F1
F0.00014334862385321102
I1
I0
I1
tp31311
sS'also,being'
p31312
(F1
F0.00014334862385321102
I1
I0
I1
tp31313
sS'cations,such'
p31314
(F1
F0.00043004587155963305
I3
I0
I3
tp31315
sS'affected,when'
p31316
(F1
F0.00028669724770642203
I0
I2
I-2
tp31317
sS'inhibitor,and'
p31318
(F1
F0.00014334862385321102
I1
I0
I1
tp31319
sS'as,garlic'
p31320
(F1
F0.00014334862385321102
I1
I0
I1
tp31321
sS'concentrations,with'
p31322
(F1
F0.00014334862385321102
I1
I0
I1
tp31323
sS'are,due'
p31324
(F1
F0.00014334862385321102
I1
I0
I1
tp31325
sS'affect,patient'
p31326
(F1
F0.00014334862385321102
I0
I1
I-1
tp31327
sS'half,of'
p31328
(F1
F0.00043004587155963305
I0
I3
I-3
tp31329
sS'theophylline,theophylline'
p31330
(F1
F0.00014334862385321102
I0
I1
I-1
tp31331
sS'progesterone-,and'
p31332
(F1
F0.00014334862385321102
I1
I0
I1
tp31333
sS'veratrum,alkaloids'
p31334
(F1
F0.00043004587155963305
I3
I0
I3
tp31335
sS'since,chronic'
p31336
(F1
F0.00014334862385321102
I0
I1
I-1
tp31337
sS'acetate,in'
p31338
(F1
F0.00014334862385321102
I1
I0
I1
tp31339
sS'humorsol,with'
p31340
(F1
F0.00014334862385321102
I1
I0
I1
tp31341
sS'prinivil,alone'
p31342
(F1
F0.00014334862385321102
I0
I1
I-1
tp31343
sS'inhibition,was'
p31344
(F1
F0.00014334862385321102
I0
I1
I-1
tp31345
sS'no,specific'
p31346
(F1
F0.00014334862385321102
I1
I0
I1
tp31347
sS'anticonvulsants,phenytoin'
p31348
(F0
F0
I1
I1
I0
tp31349
sS'humans,that'
p31350
(F1
F0.00014334862385321102
I0
I1
I-1
tp31351
sS'reduced,clearance'
p31352
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31353
sS'that,act'
p31354
(F1
F0.00014334862385321102
I1
I0
I1
tp31355
sS'of,non-depolarising'
p31356
(F1
F0.00014334862385321102
I1
I0
I1
tp31357
sS'campath,may'
p31358
(F1
F0.00014334862385321102
I0
I1
I-1
tp31359
sS'occurring,interactions'
p31360
(F1
F0.00014334862385321102
I1
I0
I1
tp31361
sS'given,before'
p31362
(F1
F0.00014334862385321102
I0
I1
I-1
tp31363
sS'made,by'
p31364
(F1
F0.00014334862385321102
I0
I1
I-1
tp31365
sS'alterations,caused'
p31366
(F1
F0.00014334862385321102
I1
I0
I1
tp31367
sS'pharmacological,i'
p31368
(F1
F0.00014334862385321102
I0
I1
I-1
tp31369
sS'day,for'
p31370
(F0.42857142857142855
F0.0008600917431192661
I4
I10
I-6
tp31371
sS'ketoconazole,concomitant'
p31372
(F1
F0.00014334862385321102
I0
I1
I-1
tp31373
sS'by,therapy'
p31374
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31375
sS'non-diabetic,and'
p31376
(F1
F0.00014334862385321102
I0
I1
I-1
tp31377
sS'mg,when'
p31378
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp31379
sS'observed,during'
p31380
(F0
F0
I1
I1
I0
tp31381
sS'older,adults'
p31382
(F1
F0.00014334862385321102
I0
I1
I-1
tp31383
sS'methods,of'
p31384
(F0
F0
I1
I1
I0
tp31385
sS'the,location'
p31386
(F1
F0.00014334862385321102
I0
I1
I-1
tp31387
sS'hypotensite,effects'
p31388
(F1
F0.00014334862385321102
I1
I0
I1
tp31389
sS'therefore,hormonal'
p31390
(F1
F0.00014334862385321102
I1
I0
I1
tp31391
sS'excessive,prolongation'
p31392
(F1
F0.00014334862385321102
I1
I0
I1
tp31393
sS'need,to'
p31394
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp31395
sS'to,hypertensive'
p31396
(F1
F0.00014334862385321102
I0
I1
I-1
tp31397
sS'a4,such'
p31398
(F1
F0.00014334862385321102
I1
I0
I1
tp31399
sS'of,absolute'
p31400
(F1
F0.00014334862385321102
I0
I1
I-1
tp31401
sS'h2,blockers'
p31402
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp31403
sS'quinolone,antibiotics'
p31404
(F1
F0.00028669724770642203
I2
I0
I2
tp31405
sS'than,have'
p31406
(F1
F0.00014334862385321102
I0
I1
I-1
tp31407
sS'interactions,are'
p31408
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31409
sS'develop,toxicity'
p31410
(F1
F0.00014334862385321102
I1
I0
I1
tp31411
sS'adjusted,accordingly'
p31412
(F1
F0.00014334862385321102
I1
I0
I1
tp31413
sS'somnolence,have'
p31414
(F1
F0.00014334862385321102
I1
I0
I1
tp31415
sS'overdosage,or'
p31416
(F1
F0.00014334862385321102
I1
I0
I1
tp31417
sS'monitor,levels'
p31418
(F1
F0.00014334862385321102
I0
I1
I-1
tp31419
sS'liver,microsomes'
p31420
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31421
sS'with,addictive'
p31422
(F1
F0.00014334862385321102
I0
I1
I-1
tp31423
sS'complications,compared'
p31424
(F1
F0.00043004587155963305
I3
I0
I3
tp31425
sS'rapidly,growing'
p31426
(F1
F0.00014334862385321102
I0
I1
I-1
tp31427
sS'quinolones,including'
p31428
(F1
F0.00057339449541284407
I4
I0
I4
tp31429
sS'gram,absorption'
p31430
(F1
F0.00014334862385321102
I1
I0
I1
tp31431
sS'glucose,concentrations'
p31432
(F1
F0.00043004587155963305
I3
I0
I3
tp31433
sS'therefore,when'
p31434
(F0.83333333333333337
F0.0014334862385321102
I11
I1
I10
tp31435
sS'elimination,the'
p31436
(F1
F0.00014334862385321102
I1
I0
I1
tp31437
sS'can,deplete'
p31438
(F1
F0.00014334862385321102
I1
I0
I1
tp31439
sS'co-administered,but'
p31440
(F1
F0.00014334862385321102
I0
I1
I-1
tp31441
sS'other,nondepolarizing'
p31442
(F0
F0
I1
I1
I0
tp31443
sS'anticoagulants,oral'
p31444
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31445
sS'and,signs'
p31446
(F0
F0
I1
I1
I0
tp31447
sS'of,substances'
p31448
(F1
F0.00057339449541284407
I0
I4
I-4
tp31449
sS'volunteers,were'
p31450
(F1
F0.00014334862385321102
I0
I1
I-1
tp31451
sS'agents,receiving'
p31452
(F1
F0.00014334862385321102
I1
I0
I1
tp31453
sS'study,demonstrates'
p31454
(F1
F0.00014334862385321102
I1
I0
I1
tp31455
sS'diarrhea,would'
p31456
(F1
F0.00014334862385321102
I1
I0
I1
tp31457
sS'probenecid,prolonged'
p31458
(F1
F0.00014334862385321102
I0
I1
I-1
tp31459
sS'epoxide,which'
p31460
(F1
F0.00014334862385321102
I0
I1
I-1
tp31461
sS'this,conjugated'
p31462
(F1
F0.00014334862385321102
I0
I1
I-1
tp31463
sS'iodine,or'
p31464
(F1
F0.00014334862385321102
I1
I0
I1
tp31465
sS'from,in'
p31466
(F0
F0
I2
I2
I0
tp31467
sS'rate,requirements'
p31468
(F1
F0.00014334862385321102
I1
I0
I1
tp31469
sS'pletal,does'
p31470
(F1
F0.00014334862385321102
I0
I1
I-1
tp31471
sS'olanzapine,treatment'
p31472
(F1
F0.00014334862385321102
I0
I1
I-1
tp31473
sS'p450,system'
p31474
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31475
sS'therefore,monitoring'
p31476
(F1
F0.00043004587155963305
I0
I3
I-3
tp31477
sS'or,which'
p31478
(F1
F0.00014334862385321102
I1
I0
I1
tp31479
sS'not,meaningfully'
p31480
(F1
F0.00014334862385321102
I0
I1
I-1
tp31481
sS'similar,potential'
p31482
(F1
F0.00028669724770642203
I2
I0
I2
tp31483
sS'hours,for'
p31484
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp31485
sS'non-depolarizing,muscle'
p31486
(F1
F0.00014334862385321102
I1
I0
I1
tp31487
sS'with,acamprosate'
p31488
(F0
F0
I1
I1
I0
tp31489
sS'of,activase'
p31490
(F1
F0.00014334862385321102
I0
I1
I-1
tp31491
sS'biotransformation,system'
p31492
(F1
F0.00028669724770642203
I2
I0
I2
tp31493
sS'with,prinivil'
p31494
(F1
F0.00028669724770642203
I2
I0
I2
tp31495
sS'antacids,on'
p31496
(F1
F0.00014334862385321102
I0
I1
I-1
tp31497
sS'antacids,or'
p31498
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31499
sS'than,parkinsons'
p31500
(F1
F0.00014334862385321102
I0
I1
I-1
tp31501
sS'prednisone,rofecoxib'
p31502
(F1
F0.00014334862385321102
I0
I1
I-1
tp31503
sS'and,duration'
p31504
(F1
F0.00028669724770642203
I2
I0
I2
tp31505
sS'regimen,i'
p31506
(F1
F0.00014334862385321102
I0
I1
I-1
tp31507
sS'cholecystokinin--of,h-spiroperidol'
p31508
(F1
F0.00014334862385321102
I0
I1
I-1
tp31509
sS'consequence,of'
p31510
(F1
F0.00028669724770642203
I2
I0
I2
tp31511
sS'iodide,i131'
p31512
(F1
F0.00014334862385321102
I1
I0
I1
tp31513
sS'because,they'
p31514
(F0.25
F0.00028669724770642203
I5
I3
I2
tp31515
sS'interrupted,when'
p31516
(F1
F0.00014334862385321102
I0
I1
I-1
tp31517
sS'in,therapeutic'
p31518
(F1
F0.00014334862385321102
I1
I0
I1
tp31519
sS'mc,ameliorate'
p31520
(F1
F0.00014334862385321102
I0
I1
I-1
tp31521
sS'observations,have'
p31522
(F1
F0.0008600917431192661
I6
I0
I6
tp31523
sS'potentially,important'
p31524
(F1
F0.00014334862385321102
I1
I0
I1
tp31525
sS'warranted,and'
p31526
(F1
F0.00014334862385321102
I1
I0
I1
tp31527
sS'piperidine,prevents'
p31528
(F1
F0.00014334862385321102
I1
I0
I1
tp31529
sS'of,brovana'
p31530
(F0
F0
I1
I1
I0
tp31531
sS'possible,increased'
p31532
(F1
F0.00028669724770642203
I0
I2
I-2
tp31533
sS'also,should'
p31534
(F1
F0.00014334862385321102
I1
I0
I1
tp31535
sS'acid,fruit'
p31536
(F1
F0.00014334862385321102
I1
I0
I1
tp31537
sS'the,authors'
p31538
(F1
F0.00043004587155963305
I0
I3
I-3
tp31539
sS'pr,interval'
p31540
(F1
F0.00014334862385321102
I1
I0
I1
tp31541
sS'not,displace'
p31542
(F1
F0.00014334862385321102
I0
I1
I-1
tp31543
sS'preparations,may'
p31544
(F1
F0.00028669724770642203
I2
I0
I2
tp31545
sS'disruption,of'
p31546
(F1
F0.00014334862385321102
I0
I1
I-1
tp31547
sS'at,steady-state'
p31548
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp31549
sS'potent,non-nucleoside'
p31550
(F1
F0.00014334862385321102
I0
I1
I-1
tp31551
sS'or,deleted'
p31552
(F1
F0.00028669724770642203
I2
I0
I2
tp31553
sS'following,other'
p31554
(F1
F0.00014334862385321102
I0
I1
I-1
tp31555
sS'increased,volume'
p31556
(F1
F0.00014334862385321102
I0
I1
I-1
tp31557
sS'low-dose,plus'
p31558
(F1
F0.00014334862385321102
I0
I1
I-1
tp31559
sS'coumadin,other'
p31560
(F1
F0.00014334862385321102
I0
I1
I-1
tp31561
sS'on,weeks'
p31562
(F1
F0.00014334862385321102
I0
I1
I-1
tp31563
sS'inhibitor,at'
p31564
(F0
F0
I1
I1
I0
tp31565
sS'study,of'
p31566
(F0.28000000000000003
F0.0010034403669724771
I9
I16
I-7
tp31567
sS'been,reports'
p31568
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp31569
sS'cyp2c9,catalyzed'
p31570
(F1
F0.00014334862385321102
I1
I0
I1
tp31571
sS'impair,the'
p31572
(F0
F0
I1
I1
I0
tp31573
sS'study,or'
p31574
(F0
F0
I1
I1
I0
tp31575
sS'article,looks'
p31576
(F1
F0.00014334862385321102
I0
I1
I-1
tp31577
sS'may,provoke'
p31578
(F0
F0
I1
I1
I0
tp31579
sS'after,nasal'
p31580
(F1
F0.00014334862385321102
I1
I0
I1
tp31581
sS'hypercalcemia,by'
p31582
(F1
F0.00043004587155963305
I0
I3
I-3
tp31583
sS'binding,proteins'
p31584
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31585
sS'appearance,of'
p31586
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31587
sS'leucovorin,the'
p31588
(F1
F0.00014334862385321102
I1
I0
I1
tp31589
sS'between,ssris'
p31590
(F1
F0.00014334862385321102
I0
I1
I-1
tp31591
sS'with,escalating'
p31592
(F1
F0.00014334862385321102
I0
I1
I-1
tp31593
sS'inhibitors,include'
p31594
(F1
F0.00014334862385321102
I0
I1
I-1
tp31595
sS'day,group'
p31596
(F1
F0.00014334862385321102
I1
I0
I1
tp31597
sS'the,toxicity'
p31598
(F0
F0
I3
I3
I0
tp31599
sS'to,cytochrome'
p31600
(F1
F0.00014334862385321102
I1
I0
I1
tp31601
sS'nabilone,has'
p31602
(F1
F0.00014334862385321102
I1
I0
I1
tp31603
sS'including,produce'
p31604
(F1
F0.00028669724770642203
I2
I0
I2
tp31605
sS'nacmc,and'
p31606
(F1
F0.00014334862385321102
I0
I1
I-1
tp31607
sS'taking,nsaids'
p31608
(F1
F0.00057339449541284407
I4
I0
I4
tp31609
sS'ratio,or'
p31610
(F0
F0
I1
I1
I0
tp31611
sS'other,than'
p31612
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp31613
sS'gastrointestinal,motility'
p31614
(F1
F0.00028669724770642203
I2
I0
I2
tp31615
sS'while,other'
p31616
(F1
F0.00014334862385321102
I0
I1
I-1
tp31617
sS'of,another'
p31618
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31619
sS'sprycel,must'
p31620
(F1
F0.00014334862385321102
I0
I1
I-1
tp31621
sS'other,depressasnts'
p31622
(F1
F0.00014334862385321102
I1
I0
I1
tp31623
sS'interactions,dactinomycin'
p31624
(F1
F0.00014334862385321102
I0
I1
I-1
tp31625
sS'narcotic,such'
p31626
(F1
F0.00014334862385321102
I1
I0
I1
tp31627
sS'tid,were'
p31628
(F1
F0.00014334862385321102
I0
I1
I-1
tp31629
sS'other,that'
p31630
(F0.12
F0.00043004587155963305
I14
I11
I3
tp31631
sS'or,parenteral'
p31632
(F1
F0.00028669724770642203
I0
I2
I-2
tp31633
sS'more,with'
p31634
(F1
F0.00014334862385321102
I1
I0
I1
tp31635
sS'function,should'
p31636
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp31637
sS'cmin,concentration'
p31638
(F0
F0
I1
I1
I0
tp31639
sS'diabetic,patients'
p31640
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp31641
sS'its,n-demethylated'
p31642
(F1
F0.00014334862385321102
I0
I1
I-1
tp31643
sS'on,components'
p31644
(F1
F0.00014334862385321102
I1
I0
I1
tp31645
sS'group,clinical'
p31646
(F1
F0.00014334862385321102
I0
I1
I-1
tp31647
sS'had,little'
p31648
(F1
F0.00014334862385321102
I0
I1
I-1
tp31649
sS'disease,who'
p31650
(F1
F0.00014334862385321102
I0
I1
I-1
tp31651
sS'of,methylpyrazole'
p31652
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31653
sS'when,subjects'
p31654
(F1
F0.00014334862385321102
I0
I1
I-1
tp31655
sS'two,groups'
p31656
(F1
F0.00014334862385321102
I0
I1
I-1
tp31657
sS'other,medications'
p31658
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp31659
sS'has,not'
p31660
(F0.38181818181818183
F0.0030103211009174314
I17
I38
I-21
tp31661
sS'of,less'
p31662
(F1
F0.00057339449541284407
I4
I0
I4
tp31663
sS'is,neither'
p31664
(F1
F0.00014334862385321102
I0
I1
I-1
tp31665
sS'ibuprofen,l-arginine'
p31666
(F1
F0.00014334862385321102
I1
I0
I1
tp31667
sS'or,incompletely'
p31668
(F1
F0.00014334862385321102
I0
I1
I-1
tp31669
sS'metabolism,rifampin'
p31670
(F1
F0.00014334862385321102
I1
I0
I1
tp31671
sS'develop,delirium'
p31672
(F1
F0.00014334862385321102
I1
I0
I1
tp31673
sS'of,certain'
p31674
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp31675
sS'potentiate,adverse'
p31676
(F1
F0.00014334862385321102
I1
I0
I1
tp31677
sS'narcotics,non-narcotic'
p31678
(F1
F0.00014334862385321102
I1
I0
I1
tp31679
sS'stimulatory,effects'
p31680
(F1
F0.00028669724770642203
I2
I0
I2
tp31681
sS'and,followed'
p31682
(F1
F0.00014334862385321102
I0
I1
I-1
tp31683
sS'exercised,if'
p31684
(F1
F0.00043004587155963305
I3
I0
I3
tp31685
sS'hamster,s'
p31686
(F1
F0.00014334862385321102
I0
I1
I-1
tp31687
sS'the,percentage'
p31688
(F0
F0
I1
I1
I0
tp31689
sS'exercised,in'
p31690
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31691
sS'administered,concurrently'
p31692
(F0.55555555555555558
F0.0014334862385321102
I14
I4
I10
tp31693
sS'than,that'
p31694
(F0.5
F0.00028669724770642203
I3
I1
I2
tp31695
sS'no,prolongation'
p31696
(F1
F0.00014334862385321102
I0
I1
I-1
tp31697
sS'carbamazepine,carbamazepine'
p31698
(F1
F0.00014334862385321102
I1
I0
I1
tp31699
sS'glucuronidation,of'
p31700
(F1
F0.00014334862385321102
I0
I1
I-1
tp31701
sS'day,course'
p31702
(F1
F0.00014334862385321102
I0
I1
I-1
tp31703
sS'the,bactercidal'
p31704
(F1
F0.00014334862385321102
I1
I0
I1
tp31705
sS'histamine-,or'
p31706
(F1
F0.00014334862385321102
I1
I0
I1
tp31707
sS'steroidal,and'
p31708
(F1
F0.00014334862385321102
I0
I1
I-1
tp31709
sS'and,therapy'
p31710
(F0
F0
I3
I3
I0
tp31711
sS'cause,induction'
p31712
(F1
F0.00014334862385321102
I0
I1
I-1
tp31713
sS'to,initiating'
p31714
(F1
F0.00014334862385321102
I1
I0
I1
tp31715
sS'followed,and'
p31716
(F1
F0.00014334862385321102
I0
I1
I-1
tp31717
sS'soybean,flour'
p31718
(F1
F0.00014334862385321102
I1
I0
I1
tp31719
sS'irreversible,brain'
p31720
(F1
F0.00014334862385321102
I1
I0
I1
tp31721
sS'bleeding,when'
p31722
(F1
F0.00014334862385321102
I1
I0
I1
tp31723
sS'neuropsychiatric,events'
p31724
(F1
F0.00014334862385321102
I1
I0
I1
tp31725
sS'following,concomitant'
p31726
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp31727
sS'levels,did'
p31728
(F1
F0.00014334862385321102
I0
I1
I-1
tp31729
sS'and,dilantin'
p31730
(F1
F0.00014334862385321102
I1
I0
I1
tp31731
sS'depression,or'
p31732
(F1
F0.00014334862385321102
I1
I0
I1
tp31733
sS'patients,five'
p31734
(F1
F0.00014334862385321102
I0
I1
I-1
tp31735
sS'dcg-iv,and'
p31736
(F1
F0.00043004587155963305
I0
I3
I-3
tp31737
sS'mglur,agonists'
p31738
(F1
F0.00014334862385321102
I0
I1
I-1
tp31739
sS'depression,of'
p31740
(F1
F0.00043004587155963305
I3
I0
I3
tp31741
sS'valproic,acid'
p31742
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp31743
sS'digoxin,keppra'
p31744
(F1
F0.00014334862385321102
I0
I1
I-1
tp31745
sS'either,the'
p31746
(F1
F0.0018635321100917432
I0
I13
I-13
tp31747
sS'several,closely'
p31748
(F1
F0.00014334862385321102
I1
I0
I1
tp31749
sS'significantly,interact'
p31750
(F1
F0.00014334862385321102
I0
I1
I-1
tp31751
sS'caused,no'
p31752
(F1
F0.00014334862385321102
I0
I1
I-1
tp31753
sS'over,the'
p31754
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp31755
sS'days,intraperitoneally'
p31756
(F1
F0.00014334862385321102
I1
I0
I1
tp31757
sS'clinicians,to'
p31758
(F1
F0.00014334862385321102
I1
I0
I1
tp31759
sS'avastin,when'
p31760
(F1
F0.00014334862385321102
I0
I1
I-1
tp31761
sS'release,tablets'
p31762
(F1
F0.00028669724770642203
I2
I0
I2
tp31763
sS'in,ultimate'
p31764
(F1
F0.00014334862385321102
I1
I0
I1
tp31765
sS'ovcon-35,resulted'
p31766
(F1
F0.00014334862385321102
I1
I0
I1
tp31767
sS'angina,or'
p31768
(F1
F0.00014334862385321102
I1
I0
I1
tp31769
sS'orencia,mtx'
p31770
(F1
F0.00014334862385321102
I0
I1
I-1
tp31771
sS'of,pipracil'
p31772
(F0
F0
I1
I1
I0
tp31773
sS'by,amphotericin'
p31774
(F1
F0.00014334862385321102
I0
I1
I-1
tp31775
sS'nanm,was'
p31776
(F1
F0.00014334862385321102
I0
I1
I-1
tp31777
sS'occasional,doses'
p31778
(F1
F0.00014334862385321102
I0
I1
I-1
tp31779
sS'a,very'
p31780
(F1
F0.00014334862385321102
I1
I0
I1
tp31781
sS'sulfate,prednisolone'
p31782
(F1
F0.00014334862385321102
I0
I1
I-1
tp31783
sS'year,pharmacokinetics'
p31784
(F1
F0.00014334862385321102
I0
I1
I-1
tp31785
sS'urinary,levels'
p31786
(F1
F0.00014334862385321102
I0
I1
I-1
tp31787
sS'randomized,crossover'
p31788
(F1
F0.00028669724770642203
I0
I2
I-2
tp31789
sS'cerebral,and'
p31790
(F1
F0.00028669724770642203
I2
I0
I2
tp31791
sS'the,dissolution'
p31792
(F1
F0.00014334862385321102
I0
I1
I-1
tp31793
sS'antianginal,effectiveness'
p31794
(F1
F0.00014334862385321102
I0
I1
I-1
tp31795
sS'certain,with'
p31796
(F1
F0.00014334862385321102
I0
I1
I-1
tp31797
sS'when,infection'
p31798
(F1
F0.00014334862385321102
I1
I0
I1
tp31799
sS'octapeptide,cholecystokinin--of'
p31800
(F1
F0.00014334862385321102
I0
I1
I-1
tp31801
sS'trough,cmin'
p31802
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp31803
sS'structures,of'
p31804
(F1
F0.00014334862385321102
I0
I1
I-1
tp31805
sS'inhibit,sodium'
p31806
(F1
F0.00014334862385321102
I1
I0
I1
tp31807
sS'data,appeared'
p31808
(F1
F0.00014334862385321102
I0
I1
I-1
tp31809
sS'this,decrease'
p31810
(F0
F0
I2
I2
I0
tp31811
sS'with,nph'
p31812
(F1
F0.00028669724770642203
I0
I2
I-2
tp31813
sS'preparations,antidiarrheal'
p31814
(F1
F0.00014334862385321102
I1
I0
I1
tp31815
sS'mg,rat'
p31816
(F1
F0.00014334862385321102
I0
I1
I-1
tp31817
sS'used,physiological'
p31818
(F1
F0.00014334862385321102
I0
I1
I-1
tp31819
sS'hypoxanthine,and'
p31820
(F1
F0.00014334862385321102
I1
I0
I1
tp31821
sS'with,systemically-administered'
p31822
(F1
F0.00014334862385321102
I1
I0
I1
tp31823
sS'tract,by'
p31824
(F1
F0.00014334862385321102
I1
I0
I1
tp31825
sS'adult,diabetics'
p31826
(F1
F0.00014334862385321102
I0
I1
I-1
tp31827
sS'only,bodyweight'
p31828
(F1
F0.00014334862385321102
I0
I1
I-1
tp31829
sS'alerted,to'
p31830
(F1
F0.00014334862385321102
I0
I1
I-1
tp31831
sS'delayed,for'
p31832
(F1
F0.00014334862385321102
I1
I0
I1
tp31833
sS'in,citrate'
p31834
(F1
F0.00014334862385321102
I0
I1
I-1
tp31835
sS'vitro,at'
p31836
(F1
F0.00014334862385321102
I0
I1
I-1
tp31837
sS'events,or'
p31838
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31839
sS'in,dogs'
p31840
(F0.5
F0.00028669724770642203
I3
I1
I2
tp31841
sS'as,compared'
p31842
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp31843
sS'conditions,of'
p31844
(F1
F0.00014334862385321102
I0
I1
I-1
tp31845
sS'conditions,or'
p31846
(F1
F0.00028669724770642203
I0
I2
I-2
tp31847
sS'lung,survanta'
p31848
(F1
F0.00014334862385321102
I0
I1
I-1
tp31849
sS'with,brevibloc'
p31850
(F1
F0.00014334862385321102
I0
I1
I-1
tp31851
sS'cerebyx,are'
p31852
(F1
F0.00014334862385321102
I0
I1
I-1
tp31853
sS'also,due'
p31854
(F1
F0.00014334862385321102
I1
I0
I1
tp31855
sS'for,minutes'
p31856
(F1
F0.00014334862385321102
I0
I1
I-1
tp31857
sS'day,each'
p31858
(F1
F0.00014334862385321102
I0
I1
I-1
tp31859
sS'but,regular'
p31860
(F1
F0.00014334862385321102
I0
I1
I-1
tp31861
sS'and,ototoxicity'
p31862
(F0
F0
I1
I1
I0
tp31863
sS'follow,the'
p31864
(F1
F0.00014334862385321102
I1
I0
I1
tp31865
sS'agents,iodine-containing'
p31866
(F1
F0.00014334862385321102
I0
I1
I-1
tp31867
sS'times,increase'
p31868
(F1
F0.00014334862385321102
I1
I0
I1
tp31869
sS'definite,nondepolarizing'
p31870
(F1
F0.00014334862385321102
I0
I1
I-1
tp31871
sS'warfarin,and'
p31872
(F1
F0.00014334862385321102
I1
I0
I1
tp31873
sS'slower,renal'
p31874
(F1
F0.00014334862385321102
I1
I0
I1
tp31875
sS'enbrel,ci'
p31876
(F1
F0.00014334862385321102
I1
I0
I1
tp31877
sS'by,effects'
p31878
(F1
F0.00014334862385321102
I0
I1
I-1
tp31879
sS'toradol,oral'
p31880
(F1
F0.00014334862385321102
I1
I0
I1
tp31881
sS'altered,when'
p31882
(F1
F0.00028669724770642203
I0
I2
I-2
tp31883
sS'by,resulting'
p31884
(F0
F0
I1
I1
I0
tp31885
sS'observed,that'
p31886
(F0
F0
I2
I2
I0
tp31887
sS'an,organophosphorous'
p31888
(F1
F0.00014334862385321102
I0
I1
I-1
tp31889
sS'has,on'
p31890
(F1
F0.00028669724770642203
I2
I0
I2
tp31891
sS'a,diminished'
p31892
(F1
F0.00028669724770642203
I2
I0
I2
tp31893
sS'had,a'
p31894
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp31895
sS'since,pletal'
p31896
(F1
F0.00014334862385321102
I1
I0
I1
tp31897
sS'diphenhydramine,diphenhydramine'
p31898
(F1
F0.00014334862385321102
I0
I1
I-1
tp31899
sS'fosinopril,may'
p31900
(F1
F0.00014334862385321102
I0
I1
I-1
tp31901
sS'administered,to'
p31902
(F0.058823529411764705
F0.00014334862385321102
I8
I9
I-1
tp31903
sS'diuretic,hydrochlorothiazide'
p31904
(F1
F0.00014334862385321102
I1
I0
I1
tp31905
sS'although,theoretically'
p31906
(F1
F0.00014334862385321102
I1
I0
I1
tp31907
sS'mydriasis,tachycardia'
p31908
(F1
F0.00014334862385321102
I1
I0
I1
tp31909
sS'and,cns'
p31910
(F0
F0
I2
I2
I0
tp31911
sS'increases,bioavailability'
p31912
(F1
F0.00014334862385321102
I0
I1
I-1
tp31913
sS'taken,hours'
p31914
(F1
F0.00014334862385321102
I0
I1
I-1
tp31915
sS'pretreatment,with'
p31916
(F1
F0.00057339449541284407
I4
I0
I4
tp31917
sS'mg,a'
p31918
(F0
F0
I1
I1
I0
tp31919
sS'mg,b'
p31920
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp31921
sS'mg,h'
p31922
(F1
F0.00014334862385321102
I1
I0
I1
tp31923
sS'single,pancreatic'
p31924
(F1
F0.00014334862385321102
I0
I1
I-1
tp31925
sS'to,by'
p31926
(F1
F0.00043004587155963305
I0
I3
I-3
tp31927
sS'mg,l'
p31928
(F0
F0
I1
I1
I0
tp31929
sS'a,novel'
p31930
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31931
sS'mg,q'
p31932
(F0.5
F0.00028669724770642203
I3
I1
I2
tp31933
sS'mg,t'
p31934
(F1
F0.00043004587155963305
I3
I0
I3
tp31935
sS'to,be'
p31936
(F0.14705882352941177
F0.0014334862385321102
I39
I29
I10
tp31937
sS'mg,x'
p31938
(F1
F0.00014334862385321102
I0
I1
I-1
tp31939
sS'of,meclofenamate'
p31940
(F1
F0.00014334862385321102
I0
I1
I-1
tp31941
sS'addition,certain'
p31942
(F1
F0.00028669724770642203
I0
I2
I-2
tp31943
sS'plus,highly'
p31944
(F1
F0.00014334862385321102
I0
I1
I-1
tp31945
sS'trial,data'
p31946
(F1
F0.00014334862385321102
I1
I0
I1
tp31947
sS'used,if'
p31948
(F1
F0.0008600917431192661
I6
I0
I6
tp31949
sS'aims,hypothesis'
p31950
(F1
F0.00014334862385321102
I0
I1
I-1
tp31951
sS'marketed,chewable'
p31952
(F1
F0.00014334862385321102
I1
I0
I1
tp31953
sS'used,in'
p31954
(F0.21951219512195122
F0.0012901376146788992
I25
I16
I9
tp31955
sS'not,studied'
p31956
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp31957
sS'used,it'
p31958
(F1
F0.00014334862385321102
I1
I0
I1
tp31959
sS'been,adequately'
p31960
(F1
F0.00014334862385321102
I0
I1
I-1
tp31961
sS'naproxen,sodium'
p31962
(F1
F0.00014334862385321102
I1
I0
I1
tp31963
sS'foods,or'
p31964
(F1
F0.00014334862385321102
I1
I0
I1
tp31965
sS'clotting,factors'
p31966
(F1
F0.00014334862385321102
I0
I1
I-1
tp31967
sS'flurbiprofen,did'
p31968
(F1
F0.00014334862385321102
I1
I0
I1
tp31969
sS'tubular,organic'
p31970
(F0
F0
I1
I1
I0
tp31971
sS'recommendations,were'
p31972
(F1
F0.00014334862385321102
I0
I1
I-1
tp31973
sS'i,selective'
p31974
(F1
F0.00014334862385321102
I1
I0
I1
tp31975
sS'four,days'
p31976
(F1
F0.00014334862385321102
I0
I1
I-1
tp31977
sS'single-dose,coadministration'
p31978
(F1
F0.00014334862385321102
I1
I0
I1
tp31979
sS'arrhythmias,qt'
p31980
(F1
F0.00014334862385321102
I0
I1
I-1
tp31981
sS'slow,phasic'
p31982
(F1
F0.00014334862385321102
I0
I1
I-1
tp31983
sS'probably,for'
p31984
(F1
F0.00014334862385321102
I0
I1
I-1
tp31985
sS'to,possible'
p31986
(F1
F0.00043004587155963305
I3
I0
I3
tp31987
sS'studies,strongly'
p31988
(F1
F0.00014334862385321102
I0
I1
I-1
tp31989
sS'rachitic,chicks'
p31990
(F1
F0.00014334862385321102
I1
I0
I1
tp31991
sS'receive,initial'
p31992
(F1
F0.00014334862385321102
I1
I0
I1
tp31993
sS'to,hypotension'
p31994
(F1
F0.00014334862385321102
I1
I0
I1
tp31995
sS'hydroxide,does'
p31996
(F1
F0.00014334862385321102
I0
I1
I-1
tp31997
sS'to,possibly'
p31998
(F1
F0.00014334862385321102
I1
I0
I1
tp31999
sS'estimation,of'
p32000
(F1
F0.00014334862385321102
I0
I1
I-1
tp32001
sS'tolerance,to'
p32002
(F1
F0.00028669724770642203
I2
I0
I2
tp32003
sS'other,have'
p32004
(F0
F0
I2
I2
I0
tp32005
sS'co-administration,leading'
p32006
(F1
F0.00014334862385321102
I1
I0
I1
tp32007
sS'and,automaticity'
p32008
(F1
F0.00014334862385321102
I1
I0
I1
tp32009
sS'hours,before'
p32010
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp32011
sS'kg,and'
p32012
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp32013
sS'quantitatively,related'
p32014
(F1
F0.00014334862385321102
I0
I1
I-1
tp32015
sS'its,serum'
p32016
(F0
F0
I1
I1
I0
tp32017
sS'normalized,ratio'
p32018
(F1
F0.00043004587155963305
I3
I0
I3
tp32019
sS'plus,were'
p32020
(F1
F0.00014334862385321102
I0
I1
I-1
tp32021
sS'a4,isozymes'
p32022
(F1
F0.00014334862385321102
I0
I1
I-1
tp32023
sS'enhancing,effects'
p32024
(F1
F0.00014334862385321102
I0
I1
I-1
tp32025
sS'thus,necessitating'
p32026
(F1
F0.00014334862385321102
I1
I0
I1
tp32027
sS'microsomes,the'
p32028
(F1
F0.00014334862385321102
I0
I1
I-1
tp32029
sS'ketorolac,does'
p32030
(F1
F0.00014334862385321102
I0
I1
I-1
tp32031
sS'ethanol,or'
p32032
(F1
F0.00014334862385321102
I0
I1
I-1
tp32033
sS'a,renal'
p32034
(F1
F0.00014334862385321102
I0
I1
I-1
tp32035
sS'ototoxicity,is'
p32036
(F1
F0.00014334862385321102
I1
I0
I1
tp32037
sS'elimination,half'
p32038
(F1
F0.00014334862385321102
I1
I0
I1
tp32039
sS'affect,its'
p32040
(F1
F0.00014334862385321102
I0
I1
I-1
tp32041
sS'to,enhance'
p32042
(F1
F0.0008600917431192661
I6
I0
I6
tp32043
sS'alcohol,increases'
p32044
(F1
F0.00014334862385321102
I0
I1
I-1
tp32045
sS'can,antagonize'
p32046
(F1
F0.00028669724770642203
I2
I0
I2
tp32047
sS'of,coly-mycin'
p32048
(F1
F0.00014334862385321102
I1
I0
I1
tp32049
sS'hydroxides,does'
p32050
(F1
F0.00014334862385321102
I0
I1
I-1
tp32051
sS'advantages,offered'
p32052
(F1
F0.00014334862385321102
I0
I1
I-1
tp32053
sS'was,established'
p32054
(F1
F0.00014334862385321102
I0
I1
I-1
tp32055
sS'on,or'
p32056
(F1
F0.00014334862385321102
I1
I0
I1
tp32057
sS'salt,intake'
p32058
(F1
F0.00071674311926605509
I5
I0
I5
tp32059
sS's,concomitantly'
p32060
(F1
F0.00014334862385321102
I1
I0
I1
tp32061
sS'nonabsorbable,complex'
p32062
(F1
F0.00014334862385321102
I1
I0
I1
tp32063
sS'sensitive,cyp3a4'
p32064
(F1
F0.00014334862385321102
I1
I0
I1
tp32065
sS'significant,shifts'
p32066
(F1
F0.00014334862385321102
I0
I1
I-1
tp32067
sS'therapy,discontinuation'
p32068
(F1
F0.00014334862385321102
I1
I0
I1
tp32069
sS'abundance,and'
p32070
(F1
F0.00014334862385321102
I0
I1
I-1
tp32071
sS'compatible,with'
p32072
(F1
F0.00014334862385321102
I0
I1
I-1
tp32073
sS'hepatotoxicity,are'
p32074
(F1
F0.00014334862385321102
I1
I0
I1
tp32075
sS'a,causal'
p32076
(F0
F0
I1
I1
I0
tp32077
sS'these,cyp3a4'
p32078
(F0
F0
I1
I1
I0
tp32079
sS'of,gastric'
p32080
(F1
F0.00014334862385321102
I1
I0
I1
tp32081
sS'racemic,exposure'
p32082
(F1
F0.00014334862385321102
I1
I0
I1
tp32083
sS'administration,of'
p32084
(F0.38095238095238093
F0.016055045871559634
I203
I91
I112
tp32085
sS'in,qt'
p32086
(F1
F0.00014334862385321102
I1
I0
I1
tp32087
sS'pharmacokinetics,of'
p32088
(F0.79166666666666663
F0.010894495412844037
I10
I86
I-76
tp32089
sS'administration,on'
p32090
(F1
F0.00028669724770642203
I0
I2
I-2
tp32091
sS'flu-like,effects'
p32092
(F1
F0.00014334862385321102
I0
I1
I-1
tp32093
sS'administration,or'
p32094
(F1
F0.00014334862385321102
I0
I1
I-1
tp32095
sS'indocin,can'
p32096
(F1
F0.00028669724770642203
I2
I0
I2
tp32097
sS'concentrations,after'
p32098
(F1
F0.00014334862385321102
I1
I0
I1
tp32099
sS'antidepressant,when'
p32100
(F1
F0.00014334862385321102
I1
I0
I1
tp32101
sS'completely,absorbed'
p32102
(F1
F0.00014334862385321102
I0
I1
I-1
tp32103
sS'pharmacokinetics,or'
p32104
(F1
F0.00057339449541284407
I0
I4
I-4
tp32105
sS'is,going'
p32106
(F1
F0.00071674311926605509
I0
I5
I-5
tp32107
sS'as,implants'
p32108
(F1
F0.00014334862385321102
I0
I1
I-1
tp32109
sS'bone,loss'
p32110
(F1
F0.00028669724770642203
I0
I2
I-2
tp32111
sS'amphotericin,foscarnet'
p32112
(F1
F0.00014334862385321102
I1
I0
I1
tp32113
sS'a,decision'
p32114
(F1
F0.00014334862385321102
I0
I1
I-1
tp32115
sS'shown,that'
p32116
(F0.21428571428571427
F0.0008600917431192661
I17
I11
I6
tp32117
sS'acid,indicating'
p32118
(F1
F0.00014334862385321102
I0
I1
I-1
tp32119
sS'administration,reaching'
p32120
(F1
F0.00014334862385321102
I0
I1
I-1
tp32121
sS'macrolide,such'
p32122
(F0
F0
I1
I1
I0
tp32123
sS'of,four'
p32124
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32125
sS'derivatives,antimycobacterial'
p32126
(F1
F0.00014334862385321102
I1
I0
I1
tp32127
sS'important,in'
p32128
(F1
F0.00014334862385321102
I0
I1
I-1
tp32129
sS'concentration,is'
p32130
(F0
F0
I1
I1
I0
tp32131
sS'sugar,concentrations'
p32132
(F1
F0.00014334862385321102
I1
I0
I1
tp32133
sS'post,and'
p32134
(F1
F0.00014334862385321102
I0
I1
I-1
tp32135
sS'control,pills'
p32136
(F1
F0.00028669724770642203
I0
I2
I-2
tp32137
sS'their,bioavailability'
p32138
(F1
F0.00014334862385321102
I1
I0
I1
tp32139
sS'human,studies'
p32140
(F1
F0.00014334862385321102
I0
I1
I-1
tp32141
sS'disease,and'
p32142
(F1
F0.00014334862385321102
I1
I0
I1
tp32143
sS'dolasetron,mesylate'
p32144
(F1
F0.00014334862385321102
I0
I1
I-1
tp32145
sS'produce,persistently'
p32146
(F1
F0.00014334862385321102
I0
I1
I-1
tp32147
sS'affecting,blood'
p32148
(F1
F0.00014334862385321102
I1
I0
I1
tp32149
sS'of,anti-platelet'
p32150
(F1
F0.00014334862385321102
I0
I1
I-1
tp32151
sS'as,slowly'
p32152
(F1
F0.00014334862385321102
I1
I0
I1
tp32153
sS'intravenous,without'
p32154
(F1
F0.00014334862385321102
I1
I0
I1
tp32155
sS'third,of'
p32156
(F1
F0.00014334862385321102
I1
I0
I1
tp32157
sS'although,the'
p32158
(F0.2857142857142857
F0.00057339449541284407
I9
I5
I4
tp32159
sS'juice,increases'
p32160
(F1
F0.00014334862385321102
I0
I1
I-1
tp32161
sS'acetaminophen,a'
p32162
(F1
F0.00014334862385321102
I1
I0
I1
tp32163
sS'a,double-blind'
p32164
(F1
F0.00014334862385321102
I0
I1
I-1
tp32165
sS'enoxacin,is'
p32166
(F1
F0.00028669724770642203
I2
I0
I2
tp32167
sS'avoided,beta-blockers'
p32168
(F1
F0.00014334862385321102
I1
I0
I1
tp32169
sS'whole,blood'
p32170
(F1
F0.00028669724770642203
I2
I0
I2
tp32171
sS'either,single'
p32172
(F1
F0.00014334862385321102
I0
I1
I-1
tp32173
sS'crystalline,preparations'
p32174
(F1
F0.00014334862385321102
I0
I1
I-1
tp32175
sS'of,more'
p32176
(F0
F0
I1
I1
I0
tp32177
sS'and,emit-d'
p32178
(F1
F0.00014334862385321102
I0
I1
I-1
tp32179
sS'b6,physiological'
p32180
(F1
F0.00014334862385321102
I0
I1
I-1
tp32181
sS'is,needed'
p32182
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp32183
sS'sensipar,may'
p32184
(F1
F0.00014334862385321102
I1
I0
I1
tp32185
sS'the,qt'
p32186
(F1
F0.0014334862385321102
I10
I0
I10
tp32187
sS'reports,suggesting'
p32188
(F1
F0.00014334862385321102
I1
I0
I1
tp32189
sS'mainly,by'
p32190
(F1
F0.00014334862385321102
I0
I1
I-1
tp32191
sS'innovar,on'
p32192
(F1
F0.00014334862385321102
I0
I1
I-1
tp32193
sS'and,mumol'
p32194
(F1
F0.00014334862385321102
I1
I0
I1
tp32195
sS'especially,important'
p32196
(F0
F0
I1
I1
I0
tp32197
sS'metabolism,are'
p32198
(F1
F0.00014334862385321102
I0
I1
I-1
tp32199
sS'for,death'
p32200
(F1
F0.00014334862385321102
I0
I1
I-1
tp32201
sS'because,moderate'
p32202
(F1
F0.00014334862385321102
I1
I0
I1
tp32203
sS'inhibition,at'
p32204
(F1
F0.00014334862385321102
I0
I1
I-1
tp32205
sS'c,has'
p32206
(F1
F0.00014334862385321102
I0
I1
I-1
tp32207
sS'as,inotropes'
p32208
(F1
F0.00014334862385321102
I1
I0
I1
tp32209
sS'conclusions,interpretation'
p32210
(F1
F0.00014334862385321102
I0
I1
I-1
tp32211
sS'human,breast'
p32212
(F1
F0.00014334862385321102
I1
I0
I1
tp32213
sS'regardless,of'
p32214
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32215
sS'hydroxy-estazolam,and'
p32216
(F1
F0.00014334862385321102
I0
I1
I-1
tp32217
sS'is,markedly'
p32218
(F1
F0.00014334862385321102
I1
I0
I1
tp32219
sS'results,during'
p32220
(F0
F0
I1
I1
I0
tp32221
sS'em,individuals'
p32222
(F1
F0.00014334862385321102
I1
I0
I1
tp32223
sS'on,monotherapy'
p32224
(F1
F0.00014334862385321102
I0
I1
I-1
tp32225
sS'fat,soluble'
p32226
(F1
F0.00014334862385321102
I0
I1
I-1
tp32227
sS'rhabdomyolysis,and'
p32228
(F1
F0.00014334862385321102
I1
I0
I1
tp32229
sS'blood,levels'
p32230
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp32231
sS'of,cerebyx'
p32232
(F1
F0.00014334862385321102
I0
I1
I-1
tp32233
sS'ingredient,of'
p32234
(F1
F0.00014334862385321102
I0
I1
I-1
tp32235
sS'gly-buride,and'
p32236
(F1
F0.00014334862385321102
I0
I1
I-1
tp32237
sS'tnf,blocking'
p32238
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32239
sS'taking,prothrombin'
p32240
(F1
F0.00014334862385321102
I1
I0
I1
tp32241
sS'anticoagulation,effects'
p32242
(F1
F0.00014334862385321102
I1
I0
I1
tp32243
sS'prothrombin,measures'
p32244
(F1
F0.00014334862385321102
I0
I1
I-1
tp32245
sS'enlargement,and'
p32246
(F1
F0.00014334862385321102
I1
I0
I1
tp32247
sS'bred,for'
p32248
(F1
F0.00014334862385321102
I0
I1
I-1
tp32249
sS'inhibit,renal'
p32250
(F1
F0.00014334862385321102
I1
I0
I1
tp32251
sS'effects,divalproex'
p32252
(F1
F0.00014334862385321102
I1
I0
I1
tp32253
sS'organs,actively'
p32254
(F1
F0.00014334862385321102
I0
I1
I-1
tp32255
sS'there,has'
p32256
(F0
F0
I2
I2
I0
tp32257
sS'with,strong'
p32258
(F1
F0.00028669724770642203
I2
I0
I2
tp32259
sS'p450-based,metabolic'
p32260
(F1
F0.00014334862385321102
I0
I1
I-1
tp32261
sS'gentamicin,did'
p32262
(F1
F0.00014334862385321102
I0
I1
I-1
tp32263
sS'works,differently'
p32264
(F1
F0.00014334862385321102
I0
I1
I-1
tp32265
sS'oral,co-administration'
p32266
(F1
F0.00014334862385321102
I1
I0
I1
tp32267
sS'cyp2d6,isoenzyme'
p32268
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32269
sS'derived,from'
p32270
(F1
F0.00028669724770642203
I2
I0
I2
tp32271
sS'non-steroidal,anti-inflammatory'
p32272
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp32273
sS'cardiac,dysrhythmias'
p32274
(F1
F0.00043004587155963305
I3
I0
I3
tp32275
sS'jaff,reaction'
p32276
(F1
F0.00014334862385321102
I0
I1
I-1
tp32277
sS'watched,during'
p32278
(F1
F0.00014334862385321102
I0
I1
I-1
tp32279
sS'consciousness,caused'
p32280
(F1
F0.00014334862385321102
I1
I0
I1
tp32281
sS'its,normal'
p32282
(F1
F0.00014334862385321102
I1
I0
I1
tp32283
sS'clinical,status'
p32284
(F1
F0.00014334862385321102
I1
I0
I1
tp32285
sS'of,aliskiren'
p32286
(F1
F0.00014334862385321102
I0
I1
I-1
tp32287
sS'is,also'
p32288
(F1
F0.0008600917431192661
I6
I0
I6
tp32289
sS'did,not'
p32290
(F0.86554621848739499
F0.014764908256880734
I8
I111
I-103
tp32291
sS'and,exert'
p32292
(F1
F0.00014334862385321102
I0
I1
I-1
tp32293
sS'concurrent,treatment'
p32294
(F0
F0
I1
I1
I0
tp32295
sS'aetiopathogenic--,for'
p32296
(F1
F0.00014334862385321102
I0
I1
I-1
tp32297
sS'vitamin,b3'
p32298
(F1
F0.00014334862385321102
I1
I0
I1
tp32299
sS'initiated,a'
p32300
(F1
F0.00014334862385321102
I0
I1
I-1
tp32301
sS'kidney,recipients'
p32302
(F1
F0.00014334862385321102
I0
I1
I-1
tp32303
sS'minutes,following'
p32304
(F1
F0.00028669724770642203
I2
I0
I2
tp32305
sS'as,arrhythmias'
p32306
(F1
F0.00014334862385321102
I1
I0
I1
tp32307
sS'two,hormonal'
p32308
(F1
F0.00014334862385321102
I1
I0
I1
tp32309
sS'inhibitors,duragesic'
p32310
(F1
F0.00014334862385321102
I1
I0
I1
tp32311
sS'events,should'
p32312
(F1
F0.00014334862385321102
I0
I1
I-1
tp32313
sS'concomitantly,by'
p32314
(F1
F0.00014334862385321102
I1
I0
I1
tp32315
sS'coenzyme,a'
p32316
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32317
sS'therapy,after'
p32318
(F1
F0.00014334862385321102
I1
I0
I1
tp32319
sS'schizophrenia,or'
p32320
(F1
F0.00028669724770642203
I0
I2
I-2
tp32321
sS'c9,decreased'
p32322
(F1
F0.00014334862385321102
I1
I0
I1
tp32323
sS'endotoxin-induced,changes'
p32324
(F1
F0.00014334862385321102
I0
I1
I-1
tp32325
sS'treated,with'
p32326
(F0.28000000000000003
F0.0020068807339449542
I32
I18
I14
tp32327
sS'pharmacokinetits,of'
p32328
(F1
F0.00014334862385321102
I0
I1
I-1
tp32329
sS'maalox,on'
p32330
(F1
F0.00014334862385321102
I0
I1
I-1
tp32331
sS'faster,with'
p32332
(F1
F0.00014334862385321102
I1
I0
I1
tp32333
sS'add,some'
p32334
(F1
F0.00014334862385321102
I1
I0
I1
tp32335
sS'drug-drug,interaction'
p32336
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp32337
sS'trial,in'
p32338
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32339
sS'unexpectedly,low'
p32340
(F1
F0.00014334862385321102
I1
I0
I1
tp32341
sS'preparations,minipills'
p32342
(F1
F0.00014334862385321102
I1
I0
I1
tp32343
sS'patient,response'
p32344
(F1
F0.00014334862385321102
I0
I1
I-1
tp32345
sS'potent,cyp3a4'
p32346
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp32347
sS'diamond,patient'
p32348
(F1
F0.00014334862385321102
I1
I0
I1
tp32349
sS'butenafine,hcl'
p32350
(F1
F0.00014334862385321102
I0
I1
I-1
tp32351
sS'sodium,and'
p32352
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp32353
sS'and,qtc'
p32354
(F1
F0.00014334862385321102
I0
I1
I-1
tp32355
sS'is,antagonized'
p32356
(F1
F0.00014334862385321102
I1
I0
I1
tp32357
sS'more,conservatively'
p32358
(F1
F0.00014334862385321102
I1
I0
I1
tp32359
sS'inducer,such'
p32360
(F1
F0.00014334862385321102
I0
I1
I-1
tp32361
sS'impaired,psychomotor'
p32362
(F1
F0.00028669724770642203
I2
I0
I2
tp32363
sS'increased,activity'
p32364
(F0
F0
I1
I1
I0
tp32365
sS'maoi,could'
p32366
(F1
F0.00014334862385321102
I1
I0
I1
tp32367
sS'when,co'
p32368
(F1
F0.00014334862385321102
I1
I0
I1
tp32369
sS'orally,min'
p32370
(F1
F0.00014334862385321102
I0
I1
I-1
tp32371
sS'diabetic,and'
p32372
(F1
F0.00014334862385321102
I0
I1
I-1
tp32373
sS'and,sucralfate'
p32374
(F1
F0.00014334862385321102
I1
I0
I1
tp32375
sS'extremely,cautiously'
p32376
(F1
F0.00014334862385321102
I1
I0
I1
tp32377
sS'color,alkaline'
p32378
(F1
F0.00014334862385321102
I0
I1
I-1
tp32379
sS'route,they'
p32380
(F1
F0.00014334862385321102
I1
I0
I1
tp32381
sS'is,desirable'
p32382
(F1
F0.00071674311926605509
I0
I5
I-5
tp32383
sS'the,ototoxic'
p32384
(F1
F0.00043004587155963305
I3
I0
I3
tp32385
sS'effect,to'
p32386
(F1
F0.00014334862385321102
I1
I0
I1
tp32387
sS'possibility,that'
p32388
(F1
F0.00057339449541284407
I4
I0
I4
tp32389
sS'in,mice'
p32390
(F1
F0.00043004587155963305
I0
I3
I-3
tp32391
sS'of,prostaglandin'
p32392
(F0.5
F0.00028669724770642203
I3
I1
I2
tp32393
sS'than,those'
p32394
(F1
F0.00043004587155963305
I3
I0
I3
tp32395
sS'its,action'
p32396
(F1
F0.00014334862385321102
I1
I0
I1
tp32397
sS'first,and'
p32398
(F1
F0.00028669724770642203
I2
I0
I2
tp32399
sS'following,methyl-4'
p32400
(F1
F0.00014334862385321102
I0
I1
I-1
tp32401
sS'found,between'
p32402
(F1
F0.00028669724770642203
I0
I2
I-2
tp32403
sS'primarily,h2'
p32404
(F1
F0.00014334862385321102
I0
I1
I-1
tp32405
sS'inhibit,cytochrome'
p32406
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp32407
sS'a,comparison'
p32408
(F1
F0.00014334862385321102
I1
I0
I1
tp32409
sS'urinary,alkalinizing'
p32410
(F1
F0.00014334862385321102
I1
I0
I1
tp32411
sS'hypotension,will'
p32412
(F1
F0.00014334862385321102
I1
I0
I1
tp32413
sS'chinese,hamsters'
p32414
(F1
F0.00014334862385321102
I0
I1
I-1
tp32415
sS'you,are'
p32416
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp32417
sS'anabolin,anavar'
p32418
(F1
F0.00014334862385321102
I0
I1
I-1
tp32419
sS'valproate,felbatol'
p32420
(F1
F0.00014334862385321102
I1
I0
I1
tp32421
sS'orally,ingested'
p32422
(F1
F0.00014334862385321102
I0
I1
I-1
tp32423
sS'aom,mg'
p32424
(F1
F0.00014334862385321102
I0
I1
I-1
tp32425
sS'can,be'
p32426
(F0.25
F0.0008600917431192661
I15
I9
I6
tp32427
sS'd,the'
p32428
(F1
F0.00043004587155963305
I0
I3
I-3
tp32429
sS'needing,to'
p32430
(F1
F0.00014334862385321102
I0
I1
I-1
tp32431
sS'cimetidine,increases'
p32432
(F1
F0.00014334862385321102
I1
I0
I1
tp32433
sS'certain,narcotic'
p32434
(F1
F0.00014334862385321102
I1
I0
I1
tp32435
sS'instability,with'
p32436
(F1
F0.00014334862385321102
I1
I0
I1
tp32437
sS'especially,and'
p32438
(F1
F0.00014334862385321102
I0
I1
I-1
tp32439
sS'no,formal'
p32440
(F1
F0.0008600917431192661
I0
I6
I-6
tp32441
sS'pose,a'
p32442
(F0
F0
I1
I1
I0
tp32443
sS'significantly,decrease'
p32444
(F1
F0.00014334862385321102
I1
I0
I1
tp32445
sS'and,synergistic'
p32446
(F1
F0.00028669724770642203
I2
I0
I2
tp32447
sS'receiving,low'
p32448
(F0
F0
I1
I1
I0
tp32449
sS'toxicity,at'
p32450
(F1
F0.00014334862385321102
I1
I0
I1
tp32451
sS'whereas,h-spiroperidol'
p32452
(F1
F0.00014334862385321102
I0
I1
I-1
tp32453
sS'modify,acth'
p32454
(F1
F0.00014334862385321102
I0
I1
I-1
tp32455
sS'cations,multivitamins'
p32456
(F1
F0.00014334862385321102
I0
I1
I-1
tp32457
sS'h,without'
p32458
(F1
F0.00014334862385321102
I1
I0
I1
tp32459
sS'on,mtc-mdp'
p32460
(F1
F0.00014334862385321102
I1
I0
I1
tp32461
sS'penicillin-type,are'
p32462
(F1
F0.00014334862385321102
I1
I0
I1
tp32463
sS'the,corrected'
p32464
(F1
F0.00014334862385321102
I0
I1
I-1
tp32465
sS'index,digoxin'
p32466
(F1
F0.00028669724770642203
I0
I2
I-2
tp32467
sS'the,salt'
p32468
(F1
F0.00057339449541284407
I4
I0
I4
tp32469
sS'and,urine'
p32470
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp32471
sS'only,one'
p32472
(F1
F0.00014334862385321102
I0
I1
I-1
tp32473
sS'and,smx'
p32474
(F1
F0.00014334862385321102
I0
I1
I-1
tp32475
sS'its,synergism'
p32476
(F1
F0.00014334862385321102
I1
I0
I1
tp32477
sS'be,clinically'
p32478
(F0
F0
I1
I1
I0
tp32479
sS'partially,related'
p32480
(F1
F0.00014334862385321102
I1
I0
I1
tp32481
sS'precipitation,of'
p32482
(F1
F0.00014334862385321102
I0
I1
I-1
tp32483
sS'brain,was'
p32484
(F1
F0.00014334862385321102
I1
I0
I1
tp32485
sS'initial,presentation'
p32486
(F1
F0.00014334862385321102
I1
I0
I1
tp32487
sS'agonists,have'
p32488
(F1
F0.00014334862385321102
I1
I0
I1
tp32489
sS'ganglionic,blocking'
p32490
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32491
sS'class,which'
p32492
(F1
F0.00014334862385321102
I0
I1
I-1
tp32493
sS'monitored,if'
p32494
(F1
F0.00028669724770642203
I2
I0
I2
tp32495
sS'the,nad'
p32496
(F1
F0.00014334862385321102
I1
I0
I1
tp32497
sS'local,use'
p32498
(F1
F0.00014334862385321102
I0
I1
I-1
tp32499
sS'level,to'
p32500
(F1
F0.00014334862385321102
I1
I0
I1
tp32501
sS'monitored,in'
p32502
(F1
F0.00043004587155963305
I3
I0
I3
tp32503
sS'contraction,followed'
p32504
(F1
F0.00014334862385321102
I0
I1
I-1
tp32505
sS'free,fraction'
p32506
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32507
sS'suboxone,should'
p32508
(F1
F0.00014334862385321102
I1
I0
I1
tp32509
sS'also,likely'
p32510
(F1
F0.00014334862385321102
I1
I0
I1
tp32511
sS'as,the'
p32512
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp32513
sS'concomitant,augmentin'
p32514
(F1
F0.00014334862385321102
I0
I1
I-1
tp32515
sS'limb,digital'
p32516
(F1
F0.00014334862385321102
I0
I1
I-1
tp32517
sS'on,dopamine2-'
p32518
(F1
F0.00014334862385321102
I0
I1
I-1
tp32519
sS'rings,from'
p32520
(F1
F0.00014334862385321102
I1
I0
I1
tp32521
sS'a,minor'
p32522
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32523
sS'that,it'
p32524
(F1
F0.00014334862385321102
I1
I0
I1
tp32525
sS'blockade,of'
p32526
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32527
sS'that,is'
p32528
(F0.63636363636363635
F0.0010034403669724771
I2
I9
I-7
tp32529
sS'inhibitors,ssris'
p32530
(F0.090909090909090912
F0.00014334862385321102
I5
I6
I-1
tp32531
sS'hydroxide,hydroxide'
p32532
(F1
F0.00014334862385321102
I1
I0
I1
tp32533
sS'antiepileptic,the'
p32534
(F1
F0.00014334862385321102
I0
I1
I-1
tp32535
sS'that,in'
p32536
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp32537
sS'nonsteroidal,given'
p32538
(F1
F0.00014334862385321102
I0
I1
I-1
tp32539
sS'suspension,reduces'
p32540
(F1
F0.00014334862385321102
I1
I0
I1
tp32541
sS'fibrulation,and'
p32542
(F1
F0.00014334862385321102
I1
I0
I1
tp32543
sS'with,potassium-depleting'
p32544
(F1
F0.00014334862385321102
I1
I0
I1
tp32545
sS'receiving,these'
p32546
(F0
F0
I2
I2
I0
tp32547
sS'may,decrease'
p32548
(F0.66666666666666663
F0.0040137614678899085
I35
I7
I28
tp32549
sS'oral,was'
p32550
(F1
F0.00014334862385321102
I1
I0
I1
tp32551
sS'when,another'
p32552
(F1
F0.00014334862385321102
I0
I1
I-1
tp32553
sS'pigeons,did'
p32554
(F1
F0.00014334862385321102
I0
I1
I-1
tp32555
sS'other,calcium-containing'
p32556
(F1
F0.00014334862385321102
I0
I1
I-1
tp32557
sS'literature,article'
p32558
(F1
F0.00014334862385321102
I1
I0
I1
tp32559
sS'may,depress'
p32560
(F1
F0.00014334862385321102
I1
I0
I1
tp32561
sS'six-day,course'
p32562
(F1
F0.00014334862385321102
I1
I0
I1
tp32563
sS'because,a'
p32564
(F1
F0.00014334862385321102
I1
I0
I1
tp32565
sS'substances,demonstrated'
p32566
(F1
F0.00014334862385321102
I1
I0
I1
tp32567
sS'embryos,in'
p32568
(F1
F0.00014334862385321102
I1
I0
I1
tp32569
sS'receiving,alone'
p32570
(F1
F0.00014334862385321102
I0
I1
I-1
tp32571
sS'inhibit,platelet'
p32572
(F0
F0
I1
I1
I0
tp32573
sS'with,chop'
p32574
(F1
F0.00014334862385321102
I0
I1
I-1
tp32575
sS'concomitantly,becausedecreases'
p32576
(F1
F0.00028669724770642203
I2
I0
I2
tp32577
sS'p450iid6,may'
p32578
(F1
F0.00014334862385321102
I0
I1
I-1
tp32579
sS'that,zebeta'
p32580
(F1
F0.00014334862385321102
I1
I0
I1
tp32581
sS'micrograms,kg'
p32582
(F1
F0.00014334862385321102
I0
I1
I-1
tp32583
sS'other,reported'
p32584
(F1
F0.00014334862385321102
I0
I1
I-1
tp32585
sS'when,coreg'
p32586
(F1
F0.00014334862385321102
I1
I0
I1
tp32587
sS'lowest,recommended'
p32588
(F1
F0.00014334862385321102
I1
I0
I1
tp32589
sS'prevent,excessive'
p32590
(F1
F0.00014334862385321102
I1
I0
I1
tp32591
sS'with,cyp3a4'
p32592
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32593
sS'steady-state,exposure'
p32594
(F1
F0.00014334862385321102
I0
I1
I-1
tp32595
sS'combined,treatment'
p32596
(F1
F0.00028669724770642203
I2
I0
I2
tp32597
sS'mucosal,cell'
p32598
(F1
F0.00014334862385321102
I0
I1
I-1
tp32599
sS'acid,etc'
p32600
(F1
F0.00028669724770642203
I2
I0
I2
tp32601
sS'd2,vitamin'
p32602
(F1
F0.00043004587155963305
I3
I0
I3
tp32603
sS'orthostatic,changes'
p32604
(F1
F0.00014334862385321102
I1
I0
I1
tp32605
sS'and,probably'
p32606
(F1
F0.00014334862385321102
I0
I1
I-1
tp32607
sS'and,background'
p32608
(F1
F0.00014334862385321102
I0
I1
I-1
tp32609
sS'the,international'
p32610
(F1
F0.00014334862385321102
I0
I1
I-1
tp32611
sS'applied,for'
p32612
(F1
F0.00014334862385321102
I0
I1
I-1
tp32613
sS'on,pregnancy'
p32614
(F1
F0.00014334862385321102
I0
I1
I-1
tp32615
sS'of,psychotic'
p32616
(F1
F0.00014334862385321102
I0
I1
I-1
tp32617
sS'hypoglycemia,may'
p32618
(F1
F0.00028669724770642203
I0
I2
I-2
tp32619
sS'the,rebound'
p32620
(F1
F0.00014334862385321102
I1
I0
I1
tp32621
sS'expected,between'
p32622
(F1
F0.00014334862385321102
I0
I1
I-1
tp32623
sS'shown,casodex'
p32624
(F1
F0.00014334862385321102
I1
I0
I1
tp32625
sS'device,and'
p32626
(F1
F0.00014334862385321102
I0
I1
I-1
tp32627
sS'the,preservative'
p32628
(F1
F0.00014334862385321102
I1
I0
I1
tp32629
sS'therapy,nicotinic'
p32630
(F1
F0.00014334862385321102
I1
I0
I1
tp32631
sS'fertility,of'
p32632
(F1
F0.00014334862385321102
I0
I1
I-1
tp32633
sS'concurrent,and'
p32634
(F0
F0
I1
I1
I0
tp32635
sS'in,parentheses'
p32636
(F1
F0.00014334862385321102
I0
I1
I-1
tp32637
sS'was,seen'
p32638
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp32639
sS'known,metabolic'
p32640
(F1
F0.00014334862385321102
I0
I1
I-1
tp32641
sS'days,should'
p32642
(F1
F0.00014334862385321102
I1
I0
I1
tp32643
sS'absolute,number'
p32644
(F1
F0.00014334862385321102
I0
I1
I-1
tp32645
sS'p450-mediated,metabolism'
p32646
(F1
F0.00014334862385321102
I0
I1
I-1
tp32647
sS'potential,effects'
p32648
(F0.5
F0.00028669724770642203
I3
I1
I2
tp32649
sS'no,pharmacodynamic'
p32650
(F1
F0.00028669724770642203
I0
I2
I-2
tp32651
sS'effect,its'
p32652
(F1
F0.00014334862385321102
I1
I0
I1
tp32653
sS'as,from'
p32654
(F1
F0.00014334862385321102
I1
I0
I1
tp32655
sS'rifampin,rifampin'
p32656
(F1
F0.00014334862385321102
I1
I0
I1
tp32657
sS'bodyweight,gain'
p32658
(F1
F0.00014334862385321102
I0
I1
I-1
tp32659
sS'of,oleate'
p32660
(F1
F0.00014334862385321102
I0
I1
I-1
tp32661
sS'propanolol,the'
p32662
(F1
F0.00014334862385321102
I0
I1
I-1
tp32663
sS'myocardium,in'
p32664
(F1
F0.00014334862385321102
I0
I1
I-1
tp32665
sS'its,long-lasting'
p32666
(F1
F0.00014334862385321102
I0
I1
I-1
tp32667
sS'produce,vertigo'
p32668
(F1
F0.00028669724770642203
I2
I0
I2
tp32669
sS'animals,where'
p32670
(F1
F0.00014334862385321102
I0
I1
I-1
tp32671
sS'concentration,index'
p32672
(F1
F0.00014334862385321102
I0
I1
I-1
tp32673
sS'most,other'
p32674
(F1
F0.00028669724770642203
I2
I0
I2
tp32675
sS'cause,bleeding'
p32676
(F1
F0.00014334862385321102
I0
I1
I-1
tp32677
sS'from,clinical'
p32678
(F1
F0.00014334862385321102
I1
I0
I1
tp32679
sS'mefloquine,is'
p32680
(F1
F0.00014334862385321102
I1
I0
I1
tp32681
sS'looks,at'
p32682
(F1
F0.00014334862385321102
I0
I1
I-1
tp32683
sS'of,although'
p32684
(F1
F0.00028669724770642203
I2
I0
I2
tp32685
sS'further,increased'
p32686
(F1
F0.00014334862385321102
I0
I1
I-1
tp32687
sS'mg,tablets'
p32688
(F0
F0
I1
I1
I0
tp32689
sS'the,bowel'
p32690
(F1
F0.00014334862385321102
I0
I1
I-1
tp32691
sS'reaction,although'
p32692
(F1
F0.00014334862385321102
I1
I0
I1
tp32693
sS'means,of'
p32694
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32695
sS'contin,prelone'
p32696
(F1
F0.00014334862385321102
I1
I0
I1
tp32697
sS'and,sulfate'
p32698
(F1
F0.00014334862385321102
I1
I0
I1
tp32699
sS'agents,by'
p32700
(F1
F0.00028669724770642203
I2
I0
I2
tp32701
sS'effects,affecting'
p32702
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp32703
sS'concentration,and'
p32704
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp32705
sS'is,assumed'
p32706
(F1
F0.00014334862385321102
I0
I1
I-1
tp32707
sS'anticoagulants,potentiation'
p32708
(F1
F0.00014334862385321102
I0
I1
I-1
tp32709
sS'monitoring,the'
p32710
(F1
F0.00014334862385321102
I0
I1
I-1
tp32711
sS'but,increased'
p32712
(F1
F0.00014334862385321102
I0
I1
I-1
tp32713
sS'observed,which'
p32714
(F1
F0.00028669724770642203
I2
I0
I2
tp32715
sS'neuromuscular,weakness'
p32716
(F1
F0.00014334862385321102
I1
I0
I1
tp32717
sS'tysabri,dose'
p32718
(F1
F0.00014334862385321102
I0
I1
I-1
tp32719
sS'very,sensitive'
p32720
(F1
F0.00014334862385321102
I0
I1
I-1
tp32721
sS'hypertonus,possibly'
p32722
(F1
F0.00014334862385321102
I1
I0
I1
tp32723
sS'patient,pharmacokinetic'
p32724
(F1
F0.00014334862385321102
I1
I0
I1
tp32725
sS'days,as'
p32726
(F1
F0.00014334862385321102
I1
I0
I1
tp32727
sS'two,agents'
p32728
(F0
F0
I1
I1
I0
tp32729
sS'bid,was'
p32730
(F1
F0.00014334862385321102
I1
I0
I1
tp32731
sS'patients,exposed'
p32732
(F1
F0.00014334862385321102
I1
I0
I1
tp32733
sS'from,cholinergic'
p32734
(F1
F0.00014334862385321102
I1
I0
I1
tp32735
sS'levels,indicating'
p32736
(F1
F0.00014334862385321102
I0
I1
I-1
tp32737
sS'omega-conotoxin,gvia'
p32738
(F1
F0.00028669724770642203
I0
I2
I-2
tp32739
sS'thiazide,and'
p32740
(F1
F0.00057339449541284407
I4
I0
I4
tp32741
sS'of,sympatholytic'
p32742
(F1
F0.00028669724770642203
I0
I2
I-2
tp32743
sS'cysteine,was'
p32744
(F1
F0.00014334862385321102
I0
I1
I-1
tp32745
sS'to,alter'
p32746
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp32747
sS'single,dose'
p32748
(F0.052631578947368418
F0.00028669724770642203
I18
I20
I-2
tp32749
sS'propose,these'
p32750
(F1
F0.00014334862385321102
I1
I0
I1
tp32751
sS'protects,against'
p32752
(F1
F0.00014334862385321102
I1
I0
I1
tp32753
sS'induces,apoptosis'
p32754
(F1
F0.00014334862385321102
I0
I1
I-1
tp32755
sS'of,nuromax'
p32756
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32757
sS'psychotropic,medications'
p32758
(F1
F0.00043004587155963305
I3
I0
I3
tp32759
sS'foradil,should'
p32760
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32761
sS'pharmacodynamics,blood'
p32762
(F1
F0.00014334862385321102
I0
I1
I-1
tp32763
sS'concentration-dependent,relaxation'
p32764
(F1
F0.00014334862385321102
I0
I1
I-1
tp32765
sS'investigated,in'
p32766
(F1
F0.0008600917431192661
I0
I6
I-6
tp32767
sS'in,niddm'
p32768
(F1
F0.00014334862385321102
I0
I1
I-1
tp32769
sS'intravenous,may'
p32770
(F1
F0.00014334862385321102
I1
I0
I1
tp32771
sS'demonstrate,that'
p32772
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp32773
sS'and,transient'
p32774
(F1
F0.00014334862385321102
I1
I0
I1
tp32775
sS'of,relative'
p32776
(F0
F0
I1
I1
I0
tp32777
sS'may,bind'
p32778
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32779
sS'of,concurrently'
p32780
(F1
F0.00014334862385321102
I0
I1
I-1
tp32781
sS'absorption,from'
p32782
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32783
sS'aged,or'
p32784
(F1
F0.00014334862385321102
I0
I1
I-1
tp32785
sS'is,inhibited'
p32786
(F1
F0.00043004587155963305
I3
I0
I3
tp32787
sS'and,potent'
p32788
(F1
F0.00014334862385321102
I0
I1
I-1
tp32789
sS'be,effective'
p32790
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32791
sS'will,increase'
p32792
(F1
F0.00014334862385321102
I1
I0
I1
tp32793
sS'and,anti-infectives'
p32794
(F1
F0.00014334862385321102
I0
I1
I-1
tp32795
sS'filtration,or'
p32796
(F1
F0.00014334862385321102
I0
I1
I-1
tp32797
sS'that,pulmozyme'
p32798
(F1
F0.00014334862385321102
I0
I1
I-1
tp32799
sS'reviewed,and'
p32800
(F1
F0.00014334862385321102
I1
I0
I1
tp32801
sS'cause,and'
p32802
(F1
F0.00014334862385321102
I1
I0
I1
tp32803
sS'sonata,reflecting'
p32804
(F1
F0.00014334862385321102
I0
I1
I-1
tp32805
sS'ulceration,or'
p32806
(F1
F0.00028669724770642203
I2
I0
I2
tp32807
sS'be,exercised'
p32808
(F0.47826086956521741
F0.0015768348623853212
I17
I6
I11
tp32809
sS'actions,and'
p32810
(F0
F0
I1
I1
I0
tp32811
sS'agent,may'
p32812
(F0
F0
I1
I1
I0
tp32813
sS'clinical,study'
p32814
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp32815
sS'mg,potentiated'
p32816
(F1
F0.00014334862385321102
I1
I0
I1
tp32817
sS'these,alterations'
p32818
(F1
F0.00014334862385321102
I1
I0
I1
tp32819
sS'or,will'
p32820
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32821
sS'celebrex,with'
p32822
(F1
F0.00014334862385321102
I1
I0
I1
tp32823
sS'three,types'
p32824
(F1
F0.00014334862385321102
I0
I1
I-1
tp32825
sS'secretion,while'
p32826
(F1
F0.00014334862385321102
I1
I0
I1
tp32827
sS'a,or'
p32828
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32829
sS'plus,for'
p32830
(F1
F0.00014334862385321102
I0
I1
I-1
tp32831
sS'buspirone,hcl'
p32832
(F1
F0.00043004587155963305
I3
I0
I3
tp32833
sS'of,sensipar'
p32834
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32835
sS'antiepilepsy,drugs'
p32836
(F0
F0
I1
I1
I0
tp32837
sS'antagonist,that'
p32838
(F1
F0.00014334862385321102
I1
I0
I1
tp32839
sS'methadone,levels'
p32840
(F1
F0.00014334862385321102
I1
I0
I1
tp32841
sS'rats,epidural'
p32842
(F1
F0.00014334862385321102
I1
I0
I1
tp32843
sS'mg,per'
p32844
(F0
F0
I2
I2
I0
tp32845
sS'specific,interaction'
p32846
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp32847
sS'glycemia,after'
p32848
(F1
F0.00014334862385321102
I0
I1
I-1
tp32849
sS'elderly,and'
p32850
(F1
F0.00014334862385321102
I0
I1
I-1
tp32851
sS'to,accelerate'
p32852
(F1
F0.00014334862385321102
I0
I1
I-1
tp32853
sS'increased,exposure'
p32854
(F1
F0.00057339449541284407
I4
I0
I4
tp32855
sS'until,data'
p32856
(F1
F0.00014334862385321102
I1
I0
I1
tp32857
sS'gleevec,is'
p32858
(F1
F0.00014334862385321102
I1
I0
I1
tp32859
sS'were,drinking'
p32860
(F1
F0.00014334862385321102
I1
I0
I1
tp32861
sS'rate,but'
p32862
(F1
F0.00014334862385321102
I0
I1
I-1
tp32863
sS'of,potential'
p32864
(F0
F0
I1
I1
I0
tp32865
sS'neomycin,has'
p32866
(F1
F0.00014334862385321102
I0
I1
I-1
tp32867
sS'the,reduction'
p32868
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp32869
sS'other,may'
p32870
(F1
F0.00057339449541284407
I4
I0
I4
tp32871
sS'ii,the'
p32872
(F1
F0.00014334862385321102
I0
I1
I-1
tp32873
sS'dietary,concentration'
p32874
(F1
F0.00014334862385321102
I0
I1
I-1
tp32875
sS'the,nerve'
p32876
(F1
F0.00014334862385321102
I0
I1
I-1
tp32877
sS'ccnu,by'
p32878
(F1
F0.00014334862385321102
I1
I0
I1
tp32879
sS'low,dietary'
p32880
(F1
F0.00014334862385321102
I0
I1
I-1
tp32881
sS'many,including'
p32882
(F1
F0.00014334862385321102
I0
I1
I-1
tp32883
sS'u937,and'
p32884
(F1
F0.00014334862385321102
I1
I0
I1
tp32885
sS'in,five'
p32886
(F1
F0.00014334862385321102
I1
I0
I1
tp32887
sS'peak,blood'
p32888
(F1
F0.00014334862385321102
I1
I0
I1
tp32889
sS'of,virologic'
p32890
(F1
F0.00028669724770642203
I0
I2
I-2
tp32891
sS'existing,therapy'
p32892
(F1
F0.00014334862385321102
I0
I1
I-1
tp32893
sS'no,reported'
p32894
(F1
F0.00014334862385321102
I0
I1
I-1
tp32895
sS'some,like'
p32896
(F1
F0.00014334862385321102
I1
I0
I1
tp32897
sS'globulin,cbg'
p32898
(F1
F0.00028669724770642203
I0
I2
I-2
tp32899
sS'with,schizophrenia'
p32900
(F1
F0.00043004587155963305
I0
I3
I-3
tp32901
sS'manner,the'
p32902
(F1
F0.00014334862385321102
I1
I0
I1
tp32903
sS'net,effect'
p32904
(F1
F0.00014334862385321102
I0
I1
I-1
tp32905
sS'isoenzyme,daily'
p32906
(F1
F0.00014334862385321102
I1
I0
I1
tp32907
sS'resemble,poor'
p32908
(F1
F0.00028669724770642203
I0
I2
I-2
tp32909
sS'interconversion,between'
p32910
(F1
F0.00014334862385321102
I0
I1
I-1
tp32911
sS'evoked,potential'
p32912
(F1
F0.00014334862385321102
I0
I1
I-1
tp32913
sS'patients,not'
p32914
(F1
F0.00043004587155963305
I3
I0
I3
tp32915
sS'among,these'
p32916
(F1
F0.00014334862385321102
I0
I1
I-1
tp32917
sS'of,tracleer'
p32918
(F1
F0.00014334862385321102
I1
I0
I1
tp32919
sS'pigeons,but'
p32920
(F1
F0.00014334862385321102
I1
I0
I1
tp32921
sS'sodium,channels'
p32922
(F1
F0.00014334862385321102
I0
I1
I-1
tp32923
sS'iv,such'
p32924
(F1
F0.00014334862385321102
I0
I1
I-1
tp32925
sS'the,volunteers'
p32926
(F1
F0.00014334862385321102
I1
I0
I1
tp32927
sS'analgesic,adjuvants'
p32928
(F1
F0.00014334862385321102
I0
I1
I-1
tp32929
sS'marrow,suppression'
p32930
(F1
F0.00014334862385321102
I1
I0
I1
tp32931
sS'without,indicated'
p32932
(F1
F0.00014334862385321102
I0
I1
I-1
tp32933
sS'on,should'
p32934
(F1
F0.00043004587155963305
I3
I0
I3
tp32935
sS'salt,substitutes'
p32936
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32937
sS'cyp2c8,drugs'
p32938
(F1
F0.00014334862385321102
I0
I1
I-1
tp32939
sS'in,postmarketing'
p32940
(F0
F0
I1
I1
I0
tp32941
sS'lowered,plasma'
p32942
(F1
F0.00014334862385321102
I0
I1
I-1
tp32943
sS'vehicle,corn'
p32944
(F1
F0.00014334862385321102
I0
I1
I-1
tp32945
sS'of,results'
p32946
(F1
F0.00014334862385321102
I1
I0
I1
tp32947
sS'of,adenocard'
p32948
(F1
F0.00014334862385321102
I1
I0
I1
tp32949
sS'fractional,mucosal'
p32950
(F1
F0.00014334862385321102
I0
I1
I-1
tp32951
sS'the,first-pass'
p32952
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32953
sS'that,impairment'
p32954
(F1
F0.00014334862385321102
I0
I1
I-1
tp32955
sS'medications,included'
p32956
(F1
F0.00014334862385321102
I0
I1
I-1
tp32957
sS'fibrillation,their'
p32958
(F1
F0.00014334862385321102
I1
I0
I1
tp32959
sS'ermbt,and'
p32960
(F1
F0.00014334862385321102
I0
I1
I-1
tp32961
sS'supporting,blood'
p32962
(F1
F0.00014334862385321102
I0
I1
I-1
tp32963
sS'in,multiple'
p32964
(F1
F0.00014334862385321102
I0
I1
I-1
tp32965
sS'permeability,of'
p32966
(F1
F0.00014334862385321102
I0
I1
I-1
tp32967
sS'decreased,serum'
p32968
(F1
F0.00028669724770642203
I2
I0
I2
tp32969
sS'hormone,may'
p32970
(F0
F0
I1
I1
I0
tp32971
sS'by,minutes'
p32972
(F1
F0.00014334862385321102
I1
I0
I1
tp32973
sS'parallel,group'
p32974
(F1
F0.00028669724770642203
I0
I2
I-2
tp32975
sS'times,or'
p32976
(F1
F0.00014334862385321102
I0
I1
I-1
tp32977
sS'of,fenofibric'
p32978
(F1
F0.00014334862385321102
I0
I1
I-1
tp32979
sS'these,oral'
p32980
(F1
F0.00014334862385321102
I1
I0
I1
tp32981
sS'and,inhibitors'
p32982
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32983
sS'viii,ix'
p32984
(F1
F0.00014334862385321102
I0
I1
I-1
tp32985
sS'ocupress,should'
p32986
(F1
F0.00014334862385321102
I1
I0
I1
tp32987
sS'parasite,reduction'
p32988
(F1
F0.00014334862385321102
I0
I1
I-1
tp32989
sS'anticoagulants,combination'
p32990
(F1
F0.00014334862385321102
I1
I0
I1
tp32991
sS'may,emerge'
p32992
(F1
F0.00014334862385321102
I1
I0
I1
tp32993
sS'sensitize,the'
p32994
(F1
F0.00057339449541284407
I4
I0
I4
tp32995
sS'the,antitumour'
p32996
(F0
F0
I1
I1
I0
tp32997
sS'with,cmi'
p32998
(F1
F0.00028669724770642203
I2
I0
I2
tp32999
sS'of,distribution'
p33000
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp33001
sS'cyp3a4,alter'
p33002
(F1
F0.00014334862385321102
I0
I1
I-1
tp33003
sS'mg,appears'
p33004
(F1
F0.00014334862385321102
I1
I0
I1
tp33005
sS'with,serotoninergic'
p33006
(F1
F0.00014334862385321102
I1
I0
I1
tp33007
sS'if,cefotan'
p33008
(F1
F0.00014334862385321102
I1
I0
I1
tp33009
sS'and,negative'
p33010
(F1
F0.00043004587155963305
I0
I3
I-3
tp33011
sS'may,add'
p33012
(F1
F0.00028669724770642203
I2
I0
I2
tp33013
sS'use,clinicians'
p33014
(F1
F0.00014334862385321102
I1
I0
I1
tp33015
sS'from,single'
p33016
(F1
F0.00014334862385321102
I0
I1
I-1
tp33017
sS'vaccines,patients'
p33018
(F1
F0.00014334862385321102
I1
I0
I1
tp33019
sS'bupropz_od,htm'
p33020
(F1
F0.00014334862385321102
I1
I0
I1
tp33021
sS'eg,may'
p33022
(F1
F0.0011467889908256881
I8
I0
I8
tp33023
sS'liquid,did'
p33024
(F1
F0.00014334862385321102
I0
I1
I-1
tp33025
sS'kingdom,with'
p33026
(F1
F0.00014334862385321102
I1
I0
I1
tp33027
sS'interactions,must'
p33028
(F1
F0.00014334862385321102
I1
I0
I1
tp33029
sS'long,half-lives'
p33030
(F1
F0.00014334862385321102
I0
I1
I-1
tp33031
sS'in,ephesus'
p33032
(F1
F0.00014334862385321102
I0
I1
I-1
tp33033
sS'nsaids,monoamine'
p33034
(F1
F0.00014334862385321102
I1
I0
I1
tp33035
sS'may,result'
p33036
(F0.58974358974358976
F0.0032970183486238534
I31
I8
I23
tp33037
sS'hundred,mg'
p33038
(F1
F0.00014334862385321102
I0
I1
I-1
tp33039
sS'given,as'
p33040
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp33041
sS'toxic,to'
p33042
(F1
F0.00014334862385321102
I0
I1
I-1
tp33043
sS'in,kidney'
p33044
(F1
F0.00014334862385321102
I0
I1
I-1
tp33045
sS'converting,difluoro-2'
p33046
(F1
F0.00014334862385321102
I1
I0
I1
tp33047
sS'p,the'
p33048
(F1
F0.00014334862385321102
I1
I0
I1
tp33049
sS'volunteers,mg'
p33050
(F1
F0.00014334862385321102
I0
I1
I-1
tp33051
sS'meal,would'
p33052
(F1
F0.00014334862385321102
I0
I1
I-1
tp33053
sS'powders,showed'
p33054
(F1
F0.00014334862385321102
I1
I0
I1
tp33055
sS'cmax,and'
p33056
(F0.68000000000000005
F0.0024369266055045873
I21
I4
I17
tp33057
sS'administration,even'
p33058
(F1
F0.00014334862385321102
I0
I1
I-1
tp33059
sS'trough,concentrations'
p33060
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp33061
sS'limited,clinical'
p33062
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33063
sS'used,concomitantly'
p33064
(F0.26315789473684209
F0.0014334862385321102
I24
I14
I10
tp33065
sS'cyp3a4,should'
p33066
(F1
F0.00014334862385321102
I1
I0
I1
tp33067
sS'gram-negative,and'
p33068
(F1
F0.00014334862385321102
I0
I1
I-1
tp33069
sS'corticosteroids,a'
p33070
(F1
F0.00043004587155963305
I3
I0
I3
tp33071
sS'given,with'
p33072
(F0.33333333333333331
F0.0010034403669724771
I14
I7
I7
tp33073
sS'fluoxetine,a'
p33074
(F1
F0.00014334862385321102
I0
I1
I-1
tp33075
sS'hypokalemia,and'
p33076
(F1
F0.00014334862385321102
I0
I1
I-1
tp33077
sS'by,pretreatment'
p33078
(F1
F0.00028669724770642203
I2
I0
I2
tp33079
sS'sterol,in'
p33080
(F1
F0.00014334862385321102
I0
I1
I-1
tp33081
sS'cellular,and'
p33082
(F1
F0.00014334862385321102
I0
I1
I-1
tp33083
sS'elimination,rate'
p33084
(F1
F0.00014334862385321102
I0
I1
I-1
tp33085
sS'because,can'
p33086
(F1
F0.00014334862385321102
I1
I0
I1
tp33087
sS'as,shown'
p33088
(F1
F0.00014334862385321102
I1
I0
I1
tp33089
sS'with,human'
p33090
(F1
F0.00043004587155963305
I0
I3
I-3
tp33091
sS'only,where'
p33092
(F1
F0.00014334862385321102
I1
I0
I1
tp33093
sS'same,episode'
p33094
(F1
F0.00014334862385321102
I0
I1
I-1
tp33095
sS'day,pretreatment'
p33096
(F1
F0.00014334862385321102
I0
I1
I-1
tp33097
sS'and,concurrently'
p33098
(F1
F0.00043004587155963305
I3
I0
I3
tp33099
sS'example,inducers'
p33100
(F1
F0.00014334862385321102
I0
I1
I-1
tp33101
sS'alkaloids,and'
p33102
(F1
F0.00028669724770642203
I2
I0
I2
tp33103
sS'upon,concomitant'
p33104
(F1
F0.00014334862385321102
I1
I0
I1
tp33105
sS'in,rats'
p33106
(F0.75
F0.0008600917431192661
I7
I1
I6
tp33107
sS'tablets,not'
p33108
(F1
F0.00014334862385321102
I1
I0
I1
tp33109
sS'fe,abstract'
p33110
(F1
F0.00014334862385321102
I0
I1
I-1
tp33111
sS'epoxide,hydrolase'
p33112
(F1
F0.00028669724770642203
I0
I2
I-2
tp33113
sS'oral,combination'
p33114
(F1
F0.00014334862385321102
I1
I0
I1
tp33115
sS'the,morning'
p33116
(F1
F0.00014334862385321102
I0
I1
I-1
tp33117
sS'in,europe'
p33118
(F1
F0.00014334862385321102
I1
I0
I1
tp33119
sS'losartan,bosentan'
p33120
(F1
F0.00014334862385321102
I0
I1
I-1
tp33121
sS'we,observed'
p33122
(F1
F0.00014334862385321102
I1
I0
I1
tp33123
sS'single,study'
p33124
(F1
F0.00014334862385321102
I1
I0
I1
tp33125
sS'taking,tarceva'
p33126
(F1
F0.00014334862385321102
I1
I0
I1
tp33127
sS'adjust,the'
p33128
(F1
F0.00014334862385321102
I1
I0
I1
tp33129
sS'is,recommended'
p33130
(F0.63636363636363635
F0.0040137614678899085
I36
I8
I28
tp33131
sS'for,yeast'
p33132
(F1
F0.00014334862385321102
I0
I1
I-1
tp33133
sS'to,adjust'
p33134
(F1
F0.00014334862385321102
I1
I0
I1
tp33135
sS'with,coadministered'
p33136
(F0
F0
I1
I1
I0
tp33137
sS'do,not'
p33138
(F0.090909090909090912
F0.00014334862385321102
I5
I6
I-1
tp33139
sS'cause,elevated'
p33140
(F1
F0.00014334862385321102
I1
I0
I1
tp33141
sS'some,including'
p33142
(F1
F0.00028669724770642203
I2
I0
I2
tp33143
sS'with,hivid'
p33144
(F0
F0
I1
I1
I0
tp33145
sS'with,mixed'
p33146
(F1
F0.00014334862385321102
I1
I0
I1
tp33147
sS'antimicrobial,effect'
p33148
(F1
F0.00014334862385321102
I0
I1
I-1
tp33149
sS'therapy,for'
p33150
(F1
F0.00028669724770642203
I0
I2
I-2
tp33151
sS'normal,but'
p33152
(F1
F0.00014334862385321102
I1
I0
I1
tp33153
sS'half-life,multiple-dose'
p33154
(F1
F0.00014334862385321102
I0
I1
I-1
tp33155
sS'evaluated,and'
p33156
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33157
sS'both,control'
p33158
(F1
F0.00014334862385321102
I0
I1
I-1
tp33159
sS'possibly,concomitant'
p33160
(F1
F0.00014334862385321102
I1
I0
I1
tp33161
sS'nc,denotes'
p33162
(F1
F0.00014334862385321102
I1
I0
I1
tp33163
sS'subjective,responses'
p33164
(F1
F0.00014334862385321102
I0
I1
I-1
tp33165
sS'enzyme,may'
p33166
(F1
F0.00014334862385321102
I0
I1
I-1
tp33167
sS'welchol,with'
p33168
(F1
F0.00014334862385321102
I0
I1
I-1
tp33169
sS'cause,much'
p33170
(F1
F0.00014334862385321102
I0
I1
I-1
tp33171
sS'for,such'
p33172
(F1
F0.00014334862385321102
I0
I1
I-1
tp33173
sS'sativum,and'
p33174
(F1
F0.00014334862385321102
I1
I0
I1
tp33175
sS'of,interactions'
p33176
(F0.25
F0.00028669724770642203
I5
I3
I2
tp33177
sS'elicited,enhancement'
p33178
(F1
F0.00014334862385321102
I1
I0
I1
tp33179
sS'many,like'
p33180
(F1
F0.00014334862385321102
I0
I1
I-1
tp33181
sS'supplements,should'
p33182
(F1
F0.00014334862385321102
I0
I1
I-1
tp33183
sS'vs,end'
p33184
(F1
F0.00014334862385321102
I0
I1
I-1
tp33185
sS'oral,cordarone'
p33186
(F1
F0.00014334862385321102
I0
I1
I-1
tp33187
sS'additive,to'
p33188
(F1
F0.00014334862385321102
I1
I0
I1
tp33189
sS'products,ace'
p33190
(F1
F0.00028669724770642203
I0
I2
I-2
tp33191
sS'to,changes'
p33192
(F1
F0.00014334862385321102
I0
I1
I-1
tp33193
sS'completely,antagonized'
p33194
(F1
F0.00014334862385321102
I1
I0
I1
tp33195
sS'dpcpx,in'
p33196
(F1
F0.00014334862385321102
I0
I1
I-1
tp33197
sS'blot,analysis'
p33198
(F1
F0.00014334862385321102
I0
I1
I-1
tp33199
sS'has,additive'
p33200
(F1
F0.00028669724770642203
I2
I0
I2
tp33201
sS'from,the'
p33202
(F0
F0
I12
I12
I0
tp33203
sS'cardioplegic,solutions'
p33204
(F1
F0.00014334862385321102
I0
I1
I-1
tp33205
sS'of,prophylactic'
p33206
(F1
F0.00014334862385321102
I0
I1
I-1
tp33207
sS'd,were'
p33208
(F1
F0.00014334862385321102
I1
I0
I1
tp33209
sS'drinking,may'
p33210
(F1
F0.00014334862385321102
I1
I0
I1
tp33211
sS'triazolam,erythromycin'
p33212
(F1
F0.00014334862385321102
I1
I0
I1
tp33213
sS'hydantoin,antiepileptic'
p33214
(F1
F0.00014334862385321102
I1
I0
I1
tp33215
sS'bound,by'
p33216
(F1
F0.00014334862385321102
I1
I0
I1
tp33217
sS'days,while'
p33218
(F1
F0.00014334862385321102
I1
I0
I1
tp33219
sS'effects,concomitant'
p33220
(F1
F0.00014334862385321102
I0
I1
I-1
tp33221
sS'of,crushed'
p33222
(F1
F0.00014334862385321102
I0
I1
I-1
tp33223
sS'reductase,inhibitors'
p33224
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp33225
sS'single,weekly'
p33226
(F1
F0.00014334862385321102
I0
I1
I-1
tp33227
sS'clinical,patterns'
p33228
(F1
F0.00014334862385321102
I0
I1
I-1
tp33229
sS'antihypertensive,necessitating'
p33230
(F1
F0.00014334862385321102
I1
I0
I1
tp33231
sS'substrate,and'
p33232
(F0
F0
I3
I3
I0
tp33233
sS'renal,precipitation'
p33234
(F1
F0.00014334862385321102
I0
I1
I-1
tp33235
sS'was,maintained'
p33236
(F1
F0.00014334862385321102
I0
I1
I-1
tp33237
sS'precedex,for'
p33238
(F1
F0.00014334862385321102
I0
I1
I-1
tp33239
sS'a,disulfiram-like'
p33240
(F1
F0.00014334862385321102
I0
I1
I-1
tp33241
sS'anion-exchange,resins'
p33242
(F1
F0.00014334862385321102
I1
I0
I1
tp33243
sS'and,buspirone'
p33244
(F1
F0.00014334862385321102
I1
I0
I1
tp33245
sS'b,intravenous'
p33246
(F1
F0.00014334862385321102
I1
I0
I1
tp33247
sS'including,normal'
p33248
(F1
F0.00014334862385321102
I0
I1
I-1
tp33249
sS'most,significant'
p33250
(F1
F0.00014334862385321102
I0
I1
I-1
tp33251
sS'hydroxide,containing'
p33252
(F1
F0.00028669724770642203
I2
I0
I2
tp33253
sS'carbamazepine,population'
p33254
(F1
F0.00014334862385321102
I1
I0
I1
tp33255
sS'nutrition,herb'
p33256
(F1
F0.00014334862385321102
I1
I0
I1
tp33257
sS'loratadine,mg'
p33258
(F1
F0.00028669724770642203
I0
I2
I-2
tp33259
sS'improves,the'
p33260
(F1
F0.00014334862385321102
I0
I1
I-1
tp33261
sS'day,against'
p33262
(F1
F0.00014334862385321102
I0
I1
I-1
tp33263
sS'fold,by'
p33264
(F1
F0.00014334862385321102
I1
I0
I1
tp33265
sS'plasma,pharmacokinetics'
p33266
(F1
F0.00014334862385321102
I0
I1
I-1
tp33267
sS'orally,for'
p33268
(F1
F0.00014334862385321102
I1
I0
I1
tp33269
sS'isuprel,should'
p33270
(F1
F0.00014334862385321102
I1
I0
I1
tp33271
sS'acid,hcl'
p33272
(F1
F0.00014334862385321102
I1
I0
I1
tp33273
sS'decreases,renal'
p33274
(F1
F0.00014334862385321102
I1
I0
I1
tp33275
sS'increased,to'
p33276
(F1
F0.00014334862385321102
I1
I0
I1
tp33277
sS'plus,to'
p33278
(F1
F0.00014334862385321102
I0
I1
I-1
tp33279
sS'with,avastin'
p33280
(F1
F0.00014334862385321102
I0
I1
I-1
tp33281
sS'when,treated'
p33282
(F1
F0.00014334862385321102
I0
I1
I-1
tp33283
sS'the,magnitude'
p33284
(F0.5
F0.00028669724770642203
I3
I1
I2
tp33285
sS'that,mptp'
p33286
(F1
F0.00014334862385321102
I1
I0
I1
tp33287
sS'on,half-life'
p33288
(F1
F0.00014334862385321102
I1
I0
I1
tp33289
sS'pharmacological,therapy'
p33290
(F1
F0.00014334862385321102
I0
I1
I-1
tp33291
sS'particular,caution'
p33292
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp33293
sS'potently,inhibits'
p33294
(F1
F0.00028669724770642203
I2
I0
I2
tp33295
sS'therapy,dose'
p33296
(F1
F0.00028669724770642203
I2
I0
I2
tp33297
sS'cohort,received'
p33298
(F1
F0.00014334862385321102
I0
I1
I-1
tp33299
sS'monotherapy,for'
p33300
(F1
F0.00014334862385321102
I0
I1
I-1
tp33301
sS'hour,prior'
p33302
(F1
F0.00014334862385321102
I1
I0
I1
tp33303
sS'dosage,schedule'
p33304
(F1
F0.00014334862385321102
I1
I0
I1
tp33305
sS'absolute,but'
p33306
(F1
F0.00014334862385321102
I0
I1
I-1
tp33307
sS'the,appearance'
p33308
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33309
sS'certain,endocrine'
p33310
(F1
F0.00028669724770642203
I0
I2
I-2
tp33311
sS'when,and'
p33312
(F0.62962962962962965
F0.0024369266055045873
I22
I5
I17
tp33313
sS'tmax,at'
p33314
(F1
F0.00014334862385321102
I0
I1
I-1
tp33315
sS'qt,prolongation'
p33316
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33317
sS'lowered,blood'
p33318
(F1
F0.00014334862385321102
I1
I0
I1
tp33319
sS'of,animals'
p33320
(F1
F0.00014334862385321102
I0
I1
I-1
tp33321
sS'by,weakness'
p33322
(F1
F0.00014334862385321102
I1
I0
I1
tp33323
sS'other,taken'
p33324
(F1
F0.00014334862385321102
I1
I0
I1
tp33325
sS'in,phosphorylation'
p33326
(F1
F0.00014334862385321102
I1
I0
I1
tp33327
sS'and,death'
p33328
(F1
F0.00014334862385321102
I1
I0
I1
tp33329
sS'is,a'
p33330
(F0
F0
I21
I21
I0
tp33331
sS'system,ketoconazole'
p33332
(F1
F0.00014334862385321102
I1
I0
I1
tp33333
sS'adrenergic,stimulant'
p33334
(F1
F0.00014334862385321102
I0
I1
I-1
tp33335
sS'study,we'
p33336
(F1
F0.00014334862385321102
I0
I1
I-1
tp33337
sS'or,substrates'
p33338
(F1
F0.00014334862385321102
I1
I0
I1
tp33339
sS'to,chemically'
p33340
(F1
F0.00014334862385321102
I0
I1
I-1
tp33341
sS'substrate,response'
p33342
(F1
F0.00014334862385321102
I0
I1
I-1
tp33343
sS'therapy,includes'
p33344
(F1
F0.00014334862385321102
I0
I1
I-1
tp33345
sS'capsules,indocin'
p33346
(F1
F0.00014334862385321102
I1
I0
I1
tp33347
sS'depresses,tubular'
p33348
(F1
F0.00014334862385321102
I1
I0
I1
tp33349
sS'equivalent,to'
p33350
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33351
sS'approximately,peak'
p33352
(F1
F0.00014334862385321102
I1
I0
I1
tp33353
sS'of,hydroxylamine'
p33354
(F1
F0.00028669724770642203
I0
I2
I-2
tp33355
sS'instances,resulted'
p33356
(F1
F0.00014334862385321102
I1
I0
I1
tp33357
sS'and,central'
p33358
(F1
F0.00014334862385321102
I0
I1
I-1
tp33359
sS's,response'
p33360
(F1
F0.00014334862385321102
I1
I0
I1
tp33361
sS'is,reasonable'
p33362
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33363
sS'as,indicated'
p33364
(F0
F0
I2
I2
I0
tp33365
sS'part,of'
p33366
(F1
F0.00014334862385321102
I0
I1
I-1
tp33367
sS'angiotensins,inhibited'
p33368
(F1
F0.00014334862385321102
I0
I1
I-1
tp33369
sS'a,non-comparative'
p33370
(F1
F0.00014334862385321102
I1
I0
I1
tp33371
sS'total,clearance'
p33372
(F1
F0.00014334862385321102
I1
I0
I1
tp33373
sS'naproxen,had'
p33374
(F1
F0.00014334862385321102
I0
I1
I-1
tp33375
sS'about,two'
p33376
(F1
F0.00014334862385321102
I1
I0
I1
tp33377
sS'preparations,since'
p33378
(F1
F0.00014334862385321102
I1
I0
I1
tp33379
sS'angiotensin-,converting'
p33380
(F1
F0.00014334862385321102
I0
I1
I-1
tp33381
sS'when,vioxx'
p33382
(F0
F0
I1
I1
I0
tp33383
sS'an,additive'
p33384
(F1
F0.0022935779816513763
I16
I0
I16
tp33385
sS'not,these'
p33386
(F1
F0.00014334862385321102
I0
I1
I-1
tp33387
sS'of,c'
p33388
(F1
F0.00028669724770642203
I2
I0
I2
tp33389
sS'of,b'
p33390
(F1
F0.00043004587155963305
I0
I3
I-3
tp33391
sS'of,a'
p33392
(F0.096774193548387094
F0.0012901376146788992
I51
I42
I9
tp33393
sS'toxicity,since'
p33394
(F1
F0.00014334862385321102
I0
I1
I-1
tp33395
sS'of,g'
p33396
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp33397
sS'doses,trough'
p33398
(F1
F0.00014334862385321102
I0
I1
I-1
tp33399
sS'of,d'
p33400
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33401
sS'doses,may'
p33402
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33403
sS'of,n'
p33404
(F0
F0
I1
I1
I0
tp33405
sS'of,m'
p33406
(F0.5
F0.00028669724770642203
I3
I1
I2
tp33407
sS'of,s'
p33408
(F1
F0.00014334862385321102
I1
I0
I1
tp33409
sS'of,r'
p33410
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp33411
sS'of,p'
p33412
(F1
F0.00014334862385321102
I1
I0
I1
tp33413
sS'tmp,smx'
p33414
(F1
F0.00014334862385321102
I0
I1
I-1
tp33415
sS'of,v'
p33416
(F1
F0.00014334862385321102
I1
I0
I1
tp33417
sS'of,u'
p33418
(F1
F0.00014334862385321102
I0
I1
I-1
tp33419
sS'of,t'
p33420
(F1
F0.00014334862385321102
I1
I0
I1
tp33421
sS'of,x'
p33422
(F1
F0.00014334862385321102
I1
I0
I1
tp33423
sS'may,vary'
p33424
(F1
F0.00071674311926605509
I0
I5
I-5
tp33425
sS'reduced,plasma'
p33426
(F0.5
F0.00028669724770642203
I3
I1
I2
tp33427
sS'which,promote'
p33428
(F1
F0.00043004587155963305
I3
I0
I3
tp33429
sS'days,followed'
p33430
(F1
F0.00028669724770642203
I0
I2
I-2
tp33431
sS'requires,more'
p33432
(F1
F0.00014334862385321102
I0
I1
I-1
tp33433
sS'inhibitors,nalidixic'
p33434
(F1
F0.00014334862385321102
I1
I0
I1
tp33435
sS'equivocally,higher'
p33436
(F1
F0.00014334862385321102
I1
I0
I1
tp33437
sS'anabolic,particularly'
p33438
(F1
F0.00014334862385321102
I0
I1
I-1
tp33439
sS'gastrointestinal,tract'
p33440
(F1
F0.00028669724770642203
I2
I0
I2
tp33441
sS'multivitamins,or'
p33442
(F1
F0.00014334862385321102
I1
I0
I1
tp33443
sS'angina,pectoris'
p33444
(F1
F0.00014334862385321102
I1
I0
I1
tp33445
sS'slight,but'
p33446
(F1
F0.00014334862385321102
I1
I0
I1
tp33447
sS'with,major'
p33448
(F1
F0.00014334862385321102
I1
I0
I1
tp33449
sS'possible,with'
p33450
(F1
F0.00014334862385321102
I0
I1
I-1
tp33451
sS'very,closely'
p33452
(F1
F0.00014334862385321102
I1
I0
I1
tp33453
sS'is,less'
p33454
(F1
F0.00014334862385321102
I1
I0
I1
tp33455
sS'oral,certain'
p33456
(F1
F0.00014334862385321102
I1
I0
I1
tp33457
sS'approximately,twice'
p33458
(F1
F0.00014334862385321102
I1
I0
I1
tp33459
sS'sites,or'
p33460
(F1
F0.00014334862385321102
I1
I0
I1
tp33461
sS'iodinated,cholestographic'
p33462
(F1
F0.00014334862385321102
I0
I1
I-1
tp33463
sS'inhibitors,concomitant'
p33464
(F1
F0.00014334862385321102
I0
I1
I-1
tp33465
sS'and,model'
p33466
(F1
F0.00014334862385321102
I0
I1
I-1
tp33467
sS'opioid-dependent,patients'
p33468
(F1
F0.00014334862385321102
I0
I1
I-1
tp33469
sS'gonadotropin,levels'
p33470
(F1
F0.00014334862385321102
I0
I1
I-1
tp33471
sS'coagulation,times'
p33472
(F1
F0.00014334862385321102
I0
I1
I-1
tp33473
sS'seen,on'
p33474
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33475
sS'juice,should'
p33476
(F1
F0.00014334862385321102
I1
I0
I1
tp33477
sS'on,certain'
p33478
(F1
F0.00014334862385321102
I1
I0
I1
tp33479
sS'on,investigation'
p33480
(F1
F0.00014334862385321102
I0
I1
I-1
tp33481
sS'excretion,glucuronidation'
p33482
(F1
F0.00014334862385321102
I0
I1
I-1
tp33483
sS'episodes,of'
p33484
(F1
F0.00014334862385321102
I0
I1
I-1
tp33485
sS'doses,mg'
p33486
(F1
F0.00028669724770642203
I2
I0
I2
tp33487
sS'cyp3a4,inhibitors'
p33488
(F0.375
F0.0008600917431192661
I11
I5
I6
tp33489
sS'on,adult'
p33490
(F1
F0.00014334862385321102
I1
I0
I1
tp33491
sS'intubating,dose'
p33492
(F1
F0.00014334862385321102
I1
I0
I1
tp33493
sS'of,elemental'
p33494
(F1
F0.00014334862385321102
I1
I0
I1
tp33495
sS'available,data'
p33496
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33497
sS'hypothesis,there'
p33498
(F1
F0.00014334862385321102
I0
I1
I-1
tp33499
sS'cause,direct'
p33500
(F1
F0.00014334862385321102
I0
I1
I-1
tp33501
sS'is,accelerated'
p33502
(F1
F0.00014334862385321102
I1
I0
I1
tp33503
sS'release,but'
p33504
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33505
sS'diminished,prothrombin'
p33506
(F1
F0.00014334862385321102
I1
I0
I1
tp33507
sS'cytochalasin,d'
p33508
(F1
F0.00028669724770642203
I2
I0
I2
tp33509
sS'tinnitus,and'
p33510
(F1
F0.00014334862385321102
I1
I0
I1
tp33511
sS'heart,block'
p33512
(F0
F0
I1
I1
I0
tp33513
sS'one,possible'
p33514
(F1
F0.00014334862385321102
I0
I1
I-1
tp33515
sS'used,combined'
p33516
(F1
F0.00014334862385321102
I0
I1
I-1
tp33517
sS'a,subsequent'
p33518
(F1
F0.00014334862385321102
I1
I0
I1
tp33519
sS'idv,does'
p33520
(F1
F0.00014334862385321102
I0
I1
I-1
tp33521
sS'diagnosis,of'
p33522
(F1
F0.00014334862385321102
I0
I1
I-1
tp33523
sS'stereoisomers,of'
p33524
(F1
F0.00014334862385321102
I0
I1
I-1
tp33525
sS'studied,of'
p33526
(F1
F0.00014334862385321102
I0
I1
I-1
tp33527
sS'protein,in'
p33528
(F1
F0.00014334862385321102
I1
I0
I1
tp33529
sS'monthly,was'
p33530
(F1
F0.00014334862385321102
I0
I1
I-1
tp33531
sS'protein,is'
p33532
(F1
F0.00014334862385321102
I0
I1
I-1
tp33533
sS'relationship,has'
p33534
(F1
F0.00014334862385321102
I1
I0
I1
tp33535
sS'the,mean'
p33536
(F0.18181818181818182
F0.00057339449541284407
I13
I9
I4
tp33537
sS'titration,of'
p33538
(F1
F0.00014334862385321102
I1
I0
I1
tp33539
sS'to,either'
p33540
(F0
F0
I1
I1
I0
tp33541
sS'vitamin,e'
p33542
(F1
F0.00014334862385321102
I1
I0
I1
tp33543
sS'platelia,aspergillus'
p33544
(F1
F0.00014334862385321102
I0
I1
I-1
tp33545
sS'vitamin,c'
p33546
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33547
sS'vitamin,a'
p33548
(F1
F0.00028669724770642203
I2
I0
I2
tp33549
sS'have,higher'
p33550
(F1
F0.00071674311926605509
I0
I5
I-5
tp33551
sS'without,other'
p33552
(F1
F0.00043004587155963305
I3
I0
I3
tp33553
sS'acetaminophen,oral'
p33554
(F1
F0.00014334862385321102
I1
I0
I1
tp33555
sS'hours,was'
p33556
(F1
F0.00014334862385321102
I1
I0
I1
tp33557
sS'the,prolongation'
p33558
(F1
F0.00028669724770642203
I2
I0
I2
tp33559
sS'kg,subcutaneous'
p33560
(F1
F0.00014334862385321102
I0
I1
I-1
tp33561
sS'rats,whereas'
p33562
(F1
F0.00014334862385321102
I0
I1
I-1
tp33563
sS'agents,leading'
p33564
(F1
F0.00043004587155963305
I3
I0
I3
tp33565
sS'dl,triglycerides'
p33566
(F1
F0.00014334862385321102
I0
I1
I-1
tp33567
sS'therefore,necessary'
p33568
(F1
F0.00014334862385321102
I0
I1
I-1
tp33569
sS'about,one-third'
p33570
(F1
F0.00014334862385321102
I1
I0
I1
tp33571
sS'are,referred'
p33572
(F1
F0.00028669724770642203
I0
I2
I-2
tp33573
sS'potentiating,cns'
p33574
(F1
F0.00014334862385321102
I1
I0
I1
tp33575
sS'deterioration,in'
p33576
(F1
F0.00014334862385321102
I0
I1
I-1
tp33577
sS'and,lower'
p33578
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33579
sS'sodation,of'
p33580
(F1
F0.00014334862385321102
I1
I0
I1
tp33581
sS'not,co-administered'
p33582
(F1
F0.00014334862385321102
I0
I1
I-1
tp33583
sS'and,hc1'
p33584
(F1
F0.00014334862385321102
I1
I0
I1
tp33585
sS'morphine-induced,locomotion'
p33586
(F1
F0.00014334862385321102
I0
I1
I-1
tp33587
sS'the,frontal'
p33588
(F1
F0.00014334862385321102
I0
I1
I-1
tp33589
sS'lower,relative'
p33590
(F1
F0.00014334862385321102
I0
I1
I-1
tp33591
sS'an,a2-selective'
p33592
(F1
F0.00014334862385321102
I1
I0
I1
tp33593
sS'is,indicated'
p33594
(F1
F0.00071674311926605509
I5
I0
I5
tp33595
sS'severe,persistent'
p33596
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33597
sS'hepatic,injury'
p33598
(F1
F0.00014334862385321102
I0
I1
I-1
tp33599
sS'inotropic,and'
p33600
(F1
F0.00014334862385321102
I0
I1
I-1
tp33601
sS'with,these'
p33602
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp33603
sS'dopamine,d2'
p33604
(F1
F0.00014334862385321102
I1
I0
I1
tp33605
sS'any,evidence'
p33606
(F1
F0.00043004587155963305
I0
I3
I-3
tp33607
sS'assessment,of'
p33608
(F1
F0.00014334862385321102
I0
I1
I-1
tp33609
sS'physostigmine,pretreatment'
p33610
(F1
F0.00014334862385321102
I1
I0
I1
tp33611
sS'a,during'
p33612
(F1
F0.00014334862385321102
I0
I1
I-1
tp33613
sS'with,local'
p33614
(F1
F0.00014334862385321102
I0
I1
I-1
tp33615
sS'attenuating,s'
p33616
(F1
F0.00014334862385321102
I1
I0
I1
tp33617
sS'may,therefore'
p33618
(F1
F0.00014334862385321102
I1
I0
I1
tp33619
sS'cimetidine,and'
p33620
(F0
F0
I1
I1
I0
tp33621
sS'with,hydroxide'
p33622
(F1
F0.00014334862385321102
I1
I0
I1
tp33623
sS'totally,known'
p33624
(F1
F0.00014334862385321102
I1
I0
I1
tp33625
sS'receiving,ace'
p33626
(F1
F0.00043004587155963305
I3
I0
I3
tp33627
sS'pharmacological,pharmacodynamic'
p33628
(F1
F0.00014334862385321102
I1
I0
I1
tp33629
sS'theophylline-related,side'
p33630
(F1
F0.00028669724770642203
I2
I0
I2
tp33631
sS'gris-peg,nizoral'
p33632
(F1
F0.00014334862385321102
I1
I0
I1
tp33633
sS'to,toxoids'
p33634
(F1
F0.00014334862385321102
I1
I0
I1
tp33635
sS'to,onset'
p33636
(F1
F0.00014334862385321102
I1
I0
I1
tp33637
sS'of,hydrobromide'
p33638
(F1
F0.00014334862385321102
I1
I0
I1
tp33639
sS'under,steady-state'
p33640
(F1
F0.00028669724770642203
I0
I2
I-2
tp33641
sS'blocker,should'
p33642
(F1
F0.00014334862385321102
I1
I0
I1
tp33643
sS'and,rises'
p33644
(F1
F0.00014334862385321102
I1
I0
I1
tp33645
sS'serum,time'
p33646
(F1
F0.00014334862385321102
I0
I1
I-1
tp33647
sS'hypotension,related'
p33648
(F0
F0
I1
I1
I0
tp33649
sS'contraindicated,since'
p33650
(F1
F0.00014334862385321102
I0
I1
I-1
tp33651
sS'these,aeds'
p33652
(F1
F0.00028669724770642203
I0
I2
I-2
tp33653
sS'phenobarbital,decreases'
p33654
(F1
F0.00014334862385321102
I1
I0
I1
tp33655
sS'commentaries,and'
p33656
(F1
F0.00014334862385321102
I0
I1
I-1
tp33657
sS'reported,l-histidine'
p33658
(F1
F0.00014334862385321102
I1
I0
I1
tp33659
sS'renin,release'
p33660
(F1
F0.00028669724770642203
I2
I0
I2
tp33661
sS'by,prothrombin'
p33662
(F1
F0.00014334862385321102
I0
I1
I-1
tp33663
sS'actinic,keratoses'
p33664
(F1
F0.00014334862385321102
I1
I0
I1
tp33665
sS'ventricular,tachycardia'
p33666
(F0.5
F0.00028669724770642203
I3
I1
I2
tp33667
sS'prolonged,recovery'
p33668
(F1
F0.00014334862385321102
I1
I0
I1
tp33669
sS'antihypertensive,medications'
p33670
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33671
sS'response,rates'
p33672
(F1
F0.00014334862385321102
I0
I1
I-1
tp33673
sS'anticoagulants,caution'
p33674
(F1
F0.00014334862385321102
I1
I0
I1
tp33675
sS'prolonged,gastrointestinal'
p33676
(F1
F0.00014334862385321102
I1
I0
I1
tp33677
sS'volunteers,toradoloral'
p33678
(F1
F0.00014334862385321102
I0
I1
I-1
tp33679
sS'disorders,treated'
p33680
(F1
F0.00014334862385321102
I1
I0
I1
tp33681
sS'times,after'
p33682
(F1
F0.00014334862385321102
I0
I1
I-1
tp33683
sS'and,therefore'
p33684
(F0
F0
I4
I4
I0
tp33685
sS'not,totally'
p33686
(F1
F0.00014334862385321102
I1
I0
I1
tp33687
sS'in,addition'
p33688
(F0
F0
I15
I15
I0
tp33689
sS'the,skeletal'
p33690
(F1
F0.00014334862385321102
I1
I0
I1
tp33691
sS'the,concentrations'
p33692
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33693
sS'the,intestinal'
p33694
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp33695
sS'local,solutions'
p33696
(F1
F0.00043004587155963305
I3
I0
I3
tp33697
sS'decreased,plasma'
p33698
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp33699
sS'dissolution,of'
p33700
(F1
F0.00028669724770642203
I0
I2
I-2
tp33701
sS'gabitril,on'
p33702
(F1
F0.00014334862385321102
I0
I1
I-1
tp33703
sS'between,and'
p33704
(F0.15789473684210525
F0.0008600917431192661
I16
I22
I-6
tp33705
sS'pegasys,once'
p33706
(F1
F0.00014334862385321102
I1
I0
I1
tp33707
sS'further,alterations'
p33708
(F1
F0.00014334862385321102
I1
I0
I1
tp33709
sS'naproxen,the'
p33710
(F1
F0.00014334862385321102
I1
I0
I1
tp33711
sS'agonists,dcg-iv'
p33712
(F1
F0.00014334862385321102
I0
I1
I-1
tp33713
sS'or,estrogen-containing'
p33714
(F1
F0.00014334862385321102
I1
I0
I1
tp33715
sS'auc,a'
p33716
(F1
F0.00028669724770642203
I2
I0
I2
tp33717
sS'auc,c'
p33718
(F1
F0.00028669724770642203
I0
I2
I-2
tp33719
sS'studies,involving'
p33720
(F1
F0.00043004587155963305
I3
I0
I3
tp33721
sS'p450,inducers'
p33722
(F1
F0.00014334862385321102
I1
I0
I1
tp33723
sS'pegasys,and'
p33724
(F1
F0.00028669724770642203
I0
I2
I-2
tp33725
sS'ml,the'
p33726
(F1
F0.00014334862385321102
I1
I0
I1
tp33727
sS'of,contraception'
p33728
(F0.5
F0.00028669724770642203
I3
I1
I2
tp33729
sS'is,about'
p33730
(F0
F0
I1
I1
I0
tp33731
sS'plendil,the'
p33732
(F1
F0.00014334862385321102
I0
I1
I-1
tp33733
sS'macrolide,class'
p33734
(F1
F0.00014334862385321102
I1
I0
I1
tp33735
sS'by,containing'
p33736
(F1
F0.00014334862385321102
I1
I0
I1
tp33737
sS'misonidazole,has'
p33738
(F1
F0.00014334862385321102
I1
I0
I1
tp33739
sS'develop,physiological'
p33740
(F1
F0.00014334862385321102
I0
I1
I-1
tp33741
sS'additional,research'
p33742
(F1
F0.00014334862385321102
I0
I1
I-1
tp33743
sS'of,mineral'
p33744
(F1
F0.00014334862385321102
I1
I0
I1
tp33745
sS'mice,from'
p33746
(F1
F0.00014334862385321102
I0
I1
I-1
tp33747
sS'the,contraceptive'
p33748
(F1
F0.00014334862385321102
I1
I0
I1
tp33749
sS'a,risk'
p33750
(F0.5
F0.00028669724770642203
I3
I1
I2
tp33751
sS'cyclosporine,doses'
p33752
(F1
F0.00014334862385321102
I0
I1
I-1
tp33753
sS'used,as'
p33754
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33755
sS'used,at'
p33756
(F1
F0.00028669724770642203
I2
I0
I2
tp33757
sS'a,rise'
p33758
(F1
F0.00014334862385321102
I1
I0
I1
tp33759
sS'cyp3a4,to'
p33760
(F1
F0.00014334862385321102
I0
I1
I-1
tp33761
sS'are,found'
p33762
(F1
F0.00014334862385321102
I1
I0
I1
tp33763
sS'containing,trisilicate'
p33764
(F1
F0.00014334862385321102
I1
I0
I1
tp33765
sS'following,observations'
p33766
(F1
F0.00014334862385321102
I0
I1
I-1
tp33767
sS'therefore,there'
p33768
(F1
F0.00014334862385321102
I0
I1
I-1
tp33769
sS'some,has'
p33770
(F1
F0.00014334862385321102
I1
I0
I1
tp33771
sS'possible,increase'
p33772
(F1
F0.00014334862385321102
I1
I0
I1
tp33773
sS'patterns,during'
p33774
(F1
F0.00014334862385321102
I0
I1
I-1
tp33775
sS'persons,taking'
p33776
(F1
F0.00014334862385321102
I0
I1
I-1
tp33777
sS'man,include'
p33778
(F0
F0
I1
I1
I0
tp33779
sS'oral,potently'
p33780
(F1
F0.00028669724770642203
I2
I0
I2
tp33781
sS'b-lactam,inhibits'
p33782
(F1
F0.00014334862385321102
I1
I0
I1
tp33783
sS'their,metabolism'
p33784
(F1
F0.00014334862385321102
I1
I0
I1
tp33785
sS'increase,by'
p33786
(F1
F0.00014334862385321102
I1
I0
I1
tp33787
sS'arrhythmias,in'
p33788
(F1
F0.00014334862385321102
I0
I1
I-1
tp33789
sS'mc,probably'
p33790
(F1
F0.00014334862385321102
I0
I1
I-1
tp33791
sS'a,well-controlled'
p33792
(F1
F0.00028669724770642203
I0
I2
I-2
tp33793
sS'and,anaerobic'
p33794
(F1
F0.00014334862385321102
I0
I1
I-1
tp33795
sS'concurrently,resulting'
p33796
(F1
F0.00014334862385321102
I1
I0
I1
tp33797
sS'receiving,the'
p33798
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp33799
sS'inhibitor,should'
p33800
(F1
F0.00014334862385321102
I1
I0
I1
tp33801
sS'a,regular'
p33802
(F1
F0.00014334862385321102
I0
I1
I-1
tp33803
sS'vitro,experiments'
p33804
(F1
F0.00014334862385321102
I0
I1
I-1
tp33805
sS'lanoxicaps,that'
p33806
(F1
F0.00014334862385321102
I1
I0
I1
tp33807
sS'or,monoamine'
p33808
(F1
F0.00014334862385321102
I1
I0
I1
tp33809
sS'the,ibandronate'
p33810
(F1
F0.00014334862385321102
I0
I1
I-1
tp33811
sS'gi,ulceration'
p33812
(F1
F0.00043004587155963305
I3
I0
I3
tp33813
sS'approximately,one-third'
p33814
(F1
F0.00014334862385321102
I1
I0
I1
tp33815
sS'may,produce'
p33816
(F0.8571428571428571
F0.0017201834862385322
I13
I1
I12
tp33817
sS'mean,increase'
p33818
(F1
F0.00028669724770642203
I2
I0
I2
tp33819
sS'cold,preparations'
p33820
(F0
F0
I1
I1
I0
tp33821
sS'c9,by'
p33822
(F1
F0.00014334862385321102
I1
I0
I1
tp33823
sS'agents,no'
p33824
(F1
F0.00028669724770642203
I0
I2
I-2
tp33825
sS'which,increase'
p33826
(F1
F0.00014334862385321102
I1
I0
I1
tp33827
sS'rate,at'
p33828
(F1
F0.00014334862385321102
I0
I1
I-1
tp33829
sS'with,occasional'
p33830
(F1
F0.00014334862385321102
I0
I1
I-1
tp33831
sS'nevirapinemay,lower'
p33832
(F1
F0.00014334862385321102
I1
I0
I1
tp33833
sS'are,summarized'
p33834
(F1
F0.00014334862385321102
I0
I1
I-1
tp33835
sS'for,adult-onset'
p33836
(F1
F0.00014334862385321102
I1
I0
I1
tp33837
sS'first,post-transplant'
p33838
(F1
F0.00014334862385321102
I0
I1
I-1
tp33839
sS'with,arimidex'
p33840
(F1
F0.00014334862385321102
I1
I0
I1
tp33841
sS'the,prior'
p33842
(F1
F0.00014334862385321102
I1
I0
I1
tp33843
sS'than,usual'
p33844
(F1
F0.00014334862385321102
I1
I0
I1
tp33845
sS'concomitantly,the'
p33846
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp33847
sS'on,gm'
p33848
(F1
F0.00014334862385321102
I1
I0
I1
tp33849
sS'charcoal,administration'
p33850
(F1
F0.00014334862385321102
I1
I0
I1
tp33851
sS'on,gi'
p33852
(F1
F0.00028669724770642203
I2
I0
I2
tp33853
sS'sensitize,resistant'
p33854
(F1
F0.00014334862385321102
I0
I1
I-1
tp33855
sS'addition,alone'
p33856
(F1
F0.00014334862385321102
I1
I0
I1
tp33857
sS'cyp2d6,increased'
p33858
(F1
F0.00014334862385321102
I1
I0
I1
tp33859
sS'co-administered,to'
p33860
(F1
F0.00014334862385321102
I1
I0
I1
tp33861
sS'n,combination'
p33862
(F1
F0.00014334862385321102
I1
I0
I1
tp33863
sS'and,containing'
p33864
(F1
F0.00028669724770642203
I2
I0
I2
tp33865
sS'in,cerebral'
p33866
(F1
F0.00014334862385321102
I1
I0
I1
tp33867
sS'inhibitors,are'
p33868
(F1
F0.00028669724770642203
I0
I2
I-2
tp33869
sS'administration,with'
p33870
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp33871
sS'oral,regularly'
p33872
(F1
F0.00014334862385321102
I0
I1
I-1
tp33873
sS'interaction,when'
p33874
(F1
F0.00057339449541284407
I0
I4
I-4
tp33875
sS'medications,are'
p33876
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp33877
sS'enhanced,tendency'
p33878
(F1
F0.00014334862385321102
I0
I1
I-1
tp33879
sS'interactions,resulting'
p33880
(F1
F0.00014334862385321102
I0
I1
I-1
tp33881
sS'or,halogenated'
p33882
(F1
F0.00028669724770642203
I2
I0
I2
tp33883
sS'in,in'
p33884
(F1
F0.00043004587155963305
I0
I3
I-3
tp33885
sS'transdermal,system'
p33886
(F1
F0.00014334862385321102
I1
I0
I1
tp33887
sS'eg,have'
p33888
(F1
F0.00014334862385321102
I0
I1
I-1
tp33889
sS'disintegrin,and'
p33890
(F1
F0.00014334862385321102
I0
I1
I-1
tp33891
sS'acitretin,interferes'
p33892
(F1
F0.00014334862385321102
I1
I0
I1
tp33893
sS'recurred,when'
p33894
(F1
F0.00014334862385321102
I0
I1
I-1
tp33895
sS'cyclosporine,digoxin'
p33896
(F1
F0.00014334862385321102
I1
I0
I1
tp33897
sS'and,plasma'
p33898
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp33899
sS'amitriptyline,in'
p33900
(F1
F0.00014334862385321102
I1
I0
I1
tp33901
sS'any,additional'
p33902
(F1
F0.00028669724770642203
I2
I0
I2
tp33903
sS'altered,in'
p33904
(F1
F0.00014334862385321102
I0
I1
I-1
tp33905
sS'be,negatively'
p33906
(F1
F0.00014334862385321102
I0
I1
I-1
tp33907
sS'likely,and'
p33908
(F1
F0.00014334862385321102
I0
I1
I-1
tp33909
sS'iv,ace'
p33910
(F1
F0.00014334862385321102
I0
I1
I-1
tp33911
sS'atromid-s,is'
p33912
(F1
F0.00014334862385321102
I1
I0
I1
tp33913
sS'symptomatology,due'
p33914
(F1
F0.00014334862385321102
I1
I0
I1
tp33915
sS'been,systematically'
p33916
(F1
F0.00014334862385321102
I1
I0
I1
tp33917
sS'as,may'
p33918
(F1
F0.00028669724770642203
I2
I0
I2
tp33919
sS'with,camp'
p33920
(F1
F0.00014334862385321102
I1
I0
I1
tp33921
sS'to,agents'
p33922
(F1
F0.00014334862385321102
I1
I0
I1
tp33923
sS'in,prolonging'
p33924
(F1
F0.00014334862385321102
I1
I0
I1
tp33925
sS'regimens,containing'
p33926
(F1
F0.00014334862385321102
I1
I0
I1
tp33927
sS'kidney,and'
p33928
(F1
F0.00014334862385321102
I0
I1
I-1
tp33929
sS'pesticide,the'
p33930
(F1
F0.00014334862385321102
I0
I1
I-1
tp33931
sS'performance,was'
p33932
(F1
F0.00014334862385321102
I1
I0
I1
tp33933
sS'corticosteroid,binding'
p33934
(F1
F0.00014334862385321102
I0
I1
I-1
tp33935
sS'to,induction'
p33936
(F0
F0
I1
I1
I0
tp33937
sS'injection,in'
p33938
(F1
F0.00014334862385321102
I1
I0
I1
tp33939
sS'the,myasthenic'
p33940
(F1
F0.00014334862385321102
I1
I0
I1
tp33941
sS'systemic,etc'
p33942
(F1
F0.00014334862385321102
I1
I0
I1
tp33943
sS'sympathomimetic,amines'
p33944
(F1
F0.00014334862385321102
I1
I0
I1
tp33945
sS'closely,if'
p33946
(F1
F0.00014334862385321102
I1
I0
I1
tp33947
sS'tambocor,are'
p33948
(F1
F0.00014334862385321102
I1
I0
I1
tp33949
sS'closely,in'
p33950
(F1
F0.00028669724770642203
I2
I0
I2
tp33951
sS'treatment,with'
p33952
(F0.375
F0.0025802752293577983
I33
I15
I18
tp33953
sS'duragesic,is'
p33954
(F0
F0
I1
I1
I0
tp33955
sS'hcl,may'
p33956
(F1
F0.00014334862385321102
I1
I0
I1
tp33957
sS'substantial,inactivation'
p33958
(F1
F0.00014334862385321102
I1
I0
I1
tp33959
sS'desyrel,and'
p33960
(F1
F0.00014334862385321102
I1
I0
I1
tp33961
sS'blocks,the'
p33962
(F1
F0.00028669724770642203
I2
I0
I2
tp33963
sS'tested,in'
p33964
(F1
F0.00043004587155963305
I0
I3
I-3
tp33965
sS'when,selecting'
p33966
(F1
F0.00028669724770642203
I2
I0
I2
tp33967
sS'aluminum-containing,had'
p33968
(F1
F0.00014334862385321102
I0
I1
I-1
tp33969
sS'hormone,or'
p33970
(F1
F0.00014334862385321102
I0
I1
I-1
tp33971
sS'concentrations,caution'
p33972
(F1
F0.00014334862385321102
I1
I0
I1
tp33973
sS'oral,suspension'
p33974
(F1
F0.00014334862385321102
I0
I1
I-1
tp33975
sS'substances,grapefruit'
p33976
(F1
F0.00014334862385321102
I0
I1
I-1
tp33977
sS'using,immunoanalytical'
p33978
(F1
F0.00014334862385321102
I0
I1
I-1
tp33979
sS'both,groups'
p33980
(F1
F0.00014334862385321102
I0
I1
I-1
tp33981
sS'to,further'
p33982
(F1
F0.00014334862385321102
I1
I0
I1
tp33983
sS'shown,not'
p33984
(F1
F0.00014334862385321102
I0
I1
I-1
tp33985
sS'although,other'
p33986
(F1
F0.00014334862385321102
I0
I1
I-1
tp33987
sS'containing,and'
p33988
(F1
F0.00028669724770642203
I2
I0
I2
tp33989
sS'flucoxacillin,and'
p33990
(F1
F0.00014334862385321102
I0
I1
I-1
tp33991
sS'r-warfarin,the'
p33992
(F1
F0.00014334862385321102
I1
I0
I1
tp33993
sS'that,ecg'
p33994
(F1
F0.00014334862385321102
I1
I0
I1
tp33995
sS'determine,whether'
p33996
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp33997
sS'determined,after'
p33998
(F1
F0.00028669724770642203
I0
I2
I-2
tp33999
sS'is,impaired'
p34000
(F1
F0.00057339449541284407
I4
I0
I4
tp34001
sS'oral,resulting'
p34002
(F1
F0.00014334862385321102
I0
I1
I-1
tp34003
sS'stimulation,by'
p34004
(F1
F0.00014334862385321102
I0
I1
I-1
tp34005
sS'iv,have'
p34006
(F1
F0.00014334862385321102
I0
I1
I-1
tp34007
sS'exerts,a'
p34008
(F1
F0.00014334862385321102
I1
I0
I1
tp34009
sS'the,and'
p34010
(F0.047619047619047616
F0.00014334862385321102
I11
I10
I1
tp34011
sS'a,new'
p34012
(F1
F0.00014334862385321102
I0
I1
I-1
tp34013
sS'rises,in'
p34014
(F1
F0.00014334862385321102
I1
I0
I1
tp34015
sS'motility,may'
p34016
(F1
F0.00014334862385321102
I1
I0
I1
tp34017
sS'gastrointestinal,bleeding'
p34018
(F1
F0.00014334862385321102
I1
I0
I1
tp34019
sS'ergotamine-containing,or'
p34020
(F1
F0.00043004587155963305
I3
I0
I3
tp34021
sS'reduce,intestinal'
p34022
(F1
F0.00043004587155963305
I3
I0
I3
tp34023
sS'when,indocin'
p34024
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp34025
sS'lithium,lithium'
p34026
(F1
F0.00043004587155963305
I3
I0
I3
tp34027
sS'are,taking'
p34028
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp34029
sS'concentration,as'
p34030
(F1
F0.00014334862385321102
I0
I1
I-1
tp34031
sS'erythrocyte,acetylcholinesterase'
p34032
(F1
F0.00014334862385321102
I1
I0
I1
tp34033
sS'sulfa,medicines'
p34034
(F1
F0.00014334862385321102
I1
I0
I1
tp34035
sS'of,doubled'
p34036
(F1
F0.00014334862385321102
I1
I0
I1
tp34037
sS'and,twice-a'
p34038
(F1
F0.00014334862385321102
I0
I1
I-1
tp34039
sS'this,medicine'
p34040
(F1
F0.00014334862385321102
I0
I1
I-1
tp34041
sS'from,concomitant'
p34042
(F0
F0
I1
I1
I0
tp34043
sS'of,about'
p34044
(F1
F0.00028669724770642203
I2
I0
I2
tp34045
sS'binding,may'
p34046
(F1
F0.00014334862385321102
I1
I0
I1
tp34047
sS'the,behavioral'
p34048
(F1
F0.00043004587155963305
I0
I3
I-3
tp34049
sS'deaths,reveal'
p34050
(F1
F0.00014334862385321102
I1
I0
I1
tp34051
sS'as,seen'
p34052
(F1
F0.00014334862385321102
I0
I1
I-1
tp34053
sS'with,antifungal'
p34054
(F1
F0.00014334862385321102
I0
I1
I-1
tp34055
sS'the,heart'
p34056
(F1
F0.00014334862385321102
I1
I0
I1
tp34057
sS'fold,respectively'
p34058
(F1
F0.00014334862385321102
I1
I0
I1
tp34059
sS'drugs,and'
p34060
(F1
F0.00014334862385321102
I1
I0
I1
tp34061
sS'extensive,metabolism'
p34062
(F1
F0.00014334862385321102
I0
I1
I-1
tp34063
sS'recovery,in'
p34064
(F1
F0.00014334862385321102
I0
I1
I-1
tp34065
sS'compounds,are'
p34066
(F1
F0.00014334862385321102
I1
I0
I1
tp34067
sS'the,beneficial'
p34068
(F1
F0.00043004587155963305
I3
I0
I3
tp34069
sS'contraceptives,including'
p34070
(F1
F0.00014334862385321102
I1
I0
I1
tp34071
sS'consequence,when'
p34072
(F1
F0.00014334862385321102
I1
I0
I1
tp34073
sS'time,determinations'
p34074
(F1
F0.00028669724770642203
I2
I0
I2
tp34075
sS'to,pressor'
p34076
(F1
F0.00014334862385321102
I1
I0
I1
tp34077
sS'enhancing,absorption'
p34078
(F1
F0.00014334862385321102
I1
I0
I1
tp34079
sS'simultaneously,because'
p34080
(F1
F0.00014334862385321102
I1
I0
I1
tp34081
sS'together,the'
p34082
(F1
F0.00014334862385321102
I1
I0
I1
tp34083
sS'binding,with'
p34084
(F1
F0.00014334862385321102
I0
I1
I-1
tp34085
sS'must,be'
p34086
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp34087
sS'are,synergistic'
p34088
(F1
F0.00028669724770642203
I2
I0
I2
tp34089
sS'cyp3a4,in'
p34090
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34091
sS'pathway,in'
p34092
(F1
F0.00014334862385321102
I0
I1
I-1
tp34093
sS'increase,its'
p34094
(F1
F0.00014334862385321102
I1
I0
I1
tp34095
sS'novel,purification'
p34096
(F1
F0.00014334862385321102
I0
I1
I-1
tp34097
sS'capsules,every'
p34098
(F1
F0.00014334862385321102
I1
I0
I1
tp34099
sS'with,agonists'
p34100
(F1
F0.00014334862385321102
I1
I0
I1
tp34101
sS'is,prescribed'
p34102
(F1
F0.00014334862385321102
I0
I1
I-1
tp34103
sS'heart,failure'
p34104
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp34105
sS'have,benign'
p34106
(F1
F0.00014334862385321102
I0
I1
I-1
tp34107
sS'received,the'
p34108
(F1
F0.00014334862385321102
I1
I0
I1
tp34109
sS'inhibiting,their'
p34110
(F1
F0.00014334862385321102
I1
I0
I1
tp34111
sS'sometimes,prescribed'
p34112
(F1
F0.00014334862385321102
I1
I0
I1
tp34113
sS'diminished,renal'
p34114
(F1
F0.00014334862385321102
I1
I0
I1
tp34115
sS'ironically,are'
p34116
(F1
F0.00014334862385321102
I0
I1
I-1
tp34117
sS'may,precipitate'
p34118
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp34119
sS'breakthrough,bleeding'
p34120
(F1
F0.00014334862385321102
I0
I1
I-1
tp34121
sS'pyrocarbonate,at'
p34122
(F1
F0.00014334862385321102
I0
I1
I-1
tp34123
sS'of,life'
p34124
(F1
F0.00014334862385321102
I0
I1
I-1
tp34125
sS'or,careful'
p34126
(F1
F0.00014334862385321102
I1
I0
I1
tp34127
sS'no,relevant'
p34128
(F1
F0.00014334862385321102
I0
I1
I-1
tp34129
sS'secondary,enzymes'
p34130
(F1
F0.00014334862385321102
I1
I0
I1
tp34131
sS'or,bleeding'
p34132
(F1
F0.00028669724770642203
I2
I0
I2
tp34133
sS'anticholinergic,may'
p34134
(F1
F0.00014334862385321102
I1
I0
I1
tp34135
sS'concomitant,intravenous'
p34136
(F1
F0.00014334862385321102
I1
I0
I1
tp34137
sS'adverse,reactions'
p34138
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp34139
sS'taking,chronically'
p34140
(F0
F0
I1
I1
I0
tp34141
sS'during,days'
p34142
(F1
F0.00014334862385321102
I0
I1
I-1
tp34143
sS'data,do'
p34144
(F1
F0.00014334862385321102
I0
I1
I-1
tp34145
sS'inhibit,cyp450s'
p34146
(F1
F0.00014334862385321102
I0
I1
I-1
tp34147
sS'by,ergosterol'
p34148
(F1
F0.00014334862385321102
I0
I1
I-1
tp34149
sS'which,requires'
p34150
(F1
F0.00014334862385321102
I0
I1
I-1
tp34151
sS'differential,effects'
p34152
(F1
F0.00028669724770642203
I0
I2
I-2
tp34153
sS'of,substantial'
p34154
(F1
F0.00014334862385321102
I1
I0
I1
tp34155
sS'been,frequently'
p34156
(F1
F0.00014334862385321102
I0
I1
I-1
tp34157
sS'cause,of'
p34158
(F1
F0.00014334862385321102
I1
I0
I1
tp34159
sS'cyp3a4,substrate'
p34160
(F0.066666666666666666
F0.00014334862385321102
I7
I8
I-1
tp34161
sS'placebo,as'
p34162
(F1
F0.00014334862385321102
I0
I1
I-1
tp34163
sS'elevate,plasma'
p34164
(F1
F0.00014334862385321102
I1
I0
I1
tp34165
sS'positive,direct'
p34166
(F1
F0.00014334862385321102
I0
I1
I-1
tp34167
sS'cause,or'
p34168
(F0
F0
I1
I1
I0
tp34169
sS'the,enhancement'
p34170
(F0
F0
I1
I1
I0
tp34171
sS'was,shown'
p34172
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp34173
sS'itraconazole,has'
p34174
(F1
F0.00014334862385321102
I1
I0
I1
tp34175
sS'for,toxicity'
p34176
(F0
F0
I1
I1
I0
tp34177
sS'other,macrolide'
p34178
(F0
F0
I1
I1
I0
tp34179
sS'bactrim,septra'
p34180
(F1
F0.00014334862385321102
I0
I1
I-1
tp34181
sS'to,were'
p34182
(F1
F0.00014334862385321102
I0
I1
I-1
tp34183
sS'matulane,eldepryl'
p34184
(F1
F0.00014334862385321102
I0
I1
I-1
tp34185
sS'oral,increased'
p34186
(F1
F0.00028669724770642203
I2
I0
I2
tp34187
sS'antianxiety,and'
p34188
(F1
F0.00014334862385321102
I0
I1
I-1
tp34189
sS'small,when'
p34190
(F1
F0.00014334862385321102
I1
I0
I1
tp34191
sS'delavirdine-based,regimens'
p34192
(F1
F0.00014334862385321102
I0
I1
I-1
tp34193
sS'after,oral'
p34194
(F1
F0.00014334862385321102
I0
I1
I-1
tp34195
sS'fractional,clearance'
p34196
(F1
F0.00014334862385321102
I1
I0
I1
tp34197
sS'bid,mg'
p34198
(F1
F0.00014334862385321102
I1
I0
I1
tp34199
sS'inducer,at'
p34200
(F1
F0.00014334862385321102
I1
I0
I1
tp34201
sS'for,clinical'
p34202
(F1
F0.00014334862385321102
I0
I1
I-1
tp34203
sS'that,acute'
p34204
(F1
F0.00014334862385321102
I0
I1
I-1
tp34205
sS'approximately,ml'
p34206
(F1
F0.00014334862385321102
I0
I1
I-1
tp34207
sS'including,convulsions'
p34208
(F1
F0.00014334862385321102
I1
I0
I1
tp34209
sS'avoid,concurrent'
p34210
(F1
F0.00014334862385321102
I1
I0
I1
tp34211
sS'that,these'
p34212
(F0
F0
I2
I2
I0
tp34213
sS'after,at'
p34214
(F1
F0.00014334862385321102
I0
I1
I-1
tp34215
sS'inhibitor,to'
p34216
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34217
sS'coating,of'
p34218
(F1
F0.00014334862385321102
I1
I0
I1
tp34219
sS'its,structural'
p34220
(F1
F0.00014334862385321102
I1
I0
I1
tp34221
sS'decreasing,the'
p34222
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34223
sS'in,maximal'
p34224
(F1
F0.00014334862385321102
I1
I0
I1
tp34225
sS'wellbutrin,tablets'
p34226
(F1
F0.00014334862385321102
I1
I0
I1
tp34227
sS'of,keppra'
p34228
(F1
F0.00014334862385321102
I0
I1
I-1
tp34229
sS'are,enhanced'
p34230
(F1
F0.00014334862385321102
I1
I0
I1
tp34231
sS'additive,use'
p34232
(F1
F0.00028669724770642203
I2
I0
I2
tp34233
sS'significance,as'
p34234
(F1
F0.00014334862385321102
I0
I1
I-1
tp34235
sS'in,clinical'
p34236
(F0.54838709677419351
F0.0024369266055045873
I7
I24
I-17
tp34237
sS'not,inhibit'
p34238
(F1
F0.00043004587155963305
I0
I3
I-3
tp34239
sS'inhibitors,drugs'
p34240
(F1
F0.00014334862385321102
I1
I0
I1
tp34241
sS'weak,inducer'
p34242
(F1
F0.00014334862385321102
I0
I1
I-1
tp34243
sS'ecg,and'
p34244
(F1
F0.00014334862385321102
I1
I0
I1
tp34245
sS'some,oxytocic'
p34246
(F1
F0.00014334862385321102
I1
I0
I1
tp34247
sS'and,serious'
p34248
(F1
F0.00014334862385321102
I1
I0
I1
tp34249
sS'cyp2c19,and'
p34250
(F1
F0.00014334862385321102
I0
I1
I-1
tp34251
sS'however,l-name'
p34252
(F1
F0.00014334862385321102
I0
I1
I-1
tp34253
sS'of,glycemia'
p34254
(F1
F0.00014334862385321102
I0
I1
I-1
tp34255
sS'least,in'
p34256
(F1
F0.00014334862385321102
I1
I0
I1
tp34257
sS'on,was'
p34258
(F1
F0.00028669724770642203
I0
I2
I-2
tp34259
sS'common,with'
p34260
(F1
F0.00014334862385321102
I1
I0
I1
tp34261
sS'fold,prolongation'
p34262
(F1
F0.00028669724770642203
I0
I2
I-2
tp34263
sS'clinical,interaction'
p34264
(F1
F0.00057339449541284407
I0
I4
I-4
tp34265
sS'undergoes,extensive'
p34266
(F1
F0.00014334862385321102
I0
I1
I-1
tp34267
sS'of,indocin'
p34268
(F1
F0.00071674311926605509
I5
I0
I5
tp34269
sS'infection,and'
p34270
(F1
F0.00014334862385321102
I1
I0
I1
tp34271
sS'as,topical'
p34272
(F1
F0.00014334862385321102
I0
I1
I-1
tp34273
sS'microalbuminuria,inspra'
p34274
(F1
F0.00014334862385321102
I1
I0
I1
tp34275
sS'relevant,consequences'
p34276
(F1
F0.00014334862385321102
I1
I0
I1
tp34277
sS'potential,twofold'
p34278
(F1
F0.00014334862385321102
I1
I0
I1
tp34279
sS'of,cholinesterase'
p34280
(F1
F0.00028669724770642203
I2
I0
I2
tp34281
sS'acarbose,and'
p34282
(F1
F0.00014334862385321102
I1
I0
I1
tp34283
sS'probably,is'
p34284
(F1
F0.00014334862385321102
I1
I0
I1
tp34285
sS'here,we'
p34286
(F1
F0.00028669724770642203
I0
I2
I-2
tp34287
sS'length,of'
p34288
(F1
F0.00014334862385321102
I1
I0
I1
tp34289
sS'phenytoin,accutane'
p34290
(F1
F0.00014334862385321102
I0
I1
I-1
tp34291
sS'cells,from'
p34292
(F1
F0.00014334862385321102
I0
I1
I-1
tp34293
sS'novolog,is'
p34294
(F1
F0.00014334862385321102
I0
I1
I-1
tp34295
sS'betaseron,administration'
p34296
(F1
F0.00014334862385321102
I1
I0
I1
tp34297
sS'bound,monoamine'
p34298
(F1
F0.00043004587155963305
I3
I0
I3
tp34299
sS'as,intravenous'
p34300
(F1
F0.00014334862385321102
I0
I1
I-1
tp34301
sS'who,is'
p34302
(F1
F0.00014334862385321102
I1
I0
I1
tp34303
sS'ssri,is'
p34304
(F1
F0.00057339449541284407
I4
I0
I4
tp34305
sS'noted,when'
p34306
(F1
F0.00028669724770642203
I0
I2
I-2
tp34307
sS'vivo,as'
p34308
(F1
F0.00014334862385321102
I1
I0
I1
tp34309
sS'general,concern'
p34310
(F1
F0.00014334862385321102
I0
I1
I-1
tp34311
sS'share,a'
p34312
(F1
F0.00014334862385321102
I0
I1
I-1
tp34313
sS'of,immobilised'
p34314
(F1
F0.00014334862385321102
I0
I1
I-1
tp34315
sS'the,theophylline-induced'
p34316
(F1
F0.00014334862385321102
I1
I0
I1
tp34317
sS'has,benefits'
p34318
(F1
F0.00014334862385321102
I0
I1
I-1
tp34319
sS'fenofibric,acid'
p34320
(F1
F0.00028669724770642203
I0
I2
I-2
tp34321
sS'receiving,zyvox'
p34322
(F1
F0.00014334862385321102
I1
I0
I1
tp34323
sS'depletors,should'
p34324
(F1
F0.00014334862385321102
I1
I0
I1
tp34325
sS'of,given'
p34326
(F0
F0
I2
I2
I0
tp34327
sS'ketoconazole,combined'
p34328
(F1
F0.00014334862385321102
I1
I0
I1
tp34329
sS'that,an'
p34330
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34331
sS'kg,dose'
p34332
(F1
F0.00014334862385321102
I1
I0
I1
tp34333
sS'for,known'
p34334
(F1
F0.00014334862385321102
I1
I0
I1
tp34335
sS'administered,during'
p34336
(F0
F0
I1
I1
I0
tp34337
sS'thinners,decongestant'
p34338
(F1
F0.00014334862385321102
I1
I0
I1
tp34339
sS'as,akineton'
p34340
(F1
F0.00014334862385321102
I1
I0
I1
tp34341
sS'p450,isoforms'
p34342
(F1
F0.00028669724770642203
I0
I2
I-2
tp34343
sS'paroxetine,produced'
p34344
(F1
F0.00014334862385321102
I1
I0
I1
tp34345
sS'cortisol,does'
p34346
(F1
F0.00014334862385321102
I0
I1
I-1
tp34347
sS'receiving,coumarin-type'
p34348
(F1
F0.00014334862385321102
I1
I0
I1
tp34349
sS'the,non-depolarizing'
p34350
(F1
F0.00014334862385321102
I1
I0
I1
tp34351
sS'known,interactions'
p34352
(F1
F0.00014334862385321102
I0
I1
I-1
tp34353
sS'with,careful'
p34354
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34355
sS'week,study'
p34356
(F1
F0.00014334862385321102
I0
I1
I-1
tp34357
sS'citrate,accumulation'
p34358
(F1
F0.00014334862385321102
I0
I1
I-1
tp34359
sS'as,reflected'
p34360
(F1
F0.00014334862385321102
I1
I0
I1
tp34361
sS'this,reason'
p34362
(F0
F0
I1
I1
I0
tp34363
sS'ethanol,clinical'
p34364
(F1
F0.00014334862385321102
I1
I0
I1
tp34365
sS'a,interaction'
p34366
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp34367
sS'co-administered,which'
p34368
(F1
F0.00014334862385321102
I1
I0
I1
tp34369
sS'v,nacmc'
p34370
(F1
F0.00014334862385321102
I0
I1
I-1
tp34371
sS'were,grouped'
p34372
(F1
F0.00014334862385321102
I0
I1
I-1
tp34373
sS'rocaltrol,may'
p34374
(F1
F0.00043004587155963305
I0
I3
I-3
tp34375
sS'relaxants,birth'
p34376
(F1
F0.00014334862385321102
I0
I1
I-1
tp34377
sS'certain,including'
p34378
(F1
F0.0008600917431192661
I6
I0
I6
tp34379
sS'absorption,is'
p34380
(F1
F0.00014334862385321102
I0
I1
I-1
tp34381
sS'agents,given'
p34382
(F1
F0.00014334862385321102
I0
I1
I-1
tp34383
sS'absorption,in'
p34384
(F1
F0.00043004587155963305
I3
I0
I3
tp34385
sS'and,rhabdomyolysis'
p34386
(F1
F0.00014334862385321102
I0
I1
I-1
tp34387
sS'the,main'
p34388
(F0
F0
I1
I1
I0
tp34389
sS'drop,in'
p34390
(F1
F0.00014334862385321102
I1
I0
I1
tp34391
sS'a,month'
p34392
(F1
F0.00028669724770642203
I0
I2
I-2
tp34393
sS'in,chemotherapy'
p34394
(F1
F0.00014334862385321102
I0
I1
I-1
tp34395
sS'information,concerning'
p34396
(F1
F0.00014334862385321102
I0
I1
I-1
tp34397
sS'clearance,by'
p34398
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp34399
sS'a,light'
p34400
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34401
sS'warfarin,in'
p34402
(F1
F0.00043004587155963305
I0
I3
I-3
tp34403
sS'of,acute'
p34404
(F1
F0.00057339449541284407
I0
I4
I-4
tp34405
sS'subsequently,increase'
p34406
(F1
F0.00014334862385321102
I0
I1
I-1
tp34407
sS'regimens,for'
p34408
(F1
F0.00014334862385321102
I0
I1
I-1
tp34409
sS'pharmacology,study'
p34410
(F0
F0
I1
I1
I0
tp34411
sS'brain,damage'
p34412
(F1
F0.00014334862385321102
I1
I0
I1
tp34413
sS'increases,in'
p34414
(F0.52941176470588236
F0.0025802752293577983
I26
I8
I18
tp34415
sS'tetracyclines,since'
p34416
(F1
F0.00014334862385321102
I1
I0
I1
tp34417
sS'human,therapeutic'
p34418
(F1
F0.00014334862385321102
I1
I0
I1
tp34419
sS'p-glycoprotein,transporter'
p34420
(F1
F0.00014334862385321102
I0
I1
I-1
tp34421
sS'events,and'
p34422
(F1
F0.00028669724770642203
I0
I2
I-2
tp34423
sS'and,mcg'
p34424
(F1
F0.00028669724770642203
I0
I2
I-2
tp34425
sS'such,use'
p34426
(F1
F0.00014334862385321102
I1
I0
I1
tp34427
sS'respectively,responsible'
p34428
(F1
F0.00014334862385321102
I1
I0
I1
tp34429
sS'mesylate,in'
p34430
(F1
F0.00014334862385321102
I1
I0
I1
tp34431
sS'oral,increase'
p34432
(F1
F0.00014334862385321102
I0
I1
I-1
tp34433
sS'the,slow'
p34434
(F1
F0.00014334862385321102
I0
I1
I-1
tp34435
sS'receptors,sodium'
p34436
(F1
F0.00014334862385321102
I0
I1
I-1
tp34437
sS'studies,using'
p34438
(F1
F0.00014334862385321102
I0
I1
I-1
tp34439
sS'oral,hypoglycemic'
p34440
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp34441
sS'or,cyp2d6'
p34442
(F1
F0.00014334862385321102
I1
I0
I1
tp34443
sS'with,lymphoma'
p34444
(F1
F0.00014334862385321102
I0
I1
I-1
tp34445
sS'aptt,such'
p34446
(F1
F0.00014334862385321102
I0
I1
I-1
tp34447
sS'from,human'
p34448
(F1
F0.00014334862385321102
I0
I1
I-1
tp34449
sS'affected,by'
p34450
(F0.73913043478260865
F0.0024369266055045873
I3
I20
I-17
tp34451
sS'relapses,for'
p34452
(F1
F0.00014334862385321102
I0
I1
I-1
tp34453
sS'with,narrow'
p34454
(F1
F0.00014334862385321102
I1
I0
I1
tp34455
sS'edemas,that'
p34456
(F1
F0.00014334862385321102
I1
I0
I1
tp34457
sS'on,combination'
p34458
(F1
F0.00014334862385321102
I0
I1
I-1
tp34459
sS'of,indigestion'
p34460
(F1
F0.00014334862385321102
I1
I0
I1
tp34461
sS'an,interaction'
p34462
(F0
F0
I5
I5
I0
tp34463
sS'rats,pd2'
p34464
(F1
F0.00014334862385321102
I1
I0
I1
tp34465
sS'digoxin,nimodipine'
p34466
(F1
F0.00014334862385321102
I0
I1
I-1
tp34467
sS'basis,it'
p34468
(F1
F0.00014334862385321102
I0
I1
I-1
tp34469
sS'certain,anticancer'
p34470
(F1
F0.00014334862385321102
I1
I0
I1
tp34471
sS'procedure,even'
p34472
(F1
F0.00014334862385321102
I0
I1
I-1
tp34473
sS'of,supplemental'
p34474
(F0
F0
I1
I1
I0
tp34475
sS'inhibitory,towards'
p34476
(F1
F0.00014334862385321102
I0
I1
I-1
tp34477
sS'of,kerlone'
p34478
(F1
F0.00014334862385321102
I0
I1
I-1
tp34479
sS'day,will'
p34480
(F1
F0.00014334862385321102
I1
I0
I1
tp34481
sS'oh,d3'
p34482
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34483
sS'events,was'
p34484
(F1
F0.00014334862385321102
I0
I1
I-1
tp34485
sS'carbamazepine,levels'
p34486
(F1
F0.00014334862385321102
I1
I0
I1
tp34487
sS'a,given'
p34488
(F1
F0.00014334862385321102
I0
I1
I-1
tp34489
sS'some,other'
p34490
(F1
F0.00028669724770642203
I2
I0
I2
tp34491
sS'thinners,coumadin'
p34492
(F1
F0.00014334862385321102
I0
I1
I-1
tp34493
sS'iga,glomerulonephritis'
p34494
(F1
F0.00014334862385321102
I1
I0
I1
tp34495
sS'non-,steroidal'
p34496
(F1
F0.00028669724770642203
I2
I0
I2
tp34497
sS'disturbances,including'
p34498
(F1
F0.00014334862385321102
I0
I1
I-1
tp34499
sS'potentiated,the'
p34500
(F1
F0.00057339449541284407
I4
I0
I4
tp34501
sS'with,most'
p34502
(F1
F0.00028669724770642203
I2
I0
I2
tp34503
sS'increases,hcl'
p34504
(F1
F0.00014334862385321102
I1
I0
I1
tp34505
sS'occur,if'
p34506
(F0
F0
I1
I1
I0
tp34507
sS'significantly,decreased'
p34508
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp34509
sS'phenobarbital,amphetamines'
p34510
(F1
F0.00028669724770642203
I2
I0
I2
tp34511
sS'occur,in'
p34512
(F1
F0.00043004587155963305
I3
I0
I3
tp34513
sS'significantly,decreases'
p34514
(F1
F0.00014334862385321102
I1
I0
I1
tp34515
sS'either,oral'
p34516
(F1
F0.00014334862385321102
I1
I0
I1
tp34517
sS'hepatotoxic,medications'
p34518
(F1
F0.00014334862385321102
I1
I0
I1
tp34519
sS'micrograms,equally'
p34520
(F1
F0.00014334862385321102
I1
I0
I1
tp34521
sS'rats,giving'
p34522
(F1
F0.00014334862385321102
I0
I1
I-1
tp34523
sS'or,activated'
p34524
(F1
F0.00014334862385321102
I1
I0
I1
tp34525
sS'substrates,in'
p34526
(F1
F0.00014334862385321102
I0
I1
I-1
tp34527
sS'taking,celebrex'
p34528
(F0
F0
I1
I1
I0
tp34529
sS'determined,by'
p34530
(F1
F0.00071674311926605509
I0
I5
I-5
tp34531
sS'others,may'
p34532
(F1
F0.00028669724770642203
I0
I2
I-2
tp34533
sS'severe,peripheral'
p34534
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34535
sS'would,include'
p34536
(F1
F0.00014334862385321102
I0
I1
I-1
tp34537
sS'and,instruct'
p34538
(F1
F0.00014334862385321102
I0
I1
I-1
tp34539
sS'ix,and'
p34540
(F1
F0.00014334862385321102
I0
I1
I-1
tp34541
sS'relapse,rehospitalisation'
p34542
(F1
F0.00014334862385321102
I0
I1
I-1
tp34543
sS'controlled,trial'
p34544
(F1
F0.00014334862385321102
I0
I1
I-1
tp34545
sS'present,work'
p34546
(F1
F0.00014334862385321102
I0
I1
I-1
tp34547
sS'reduced,tolerance'
p34548
(F1
F0.00014334862385321102
I1
I0
I1
tp34549
sS'or,surgery'
p34550
(F1
F0.00014334862385321102
I0
I1
I-1
tp34551
sS'with,incisive'
p34552
(F1
F0.00014334862385321102
I0
I1
I-1
tp34553
sS'subsequent,adjustment'
p34554
(F1
F0.00014334862385321102
I0
I1
I-1
tp34555
sS'nuprin,others'
p34556
(F1
F0.00014334862385321102
I0
I1
I-1
tp34557
sS'expected,changes'
p34558
(F1
F0.00014334862385321102
I0
I1
I-1
tp34559
sS'on,clinical'
p34560
(F1
F0.00014334862385321102
I1
I0
I1
tp34561
sS'the,benefits'
p34562
(F1
F0.00028669724770642203
I2
I0
I2
tp34563
sS'was,expected'
p34564
(F1
F0.00014334862385321102
I0
I1
I-1
tp34565
sS'by,competitive'
p34566
(F1
F0.00014334862385321102
I1
I0
I1
tp34567
sS'antipyrine,pharmacokinetics'
p34568
(F1
F0.00014334862385321102
I0
I1
I-1
tp34569
sS'dose,fractions'
p34570
(F1
F0.00014334862385321102
I0
I1
I-1
tp34571
sS'strongyloidiasis,during'
p34572
(F1
F0.00014334862385321102
I1
I0
I1
tp34573
sS'verapamil,produced'
p34574
(F1
F0.00014334862385321102
I0
I1
I-1
tp34575
sS'with,had'
p34576
(F1
F0.00028669724770642203
I0
I2
I-2
tp34577
sS'fade,recovery'
p34578
(F1
F0.00014334862385321102
I1
I0
I1
tp34579
sS'partially,counteract'
p34580
(F1
F0.00028669724770642203
I2
I0
I2
tp34581
sS'cmax,the'
p34582
(F1
F0.00014334862385321102
I0
I1
I-1
tp34583
sS'than,mm'
p34584
(F1
F0.00014334862385321102
I0
I1
I-1
tp34585
sS'intracranial,pressure'
p34586
(F1
F0.00014334862385321102
I1
I0
I1
tp34587
sS'than,mg'
p34588
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp34589
sS'lowering,the'
p34590
(F1
F0.00028669724770642203
I2
I0
I2
tp34591
sS'a,patient'
p34592
(F0.76000000000000001
F0.0027236238532110093
I22
I3
I19
tp34593
sS'hours,q24h'
p34594
(F1
F0.00014334862385321102
I1
I0
I1
tp34595
sS'demonstrated,superiority'
p34596
(F1
F0.00014334862385321102
I0
I1
I-1
tp34597
sS'agents,along'
p34598
(F1
F0.00014334862385321102
I1
I0
I1
tp34599
sS'experiences,and'
p34600
(F1
F0.00014334862385321102
I1
I0
I1
tp34601
sS'developed,rash'
p34602
(F1
F0.00014334862385321102
I1
I0
I1
tp34603
sS'a,agent'
p34604
(F1
F0.00014334862385321102
I1
I0
I1
tp34605
sS'on,indicates'
p34606
(F1
F0.00014334862385321102
I1
I0
I1
tp34607
sS'adjustment,may'
p34608
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34609
sS'the,endotoxin-treated'
p34610
(F1
F0.00014334862385321102
I1
I0
I1
tp34611
sS'days,in'
p34612
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp34613
sS'by,dmpge2'
p34614
(F1
F0.00014334862385321102
I0
I1
I-1
tp34615
sS'adrenergic,from'
p34616
(F1
F0.00014334862385321102
I0
I1
I-1
tp34617
sS'in,combining'
p34618
(F1
F0.00014334862385321102
I1
I0
I1
tp34619
sS'from,its'
p34620
(F1
F0.00057339449541284407
I4
I0
I4
tp34621
sS'deficiencies,by'
p34622
(F1
F0.00014334862385321102
I0
I1
I-1
tp34623
sS'adjustment,should'
p34624
(F1
F0.00014334862385321102
I1
I0
I1
tp34625
sS'shown,by'
p34626
(F1
F0.00014334862385321102
I0
I1
I-1
tp34627
sS'crises,have'
p34628
(F1
F0.00014334862385321102
I1
I0
I1
tp34629
sS'develop,in'
p34630
(F1
F0.00014334862385321102
I1
I0
I1
tp34631
sS'advised,especially'
p34632
(F1
F0.00014334862385321102
I0
I1
I-1
tp34633
sS'with,intramuscular'
p34634
(F1
F0.00014334862385321102
I0
I1
I-1
tp34635
sS'is,not'
p34636
(F0.034482758620689655
F0.00028669724770642203
I30
I28
I2
tp34637
sS'be,decreased'
p34638
(F1
F0.00043004587155963305
I3
I0
I3
tp34639
sS'pharmacodynamic,drug-drug'
p34640
(F1
F0.00014334862385321102
I0
I1
I-1
tp34641
sS'is,taken'
p34642
(F0.5
F0.00028669724770642203
I3
I1
I2
tp34643
sS'with,elevations'
p34644
(F1
F0.00043004587155963305
I3
I0
I3
tp34645
sS'and,pupil'
p34646
(F1
F0.00014334862385321102
I0
I1
I-1
tp34647
sS'more,efficient'
p34648
(F1
F0.00014334862385321102
I0
I1
I-1
tp34649
sS'the,intestine'
p34650
(F1
F0.00014334862385321102
I1
I0
I1
tp34651
sS'prolonged,therapy'
p34652
(F1
F0.00014334862385321102
I0
I1
I-1
tp34653
sS'pure,agonist'
p34654
(F1
F0.00014334862385321102
I1
I0
I1
tp34655
sS'is,adjusted'
p34656
(F1
F0.00014334862385321102
I1
I0
I1
tp34657
sS'apraclonidine,should'
p34658
(F1
F0.00014334862385321102
I1
I0
I1
tp34659
sS'increase,due'
p34660
(F1
F0.00014334862385321102
I1
I0
I1
tp34661
sS'long-term,therapy'
p34662
(F1
F0.00014334862385321102
I1
I0
I1
tp34663
sS'percent,of'
p34664
(F1
F0.00028669724770642203
I2
I0
I2
tp34665
sS'cyp3a4,such'
p34666
(F1
F0.00028669724770642203
I2
I0
I2
tp34667
sS'a,net'
p34668
(F1
F0.00057339449541284407
I4
I0
I4
tp34669
sS'concerning,published'
p34670
(F1
F0.00014334862385321102
I0
I1
I-1
tp34671
sS'sodium,blood'
p34672
(F1
F0.00014334862385321102
I1
I0
I1
tp34673
sS'margin,such'
p34674
(F1
F0.00014334862385321102
I0
I1
I-1
tp34675
sS'a-chloralose,anesthetized'
p34676
(F1
F0.00014334862385321102
I0
I1
I-1
tp34677
sS'polyene,many'
p34678
(F1
F0.00014334862385321102
I0
I1
I-1
tp34679
sS'concomitant,high-dose'
p34680
(F1
F0.00014334862385321102
I1
I0
I1
tp34681
sS'supplemental,in'
p34682
(F1
F0.00014334862385321102
I1
I0
I1
tp34683
sS'or,beta-adrenergic'
p34684
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34685
sS'known,microsomal'
p34686
(F1
F0.00014334862385321102
I1
I0
I1
tp34687
sS'innovar,vet'
p34688
(F1
F0.00014334862385321102
I1
I0
I1
tp34689
sS'times,daily'
p34690
(F0
F0
I2
I2
I0
tp34691
sS'and,primarily'
p34692
(F1
F0.00014334862385321102
I0
I1
I-1
tp34693
sS'as,evidenced'
p34694
(F1
F0.00014334862385321102
I1
I0
I1
tp34695
sS'with,intact'
p34696
(F1
F0.00014334862385321102
I1
I0
I1
tp34697
sS'pharmacologically,with'
p34698
(F1
F0.00014334862385321102
I1
I0
I1
tp34699
sS'of,ascorbic'
p34700
(F1
F0.00014334862385321102
I1
I0
I1
tp34701
sS'from,working'
p34702
(F1
F0.00014334862385321102
I0
I1
I-1
tp34703
sS'similar,properties'
p34704
(F1
F0.00014334862385321102
I1
I0
I1
tp34705
sS'receiving,acarbose'
p34706
(F1
F0.00014334862385321102
I0
I1
I-1
tp34707
sS'when,simulect'
p34708
(F1
F0.00014334862385321102
I0
I1
I-1
tp34709
sS'in,dosing'
p34710
(F1
F0.00014334862385321102
I0
I1
I-1
tp34711
sS'were,unaltered'
p34712
(F1
F0.00014334862385321102
I0
I1
I-1
tp34713
sS'nonclinical,studies'
p34714
(F1
F0.00014334862385321102
I0
I1
I-1
tp34715
sS'to,bind'
p34716
(F1
F0.00014334862385321102
I0
I1
I-1
tp34717
sS'patients,suffering'
p34718
(F1
F0.00043004587155963305
I3
I0
I3
tp34719
sS'norepinephrine,amphetamines'
p34720
(F1
F0.00028669724770642203
I2
I0
I2
tp34721
sS'on,malignant'
p34722
(F1
F0.00014334862385321102
I1
I0
I1
tp34723
sS'a,high'
p34724
(F1
F0.0010034403669724771
I7
I0
I7
tp34725
sS'significant,interactions'
p34726
(F0.83333333333333337
F0.0014334862385321102
I1
I11
I-10
tp34727
sS'seen,during'
p34728
(F1
F0.00028669724770642203
I2
I0
I2
tp34729
sS'kg,resulted'
p34730
(F1
F0.00014334862385321102
I0
I1
I-1
tp34731
sS'this,drug'
p34732
(F1
F0.00014334862385321102
I0
I1
I-1
tp34733
sS'changes,resulting'
p34734
(F1
F0.00014334862385321102
I0
I1
I-1
tp34735
sS'respectively,compared'
p34736
(F1
F0.00014334862385321102
I1
I0
I1
tp34737
sS'chirocaine,should'
p34738
(F1
F0.00014334862385321102
I1
I0
I1
tp34739
sS'inhibitors,elevated'
p34740
(F1
F0.00014334862385321102
I0
I1
I-1
tp34741
sS'stimulator,of'
p34742
(F1
F0.00014334862385321102
I1
I0
I1
tp34743
sS'neural,plasticity'
p34744
(F1
F0.00014334862385321102
I0
I1
I-1
tp34745
sS'describing,patients'
p34746
(F1
F0.00014334862385321102
I1
I0
I1
tp34747
sS'of,caution'
p34748
(F1
F0.00028669724770642203
I2
I0
I2
tp34749
sS'in,reversible'
p34750
(F1
F0.00014334862385321102
I1
I0
I1
tp34751
sS'temporarily,raise'
p34752
(F1
F0.00014334862385321102
I1
I0
I1
tp34753
sS'medications,patients'
p34754
(F1
F0.00014334862385321102
I1
I0
I1
tp34755
sS'tacrolimus,co-administration'
p34756
(F1
F0.00014334862385321102
I0
I1
I-1
tp34757
sS'found,to'
p34758
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp34759
sS'the,conventional'
p34760
(F1
F0.00014334862385321102
I0
I1
I-1
tp34761
sS'medications,concurrent'
p34762
(F1
F0.00014334862385321102
I0
I1
I-1
tp34763
sS'such,interaction'
p34764
(F1
F0.00014334862385321102
I0
I1
I-1
tp34765
sS'peripherally,restricted'
p34766
(F1
F0.00014334862385321102
I1
I0
I1
tp34767
sS'that,might'
p34768
(F1
F0.00014334862385321102
I1
I0
I1
tp34769
sS'novel,peripherally'
p34770
(F1
F0.00014334862385321102
I1
I0
I1
tp34771
sS'isosorbide,dinitrate'
p34772
(F0
F0
I1
I1
I0
tp34773
sS'drops,containing'
p34774
(F1
F0.00014334862385321102
I0
I1
I-1
tp34775
sS'before,one'
p34776
(F1
F0.00014334862385321102
I0
I1
I-1
tp34777
sS'inn,when'
p34778
(F1
F0.00014334862385321102
I0
I1
I-1
tp34779
sS'or,avoided'
p34780
(F1
F0.00014334862385321102
I1
I0
I1
tp34781
sS'antiparkinson,or'
p34782
(F1
F0.00014334862385321102
I1
I0
I1
tp34783
sS'gastric,emptying'
p34784
(F1
F0.00014334862385321102
I1
I0
I1
tp34785
sS'this,could'
p34786
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp34787
sS'when,therapy'
p34788
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp34789
sS'low,compared'
p34790
(F1
F0.00014334862385321102
I0
I1
I-1
tp34791
sS'only,slightly'
p34792
(F1
F0.00014334862385321102
I1
I0
I1
tp34793
sS'ketamine,is'
p34794
(F1
F0.00014334862385321102
I0
I1
I-1
tp34795
sS'manifested,as'
p34796
(F1
F0.00014334862385321102
I0
I1
I-1
tp34797
sS'antacids,and'
p34798
(F1
F0.00028669724770642203
I2
I0
I2
tp34799
sS'magnesium-containing,concomitant'
p34800
(F1
F0.00014334862385321102
I1
I0
I1
tp34801
sS'increase,and'
p34802
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34803
sS'amphetamines,enhance'
p34804
(F1
F0.00028669724770642203
I2
I0
I2
tp34805
sS'potential,nephrotoxicity'
p34806
(F1
F0.00014334862385321102
I0
I1
I-1
tp34807
sS'of,psychotropic'
p34808
(F1
F0.00014334862385321102
I1
I0
I1
tp34809
sS'bradycardia,which'
p34810
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34811
sS'including,hyperglycemia'
p34812
(F1
F0.00014334862385321102
I1
I0
I1
tp34813
sS'e-strain,subjects'
p34814
(F1
F0.00014334862385321102
I0
I1
I-1
tp34815
sS'efficiently,inhibited'
p34816
(F1
F0.00014334862385321102
I0
I1
I-1
tp34817
sS'fungal,resistance'
p34818
(F1
F0.00014334862385321102
I1
I0
I1
tp34819
sS'haart,with'
p34820
(F1
F0.00014334862385321102
I0
I1
I-1
tp34821
sS'vasodilation,induced'
p34822
(F1
F0.00014334862385321102
I1
I0
I1
tp34823
sS'and,normal'
p34824
(F1
F0.00028669724770642203
I2
I0
I2
tp34825
sS'amphotericin,b-'
p34826
(F1
F0.00014334862385321102
I1
I0
I1
tp34827
sS'further,deterioration'
p34828
(F1
F0.00028669724770642203
I2
I0
I2
tp34829
sS'supersensitive,to'
p34830
(F1
F0.00028669724770642203
I2
I0
I2
tp34831
sS'a,tablet'
p34832
(F1
F0.00028669724770642203
I2
I0
I2
tp34833
sS'produced,additive'
p34834
(F1
F0.00028669724770642203
I2
I0
I2
tp34835
sS'to,ace'
p34836
(F1
F0.00028669724770642203
I2
I0
I2
tp34837
sS'additional,calcium-containing'
p34838
(F1
F0.00043004587155963305
I0
I3
I-3
tp34839
sS'binding,thiazide'
p34840
(F1
F0.00014334862385321102
I1
I0
I1
tp34841
sS'local,agents'
p34842
(F1
F0.00028669724770642203
I0
I2
I-2
tp34843
sS'reversible,increases'
p34844
(F1
F0.00014334862385321102
I1
I0
I1
tp34845
sS'medical,supervision'
p34846
(F1
F0.00014334862385321102
I1
I0
I1
tp34847
sS'studies,caused'
p34848
(F1
F0.00014334862385321102
I0
I1
I-1
tp34849
sS'reduced,antihypertensive'
p34850
(F1
F0.00014334862385321102
I0
I1
I-1
tp34851
sS'since,are'
p34852
(F1
F0.00014334862385321102
I1
I0
I1
tp34853
sS'by,meth'
p34854
(F1
F0.00014334862385321102
I0
I1
I-1
tp34855
sS'man,the'
p34856
(F1
F0.00014334862385321102
I1
I0
I1
tp34857
sS'doubled,the'
p34858
(F1
F0.00014334862385321102
I1
I0
I1
tp34859
sS'and,mental'
p34860
(F1
F0.00014334862385321102
I1
I0
I1
tp34861
sS'should,have'
p34862
(F0.5
F0.00028669724770642203
I3
I1
I2
tp34863
sS'additive,ocular'
p34864
(F1
F0.00014334862385321102
I0
I1
I-1
tp34865
sS'tylenol,such'
p34866
(F1
F0.00014334862385321102
I1
I0
I1
tp34867
sS'and,vasodilators'
p34868
(F1
F0.00014334862385321102
I1
I0
I1
tp34869
sS'depend,on'
p34870
(F1
F0.00071674311926605509
I5
I0
I5
tp34871
sS'and,auc'
p34872
(F0.54545454545454541
F0.0017201834862385322
I17
I5
I12
tp34873
sS'produce,antabuse-like'
p34874
(F1
F0.00014334862385321102
I1
I0
I1
tp34875
sS'with,tests'
p34876
(F1
F0.00028669724770642203
I0
I2
I-2
tp34877
sS'produced,pharmacological'
p34878
(F1
F0.00014334862385321102
I0
I1
I-1
tp34879
sS'therapeutic,dose'
p34880
(F1
F0.00014334862385321102
I1
I0
I1
tp34881
sS'system,at'
p34882
(F1
F0.00014334862385321102
I1
I0
I1
tp34883
sS'complications,of'
p34884
(F0
F0
I1
I1
I0
tp34885
sS'elderly,patients'
p34886
(F1
F0.00014334862385321102
I1
I0
I1
tp34887
sS'colonic,fluid'
p34888
(F1
F0.00014334862385321102
I0
I1
I-1
tp34889
sS'the,manifestation'
p34890
(F1
F0.00014334862385321102
I1
I0
I1
tp34891
sS'acid,combination'
p34892
(F1
F0.00028669724770642203
I2
I0
I2
tp34893
sS'combination,hormonal'
p34894
(F1
F0.0015768348623853212
I11
I0
I11
tp34895
sS'agents,experience'
p34896
(F1
F0.00014334862385321102
I1
I0
I1
tp34897
sS'tension,hoof'
p34898
(F1
F0.00014334862385321102
I0
I1
I-1
tp34899
sS'in,such'
p34900
(F0.5
F0.00028669724770642203
I3
I1
I2
tp34901
sS'can,significantly'
p34902
(F1
F0.00014334862385321102
I1
I0
I1
tp34903
sS'would,cause'
p34904
(F1
F0.00014334862385321102
I0
I1
I-1
tp34905
sS'subjects,there'
p34906
(F1
F0.00014334862385321102
I0
I1
I-1
tp34907
sS'longterm,treatment'
p34908
(F1
F0.00014334862385321102
I0
I1
I-1
tp34909
sS'rifampin,an'
p34910
(F1
F0.00014334862385321102
I1
I0
I1
tp34911
sS'although,betagan'
p34912
(F1
F0.00014334862385321102
I1
I0
I1
tp34913
sS'allowing,gradually'
p34914
(F1
F0.00014334862385321102
I0
I1
I-1
tp34915
sS'consciousness,when'
p34916
(F1
F0.00014334862385321102
I1
I0
I1
tp34917
sS'cyp2e1,or'
p34918
(F1
F0.00014334862385321102
I0
I1
I-1
tp34919
sS'fluctuations,of'
p34920
(F1
F0.00014334862385321102
I1
I0
I1
tp34921
sS'signs,of'
p34922
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp34923
sS'pharmacologic,effects'
p34924
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34925
sS'k,oral'
p34926
(F1
F0.00014334862385321102
I1
I0
I1
tp34927
sS'signs,or'
p34928
(F1
F0.00043004587155963305
I3
I0
I3
tp34929
sS'heart,medicine'
p34930
(F1
F0.00014334862385321102
I1
I0
I1
tp34931
sS'extract,from'
p34932
(F1
F0.00014334862385321102
I0
I1
I-1
tp34933
sS'subject,to'
p34934
(F1
F0.00014334862385321102
I0
I1
I-1
tp34935
sS'since,inhibits'
p34936
(F1
F0.00014334862385321102
I1
I0
I1
tp34937
sS'and,decrease'
p34938
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp34939
sS'a,less'
p34940
(F1
F0.00028669724770642203
I2
I0
I2
tp34941
sS'found,with'
p34942
(F1
F0.00014334862385321102
I0
I1
I-1
tp34943
sS'modest,cyp2d6'
p34944
(F1
F0.00014334862385321102
I1
I0
I1
tp34945
sS'although,overall'
p34946
(F1
F0.00014334862385321102
I1
I0
I1
tp34947
sS'reports,regarding'
p34948
(F1
F0.00014334862385321102
I0
I1
I-1
tp34949
sS'and,may'
p34950
(F0.60606060606060608
F0.0057339449541284407
I53
I13
I40
tp34951
sS'and,mac'
p34952
(F1
F0.00014334862385321102
I1
I0
I1
tp34953
sS'digit,symbol'
p34954
(F1
F0.00014334862385321102
I1
I0
I1
tp34955
sS'a2,and'
p34956
(F1
F0.00014334862385321102
I1
I0
I1
tp34957
sS'of,pharmacologic'
p34958
(F1
F0.00014334862385321102
I1
I0
I1
tp34959
sS'days,before'
p34960
(F1
F0.00043004587155963305
I3
I0
I3
tp34961
sS'ibuprofen,produced'
p34962
(F1
F0.00014334862385321102
I1
I0
I1
tp34963
sS'antithyroid,agents'
p34964
(F1
F0.00014334862385321102
I1
I0
I1
tp34965
sS'sites,during'
p34966
(F1
F0.00028669724770642203
I2
I0
I2
tp34967
sS'reasons,it'
p34968
(F1
F0.00014334862385321102
I1
I0
I1
tp34969
sS'total,daily'
p34970
(F1
F0.00014334862385321102
I0
I1
I-1
tp34971
sS'other,related'
p34972
(F1
F0.00028669724770642203
I2
I0
I2
tp34973
sS'this,parenteral'
p34974
(F1
F0.00014334862385321102
I1
I0
I1
tp34975
sS'and,degenerative'
p34976
(F1
F0.00014334862385321102
I0
I1
I-1
tp34977
sS'conditions,had'
p34978
(F1
F0.00014334862385321102
I0
I1
I-1
tp34979
sS'that,dose'
p34980
(F1
F0.00014334862385321102
I1
I0
I1
tp34981
sS'in,proportion'
p34982
(F1
F0.00014334862385321102
I0
I1
I-1
tp34983
sS'the,absence'
p34984
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp34985
sS'decrease,between'
p34986
(F1
F0.00014334862385321102
I0
I1
I-1
tp34987
sS'cytochrome,cyp'
p34988
(F1
F0.00028669724770642203
I0
I2
I-2
tp34989
sS'or,above'
p34990
(F1
F0.00014334862385321102
I1
I0
I1
tp34991
sS'a4,and'
p34992
(F1
F0.00028669724770642203
I0
I2
I-2
tp34993
sS'ketoprofen,like'
p34994
(F1
F0.00014334862385321102
I1
I0
I1
tp34995
sS'tests,occur'
p34996
(F1
F0.00014334862385321102
I1
I0
I1
tp34997
sS'functioning,gland'
p34998
(F1
F0.00014334862385321102
I1
I0
I1
tp34999
sS'requirements,of'
p35000
(F1
F0.00014334862385321102
I1
I0
I1
tp35001
sS'half-life,increased'
p35002
(F1
F0.00043004587155963305
I3
I0
I3
tp35003
sS'local,or'
p35004
(F1
F0.00014334862385321102
I1
I0
I1
tp35005
sS'cns,effect'
p35006
(F1
F0.00014334862385321102
I1
I0
I1
tp35007
sS'acidic,or'
p35008
(F1
F0.00014334862385321102
I1
I0
I1
tp35009
sS'aed,on'
p35010
(F1
F0.00014334862385321102
I0
I1
I-1
tp35011
sS'of,sustained-release'
p35012
(F1
F0.00014334862385321102
I1
I0
I1
tp35013
sS'interaction,was'
p35014
(F1
F0.00043004587155963305
I0
I3
I-3
tp35015
sS'inhibitors,indinavir'
p35016
(F1
F0.00014334862385321102
I1
I0
I1
tp35017
sS'day,administration'
p35018
(F1
F0.00014334862385321102
I0
I1
I-1
tp35019
sS'other,hormonal'
p35020
(F1
F0.00014334862385321102
I0
I1
I-1
tp35021
sS'humans,and'
p35022
(F1
F0.00014334862385321102
I1
I0
I1
tp35023
sS'renal,dysfunction'
p35024
(F1
F0.00014334862385321102
I1
I0
I1
tp35025
sS'by,was'
p35026
(F1
F0.00028669724770642203
I2
I0
I2
tp35027
sS'combination,see'
p35028
(F1
F0.00014334862385321102
I0
I1
I-1
tp35029
sS'form,a'
p35030
(F1
F0.00028669724770642203
I2
I0
I2
tp35031
sS'anticholinesterases,neostgmine'
p35032
(F1
F0.00014334862385321102
I0
I1
I-1
tp35033
sS'was,obtained'
p35034
(F1
F0.00014334862385321102
I0
I1
I-1
tp35035
sS'type,c'
p35036
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp35037
sS'in,mcf-7'
p35038
(F1
F0.00014334862385321102
I0
I1
I-1
tp35039
sS'in,excessive'
p35040
(F1
F0.00028669724770642203
I2
I0
I2
tp35041
sS'dosage,should'
p35042
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp35043
sS'found,in'
p35044
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp35045
sS'and,tablets'
p35046
(F1
F0.00043004587155963305
I3
I0
I3
tp35047
sS'a,competitive'
p35048
(F1
F0.00014334862385321102
I1
I0
I1
tp35049
sS'other,nsaid'
p35050
(F0
F0
I1
I1
I0
tp35051
sS'affect,other'
p35052
(F1
F0.00028669724770642203
I0
I2
I-2
tp35053
sS'cyclosporine,administration'
p35054
(F1
F0.00014334862385321102
I1
I0
I1
tp35055
sS'vivo,studies'
p35056
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35057
sS'some,forms'
p35058
(F1
F0.00014334862385321102
I0
I1
I-1
tp35059
sS'produced,a'
p35060
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp35061
sS'and,chemotherapy'
p35062
(F1
F0.00014334862385321102
I0
I1
I-1
tp35063
sS'studied,certain'
p35064
(F1
F0.00014334862385321102
I1
I0
I1
tp35065
sS'aed,concentration'
p35066
(F1
F0.00014334862385321102
I0
I1
I-1
tp35067
sS'four,kinds'
p35068
(F1
F0.00014334862385321102
I0
I1
I-1
tp35069
sS'addiction,while'
p35070
(F1
F0.00014334862385321102
I0
I1
I-1
tp35071
sS'synthesis,have'
p35072
(F1
F0.00014334862385321102
I1
I0
I1
tp35073
sS'and,pharmacokinetics'
p35074
(F1
F0.00043004587155963305
I0
I3
I-3
tp35075
sS'of,phosphorylated'
p35076
(F1
F0.00014334862385321102
I0
I1
I-1
tp35077
sS'same,cytochrome'
p35078
(F1
F0.00014334862385321102
I0
I1
I-1
tp35079
sS'changed,by'
p35080
(F1
F0.00014334862385321102
I1
I0
I1
tp35081
sS'bacteriostatic,such'
p35082
(F1
F0.00014334862385321102
I1
I0
I1
tp35083
sS'indomethacin,are'
p35084
(F1
F0.00014334862385321102
I0
I1
I-1
tp35085
sS'multivalent,cations'
p35086
(F1
F0.00043004587155963305
I3
I0
I3
tp35087
sS'pharmacokinetics,were'
p35088
(F1
F0.00043004587155963305
I0
I3
I-3
tp35089
sS'with,medications'
p35090
(F1
F0.00014334862385321102
I1
I0
I1
tp35091
sS'pharmacological,analysis'
p35092
(F1
F0.00014334862385321102
I0
I1
I-1
tp35093
sS'to,although'
p35094
(F1
F0.00014334862385321102
I1
I0
I1
tp35095
sS'trecator,may'
p35096
(F1
F0.00014334862385321102
I1
I0
I1
tp35097
sS'identified,involving'
p35098
(F1
F0.00014334862385321102
I1
I0
I1
tp35099
sS'hypokalemia,may'
p35100
(F1
F0.00028669724770642203
I2
I0
I2
tp35101
sS'of,mixing'
p35102
(F1
F0.00014334862385321102
I0
I1
I-1
tp35103
sS'of,placebo'
p35104
(F1
F0.00014334862385321102
I0
I1
I-1
tp35105
sS'indigestion,remedies'
p35106
(F1
F0.00014334862385321102
I1
I0
I1
tp35107
sS'period,following'
p35108
(F0
F0
I1
I1
I0
tp35109
sS'peak,concentration'
p35110
(F1
F0.00014334862385321102
I0
I1
I-1
tp35111
sS'decreases,stomach'
p35112
(F1
F0.00014334862385321102
I0
I1
I-1
tp35113
sS'alkaloids,may'
p35114
(F1
F0.00014334862385321102
I1
I0
I1
tp35115
sS'other,there'
p35116
(F1
F0.00014334862385321102
I0
I1
I-1
tp35117
sS'although,lexapro'
p35118
(F1
F0.00014334862385321102
I1
I0
I1
tp35119
sS'with,inducers'
p35120
(F1
F0.00014334862385321102
I1
I0
I1
tp35121
sS'depressants,or'
p35122
(F1
F0.00028669724770642203
I2
I0
I2
tp35123
sS'usually,well'
p35124
(F0
F0
I1
I1
I0
tp35125
sS'the,dopaminergic'
p35126
(F1
F0.00014334862385321102
I1
I0
I1
tp35127
sS'information,on'
p35128
(F1
F0.00043004587155963305
I0
I3
I-3
tp35129
sS'increasing,plasma'
p35130
(F1
F0.00014334862385321102
I1
I0
I1
tp35131
sS'hemostatic,defense'
p35132
(F1
F0.00014334862385321102
I1
I0
I1
tp35133
sS'using,these'
p35134
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35135
sS'or,no'
p35136
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp35137
sS'coated,aspirin'
p35138
(F1
F0.00014334862385321102
I1
I0
I1
tp35139
sS'drugs,at'
p35140
(F1
F0.00014334862385321102
I0
I1
I-1
tp35141
sS'study,with'
p35142
(F0.59999999999999998
F0.0008600917431192661
I2
I8
I-6
tp35143
sS'trials,due'
p35144
(F1
F0.00014334862385321102
I0
I1
I-1
tp35145
sS'blood,elements'
p35146
(F1
F0.00014334862385321102
I1
I0
I1
tp35147
sS'leukocytosis,elevated'
p35148
(F1
F0.00014334862385321102
I1
I0
I1
tp35149
sS'it,adversely'
p35150
(F1
F0.00014334862385321102
I1
I0
I1
tp35151
sS'concurrent,usage'
p35152
(F1
F0.00014334862385321102
I0
I1
I-1
tp35153
sS'various,doses'
p35154
(F1
F0.00014334862385321102
I0
I1
I-1
tp35155
sS'of,absorbed'
p35156
(F0
F0
I1
I1
I0
tp35157
sS'suffering,from'
p35158
(F1
F0.00014334862385321102
I1
I0
I1
tp35159
sS'and,and'
p35160
(F0.032258064516129031
F0.00014334862385321102
I15
I16
I-1
tp35161
sS'and,cortex'
p35162
(F1
F0.00014334862385321102
I1
I0
I1
tp35163
sS'hydrophilic,molecule'
p35164
(F1
F0.00014334862385321102
I0
I1
I-1
tp35165
sS'of,after'
p35166
(F1
F0.00043004587155963305
I0
I3
I-3
tp35167
sS'a,period'
p35168
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35169
sS'of,baseline'
p35170
(F1
F0.00014334862385321102
I0
I1
I-1
tp35171
sS'a,critical'
p35172
(F1
F0.00014334862385321102
I0
I1
I-1
tp35173
sS'inhibitors,maois'
p35174
(F1
F0.00014334862385321102
I1
I0
I1
tp35175
sS'be,resistant'
p35176
(F1
F0.00014334862385321102
I1
I0
I1
tp35177
sS'xanthine,derivatives'
p35178
(F1
F0.00014334862385321102
I1
I0
I1
tp35179
sS'of,av'
p35180
(F1
F0.00028669724770642203
I2
I0
I2
tp35181
sS'of,at'
p35182
(F0.22222222222222221
F0.00057339449541284407
I11
I7
I4
tp35183
sS'of,as'
p35184
(F0.38461538461538464
F0.00071674311926605509
I4
I9
I-5
tp35185
sS'following,alfenta'
p35186
(F1
F0.00014334862385321102
I1
I0
I1
tp35187
sS'of,an'
p35188
(F0.33333333333333331
F0.0010034403669724771
I14
I7
I7
tp35189
sS'data,vardenafil'
p35190
(F1
F0.00014334862385321102
I1
I0
I1
tp35191
sS'its,dose'
p35192
(F1
F0.00014334862385321102
I1
I0
I1
tp35193
sS'of,targretin'
p35194
(F1
F0.00014334862385321102
I1
I0
I1
tp35195
sS'early,therapy'
p35196
(F1
F0.00014334862385321102
I1
I0
I1
tp35197
sS'and,prevention'
p35198
(F1
F0.00014334862385321102
I0
I1
I-1
tp35199
sS'alcohol,although'
p35200
(F1
F0.00014334862385321102
I1
I0
I1
tp35201
sS'and,antidotal'
p35202
(F1
F0.00014334862385321102
I1
I0
I1
tp35203
sS'blocking,effect'
p35204
(F1
F0.00014334862385321102
I1
I0
I1
tp35205
sS'cholestyramine,may'
p35206
(F1
F0.00043004587155963305
I3
I0
I3
tp35207
sS'amprenavir,inhibits'
p35208
(F1
F0.00014334862385321102
I0
I1
I-1
tp35209
sS'acetaminophen,and'
p35210
(F0
F0
I1
I1
I0
tp35211
sS'variables,of'
p35212
(F1
F0.00014334862385321102
I0
I1
I-1
tp35213
sS'on,clonidines'
p35214
(F1
F0.00014334862385321102
I0
I1
I-1
tp35215
sS'methotrexate,ibuprofen'
p35216
(F1
F0.00014334862385321102
I1
I0
I1
tp35217
sS'to,should'
p35218
(F1
F0.00028669724770642203
I2
I0
I2
tp35219
sS'and,prothrombin'
p35220
(F0
F0
I2
I2
I0
tp35221
sS'completely,blocked'
p35222
(F1
F0.00014334862385321102
I1
I0
I1
tp35223
sS'intravenous,agents'
p35224
(F1
F0.00014334862385321102
I0
I1
I-1
tp35225
sS'in,external'
p35226
(F1
F0.00014334862385321102
I0
I1
I-1
tp35227
sS'within,the'
p35228
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp35229
sS'in,poor'
p35230
(F1
F0.00014334862385321102
I0
I1
I-1
tp35231
sS'nevertheless,clinical'
p35232
(F1
F0.00014334862385321102
I1
I0
I1
tp35233
sS'daily,to'
p35234
(F1
F0.00014334862385321102
I0
I1
I-1
tp35235
sS'alter,hormone'
p35236
(F1
F0.00014334862385321102
I0
I1
I-1
tp35237
sS'mm,declining'
p35238
(F1
F0.00014334862385321102
I0
I1
I-1
tp35239
sS'cimetidine,does'
p35240
(F1
F0.00014334862385321102
I0
I1
I-1
tp35241
sS'have,all'
p35242
(F1
F0.00014334862385321102
I0
I1
I-1
tp35243
sS'effects,ways'
p35244
(F1
F0.00014334862385321102
I0
I1
I-1
tp35245
sS'exceeded,in'
p35246
(F1
F0.00014334862385321102
I1
I0
I1
tp35247
sS'd6,poor'
p35248
(F1
F0.00014334862385321102
I1
I0
I1
tp35249
sS'in,turn'
p35250
(F0
F0
I1
I1
I0
tp35251
sS'was,applied'
p35252
(F1
F0.00014334862385321102
I1
I0
I1
tp35253
sS'with,imidazole'
p35254
(F1
F0.00014334862385321102
I1
I0
I1
tp35255
sS'was,initiated'
p35256
(F1
F0.00014334862385321102
I1
I0
I1
tp35257
sS'accentuate,the'
p35258
(F1
F0.00028669724770642203
I2
I0
I2
tp35259
sS'with,uricosuric'
p35260
(F1
F0.00014334862385321102
I0
I1
I-1
tp35261
sS'accutane,and'
p35262
(F1
F0.00014334862385321102
I1
I0
I1
tp35263
sS'the,appropriate'
p35264
(F1
F0.00043004587155963305
I0
I3
I-3
tp35265
sS'toxicology,studies'
p35266
(F0
F0
I1
I1
I0
tp35267
sS'electrocardiographic,parameters'
p35268
(F1
F0.00043004587155963305
I0
I3
I-3
tp35269
sS'administered,until'
p35270
(F1
F0.00014334862385321102
I1
I0
I1
tp35271
sS'pneumocystis,carinii'
p35272
(F1
F0.00014334862385321102
I1
I0
I1
tp35273
sS'monitored,for'
p35274
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp35275
sS'concentration-time,curve'
p35276
(F0
F0
I1
I1
I0
tp35277
sS'therefore,this'
p35278
(F1
F0.00014334862385321102
I0
I1
I-1
tp35279
sS'significantly,alter'
p35280
(F1
F0.00014334862385321102
I1
I0
I1
tp35281
sS'although,there'
p35282
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp35283
sS'between,uroxatral'
p35284
(F1
F0.00014334862385321102
I0
I1
I-1
tp35285
sS'to,antagonize'
p35286
(F1
F0.00028669724770642203
I2
I0
I2
tp35287
sS'significantly,lower'
p35288
(F1
F0.00014334862385321102
I0
I1
I-1
tp35289
sS'with,ganglionic'
p35290
(F1
F0.00014334862385321102
I0
I1
I-1
tp35291
sS'extensor,tension'
p35292
(F1
F0.00014334862385321102
I0
I1
I-1
tp35293
sS'are,reduced'
p35294
(F1
F0.00028669724770642203
I2
I0
I2
tp35295
sS'nsaids,antigout'
p35296
(F1
F0.00014334862385321102
I0
I1
I-1
tp35297
sS'taking,beta'
p35298
(F1
F0.00014334862385321102
I1
I0
I1
tp35299
sS'representing,a'
p35300
(F1
F0.00014334862385321102
I1
I0
I1
tp35301
sS'receiving,or'
p35302
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp35303
sS'urinary,alkalinizers'
p35304
(F1
F0.00014334862385321102
I0
I1
I-1
tp35305
sS'no,inhibition'
p35306
(F1
F0.00014334862385321102
I0
I1
I-1
tp35307
sS'b12,because'
p35308
(F1
F0.00014334862385321102
I0
I1
I-1
tp35309
sS'with,moderate'
p35310
(F1
F0.00014334862385321102
I1
I0
I1
tp35311
sS'with,racemic'
p35312
(F1
F0.00028669724770642203
I2
I0
I2
tp35313
sS'with,either'
p35314
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp35315
sS'slowly,over'
p35316
(F1
F0.00014334862385321102
I1
I0
I1
tp35317
sS'anitagonism,without'
p35318
(F1
F0.00014334862385321102
I1
I0
I1
tp35319
sS'dictate,against'
p35320
(F1
F0.00014334862385321102
I1
I0
I1
tp35321
sS'in,post-marketing'
p35322
(F1
F0.00057339449541284407
I4
I0
I4
tp35323
sS'of,pseudotumor'
p35324
(F1
F0.00014334862385321102
I1
I0
I1
tp35325
sS'exceed,mg'
p35326
(F1
F0.00014334862385321102
I1
I0
I1
tp35327
sS'with,atacand'
p35328
(F1
F0.00014334862385321102
I1
I0
I1
tp35329
sS'starting,other'
p35330
(F1
F0.00014334862385321102
I0
I1
I-1
tp35331
sS'and,inducers'
p35332
(F1
F0.00014334862385321102
I1
I0
I1
tp35333
sS'temporarily,reduced'
p35334
(F1
F0.00014334862385321102
I1
I0
I1
tp35335
sS'arthritis,patients'
p35336
(F1
F0.00028669724770642203
I0
I2
I-2
tp35337
sS'accordance,with'
p35338
(F1
F0.00014334862385321102
I0
I1
I-1
tp35339
sS'to,healthy'
p35340
(F0.42857142857142855
F0.0008600917431192661
I4
I10
I-6
tp35341
sS'of,lapatinib'
p35342
(F1
F0.00014334862385321102
I0
I1
I-1
tp35343
sS'stable,plasma'
p35344
(F1
F0.00028669724770642203
I2
I0
I2
tp35345
sS'other,broad-spectrum'
p35346
(F1
F0.00014334862385321102
I1
I0
I1
tp35347
sS'times,long-sedation'
p35348
(F1
F0.00014334862385321102
I0
I1
I-1
tp35349
sS'in,sn38'
p35350
(F1
F0.00014334862385321102
I0
I1
I-1
tp35351
sS'relationships,and'
p35352
(F1
F0.00014334862385321102
I0
I1
I-1
tp35353
sS'antibiotics,no'
p35354
(F1
F0.00014334862385321102
I0
I1
I-1
tp35355
sS'lasting,depletions'
p35356
(F1
F0.00014334862385321102
I1
I0
I1
tp35357
sS'while,you'
p35358
(F1
F0.00028669724770642203
I2
I0
I2
tp35359
sS'however,beta'
p35360
(F1
F0.00014334862385321102
I0
I1
I-1
tp35361
sS'cmax,increased'
p35362
(F1
F0.00014334862385321102
I1
I0
I1
tp35363
sS'avoid,additive'
p35364
(F1
F0.00014334862385321102
I1
I0
I1
tp35365
sS'of,striatal'
p35366
(F1
F0.00028669724770642203
I2
I0
I2
tp35367
sS'water,from'
p35368
(F1
F0.00014334862385321102
I0
I1
I-1
tp35369
sS'have,several'
p35370
(F1
F0.00014334862385321102
I0
I1
I-1
tp35371
sS'o,every'
p35372
(F1
F0.00014334862385321102
I1
I0
I1
tp35373
sS'with,decreased'
p35374
(F1
F0.00014334862385321102
I0
I1
I-1
tp35375
sS'abnormalities,and'
p35376
(F1
F0.00028669724770642203
I2
I0
I2
tp35377
sS'the,experiments'
p35378
(F1
F0.00014334862385321102
I0
I1
I-1
tp35379
sS'with,tuberculosis'
p35380
(F0
F0
I1
I1
I0
tp35381
sS'without,disturbing'
p35382
(F1
F0.00014334862385321102
I0
I1
I-1
tp35383
sS'these,subjects'
p35384
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35385
sS'mycophenolate,mofetil'
p35386
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35387
sS'with,decreases'
p35388
(F1
F0.00014334862385321102
I1
I0
I1
tp35389
sS'the,antagonism'
p35390
(F1
F0.00014334862385321102
I1
I0
I1
tp35391
sS'increasing,its'
p35392
(F1
F0.00028669724770642203
I2
I0
I2
tp35393
sS'pathway,showed'
p35394
(F1
F0.00014334862385321102
I1
I0
I1
tp35395
sS'the,antagonist'
p35396
(F1
F0.00014334862385321102
I0
I1
I-1
tp35397
sS'increase,resulting'
p35398
(F1
F0.00014334862385321102
I1
I0
I1
tp35399
sS'perchlorate,in'
p35400
(F1
F0.00014334862385321102
I0
I1
I-1
tp35401
sS'heart,disease'
p35402
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35403
sS'and,persistent'
p35404
(F1
F0.00014334862385321102
I1
I0
I1
tp35405
sS'healthy,subjects'
p35406
(F0
F0
I15
I15
I0
tp35407
sS'atorvastatin,plasma'
p35408
(F1
F0.00014334862385321102
I0
I1
I-1
tp35409
sS'ketamine,marked'
p35410
(F1
F0.00014334862385321102
I1
I0
I1
tp35411
sS'on,aliskiren'
p35412
(F1
F0.00014334862385321102
I0
I1
I-1
tp35413
sS'and,hyperreninemia'
p35414
(F1
F0.00014334862385321102
I1
I0
I1
tp35415
sS'care,professional'
p35416
(F1
F0.00014334862385321102
I1
I0
I1
tp35417
sS'deplete,and'
p35418
(F1
F0.00014334862385321102
I1
I0
I1
tp35419
sS'hours,postdose'
p35420
(F1
F0.00014334862385321102
I1
I0
I1
tp35421
sS'for,periods'
p35422
(F1
F0.00014334862385321102
I0
I1
I-1
tp35423
sS'nifedipine,vardenafil'
p35424
(F1
F0.00014334862385321102
I0
I1
I-1
tp35425
sS'hormones,such'
p35426
(F1
F0.00014334862385321102
I1
I0
I1
tp35427
sS'of,medicinal'
p35428
(F1
F0.00014334862385321102
I1
I0
I1
tp35429
sS'day,orally'
p35430
(F1
F0.00014334862385321102
I1
I0
I1
tp35431
sS'requiring,treatment'
p35432
(F1
F0.00014334862385321102
I0
I1
I-1
tp35433
sS'not,associated'
p35434
(F1
F0.00028669724770642203
I0
I2
I-2
tp35435
sS'stimulant,type'
p35436
(F1
F0.00014334862385321102
I0
I1
I-1
tp35437
sS'tend,to'
p35438
(F1
F0.00014334862385321102
I0
I1
I-1
tp35439
sS'lorazepam,coadministration'
p35440
(F1
F0.00014334862385321102
I0
I1
I-1
tp35441
sS'which,eight'
p35442
(F1
F0.00014334862385321102
I0
I1
I-1
tp35443
sS'including,tricor'
p35444
(F1
F0.00014334862385321102
I1
I0
I1
tp35445
sS'nor,the'
p35446
(F1
F0.00014334862385321102
I0
I1
I-1
tp35447
sS'laboratories,platelia'
p35448
(F1
F0.00014334862385321102
I0
I1
I-1
tp35449
sS'another,extended'
p35450
(F1
F0.00014334862385321102
I0
I1
I-1
tp35451
sS'h1-blocking,agents'
p35452
(F1
F0.00014334862385321102
I1
I0
I1
tp35453
sS'of,eleven'
p35454
(F1
F0.00014334862385321102
I1
I0
I1
tp35455
sS'cyp,p450'
p35456
(F1
F0.00014334862385321102
I0
I1
I-1
tp35457
sS'oral,agents'
p35458
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp35459
sS'many,other'
p35460
(F1
F0.00071674311926605509
I0
I5
I-5
tp35461
sS'depression,stupor'
p35462
(F1
F0.00014334862385321102
I1
I0
I1
tp35463
sS'and,concomitantly'
p35464
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp35465
sS'were,resistant'
p35466
(F1
F0.00014334862385321102
I0
I1
I-1
tp35467
sS'ratios,confidence'
p35468
(F1
F0.00014334862385321102
I0
I1
I-1
tp35469
sS'the,biologic'
p35470
(F1
F0.00014334862385321102
I1
I0
I1
tp35471
sS'and,hydroxides'
p35472
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35473
sS'recommended,due'
p35474
(F1
F0.00043004587155963305
I3
I0
I3
tp35475
sS'for,patients'
p35476
(F0
F0
I2
I2
I0
tp35477
sS'other,in'
p35478
(F1
F0.00028669724770642203
I0
I2
I-2
tp35479
sS'but,may'
p35480
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp35481
sS'other,is'
p35482
(F0
F0
I1
I1
I0
tp35483
sS'by,conjugation'
p35484
(F1
F0.00014334862385321102
I0
I1
I-1
tp35485
sS'in,many'
p35486
(F1
F0.00014334862385321102
I0
I1
I-1
tp35487
sS'by,lowering'
p35488
(F1
F0.00014334862385321102
I1
I0
I1
tp35489
sS'analyzed,for'
p35490
(F1
F0.00014334862385321102
I0
I1
I-1
tp35491
sS'be,weighed'
p35492
(F1
F0.00014334862385321102
I1
I0
I1
tp35493
sS'terminal,half-life'
p35494
(F1
F0.00043004587155963305
I3
I0
I3
tp35495
sS'molecular,weight'
p35496
(F1
F0.00014334862385321102
I0
I1
I-1
tp35497
sS'vitro,and'
p35498
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp35499
sS'molecular,basis'
p35500
(F0
F0
I1
I1
I0
tp35501
sS'individual,patients'
p35502
(F1
F0.00014334862385321102
I1
I0
I1
tp35503
sS'other,cardiovascular'
p35504
(F1
F0.00014334862385321102
I0
I1
I-1
tp35505
sS'alcohol,g'
p35506
(F1
F0.00014334862385321102
I0
I1
I-1
tp35507
sS'dose,reduced'
p35508
(F1
F0.00014334862385321102
I1
I0
I1
tp35509
sS'weeks,after'
p35510
(F1
F0.00057339449541284407
I4
I0
I4
tp35511
sS'this,change'
p35512
(F1
F0.00014334862385321102
I0
I1
I-1
tp35513
sS'twice,a'
p35514
(F1
F0.00028669724770642203
I0
I2
I-2
tp35515
sS'compounds,should'
p35516
(F1
F0.00028669724770642203
I2
I0
I2
tp35517
sS'and,except'
p35518
(F1
F0.00014334862385321102
I0
I1
I-1
tp35519
sS'of,zebeta'
p35520
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35521
sS'inr,should'
p35522
(F1
F0.00014334862385321102
I1
I0
I1
tp35523
sS'cognitive,enhancing'
p35524
(F1
F0.00014334862385321102
I0
I1
I-1
tp35525
sS'increased,decreased'
p35526
(F1
F0.00014334862385321102
I1
I0
I1
tp35527
sS'receptors,such'
p35528
(F1
F0.00014334862385321102
I1
I0
I1
tp35529
sS'subjects,stabilized'
p35530
(F1
F0.00014334862385321102
I1
I0
I1
tp35531
sS'of,reportedly'
p35532
(F1
F0.00014334862385321102
I1
I0
I1
tp35533
sS'mg,with'
p35534
(F0.5
F0.00057339449541284407
I6
I2
I4
tp35535
sS'transit,time'
p35536
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35537
sS'kg,per'
p35538
(F1
F0.00014334862385321102
I1
I0
I1
tp35539
sS'nevertheless,the'
p35540
(F1
F0.00043004587155963305
I3
I0
I3
tp35541
sS'and,cyp2d6'
p35542
(F1
F0.00014334862385321102
I0
I1
I-1
tp35543
sS'paroxetine,coadministration'
p35544
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35545
sS'discussing,the'
p35546
(F1
F0.00014334862385321102
I0
I1
I-1
tp35547
sS'bradycardia,or'
p35548
(F1
F0.00014334862385321102
I1
I0
I1
tp35549
sS'fumarate,seroquel'
p35550
(F1
F0.00014334862385321102
I0
I1
I-1
tp35551
sS'l-glutamine,and'
p35552
(F1
F0.00028669724770642203
I2
I0
I2
tp35553
sS'animals,were'
p35554
(F1
F0.00014334862385321102
I0
I1
I-1
tp35555
sS'too,small'
p35556
(F1
F0.00014334862385321102
I0
I1
I-1
tp35557
sS'receiving,itraconazole'
p35558
(F1
F0.00028669724770642203
I2
I0
I2
tp35559
sS'small,yet'
p35560
(F1
F0.00014334862385321102
I0
I1
I-1
tp35561
sS'krm-1648,either'
p35562
(F1
F0.00028669724770642203
I0
I2
I-2
tp35563
sS'of,viracept'
p35564
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp35565
sS'studies,document'
p35566
(F1
F0.00014334862385321102
I0
I1
I-1
tp35567
sS'the,gonadotropin'
p35568
(F1
F0.00014334862385321102
I0
I1
I-1
tp35569
sS'depression,may'
p35570
(F1
F0.00028669724770642203
I2
I0
I2
tp35571
sS'determined,prior'
p35572
(F1
F0.00014334862385321102
I1
I0
I1
tp35573
sS'if,any'
p35574
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35575
sS'with,torsades'
p35576
(F1
F0.00014334862385321102
I0
I1
I-1
tp35577
sS'p-450,isozymes'
p35578
(F1
F0.00028669724770642203
I2
I0
I2
tp35579
sS'if,and'
p35580
(F1
F0.00043004587155963305
I3
I0
I3
tp35581
sS'other,antiplatelet'
p35582
(F1
F0.00014334862385321102
I1
I0
I1
tp35583
sS'time,when'
p35584
(F0
F0
I1
I1
I0
tp35585
sS'reported,examples'
p35586
(F1
F0.00043004587155963305
I0
I3
I-3
tp35587
sS'therapy,are'
p35588
(F1
F0.00014334862385321102
I1
I0
I1
tp35589
sS'a,higher'
p35590
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp35591
sS'and,both'
p35592
(F1
F0.00043004587155963305
I0
I3
I-3
tp35593
sS'anti-cryptosporidial,activity'
p35594
(F1
F0.00014334862385321102
I0
I1
I-1
tp35595
sS'of,toxicity'
p35596
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp35597
sS'c,completely'
p35598
(F1
F0.00014334862385321102
I1
I0
I1
tp35599
sS'and,herbs'
p35600
(F1
F0.00014334862385321102
I1
I0
I1
tp35601
sS'caused,an'
p35602
(F1
F0.00014334862385321102
I1
I0
I1
tp35603
sS'day,monotherapy'
p35604
(F1
F0.00014334862385321102
I0
I1
I-1
tp35605
sS'in,overdose'
p35606
(F1
F0.00014334862385321102
I1
I0
I1
tp35607
sS'direct,cardiac'
p35608
(F1
F0.00014334862385321102
I1
I0
I1
tp35609
sS'with,nalfon'
p35610
(F1
F0.00014334862385321102
I1
I0
I1
tp35611
sS'in,balance'
p35612
(F1
F0.00014334862385321102
I0
I1
I-1
tp35613
sS'minipills,that'
p35614
(F1
F0.00014334862385321102
I1
I0
I1
tp35615
sS'fixed,g'
p35616
(F1
F0.00014334862385321102
I0
I1
I-1
tp35617
sS'users,experiencing'
p35618
(F1
F0.00014334862385321102
I0
I1
I-1
tp35619
sS'vioxx,therapy'
p35620
(F1
F0.00014334862385321102
I1
I0
I1
tp35621
sS'be,discontinued'
p35622
(F1
F0.00057339449541284407
I4
I0
I4
tp35623
sS'tricyclic,metabolism'
p35624
(F1
F0.00014334862385321102
I1
I0
I1
tp35625
sS'possible,decrease'
p35626
(F1
F0.00043004587155963305
I3
I0
I3
tp35627
sS'were,approximately'
p35628
(F1
F0.00014334862385321102
I1
I0
I1
tp35629
sS'be,affected'
p35630
(F0
F0
I3
I3
I0
tp35631
sS'co-administration,mean'
p35632
(F1
F0.00014334862385321102
I0
I1
I-1
tp35633
sS'from,high-estradiol'
p35634
(F1
F0.00014334862385321102
I1
I0
I1
tp35635
sS'v,significantly'
p35636
(F1
F0.00014334862385321102
I0
I1
I-1
tp35637
sS'clinical,use'
p35638
(F0
F0
I1
I1
I0
tp35639
sS'hypersensitive,to'
p35640
(F1
F0.00014334862385321102
I1
I0
I1
tp35641
sS'uric,acid'
p35642
(F1
F0.00028669724770642203
I2
I0
I2
tp35643
sS'egf,ng'
p35644
(F1
F0.00014334862385321102
I0
I1
I-1
tp35645
sS'and,certainly'
p35646
(F1
F0.00014334862385321102
I1
I0
I1
tp35647
sS'anti-inflammatory,nsaids'
p35648
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35649
sS'peritoneal,cavity'
p35650
(F1
F0.00014334862385321102
I0
I1
I-1
tp35651
sS'daily,did'
p35652
(F1
F0.0011467889908256881
I0
I8
I-8
tp35653
sS'the,carbachol-stimulated'
p35654
(F1
F0.00014334862385321102
I1
I0
I1
tp35655
sS'reductase,inhibitor'
p35656
(F0.5
F0.00028669724770642203
I3
I1
I2
tp35657
sS'arrest,with'
p35658
(F1
F0.00014334862385321102
I0
I1
I-1
tp35659
sS'gritty,substance'
p35660
(F1
F0.00014334862385321102
I1
I0
I1
tp35661
sS'are,extensively'
p35662
(F1
F0.00014334862385321102
I1
I0
I1
tp35663
sS'prior,ingestion'
p35664
(F1
F0.00014334862385321102
I1
I0
I1
tp35665
sS'even,in'
p35666
(F1
F0.00014334862385321102
I1
I0
I1
tp35667
sS'fluvoxamine,increased'
p35668
(F1
F0.00014334862385321102
I1
I0
I1
tp35669
sS'fashion,to'
p35670
(F1
F0.00014334862385321102
I0
I1
I-1
tp35671
sS'the,pancreatic'
p35672
(F1
F0.00014334862385321102
I0
I1
I-1
tp35673
sS'been,conflicting'
p35674
(F1
F0.00014334862385321102
I1
I0
I1
tp35675
sS'or,less'
p35676
(F0
F0
I1
I1
I0
tp35677
sS'be,closely'
p35678
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp35679
sS'or,use'
p35680
(F0
F0
I1
I1
I0
tp35681
sS'and,calcium-rich'
p35682
(F1
F0.00014334862385321102
I1
I0
I1
tp35683
sS'studies,intravenous'
p35684
(F1
F0.00014334862385321102
I0
I1
I-1
tp35685
sS'is,moderately'
p35686
(F1
F0.00014334862385321102
I0
I1
I-1
tp35687
sS'strongly,induce'
p35688
(F1
F0.00014334862385321102
I1
I0
I1
tp35689
sS'coumarin-type,anticoagulants'
p35690
(F1
F0.00014334862385321102
I0
I1
I-1
tp35691
sS'males,in'
p35692
(F1
F0.00014334862385321102
I0
I1
I-1
tp35693
sS'arthritis,clinical'
p35694
(F1
F0.00014334862385321102
I0
I1
I-1
tp35695
sS'with,lotensin'
p35696
(F1
F0.00014334862385321102
I1
I0
I1
tp35697
sS'ritonavir,combined'
p35698
(F1
F0.00014334862385321102
I0
I1
I-1
tp35699
sS'inhalation,mefenamic'
p35700
(F1
F0.00014334862385321102
I1
I0
I1
tp35701
sS'dosing,interval'
p35702
(F1
F0.00014334862385321102
I0
I1
I-1
tp35703
sS'of,cyp450'
p35704
(F1
F0.00014334862385321102
I0
I1
I-1
tp35705
sS'and,after'
p35706
(F1
F0.00043004587155963305
I0
I3
I-3
tp35707
sS'of,acetylsalicylic'
p35708
(F1
F0.00028669724770642203
I0
I2
I-2
tp35709
sS'with,compounds'
p35710
(F1
F0.00014334862385321102
I1
I0
I1
tp35711
sS'with,mild'
p35712
(F0
F0
I2
I2
I0
tp35713
sS'as,p-glycoprotein'
p35714
(F1
F0.00014334862385321102
I1
I0
I1
tp35715
sS'in,an'
p35716
(F0.69230769230769229
F0.0038704128440366975
I33
I6
I27
tp35717
sS'at,high'
p35718
(F0.5
F0.00028669724770642203
I3
I1
I2
tp35719
sS'supplements,oral'
p35720
(F1
F0.00014334862385321102
I0
I1
I-1
tp35721
sS'sodium,following'
p35722
(F1
F0.00014334862385321102
I0
I1
I-1
tp35723
sS'but,decreased'
p35724
(F1
F0.00014334862385321102
I1
I0
I1
tp35725
sS'transport,pathway'
p35726
(F1
F0.00014334862385321102
I0
I1
I-1
tp35727
sS'more,pronounced'
p35728
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35729
sS'certain,concomitant'
p35730
(F1
F0.00028669724770642203
I0
I2
I-2
tp35731
sS'toradoloral,was'
p35732
(F1
F0.00014334862385321102
I0
I1
I-1
tp35733
sS'or,tsh'
p35734
(F1
F0.00014334862385321102
I0
I1
I-1
tp35735
sS'ketoconazole,has'
p35736
(F1
F0.00014334862385321102
I1
I0
I1
tp35737
sS'been,isolated'
p35738
(F1
F0.00043004587155963305
I3
I0
I3
tp35739
sS'sirolimus,mammalian'
p35740
(F1
F0.00014334862385321102
I0
I1
I-1
tp35741
sS'concentration,was'
p35742
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp35743
sS'effect,digitalis'
p35744
(F1
F0.00014334862385321102
I1
I0
I1
tp35745
sS'of,foods'
p35746
(F1
F0.00014334862385321102
I0
I1
I-1
tp35747
sS'when,administering'
p35748
(F1
F0.0015768348623853212
I11
I0
I11
tp35749
sS'transdermal,with'
p35750
(F1
F0.00014334862385321102
I1
I0
I1
tp35751
sS'of,ruthenium'
p35752
(F1
F0.00014334862385321102
I0
I1
I-1
tp35753
sS'and,immediately'
p35754
(F1
F0.00014334862385321102
I1
I0
I1
tp35755
sS'vitro,can'
p35756
(F1
F0.00014334862385321102
I1
I0
I1
tp35757
sS'be,applied'
p35758
(F1
F0.00014334862385321102
I0
I1
I-1
tp35759
sS'with,physicians'
p35760
(F1
F0.00014334862385321102
I0
I1
I-1
tp35761
sS'genotypes,of'
p35762
(F1
F0.00014334862385321102
I0
I1
I-1
tp35763
sS'substrates,for'
p35764
(F1
F0.0008600917431192661
I0
I6
I-6
tp35765
sS'tool,for'
p35766
(F1
F0.00014334862385321102
I0
I1
I-1
tp35767
sS'between,novoseven'
p35768
(F1
F0.00014334862385321102
I0
I1
I-1
tp35769
sS'other,concomitant'
p35770
(F1
F0.00057339449541284407
I0
I4
I-4
tp35771
sS'may,inhibit'
p35772
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp35773
sS'eliminate,the'
p35774
(F1
F0.00014334862385321102
I1
I0
I1
tp35775
sS'it,be'
p35776
(F1
F0.00014334862385321102
I1
I0
I1
tp35777
sS'cancers,were'
p35778
(F1
F0.00014334862385321102
I0
I1
I-1
tp35779
sS'difluoroacetone,a'
p35780
(F1
F0.00014334862385321102
I0
I1
I-1
tp35781
sS'the,latter'
p35782
(F1
F0.00014334862385321102
I1
I0
I1
tp35783
sS'during,omnicef'
p35784
(F1
F0.00028669724770642203
I2
I0
I2
tp35785
sS'whom,either'
p35786
(F1
F0.00014334862385321102
I0
I1
I-1
tp35787
sS'related,anabolic'
p35788
(F0
F0
I1
I1
I0
tp35789
sS'excessive,reduction'
p35790
(F1
F0.00071674311926605509
I5
I0
I5
tp35791
sS'with,demonstrated'
p35792
(F1
F0.00028669724770642203
I0
I2
I-2
tp35793
sS'that,sensitize'
p35794
(F1
F0.00014334862385321102
I1
I0
I1
tp35795
sS'or,abolish'
p35796
(F1
F0.00014334862385321102
I1
I0
I1
tp35797
sS'and,class'
p35798
(F1
F0.00014334862385321102
I1
I0
I1
tp35799
sS'to,mg'
p35800
(F0.17647058823529413
F0.0008600917431192661
I20
I14
I6
tp35801
sS'meal,h'
p35802
(F1
F0.00014334862385321102
I1
I0
I1
tp35803
sS'astramorph,kadian'
p35804
(F1
F0.00014334862385321102
I1
I0
I1
tp35805
sS'to,mm'
p35806
(F1
F0.00028669724770642203
I0
I2
I-2
tp35807
sS'to,ml'
p35808
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35809
sS'both,mc'
p35810
(F1
F0.00014334862385321102
I0
I1
I-1
tp35811
sS'decrease,extracellular'
p35812
(F1
F0.00014334862385321102
I0
I1
I-1
tp35813
sS'was,reported'
p35814
(F1
F0.00014334862385321102
I1
I0
I1
tp35815
sS'clonazepam,literature'
p35816
(F1
F0.00014334862385321102
I0
I1
I-1
tp35817
sS'decreased,and'
p35818
(F1
F0.00014334862385321102
I1
I0
I1
tp35819
sS'conjugates,on'
p35820
(F1
F0.00014334862385321102
I0
I1
I-1
tp35821
sS'was,lowered'
p35822
(F1
F0.00014334862385321102
I1
I0
I1
tp35823
sS'cyp3a4,as'
p35824
(F1
F0.00014334862385321102
I0
I1
I-1
tp35825
sS'its,primary'
p35826
(F1
F0.00014334862385321102
I1
I0
I1
tp35827
sS'non-nucleoside,reverse'
p35828
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35829
sS'magnesium-containing,preparations'
p35830
(F1
F0.00043004587155963305
I3
I0
I3
tp35831
sS'impairment,reportedly'
p35832
(F1
F0.00014334862385321102
I1
I0
I1
tp35833
sS'be,continuously'
p35834
(F1
F0.00014334862385321102
I1
I0
I1
tp35835
sS'severe,dietary'
p35836
(F1
F0.00014334862385321102
I1
I0
I1
tp35837
sS'utilization,including'
p35838
(F1
F0.00014334862385321102
I1
I0
I1
tp35839
sS'attenuates,but'
p35840
(F1
F0.00014334862385321102
I1
I0
I1
tp35841
sS'cyp2c8,cyp2c9'
p35842
(F1
F0.00014334862385321102
I0
I1
I-1
tp35843
sS'myasthenia,gravis'
p35844
(F1
F0.00014334862385321102
I1
I0
I1
tp35845
sS'kcl,mmol'
p35846
(F1
F0.00014334862385321102
I0
I1
I-1
tp35847
sS'a,dose-dependent'
p35848
(F1
F0.00071674311926605509
I5
I0
I5
tp35849
sS'and,antithrombin'
p35850
(F1
F0.00014334862385321102
I0
I1
I-1
tp35851
sS'addition,is'
p35852
(F1
F0.00014334862385321102
I0
I1
I-1
tp35853
sS'is,unlikely'
p35854
(F1
F0.0014334862385321102
I0
I10
I-10
tp35855
sS'and,mepron'
p35856
(F1
F0.00014334862385321102
I1
I0
I1
tp35857
sS'activity,eg'
p35858
(F1
F0.00028669724770642203
I2
I0
I2
tp35859
sS'ritonavir,coadministration'
p35860
(F1
F0.00014334862385321102
I1
I0
I1
tp35861
sS'are,either'
p35862
(F1
F0.00014334862385321102
I1
I0
I1
tp35863
sS'smaller,doses'
p35864
(F1
F0.00014334862385321102
I1
I0
I1
tp35865
sS'unsatisfactory,lipid'
p35866
(F1
F0.00014334862385321102
I1
I0
I1
tp35867
sS'biopharmaceutical,properties'
p35868
(F1
F0.00014334862385321102
I0
I1
I-1
tp35869
sS'of,orencia'
p35870
(F1
F0.00014334862385321102
I1
I0
I1
tp35871
sS'to,effects'
p35872
(F1
F0.00014334862385321102
I1
I0
I1
tp35873
sS'considerably,lower'
p35874
(F1
F0.00057339449541284407
I4
I0
I4
tp35875
sS'bleeding,in'
p35876
(F1
F0.00014334862385321102
I1
I0
I1
tp35877
sS'gastrointestinal,secretion'
p35878
(F1
F0.00014334862385321102
I1
I0
I1
tp35879
sS'extremities,and'
p35880
(F1
F0.00014334862385321102
I0
I1
I-1
tp35881
sS'and,diabetic'
p35882
(F1
F0.00014334862385321102
I0
I1
I-1
tp35883
sS'bleeding,if'
p35884
(F1
F0.00014334862385321102
I1
I0
I1
tp35885
sS'concentrate,should'
p35886
(F1
F0.00014334862385321102
I1
I0
I1
tp35887
sS'using,should'
p35888
(F1
F0.00014334862385321102
I1
I0
I1
tp35889
sS'bleeding,is'
p35890
(F1
F0.00014334862385321102
I0
I1
I-1
tp35891
sS'and,anticoagulants'
p35892
(F1
F0.00014334862385321102
I1
I0
I1
tp35893
sS'this,potentiation'
p35894
(F1
F0.00014334862385321102
I1
I0
I1
tp35895
sS'regimens,was'
p35896
(F1
F0.00014334862385321102
I0
I1
I-1
tp35897
sS'inhibitors,acetylsalicylic'
p35898
(F1
F0.00014334862385321102
I0
I1
I-1
tp35899
sS'amphetamines,can'
p35900
(F1
F0.00014334862385321102
I1
I0
I1
tp35901
sS'which,causes'
p35902
(F1
F0.00014334862385321102
I1
I0
I1
tp35903
sS'humans,have'
p35904
(F1
F0.00043004587155963305
I0
I3
I-3
tp35905
sS'are,hypersensitive'
p35906
(F1
F0.00014334862385321102
I1
I0
I1
tp35907
sS'however,ldl-c'
p35908
(F1
F0.00014334862385321102
I1
I0
I1
tp35909
sS'we,report'
p35910
(F1
F0.00014334862385321102
I1
I0
I1
tp35911
sS'expected,to'
p35912
(F0.25
F0.0008600917431192661
I15
I9
I6
tp35913
sS'weakness,may'
p35914
(F1
F0.00014334862385321102
I1
I0
I1
tp35915
sS'three-fold,compared'
p35916
(F1
F0.00014334862385321102
I0
I1
I-1
tp35917
sS'requiring,an'
p35918
(F1
F0.00014334862385321102
I1
I0
I1
tp35919
sS'fed,further'
p35920
(F1
F0.00014334862385321102
I0
I1
I-1
tp35921
sS'not,reported'
p35922
(F1
F0.00028669724770642203
I2
I0
I2
tp35923
sS'major,clinical'
p35924
(F1
F0.00014334862385321102
I1
I0
I1
tp35925
sS'female,volunteers'
p35926
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35927
sS'several,clinically'
p35928
(F1
F0.00014334862385321102
I0
I1
I-1
tp35929
sS'minimal,effects'
p35930
(F1
F0.00014334862385321102
I0
I1
I-1
tp35931
sS'v,and'
p35932
(F1
F0.00014334862385321102
I0
I1
I-1
tp35933
sS'substantially,greater'
p35934
(F1
F0.00014334862385321102
I0
I1
I-1
tp35935
sS'a,recent'
p35936
(F1
F0.00028669724770642203
I2
I0
I2
tp35937
sS'this,appears'
p35938
(F1
F0.00014334862385321102
I1
I0
I1
tp35939
sS'found,that'
p35940
(F1
F0.00014334862385321102
I1
I0
I1
tp35941
sS'bleeding,have'
p35942
(F1
F0.00028669724770642203
I2
I0
I2
tp35943
sS'inhibit,accumulation'
p35944
(F1
F0.00014334862385321102
I1
I0
I1
tp35945
sS'metabolism,due'
p35946
(F1
F0.00014334862385321102
I1
I0
I1
tp35947
sS'on,placental'
p35948
(F1
F0.00014334862385321102
I0
I1
I-1
tp35949
sS'creatinine,and'
p35950
(F1
F0.00028669724770642203
I2
I0
I2
tp35951
sS'a,precipitous'
p35952
(F1
F0.00014334862385321102
I1
I0
I1
tp35953
sS'antagonists,co-administration'
p35954
(F1
F0.00014334862385321102
I1
I0
I1
tp35955
sS'exhibit,a'
p35956
(F1
F0.00014334862385321102
I1
I0
I1
tp35957
sS'significance,is'
p35958
(F0
F0
I1
I1
I0
tp35959
sS'these,six'
p35960
(F1
F0.00014334862385321102
I0
I1
I-1
tp35961
sS'lodine,should'
p35962
(F1
F0.00014334862385321102
I0
I1
I-1
tp35963
sS'results,regarding'
p35964
(F1
F0.00014334862385321102
I1
I0
I1
tp35965
sS'agents,amphotericin'
p35966
(F1
F0.00014334862385321102
I1
I0
I1
tp35967
sS'control,rats'
p35968
(F1
F0.00014334862385321102
I0
I1
I-1
tp35969
sS'raise,the'
p35970
(F1
F0.00043004587155963305
I3
I0
I3
tp35971
sS'receiving,could'
p35972
(F1
F0.00014334862385321102
I0
I1
I-1
tp35973
sS'the,cure'
p35974
(F0
F0
I1
I1
I0
tp35975
sS'concentrations,has'
p35976
(F1
F0.00043004587155963305
I0
I3
I-3
tp35977
sS'paralytic,ileus'
p35978
(F1
F0.00014334862385321102
I1
I0
I1
tp35979
sS'was,taking'
p35980
(F1
F0.00014334862385321102
I0
I1
I-1
tp35981
sS'intramuscular,doses'
p35982
(F1
F0.00014334862385321102
I0
I1
I-1
tp35983
sS'novoseven,and'
p35984
(F1
F0.00014334862385321102
I0
I1
I-1
tp35985
sS'argatroban,and'
p35986
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp35987
sS'as,they'
p35988
(F0.5
F0.00028669724770642203
I3
I1
I2
tp35989
sS'toxicity,from'
p35990
(F1
F0.00014334862385321102
I0
I1
I-1
tp35991
sS'short-acting,inhaled'
p35992
(F1
F0.00014334862385321102
I0
I1
I-1
tp35993
sS'conducted,between'
p35994
(F1
F0.00014334862385321102
I1
I0
I1
tp35995
sS'in,toxicity'
p35996
(F1
F0.00014334862385321102
I1
I0
I1
tp35997
sS'antidepressant,class'
p35998
(F1
F0.00028669724770642203
I0
I2
I-2
tp35999
sS'agents,particularly'
p36000
(F1
F0.00014334862385321102
I1
I0
I1
tp36001
sS'decreased,mean'
p36002
(F1
F0.00014334862385321102
I1
I0
I1
tp36003
sS'must,elapse'
p36004
(F1
F0.00014334862385321102
I1
I0
I1
tp36005
sS'doubling,of'
p36006
(F1
F0.00014334862385321102
I1
I0
I1
tp36007
sS'substrate,for'
p36008
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp36009
sS'from,breast'
p36010
(F1
F0.00014334862385321102
I0
I1
I-1
tp36011
sS'max,and'
p36012
(F1
F0.00014334862385321102
I0
I1
I-1
tp36013
sS'between,argatroban'
p36014
(F1
F0.00043004587155963305
I0
I3
I-3
tp36015
sS'hypotension,seen'
p36016
(F1
F0.00014334862385321102
I1
I0
I1
tp36017
sS'and,irrational'
p36018
(F1
F0.00014334862385321102
I1
I0
I1
tp36019
sS'for,potentially'
p36020
(F1
F0.00014334862385321102
I1
I0
I1
tp36021
sS'receiving,should'
p36022
(F1
F0.00014334862385321102
I1
I0
I1
tp36023
sS'interactions,noted'
p36024
(F1
F0.00014334862385321102
I0
I1
I-1
tp36025
sS'be,halved'
p36026
(F1
F0.00014334862385321102
I1
I0
I1
tp36027
sS'for,excretion'
p36028
(F1
F0.00014334862385321102
I1
I0
I1
tp36029
sS'where,iressa'
p36030
(F1
F0.00014334862385321102
I1
I0
I1
tp36031
sS'divided,attention'
p36032
(F1
F0.00014334862385321102
I1
I0
I1
tp36033
sS'an,deficiency'
p36034
(F1
F0.00014334862385321102
I1
I0
I1
tp36035
sS'tmp,and'
p36036
(F1
F0.00014334862385321102
I0
I1
I-1
tp36037
sS'pathway,for'
p36038
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36039
sS'doctor,if'
p36040
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36041
sS'with,krm-1648'
p36042
(F1
F0.00014334862385321102
I1
I0
I1
tp36043
sS'times,the'
p36044
(F0
F0
I2
I2
I0
tp36045
sS'and,careful'
p36046
(F0
F0
I2
I2
I0
tp36047
sS'the,interactions'
p36048
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36049
sS'mefenamic,acid'
p36050
(F1
F0.00028669724770642203
I2
I0
I2
tp36051
sS'see,if'
p36052
(F1
F0.00014334862385321102
I1
I0
I1
tp36053
sS'an,arbutamine-mediated'
p36054
(F1
F0.00014334862385321102
I1
I0
I1
tp36055
sS'results,the'
p36056
(F1
F0.00014334862385321102
I1
I0
I1
tp36057
sS'receive,tablets'
p36058
(F1
F0.00014334862385321102
I0
I1
I-1
tp36059
sS'chronic,concurrent'
p36060
(F1
F0.00014334862385321102
I1
I0
I1
tp36061
sS'nanm,were'
p36062
(F0
F0
I1
I1
I0
tp36063
sS'the,sirolimus-diltiazem'
p36064
(F1
F0.00014334862385321102
I1
I0
I1
tp36065
sS'test,was'
p36066
(F1
F0.00014334862385321102
I0
I1
I-1
tp36067
sS'acid,hepatotoxic'
p36068
(F1
F0.00014334862385321102
I1
I0
I1
tp36069
sS'with,viracept'
p36070
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp36071
sS'threshold,voltage-dependent'
p36072
(F1
F0.00014334862385321102
I0
I1
I-1
tp36073
sS'nonlinear,kinetic'
p36074
(F1
F0.00014334862385321102
I0
I1
I-1
tp36075
sS'acid,increased'
p36076
(F1
F0.00014334862385321102
I1
I0
I1
tp36077
sS'decrease,serum'
p36078
(F1
F0.00028669724770642203
I2
I0
I2
tp36079
sS'channels,in'
p36080
(F1
F0.00014334862385321102
I0
I1
I-1
tp36081
sS'probably,at'
p36082
(F1
F0.00014334862385321102
I1
I0
I1
tp36083
sS'esomeprazole,may'
p36084
(F1
F0.00014334862385321102
I0
I1
I-1
tp36085
sS'while,in'
p36086
(F1
F0.00014334862385321102
I0
I1
I-1
tp36087
sS'opioid,analgesics'
p36088
(F1
F0.00014334862385321102
I1
I0
I1
tp36089
sS'prospective,clinical'
p36090
(F1
F0.00014334862385321102
I0
I1
I-1
tp36091
sS'partially,impaired'
p36092
(F1
F0.00014334862385321102
I0
I1
I-1
tp36093
sS'sodium,including'
p36094
(F1
F0.00028669724770642203
I2
I0
I2
tp36095
sS'to,other'
p36096
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36097
sS'the,ph'
p36098
(F1
F0.00014334862385321102
I1
I0
I1
tp36099
sS'however,reduced'
p36100
(F1
F0.00014334862385321102
I1
I0
I1
tp36101
sS'are,employed'
p36102
(F1
F0.00014334862385321102
I1
I0
I1
tp36103
sS'if,possible'
p36104
(F1
F0.00028669724770642203
I2
I0
I2
tp36105
sS'nsaids,like'
p36106
(F1
F0.00014334862385321102
I1
I0
I1
tp36107
sS'benefit,of'
p36108
(F1
F0.00014334862385321102
I1
I0
I1
tp36109
sS'red,blood'
p36110
(F1
F0.00014334862385321102
I0
I1
I-1
tp36111
sS'with,commonly'
p36112
(F1
F0.00014334862385321102
I0
I1
I-1
tp36113
sS'metabolism,by'
p36114
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp36115
sS'medicine,that'
p36116
(F1
F0.00014334862385321102
I1
I0
I1
tp36117
sS'a,study'
p36118
(F0.22222222222222221
F0.0011467889908256881
I22
I14
I8
tp36119
sS'study,rats'
p36120
(F1
F0.00014334862385321102
I1
I0
I1
tp36121
sS'acetazolamide,azole'
p36122
(F1
F0.00014334862385321102
I1
I0
I1
tp36123
sS'mask,the'
p36124
(F0
F0
I1
I1
I0
tp36125
sS'with,angina'
p36126
(F1
F0.00014334862385321102
I1
I0
I1
tp36127
sS'deaths,from'
p36128
(F1
F0.00014334862385321102
I1
I0
I1
tp36129
sS'frequent,cause'
p36130
(F1
F0.00014334862385321102
I1
I0
I1
tp36131
sS'employing,mtc-mdp'
p36132
(F1
F0.00014334862385321102
I0
I1
I-1
tp36133
sS'than,recommended'
p36134
(F1
F0.00014334862385321102
I1
I0
I1
tp36135
sS'relaxant,effect'
p36136
(F1
F0.00014334862385321102
I1
I0
I1
tp36137
sS'environmental,may'
p36138
(F1
F0.00014334862385321102
I1
I0
I1
tp36139
sS'its,lack'
p36140
(F1
F0.00043004587155963305
I0
I3
I-3
tp36141
sS'of,steady-state'
p36142
(F1
F0.00028669724770642203
I0
I2
I-2
tp36143
sS'cause,additive'
p36144
(F1
F0.00014334862385321102
I1
I0
I1
tp36145
sS'contraception,inwomen'
p36146
(F1
F0.00014334862385321102
I1
I0
I1
tp36147
sS'calcium,antagonists'
p36148
(F1
F0.00014334862385321102
I1
I0
I1
tp36149
sS'sensitivity,of'
p36150
(F1
F0.00014334862385321102
I0
I1
I-1
tp36151
sS'chemotherapy,regimen'
p36152
(F1
F0.00014334862385321102
I0
I1
I-1
tp36153
sS'with,extracellular'
p36154
(F1
F0.00014334862385321102
I1
I0
I1
tp36155
sS'reduced,interaction'
p36156
(F1
F0.00014334862385321102
I0
I1
I-1
tp36157
sS'to,determine'
p36158
(F0
F0
I8
I8
I0
tp36159
sS'calcium-entry,blocking'
p36160
(F1
F0.00014334862385321102
I0
I1
I-1
tp36161
sS'increasing,the'
p36162
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp36163
sS'lanoxin,lanoxicaps'
p36164
(F1
F0.00014334862385321102
I1
I0
I1
tp36165
sS'the,nephrotoxicity'
p36166
(F1
F0.00014334862385321102
I1
I0
I1
tp36167
sS'that,peak'
p36168
(F1
F0.00014334862385321102
I0
I1
I-1
tp36169
sS'according,to'
p36170
(F1
F0.00014334862385321102
I1
I0
I1
tp36171
sS'on,chronic'
p36172
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp36173
sS'day,with'
p36174
(F1
F0.00014334862385321102
I1
I0
I1
tp36175
sS'in,mind'
p36176
(F0
F0
I2
I2
I0
tp36177
sS'than,and'
p36178
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp36179
sS'incompatibility,of'
p36180
(F1
F0.00028669724770642203
I0
I2
I-2
tp36181
sS'inhibitor,is'
p36182
(F1
F0.00014334862385321102
I1
I0
I1
tp36183
sS'inhibitor,it'
p36184
(F1
F0.00014334862385321102
I1
I0
I1
tp36185
sS'capsules,mg'
p36186
(F0
F0
I1
I1
I0
tp36187
sS'had,depleting'
p36188
(F1
F0.00014334862385321102
I0
I1
I-1
tp36189
sS'polyphenols,as'
p36190
(F1
F0.00014334862385321102
I0
I1
I-1
tp36191
sS'inhibitor,in'
p36192
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36193
sS'drugs,with'
p36194
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36195
sS'in,surgery'
p36196
(F1
F0.00014334862385321102
I0
I1
I-1
tp36197
sS'test,agent'
p36198
(F1
F0.00014334862385321102
I0
I1
I-1
tp36199
sS'and,infusion'
p36200
(F1
F0.00014334862385321102
I1
I0
I1
tp36201
sS'moreover,the'
p36202
(F1
F0.00014334862385321102
I0
I1
I-1
tp36203
sS'was,made'
p36204
(F1
F0.00014334862385321102
I0
I1
I-1
tp36205
sS'the,disruptive'
p36206
(F1
F0.00014334862385321102
I1
I0
I1
tp36207
sS'having,similar'
p36208
(F1
F0.00014334862385321102
I1
I0
I1
tp36209
sS'occur,at'
p36210
(F1
F0.00014334862385321102
I0
I1
I-1
tp36211
sS'relaxants,has'
p36212
(F1
F0.00014334862385321102
I0
I1
I-1
tp36213
sS'phencyclidine,pcp'
p36214
(F1
F0.00014334862385321102
I0
I1
I-1
tp36215
sS'or,peripheral'
p36216
(F1
F0.00014334862385321102
I0
I1
I-1
tp36217
sS'given,should'
p36218
(F1
F0.00028669724770642203
I2
I0
I2
tp36219
sS'possible,pharmacodynamic'
p36220
(F1
F0.00014334862385321102
I1
I0
I1
tp36221
sS'sular,with'
p36222
(F1
F0.00014334862385321102
I1
I0
I1
tp36223
sS'experience,a'
p36224
(F1
F0.00028669724770642203
I2
I0
I2
tp36225
sS'the,stimulatory'
p36226
(F1
F0.00014334862385321102
I1
I0
I1
tp36227
sS'therapy,such'
p36228
(F1
F0.00014334862385321102
I1
I0
I1
tp36229
sS'nizoral,muscle'
p36230
(F1
F0.00014334862385321102
I0
I1
I-1
tp36231
sS'tambocor,clinical'
p36232
(F1
F0.00014334862385321102
I0
I1
I-1
tp36233
sS'insulin,a'
p36234
(F1
F0.00014334862385321102
I0
I1
I-1
tp36235
sS'subsequent,diagnostic'
p36236
(F1
F0.00014334862385321102
I0
I1
I-1
tp36237
sS'potential,prolonged'
p36238
(F1
F0.00014334862385321102
I0
I1
I-1
tp36239
sS'patient,to'
p36240
(F1
F0.00014334862385321102
I1
I0
I1
tp36241
sS'however,preliminary'
p36242
(F1
F0.00014334862385321102
I0
I1
I-1
tp36243
sS'and,veratrum'
p36244
(F1
F0.00014334862385321102
I1
I0
I1
tp36245
sS'with,accutane'
p36246
(F1
F0.00014334862385321102
I1
I0
I1
tp36247
sS'and,norethindrone'
p36248
(F1
F0.00014334862385321102
I1
I0
I1
tp36249
sS'at,either'
p36250
(F1
F0.00014334862385321102
I0
I1
I-1
tp36251
sS'and,arthralgia'
p36252
(F1
F0.00014334862385321102
I1
I0
I1
tp36253
sS'intravenous,sodium'
p36254
(F0
F0
I1
I1
I0
tp36255
sS'advised,in'
p36256
(F1
F0.00057339449541284407
I4
I0
I4
tp36257
sS'p-aminosalicylic,acid'
p36258
(F1
F0.00014334862385321102
I0
I1
I-1
tp36259
sS'experience,increased'
p36260
(F1
F0.00014334862385321102
I0
I1
I-1
tp36261
sS'easy,and'
p36262
(F1
F0.00014334862385321102
I0
I1
I-1
tp36263
sS'studies,with'
p36264
(F0.5
F0.0017201834862385322
I6
I18
I-12
tp36265
sS'hivid,has'
p36266
(F1
F0.00014334862385321102
I1
I0
I1
tp36267
sS'pemphigoid,and'
p36268
(F1
F0.00014334862385321102
I1
I0
I1
tp36269
sS'proteins,or'
p36270
(F1
F0.00014334862385321102
I1
I0
I1
tp36271
sS'effect,of'
p36272
(F0.055214723926380369
F0.0012901376146788992
I86
I77
I9
tp36273
sS'with,potassium-sparing'
p36274
(F1
F0.00014334862385321102
I1
I0
I1
tp36275
sS'effect,on'
p36276
(F0.52380952380952384
F0.0078841743119266051
I25
I80
I-55
tp36277
sS'of,methotrexate-related'
p36278
(F1
F0.00028669724770642203
I2
I0
I2
tp36279
sS'of,spontaneous'
p36280
(F1
F0.00028669724770642203
I2
I0
I2
tp36281
sS'an,anionic-binding'
p36282
(F1
F0.00014334862385321102
I1
I0
I1
tp36283
sS'inspra,and'
p36284
(F1
F0.00014334862385321102
I1
I0
I1
tp36285
sS'area,under'
p36286
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp36287
sS'proportion,to'
p36288
(F1
F0.00014334862385321102
I0
I1
I-1
tp36289
sS'is,inadvisable'
p36290
(F1
F0.00014334862385321102
I1
I0
I1
tp36291
sS'diminish,or'
p36292
(F1
F0.00014334862385321102
I1
I0
I1
tp36293
sS'iv,myocardium'
p36294
(F1
F0.00014334862385321102
I0
I1
I-1
tp36295
sS'it,may'
p36296
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp36297
sS'monitored,closely'
p36298
(F0.5
F0.00057339449541284407
I6
I2
I4
tp36299
sS'zollinger-ellison,ze'
p36300
(F1
F0.00014334862385321102
I0
I1
I-1
tp36301
sS'also,result'
p36302
(F1
F0.00057339449541284407
I4
I0
I4
tp36303
sS'including,both'
p36304
(F1
F0.00014334862385321102
I1
I0
I1
tp36305
sS'kg,via'
p36306
(F1
F0.00014334862385321102
I1
I0
I1
tp36307
sS'alone,can'
p36308
(F0
F0
I1
I1
I0
tp36309
sS'alternatively,the'
p36310
(F1
F0.00014334862385321102
I0
I1
I-1
tp36311
sS'and,subsalicylate'
p36312
(F1
F0.00014334862385321102
I1
I0
I1
tp36313
sS'protein,and'
p36314
(F1
F0.00014334862385321102
I0
I1
I-1
tp36315
sS'or,altering'
p36316
(F1
F0.00014334862385321102
I0
I1
I-1
tp36317
sS'inhibit,cyp3a'
p36318
(F1
F0.00014334862385321102
I0
I1
I-1
tp36319
sS'about,times'
p36320
(F1
F0.00014334862385321102
I0
I1
I-1
tp36321
sS'conversion,could'
p36322
(F1
F0.00014334862385321102
I0
I1
I-1
tp36323
sS'precede,dosing'
p36324
(F1
F0.00014334862385321102
I0
I1
I-1
tp36325
sS'potassium-depleting,are'
p36326
(F1
F0.00014334862385321102
I1
I0
I1
tp36327
sS'effect,although'
p36328
(F1
F0.00014334862385321102
I0
I1
I-1
tp36329
sS'adrenergic,are'
p36330
(F1
F0.00014334862385321102
I1
I0
I1
tp36331
sS'we,examined'
p36332
(F1
F0.00028669724770642203
I0
I2
I-2
tp36333
sS'the,several-fold'
p36334
(F1
F0.00014334862385321102
I0
I1
I-1
tp36335
sS'a4,but'
p36336
(F1
F0.00014334862385321102
I0
I1
I-1
tp36337
sS'warned,of'
p36338
(F1
F0.00014334862385321102
I1
I0
I1
tp36339
sS'stable,therapy'
p36340
(F1
F0.00014334862385321102
I0
I1
I-1
tp36341
sS'premature,ventricular'
p36342
(F1
F0.00014334862385321102
I0
I1
I-1
tp36343
sS'altered,decrease'
p36344
(F1
F0.00014334862385321102
I1
I0
I1
tp36345
sS'were,and'
p36346
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp36347
sS'sigma-2,receptors'
p36348
(F1
F0.00014334862385321102
I0
I1
I-1
tp36349
sS'kind,with'
p36350
(F1
F0.00014334862385321102
I1
I0
I1
tp36351
sS'whether,to'
p36352
(F1
F0.00014334862385321102
I0
I1
I-1
tp36353
sS'between,revia'
p36354
(F1
F0.00014334862385321102
I0
I1
I-1
tp36355
sS'stomach,to'
p36356
(F1
F0.00014334862385321102
I1
I0
I1
tp36357
sS'from,severe'
p36358
(F1
F0.00014334862385321102
I1
I0
I1
tp36359
sS'may,activate'
p36360
(F1
F0.00014334862385321102
I0
I1
I-1
tp36361
sS'partly,antagonized'
p36362
(F1
F0.00014334862385321102
I1
I0
I1
tp36363
sS'action,on'
p36364
(F0
F0
I2
I2
I0
tp36365
sS'action,of'
p36366
(F0.64444444444444449
F0.0041571100917431195
I37
I8
I29
tp36367
sS'estimated,number'
p36368
(F1
F0.00014334862385321102
I0
I1
I-1
tp36369
sS'were,stabilized'
p36370
(F1
F0.00028669724770642203
I0
I2
I-2
tp36371
sS'phenytoin,protease'
p36372
(F1
F0.00014334862385321102
I1
I0
I1
tp36373
sS'myocarditis,ventricular'
p36374
(F1
F0.00014334862385321102
I1
I0
I1
tp36375
sS'and,antagonists'
p36376
(F1
F0.00028669724770642203
I2
I0
I2
tp36377
sS'and,ischemia'
p36378
(F1
F0.00014334862385321102
I0
I1
I-1
tp36379
sS'action,or'
p36380
(F1
F0.00028669724770642203
I0
I2
I-2
tp36381
sS'monooxygenase,activities'
p36382
(F1
F0.00014334862385321102
I0
I1
I-1
tp36383
sS'or,multiple'
p36384
(F1
F0.00014334862385321102
I0
I1
I-1
tp36385
sS'prostatic,hyperplasia'
p36386
(F1
F0.00014334862385321102
I0
I1
I-1
tp36387
sS'the,anxiogenic'
p36388
(F1
F0.00014334862385321102
I1
I0
I1
tp36389
sS'hours,does'
p36390
(F1
F0.00028669724770642203
I2
I0
I2
tp36391
sS'be,transiently'
p36392
(F1
F0.00014334862385321102
I0
I1
I-1
tp36393
sS'showed,the'
p36394
(F1
F0.00014334862385321102
I0
I1
I-1
tp36395
sS'the,hydroxytamoxifen'
p36396
(F1
F0.00014334862385321102
I0
I1
I-1
tp36397
sS'increased,when'
p36398
(F1
F0.00071674311926605509
I5
I0
I5
tp36399
sS'and,racemic'
p36400
(F1
F0.00014334862385321102
I0
I1
I-1
tp36401
sS'oral,with'
p36402
(F1
F0.00028669724770642203
I2
I0
I2
tp36403
sS'and,partly'
p36404
(F1
F0.00014334862385321102
I1
I0
I1
tp36405
sS'alternative,or'
p36406
(F1
F0.00014334862385321102
I1
I0
I1
tp36407
sS'cmi,because'
p36408
(F1
F0.00014334862385321102
I1
I0
I1
tp36409
sS'estimates,of'
p36410
(F1
F0.00014334862385321102
I0
I1
I-1
tp36411
sS'linked,to'
p36412
(F1
F0.00014334862385321102
I0
I1
I-1
tp36413
sS'depressants,other'
p36414
(F1
F0.00014334862385321102
I0
I1
I-1
tp36415
sS'containing,mg'
p36416
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp36417
sS'resveratrol,micromol'
p36418
(F1
F0.00014334862385321102
I0
I1
I-1
tp36419
sS'myopathy,which'
p36420
(F1
F0.00014334862385321102
I0
I1
I-1
tp36421
sS'initiation,of'
p36422
(F0.46153846153846156
F0.0017201834862385322
I19
I7
I12
tp36423
sS'first-pass,metabolism'
p36424
(F1
F0.00014334862385321102
I0
I1
I-1
tp36425
sS'acute,administration'
p36426
(F1
F0.00014334862385321102
I0
I1
I-1
tp36427
sS'to,deaths'
p36428
(F1
F0.00014334862385321102
I0
I1
I-1
tp36429
sS'given,both'
p36430
(F1
F0.00014334862385321102
I1
I0
I1
tp36431
sS'gleevec,oral-dose'
p36432
(F1
F0.00014334862385321102
I1
I0
I1
tp36433
sS'epidural,local'
p36434
(F1
F0.00014334862385321102
I1
I0
I1
tp36435
sS'may,subsequently'
p36436
(F1
F0.00014334862385321102
I0
I1
I-1
tp36437
sS'a,nonlethal'
p36438
(F0
F0
I1
I1
I0
tp36439
sS'respectively,and'
p36440
(F1
F0.00057339449541284407
I4
I0
I4
tp36441
sS'recent,case'
p36442
(F1
F0.00014334862385321102
I1
I0
I1
tp36443
sS'lotensin,can'
p36444
(F1
F0.00028669724770642203
I2
I0
I2
tp36445
sS'mao-b,inhibitor'
p36446
(F1
F0.00014334862385321102
I0
I1
I-1
tp36447
sS'synthesis,in'
p36448
(F1
F0.00014334862385321102
I0
I1
I-1
tp36449
sS'lexapro,is'
p36450
(F1
F0.00014334862385321102
I1
I0
I1
tp36451
sS'synthesis,it'
p36452
(F1
F0.00014334862385321102
I1
I0
I1
tp36453
sS'high,dose'
p36454
(F1
F0.00043004587155963305
I3
I0
I3
tp36455
sS'propoxyphene,in'
p36456
(F1
F0.00028669724770642203
I2
I0
I2
tp36457
sS'the,probable'
p36458
(F1
F0.00014334862385321102
I1
I0
I1
tp36459
sS'mean,steady-state'
p36460
(F0
F0
I1
I1
I0
tp36461
sS'furosemide,administered'
p36462
(F1
F0.00014334862385321102
I0
I1
I-1
tp36463
sS'diethyl,pyrocarbonate'
p36464
(F1
F0.00057339449541284407
I0
I4
I-4
tp36465
sS'the,resolution'
p36466
(F1
F0.00014334862385321102
I1
I0
I1
tp36467
sS'when,beginning'
p36468
(F1
F0.00014334862385321102
I1
I0
I1
tp36469
sS'not,inhibitory'
p36470
(F1
F0.00014334862385321102
I0
I1
I-1
tp36471
sS'cevimeline,should'
p36472
(F1
F0.00014334862385321102
I1
I0
I1
tp36473
sS'vascular,dilation'
p36474
(F1
F0.00014334862385321102
I1
I0
I1
tp36475
sS'not,inhibitors'
p36476
(F1
F0.00014334862385321102
I0
I1
I-1
tp36477
sS'pra,as'
p36478
(F1
F0.00014334862385321102
I0
I1
I-1
tp36479
sS'attenuated,the'
p36480
(F1
F0.00028669724770642203
I2
I0
I2
tp36481
sS'as,sulfamethoxazole-trimethoprim'
p36482
(F1
F0.00014334862385321102
I0
I1
I-1
tp36483
sS'lower,plasma'
p36484
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp36485
sS'will,depend'
p36486
(F1
F0.00071674311926605509
I5
I0
I5
tp36487
sS'commonly,in'
p36488
(F1
F0.00014334862385321102
I1
I0
I1
tp36489
sS'sequestrants,may'
p36490
(F1
F0.00014334862385321102
I1
I0
I1
tp36491
sS'cholestyramine,the'
p36492
(F1
F0.00014334862385321102
I0
I1
I-1
tp36493
sS'responses,being'
p36494
(F1
F0.00014334862385321102
I0
I1
I-1
tp36495
sS'agents,of'
p36496
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36497
sS'is,changed'
p36498
(F1
F0.00014334862385321102
I1
I0
I1
tp36499
sS'or,stopping'
p36500
(F1
F0.00014334862385321102
I1
I0
I1
tp36501
sS'agents,or'
p36502
(F0.25
F0.00028669724770642203
I5
I3
I2
tp36503
sS'a,rauwolfia'
p36504
(F1
F0.00014334862385321102
I1
I0
I1
tp36505
sS'of,min'
p36506
(F1
F0.00028669724770642203
I2
I0
I2
tp36507
sS'muscle,relaxing'
p36508
(F1
F0.00014334862385321102
I1
I0
I1
tp36509
sS'contraceptives,a'
p36510
(F1
F0.00014334862385321102
I0
I1
I-1
tp36511
sS'atracurium,was'
p36512
(F1
F0.00014334862385321102
I0
I1
I-1
tp36513
sS'cups,of'
p36514
(F1
F0.00014334862385321102
I0
I1
I-1
tp36515
sS'that,this'
p36516
(F1
F0.00028669724770642203
I0
I2
I-2
tp36517
sS'day,when'
p36518
(F1
F0.00043004587155963305
I3
I0
I3
tp36519
sS'taking,an'
p36520
(F1
F0.00014334862385321102
I1
I0
I1
tp36521
sS'subjects,and'
p36522
(F1
F0.00014334862385321102
I1
I0
I1
tp36523
sS'levels,increased'
p36524
(F1
F0.00028669724770642203
I2
I0
I2
tp36525
sS'withdrawal,syndrome'
p36526
(F1
F0.00014334862385321102
I1
I0
I1
tp36527
sS'events,were'
p36528
(F1
F0.00014334862385321102
I1
I0
I1
tp36529
sS'and,clotibrate'
p36530
(F1
F0.00014334862385321102
I0
I1
I-1
tp36531
sS'as,might'
p36532
(F1
F0.00014334862385321102
I1
I0
I1
tp36533
sS'and,hivid'
p36534
(F1
F0.00014334862385321102
I1
I0
I1
tp36535
sS'patient,on'
p36536
(F1
F0.00028669724770642203
I2
I0
I2
tp36537
sS'the,translocating'
p36538
(F1
F0.00014334862385321102
I0
I1
I-1
tp36539
sS'on,absorption'
p36540
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp36541
sS'does,not'
p36542
(F0.82456140350877194
F0.0067373853211009178
I5
I52
I-47
tp36543
sS'system,is'
p36544
(F1
F0.00014334862385321102
I0
I1
I-1
tp36545
sS'conditions,concentrations'
p36546
(F1
F0.00014334862385321102
I0
I1
I-1
tp36547
sS'stomach,drugs'
p36548
(F1
F0.00014334862385321102
I1
I0
I1
tp36549
sS'not,affect'
p36550
(F0.82608695652173914
F0.0054472477064220187
I4
I42
I-38
tp36551
sS'delirium,high'
p36552
(F1
F0.00014334862385321102
I1
I0
I1
tp36553
sS'two,medicines'
p36554
(F1
F0.00014334862385321102
I1
I0
I1
tp36555
sS'effectively,and'
p36556
(F1
F0.00014334862385321102
I0
I1
I-1
tp36557
sS'of,dynacirc'
p36558
(F1
F0.00028669724770642203
I0
I2
I-2
tp36559
sS'agents,prinivil'
p36560
(F1
F0.00014334862385321102
I0
I1
I-1
tp36561
sS'kill,curves'
p36562
(F1
F0.00014334862385321102
I1
I0
I1
tp36563
sS'of,wellbutrin'
p36564
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36565
sS'and,weight'
p36566
(F1
F0.00028669724770642203
I2
I0
I2
tp36567
sS'cytochrome,p450'
p36568
(F0.40540540540540543
F0.0021502293577981653
I11
I26
I-15
tp36569
sS'alpha-,or'
p36570
(F1
F0.00014334862385321102
I0
I1
I-1
tp36571
sS'avoided,when'
p36572
(F1
F0.00014334862385321102
I1
I0
I1
tp36573
sS'rifampin,is'
p36574
(F1
F0.00014334862385321102
I0
I1
I-1
tp36575
sS'with,wellbutrin'
p36576
(F1
F0.00014334862385321102
I1
I0
I1
tp36577
sS'sodium,from'
p36578
(F1
F0.00014334862385321102
I1
I0
I1
tp36579
sS'hormone,response'
p36580
(F1
F0.00014334862385321102
I1
I0
I1
tp36581
sS'johns,wort'
p36582
(F0
F0
I1
I1
I0
tp36583
sS'coadministered,steady-state'
p36584
(F1
F0.00014334862385321102
I1
I0
I1
tp36585
sS'gets,absorbed'
p36586
(F1
F0.00014334862385321102
I1
I0
I1
tp36587
sS'subjects,was'
p36588
(F1
F0.00014334862385321102
I1
I0
I1
tp36589
sS'grepafloxacin,is'
p36590
(F1
F0.00014334862385321102
I1
I0
I1
tp36591
sS'hydrochloride,was'
p36592
(F0
F0
I1
I1
I0
tp36593
sS'cyclic,may'
p36594
(F1
F0.00014334862385321102
I1
I0
I1
tp36595
sS'gland,who'
p36596
(F1
F0.00028669724770642203
I2
I0
I2
tp36597
sS'concomitant,hydrochloride'
p36598
(F1
F0.00014334862385321102
I0
I1
I-1
tp36599
sS'lysing,human'
p36600
(F1
F0.00014334862385321102
I0
I1
I-1
tp36601
sS'reactions,is'
p36602
(F1
F0.00014334862385321102
I1
I0
I1
tp36603
sS'constant,volume'
p36604
(F1
F0.00014334862385321102
I0
I1
I-1
tp36605
sS'effectiveness,is'
p36606
(F1
F0.00014334862385321102
I0
I1
I-1
tp36607
sS'sh,da'
p36608
(F1
F0.00014334862385321102
I0
I1
I-1
tp36609
sS'effectiveness,in'
p36610
(F1
F0.00028669724770642203
I0
I2
I-2
tp36611
sS'reactions,in'
p36612
(F1
F0.00028669724770642203
I0
I2
I-2
tp36613
sS'augmented,the'
p36614
(F1
F0.00014334862385321102
I1
I0
I1
tp36615
sS'the,pharmacology'
p36616
(F1
F0.00014334862385321102
I1
I0
I1
tp36617
sS'advised,digoxin'
p36618
(F1
F0.00014334862385321102
I0
I1
I-1
tp36619
sS'interval,whole'
p36620
(F1
F0.00014334862385321102
I1
I0
I1
tp36621
sS'displace,tightly'
p36622
(F1
F0.00014334862385321102
I0
I1
I-1
tp36623
sS'reported,itraconazole'
p36624
(F1
F0.00014334862385321102
I0
I1
I-1
tp36625
sS'other,antineoplastic'
p36626
(F1
F0.00014334862385321102
I1
I0
I1
tp36627
sS'a,vitamin'
p36628
(F0
F0
I1
I1
I0
tp36629
sS'agents,enalapril'
p36630
(F1
F0.00014334862385321102
I0
I1
I-1
tp36631
sS'in,female'
p36632
(F1
F0.00014334862385321102
I0
I1
I-1
tp36633
sS'a,follow-up'
p36634
(F1
F0.00014334862385321102
I0
I1
I-1
tp36635
sS'time-curve,increased'
p36636
(F1
F0.00014334862385321102
I1
I0
I1
tp36637
sS'of,baraclude'
p36638
(F1
F0.00028669724770642203
I0
I2
I-2
tp36639
sS'descarboethoxyloratadine,after'
p36640
(F1
F0.00014334862385321102
I0
I1
I-1
tp36641
sS'just,prior'
p36642
(F1
F0.00014334862385321102
I0
I1
I-1
tp36643
sS'any,clinically'
p36644
(F1
F0.0008600917431192661
I0
I6
I-6
tp36645
sS'as,which'
p36646
(F1
F0.00014334862385321102
I1
I0
I1
tp36647
sS'after,ethyl'
p36648
(F1
F0.00014334862385321102
I1
I0
I1
tp36649
sS'inhibitor,plus'
p36650
(F1
F0.00014334862385321102
I1
I0
I1
tp36651
sS'peptide,and'
p36652
(F1
F0.00014334862385321102
I0
I1
I-1
tp36653
sS'cholinesterase,inhibitors'
p36654
(F1
F0.00028669724770642203
I2
I0
I2
tp36655
sS'in,cases'
p36656
(F1
F0.00057339449541284407
I4
I0
I4
tp36657
sS'the,serotonergic'
p36658
(F1
F0.00014334862385321102
I1
I0
I1
tp36659
sS'been,completed'
p36660
(F1
F0.00014334862385321102
I0
I1
I-1
tp36661
sS'induced,locomotion'
p36662
(F1
F0.00014334862385321102
I0
I1
I-1
tp36663
sS'd,or'
p36664
(F0
F0
I1
I1
I0
tp36665
sS'patients,are'
p36666
(F1
F0.00043004587155963305
I3
I0
I3
tp36667
sS'conduction,through'
p36668
(F1
F0.00014334862385321102
I1
I0
I1
tp36669
sS'or,fr'
p36670
(F1
F0.00014334862385321102
I1
I0
I1
tp36671
sS'camptosar,the'
p36672
(F1
F0.00014334862385321102
I1
I0
I1
tp36673
sS'not,produce'
p36674
(F1
F0.00014334862385321102
I0
I1
I-1
tp36675
sS'ccnu,is'
p36676
(F1
F0.00014334862385321102
I0
I1
I-1
tp36677
sS'a,href'
p36678
(F1
F0.00028669724770642203
I2
I0
I2
tp36679
sS'node,function'
p36680
(F1
F0.00014334862385321102
I1
I0
I1
tp36681
sS'degrees,of'
p36682
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36683
sS'atorvastatin,atorvastatin'
p36684
(F1
F0.00014334862385321102
I1
I0
I1
tp36685
sS'is,administered'
p36686
(F0.76470588235294112
F0.0037270642201834864
I30
I4
I26
tp36687
sS'that,resemble'
p36688
(F1
F0.00014334862385321102
I0
I1
I-1
tp36689
sS'dosing,reduced'
p36690
(F1
F0.00014334862385321102
I0
I1
I-1
tp36691
sS'employed,cautiously'
p36692
(F1
F0.00014334862385321102
I0
I1
I-1
tp36693
sS'therefore,patients'
p36694
(F1
F0.00057339449541284407
I4
I0
I4
tp36695
sS'erbitux,was'
p36696
(F1
F0.00014334862385321102
I0
I1
I-1
tp36697
sS'and,min'
p36698
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36699
sS'particularly,diabetics'
p36700
(F1
F0.00014334862385321102
I1
I0
I1
tp36701
sS'contraceptives,the'
p36702
(F1
F0.00014334862385321102
I0
I1
I-1
tp36703
sS'or,clinical'
p36704
(F1
F0.00014334862385321102
I0
I1
I-1
tp36705
sS'both,and'
p36706
(F0.22222222222222221
F0.00057339449541284407
I11
I7
I4
tp36707
sS'at,arterial'
p36708
(F1
F0.00014334862385321102
I0
I1
I-1
tp36709
sS'quetiapine,fumarate'
p36710
(F1
F0.00014334862385321102
I0
I1
I-1
tp36711
sS'is,unclear'
p36712
(F1
F0.00014334862385321102
I1
I0
I1
tp36713
sS'as,one'
p36714
(F1
F0.00014334862385321102
I0
I1
I-1
tp36715
sS'since,higher'
p36716
(F1
F0.00014334862385321102
I1
I0
I1
tp36717
sS'enterococcus,three'
p36718
(F1
F0.00014334862385321102
I0
I1
I-1
tp36719
sS'that,antagonized'
p36720
(F1
F0.00014334862385321102
I1
I0
I1
tp36721
sS'qd,cohort'
p36722
(F1
F0.00014334862385321102
I0
I1
I-1
tp36723
sS'day,increased'
p36724
(F1
F0.00014334862385321102
I1
I0
I1
tp36725
sS'identified,that'
p36726
(F1
F0.00014334862385321102
I0
I1
I-1
tp36727
sS'isrecommended,in'
p36728
(F1
F0.00014334862385321102
I1
I0
I1
tp36729
sS'no,information'
p36730
(F1
F0.00043004587155963305
I0
I3
I-3
tp36731
sS'another,interaction'
p36732
(F1
F0.00014334862385321102
I1
I0
I1
tp36733
sS's,nephrotoxicity'
p36734
(F1
F0.00014334862385321102
I0
I1
I-1
tp36735
sS'fever,severe'
p36736
(F1
F0.00014334862385321102
I1
I0
I1
tp36737
sS'ml,resulted'
p36738
(F1
F0.00014334862385321102
I0
I1
I-1
tp36739
sS'the,agents'
p36740
(F1
F0.00028669724770642203
I2
I0
I2
tp36741
sS'clinical,pharmacokinetic'
p36742
(F1
F0.00014334862385321102
I0
I1
I-1
tp36743
sS'the,natriuretic'
p36744
(F1
F0.0018635321100917432
I13
I0
I13
tp36745
sS'date,has'
p36746
(F1
F0.00014334862385321102
I0
I1
I-1
tp36747
sS'appropriate,monitoring'
p36748
(F1
F0.00014334862385321102
I1
I0
I1
tp36749
sS'using,small'
p36750
(F1
F0.00014334862385321102
I1
I0
I1
tp36751
sS'loss,caused'
p36752
(F1
F0.00043004587155963305
I3
I0
I3
tp36753
sS'duragesic,transdermal'
p36754
(F1
F0.00014334862385321102
I1
I0
I1
tp36755
sS'possible,atrioventricular'
p36756
(F1
F0.00014334862385321102
I1
I0
I1
tp36757
sS'cause,coronary'
p36758
(F1
F0.00014334862385321102
I1
I0
I1
tp36759
sS'bioavailabillty,when'
p36760
(F1
F0.00014334862385321102
I1
I0
I1
tp36761
sS'off,before'
p36762
(F1
F0.00014334862385321102
I0
I1
I-1
tp36763
sS'a,starting'
p36764
(F1
F0.00014334862385321102
I0
I1
I-1
tp36765
sS'pediatric,powder'
p36766
(F1
F0.0011467889908256881
I8
I0
I8
tp36767
sS'chylomicron-like,emulsion'
p36768
(F1
F0.00014334862385321102
I0
I1
I-1
tp36769
sS'in,free'
p36770
(F1
F0.00028669724770642203
I2
I0
I2
tp36771
sS'vessels,was'
p36772
(F1
F0.00014334862385321102
I0
I1
I-1
tp36773
sS'receiving,bolus-ifl'
p36774
(F1
F0.00028669724770642203
I0
I2
I-2
tp36775
sS'mouth,urinary'
p36776
(F1
F0.00028669724770642203
I2
I0
I2
tp36777
sS'it,interfere'
p36778
(F1
F0.00014334862385321102
I0
I1
I-1
tp36779
sS'of,n-methylthiotetrazole'
p36780
(F1
F0.00014334862385321102
I0
I1
I-1
tp36781
sS'or,qtc'
p36782
(F1
F0.00014334862385321102
I0
I1
I-1
tp36783
sS'that,block'
p36784
(F1
F0.00014334862385321102
I0
I1
I-1
tp36785
sS'competitively,displaces'
p36786
(F1
F0.00014334862385321102
I1
I0
I1
tp36787
sS'require,dosage'
p36788
(F0
F0
I1
I1
I0
tp36789
sS'oral,self-administration'
p36790
(F1
F0.00014334862385321102
I0
I1
I-1
tp36791
sS'levels,with'
p36792
(F0
F0
I2
I2
I0
tp36793
sS'indanedione,including'
p36794
(F1
F0.00014334862385321102
I0
I1
I-1
tp36795
sS'delay,intestinal'
p36796
(F1
F0.0008600917431192661
I6
I0
I6
tp36797
sS'drugs,is'
p36798
(F1
F0.00014334862385321102
I0
I1
I-1
tp36799
sS'the,within'
p36800
(F1
F0.00014334862385321102
I1
I0
I1
tp36801
sS'p-,by'
p36802
(F1
F0.00014334862385321102
I0
I1
I-1
tp36803
sS'large,amounts'
p36804
(F1
F0.00014334862385321102
I1
I0
I1
tp36805
sS'end,fo'
p36806
(F1
F0.00014334862385321102
I0
I1
I-1
tp36807
sS'possibly,by'
p36808
(F1
F0.00043004587155963305
I3
I0
I3
tp36809
sS'preservative,in'
p36810
(F1
F0.00014334862385321102
I1
I0
I1
tp36811
sS'drugs,in'
p36812
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp36813
sS'are,available'
p36814
(F1
F0.00028669724770642203
I0
I2
I-2
tp36815
sS'then,the'
p36816
(F1
F0.00014334862385321102
I0
I1
I-1
tp36817
sS'local,close'
p36818
(F1
F0.00014334862385321102
I0
I1
I-1
tp36819
sS'of,involvement'
p36820
(F1
F0.00014334862385321102
I0
I1
I-1
tp36821
sS'wait,weeks'
p36822
(F1
F0.00028669724770642203
I2
I0
I2
tp36823
sS'other,ht1'
p36824
(F0
F0
I1
I1
I0
tp36825
sS'of,supplements'
p36826
(F1
F0.00014334862385321102
I1
I0
I1
tp36827
sS'of,proton'
p36828
(F1
F0.00014334862385321102
I0
I1
I-1
tp36829
sS'in,all'
p36830
(F0
F0
I2
I2
I0
tp36831
sS'first,hours'
p36832
(F1
F0.00014334862385321102
I0
I1
I-1
tp36833
sS'showed,a'
p36834
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36835
sS'complete,heart'
p36836
(F1
F0.00014334862385321102
I0
I1
I-1
tp36837
sS'see,whether'
p36838
(F1
F0.00014334862385321102
I1
I0
I1
tp36839
sS'indifferent,for'
p36840
(F1
F0.00028669724770642203
I2
I0
I2
tp36841
sS'that,increase'
p36842
(F1
F0.00028669724770642203
I2
I0
I2
tp36843
sS'antacid,magnesium-aluminum'
p36844
(F1
F0.00014334862385321102
I0
I1
I-1
tp36845
sS'by,mouth'
p36846
(F1
F0.00014334862385321102
I1
I0
I1
tp36847
sS'care,should'
p36848
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36849
sS'motrin,advil'
p36850
(F1
F0.00014334862385321102
I0
I1
I-1
tp36851
sS'and,cytoprotective'
p36852
(F1
F0.00014334862385321102
I0
I1
I-1
tp36853
sS'only,to'
p36854
(F1
F0.00014334862385321102
I1
I0
I1
tp36855
sS'long-acting,such'
p36856
(F1
F0.00014334862385321102
I0
I1
I-1
tp36857
sS'with,metal'
p36858
(F1
F0.00014334862385321102
I1
I0
I1
tp36859
sS'are,no'
p36860
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp36861
sS'performed,based'
p36862
(F1
F0.00014334862385321102
I1
I0
I1
tp36863
sS'tosylate,these'
p36864
(F1
F0.00014334862385321102
I0
I1
I-1
tp36865
sS'not,greatly'
p36866
(F1
F0.00014334862385321102
I0
I1
I-1
tp36867
sS'for,heparins'
p36868
(F1
F0.00014334862385321102
I0
I1
I-1
tp36869
sS'anticancer,and'
p36870
(F1
F0.00014334862385321102
I1
I0
I1
tp36871
sS'certain,especially'
p36872
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36873
sS'appropriate,dosage'
p36874
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp36875
sS'combination,with'
p36876
(F0.2537313432835821
F0.0024369266055045873
I25
I42
I-17
tp36877
sS'parenteral,are'
p36878
(F1
F0.00014334862385321102
I0
I1
I-1
tp36879
sS'or,maximum'
p36880
(F1
F0.00014334862385321102
I0
I1
I-1
tp36881
sS'morphine,toradoliv'
p36882
(F1
F0.00014334862385321102
I0
I1
I-1
tp36883
sS'investigation,of'
p36884
(F1
F0.00014334862385321102
I0
I1
I-1
tp36885
sS'ge,nerally'
p36886
(F1
F0.00014334862385321102
I0
I1
I-1
tp36887
sS'aptt,to'
p36888
(F1
F0.00014334862385321102
I0
I1
I-1
tp36889
sS'prinivil,attenuates'
p36890
(F1
F0.00014334862385321102
I1
I0
I1
tp36891
sS'examined,in'
p36892
(F1
F0.00014334862385321102
I0
I1
I-1
tp36893
sS'oral,adl'
p36894
(F1
F0.00014334862385321102
I0
I1
I-1
tp36895
sS'patients,administered'
p36896
(F1
F0.00014334862385321102
I1
I0
I1
tp36897
sS'been,evaluated'
p36898
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp36899
sS'a,non-matched'
p36900
(F1
F0.00014334862385321102
I1
I0
I1
tp36901
sS'similar,effect'
p36902
(F1
F0.00014334862385321102
I0
I1
I-1
tp36903
sS'an,animal'
p36904
(F1
F0.00014334862385321102
I1
I0
I1
tp36905
sS'reactions,patients'
p36906
(F1
F0.00014334862385321102
I1
I0
I1
tp36907
sS'hepatic,enzyme'
p36908
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp36909
sS'irrational,behavior'
p36910
(F1
F0.00014334862385321102
I1
I0
I1
tp36911
sS'simultaneous,treatment'
p36912
(F1
F0.00014334862385321102
I1
I0
I1
tp36913
sS'non-steroidal,the'
p36914
(F1
F0.00014334862385321102
I1
I0
I1
tp36915
sS'it,has'
p36916
(F0.52941176470588236
F0.0012901376146788992
I13
I4
I9
tp36917
sS'phase,schizophrenia'
p36918
(F1
F0.00014334862385321102
I0
I1
I-1
tp36919
sS'with,prothrombin'
p36920
(F1
F0.00014334862385321102
I1
I0
I1
tp36921
sS'time,hydrogen'
p36922
(F1
F0.00014334862385321102
I0
I1
I-1
tp36923
sS'tikosyn,as'
p36924
(F1
F0.00014334862385321102
I1
I0
I1
tp36925
sS'antagonists,such'
p36926
(F0.5
F0.00028669724770642203
I3
I1
I2
tp36927
sS'decreased,effect'
p36928
(F1
F0.00014334862385321102
I0
I1
I-1
tp36929
sS'with,bioassay'
p36930
(F1
F0.00014334862385321102
I0
I1
I-1
tp36931
sS'increased,risks'
p36932
(F1
F0.00014334862385321102
I1
I0
I1
tp36933
sS'a,major'
p36934
(F0
F0
I1
I1
I0
tp36935
sS'or,vitamin'
p36936
(F1
F0.00014334862385321102
I1
I0
I1
tp36937
sS'abolish,the'
p36938
(F1
F0.00014334862385321102
I1
I0
I1
tp36939
sS'sex,hormone-binding'
p36940
(F1
F0.00014334862385321102
I0
I1
I-1
tp36941
sS'to,reported'
p36942
(F1
F0.00014334862385321102
I1
I0
I1
tp36943
sS'sodium,unreliable'
p36944
(F1
F0.00014334862385321102
I1
I0
I1
tp36945
sS'folic,acid'
p36946
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp36947
sS'of,in'
p36948
(F0.16
F0.0011467889908256881
I21
I29
I-8
tp36949
sS'of,if'
p36950
(F1
F0.00043004587155963305
I3
I0
I3
tp36951
sS'to,adverse'
p36952
(F1
F0.00014334862385321102
I0
I1
I-1
tp36953
sS'if,their'
p36954
(F1
F0.00014334862385321102
I1
I0
I1
tp36955
sS'of,it'
p36956
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp36957
sS'of,is'
p36958
(F0.51724137931034486
F0.0021502293577981653
I22
I7
I15
tp36959
sS'versus,nonfailing'
p36960
(F1
F0.00014334862385321102
I0
I1
I-1
tp36961
sS'also,markedly'
p36962
(F1
F0.00014334862385321102
I1
I0
I1
tp36963
sS'xr,should'
p36964
(F1
F0.00014334862385321102
I0
I1
I-1
tp36965
sS'non-matched,historicalcontrol'
p36966
(F1
F0.00014334862385321102
I1
I0
I1
tp36967
sS'given,high'
p36968
(F1
F0.00014334862385321102
I1
I0
I1
tp36969
sS'days,the'
p36970
(F1
F0.00014334862385321102
I0
I1
I-1
tp36971
sS'show,significant'
p36972
(F1
F0.00014334862385321102
I0
I1
I-1
tp36973
sS'as,acute'
p36974
(F1
F0.00014334862385321102
I0
I1
I-1
tp36975
sS'alternative,non-cyp3a4'
p36976
(F1
F0.00014334862385321102
I0
I1
I-1
tp36977
sS'towards,the'
p36978
(F1
F0.00014334862385321102
I0
I1
I-1
tp36979
sS'strong,selective'
p36980
(F1
F0.00028669724770642203
I2
I0
I2
tp36981
sS'serious,constellation'
p36982
(F1
F0.00014334862385321102
I1
I0
I1
tp36983
sS'l-ccg,upon'
p36984
(F1
F0.00014334862385321102
I0
I1
I-1
tp36985
sS'particularly,of'
p36986
(F1
F0.00014334862385321102
I1
I0
I1
tp36987
sS'and,implantable'
p36988
(F1
F0.00028669724770642203
I2
I0
I2
tp36989
sS'receiving,gm'
p36990
(F1
F0.00014334862385321102
I1
I0
I1
tp36991
sS'in,studies'
p36992
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp36993
sS'acute,toxicity'
p36994
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp36995
sS'nasal,vasoconstrictor'
p36996
(F1
F0.00014334862385321102
I0
I1
I-1
tp36997
sS'sodium,a'
p36998
(F1
F0.00014334862385321102
I1
I0
I1
tp36999
sS'glycosides,could'
p37000
(F1
F0.00014334862385321102
I1
I0
I1
tp37001
sS'cholecystokinin,octapeptide'
p37002
(F1
F0.00014334862385321102
I0
I1
I-1
tp37003
sS'on,tyrosine'
p37004
(F1
F0.00014334862385321102
I1
I0
I1
tp37005
sS'agents,structurally'
p37006
(F1
F0.00014334862385321102
I1
I0
I1
tp37007
sS'lines,u937'
p37008
(F1
F0.00014334862385321102
I1
I0
I1
tp37009
sS'apart,on'
p37010
(F1
F0.00014334862385321102
I1
I0
I1
tp37011
sS'time,should'
p37012
(F1
F0.00043004587155963305
I3
I0
I3
tp37013
sS'significant,sustained'
p37014
(F1
F0.00014334862385321102
I1
I0
I1
tp37015
sS'maximally,suppresses'
p37016
(F1
F0.00014334862385321102
I0
I1
I-1
tp37017
sS'liver,enzyme'
p37018
(F1
F0.00014334862385321102
I1
I0
I1
tp37019
sS'occurs,when'
p37020
(F1
F0.00014334862385321102
I0
I1
I-1
tp37021
sS'of,days'
p37022
(F1
F0.00014334862385321102
I0
I1
I-1
tp37023
sS'a,long-acting'
p37024
(F1
F0.00014334862385321102
I0
I1
I-1
tp37025
sS'keratoses,treated'
p37026
(F1
F0.00014334862385321102
I1
I0
I1
tp37027
sS'concomitant,protease'
p37028
(F1
F0.00014334862385321102
I1
I0
I1
tp37029
sS'the,antiepileptic'
p37030
(F1
F0.00014334862385321102
I1
I0
I1
tp37031
sS'and,thiazide'
p37032
(F1
F0.00014334862385321102
I1
I0
I1
tp37033
sS'on,inositol'
p37034
(F1
F0.00014334862385321102
I0
I1
I-1
tp37035
sS'the,kidney'
p37036
(F1
F0.00028669724770642203
I0
I2
I-2
tp37037
sS'development,of'
p37038
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp37039
sS'ml,sc'
p37040
(F1
F0.00014334862385321102
I0
I1
I-1
tp37041
sS'was,designed'
p37042
(F1
F0.00014334862385321102
I0
I1
I-1
tp37043
sS'regular,monitoring'
p37044
(F1
F0.00014334862385321102
I0
I1
I-1
tp37045
sS'of,revia'
p37046
(F1
F0.00014334862385321102
I1
I0
I1
tp37047
sS'curve,of'
p37048
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37049
sS'fold,in'
p37050
(F1
F0.00028669724770642203
I2
I0
I2
tp37051
sS'may,counteract'
p37052
(F1
F0.00071674311926605509
I5
I0
I5
tp37053
sS'fractional,transfer'
p37054
(F1
F0.00014334862385321102
I0
I1
I-1
tp37055
sS'reports,indicate'
p37056
(F1
F0.00028669724770642203
I2
I0
I2
tp37057
sS'by,especially'
p37058
(F1
F0.00014334862385321102
I1
I0
I1
tp37059
sS'diazepam,valium'
p37060
(F1
F0.00014334862385321102
I0
I1
I-1
tp37061
sS'with,such'
p37062
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp37063
sS'daily,resulted'
p37064
(F1
F0.00043004587155963305
I3
I0
I3
tp37065
sS'role,in'
p37066
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37067
sS'of,chemotherapy'
p37068
(F1
F0.00014334862385321102
I0
I1
I-1
tp37069
sS'catecholamine-depleting,may'
p37070
(F1
F0.00028669724770642203
I2
I0
I2
tp37071
sS'and,which'
p37072
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp37073
sS'pci,co-administration'
p37074
(F1
F0.00014334862385321102
I1
I0
I1
tp37075
sS'for,only'
p37076
(F1
F0.00014334862385321102
I0
I1
I-1
tp37077
sS'phenytoin,and'
p37078
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp37079
sS'not,been'
p37080
(F0.16363636363636364
F0.0012901376146788992
I23
I32
I-9
tp37081
sS'therefore,not'
p37082
(F1
F0.00043004587155963305
I3
I0
I3
tp37083
sS'major,metabolites'
p37084
(F1
F0.00014334862385321102
I0
I1
I-1
tp37085
sS'total,circulating'
p37086
(F1
F0.00028669724770642203
I0
I2
I-2
tp37087
sS'maois,which'
p37088
(F1
F0.00014334862385321102
I0
I1
I-1
tp37089
sS'and,international'
p37090
(F0
F0
I1
I1
I0
tp37091
sS'increased,blood'
p37092
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37093
sS'inr,or'
p37094
(F1
F0.00014334862385321102
I0
I1
I-1
tp37095
sS'exjade,with'
p37096
(F1
F0.00014334862385321102
I0
I1
I-1
tp37097
sS'vasoconstricting,agents'
p37098
(F1
F0.00014334862385321102
I1
I0
I1
tp37099
sS'cns,depression'
p37100
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp37101
sS'lessen,its'
p37102
(F1
F0.00014334862385321102
I0
I1
I-1
tp37103
sS'is,some'
p37104
(F1
F0.00014334862385321102
I1
I0
I1
tp37105
sS'was,found'
p37106
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp37107
sS'only,in'
p37108
(F1
F0.00028669724770642203
I2
I0
I2
tp37109
sS'only,if'
p37110
(F1
F0.00014334862385321102
I1
I0
I1
tp37111
sS'prothrombin,test'
p37112
(F1
F0.00028669724770642203
I0
I2
I-2
tp37113
sS'exercised,nonetheless'
p37114
(F1
F0.00014334862385321102
I1
I0
I1
tp37115
sS'now,available'
p37116
(F1
F0.00014334862385321102
I0
I1
I-1
tp37117
sS'meaningful,increases'
p37118
(F1
F0.00014334862385321102
I0
I1
I-1
tp37119
sS'from,ng'
p37120
(F1
F0.00014334862385321102
I0
I1
I-1
tp37121
sS'or,potentiate'
p37122
(F1
F0.00028669724770642203
I2
I0
I2
tp37123
sS'inhibition,are'
p37124
(F1
F0.00014334862385321102
I1
I0
I1
tp37125
sS'with,all'
p37126
(F1
F0.00028669724770642203
I2
I0
I2
tp37127
sS'max,were'
p37128
(F1
F0.00014334862385321102
I0
I1
I-1
tp37129
sS'cell,accumulation'
p37130
(F1
F0.00014334862385321102
I0
I1
I-1
tp37131
sS'in,part'
p37132
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37133
sS'bolus-ifl,with'
p37134
(F1
F0.00014334862385321102
I0
I1
I-1
tp37135
sS'chemical,reaction'
p37136
(F1
F0.00014334862385321102
I1
I0
I1
tp37137
sS'of,users'
p37138
(F1
F0.00014334862385321102
I1
I0
I1
tp37139
sS'be,a'
p37140
(F1
F0.00057339449541284407
I0
I4
I-4
tp37141
sS'iv,compared'
p37142
(F1
F0.00014334862385321102
I0
I1
I-1
tp37143
sS'with,both'
p37144
(F1
F0.00014334862385321102
I0
I1
I-1
tp37145
sS'significant,metabolism'
p37146
(F1
F0.00014334862385321102
I1
I0
I1
tp37147
sS'other,as'
p37148
(F1
F0.00014334862385321102
I1
I0
I1
tp37149
sS'medicines,or'
p37150
(F1
F0.00028669724770642203
I2
I0
I2
tp37151
sS'duloxetine,both'
p37152
(F1
F0.00014334862385321102
I0
I1
I-1
tp37153
sS'is,reported'
p37154
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37155
sS'containing,gram'
p37156
(F1
F0.00014334862385321102
I1
I0
I1
tp37157
sS'on,hepatotoxicity'
p37158
(F1
F0.00014334862385321102
I1
I0
I1
tp37159
sS'reaction,profile'
p37160
(F1
F0.00014334862385321102
I0
I1
I-1
tp37161
sS'serum,tests'
p37162
(F1
F0.00014334862385321102
I0
I1
I-1
tp37163
sS'of,use'
p37164
(F1
F0.00014334862385321102
I0
I1
I-1
tp37165
sS'defect,in'
p37166
(F1
F0.00014334862385321102
I0
I1
I-1
tp37167
sS'of,usp'
p37168
(F1
F0.00014334862385321102
I1
I0
I1
tp37169
sS'trials,suggest'
p37170
(F1
F0.00014334862385321102
I0
I1
I-1
tp37171
sS'and,serotonin2-receptors'
p37172
(F1
F0.00014334862385321102
I0
I1
I-1
tp37173
sS'likely,will'
p37174
(F1
F0.00014334862385321102
I1
I0
I1
tp37175
sS'enhance,toxicity'
p37176
(F1
F0.00014334862385321102
I0
I1
I-1
tp37177
sS'trials,flolan'
p37178
(F1
F0.00014334862385321102
I1
I0
I1
tp37179
sS'however,possible'
p37180
(F1
F0.00014334862385321102
I1
I0
I1
tp37181
sS'seizures,have'
p37182
(F1
F0.00043004587155963305
I3
I0
I3
tp37183
sS'systematic,changes'
p37184
(F1
F0.00014334862385321102
I0
I1
I-1
tp37185
sS'two,instances'
p37186
(F1
F0.00014334862385321102
I1
I0
I1
tp37187
sS'indicate,no'
p37188
(F1
F0.00014334862385321102
I0
I1
I-1
tp37189
sS'implicated,in'
p37190
(F0
F0
I1
I1
I0
tp37191
sS'however,pretreatment'
p37192
(F1
F0.00014334862385321102
I0
I1
I-1
tp37193
sS'reduction,should'
p37194
(F1
F0.00014334862385321102
I0
I1
I-1
tp37195
sS'serotonin,syndrome'
p37196
(F0.5
F0.00028669724770642203
I3
I1
I2
tp37197
sS'range,observed'
p37198
(F1
F0.00014334862385321102
I0
I1
I-1
tp37199
sS'lessened,physiologic'
p37200
(F1
F0.00014334862385321102
I1
I0
I1
tp37201
sS'causing,an'
p37202
(F1
F0.00014334862385321102
I1
I0
I1
tp37203
sS'epileptic,patients'
p37204
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37205
sS'anxiety,depressive'
p37206
(F1
F0.00014334862385321102
I0
I1
I-1
tp37207
sS'diarrhea,induced'
p37208
(F1
F0.00014334862385321102
I1
I0
I1
tp37209
sS'fewer,infusion'
p37210
(F1
F0.00014334862385321102
I0
I1
I-1
tp37211
sS'distribution,and'
p37212
(F1
F0.00014334862385321102
I0
I1
I-1
tp37213
sS'differently,from'
p37214
(F1
F0.00028669724770642203
I0
I2
I-2
tp37215
sS'rifampin,markedly'
p37216
(F1
F0.00014334862385321102
I1
I0
I1
tp37217
sS'additional,significantly'
p37218
(F1
F0.00014334862385321102
I1
I0
I1
tp37219
sS'other,hand'
p37220
(F0
F0
I1
I1
I0
tp37221
sS'when,administered'
p37222
(F0.36363636363636365
F0.0011467889908256881
I15
I7
I8
tp37223
sS'the,cyp2b6'
p37224
(F1
F0.00014334862385321102
I1
I0
I1
tp37225
sS'when,heart'
p37226
(F1
F0.00014334862385321102
I1
I0
I1
tp37227
sS'and,indocin'
p37228
(F1
F0.00014334862385321102
I1
I0
I1
tp37229
sS'during,treatment'
p37230
(F0.5
F0.00057339449541284407
I6
I2
I4
tp37231
sS'while,fractional'
p37232
(F1
F0.00014334862385321102
I0
I1
I-1
tp37233
sS'disease,including'
p37234
(F1
F0.00014334862385321102
I0
I1
I-1
tp37235
sS'be,unlikely'
p37236
(F1
F0.00028669724770642203
I0
I2
I-2
tp37237
sS'to,daily'
p37238
(F1
F0.00014334862385321102
I0
I1
I-1
tp37239
sS'day,doses'
p37240
(F1
F0.00014334862385321102
I0
I1
I-1
tp37241
sS'therefore,concomitant'
p37242
(F1
F0.00043004587155963305
I3
I0
I3
tp37243
sS'd,produced'
p37244
(F1
F0.00028669724770642203
I2
I0
I2
tp37245
sS'pancreatitis,possibly'
p37246
(F1
F0.00014334862385321102
I1
I0
I1
tp37247
sS'formula,mg'
p37248
(F1
F0.00014334862385321102
I0
I1
I-1
tp37249
sS'href,bupropz_od'
p37250
(F1
F0.00014334862385321102
I1
I0
I1
tp37251
sS'serious,toxicity'
p37252
(F1
F0.00014334862385321102
I1
I0
I1
tp37253
sS'of,orally'
p37254
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp37255
sS'or,concurrent'
p37256
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37257
sS'antiretroviral,medications'
p37258
(F1
F0.00014334862385321102
I0
I1
I-1
tp37259
sS'potential,should'
p37260
(F1
F0.00014334862385321102
I0
I1
I-1
tp37261
sS'antibiotics,such'
p37262
(F1
F0.00014334862385321102
I1
I0
I1
tp37263
sS'zidovudine,should'
p37264
(F1
F0.00014334862385321102
I1
I0
I1
tp37265
sS'for,serious'
p37266
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp37267
sS'to,pentobarbital-induced'
p37268
(F1
F0.00014334862385321102
I0
I1
I-1
tp37269
sS'peripheral,neuropathy'
p37270
(F0
F0
I1
I1
I0
tp37271
sS'and,its'
p37272
(F0.15384615384615385
F0.00057339449541284407
I15
I11
I4
tp37273
sS'addition,studies'
p37274
(F1
F0.00014334862385321102
I0
I1
I-1
tp37275
sS'preparations,sunscreens'
p37276
(F1
F0.00014334862385321102
I1
I0
I1
tp37277
sS'torsades,de'
p37278
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37279
sS'range,of'
p37280
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp37281
sS'hyperbilirubinemia,confusion'
p37282
(F1
F0.00014334862385321102
I1
I0
I1
tp37283
sS'a,complex'
p37284
(F0
F0
I1
I1
I0
tp37285
sS'central,effects'
p37286
(F1
F0.00014334862385321102
I1
I0
I1
tp37287
sS'serum,concentrations'
p37288
(F0.33333333333333331
F0.0011467889908256881
I16
I8
I8
tp37289
sS'human,plasma'
p37290
(F1
F0.00057339449541284407
I0
I4
I-4
tp37291
sS'inhibit,neuronal'
p37292
(F1
F0.00014334862385321102
I0
I1
I-1
tp37293
sS'b,for'
p37294
(F1
F0.00014334862385321102
I0
I1
I-1
tp37295
sS'lower,intestine'
p37296
(F1
F0.00014334862385321102
I1
I0
I1
tp37297
sS'an,angiotensin-converting'
p37298
(F1
F0.00014334862385321102
I1
I0
I1
tp37299
sS'prostin,e2'
p37300
(F1
F0.00014334862385321102
I1
I0
I1
tp37301
sS'international,pharmaceutical'
p37302
(F1
F0.00014334862385321102
I0
I1
I-1
tp37303
sS'effects,could'
p37304
(F1
F0.00014334862385321102
I1
I0
I1
tp37305
sS'an,approximate'
p37306
(F1
F0.0012901376146788992
I9
I0
I9
tp37307
sS'the,cumulative'
p37308
(F1
F0.00014334862385321102
I0
I1
I-1
tp37309
sS'the,csf'
p37310
(F1
F0.00014334862385321102
I0
I1
I-1
tp37311
sS'maximum,approved'
p37312
(F1
F0.00014334862385321102
I1
I0
I1
tp37313
sS'increase,respiratory'
p37314
(F1
F0.00014334862385321102
I1
I0
I1
tp37315
sS'cytochrome,isozymes'
p37316
(F1
F0.00014334862385321102
I0
I1
I-1
tp37317
sS'inhibitors,long-term'
p37318
(F1
F0.00014334862385321102
I1
I0
I1
tp37319
sS'contrast,mm'
p37320
(F1
F0.00014334862385321102
I0
I1
I-1
tp37321
sS'monitor,tcaplasma'
p37322
(F1
F0.00014334862385321102
I0
I1
I-1
tp37323
sS'of,does'
p37324
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp37325
sS'hypoglycemics,initiating'
p37326
(F1
F0.00014334862385321102
I0
I1
I-1
tp37327
sS'apoptosis,assessed'
p37328
(F1
F0.00014334862385321102
I1
I0
I1
tp37329
sS'aware,when'
p37330
(F1
F0.00014334862385321102
I1
I0
I1
tp37331
sS'events,by'
p37332
(F1
F0.00014334862385321102
I1
I0
I1
tp37333
sS'is,easy'
p37334
(F1
F0.00014334862385321102
I0
I1
I-1
tp37335
sS'prinivil,at'
p37336
(F1
F0.00014334862385321102
I1
I0
I1
tp37337
sS'withdrawn,and'
p37338
(F1
F0.00014334862385321102
I0
I1
I-1
tp37339
sS'triazolam,combined'
p37340
(F1
F0.00014334862385321102
I0
I1
I-1
tp37341
sS'acid,aminocaproic'
p37342
(F1
F0.00014334862385321102
I0
I1
I-1
tp37343
sS'mechanism,may'
p37344
(F1
F0.00014334862385321102
I1
I0
I1
tp37345
sS'e,mg'
p37346
(F1
F0.00014334862385321102
I1
I0
I1
tp37347
sS'necessitate,raising'
p37348
(F1
F0.00014334862385321102
I1
I0
I1
tp37349
sS'renal,nonrenal'
p37350
(F1
F0.00014334862385321102
I0
I1
I-1
tp37351
sS'active,renal'
p37352
(F1
F0.00014334862385321102
I1
I0
I1
tp37353
sS'by,infusion'
p37354
(F1
F0.00028669724770642203
I0
I2
I-2
tp37355
sS'by,hepatic'
p37356
(F1
F0.00043004587155963305
I3
I0
I3
tp37357
sS'rare,occasions'
p37358
(F1
F0.00028669724770642203
I2
I0
I2
tp37359
sS'vivo,interaction'
p37360
(F1
F0.00071674311926605509
I0
I5
I-5
tp37361
sS'rarely,associated'
p37362
(F1
F0.00028669724770642203
I2
I0
I2
tp37363
sS'definitely,indicated'
p37364
(F1
F0.00014334862385321102
I1
I0
I1
tp37365
sS'additionally,did'
p37366
(F1
F0.00014334862385321102
I0
I1
I-1
tp37367
sS'patient,currently'
p37368
(F1
F0.00028669724770642203
I2
I0
I2
tp37369
sS'interactions,certain'
p37370
(F1
F0.00014334862385321102
I0
I1
I-1
tp37371
sS'agents,derivatives'
p37372
(F1
F0.00028669724770642203
I0
I2
I-2
tp37373
sS'from,therapy'
p37374
(F1
F0.00014334862385321102
I0
I1
I-1
tp37375
sS'including,hypertensive'
p37376
(F1
F0.00014334862385321102
I1
I0
I1
tp37377
sS'release,whereas'
p37378
(F1
F0.00014334862385321102
I0
I1
I-1
tp37379
sS'mentax,butenafine'
p37380
(F1
F0.00014334862385321102
I0
I1
I-1
tp37381
sS'or,elevated'
p37382
(F1
F0.00028669724770642203
I2
I0
I2
tp37383
sS'concentrations,drugs'
p37384
(F1
F0.00014334862385321102
I1
I0
I1
tp37385
sS'deet,toxicity'
p37386
(F1
F0.00014334862385321102
I0
I1
I-1
tp37387
sS'with,spectrophotometrically'
p37388
(F1
F0.00014334862385321102
I0
I1
I-1
tp37389
sS'pressure,caution'
p37390
(F1
F0.00014334862385321102
I1
I0
I1
tp37391
sS'or,excess'
p37392
(F1
F0.00014334862385321102
I1
I0
I1
tp37393
sS'adverse,neuropsychiatric'
p37394
(F1
F0.00014334862385321102
I1
I0
I1
tp37395
sS'those,patients'
p37396
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37397
sS'metformin,in'
p37398
(F0
F0
I1
I1
I0
tp37399
sS'antagonists,may'
p37400
(F1
F0.00028669724770642203
I2
I0
I2
tp37401
sS'to,was'
p37402
(F1
F0.00071674311926605509
I5
I0
I5
tp37403
sS'the,breath'
p37404
(F1
F0.00014334862385321102
I0
I1
I-1
tp37405
sS'have,allergic'
p37406
(F1
F0.00014334862385321102
I0
I1
I-1
tp37407
sS'probenecid,depresses'
p37408
(F1
F0.00014334862385321102
I1
I0
I1
tp37409
sS'withdrawal,and'
p37410
(F1
F0.00014334862385321102
I1
I0
I1
tp37411
sS'coumarin-derivative,concomitantly'
p37412
(F1
F0.00014334862385321102
I1
I0
I1
tp37413
sS'induced,concentration-dependent'
p37414
(F1
F0.00014334862385321102
I0
I1
I-1
tp37415
sS'on,smooth'
p37416
(F1
F0.00014334862385321102
I0
I1
I-1
tp37417
sS'receiving,and'
p37418
(F0.25
F0.00028669724770642203
I5
I3
I2
tp37419
sS'symptomatic,orthostatic'
p37420
(F1
F0.00028669724770642203
I2
I0
I2
tp37421
sS'prolongation,ischemic'
p37422
(F1
F0.00014334862385321102
I1
I0
I1
tp37423
sS'be,separated'
p37424
(F1
F0.00014334862385321102
I1
I0
I1
tp37425
sS'under,fasting'
p37426
(F1
F0.00014334862385321102
I0
I1
I-1
tp37427
sS'novel,chemical'
p37428
(F1
F0.00014334862385321102
I1
I0
I1
tp37429
sS'nalfon,the'
p37430
(F1
F0.00014334862385321102
I1
I0
I1
tp37431
sS'total,body'
p37432
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp37433
sS'efficacy,and'
p37434
(F1
F0.00014334862385321102
I0
I1
I-1
tp37435
sS'by,that'
p37436
(F1
F0.00014334862385321102
I1
I0
I1
tp37437
sS'permit,larger'
p37438
(F1
F0.00014334862385321102
I0
I1
I-1
tp37439
sS'nsaid,or'
p37440
(F1
F0.00014334862385321102
I1
I0
I1
tp37441
sS'in,pcp'
p37442
(F1
F0.00014334862385321102
I0
I1
I-1
tp37443
sS'by,alt'
p37444
(F1
F0.00014334862385321102
I0
I1
I-1
tp37445
sS'urine,of'
p37446
(F1
F0.00028669724770642203
I0
I2
I-2
tp37447
sS'cyp2d6,was'
p37448
(F1
F0.00014334862385321102
I0
I1
I-1
tp37449
sS'significant,reductions'
p37450
(F1
F0.00014334862385321102
I1
I0
I1
tp37451
sS'of,including'
p37452
(F1
F0.00043004587155963305
I3
I0
I3
tp37453
sS'period,of'
p37454
(F0
F0
I3
I3
I0
tp37455
sS'oral,resulted'
p37456
(F1
F0.00014334862385321102
I1
I0
I1
tp37457
sS'with,allopurinol'
p37458
(F1
F0.00014334862385321102
I1
I0
I1
tp37459
sS'the,is'
p37460
(F0
F0
I1
I1
I0
tp37461
sS'the,iv'
p37462
(F1
F0.00014334862385321102
I1
I0
I1
tp37463
sS'the,difference'
p37464
(F1
F0.00014334862385321102
I0
I1
I-1
tp37465
sS'that,chloral'
p37466
(F1
F0.00014334862385321102
I0
I1
I-1
tp37467
sS'and,n-oxide'
p37468
(F1
F0.00014334862385321102
I0
I1
I-1
tp37469
sS'gradual,in'
p37470
(F1
F0.00014334862385321102
I1
I0
I1
tp37471
sS'respectively,by'
p37472
(F1
F0.00014334862385321102
I1
I0
I1
tp37473
sS'tablets,at'
p37474
(F0
F0
I1
I1
I0
tp37475
sS'the,in'
p37476
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp37477
sS'concomitantly,and'
p37478
(F1
F0.00014334862385321102
I1
I0
I1
tp37479
sS'indeed,have'
p37480
(F1
F0.00014334862385321102
I1
I0
I1
tp37481
sS'attenuates,certain'
p37482
(F1
F0.00014334862385321102
I1
I0
I1
tp37483
sS'concomitantly,any'
p37484
(F1
F0.00014334862385321102
I1
I0
I1
tp37485
sS'cyp3a4,inducer'
p37486
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp37487
sS'patients,without'
p37488
(F0
F0
I1
I1
I0
tp37489
sS'increase,of'
p37490
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp37491
sS'at,stable'
p37492
(F1
F0.00014334862385321102
I0
I1
I-1
tp37493
sS'increase,or'
p37494
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp37495
sS'a,delayed'
p37496
(F1
F0.00014334862385321102
I0
I1
I-1
tp37497
sS'subsequently,administered'
p37498
(F1
F0.00014334862385321102
I1
I0
I1
tp37499
sS'first,sixty'
p37500
(F1
F0.00014334862385321102
I1
I0
I1
tp37501
sS'data,to'
p37502
(F1
F0.00014334862385321102
I1
I0
I1
tp37503
sS'all,metabolized'
p37504
(F1
F0.00014334862385321102
I1
I0
I1
tp37505
sS'conduction,channel'
p37506
(F1
F0.00014334862385321102
I1
I0
I1
tp37507
sS'possible,clinical'
p37508
(F1
F0.00014334862385321102
I1
I0
I1
tp37509
sS'that,dopamine'
p37510
(F1
F0.00014334862385321102
I1
I0
I1
tp37511
sS'although,acid-base'
p37512
(F1
F0.00014334862385321102
I1
I0
I1
tp37513
sS'cardioactive,drugs'
p37514
(F1
F0.00014334862385321102
I0
I1
I-1
tp37515
sS'renin,activity'
p37516
(F1
F0.00014334862385321102
I0
I1
I-1
tp37517
sS'inapsine,the'
p37518
(F1
F0.00014334862385321102
I1
I0
I1
tp37519
sS'terms,viagra'
p37520
(F1
F0.00014334862385321102
I0
I1
I-1
tp37521
sS'in,function'
p37522
(F1
F0.00014334862385321102
I0
I1
I-1
tp37523
sS'containing,preparations'
p37524
(F1
F0.00014334862385321102
I1
I0
I1
tp37525
sS'these,medications'
p37526
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp37527
sS'vasoconstrictor,but'
p37528
(F1
F0.00014334862385321102
I0
I1
I-1
tp37529
sS'found,minutes'
p37530
(F1
F0.00014334862385321102
I0
I1
I-1
tp37531
sS'fi,or'
p37532
(F1
F0.00014334862385321102
I1
I0
I1
tp37533
sS'serum,clearance'
p37534
(F1
F0.00014334862385321102
I1
I0
I1
tp37535
sS'iv,was'
p37536
(F1
F0.00014334862385321102
I0
I1
I-1
tp37537
sS'survanta,a'
p37538
(F1
F0.00014334862385321102
I0
I1
I-1
tp37539
sS'with,was'
p37540
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp37541
sS'coli,and'
p37542
(F1
F0.00014334862385321102
I0
I1
I-1
tp37543
sS'whether,would'
p37544
(F1
F0.00014334862385321102
I0
I1
I-1
tp37545
sS'in,particular'
p37546
(F1
F0.00014334862385321102
I1
I0
I1
tp37547
sS'agents,concurrent'
p37548
(F0
F0
I1
I1
I0
tp37549
sS'isoenzyme,and'
p37550
(F1
F0.00028669724770642203
I0
I2
I-2
tp37551
sS'concomitant,n'
p37552
(F1
F0.00014334862385321102
I1
I0
I1
tp37553
sS'griseofulvin,may'
p37554
(F1
F0.00014334862385321102
I1
I0
I1
tp37555
sS'the,including'
p37556
(F1
F0.00028669724770642203
I2
I0
I2
tp37557
sS'nonclinical,data'
p37558
(F1
F0.00014334862385321102
I0
I1
I-1
tp37559
sS'acid,nonsteroidal'
p37560
(F1
F0.00014334862385321102
I1
I0
I1
tp37561
sS'metabolism,decreased'
p37562
(F1
F0.00014334862385321102
I1
I0
I1
tp37563
sS'fluvoxamine,has'
p37564
(F1
F0.00014334862385321102
I1
I0
I1
tp37565
sS'oral,heparin'
p37566
(F1
F0.00014334862385321102
I0
I1
I-1
tp37567
sS'gabapentin,had'
p37568
(F1
F0.00014334862385321102
I0
I1
I-1
tp37569
sS'dose-related,decrease'
p37570
(F1
F0.00014334862385321102
I1
I0
I1
tp37571
sS'route,of'
p37572
(F1
F0.00014334862385321102
I1
I0
I1
tp37573
sS'medication,and'
p37574
(F1
F0.00014334862385321102
I0
I1
I-1
tp37575
sS'abstract,truncated'
p37576
(F1
F0.00014334862385321102
I0
I1
I-1
tp37577
sS'subjective,and'
p37578
(F1
F0.00028669724770642203
I0
I2
I-2
tp37579
sS'be,ingested'
p37580
(F1
F0.00014334862385321102
I1
I0
I1
tp37581
sS'sampling,for'
p37582
(F1
F0.00014334862385321102
I0
I1
I-1
tp37583
sS'digitalis,vitamin'
p37584
(F1
F0.00043004587155963305
I3
I0
I3
tp37585
sS'medium,consisting'
p37586
(F1
F0.00014334862385321102
I0
I1
I-1
tp37587
sS'isolated,cases'
p37588
(F1
F0.00028669724770642203
I2
I0
I2
tp37589
sS'sympathetic,effects'
p37590
(F1
F0.00014334862385321102
I1
I0
I1
tp37591
sS'm1,the'
p37592
(F1
F0.00014334862385321102
I1
I0
I1
tp37593
sS'of,acarbose'
p37594
(F1
F0.00014334862385321102
I1
I0
I1
tp37595
sS'or,renal'
p37596
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp37597
sS'are,concurrently'
p37598
(F1
F0.00028669724770642203
I2
I0
I2
tp37599
sS'with,water-miscible'
p37600
(F1
F0.00014334862385321102
I0
I1
I-1
tp37601
sS'sometimes,proves'
p37602
(F1
F0.00014334862385321102
I1
I0
I1
tp37603
sS'hemostasis,nsaids'
p37604
(F1
F0.00014334862385321102
I0
I1
I-1
tp37605
sS'angiomax,and'
p37606
(F1
F0.00014334862385321102
I0
I1
I-1
tp37607
sS'extracellular,levels'
p37608
(F1
F0.00014334862385321102
I0
I1
I-1
tp37609
sS'combinations,were'
p37610
(F1
F0.00014334862385321102
I0
I1
I-1
tp37611
sS'therapy,oral'
p37612
(F1
F0.00014334862385321102
I0
I1
I-1
tp37613
sS'mg,qid'
p37614
(F0
F0
I1
I1
I0
tp37615
sS'influence,on'
p37616
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37617
sS'both,synthetic'
p37618
(F1
F0.00043004587155963305
I3
I0
I3
tp37619
sS'influence,of'
p37620
(F1
F0.0012901376146788992
I0
I9
I-9
tp37621
sS'clearance,that'
p37622
(F1
F0.00014334862385321102
I1
I0
I1
tp37623
sS'these,techniques'
p37624
(F1
F0.00014334862385321102
I0
I1
I-1
tp37625
sS'well,and'
p37626
(F1
F0.00014334862385321102
I0
I1
I-1
tp37627
sS'treatment,folic'
p37628
(F1
F0.00014334862385321102
I1
I0
I1
tp37629
sS'inhibitors,or'
p37630
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp37631
sS'have,resulted'
p37632
(F1
F0.00043004587155963305
I3
I0
I3
tp37633
sS'inhibitors,on'
p37634
(F1
F0.00014334862385321102
I1
I0
I1
tp37635
sS'd,co-administered'
p37636
(F1
F0.00028669724770642203
I2
I0
I2
tp37637
sS'each,be'
p37638
(F1
F0.00014334862385321102
I1
I0
I1
tp37639
sS'inhibitors,of'
p37640
(F0.18518518518518517
F0.00071674311926605509
I16
I11
I5
tp37641
sS'closely,to'
p37642
(F0.75
F0.0008600917431192661
I7
I1
I6
tp37643
sS'systemic,medications'
p37644
(F1
F0.00014334862385321102
I1
I0
I1
tp37645
sS'microsomal,monooxygenase'
p37646
(F1
F0.00014334862385321102
I0
I1
I-1
tp37647
sS'of,changes'
p37648
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37649
sS'disease,control'
p37650
(F1
F0.00014334862385321102
I1
I0
I1
tp37651
sS'of,changed'
p37652
(F1
F0.00014334862385321102
I1
I0
I1
tp37653
sS'treatment,in'
p37654
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp37655
sS'between,given'
p37656
(F1
F0.00014334862385321102
I0
I1
I-1
tp37657
sS'case,that'
p37658
(F1
F0.00014334862385321102
I1
I0
I1
tp37659
sS'reveal,frequent'
p37660
(F1
F0.00014334862385321102
I1
I0
I1
tp37661
sS'including,but'
p37662
(F1
F0.00014334862385321102
I1
I0
I1
tp37663
sS'pneumonia,treatment'
p37664
(F1
F0.00014334862385321102
I1
I0
I1
tp37665
sS'two,patients'
p37666
(F1
F0.00028669724770642203
I2
I0
I2
tp37667
sS'various,such'
p37668
(F1
F0.00014334862385321102
I1
I0
I1
tp37669
sS'time-dependent,inhibitor'
p37670
(F1
F0.00014334862385321102
I0
I1
I-1
tp37671
sS'rr,microm'
p37672
(F1
F0.00028669724770642203
I2
I0
I2
tp37673
sS'a,fluoroquinolone'
p37674
(F1
F0.00014334862385321102
I1
I0
I1
tp37675
sS'case,of'
p37676
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp37677
sS'itraconazole,therapy'
p37678
(F1
F0.00014334862385321102
I1
I0
I1
tp37679
sS'isoforms,cyp1a2'
p37680
(F1
F0.00014334862385321102
I0
I1
I-1
tp37681
sS'conduction,can'
p37682
(F1
F0.00014334862385321102
I1
I0
I1
tp37683
sS'the,qtc'
p37684
(F1
F0.00028669724770642203
I2
I0
I2
tp37685
sS'resins,since'
p37686
(F1
F0.00014334862385321102
I1
I0
I1
tp37687
sS'serotonin,in'
p37688
(F1
F0.00014334862385321102
I0
I1
I-1
tp37689
sS'of,inspra'
p37690
(F1
F0.00028669724770642203
I2
I0
I2
tp37691
sS'stimulated,by'
p37692
(F1
F0.00014334862385321102
I0
I1
I-1
tp37693
sS'danger,inherent'
p37694
(F1
F0.00014334862385321102
I1
I0
I1
tp37695
sS'serentil,trilafon'
p37696
(F1
F0.00014334862385321102
I0
I1
I-1
tp37697
sS'peripheral,vasoconstriction'
p37698
(F1
F0.00014334862385321102
I1
I0
I1
tp37699
sS'contraceptives,it'
p37700
(F1
F0.00014334862385321102
I0
I1
I-1
tp37701
sS'several,studies'
p37702
(F1
F0.00028669724770642203
I0
I2
I-2
tp37703
sS'anti-malarial,such'
p37704
(F1
F0.00014334862385321102
I1
I0
I1
tp37705
sS'in,hormone'
p37706
(F1
F0.00014334862385321102
I0
I1
I-1
tp37707
sS'anticholinesterase,agents'
p37708
(F1
F0.00028669724770642203
I2
I0
I2
tp37709
sS'or,pharmacodynamics'
p37710
(F1
F0.00043004587155963305
I0
I3
I-3
tp37711
sS'men,years'
p37712
(F1
F0.00014334862385321102
I0
I1
I-1
tp37713
sS'intestinal,cancers'
p37714
(F1
F0.00028669724770642203
I0
I2
I-2
tp37715
sS'dostinex,should'
p37716
(F1
F0.00014334862385321102
I1
I0
I1
tp37717
sS'day,showed'
p37718
(F0
F0
I1
I1
I0
tp37719
sS'in,inr'
p37720
(F0
F0
I1
I1
I0
tp37721
sS'three,hours'
p37722
(F1
F0.00014334862385321102
I0
I1
I-1
tp37723
sS'therefore,in'
p37724
(F1
F0.00014334862385321102
I0
I1
I-1
tp37725
sS'by,overdose'
p37726
(F1
F0.00014334862385321102
I1
I0
I1
tp37727
sS'geometric,mean'
p37728
(F0
F0
I1
I1
I0
tp37729
sS'therefore,if'
p37730
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37731
sS'the,to'
p37732
(F1
F0.00028669724770642203
I0
I2
I-2
tp37733
sS'the,th'
p37734
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37735
sS'with,dual'
p37736
(F1
F0.00014334862385321102
I0
I1
I-1
tp37737
sS'sulindac,the'
p37738
(F1
F0.00014334862385321102
I1
I0
I1
tp37739
sS'therefore,it'
p37740
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37741
sS'antipsychotic,was'
p37742
(F1
F0.00014334862385321102
I0
I1
I-1
tp37743
sS'clonidine,hydrochloride'
p37744
(F1
F0.00014334862385321102
I1
I0
I1
tp37745
sS'body,it'
p37746
(F1
F0.00014334862385321102
I0
I1
I-1
tp37747
sS'ketoconazole,mg'
p37748
(F0
F0
I1
I1
I0
tp37749
sS'phosphorylation,inhibition'
p37750
(F1
F0.00014334862385321102
I1
I0
I1
tp37751
sS'who,have'
p37752
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp37753
sS'in,dependence'
p37754
(F1
F0.00014334862385321102
I0
I1
I-1
tp37755
sS'depressants,with'
p37756
(F1
F0.00014334862385321102
I0
I1
I-1
tp37757
sS'done,it'
p37758
(F1
F0.00014334862385321102
I0
I1
I-1
tp37759
sS'of,romazicon'
p37760
(F1
F0.00028669724770642203
I0
I2
I-2
tp37761
sS'renal,tubular'
p37762
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp37763
sS'carbimazole,and'
p37764
(F1
F0.00014334862385321102
I1
I0
I1
tp37765
sS'diabetic,rats'
p37766
(F1
F0.00014334862385321102
I0
I1
I-1
tp37767
sS'maleate,mg'
p37768
(F1
F0.00028669724770642203
I2
I0
I2
tp37769
sS'the,determination'
p37770
(F1
F0.00014334862385321102
I0
I1
I-1
tp37771
sS'autonomic,irritability'
p37772
(F1
F0.00014334862385321102
I1
I0
I1
tp37773
sS'provoke,convulsions'
p37774
(F1
F0.00014334862385321102
I0
I1
I-1
tp37775
sS'any,one'
p37776
(F1
F0.00014334862385321102
I0
I1
I-1
tp37777
sS'immune,system'
p37778
(F1
F0.00014334862385321102
I0
I1
I-1
tp37779
sS'multiple,oral'
p37780
(F0
F0
I1
I1
I0
tp37781
sS'antagonists,hmg-coa'
p37782
(F1
F0.00014334862385321102
I0
I1
I-1
tp37783
sS'continued,if'
p37784
(F1
F0.00014334862385321102
I1
I0
I1
tp37785
sS'volume,and'
p37786
(F1
F0.00014334862385321102
I1
I0
I1
tp37787
sS'body,via'
p37788
(F1
F0.00014334862385321102
I1
I0
I1
tp37789
sS'analogues,should'
p37790
(F1
F0.00043004587155963305
I0
I3
I-3
tp37791
sS'agents,primarily'
p37792
(F1
F0.00014334862385321102
I0
I1
I-1
tp37793
sS'busulfex,at'
p37794
(F1
F0.00014334862385321102
I1
I0
I1
tp37795
sS'and,aetiopathogenic--'
p37796
(F1
F0.00014334862385321102
I0
I1
I-1
tp37797
sS'also,refer'
p37798
(F1
F0.00014334862385321102
I0
I1
I-1
tp37799
sS'a,role'
p37800
(F1
F0.00014334862385321102
I0
I1
I-1
tp37801
sS'of,fibric'
p37802
(F1
F0.00014334862385321102
I0
I1
I-1
tp37803
sS'while,receiving'
p37804
(F1
F0.00014334862385321102
I1
I0
I1
tp37805
sS'with,patients'
p37806
(F1
F0.00028669724770642203
I2
I0
I2
tp37807
sS'of,atrovent'
p37808
(F0
F0
I1
I1
I0
tp37809
sS'cpa,an'
p37810
(F1
F0.00014334862385321102
I1
I0
I1
tp37811
sS'non-ionized,species'
p37812
(F1
F0.00014334862385321102
I1
I0
I1
tp37813
sS'reduce,serum'
p37814
(F1
F0.00014334862385321102
I1
I0
I1
tp37815
sS'fluids,might'
p37816
(F1
F0.00014334862385321102
I0
I1
I-1
tp37817
sS'potent,inhibitor'
p37818
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp37819
sS'may,substantially'
p37820
(F1
F0.00057339449541284407
I4
I0
I4
tp37821
sS'with,subsequent'
p37822
(F1
F0.00014334862385321102
I0
I1
I-1
tp37823
sS'the,cytochrome'
p37824
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp37825
sS'did,slightly'
p37826
(F1
F0.00014334862385321102
I1
I0
I1
tp37827
sS'sufficient,to'
p37828
(F0
F0
I1
I1
I0
tp37829
sS'intravenous,or'
p37830
(F1
F0.00014334862385321102
I1
I0
I1
tp37831
sS'nucleoside,analogues'
p37832
(F1
F0.00014334862385321102
I1
I0
I1
tp37833
sS'notably,oral'
p37834
(F1
F0.00014334862385321102
I1
I0
I1
tp37835
sS'sprycel,close'
p37836
(F1
F0.00014334862385321102
I0
I1
I-1
tp37837
sS'united,states'
p37838
(F1
F0.00014334862385321102
I0
I1
I-1
tp37839
sS'decreased,clearance'
p37840
(F1
F0.00057339449541284407
I4
I0
I4
tp37841
sS'ethanol,sonata'
p37842
(F1
F0.00014334862385321102
I1
I0
I1
tp37843
sS'special,consideration'
p37844
(F1
F0.00014334862385321102
I1
I0
I1
tp37845
sS'themselves,produce'
p37846
(F1
F0.00014334862385321102
I1
I0
I1
tp37847
sS'of,symptom'
p37848
(F1
F0.00014334862385321102
I1
I0
I1
tp37849
sS'the,consequences'
p37850
(F1
F0.00014334862385321102
I0
I1
I-1
tp37851
sS'stimulating,effect'
p37852
(F1
F0.00014334862385321102
I1
I0
I1
tp37853
sS'when,cancidas'
p37854
(F1
F0.00028669724770642203
I2
I0
I2
tp37855
sS'for,binding'
p37856
(F1
F0.00014334862385321102
I1
I0
I1
tp37857
sS'nsaid,and'
p37858
(F1
F0.00014334862385321102
I0
I1
I-1
tp37859
sS'de,pointes-type'
p37860
(F1
F0.00014334862385321102
I0
I1
I-1
tp37861
sS'between,xanthine'
p37862
(F1
F0.00014334862385321102
I1
I0
I1
tp37863
sS'which,healthy'
p37864
(F0
F0
I1
I1
I0
tp37865
sS'discontinuing,the'
p37866
(F1
F0.00071674311926605509
I5
I0
I5
tp37867
sS'hivid-associated,adverse'
p37868
(F1
F0.00014334862385321102
I1
I0
I1
tp37869
sS'observed,to'
p37870
(F1
F0.00043004587155963305
I3
I0
I3
tp37871
sS'some,reports'
p37872
(F0.5
F0.00028669724770642203
I3
I1
I2
tp37873
sS'having,a'
p37874
(F1
F0.00014334862385321102
I0
I1
I-1
tp37875
sS'toradol,on'
p37876
(F0
F0
I1
I1
I0
tp37877
sS'unexpected,adverse'
p37878
(F1
F0.00028669724770642203
I0
I2
I-2
tp37879
sS'coumarin-derivative,such'
p37880
(F1
F0.00014334862385321102
I1
I0
I1
tp37881
sS'b-blocking,properties'
p37882
(F1
F0.00071674311926605509
I5
I0
I5
tp37883
sS'mexate,use'
p37884
(F1
F0.00014334862385321102
I1
I0
I1
tp37885
sS'hour,and'
p37886
(F1
F0.00014334862385321102
I1
I0
I1
tp37887
sS'thrombocytopenia,the'
p37888
(F1
F0.00014334862385321102
I0
I1
I-1
tp37889
sS'furosemide,clinical'
p37890
(F1
F0.00071674311926605509
I5
I0
I5
tp37891
sS'differently,than'
p37892
(F1
F0.00014334862385321102
I0
I1
I-1
tp37893
sS'was,effective'
p37894
(F1
F0.00014334862385321102
I1
I0
I1
tp37895
sS'acid,from'
p37896
(F1
F0.00014334862385321102
I0
I1
I-1
tp37897
sS'use,may'
p37898
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp37899
sS'alpha,interferons'
p37900
(F1
F0.00014334862385321102
I0
I1
I-1
tp37901
sS'beta-adrenergic,blocker'
p37902
(F1
F0.00014334862385321102
I1
I0
I1
tp37903
sS'eliminated,the'
p37904
(F1
F0.00014334862385321102
I1
I0
I1
tp37905
sS'alkaline,earth'
p37906
(F1
F0.00014334862385321102
I0
I1
I-1
tp37907
sS'or,tenofovir'
p37908
(F1
F0.00014334862385321102
I0
I1
I-1
tp37909
sS'of,diarrhea'
p37910
(F1
F0.00014334862385321102
I1
I0
I1
tp37911
sS'limit,decrease'
p37912
(F1
F0.00014334862385321102
I0
I1
I-1
tp37913
sS'allopurinol,in'
p37914
(F1
F0.00014334862385321102
I0
I1
I-1
tp37915
sS'life-threatening,ventricular'
p37916
(F1
F0.00014334862385321102
I0
I1
I-1
tp37917
sS'superiority,of'
p37918
(F1
F0.00014334862385321102
I0
I1
I-1
tp37919
sS'formulation,comparable'
p37920
(F1
F0.00028669724770642203
I2
I0
I2
tp37921
sS'stimulated,but'
p37922
(F1
F0.00014334862385321102
I1
I0
I1
tp37923
sS'and,reached'
p37924
(F1
F0.00014334862385321102
I1
I0
I1
tp37925
sS'increase,two-fold'
p37926
(F1
F0.00014334862385321102
I1
I0
I1
tp37927
sS'fractional,inhibitory'
p37928
(F1
F0.00014334862385321102
I0
I1
I-1
tp37929
sS'to,crixivan'
p37930
(F1
F0.00028669724770642203
I0
I2
I-2
tp37931
sS'of,mefenamic'
p37932
(F1
F0.00014334862385321102
I1
I0
I1
tp37933
sS'was,with'
p37934
(F1
F0.00014334862385321102
I1
I0
I1
tp37935
sS'and,type'
p37936
(F1
F0.00057339449541284407
I4
I0
I4
tp37937
sS'cyp,metabolism'
p37938
(F1
F0.00014334862385321102
I1
I0
I1
tp37939
sS'after,receiving'
p37940
(F1
F0.00028669724770642203
I2
I0
I2
tp37941
sS'oral,load'
p37942
(F1
F0.00014334862385321102
I0
I1
I-1
tp37943
sS'were,in'
p37944
(F0
F0
I1
I1
I0
tp37945
sS'motility,in'
p37946
(F1
F0.00014334862385321102
I1
I0
I1
tp37947
sS'no,binding'
p37948
(F1
F0.00014334862385321102
I0
I1
I-1
tp37949
sS'electrolyte,loss'
p37950
(F1
F0.00028669724770642203
I2
I0
I2
tp37951
sS'of,combination'
p37952
(F1
F0.00014334862385321102
I1
I0
I1
tp37953
sS'fold,increases'
p37954
(F0
F0
I1
I1
I0
tp37955
sS'before,to'
p37956
(F1
F0.00028669724770642203
I0
I2
I-2
tp37957
sS'in,proprietary'
p37958
(F1
F0.00014334862385321102
I1
I0
I1
tp37959
sS'with,amevive'
p37960
(F1
F0.00014334862385321102
I0
I1
I-1
tp37961
sS'seen,prior'
p37962
(F1
F0.00014334862385321102
I1
I0
I1
tp37963
sS'agents,clomipramine'
p37964
(F1
F0.00014334862385321102
I1
I0
I1
tp37965
sS'as,myelosuppression'
p37966
(F1
F0.00014334862385321102
I1
I0
I1
tp37967
sS'altering,prothrombin'
p37968
(F1
F0.00014334862385321102
I1
I0
I1
tp37969
sS'of,ergocalcitriol'
p37970
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp37971
sS'striatal,concentrations'
p37972
(F1
F0.00014334862385321102
I1
I0
I1
tp37973
sS'inhibitors,prostaglandin'
p37974
(F1
F0.00014334862385321102
I0
I1
I-1
tp37975
sS'administered,hydrochloride'
p37976
(F1
F0.00014334862385321102
I0
I1
I-1
tp37977
sS'and,effects'
p37978
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp37979
sS'enhancement,effect'
p37980
(F1
F0.00014334862385321102
I1
I0
I1
tp37981
sS'systemic,non-hodgkin'
p37982
(F1
F0.00014334862385321102
I0
I1
I-1
tp37983
sS'copegus,should'
p37984
(F1
F0.00014334862385321102
I0
I1
I-1
tp37985
sS'mercaptopurine,azathioprine'
p37986
(F1
F0.00014334862385321102
I1
I0
I1
tp37987
sS'twitch,was'
p37988
(F0
F0
I1
I1
I0
tp37989
sS'significant,degree'
p37990
(F1
F0.00014334862385321102
I0
I1
I-1
tp37991
sS'and,cholestytamine'
p37992
(F1
F0.00014334862385321102
I1
I0
I1
tp37993
sS'proof,of'
p37994
(F1
F0.00014334862385321102
I0
I1
I-1
tp37995
sS'because,nephrotoxicity'
p37996
(F1
F0.00014334862385321102
I1
I0
I1
tp37997
sS'and,would'
p37998
(F0
F0
I2
I2
I0
tp37999
sS'immunodeficiency,virus-positive'
p38000
(F1
F0.00014334862385321102
I0
I1
I-1
tp38001
sS'was,prevented'
p38002
(F1
F0.00028669724770642203
I2
I0
I2
tp38003
sS'similar,compounds'
p38004
(F1
F0.00014334862385321102
I0
I1
I-1
tp38005
sS'verapamil,coadministration'
p38006
(F1
F0.00014334862385321102
I1
I0
I1
tp38007
sS'rats,responses'
p38008
(F1
F0.00014334862385321102
I0
I1
I-1
tp38009
sS'aprepitant,given'
p38010
(F1
F0.00014334862385321102
I1
I0
I1
tp38011
sS'the,curariform'
p38012
(F1
F0.00014334862385321102
I1
I0
I1
tp38013
sS'reports,of'
p38014
(F0.41176470588235292
F0.0020068807339449542
I24
I10
I14
tp38015
sS'is,almost'
p38016
(F1
F0.00014334862385321102
I0
I1
I-1
tp38017
sS'the,effectiveness'
p38018
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp38019
sS'hydrochloride,in'
p38020
(F1
F0.00014334862385321102
I1
I0
I1
tp38021
sS'clearance,of'
p38022
(F0.7142857142857143
F0.0050172018348623856
I42
I7
I35
tp38023
sS'of,anticholinesterase'
p38024
(F1
F0.00028669724770642203
I2
I0
I2
tp38025
sS'appeared,to'
p38026
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp38027
sS'proteins,in'
p38028
(F1
F0.00014334862385321102
I0
I1
I-1
tp38029
sS'probenecid,is'
p38030
(F0
F0
I1
I1
I0
tp38031
sS'clearance,or'
p38032
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38033
sS'hydrochloride,is'
p38034
(F0.5
F0.00028669724770642203
I3
I1
I2
tp38035
sS'also,interfere'
p38036
(F1
F0.00014334862385321102
I1
I0
I1
tp38037
sS'may,intensify'
p38038
(F0
F0
I1
I1
I0
tp38039
sS'or,who'
p38040
(F1
F0.00028669724770642203
I2
I0
I2
tp38041
sS'dosing,schedule'
p38042
(F1
F0.00014334862385321102
I0
I1
I-1
tp38043
sS'one,dose'
p38044
(F1
F0.00014334862385321102
I1
I0
I1
tp38045
sS'report,the'
p38046
(F1
F0.00014334862385321102
I1
I0
I1
tp38047
sS'volunteers,with'
p38048
(F0
F0
I1
I1
I0
tp38049
sS'of,platelet'
p38050
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38051
sS'elimination,but'
p38052
(F1
F0.00014334862385321102
I1
I0
I1
tp38053
sS'following,symptom'
p38054
(F1
F0.00014334862385321102
I0
I1
I-1
tp38055
sS'cystic,fibrosis'
p38056
(F1
F0.00014334862385321102
I0
I1
I-1
tp38057
sS'potentiation,by'
p38058
(F1
F0.00014334862385321102
I1
I0
I1
tp38059
sS'indicating,an'
p38060
(F1
F0.00014334862385321102
I0
I1
I-1
tp38061
sS'which,only'
p38062
(F1
F0.00014334862385321102
I0
I1
I-1
tp38063
sS'add,to'
p38064
(F1
F0.00028669724770642203
I2
I0
I2
tp38065
sS'blockade,by'
p38066
(F1
F0.00028669724770642203
I2
I0
I2
tp38067
sS'anti-inflammatory,agents'
p38068
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp38069
sS'or,with'
p38070
(F0.076923076923076927
F0.00014334862385321102
I7
I6
I1
tp38071
sS'oral,azole'
p38072
(F1
F0.00014334862385321102
I1
I0
I1
tp38073
sS'their,effectiveness'
p38074
(F1
F0.00014334862385321102
I0
I1
I-1
tp38075
sS'ssris,many'
p38076
(F1
F0.00014334862385321102
I0
I1
I-1
tp38077
sS'taking,labetalol'
p38078
(F1
F0.00014334862385321102
I1
I0
I1
tp38079
sS'with,fondaparinux'
p38080
(F1
F0.00014334862385321102
I0
I1
I-1
tp38081
sS'hallucinations,have'
p38082
(F1
F0.00014334862385321102
I1
I0
I1
tp38083
sS'above,or'
p38084
(F1
F0.00014334862385321102
I1
I0
I1
tp38085
sS'containing,medicines'
p38086
(F1
F0.00014334862385321102
I1
I0
I1
tp38087
sS'above,of'
p38088
(F1
F0.00014334862385321102
I1
I0
I1
tp38089
sS'during,administration'
p38090
(F0.5
F0.00028669724770642203
I3
I1
I2
tp38091
sS'kappa-selective,was'
p38092
(F1
F0.00014334862385321102
I0
I1
I-1
tp38093
sS'tcas,decrease'
p38094
(F1
F0.00014334862385321102
I1
I0
I1
tp38095
sS'to,rachitic'
p38096
(F1
F0.00014334862385321102
I1
I0
I1
tp38097
sS'cardiac,output'
p38098
(F1
F0.00028669724770642203
I2
I0
I2
tp38099
sS'cmax,respectively'
p38100
(F1
F0.00014334862385321102
I0
I1
I-1
tp38101
sS'confidence,limit'
p38102
(F1
F0.00014334862385321102
I0
I1
I-1
tp38103
sS'in,phase'
p38104
(F1
F0.00014334862385321102
I0
I1
I-1
tp38105
sS'mellitus,and'
p38106
(F1
F0.00014334862385321102
I0
I1
I-1
tp38107
sS'indomethacin,concomitant'
p38108
(F1
F0.00014334862385321102
I1
I0
I1
tp38109
sS'on,blocking'
p38110
(F1
F0.00014334862385321102
I0
I1
I-1
tp38111
sS'n-diethyl,m-toluamide'
p38112
(F1
F0.00014334862385321102
I1
I0
I1
tp38113
sS'methotrexate,vioxx'
p38114
(F1
F0.00014334862385321102
I0
I1
I-1
tp38115
sS'pyrocarbonate,revealed'
p38116
(F1
F0.00014334862385321102
I0
I1
I-1
tp38117
sS'synthesis,secretion'
p38118
(F1
F0.00014334862385321102
I0
I1
I-1
tp38119
sS'growth,response'
p38120
(F1
F0.00014334862385321102
I0
I1
I-1
tp38121
sS'generalized,urticaria'
p38122
(F1
F0.00014334862385321102
I0
I1
I-1
tp38123
sS'sinus,arrest'
p38124
(F1
F0.00014334862385321102
I0
I1
I-1
tp38125
sS'when,systemic'
p38126
(F1
F0.00014334862385321102
I1
I0
I1
tp38127
sS'the,impact'
p38128
(F1
F0.00014334862385321102
I0
I1
I-1
tp38129
sS'years,old'
p38130
(F1
F0.00014334862385321102
I0
I1
I-1
tp38131
sS'cholestyramine,cholestyramine'
p38132
(F1
F0.00071674311926605509
I5
I0
I5
tp38133
sS'of,level'
p38134
(F1
F0.00014334862385321102
I1
I0
I1
tp38135
sS'of,excretion'
p38136
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38137
sS'protective,or'
p38138
(F1
F0.00014334862385321102
I0
I1
I-1
tp38139
sS'of,may'
p38140
(F0.84313725490196079
F0.0061639908256880737
I47
I4
I43
tp38141
sS'of,pcp'
p38142
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp38143
sS'long-term,suppression'
p38144
(F1
F0.00014334862385321102
I1
I0
I1
tp38145
sS'safety,and'
p38146
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp38147
sS'its,pharmacologically'
p38148
(F1
F0.00014334862385321102
I0
I1
I-1
tp38149
sS'of,mao'
p38150
(F1
F0.00014334862385321102
I1
I0
I1
tp38151
sS'samples,may'
p38152
(F1
F0.00014334862385321102
I0
I1
I-1
tp38153
sS'false,increases'
p38154
(F1
F0.00028669724770642203
I0
I2
I-2
tp38155
sS'secondary,deficiencies'
p38156
(F1
F0.00014334862385321102
I0
I1
I-1
tp38157
sS'k,can'
p38158
(F1
F0.00014334862385321102
I1
I0
I1
tp38159
sS'a4,grapefruit'
p38160
(F1
F0.00014334862385321102
I1
I0
I1
tp38161
sS'of,erythrocyte'
p38162
(F1
F0.00014334862385321102
I1
I0
I1
tp38163
sS'patients,either'
p38164
(F1
F0.00014334862385321102
I0
I1
I-1
tp38165
sS'results,sildenafil'
p38166
(F1
F0.00014334862385321102
I0
I1
I-1
tp38167
sS'iii,human'
p38168
(F1
F0.00014334862385321102
I1
I0
I1
tp38169
sS'function,are'
p38170
(F1
F0.00014334862385321102
I0
I1
I-1
tp38171
sS'because,bleeding'
p38172
(F1
F0.00014334862385321102
I1
I0
I1
tp38173
sS'the,that'
p38174
(F1
F0.00014334862385321102
I1
I0
I1
tp38175
sS'of,diamox'
p38176
(F1
F0.00028669724770642203
I2
I0
I2
tp38177
sS'compound,and'
p38178
(F1
F0.00014334862385321102
I0
I1
I-1
tp38179
sS'humira,may'
p38180
(F1
F0.00014334862385321102
I1
I0
I1
tp38181
sS'formulations,of'
p38182
(F1
F0.00014334862385321102
I1
I0
I1
tp38183
sS'control,should'
p38184
(F1
F0.00014334862385321102
I1
I0
I1
tp38185
sS'failure,receiving'
p38186
(F1
F0.00014334862385321102
I1
I0
I1
tp38187
sS'to,compromise'
p38188
(F1
F0.00014334862385321102
I1
I0
I1
tp38189
sS'administering,celebrex'
p38190
(F1
F0.00014334862385321102
I1
I0
I1
tp38191
sS'duodenal,absorption'
p38192
(F1
F0.00014334862385321102
I1
I0
I1
tp38193
sS'enzymes,primarily'
p38194
(F1
F0.00014334862385321102
I0
I1
I-1
tp38195
sS'ranitidine,mg'
p38196
(F1
F0.00014334862385321102
I0
I1
I-1
tp38197
sS'and,comparison'
p38198
(F1
F0.00014334862385321102
I0
I1
I-1
tp38199
sS'there,are'
p38200
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp38201
sS'abnormalities,arrhythmia'
p38202
(F1
F0.00014334862385321102
I1
I0
I1
tp38203
sS'with,moieties'
p38204
(F1
F0.00014334862385321102
I0
I1
I-1
tp38205
sS'more,were'
p38206
(F1
F0.00014334862385321102
I0
I1
I-1
tp38207
sS'the,a-v'
p38208
(F1
F0.00014334862385321102
I1
I0
I1
tp38209
sS'ld50,of'
p38210
(F1
F0.00014334862385321102
I1
I0
I1
tp38211
sS'significant,inhibition'
p38212
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38213
sS'novolog,with'
p38214
(F1
F0.00028669724770642203
I0
I2
I-2
tp38215
sS'users,is'
p38216
(F1
F0.00014334862385321102
I0
I1
I-1
tp38217
sS'consequently,the'
p38218
(F1
F0.00028669724770642203
I2
I0
I2
tp38219
sS'other,should'
p38220
(F1
F0.00057339449541284407
I4
I0
I4
tp38221
sS'that,acarbose'
p38222
(F1
F0.00014334862385321102
I0
I1
I-1
tp38223
sS'tam,significantly'
p38224
(F1
F0.00014334862385321102
I1
I0
I1
tp38225
sS'that,several'
p38226
(F1
F0.00014334862385321102
I0
I1
I-1
tp38227
sS'maximum,human'
p38228
(F1
F0.00014334862385321102
I1
I0
I1
tp38229
sS'when,ht1'
p38230
(F1
F0.00014334862385321102
I1
I0
I1
tp38231
sS'case,reports'
p38232
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38233
sS'year,risk'
p38234
(F1
F0.00014334862385321102
I0
I1
I-1
tp38235
sS'more,likely'
p38236
(F1
F0.00014334862385321102
I0
I1
I-1
tp38237
sS'cause,a'
p38238
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp38239
sS'cause,k'
p38240
(F1
F0.00014334862385321102
I0
I1
I-1
tp38241
sS'with,long-term'
p38242
(F0
F0
I1
I1
I0
tp38243
sS'digoxin,sonata'
p38244
(F1
F0.00014334862385321102
I0
I1
I-1
tp38245
sS'other,anti-asthma'
p38246
(F1
F0.00014334862385321102
I0
I1
I-1
tp38247
sS'group,specifically'
p38248
(F1
F0.00014334862385321102
I0
I1
I-1
tp38249
sS'disulfiram-like,reaction'
p38250
(F1
F0.00014334862385321102
I0
I1
I-1
tp38251
sS'psychotomimetic,effects'
p38252
(F1
F0.00014334862385321102
I0
I1
I-1
tp38253
sS'atropinization,flushing'
p38254
(F1
F0.00014334862385321102
I1
I0
I1
tp38255
sS'these,peptides'
p38256
(F1
F0.00014334862385321102
I0
I1
I-1
tp38257
sS'january,and'
p38258
(F1
F0.00014334862385321102
I0
I1
I-1
tp38259
sS'are,strong'
p38260
(F1
F0.00014334862385321102
I0
I1
I-1
tp38261
sS'a,twofold'
p38262
(F1
F0.00014334862385321102
I1
I0
I1
tp38263
sS'affect,duloxetine'
p38264
(F1
F0.00014334862385321102
I0
I1
I-1
tp38265
sS'repeating,the'
p38266
(F1
F0.00014334862385321102
I0
I1
I-1
tp38267
sS'of,postoperative'
p38268
(F1
F0.00014334862385321102
I0
I1
I-1
tp38269
sS'hydrochlorothiazide,given'
p38270
(F1
F0.00014334862385321102
I1
I0
I1
tp38271
sS'or,but'
p38272
(F1
F0.00014334862385321102
I1
I0
I1
tp38273
sS'or,tumor'
p38274
(F1
F0.00014334862385321102
I0
I1
I-1
tp38275
sS'determined,urinary'
p38276
(F1
F0.00014334862385321102
I0
I1
I-1
tp38277
sS'to,iodinated'
p38278
(F1
F0.00014334862385321102
I1
I0
I1
tp38279
sS'agents,was'
p38280
(F1
F0.00028669724770642203
I0
I2
I-2
tp38281
sS'may,also'
p38282
(F0.33333333333333331
F0.0008600917431192661
I12
I6
I6
tp38283
sS'symptom,control'
p38284
(F1
F0.00014334862385321102
I1
I0
I1
tp38285
sS'pivoxil,had'
p38286
(F1
F0.00014334862385321102
I0
I1
I-1
tp38287
sS'antitumor,activity'
p38288
(F1
F0.00014334862385321102
I0
I1
I-1
tp38289
sS'meperidine,amphetamines'
p38290
(F1
F0.00028669724770642203
I2
I0
I2
tp38291
sS'no,dose'
p38292
(F1
F0.00071674311926605509
I0
I5
I-5
tp38293
sS'of,pegasys'
p38294
(F1
F0.00043004587155963305
I0
I3
I-3
tp38295
sS'cisplatin,was'
p38296
(F1
F0.00014334862385321102
I0
I1
I-1
tp38297
sS'or,thiazide'
p38298
(F1
F0.00014334862385321102
I1
I0
I1
tp38299
sS'nardil,matulane'
p38300
(F1
F0.00014334862385321102
I0
I1
I-1
tp38301
sS'dosing,beta-1a'
p38302
(F1
F0.00014334862385321102
I1
I0
I1
tp38303
sS'n-type,or'
p38304
(F1
F0.00014334862385321102
I0
I1
I-1
tp38305
sS'a,antimicrobial'
p38306
(F1
F0.00028669724770642203
I2
I0
I2
tp38307
sS'approximately,times'
p38308
(F1
F0.00028669724770642203
I2
I0
I2
tp38309
sS'serious,reaction'
p38310
(F1
F0.00014334862385321102
I1
I0
I1
tp38311
sS'given,concomitantly'
p38312
(F0.1111111111111111
F0.00028669724770642203
I10
I8
I2
tp38313
sS'some,are'
p38314
(F1
F0.00014334862385321102
I0
I1
I-1
tp38315
sS'careful,observations'
p38316
(F1
F0.00014334862385321102
I1
I0
I1
tp38317
sS'suspending,use'
p38318
(F1
F0.00014334862385321102
I1
I0
I1
tp38319
sS'significantly,increased'
p38320
(F1
F0.0010034403669724771
I7
I0
I7
tp38321
sS'failure,have'
p38322
(F1
F0.00014334862385321102
I1
I0
I1
tp38323
sS'sometimes,mcg'
p38324
(F1
F0.00014334862385321102
I0
I1
I-1
tp38325
sS'patch-clamp,whole-cell'
p38326
(F1
F0.00014334862385321102
I0
I1
I-1
tp38327
sS'volunteers,a'
p38328
(F1
F0.00043004587155963305
I3
I0
I3
tp38329
sS'the,treatment'
p38330
(F0.21739130434782608
F0.00071674311926605509
I9
I14
I-5
tp38331
sS'of,influence'
p38332
(F1
F0.00014334862385321102
I0
I1
I-1
tp38333
sS'volunteers,n'
p38334
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp38335
sS'hyperkalemia,in'
p38336
(F1
F0.00014334862385321102
I1
I0
I1
tp38337
sS'and,channel'
p38338
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38339
sS'an,week'
p38340
(F1
F0.00028669724770642203
I0
I2
I-2
tp38341
sS'lymphocytopenia,has'
p38342
(F1
F0.00014334862385321102
I1
I0
I1
tp38343
sS'oral,a'
p38344
(F1
F0.00014334862385321102
I1
I0
I1
tp38345
sS'mg,m2'
p38346
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38347
sS'or,similarly'
p38348
(F1
F0.00014334862385321102
I0
I1
I-1
tp38349
sS'that,not'
p38350
(F1
F0.00014334862385321102
I1
I0
I1
tp38351
sS'widening,of'
p38352
(F1
F0.00014334862385321102
I1
I0
I1
tp38353
sS'fluoxetine,ocs'
p38354
(F1
F0.00014334862385321102
I0
I1
I-1
tp38355
sS'if,hydrochloride'
p38356
(F1
F0.00014334862385321102
I1
I0
I1
tp38357
sS'other,including'
p38358
(F0
F0
I2
I2
I0
tp38359
sS'given,plasma'
p38360
(F1
F0.00014334862385321102
I0
I1
I-1
tp38361
sS'mg,mg'
p38362
(F1
F0.00043004587155963305
I0
I3
I-3
tp38363
sS'pointes-type,ventricular'
p38364
(F1
F0.00014334862385321102
I0
I1
I-1
tp38365
sS'an,intubating'
p38366
(F1
F0.00014334862385321102
I1
I0
I1
tp38367
sS'caused,subnormal'
p38368
(F1
F0.00014334862385321102
I0
I1
I-1
tp38369
sS'toxicity,have'
p38370
(F1
F0.00057339449541284407
I4
I0
I4
tp38371
sS'gleevec,will'
p38372
(F1
F0.00014334862385321102
I1
I0
I1
tp38373
sS'tambocor,has'
p38374
(F1
F0.00028669724770642203
I0
I2
I-2
tp38375
sS'increased,rate'
p38376
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38377
sS'severe,orthostatic'
p38378
(F1
F0.00014334862385321102
I1
I0
I1
tp38379
sS'derivatives,indandione'
p38380
(F1
F0.00014334862385321102
I1
I0
I1
tp38381
sS'to,environmental'
p38382
(F1
F0.00014334862385321102
I1
I0
I1
tp38383
sS'administered,several'
p38384
(F1
F0.00014334862385321102
I0
I1
I-1
tp38385
sS'including,sodium'
p38386
(F1
F0.00014334862385321102
I1
I0
I1
tp38387
sS'two-fold,increase'
p38388
(F1
F0.00014334862385321102
I1
I0
I1
tp38389
sS'carried,out'
p38390
(F1
F0.00057339449541284407
I0
I4
I-4
tp38391
sS'activated,prothrombin'
p38392
(F1
F0.00014334862385321102
I0
I1
I-1
tp38393
sS'synthetic,hydroalcoholic'
p38394
(F1
F0.00014334862385321102
I0
I1
I-1
tp38395
sS'blood,platelets'
p38396
(F1
F0.00014334862385321102
I1
I0
I1
tp38397
sS'of,disrupts'
p38398
(F1
F0.00014334862385321102
I0
I1
I-1
tp38399
sS'clearance,such'
p38400
(F1
F0.00014334862385321102
I1
I0
I1
tp38401
sS'second,response'
p38402
(F1
F0.00014334862385321102
I0
I1
I-1
tp38403
sS'acid,antagonists'
p38404
(F1
F0.00014334862385321102
I1
I0
I1
tp38405
sS'other,products'
p38406
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38407
sS'hallucinations,and'
p38408
(F1
F0.00014334862385321102
I1
I0
I1
tp38409
sS'fractions,on'
p38410
(F1
F0.00014334862385321102
I0
I1
I-1
tp38411
sS'male,subjects'
p38412
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38413
sS'symptoms,of'
p38414
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp38415
sS'events,have'
p38416
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38417
sS'zalcitabine,also'
p38418
(F1
F0.00014334862385321102
I1
I0
I1
tp38419
sS'toxicity,because'
p38420
(F1
F0.00014334862385321102
I0
I1
I-1
tp38421
sS'tolbutamide,aprepitant'
p38422
(F1
F0.00014334862385321102
I1
I0
I1
tp38423
sS'sildenafil,is'
p38424
(F1
F0.00014334862385321102
I1
I0
I1
tp38425
sS'variability,in'
p38426
(F1
F0.00028669724770642203
I2
I0
I2
tp38427
sS'intrathecal,micrograms'
p38428
(F1
F0.00014334862385321102
I1
I0
I1
tp38429
sS'insufficient,plasma'
p38430
(F1
F0.00014334862385321102
I1
I0
I1
tp38431
sS'that,concentrations'
p38432
(F1
F0.00014334862385321102
I1
I0
I1
tp38433
sS'both,sensory'
p38434
(F1
F0.00014334862385321102
I1
I0
I1
tp38435
sS'commonly,used'
p38436
(F1
F0.0010034403669724771
I0
I7
I-7
tp38437
sS'inderal,tenormin'
p38438
(F1
F0.00014334862385321102
I0
I1
I-1
tp38439
sS'hypertensive,responses'
p38440
(F1
F0.00014334862385321102
I1
I0
I1
tp38441
sS'of,once'
p38442
(F1
F0.00028669724770642203
I2
I0
I2
tp38443
sS'lithium,toxicity'
p38444
(F1
F0.00043004587155963305
I3
I0
I3
tp38445
sS'erythromycin,on'
p38446
(F1
F0.00014334862385321102
I0
I1
I-1
tp38447
sS'high-dose,mg'
p38448
(F1
F0.00014334862385321102
I1
I0
I1
tp38449
sS'important,role'
p38450
(F1
F0.00028669724770642203
I2
I0
I2
tp38451
sS'at,steady'
p38452
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp38453
sS'predictable,sympathetic'
p38454
(F1
F0.00014334862385321102
I1
I0
I1
tp38455
sS'dose,and'
p38456
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp38457
sS'ketoconazole,fexofenadine'
p38458
(F1
F0.00014334862385321102
I0
I1
I-1
tp38459
sS'review,of'
p38460
(F1
F0.00014334862385321102
I1
I0
I1
tp38461
sS'a,pharmacokinetic'
p38462
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp38463
sS'for,strains'
p38464
(F1
F0.00014334862385321102
I1
I0
I1
tp38465
sS'bezalip,and'
p38466
(F1
F0.00014334862385321102
I1
I0
I1
tp38467
sS'strain,of'
p38468
(F1
F0.00014334862385321102
I0
I1
I-1
tp38469
sS'conversely,the'
p38470
(F0
F0
I1
I1
I0
tp38471
sS'in,rheumatoid'
p38472
(F1
F0.00043004587155963305
I0
I3
I-3
tp38473
sS'is,clinically'
p38474
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp38475
sS'also,shown'
p38476
(F1
F0.00014334862385321102
I1
I0
I1
tp38477
sS'for,by'
p38478
(F1
F0.00014334862385321102
I1
I0
I1
tp38479
sS'a,reduced'
p38480
(F0
F0
I1
I1
I0
tp38481
sS'the,total'
p38482
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38483
sS'substantially,the'
p38484
(F1
F0.00014334862385321102
I1
I0
I1
tp38485
sS'or,neuromuscular'
p38486
(F1
F0.00014334862385321102
I0
I1
I-1
tp38487
sS'lower,maintenance'
p38488
(F1
F0.00014334862385321102
I1
I0
I1
tp38489
sS'of,cyp-2c19'
p38490
(F1
F0.00014334862385321102
I0
I1
I-1
tp38491
sS'fici,was'
p38492
(F1
F0.00014334862385321102
I0
I1
I-1
tp38493
sS'as,salicylic'
p38494
(F1
F0.00014334862385321102
I0
I1
I-1
tp38495
sS'since,a'
p38496
(F1
F0.00014334862385321102
I0
I1
I-1
tp38497
sS'both,cyp2c9'
p38498
(F1
F0.00014334862385321102
I0
I1
I-1
tp38499
sS'acamprosate,produced'
p38500
(F1
F0.00014334862385321102
I1
I0
I1
tp38501
sS'would,not'
p38502
(F1
F0.00057339449541284407
I0
I4
I-4
tp38503
sS'cases,of'
p38504
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp38505
sS'pharmacokinetic,variables'
p38506
(F1
F0.00028669724770642203
I0
I2
I-2
tp38507
sS'of,amevive'
p38508
(F1
F0.00014334862385321102
I0
I1
I-1
tp38509
sS'because,prostaglandins'
p38510
(F1
F0.00014334862385321102
I1
I0
I1
tp38511
sS'enzymes,the'
p38512
(F1
F0.00014334862385321102
I1
I0
I1
tp38513
sS'observed,for'
p38514
(F0
F0
I5
I5
I0
tp38515
sS'because,prostaglandina'
p38516
(F1
F0.00014334862385321102
I1
I0
I1
tp38517
sS'and,lessened'
p38518
(F1
F0.00014334862385321102
I1
I0
I1
tp38519
sS'clonidines,analgesic'
p38520
(F1
F0.00014334862385321102
I0
I1
I-1
tp38521
sS'high,inter-patient'
p38522
(F1
F0.00014334862385321102
I0
I1
I-1
tp38523
sS'blood,auc0-12'
p38524
(F1
F0.00014334862385321102
I1
I0
I1
tp38525
sS'cream,and'
p38526
(F1
F0.00014334862385321102
I0
I1
I-1
tp38527
sS'rebif,is'
p38528
(F1
F0.00014334862385321102
I0
I1
I-1
tp38529
sS'although,additional'
p38530
(F1
F0.00014334862385321102
I0
I1
I-1
tp38531
sS'to,representing'
p38532
(F1
F0.00014334862385321102
I1
I0
I1
tp38533
sS'contraceptives,keppra'
p38534
(F1
F0.00014334862385321102
I0
I1
I-1
tp38535
sS'in,causing'
p38536
(F1
F0.00014334862385321102
I1
I0
I1
tp38537
sS'cyp2c8,in'
p38538
(F1
F0.00014334862385321102
I0
I1
I-1
tp38539
sS'developing,an'
p38540
(F1
F0.00014334862385321102
I1
I0
I1
tp38541
sS'antidepressants,use'
p38542
(F1
F0.00014334862385321102
I1
I0
I1
tp38543
sS'doses,up'
p38544
(F0
F0
I1
I1
I0
tp38545
sS'a,beta-adrenergic'
p38546
(F1
F0.00014334862385321102
I1
I0
I1
tp38547
sS'agitation,progressing'
p38548
(F1
F0.00014334862385321102
I1
I0
I1
tp38549
sS'if,or'
p38550
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38551
sS'disease,or'
p38552
(F1
F0.00014334862385321102
I1
I0
I1
tp38553
sS'local,since'
p38554
(F1
F0.00014334862385321102
I1
I0
I1
tp38555
sS'acute,symptoms'
p38556
(F1
F0.00014334862385321102
I0
I1
I-1
tp38557
sS'times,more'
p38558
(F1
F0.00014334862385321102
I0
I1
I-1
tp38559
sS'verified,by'
p38560
(F1
F0.00014334862385321102
I0
I1
I-1
tp38561
sS'in,pharmacokinetics'
p38562
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38563
sS'or,videx'
p38564
(F1
F0.00043004587155963305
I3
I0
I3
tp38565
sS'larger,doses'
p38566
(F0
F0
I1
I1
I0
tp38567
sS'that,adl'
p38568
(F1
F0.00014334862385321102
I1
I0
I1
tp38569
sS'diarrhea,and'
p38570
(F1
F0.00014334862385321102
I1
I0
I1
tp38571
sS'sodium,sulfate'
p38572
(F1
F0.00014334862385321102
I0
I1
I-1
tp38573
sS'atrioventricular,conduction'
p38574
(F1
F0.00014334862385321102
I1
I0
I1
tp38575
sS'preparations,nsaids'
p38576
(F1
F0.00014334862385321102
I0
I1
I-1
tp38577
sS'a,multiple'
p38578
(F0
F0
I1
I1
I0
tp38579
sS'was,far'
p38580
(F1
F0.00014334862385321102
I0
I1
I-1
tp38581
sS'whether,this'
p38582
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38583
sS'antagonism,between'
p38584
(F1
F0.00014334862385321102
I1
I0
I1
tp38585
sS'further,in'
p38586
(F1
F0.00014334862385321102
I0
I1
I-1
tp38587
sS'to,exceed'
p38588
(F1
F0.00043004587155963305
I3
I0
I3
tp38589
sS'are,receiving'
p38590
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp38591
sS'between,the'
p38592
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp38593
sS'transmission,at'
p38594
(F1
F0.00014334862385321102
I0
I1
I-1
tp38595
sS'was,concluded'
p38596
(F0
F0
I1
I1
I0
tp38597
sS'what,to'
p38598
(F1
F0.00014334862385321102
I0
I1
I-1
tp38599
sS'toradol,with'
p38600
(F1
F0.00014334862385321102
I0
I1
I-1
tp38601
sS'triazolam,no'
p38602
(F1
F0.00014334862385321102
I0
I1
I-1
tp38603
sS'or,dialysis'
p38604
(F1
F0.00014334862385321102
I1
I0
I1
tp38605
sS'phenyl-butazone,sodium'
p38606
(F1
F0.00014334862385321102
I0
I1
I-1
tp38607
sS'the,beginning'
p38608
(F1
F0.00014334862385321102
I0
I1
I-1
tp38609
sS'antimuscarinic,effects'
p38610
(F1
F0.00014334862385321102
I1
I0
I1
tp38611
sS'concurrently,administered'
p38612
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38613
sS'in,hypothyroid'
p38614
(F1
F0.00028669724770642203
I0
I2
I-2
tp38615
sS'bioavailability,auc'
p38616
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38617
sS'toxicity,has'
p38618
(F1
F0.00057339449541284407
I4
I0
I4
tp38619
sS'cataflam,lodine'
p38620
(F1
F0.00014334862385321102
I0
I1
I-1
tp38621
sS'this,enzyme'
p38622
(F0
F0
I3
I3
I0
tp38623
sS'hydroxide,reduce'
p38624
(F1
F0.00014334862385321102
I1
I0
I1
tp38625
sS'manner,similar'
p38626
(F1
F0.00014334862385321102
I0
I1
I-1
tp38627
sS'exposure-response,relationships'
p38628
(F1
F0.00014334862385321102
I0
I1
I-1
tp38629
sS'gastrointestinal,effects'
p38630
(F1
F0.00028669724770642203
I2
I0
I2
tp38631
sS'with,little'
p38632
(F1
F0.00028669724770642203
I2
I0
I2
tp38633
sS'synergism,between'
p38634
(F1
F0.00014334862385321102
I1
I0
I1
tp38635
sS'increased,catabloism'
p38636
(F1
F0.00014334862385321102
I0
I1
I-1
tp38637
sS'and,extensive'
p38638
(F1
F0.00014334862385321102
I0
I1
I-1
tp38639
sS'patients,to'
p38640
(F1
F0.00028669724770642203
I2
I0
I2
tp38641
sS'any,other'
p38642
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38643
sS'a,has'
p38644
(F1
F0.00014334862385321102
I1
I0
I1
tp38645
sS'retard,may'
p38646
(F1
F0.00014334862385321102
I1
I0
I1
tp38647
sS'iressa,may'
p38648
(F1
F0.00014334862385321102
I1
I0
I1
tp38649
sS'in,other'
p38650
(F1
F0.00014334862385321102
I1
I0
I1
tp38651
sS'data,emphasize'
p38652
(F1
F0.00014334862385321102
I0
I1
I-1
tp38653
sS'of,basal'
p38654
(F1
F0.00014334862385321102
I0
I1
I-1
tp38655
sS'is,increased'
p38656
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp38657
sS'including,nonsteroidal'
p38658
(F1
F0.00057339449541284407
I4
I0
I4
tp38659
sS'and,administration'
p38660
(F1
F0.00014334862385321102
I0
I1
I-1
tp38661
sS'when,initiating'
p38662
(F1
F0.0011467889908256881
I8
I0
I8
tp38663
sS'significant,changes'
p38664
(F1
F0.0008600917431192661
I0
I6
I-6
tp38665
sS'nalfon,may'
p38666
(F1
F0.00028669724770642203
I2
I0
I2
tp38667
sS'markedly,increases'
p38668
(F1
F0.00014334862385321102
I1
I0
I1
tp38669
sS'tmax,by'
p38670
(F1
F0.00014334862385321102
I1
I0
I1
tp38671
sS'metabolized,should'
p38672
(F1
F0.00014334862385321102
I1
I0
I1
tp38673
sS'equetrotm,and'
p38674
(F0
F0
I1
I1
I0
tp38675
sS'markedly,increased'
p38676
(F1
F0.00028669724770642203
I2
I0
I2
tp38677
sS'activation,in'
p38678
(F1
F0.00014334862385321102
I0
I1
I-1
tp38679
sS'ingested,or'
p38680
(F1
F0.00014334862385321102
I0
I1
I-1
tp38681
sS'dosage,reduced'
p38682
(F1
F0.00014334862385321102
I1
I0
I1
tp38683
sS'nonselective,monoamine'
p38684
(F1
F0.00014334862385321102
I1
I0
I1
tp38685
sS'pharmacology,drug-'
p38686
(F1
F0.00014334862385321102
I0
I1
I-1
tp38687
sS'faecalis,and'
p38688
(F1
F0.00014334862385321102
I0
I1
I-1
tp38689
sS'fluconazole,an'
p38690
(F1
F0.00014334862385321102
I1
I0
I1
tp38691
sS'cmc-cys,conjugates'
p38692
(F1
F0.00014334862385321102
I0
I1
I-1
tp38693
sS'be,without'
p38694
(F1
F0.00014334862385321102
I1
I0
I1
tp38695
sS'not,shown'
p38696
(F0
F0
I1
I1
I0
tp38697
sS'low-dose,mg'
p38698
(F1
F0.00028669724770642203
I0
I2
I-2
tp38699
sS'neurons,hyperpolarized'
p38700
(F1
F0.00014334862385321102
I0
I1
I-1
tp38701
sS'by,certain'
p38702
(F1
F0.00043004587155963305
I3
I0
I3
tp38703
sS'the,uptake'
p38704
(F0
F0
I1
I1
I0
tp38705
sS'similar,regardless'
p38706
(F1
F0.00014334862385321102
I0
I1
I-1
tp38707
sS'fold,at'
p38708
(F1
F0.00014334862385321102
I1
I0
I1
tp38709
sS'plasma,and'
p38710
(F0
F0
I4
I4
I0
tp38711
sS'and,toxicokinetic'
p38712
(F1
F0.00014334862385321102
I0
I1
I-1
tp38713
sS'although,inhibition'
p38714
(F1
F0.00014334862385321102
I0
I1
I-1
tp38715
sS'for,interactions'
p38716
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38717
sS'although,did'
p38718
(F1
F0.00014334862385321102
I1
I0
I1
tp38719
sS'discontinued,for'
p38720
(F1
F0.00014334862385321102
I1
I0
I1
tp38721
sS'of,bleeding'
p38722
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp38723
sS'drugs,hallucinations'
p38724
(F1
F0.00014334862385321102
I1
I0
I1
tp38725
sS'make,your'
p38726
(F1
F0.00014334862385321102
I0
I1
I-1
tp38727
sS'acid,because'
p38728
(F1
F0.00014334862385321102
I1
I0
I1
tp38729
sS'kg,person'
p38730
(F1
F0.00014334862385321102
I0
I1
I-1
tp38731
sS'urine,using'
p38732
(F1
F0.00014334862385321102
I0
I1
I-1
tp38733
sS'multiple,fixed-interval'
p38734
(F1
F0.00014334862385321102
I0
I1
I-1
tp38735
sS'toxic,action'
p38736
(F1
F0.00014334862385321102
I0
I1
I-1
tp38737
sS'subjects,increased'
p38738
(F1
F0.00028669724770642203
I2
I0
I2
tp38739
sS'potentiating,effect'
p38740
(F1
F0.00043004587155963305
I3
I0
I3
tp38741
sS'time,sst'
p38742
(F1
F0.00014334862385321102
I0
I1
I-1
tp38743
sS'per,kg'
p38744
(F1
F0.00014334862385321102
I1
I0
I1
tp38745
sS'increased,clinical'
p38746
(F1
F0.00014334862385321102
I1
I0
I1
tp38747
sS'comparing,the'
p38748
(F1
F0.00028669724770642203
I0
I2
I-2
tp38749
sS'other,binding'
p38750
(F1
F0.00028669724770642203
I0
I2
I-2
tp38751
sS'is,mg'
p38752
(F1
F0.00014334862385321102
I0
I1
I-1
tp38753
sS'diminished,response'
p38754
(F1
F0.00014334862385321102
I1
I0
I1
tp38755
sS'formation,from'
p38756
(F1
F0.00014334862385321102
I1
I0
I1
tp38757
sS'on,travelers'
p38758
(F1
F0.00014334862385321102
I1
I0
I1
tp38759
sS'uniformity,and'
p38760
(F1
F0.00014334862385321102
I0
I1
I-1
tp38761
sS'an,hydroxide'
p38762
(F1
F0.00028669724770642203
I2
I0
I2
tp38763
sS'the,conversion'
p38764
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp38765
sS'interaction,because'
p38766
(F1
F0.00014334862385321102
I0
I1
I-1
tp38767
sS'neither,reversed'
p38768
(F1
F0.00014334862385321102
I1
I0
I1
tp38769
sS'human,serum'
p38770
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38771
sS'over,several'
p38772
(F1
F0.00014334862385321102
I1
I0
I1
tp38773
sS'daily,of'
p38774
(F0
F0
I1
I1
I0
tp38775
sS'adjustment,for'
p38776
(F0
F0
I1
I1
I0
tp38777
sS'tablet,volume'
p38778
(F1
F0.00014334862385321102
I0
I1
I-1
tp38779
sS'theophylline,as'
p38780
(F1
F0.00014334862385321102
I1
I0
I1
tp38781
sS'adults,were'
p38782
(F1
F0.00014334862385321102
I0
I1
I-1
tp38783
sS'sodium,binding'
p38784
(F1
F0.00014334862385321102
I1
I0
I1
tp38785
sS'alfenta,doses'
p38786
(F1
F0.00014334862385321102
I0
I1
I-1
tp38787
sS'inhibitors,atomoxetine'
p38788
(F1
F0.00014334862385321102
I0
I1
I-1
tp38789
sS'and,other'
p38790
(F0.33333333333333331
F0.0030103211009174314
I42
I21
I21
tp38791
sS'and,less'
p38792
(F1
F0.00014334862385321102
I0
I1
I-1
tp38793
sS'account,for'
p38794
(F1
F0.00014334862385321102
I0
I1
I-1
tp38795
sS'adjustment,is'
p38796
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp38797
sS'taking,both'
p38798
(F1
F0.00028669724770642203
I2
I0
I2
tp38799
sS'hypercalcemia,in'
p38800
(F1
F0.00043004587155963305
I3
I0
I3
tp38801
sS'resin,may'
p38802
(F1
F0.00014334862385321102
I0
I1
I-1
tp38803
sS'decreased,synthesis'
p38804
(F1
F0.00028669724770642203
I2
I0
I2
tp38805
sS'hydroxyzine,must'
p38806
(F1
F0.00014334862385321102
I1
I0
I1
tp38807
sS'or,weakness'
p38808
(F1
F0.00014334862385321102
I0
I1
I-1
tp38809
sS'substrates,that'
p38810
(F1
F0.00014334862385321102
I1
I0
I1
tp38811
sS'interactions,attributed'
p38812
(F1
F0.00014334862385321102
I1
I0
I1
tp38813
sS'adjustment,in'
p38814
(F1
F0.00028669724770642203
I0
I2
I-2
tp38815
sS'volume,of'
p38816
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp38817
sS'monitored,and'
p38818
(F0.5
F0.00057339449541284407
I6
I2
I4
tp38819
sS'or,abolished'
p38820
(F1
F0.00014334862385321102
I1
I0
I1
tp38821
sS'therapy,with'
p38822
(F0.6216216216216216
F0.0032970183486238534
I30
I7
I23
tp38823
sS'amplifies,the'
p38824
(F1
F0.00014334862385321102
I1
I0
I1
tp38825
sS'neurontin,and'
p38826
(F1
F0.00014334862385321102
I0
I1
I-1
tp38827
sS'dyspnea,requiring'
p38828
(F1
F0.00014334862385321102
I0
I1
I-1
tp38829
sS'following,ultracentrifugation'
p38830
(F1
F0.00014334862385321102
I0
I1
I-1
tp38831
sS'methotrexate,humira'
p38832
(F1
F0.00014334862385321102
I0
I1
I-1
tp38833
sS'stomach,of'
p38834
(F1
F0.00014334862385321102
I1
I0
I1
tp38835
sS'might,be'
p38836
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38837
sS'same,age'
p38838
(F1
F0.00014334862385321102
I0
I1
I-1
tp38839
sS'of,mefloquine'
p38840
(F1
F0.00043004587155963305
I3
I0
I3
tp38841
sS'ii,receptor'
p38842
(F0
F0
I1
I1
I0
tp38843
sS'the,judgment'
p38844
(F1
F0.00014334862385321102
I1
I0
I1
tp38845
sS'at,an'
p38846
(F1
F0.00028669724770642203
I2
I0
I2
tp38847
sS'taking,since'
p38848
(F1
F0.00028669724770642203
I2
I0
I2
tp38849
sS'an,analysis'
p38850
(F1
F0.00014334862385321102
I1
I0
I1
tp38851
sS'and,maalox'
p38852
(F1
F0.00014334862385321102
I1
I0
I1
tp38853
sS'have,occasionally'
p38854
(F1
F0.00028669724770642203
I0
I2
I-2
tp38855
sS'at,as'
p38856
(F1
F0.00028669724770642203
I0
I2
I-2
tp38857
sS'hydrocodone,increases'
p38858
(F1
F0.00014334862385321102
I1
I0
I1
tp38859
sS'that,prolonged'
p38860
(F1
F0.00014334862385321102
I0
I1
I-1
tp38861
sS'trileptal,topamax'
p38862
(F1
F0.00014334862385321102
I1
I0
I1
tp38863
sS'ph,was'
p38864
(F0
F0
I1
I1
I0
tp38865
sS'difference,was'
p38866
(F1
F0.00014334862385321102
I0
I1
I-1
tp38867
sS'who,received'
p38868
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp38869
sS'trials,database'
p38870
(F1
F0.00014334862385321102
I0
I1
I-1
tp38871
sS'tachycardia,have'
p38872
(F1
F0.00014334862385321102
I1
I0
I1
tp38873
sS'fluid,were'
p38874
(F1
F0.00014334862385321102
I1
I0
I1
tp38875
sS'pediatrics,mean'
p38876
(F1
F0.00014334862385321102
I1
I0
I1
tp38877
sS'metabolites,dfur'
p38878
(F1
F0.00014334862385321102
I0
I1
I-1
tp38879
sS'nonsteroidal,the'
p38880
(F1
F0.00014334862385321102
I1
I0
I1
tp38881
sS'cmax,t1'
p38882
(F1
F0.00014334862385321102
I1
I0
I1
tp38883
sS'daily,followed'
p38884
(F1
F0.00014334862385321102
I1
I0
I1
tp38885
sS'with,interferon'
p38886
(F1
F0.00014334862385321102
I0
I1
I-1
tp38887
sS'products,with'
p38888
(F1
F0.00028669724770642203
I2
I0
I2
tp38889
sS'taking,mao'
p38890
(F1
F0.00014334862385321102
I1
I0
I1
tp38891
sS'in,two-lever'
p38892
(F1
F0.00014334862385321102
I0
I1
I-1
tp38893
sS'a,parallel'
p38894
(F1
F0.00014334862385321102
I0
I1
I-1
tp38895
sS'the,hydantoin'
p38896
(F1
F0.00014334862385321102
I1
I0
I1
tp38897
sS'infections,was'
p38898
(F1
F0.00028669724770642203
I2
I0
I2
tp38899
sS'when,cyp3a4'
p38900
(F1
F0.00014334862385321102
I0
I1
I-1
tp38901
sS'was,administered'
p38902
(F0.030303030303030304
F0.00014334862385321102
I17
I16
I1
tp38903
sS'randomized,multiple-dose'
p38904
(F1
F0.00014334862385321102
I0
I1
I-1
tp38905
sS'occurs,with'
p38906
(F1
F0.00028669724770642203
I0
I2
I-2
tp38907
sS'these,trace'
p38908
(F1
F0.00014334862385321102
I0
I1
I-1
tp38909
sS'release,captopril'
p38910
(F1
F0.00014334862385321102
I1
I0
I1
tp38911
sS'recommended,for'
p38912
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp38913
sS'of,beta-adrenoceptor'
p38914
(F1
F0.00028669724770642203
I2
I0
I2
tp38915
sS'of,bioavailability'
p38916
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38917
sS'trials,of'
p38918
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38919
sS'epidural,include'
p38920
(F1
F0.00014334862385321102
I1
I0
I1
tp38921
sS'eg,an'
p38922
(F1
F0.00014334862385321102
I1
I0
I1
tp38923
sS'week,trial'
p38924
(F1
F0.00014334862385321102
I0
I1
I-1
tp38925
sS'using,in'
p38926
(F1
F0.00014334862385321102
I1
I0
I1
tp38927
sS'and,serum'
p38928
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38929
sS'lipid-lowering,activity'
p38930
(F1
F0.00014334862385321102
I0
I1
I-1
tp38931
sS'antidepressant,was'
p38932
(F1
F0.00014334862385321102
I0
I1
I-1
tp38933
sS'regulate,the'
p38934
(F1
F0.00014334862385321102
I1
I0
I1
tp38935
sS'contain,deet'
p38936
(F1
F0.00014334862385321102
I1
I0
I1
tp38937
sS'of,vitamin-d'
p38938
(F1
F0.00014334862385321102
I0
I1
I-1
tp38939
sS'using,it'
p38940
(F1
F0.00028669724770642203
I2
I0
I2
tp38941
sS'sumatriptan,has'
p38942
(F1
F0.00014334862385321102
I1
I0
I1
tp38943
sS'minimum,alveolar'
p38944
(F1
F0.00028669724770642203
I2
I0
I2
tp38945
sS'disrupts,the'
p38946
(F1
F0.00014334862385321102
I0
I1
I-1
tp38947
sS'approximately,twofold'
p38948
(F1
F0.00014334862385321102
I1
I0
I1
tp38949
sS'potentiates,other'
p38950
(F1
F0.00014334862385321102
I1
I0
I1
tp38951
sS'as,hours'
p38952
(F1
F0.00014334862385321102
I1
I0
I1
tp38953
sS'serious,reactions'
p38954
(F1
F0.00014334862385321102
I0
I1
I-1
tp38955
sS'may,augment'
p38956
(F1
F0.00043004587155963305
I3
I0
I3
tp38957
sS'the,absorption'
p38958
(F0.72413793103448276
F0.0030103211009174314
I25
I4
I21
tp38959
sS'those,taking'
p38960
(F0
F0
I1
I1
I0
tp38961
sS'antipyrine,antipyrine'
p38962
(F1
F0.00014334862385321102
I0
I1
I-1
tp38963
sS'of,action'
p38964
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp38965
sS'reported,for'
p38966
(F1
F0.00014334862385321102
I0
I1
I-1
tp38967
sS'im,once'
p38968
(F0
F0
I1
I1
I0
tp38969
sS'cimetidine,at'
p38970
(F1
F0.00028669724770642203
I2
I0
I2
tp38971
sS'potential,intravenous'
p38972
(F1
F0.00014334862385321102
I1
I0
I1
tp38973
sS'cimetidine,an'
p38974
(F1
F0.00014334862385321102
I1
I0
I1
tp38975
sS'a,corresponding'
p38976
(F1
F0.00028669724770642203
I2
I0
I2
tp38977
sS'contrast,preliminary'
p38978
(F1
F0.00014334862385321102
I0
I1
I-1
tp38979
sS'the,experiment'
p38980
(F1
F0.00014334862385321102
I0
I1
I-1
tp38981
sS'plasma,auc'
p38982
(F1
F0.00071674311926605509
I5
I0
I5
tp38983
sS'the,lumen'
p38984
(F1
F0.00014334862385321102
I0
I1
I-1
tp38985
sS'rifampin,co-administration'
p38986
(F1
F0.00014334862385321102
I1
I0
I1
tp38987
sS'no,data'
p38988
(F1
F0.00043004587155963305
I0
I3
I-3
tp38989
sS'times,should'
p38990
(F0
F0
I1
I1
I0
tp38991
sS'for,p450'
p38992
(F1
F0.00071674311926605509
I0
I5
I-5
tp38993
sS'healthy,men'
p38994
(F1
F0.00014334862385321102
I0
I1
I-1
tp38995
sS'since,zarontin'
p38996
(F1
F0.00014334862385321102
I1
I0
I1
tp38997
sS'ip,injections'
p38998
(F1
F0.00014334862385321102
I0
I1
I-1
tp38999
sS'develop,increased'
p39000
(F1
F0.00014334862385321102
I1
I0
I1
tp39001
sS'are,indicated'
p39002
(F1
F0.00014334862385321102
I0
I1
I-1
tp39003
sS'three,equal'
p39004
(F1
F0.00014334862385321102
I0
I1
I-1
tp39005
sS'of,unsteady'
p39006
(F1
F0.00014334862385321102
I1
I0
I1
tp39007
sS'and,aggressive'
p39008
(F1
F0.00014334862385321102
I0
I1
I-1
tp39009
sS'did,augment'
p39010
(F1
F0.00014334862385321102
I1
I0
I1
tp39011
sS'mcf-7,cells'
p39012
(F1
F0.00014334862385321102
I0
I1
I-1
tp39013
sS'oil,ml'
p39014
(F1
F0.00014334862385321102
I0
I1
I-1
tp39015
sS'diuretics,furosemide'
p39016
(F1
F0.00014334862385321102
I0
I1
I-1
tp39017
sS'and,displacement'
p39018
(F1
F0.00014334862385321102
I1
I0
I1
tp39019
sS'on,average'
p39020
(F0
F0
I1
I1
I0
tp39021
sS'were,unaffected'
p39022
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp39023
sS'known,health'
p39024
(F1
F0.00014334862385321102
I0
I1
I-1
tp39025
sS'in,evaluating'
p39026
(F1
F0.00014334862385321102
I0
I1
I-1
tp39027
sS'the,hemodynamic'
p39028
(F1
F0.00014334862385321102
I1
I0
I1
tp39029
sS'the,superiority'
p39030
(F1
F0.00014334862385321102
I0
I1
I-1
tp39031
sS'patients,liver'
p39032
(F1
F0.00014334862385321102
I1
I0
I1
tp39033
sS'by,this'
p39034
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp39035
sS'fdf,at'
p39036
(F1
F0.00043004587155963305
I3
I0
I3
tp39037
sS'may,even'
p39038
(F0
F0
I1
I1
I0
tp39039
sS'reduces,both'
p39040
(F1
F0.00014334862385321102
I1
I0
I1
tp39041
sS'their,coagulation'
p39042
(F1
F0.00014334862385321102
I1
I0
I1
tp39043
sS'block,may'
p39044
(F1
F0.00028669724770642203
I2
I0
I2
tp39045
sS'and,t3'
p39046
(F1
F0.00014334862385321102
I1
I0
I1
tp39047
sS'including,inhaled'
p39048
(F1
F0.00014334862385321102
I0
I1
I-1
tp39049
sS'groups,of'
p39050
(F1
F0.00028669724770642203
I0
I2
I-2
tp39051
sS'day,lexapro'
p39052
(F1
F0.00014334862385321102
I1
I0
I1
tp39053
sS'acid,are'
p39054
(F1
F0.00014334862385321102
I0
I1
I-1
tp39055
sS'cns,including'
p39056
(F1
F0.00014334862385321102
I0
I1
I-1
tp39057
sS'are,coadministered'
p39058
(F1
F0.00014334862385321102
I1
I0
I1
tp39059
sS'synergism,in'
p39060
(F1
F0.00014334862385321102
I1
I0
I1
tp39061
sS'the,known'
p39062
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp39063
sS'responding,produced'
p39064
(F1
F0.00014334862385321102
I1
I0
I1
tp39065
sS'cocaine,sometimes'
p39066
(F1
F0.00014334862385321102
I1
I0
I1
tp39067
sS'norpace,does'
p39068
(F1
F0.00014334862385321102
I0
I1
I-1
tp39069
sS'greater,than'
p39070
(F0.16666666666666666
F0.00028669724770642203
I7
I5
I2
tp39071
sS'however,careful'
p39072
(F1
F0.00014334862385321102
I1
I0
I1
tp39073
sS'interferon,beta'
p39074
(F1
F0.00014334862385321102
I0
I1
I-1
tp39075
sS'combination,therapy'
p39076
(F0
F0
I2
I2
I0
tp39077
sS'and,to'
p39078
(F0.40000000000000002
F0.0011467889908256881
I6
I14
I-8
tp39079
sS'and,tm'
p39080
(F1
F0.00014334862385321102
I1
I0
I1
tp39081
sS'coombs,reactions'
p39082
(F1
F0.00014334862385321102
I0
I1
I-1
tp39083
sS'conducted,it'
p39084
(F1
F0.00014334862385321102
I1
I0
I1
tp39085
sS'status,is'
p39086
(F1
F0.00014334862385321102
I1
I0
I1
tp39087
sS'the,high-dose'
p39088
(F1
F0.00014334862385321102
I1
I0
I1
tp39089
sS'nsaids,are'
p39090
(F1
F0.00028669724770642203
I2
I0
I2
tp39091
sS'a,separate'
p39092
(F0
F0
I1
I1
I0
tp39093
sS'anions,other'
p39094
(F1
F0.00014334862385321102
I0
I1
I-1
tp39095
sS'with,short'
p39096
(F1
F0.00014334862385321102
I0
I1
I-1
tp39097
sS'conducted,in'
p39098
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39099
sS'been,no'
p39100
(F1
F0.00057339449541284407
I0
I4
I-4
tp39101
sS'betagan,used'
p39102
(F1
F0.00014334862385321102
I1
I0
I1
tp39103
sS'of,enablex'
p39104
(F1
F0.00028669724770642203
I2
I0
I2
tp39105
sS'inhibit,the'
p39106
(F0.62962962962962965
F0.0024369266055045873
I22
I5
I17
tp39107
sS'by,possibly'
p39108
(F1
F0.00028669724770642203
I2
I0
I2
tp39109
sS'gene,expression'
p39110
(F1
F0.00014334862385321102
I0
I1
I-1
tp39111
sS'to,convulsions'
p39112
(F1
F0.00014334862385321102
I1
I0
I1
tp39113
sS'other,which'
p39114
(F1
F0.00028669724770642203
I2
I0
I2
tp39115
sS'by,administration'
p39116
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39117
sS'to,diminish'
p39118
(F1
F0.00028669724770642203
I2
I0
I2
tp39119
sS'pulmonary,arterial'
p39120
(F1
F0.00014334862385321102
I0
I1
I-1
tp39121
sS'effect,has'
p39122
(F1
F0.00014334862385321102
I1
I0
I1
tp39123
sS'within,minutes'
p39124
(F0
F0
I1
I1
I0
tp39125
sS'agitation,while'
p39126
(F1
F0.00014334862385321102
I0
I1
I-1
tp39127
sS'the,from'
p39128
(F1
F0.00028669724770642203
I2
I0
I2
tp39129
sS'ii,antagonists'
p39130
(F0
F0
I1
I1
I0
tp39131
sS'wellbutrin,following'
p39132
(F1
F0.00014334862385321102
I0
I1
I-1
tp39133
sS'and,frova'
p39134
(F1
F0.00014334862385321102
I1
I0
I1
tp39135
sS'aliskiren,on'
p39136
(F1
F0.00014334862385321102
I0
I1
I-1
tp39137
sS'the,reflex'
p39138
(F1
F0.00014334862385321102
I1
I0
I1
tp39139
sS'tylenol,chloromycetin'
p39140
(F1
F0.00014334862385321102
I1
I0
I1
tp39141
sS'to,midcycle'
p39142
(F1
F0.00014334862385321102
I0
I1
I-1
tp39143
sS'qd,increased'
p39144
(F1
F0.00014334862385321102
I1
I0
I1
tp39145
sS'while,attenuating'
p39146
(F1
F0.00014334862385321102
I1
I0
I1
tp39147
sS'in,plasmaconcentrations'
p39148
(F1
F0.00028669724770642203
I2
I0
I2
tp39149
sS'a,ten-subject'
p39150
(F1
F0.00014334862385321102
I1
I0
I1
tp39151
sS'three,cancer'
p39152
(F1
F0.00014334862385321102
I1
I0
I1
tp39153
sS'tam,enhances'
p39154
(F1
F0.00014334862385321102
I1
I0
I1
tp39155
sS'be,prevented'
p39156
(F1
F0.00014334862385321102
I1
I0
I1
tp39157
sS'including,more'
p39158
(F1
F0.00014334862385321102
I0
I1
I-1
tp39159
sS'inhibit,cyp3a4'
p39160
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp39161
sS'both,its'
p39162
(F1
F0.00028669724770642203
I0
I2
I-2
tp39163
sS'myocardium,versus'
p39164
(F1
F0.00014334862385321102
I0
I1
I-1
tp39165
sS'or,induce'
p39166
(F1
F0.00028669724770642203
I0
I2
I-2
tp39167
sS'invasion,of'
p39168
(F1
F0.00014334862385321102
I1
I0
I1
tp39169
sS'receiving,hctz'
p39170
(F1
F0.00014334862385321102
I1
I0
I1
tp39171
sS'radical-mediated,tissue'
p39172
(F1
F0.00014334862385321102
I1
I0
I1
tp39173
sS'the,conclusion'
p39174
(F1
F0.00014334862385321102
I1
I0
I1
tp39175
sS'assess,if'
p39176
(F1
F0.00028669724770642203
I0
I2
I-2
tp39177
sS'during,placebo-controlled'
p39178
(F1
F0.00014334862385321102
I0
I1
I-1
tp39179
sS'loss,of'
p39180
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp39181
sS'cause,increased'
p39182
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp39183
sS'decreases,blood'
p39184
(F1
F0.00014334862385321102
I1
I0
I1
tp39185
sS'concentrations,below'
p39186
(F1
F0.00014334862385321102
I1
I0
I1
tp39187
sS'the,coumarin'
p39188
(F1
F0.00014334862385321102
I0
I1
I-1
tp39189
sS'substantial,period'
p39190
(F1
F0.00014334862385321102
I0
I1
I-1
tp39191
sS'subjects,dosed'
p39192
(F1
F0.00028669724770642203
I2
I0
I2
tp39193
sS'thrombolytic,agents'
p39194
(F1
F0.00014334862385321102
I0
I1
I-1
tp39195
sS'auc,by'
p39196
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp39197
sS'days,through'
p39198
(F1
F0.00014334862385321102
I1
I0
I1
tp39199
sS'mediation,of'
p39200
(F1
F0.00014334862385321102
I0
I1
I-1
tp39201
sS'retard,is'
p39202
(F1
F0.00028669724770642203
I2
I0
I2
tp39203
sS'possibly,increase'
p39204
(F1
F0.00014334862385321102
I1
I0
I1
tp39205
sS'effect,and'
p39206
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp39207
sS'a2,an'
p39208
(F1
F0.00014334862385321102
I1
I0
I1
tp39209
sS'are,withdrawn'
p39210
(F1
F0.00014334862385321102
I0
I1
I-1
tp39211
sS'reaction,during'
p39212
(F1
F0.00014334862385321102
I0
I1
I-1
tp39213
sS'persists,as'
p39214
(F1
F0.00014334862385321102
I1
I0
I1
tp39215
sS'pharmacologic,studies'
p39216
(F1
F0.00014334862385321102
I1
I0
I1
tp39217
sS'for,recovery'
p39218
(F1
F0.00014334862385321102
I0
I1
I-1
tp39219
sS'these,concomitant'
p39220
(F1
F0.00014334862385321102
I1
I0
I1
tp39221
sS'methylxanthines,and'
p39222
(F1
F0.00014334862385321102
I1
I0
I1
tp39223
sS'of,oral'
p39224
(F0.20000000000000001
F0.0008600917431192661
I18
I12
I6
tp39225
sS'with,absorption'
p39226
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp39227
sS'in,lean'
p39228
(F1
F0.00014334862385321102
I0
I1
I-1
tp39229
sS'compounds,enhanced'
p39230
(F1
F0.00014334862385321102
I0
I1
I-1
tp39231
sS'inr,international'
p39232
(F1
F0.00014334862385321102
I1
I0
I1
tp39233
sS'supplementation,which'
p39234
(F1
F0.00014334862385321102
I0
I1
I-1
tp39235
sS'tested,to'
p39236
(F1
F0.00014334862385321102
I0
I1
I-1
tp39237
sS'additive,with'
p39238
(F1
F0.00057339449541284407
I4
I0
I4
tp39239
sS'mesylate,with'
p39240
(F1
F0.00014334862385321102
I1
I0
I1
tp39241
sS'radiation,therapy'
p39242
(F1
F0.00014334862385321102
I0
I1
I-1
tp39243
sS'vitro,mixing'
p39244
(F1
F0.00014334862385321102
I1
I0
I1
tp39245
sS'in,fi'
p39246
(F0
F0
I1
I1
I0
tp39247
sS'by,increasing'
p39248
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp39249
sS'to,similar'
p39250
(F1
F0.00014334862385321102
I0
I1
I-1
tp39251
sS'however,the'
p39252
(F0
F0
I4
I4
I0
tp39253
sS'the,contrary'
p39254
(F1
F0.00014334862385321102
I1
I0
I1
tp39255
sS'because,cyp2d6'
p39256
(F1
F0.00014334862385321102
I0
I1
I-1
tp39257
sS'suspension,yielded'
p39258
(F1
F0.00014334862385321102
I0
I1
I-1
tp39259
sS'or,fatal'
p39260
(F1
F0.00014334862385321102
I0
I1
I-1
tp39261
sS'antiarrhythmics,antihistamines'
p39262
(F1
F0.00014334862385321102
I1
I0
I1
tp39263
sS'and,uncontrolled'
p39264
(F1
F0.00014334862385321102
I0
I1
I-1
tp39265
sS'exogenous,also'
p39266
(F1
F0.00014334862385321102
I1
I0
I1
tp39267
sS'receiving,nalfon'
p39268
(F1
F0.00014334862385321102
I1
I0
I1
tp39269
sS'cells,respond'
p39270
(F1
F0.00014334862385321102
I0
I1
I-1
tp39271
sS'significantly,with'
p39272
(F1
F0.00028669724770642203
I0
I2
I-2
tp39273
sS'impaired,but'
p39274
(F1
F0.00014334862385321102
I0
I1
I-1
tp39275
sS'concurrently,without'
p39276
(F1
F0.00014334862385321102
I0
I1
I-1
tp39277
sS'an,adolescent'
p39278
(F1
F0.00014334862385321102
I1
I0
I1
tp39279
sS'the,metabolic'
p39280
(F1
F0.0008600917431192661
I6
I0
I6
tp39281
sS'restricted,and'
p39282
(F1
F0.00014334862385321102
I0
I1
I-1
tp39283
sS'ampicillin,amoxicillin'
p39284
(F1
F0.00014334862385321102
I1
I0
I1
tp39285
sS'were,significantly'
p39286
(F0
F0
I1
I1
I0
tp39287
sS'the,marrow'
p39288
(F1
F0.00014334862385321102
I0
I1
I-1
tp39289
sS'responsiveness,to'
p39290
(F1
F0.00028669724770642203
I0
I2
I-2
tp39291
sS'radiographic,iodinated'
p39292
(F1
F0.00014334862385321102
I1
I0
I1
tp39293
sS'hydrocarbon,increase'
p39294
(F1
F0.00014334862385321102
I1
I0
I1
tp39295
sS'hydrochloride,desyrel'
p39296
(F1
F0.00014334862385321102
I1
I0
I1
tp39297
sS'used,preanesthetic'
p39298
(F1
F0.00014334862385321102
I0
I1
I-1
tp39299
sS'ergotamine-containing,when'
p39300
(F1
F0.00014334862385321102
I1
I0
I1
tp39301
sS'potential,exists'
p39302
(F1
F0.00014334862385321102
I1
I0
I1
tp39303
sS'potentiated,and'
p39304
(F1
F0.00028669724770642203
I2
I0
I2
tp39305
sS'altered,its'
p39306
(F1
F0.00014334862385321102
I0
I1
I-1
tp39307
sS'of,dehydration'
p39308
(F1
F0.00014334862385321102
I1
I0
I1
tp39309
sS'theophylline,grepafloxacin'
p39310
(F1
F0.00014334862385321102
I1
I0
I1
tp39311
sS'pharmacokinetics,effectiveness'
p39312
(F1
F0.00014334862385321102
I0
I1
I-1
tp39313
sS'immediately,beginning'
p39314
(F1
F0.00014334862385321102
I1
I0
I1
tp39315
sS'as,nuromax'
p39316
(F1
F0.00014334862385321102
I1
I0
I1
tp39317
sS'days,for'
p39318
(F1
F0.00014334862385321102
I0
I1
I-1
tp39319
sS'experienced,a'
p39320
(F1
F0.00071674311926605509
I5
I0
I5
tp39321
sS'volunteers,established'
p39322
(F1
F0.00014334862385321102
I0
I1
I-1
tp39323
sS'known,inhibition'
p39324
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39325
sS'mean,of'
p39326
(F0
F0
I1
I1
I0
tp39327
sS'two-lever,discrimination'
p39328
(F1
F0.00014334862385321102
I0
I1
I-1
tp39329
sS'blood,glucose'
p39330
(F0.2857142857142857
F0.00057339449541284407
I9
I5
I4
tp39331
sS'that,binds'
p39332
(F1
F0.00014334862385321102
I0
I1
I-1
tp39333
sS'early-phase,schizophrenia'
p39334
(F1
F0.00014334862385321102
I0
I1
I-1
tp39335
sS'least,a'
p39336
(F1
F0.00014334862385321102
I1
I0
I1
tp39337
sS'allopurinol,inhibits'
p39338
(F1
F0.00014334862385321102
I1
I0
I1
tp39339
sS'nonsteroidal,were'
p39340
(F1
F0.00028669724770642203
I0
I2
I-2
tp39341
sS'brevibloc,steady-state'
p39342
(F1
F0.00014334862385321102
I1
I0
I1
tp39343
sS'and,of'
p39344
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp39345
sS'mhd,and'
p39346
(F1
F0.00014334862385321102
I0
I1
I-1
tp39347
sS'and,on'
p39348
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp39349
sS'of,trazodone'
p39350
(F1
F0.00014334862385321102
I1
I0
I1
tp39351
sS'reactions,related'
p39352
(F1
F0.00014334862385321102
I0
I1
I-1
tp39353
sS'primary,elimination'
p39354
(F1
F0.00014334862385321102
I1
I0
I1
tp39355
sS'coagulation,factor'
p39356
(F1
F0.00014334862385321102
I0
I1
I-1
tp39357
sS'and,or'
p39358
(F0.40625
F0.0037270642201834864
I45
I19
I26
tp39359
sS'inducer,with'
p39360
(F1
F0.00014334862385321102
I1
I0
I1
tp39361
sS'state,auc'
p39362
(F1
F0.00014334862385321102
I1
I0
I1
tp39363
sS'supplementation,with'
p39364
(F1
F0.00014334862385321102
I0
I1
I-1
tp39365
sS'with,activity--such'
p39366
(F1
F0.00014334862385321102
I1
I0
I1
tp39367
sS'conducted,to'
p39368
(F1
F0.00043004587155963305
I0
I3
I-3
tp39369
sS'concomitantly,of'
p39370
(F1
F0.00014334862385321102
I0
I1
I-1
tp39371
sS'prophylactic,doses'
p39372
(F1
F0.00014334862385321102
I0
I1
I-1
tp39373
sS'will,lead'
p39374
(F1
F0.00014334862385321102
I1
I0
I1
tp39375
sS'of,age'
p39376
(F1
F0.00014334862385321102
I0
I1
I-1
tp39377
sS'have,failed'
p39378
(F1
F0.00014334862385321102
I0
I1
I-1
tp39379
sS'c-17,alkylated'
p39380
(F1
F0.00014334862385321102
I0
I1
I-1
tp39381
sS'data,in'
p39382
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp39383
sS'growing,class'
p39384
(F1
F0.00014334862385321102
I0
I1
I-1
tp39385
sS'of,corneal'
p39386
(F1
F0.00014334862385321102
I1
I0
I1
tp39387
sS'ventricular,fibrillation'
p39388
(F0
F0
I1
I1
I0
tp39389
sS'with,difluoro-2'
p39390
(F1
F0.00014334862385321102
I1
I0
I1
tp39391
sS'when,lodine'
p39392
(F1
F0.00014334862385321102
I1
I0
I1
tp39393
sS'mean,concentrations'
p39394
(F1
F0.00014334862385321102
I0
I1
I-1
tp39395
sS'romazicon,may'
p39396
(F1
F0.00014334862385321102
I0
I1
I-1
tp39397
sS'postmarketing,experience'
p39398
(F0
F0
I1
I1
I0
tp39399
sS'leukocyte,transfusions'
p39400
(F1
F0.00014334862385321102
I1
I0
I1
tp39401
sS'pyrocarbonate,abolished'
p39402
(F1
F0.00014334862385321102
I0
I1
I-1
tp39403
sS'of,mevacor'
p39404
(F1
F0.00014334862385321102
I0
I1
I-1
tp39405
sS'tsh,secretion'
p39406
(F1
F0.00014334862385321102
I0
I1
I-1
tp39407
sS'in,peak'
p39408
(F1
F0.00071674311926605509
I5
I0
I5
tp39409
sS'and,administration-dosage'
p39410
(F1
F0.00014334862385321102
I0
I1
I-1
tp39411
sS'amide-type,local'
p39412
(F1
F0.00014334862385321102
I1
I0
I1
tp39413
sS'decrease,metabolism'
p39414
(F1
F0.00014334862385321102
I1
I0
I1
tp39415
sS'cause,clinically'
p39416
(F1
F0.00014334862385321102
I0
I1
I-1
tp39417
sS'bolus-ifl,in'
p39418
(F1
F0.00014334862385321102
I0
I1
I-1
tp39419
sS'index,such'
p39420
(F1
F0.00014334862385321102
I1
I0
I1
tp39421
sS'necessary,should'
p39422
(F1
F0.00014334862385321102
I0
I1
I-1
tp39423
sS'change,of'
p39424
(F1
F0.00057339449541284407
I4
I0
I4
tp39425
sS'failure,nyha'
p39426
(F1
F0.00014334862385321102
I0
I1
I-1
tp39427
sS'pathway,suggesting'
p39428
(F1
F0.00014334862385321102
I0
I1
I-1
tp39429
sS'candesartan,cilexetil'
p39430
(F1
F0.00014334862385321102
I0
I1
I-1
tp39431
sS'superiority,over'
p39432
(F1
F0.00014334862385321102
I0
I1
I-1
tp39433
sS'enalapril,and'
p39434
(F0
F0
I1
I1
I0
tp39435
sS'in,zaleplons'
p39436
(F1
F0.00014334862385321102
I1
I0
I1
tp39437
sS'identify,chromatin'
p39438
(F1
F0.00014334862385321102
I1
I0
I1
tp39439
sS'therapies,in'
p39440
(F1
F0.00014334862385321102
I0
I1
I-1
tp39441
sS'i,increase'
p39442
(F1
F0.00014334862385321102
I1
I0
I1
tp39443
sS'parameters,affected'
p39444
(F1
F0.00014334862385321102
I0
I1
I-1
tp39445
sS'substrate,resulted'
p39446
(F1
F0.00014334862385321102
I1
I0
I1
tp39447
sS'include,extreme'
p39448
(F1
F0.00014334862385321102
I1
I0
I1
tp39449
sS'agents,employed'
p39450
(F1
F0.00014334862385321102
I1
I0
I1
tp39451
sS'the,cns-depressant'
p39452
(F1
F0.00014334862385321102
I1
I0
I1
tp39453
sS'administered,with'
p39454
(F0.40000000000000002
F0.0022935779816513763
I28
I12
I16
tp39455
sS'not,on'
p39456
(F1
F0.00014334862385321102
I0
I1
I-1
tp39457
sS'moderate,to'
p39458
(F1
F0.00028669724770642203
I2
I0
I2
tp39459
sS'potentially,interfere'
p39460
(F1
F0.00014334862385321102
I0
I1
I-1
tp39461
sS'committed,step'
p39462
(F1
F0.00014334862385321102
I1
I0
I1
tp39463
sS'which,inhibits'
p39464
(F1
F0.00014334862385321102
I1
I0
I1
tp39465
sS'cautioned,that'
p39466
(F1
F0.00014334862385321102
I0
I1
I-1
tp39467
sS'the,hypotension'
p39468
(F1
F0.00043004587155963305
I3
I0
I3
tp39469
sS'affect,subjective'
p39470
(F1
F0.00014334862385321102
I0
I1
I-1
tp39471
sS'iodine-containing,compounds'
p39472
(F1
F0.00014334862385321102
I0
I1
I-1
tp39473
sS'time,by'
p39474
(F0
F0
I1
I1
I0
tp39475
sS'inhibits,both'
p39476
(F1
F0.00014334862385321102
I1
I0
I1
tp39477
sS'time,be'
p39478
(F1
F0.00028669724770642203
I2
I0
I2
tp39479
sS'microgram,ml'
p39480
(F1
F0.00014334862385321102
I0
I1
I-1
tp39481
sS'this,category'
p39482
(F1
F0.00014334862385321102
I1
I0
I1
tp39483
sS'can,decrease'
p39484
(F1
F0.00028669724770642203
I2
I0
I2
tp39485
sS'other,drugs'
p39486
(F0.78947368421052633
F0.0021502293577981653
I2
I17
I-15
tp39487
sS'ribavirin,is'
p39488
(F1
F0.00014334862385321102
I0
I1
I-1
tp39489
sS'its,effect'
p39490
(F1
F0.00014334862385321102
I1
I0
I1
tp39491
sS'are,renally'
p39492
(F1
F0.00014334862385321102
I0
I1
I-1
tp39493
sS'either,is'
p39494
(F0
F0
I1
I1
I0
tp39495
sS'additive,hypotensite'
p39496
(F1
F0.00014334862385321102
I1
I0
I1
tp39497
sS'mao-inhibitors,with'
p39498
(F1
F0.00014334862385321102
I1
I0
I1
tp39499
sS'nephrotoxic,such'
p39500
(F1
F0.00014334862385321102
I1
I0
I1
tp39501
sS'to,wide'
p39502
(F1
F0.00014334862385321102
I1
I0
I1
tp39503
sS'for,equetrotm'
p39504
(F0
F0
I1
I1
I0
tp39505
sS'other,potentially'
p39506
(F1
F0.00028669724770642203
I2
I0
I2
tp39507
sS'of,american'
p39508
(F1
F0.00014334862385321102
I0
I1
I-1
tp39509
sS'rate,when'
p39510
(F1
F0.00014334862385321102
I1
I0
I1
tp39511
sS'assumed,that'
p39512
(F1
F0.00014334862385321102
I0
I1
I-1
tp39513
sS'dose,study'
p39514
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp39515
sS'iodinated,contrast'
p39516
(F1
F0.00014334862385321102
I1
I0
I1
tp39517
sS'or,undesirable'
p39518
(F1
F0.00028669724770642203
I0
I2
I-2
tp39519
sS'novolog,were'
p39520
(F1
F0.00014334862385321102
I0
I1
I-1
tp39521
sS'including,indocin'
p39522
(F1
F0.00028669724770642203
I2
I0
I2
tp39523
sS'insulin,sulfonylureas'
p39524
(F1
F0.00014334862385321102
I0
I1
I-1
tp39525
sS'may,rise'
p39526
(F1
F0.00014334862385321102
I0
I1
I-1
tp39527
sS'of,three'
p39528
(F1
F0.00014334862385321102
I0
I1
I-1
tp39529
sS'between,deficiency'
p39530
(F1
F0.00014334862385321102
I0
I1
I-1
tp39531
sS'serum,half-life'
p39532
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp39533
sS'with,aluminum-'
p39534
(F1
F0.00014334862385321102
I0
I1
I-1
tp39535
sS'highly,fortified'
p39536
(F1
F0.00014334862385321102
I0
I1
I-1
tp39537
sS'results,demonstrate'
p39538
(F1
F0.00014334862385321102
I0
I1
I-1
tp39539
sS'volunteers,coadministration'
p39540
(F1
F0.00014334862385321102
I0
I1
I-1
tp39541
sS'showed,an'
p39542
(F1
F0.00014334862385321102
I1
I0
I1
tp39543
sS'directly,interfere'
p39544
(F1
F0.00014334862385321102
I1
I0
I1
tp39545
sS'codeine,in'
p39546
(F1
F0.00014334862385321102
I1
I0
I1
tp39547
sS'arabinoside,a'
p39548
(F1
F0.00014334862385321102
I1
I0
I1
tp39549
sS'to,hypoparathyroid'
p39550
(F1
F0.00028669724770642203
I2
I0
I2
tp39551
sS'also,concomitant'
p39552
(F1
F0.00014334862385321102
I1
I0
I1
tp39553
sS'vivo,by'
p39554
(F1
F0.00014334862385321102
I0
I1
I-1
tp39555
sS'seen,when'
p39556
(F0
F0
I2
I2
I0
tp39557
sS'with,measurement'
p39558
(F1
F0.00028669724770642203
I0
I2
I-2
tp39559
sS'resulted,from'
p39560
(F1
F0.00014334862385321102
I1
I0
I1
tp39561
sS'cytochrome,p450iiia4'
p39562
(F1
F0.00014334862385321102
I1
I0
I1
tp39563
sS'turn,discussing'
p39564
(F1
F0.00014334862385321102
I0
I1
I-1
tp39565
sS'behavioral,effects'
p39566
(F1
F0.00043004587155963305
I0
I3
I-3
tp39567
sS'between,use'
p39568
(F1
F0.00014334862385321102
I1
I0
I1
tp39569
sS'and,the'
p39570
(F0.075268817204301078
F0.0010034403669724771
I43
I50
I-7
tp39571
sS'containing,regimen'
p39572
(F1
F0.00014334862385321102
I0
I1
I-1
tp39573
sS'the,cyclooxygenase-2'
p39574
(F1
F0.00014334862385321102
I0
I1
I-1
tp39575
sS'prolonged,by'
p39576
(F1
F0.00043004587155963305
I3
I0
I3
tp39577
sS'agents,ethinyl'
p39578
(F1
F0.00014334862385321102
I0
I1
I-1
tp39579
sS'of,non-nucleoside'
p39580
(F1
F0.00014334862385321102
I0
I1
I-1
tp39581
sS'administering,or'
p39582
(F1
F0.00014334862385321102
I1
I0
I1
tp39583
sS'dose,increase'
p39584
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp39585
sS'any,such'
p39586
(F1
F0.00014334862385321102
I1
I0
I1
tp39587
sS'as,inr'
p39588
(F1
F0.00014334862385321102
I1
I0
I1
tp39589
sS'supplement,st'
p39590
(F1
F0.00014334862385321102
I0
I1
I-1
tp39591
sS'pressure,usually'
p39592
(F1
F0.00014334862385321102
I1
I0
I1
tp39593
sS'is,usually'
p39594
(F0
F0
I1
I1
I0
tp39595
sS'class,iii'
p39596
(F1
F0.00014334862385321102
I1
I0
I1
tp39597
sS'available,hmgcoa'
p39598
(F1
F0.00014334862385321102
I0
I1
I-1
tp39599
sS'prescribed,for'
p39600
(F1
F0.0010034403669724771
I0
I7
I-7
tp39601
sS'of,simulect'
p39602
(F1
F0.00014334862385321102
I1
I0
I1
tp39603
sS'approved,prescription'
p39604
(F1
F0.00014334862385321102
I1
I0
I1
tp39605
sS'felbatol,on'
p39606
(F0
F0
I1
I1
I0
tp39607
sS'side,effect'
p39608
(F1
F0.00014334862385321102
I0
I1
I-1
tp39609
sS'catecholamine,depletor'
p39610
(F1
F0.00014334862385321102
I0
I1
I-1
tp39611
sS'suggesting,that'
p39612
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp39613
sS'digitalis,enhanced'
p39614
(F1
F0.00014334862385321102
I0
I1
I-1
tp39615
sS'to,factrel'
p39616
(F1
F0.00014334862385321102
I1
I0
I1
tp39617
sS'a,concomitantly'
p39618
(F1
F0.00014334862385321102
I1
I0
I1
tp39619
sS'variables,for'
p39620
(F1
F0.00014334862385321102
I0
I1
I-1
tp39621
sS'mean,change'
p39622
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39623
sS'state,and'
p39624
(F1
F0.00028669724770642203
I2
I0
I2
tp39625
sS'were,submitted'
p39626
(F1
F0.00014334862385321102
I0
I1
I-1
tp39627
sS'antiepileptic,drugs'
p39628
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp39629
sS'absorption,after'
p39630
(F1
F0.00014334862385321102
I0
I1
I-1
tp39631
sS'resecting,the'
p39632
(F1
F0.00014334862385321102
I0
I1
I-1
tp39633
sS'been,some'
p39634
(F1
F0.00014334862385321102
I1
I0
I1
tp39635
sS'common,medications'
p39636
(F1
F0.00014334862385321102
I0
I1
I-1
tp39637
sS'pharmacological,doses'
p39638
(F1
F0.00014334862385321102
I0
I1
I-1
tp39639
sS'probenecid,as'
p39640
(F1
F0.00057339449541284407
I4
I0
I4
tp39641
sS'verapamil,the'
p39642
(F1
F0.00014334862385321102
I1
I0
I1
tp39643
sS'each,task'
p39644
(F1
F0.00014334862385321102
I0
I1
I-1
tp39645
sS'vitro,the'
p39646
(F1
F0.00014334862385321102
I0
I1
I-1
tp39647
sS'subjects,r'
p39648
(F1
F0.00014334862385321102
I0
I1
I-1
tp39649
sS'subjects,n'
p39650
(F1
F0.00014334862385321102
I1
I0
I1
tp39651
sS'disintegrins,and'
p39652
(F1
F0.00014334862385321102
I0
I1
I-1
tp39653
sS'observation,of'
p39654
(F1
F0.0008600917431192661
I6
I0
I6
tp39655
sS'least,hour'
p39656
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp39657
sS'overload,both'
p39658
(F1
F0.00014334862385321102
I0
I1
I-1
tp39659
sS'report,of'
p39660
(F0.5
F0.00028669724770642203
I3
I1
I2
tp39661
sS'that,do'
p39662
(F1
F0.00014334862385321102
I1
I0
I1
tp39663
sS'fluid,by'
p39664
(F1
F0.00014334862385321102
I0
I1
I-1
tp39665
sS'initiated,apparent'
p39666
(F1
F0.00014334862385321102
I1
I0
I1
tp39667
sS'several,interaction'
p39668
(F1
F0.00014334862385321102
I0
I1
I-1
tp39669
sS'of,urate'
p39670
(F1
F0.00014334862385321102
I1
I0
I1
tp39671
sS'over,to'
p39672
(F1
F0.00014334862385321102
I0
I1
I-1
tp39673
sS'this,study'
p39674
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp39675
sS'inhibiting,eg'
p39676
(F1
F0.00014334862385321102
I1
I0
I1
tp39677
sS'sparine,phenergan'
p39678
(F1
F0.00014334862385321102
I0
I1
I-1
tp39679
sS'l,while'
p39680
(F1
F0.00014334862385321102
I0
I1
I-1
tp39681
sS'level,while'
p39682
(F0
F0
I1
I1
I0
tp39683
sS'tambocor,with'
p39684
(F1
F0.00014334862385321102
I0
I1
I-1
tp39685
sS'literature,suggest'
p39686
(F1
F0.00014334862385321102
I1
I0
I1
tp39687
sS'inhibitors,calcium-channel'
p39688
(F1
F0.00014334862385321102
I0
I1
I-1
tp39689
sS'have,not'
p39690
(F0.5
F0.0031536697247706424
I11
I33
I-22
tp39691
sS'cyp2a6,hydroxylation'
p39692
(F1
F0.00014334862385321102
I1
I0
I1
tp39693
sS'increased,incidence'
p39694
(F0
F0
I1
I1
I0
tp39695
sS'inhibitors,guanethidine'
p39696
(F1
F0.00014334862385321102
I0
I1
I-1
tp39697
sS'occurs,dose'
p39698
(F1
F0.00014334862385321102
I1
I0
I1
tp39699
sS'the,calcium-entry'
p39700
(F1
F0.00014334862385321102
I0
I1
I-1
tp39701
sS'hydrochloride,therapy'
p39702
(F1
F0.00014334862385321102
I1
I0
I1
tp39703
sS'measurable,limit'
p39704
(F1
F0.00014334862385321102
I1
I0
I1
tp39705
sS'on,metabolism'
p39706
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39707
sS'tendency,to'
p39708
(F1
F0.00028669724770642203
I2
I0
I2
tp39709
sS'result,in'
p39710
(F0.41333333333333333
F0.0044438073394495415
I53
I22
I31
tp39711
sS'blockers,isolated'
p39712
(F1
F0.00014334862385321102
I1
I0
I1
tp39713
sS'intestinal,beta-glucuronidase'
p39714
(F1
F0.00014334862385321102
I0
I1
I-1
tp39715
sS'syndrome,can'
p39716
(F1
F0.00014334862385321102
I1
I0
I1
tp39717
sS'medications,other'
p39718
(F1
F0.00014334862385321102
I0
I1
I-1
tp39719
sS'going,to'
p39720
(F1
F0.00071674311926605509
I0
I5
I-5
tp39721
sS'laboratorytest,interactions'
p39722
(F1
F0.00014334862385321102
I0
I1
I-1
tp39723
sS'which,may'
p39724
(F0.36363636363636365
F0.0011467889908256881
I15
I7
I8
tp39725
sS'first,step'
p39726
(F1
F0.00014334862385321102
I0
I1
I-1
tp39727
sS'sular,tended'
p39728
(F1
F0.00014334862385321102
I1
I0
I1
tp39729
sS'recovery,took'
p39730
(F1
F0.00014334862385321102
I1
I0
I1
tp39731
sS'most,psychoactive'
p39732
(F1
F0.00014334862385321102
I1
I0
I1
tp39733
sS'part,a'
p39734
(F1
F0.00014334862385321102
I0
I1
I-1
tp39735
sS'may,enhance'
p39736
(F0.89743589743589747
F0.0050172018348623856
I37
I2
I35
tp39737
sS'for,kappa'
p39738
(F1
F0.00014334862385321102
I0
I1
I-1
tp39739
sS'nose,may'
p39740
(F1
F0.00014334862385321102
I1
I0
I1
tp39741
sS'database,three'
p39742
(F1
F0.00014334862385321102
I0
I1
I-1
tp39743
sS'that,buspirone'
p39744
(F1
F0.00014334862385321102
I1
I0
I1
tp39745
sS'periodic,serum'
p39746
(F1
F0.00014334862385321102
I1
I0
I1
tp39747
sS'drowsiness-causing,any'
p39748
(F1
F0.00014334862385321102
I0
I1
I-1
tp39749
sS'of,cyp2d6'
p39750
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp39751
sS'pharmacokinetic,studies'
p39752
(F0.40000000000000002
F0.00057339449541284407
I3
I7
I-4
tp39753
sS'similarity,to'
p39754
(F1
F0.00014334862385321102
I1
I0
I1
tp39755
sS'organic,if'
p39756
(F1
F0.00014334862385321102
I1
I0
I1
tp39757
sS'in,hypercholesterolemic'
p39758
(F0
F0
I1
I1
I0
tp39759
sS'doses,should'
p39760
(F0
F0
I1
I1
I0
tp39761
sS'recommended,maximum'
p39762
(F1
F0.00028669724770642203
I2
I0
I2
tp39763
sS'maalox,maalox'
p39764
(F1
F0.00014334862385321102
I1
I0
I1
tp39765
sS'observed,in'
p39766
(F0.33333333333333331
F0.00057339449541284407
I4
I8
I-4
tp39767
sS'observed,it'
p39768
(F1
F0.00014334862385321102
I1
I0
I1
tp39769
sS'practice,dictates'
p39770
(F1
F0.00014334862385321102
I1
I0
I1
tp39771
sS'to,unique'
p39772
(F1
F0.00014334862385321102
I0
I1
I-1
tp39773
sS'effects,is'
p39774
(F1
F0.00014334862385321102
I1
I0
I1
tp39775
sS'effects,in'
p39776
(F0
F0
I3
I3
I0
tp39777
sS'systemic,exposure'
p39778
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp39779
sS'crossover,double-blind'
p39780
(F1
F0.00014334862385321102
I0
I1
I-1
tp39781
sS'reported,here'
p39782
(F1
F0.00014334862385321102
I0
I1
I-1
tp39783
sS'agents,channel'
p39784
(F1
F0.00014334862385321102
I1
I0
I1
tp39785
sS'patients,beginning'
p39786
(F1
F0.00014334862385321102
I1
I0
I1
tp39787
sS'of,parietal'
p39788
(F1
F0.00014334862385321102
I0
I1
I-1
tp39789
sS'the,underlying'
p39790
(F1
F0.00014334862385321102
I1
I0
I1
tp39791
sS'viracept,with'
p39792
(F1
F0.00014334862385321102
I1
I0
I1
tp39793
sS'associated,adverse'
p39794
(F1
F0.00014334862385321102
I0
I1
I-1
tp39795
sS'and,adjust'
p39796
(F1
F0.00014334862385321102
I1
I0
I1
tp39797
sS'ames,n-multistix'
p39798
(F1
F0.00014334862385321102
I0
I1
I-1
tp39799
sS'u,of'
p39800
(F1
F0.00014334862385321102
I0
I1
I-1
tp39801
sS'although,combining'
p39802
(F1
F0.00014334862385321102
I0
I1
I-1
tp39803
sS'use,the'
p39804
(F1
F0.00014334862385321102
I0
I1
I-1
tp39805
sS'three,pharmacokinetic'
p39806
(F1
F0.00014334862385321102
I0
I1
I-1
tp39807
sS'drug,eg'
p39808
(F1
F0.00014334862385321102
I1
I0
I1
tp39809
sS'human,liver'
p39810
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39811
sS'not,clear'
p39812
(F1
F0.00014334862385321102
I0
I1
I-1
tp39813
sS'psychotropic,have'
p39814
(F1
F0.00014334862385321102
I1
I0
I1
tp39815
sS'volatile,inhalation'
p39816
(F1
F0.00014334862385321102
I1
I0
I1
tp39817
sS'of,needed'
p39818
(F1
F0.00014334862385321102
I1
I0
I1
tp39819
sS'as,those'
p39820
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp39821
sS'taken,during'
p39822
(F1
F0.00043004587155963305
I3
I0
I3
tp39823
sS'acetazolamide,reduces'
p39824
(F1
F0.00014334862385321102
I1
I0
I1
tp39825
sS'published,information'
p39826
(F1
F0.00014334862385321102
I0
I1
I-1
tp39827
sS'of,d-penicillamine'
p39828
(F1
F0.00014334862385321102
I0
I1
I-1
tp39829
sS'ewes,with'
p39830
(F1
F0.00014334862385321102
I1
I0
I1
tp39831
sS'n-dodecyl,gallate'
p39832
(F1
F0.00014334862385321102
I0
I1
I-1
tp39833
sS'of,its'
p39834
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp39835
sS'ammonium,chloride'
p39836
(F1
F0.00028669724770642203
I2
I0
I2
tp39837
sS'pivoxil,be'
p39838
(F0
F0
I1
I1
I0
tp39839
sS'platelet,inhibitors'
p39840
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39841
sS'respectively,when'
p39842
(F1
F0.00028669724770642203
I2
I0
I2
tp39843
sS'aspirin,concurrent'
p39844
(F1
F0.00028669724770642203
I2
I0
I2
tp39845
sS'control,vs'
p39846
(F1
F0.00014334862385321102
I1
I0
I1
tp39847
sS'and,even'
p39848
(F0
F0
I1
I1
I0
tp39849
sS'decreased,on'
p39850
(F1
F0.00014334862385321102
I1
I0
I1
tp39851
sS'therapy,who'
p39852
(F1
F0.00014334862385321102
I1
I0
I1
tp39853
sS'and,compared'
p39854
(F1
F0.00028669724770642203
I0
I2
I-2
tp39855
sS'administered,without'
p39856
(F1
F0.00014334862385321102
I0
I1
I-1
tp39857
sS'of,amprenavir'
p39858
(F1
F0.00014334862385321102
I1
I0
I1
tp39859
sS'a,reversible'
p39860
(F1
F0.00014334862385321102
I1
I0
I1
tp39861
sS'aminosalicylic,acid'
p39862
(F1
F0.00071674311926605509
I5
I0
I5
tp39863
sS'smaller,initial'
p39864
(F1
F0.00014334862385321102
I1
I0
I1
tp39865
sS'clinically,relevant'
p39866
(F0.46666666666666667
F0.0010034403669724771
I4
I11
I-7
tp39867
sS'approach,to'
p39868
(F1
F0.00014334862385321102
I0
I1
I-1
tp39869
sS'earlier,than'
p39870
(F1
F0.00014334862385321102
I1
I0
I1
tp39871
sS'tolerant,patients'
p39872
(F1
F0.00014334862385321102
I0
I1
I-1
tp39873
sS'even,decrease'
p39874
(F1
F0.00014334862385321102
I0
I1
I-1
tp39875
sS'reduction,when'
p39876
(F1
F0.00014334862385321102
I1
I0
I1
tp39877
sS'b,and'
p39878
(F1
F0.00071674311926605509
I5
I0
I5
tp39879
sS'following,oral'
p39880
(F1
F0.00028669724770642203
I0
I2
I-2
tp39881
sS'nacmc,at'
p39882
(F1
F0.00014334862385321102
I0
I1
I-1
tp39883
sS'cimetidine,ranitidine'
p39884
(F1
F0.00014334862385321102
I1
I0
I1
tp39885
sS'be,elevated'
p39886
(F1
F0.00028669724770642203
I0
I2
I-2
tp39887
sS'for,oral'
p39888
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp39889
sS'those,found'
p39890
(F0
F0
I1
I1
I0
tp39891
sS'of,activity'
p39892
(F1
F0.00014334862385321102
I0
I1
I-1
tp39893
sS'between,mao'
p39894
(F1
F0.00014334862385321102
I1
I0
I1
tp39895
sS'whether,or'
p39896
(F1
F0.00028669724770642203
I0
I2
I-2
tp39897
sS'consumption,of'
p39898
(F1
F0.00014334862385321102
I1
I0
I1
tp39899
sS'products,that'
p39900
(F1
F0.00014334862385321102
I1
I0
I1
tp39901
sS'source,or'
p39902
(F1
F0.00014334862385321102
I0
I1
I-1
tp39903
sS'carbamazepine,combined'
p39904
(F1
F0.00014334862385321102
I0
I1
I-1
tp39905
sS'animals,demonstrate'
p39906
(F1
F0.00014334862385321102
I1
I0
I1
tp39907
sS'to,enhancing'
p39908
(F1
F0.00014334862385321102
I1
I0
I1
tp39909
sS'factor,viii'
p39910
(F1
F0.00014334862385321102
I0
I1
I-1
tp39911
sS'including,myocardial'
p39912
(F1
F0.00014334862385321102
I1
I0
I1
tp39913
sS'corticosteroids,or'
p39914
(F1
F0.00014334862385321102
I0
I1
I-1
tp39915
sS'these,should'
p39916
(F1
F0.00057339449541284407
I4
I0
I4
tp39917
sS'of,leading'
p39918
(F1
F0.00071674311926605509
I5
I0
I5
tp39919
sS'there,were'
p39920
(F0.7142857142857143
F0.0014334862385321102
I2
I12
I-10
tp39921
sS'pregnant,into'
p39922
(F1
F0.00014334862385321102
I0
I1
I-1
tp39923
sS'intestinal,absorption'
p39924
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp39925
sS'monkeys,responding'
p39926
(F1
F0.00014334862385321102
I0
I1
I-1
tp39927
sS'concomitant,antihypertensive'
p39928
(F1
F0.00014334862385321102
I1
I0
I1
tp39929
sS'been,noted'
p39930
(F1
F0.00028669724770642203
I2
I0
I2
tp39931
sS'inhibitors,warning'
p39932
(F1
F0.00014334862385321102
I0
I1
I-1
tp39933
sS'and,doses'
p39934
(F1
F0.00014334862385321102
I0
I1
I-1
tp39935
sS'sulfonamide,is'
p39936
(F1
F0.00014334862385321102
I1
I0
I1
tp39937
sS'frequently,and'
p39938
(F1
F0.00014334862385321102
I0
I1
I-1
tp39939
sS'postoperatively,patients'
p39940
(F1
F0.00014334862385321102
I0
I1
I-1
tp39941
sS'with,innovar'
p39942
(F1
F0.00014334862385321102
I1
I0
I1
tp39943
sS'be,maintained'
p39944
(F1
F0.00014334862385321102
I1
I0
I1
tp39945
sS'cause,increases'
p39946
(F1
F0.00043004587155963305
I0
I3
I-3
tp39947
sS'was,used'
p39948
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp39949
sS'therapy,including'
p39950
(F1
F0.00028669724770642203
I0
I2
I-2
tp39951
sS'closely,associated'
p39952
(F1
F0.00014334862385321102
I0
I1
I-1
tp39953
sS'certain,by'
p39954
(F1
F0.00014334862385321102
I1
I0
I1
tp39955
sS'occasionally,experience'
p39956
(F1
F0.00071674311926605509
I5
I0
I5
tp39957
sS'or,serum'
p39958
(F1
F0.00014334862385321102
I1
I0
I1
tp39959
sS'the,dimethylprostaglandin'
p39960
(F1
F0.00014334862385321102
I0
I1
I-1
tp39961
sS'induced,in'
p39962
(F1
F0.00014334862385321102
I0
I1
I-1
tp39963
sS'and,cystic'
p39964
(F1
F0.00014334862385321102
I1
I0
I1
tp39965
sS'the,cognitive'
p39966
(F1
F0.00014334862385321102
I1
I0
I1
tp39967
sS'receiving,blocking'
p39968
(F1
F0.00014334862385321102
I0
I1
I-1
tp39969
sS'of,udp-glucuronyl'
p39970
(F1
F0.00014334862385321102
I0
I1
I-1
tp39971
sS'family,cyp3a4'
p39972
(F1
F0.00014334862385321102
I0
I1
I-1
tp39973
sS'requirements,may'
p39974
(F1
F0.00014334862385321102
I1
I0
I1
tp39975
sS'mc,mg'
p39976
(F1
F0.00014334862385321102
I0
I1
I-1
tp39977
sS'to,depress'
p39978
(F1
F0.00028669724770642203
I2
I0
I2
tp39979
sS'involving,healthy'
p39980
(F1
F0.00014334862385321102
I1
I0
I1
tp39981
sS'necessary,but'
p39982
(F1
F0.00014334862385321102
I0
I1
I-1
tp39983
sS'is,similar'
p39984
(F1
F0.00014334862385321102
I1
I0
I1
tp39985
sS'of,young'
p39986
(F1
F0.00014334862385321102
I0
I1
I-1
tp39987
sS'of,symptoms'
p39988
(F1
F0.00014334862385321102
I1
I0
I1
tp39989
sS'gm,day'
p39990
(F1
F0.00014334862385321102
I1
I0
I1
tp39991
sS'to,inter-patient'
p39992
(F1
F0.00014334862385321102
I1
I0
I1
tp39993
sS'carbohydrate-splitting,enzymes'
p39994
(F1
F0.00014334862385321102
I1
I0
I1
tp39995
sS'direct,pharmacokinetic'
p39996
(F1
F0.00014334862385321102
I0
I1
I-1
tp39997
sS'compounds,tested'
p39998
(F1
F0.00014334862385321102
I0
I1
I-1
tp39999
sS'prolonging,av'
p40000
(F1
F0.00014334862385321102
I1
I0
I1
tp40001
sS'the,stomach'
p40002
(F1
F0.00043004587155963305
I3
I0
I3
tp40003
sS'levels,have'
p40004
(F1
F0.00043004587155963305
I3
I0
I3
tp40005
sS'acetylcholinesterase,ache'
p40006
(F1
F0.00014334862385321102
I1
I0
I1
tp40007
sS'of,following'
p40008
(F1
F0.00028669724770642203
I0
I2
I-2
tp40009
sS'other,tnfa-blocking'
p40010
(F1
F0.00014334862385321102
I1
I0
I1
tp40011
sS'have,neuromuscular'
p40012
(F1
F0.00028669724770642203
I2
I0
I2
tp40013
sS'l-methionine,may'
p40014
(F1
F0.00014334862385321102
I1
I0
I1
tp40015
sS'hctz,alone'
p40016
(F0
F0
I1
I1
I0
tp40017
sS'before,meals'
p40018
(F1
F0.00057339449541284407
I0
I4
I-4
tp40019
sS'excretion,compared'
p40020
(F1
F0.00028669724770642203
I2
I0
I2
tp40021
sS'were,subsequently'
p40022
(F0
F0
I1
I1
I0
tp40023
sS'metab-olizers,resemble'
p40024
(F1
F0.00014334862385321102
I0
I1
I-1
tp40025
sS'were,taken'
p40026
(F1
F0.00028669724770642203
I0
I2
I-2
tp40027
sS'and,amantadine'
p40028
(F1
F0.00014334862385321102
I1
I0
I1
tp40029
sS'demonstrated,between'
p40030
(F0
F0
I1
I1
I0
tp40031
sS'treatment,dyspnea'
p40032
(F1
F0.00014334862385321102
I0
I1
I-1
tp40033
sS'in,mac'
p40034
(F1
F0.00014334862385321102
I0
I1
I-1
tp40035
sS'been,seen'
p40036
(F0.5
F0.00028669724770642203
I3
I1
I2
tp40037
sS'when,coadministered'
p40038
(F0.40000000000000002
F0.0011467889908256881
I14
I6
I8
tp40039
sS'in,man'
p40040
(F0
F0
I3
I3
I0
tp40041
sS'of,pseudomonas'
p40042
(F1
F0.00028669724770642203
I0
I2
I-2
tp40043
sS'antiarrhythmic,agents'
p40044
(F1
F0.00014334862385321102
I0
I1
I-1
tp40045
sS'first,response'
p40046
(F1
F0.00014334862385321102
I0
I1
I-1
tp40047
sS'system,or'
p40048
(F0
F0
I1
I1
I0
tp40049
sS'mouse,mammary'
p40050
(F1
F0.00014334862385321102
I0
I1
I-1
tp40051
sS'these,were'
p40052
(F0
F0
I1
I1
I0
tp40053
sS'taken,concurrently'
p40054
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40055
sS'anti,inflammatory'
p40056
(F1
F0.00014334862385321102
I1
I0
I1
tp40057
sS'ketoprofen,does'
p40058
(F1
F0.00014334862385321102
I0
I1
I-1
tp40059
sS'neuromuscular,transmission'
p40060
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40061
sS'warfarin,keppra'
p40062
(F1
F0.00014334862385321102
I0
I1
I-1
tp40063
sS'component,of'
p40064
(F1
F0.00028669724770642203
I2
I0
I2
tp40065
sS'solution,can'
p40066
(F1
F0.00014334862385321102
I1
I0
I1
tp40067
sS'estrogen-containing,therapies'
p40068
(F1
F0.00014334862385321102
I1
I0
I1
tp40069
sS'abrupt,suppression'
p40070
(F1
F0.00014334862385321102
I1
I0
I1
tp40071
sS'between,discontinuation'
p40072
(F1
F0.00028669724770642203
I2
I0
I2
tp40073
sS'like,aleve'
p40074
(F1
F0.00014334862385321102
I1
I0
I1
tp40075
sS'drugs,whose'
p40076
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40077
sS'studies,indicate'
p40078
(F0
F0
I6
I6
I0
tp40079
sS'other,metal'
p40080
(F1
F0.00014334862385321102
I1
I0
I1
tp40081
sS'function,since'
p40082
(F1
F0.00014334862385321102
I0
I1
I-1
tp40083
sS'as,other'
p40084
(F1
F0.00028669724770642203
I2
I0
I2
tp40085
sS'receiving,injection'
p40086
(F1
F0.00014334862385321102
I0
I1
I-1
tp40087
sS'of,tcas'
p40088
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp40089
sS'ketoconazole,co-administration'
p40090
(F1
F0.00028669724770642203
I2
I0
I2
tp40091
sS'systems,has'
p40092
(F1
F0.00014334862385321102
I1
I0
I1
tp40093
sS'levels,may'
p40094
(F0.25
F0.00028669724770642203
I5
I3
I2
tp40095
sS'overdose,especially'
p40096
(F1
F0.00014334862385321102
I1
I0
I1
tp40097
sS'or,inactivated'
p40098
(F1
F0.00014334862385321102
I1
I0
I1
tp40099
sS'auc0-12,and'
p40100
(F1
F0.00014334862385321102
I1
I0
I1
tp40101
sS'and,nuclear'
p40102
(F1
F0.00014334862385321102
I1
I0
I1
tp40103
sS'terfenadine,administration'
p40104
(F1
F0.00014334862385321102
I0
I1
I-1
tp40105
sS'newly,introduced'
p40106
(F1
F0.00014334862385321102
I0
I1
I-1
tp40107
sS'other,narcotic'
p40108
(F1
F0.00014334862385321102
I1
I0
I1
tp40109
sS'with,fluothane'
p40110
(F1
F0.00014334862385321102
I1
I0
I1
tp40111
sS'be,lower'
p40112
(F0
F0
I1
I1
I0
tp40113
sS'the,diamond'
p40114
(F1
F0.00028669724770642203
I0
I2
I-2
tp40115
sS'diazepam,at'
p40116
(F1
F0.00014334862385321102
I1
I0
I1
tp40117
sS'restriction,or'
p40118
(F1
F0.00014334862385321102
I1
I0
I1
tp40119
sS'approximately,and'
p40120
(F1
F0.00071674311926605509
I5
I0
I5
tp40121
sS'cyclosporine,concomitant'
p40122
(F1
F0.00014334862385321102
I0
I1
I-1
tp40123
sS'effects,without'
p40124
(F1
F0.00014334862385321102
I1
I0
I1
tp40125
sS'altered,coagulation'
p40126
(F1
F0.00014334862385321102
I1
I0
I1
tp40127
sS'nonfailing,myocardium'
p40128
(F1
F0.00014334862385321102
I1
I0
I1
tp40129
sS'in,corrected'
p40130
(F1
F0.00014334862385321102
I0
I1
I-1
tp40131
sS'neurotoxic,therapy'
p40132
(F1
F0.00014334862385321102
I0
I1
I-1
tp40133
sS'bun,serum'
p40134
(F1
F0.00014334862385321102
I1
I0
I1
tp40135
sS'a,review'
p40136
(F1
F0.00014334862385321102
I1
I0
I1
tp40137
sS'include,vaiproic'
p40138
(F1
F0.00014334862385321102
I1
I0
I1
tp40139
sS'hydrochloride,not'
p40140
(F1
F0.00014334862385321102
I1
I0
I1
tp40141
sS'tricor,at'
p40142
(F1
F0.00014334862385321102
I1
I0
I1
tp40143
sS'mechanisms,underlying'
p40144
(F1
F0.00014334862385321102
I0
I1
I-1
tp40145
sS'primarily,cyp3a4'
p40146
(F1
F0.00014334862385321102
I0
I1
I-1
tp40147
sS'decreased,to'
p40148
(F1
F0.00014334862385321102
I1
I0
I1
tp40149
sS'difluoroacetone,in'
p40150
(F1
F0.00014334862385321102
I1
I0
I1
tp40151
sS'rarely,in'
p40152
(F1
F0.00014334862385321102
I1
I0
I1
tp40153
sS'fasting,conditions'
p40154
(F1
F0.00014334862385321102
I0
I1
I-1
tp40155
sS'the,human'
p40156
(F1
F0.00028669724770642203
I0
I2
I-2
tp40157
sS'as,videx'
p40158
(F1
F0.00028669724770642203
I2
I0
I2
tp40159
sS'day,provided'
p40160
(F1
F0.00014334862385321102
I1
I0
I1
tp40161
sS'times,a'
p40162
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40163
sS'the,jaff'
p40164
(F1
F0.00014334862385321102
I0
I1
I-1
tp40165
sS'study,who'
p40166
(F1
F0.00014334862385321102
I1
I0
I1
tp40167
sS'marked,hypertension'
p40168
(F1
F0.00014334862385321102
I1
I0
I1
tp40169
sS'an,blood'
p40170
(F1
F0.00014334862385321102
I1
I0
I1
tp40171
sS'of,voltage-dependent'
p40172
(F1
F0.00014334862385321102
I0
I1
I-1
tp40173
sS'with,lodine'
p40174
(F1
F0.00014334862385321102
I0
I1
I-1
tp40175
sS'alpha,and'
p40176
(F1
F0.00014334862385321102
I0
I1
I-1
tp40177
sS'been,rare'
p40178
(F1
F0.00071674311926605509
I5
I0
I5
tp40179
sS'temperature,was'
p40180
(F1
F0.00014334862385321102
I1
I0
I1
tp40181
sS'catecholamine-depleting,agents'
p40182
(F1
F0.00014334862385321102
I1
I0
I1
tp40183
sS'were,increased'
p40184
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp40185
sS'reserved,for'
p40186
(F1
F0.00014334862385321102
I0
I1
I-1
tp40187
sS'markers,that'
p40188
(F1
F0.00014334862385321102
I1
I0
I1
tp40189
sS'reduction,in'
p40190
(F0.76000000000000001
F0.0027236238532110093
I22
I3
I19
tp40191
sS'theophylline,decreased'
p40192
(F1
F0.00014334862385321102
I1
I0
I1
tp40193
sS'concomitant,crohn'
p40194
(F1
F0.00014334862385321102
I0
I1
I-1
tp40195
sS'enhance,cns'
p40196
(F1
F0.00014334862385321102
I1
I0
I1
tp40197
sS'altered,consciousness'
p40198
(F1
F0.00014334862385321102
I1
I0
I1
tp40199
sS'between,or'
p40200
(F1
F0.00014334862385321102
I1
I0
I1
tp40201
sS'profiles,of'
p40202
(F1
F0.00014334862385321102
I0
I1
I-1
tp40203
sS'hypertension,including'
p40204
(F1
F0.00014334862385321102
I1
I0
I1
tp40205
sS'between,oh'
p40206
(F1
F0.00014334862385321102
I0
I1
I-1
tp40207
sS'both,resorptions'
p40208
(F1
F0.00014334862385321102
I1
I0
I1
tp40209
sS'channel,blocker'
p40210
(F1
F0.00028669724770642203
I0
I2
I-2
tp40211
sS'hepatic,clearance'
p40212
(F1
F0.00014334862385321102
I0
I1
I-1
tp40213
sS'and,nondepolarizing'
p40214
(F1
F0.00014334862385321102
I0
I1
I-1
tp40215
sS'the,relevance'
p40216
(F1
F0.00014334862385321102
I1
I0
I1
tp40217
sS'cervical,laceration'
p40218
(F1
F0.00014334862385321102
I1
I0
I1
tp40219
sS'the,level'
p40220
(F0
F0
I3
I3
I0
tp40221
sS'empiric,adjustment'
p40222
(F1
F0.00014334862385321102
I0
I1
I-1
tp40223
sS'of,malignant'
p40224
(F1
F0.00014334862385321102
I1
I0
I1
tp40225
sS'study,comparing'
p40226
(F1
F0.00014334862385321102
I0
I1
I-1
tp40227
sS'hydrochloride,given'
p40228
(F1
F0.00014334862385321102
I1
I0
I1
tp40229
sS'since,an'
p40230
(F1
F0.00014334862385321102
I1
I0
I1
tp40231
sS'performed,in'
p40232
(F1
F0.00043004587155963305
I0
I3
I-3
tp40233
sS'greater,degrees'
p40234
(F1
F0.00014334862385321102
I1
I0
I1
tp40235
sS'co-infected,with'
p40236
(F1
F0.00014334862385321102
I0
I1
I-1
tp40237
sS'relationship,between'
p40238
(F1
F0.00028669724770642203
I0
I2
I-2
tp40239
sS'kg,ip'
p40240
(F1
F0.00014334862385321102
I1
I0
I1
tp40241
sS'kg,in'
p40242
(F1
F0.00014334862385321102
I0
I1
I-1
tp40243
sS'were,a'
p40244
(F1
F0.00014334862385321102
I0
I1
I-1
tp40245
sS'prescription,and'
p40246
(F1
F0.00014334862385321102
I0
I1
I-1
tp40247
sS'rating,scales'
p40248
(F1
F0.00014334862385321102
I0
I1
I-1
tp40249
sS'the,advice'
p40250
(F1
F0.00014334862385321102
I1
I0
I1
tp40251
sS'report,a'
p40252
(F1
F0.00014334862385321102
I0
I1
I-1
tp40253
sS'the,interaction'
p40254
(F0.33333333333333331
F0.0008600917431192661
I6
I12
I-6
tp40255
sS'randomized,trial'
p40256
(F1
F0.00014334862385321102
I1
I0
I1
tp40257
sS'extensive,metabolizers'
p40258
(F1
F0.00014334862385321102
I1
I0
I1
tp40259
sS'of,these'
p40260
(F0.17948717948717949
F0.0010034403669724771
I23
I16
I7
tp40261
sS'maximal,decrease'
p40262
(F1
F0.00014334862385321102
I0
I1
I-1
tp40263
sS'administered,iron-fortified'
p40264
(F1
F0.00014334862385321102
I0
I1
I-1
tp40265
sS'hypotensive,episodes'
p40266
(F1
F0.00014334862385321102
I1
I0
I1
tp40267
sS'that,was'
p40268
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40269
sS'by,which'
p40270
(F0
F0
I1
I1
I0
tp40271
sS'of,significant'
p40272
(F1
F0.00028669724770642203
I2
I0
I2
tp40273
sS'of,life-'
p40274
(F1
F0.00014334862385321102
I1
I0
I1
tp40275
sS'of,medications'
p40276
(F1
F0.00014334862385321102
I0
I1
I-1
tp40277
sS'agent,can'
p40278
(F1
F0.00071674311926605509
I5
I0
I5
tp40279
sS'significantly,inhibit'
p40280
(F1
F0.00028669724770642203
I2
I0
I2
tp40281
sS'to,their'
p40282
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40283
sS'were,only'
p40284
(F1
F0.00014334862385321102
I0
I1
I-1
tp40285
sS'results,do'
p40286
(F1
F0.00014334862385321102
I1
I0
I1
tp40287
sS'blood,concentration'
p40288
(F0
F0
I1
I1
I0
tp40289
sS'reduced,infusion'
p40290
(F1
F0.00014334862385321102
I1
I0
I1
tp40291
sS'large,doses'
p40292
(F1
F0.00043004587155963305
I0
I3
I-3
tp40293
sS'increased,lipid'
p40294
(F1
F0.00014334862385321102
I0
I1
I-1
tp40295
sS'intravenous,has'
p40296
(F0
F0
I1
I1
I0
tp40297
sS'iron-fortified,infant'
p40298
(F1
F0.00014334862385321102
I0
I1
I-1
tp40299
sS'steady,state'
p40300
(F0.1111111111111111
F0.00028669724770642203
I8
I10
I-2
tp40301
sS'profound,hypotension'
p40302
(F1
F0.00014334862385321102
I1
I0
I1
tp40303
sS'administration,was'
p40304
(F1
F0.00014334862385321102
I1
I0
I1
tp40305
sS'scale,of'
p40306
(F1
F0.00014334862385321102
I0
I1
I-1
tp40307
sS'consume,and'
p40308
(F1
F0.00014334862385321102
I1
I0
I1
tp40309
sS'of,elevated'
p40310
(F1
F0.00014334862385321102
I0
I1
I-1
tp40311
sS'and,confusional'
p40312
(F1
F0.00014334862385321102
I1
I0
I1
tp40313
sS'nondepolarizing,blocking'
p40314
(F1
F0.00014334862385321102
I0
I1
I-1
tp40315
sS'naftate,cephalothin'
p40316
(F1
F0.00014334862385321102
I0
I1
I-1
tp40317
sS'lunch,doses'
p40318
(F1
F0.00014334862385321102
I0
I1
I-1
tp40319
sS'in,experiments'
p40320
(F1
F0.00014334862385321102
I0
I1
I-1
tp40321
sS'apparently,by'
p40322
(F1
F0.00014334862385321102
I0
I1
I-1
tp40323
sS'panretin,gel'
p40324
(F0
F0
I1
I1
I0
tp40325
sS'butyrophenones,such'
p40326
(F1
F0.00014334862385321102
I1
I0
I1
tp40327
sS'example,may'
p40328
(F1
F0.00014334862385321102
I0
I1
I-1
tp40329
sS'elderly,may'
p40330
(F1
F0.00014334862385321102
I1
I0
I1
tp40331
sS'small,doses'
p40332
(F1
F0.00014334862385321102
I1
I0
I1
tp40333
sS'metal,cations'
p40334
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40335
sS'attenuate,loss'
p40336
(F1
F0.00043004587155963305
I3
I0
I3
tp40337
sS'amyl,nitrite'
p40338
(F1
F0.00014334862385321102
I1
I0
I1
tp40339
sS'values,are'
p40340
(F1
F0.00014334862385321102
I0
I1
I-1
tp40341
sS'increased,in'
p40342
(F0
F0
I1
I1
I0
tp40343
sS'overdose,with'
p40344
(F1
F0.00014334862385321102
I1
I0
I1
tp40345
sS'neurons,and'
p40346
(F1
F0.00014334862385321102
I1
I0
I1
tp40347
sS'increased,if'
p40348
(F1
F0.00014334862385321102
I1
I0
I1
tp40349
sS'hivid,should'
p40350
(F0
F0
I1
I1
I0
tp40351
sS'tests,response'
p40352
(F1
F0.00014334862385321102
I0
I1
I-1
tp40353
sS'low,and'
p40354
(F1
F0.00014334862385321102
I0
I1
I-1
tp40355
sS'antineoplastic,agents'
p40356
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp40357
sS'and,stimulatory'
p40358
(F1
F0.00014334862385321102
I1
I0
I1
tp40359
sS'the,danger'
p40360
(F1
F0.00043004587155963305
I3
I0
I3
tp40361
sS'following,mptp'
p40362
(F1
F0.00014334862385321102
I0
I1
I-1
tp40363
sS'or,magnesium-containing'
p40364
(F1
F0.00014334862385321102
I1
I0
I1
tp40365
sS'substantially,increased'
p40366
(F1
F0.00014334862385321102
I1
I0
I1
tp40367
sS'both,periods'
p40368
(F1
F0.00014334862385321102
I0
I1
I-1
tp40369
sS'weight,were'
p40370
(F1
F0.00014334862385321102
I0
I1
I-1
tp40371
sS'the,labeling'
p40372
(F1
F0.00014334862385321102
I0
I1
I-1
tp40373
sS'others,choline'
p40374
(F1
F0.00014334862385321102
I1
I0
I1
tp40375
sS'which,suggest'
p40376
(F1
F0.00014334862385321102
I1
I0
I1
tp40377
sS'however,administration'
p40378
(F1
F0.00014334862385321102
I0
I1
I-1
tp40379
sS'permitil,compazine'
p40380
(F1
F0.00014334862385321102
I0
I1
I-1
tp40381
sS'azathioprine,allopurinol'
p40382
(F1
F0.00014334862385321102
I1
I0
I1
tp40383
sS'mg,sodium'
p40384
(F1
F0.00028669724770642203
I2
I0
I2
tp40385
sS'hour,after'
p40386
(F0.5
F0.00028669724770642203
I3
I1
I2
tp40387
sS'dramatically,from'
p40388
(F1
F0.00014334862385321102
I0
I1
I-1
tp40389
sS'were,tested'
p40390
(F1
F0.00014334862385321102
I0
I1
I-1
tp40391
sS'ml,and'
p40392
(F0
F0
I2
I2
I0
tp40393
sS'as,possible'
p40394
(F1
F0.00028669724770642203
I0
I2
I-2
tp40395
sS'a,drug-drug'
p40396
(F0
F0
I1
I1
I0
tp40397
sS'theoretically,interfere'
p40398
(F1
F0.00014334862385321102
I0
I1
I-1
tp40399
sS'vasospasm,and'
p40400
(F0
F0
I1
I1
I0
tp40401
sS'other,had'
p40402
(F1
F0.00014334862385321102
I0
I1
I-1
tp40403
sS'possible,effectiveness'
p40404
(F1
F0.00014334862385321102
I1
I0
I1
tp40405
sS'the,binding'
p40406
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp40407
sS'may,reduce'
p40408
(F0.70588235294117652
F0.0034403669724770644
I29
I5
I24
tp40409
sS'concentration,should'
p40410
(F0
F0
I1
I1
I0
tp40411
sS'who,become'
p40412
(F1
F0.00014334862385321102
I0
I1
I-1
tp40413
sS'hepatic,toxicity'
p40414
(F1
F0.00014334862385321102
I1
I0
I1
tp40415
sS'the,usual'
p40416
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp40417
sS'necessary,eg'
p40418
(F1
F0.00014334862385321102
I1
I0
I1
tp40419
sS'define,the'
p40420
(F1
F0.00014334862385321102
I0
I1
I-1
tp40421
sS'no,clinical'
p40422
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40423
sS'before,blood'
p40424
(F1
F0.00014334862385321102
I1
I0
I1
tp40425
sS'above,chronic'
p40426
(F1
F0.00014334862385321102
I0
I1
I-1
tp40427
sS'acarbose,may'
p40428
(F1
F0.00014334862385321102
I0
I1
I-1
tp40429
sS'the,ingested'
p40430
(F1
F0.00014334862385321102
I1
I0
I1
tp40431
sS'from,succinylcholine-induced'
p40432
(F1
F0.00014334862385321102
I1
I0
I1
tp40433
sS'time,with'
p40434
(F1
F0.00028669724770642203
I2
I0
I2
tp40435
sS'biogen,pregnancy'
p40436
(F1
F0.00014334862385321102
I0
I1
I-1
tp40437
sS'antacids,may'
p40438
(F1
F0.00014334862385321102
I1
I0
I1
tp40439
sS'inspra,is'
p40440
(F1
F0.00014334862385321102
I1
I0
I1
tp40441
sS'or,stimulus'
p40442
(F1
F0.00014334862385321102
I0
I1
I-1
tp40443
sS'calcidiol,cholestyramine'
p40444
(F1
F0.00043004587155963305
I3
I0
I3
tp40445
sS'mainly,eliminated'
p40446
(F1
F0.00014334862385321102
I0
I1
I-1
tp40447
sS'on,concomitant'
p40448
(F0
F0
I4
I4
I0
tp40449
sS'may,reach'
p40450
(F1
F0.00014334862385321102
I0
I1
I-1
tp40451
sS'may,react'
p40452
(F1
F0.00014334862385321102
I1
I0
I1
tp40453
sS'hyperpolarized,by'
p40454
(F1
F0.00014334862385321102
I0
I1
I-1
tp40455
sS'theophylline,in'
p40456
(F1
F0.00014334862385321102
I0
I1
I-1
tp40457
sS'magan,or'
p40458
(F1
F0.00014334862385321102
I1
I0
I1
tp40459
sS'has,demonstrated'
p40460
(F1
F0.00028669724770642203
I0
I2
I-2
tp40461
sS'antiedematous,action'
p40462
(F1
F0.00014334862385321102
I1
I0
I1
tp40463
sS'studies,hydrochloride'
p40464
(F1
F0.00014334862385321102
I0
I1
I-1
tp40465
sS'when,rebif'
p40466
(F1
F0.00014334862385321102
I0
I1
I-1
tp40467
sS'no,additional'
p40468
(F1
F0.00028669724770642203
I2
I0
I2
tp40469
sS'and,aminoglycosides'
p40470
(F1
F0.00014334862385321102
I1
I0
I1
tp40471
sS'magnitude,or'
p40472
(F1
F0.00014334862385321102
I0
I1
I-1
tp40473
sS'usp,or'
p40474
(F1
F0.00014334862385321102
I1
I0
I1
tp40475
sS'adjustment,as'
p40476
(F1
F0.00014334862385321102
I0
I1
I-1
tp40477
sS'chewable,buffered'
p40478
(F1
F0.0010034403669724771
I7
I0
I7
tp40479
sS'four,times'
p40480
(F1
F0.00028669724770642203
I0
I2
I-2
tp40481
sS'magnitude,of'
p40482
(F1
F0.00014334862385321102
I1
I0
I1
tp40483
sS'inadvisable,to'
p40484
(F1
F0.00014334862385321102
I1
I0
I1
tp40485
sS'stavudine,and'
p40486
(F1
F0.00014334862385321102
I1
I0
I1
tp40487
sS'iiia4,blocks'
p40488
(F1
F0.00014334862385321102
I1
I0
I1
tp40489
sS'celebrex,can'
p40490
(F1
F0.00014334862385321102
I1
I0
I1
tp40491
sS'anti-coagulant,effect'
p40492
(F1
F0.00014334862385321102
I0
I1
I-1
tp40493
sS'combinations,of'
p40494
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp40495
sS'postoperative,pain'
p40496
(F1
F0.00014334862385321102
I0
I1
I-1
tp40497
sS'weeks,of'
p40498
(F0
F0
I1
I1
I0
tp40499
sS'although,no'
p40500
(F1
F0.00057339449541284407
I4
I0
I4
tp40501
sS'extend,outside'
p40502
(F1
F0.00014334862385321102
I0
I1
I-1
tp40503
sS'anti-platelet,activity'
p40504
(F1
F0.00014334862385321102
I0
I1
I-1
tp40505
sS'sequestered,in'
p40506
(F1
F0.00014334862385321102
I0
I1
I-1
tp40507
sS'year,controlled'
p40508
(F1
F0.00014334862385321102
I0
I1
I-1
tp40509
sS'agent,or'
p40510
(F1
F0.00043004587155963305
I0
I3
I-3
tp40511
sS'not,different'
p40512
(F1
F0.00014334862385321102
I0
I1
I-1
tp40513
sS'or,clinitest'
p40514
(F1
F0.00014334862385321102
I0
I1
I-1
tp40515
sS'cardiovascular,disease'
p40516
(F0
F0
I1
I1
I0
tp40517
sS'to,cups'
p40518
(F1
F0.00014334862385321102
I0
I1
I-1
tp40519
sS'create,possible'
p40520
(F1
F0.00043004587155963305
I0
I3
I-3
tp40521
sS'agent,of'
p40522
(F1
F0.00014334862385321102
I0
I1
I-1
tp40523
sS'in,adverse'
p40524
(F1
F0.00071674311926605509
I0
I5
I-5
tp40525
sS'agent,on'
p40526
(F1
F0.00014334862385321102
I0
I1
I-1
tp40527
sS'imidazole,compounds'
p40528
(F1
F0.00014334862385321102
I1
I0
I1
tp40529
sS'drugs,decreasing'
p40530
(F1
F0.00014334862385321102
I1
I0
I1
tp40531
sS'difluoroacetone,did'
p40532
(F1
F0.00014334862385321102
I0
I1
I-1
tp40533
sS'their,tolerance'
p40534
(F1
F0.00014334862385321102
I1
I0
I1
tp40535
sS'the,hypoprothrombinemia'
p40536
(F1
F0.00014334862385321102
I0
I1
I-1
tp40537
sS'the,hypoprothrombinemic'
p40538
(F1
F0.00014334862385321102
I0
I1
I-1
tp40539
sS'under,clinical'
p40540
(F1
F0.00014334862385321102
I0
I1
I-1
tp40541
sS'place,of'
p40542
(F1
F0.00014334862385321102
I1
I0
I1
tp40543
sS'selegiline,hydrochloride'
p40544
(F1
F0.00014334862385321102
I1
I0
I1
tp40545
sS'organisms,but'
p40546
(F1
F0.00014334862385321102
I0
I1
I-1
tp40547
sS'preparations,novolog'
p40548
(F1
F0.00014334862385321102
I0
I1
I-1
tp40549
sS'prothrombin,complex'
p40550
(F1
F0.00014334862385321102
I0
I1
I-1
tp40551
sS'elevations,with'
p40552
(F1
F0.00014334862385321102
I0
I1
I-1
tp40553
sS'and,motor'
p40554
(F0
F0
I1
I1
I0
tp40555
sS'judgment,of'
p40556
(F1
F0.00014334862385321102
I1
I0
I1
tp40557
sS'a,tolerance'
p40558
(F1
F0.00014334862385321102
I1
I0
I1
tp40559
sS'deficiencies,constitute'
p40560
(F1
F0.00014334862385321102
I0
I1
I-1
tp40561
sS'co-administered,dose'
p40562
(F1
F0.00014334862385321102
I0
I1
I-1
tp40563
sS'h,did'
p40564
(F1
F0.00014334862385321102
I0
I1
I-1
tp40565
sS'literature,revealed'
p40566
(F1
F0.00014334862385321102
I1
I0
I1
tp40567
sS'day,have'
p40568
(F1
F0.00014334862385321102
I1
I0
I1
tp40569
sS'following,agents'
p40570
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp40571
sS'rate,increase'
p40572
(F1
F0.00014334862385321102
I1
I0
I1
tp40573
sS'systematically,in'
p40574
(F1
F0.00014334862385321102
I0
I1
I-1
tp40575
sS'also,has'
p40576
(F0
F0
I1
I1
I0
tp40577
sS'minor,changes'
p40578
(F1
F0.00028669724770642203
I2
I0
I2
tp40579
sS'potassium-sparing,on'
p40580
(F1
F0.00014334862385321102
I1
I0
I1
tp40581
sS'causes,an'
p40582
(F1
F0.00071674311926605509
I5
I0
I5
tp40583
sS'barbiturates,may'
p40584
(F1
F0.00014334862385321102
I1
I0
I1
tp40585
sS'thioridazine,coadministration'
p40586
(F1
F0.00014334862385321102
I1
I0
I1
tp40587
sS'greater,amount'
p40588
(F1
F0.00014334862385321102
I1
I0
I1
tp40589
sS'potentiate,sulfate'
p40590
(F1
F0.00014334862385321102
I0
I1
I-1
tp40591
sS'herb,interactions'
p40592
(F1
F0.00014334862385321102
I1
I0
I1
tp40593
sS'valproate,mg'
p40594
(F1
F0.00014334862385321102
I0
I1
I-1
tp40595
sS'low,therapeutic'
p40596
(F1
F0.00028669724770642203
I0
I2
I-2
tp40597
sS'physicians,query'
p40598
(F1
F0.00014334862385321102
I0
I1
I-1
tp40599
sS'the,antinaturetic'
p40600
(F1
F0.00014334862385321102
I1
I0
I1
tp40601
sS'it,should'
p40602
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp40603
sS'decreased,the'
p40604
(F0.86206896551724133
F0.0035837155963302754
I27
I2
I25
tp40605
sS'of,relapse'
p40606
(F1
F0.00014334862385321102
I0
I1
I-1
tp40607
sS'by,camptosar'
p40608
(F1
F0.00014334862385321102
I1
I0
I1
tp40609
sS'supplements,use'
p40610
(F1
F0.00014334862385321102
I1
I0
I1
tp40611
sS'antiacid,didanosine'
p40612
(F1
F0.00014334862385321102
I0
I1
I-1
tp40613
sS'without,replacement'
p40614
(F1
F0.00014334862385321102
I0
I1
I-1
tp40615
sS'for,hours'
p40616
(F1
F0.00014334862385321102
I1
I0
I1
tp40617
sS'radioligand,binding'
p40618
(F1
F0.00014334862385321102
I0
I1
I-1
tp40619
sS'marked,symptomatic'
p40620
(F1
F0.00028669724770642203
I2
I0
I2
tp40621
sS'or,stopped'
p40622
(F1
F0.00014334862385321102
I1
I0
I1
tp40623
sS'bwt,were'
p40624
(F1
F0.00014334862385321102
I0
I1
I-1
tp40625
sS'cardiovascular,adverse'
p40626
(F1
F0.00014334862385321102
I1
I0
I1
tp40627
sS'interactions,may'
p40628
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp40629
sS'to,induce'
p40630
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp40631
sS'spontaneous,motility'
p40632
(F1
F0.00028669724770642203
I2
I0
I2
tp40633
sS'although,trough'
p40634
(F1
F0.00014334862385321102
I1
I0
I1
tp40635
sS'between,toradol'
p40636
(F1
F0.00014334862385321102
I1
I0
I1
tp40637
sS'bound,to'
p40638
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40639
sS'interact,with'
p40640
(F0.25
F0.0011467889908256881
I20
I12
I8
tp40641
sS'human,pharmacokinetic'
p40642
(F1
F0.00014334862385321102
I1
I0
I1
tp40643
sS'chicks,was'
p40644
(F1
F0.00014334862385321102
I1
I0
I1
tp40645
sS'ml,twice'
p40646
(F1
F0.00014334862385321102
I1
I0
I1
tp40647
sS'with,nitrous'
p40648
(F1
F0.00014334862385321102
I1
I0
I1
tp40649
sS'reaction,between'
p40650
(F1
F0.00014334862385321102
I1
I0
I1
tp40651
sS'using,an'
p40652
(F1
F0.00014334862385321102
I1
I0
I1
tp40653
sS'or,stereotypic'
p40654
(F1
F0.00014334862385321102
I0
I1
I-1
tp40655
sS'with,one-stage'
p40656
(F1
F0.00014334862385321102
I0
I1
I-1
tp40657
sS'with,hepatotoxic'
p40658
(F1
F0.00014334862385321102
I1
I0
I1
tp40659
sS'of,neurotoxic'
p40660
(F1
F0.00014334862385321102
I1
I0
I1
tp40661
sS'intraperitoneal,injections'
p40662
(F1
F0.00014334862385321102
I0
I1
I-1
tp40663
sS'responses,in'
p40664
(F1
F0.00014334862385321102
I1
I0
I1
tp40665
sS'double-blind,comparative'
p40666
(F1
F0.00014334862385321102
I0
I1
I-1
tp40667
sS'cimetidine,in'
p40668
(F1
F0.00043004587155963305
I3
I0
I3
tp40669
sS'concentration,that'
p40670
(F1
F0.00014334862385321102
I0
I1
I-1
tp40671
sS'of,because'
p40672
(F0.5
F0.00028669724770642203
I3
I1
I2
tp40673
sS'anticoagulants,altered'
p40674
(F1
F0.00014334862385321102
I1
I0
I1
tp40675
sS'cyp2d6,may'
p40676
(F1
F0.00014334862385321102
I0
I1
I-1
tp40677
sS'cimetidine,is'
p40678
(F1
F0.00014334862385321102
I1
I0
I1
tp40679
sS'are,not'
p40680
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp40681
sS'platelet,aggregation'
p40682
(F0
F0
I2
I2
I0
tp40683
sS'of,ergotamine-containing'
p40684
(F1
F0.00057339449541284407
I4
I0
I4
tp40685
sS'without,tdp'
p40686
(F1
F0.00014334862385321102
I0
I1
I-1
tp40687
sS'be,reversed'
p40688
(F0
F0
I1
I1
I0
tp40689
sS'is,possible'
p40690
(F1
F0.00043004587155963305
I3
I0
I3
tp40691
sS'interindividual,variability'
p40692
(F1
F0.00014334862385321102
I1
I0
I1
tp40693
sS'with,practically'
p40694
(F1
F0.00014334862385321102
I0
I1
I-1
tp40695
sS'a,consequence'
p40696
(F1
F0.00043004587155963305
I3
I0
I3
tp40697
sS'actively,concentrating'
p40698
(F1
F0.00014334862385321102
I0
I1
I-1
tp40699
sS'decreased,prothrom-bin'
p40700
(F1
F0.00028669724770642203
I2
I0
I2
tp40701
sS'attention,must'
p40702
(F1
F0.00014334862385321102
I1
I0
I1
tp40703
sS'one-tenth,of'
p40704
(F1
F0.00014334862385321102
I1
I0
I1
tp40705
sS'addition,that'
p40706
(F1
F0.00014334862385321102
I1
I0
I1
tp40707
sS'in,both'
p40708
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40709
sS'dilantin,phenobarbital'
p40710
(F1
F0.00014334862385321102
I1
I0
I1
tp40711
sS'bile,acids'
p40712
(F1
F0.00014334862385321102
I0
I1
I-1
tp40713
sS'among,patients'
p40714
(F0.5
F0.00028669724770642203
I3
I1
I2
tp40715
sS'test,alterations'
p40716
(F1
F0.00014334862385321102
I0
I1
I-1
tp40717
sS'becausedecreases,in'
p40718
(F1
F0.00028669724770642203
I2
I0
I2
tp40719
sS'moieties,are'
p40720
(F1
F0.00014334862385321102
I0
I1
I-1
tp40721
sS'be,metabolized'
p40722
(F0
F0
I1
I1
I0
tp40723
sS'before,resulted'
p40724
(F1
F0.00014334862385321102
I1
I0
I1
tp40725
sS'ribavirin,ribavirin'
p40726
(F1
F0.00014334862385321102
I0
I1
I-1
tp40727
sS'or,reduced'
p40728
(F1
F0.00028669724770642203
I2
I0
I2
tp40729
sS'pesticide,gliftor'
p40730
(F1
F0.00014334862385321102
I0
I1
I-1
tp40731
sS'sulfate,may'
p40732
(F1
F0.00028669724770642203
I2
I0
I2
tp40733
sS'intervals,in'
p40734
(F1
F0.00014334862385321102
I0
I1
I-1
tp40735
sS'preventing,its'
p40736
(F1
F0.00014334862385321102
I1
I0
I1
tp40737
sS'and,tachycardia'
p40738
(F1
F0.00014334862385321102
I1
I0
I1
tp40739
sS'cessation,of'
p40740
(F1
F0.00014334862385321102
I0
I1
I-1
tp40741
sS'survive,in'
p40742
(F1
F0.00014334862385321102
I0
I1
I-1
tp40743
sS'suggest,similar'
p40744
(F1
F0.00014334862385321102
I0
I1
I-1
tp40745
sS'studies,case'
p40746
(F1
F0.00014334862385321102
I0
I1
I-1
tp40747
sS'alone,were'
p40748
(F1
F0.00014334862385321102
I0
I1
I-1
tp40749
sS'of,competitive'
p40750
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40751
sS'recognized,by'
p40752
(F1
F0.00014334862385321102
I0
I1
I-1
tp40753
sS'bolus,doses'
p40754
(F1
F0.00014334862385321102
I0
I1
I-1
tp40755
sS'pattern,of'
p40756
(F1
F0.00014334862385321102
I0
I1
I-1
tp40757
sS'have,decreased'
p40758
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40759
sS'hamsters,in'
p40760
(F1
F0.00014334862385321102
I0
I1
I-1
tp40761
sS'aggregation,but'
p40762
(F1
F0.00014334862385321102
I1
I0
I1
tp40763
sS'interaction,occurred'
p40764
(F1
F0.00014334862385321102
I0
I1
I-1
tp40765
sS'test,for'
p40766
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp40767
sS'persistent,hypertension'
p40768
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40769
sS'classified,as'
p40770
(F0
F0
I1
I1
I0
tp40771
sS'xigris,may'
p40772
(F1
F0.00014334862385321102
I0
I1
I-1
tp40773
sS'bacteriostatic,may'
p40774
(F1
F0.00043004587155963305
I3
I0
I3
tp40775
sS'its,therapeutic'
p40776
(F1
F0.00014334862385321102
I0
I1
I-1
tp40777
sS'and,adrenoreceptors'
p40778
(F1
F0.00014334862385321102
I0
I1
I-1
tp40779
sS'usp,to'
p40780
(F1
F0.00014334862385321102
I1
I0
I1
tp40781
sS'after,being'
p40782
(F1
F0.00014334862385321102
I0
I1
I-1
tp40783
sS'gastrointestinal,toxicity'
p40784
(F1
F0.00043004587155963305
I3
I0
I3
tp40785
sS'aspirin,vardenafil'
p40786
(F1
F0.00014334862385321102
I0
I1
I-1
tp40787
sS'viracept,astramorph'
p40788
(F1
F0.00014334862385321102
I1
I0
I1
tp40789
sS'should,precede'
p40790
(F1
F0.00014334862385321102
I0
I1
I-1
tp40791
sS'approximately,hours'
p40792
(F1
F0.00014334862385321102
I1
I0
I1
tp40793
sS'are,mainly'
p40794
(F0
F0
I1
I1
I0
tp40795
sS'and,well-controlled'
p40796
(F1
F0.00014334862385321102
I0
I1
I-1
tp40797
sS'and,cyclopentyl-1'
p40798
(F1
F0.00014334862385321102
I0
I1
I-1
tp40799
sS'rifampin,following'
p40800
(F1
F0.00014334862385321102
I1
I0
I1
tp40801
sS'some,increase'
p40802
(F1
F0.00014334862385321102
I1
I0
I1
tp40803
sS'cytosine,arabinoside'
p40804
(F1
F0.00014334862385321102
I1
I0
I1
tp40805
sS'were,unchanged'
p40806
(F1
F0.00043004587155963305
I0
I3
I-3
tp40807
sS'cyclosporine,because'
p40808
(F1
F0.00014334862385321102
I1
I0
I1
tp40809
sS'cyclopentolate,may'
p40810
(F1
F0.00014334862385321102
I1
I0
I1
tp40811
sS'monitored,with'
p40812
(F1
F0.00028669724770642203
I0
I2
I-2
tp40813
sS'with,beta-adrenergic'
p40814
(F0.5
F0.00028669724770642203
I3
I1
I2
tp40815
sS'a,homodimeric'
p40816
(F1
F0.00014334862385321102
I0
I1
I-1
tp40817
sS'another,study'
p40818
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp40819
sS'and,css'
p40820
(F1
F0.00014334862385321102
I1
I0
I1
tp40821
sS'c8,c9'
p40822
(F1
F0.00014334862385321102
I0
I1
I-1
tp40823
sS'amiodarone,or'
p40824
(F1
F0.00014334862385321102
I1
I0
I1
tp40825
sS'certain,and'
p40826
(F1
F0.00071674311926605509
I5
I0
I5
tp40827
sS'experiencing,increases'
p40828
(F1
F0.00014334862385321102
I1
I0
I1
tp40829
sS'testing,should'
p40830
(F1
F0.00014334862385321102
I1
I0
I1
tp40831
sS'grouped,as'
p40832
(F1
F0.00014334862385321102
I0
I1
I-1
tp40833
sS'prolongs,and'
p40834
(F1
F0.00014334862385321102
I0
I1
I-1
tp40835
sS'hexalen,and'
p40836
(F1
F0.00028669724770642203
I2
I0
I2
tp40837
sS'depressant,effects'
p40838
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp40839
sS'decrease,clozapine'
p40840
(F1
F0.00014334862385321102
I1
I0
I1
tp40841
sS'with,weakness'
p40842
(F1
F0.00014334862385321102
I1
I0
I1
tp40843
sS'any,condition'
p40844
(F1
F0.00014334862385321102
I1
I0
I1
tp40845
sS'kytril,have'
p40846
(F1
F0.00014334862385321102
I0
I1
I-1
tp40847
sS'accelerated,markedly'
p40848
(F1
F0.00014334862385321102
I1
I0
I1
tp40849
sS'concentrations,and'
p40850
(F0
F0
I9
I9
I0
tp40851
sS'benefits,of'
p40852
(F1
F0.00028669724770642203
I2
I0
I2
tp40853
sS'diamox,in'
p40854
(F1
F0.00014334862385321102
I1
I0
I1
tp40855
sS'medication,such'
p40856
(F1
F0.00014334862385321102
I1
I0
I1
tp40857
sS'theophylline-related,side-effects'
p40858
(F1
F0.00014334862385321102
I1
I0
I1
tp40859
sS'prior,administration'
p40860
(F0
F0
I2
I2
I0
tp40861
sS'to,sodium'
p40862
(F1
F0.00014334862385321102
I0
I1
I-1
tp40863
sS'enhanced,and'
p40864
(F1
F0.00014334862385321102
I1
I0
I1
tp40865
sS'pharmacoeconomic,analyses'
p40866
(F1
F0.00014334862385321102
I0
I1
I-1
tp40867
sS'red,cells'
p40868
(F1
F0.00014334862385321102
I0
I1
I-1
tp40869
sS'are,obtained'
p40870
(F1
F0.00014334862385321102
I1
I0
I1
tp40871
sS'below,a'
p40872
(F1
F0.00014334862385321102
I0
I1
I-1
tp40873
sS'of,aggression'
p40874
(F1
F0.00014334862385321102
I0
I1
I-1
tp40875
sS'elevations,of'
p40876
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40877
sS'inhibitors,concurrent'
p40878
(F0
F0
I2
I2
I0
tp40879
sS'elevations,on'
p40880
(F1
F0.00014334862385321102
I1
I0
I1
tp40881
sS'serum,total'
p40882
(F1
F0.00014334862385321102
I0
I1
I-1
tp40883
sS'and,inflammatory'
p40884
(F1
F0.00014334862385321102
I1
I0
I1
tp40885
sS'with,their'
p40886
(F1
F0.00014334862385321102
I1
I0
I1
tp40887
sS'that,tikosyn'
p40888
(F1
F0.00028669724770642203
I0
I2
I-2
tp40889
sS'orally,prior'
p40890
(F1
F0.00014334862385321102
I1
I0
I1
tp40891
sS'than,two-second'
p40892
(F1
F0.00014334862385321102
I1
I0
I1
tp40893
sS'sample,size'
p40894
(F1
F0.00014334862385321102
I0
I1
I-1
tp40895
sS'related,member'
p40896
(F1
F0.00014334862385321102
I1
I0
I1
tp40897
sS'medicines,including'
p40898
(F1
F0.00014334862385321102
I0
I1
I-1
tp40899
sS'for,subjects'
p40900
(F1
F0.00014334862385321102
I0
I1
I-1
tp40901
sS'previously,been'
p40902
(F1
F0.00014334862385321102
I0
I1
I-1
tp40903
sS'ferrous,sulfate'
p40904
(F1
F0.00028669724770642203
I2
I0
I2
tp40905
sS'dipotassium,prolongs'
p40906
(F1
F0.00014334862385321102
I1
I0
I1
tp40907
sS'in,view'
p40908
(F0
F0
I1
I1
I0
tp40909
sS'relaxants,eg'
p40910
(F1
F0.00014334862385321102
I1
I0
I1
tp40911
sS'by,sodium'
p40912
(F1
F0.00014334862385321102
I0
I1
I-1
tp40913
sS'methotrexate,nsaids'
p40914
(F1
F0.00014334862385321102
I1
I0
I1
tp40915
sS'therapy,has'
p40916
(F1
F0.00028669724770642203
I0
I2
I-2
tp40917
sS'enablex,should'
p40918
(F1
F0.00014334862385321102
I1
I0
I1
tp40919
sS'augmentin,xr'
p40920
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40921
sS'dimethylprostaglandin,e2'
p40922
(F1
F0.00014334862385321102
I0
I1
I-1
tp40923
sS'be,aware'
p40924
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40925
sS'addition,several'
p40926
(F1
F0.00014334862385321102
I1
I0
I1
tp40927
sS'decreased,dosing'
p40928
(F1
F0.00014334862385321102
I0
I1
I-1
tp40929
sS'closely,for'
p40930
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp40931
sS'b,or'
p40932
(F1
F0.00043004587155963305
I0
I3
I-3
tp40933
sS'smaller,week'
p40934
(F1
F0.00014334862385321102
I0
I1
I-1
tp40935
sS'your,health'
p40936
(F1
F0.00014334862385321102
I1
I0
I1
tp40937
sS'with,ischemic'
p40938
(F1
F0.00014334862385321102
I1
I0
I1
tp40939
sS'in,uptake-1'
p40940
(F1
F0.00014334862385321102
I0
I1
I-1
tp40941
sS'bleeding,are'
p40942
(F1
F0.00028669724770642203
I2
I0
I2
tp40943
sS'but,no'
p40944
(F0
F0
I2
I2
I0
tp40945
sS'mechanisms,of'
p40946
(F1
F0.00043004587155963305
I0
I3
I-3
tp40947
sS'started,in'
p40948
(F1
F0.00014334862385321102
I1
I0
I1
tp40949
sS'data,from'
p40950
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp40951
sS'phenobarbital,the'
p40952
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40953
sS'when,mesylate'
p40954
(F1
F0.00014334862385321102
I1
I0
I1
tp40955
sS'b-blocking,agent'
p40956
(F1
F0.00014334862385321102
I1
I0
I1
tp40957
sS'antagonists,cimetidine'
p40958
(F1
F0.00028669724770642203
I2
I0
I2
tp40959
sS'discontinued,it'
p40960
(F1
F0.00014334862385321102
I1
I0
I1
tp40961
sS'take,first'
p40962
(F1
F0.00014334862385321102
I1
I0
I1
tp40963
sS'desired,lactulose-induced'
p40964
(F1
F0.00014334862385321102
I1
I0
I1
tp40965
sS'retention,in'
p40966
(F1
F0.00014334862385321102
I0
I1
I-1
tp40967
sS'to,fade'
p40968
(F1
F0.00014334862385321102
I1
I0
I1
tp40969
sS'subjects,ingesting'
p40970
(F1
F0.00014334862385321102
I1
I0
I1
tp40971
sS'situ,ligated'
p40972
(F1
F0.00014334862385321102
I0
I1
I-1
tp40973
sS'active,sulfide'
p40974
(F1
F0.00014334862385321102
I1
I0
I1
tp40975
sS'involving,six-healthy'
p40976
(F1
F0.00014334862385321102
I0
I1
I-1
tp40977
sS'in,sprycel'
p40978
(F1
F0.00014334862385321102
I0
I1
I-1
tp40979
sS'discontinued,in'
p40980
(F1
F0.00014334862385321102
I1
I0
I1
tp40981
sS'kemstro,the'
p40982
(F1
F0.00014334862385321102
I0
I1
I-1
tp40983
sS'as,effective'
p40984
(F1
F0.00014334862385321102
I0
I1
I-1
tp40985
sS'the,emerging'
p40986
(F1
F0.00014334862385321102
I0
I1
I-1
tp40987
sS'compounds,eg'
p40988
(F1
F0.00014334862385321102
I1
I0
I1
tp40989
sS'is,suggested'
p40990
(F1
F0.00071674311926605509
I5
I0
I5
tp40991
sS'heparin,sodium'
p40992
(F1
F0.00028669724770642203
I0
I2
I-2
tp40993
sS'anafranil,to'
p40994
(F1
F0.00014334862385321102
I1
I0
I1
tp40995
sS'displace,from'
p40996
(F1
F0.00014334862385321102
I1
I0
I1
tp40997
sS'side,reactions'
p40998
(F1
F0.00014334862385321102
I1
I0
I1
tp40999
sS'exposures,to'
p41000
(F1
F0.00014334862385321102
I1
I0
I1
tp41001
sS'that,patients'
p41002
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41003
sS'diphen-hydramine,and'
p41004
(F1
F0.00014334862385321102
I0
I1
I-1
tp41005
sS'although,consistent'
p41006
(F1
F0.00014334862385321102
I0
I1
I-1
tp41007
sS'titrated,to'
p41008
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp41009
sS'to,groups'
p41010
(F0
F0
I1
I1
I0
tp41011
sS'was,observed'
p41012
(F0.1111111111111111
F0.00028669724770642203
I10
I8
I2
tp41013
sS'isozyme,and'
p41014
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41015
sS'taking,most'
p41016
(F1
F0.00014334862385321102
I0
I1
I-1
tp41017
sS'hours,or'
p41018
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp41019
sS'no,change'
p41020
(F0
F0
I3
I3
I0
tp41021
sS'by,its'
p41022
(F1
F0.00028669724770642203
I2
I0
I2
tp41023
sS'be,restricted'
p41024
(F1
F0.00014334862385321102
I0
I1
I-1
tp41025
sS'bleeding,particularly'
p41026
(F1
F0.00014334862385321102
I1
I0
I1
tp41027
sS'are,incompletely'
p41028
(F1
F0.00014334862385321102
I0
I1
I-1
tp41029
sS'serum,binding'
p41030
(F1
F0.00014334862385321102
I1
I0
I1
tp41031
sS'to,form'
p41032
(F1
F0.00028669724770642203
I2
I0
I2
tp41033
sS'extensively,studied'
p41034
(F1
F0.00014334862385321102
I0
I1
I-1
tp41035
sS'baraclude,is'
p41036
(F1
F0.00014334862385321102
I0
I1
I-1
tp41037
sS'kidneys,coadministration'
p41038
(F1
F0.00014334862385321102
I0
I1
I-1
tp41039
sS'by,pcp'
p41040
(F1
F0.00014334862385321102
I0
I1
I-1
tp41041
sS'be,superior'
p41042
(F1
F0.00014334862385321102
I0
I1
I-1
tp41043
sS'or,immediately'
p41044
(F1
F0.00014334862385321102
I1
I0
I1
tp41045
sS'para-aminosalicylic,acid'
p41046
(F1
F0.00014334862385321102
I1
I0
I1
tp41047
sS'respectively,in'
p41048
(F1
F0.00014334862385321102
I1
I0
I1
tp41049
sS'cobalt,excretion'
p41050
(F1
F0.00014334862385321102
I0
I1
I-1
tp41051
sS'dmpge2,induced'
p41052
(F1
F0.00014334862385321102
I0
I1
I-1
tp41053
sS'may,increase'
p41054
(F0.5056179775280899
F0.0064506880733944958
I67
I22
I45
tp41055
sS'of,healthy'
p41056
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp41057
sS'or,led'
p41058
(F1
F0.00014334862385321102
I1
I0
I1
tp41059
sS'higher,cardiac'
p41060
(F1
F0.00014334862385321102
I1
I0
I1
tp41061
sS'can,exert'
p41062
(F1
F0.00014334862385321102
I0
I1
I-1
tp41063
sS'when,clozapine'
p41064
(F1
F0.00014334862385321102
I1
I0
I1
tp41065
sS'mean,area'
p41066
(F1
F0.00014334862385321102
I1
I0
I1
tp41067
sS'or,imuran'
p41068
(F1
F0.00014334862385321102
I1
I0
I1
tp41069
sS'mean,clearances'
p41070
(F1
F0.00014334862385321102
I1
I0
I1
tp41071
sS'use,in'
p41072
(F0.5
F0.00028669724770642203
I3
I1
I2
tp41073
sS'between,toradoliv'
p41074
(F1
F0.00014334862385321102
I0
I1
I-1
tp41075
sS'established,and'
p41076
(F1
F0.00014334862385321102
I0
I1
I-1
tp41077
sS'coli,in'
p41078
(F1
F0.00014334862385321102
I0
I1
I-1
tp41079
sS'weeks,was'
p41080
(F1
F0.00014334862385321102
I1
I0
I1
tp41081
sS'patients,coadministered'
p41082
(F1
F0.00014334862385321102
I1
I0
I1
tp41083
sS'and,especially'
p41084
(F1
F0.00043004587155963305
I3
I0
I3
tp41085
sS'and,gi'
p41086
(F1
F0.00014334862385321102
I0
I1
I-1
tp41087
sS'clindamycin,has'
p41088
(F1
F0.00014334862385321102
I1
I0
I1
tp41089
sS'use,is'
p41090
(F1
F0.00014334862385321102
I1
I0
I1
tp41091
sS'cancer,were'
p41092
(F0
F0
I1
I1
I0
tp41093
sS'and,sinus'
p41094
(F1
F0.00014334862385321102
I1
I0
I1
tp41095
sS'interactions,have'
p41096
(F0.47368421052631576
F0.0012901376146788992
I5
I14
I-9
tp41097
sS'etonogestrel,may'
p41098
(F1
F0.00014334862385321102
I1
I0
I1
tp41099
sS'renal,excretion'
p41100
(F0.5
F0.00057339449541284407
I6
I2
I4
tp41101
sS'or,both'
p41102
(F1
F0.00028669724770642203
I2
I0
I2
tp41103
sS'parameters,in'
p41104
(F1
F0.00014334862385321102
I1
I0
I1
tp41105
sS'an,index'
p41106
(F1
F0.00014334862385321102
I0
I1
I-1
tp41107
sS'monotherapy,did'
p41108
(F1
F0.00014334862385321102
I0
I1
I-1
tp41109
sS'of,rhabdomyolysis'
p41110
(F1
F0.00014334862385321102
I0
I1
I-1
tp41111
sS'singly,and'
p41112
(F1
F0.00014334862385321102
I0
I1
I-1
tp41113
sS'release,in'
p41114
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp41115
sS'direct,effect'
p41116
(F1
F0.00014334862385321102
I0
I1
I-1
tp41117
sS'corresponding,values'
p41118
(F1
F0.00028669724770642203
I0
I2
I-2
tp41119
sS'l,or'
p41120
(F1
F0.00014334862385321102
I0
I1
I-1
tp41121
sS'are,indeed'
p41122
(F1
F0.00014334862385321102
I0
I1
I-1
tp41123
sS'proteins,the'
p41124
(F1
F0.00014334862385321102
I1
I0
I1
tp41125
sS'of,vioxx'
p41126
(F0
F0
I2
I2
I0
tp41127
sS'of,renal'
p41128
(F0
F0
I5
I5
I0
tp41129
sS'transmission,curare-like'
p41130
(F1
F0.00028669724770642203
I2
I0
I2
tp41131
sS'can,interfere'
p41132
(F1
F0.00028669724770642203
I2
I0
I2
tp41133
sS'ldl-c,reduction'
p41134
(F0
F0
I1
I1
I0
tp41135
sS'taken,within'
p41136
(F1
F0.00043004587155963305
I3
I0
I3
tp41137
sS'nonprescription,products'
p41138
(F1
F0.00014334862385321102
I0
I1
I-1
tp41139
sS'to,ph'
p41140
(F1
F0.00014334862385321102
I0
I1
I-1
tp41141
sS'irinotecan,concentrations'
p41142
(F1
F0.00014334862385321102
I0
I1
I-1
tp41143
sS'from,chronic'
p41144
(F1
F0.00014334862385321102
I1
I0
I1
tp41145
sS'of,erection-supporting'
p41146
(F1
F0.00014334862385321102
I0
I1
I-1
tp41147
sS'decrease,for'
p41148
(F1
F0.00014334862385321102
I1
I0
I1
tp41149
sS'frequently,if'
p41150
(F1
F0.00043004587155963305
I3
I0
I3
tp41151
sS'sugar,in'
p41152
(F1
F0.00014334862385321102
I1
I0
I1
tp41153
sS'attention,test'
p41154
(F1
F0.00014334862385321102
I1
I0
I1
tp41155
sS'isomer,of'
p41156
(F1
F0.00014334862385321102
I1
I0
I1
tp41157
sS'hcl,cream'
p41158
(F1
F0.00014334862385321102
I0
I1
I-1
tp41159
sS'multiple-dose,pharmacokinetic'
p41160
(F1
F0.00014334862385321102
I0
I1
I-1
tp41161
sS'aged,years'
p41162
(F0
F0
I1
I1
I0
tp41163
sS'the,atac'
p41164
(F1
F0.00014334862385321102
I1
I0
I1
tp41165
sS'antagonized,in'
p41166
(F1
F0.00014334862385321102
I1
I0
I1
tp41167
sS'inh,isoniazid'
p41168
(F1
F0.00014334862385321102
I1
I0
I1
tp41169
sS'including,vitamin'
p41170
(F1
F0.00014334862385321102
I1
I0
I1
tp41171
sS'elimination,of'
p41172
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp41173
sS'urine,for'
p41174
(F1
F0.00014334862385321102
I0
I1
I-1
tp41175
sS'suggesting,an'
p41176
(F1
F0.00014334862385321102
I1
I0
I1
tp41177
sS'of-low,rates'
p41178
(F1
F0.00014334862385321102
I0
I1
I-1
tp41179
sS'bradycardia,qt'
p41180
(F1
F0.00014334862385321102
I1
I0
I1
tp41181
sS'dose,levels'
p41182
(F1
F0.00014334862385321102
I0
I1
I-1
tp41183
sS'with,ethyl'
p41184
(F1
F0.00014334862385321102
I1
I0
I1
tp41185
sS'which,to'
p41186
(F1
F0.00014334862385321102
I0
I1
I-1
tp41187
sS'and,unpredictable'
p41188
(F1
F0.00014334862385321102
I1
I0
I1
tp41189
sS'five,commonly'
p41190
(F1
F0.00014334862385321102
I0
I1
I-1
tp41191
sS'eg,rt-pa'
p41192
(F1
F0.00014334862385321102
I0
I1
I-1
tp41193
sS'of,aom'
p41194
(F1
F0.00014334862385321102
I0
I1
I-1
tp41195
sS'accutane,use'
p41196
(F1
F0.00014334862385321102
I1
I0
I1
tp41197
sS'cardiotoxic,or'
p41198
(F1
F0.00014334862385321102
I1
I0
I1
tp41199
sS'study,data'
p41200
(F1
F0.00014334862385321102
I1
I0
I1
tp41201
sS'inconclusive,with'
p41202
(F1
F0.00014334862385321102
I0
I1
I-1
tp41203
sS'an,opposite'
p41204
(F1
F0.00014334862385321102
I1
I0
I1
tp41205
sS'tablets,simultaneous'
p41206
(F1
F0.00014334862385321102
I1
I0
I1
tp41207
sS'hour,observation'
p41208
(F1
F0.00014334862385321102
I0
I1
I-1
tp41209
sS'in,cecectomized'
p41210
(F1
F0.00028669724770642203
I0
I2
I-2
tp41211
sS'enteric,coated'
p41212
(F0
F0
I1
I1
I0
tp41213
sS'to,continue'
p41214
(F1
F0.00043004587155963305
I3
I0
I3
tp41215
sS'long-acting,or'
p41216
(F1
F0.00014334862385321102
I1
I0
I1
tp41217
sS'measuring,serum'
p41218
(F1
F0.00014334862385321102
I0
I1
I-1
tp41219
sS'general,these'
p41220
(F1
F0.00014334862385321102
I0
I1
I-1
tp41221
sS'tid,mg'
p41222
(F1
F0.00014334862385321102
I1
I0
I1
tp41223
sS'for,placebo'
p41224
(F1
F0.00014334862385321102
I0
I1
I-1
tp41225
sS'on,bioavailability'
p41226
(F1
F0.00014334862385321102
I0
I1
I-1
tp41227
sS'on,kinetics'
p41228
(F1
F0.00014334862385321102
I1
I0
I1
tp41229
sS'involving,the'
p41230
(F1
F0.00014334862385321102
I1
I0
I1
tp41231
sS'prinivil,can'
p41232
(F1
F0.00014334862385321102
I1
I0
I1
tp41233
sS'case,were'
p41234
(F1
F0.00014334862385321102
I0
I1
I-1
tp41235
sS'with,chronic'
p41236
(F0
F0
I1
I1
I0
tp41237
sS'may,antagonize'
p41238
(F1
F0.0014334862385321102
I10
I0
I10
tp41239
sS'spray,but'
p41240
(F1
F0.00014334862385321102
I1
I0
I1
tp41241
sS'bid,n'
p41242
(F1
F0.00014334862385321102
I0
I1
I-1
tp41243
sS'whom,therapy'
p41244
(F1
F0.00071674311926605509
I5
I0
I5
tp41245
sS'its,renal'
p41246
(F1
F0.00043004587155963305
I3
I0
I3
tp41247
sS'drug,transport'
p41248
(F1
F0.00014334862385321102
I0
I1
I-1
tp41249
sS'kidney,allograft'
p41250
(F1
F0.00014334862385321102
I0
I1
I-1
tp41251
sS'stimulant,action'
p41252
(F1
F0.00014334862385321102
I0
I1
I-1
tp41253
sS'concomitant,treatment'
p41254
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp41255
sS'cromolyn,sodium'
p41256
(F0
F0
I1
I1
I0
tp41257
sS'oxidation,system'
p41258
(F1
F0.00014334862385321102
I0
I1
I-1
tp41259
sS'physician,is'
p41260
(F1
F0.00014334862385321102
I0
I1
I-1
tp41261
sS'metabolic,effects'
p41262
(F1
F0.00028669724770642203
I2
I0
I2
tp41263
sS'of,heart'
p41264
(F1
F0.00014334862385321102
I1
I0
I1
tp41265
sS'probably,has'
p41266
(F1
F0.00014334862385321102
I0
I1
I-1
tp41267
sS'pumps,for'
p41268
(F1
F0.00014334862385321102
I0
I1
I-1
tp41269
sS'surgery,because'
p41270
(F1
F0.00014334862385321102
I0
I1
I-1
tp41271
sS'potentiate,amphotericin'
p41272
(F1
F0.00014334862385321102
I1
I0
I1
tp41273
sS'the,renin-angiotensin'
p41274
(F1
F0.00014334862385321102
I0
I1
I-1
tp41275
sS'nsaids,affect'
p41276
(F1
F0.00014334862385321102
I1
I0
I1
tp41277
sS'inhibitory,concentration'
p41278
(F1
F0.00043004587155963305
I0
I3
I-3
tp41279
sS'moreover,additional'
p41280
(F1
F0.00014334862385321102
I0
I1
I-1
tp41281
sS'hydrate,diet'
p41282
(F1
F0.00014334862385321102
I1
I0
I1
tp41283
sS'following,macrolide'
p41284
(F1
F0.00014334862385321102
I1
I0
I1
tp41285
sS'and,without'
p41286
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp41287
sS'the,minimal'
p41288
(F1
F0.00014334862385321102
I0
I1
I-1
tp41289
sS'additive,when'
p41290
(F1
F0.00014334862385321102
I0
I1
I-1
tp41291
sS'the,purpose'
p41292
(F1
F0.00014334862385321102
I0
I1
I-1
tp41293
sS'effects,prothrombin'
p41294
(F1
F0.00014334862385321102
I1
I0
I1
tp41295
sS'lines,divergently'
p41296
(F1
F0.00014334862385321102
I0
I1
I-1
tp41297
sS'studies,failed'
p41298
(F1
F0.00014334862385321102
I0
I1
I-1
tp41299
sS'monitored,because'
p41300
(F1
F0.00028669724770642203
I2
I0
I2
tp41301
sS'trials,was'
p41302
(F1
F0.00014334862385321102
I0
I1
I-1
tp41303
sS'on,diuretic'
p41304
(F1
F0.00043004587155963305
I3
I0
I3
tp41305
sS'general,exaggeration'
p41306
(F1
F0.00014334862385321102
I1
I0
I1
tp41307
sS'early,components'
p41308
(F1
F0.00014334862385321102
I1
I0
I1
tp41309
sS'sodium,capsules'
p41310
(F0
F0
I1
I1
I0
tp41311
sS'therapy,could'
p41312
(F1
F0.00014334862385321102
I1
I0
I1
tp41313
sS'the,biological'
p41314
(F1
F0.00014334862385321102
I1
I0
I1
tp41315
sS'the,mixing'
p41316
(F1
F0.00014334862385321102
I1
I0
I1
tp41317
sS'to,microg'
p41318
(F1
F0.00014334862385321102
I0
I1
I-1
tp41319
sS'beta-adrenoceptor,blocking'
p41320
(F1
F0.00028669724770642203
I2
I0
I2
tp41321
sS'digoxin,concentrations'
p41322
(F1
F0.00014334862385321102
I1
I0
I1
tp41323
sS'consequently,alter'
p41324
(F1
F0.00014334862385321102
I0
I1
I-1
tp41325
sS'additionally,and'
p41326
(F1
F0.00014334862385321102
I0
I1
I-1
tp41327
sS'three,products'
p41328
(F1
F0.00014334862385321102
I1
I0
I1
tp41329
sS'denotes,a'
p41330
(F1
F0.00014334862385321102
I1
I0
I1
tp41331
sS'not,contain'
p41332
(F1
F0.00014334862385321102
I1
I0
I1
tp41333
sS'oral,has'
p41334
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp41335
sS'gaba-ergic,system'
p41336
(F1
F0.00014334862385321102
I1
I0
I1
tp41337
sS'with,combined'
p41338
(F1
F0.00014334862385321102
I1
I0
I1
tp41339
sS'state,plasma'
p41340
(F0.5
F0.00028669724770642203
I3
I1
I2
tp41341
sS'double-blind,fashion'
p41342
(F1
F0.00014334862385321102
I0
I1
I-1
tp41343
sS'duloxetine,may'
p41344
(F1
F0.00014334862385321102
I0
I1
I-1
tp41345
sS'induce,both'
p41346
(F1
F0.00014334862385321102
I0
I1
I-1
tp41347
sS'level,in'
p41348
(F1
F0.00014334862385321102
I1
I0
I1
tp41349
sS'patients,enrolled'
p41350
(F1
F0.00014334862385321102
I0
I1
I-1
tp41351
sS'of,potentiating'
p41352
(F1
F0.00014334862385321102
I1
I0
I1
tp41353
sS'alone,and'
p41354
(F0.1111111111111111
F0.00028669724770642203
I8
I10
I-2
tp41355
sS'green,tea'
p41356
(F1
F0.00014334862385321102
I0
I1
I-1
tp41357
sS'hours,two'
p41358
(F1
F0.00014334862385321102
I0
I1
I-1
tp41359
sS'tca,plasma'
p41360
(F1
F0.00057339449541284407
I0
I4
I-4
tp41361
sS'take,a'
p41362
(F1
F0.00014334862385321102
I1
I0
I1
tp41363
sS'level,is'
p41364
(F1
F0.00014334862385321102
I0
I1
I-1
tp41365
sS'with,elevated'
p41366
(F0.5
F0.00028669724770642203
I3
I1
I2
tp41367
sS'bioavailabillty,and'
p41368
(F1
F0.00014334862385321102
I0
I1
I-1
tp41369
sS'sodium,pertechnetate'
p41370
(F1
F0.00014334862385321102
I0
I1
I-1
tp41371
sS'produce,electrocardiographic'
p41372
(F1
F0.00014334862385321102
I1
I0
I1
tp41373
sS'nizoral,sporanox'
p41374
(F1
F0.00014334862385321102
I1
I0
I1
tp41375
sS'monitored,to'
p41376
(F1
F0.00014334862385321102
I1
I0
I1
tp41377
sS'gi,motility'
p41378
(F1
F0.00014334862385321102
I0
I1
I-1
tp41379
sS'prostate,epithelium'
p41380
(F1
F0.00014334862385321102
I1
I0
I1
tp41381
sS'norvir,viracept'
p41382
(F1
F0.00014334862385321102
I1
I0
I1
tp41383
sS'have,had'
p41384
(F1
F0.00014334862385321102
I1
I0
I1
tp41385
sS'when,myocardial'
p41386
(F1
F0.00014334862385321102
I1
I0
I1
tp41387
sS'a,greater'
p41388
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp41389
sS'of,microg'
p41390
(F1
F0.00014334862385321102
I0
I1
I-1
tp41391
sS'posed,by'
p41392
(F1
F0.00014334862385321102
I0
I1
I-1
tp41393
sS'other,neuromuscular'
p41394
(F1
F0.00028669724770642203
I2
I0
I2
tp41395
sS'neuromuscular,blockade'
p41396
(F0
F0
I3
I3
I0
tp41397
sS'transdermal,may'
p41398
(F1
F0.00014334862385321102
I1
I0
I1
tp41399
sS'reactions,when'
p41400
(F1
F0.00014334862385321102
I0
I1
I-1
tp41401
sS'adult-onset,diabetics'
p41402
(F1
F0.00014334862385321102
I1
I0
I1
tp41403
sS'treatment,which'
p41404
(F1
F0.00014334862385321102
I1
I0
I1
tp41405
sS'with,dsm-iv'
p41406
(F1
F0.00014334862385321102
I1
I0
I1
tp41407
sS'n,as'
p41408
(F1
F0.00014334862385321102
I0
I1
I-1
tp41409
sS'the,proton'
p41410
(F1
F0.00014334862385321102
I1
I0
I1
tp41411
sS'cold,and'
p41412
(F1
F0.00014334862385321102
I1
I0
I1
tp41413
sS'this,did'
p41414
(F1
F0.00014334862385321102
I0
I1
I-1
tp41415
sS'p-type,in'
p41416
(F1
F0.00014334862385321102
I0
I1
I-1
tp41417
sS'of,organs'
p41418
(F1
F0.00014334862385321102
I0
I1
I-1
tp41419
sS'addictive,medications'
p41420
(F1
F0.00014334862385321102
I0
I1
I-1
tp41421
sS'nanm,antagonized'
p41422
(F1
F0.00014334862385321102
I1
I0
I1
tp41423
sS'as,feso4'
p41424
(F1
F0.00014334862385321102
I1
I0
I1
tp41425
sS'when,mg'
p41426
(F1
F0.00057339449541284407
I4
I0
I4
tp41427
sS'of,cromolyn'
p41428
(F1
F0.00014334862385321102
I1
I0
I1
tp41429
sS'agents,that'
p41430
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp41431
sS'cyp3a,a'
p41432
(F1
F0.00014334862385321102
I1
I0
I1
tp41433
sS'thus,requiring'
p41434
(F1
F0.00014334862385321102
I1
I0
I1
tp41435
sS'bioavailability,is'
p41436
(F1
F0.00014334862385321102
I1
I0
I1
tp41437
sS'predominant,plasma'
p41438
(F1
F0.00014334862385321102
I0
I1
I-1
tp41439
sS'such,drugs'
p41440
(F1
F0.00014334862385321102
I0
I1
I-1
tp41441
sS'for,regarding'
p41442
(F1
F0.00014334862385321102
I0
I1
I-1
tp41443
sS'first,synthetic'
p41444
(F1
F0.00014334862385321102
I0
I1
I-1
tp41445
sS'ten-subject,study'
p41446
(F1
F0.00014334862385321102
I1
I0
I1
tp41447
sS'intraventricular,and'
p41448
(F1
F0.00043004587155963305
I0
I3
I-3
tp41449
sS'warfarin,no'
p41450
(F1
F0.00014334862385321102
I0
I1
I-1
tp41451
sS'when,duragesic'
p41452
(F1
F0.00014334862385321102
I0
I1
I-1
tp41453
sS'precipitation,occurs'
p41454
(F1
F0.00014334862385321102
I0
I1
I-1
tp41455
sS'serious,side'
p41456
(F1
F0.00014334862385321102
I0
I1
I-1
tp41457
sS'inhibit,phosphatase'
p41458
(F1
F0.00014334862385321102
I1
I0
I1
tp41459
sS'sodium,excretion'
p41460
(F1
F0.00028669724770642203
I2
I0
I2
tp41461
sS'acting,triclofos'
p41462
(F1
F0.00014334862385321102
I1
I0
I1
tp41463
sS'proliferation,stimulated'
p41464
(F1
F0.00014334862385321102
I1
I0
I1
tp41465
sS'and,joint'
p41466
(F1
F0.00014334862385321102
I1
I0
I1
tp41467
sS'metabolism,concomitant'
p41468
(F1
F0.00014334862385321102
I0
I1
I-1
tp41469
sS'flupenthixol,may'
p41470
(F1
F0.00014334862385321102
I1
I0
I1
tp41471
sS'concentration,c12hr'
p41472
(F1
F0.00014334862385321102
I1
I0
I1
tp41473
sS'towards,cyp1a2'
p41474
(F1
F0.00014334862385321102
I1
I0
I1
tp41475
sS'and,pharmacodynamic'
p41476
(F1
F0.00014334862385321102
I0
I1
I-1
tp41477
sS'blockers,may'
p41478
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp41479
sS'cause,qt'
p41480
(F1
F0.00014334862385321102
I0
I1
I-1
tp41481
sS'see,contraindications'
p41482
(F1
F0.00014334862385321102
I0
I1
I-1
tp41483
sS'growth,of'
p41484
(F1
F0.00028669724770642203
I0
I2
I-2
tp41485
sS'and,maintenance'
p41486
(F1
F0.00014334862385321102
I1
I0
I1
tp41487
sS'acidic,such'
p41488
(F1
F0.00014334862385321102
I1
I0
I1
tp41489
sS'increased,approximately'
p41490
(F1
F0.00071674311926605509
I5
I0
I5
tp41491
sS'others,plasma'
p41492
(F1
F0.00014334862385321102
I0
I1
I-1
tp41493
sS'are,listed'
p41494
(F1
F0.00014334862385321102
I1
I0
I1
tp41495
sS'adrenergic,neuron'
p41496
(F1
F0.00014334862385321102
I0
I1
I-1
tp41497
sS'consulting,the'
p41498
(F1
F0.00014334862385321102
I0
I1
I-1
tp41499
sS'interactions,albuterol'
p41500
(F1
F0.00014334862385321102
I1
I0
I1
tp41501
sS'these,may'
p41502
(F1
F0.00014334862385321102
I1
I0
I1
tp41503
sS'activity,which'
p41504
(F1
F0.00014334862385321102
I1
I0
I1
tp41505
sS'reduced,absorption'
p41506
(F1
F0.00014334862385321102
I0
I1
I-1
tp41507
sS'phosphorylation,in'
p41508
(F0
F0
I2
I2
I0
tp41509
sS'coupled,to'
p41510
(F1
F0.00014334862385321102
I0
I1
I-1
tp41511
sS'method,this'
p41512
(F1
F0.00014334862385321102
I0
I1
I-1
tp41513
sS'account,bezalip'
p41514
(F1
F0.00014334862385321102
I1
I0
I1
tp41515
sS'were,collected'
p41516
(F1
F0.00014334862385321102
I0
I1
I-1
tp41517
sS'mean,peak'
p41518
(F1
F0.00028669724770642203
I2
I0
I2
tp41519
sS'that,with'
p41520
(F1
F0.00014334862385321102
I0
I1
I-1
tp41521
sS'represents,an'
p41522
(F1
F0.00014334862385321102
I0
I1
I-1
tp41523
sS'for,two'
p41524
(F1
F0.00014334862385321102
I1
I0
I1
tp41525
sS'arecoline,eproxindine'
p41526
(F1
F0.00014334862385321102
I1
I0
I1
tp41527
sS'displaced,from'
p41528
(F1
F0.00043004587155963305
I3
I0
I3
tp41529
sS'other,nsaids'
p41530
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp41531
sS'increased,potential'
p41532
(F1
F0.00014334862385321102
I1
I0
I1
tp41533
sS'kineret,and'
p41534
(F1
F0.00028669724770642203
I2
I0
I2
tp41535
sS'muscle,relaxant'
p41536
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41537
sS'c,a'
p41538
(F1
F0.00014334862385321102
I1
I0
I1
tp41539
sS'a,cardioselective'
p41540
(F1
F0.00014334862385321102
I0
I1
I-1
tp41541
sS'about,mm'
p41542
(F1
F0.00014334862385321102
I1
I0
I1
tp41543
sS'involving,nizoral'
p41544
(F1
F0.00014334862385321102
I1
I0
I1
tp41545
sS'hypoglycemic,medications'
p41546
(F1
F0.00014334862385321102
I1
I0
I1
tp41547
sS'because,is'
p41548
(F0.33333333333333331
F0.00057339449541284407
I4
I8
I-4
tp41549
sS'not,when'
p41550
(F1
F0.00014334862385321102
I1
I0
I1
tp41551
sS'were,to'
p41552
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41553
sS'of,accutane'
p41554
(F1
F0.00014334862385321102
I1
I0
I1
tp41555
sS'when,considering'
p41556
(F1
F0.00014334862385321102
I1
I0
I1
tp41557
sS'days,to'
p41558
(F1
F0.00028669724770642203
I0
I2
I-2
tp41559
sS'various,chemotherapy'
p41560
(F1
F0.00014334862385321102
I0
I1
I-1
tp41561
sS'of,buforin'
p41562
(F1
F0.00028669724770642203
I0
I2
I-2
tp41563
sS'plasma,mean'
p41564
(F1
F0.00014334862385321102
I1
I0
I1
tp41565
sS'in,elevated'
p41566
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp41567
sS'kept,in'
p41568
(F0
F0
I1
I1
I0
tp41569
sS'more,commonly'
p41570
(F1
F0.00028669724770642203
I2
I0
I2
tp41571
sS'is,used'
p41572
(F0.73333333333333328
F0.0015768348623853212
I13
I2
I11
tp41573
sS'in,some'
p41574
(F0.7857142857142857
F0.0031536697247706424
I25
I3
I22
tp41575
sS'or,can'
p41576
(F1
F0.00028669724770642203
I2
I0
I2
tp41577
sS'a,mechanism'
p41578
(F1
F0.00014334862385321102
I1
I0
I1
tp41579
sS'effects,an'
p41580
(F1
F0.00014334862385321102
I1
I0
I1
tp41581
sS'inhibitor,resulted'
p41582
(F1
F0.00014334862385321102
I0
I1
I-1
tp41583
sS'patients,given'
p41584
(F1
F0.00028669724770642203
I2
I0
I2
tp41585
sS'plasma,protein'
p41586
(F1
F0.00071674311926605509
I0
I5
I-5
tp41587
sS'distilled,and'
p41588
(F1
F0.00014334862385321102
I0
I1
I-1
tp41589
sS'toxicity,of'
p41590
(F0
F0
I4
I4
I0
tp41591
sS'domestic,studies'
p41592
(F1
F0.00014334862385321102
I0
I1
I-1
tp41593
sS'life,in'
p41594
(F1
F0.00014334862385321102
I0
I1
I-1
tp41595
sS'the,risk'
p41596
(F0.42857142857142855
F0.0025802752293577983
I30
I12
I18
tp41597
sS'systemic,it'
p41598
(F1
F0.00014334862385321102
I1
I0
I1
tp41599
sS'of,cholinergic'
p41600
(F1
F0.00014334862385321102
I0
I1
I-1
tp41601
sS'heparin,since'
p41602
(F1
F0.00014334862385321102
I0
I1
I-1
tp41603
sS'as,manifested'
p41604
(F1
F0.00014334862385321102
I0
I1
I-1
tp41605
sS'moreover,its'
p41606
(F1
F0.00014334862385321102
I0
I1
I-1
tp41607
sS'leukopenic,activity'
p41608
(F1
F0.00014334862385321102
I1
I0
I1
tp41609
sS'metoclopramide,bioavailability'
p41610
(F1
F0.00014334862385321102
I1
I0
I1
tp41611
sS'd3,oh'
p41612
(F1
F0.00014334862385321102
I0
I1
I-1
tp41613
sS'dynamic,and'
p41614
(F1
F0.00014334862385321102
I0
I1
I-1
tp41615
sS'is,evidence'
p41616
(F1
F0.00014334862385321102
I0
I1
I-1
tp41617
sS'contraceptive,effect'
p41618
(F1
F0.00014334862385321102
I1
I0
I1
tp41619
sS'also,been'
p41620
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp41621
sS'antagonists,a'
p41622
(F1
F0.00014334862385321102
I0
I1
I-1
tp41623
sS'for,weeks'
p41624
(F1
F0.00043004587155963305
I3
I0
I3
tp41625
sS'a,two-way'
p41626
(F1
F0.00014334862385321102
I1
I0
I1
tp41627
sS'specifically,cytochromes'
p41628
(F1
F0.00014334862385321102
I0
I1
I-1
tp41629
sS'variety,of'
p41630
(F1
F0.00057339449541284407
I0
I4
I-4
tp41631
sS'changes,seen'
p41632
(F1
F0.00014334862385321102
I0
I1
I-1
tp41633
sS'hydroxydesloratadine,were'
p41634
(F1
F0.00014334862385321102
I0
I1
I-1
tp41635
sS's,and'
p41636
(F1
F0.00014334862385321102
I1
I0
I1
tp41637
sS'capsules,and'
p41638
(F1
F0.00028669724770642203
I2
I0
I2
tp41639
sS'concentrate,and'
p41640
(F1
F0.00014334862385321102
I1
I0
I1
tp41641
sS'chronic,obstructive'
p41642
(F1
F0.00014334862385321102
I0
I1
I-1
tp41643
sS'nephrotoxicity,with'
p41644
(F1
F0.00014334862385321102
I1
I0
I1
tp41645
sS'against,positive'
p41646
(F1
F0.00014334862385321102
I0
I1
I-1
tp41647
sS'potentiation,of'
p41648
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp41649
sS'potassium-depleting,agents'
p41650
(F1
F0.00014334862385321102
I1
I0
I1
tp41651
sS'inr,and'
p41652
(F1
F0.00014334862385321102
I1
I0
I1
tp41653
sS'to,alterations'
p41654
(F1
F0.00014334862385321102
I1
I0
I1
tp41655
sS'vitro,perfused'
p41656
(F1
F0.00014334862385321102
I0
I1
I-1
tp41657
sS'azithromycin,did'
p41658
(F1
F0.00014334862385321102
I0
I1
I-1
tp41659
sS'nrtis,other'
p41660
(F1
F0.00014334862385321102
I0
I1
I-1
tp41661
sS'occur,because'
p41662
(F1
F0.00014334862385321102
I1
I0
I1
tp41663
sS'or,channel'
p41664
(F0
F0
I1
I1
I0
tp41665
sS'established,that'
p41666
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41667
sS'c9,respectively'
p41668
(F1
F0.00014334862385321102
I0
I1
I-1
tp41669
sS'toxicity,including'
p41670
(F1
F0.00014334862385321102
I1
I0
I1
tp41671
sS'rats,hours'
p41672
(F1
F0.00014334862385321102
I0
I1
I-1
tp41673
sS'turn,resulted'
p41674
(F1
F0.00014334862385321102
I1
I0
I1
tp41675
sS'a,low'
p41676
(F1
F0.00028669724770642203
I0
I2
I-2
tp41677
sS'of,associated'
p41678
(F1
F0.00014334862385321102
I0
I1
I-1
tp41679
sS'mediated,signalling'
p41680
(F1
F0.00014334862385321102
I0
I1
I-1
tp41681
sS'of,administered'
p41682
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp41683
sS'copegus,in'
p41684
(F1
F0.00014334862385321102
I0
I1
I-1
tp41685
sS'treat,an'
p41686
(F1
F0.00014334862385321102
I0
I1
I-1
tp41687
sS'of,acidity'
p41688
(F1
F0.00014334862385321102
I1
I0
I1
tp41689
sS'as,convulsions'
p41690
(F1
F0.00014334862385321102
I1
I0
I1
tp41691
sS'not,only'
p41692
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41693
sS'adjusted,when'
p41694
(F1
F0.00014334862385321102
I0
I1
I-1
tp41695
sS'relaxation,of'
p41696
(F1
F0.00014334862385321102
I0
I1
I-1
tp41697
sS'altering,their'
p41698
(F1
F0.00014334862385321102
I0
I1
I-1
tp41699
sS'with,coadministration'
p41700
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp41701
sS'reversible,upon'
p41702
(F1
F0.00014334862385321102
I1
I0
I1
tp41703
sS'inhibitor,does'
p41704
(F1
F0.00014334862385321102
I0
I1
I-1
tp41705
sS'but,coadministration'
p41706
(F1
F0.00014334862385321102
I0
I1
I-1
tp41707
sS'bound,drugs'
p41708
(F1
F0.00014334862385321102
I0
I1
I-1
tp41709
sS'and,fold'
p41710
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41711
sS'sites,may'
p41712
(F1
F0.00014334862385321102
I0
I1
I-1
tp41713
sS'times,higher'
p41714
(F1
F0.00014334862385321102
I1
I0
I1
tp41715
sS'digoxin,some'
p41716
(F1
F0.00014334862385321102
I1
I0
I1
tp41717
sS'antacids,the'
p41718
(F1
F0.00014334862385321102
I0
I1
I-1
tp41719
sS'triple,therapy'
p41720
(F1
F0.00014334862385321102
I0
I1
I-1
tp41721
sS'through,pharmacokinetic'
p41722
(F1
F0.00014334862385321102
I0
I1
I-1
tp41723
sS'co-administration,systemic'
p41724
(F1
F0.00014334862385321102
I0
I1
I-1
tp41725
sS'clinical,data'
p41726
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp41727
sS'receiving,will'
p41728
(F1
F0.00014334862385321102
I1
I0
I1
tp41729
sS'significantly,include'
p41730
(F1
F0.00028669724770642203
I2
I0
I2
tp41731
sS'were,indifferent'
p41732
(F1
F0.00028669724770642203
I2
I0
I2
tp41733
sS'side,chains'
p41734
(F1
F0.00014334862385321102
I0
I1
I-1
tp41735
sS'more,potent'
p41736
(F1
F0.00043004587155963305
I0
I3
I-3
tp41737
sS'or,disruption'
p41738
(F1
F0.00014334862385321102
I0
I1
I-1
tp41739
sS'analogues,didanosine'
p41740
(F1
F0.00014334862385321102
I1
I0
I1
tp41741
sS'the,peak'
p41742
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41743
sS'the,genotypes'
p41744
(F1
F0.00014334862385321102
I0
I1
I-1
tp41745
sS'of,clinical'
p41746
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp41747
sS'receiving,concomitantly'
p41748
(F1
F0.00043004587155963305
I3
I0
I3
tp41749
sS'reduced,from'
p41750
(F1
F0.00028669724770642203
I2
I0
I2
tp41751
sS'raise,serum'
p41752
(F1
F0.00028669724770642203
I2
I0
I2
tp41753
sS'increased,monitoring'
p41754
(F1
F0.00014334862385321102
I1
I0
I1
tp41755
sS'of,whom'
p41756
(F1
F0.00014334862385321102
I0
I1
I-1
tp41757
sS'itraconazole,decreases'
p41758
(F1
F0.00014334862385321102
I1
I0
I1
tp41759
sS'iatrogenic,alteration'
p41760
(F1
F0.00014334862385321102
I0
I1
I-1
tp41761
sS'contraceptives,estrogens'
p41762
(F1
F0.00014334862385321102
I0
I1
I-1
tp41763
sS'of,treatment'
p41764
(F0.53846153846153844
F0.0010034403669724771
I10
I3
I7
tp41765
sS'progestogen,administration'
p41766
(F1
F0.00014334862385321102
I0
I1
I-1
tp41767
sS'uricosuric,such'
p41768
(F1
F0.00014334862385321102
I1
I0
I1
tp41769
sS'acid,excretion'
p41770
(F1
F0.00014334862385321102
I1
I0
I1
tp41771
sS'aspirin,may'
p41772
(F1
F0.00014334862385321102
I1
I0
I1
tp41773
sS'vardenafil,had'
p41774
(F1
F0.00014334862385321102
I0
I1
I-1
tp41775
sS'belladonna,alkaloids'
p41776
(F1
F0.00014334862385321102
I1
I0
I1
tp41777
sS'transiently,elevated'
p41778
(F1
F0.00014334862385321102
I0
I1
I-1
tp41779
sS'and,r-warfarin'
p41780
(F1
F0.00014334862385321102
I1
I0
I1
tp41781
sS'purification,protocol'
p41782
(F1
F0.00014334862385321102
I0
I1
I-1
tp41783
sS'between,systemic'
p41784
(F1
F0.00014334862385321102
I0
I1
I-1
tp41785
sS'urinary,homocysteine'
p41786
(F1
F0.00014334862385321102
I0
I1
I-1
tp41787
sS'and,incoordination'
p41788
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp41789
sS'with,some'
p41790
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp41791
sS'geocillin,carbenicillin'
p41792
(F1
F0.00014334862385321102
I1
I0
I1
tp41793
sS'although,this'
p41794
(F1
F0.00028669724770642203
I2
I0
I2
tp41795
sS'influence,the'
p41796
(F0.53846153846153844
F0.0010034403669724771
I3
I10
I-7
tp41797
sS'digoxin,in'
p41798
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp41799
sS'than,nanm'
p41800
(F1
F0.00014334862385321102
I0
I1
I-1
tp41801
sS'of,addiction'
p41802
(F1
F0.00014334862385321102
I0
I1
I-1
tp41803
sS'glyburide,glyburide'
p41804
(F1
F0.00014334862385321102
I0
I1
I-1
tp41805
sS'was,taken'
p41806
(F0
F0
I2
I2
I0
tp41807
sS'derivatives,and'
p41808
(F1
F0.00071674311926605509
I5
I0
I5
tp41809
sS'agent,should'
p41810
(F0
F0
I1
I1
I0
tp41811
sS'decrease,overall'
p41812
(F1
F0.00014334862385321102
I0
I1
I-1
tp41813
sS'a,valid'
p41814
(F1
F0.00014334862385321102
I1
I0
I1
tp41815
sS'diabetes,were'
p41816
(F1
F0.00014334862385321102
I0
I1
I-1
tp41817
sS'liver,and'
p41818
(F1
F0.00057339449541284407
I4
I0
I4
tp41819
sS'the,increases'
p41820
(F1
F0.00028669724770642203
I2
I0
I2
tp41821
sS'nonrenal,and'
p41822
(F1
F0.00014334862385321102
I0
I1
I-1
tp41823
sS'days,has'
p41824
(F0.5
F0.00028669724770642203
I3
I1
I2
tp41825
sS'copegus,did'
p41826
(F1
F0.00014334862385321102
I0
I1
I-1
tp41827
sS'long,periods'
p41828
(F1
F0.00014334862385321102
I0
I1
I-1
tp41829
sS'six,patients'
p41830
(F1
F0.00014334862385321102
I0
I1
I-1
tp41831
sS'the,increased'
p41832
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp41833
sS'as,vertigo'
p41834
(F1
F0.00014334862385321102
I1
I0
I1
tp41835
sS'days,had'
p41836
(F1
F0.00057339449541284407
I0
I4
I-4
tp41837
sS'occur,between'
p41838
(F1
F0.00014334862385321102
I1
I0
I1
tp41839
sS'anabolic,anabolin'
p41840
(F1
F0.00014334862385321102
I0
I1
I-1
tp41841
sS'that,contain'
p41842
(F1
F0.00014334862385321102
I1
I0
I1
tp41843
sS'quinolones,form'
p41844
(F1
F0.00028669724770642203
I0
I2
I-2
tp41845
sS'chemotherapeutic,agents'
p41846
(F1
F0.00014334862385321102
I0
I1
I-1
tp41847
sS'hypotension,was'
p41848
(F1
F0.00028669724770642203
I0
I2
I-2
tp41849
sS'sequential,infusions'
p41850
(F1
F0.00014334862385321102
I1
I0
I1
tp41851
sS'increased,frequency'
p41852
(F1
F0.00014334862385321102
I0
I1
I-1
tp41853
sS'will,not'
p41854
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41855
sS'minus,in'
p41856
(F1
F0.00014334862385321102
I1
I0
I1
tp41857
sS'sirolimus,works'
p41858
(F1
F0.00014334862385321102
I0
I1
I-1
tp41859
sS'small,with'
p41860
(F1
F0.00014334862385321102
I0
I1
I-1
tp41861
sS'synergism,has'
p41862
(F1
F0.00014334862385321102
I1
I0
I1
tp41863
sS'of,recovery'
p41864
(F1
F0.00014334862385321102
I0
I1
I-1
tp41865
sS'cyp3a,and'
p41866
(F0
F0
I1
I1
I0
tp41867
sS'or,patients'
p41868
(F0
F0
I1
I1
I0
tp41869
sS'in,monkeys'
p41870
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41871
sS'deeper,and'
p41872
(F1
F0.00014334862385321102
I1
I0
I1
tp41873
sS'that,both'
p41874
(F0
F0
I1
I1
I0
tp41875
sS'chlorthalidone,may'
p41876
(F1
F0.00014334862385321102
I1
I0
I1
tp41877
sS'releaser,and'
p41878
(F1
F0.00014334862385321102
I1
I0
I1
tp41879
sS'both,weight'
p41880
(F1
F0.00014334862385321102
I1
I0
I1
tp41881
sS'systems,lapatinib'
p41882
(F1
F0.00014334862385321102
I0
I1
I-1
tp41883
sS'been,greater'
p41884
(F1
F0.00028669724770642203
I2
I0
I2
tp41885
sS'not,effected'
p41886
(F1
F0.00014334862385321102
I0
I1
I-1
tp41887
sS'cyp2d6,in'
p41888
(F1
F0.00014334862385321102
I0
I1
I-1
tp41889
sS'emit-d,a'
p41890
(F1
F0.00014334862385321102
I0
I1
I-1
tp41891
sS'protein,bound'
p41892
(F0.5
F0.00028669724770642203
I3
I1
I2
tp41893
sS'decreased,from'
p41894
(F1
F0.00014334862385321102
I0
I1
I-1
tp41895
sS'to,infusions'
p41896
(F1
F0.00014334862385321102
I1
I0
I1
tp41897
sS'benedicts,solution'
p41898
(F1
F0.00014334862385321102
I0
I1
I-1
tp41899
sS'cyp2d6,is'
p41900
(F1
F0.00028669724770642203
I0
I2
I-2
tp41901
sS'when,analgesia'
p41902
(F1
F0.00014334862385321102
I1
I0
I1
tp41903
sS'of,p450'
p41904
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41905
sS'long-,and'
p41906
(F1
F0.00014334862385321102
I0
I1
I-1
tp41907
sS'caution,and'
p41908
(F1
F0.00028669724770642203
I2
I0
I2
tp41909
sS'other,agent'
p41910
(F1
F0.00014334862385321102
I0
I1
I-1
tp41911
sS'cmax,were'
p41912
(F1
F0.00014334862385321102
I0
I1
I-1
tp41913
sS'such,interactions'
p41914
(F1
F0.00014334862385321102
I0
I1
I-1
tp41915
sS'aliskiren,based'
p41916
(F1
F0.00014334862385321102
I0
I1
I-1
tp41917
sS'function,such'
p41918
(F1
F0.00014334862385321102
I1
I0
I1
tp41919
sS'netilmicin,should'
p41920
(F1
F0.00014334862385321102
I1
I0
I1
tp41921
sS'or,repeated'
p41922
(F1
F0.00014334862385321102
I0
I1
I-1
tp41923
sS'minimum,inhibitory'
p41924
(F1
F0.00014334862385321102
I0
I1
I-1
tp41925
sS'and,calcidiol'
p41926
(F1
F0.00043004587155963305
I3
I0
I3
tp41927
sS'or,total'
p41928
(F1
F0.00014334862385321102
I0
I1
I-1
tp41929
sS'meaningfully,alter'
p41930
(F1
F0.00014334862385321102
I0
I1
I-1
tp41931
sS'to,expect'
p41932
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41933
sS'study,and'
p41934
(F1
F0.00028669724770642203
I0
I2
I-2
tp41935
sS'should,be'
p41936
(F0.47962382445141066
F0.021932339449541285
I236
I83
I153
tp41937
sS'inducer,the'
p41938
(F1
F0.00014334862385321102
I1
I0
I1
tp41939
sS'weak,acids'
p41940
(F1
F0.00014334862385321102
I1
I0
I1
tp41941
sS'combination,regimens'
p41942
(F1
F0.00014334862385321102
I1
I0
I1
tp41943
sS'blockers,calcium-channel'
p41944
(F1
F0.00014334862385321102
I0
I1
I-1
tp41945
sS'the,extent'
p41946
(F0.40000000000000002
F0.0011467889908256881
I6
I14
I-8
tp41947
sS'or,as'
p41948
(F1
F0.00028669724770642203
I2
I0
I2
tp41949
sS'mildly,reduced'
p41950
(F1
F0.00014334862385321102
I1
I0
I1
tp41951
sS'sirolimus-diltiazem,interaction'
p41952
(F1
F0.00014334862385321102
I1
I0
I1
tp41953
sS'or,av'
p41954
(F1
F0.00014334862385321102
I1
I0
I1
tp41955
sS'or,at'
p41956
(F1
F0.00014334862385321102
I0
I1
I-1
tp41957
sS'the,choice'
p41958
(F1
F0.00014334862385321102
I0
I1
I-1
tp41959
sS'copegus,and'
p41960
(F1
F0.00014334862385321102
I1
I0
I1
tp41961
sS'been,prescribed'
p41962
(F1
F0.00014334862385321102
I0
I1
I-1
tp41963
sS'periods,of'
p41964
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41965
sS'were,measured'
p41966
(F1
F0.00028669724770642203
I0
I2
I-2
tp41967
sS'or,an'
p41968
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41969
sS'the,hypertensive'
p41970
(F1
F0.00014334862385321102
I1
I0
I1
tp41971
sS'receiving,tricyclic'
p41972
(F1
F0.00014334862385321102
I1
I0
I1
tp41973
sS'since,is'
p41974
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp41975
sS'conducted,with'
p41976
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp41977
sS'since,it'
p41978
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41979
sS'antagonist,sch-23390'
p41980
(F1
F0.00014334862385321102
I1
I0
I1
tp41981
sS'subjects,clearance'
p41982
(F1
F0.00014334862385321102
I0
I1
I-1
tp41983
sS'cyp1a1,cyp1a2'
p41984
(F1
F0.00014334862385321102
I0
I1
I-1
tp41985
sS'since,in'
p41986
(F1
F0.00014334862385321102
I1
I0
I1
tp41987
sS'template,bleeding'
p41988
(F1
F0.00014334862385321102
I0
I1
I-1
tp41989
sS'included,a'
p41990
(F1
F0.00014334862385321102
I0
I1
I-1
tp41991
sS'higher,dosages'
p41992
(F1
F0.00014334862385321102
I0
I1
I-1
tp41993
sS'cyp3a4,rifampicin'
p41994
(F1
F0.00014334862385321102
I1
I0
I1
tp41995
sS'through,hours'
p41996
(F1
F0.00014334862385321102
I0
I1
I-1
tp41997
sS'tablet,if'
p41998
(F1
F0.00014334862385321102
I1
I0
I1
tp41999
sS'increased,an'
p42000
(F1
F0.00014334862385321102
I1
I0
I1
tp42001
sS'camp-stimulated,acid'
p42002
(F1
F0.00014334862385321102
I1
I0
I1
tp42003
sS'day,during'
p42004
(F1
F0.00014334862385321102
I1
I0
I1
tp42005
sS'as,thorazine'
p42006
(F1
F0.00014334862385321102
I0
I1
I-1
tp42007
sS'transfusions,acute'
p42008
(F1
F0.00014334862385321102
I1
I0
I1
tp42009
sS'by,include'
p42010
(F1
F0.00014334862385321102
I1
I0
I1
tp42011
sS'receiving,azole'
p42012
(F1
F0.00014334862385321102
I1
I0
I1
tp42013
sS'mefloquine,although'
p42014
(F1
F0.00014334862385321102
I1
I0
I1
tp42015
sS'most,instances'
p42016
(F1
F0.00014334862385321102
I1
I0
I1
tp42017
sS'few,weeks'
p42018
(F1
F0.00014334862385321102
I1
I0
I1
tp42019
sS'an,acute'
p42020
(F1
F0.00014334862385321102
I0
I1
I-1
tp42021
sS'ii,diabetic'
p42022
(F1
F0.00014334862385321102
I1
I0
I1
tp42023
sS'target,of'
p42024
(F1
F0.00014334862385321102
I0
I1
I-1
tp42025
sS'on,tolerance'
p42026
(F1
F0.00014334862385321102
I0
I1
I-1
tp42027
sS'specific,toxicities'
p42028
(F1
F0.00014334862385321102
I0
I1
I-1
tp42029
sS'activated,in'
p42030
(F1
F0.00014334862385321102
I1
I0
I1
tp42031
sS'including,hyperthermia'
p42032
(F1
F0.00014334862385321102
I1
I0
I1
tp42033
sS'nerves,and'
p42034
(F1
F0.00014334862385321102
I0
I1
I-1
tp42035
sS'synthetic,steroidal'
p42036
(F1
F0.00014334862385321102
I0
I1
I-1
tp42037
sS'fluoxetine,indanavir'
p42038
(F1
F0.00014334862385321102
I0
I1
I-1
tp42039
sS'anesthesia,severe'
p42040
(F1
F0.00014334862385321102
I1
I0
I1
tp42041
sS'concomitan,administration'
p42042
(F1
F0.00014334862385321102
I1
I0
I1
tp42043
sS'glucuronide,account'
p42044
(F1
F0.00014334862385321102
I0
I1
I-1
tp42045
sS'danazol,the'
p42046
(F1
F0.00014334862385321102
I1
I0
I1
tp42047
sS'd,and'
p42048
(F1
F0.00028669724770642203
I2
I0
I2
tp42049
sS'of,myopathy'
p42050
(F0
F0
I2
I2
I0
tp42051
sS'has,a'
p42052
(F0.5
F0.00057339449541284407
I6
I2
I4
tp42053
sS'interaction,trials'
p42054
(F1
F0.00014334862385321102
I0
I1
I-1
tp42055
sS'to,slower'
p42056
(F1
F0.00014334862385321102
I1
I0
I1
tp42057
sS'product,in'
p42058
(F1
F0.00014334862385321102
I0
I1
I-1
tp42059
sS'indocin,is'
p42060
(F1
F0.00043004587155963305
I3
I0
I3
tp42061
sS'than,myopathy'
p42062
(F1
F0.00014334862385321102
I0
I1
I-1
tp42063
sS'both,increase'
p42064
(F1
F0.00014334862385321102
I1
I0
I1
tp42065
sS'other,hiv'
p42066
(F1
F0.00014334862385321102
I0
I1
I-1
tp42067
sS'alkalinizers,decrease'
p42068
(F1
F0.00014334862385321102
I0
I1
I-1
tp42069
sS'taxol,mg'
p42070
(F1
F0.00014334862385321102
I1
I0
I1
tp42071
sS'the,relative'
p42072
(F1
F0.00014334862385321102
I0
I1
I-1
tp42073
sS'other,diagnostic'
p42074
(F1
F0.00014334862385321102
I0
I1
I-1
tp42075
sS'microg,ml'
p42076
(F1
F0.00014334862385321102
I0
I1
I-1
tp42077
sS'ways,to'
p42078
(F1
F0.00014334862385321102
I0
I1
I-1
tp42079
sS'in,ambulatory'
p42080
(F1
F0.00014334862385321102
I0
I1
I-1
tp42081
sS'regular,basis'
p42082
(F1
F0.00014334862385321102
I0
I1
I-1
tp42083
sS'of,intravenous'
p42084
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp42085
sS'used,concurrently'
p42086
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp42087
sS'superior,to'
p42088
(F1
F0.00043004587155963305
I0
I3
I-3
tp42089
sS'decline,in'
p42090
(F1
F0.00014334862385321102
I0
I1
I-1
tp42091
sS'were,divided'
p42092
(F1
F0.00014334862385321102
I0
I1
I-1
tp42093
sS'toxicity,were'
p42094
(F1
F0.00014334862385321102
I1
I0
I1
tp42095
sS'for,in'
p42096
(F1
F0.00028669724770642203
I0
I2
I-2
tp42097
sS'for,is'
p42098
(F1
F0.00014334862385321102
I0
I1
I-1
tp42099
sS'rarely,to'
p42100
(F0
F0
I1
I1
I0
tp42101
sS'enalapril,iv'
p42102
(F1
F0.00014334862385321102
I0
I1
I-1
tp42103
sS'the,exception'
p42104
(F1
F0.00028669724770642203
I0
I2
I-2
tp42105
sS'anaesthetised,with'
p42106
(F1
F0.00014334862385321102
I1
I0
I1
tp42107
sS'adrenal,insufficiency'
p42108
(F1
F0.00014334862385321102
I1
I0
I1
tp42109
sS'interactions,oral'
p42110
(F1
F0.00014334862385321102
I0
I1
I-1
tp42111
sS'that,included'
p42112
(F1
F0.00028669724770642203
I0
I2
I-2
tp42113
sS'in,severe'
p42114
(F1
F0.00014334862385321102
I1
I0
I1
tp42115
sS'porpranolol,may'
p42116
(F1
F0.00014334862385321102
I1
I0
I1
tp42117
sS'is,limited'
p42118
(F0
F0
I1
I1
I0
tp42119
sS'also,referred'
p42120
(F1
F0.00014334862385321102
I0
I1
I-1
tp42121
sS'sustained-release,tablets'
p42122
(F1
F0.00014334862385321102
I0
I1
I-1
tp42123
sS'neither,racemic'
p42124
(F1
F0.00014334862385321102
I0
I1
I-1
tp42125
sS'the,antithrombotic'
p42126
(F1
F0.00014334862385321102
I1
I0
I1
tp42127
sS'the,median'
p42128
(F1
F0.00014334862385321102
I1
I0
I1
tp42129
sS'qd,or'
p42130
(F1
F0.00028669724770642203
I0
I2
I-2
tp42131
sS'before,the'
p42132
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp42133
sS'hypertension,and'
p42134
(F1
F0.00014334862385321102
I1
I0
I1
tp42135
sS'parameters,should'
p42136
(F1
F0.00014334862385321102
I0
I1
I-1
tp42137
sS'if,taken'
p42138
(F1
F0.00014334862385321102
I0
I1
I-1
tp42139
sS'tricyclic,thereby'
p42140
(F1
F0.00014334862385321102
I1
I0
I1
tp42141
sS'and,ace'
p42142
(F1
F0.00014334862385321102
I1
I0
I1
tp42143
sS'between,both'
p42144
(F1
F0.00028669724770642203
I0
I2
I-2
tp42145
sS'qd,of'
p42146
(F1
F0.00014334862385321102
I0
I1
I-1
tp42147
sS'was,unaffected'
p42148
(F1
F0.00014334862385321102
I1
I0
I1
tp42149
sS'chronic,administration'
p42150
(F1
F0.00028669724770642203
I2
I0
I2
tp42151
sS'topamax,felbatol'
p42152
(F1
F0.00014334862385321102
I1
I0
I1
tp42153
sS'of,post-heparin'
p42154
(F1
F0.00014334862385321102
I1
I0
I1
tp42155
sS'pretreatment,augmented'
p42156
(F1
F0.00014334862385321102
I1
I0
I1
tp42157
sS'depakene,use'
p42158
(F1
F0.00014334862385321102
I0
I1
I-1
tp42159
sS'slightly,greater'
p42160
(F1
F0.00014334862385321102
I1
I0
I1
tp42161
sS'receiving,long-'
p42162
(F1
F0.00014334862385321102
I1
I0
I1
tp42163
sS'these,findings'
p42164
(F1
F0.00014334862385321102
I1
I0
I1
tp42165
sS'molecule,thereby'
p42166
(F1
F0.00043004587155963305
I3
I0
I3
tp42167
sS'to,treatpatients'
p42168
(F1
F0.00014334862385321102
I0
I1
I-1
tp42169
sS'pentagastrin-,and'
p42170
(F1
F0.00014334862385321102
I0
I1
I-1
tp42171
sS'than,episodes'
p42172
(F1
F0.00014334862385321102
I0
I1
I-1
tp42173
sS'demonstrated,less'
p42174
(F1
F0.00014334862385321102
I1
I0
I1
tp42175
sS'pointes,most'
p42176
(F1
F0.00014334862385321102
I1
I0
I1
tp42177
sS'are,potent'
p42178
(F1
F0.00043004587155963305
I3
I0
I3
tp42179
sS'responses,were'
p42180
(F1
F0.00014334862385321102
I0
I1
I-1
tp42181
sS'omega-agatoxin,iva'
p42182
(F1
F0.00014334862385321102
I0
I1
I-1
tp42183
sS'reports,there'
p42184
(F1
F0.00014334862385321102
I1
I0
I1
tp42185
sS'reduce,the'
p42186
(F0.82978723404255317
F0.0055905963302752297
I43
I4
I39
tp42187
sS'tenofovir,disoproxil'
p42188
(F1
F0.00014334862385321102
I0
I1
I-1
tp42189
sS'effect,one'
p42190
(F1
F0.00014334862385321102
I1
I0
I1
tp42191
sS'phase,in'
p42192
(F1
F0.00014334862385321102
I0
I1
I-1
tp42193
sS'of,produced'
p42194
(F1
F0.00014334862385321102
I1
I0
I1
tp42195
sS'usual,prescription'
p42196
(F1
F0.00014334862385321102
I1
I0
I1
tp42197
sS'and,prolong'
p42198
(F1
F0.00028669724770642203
I2
I0
I2
tp42199
sS'methadone,maintained'
p42200
(F1
F0.00014334862385321102
I1
I0
I1
tp42201
sS'starlix,is'
p42202
(F1
F0.00014334862385321102
I1
I0
I1
tp42203
sS'that,allegra'
p42204
(F1
F0.00014334862385321102
I0
I1
I-1
tp42205
sS'screening,urine'
p42206
(F1
F0.00014334862385321102
I0
I1
I-1
tp42207
sS'of,interfere'
p42208
(F1
F0.00014334862385321102
I1
I0
I1
tp42209
sS'phenytoin,isoniazid'
p42210
(F1
F0.00014334862385321102
I1
I0
I1
tp42211
sS'inhibitors,grapefruit'
p42212
(F1
F0.00014334862385321102
I1
I0
I1
tp42213
sS'mcg,twice'
p42214
(F1
F0.00014334862385321102
I0
I1
I-1
tp42215
sS'the,most'
p42216
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp42217
sS'medicines,may'
p42218
(F1
F0.00057339449541284407
I0
I4
I-4
tp42219
sS'in,serum'
p42220
(F0.23809523809523808
F0.00071674311926605509
I13
I8
I5
tp42221
sS'major,are'
p42222
(F1
F0.00014334862385321102
I1
I0
I1
tp42223
sS'trileptal,doses'
p42224
(F1
F0.00014334862385321102
I1
I0
I1
tp42225
sS'into,account'
p42226
(F1
F0.00014334862385321102
I1
I0
I1
tp42227
sS'that,apoptosis'
p42228
(F1
F0.00014334862385321102
I0
I1
I-1
tp42229
sS'concentrations,reach'
p42230
(F1
F0.00014334862385321102
I1
I0
I1
tp42231
sS'no,evidence'
p42232
(F1
F0.0011467889908256881
I0
I8
I-8
tp42233
sS'zdv,as'
p42234
(F1
F0.00014334862385321102
I1
I0
I1
tp42235
sS'myoclonus,autonomic'
p42236
(F1
F0.00014334862385321102
I1
I0
I1
tp42237
sS'immediate,release'
p42238
(F1
F0.00043004587155963305
I3
I0
I3
tp42239
sS'in,which'
p42240
(F0.14285714285714285
F0.00028669724770642203
I8
I6
I2
tp42241
sS'common,adverse'
p42242
(F1
F0.00014334862385321102
I0
I1
I-1
tp42243
sS'converting,enzyme'
p42244
(F0
F0
I3
I3
I0
tp42245
sS'has,shown'
p42246
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp42247
sS'are,cyp'
p42248
(F1
F0.00014334862385321102
I1
I0
I1
tp42249
sS'cation,transport'
p42250
(F1
F0.00014334862385321102
I0
I1
I-1
tp42251
sS'when,new'
p42252
(F1
F0.00014334862385321102
I0
I1
I-1
tp42253
sS'not,established'
p42254
(F1
F0.00014334862385321102
I1
I0
I1
tp42255
sS'the,brief'
p42256
(F1
F0.00014334862385321102
I1
I0
I1
tp42257
sS'prolonged,concurrent'
p42258
(F1
F0.00014334862385321102
I0
I1
I-1
tp42259
sS'mesenteric,vasodilation'
p42260
(F0
F0
I1
I1
I0
tp42261
sS'is,either'
p42262
(F1
F0.00014334862385321102
I1
I0
I1
tp42263
sS'anticholinergics,antagonize'
p42264
(F1
F0.00014334862385321102
I0
I1
I-1
tp42265
sS'b,can'
p42266
(F1
F0.00014334862385321102
I0
I1
I-1
tp42267
sS'using,stadol'
p42268
(F1
F0.00014334862385321102
I0
I1
I-1
tp42269
sS'formation,of'
p42270
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp42271
sS'important,pharmacokinetic'
p42272
(F1
F0.00057339449541284407
I0
I4
I-4
tp42273
sS'contraindicated,and'
p42274
(F1
F0.00014334862385321102
I1
I0
I1
tp42275
sS'be,fatal'
p42276
(F1
F0.00014334862385321102
I1
I0
I1
tp42277
sS'intestine,thus'
p42278
(F1
F0.00014334862385321102
I1
I0
I1
tp42279
sS'diltiazem,plasma'
p42280
(F1
F0.00014334862385321102
I0
I1
I-1
tp42281
sS'gl,was'
p42282
(F1
F0.00014334862385321102
I1
I0
I1
tp42283
sS'by,oxc'
p42284
(F1
F0.00028669724770642203
I0
I2
I-2
tp42285
sS'days,produced'
p42286
(F0
F0
I1
I1
I0
tp42287
sS'day,until'
p42288
(F1
F0.00014334862385321102
I0
I1
I-1
tp42289
sS'when,agents'
p42290
(F1
F0.00014334862385321102
I1
I0
I1
tp42291
sS'they,are'
p42292
(F0.5
F0.00028669724770642203
I3
I1
I2
tp42293
sS'given,the'
p42294
(F0.25
F0.00028669724770642203
I5
I3
I2
tp42295
sS'c19,substrate'
p42296
(F1
F0.00014334862385321102
I0
I1
I-1
tp42297
sS'may,use'
p42298
(F1
F0.00014334862385321102
I0
I1
I-1
tp42299
sS'how,soon'
p42300
(F1
F0.00014334862385321102
I1
I0
I1
tp42301
sS'derivative,implications'
p42302
(F1
F0.00014334862385321102
I0
I1
I-1
tp42303
sS'cyp450,enzymes'
p42304
(F1
F0.00014334862385321102
I0
I1
I-1
tp42305
sS'during,or'
p42306
(F1
F0.00028669724770642203
I2
I0
I2
tp42307
sS'unconjugated,nacmc'
p42308
(F1
F0.00014334862385321102
I0
I1
I-1
tp42309
sS'reversible,impairment'
p42310
(F1
F0.00014334862385321102
I1
I0
I1
tp42311
sS'between,keppra'
p42312
(F1
F0.00028669724770642203
I0
I2
I-2
tp42313
sS'high-dose,and'
p42314
(F1
F0.00014334862385321102
I1
I0
I1
tp42315
sS'the,preparation'
p42316
(F1
F0.00014334862385321102
I1
I0
I1
tp42317
sS'the,package'
p42318
(F1
F0.00028669724770642203
I2
I0
I2
tp42319
sS'to,avoid'
p42320
(F0.33333333333333331
F0.0008600917431192661
I12
I6
I6
tp42321
sS'other,injectable'
p42322
(F1
F0.00014334862385321102
I1
I0
I1
tp42323
sS'accelerate,the'
p42324
(F1
F0.00014334862385321102
I0
I1
I-1
tp42325
sS'multiple,cytochrome'
p42326
(F1
F0.00014334862385321102
I0
I1
I-1
tp42327
sS'of,modest'
p42328
(F1
F0.00014334862385321102
I0
I1
I-1
tp42329
sS'and,patients'
p42330
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42331
sS'these,three'
p42332
(F1
F0.00014334862385321102
I1
I0
I1
tp42333
sS'both,increases'
p42334
(F1
F0.00014334862385321102
I1
I0
I1
tp42335
sS'hypertension,when'
p42336
(F1
F0.00014334862385321102
I1
I0
I1
tp42337
sS'on,a'
p42338
(F0
F0
I4
I4
I0
tp42339
sS'k,contribution'
p42340
(F1
F0.00014334862385321102
I0
I1
I-1
tp42341
sS'm2,without'
p42342
(F1
F0.00014334862385321102
I0
I1
I-1
tp42343
sS'mevacor,in'
p42344
(F1
F0.00014334862385321102
I0
I1
I-1
tp42345
sS'studies,had'
p42346
(F1
F0.00014334862385321102
I0
I1
I-1
tp42347
sS'therapies,should'
p42348
(F1
F0.00014334862385321102
I1
I0
I1
tp42349
sS'xigris,caution'
p42350
(F1
F0.00014334862385321102
I0
I1
I-1
tp42351
sS'descending,pain'
p42352
(F1
F0.00014334862385321102
I0
I1
I-1
tp42353
sS'a,consequent'
p42354
(F1
F0.00014334862385321102
I1
I0
I1
tp42355
sS'competitive,suppression'
p42356
(F1
F0.00014334862385321102
I0
I1
I-1
tp42357
sS'an,eg'
p42358
(F1
F0.00014334862385321102
I1
I0
I1
tp42359
sS'no,differences'
p42360
(F1
F0.00014334862385321102
I0
I1
I-1
tp42361
sS'other,antiepileptic'
p42362
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp42363
sS'are,representations'
p42364
(F1
F0.00014334862385321102
I0
I1
I-1
tp42365
sS'responses,both'
p42366
(F1
F0.00014334862385321102
I1
I0
I1
tp42367
sS'is,potentiated'
p42368
(F1
F0.00043004587155963305
I3
I0
I3
tp42369
sS'a,year'
p42370
(F1
F0.00014334862385321102
I0
I1
I-1
tp42371
sS'inhibitors,amprenavir'
p42372
(F1
F0.00014334862385321102
I1
I0
I1
tp42373
sS'aleve,or'
p42374
(F1
F0.00014334862385321102
I1
I0
I1
tp42375
sS'were,considered'
p42376
(F1
F0.00014334862385321102
I1
I0
I1
tp42377
sS'three,times'
p42378
(F0
F0
I3
I3
I0
tp42379
sS'were,transient'
p42380
(F1
F0.00014334862385321102
I1
I0
I1
tp42381
sS'to,result'
p42382
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp42383
sS'pharmacokinetic,evaluation'
p42384
(F1
F0.00014334862385321102
I0
I1
I-1
tp42385
sS'ellence,with'
p42386
(F1
F0.00014334862385321102
I1
I0
I1
tp42387
sS'and,associated'
p42388
(F1
F0.00014334862385321102
I1
I0
I1
tp42389
sS'lithium,inhibition'
p42390
(F1
F0.00014334862385321102
I0
I1
I-1
tp42391
sS'complete,prescribing'
p42392
(F1
F0.00014334862385321102
I0
I1
I-1
tp42393
sS'to,one-fourth'
p42394
(F1
F0.00014334862385321102
I1
I0
I1
tp42395
sS'could,increase'
p42396
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42397
sS'diminished,when'
p42398
(F1
F0.00014334862385321102
I1
I0
I1
tp42399
sS'plasma,was'
p42400
(F1
F0.00014334862385321102
I0
I1
I-1
tp42401
sS'immunoanalytical,methods'
p42402
(F1
F0.00014334862385321102
I0
I1
I-1
tp42403
sS'repeat,dose'
p42404
(F1
F0.00014334862385321102
I0
I1
I-1
tp42405
sS'immunosuppressant,metabolized'
p42406
(F1
F0.00014334862385321102
I0
I1
I-1
tp42407
sS'give,rise'
p42408
(F1
F0.00014334862385321102
I1
I0
I1
tp42409
sS'in,study'
p42410
(F1
F0.00014334862385321102
I0
I1
I-1
tp42411
sS'to,those'
p42412
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp42413
sS'include,and'
p42414
(F1
F0.00028669724770642203
I0
I2
I-2
tp42415
sS'on,balance'
p42416
(F1
F0.00014334862385321102
I1
I0
I1
tp42417
sS'adjustment,to'
p42418
(F1
F0.00028669724770642203
I0
I2
I-2
tp42419
sS'psa,levels'
p42420
(F1
F0.00014334862385321102
I0
I1
I-1
tp42421
sS'however,caution'
p42422
(F1
F0.00028669724770642203
I2
I0
I2
tp42423
sS'adrenocortical,dependent'
p42424
(F1
F0.00014334862385321102
I1
I0
I1
tp42425
sS'the,day'
p42426
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp42427
sS'potassium-containing,salt'
p42428
(F0
F0
I1
I1
I0
tp42429
sS'neither,case'
p42430
(F1
F0.00014334862385321102
I0
I1
I-1
tp42431
sS'day,racemic'
p42432
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp42433
sS'being,dosed'
p42434
(F1
F0.00014334862385321102
I0
I1
I-1
tp42435
sS'was,studied'
p42436
(F1
F0.0008600917431192661
I0
I6
I-6
tp42437
sS'reactions,such'
p42438
(F1
F0.00057339449541284407
I0
I4
I-4
tp42439
sS'strong,affinity'
p42440
(F1
F0.00014334862385321102
I0
I1
I-1
tp42441
sS'and,cyp2c8'
p42442
(F1
F0.00028669724770642203
I0
I2
I-2
tp42443
sS'diflunisal,decreased'
p42444
(F1
F0.00028669724770642203
I2
I0
I2
tp42445
sS'avonex,mcg'
p42446
(F0
F0
I1
I1
I0
tp42447
sS'culture,and'
p42448
(F1
F0.00014334862385321102
I1
I0
I1
tp42449
sS'agents,with'
p42450
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp42451
sS'beta-adrenergic,blocking'
p42452
(F0.36363636363636365
F0.0011467889908256881
I15
I7
I8
tp42453
sS'who,switched'
p42454
(F1
F0.00014334862385321102
I0
I1
I-1
tp42455
sS'weeks,may'
p42456
(F1
F0.00028669724770642203
I2
I0
I2
tp42457
sS'containing,carbohydrate-splitting'
p42458
(F1
F0.00014334862385321102
I1
I0
I1
tp42459
sS'at,to'
p42460
(F1
F0.00014334862385321102
I1
I0
I1
tp42461
sS'vitro,inhibitor'
p42462
(F1
F0.00014334862385321102
I0
I1
I-1
tp42463
sS'and,nonsteroidal'
p42464
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp42465
sS'tikosyn,with'
p42466
(F1
F0.00014334862385321102
I1
I0
I1
tp42467
sS'or,vehicle'
p42468
(F1
F0.00014334862385321102
I0
I1
I-1
tp42469
sS'pharmacokinetics,produced'
p42470
(F1
F0.00014334862385321102
I1
I0
I1
tp42471
sS'used,general'
p42472
(F1
F0.00014334862385321102
I0
I1
I-1
tp42473
sS'concomitantly,administered'
p42474
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp42475
sS'aware,of'
p42476
(F1
F0.00014334862385321102
I0
I1
I-1
tp42477
sS'sodium,fluorescein'
p42478
(F1
F0.00014334862385321102
I0
I1
I-1
tp42479
sS'with,the'
p42480
(F0.23478260869565218
F0.0038704128440366975
I71
I44
I27
tp42481
sS'pd2,values'
p42482
(F1
F0.00028669724770642203
I2
I0
I2
tp42483
sS'to,nonlethal'
p42484
(F1
F0.00014334862385321102
I0
I1
I-1
tp42485
sS'substrate,single'
p42486
(F1
F0.00028669724770642203
I0
I2
I-2
tp42487
sS'comprehensive,review'
p42488
(F1
F0.00014334862385321102
I0
I1
I-1
tp42489
sS'preparations,are'
p42490
(F1
F0.00028669724770642203
I2
I0
I2
tp42491
sS'low,measurement'
p42492
(F1
F0.00014334862385321102
I0
I1
I-1
tp42493
sS'a,few'
p42494
(F1
F0.00043004587155963305
I3
I0
I3
tp42495
sS'by,chronic'
p42496
(F1
F0.00014334862385321102
I1
I0
I1
tp42497
sS'seen,as'
p42498
(F1
F0.00014334862385321102
I1
I0
I1
tp42499
sS'levels,occurred'
p42500
(F1
F0.00014334862385321102
I1
I0
I1
tp42501
sS'alkylated,such'
p42502
(F1
F0.00014334862385321102
I0
I1
I-1
tp42503
sS'useful,for'
p42504
(F1
F0.00014334862385321102
I0
I1
I-1
tp42505
sS'doxylamine,may'
p42506
(F1
F0.00014334862385321102
I1
I0
I1
tp42507
sS'of,betaseron'
p42508
(F1
F0.00014334862385321102
I1
I0
I1
tp42509
sS's,alpha'
p42510
(F1
F0.00014334862385321102
I0
I1
I-1
tp42511
sS'at,doses'
p42512
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp42513
sS'urine,test'
p42514
(F1
F0.00014334862385321102
I0
I1
I-1
tp42515
sS'may,make'
p42516
(F1
F0.00057339449541284407
I0
I4
I-4
tp42517
sS'few,days'
p42518
(F1
F0.00028669724770642203
I2
I0
I2
tp42519
sS'using,comparisons'
p42520
(F1
F0.00014334862385321102
I0
I1
I-1
tp42521
sS'taking,low-dose'
p42522
(F1
F0.00028669724770642203
I0
I2
I-2
tp42523
sS'experiments,reported'
p42524
(F1
F0.00014334862385321102
I0
I1
I-1
tp42525
sS'level,that'
p42526
(F0
F0
I1
I1
I0
tp42527
sS'response,and'
p42528
(F1
F0.00057339449541284407
I0
I4
I-4
tp42529
sS'a,cyp2d6'
p42530
(F1
F0.00014334862385321102
I1
I0
I1
tp42531
sS'c9,and'
p42532
(F1
F0.00014334862385321102
I0
I1
I-1
tp42533
sS'tysabri,and'
p42534
(F1
F0.00014334862385321102
I0
I1
I-1
tp42535
sS'may,accentuate'
p42536
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42537
sS'studies,tilade'
p42538
(F1
F0.00014334862385321102
I0
I1
I-1
tp42539
sS'patients,as'
p42540
(F1
F0.00028669724770642203
I0
I2
I-2
tp42541
sS'agents,gastrointestinal'
p42542
(F1
F0.00028669724770642203
I2
I0
I2
tp42543
sS'hypertensive,patients'
p42544
(F1
F0.00028669724770642203
I0
I2
I-2
tp42545
sS'diuretics,the'
p42546
(F1
F0.00014334862385321102
I1
I0
I1
tp42547
sS'immunization,cannot'
p42548
(F1
F0.00014334862385321102
I1
I0
I1
tp42549
sS'current,evidence'
p42550
(F1
F0.00014334862385321102
I1
I0
I1
tp42551
sS'thienobenzodiazepine,derivative'
p42552
(F1
F0.00014334862385321102
I0
I1
I-1
tp42553
sS'thirty,male'
p42554
(F1
F0.00014334862385321102
I0
I1
I-1
tp42555
sS'a4,increased'
p42556
(F1
F0.00014334862385321102
I1
I0
I1
tp42557
sS'metabolite,hydroxy-estazolam'
p42558
(F1
F0.00014334862385321102
I0
I1
I-1
tp42559
sS'since,animal'
p42560
(F1
F0.00014334862385321102
I1
I0
I1
tp42561
sS'people,who'
p42562
(F1
F0.00014334862385321102
I1
I0
I1
tp42563
sS'are,that'
p42564
(F1
F0.00014334862385321102
I0
I1
I-1
tp42565
sS'that,your'
p42566
(F1
F0.00014334862385321102
I1
I0
I1
tp42567
sS'for,were'
p42568
(F1
F0.00014334862385321102
I0
I1
I-1
tp42569
sS'h,ml'
p42570
(F1
F0.00028669724770642203
I2
I0
I2
tp42571
sS'subcutaneous,injections'
p42572
(F1
F0.00028669724770642203
I0
I2
I-2
tp42573
sS'discontinued,at'
p42574
(F1
F0.00014334862385321102
I1
I0
I1
tp42575
sS'triple,combination'
p42576
(F1
F0.00014334862385321102
I0
I1
I-1
tp42577
sS'in,de'
p42578
(F1
F0.00028669724770642203
I0
I2
I-2
tp42579
sS'tablets,usp'
p42580
(F1
F0.00014334862385321102
I1
I0
I1
tp42581
sS'and,decreases'
p42582
(F1
F0.00014334862385321102
I1
I0
I1
tp42583
sS'to,resulting'
p42584
(F1
F0.00014334862385321102
I1
I0
I1
tp42585
sS'mesylate,did'
p42586
(F1
F0.00014334862385321102
I0
I1
I-1
tp42587
sS'and,decreased'
p42588
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp42589
sS'days,resulted'
p42590
(F1
F0.00071674311926605509
I5
I0
I5
tp42591
sS'with,care'
p42592
(F1
F0.00071674311926605509
I5
I0
I5
tp42593
sS'altered,distribution'
p42594
(F1
F0.00014334862385321102
I1
I0
I1
tp42595
sS'as,hypotension'
p42596
(F1
F0.00014334862385321102
I0
I1
I-1
tp42597
sS'be,initiated'
p42598
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42599
sS'time,caused'
p42600
(F1
F0.00014334862385321102
I0
I1
I-1
tp42601
sS'gleevec,increased'
p42602
(F1
F0.00014334862385321102
I1
I0
I1
tp42603
sS'zebeta,on'
p42604
(F1
F0.00014334862385321102
I0
I1
I-1
tp42605
sS'nanm,or'
p42606
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42607
sS'possible,diminished'
p42608
(F1
F0.00014334862385321102
I0
I1
I-1
tp42609
sS'gleevec,increases'
p42610
(F1
F0.00014334862385321102
I1
I0
I1
tp42611
sS'with,alone'
p42612
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp42613
sS'of,goal-directed'
p42614
(F1
F0.00014334862385321102
I0
I1
I-1
tp42615
sS'a,maximal'
p42616
(F1
F0.00014334862385321102
I0
I1
I-1
tp42617
sS'affect,conversion'
p42618
(F1
F0.00014334862385321102
I0
I1
I-1
tp42619
sS'via,dehydrogenase'
p42620
(F1
F0.00014334862385321102
I1
I0
I1
tp42621
sS'min,and'
p42622
(F1
F0.00014334862385321102
I0
I1
I-1
tp42623
sS's,bioavailability'
p42624
(F1
F0.00014334862385321102
I0
I1
I-1
tp42625
sS'certain,may'
p42626
(F1
F0.00014334862385321102
I1
I0
I1
tp42627
sS'however,interactions'
p42628
(F1
F0.00014334862385321102
I1
I0
I1
tp42629
sS'and,risks'
p42630
(F1
F0.00014334862385321102
I1
I0
I1
tp42631
sS'transfer,to'
p42632
(F1
F0.00028669724770642203
I0
I2
I-2
tp42633
sS'and,nor'
p42634
(F1
F0.00014334862385321102
I0
I1
I-1
tp42635
sS'rifampin,may'
p42636
(F1
F0.00014334862385321102
I1
I0
I1
tp42637
sS'coadministered,in'
p42638
(F1
F0.00014334862385321102
I0
I1
I-1
tp42639
sS'kaolin-pectin,certain'
p42640
(F1
F0.00014334862385321102
I1
I0
I1
tp42641
sS'hypokalemia,which'
p42642
(F1
F0.00014334862385321102
I1
I0
I1
tp42643
sS'coumarin-like,should'
p42644
(F1
F0.00014334862385321102
I1
I0
I1
tp42645
sS'subtypes,using'
p42646
(F1
F0.00014334862385321102
I0
I1
I-1
tp42647
sS'reduces,basal'
p42648
(F1
F0.00014334862385321102
I0
I1
I-1
tp42649
sS'inhibitors,reports'
p42650
(F1
F0.00043004587155963305
I3
I0
I3
tp42651
sS'failing,heart'
p42652
(F1
F0.00014334862385321102
I0
I1
I-1
tp42653
sS'drugs,l-phenylalanine'
p42654
(F1
F0.00014334862385321102
I1
I0
I1
tp42655
sS'weeks,prior'
p42656
(F1
F0.00028669724770642203
I2
I0
I2
tp42657
sS'or,may'
p42658
(F0.90000000000000002
F0.0025802752293577983
I19
I1
I18
tp42659
sS'concomitantly,only'
p42660
(F1
F0.00028669724770642203
I0
I2
I-2
tp42661
sS'though,has'
p42662
(F1
F0.00028669724770642203
I0
I2
I-2
tp42663
sS'requirements,i'
p42664
(F1
F0.00014334862385321102
I0
I1
I-1
tp42665
sS'stimulant,effects'
p42666
(F1
F0.00028669724770642203
I2
I0
I2
tp42667
sS'tubules,seminiferous'
p42668
(F1
F0.00014334862385321102
I0
I1
I-1
tp42669
sS'from,these'
p42670
(F1
F0.00014334862385321102
I1
I0
I1
tp42671
sS'any,great'
p42672
(F1
F0.00014334862385321102
I0
I1
I-1
tp42673
sS'and,excretion'
p42674
(F0
F0
I1
I1
I0
tp42675
sS'adverse,effects'
p42676
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp42677
sS'by,patients'
p42678
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp42679
sS'pipracil,may'
p42680
(F1
F0.00014334862385321102
I0
I1
I-1
tp42681
sS'progestin-only,pills'
p42682
(F1
F0.00014334862385321102
I1
I0
I1
tp42683
sS'use,as'
p42684
(F1
F0.00014334862385321102
I0
I1
I-1
tp42685
sS'tolerated,but'
p42686
(F0
F0
I1
I1
I0
tp42687
sS'but,these'
p42688
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42689
sS'use,at'
p42690
(F1
F0.00014334862385321102
I0
I1
I-1
tp42691
sS'greater,risk'
p42692
(F1
F0.00014334862385321102
I0
I1
I-1
tp42693
sS'concomitant,serotonergic'
p42694
(F1
F0.00014334862385321102
I1
I0
I1
tp42695
sS'the,ace'
p42696
(F1
F0.00043004587155963305
I3
I0
I3
tp42697
sS'be,approached'
p42698
(F1
F0.0011467889908256881
I8
I0
I8
tp42699
sS'important,effect'
p42700
(F1
F0.0008600917431192661
I0
I6
I-6
tp42701
sS'toxic,and'
p42702
(F1
F0.00014334862385321102
I1
I0
I1
tp42703
sS'additional,supine'
p42704
(F1
F0.00014334862385321102
I1
I0
I1
tp42705
sS'patients,may'
p42706
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp42707
sS'the,beta-adrenergic'
p42708
(F1
F0.00014334862385321102
I1
I0
I1
tp42709
sS'immunosuppressives,cyclosporine'
p42710
(F1
F0.00014334862385321102
I0
I1
I-1
tp42711
sS'ascorbic,acid'
p42712
(F1
F0.00028669724770642203
I2
I0
I2
tp42713
sS'vasoconstriction,in'
p42714
(F1
F0.00014334862385321102
I1
I0
I1
tp42715
sS'mu,systems'
p42716
(F1
F0.00014334862385321102
I0
I1
I-1
tp42717
sS'that,cause'
p42718
(F1
F0.00043004587155963305
I3
I0
I3
tp42719
sS'for,chelation'
p42720
(F1
F0.00014334862385321102
I0
I1
I-1
tp42721
sS'two,reverse'
p42722
(F1
F0.00014334862385321102
I0
I1
I-1
tp42723
sS'this,increase'
p42724
(F1
F0.00014334862385321102
I1
I0
I1
tp42725
sS'if,clearance'
p42726
(F1
F0.00014334862385321102
I1
I0
I1
tp42727
sS'disorders,and'
p42728
(F1
F0.00014334862385321102
I0
I1
I-1
tp42729
sS'blocker,was'
p42730
(F1
F0.00014334862385321102
I0
I1
I-1
tp42731
sS'for,example'
p42732
(F0
F0
I3
I3
I0
tp42733
sS'mg,ethinyl'
p42734
(F1
F0.00028669724770642203
I0
I2
I-2
tp42735
sS'cancers,it'
p42736
(F1
F0.00014334862385321102
I0
I1
I-1
tp42737
sS'daily,alternating'
p42738
(F1
F0.00014334862385321102
I0
I1
I-1
tp42739
sS'or,trivalent'
p42740
(F1
F0.00014334862385321102
I0
I1
I-1
tp42741
sS'very,little'
p42742
(F1
F0.00014334862385321102
I1
I0
I1
tp42743
sS'as,international'
p42744
(F1
F0.00014334862385321102
I1
I0
I1
tp42745
sS'the,substantial'
p42746
(F1
F0.00014334862385321102
I1
I0
I1
tp42747
sS'at,daily'
p42748
(F1
F0.00014334862385321102
I0
I1
I-1
tp42749
sS'aeds,were'
p42750
(F1
F0.00014334862385321102
I0
I1
I-1
tp42751
sS'ace,inhibitor'
p42752
(F1
F0.00043004587155963305
I3
I0
I3
tp42753
sS'antidiabetics,because'
p42754
(F1
F0.00014334862385321102
I1
I0
I1
tp42755
sS'subjects,no'
p42756
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp42757
sS'containing,cremophor'
p42758
(F1
F0.00014334862385321102
I1
I0
I1
tp42759
sS'involving,even'
p42760
(F1
F0.00028669724770642203
I0
I2
I-2
tp42761
sS'intravenously,administered'
p42762
(F1
F0.00043004587155963305
I3
I0
I3
tp42763
sS'with,brovana'
p42764
(F1
F0.00014334862385321102
I0
I1
I-1
tp42765
sS'potent,inhibitors'
p42766
(F0
F0
I2
I2
I0
tp42767
sS'both,dietary'
p42768
(F1
F0.00014334862385321102
I0
I1
I-1
tp42769
sS'after,repeated'
p42770
(F1
F0.00014334862385321102
I1
I0
I1
tp42771
sS'camptosar,and'
p42772
(F1
F0.00028669724770642203
I2
I0
I2
tp42773
sS'on,possible'
p42774
(F1
F0.00014334862385321102
I1
I0
I1
tp42775
sS'vardenafil,or'
p42776
(F1
F0.00014334862385321102
I1
I0
I1
tp42777
sS'arthropan,magan'
p42778
(F1
F0.00014334862385321102
I1
I0
I1
tp42779
sS'family,may'
p42780
(F1
F0.00014334862385321102
I0
I1
I-1
tp42781
sS'concentrations,within'
p42782
(F1
F0.00014334862385321102
I0
I1
I-1
tp42783
sS'agents,increasing'
p42784
(F1
F0.00028669724770642203
I2
I0
I2
tp42785
sS'registry,by'
p42786
(F1
F0.00014334862385321102
I0
I1
I-1
tp42787
sS'to,ensure'
p42788
(F1
F0.00028669724770642203
I2
I0
I2
tp42789
sS'of,gastrointestinal'
p42790
(F1
F0.00057339449541284407
I4
I0
I4
tp42791
sS'decreased,bioavailability'
p42792
(F1
F0.00014334862385321102
I1
I0
I1
tp42793
sS'renal,function'
p42794
(F0.20000000000000001
F0.00057339449541284407
I12
I8
I4
tp42795
sS'to,extend'
p42796
(F1
F0.00014334862385321102
I1
I0
I1
tp42797
sS'deaths,among'
p42798
(F1
F0.00014334862385321102
I0
I1
I-1
tp42799
sS'doses,greater'
p42800
(F1
F0.00014334862385321102
I0
I1
I-1
tp42801
sS'emtriva,has'
p42802
(F1
F0.00014334862385321102
I0
I1
I-1
tp42803
sS'physiological,doses'
p42804
(F1
F0.00014334862385321102
I0
I1
I-1
tp42805
sS'nor,inhibits'
p42806
(F1
F0.00014334862385321102
I0
I1
I-1
tp42807
sS'that,identify'
p42808
(F1
F0.00014334862385321102
I1
I0
I1
tp42809
sS'acid,metabolite'
p42810
(F0
F0
I1
I1
I0
tp42811
sS'narrow,therapeutic'
p42812
(F0.25
F0.00028669724770642203
I5
I3
I2
tp42813
sS'nsaids,through'
p42814
(F1
F0.00014334862385321102
I1
I0
I1
tp42815
sS'dosing,effects'
p42816
(F1
F0.00014334862385321102
I0
I1
I-1
tp42817
sS'cmin,concentrations'
p42818
(F1
F0.00028669724770642203
I0
I2
I-2
tp42819
sS'a,sulfonamide'
p42820
(F1
F0.00014334862385321102
I1
I0
I1
tp42821
sS'a,metabolite'
p42822
(F0
F0
I2
I2
I0
tp42823
sS'other,ace'
p42824
(F1
F0.00014334862385321102
I1
I0
I1
tp42825
sS'mao,inhibition'
p42826
(F1
F0.00014334862385321102
I0
I1
I-1
tp42827
sS'not,interfere'
p42828
(F1
F0.0008600917431192661
I0
I6
I-6
tp42829
sS'sodium,carboxymethylcellulose'
p42830
(F1
F0.00014334862385321102
I0
I1
I-1
tp42831
sS'dose,administration'
p42832
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp42833
sS'but,given'
p42834
(F1
F0.00014334862385321102
I0
I1
I-1
tp42835
sS'if,coreg'
p42836
(F1
F0.00014334862385321102
I1
I0
I1
tp42837
sS'changes,and'
p42838
(F1
F0.00014334862385321102
I1
I0
I1
tp42839
sS'evaluated,after'
p42840
(F1
F0.00014334862385321102
I1
I0
I1
tp42841
sS'important,drug'
p42842
(F1
F0.00014334862385321102
I1
I0
I1
tp42843
sS'adequately,evaluated'
p42844
(F1
F0.00014334862385321102
I0
I1
I-1
tp42845
sS'maintained,on'
p42846
(F0
F0
I2
I2
I0
tp42847
sS'anti-depressants,could'
p42848
(F1
F0.00014334862385321102
I1
I0
I1
tp42849
sS'the,diabectics'
p42850
(F1
F0.00014334862385321102
I0
I1
I-1
tp42851
sS'lowering,of'
p42852
(F1
F0.00014334862385321102
I1
I0
I1
tp42853
sS'serotonergic,effects'
p42854
(F1
F0.00014334862385321102
I1
I0
I1
tp42855
sS'to,elevated'
p42856
(F1
F0.00057339449541284407
I4
I0
I4
tp42857
sS'disturbance,rarely'
p42858
(F1
F0.00014334862385321102
I1
I0
I1
tp42859
sS'relaxants,intravenous'
p42860
(F1
F0.00014334862385321102
I0
I1
I-1
tp42861
sS'tested,for'
p42862
(F1
F0.00014334862385321102
I0
I1
I-1
tp42863
sS'are,rare'
p42864
(F1
F0.00014334862385321102
I1
I0
I1
tp42865
sS'morning,and'
p42866
(F1
F0.00014334862385321102
I0
I1
I-1
tp42867
sS'observed,increase'
p42868
(F1
F0.00014334862385321102
I1
I0
I1
tp42869
sS'most,may'
p42870
(F1
F0.00014334862385321102
I0
I1
I-1
tp42871
sS'pharmacokinetics,at'
p42872
(F1
F0.00014334862385321102
I0
I1
I-1
tp42873
sS'aspirin,ketoprofen'
p42874
(F1
F0.00014334862385321102
I0
I1
I-1
tp42875
sS'applying,panretin'
p42876
(F1
F0.00014334862385321102
I1
I0
I1
tp42877
sS'patients,over'
p42878
(F1
F0.00014334862385321102
I1
I0
I1
tp42879
sS'diagnosed,schizophrenia'
p42880
(F1
F0.00014334862385321102
I1
I0
I1
tp42881
sS'oxolinic,acid'
p42882
(F1
F0.00014334862385321102
I1
I0
I1
tp42883
sS'estradiol,may'
p42884
(F1
F0.00028669724770642203
I2
I0
I2
tp42885
sS'trans-diol,by'
p42886
(F1
F0.00014334862385321102
I0
I1
I-1
tp42887
sS'ethopropazine,may'
p42888
(F1
F0.00014334862385321102
I1
I0
I1
tp42889
sS'be,delayed'
p42890
(F1
F0.00014334862385321102
I1
I0
I1
tp42891
sS'ibogaine,but'
p42892
(F1
F0.00014334862385321102
I0
I1
I-1
tp42893
sS'that,increased'
p42894
(F0
F0
I1
I1
I0
tp42895
sS'competing,for'
p42896
(F1
F0.00028669724770642203
I2
I0
I2
tp42897
sS'studies,received'
p42898
(F1
F0.00014334862385321102
I0
I1
I-1
tp42899
sS'reducing,absorption'
p42900
(F1
F0.00014334862385321102
I1
I0
I1
tp42901
sS'cyst,patients'
p42902
(F1
F0.00014334862385321102
I1
I0
I1
tp42903
sS'six,typical'
p42904
(F1
F0.00014334862385321102
I0
I1
I-1
tp42905
sS'organic,cation'
p42906
(F0
F0
I1
I1
I0
tp42907
sS'caffeine,administered'
p42908
(F1
F0.00014334862385321102
I1
I0
I1
tp42909
sS'not,under'
p42910
(F1
F0.00014334862385321102
I0
I1
I-1
tp42911
sS'oral,for'
p42912
(F1
F0.00028669724770642203
I2
I0
I2
tp42913
sS'advice,of'
p42914
(F1
F0.00014334862385321102
I1
I0
I1
tp42915
sS'extraneal,in'
p42916
(F1
F0.00014334862385321102
I1
I0
I1
tp42917
sS'uptake,of'
p42918
(F0
F0
I1
I1
I0
tp42919
sS'eight-fold,increase'
p42920
(F1
F0.00057339449541284407
I4
I0
I4
tp42921
sS'following,eight'
p42922
(F1
F0.00014334862385321102
I0
I1
I-1
tp42923
sS'of,seizures'
p42924
(F1
F0.00028669724770642203
I2
I0
I2
tp42925
sS'levels,and'
p42926
(F0.67567567567567566
F0.0035837155963302754
I31
I6
I25
tp42927
sS'functional,antagonism'
p42928
(F1
F0.00043004587155963305
I3
I0
I3
tp42929
sS'same,procedures'
p42930
(F1
F0.00014334862385321102
I0
I1
I-1
tp42931
sS'food,is'
p42932
(F1
F0.00014334862385321102
I1
I0
I1
tp42933
sS'and,monitoring'
p42934
(F1
F0.00014334862385321102
I1
I0
I1
tp42935
sS'the,nonsteroidal'
p42936
(F1
F0.00014334862385321102
I1
I0
I1
tp42937
sS'may,need'
p42938
(F0.75
F0.0008600917431192661
I7
I1
I6
tp42939
sS'earth,and'
p42940
(F1
F0.00014334862385321102
I0
I1
I-1
tp42941
sS'hypersensitivity,reactions'
p42942
(F0
F0
I2
I2
I0
tp42943
sS'uptake,blocking'
p42944
(F1
F0.00014334862385321102
I0
I1
I-1
tp42945
sS'and,rats'
p42946
(F1
F0.00014334862385321102
I1
I0
I1
tp42947
sS'concentration,greater'
p42948
(F1
F0.00014334862385321102
I0
I1
I-1
tp42949
sS'toxicology,study'
p42950
(F1
F0.00014334862385321102
I0
I1
I-1
tp42951
sS'studies,m1'
p42952
(F1
F0.00028669724770642203
I0
I2
I-2
tp42953
sS'via,cyp3a4'
p42954
(F0
F0
I1
I1
I0
tp42955
sS'be,receiving'
p42956
(F1
F0.00014334862385321102
I1
I0
I1
tp42957
sS'and,monitored'
p42958
(F1
F0.00014334862385321102
I0
I1
I-1
tp42959
sS'displace,acidic'
p42960
(F1
F0.00014334862385321102
I1
I0
I1
tp42961
sS'multi-day,course'
p42962
(F1
F0.00014334862385321102
I1
I0
I1
tp42963
sS'impact,of'
p42964
(F1
F0.00014334862385321102
I0
I1
I-1
tp42965
sS'not,induce'
p42966
(F1
F0.00043004587155963305
I0
I3
I-3
tp42967
sS'impact,on'
p42968
(F1
F0.00014334862385321102
I1
I0
I1
tp42969
sS'postmarketing,observations'
p42970
(F1
F0.00014334862385321102
I1
I0
I1
tp42971
sS'administered,shortly'
p42972
(F0
F0
I1
I1
I0
tp42973
sS'omeprazole,the'
p42974
(F1
F0.00014334862385321102
I0
I1
I-1
tp42975
sS'ph,on'
p42976
(F1
F0.00014334862385321102
I0
I1
I-1
tp42977
sS'ph,of'
p42978
(F1
F0.00014334862385321102
I1
I0
I1
tp42979
sS'a,small'
p42980
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp42981
sS'fold,when'
p42982
(F1
F0.00014334862385321102
I1
I0
I1
tp42983
sS'amines,have'
p42984
(F1
F0.00014334862385321102
I1
I0
I1
tp42985
sS'effects,prolonged'
p42986
(F1
F0.00014334862385321102
I1
I0
I1
tp42987
sS'for,both'
p42988
(F1
F0.00014334862385321102
I0
I1
I-1
tp42989
sS'synthetic,and'
p42990
(F1
F0.00043004587155963305
I3
I0
I3
tp42991
sS'increase,excretion'
p42992
(F1
F0.00014334862385321102
I0
I1
I-1
tp42993
sS'cardiac,arrythmias'
p42994
(F1
F0.00014334862385321102
I1
I0
I1
tp42995
sS'efficacy,as'
p42996
(F1
F0.00014334862385321102
I0
I1
I-1
tp42997
sS'was,due'
p42998
(F1
F0.00014334862385321102
I0
I1
I-1
tp42999
sS'dmpge2,mg'
p43000
(F1
F0.00014334862385321102
I1
I0
I1
tp43001
sS'at,m'
p43002
(F0
F0
I1
I1
I0
tp43003
sS'highly,protein-bound'
p43004
(F1
F0.00014334862385321102
I0
I1
I-1
tp43005
sS'be,aggravated'
p43006
(F1
F0.00014334862385321102
I1
I0
I1
tp43007
sS'at,a'
p43008
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp43009
sS'aprepitant,mg'
p43010
(F1
F0.00014334862385321102
I1
I0
I1
tp43011
sS'recommended,not'
p43012
(F1
F0.00043004587155963305
I3
I0
I3
tp43013
sS'alcohol,when'
p43014
(F1
F0.00014334862385321102
I0
I1
I-1
tp43015
sS'was,correlated'
p43016
(F1
F0.00014334862385321102
I0
I1
I-1
tp43017
sS'separate,group'
p43018
(F1
F0.00014334862385321102
I1
I0
I1
tp43019
sS'i,potency'
p43020
(F1
F0.00014334862385321102
I0
I1
I-1
tp43021
sS'commonly,occurring'
p43022
(F1
F0.00014334862385321102
I1
I0
I1
tp43023
sS'treat,pneumocystis'
p43024
(F0
F0
I1
I1
I0
tp43025
sS'in,combination'
p43026
(F0.25641025641025639
F0.0028669724770642203
I29
I49
I-20
tp43027
sS'qtc,prolongation'
p43028
(F1
F0.00014334862385321102
I0
I1
I-1
tp43029
sS'rifabutin,another'
p43030
(F1
F0.00014334862385321102
I0
I1
I-1
tp43031
sS'controlled-release,capsule'
p43032
(F1
F0.00014334862385321102
I1
I0
I1
tp43033
sS'maintaining,a'
p43034
(F1
F0.00014334862385321102
I0
I1
I-1
tp43035
sS'possible,over-'
p43036
(F1
F0.00043004587155963305
I3
I0
I3
tp43037
sS'of,previously'
p43038
(F0
F0
I1
I1
I0
tp43039
sS'clinically,or'
p43040
(F1
F0.00014334862385321102
I0
I1
I-1
tp43041
sS'other,clotting'
p43042
(F1
F0.00014334862385321102
I0
I1
I-1
tp43043
sS'n,in'
p43044
(F1
F0.00028669724770642203
I0
I2
I-2
tp43045
sS'depressed,the'
p43046
(F1
F0.00014334862385321102
I1
I0
I1
tp43047
sS'kt,oruvail'
p43048
(F1
F0.00014334862385321102
I0
I1
I-1
tp43049
sS'lithium,in'
p43050
(F1
F0.00014334862385321102
I1
I0
I1
tp43051
sS'to,prolong'
p43052
(F1
F0.00057339449541284407
I4
I0
I4
tp43053
sS'confirmation,should'
p43054
(F1
F0.00014334862385321102
I0
I1
I-1
tp43055
sS'the,ecg'
p43056
(F1
F0.00014334862385321102
I1
I0
I1
tp43057
sS'hours,after'
p43058
(F0.69230769230769229
F0.0012901376146788992
I11
I2
I9
tp43059
sS'sildenafil,citrate'
p43060
(F1
F0.00014334862385321102
I1
I0
I1
tp43061
sS'carbidopa,given'
p43062
(F1
F0.00014334862385321102
I0
I1
I-1
tp43063
sS'pharmacokinetic,drug-drug'
p43064
(F1
F0.00043004587155963305
I0
I3
I-3
tp43065
sS'onset,and'
p43066
(F1
F0.00014334862385321102
I1
I0
I1
tp43067
sS'for,therapy'
p43068
(F0
F0
I1
I1
I0
tp43069
sS'day,proved'
p43070
(F1
F0.00014334862385321102
I0
I1
I-1
tp43071
sS'cyclopropane,or'
p43072
(F1
F0.00014334862385321102
I1
I0
I1
tp43073
sS'in,effectiveness'
p43074
(F1
F0.00014334862385321102
I1
I0
I1
tp43075
sS'treated,concomitantly'
p43076
(F1
F0.00014334862385321102
I1
I0
I1
tp43077
sS'sulfamethoxazole-trimethoprim,bactrim'
p43078
(F1
F0.00014334862385321102
I0
I1
I-1
tp43079
sS'either,discontinuing'
p43080
(F1
F0.00071674311926605509
I5
I0
I5
tp43081
sS'time,window'
p43082
(F1
F0.00014334862385321102
I1
I0
I1
tp43083
sS'factive,and'
p43084
(F1
F0.00014334862385321102
I1
I0
I1
tp43085
sS'of,veratrum'
p43086
(F1
F0.00014334862385321102
I1
I0
I1
tp43087
sS'function,is'
p43088
(F0
F0
I1
I1
I0
tp43089
sS'and,blurred'
p43090
(F1
F0.00014334862385321102
I1
I0
I1
tp43091
sS'increasing,steady-state'
p43092
(F1
F0.00014334862385321102
I1
I0
I1
tp43093
sS'cascade,impactor'
p43094
(F1
F0.00014334862385321102
I0
I1
I-1
tp43095
sS'cyp2d6,many'
p43096
(F1
F0.00014334862385321102
I0
I1
I-1
tp43097
sS'been,treated'
p43098
(F1
F0.00014334862385321102
I1
I0
I1
tp43099
sS'function,in'
p43100
(F1
F0.00014334862385321102
I0
I1
I-1
tp43101
sS'one,contra-indication'
p43102
(F1
F0.00014334862385321102
I0
I1
I-1
tp43103
sS'exclusively,by'
p43104
(F1
F0.00014334862385321102
I0
I1
I-1
tp43105
sS'copd,medications'
p43106
(F1
F0.00014334862385321102
I0
I1
I-1
tp43107
sS'healthy,female'
p43108
(F1
F0.00028669724770642203
I0
I2
I-2
tp43109
sS'repeated,doses'
p43110
(F0
F0
I1
I1
I0
tp43111
sS'steady-state,serum'
p43112
(F1
F0.00071674311926605509
I5
I0
I5
tp43113
sS'phenytoin,altered'
p43114
(F1
F0.00014334862385321102
I1
I0
I1
tp43115
sS'induced,hypertension'
p43116
(F1
F0.00028669724770642203
I0
I2
I-2
tp43117
sS'oxidase,mao'
p43118
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp43119
sS'administered,after'
p43120
(F1
F0.00028669724770642203
I0
I2
I-2
tp43121
sS'in,unconjugated'
p43122
(F1
F0.00014334862385321102
I0
I1
I-1
tp43123
sS'of,naflu'
p43124
(F1
F0.00043004587155963305
I0
I3
I-3
tp43125
sS'or,symptoms'
p43126
(F1
F0.00043004587155963305
I3
I0
I3
tp43127
sS'between,mentax'
p43128
(F1
F0.00014334862385321102
I0
I1
I-1
tp43129
sS'the,control'
p43130
(F1
F0.00028669724770642203
I0
I2
I-2
tp43131
sS'significant,alteration'
p43132
(F1
F0.00014334862385321102
I1
I0
I1
tp43133
sS'other,therapy'
p43134
(F1
F0.00028669724770642203
I0
I2
I-2
tp43135
sS'be,related'
p43136
(F1
F0.00014334862385321102
I0
I1
I-1
tp43137
sS'some,organisms'
p43138
(F1
F0.00014334862385321102
I1
I0
I1
tp43139
sS'bilirubin,urobilin'
p43140
(F1
F0.00014334862385321102
I0
I1
I-1
tp43141
sS'percentage,of'
p43142
(F0
F0
I1
I1
I0
tp43143
sS'tnf-blocking,agent'
p43144
(F1
F0.00014334862385321102
I1
I0
I1
tp43145
sS'following,ip'
p43146
(F1
F0.00014334862385321102
I0
I1
I-1
tp43147
sS'may,pose'
p43148
(F1
F0.00071674311926605509
I5
I0
I5
tp43149
sS'a,common'
p43150
(F0
F0
I1
I1
I0
tp43151
sS'parentheses,were'
p43152
(F1
F0.00014334862385321102
I0
I1
I-1
tp43153
sS'been,safely'
p43154
(F1
F0.00071674311926605509
I0
I5
I-5
tp43155
sS'a,diabetic'
p43156
(F1
F0.00014334862385321102
I1
I0
I1
tp43157
sS'isoflurane,and'
p43158
(F1
F0.00014334862385321102
I1
I0
I1
tp43159
sS'app,polymer'
p43160
(F1
F0.00014334862385321102
I0
I1
I-1
tp43161
sS'safe,problem'
p43162
(F1
F0.00014334862385321102
I1
I0
I1
tp43163
sS'spermine,and'
p43164
(F1
F0.00014334862385321102
I0
I1
I-1
tp43165
sS'tachypnea,lethargy'
p43166
(F1
F0.00014334862385321102
I1
I0
I1
tp43167
sS'injected,and'
p43168
(F1
F0.00014334862385321102
I0
I1
I-1
tp43169
sS'e,mesylate'
p43170
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp43171
sS'phosphorylation,at'
p43172
(F1
F0.00014334862385321102
I1
I0
I1
tp43173
sS'fold,elevation'
p43174
(F1
F0.00014334862385321102
I1
I0
I1
tp43175
sS'also,have'
p43176
(F0
F0
I1
I1
I0
tp43177
sS'or,have'
p43178
(F1
F0.00014334862385321102
I0
I1
I-1
tp43179
sS'p450,cyp450'
p43180
(F1
F0.00014334862385321102
I0
I1
I-1
tp43181
sS'clinical,effect'
p43182
(F1
F0.00014334862385321102
I0
I1
I-1
tp43183
sS'with,serial'
p43184
(F1
F0.00014334862385321102
I0
I1
I-1
tp43185
sS'mg,taken'
p43186
(F1
F0.00014334862385321102
I1
I0
I1
tp43187
sS'consisted,of'
p43188
(F1
F0.00014334862385321102
I0
I1
I-1
tp43189
sS'experienced,more'
p43190
(F1
F0.00014334862385321102
I1
I0
I1
tp43191
sS'dose-dependent,manner'
p43192
(F1
F0.00028669724770642203
I2
I0
I2
tp43193
sS'was,withdrawn'
p43194
(F1
F0.00014334862385321102
I0
I1
I-1
tp43195
sS'constitute,the'
p43196
(F1
F0.00014334862385321102
I0
I1
I-1
tp43197
sS'psychotropic,that'
p43198
(F1
F0.00014334862385321102
I1
I0
I1
tp43199
sS't24,cells'
p43200
(F1
F0.00014334862385321102
I1
I0
I1
tp43201
sS'to,results'
p43202
(F1
F0.00014334862385321102
I1
I0
I1
tp43203
sS'level,dosage'
p43204
(F1
F0.00014334862385321102
I1
I0
I1
tp43205
sS'are,unaltered'
p43206
(F1
F0.00014334862385321102
I0
I1
I-1
tp43207
sS'other,members'
p43208
(F1
F0.00028669724770642203
I2
I0
I2
tp43209
sS'fondaparinux,neither'
p43210
(F1
F0.00014334862385321102
I0
I1
I-1
tp43211
sS'diabetes,there'
p43212
(F1
F0.00014334862385321102
I0
I1
I-1
tp43213
sS'than,doubled'
p43214
(F1
F0.00014334862385321102
I0
I1
I-1
tp43215
sS'ergomar,and'
p43216
(F1
F0.00014334862385321102
I1
I0
I1
tp43217
sS'when,levsin'
p43218
(F1
F0.00014334862385321102
I1
I0
I1
tp43219
sS'its,components'
p43220
(F1
F0.00014334862385321102
I0
I1
I-1
tp43221
sS'haloperidol,haloperidol'
p43222
(F1
F0.00028669724770642203
I2
I0
I2
tp43223
sS'and,study'
p43224
(F1
F0.00014334862385321102
I0
I1
I-1
tp43225
sS'terfenadine,no'
p43226
(F1
F0.00014334862385321102
I0
I1
I-1
tp43227
sS'a,potential'
p43228
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp43229
sS'therapeutic,indices'
p43230
(F1
F0.00014334862385321102
I1
I0
I1
tp43231
sS'postmarketing,reports'
p43232
(F1
F0.00028669724770642203
I2
I0
I2
tp43233
sS'or,norpace'
p43234
(F1
F0.00014334862385321102
I1
I0
I1
tp43235
sS'supplementation,and'
p43236
(F1
F0.00014334862385321102
I0
I1
I-1
tp43237
sS'to,patients'
p43238
(F0.46341463414634149
F0.0027236238532110093
I30
I11
I19
tp43239
sS'proteins,indicate'
p43240
(F1
F0.00014334862385321102
I0
I1
I-1
tp43241
sS'pentobarbital-induced,sedation'
p43242
(F1
F0.00014334862385321102
I0
I1
I-1
tp43243
sS'exacerbate,the'
p43244
(F1
F0.00043004587155963305
I3
I0
I3
tp43245
sS'interaction,could'
p43246
(F1
F0.00014334862385321102
I0
I1
I-1
tp43247
sS'initiating,tcatreatment'
p43248
(F1
F0.00014334862385321102
I1
I0
I1
tp43249
sS'acid,channel'
p43250
(F1
F0.00028669724770642203
I0
I2
I-2
tp43251
sS'inhibitor,cannot'
p43252
(F1
F0.00014334862385321102
I0
I1
I-1
tp43253
sS'marked,effect'
p43254
(F1
F0.00014334862385321102
I1
I0
I1
tp43255
sS'threatening,cardiac'
p43256
(F1
F0.00014334862385321102
I1
I0
I1
tp43257
sS'median,follow-up'
p43258
(F1
F0.00014334862385321102
I0
I1
I-1
tp43259
sS'tumor,vascularity'
p43260
(F1
F0.00014334862385321102
I0
I1
I-1
tp43261
sS'of,particularly'
p43262
(F1
F0.00014334862385321102
I1
I0
I1
tp43263
sS'small,increase'
p43264
(F1
F0.00014334862385321102
I0
I1
I-1
tp43265
sS'concentrations,increase'
p43266
(F1
F0.00014334862385321102
I1
I0
I1
tp43267
sS'medicines,thiazide'
p43268
(F1
F0.00014334862385321102
I1
I0
I1
tp43269
sS'carbamazepine,equetrotm'
p43270
(F1
F0.00014334862385321102
I1
I0
I1
tp43271
sS'interactions,vardenafil'
p43272
(F1
F0.00014334862385321102
I0
I1
I-1
tp43273
sS'was,altered'
p43274
(F1
F0.00014334862385321102
I0
I1
I-1
tp43275
sS'to,these'
p43276
(F1
F0.00028669724770642203
I2
I0
I2
tp43277
sS'carbamazepine,epoxide'
p43278
(F1
F0.00014334862385321102
I0
I1
I-1
tp43279
sS'administered,could'
p43280
(F1
F0.00014334862385321102
I0
I1
I-1
tp43281
sS'day,divided'
p43282
(F1
F0.00014334862385321102
I1
I0
I1
tp43283
sS'bioassay,procedures'
p43284
(F1
F0.00014334862385321102
I0
I1
I-1
tp43285
sS'of,femara'
p43286
(F0
F0
I1
I1
I0
tp43287
sS'at,baseline'
p43288
(F1
F0.00014334862385321102
I0
I1
I-1
tp43289
sS'however,concomitant'
p43290
(F1
F0.00014334862385321102
I1
I0
I1
tp43291
sS'increase,sensitivity'
p43292
(F1
F0.00028669724770642203
I2
I0
I2
tp43293
sS'inducer,may'
p43294
(F1
F0.00014334862385321102
I1
I0
I1
tp43295
sS'cyp3a4,there'
p43296
(F1
F0.00014334862385321102
I0
I1
I-1
tp43297
sS'the,metabolism'
p43298
(F0.57446808510638303
F0.0038704128440366975
I37
I10
I27
tp43299
sS'preceded,by'
p43300
(F1
F0.00014334862385321102
I0
I1
I-1
tp43301
sS'methadone,coadministration'
p43302
(F1
F0.00014334862385321102
I1
I0
I1
tp43303
sS'iii,and'
p43304
(F1
F0.00028669724770642203
I0
I2
I-2
tp43305
sS'episode,of'
p43306
(F1
F0.00014334862385321102
I0
I1
I-1
tp43307
sS'upward,the'
p43308
(F1
F0.00014334862385321102
I1
I0
I1
tp43309
sS'therefore,extreme'
p43310
(F1
F0.00014334862385321102
I1
I0
I1
tp43311
sS'of,serum'
p43312
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp43313
sS'measured,during'
p43314
(F1
F0.00014334862385321102
I0
I1
I-1
tp43315
sS'were,conducted'
p43316
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp43317
sS'developed,in'
p43318
(F1
F0.00014334862385321102
I1
I0
I1
tp43319
sS'nsaids,is'
p43320
(F1
F0.00028669724770642203
I2
I0
I2
tp43321
sS'nsaids,in'
p43322
(F0
F0
I1
I1
I0
tp43323
sS'and,intravenously'
p43324
(F1
F0.00014334862385321102
I1
I0
I1
tp43325
sS'competitive,displacement'
p43326
(F1
F0.00014334862385321102
I0
I1
I-1
tp43327
sS'and,injectables'
p43328
(F1
F0.00014334862385321102
I0
I1
I-1
tp43329
sS'reactions,develop'
p43330
(F1
F0.00014334862385321102
I1
I0
I1
tp43331
sS'calcium,channel-blocking'
p43332
(F1
F0.00014334862385321102
I0
I1
I-1
tp43333
sS'that,of'
p43334
(F0
F0
I3
I3
I0
tp43335
sS'tarceva,dose'
p43336
(F1
F0.00014334862385321102
I1
I0
I1
tp43337
sS'activity,transient'
p43338
(F1
F0.00014334862385321102
I1
I0
I1
tp43339
sS'of,tail-flick'
p43340
(F1
F0.00014334862385321102
I0
I1
I-1
tp43341
sS'containing,regimens'
p43342
(F1
F0.00014334862385321102
I1
I0
I1
tp43343
sS'components,are'
p43344
(F1
F0.00028669724770642203
I0
I2
I-2
tp43345
sS'that,or'
p43346
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43347
sS'of,phosphatase'
p43348
(F1
F0.00014334862385321102
I0
I1
I-1
tp43349
sS'when,taken'
p43350
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43351
sS'halved,and'
p43352
(F1
F0.00014334862385321102
I1
I0
I1
tp43353
sS'the,test'
p43354
(F1
F0.00014334862385321102
I1
I0
I1
tp43355
sS'in,contrast'
p43356
(F1
F0.00043004587155963305
I0
I3
I-3
tp43357
sS'and,diarrhea'
p43358
(F1
F0.00014334862385321102
I1
I0
I1
tp43359
sS'therefore,such'
p43360
(F1
F0.00028669724770642203
I2
I0
I2
tp43361
sS'reported,due'
p43362
(F1
F0.00014334862385321102
I1
I0
I1
tp43363
sS'substitution,test'
p43364
(F1
F0.00014334862385321102
I1
I0
I1
tp43365
sS'majority,of'
p43366
(F1
F0.00014334862385321102
I0
I1
I-1
tp43367
sS'elevated,serum'
p43368
(F1
F0.0018635321100917432
I13
I0
I13
tp43369
sS'a,serotonin'
p43370
(F1
F0.00014334862385321102
I1
I0
I1
tp43371
sS'dependence,may'
p43372
(F1
F0.00014334862385321102
I0
I1
I-1
tp43373
sS'in,urinary'
p43374
(F0.5
F0.00028669724770642203
I3
I1
I2
tp43375
sS'to,when'
p43376
(F1
F0.00071674311926605509
I5
I0
I5
tp43377
sS'glibenclamide,in'
p43378
(F1
F0.00014334862385321102
I1
I0
I1
tp43379
sS'with,iron-fortified'
p43380
(F1
F0.00014334862385321102
I0
I1
I-1
tp43381
sS'with,carbamazepine'
p43382
(F1
F0.00014334862385321102
I1
I0
I1
tp43383
sS'renal,prostaglandins'
p43384
(F0
F0
I1
I1
I0
tp43385
sS'in,reducing'
p43386
(F1
F0.00014334862385321102
I1
I0
I1
tp43387
sS'with,acute'
p43388
(F1
F0.00043004587155963305
I3
I0
I3
tp43389
sS'involved,concomitant'
p43390
(F1
F0.00014334862385321102
I1
I0
I1
tp43391
sS'intraventricular,injection'
p43392
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43393
sS'nalfon,to'
p43394
(F1
F0.00014334862385321102
I1
I0
I1
tp43395
sS'serious,symptoms'
p43396
(F1
F0.00028669724770642203
I2
I0
I2
tp43397
sS'subsalicylate,should'
p43398
(F1
F0.00014334862385321102
I1
I0
I1
tp43399
sS'studied,but'
p43400
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43401
sS'function,who'
p43402
(F1
F0.00028669724770642203
I2
I0
I2
tp43403
sS'non-steroidal,agents'
p43404
(F1
F0.00028669724770642203
I2
I0
I2
tp43405
sS'of,invirase'
p43406
(F1
F0.00014334862385321102
I0
I1
I-1
tp43407
sS'affected,significantly'
p43408
(F1
F0.00014334862385321102
I0
I1
I-1
tp43409
sS'than,users'
p43410
(F1
F0.00014334862385321102
I1
I0
I1
tp43411
sS'a,smaller'
p43412
(F0
F0
I1
I1
I0
tp43413
sS'case-control,and'
p43414
(F1
F0.00014334862385321102
I1
I0
I1
tp43415
sS'inotropes,and'
p43416
(F1
F0.00014334862385321102
I1
I0
I1
tp43417
sS'thinners,may'
p43418
(F1
F0.00014334862385321102
I1
I0
I1
tp43419
sS'indocin,reduces'
p43420
(F1
F0.00014334862385321102
I0
I1
I-1
tp43421
sS'achieved,steady-state'
p43422
(F1
F0.00014334862385321102
I0
I1
I-1
tp43423
sS'subcortical,structures'
p43424
(F1
F0.00014334862385321102
I0
I1
I-1
tp43425
sS'these,events'
p43426
(F1
F0.00014334862385321102
I0
I1
I-1
tp43427
sS'd,doses'
p43428
(F1
F0.00014334862385321102
I0
I1
I-1
tp43429
sS'serum,auc'
p43430
(F1
F0.00014334862385321102
I1
I0
I1
tp43431
sS'zalcitabine,inhibited'
p43432
(F1
F0.00014334862385321102
I1
I0
I1
tp43433
sS'also,appeared'
p43434
(F1
F0.00014334862385321102
I1
I0
I1
tp43435
sS'recovery,of'
p43436
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43437
sS'or,including'
p43438
(F1
F0.00014334862385321102
I0
I1
I-1
tp43439
sS'to,pooled'
p43440
(F1
F0.00014334862385321102
I0
I1
I-1
tp43441
sS'of,dry'
p43442
(F1
F0.00014334862385321102
I1
I0
I1
tp43443
sS'and,compromise'
p43444
(F1
F0.00014334862385321102
I1
I0
I1
tp43445
sS'have,pre-existing'
p43446
(F1
F0.00014334862385321102
I1
I0
I1
tp43447
sS'intake,approximately'
p43448
(F1
F0.00014334862385321102
I1
I0
I1
tp43449
sS'most,subjects'
p43450
(F1
F0.00014334862385321102
I1
I0
I1
tp43451
sS'probenecid,a'
p43452
(F1
F0.00014334862385321102
I0
I1
I-1
tp43453
sS'either,inhibit'
p43454
(F1
F0.00014334862385321102
I1
I0
I1
tp43455
sS'pesticides,this'
p43456
(F1
F0.00014334862385321102
I0
I1
I-1
tp43457
sS'receiving,with'
p43458
(F1
F0.00014334862385321102
I1
I0
I1
tp43459
sS'warning,potential'
p43460
(F1
F0.00014334862385321102
I0
I1
I-1
tp43461
sS'including,the'
p43462
(F1
F0.00028669724770642203
I0
I2
I-2
tp43463
sS'severe,hypoglycemia'
p43464
(F1
F0.0008600917431192661
I6
I0
I6
tp43465
sS'alveolar,concentration'
p43466
(F1
F0.00028669724770642203
I2
I0
I2
tp43467
sS'blocking,cardiac'
p43468
(F1
F0.00014334862385321102
I1
I0
I1
tp43469
sS'quickens,the'
p43470
(F1
F0.00014334862385321102
I1
I0
I1
tp43471
sS'of,barrier'
p43472
(F1
F0.00014334862385321102
I1
I0
I1
tp43473
sS'difference,exists'
p43474
(F1
F0.00014334862385321102
I0
I1
I-1
tp43475
sS'increased,following'
p43476
(F1
F0.00014334862385321102
I1
I0
I1
tp43477
sS'cr,lower'
p43478
(F1
F0.00014334862385321102
I1
I0
I1
tp43479
sS'as,valium'
p43480
(F1
F0.00014334862385321102
I1
I0
I1
tp43481
sS'proliferation,of'
p43482
(F1
F0.00043004587155963305
I3
I0
I3
tp43483
sS'refractory,to'
p43484
(F1
F0.00014334862385321102
I1
I0
I1
tp43485
sS'the,depressant'
p43486
(F1
F0.00014334862385321102
I1
I0
I1
tp43487
sS'be,taken'
p43488
(F0.55555555555555558
F0.0021502293577981653
I21
I6
I15
tp43489
sS'with,mg'
p43490
(F0.12195121951219512
F0.00071674311926605509
I23
I18
I5
tp43491
sS'of,duragesic'
p43492
(F1
F0.00014334862385321102
I1
I0
I1
tp43493
sS'with,ml'
p43494
(F1
F0.00014334862385321102
I1
I0
I1
tp43495
sS'with,drugs'
p43496
(F1
F0.00028669724770642203
I0
I2
I-2
tp43497
sS'plasma,concentration-time'
p43498
(F0
F0
I1
I1
I0
tp43499
sS'a,maintenance'
p43500
(F0.5
F0.00028669724770642203
I3
I1
I2
tp43501
sS'sd,cumulative'
p43502
(F1
F0.00014334862385321102
I0
I1
I-1
tp43503
sS'accumbens,but'
p43504
(F1
F0.00014334862385321102
I0
I1
I-1
tp43505
sS'mm,or'
p43506
(F1
F0.00014334862385321102
I0
I1
I-1
tp43507
sS'additive,adverse'
p43508
(F1
F0.00014334862385321102
I1
I0
I1
tp43509
sS'in,animals'
p43510
(F1
F0.00057339449541284407
I4
I0
I4
tp43511
sS'the,activation'
p43512
(F0
F0
I1
I1
I0
tp43513
sS'necessitated,changes'
p43514
(F1
F0.00014334862385321102
I1
I0
I1
tp43515
sS'implication,that'
p43516
(F1
F0.00014334862385321102
I1
I0
I1
tp43517
sS'on,endotoxin-induced'
p43518
(F1
F0.00014334862385321102
I0
I1
I-1
tp43519
sS'secretion,p-aminosalicylic'
p43520
(F1
F0.00014334862385321102
I0
I1
I-1
tp43521
sS'and,pharmacokinetic'
p43522
(F1
F0.00014334862385321102
I1
I0
I1
tp43523
sS'gleevec,with'
p43524
(F1
F0.00028669724770642203
I2
I0
I2
tp43525
sS'minutes,any'
p43526
(F1
F0.00014334862385321102
I1
I0
I1
tp43527
sS'of,bradycardia'
p43528
(F1
F0.00014334862385321102
I0
I1
I-1
tp43529
sS'its,synthetic'
p43530
(F1
F0.00014334862385321102
I0
I1
I-1
tp43531
sS'permits,at'
p43532
(F1
F0.00014334862385321102
I1
I0
I1
tp43533
sS'b-lactam,co-administration'
p43534
(F1
F0.00014334862385321102
I1
I0
I1
tp43535
sS'of,cyp3a'
p43536
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43537
sS'duodenum,and'
p43538
(F1
F0.00014334862385321102
I0
I1
I-1
tp43539
sS'no,interactions'
p43540
(F1
F0.00057339449541284407
I0
I4
I-4
tp43541
sS'effects,seen'
p43542
(F1
F0.00014334862385321102
I1
I0
I1
tp43543
sS'pharmacokinetics,auc'
p43544
(F1
F0.00014334862385321102
I0
I1
I-1
tp43545
sS'inducers,inhibitors'
p43546
(F1
F0.00014334862385321102
I1
I0
I1
tp43547
sS'normal,fat'
p43548
(F1
F0.00014334862385321102
I0
I1
I-1
tp43549
sS'with,experimental'
p43550
(F1
F0.00014334862385321102
I1
I0
I1
tp43551
sS'exposure,when'
p43552
(F1
F0.00014334862385321102
I1
I0
I1
tp43553
sS'upon,chylomicron'
p43554
(F1
F0.00014334862385321102
I0
I1
I-1
tp43555
sS'disease,except'
p43556
(F1
F0.00014334862385321102
I1
I0
I1
tp43557
sS'effectiveness,by'
p43558
(F0
F0
I1
I1
I0
tp43559
sS'antagonism,exists'
p43560
(F1
F0.00043004587155963305
I3
I0
I3
tp43561
sS'titers,may'
p43562
(F1
F0.00014334862385321102
I0
I1
I-1
tp43563
sS'the,fraction'
p43564
(F1
F0.00014334862385321102
I0
I1
I-1
tp43565
sS'where,serious'
p43566
(F1
F0.00014334862385321102
I0
I1
I-1
tp43567
sS'oral,in'
p43568
(F1
F0.00057339449541284407
I0
I4
I-4
tp43569
sS'or,copd'
p43570
(F1
F0.00014334862385321102
I0
I1
I-1
tp43571
sS'given,to'
p43572
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp43573
sS'oral,is'
p43574
(F1
F0.00014334862385321102
I1
I0
I1
tp43575
sS'vaprisol,the'
p43576
(F1
F0.00014334862385321102
I1
I0
I1
tp43577
sS'by,after'
p43578
(F1
F0.00043004587155963305
I0
I3
I-3
tp43579
sS'output,and'
p43580
(F1
F0.00028669724770642203
I2
I0
I2
tp43581
sS'potent,inhibition'
p43582
(F1
F0.00014334862385321102
I0
I1
I-1
tp43583
sS'studied,extensively'
p43584
(F1
F0.00014334862385321102
I0
I1
I-1
tp43585
sS'nrtis,are'
p43586
(F1
F0.00014334862385321102
I0
I1
I-1
tp43587
sS'to,inhibit'
p43588
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp43589
sS'was,separated'
p43590
(F1
F0.00014334862385321102
I1
I0
I1
tp43591
sS'cells,but'
p43592
(F1
F0.00014334862385321102
I1
I0
I1
tp43593
sS'demonstrated,no'
p43594
(F1
F0.00057339449541284407
I0
I4
I-4
tp43595
sS'index,of'
p43596
(F1
F0.00043004587155963305
I0
I3
I-3
tp43597
sS'mg,also'
p43598
(F1
F0.00014334862385321102
I0
I1
I-1
tp43599
sS'body,clearance'
p43600
(F1
F0.00043004587155963305
I3
I0
I3
tp43601
sS'are,tolerated'
p43602
(F1
F0.00014334862385321102
I0
I1
I-1
tp43603
sS'index,or'
p43604
(F1
F0.00014334862385321102
I0
I1
I-1
tp43605
sS'dopamine-induced,renal'
p43606
(F1
F0.00014334862385321102
I0
I1
I-1
tp43607
sS'pharmacokinetic,data'
p43608
(F1
F0.00057339449541284407
I4
I0
I4
tp43609
sS'day,are'
p43610
(F1
F0.00014334862385321102
I0
I1
I-1
tp43611
sS'increased,exposures'
p43612
(F1
F0.00028669724770642203
I2
I0
I2
tp43613
sS'assigned,in'
p43614
(F1
F0.00014334862385321102
I0
I1
I-1
tp43615
sS'sildenafil,has'
p43616
(F1
F0.00014334862385321102
I0
I1
I-1
tp43617
sS'in,inhibition'
p43618
(F1
F0.00014334862385321102
I1
I0
I1
tp43619
sS'possibly,related'
p43620
(F1
F0.00014334862385321102
I1
I0
I1
tp43621
sS'class,see'
p43622
(F1
F0.00014334862385321102
I1
I0
I1
tp43623
sS'if,patients'
p43624
(F1
F0.00014334862385321102
I1
I0
I1
tp43625
sS'of,drug'
p43626
(F1
F0.00014334862385321102
I0
I1
I-1
tp43627
sS'ig,for'
p43628
(F1
F0.00014334862385321102
I1
I0
I1
tp43629
sS'relevance,of'
p43630
(F1
F0.00014334862385321102
I1
I0
I1
tp43631
sS'recommended,as'
p43632
(F1
F0.00014334862385321102
I0
I1
I-1
tp43633
sS'recommended,at'
p43634
(F1
F0.00014334862385321102
I0
I1
I-1
tp43635
sS'vioxx,concomitantly'
p43636
(F1
F0.00014334862385321102
I1
I0
I1
tp43637
sS'blocks,and'
p43638
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp43639
sS'diminish,fluoride'
p43640
(F1
F0.00014334862385321102
I0
I1
I-1
tp43641
sS'enhance,activity'
p43642
(F1
F0.00014334862385321102
I1
I0
I1
tp43643
sS'exposure,in'
p43644
(F1
F0.00014334862385321102
I0
I1
I-1
tp43645
sS'to,moderate'
p43646
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43647
sS'generally,recommended'
p43648
(F1
F0.00028669724770642203
I2
I0
I2
tp43649
sS'experience,of'
p43650
(F1
F0.00014334862385321102
I1
I0
I1
tp43651
sS'certain,hmg-coa'
p43652
(F1
F0.00014334862385321102
I1
I0
I1
tp43653
sS'fe,per'
p43654
(F1
F0.00014334862385321102
I1
I0
I1
tp43655
sS'a,simultaneous'
p43656
(F1
F0.00014334862385321102
I1
I0
I1
tp43657
sS'and,glucose'
p43658
(F1
F0.00014334862385321102
I0
I1
I-1
tp43659
sS'mean,trough'
p43660
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43661
sS'hepatotoxic,effects'
p43662
(F1
F0.00014334862385321102
I1
I0
I1
tp43663
sS'the,study'
p43664
(F1
F0.00057339449541284407
I0
I4
I-4
tp43665
sS'hormone,synthesis'
p43666
(F1
F0.00014334862385321102
I0
I1
I-1
tp43667
sS'take,tricor'
p43668
(F1
F0.00014334862385321102
I1
I0
I1
tp43669
sS'for,development'
p43670
(F1
F0.00014334862385321102
I1
I0
I1
tp43671
sS'preparations,before'
p43672
(F1
F0.00028669724770642203
I2
I0
I2
tp43673
sS'are,likely'
p43674
(F0.5
F0.00028669724770642203
I3
I1
I2
tp43675
sS'or,in'
p43676
(F0.36363636363636365
F0.0011467889908256881
I7
I15
I-8
tp43677
sS'substrates,drugs'
p43678
(F1
F0.00014334862385321102
I1
I0
I1
tp43679
sS'mg,by'
p43680
(F1
F0.00014334862385321102
I1
I0
I1
tp43681
sS'tablet,was'
p43682
(F1
F0.00014334862385321102
I1
I0
I1
tp43683
sS'the,time'
p43684
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp43685
sS'despite,the'
p43686
(F1
F0.00014334862385321102
I0
I1
I-1
tp43687
sS'didanosine,co-administration'
p43688
(F1
F0.00014334862385321102
I1
I0
I1
tp43689
sS'cholestyramine,increases'
p43690
(F1
F0.00014334862385321102
I0
I1
I-1
tp43691
sS'repeated,co-administration'
p43692
(F1
F0.00014334862385321102
I1
I0
I1
tp43693
sS'indocin,given'
p43694
(F1
F0.00014334862385321102
I1
I0
I1
tp43695
sS'usual,amounts'
p43696
(F1
F0.00014334862385321102
I0
I1
I-1
tp43697
sS'amiodarone,caused'
p43698
(F1
F0.00014334862385321102
I0
I1
I-1
tp43699
sS'other,cardioactive'
p43700
(F0
F0
I1
I1
I0
tp43701
sS'long,surgical'
p43702
(F1
F0.00014334862385321102
I1
I0
I1
tp43703
sS'auc,more'
p43704
(F1
F0.00014334862385321102
I0
I1
I-1
tp43705
sS'that,transferred'
p43706
(F1
F0.00014334862385321102
I0
I1
I-1
tp43707
sS'its,protein'
p43708
(F1
F0.00014334862385321102
I1
I0
I1
tp43709
sS'theophylline-induced,anxiogenic'
p43710
(F1
F0.00014334862385321102
I1
I0
I1
tp43711
sS'aware,that'
p43712
(F1
F0.00014334862385321102
I1
I0
I1
tp43713
sS'initiating,therapy'
p43714
(F1
F0.00028669724770642203
I2
I0
I2
tp43715
sS'glycemia,induced'
p43716
(F1
F0.00014334862385321102
I0
I1
I-1
tp43717
sS'carefully,if'
p43718
(F1
F0.00014334862385321102
I1
I0
I1
tp43719
sS'by,hour'
p43720
(F1
F0.00014334862385321102
I1
I0
I1
tp43721
sS'cyp1a2,is'
p43722
(F1
F0.00014334862385321102
I1
I0
I1
tp43723
sS'theoretically,adversely'
p43724
(F1
F0.00014334862385321102
I1
I0
I1
tp43725
sS'and,isoniazid'
p43726
(F1
F0.00014334862385321102
I1
I0
I1
tp43727
sS'as,to'
p43728
(F0
F0
I1
I1
I0
tp43729
sS'neurontin,in'
p43730
(F1
F0.00014334862385321102
I0
I1
I-1
tp43731
sS'd,have'
p43732
(F1
F0.00057339449541284407
I0
I4
I-4
tp43733
sS'bid,day'
p43734
(F0
F0
I1
I1
I0
tp43735
sS'increasing,salt'
p43736
(F1
F0.00014334862385321102
I1
I0
I1
tp43737
sS'of,did'
p43738
(F1
F0.0010034403669724771
I0
I7
I-7
tp43739
sS'because,nalfon'
p43740
(F1
F0.00014334862385321102
I1
I0
I1
tp43741
sS'hypotension,caused'
p43742
(F1
F0.00014334862385321102
I1
I0
I1
tp43743
sS'should,provide'
p43744
(F1
F0.00014334862385321102
I0
I1
I-1
tp43745
sS'their,clearance'
p43746
(F1
F0.00014334862385321102
I0
I1
I-1
tp43747
sS'on,blood'
p43748
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp43749
sS'important,that'
p43750
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43751
sS'glucose,lowering'
p43752
(F1
F0.00014334862385321102
I1
I0
I1
tp43753
sS'aprepitant,reflects'
p43754
(F1
F0.00014334862385321102
I1
I0
I1
tp43755
sS'auc0-24hr,in'
p43756
(F0
F0
I1
I1
I0
tp43757
sS'the,specific'
p43758
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43759
sS'with,maleate'
p43760
(F1
F0.00014334862385321102
I1
I0
I1
tp43761
sS'any,alterations'
p43762
(F1
F0.00014334862385321102
I0
I1
I-1
tp43763
sS'took,min'
p43764
(F1
F0.00028669724770642203
I2
I0
I2
tp43765
sS'begin,taking'
p43766
(F1
F0.00014334862385321102
I1
I0
I1
tp43767
sS'gl,with'
p43768
(F0
F0
I1
I1
I0
tp43769
sS'than,might'
p43770
(F1
F0.00014334862385321102
I1
I0
I1
tp43771
sS'opioids,are'
p43772
(F1
F0.00014334862385321102
I0
I1
I-1
tp43773
sS'animal,model'
p43774
(F1
F0.00014334862385321102
I1
I0
I1
tp43775
sS'of,effect'
p43776
(F1
F0.00014334862385321102
I0
I1
I-1
tp43777
sS'stable,dosage'
p43778
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43779
sS'one,man'
p43780
(F1
F0.00014334862385321102
I1
I0
I1
tp43781
sS'diabetes,medicine'
p43782
(F1
F0.00014334862385321102
I1
I0
I1
tp43783
sS'already,stabilized'
p43784
(F1
F0.00014334862385321102
I1
I0
I1
tp43785
sS'aspecific,treatments'
p43786
(F1
F0.00014334862385321102
I0
I1
I-1
tp43787
sS'therapy,in'
p43788
(F0
F0
I2
I2
I0
tp43789
sS'therapy,if'
p43790
(F1
F0.00014334862385321102
I1
I0
I1
tp43791
sS'interactions,no'
p43792
(F1
F0.00028669724770642203
I0
I2
I-2
tp43793
sS'nephrotoxicity,may'
p43794
(F1
F0.00028669724770642203
I2
I0
I2
tp43795
sS'combining,with'
p43796
(F0
F0
I1
I1
I0
tp43797
sS'prudent,medical'
p43798
(F1
F0.00014334862385321102
I1
I0
I1
tp43799
sS'of,orthostatic'
p43800
(F1
F0.00014334862385321102
I0
I1
I-1
tp43801
sS'alertness,and'
p43802
(F1
F0.00028669724770642203
I2
I0
I2
tp43803
sS'remains,constant'
p43804
(F1
F0.00014334862385321102
I0
I1
I-1
tp43805
sS'taken,concomitantly'
p43806
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp43807
sS'or,metabolite'
p43808
(F1
F0.00014334862385321102
I0
I1
I-1
tp43809
sS'received,plus'
p43810
(F1
F0.00014334862385321102
I0
I1
I-1
tp43811
sS'binding,globulin'
p43812
(F1
F0.00028669724770642203
I0
I2
I-2
tp43813
sS'type,ii'
p43814
(F1
F0.00014334862385321102
I1
I0
I1
tp43815
sS'after,and'
p43816
(F1
F0.00014334862385321102
I1
I0
I1
tp43817
sS'for,at'
p43818
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43819
sS'concurrently,treated'
p43820
(F1
F0.00014334862385321102
I1
I0
I1
tp43821
sS'improve,the'
p43822
(F1
F0.00028669724770642203
I0
I2
I-2
tp43823
sS'by,cgs'
p43824
(F1
F0.00014334862385321102
I1
I0
I1
tp43825
sS'elevating,duodenal'
p43826
(F1
F0.00014334862385321102
I1
I0
I1
tp43827
sS'urinary,recovery'
p43828
(F1
F0.00014334862385321102
I0
I1
I-1
tp43829
sS'large,quantities'
p43830
(F1
F0.00014334862385321102
I0
I1
I-1
tp43831
sS'type,it'
p43832
(F1
F0.00014334862385321102
I1
I0
I1
tp43833
sS'protease,inhibitors'
p43834
(F0.14285714285714285
F0.00028669724770642203
I6
I8
I-2
tp43835
sS'coadministered,although'
p43836
(F1
F0.00014334862385321102
I0
I1
I-1
tp43837
sS'increased,effects'
p43838
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43839
sS'when,amines'
p43840
(F1
F0.00014334862385321102
I1
I0
I1
tp43841
sS'and,hydroxydesloratadine'
p43842
(F1
F0.00028669724770642203
I0
I2
I-2
tp43843
sS'given,on'
p43844
(F1
F0.00014334862385321102
I1
I0
I1
tp43845
sS'thiazide,to'
p43846
(F1
F0.00028669724770642203
I2
I0
I2
tp43847
sS'given,or'
p43848
(F1
F0.00014334862385321102
I0
I1
I-1
tp43849
sS'dose,resulted'
p43850
(F1
F0.00014334862385321102
I1
I0
I1
tp43851
sS'until,further'
p43852
(F1
F0.00014334862385321102
I0
I1
I-1
tp43853
sS'slightly,enhance'
p43854
(F1
F0.00014334862385321102
I1
I0
I1
tp43855
sS'be,cyp'
p43856
(F1
F0.00028669724770642203
I2
I0
I2
tp43857
sS'its,vasculature'
p43858
(F1
F0.00014334862385321102
I0
I1
I-1
tp43859
sS'serious,sometimes'
p43860
(F1
F0.00028669724770642203
I2
I0
I2
tp43861
sS'agents,nsaids'
p43862
(F1
F0.00028669724770642203
I2
I0
I2
tp43863
sS'administration,trough'
p43864
(F1
F0.00014334862385321102
I0
I1
I-1
tp43865
sS'signalling,or'
p43866
(F1
F0.00014334862385321102
I0
I1
I-1
tp43867
sS'adverse,reaction'
p43868
(F1
F0.00043004587155963305
I0
I3
I-3
tp43869
sS'insufficient,intake'
p43870
(F1
F0.00014334862385321102
I0
I1
I-1
tp43871
sS'in,transferring'
p43872
(F1
F0.00014334862385321102
I0
I1
I-1
tp43873
sS'steady-state,were'
p43874
(F1
F0.00014334862385321102
I0
I1
I-1
tp43875
sS'to,bleeding'
p43876
(F1
F0.00014334862385321102
I1
I0
I1
tp43877
sS'appropriate,adjustment'
p43878
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43879
sS'enzymes,evaluated'
p43880
(F1
F0.00014334862385321102
I0
I1
I-1
tp43881
sS'urine,immunoreactive'
p43882
(F1
F0.00014334862385321102
I0
I1
I-1
tp43883
sS'hiv-nhl,who'
p43884
(F1
F0.00014334862385321102
I0
I1
I-1
tp43885
sS'phenylbutazone,phenylbutazone'
p43886
(F1
F0.00014334862385321102
I1
I0
I1
tp43887
sS'cyp3a4,would'
p43888
(F1
F0.00014334862385321102
I0
I1
I-1
tp43889
sS'major,metabolic'
p43890
(F1
F0.00014334862385321102
I0
I1
I-1
tp43891
sS'of,to'
p43892
(F0.3125
F0.0014334862385321102
I21
I11
I10
tp43893
sS'on,pentagastrin-'
p43894
(F1
F0.00014334862385321102
I0
I1
I-1
tp43895
sS'decreases,in'
p43896
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp43897
sS'mg,controlled-release'
p43898
(F1
F0.00014334862385321102
I1
I0
I1
tp43899
sS'are,co'
p43900
(F1
F0.00014334862385321102
I1
I0
I1
tp43901
sS'complex,effect'
p43902
(F1
F0.00014334862385321102
I1
I0
I1
tp43903
sS'such,users'
p43904
(F1
F0.00014334862385321102
I0
I1
I-1
tp43905
sS'established,but'
p43906
(F0
F0
I1
I1
I0
tp43907
sS'sensipar,sensipar'
p43908
(F1
F0.00014334862385321102
I0
I1
I-1
tp43909
sS'have,additive'
p43910
(F1
F0.00057339449541284407
I4
I0
I4
tp43911
sS'certain,other'
p43912
(F1
F0.00014334862385321102
I0
I1
I-1
tp43913
sS'will,be'
p43914
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp43915
sS'tbg,concentrations'
p43916
(F1
F0.00014334862385321102
I0
I1
I-1
tp43917
sS'no,are'
p43918
(F1
F0.00014334862385321102
I0
I1
I-1
tp43919
sS'h-spiroperidol,binding'
p43920
(F1
F0.00014334862385321102
I0
I1
I-1
tp43921
sS'binding,experiments'
p43922
(F1
F0.00014334862385321102
I0
I1
I-1
tp43923
sS'inhibitors,mao'
p43924
(F1
F0.00014334862385321102
I0
I1
I-1
tp43925
sS'on,mhd'
p43926
(F1
F0.00014334862385321102
I0
I1
I-1
tp43927
sS'dosing,requirements'
p43928
(F1
F0.00014334862385321102
I0
I1
I-1
tp43929
sS'inhibitors,may'
p43930
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp43931
sS'induction,thus'
p43932
(F1
F0.00014334862385321102
I1
I0
I1
tp43933
sS'receiving,brovana'
p43934
(F1
F0.00014334862385321102
I0
I1
I-1
tp43935
sS'when,given'
p43936
(F0.25925925925925924
F0.0010034403669724771
I17
I10
I7
tp43937
sS'be,directed'
p43938
(F1
F0.00014334862385321102
I1
I0
I1
tp43939
sS'epidemiological,studies'
p43940
(F1
F0.00014334862385321102
I1
I0
I1
tp43941
sS'felbatol,causes'
p43942
(F1
F0.00043004587155963305
I3
I0
I3
tp43943
sS'interaction,probably'
p43944
(F1
F0.00014334862385321102
I1
I0
I1
tp43945
sS'levels,were'
p43946
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp43947
sS'within14,days'
p43948
(F1
F0.00014334862385321102
I1
I0
I1
tp43949
sS'slight,delay'
p43950
(F1
F0.00014334862385321102
I1
I0
I1
tp43951
sS'and,safely'
p43952
(F1
F0.00014334862385321102
I0
I1
I-1
tp43953
sS'were,not'
p43954
(F0.89473684210526316
F0.0048738532110091746
I2
I36
I-34
tp43955
sS'the,physiological'
p43956
(F1
F0.00014334862385321102
I0
I1
I-1
tp43957
sS'monitored,when'
p43958
(F1
F0.0015768348623853212
I11
I0
I11
tp43959
sS'with,gastrointestinal'
p43960
(F1
F0.00014334862385321102
I1
I0
I1
tp43961
sS'and,valproic'
p43962
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43963
sS'would,permit'
p43964
(F1
F0.00014334862385321102
I0
I1
I-1
tp43965
sS'the,proliferation'
p43966
(F1
F0.00028669724770642203
I2
I0
I2
tp43967
sS'of,homocysteine'
p43968
(F1
F0.00014334862385321102
I0
I1
I-1
tp43969
sS'o,induced'
p43970
(F1
F0.00014334862385321102
I1
I0
I1
tp43971
sS'complex,concentrates'
p43972
(F1
F0.00014334862385321102
I0
I1
I-1
tp43973
sS'the,enteric'
p43974
(F1
F0.00014334862385321102
I1
I0
I1
tp43975
sS'were,seen'
p43976
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43977
sS'sodium,or'
p43978
(F1
F0.00014334862385321102
I1
I0
I1
tp43979
sS'changed,to'
p43980
(F1
F0.00014334862385321102
I0
I1
I-1
tp43981
sS'consider,discontinuation'
p43982
(F1
F0.00014334862385321102
I1
I0
I1
tp43983
sS'ruthenium,red'
p43984
(F1
F0.00014334862385321102
I0
I1
I-1
tp43985
sS'especially,the'
p43986
(F1
F0.00014334862385321102
I1
I0
I1
tp43987
sS'a,narrower'
p43988
(F1
F0.00014334862385321102
I0
I1
I-1
tp43989
sS'state,in'
p43990
(F1
F0.00014334862385321102
I0
I1
I-1
tp43991
sS'cerebyx,were'
p43992
(F1
F0.00014334862385321102
I0
I1
I-1
tp43993
sS'severe,enterocolitis'
p43994
(F1
F0.00014334862385321102
I1
I0
I1
tp43995
sS'increased,metabolism'
p43996
(F1
F0.00057339449541284407
I4
I0
I4
tp43997
sS'indinavir-based,regimens'
p43998
(F1
F0.00014334862385321102
I0
I1
I-1
tp43999
sS'lamprene,have'
p44000
(F1
F0.00014334862385321102
I1
I0
I1
tp44001
sS'during,muscle'
p44002
(F1
F0.00014334862385321102
I0
I1
I-1
tp44003
sS'recovery,from'
p44004
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp44005
sS'estrogenic,component'
p44006
(F1
F0.00014334862385321102
I0
I1
I-1
tp44007
sS'potentiated,apparently'
p44008
(F1
F0.00014334862385321102
I0
I1
I-1
tp44009
sS'on,potassium'
p44010
(F1
F0.00014334862385321102
I1
I0
I1
tp44011
sS'article,reported'
p44012
(F1
F0.00014334862385321102
I1
I0
I1
tp44013
sS'study,patients'
p44014
(F1
F0.00028669724770642203
I0
I2
I-2
tp44015
sS'consideration,should'
p44016
(F1
F0.00043004587155963305
I3
I0
I3
tp44017
sS'of,male'
p44018
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44019
sS'been,little'
p44020
(F1
F0.00014334862385321102
I0
I1
I-1
tp44021
sS'when,alfenta'
p44022
(F1
F0.00014334862385321102
I1
I0
I1
tp44023
sS'considering,the'
p44024
(F1
F0.00014334862385321102
I1
I0
I1
tp44025
sS'for,peroral'
p44026
(F1
F0.00014334862385321102
I0
I1
I-1
tp44027
sS'nor,does'
p44028
(F1
F0.00043004587155963305
I0
I3
I-3
tp44029
sS'some,instances'
p44030
(F1
F0.00028669724770642203
I2
I0
I2
tp44031
sS'dogs,the'
p44032
(F1
F0.00014334862385321102
I1
I0
I1
tp44033
sS'the,nucleus'
p44034
(F1
F0.00014334862385321102
I0
I1
I-1
tp44035
sS'hydroxyphenyl,piperidine'
p44036
(F1
F0.00014334862385321102
I1
I0
I1
tp44037
sS'when,this'
p44038
(F0
F0
I1
I1
I0
tp44039
sS'clearances,of'
p44040
(F1
F0.00014334862385321102
I1
I0
I1
tp44041
sS'site,fecal'
p44042
(F1
F0.00014334862385321102
I0
I1
I-1
tp44043
sS'submitted,to'
p44044
(F1
F0.00028669724770642203
I0
I2
I-2
tp44045
sS'suspension,can'
p44046
(F1
F0.00014334862385321102
I0
I1
I-1
tp44047
sS'dose,at'
p44048
(F1
F0.00014334862385321102
I0
I1
I-1
tp44049
sS'acarbose,due'
p44050
(F1
F0.00014334862385321102
I1
I0
I1
tp44051
sS'inflammation,associated'
p44052
(F1
F0.00014334862385321102
I1
I0
I1
tp44053
sS'nor,binding'
p44054
(F1
F0.00014334862385321102
I0
I1
I-1
tp44055
sS'contraception,during'
p44056
(F1
F0.00014334862385321102
I1
I0
I1
tp44057
sS'exogenously,infused'
p44058
(F1
F0.00014334862385321102
I0
I1
I-1
tp44059
sS'mean,values'
p44060
(F1
F0.00014334862385321102
I0
I1
I-1
tp44061
sS'drug,metabolizing'
p44062
(F1
F0.00014334862385321102
I0
I1
I-1
tp44063
sS'have,the'
p44064
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44065
sS'those,used'
p44066
(F1
F0.00014334862385321102
I0
I1
I-1
tp44067
sS'antagonists,is'
p44068
(F1
F0.00014334862385321102
I1
I0
I1
tp44069
sS'or,known'
p44070
(F1
F0.00014334862385321102
I1
I0
I1
tp44071
sS'regimens,including'
p44072
(F1
F0.00014334862385321102
I0
I1
I-1
tp44073
sS'factor,concentrates'
p44074
(F1
F0.00014334862385321102
I0
I1
I-1
tp44075
sS'preparation,causing'
p44076
(F1
F0.00014334862385321102
I1
I0
I1
tp44077
sS'the,elderly'
p44078
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44079
sS'auc,higher'
p44080
(F1
F0.00014334862385321102
I1
I0
I1
tp44081
sS'cmc-cys,exhibiting'
p44082
(F1
F0.00014334862385321102
I0
I1
I-1
tp44083
sS'antagonists,in'
p44084
(F1
F0.00028669724770642203
I0
I2
I-2
tp44085
sS'the,ability'
p44086
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp44087
sS'taking,aminosalicylic'
p44088
(F1
F0.00014334862385321102
I1
I0
I1
tp44089
sS'activity,but'
p44090
(F1
F0.00014334862385321102
I0
I1
I-1
tp44091
sS'estradiol,were'
p44092
(F1
F0.00014334862385321102
I0
I1
I-1
tp44093
sS'the,ureidopenicillins'
p44094
(F1
F0.00014334862385321102
I1
I0
I1
tp44095
sS'pcp,treatment'
p44096
(F1
F0.00014334862385321102
I1
I0
I1
tp44097
sS'in,fold'
p44098
(F1
F0.00014334862385321102
I1
I0
I1
tp44099
sS'include,azole'
p44100
(F1
F0.00014334862385321102
I0
I1
I-1
tp44101
sS'report,which'
p44102
(F1
F0.00014334862385321102
I1
I0
I1
tp44103
sS'trans-3,dimethyl-4'
p44104
(F1
F0.00014334862385321102
I1
I0
I1
tp44105
sS'dihydropyridine,channel'
p44106
(F1
F0.00014334862385321102
I1
I0
I1
tp44107
sS'co-administer,and'
p44108
(F1
F0.00014334862385321102
I1
I0
I1
tp44109
sS'similar,affinities'
p44110
(F1
F0.00014334862385321102
I0
I1
I-1
tp44111
sS'only,be'
p44112
(F1
F0.00028669724770642203
I2
I0
I2
tp44113
sS'after,multiple-dose'
p44114
(F1
F0.00014334862385321102
I0
I1
I-1
tp44115
sS'was,compared'
p44116
(F1
F0.00014334862385321102
I0
I1
I-1
tp44117
sS'reportedly,may'
p44118
(F1
F0.00028669724770642203
I2
I0
I2
tp44119
sS'for,flolan'
p44120
(F1
F0.00014334862385321102
I1
I0
I1
tp44121
sS'on,arterial'
p44122
(F1
F0.00014334862385321102
I1
I0
I1
tp44123
sS'uricosuric,agents'
p44124
(F0.5
F0.00028669724770642203
I3
I1
I2
tp44125
sS'a,strong'
p44126
(F0.5
F0.00057339449541284407
I6
I2
I4
tp44127
sS'alterations,associated'
p44128
(F1
F0.00014334862385321102
I0
I1
I-1
tp44129
sS'malignant,cells'
p44130
(F1
F0.00014334862385321102
I1
I0
I1
tp44131
sS'desirable,or'
p44132
(F1
F0.00028669724770642203
I0
I2
I-2
tp44133
sS'exhibit,minimal'
p44134
(F1
F0.00014334862385321102
I0
I1
I-1
tp44135
sS'after,completion'
p44136
(F1
F0.00014334862385321102
I1
I0
I1
tp44137
sS'act,on'
p44138
(F1
F0.00014334862385321102
I1
I0
I1
tp44139
sS'receiving,inspra'
p44140
(F1
F0.00014334862385321102
I0
I1
I-1
tp44141
sS'increased,vasoconstriction'
p44142
(F1
F0.00014334862385321102
I1
I0
I1
tp44143
sS'possibility,nitric'
p44144
(F1
F0.00014334862385321102
I1
I0
I1
tp44145
sS'collected,on'
p44146
(F1
F0.00014334862385321102
I0
I1
I-1
tp44147
sS'with,orally'
p44148
(F1
F0.00014334862385321102
I1
I0
I1
tp44149
sS'ethopropazine,can'
p44150
(F1
F0.00014334862385321102
I1
I0
I1
tp44151
sS'attenuate,some'
p44152
(F1
F0.00028669724770642203
I0
I2
I-2
tp44153
sS'the,prothrombin'
p44154
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp44155
sS'including,ethacrynic'
p44156
(F1
F0.00014334862385321102
I1
I0
I1
tp44157
sS'valium,and'
p44158
(F1
F0.00014334862385321102
I1
I0
I1
tp44159
sS'several,have'
p44160
(F1
F0.00014334862385321102
I1
I0
I1
tp44161
sS'by,about'
p44162
(F0.75
F0.0008600917431192661
I7
I1
I6
tp44163
sS'requires,tikosyn'
p44164
(F1
F0.00014334862385321102
I1
I0
I1
tp44165
sS'probenecid,given'
p44166
(F1
F0.00014334862385321102
I1
I0
I1
tp44167
sS'arthritis,thyroiditis'
p44168
(F1
F0.00014334862385321102
I1
I0
I1
tp44169
sS'year,monthly'
p44170
(F1
F0.00014334862385321102
I0
I1
I-1
tp44171
sS'depleting,added'
p44172
(F1
F0.00014334862385321102
I0
I1
I-1
tp44173
sS'depression,producing'
p44174
(F1
F0.00014334862385321102
I0
I1
I-1
tp44175
sS'by,during'
p44176
(F1
F0.00014334862385321102
I0
I1
I-1
tp44177
sS'previously,unrecognized'
p44178
(F1
F0.00014334862385321102
I1
I0
I1
tp44179
sS'a,newly'
p44180
(F1
F0.00014334862385321102
I0
I1
I-1
tp44181
sS'misonidazole,protects'
p44182
(F1
F0.00014334862385321102
I1
I0
I1
tp44183
sS'if,these'
p44184
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp44185
sS'lowering,effects'
p44186
(F1
F0.00014334862385321102
I1
I0
I1
tp44187
sS'drugs,metabolized'
p44188
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp44189
sS'results,from'
p44190
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp44191
sS'those,observed'
p44192
(F1
F0.00014334862385321102
I1
I0
I1
tp44193
sS'most,excretion'
p44194
(F1
F0.00014334862385321102
I0
I1
I-1
tp44195
sS'acid,oxolinic'
p44196
(F1
F0.00014334862385321102
I1
I0
I1
tp44197
sS'at,these'
p44198
(F1
F0.00014334862385321102
I1
I0
I1
tp44199
sS'adjuvant,treatment'
p44200
(F1
F0.00014334862385321102
I1
I0
I1
tp44201
sS'results,suggest'
p44202
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp44203
sS'are,contraindicated'
p44204
(F1
F0.00014334862385321102
I1
I0
I1
tp44205
sS'was,preceded'
p44206
(F1
F0.00014334862385321102
I0
I1
I-1
tp44207
sS'to,predict'
p44208
(F1
F0.00014334862385321102
I0
I1
I-1
tp44209
sS'concern,regarding'
p44210
(F1
F0.00014334862385321102
I0
I1
I-1
tp44211
sS'an,solution'
p44212
(F1
F0.00014334862385321102
I0
I1
I-1
tp44213
sS'of,insufficient'
p44214
(F1
F0.00014334862385321102
I1
I0
I1
tp44215
sS'a,manner'
p44216
(F1
F0.00014334862385321102
I0
I1
I-1
tp44217
sS'and,losartan'
p44218
(F1
F0.00014334862385321102
I0
I1
I-1
tp44219
sS'the,cyp3a4'
p44220
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp44221
sS'trileptal,greater'
p44222
(F1
F0.00014334862385321102
I1
I0
I1
tp44223
sS'unbound,to'
p44224
(F1
F0.00014334862385321102
I0
I1
I-1
tp44225
sS'cell,permeability'
p44226
(F1
F0.00014334862385321102
I0
I1
I-1
tp44227
sS'levels,resulting'
p44228
(F1
F0.00014334862385321102
I1
I0
I1
tp44229
sS'anesthetics,sedatives'
p44230
(F1
F0.00014334862385321102
I1
I0
I1
tp44231
sS'potassium-sparing,with'
p44232
(F1
F0.00014334862385321102
I1
I0
I1
tp44233
sS'for,sustiva'
p44234
(F1
F0.00014334862385321102
I0
I1
I-1
tp44235
sS'and,para-aminobenzoic'
p44236
(F1
F0.00014334862385321102
I1
I0
I1
tp44237
sS'including,blood'
p44238
(F1
F0.00014334862385321102
I0
I1
I-1
tp44239
sS'duloxetine,and'
p44240
(F0
F0
I1
I1
I0
tp44241
sS'artery,disease'
p44242
(F1
F0.00014334862385321102
I0
I1
I-1
tp44243
sS'transport,systems'
p44244
(F1
F0.00014334862385321102
I0
I1
I-1
tp44245
sS'refludan,on'
p44246
(F1
F0.00014334862385321102
I0
I1
I-1
tp44247
sS'required,it'
p44248
(F1
F0.00014334862385321102
I1
I0
I1
tp44249
sS'to,control'
p44250
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp44251
sS'required,if'
p44252
(F1
F0.00028669724770642203
I0
I2
I-2
tp44253
sS'was,followed'
p44254
(F1
F0.00014334862385321102
I1
I0
I1
tp44255
sS'interaction,whole'
p44256
(F1
F0.00014334862385321102
I1
I0
I1
tp44257
sS'the,stereoisomers'
p44258
(F1
F0.00014334862385321102
I0
I1
I-1
tp44259
sS'blood,at'
p44260
(F1
F0.00014334862385321102
I0
I1
I-1
tp44261
sS'used,to'
p44262
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp44263
sS'blood-sugar,reducing'
p44264
(F1
F0.00014334862385321102
I1
I0
I1
tp44265
sS'adrenergic,antagonists'
p44266
(F1
F0.00014334862385321102
I1
I0
I1
tp44267
sS'an,unusually'
p44268
(F1
F0.00014334862385321102
I1
I0
I1
tp44269
sS'its,binding'
p44270
(F1
F0.00043004587155963305
I3
I0
I3
tp44271
sS'hormonal,co-administration'
p44272
(F1
F0.00014334862385321102
I1
I0
I1
tp44273
sS'tiagabine,causes'
p44274
(F1
F0.00014334862385321102
I1
I0
I1
tp44275
sS'an,omega-conotoxin'
p44276
(F1
F0.00014334862385321102
I0
I1
I-1
tp44277
sS'fumarate,capsules'
p44278
(F1
F0.00014334862385321102
I0
I1
I-1
tp44279
sS'receiving,antabuse'
p44280
(F1
F0.00014334862385321102
I1
I0
I1
tp44281
sS'contraindications,significant'
p44282
(F1
F0.00014334862385321102
I0
I1
I-1
tp44283
sS'and,non-'
p44284
(F1
F0.00014334862385321102
I1
I0
I1
tp44285
sS'tca,concentrations'
p44286
(F1
F0.00014334862385321102
I1
I0
I1
tp44287
sS'seen,in'
p44288
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp44289
sS'baseline,phenytoin'
p44290
(F1
F0.00014334862385321102
I1
I0
I1
tp44291
sS'alkaloids,should'
p44292
(F1
F0.00014334862385321102
I1
I0
I1
tp44293
sS'cardioactive,compounds'
p44294
(F1
F0.00014334862385321102
I1
I0
I1
tp44295
sS'the,enzyme'
p44296
(F0
F0
I1
I1
I0
tp44297
sS'the,cyp3a4-mediated'
p44298
(F1
F0.00014334862385321102
I1
I0
I1
tp44299
sS'because,there'
p44300
(F0.5
F0.00028669724770642203
I3
I1
I2
tp44301
sS'using,this'
p44302
(F1
F0.00014334862385321102
I0
I1
I-1
tp44303
sS'best,tool'
p44304
(F1
F0.00014334862385321102
I0
I1
I-1
tp44305
sS'for,plasma'
p44306
(F1
F0.00014334862385321102
I0
I1
I-1
tp44307
sS'erythromycin,co-administration'
p44308
(F1
F0.00014334862385321102
I0
I1
I-1
tp44309
sS'elements,were'
p44310
(F1
F0.00014334862385321102
I0
I1
I-1
tp44311
sS'post-marketing,observations'
p44312
(F1
F0.00043004587155963305
I3
I0
I3
tp44313
sS'to,maximize'
p44314
(F1
F0.00014334862385321102
I0
I1
I-1
tp44315
sS'metabolic,disturbances'
p44316
(F1
F0.00014334862385321102
I0
I1
I-1
tp44317
sS'to,treated'
p44318
(F1
F0.00014334862385321102
I0
I1
I-1
tp44319
sS'results,raise'
p44320
(F1
F0.00014334862385321102
I1
I0
I1
tp44321
sS'the,derivative'
p44322
(F1
F0.00014334862385321102
I0
I1
I-1
tp44323
sS'laboratory,assessments'
p44324
(F1
F0.00014334862385321102
I0
I1
I-1
tp44325
sS'serum,reverse'
p44326
(F1
F0.00014334862385321102
I0
I1
I-1
tp44327
sS'confusional,states'
p44328
(F1
F0.00014334862385321102
I1
I0
I1
tp44329
sS'trial,that'
p44330
(F1
F0.00014334862385321102
I0
I1
I-1
tp44331
sS'failure,post-myocardial'
p44332
(F1
F0.00014334862385321102
I0
I1
I-1
tp44333
sS'not,enhance'
p44334
(F0
F0
I1
I1
I0
tp44335
sS'kerastick,for'
p44336
(F1
F0.00014334862385321102
I1
I0
I1
tp44337
sS'colonic,transit-enhancing'
p44338
(F1
F0.00014334862385321102
I0
I1
I-1
tp44339
sS'anticoagulants,interaction'
p44340
(F1
F0.00028669724770642203
I0
I2
I-2
tp44341
sS'evaluated,these'
p44342
(F1
F0.00014334862385321102
I0
I1
I-1
tp44343
sS'radiolabeled,ions'
p44344
(F1
F0.00014334862385321102
I0
I1
I-1
tp44345
sS'patients,if'
p44346
(F1
F0.00014334862385321102
I1
I0
I1
tp44347
sS'stopped,to'
p44348
(F1
F0.00014334862385321102
I1
I0
I1
tp44349
sS'patients,in'
p44350
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp44351
sS'of,tolerance'
p44352
(F0
F0
I1
I1
I0
tp44353
sS'therapeutic,doses'
p44354
(F0
F0
I2
I2
I0
tp44355
sS'a,regimen'
p44356
(F1
F0.00057339449541284407
I4
I0
I4
tp44357
sS'were,homozygous'
p44358
(F1
F0.00014334862385321102
I0
I1
I-1
tp44359
sS'assessments,of'
p44360
(F1
F0.00014334862385321102
I0
I1
I-1
tp44361
sS'the,sum'
p44362
(F1
F0.00014334862385321102
I0
I1
I-1
tp44363
sS'steady-state,epoxide'
p44364
(F1
F0.00014334862385321102
I1
I0
I1
tp44365
sS'steady-state,trough'
p44366
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp44367
sS'predominantly,metabolized'
p44368
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44369
sS'antagonism,has'
p44370
(F1
F0.00028669724770642203
I2
I0
I2
tp44371
sS'studied,in'
p44372
(F0.8571428571428571
F0.0017201834862385322
I1
I13
I-12
tp44373
sS'have,their'
p44374
(F0
F0
I2
I2
I0
tp44375
sS'substrates,known'
p44376
(F1
F0.00014334862385321102
I1
I0
I1
tp44377
sS'the,signs'
p44378
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp44379
sS'slightly,the'
p44380
(F1
F0.00014334862385321102
I1
I0
I1
tp44381
sS'that,mesylate'
p44382
(F1
F0.00014334862385321102
I0
I1
I-1
tp44383
sS'relaxing,effect'
p44384
(F1
F0.00014334862385321102
I1
I0
I1
tp44385
sS'mean,additional'
p44386
(F1
F0.00014334862385321102
I1
I0
I1
tp44387
sS'humans,remain'
p44388
(F1
F0.00014334862385321102
I0
I1
I-1
tp44389
sS'differential-reinforcement,of-low'
p44390
(F1
F0.00014334862385321102
I0
I1
I-1
tp44391
sS'deterioration,of'
p44392
(F1
F0.00028669724770642203
I2
I0
I2
tp44393
sS'cumulative,incidence'
p44394
(F1
F0.00014334862385321102
I0
I1
I-1
tp44395
sS'nelfinavir,steady-state'
p44396
(F1
F0.00014334862385321102
I1
I0
I1
tp44397
sS'excessive,effects'
p44398
(F1
F0.00014334862385321102
I1
I0
I1
tp44399
sS'altered,to'
p44400
(F1
F0.00014334862385321102
I0
I1
I-1
tp44401
sS'was,ng'
p44402
(F1
F0.00014334862385321102
I1
I0
I1
tp44403
sS'where,and'
p44404
(F1
F0.00014334862385321102
I0
I1
I-1
tp44405
sS'was,no'
p44406
(F0.75
F0.0017201834862385322
I2
I14
I-12
tp44407
sS'might,have'
p44408
(F1
F0.00014334862385321102
I0
I1
I-1
tp44409
sS'for,active'
p44410
(F0
F0
I1
I1
I0
tp44411
sS'pt,and'
p44412
(F0
F0
I1
I1
I0
tp44413
sS'weekly,doses'
p44414
(F1
F0.00014334862385321102
I0
I1
I-1
tp44415
sS'can,potentially'
p44416
(F1
F0.00014334862385321102
I1
I0
I1
tp44417
sS'nnrti-based,regimens'
p44418
(F1
F0.00014334862385321102
I0
I1
I-1
tp44419
sS'or,preanesthetic'
p44420
(F1
F0.00014334862385321102
I0
I1
I-1
tp44421
sS'or,concurrently'
p44422
(F1
F0.00028669724770642203
I2
I0
I2
tp44423
sS'dose,once'
p44424
(F1
F0.00014334862385321102
I0
I1
I-1
tp44425
sS'in,cell'
p44426
(F1
F0.00014334862385321102
I1
I0
I1
tp44427
sS'drug,combinations'
p44428
(F1
F0.00014334862385321102
I0
I1
I-1
tp44429
sS'neuropathy,or'
p44430
(F0
F0
I1
I1
I0
tp44431
sS'a,pharmacodynamic'
p44432
(F1
F0.00014334862385321102
I1
I0
I1
tp44433
sS'azoles,are'
p44434
(F1
F0.00014334862385321102
I0
I1
I-1
tp44435
sS'enzyme,system'
p44436
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp44437
sS'excretion,seen'
p44438
(F1
F0.00014334862385321102
I1
I0
I1
tp44439
sS'after,the'
p44440
(F0.5
F0.0008600917431192661
I9
I3
I6
tp44441
sS'was,between'
p44442
(F1
F0.00014334862385321102
I0
I1
I-1
tp44443
sS'include,medications'
p44444
(F1
F0.00014334862385321102
I0
I1
I-1
tp44445
sS'patients,anaesthetised'
p44446
(F1
F0.00014334862385321102
I1
I0
I1
tp44447
sS'even,clozapine'
p44448
(F1
F0.00014334862385321102
I0
I1
I-1
tp44449
sS'analgesics,agonist'
p44450
(F1
F0.00014334862385321102
I1
I0
I1
tp44451
sS'increases,gastrointestinal'
p44452
(F1
F0.00014334862385321102
I1
I0
I1
tp44453
sS'high-dose,a'
p44454
(F1
F0.00014334862385321102
I1
I0
I1
tp44455
sS'clinical,course'
p44456
(F1
F0.00014334862385321102
I0
I1
I-1
tp44457
sS'mic,of'
p44458
(F1
F0.00014334862385321102
I0
I1
I-1
tp44459
sS'lowest,possible'
p44460
(F1
F0.00014334862385321102
I1
I0
I1
tp44461
sS'p450,enzyme-inducer'
p44462
(F1
F0.00014334862385321102
I1
I0
I1
tp44463
sS'channel,blockers'
p44464
(F0.36842105263157893
F0.0010034403669724771
I13
I6
I7
tp44465
sS'disorders,has'
p44466
(F1
F0.00014334862385321102
I1
I0
I1
tp44467
sS'mc,decreases'
p44468
(F1
F0.00014334862385321102
I0
I1
I-1
tp44469
sS'and,zidovudine'
p44470
(F1
F0.00014334862385321102
I1
I0
I1
tp44471
sS'certain,tcas'
p44472
(F1
F0.00014334862385321102
I1
I0
I1
tp44473
sS'aminoglycoside,are'
p44474
(F1
F0.00014334862385321102
I1
I0
I1
tp44475
sS'orencia,and'
p44476
(F1
F0.00014334862385321102
I1
I0
I1
tp44477
sS'glatiramer,acetate'
p44478
(F1
F0.00014334862385321102
I0
I1
I-1
tp44479
sS'these,would'
p44480
(F0
F0
I1
I1
I0
tp44481
sS'data,show'
p44482
(F1
F0.00014334862385321102
I1
I0
I1
tp44483
sS'complications,careful'
p44484
(F1
F0.00014334862385321102
I0
I1
I-1
tp44485
sS'subjects,receiving'
p44486
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp44487
sS'oral,contraceptives'
p44488
(F0.77777777777777779
F0.0010034403669724771
I1
I8
I-7
tp44489
sS'of,several'
p44490
(F0
F0
I1
I1
I0
tp44491
sS'of,clinically'
p44492
(F1
F0.0008600917431192661
I0
I6
I-6
tp44493
sS'magnesium-aluminum,hydroxide'
p44494
(F1
F0.00014334862385321102
I0
I1
I-1
tp44495
sS'receiving,vioxx'
p44496
(F1
F0.00014334862385321102
I1
I0
I1
tp44497
sS'tolerance,allowing'
p44498
(F1
F0.00014334862385321102
I0
I1
I-1
tp44499
sS'antiparkinsonian,agents'
p44500
(F1
F0.00014334862385321102
I1
I0
I1
tp44501
sS'considered,to'
p44502
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp44503
sS'of,prothrombin'
p44504
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp44505
sS'the,reports'
p44506
(F1
F0.00014334862385321102
I1
I0
I1
tp44507
sS'as,antiparkinson'
p44508
(F1
F0.00014334862385321102
I1
I0
I1
tp44509
sS'synergistic,effect'
p44510
(F1
F0.00014334862385321102
I1
I0
I1
tp44511
sS'more,specific'
p44512
(F1
F0.00028669724770642203
I0
I2
I-2
tp44513
sS'a4,to'
p44514
(F1
F0.00014334862385321102
I0
I1
I-1
tp44515
sS'stimulus-induced,neural'
p44516
(F1
F0.00014334862385321102
I0
I1
I-1
tp44517
sS'antihistamines,contraindicated'
p44518
(F1
F0.00014334862385321102
I0
I1
I-1
tp44519
sS'from,nerves'
p44520
(F1
F0.00014334862385321102
I0
I1
I-1
tp44521
sS'itraconazole,enhances'
p44522
(F1
F0.00014334862385321102
I1
I0
I1
tp44523
sS'the,depression'
p44524
(F1
F0.00028669724770642203
I2
I0
I2
tp44525
sS'its,metabolism'
p44526
(F0
F0
I1
I1
I0
tp44527
sS'inhalational,muscle'
p44528
(F1
F0.00014334862385321102
I0
I1
I-1
tp44529
sS'conversion,from'
p44530
(F1
F0.00014334862385321102
I0
I1
I-1
tp44531
sS'furthermore,and'
p44532
(F0
F0
I1
I1
I0
tp44533
sS'urate,are'
p44534
(F1
F0.00014334862385321102
I1
I0
I1
tp44535
sS'or,toxicity'
p44536
(F1
F0.00014334862385321102
I0
I1
I-1
tp44537
sS'much,in'
p44538
(F0
F0
I1
I1
I0
tp44539
sS'rate,in'
p44540
(F1
F0.00014334862385321102
I0
I1
I-1
tp44541
sS'these,enzymes'
p44542
(F1
F0.00014334862385321102
I0
I1
I-1
tp44543
sS'signalled-unsignalled,differential-reinforcement'
p44544
(F1
F0.00014334862385321102
I0
I1
I-1
tp44545
sS'nevirapine-,or'
p44546
(F1
F0.00014334862385321102
I0
I1
I-1
tp44547
sS'used,on'
p44548
(F1
F0.00014334862385321102
I0
I1
I-1
tp44549
sS'therapy,see'
p44550
(F1
F0.00014334862385321102
I0
I1
I-1
tp44551
sS'rheumatic,disease'
p44552
(F1
F0.00014334862385321102
I1
I0
I1
tp44553
sS'giving,superimposed'
p44554
(F1
F0.00014334862385321102
I0
I1
I-1
tp44555
sS'predispose,to'
p44556
(F1
F0.00014334862385321102
I0
I1
I-1
tp44557
sS'this,therapy'
p44558
(F1
F0.00014334862385321102
I0
I1
I-1
tp44559
sS'the,reduced'
p44560
(F1
F0.00043004587155963305
I0
I3
I-3
tp44561
sS'necrolysis,has'
p44562
(F1
F0.00014334862385321102
I0
I1
I-1
tp44563
sS'and,august'
p44564
(F1
F0.00014334862385321102
I0
I1
I-1
tp44565
sS'coumarin,type'
p44566
(F1
F0.00014334862385321102
I0
I1
I-1
tp44567
sS'the,cns-impairing'
p44568
(F1
F0.00014334862385321102
I1
I0
I1
tp44569
sS'qtc,intervals'
p44570
(F1
F0.00014334862385321102
I0
I1
I-1
tp44571
sS'maintain,levels'
p44572
(F1
F0.00014334862385321102
I1
I0
I1
tp44573
sS'by,interaction'
p44574
(F1
F0.00014334862385321102
I1
I0
I1
tp44575
sS'before,use'
p44576
(F1
F0.00028669724770642203
I2
I0
I2
tp44577
sS'angina,patients'
p44578
(F1
F0.00014334862385321102
I0
I1
I-1
tp44579
sS'of,interference'
p44580
(F1
F0.00014334862385321102
I0
I1
I-1
tp44581
sS'patients,combined'
p44582
(F1
F0.00014334862385321102
I1
I0
I1
tp44583
sS'downward,dose'
p44584
(F1
F0.00014334862385321102
I1
I0
I1
tp44585
sS'support,the'
p44586
(F1
F0.00028669724770642203
I0
I2
I-2
tp44587
sS'of,sn38'
p44588
(F1
F0.00014334862385321102
I0
I1
I-1
tp44589
sS'phenobarbital,toxicity'
p44590
(F1
F0.00014334862385321102
I1
I0
I1
tp44591
sS'mg,combined'
p44592
(F1
F0.00014334862385321102
I1
I0
I1
tp44593
sS'oral,antifungal'
p44594
(F1
F0.00014334862385321102
I1
I0
I1
tp44595
sS'constellation,of'
p44596
(F1
F0.00014334862385321102
I1
I0
I1
tp44597
sS'serial,measurement'
p44598
(F1
F0.00014334862385321102
I1
I0
I1
tp44599
sS'inducers,that'
p44600
(F1
F0.00014334862385321102
I1
I0
I1
tp44601
sS'dose,had'
p44602
(F1
F0.00043004587155963305
I0
I3
I-3
tp44603
sS'with,coronary'
p44604
(F1
F0.00014334862385321102
I0
I1
I-1
tp44605
sS'evaluated,the'
p44606
(F1
F0.00014334862385321102
I0
I1
I-1
tp44607
sS'prescribers,should'
p44608
(F1
F0.00014334862385321102
I0
I1
I-1
tp44609
sS'a,plasma'
p44610
(F1
F0.00014334862385321102
I0
I1
I-1
tp44611
sS'dose,when'
p44612
(F1
F0.00028669724770642203
I2
I0
I2
tp44613
sS'cyp2d6,cyp2e1'
p44614
(F1
F0.00057339449541284407
I0
I4
I-4
tp44615
sS'trials,patients'
p44616
(F1
F0.00028669724770642203
I0
I2
I-2
tp44617
sS'who,are'
p44618
(F0.69999999999999996
F0.0020068807339449542
I17
I3
I14
tp44619
sS'short,s'
p44620
(F1
F0.00014334862385321102
I0
I1
I-1
tp44621
sS'antibiotics,in'
p44622
(F1
F0.00014334862385321102
I1
I0
I1
tp44623
sS'of,maalox'
p44624
(F1
F0.00014334862385321102
I0
I1
I-1
tp44625
sS'receiving,n'
p44626
(F1
F0.00014334862385321102
I0
I1
I-1
tp44627
sS'mixed-function,mono-oxidases'
p44628
(F1
F0.00014334862385321102
I0
I1
I-1
tp44629
sS'studies,have'
p44630
(F0.13333333333333333
F0.00057339449541284407
I13
I17
I-4
tp44631
sS'the,concurrent'
p44632
(F0.16666666666666666
F0.00028669724770642203
I7
I5
I2
tp44633
sS'acetate,x'
p44634
(F1
F0.00014334862385321102
I1
I0
I1
tp44635
sS'eprosartan,doses'
p44636
(F1
F0.00014334862385321102
I0
I1
I-1
tp44637
sS'saquinavir,coadministration'
p44638
(F1
F0.00014334862385321102
I1
I0
I1
tp44639
sS'of,indications'
p44640
(F1
F0.00014334862385321102
I0
I1
I-1
tp44641
sS'require,lower'
p44642
(F1
F0.0010034403669724771
I0
I7
I-7
tp44643
sS'a,one-week'
p44644
(F1
F0.00014334862385321102
I1
I0
I1
tp44645
sS'lithium,carbonate'
p44646
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44647
sS'enhanced,bone'
p44648
(F1
F0.00014334862385321102
I1
I0
I1
tp44649
sS'receive,adl'
p44650
(F1
F0.00014334862385321102
I0
I1
I-1
tp44651
sS'dose,was'
p44652
(F1
F0.00014334862385321102
I0
I1
I-1
tp44653
sS'containing,iodine-containing'
p44654
(F1
F0.00014334862385321102
I0
I1
I-1
tp44655
sS'at,receptors'
p44656
(F1
F0.00014334862385321102
I1
I0
I1
tp44657
sS'clinically,because'
p44658
(F1
F0.00014334862385321102
I0
I1
I-1
tp44659
sS'weight,was'
p44660
(F0
F0
I1
I1
I0
tp44661
sS'mhd,induce'
p44662
(F1
F0.00014334862385321102
I0
I1
I-1
tp44663
sS'the,locomotor'
p44664
(F1
F0.00014334862385321102
I0
I1
I-1
tp44665
sS'somatropin,excessive'
p44666
(F1
F0.00014334862385321102
I0
I1
I-1
tp44667
sS'which,ssri-tcainteractions'
p44668
(F1
F0.00014334862385321102
I1
I0
I1
tp44669
sS'administration,mg'
p44670
(F1
F0.00014334862385321102
I0
I1
I-1
tp44671
sS'half,the'
p44672
(F1
F0.00014334862385321102
I1
I0
I1
tp44673
sS'digoxin,enoxacin'
p44674
(F1
F0.00014334862385321102
I1
I0
I1
tp44675
sS'times,with'
p44676
(F1
F0.00014334862385321102
I1
I0
I1
tp44677
sS'or,caused'
p44678
(F1
F0.00014334862385321102
I0
I1
I-1
tp44679
sS'generally,should'
p44680
(F1
F0.00071674311926605509
I5
I0
I5
tp44681
sS'other,centrally'
p44682
(F1
F0.00028669724770642203
I2
I0
I2
tp44683
sS'these,doses'
p44684
(F1
F0.00014334862385321102
I1
I0
I1
tp44685
sS'drugs,aripiprazole'
p44686
(F1
F0.00014334862385321102
I0
I1
I-1
tp44687
sS'with,diabetes'
p44688
(F1
F0.00014334862385321102
I0
I1
I-1
tp44689
sS'of,hypotension'
p44690
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp44691
sS'minutes,faster'
p44692
(F1
F0.00014334862385321102
I1
I0
I1
tp44693
sS'antagonist,was'
p44694
(F1
F0.00014334862385321102
I1
I0
I1
tp44695
sS'two,or'
p44696
(F1
F0.00014334862385321102
I1
I0
I1
tp44697
sS'cmi,has'
p44698
(F1
F0.00028669724770642203
I2
I0
I2
tp44699
sS'inducers,or'
p44700
(F1
F0.00014334862385321102
I0
I1
I-1
tp44701
sS'two,of'
p44702
(F1
F0.00028669724770642203
I2
I0
I2
tp44703
sS'of,taxol'
p44704
(F0
F0
I1
I1
I0
tp44705
sS'over,use'
p44706
(F1
F0.00014334862385321102
I1
I0
I1
tp44707
sS'without,altering'
p44708
(F1
F0.00014334862385321102
I1
I0
I1
tp44709
sS'dose,followed'
p44710
(F1
F0.00014334862385321102
I1
I0
I1
tp44711
sS'responsible,for'
p44712
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp44713
sS'be,combined'
p44714
(F1
F0.00028669724770642203
I2
I0
I2
tp44715
sS'with,invirase'
p44716
(F1
F0.00014334862385321102
I0
I1
I-1
tp44717
sS'exceed,a'
p44718
(F1
F0.0008600917431192661
I6
I0
I6
tp44719
sS'concentration,of'
p44720
(F0.38461538461538464
F0.0014334862385321102
I18
I8
I10
tp44721
sS'isoflurane,or'
p44722
(F1
F0.00014334862385321102
I1
I0
I1
tp44723
sS'a4,isoenzyme'
p44724
(F1
F0.00014334862385321102
I0
I1
I-1
tp44725
sS'of,cmax'
p44726
(F1
F0.00028669724770642203
I0
I2
I-2
tp44727
sS'induction,or'
p44728
(F1
F0.00014334862385321102
I0
I1
I-1
tp44729
sS'anticoagulant,activity'
p44730
(F1
F0.00014334862385321102
I1
I0
I1
tp44731
sS'peritoneal,metastasis'
p44732
(F0
F0
I1
I1
I0
tp44733
sS's-,enantiomers'
p44734
(F1
F0.00014334862385321102
I0
I1
I-1
tp44735
sS'of,dose'
p44736
(F1
F0.00014334862385321102
I1
I0
I1
tp44737
sS'endothelial,function'
p44738
(F1
F0.00014334862385321102
I0
I1
I-1
tp44739
sS'and,was'
p44740
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp44741
sS'or,disposition'
p44742
(F1
F0.00014334862385321102
I0
I1
I-1
tp44743
sS'with,against'
p44744
(F0
F0
I1
I1
I0
tp44745
sS'symptoms,termed'
p44746
(F1
F0.00014334862385321102
I1
I0
I1
tp44747
sS'on,discrimination'
p44748
(F1
F0.00014334862385321102
I0
I1
I-1
tp44749
sS'injection,of'
p44750
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp44751
sS'during,use'
p44752
(F1
F0.00014334862385321102
I0
I1
I-1
tp44753
sS'slowly,dissolving'
p44754
(F1
F0.00014334862385321102
I1
I0
I1
tp44755
sS'a,gritty'
p44756
(F1
F0.00014334862385321102
I1
I0
I1
tp44757
sS'and,pharmacologic'
p44758
(F1
F0.00014334862385321102
I0
I1
I-1
tp44759
sS'alone,has'
p44760
(F1
F0.00014334862385321102
I1
I0
I1
tp44761
sS'efficacy,is'
p44762
(F1
F0.00043004587155963305
I3
I0
I3
tp44763
sS'magnesium,aluminum-containing'
p44764
(F1
F0.00014334862385321102
I0
I1
I-1
tp44765
sS'therefore,no'
p44766
(F1
F0.00014334862385321102
I0
I1
I-1
tp44767
sS'alone,had'
p44768
(F1
F0.00028669724770642203
I2
I0
I2
tp44769
sS'received,mg'
p44770
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp44771
sS'ia,such'
p44772
(F1
F0.00014334862385321102
I1
I0
I1
tp44773
sS'such,as'
p44774
(F0.25
F0.0054472477064220187
I95
I57
I38
tp44775
sS'produce,false'
p44776
(F1
F0.00028669724770642203
I0
I2
I-2
tp44777
sS'cocaine-induced,increases'
p44778
(F1
F0.00014334862385321102
I1
I0
I1
tp44779
sS'were,agonists'
p44780
(F1
F0.00014334862385321102
I1
I0
I1
tp44781
sS'd,had'
p44782
(F1
F0.00014334862385321102
I0
I1
I-1
tp44783
sS'potential,that'
p44784
(F1
F0.00014334862385321102
I0
I1
I-1
tp44785
sS'in,serious'
p44786
(F1
F0.00014334862385321102
I0
I1
I-1
tp44787
sS'with,slow-release'
p44788
(F1
F0.00014334862385321102
I0
I1
I-1
tp44789
sS'cyclosporine,combination'
p44790
(F1
F0.00014334862385321102
I1
I0
I1
tp44791
sS'toxicologic,and'
p44792
(F1
F0.00014334862385321102
I0
I1
I-1
tp44793
sS'phenytoin,amphetamines'
p44794
(F1
F0.00028669724770642203
I2
I0
I2
tp44795
sS'cremophor,el'
p44796
(F1
F0.00014334862385321102
I1
I0
I1
tp44797
sS'choline,trilisate'
p44798
(F1
F0.00014334862385321102
I1
I0
I1
tp44799
sS'administered,mg'
p44800
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp44801
sS'active,phosphorylated'
p44802
(F1
F0.00014334862385321102
I1
I0
I1
tp44803
sS'gastroduodenal,ulcers'
p44804
(F1
F0.00014334862385321102
I0
I1
I-1
tp44805
sS'however,co-administration'
p44806
(F1
F0.00014334862385321102
I0
I1
I-1
tp44807
sS'l,to'
p44808
(F1
F0.00014334862385321102
I1
I0
I1
tp44809
sS'or,oral'
p44810
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp44811
sS'other,medicines'
p44812
(F1
F0.00014334862385321102
I1
I0
I1
tp44813
sS'the,deaths'
p44814
(F1
F0.00014334862385321102
I0
I1
I-1
tp44815
sS'factors,studied'
p44816
(F1
F0.00014334862385321102
I1
I0
I1
tp44817
sS'a,four-session'
p44818
(F1
F0.00014334862385321102
I0
I1
I-1
tp44819
sS'l-tryptophan,may'
p44820
(F1
F0.00014334862385321102
I0
I1
I-1
tp44821
sS'studied,alternative'
p44822
(F1
F0.00014334862385321102
I1
I0
I1
tp44823
sS'aggregation,and'
p44824
(F1
F0.00014334862385321102
I0
I1
I-1
tp44825
sS'protective,effect'
p44826
(F1
F0.00014334862385321102
I1
I0
I1
tp44827
sS'approximate,decrease'
p44828
(F1
F0.00057339449541284407
I4
I0
I4
tp44829
sS'mepron,suspension'
p44830
(F1
F0.00014334862385321102
I1
I0
I1
tp44831
sS'incompatible,with'
p44832
(F1
F0.00014334862385321102
I0
I1
I-1
tp44833
sS'small,groups'
p44834
(F1
F0.00014334862385321102
I0
I1
I-1
tp44835
sS'estrogen,oral'
p44836
(F1
F0.00014334862385321102
I0
I1
I-1
tp44837
sS'inhibitor,due'
p44838
(F1
F0.00014334862385321102
I0
I1
I-1
tp44839
sS'with,phenyl-butazone'
p44840
(F1
F0.00014334862385321102
I0
I1
I-1
tp44841
sS'receiving,beta-adrenergic'
p44842
(F1
F0.00028669724770642203
I2
I0
I2
tp44843
sS'and,molt-4'
p44844
(F1
F0.00014334862385321102
I1
I0
I1
tp44845
sS'cellular,uptake'
p44846
(F1
F0.00014334862385321102
I1
I0
I1
tp44847
sS'function,as'
p44848
(F0
F0
I2
I2
I0
tp44849
sS'tylenol,with'
p44850
(F1
F0.00014334862385321102
I1
I0
I1
tp44851
sS'antagonized,by'
p44852
(F0.5
F0.00028669724770642203
I3
I1
I2
tp44853
sS'iressa,and'
p44854
(F1
F0.00028669724770642203
I2
I0
I2
tp44855
sS'pharmacokinetic,analyses'
p44856
(F0.5
F0.00028669724770642203
I3
I1
I2
tp44857
sS'and,intravenous'
p44858
(F0
F0
I3
I3
I0
tp44859
sS'reports,describing'
p44860
(F1
F0.00014334862385321102
I1
I0
I1
tp44861
sS'eprosartan,up'
p44862
(F1
F0.00014334862385321102
I0
I1
I-1
tp44863
sS'orudis,kt'
p44864
(F1
F0.00014334862385321102
I0
I1
I-1
tp44865
sS'after,overload'
p44866
(F1
F0.00014334862385321102
I0
I1
I-1
tp44867
sS'any,effect'
p44868
(F1
F0.00043004587155963305
I0
I3
I-3
tp44869
sS'not,by'
p44870
(F1
F0.00028669724770642203
I2
I0
I2
tp44871
sS'animals,dosed'
p44872
(F1
F0.00014334862385321102
I0
I1
I-1
tp44873
sS'block,contortrostatin-induced'
p44874
(F1
F0.00014334862385321102
I1
I0
I1
tp44875
sS'secondary,actions'
p44876
(F1
F0.00014334862385321102
I1
I0
I1
tp44877
sS'or,glycoprotein'
p44878
(F1
F0.00014334862385321102
I1
I0
I1
tp44879
sS'in,death'
p44880
(F1
F0.00014334862385321102
I1
I0
I1
tp44881
sS'voltage-dependent,ca'
p44882
(F1
F0.00028669724770642203
I0
I2
I-2
tp44883
sS'of,endotoxin-induced'
p44884
(F1
F0.00014334862385321102
I1
I0
I1
tp44885
sS'not,be'
p44886
(F0.69999999999999996
F0.008027522935779817
I68
I12
I56
tp44887
sS'no,experience'
p44888
(F1
F0.00014334862385321102
I0
I1
I-1
tp44889
sS'acute,myocardial'
p44890
(F1
F0.00028669724770642203
I0
I2
I-2
tp44891
sS'agents,nitrogen'
p44892
(F1
F0.00014334862385321102
I0
I1
I-1
tp44893
sS'of,protease'
p44894
(F1
F0.00014334862385321102
I0
I1
I-1
tp44895
sS'its,acid'
p44896
(F1
F0.00014334862385321102
I0
I1
I-1
tp44897
sS'with,healthy'
p44898
(F1
F0.00014334862385321102
I0
I1
I-1
tp44899
sS'of,gabitril'
p44900
(F1
F0.00043004587155963305
I0
I3
I-3
tp44901
sS'by,cyp1a2'
p44902
(F1
F0.00014334862385321102
I0
I1
I-1
tp44903
sS'for,p-glycoprotein'
p44904
(F1
F0.00014334862385321102
I0
I1
I-1
tp44905
sS'since,exhibits'
p44906
(F1
F0.00014334862385321102
I1
I0
I1
tp44907
sS'the,body'
p44908
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp44909
sS'their,usual'
p44910
(F1
F0.00014334862385321102
I1
I0
I1
tp44911
sS'vehicle,or'
p44912
(F1
F0.00014334862385321102
I1
I0
I1
tp44913
sS'smooth,muscle'
p44914
(F1
F0.00014334862385321102
I0
I1
I-1
tp44915
sS'the,phosphohydrolase'
p44916
(F1
F0.00014334862385321102
I0
I1
I-1
tp44917
sS'of,particular'
p44918
(F1
F0.00014334862385321102
I1
I0
I1
tp44919
sS'serum,txb2'
p44920
(F1
F0.00014334862385321102
I0
I1
I-1
tp44921
sS'know,how'
p44922
(F1
F0.00014334862385321102
I0
I1
I-1
tp44923
sS'receiving,resulted'
p44924
(F1
F0.00014334862385321102
I0
I1
I-1
tp44925
sS'following,an'
p44926
(F1
F0.00014334862385321102
I1
I0
I1
tp44927
sS'upon,combination'
p44928
(F1
F0.00014334862385321102
I1
I0
I1
tp44929
sS'cause,an'
p44930
(F1
F0.00043004587155963305
I3
I0
I3
tp44931
sS'in,anhydrous'
p44932
(F1
F0.00014334862385321102
I1
I0
I1
tp44933
sS'as,sole'
p44934
(F1
F0.00014334862385321102
I0
I1
I-1
tp44935
sS'isozymes,are'
p44936
(F1
F0.00014334862385321102
I0
I1
I-1
tp44937
sS'patients,demonstrated'
p44938
(F0
F0
I1
I1
I0
tp44939
sS'combination,has'
p44940
(F1
F0.00014334862385321102
I1
I0
I1
tp44941
sS'vitro,antiviral'
p44942
(F1
F0.00014334862385321102
I1
I0
I1
tp44943
sS'agents,calcium'
p44944
(F1
F0.00014334862385321102
I0
I1
I-1
tp44945
sS'weight,for'
p44946
(F1
F0.00014334862385321102
I0
I1
I-1
tp44947
sS'because,competitively'
p44948
(F1
F0.00014334862385321102
I1
I0
I1
tp44949
sS'or,hours'
p44950
(F1
F0.0011467889908256881
I8
I0
I8
tp44951
sS'paba,containing'
p44952
(F1
F0.00014334862385321102
I1
I0
I1
tp44953
sS'concentrations,when'
p44954
(F0
F0
I2
I2
I0
tp44955
sS'and,triglycerides'
p44956
(F1
F0.00014334862385321102
I1
I0
I1
tp44957
sS'week,course'
p44958
(F1
F0.00043004587155963305
I3
I0
I3
tp44959
sS'or,duloxetine'
p44960
(F1
F0.00014334862385321102
I0
I1
I-1
tp44961
sS'hypoglycemia,have'
p44962
(F1
F0.00014334862385321102
I1
I0
I1
tp44963
sS'a,water'
p44964
(F1
F0.00014334862385321102
I0
I1
I-1
tp44965
sS'daily,given'
p44966
(F1
F0.00014334862385321102
I1
I0
I1
tp44967
sS'must,not'
p44968
(F1
F0.00028669724770642203
I2
I0
I2
tp44969
sS'containing,divalent'
p44970
(F1
F0.00028669724770642203
I2
I0
I2
tp44971
sS'in,pharmacokinetic'
p44972
(F1
F0.00014334862385321102
I0
I1
I-1
tp44973
sS'sparing,such'
p44974
(F1
F0.00014334862385321102
I1
I0
I1
tp44975
sS'addition,deaths'
p44976
(F1
F0.00014334862385321102
I1
I0
I1
tp44977
sS'and,significantly'
p44978
(F1
F0.00057339449541284407
I4
I0
I4
tp44979
sS'live-attenuated,should'
p44980
(F1
F0.00014334862385321102
I1
I0
I1
tp44981
sS'rifampin,when'
p44982
(F1
F0.00014334862385321102
I1
I0
I1
tp44983
sS'viracept,should'
p44984
(F1
F0.00028669724770642203
I2
I0
I2
tp44985
sS'addition,and'
p44986
(F1
F0.00014334862385321102
I0
I1
I-1
tp44987
sS'mitogenic,effect'
p44988
(F1
F0.00014334862385321102
I1
I0
I1
tp44989
sS'multivitamin,preparations'
p44990
(F1
F0.00014334862385321102
I1
I0
I1
tp44991
sS'sulfate,neuromuscular'
p44992
(F1
F0.00014334862385321102
I0
I1
I-1
tp44993
sS'concomitantly,toxicity'
p44994
(F1
F0.00014334862385321102
I1
I0
I1
tp44995
sS'nor,were'
p44996
(F1
F0.00014334862385321102
I0
I1
I-1
tp44997
sS'when,sodium'
p44998
(F1
F0.00014334862385321102
I1
I0
I1
tp44999
sS'coadministering,these'
p45000
(F1
F0.00014334862385321102
I1
I0
I1
tp45001
sS'loratadine,and'
p45002
(F1
F0.00014334862385321102
I0
I1
I-1
tp45003
sS'on,fi'
p45004
(F1
F0.00014334862385321102
I1
I0
I1
tp45005
sS'plasma,renin'
p45006
(F1
F0.00014334862385321102
I0
I1
I-1
tp45007
sS'older,men'
p45008
(F1
F0.00014334862385321102
I0
I1
I-1
tp45009
sS'binding,decrease'
p45010
(F1
F0.00014334862385321102
I1
I0
I1
tp45011
sS'on,felbatol'
p45012
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp45013
sS'medication,may'
p45014
(F1
F0.00014334862385321102
I1
I0
I1
tp45015
sS'time,inr'
p45016
(F1
F0.00014334862385321102
I1
I0
I1
tp45017
sS'have,clinically'
p45018
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp45019
sS'fade,hoof'
p45020
(F1
F0.00014334862385321102
I1
I0
I1
tp45021
sS'then,mg'
p45022
(F1
F0.00014334862385321102
I0
I1
I-1
tp45023
sS'wide,distribution'
p45024
(F1
F0.00014334862385321102
I0
I1
I-1
tp45025
sS'dose,pharmacokinetics'
p45026
(F1
F0.00028669724770642203
I0
I2
I-2
tp45027
sS'epilepsy,also'
p45028
(F1
F0.00014334862385321102
I0
I1
I-1
tp45029
sS'diabetic,patient'
p45030
(F1
F0.00028669724770642203
I2
I0
I2
tp45031
sS'i,binding'
p45032
(F1
F0.00014334862385321102
I0
I1
I-1
tp45033
sS'oral-dose,clearance'
p45034
(F1
F0.00014334862385321102
I1
I0
I1
tp45035
sS'direct,coombs'
p45036
(F1
F0.00014334862385321102
I0
I1
I-1
tp45037
sS'primarily,eliminated'
p45038
(F1
F0.00014334862385321102
I0
I1
I-1
tp45039
sS'doses,from'
p45040
(F1
F0.00014334862385321102
I0
I1
I-1
tp45041
sS'celebrex,is'
p45042
(F0
F0
I1
I1
I0
tp45043
sS'the,drying'
p45044
(F1
F0.00014334862385321102
I1
I0
I1
tp45045
sS'receiving,appeared'
p45046
(F1
F0.00014334862385321102
I1
I0
I1
tp45047
sS'alone,the'
p45048
(F1
F0.00014334862385321102
I1
I0
I1
tp45049
sS'be,active'
p45050
(F1
F0.00014334862385321102
I1
I0
I1
tp45051
sS'differences,were'
p45052
(F1
F0.00057339449541284407
I0
I4
I-4
tp45053
sS'warfarin,a'
p45054
(F1
F0.00014334862385321102
I0
I1
I-1
tp45055
sS'of,cardiac'
p45056
(F1
F0.00028669724770642203
I2
I0
I2
tp45057
sS'be,warned'
p45058
(F1
F0.00014334862385321102
I1
I0
I1
tp45059
sS'conventional,formulation'
p45060
(F1
F0.00014334862385321102
I0
I1
I-1
tp45061
sS'that,resulted'
p45062
(F0
F0
I1
I1
I0
tp45063
sS'and,completely'
p45064
(F1
F0.00014334862385321102
I1
I0
I1
tp45065
sS'assays,using'
p45066
(F1
F0.00014334862385321102
I0
I1
I-1
tp45067
sS'gradual,withdrawal'
p45068
(F1
F0.00014334862385321102
I0
I1
I-1
tp45069
sS'procedures,were'
p45070
(F1
F0.00014334862385321102
I0
I1
I-1
tp45071
sS'for,uptake-1'
p45072
(F1
F0.00014334862385321102
I0
I1
I-1
tp45073
sS'and,citrate'
p45074
(F1
F0.00014334862385321102
I1
I0
I1
tp45075
sS'dose,should'
p45076
(F0.88235294117647056
F0.0021502293577981653
I16
I1
I15
tp45077
sS'of,low'
p45078
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45079
sS'continuously,observed'
p45080
(F1
F0.00014334862385321102
I1
I0
I1
tp45081
sS'the,resulting'
p45082
(F0
F0
I1
I1
I0
tp45083
sS'inhibitor,which'
p45084
(F1
F0.00014334862385321102
I1
I0
I1
tp45085
sS'allergic,reaction'
p45086
(F1
F0.00014334862385321102
I1
I0
I1
tp45087
sS'b,injection'
p45088
(F1
F0.00014334862385321102
I1
I0
I1
tp45089
sS'the,area'
p45090
(F1
F0.0008600917431192661
I6
I0
I6
tp45091
sS'directly,to'
p45092
(F1
F0.00014334862385321102
I0
I1
I-1
tp45093
sS'antibiotics,rifampin'
p45094
(F1
F0.00014334862385321102
I0
I1
I-1
tp45095
sS'cholestographic,agents'
p45096
(F1
F0.00014334862385321102
I0
I1
I-1
tp45097
sS'a,dihydropyridine'
p45098
(F1
F0.00014334862385321102
I0
I1
I-1
tp45099
sS'liver,enzymes'
p45100
(F1
F0.00028669724770642203
I2
I0
I2
tp45101
sS'may,selectively'
p45102
(F1
F0.00014334862385321102
I1
I0
I1
tp45103
sS'non-cyp3a4,substrate'
p45104
(F1
F0.00014334862385321102
I0
I1
I-1
tp45105
sS'as,cough'
p45106
(F1
F0.00014334862385321102
I1
I0
I1
tp45107
sS'not,appear'
p45108
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp45109
sS'a4,may'
p45110
(F0
F0
I1
I1
I0
tp45111
sS'macrolide,inhibit'
p45112
(F1
F0.00014334862385321102
I1
I0
I1
tp45113
sS'concentrations,to'
p45114
(F1
F0.00028669724770642203
I2
I0
I2
tp45115
sS'the,diet'
p45116
(F0
F0
I1
I1
I0
tp45117
sS'as,stadol'
p45118
(F1
F0.00028669724770642203
I0
I2
I-2
tp45119
sS'light,zone'
p45120
(F1
F0.00014334862385321102
I1
I0
I1
tp45121
sS'was,evaluated'
p45122
(F1
F0.0011467889908256881
I0
I8
I-8
tp45123
sS'investigations,into'
p45124
(F1
F0.00014334862385321102
I0
I1
I-1
tp45125
sS'significantly,interfere'
p45126
(F1
F0.00014334862385321102
I0
I1
I-1
tp45127
sS'concentration,may'
p45128
(F1
F0.00014334862385321102
I1
I0
I1
tp45129
sS'if,administered'
p45130
(F1
F0.00014334862385321102
I1
I0
I1
tp45131
sS'absorption,of'
p45132
(F0.65957446808510634
F0.0044438073394495415
I39
I8
I31
tp45133
sS'although,specific'
p45134
(F0
F0
I2
I2
I0
tp45135
sS'was,also'
p45136
(F1
F0.00057339449541284407
I0
I4
I-4
tp45137
sS'significantly,altered'
p45138
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45139
sS'absorption,or'
p45140
(F1
F0.00028669724770642203
I0
I2
I-2
tp45141
sS'plus,without'
p45142
(F1
F0.00014334862385321102
I0
I1
I-1
tp45143
sS'of,nalfon'
p45144
(F1
F0.00043004587155963305
I3
I0
I3
tp45145
sS'when,the'
p45146
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp45147
sS'css,max'
p45148
(F1
F0.00014334862385321102
I1
I0
I1
tp45149
sS'is,rapid'
p45150
(F1
F0.00014334862385321102
I0
I1
I-1
tp45151
sS'above,behavioral'
p45152
(F1
F0.00014334862385321102
I0
I1
I-1
tp45153
sS'sixth,day'
p45154
(F1
F0.00014334862385321102
I1
I0
I1
tp45155
sS'the,training'
p45156
(F1
F0.00014334862385321102
I0
I1
I-1
tp45157
sS'isolated,from'
p45158
(F1
F0.00014334862385321102
I0
I1
I-1
tp45159
sS'subtypes,by'
p45160
(F1
F0.00014334862385321102
I0
I1
I-1
tp45161
sS'neuropathy,during'
p45162
(F1
F0.00014334862385321102
I0
I1
I-1
tp45163
sS'oxidase,inhibiting'
p45164
(F1
F0.00014334862385321102
I1
I0
I1
tp45165
sS'increases,of'
p45166
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45167
sS'this,allows'
p45168
(F1
F0.00014334862385321102
I1
I0
I1
tp45169
sS'of,deaths'
p45170
(F1
F0.00014334862385321102
I0
I1
I-1
tp45171
sS'used,the'
p45172
(F1
F0.00014334862385321102
I1
I0
I1
tp45173
sS'residual,effects'
p45174
(F1
F0.00014334862385321102
I1
I0
I1
tp45175
sS'that,tam'
p45176
(F1
F0.00014334862385321102
I1
I0
I1
tp45177
sS'disintegrating,tablet'
p45178
(F1
F0.00014334862385321102
I1
I0
I1
tp45179
sS'lowering,effect'
p45180
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp45181
sS'and,non-selective'
p45182
(F1
F0.00043004587155963305
I3
I0
I3
tp45183
sS'bph,psa'
p45184
(F1
F0.00014334862385321102
I0
I1
I-1
tp45185
sS'structures,whereas'
p45186
(F1
F0.00014334862385321102
I0
I1
I-1
tp45187
sS'x,m'
p45188
(F1
F0.00028669724770642203
I2
I0
I2
tp45189
sS'spray,the'
p45190
(F1
F0.00014334862385321102
I1
I0
I1
tp45191
sS'x,h'
p45192
(F1
F0.00014334862385321102
I1
I0
I1
tp45193
sS'if,indocin'
p45194
(F1
F0.00014334862385321102
I1
I0
I1
tp45195
sS'increased,ectopic'
p45196
(F1
F0.00014334862385321102
I1
I0
I1
tp45197
sS'by,elevated'
p45198
(F1
F0.00014334862385321102
I1
I0
I1
tp45199
sS'is,thus'
p45200
(F1
F0.00014334862385321102
I1
I0
I1
tp45201
sS'on,decreased'
p45202
(F1
F0.00028669724770642203
I2
I0
I2
tp45203
sS'were,comparable'
p45204
(F1
F0.00014334862385321102
I1
I0
I1
tp45205
sS'is,at'
p45206
(F1
F0.00014334862385321102
I0
I1
I-1
tp45207
sS'order,to'
p45208
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp45209
sS'ip,the'
p45210
(F1
F0.00014334862385321102
I1
I0
I1
tp45211
sS'including,quinolone'
p45212
(F1
F0.00014334862385321102
I1
I0
I1
tp45213
sS'have,in'
p45214
(F1
F0.00014334862385321102
I1
I0
I1
tp45215
sS'to,achieve'
p45216
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp45217
sS'for,documented'
p45218
(F1
F0.00014334862385321102
I0
I1
I-1
tp45219
sS'life-threatening,interactions'
p45220
(F1
F0.00014334862385321102
I1
I0
I1
tp45221
sS'enhances,cocaine-induced'
p45222
(F1
F0.00014334862385321102
I1
I0
I1
tp45223
sS'influenced,the'
p45224
(F1
F0.00014334862385321102
I0
I1
I-1
tp45225
sS'inhibitors,maoi'
p45226
(F1
F0.00057339449541284407
I4
I0
I4
tp45227
sS'tuberculosis,showed'
p45228
(F1
F0.00014334862385321102
I1
I0
I1
tp45229
sS'and,parnate'
p45230
(F1
F0.00014334862385321102
I0
I1
I-1
tp45231
sS'antifungals,in'
p45232
(F1
F0.00014334862385321102
I1
I0
I1
tp45233
sS'nephrotoxic,potential'
p45234
(F1
F0.00014334862385321102
I1
I0
I1
tp45235
sS'in,levels'
p45236
(F0.5
F0.00028669724770642203
I3
I1
I2
tp45237
sS'in,urine'
p45238
(F1
F0.00014334862385321102
I1
I0
I1
tp45239
sS'chemically,modify'
p45240
(F1
F0.00014334862385321102
I0
I1
I-1
tp45241
sS'pletal,is'
p45242
(F1
F0.00014334862385321102
I1
I0
I1
tp45243
sS'dosing,caution'
p45244
(F1
F0.00014334862385321102
I1
I0
I1
tp45245
sS'synergistic,for'
p45246
(F1
F0.00014334862385321102
I1
I0
I1
tp45247
sS'with,eg'
p45248
(F1
F0.00014334862385321102
I0
I1
I-1
tp45249
sS'basis,of'
p45250
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp45251
sS'by,active'
p45252
(F1
F0.00014334862385321102
I1
I0
I1
tp45253
sS'antihistamines,benzodiazepines'
p45254
(F1
F0.00014334862385321102
I0
I1
I-1
tp45255
sS'ptx,m'
p45256
(F1
F0.00014334862385321102
I1
I0
I1
tp45257
sS'containing,mcg'
p45258
(F1
F0.00014334862385321102
I1
I0
I1
tp45259
sS'other,ht1b'
p45260
(F1
F0.00014334862385321102
I1
I0
I1
tp45261
sS'negatively,impacted'
p45262
(F1
F0.00014334862385321102
I0
I1
I-1
tp45263
sS'unknown,whether'
p45264
(F1
F0.00014334862385321102
I0
I1
I-1
tp45265
sS'by,compared'
p45266
(F1
F0.00028669724770642203
I2
I0
I2
tp45267
sS'of,placental'
p45268
(F1
F0.00014334862385321102
I1
I0
I1
tp45269
sS'some,individuals'
p45270
(F1
F0.00014334862385321102
I1
I0
I1
tp45271
sS'etodolac,has'
p45272
(F1
F0.00043004587155963305
I0
I3
I-3
tp45273
sS'other,coadministration'
p45274
(F1
F0.00014334862385321102
I0
I1
I-1
tp45275
sS'hydrochloride,injection'
p45276
(F1
F0.00014334862385321102
I1
I0
I1
tp45277
sS'agonists,concomitant'
p45278
(F1
F0.00014334862385321102
I1
I0
I1
tp45279
sS'both,aldehyde'
p45280
(F1
F0.00014334862385321102
I1
I0
I1
tp45281
sS'all,patients'
p45282
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45283
sS'measured,as'
p45284
(F1
F0.00028669724770642203
I2
I0
I2
tp45285
sS'measured,at'
p45286
(F1
F0.00014334862385321102
I0
I1
I-1
tp45287
sS'brevibloc,but'
p45288
(F1
F0.00014334862385321102
I1
I0
I1
tp45289
sS'for,exjade'
p45290
(F1
F0.00014334862385321102
I1
I0
I1
tp45291
sS'sandimmune,hiv'
p45292
(F1
F0.00014334862385321102
I1
I0
I1
tp45293
sS'or,prolonged'
p45294
(F1
F0.00014334862385321102
I0
I1
I-1
tp45295
sS'but,can'
p45296
(F1
F0.00014334862385321102
I1
I0
I1
tp45297
sS'steroids,enhance'
p45298
(F1
F0.00014334862385321102
I1
I0
I1
tp45299
sS'for,n'
p45300
(F1
F0.00014334862385321102
I1
I0
I1
tp45301
sS'of,reactive'
p45302
(F1
F0.00014334862385321102
I0
I1
I-1
tp45303
sS'for,h'
p45304
(F1
F0.00014334862385321102
I0
I1
I-1
tp45305
sS'for,i'
p45306
(F1
F0.00014334862385321102
I1
I0
I1
tp45307
sS'for,a'
p45308
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp45309
sS'tricky,using'
p45310
(F1
F0.00014334862385321102
I0
I1
I-1
tp45311
sS'with,active'
p45312
(F1
F0.00028669724770642203
I2
I0
I2
tp45313
sS'oral,as'
p45314
(F1
F0.00014334862385321102
I0
I1
I-1
tp45315
sS'increased,altretamines'
p45316
(F1
F0.00014334862385321102
I1
I0
I1
tp45317
sS'steady-state,pharmacokinetic'
p45318
(F1
F0.00028669724770642203
I0
I2
I-2
tp45319
sS'smx,were'
p45320
(F1
F0.00014334862385321102
I0
I1
I-1
tp45321
sS'the,replication'
p45322
(F1
F0.00014334862385321102
I1
I0
I1
tp45323
sS'benzodiazepines,combination'
p45324
(F1
F0.00014334862385321102
I1
I0
I1
tp45325
sS'hydrochloride,has'
p45326
(F1
F0.00043004587155963305
I3
I0
I3
tp45327
sS'methotrexate,caution'
p45328
(F1
F0.00014334862385321102
I1
I0
I1
tp45329
sS'pregnancy,cromolyn'
p45330
(F1
F0.00014334862385321102
I0
I1
I-1
tp45331
sS'induce,the'
p45332
(F0.5
F0.00028669724770642203
I3
I1
I2
tp45333
sS'mg,p'
p45334
(F1
F0.00014334862385321102
I1
I0
I1
tp45335
sS'has,the'
p45336
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp45337
sS'hydrolyzed,intravenous'
p45338
(F1
F0.00014334862385321102
I0
I1
I-1
tp45339
sS'decreased,active'
p45340
(F1
F0.00014334862385321102
I1
I0
I1
tp45341
sS'reduce,seizure'
p45342
(F1
F0.00014334862385321102
I1
I0
I1
tp45343
sS'allow,for'
p45344
(F1
F0.00014334862385321102
I0
I1
I-1
tp45345
sS's,wort'
p45346
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45347
sS'continue,to'
p45348
(F1
F0.00014334862385321102
I1
I0
I1
tp45349
sS'videx,therapy'
p45350
(F1
F0.00014334862385321102
I0
I1
I-1
tp45351
sS'n-type,channel'
p45352
(F1
F0.00014334862385321102
I0
I1
I-1
tp45353
sS'disease,aged'
p45354
(F1
F0.00014334862385321102
I0
I1
I-1
tp45355
sS'agents,aspirin'
p45356
(F1
F0.00028669724770642203
I2
I0
I2
tp45357
sS'by,approx'
p45358
(F1
F0.00014334862385321102
I1
I0
I1
tp45359
sS'of,nephrotoxicity'
p45360
(F1
F0.00014334862385321102
I1
I0
I1
tp45361
sS'including,have'
p45362
(F1
F0.00028669724770642203
I2
I0
I2
tp45363
sS'under,the'
p45364
(F0.5
F0.0008600917431192661
I9
I3
I6
tp45365
sS'elspar,or'
p45366
(F1
F0.00014334862385321102
I1
I0
I1
tp45367
sS'olanzapine,demonstrated'
p45368
(F1
F0.00014334862385321102
I0
I1
I-1
tp45369
sS'hormonal,are'
p45370
(F0
F0
I1
I1
I0
tp45371
sS'of,assays'
p45372
(F1
F0.00014334862385321102
I0
I1
I-1
tp45373
sS'and,drug'
p45374
(F1
F0.00014334862385321102
I0
I1
I-1
tp45375
sS'retention,blurred'
p45376
(F1
F0.00014334862385321102
I1
I0
I1
tp45377
sS'and,potentiate'
p45378
(F1
F0.00014334862385321102
I0
I1
I-1
tp45379
sS'of,gross'
p45380
(F1
F0.00014334862385321102
I0
I1
I-1
tp45381
sS'this,effect'
p45382
(F0
F0
I3
I3
I0
tp45383
sS'dosage,are'
p45384
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45385
sS'were,systematically'
p45386
(F1
F0.00014334862385321102
I0
I1
I-1
tp45387
sS'or,decreases'
p45388
(F1
F0.00014334862385321102
I1
I0
I1
tp45389
sS'model,using'
p45390
(F1
F0.00014334862385321102
I0
I1
I-1
tp45391
sS'require,additional'
p45392
(F0
F0
I1
I1
I0
tp45393
sS'of,microdosed'
p45394
(F1
F0.00028669724770642203
I2
I0
I2
tp45395
sS'beta-lactamtype,or'
p45396
(F1
F0.00014334862385321102
I1
I0
I1
tp45397
sS'or,decreased'
p45398
(F1
F0.00014334862385321102
I1
I0
I1
tp45399
sS'dsm-iv,diagnosed'
p45400
(F1
F0.00014334862385321102
I1
I0
I1
tp45401
sS'hypotension,bradycardia'
p45402
(F1
F0.00014334862385321102
I0
I1
I-1
tp45403
sS'lexapro,for'
p45404
(F1
F0.00014334862385321102
I1
I0
I1
tp45405
sS'mg,week'
p45406
(F1
F0.00014334862385321102
I1
I0
I1
tp45407
sS'approximately,when'
p45408
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp45409
sS'mptp,induced'
p45410
(F1
F0.00014334862385321102
I1
I0
I1
tp45411
sS'recommended,it'
p45412
(F1
F0.00014334862385321102
I1
I0
I1
tp45413
sS'and,susceptibility'
p45414
(F1
F0.00028669724770642203
I0
I2
I-2
tp45415
sS'produced,by'
p45416
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp45417
sS'recommended,in'
p45418
(F1
F0.00014334862385321102
I1
I0
I1
tp45419
sS'a,known'
p45420
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp45421
sS'the,reaction'
p45422
(F1
F0.00014334862385321102
I1
I0
I1
tp45423
sS'survanta,increased'
p45424
(F1
F0.00014334862385321102
I0
I1
I-1
tp45425
sS'subjects,treated'
p45426
(F1
F0.00028669724770642203
I0
I2
I-2
tp45427
sS'by,intermediate'
p45428
(F1
F0.00014334862385321102
I1
I0
I1
tp45429
sS'untreated,hypothyroidism'
p45430
(F1
F0.00014334862385321102
I0
I1
I-1
tp45431
sS'urine,samples'
p45432
(F1
F0.00014334862385321102
I0
I1
I-1
tp45433
sS'a,is'
p45434
(F1
F0.00071674311926605509
I5
I0
I5
tp45435
sS'whereas,the'
p45436
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp45437
sS'if,leprosy-associated'
p45438
(F1
F0.00014334862385321102
I1
I0
I1
tp45439
sS'fold,compared'
p45440
(F1
F0.00014334862385321102
I1
I0
I1
tp45441
sS'indocin,and'
p45442
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp45443
sS'respiratory,exchange'
p45444
(F1
F0.00014334862385321102
I0
I1
I-1
tp45445
sS'with,severe'
p45446
(F1
F0.00014334862385321102
I1
I0
I1
tp45447
sS'effects,and'
p45448
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp45449
sS'a,stock'
p45450
(F1
F0.00014334862385321102
I0
I1
I-1
tp45451
sS'hypotensive,effect'
p45452
(F1
F0.0014334862385321102
I10
I0
I10
tp45453
sS'follow-up,study'
p45454
(F1
F0.00014334862385321102
I0
I1
I-1
tp45455
sS'nsaid,has'
p45456
(F1
F0.00014334862385321102
I0
I1
I-1
tp45457
sS'of,short-acting'
p45458
(F1
F0.00014334862385321102
I0
I1
I-1
tp45459
sS'with,proscar'
p45460
(F1
F0.00014334862385321102
I0
I1
I-1
tp45461
sS'monitored,forevidence'
p45462
(F1
F0.00014334862385321102
I1
I0
I1
tp45463
sS'excretion,ibuprofen'
p45464
(F1
F0.00014334862385321102
I0
I1
I-1
tp45465
sS'with,xigris'
p45466
(F1
F0.00014334862385321102
I0
I1
I-1
tp45467
sS'phenobarbital,coadministration'
p45468
(F1
F0.00014334862385321102
I1
I0
I1
tp45469
sS'theo-dur,and'
p45470
(F1
F0.00014334862385321102
I1
I0
I1
tp45471
sS'volunteers,show'
p45472
(F1
F0.00014334862385321102
I0
I1
I-1
tp45473
sS'aom,and'
p45474
(F1
F0.00014334862385321102
I0
I1
I-1
tp45475
sS'healthy,non-smoking'
p45476
(F1
F0.00014334862385321102
I0
I1
I-1
tp45477
sS'not,a'
p45478
(F0.55555555555555558
F0.00071674311926605509
I2
I7
I-5
tp45479
sS'a,case'
p45480
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45481
sS'habituation,or'
p45482
(F1
F0.00014334862385321102
I0
I1
I-1
tp45483
sS'agents,should'
p45484
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp45485
sS'the,added'
p45486
(F0
F0
I1
I1
I0
tp45487
sS'alkaline,urine'
p45488
(F1
F0.00014334862385321102
I0
I1
I-1
tp45489
sS'performed,doses'
p45490
(F1
F0.00014334862385321102
I0
I1
I-1
tp45491
sS'treatment,ataxia'
p45492
(F1
F0.00014334862385321102
I0
I1
I-1
tp45493
sS'induce,microsomal'
p45494
(F1
F0.00014334862385321102
I1
I0
I1
tp45495
sS'been,associated'
p45496
(F0.56521739130434778
F0.0018635321100917432
I18
I5
I13
tp45497
sS'juice,resulted'
p45498
(F1
F0.00014334862385321102
I0
I1
I-1
tp45499
sS'angioedema,or'
p45500
(F1
F0.00014334862385321102
I0
I1
I-1
tp45501
sS'to,aid'
p45502
(F1
F0.00014334862385321102
I0
I1
I-1
tp45503
sS'bid,did'
p45504
(F1
F0.00043004587155963305
I0
I3
I-3
tp45505
sS'for,changes'
p45506
(F1
F0.00014334862385321102
I0
I1
I-1
tp45507
sS'cyp2d6,inhibitory'
p45508
(F1
F0.00014334862385321102
I1
I0
I1
tp45509
sS'cyp2d6,inhibitors'
p45510
(F1
F0.00014334862385321102
I0
I1
I-1
tp45511
sS'either,enbrel'
p45512
(F1
F0.00014334862385321102
I1
I0
I1
tp45513
sS'and,celexa'
p45514
(F1
F0.00014334862385321102
I1
I0
I1
tp45515
sS'double,blind'
p45516
(F1
F0.00014334862385321102
I0
I1
I-1
tp45517
sS'post-marketing,reports'
p45518
(F1
F0.00014334862385321102
I0
I1
I-1
tp45519
sS'absorption,results'
p45520
(F1
F0.00014334862385321102
I0
I1
I-1
tp45521
sS'differed,from'
p45522
(F1
F0.00014334862385321102
I0
I1
I-1
tp45523
sS'concern,about'
p45524
(F1
F0.00014334862385321102
I1
I0
I1
tp45525
sS'was,similar'
p45526
(F1
F0.0008600917431192661
I0
I6
I-6
tp45527
sS'studies,show'
p45528
(F1
F0.00028669724770642203
I0
I2
I-2
tp45529
sS'of,argatroban'
p45530
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp45531
sS'known,photosensitizing'
p45532
(F1
F0.00014334862385321102
I1
I0
I1
tp45533
sS'affect,steady-state'
p45534
(F1
F0.00014334862385321102
I0
I1
I-1
tp45535
sS'animal,and'
p45536
(F1
F0.00014334862385321102
I0
I1
I-1
tp45537
sS'invirase,and'
p45538
(F1
F0.00014334862385321102
I0
I1
I-1
tp45539
sS'supraventricular,tachycardia'
p45540
(F1
F0.00014334862385321102
I1
I0
I1
tp45541
sS'possibility,should'
p45542
(F1
F0.00014334862385321102
I0
I1
I-1
tp45543
sS'were,used'
p45544
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45545
sS'g,sometimes'
p45546
(F1
F0.00014334862385321102
I0
I1
I-1
tp45547
sS'of,ponstel'
p45548
(F1
F0.00028669724770642203
I2
I0
I2
tp45549
sS'methamphetamine,like'
p45550
(F1
F0.00014334862385321102
I1
I0
I1
tp45551
sS'an,anion'
p45552
(F1
F0.00014334862385321102
I0
I1
I-1
tp45553
sS'careful,attention'
p45554
(F1
F0.00014334862385321102
I1
I0
I1
tp45555
sS'p1,and'
p45556
(F1
F0.00014334862385321102
I1
I0
I1
tp45557
sS'felbatol,phenytoin'
p45558
(F1
F0.00014334862385321102
I1
I0
I1
tp45559
sS'worsen,the'
p45560
(F1
F0.00014334862385321102
I1
I0
I1
tp45561
sS'and,quinolones'
p45562
(F1
F0.00014334862385321102
I0
I1
I-1
tp45563
sS'likelihood,of'
p45564
(F1
F0.00057339449541284407
I4
I0
I4
tp45565
sS'of,conjugated'
p45566
(F1
F0.00014334862385321102
I0
I1
I-1
tp45567
sS'phenothiazine-related,compounds'
p45568
(F1
F0.00014334862385321102
I1
I0
I1
tp45569
sS'a,loss'
p45570
(F1
F0.00014334862385321102
I0
I1
I-1
tp45571
sS'concomitant,such'
p45572
(F1
F0.00014334862385321102
I0
I1
I-1
tp45573
sS'cyp3a4,substrates'
p45574
(F0
F0
I2
I2
I0
tp45575
sS'supplements,taken'
p45576
(F1
F0.00014334862385321102
I1
I0
I1
tp45577
sS'fibric,acid'
p45578
(F1
F0.00028669724770642203
I0
I2
I-2
tp45579
sS'in,human'
p45580
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp45581
sS'ros,has'
p45582
(F1
F0.00014334862385321102
I0
I1
I-1
tp45583
sS'simvastatin,cyp3a4'
p45584
(F1
F0.00014334862385321102
I0
I1
I-1
tp45585
sS'approximately,fold'
p45586
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp45587
sS'of,otthostatic'
p45588
(F1
F0.00014334862385321102
I0
I1
I-1
tp45589
sS'effect,was'
p45590
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45591
sS'medicines,diabetic'
p45592
(F1
F0.00014334862385321102
I1
I0
I1
tp45593
sS'meth,caused'
p45594
(F1
F0.00014334862385321102
I1
I0
I1
tp45595
sS'this,antagonistic'
p45596
(F1
F0.00014334862385321102
I1
I0
I1
tp45597
sS'auc,after'
p45598
(F1
F0.00043004587155963305
I3
I0
I3
tp45599
sS'kg,diet'
p45600
(F1
F0.00014334862385321102
I1
I0
I1
tp45601
sS'assay,for'
p45602
(F1
F0.00014334862385321102
I0
I1
I-1
tp45603
sS'cancer,cell'
p45604
(F1
F0.00014334862385321102
I0
I1
I-1
tp45605
sS'reuptake,inhibitor'
p45606
(F1
F0.00043004587155963305
I3
I0
I3
tp45607
sS'hormone,concomitant'
p45608
(F1
F0.00014334862385321102
I1
I0
I1
tp45609
sS'upon,administration'
p45610
(F1
F0.00014334862385321102
I1
I0
I1
tp45611
sS'affect,this'
p45612
(F1
F0.00014334862385321102
I0
I1
I-1
tp45613
sS'have,identified'
p45614
(F1
F0.00014334862385321102
I1
I0
I1
tp45615
sS'specific,d1'
p45616
(F1
F0.00014334862385321102
I1
I0
I1
tp45617
sS'glyburide,the'
p45618
(F1
F0.00014334862385321102
I1
I0
I1
tp45619
sS'no,changes'
p45620
(F1
F0.00014334862385321102
I0
I1
I-1
tp45621
sS'disalcid,others'
p45622
(F1
F0.00014334862385321102
I1
I0
I1
tp45623
sS'only,half'
p45624
(F1
F0.00014334862385321102
I0
I1
I-1
tp45625
sS'and,asa'
p45626
(F1
F0.00014334862385321102
I0
I1
I-1
tp45627
sS'cells,in'
p45628
(F1
F0.00028669724770642203
I0
I2
I-2
tp45629
sS'weekly,dosage'
p45630
(F1
F0.00014334862385321102
I1
I0
I1
tp45631
sS'inhibitors,including'
p45632
(F0
F0
I2
I2
I0
tp45633
sS'were,noted'
p45634
(F0
F0
I1
I1
I0
tp45635
sS'multiple,dosing'
p45636
(F1
F0.00028669724770642203
I2
I0
I2
tp45637
sS'volunteers,or'
p45638
(F1
F0.00014334862385321102
I0
I1
I-1
tp45639
sS'volunteers,of'
p45640
(F1
F0.00014334862385321102
I1
I0
I1
tp45641
sS'were,concurrently'
p45642
(F1
F0.00028669724770642203
I0
I2
I-2
tp45643
sS'treated,rats'
p45644
(F1
F0.00014334862385321102
I1
I0
I1
tp45645
sS'glucose,levels'
p45646
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45647
sS'small,gradual'
p45648
(F1
F0.00014334862385321102
I1
I0
I1
tp45649
sS'not,cause'
p45650
(F1
F0.00014334862385321102
I0
I1
I-1
tp45651
sS'with,biliary'
p45652
(F1
F0.00014334862385321102
I0
I1
I-1
tp45653
sS'subjects,given'
p45654
(F1
F0.00028669724770642203
I2
I0
I2
tp45655
sS'in,otherwise'
p45656
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45657
sS'with,supplements'
p45658
(F1
F0.00014334862385321102
I0
I1
I-1
tp45659
sS'insert,for'
p45660
(F1
F0.00028669724770642203
I2
I0
I2
tp45661
sS'decrease,prior'
p45662
(F1
F0.00014334862385321102
I0
I1
I-1
tp45663
sS'd,at'
p45664
(F1
F0.00014334862385321102
I1
I0
I1
tp45665
sS'for,reexacerbation'
p45666
(F1
F0.00014334862385321102
I1
I0
I1
tp45667
sS'curare-like,compounds'
p45668
(F1
F0.00028669724770642203
I2
I0
I2
tp45669
sS'with,simulect'
p45670
(F1
F0.00014334862385321102
I0
I1
I-1
tp45671
sS'two,potentially'
p45672
(F1
F0.00014334862385321102
I1
I0
I1
tp45673
sS'the,tardive'
p45674
(F1
F0.00014334862385321102
I1
I0
I1
tp45675
sS'given,number'
p45676
(F1
F0.00014334862385321102
I0
I1
I-1
tp45677
sS'decrease,anti-inflammatory'
p45678
(F1
F0.00014334862385321102
I1
I0
I1
tp45679
sS'gross,motor'
p45680
(F1
F0.00014334862385321102
I0
I1
I-1
tp45681
sS'are,highly'
p45682
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp45683
sS'ibuprofen,and'
p45684
(F1
F0.00014334862385321102
I1
I0
I1
tp45685
sS'by,blocking'
p45686
(F1
F0.00014334862385321102
I1
I0
I1
tp45687
sS'interval,msec'
p45688
(F1
F0.00014334862385321102
I1
I0
I1
tp45689
sS'pharmacokinetic,parameters'
p45690
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp45691
sS'taking,that'
p45692
(F1
F0.00014334862385321102
I0
I1
I-1
tp45693
sS'fluctuations,in'
p45694
(F1
F0.00014334862385321102
I1
I0
I1
tp45695
sS'all,subjects'
p45696
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45697
sS'tagamet,apparently'
p45698
(F1
F0.00014334862385321102
I1
I0
I1
tp45699
sS'of,ellence'
p45700
(F1
F0.00014334862385321102
I1
I0
I1
tp45701
sS'recommended,to'
p45702
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45703
sS'apoptosis,in'
p45704
(F1
F0.00028669724770642203
I0
I2
I-2
tp45705
sS'therefore,administration'
p45706
(F1
F0.00028669724770642203
I0
I2
I-2
tp45707
sS'was,well'
p45708
(F1
F0.00014334862385321102
I0
I1
I-1
tp45709
sS'wshow,that'
p45710
(F0
F0
I1
I1
I0
tp45711
sS'protease,inhibitor'
p45712
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp45713
sS'min,mean'
p45714
(F1
F0.00014334862385321102
I1
I0
I1
tp45715
sS'to,establish'
p45716
(F1
F0.00014334862385321102
I1
I0
I1
tp45717
sS'amitriptyline,concurrent'
p45718
(F1
F0.00014334862385321102
I1
I0
I1
tp45719
sS'glucuronidation,and'
p45720
(F1
F0.00014334862385321102
I0
I1
I-1
tp45721
sS'synthesis,and'
p45722
(F0
F0
I1
I1
I0
tp45723
sS'with,type'
p45724
(F1
F0.00028669724770642203
I0
I2
I-2
tp45725
sS'randomly,assigned'
p45726
(F1
F0.00028669724770642203
I0
I2
I-2
tp45727
sS'a,hmg-coa'
p45728
(F1
F0.00014334862385321102
I1
I0
I1
tp45729
sS'and,mg2'
p45730
(F1
F0.00014334862385321102
I0
I1
I-1
tp45731
sS'mofetil,ml'
p45732
(F1
F0.00014334862385321102
I0
I1
I-1
tp45733
sS'in,organ'
p45734
(F1
F0.00014334862385321102
I1
I0
I1
tp45735
sS'coadministered,oral'
p45736
(F1
F0.00014334862385321102
I1
I0
I1
tp45737
sS'counteract,the'
p45738
(F1
F0.0010034403669724771
I7
I0
I7
tp45739
sS'dose,even'
p45740
(F1
F0.00014334862385321102
I0
I1
I-1
tp45741
sS'paraclinical,pattern'
p45742
(F1
F0.00014334862385321102
I0
I1
I-1
tp45743
sS'with,ibandronate'
p45744
(F1
F0.00014334862385321102
I0
I1
I-1
tp45745
sS'and,low'
p45746
(F1
F0.00028669724770642203
I0
I2
I-2
tp45747
sS'also,potentiate'
p45748
(F1
F0.00014334862385321102
I1
I0
I1
tp45749
sS'week,endoscopy'
p45750
(F1
F0.00014334862385321102
I0
I1
I-1
tp45751
sS'c19,and'
p45752
(F1
F0.00014334862385321102
I0
I1
I-1
tp45753
sS'triazolo-benzodiazepines,dihydropyridine'
p45754
(F1
F0.00014334862385321102
I1
I0
I1
tp45755
sS'receiving,tambocor'
p45756
(F1
F0.00014334862385321102
I1
I0
I1
tp45757
sS'dexbrompheniramine,can'
p45758
(F1
F0.00028669724770642203
I2
I0
I2
tp45759
sS'oral,contraceptive'
p45760
(F1
F0.00028669724770642203
I0
I2
I-2
tp45761
sS'divalent,or'
p45762
(F1
F0.00014334862385321102
I0
I1
I-1
tp45763
sS'attenuation,of'
p45764
(F1
F0.00014334862385321102
I1
I0
I1
tp45765
sS'or,to'
p45766
(F0
F0
I5
I5
I0
tp45767
sS'consequences,following'
p45768
(F1
F0.00028669724770642203
I0
I2
I-2
tp45769
sS'category,and'
p45770
(F1
F0.00014334862385321102
I1
I0
I1
tp45771
sS'study,a'
p45772
(F0
F0
I1
I1
I0
tp45773
sS'bedtime,and'
p45774
(F1
F0.00014334862385321102
I0
I1
I-1
tp45775
sS'study,n'
p45776
(F1
F0.00014334862385321102
I1
I0
I1
tp45777
sS'n,later'
p45778
(F1
F0.00014334862385321102
I0
I1
I-1
tp45779
sS'studied,with'
p45780
(F1
F0.00014334862385321102
I1
I0
I1
tp45781
sS'of,central'
p45782
(F1
F0.00028669724770642203
I2
I0
I2
tp45783
sS'during,pregnancy'
p45784
(F1
F0.00014334862385321102
I0
I1
I-1
tp45785
sS'of,adequate'
p45786
(F1
F0.00014334862385321102
I1
I0
I1
tp45787
sS'ophthalmic,suspension'
p45788
(F1
F0.00014334862385321102
I0
I1
I-1
tp45789
sS'since,both'
p45790
(F1
F0.00014334862385321102
I1
I0
I1
tp45791
sS'beta,cells'
p45792
(F1
F0.00014334862385321102
I0
I1
I-1
tp45793
sS'increase,plasmaconcentration'
p45794
(F1
F0.00014334862385321102
I1
I0
I1
tp45795
sS'that,levels'
p45796
(F1
F0.00057339449541284407
I4
I0
I4
tp45797
sS'contributing,factor'
p45798
(F1
F0.00014334862385321102
I1
I0
I1
tp45799
sS'antihistamines,may'
p45800
(F1
F0.00043004587155963305
I3
I0
I3
tp45801
sS'correlated,with'
p45802
(F1
F0.00014334862385321102
I0
I1
I-1
tp45803
sS'all,the'
p45804
(F1
F0.00071674311926605509
I0
I5
I-5
tp45805
sS'dose,if'
p45806
(F1
F0.00014334862385321102
I1
I0
I1
tp45807
sS'oral,birth'
p45808
(F1
F0.00014334862385321102
I0
I1
I-1
tp45809
sS'table,changes'
p45810
(F1
F0.00014334862385321102
I0
I1
I-1
tp45811
sS'constant,while'
p45812
(F1
F0.00014334862385321102
I0
I1
I-1
tp45813
sS'cyp1a2-mediated,metabolism'
p45814
(F1
F0.00014334862385321102
I0
I1
I-1
tp45815
sS'dose,is'
p45816
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45817
sS'for,free'
p45818
(F1
F0.00014334862385321102
I0
I1
I-1
tp45819
sS'to,open'
p45820
(F1
F0.00014334862385321102
I1
I0
I1
tp45821
sS'lucidum,extract'
p45822
(F1
F0.00014334862385321102
I0
I1
I-1
tp45823
sS'on,severe'
p45824
(F1
F0.00014334862385321102
I1
I0
I1
tp45825
sS'because,amplifies'
p45826
(F1
F0.00014334862385321102
I1
I0
I1
tp45827
sS'accumulation,characteristic'
p45828
(F1
F0.00014334862385321102
I0
I1
I-1
tp45829
sS'by,competing'
p45830
(F1
F0.00028669724770642203
I2
I0
I2
tp45831
sS'small,clinical'
p45832
(F1
F0.00014334862385321102
I0
I1
I-1
tp45833
sS'usually,prescribed'
p45834
(F1
F0.0010034403669724771
I0
I7
I-7
tp45835
sS'tiagabine,had'
p45836
(F1
F0.00028669724770642203
I0
I2
I-2
tp45837
sS'taking,monoamine'
p45838
(F1
F0.00014334862385321102
I1
I0
I1
tp45839
sS'ml,egf'
p45840
(F1
F0.00014334862385321102
I0
I1
I-1
tp45841
sS'no,clinically'
p45842
(F0.93939393939393945
F0.0044438073394495415
I1
I32
I-31
tp45843
sS'longer,in'
p45844
(F0
F0
I1
I1
I0
tp45845
sS'serial,plasma'
p45846
(F1
F0.00014334862385321102
I0
I1
I-1
tp45847
sS'arrival,of'
p45848
(F1
F0.00014334862385321102
I0
I1
I-1
tp45849
sS'atrial,fibrillation'
p45850
(F1
F0.00014334862385321102
I1
I0
I1
tp45851
sS'designed,to'
p45852
(F1
F0.00028669724770642203
I0
I2
I-2
tp45853
sS'of,equivalent'
p45854
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45855
sS'atromid-s,neoral'
p45856
(F1
F0.00014334862385321102
I1
I0
I1
tp45857
sS'well,acquainted'
p45858
(F1
F0.00014334862385321102
I0
I1
I-1
tp45859
sS'synthase,inhibiting'
p45860
(F1
F0.00014334862385321102
I1
I0
I1
tp45861
sS'would,coincide'
p45862
(F1
F0.00014334862385321102
I0
I1
I-1
tp45863
sS'agents,class'
p45864
(F1
F0.00014334862385321102
I0
I1
I-1
tp45865
sS'in,overall'
p45866
(F1
F0.00014334862385321102
I0
I1
I-1
tp45867
sS'the,more'
p45868
(F1
F0.00014334862385321102
I0
I1
I-1
tp45869
sS'first,study'
p45870
(F0
F0
I1
I1
I0
tp45871
sS'non-selective,beta-adrenergic'
p45872
(F1
F0.00014334862385321102
I1
I0
I1
tp45873
sS'hormonal,components'
p45874
(F1
F0.00014334862385321102
I1
I0
I1
tp45875
sS'action,which'
p45876
(F1
F0.00014334862385321102
I0
I1
I-1
tp45877
sS'and,concentration'
p45878
(F1
F0.00014334862385321102
I0
I1
I-1
tp45879
sS'decrease,platelet'
p45880
(F1
F0.00014334862385321102
I0
I1
I-1
tp45881
sS'ketoconazole,potential'
p45882
(F1
F0.00014334862385321102
I1
I0
I1
tp45883
sS'we,demonstrate'
p45884
(F1
F0.00014334862385321102
I0
I1
I-1
tp45885
sS'results,and'
p45886
(F1
F0.00014334862385321102
I1
I0
I1
tp45887
sS'gm,daily'
p45888
(F1
F0.00014334862385321102
I1
I0
I1
tp45889
sS'cimetidine,concomitant'
p45890
(F0
F0
I1
I1
I0
tp45891
sS'problems,will'
p45892
(F1
F0.00071674311926605509
I5
I0
I5
tp45893
sS'human,trials'
p45894
(F1
F0.00014334862385321102
I1
I0
I1
tp45895
sS'safely,to'
p45896
(F1
F0.00014334862385321102
I0
I1
I-1
tp45897
sS'following,table'
p45898
(F1
F0.00028669724770642203
I0
I2
I-2
tp45899
sS'can,give'
p45900
(F0
F0
I1
I1
I0
tp45901
sS'enzymatic,test'
p45902
(F1
F0.00014334862385321102
I0
I1
I-1
tp45903
sS'given,very'
p45904
(F1
F0.00014334862385321102
I1
I0
I1
tp45905
sS'agents,patients'
p45906
(F1
F0.00014334862385321102
I1
I0
I1
tp45907
sS'antiretroviral,agents'
p45908
(F1
F0.00028669724770642203
I0
I2
I-2
tp45909
sS'b-lactam,renal'
p45910
(F1
F0.00014334862385321102
I1
I0
I1
tp45911
sS'patients,received'
p45912
(F1
F0.00014334862385321102
I0
I1
I-1
tp45913
sS'severe,and'
p45914
(F1
F0.00014334862385321102
I1
I0
I1
tp45915
sS'most,and'
p45916
(F1
F0.00014334862385321102
I0
I1
I-1
tp45917
sS'than,the'
p45918
(F1
F0.00071674311926605509
I0
I5
I-5
tp45919
sS'antagonistic,to'
p45920
(F1
F0.00014334862385321102
I1
I0
I1
tp45921
sS'through,effects'
p45922
(F1
F0.00014334862385321102
I1
I0
I1
tp45923
sS'groups,fed'
p45924
(F1
F0.00014334862385321102
I0
I1
I-1
tp45925
sS'erythro-fluorocitrate,in'
p45926
(F1
F0.00014334862385321102
I1
I0
I1
tp45927
sS'be,alert'
p45928
(F0
F0
I2
I2
I0
tp45929
sS'although,studies'
p45930
(F1
F0.00014334862385321102
I0
I1
I-1
tp45931
sS'also,assessed'
p45932
(F1
F0.00014334862385321102
I0
I1
I-1
tp45933
sS'histidine,residues'
p45934
(F1
F0.00028669724770642203
I0
I2
I-2
tp45935
sS'interest,to'
p45936
(F1
F0.00014334862385321102
I0
I1
I-1
tp45937
sS'symptoms,support'
p45938
(F1
F0.00014334862385321102
I0
I1
I-1
tp45939
sS'excretion,and'
p45940
(F1
F0.00014334862385321102
I1
I0
I1
tp45941
sS'of,myalgia'
p45942
(F1
F0.00014334862385321102
I1
I0
I1
tp45943
sS'synergistic,such'
p45944
(F1
F0.00028669724770642203
I2
I0
I2
tp45945
sS'by,intraventricular'
p45946
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45947
sS'antimicrobial,combinations'
p45948
(F0
F0
I1
I1
I0
tp45949
sS'auc0-120hr,by'
p45950
(F1
F0.00014334862385321102
I1
I0
I1
tp45951
sS'there,was'
p45952
(F0.39130434782608697
F0.0012901376146788992
I7
I16
I-9
tp45953
sS'therapeutic,window'
p45954
(F1
F0.00014334862385321102
I1
I0
I1
tp45955
sS'trisphosphate,insp'
p45956
(F1
F0.00014334862385321102
I0
I1
I-1
tp45957
sS'once,every'
p45958
(F1
F0.00028669724770642203
I0
I2
I-2
tp45959
sS'a,prospective'
p45960
(F1
F0.00014334862385321102
I0
I1
I-1
tp45961
sS'to,loss'
p45962
(F1
F0.00028669724770642203
I0
I2
I-2
tp45963
sS'of,gl'
p45964
(F0
F0
I1
I1
I0
tp45965
sS'of,gi'
p45966
(F1
F0.00043004587155963305
I3
I0
I3
tp45967
sS'specific,for'
p45968
(F1
F0.00014334862385321102
I0
I1
I-1
tp45969
sS'medications,were'
p45970
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45971
sS'and,alternative'
p45972
(F1
F0.00043004587155963305
I3
I0
I3
tp45973
sS'and,reuptake'
p45974
(F1
F0.00043004587155963305
I3
I0
I3
tp45975
sS'agents,other'
p45976
(F1
F0.00014334862385321102
I1
I0
I1
tp45977
sS'anticoagulant,therapy'
p45978
(F1
F0.00014334862385321102
I1
I0
I1
tp45979
sS'causing,no'
p45980
(F1
F0.00014334862385321102
I0
I1
I-1
tp45981
sS'vascular,response'
p45982
(F1
F0.00014334862385321102
I1
I0
I1
tp45983
sS'capacity,to'
p45984
(F0
F0
I1
I1
I0
tp45985
sS'administered,concomitantly'
p45986
(F0.40000000000000002
F0.0017201834862385322
I21
I9
I12
tp45987
sS'a,family'
p45988
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45989
sS'units,day'
p45990
(F1
F0.00014334862385321102
I0
I1
I-1
tp45991
sS'loop,or'
p45992
(F1
F0.00014334862385321102
I1
I0
I1
tp45993
sS'gram,of'
p45994
(F1
F0.00028669724770642203
I2
I0
I2
tp45995
sS'are,metabolized'
p45996
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp45997
sS'antacids,nonclinical'
p45998
(F1
F0.00014334862385321102
I0
I1
I-1
tp45999
sS'for,auc'
p46000
(F0
F0
I1
I1
I0
tp46001
sS'exjade,and'
p46002
(F1
F0.00028669724770642203
I0
I2
I-2
tp46003
sS'corticotropin,acth'
p46004
(F1
F0.00014334862385321102
I1
I0
I1
tp46005
sS'non-steroidal,antiinflammatory'
p46006
(F1
F0.00014334862385321102
I1
I0
I1
tp46007
sS'of,arava'
p46008
(F1
F0.00028669724770642203
I2
I0
I2
tp46009
sS'revealed,a'
p46010
(F1
F0.00014334862385321102
I0
I1
I-1
tp46011
sS'that,fluvoxamine'
p46012
(F1
F0.00014334862385321102
I1
I0
I1
tp46013
sS'history,prior'
p46014
(F1
F0.00014334862385321102
I0
I1
I-1
tp46015
sS'is,metabolized'
p46016
(F1
F0.0018635321100917432
I0
I13
I-13
tp46017
sS'abolished,by'
p46018
(F1
F0.00014334862385321102
I1
I0
I1
tp46019
sS'diastolic,or'
p46020
(F1
F0.00014334862385321102
I0
I1
I-1
tp46021
sS'increases,ethinyl'
p46022
(F1
F0.00014334862385321102
I0
I1
I-1
tp46023
sS'initiating,a'
p46024
(F1
F0.00014334862385321102
I1
I0
I1
tp46025
sS'man,we'
p46026
(F1
F0.00014334862385321102
I0
I1
I-1
tp46027
sS'pressor,effects'
p46028
(F1
F0.00028669724770642203
I2
I0
I2
tp46029
sS'by,inhibition'
p46030
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46031
sS'dinitrate,may'
p46032
(F1
F0.00014334862385321102
I1
I0
I1
tp46033
sS'antagonist,class'
p46034
(F1
F0.00014334862385321102
I1
I0
I1
tp46035
sS'in,increases'
p46036
(F1
F0.00057339449541284407
I4
I0
I4
tp46037
sS'state,while'
p46038
(F1
F0.00014334862385321102
I1
I0
I1
tp46039
sS'in,increased'
p46040
(F0.5
F0.0011467889908256881
I12
I4
I8
tp46041
sS'experiment,non-diabetic'
p46042
(F1
F0.00014334862385321102
I0
I1
I-1
tp46043
sS'receiving,decreased'
p46044
(F1
F0.00014334862385321102
I1
I0
I1
tp46045
sS'ml,at'
p46046
(F1
F0.00014334862385321102
I0
I1
I-1
tp46047
sS'without,mg'
p46048
(F1
F0.00014334862385321102
I0
I1
I-1
tp46049
sS'by,using'
p46050
(F1
F0.00028669724770642203
I0
I2
I-2
tp46051
sS'were,coadministered'
p46052
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46053
sS'other,nonsteroidal'
p46054
(F0.5
F0.00057339449541284407
I6
I2
I4
tp46055
sS'in,previous'
p46056
(F1
F0.00014334862385321102
I1
I0
I1
tp46057
sS'iodine-containing,preparations'
p46058
(F1
F0.00014334862385321102
I0
I1
I-1
tp46059
sS'conversely,decreases'
p46060
(F1
F0.00014334862385321102
I1
I0
I1
tp46061
sS'that,associated'
p46062
(F1
F0.00014334862385321102
I0
I1
I-1
tp46063
sS'cimetidine,increased'
p46064
(F1
F0.00014334862385321102
I1
I0
I1
tp46065
sS'symptoms,should'
p46066
(F1
F0.00014334862385321102
I0
I1
I-1
tp46067
sS'mg,tricor'
p46068
(F1
F0.00028669724770642203
I2
I0
I2
tp46069
sS'analgesia,and'
p46070
(F1
F0.00014334862385321102
I0
I1
I-1
tp46071
sS'influenza,virus'
p46072
(F1
F0.00014334862385321102
I1
I0
I1
tp46073
sS'to,administering'
p46074
(F1
F0.00014334862385321102
I1
I0
I1
tp46075
sS'subcutaneous,injection'
p46076
(F1
F0.00014334862385321102
I0
I1
I-1
tp46077
sS'seven,days'
p46078
(F1
F0.00014334862385321102
I0
I1
I-1
tp46079
sS'therapy,alone'
p46080
(F1
F0.00014334862385321102
I0
I1
I-1
tp46081
sS'or,after'
p46082
(F1
F0.00043004587155963305
I3
I0
I3
tp46083
sS'by,self-injection'
p46084
(F1
F0.00014334862385321102
I0
I1
I-1
tp46085
sS'related,have'
p46086
(F1
F0.00014334862385321102
I1
I0
I1
tp46087
sS'europe,nimotop'
p46088
(F1
F0.00014334862385321102
I1
I0
I1
tp46089
sS'avoid,while'
p46090
(F1
F0.00014334862385321102
I1
I0
I1
tp46091
sS'patient,maintained'
p46092
(F1
F0.00028669724770642203
I2
I0
I2
tp46093
sS'by,determination'
p46094
(F1
F0.00028669724770642203
I0
I2
I-2
tp46095
sS'a,including'
p46096
(F1
F0.00014334862385321102
I1
I0
I1
tp46097
sS'inhibitor,can'
p46098
(F1
F0.00014334862385321102
I1
I0
I1
tp46099
sS'mice,min'
p46100
(F1
F0.00014334862385321102
I0
I1
I-1
tp46101
sS'formed,via'
p46102
(F1
F0.00014334862385321102
I0
I1
I-1
tp46103
sS'cardiac,contractility'
p46104
(F1
F0.00028669724770642203
I2
I0
I2
tp46105
sS'studied,as'
p46106
(F1
F0.00014334862385321102
I0
I1
I-1
tp46107
sS'asthma,therapy'
p46108
(F1
F0.00014334862385321102
I0
I1
I-1
tp46109
sS'to,recommend'
p46110
(F1
F0.00014334862385321102
I0
I1
I-1
tp46111
sS'caused,to'
p46112
(F1
F0.00014334862385321102
I1
I0
I1
tp46113
sS'average,and'
p46114
(F1
F0.00014334862385321102
I1
I0
I1
tp46115
sS'other,inhibitors'
p46116
(F1
F0.00014334862385321102
I1
I0
I1
tp46117
sS'clozapine,is'
p46118
(F1
F0.00014334862385321102
I1
I0
I1
tp46119
sS'medications,have'
p46120
(F1
F0.00043004587155963305
I0
I3
I-3
tp46121
sS'ketoconazole,sensipar'
p46122
(F1
F0.00014334862385321102
I0
I1
I-1
tp46123
sS'the,severity'
p46124
(F1
F0.00014334862385321102
I1
I0
I1
tp46125
sS'failure,are'
p46126
(F1
F0.00014334862385321102
I0
I1
I-1
tp46127
sS'when,proquin'
p46128
(F1
F0.00014334862385321102
I0
I1
I-1
tp46129
sS'on,natriuresis'
p46130
(F1
F0.00014334862385321102
I1
I0
I1
tp46131
sS'of,would'
p46132
(F1
F0.00014334862385321102
I0
I1
I-1
tp46133
sS'heat,stimulus'
p46134
(F1
F0.00014334862385321102
I0
I1
I-1
tp46135
sS'cyp1a2,cyp3a'
p46136
(F1
F0.00014334862385321102
I1
I0
I1
tp46137
sS'the,inr'
p46138
(F1
F0.00014334862385321102
I0
I1
I-1
tp46139
sS'decrease,mean'
p46140
(F1
F0.00014334862385321102
I0
I1
I-1
tp46141
sS'requires,close'
p46142
(F1
F0.00043004587155963305
I3
I0
I3
tp46143
sS'orthostatic,hypotension'
p46144
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46145
sS'the,survanta'
p46146
(F1
F0.00014334862385321102
I0
I1
I-1
tp46147
sS'uptake,inhibitor'
p46148
(F1
F0.00014334862385321102
I0
I1
I-1
tp46149
sS'since,there'
p46150
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp46151
sS'the,use'
p46152
(F0.071428571428571425
F0.00028669724770642203
I15
I13
I2
tp46153
sS'dose,unfractionated'
p46154
(F1
F0.00014334862385321102
I0
I1
I-1
tp46155
sS'see,warnings'
p46156
(F1
F0.00028669724770642203
I2
I0
I2
tp46157
sS'g,hour'
p46158
(F1
F0.00014334862385321102
I1
I0
I1
tp46159
sS'higher,degrees'
p46160
(F1
F0.00014334862385321102
I1
I0
I1
tp46161
sS'and,acute'
p46162
(F1
F0.00014334862385321102
I1
I0
I1
tp46163
sS'oruvail,voltaren'
p46164
(F1
F0.00014334862385321102
I0
I1
I-1
tp46165
sS'impactor,for'
p46166
(F1
F0.00014334862385321102
I0
I1
I-1
tp46167
sS'lithium,nonsteroidal'
p46168
(F1
F0.00014334862385321102
I1
I0
I1
tp46169
sS'cefamandole,naftate'
p46170
(F1
F0.00014334862385321102
I0
I1
I-1
tp46171
sS'and,these'
p46172
(F1
F0.0011467889908256881
I0
I8
I-8
tp46173
sS'c,max'
p46174
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp46175
sS'vs,and'
p46176
(F0
F0
I1
I1
I0
tp46177
sS'medications,especially'
p46178
(F1
F0.00014334862385321102
I0
I1
I-1
tp46179
sS'will,interfere'
p46180
(F1
F0.00014334862385321102
I1
I0
I1
tp46181
sS'and,moderate'
p46182
(F1
F0.00014334862385321102
I1
I0
I1
tp46183
sS'include,a'
p46184
(F1
F0.00014334862385321102
I0
I1
I-1
tp46185
sS'pronounced,if'
p46186
(F1
F0.00014334862385321102
I1
I0
I1
tp46187
sS'copaxone,has'
p46188
(F1
F0.00014334862385321102
I0
I1
I-1
tp46189
sS'decrease,absorption'
p46190
(F1
F0.00014334862385321102
I1
I0
I1
tp46191
sS'buforin,ii'
p46192
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp46193
sS'in,concentrations'
p46194
(F1
F0.00028669724770642203
I2
I0
I2
tp46195
sS'multiple,doses'
p46196
(F0
F0
I6
I6
I0
tp46197
sS'tests,benedicts'
p46198
(F1
F0.00014334862385321102
I0
I1
I-1
tp46199
sS'presentation,of'
p46200
(F1
F0.00014334862385321102
I1
I0
I1
tp46201
sS'therefore,prothrombin'
p46202
(F1
F0.00014334862385321102
I1
I0
I1
tp46203
sS'as,choline'
p46204
(F1
F0.00014334862385321102
I1
I0
I1
tp46205
sS'as,acetylsalicylic'
p46206
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46207
sS'small,effect'
p46208
(F0
F0
I1
I1
I0
tp46209
sS'concentration,especially'
p46210
(F1
F0.00014334862385321102
I1
I0
I1
tp46211
sS'mean,maximum'
p46212
(F1
F0.00014334862385321102
I1
I0
I1
tp46213
sS'significant,hypotension'
p46214
(F1
F0.00014334862385321102
I1
I0
I1
tp46215
sS'hcl,has'
p46216
(F0
F0
I1
I1
I0
tp46217
sS'hg,compared'
p46218
(F1
F0.00028669724770642203
I2
I0
I2
tp46219
sS'and,evidence'
p46220
(F1
F0.00014334862385321102
I1
I0
I1
tp46221
sS'also,taking'
p46222
(F1
F0.00014334862385321102
I1
I0
I1
tp46223
sS'intoxication,plasma'
p46224
(F1
F0.00014334862385321102
I0
I1
I-1
tp46225
sS'increased,intestinal'
p46226
(F1
F0.00014334862385321102
I1
I0
I1
tp46227
sS'alt,in'
p46228
(F1
F0.00028669724770642203
I2
I0
I2
tp46229
sS'suitable,coagulation'
p46230
(F1
F0.00028669724770642203
I2
I0
I2
tp46231
sS'arrhythmias,who'
p46232
(F1
F0.00014334862385321102
I0
I1
I-1
tp46233
sS'agents,are'
p46234
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp46235
sS'phenobarbital,primidone'
p46236
(F1
F0.00014334862385321102
I1
I0
I1
tp46237
sS'reversible,enhancement'
p46238
(F1
F0.00014334862385321102
I1
I0
I1
tp46239
sS'as,competition'
p46240
(F1
F0.00014334862385321102
I1
I0
I1
tp46241
sS'following,interactions'
p46242
(F1
F0.00028669724770642203
I2
I0
I2
tp46243
sS'inhibitory,activity'
p46244
(F1
F0.00028669724770642203
I2
I0
I2
tp46245
sS'used,during'
p46246
(F1
F0.00014334862385321102
I0
I1
I-1
tp46247
sS'transport,were'
p46248
(F1
F0.00014334862385321102
I0
I1
I-1
tp46249
sS'a,mao'
p46250
(F1
F0.00014334862385321102
I1
I0
I1
tp46251
sS'dissolution,in'
p46252
(F1
F0.00014334862385321102
I0
I1
I-1
tp46253
sS'estradiol,levels'
p46254
(F1
F0.00014334862385321102
I1
I0
I1
tp46255
sS'every,other'
p46256
(F1
F0.00014334862385321102
I0
I1
I-1
tp46257
sS'and,commonly'
p46258
(F1
F0.00014334862385321102
I0
I1
I-1
tp46259
sS'a,may'
p46260
(F1
F0.00014334862385321102
I1
I0
I1
tp46261
sS'inhibit,this'
p46262
(F1
F0.00028669724770642203
I2
I0
I2
tp46263
sS'different,levels'
p46264
(F1
F0.00014334862385321102
I0
I1
I-1
tp46265
sS'enhanced,clearance'
p46266
(F1
F0.00014334862385321102
I1
I0
I1
tp46267
sS'cns-depressive,effect'
p46268
(F1
F0.00014334862385321102
I1
I0
I1
tp46269
sS'carefully,considered'
p46270
(F1
F0.00014334862385321102
I1
I0
I1
tp46271
sS'study,suggested'
p46272
(F1
F0.00014334862385321102
I0
I1
I-1
tp46273
sS'vardenafil,dosing'
p46274
(F1
F0.00014334862385321102
I1
I0
I1
tp46275
sS'which,inhibit'
p46276
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46277
sS'c,and'
p46278
(F1
F0.00057339449541284407
I4
I0
I4
tp46279
sS'beta,adrenergic-blocking'
p46280
(F1
F0.00014334862385321102
I0
I1
I-1
tp46281
sS'much,as'
p46282
(F0
F0
I1
I1
I0
tp46283
sS'psychotic,patients'
p46284
(F1
F0.00014334862385321102
I0
I1
I-1
tp46285
sS'perfused,pancreases'
p46286
(F1
F0.00014334862385321102
I0
I1
I-1
tp46287
sS'in,one'
p46288
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp46289
sS'of,with'
p46290
(F0.33980582524271846
F0.0050172018348623856
I69
I34
I35
tp46291
sS'inter-patient,variability'
p46292
(F1
F0.00014334862385321102
I0
I1
I-1
tp46293
sS'the,neurochemical'
p46294
(F1
F0.00014334862385321102
I0
I1
I-1
tp46295
sS'less,enzyme'
p46296
(F1
F0.00014334862385321102
I0
I1
I-1
tp46297
sS'of,bextra'
p46298
(F1
F0.00014334862385321102
I0
I1
I-1
tp46299
sS'when,combining'
p46300
(F1
F0.00014334862385321102
I0
I1
I-1
tp46301
sS'aptt,assay'
p46302
(F1
F0.00014334862385321102
I0
I1
I-1
tp46303
sS'concentration,time-curve'
p46304
(F1
F0.00014334862385321102
I1
I0
I1
tp46305
sS'simultaneous,fold'
p46306
(F1
F0.00014334862385321102
I1
I0
I1
tp46307
sS't1,of'
p46308
(F1
F0.00014334862385321102
I1
I0
I1
tp46309
sS'hepatotoxicity,of'
p46310
(F1
F0.00014334862385321102
I1
I0
I1
tp46311
sS'to,block'
p46312
(F1
F0.00014334862385321102
I1
I0
I1
tp46313
sS'was,tested'
p46314
(F1
F0.00028669724770642203
I0
I2
I-2
tp46315
sS'and,renal'
p46316
(F0.5
F0.00057339449541284407
I6
I2
I4
tp46317
sS'activity,ganglionic'
p46318
(F1
F0.00014334862385321102
I0
I1
I-1
tp46319
sS'with,congestive'
p46320
(F0
F0
I1
I1
I0
tp46321
sS'unaffected,by'
p46322
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp46323
sS'with,general'
p46324
(F1
F0.00014334862385321102
I0
I1
I-1
tp46325
sS'these,two'
p46326
(F1
F0.00014334862385321102
I1
I0
I1
tp46327
sS'arrhythmias,or'
p46328
(F1
F0.00014334862385321102
I0
I1
I-1
tp46329
sS'that,range'
p46330
(F1
F0.00014334862385321102
I1
I0
I1
tp46331
sS'cimetidine,coadministration'
p46332
(F1
F0.00014334862385321102
I1
I0
I1
tp46333
sS'active,metabolite'
p46334
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp46335
sS'rhabdomyolysis,secondary'
p46336
(F1
F0.00014334862385321102
I1
I0
I1
tp46337
sS'vii,when'
p46338
(F1
F0.00014334862385321102
I0
I1
I-1
tp46339
sS'being,withdrawn'
p46340
(F1
F0.00014334862385321102
I1
I0
I1
tp46341
sS'beadministered,concomitantly'
p46342
(F1
F0.00028669724770642203
I2
I0
I2
tp46343
sS'metabolite,exposure'
p46344
(F1
F0.00014334862385321102
I1
I0
I1
tp46345
sS'not,antagonized'
p46346
(F1
F0.00014334862385321102
I0
I1
I-1
tp46347
sS'immune,response'
p46348
(F1
F0.00028669724770642203
I0
I2
I-2
tp46349
sS'regimen,of'
p46350
(F0.53846153846153844
F0.0010034403669724771
I10
I3
I7
tp46351
sS'v,solution'
p46352
(F1
F0.00014334862385321102
I0
I1
I-1
tp46353
sS'node,higher'
p46354
(F1
F0.00014334862385321102
I1
I0
I1
tp46355
sS'has,an'
p46356
(F0
F0
I1
I1
I0
tp46357
sS'was,abolished'
p46358
(F1
F0.00014334862385321102
I1
I0
I1
tp46359
sS'than,pediatrics'
p46360
(F1
F0.00014334862385321102
I1
I0
I1
tp46361
sS'ethanol,an'
p46362
(F1
F0.00014334862385321102
I1
I0
I1
tp46363
sS'suspension,contains'
p46364
(F1
F0.00014334862385321102
I0
I1
I-1
tp46365
sS'chloramphenicol,or'
p46366
(F1
F0.00014334862385321102
I1
I0
I1
tp46367
sS'greater,when'
p46368
(F1
F0.00014334862385321102
I1
I0
I1
tp46369
sS'm,inhibits'
p46370
(F1
F0.00014334862385321102
I1
I0
I1
tp46371
sS'and,reduction'
p46372
(F1
F0.00014334862385321102
I1
I0
I1
tp46373
sS'alfenta,can'
p46374
(F1
F0.00014334862385321102
I1
I0
I1
tp46375
sS'fluoroquinolone,has'
p46376
(F1
F0.00014334862385321102
I1
I0
I1
tp46377
sS'fluoride,levels'
p46378
(F1
F0.00014334862385321102
I0
I1
I-1
tp46379
sS'the,beta'
p46380
(F1
F0.00014334862385321102
I1
I0
I1
tp46381
sS'to,receive'
p46382
(F1
F0.00028669724770642203
I0
I2
I-2
tp46383
sS'used,anti-peptic'
p46384
(F1
F0.00014334862385321102
I0
I1
I-1
tp46385
sS'slight,decrease'
p46386
(F1
F0.00028669724770642203
I2
I0
I2
tp46387
sS'sharp,fall'
p46388
(F1
F0.00014334862385321102
I1
I0
I1
tp46389
sS'on,either'
p46390
(F1
F0.0008600917431192661
I0
I6
I-6
tp46391
sS'injectable,an'
p46392
(F1
F0.00014334862385321102
I1
I0
I1
tp46393
sS'qd,has'
p46394
(F1
F0.00014334862385321102
I0
I1
I-1
tp46395
sS'agents,when'
p46396
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp46397
sS'mono-oxidases,in'
p46398
(F1
F0.00014334862385321102
I0
I1
I-1
tp46399
sS'curve,and'
p46400
(F1
F0.00014334862385321102
I1
I0
I1
tp46401
sS'orally,has'
p46402
(F1
F0.00014334862385321102
I0
I1
I-1
tp46403
sS'or,times'
p46404
(F1
F0.00014334862385321102
I0
I1
I-1
tp46405
sS'concurrent,therapy'
p46406
(F1
F0.00071674311926605509
I5
I0
I5
tp46407
sS'days,plus'
p46408
(F1
F0.00014334862385321102
I0
I1
I-1
tp46409
sS'with,flolan'
p46410
(F1
F0.00028669724770642203
I2
I0
I2
tp46411
sS'with,has'
p46412
(F0
F0
I5
I5
I0
tp46413
sS'cancidas,and'
p46414
(F1
F0.00014334862385321102
I1
I0
I1
tp46415
sS'hyperpyrexia,has'
p46416
(F1
F0.00014334862385321102
I1
I0
I1
tp46417
sS'telithromycin,hiv'
p46418
(F1
F0.00014334862385321102
I0
I1
I-1
tp46419
sS'taking,vitamin'
p46420
(F1
F0.00014334862385321102
I1
I0
I1
tp46421
sS'be,produced'
p46422
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp46423
sS'as,loop'
p46424
(F1
F0.00014334862385321102
I1
I0
I1
tp46425
sS'cimetidine,a'
p46426
(F1
F0.00014334862385321102
I1
I0
I1
tp46427
sS'txb2,generation'
p46428
(F1
F0.00014334862385321102
I0
I1
I-1
tp46429
sS'metformin,when'
p46430
(F1
F0.00014334862385321102
I0
I1
I-1
tp46431
sS'degree,of'
p46432
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp46433
sS'anafranil,is'
p46434
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46435
sS'that,haldol'
p46436
(F1
F0.00014334862385321102
I1
I0
I1
tp46437
sS'intraperitoneal,doses'
p46438
(F1
F0.00014334862385321102
I1
I0
I1
tp46439
sS'possible,potentiation'
p46440
(F1
F0.00014334862385321102
I0
I1
I-1
tp46441
sS'because,some'
p46442
(F1
F0.00028669724770642203
I2
I0
I2
tp46443
sS'and,short-acting'
p46444
(F1
F0.00014334862385321102
I0
I1
I-1
tp46445
sS'i,acute'
p46446
(F1
F0.00014334862385321102
I0
I1
I-1
tp46447
sS'therefore,use'
p46448
(F1
F0.00014334862385321102
I1
I0
I1
tp46449
sS'day,to'
p46450
(F1
F0.00043004587155963305
I0
I3
I-3
tp46451
sS'endothelial,denudation'
p46452
(F1
F0.00014334862385321102
I0
I1
I-1
tp46453
sS'tricor,and'
p46454
(F1
F0.00014334862385321102
I1
I0
I1
tp46455
sS'agents,actions'
p46456
(F1
F0.00014334862385321102
I0
I1
I-1
tp46457
sS'under,therapy'
p46458
(F1
F0.00014334862385321102
I1
I0
I1
tp46459
sS'likely,by'
p46460
(F1
F0.00014334862385321102
I1
I0
I1
tp46461
sS'the,protein'
p46462
(F0
F0
I2
I2
I0
tp46463
sS'reported,very'
p46464
(F1
F0.00014334862385321102
I1
I0
I1
tp46465
sS'some,general'
p46466
(F1
F0.00014334862385321102
I0
I1
I-1
tp46467
sS'same,proportions'
p46468
(F1
F0.00014334862385321102
I0
I1
I-1
tp46469
sS'conclusions,macrolide'
p46470
(F1
F0.00014334862385321102
I1
I0
I1
tp46471
sS'the,evening'
p46472
(F0
F0
I1
I1
I0
tp46473
sS'glutamic,acid'
p46474
(F1
F0.00014334862385321102
I1
I0
I1
tp46475
sS'but,mc'
p46476
(F1
F0.00014334862385321102
I1
I0
I1
tp46477
sS'least,halved'
p46478
(F1
F0.00014334862385321102
I1
I0
I1
tp46479
sS'm,ptx'
p46480
(F1
F0.00014334862385321102
I1
I0
I1
tp46481
sS'trials,that'
p46482
(F1
F0.00014334862385321102
I0
I1
I-1
tp46483
sS'a,balanced'
p46484
(F1
F0.00014334862385321102
I0
I1
I-1
tp46485
sS'by,decreased'
p46486
(F1
F0.00043004587155963305
I3
I0
I3
tp46487
sS'anticoagulants,including'
p46488
(F1
F0.00014334862385321102
I1
I0
I1
tp46489
sS'potassium,enalapril'
p46490
(F1
F0.00014334862385321102
I1
I0
I1
tp46491
sS'serum,uric'
p46492
(F1
F0.00014334862385321102
I1
I0
I1
tp46493
sS'multidrug-resistant,organisms'
p46494
(F1
F0.00014334862385321102
I0
I1
I-1
tp46495
sS'like,monoamine'
p46496
(F1
F0.00014334862385321102
I1
I0
I1
tp46497
sS'high,affinity'
p46498
(F1
F0.00028669724770642203
I0
I2
I-2
tp46499
sS'digoxin,supraventricular'
p46500
(F1
F0.00014334862385321102
I0
I1
I-1
tp46501
sS'that,seen'
p46502
(F1
F0.00014334862385321102
I0
I1
I-1
tp46503
sS'and,usually'
p46504
(F1
F0.00028669724770642203
I2
I0
I2
tp46505
sS'aureus,a'
p46506
(F1
F0.00014334862385321102
I1
I0
I1
tp46507
sS'structurally,distinct'
p46508
(F1
F0.00014334862385321102
I0
I1
I-1
tp46509
sS'antipsychotic,efficacy'
p46510
(F1
F0.00014334862385321102
I0
I1
I-1
tp46511
sS'extrapyramidal,symptoms'
p46512
(F0
F0
I1
I1
I0
tp46513
sS'are,given'
p46514
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp46515
sS'citalopram,citalopram'
p46516
(F1
F0.00014334862385321102
I1
I0
I1
tp46517
sS'include,increased'
p46518
(F1
F0.00014334862385321102
I1
I0
I1
tp46519
sS'with,grapefruit'
p46520
(F1
F0.00014334862385321102
I0
I1
I-1
tp46521
sS's,regimen'
p46522
(F1
F0.00014334862385321102
I1
I0
I1
tp46523
sS'paroxetine,mg'
p46524
(F1
F0.00014334862385321102
I1
I0
I1
tp46525
sS'who,has'
p46526
(F1
F0.00028669724770642203
I2
I0
I2
tp46527
sS'low,affinity'
p46528
(F1
F0.00014334862385321102
I0
I1
I-1
tp46529
sS'm2,dose'
p46530
(F1
F0.00014334862385321102
I0
I1
I-1
tp46531
sS'who,had'
p46532
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp46533
sS'small,initial'
p46534
(F1
F0.00014334862385321102
I1
I0
I1
tp46535
sS'acetate,stimulated'
p46536
(F1
F0.00014334862385321102
I1
I0
I1
tp46537
sS'of,intramuscularly'
p46538
(F1
F0.00014334862385321102
I0
I1
I-1
tp46539
sS'non-potassium,sparing'
p46540
(F1
F0.00014334862385321102
I1
I0
I1
tp46541
sS'acid,as'
p46542
(F1
F0.00014334862385321102
I1
I0
I1
tp46543
sS'stimulation,study'
p46544
(F1
F0.00014334862385321102
I0
I1
I-1
tp46545
sS'increase,the'
p46546
(F0.52475247524752477
F0.0075974770642201839
I77
I24
I53
tp46547
sS'be,done'
p46548
(F1
F0.00014334862385321102
I1
I0
I1
tp46549
sS'cyp3a4,ketoconazole'
p46550
(F1
F0.00014334862385321102
I0
I1
I-1
tp46551
sS'produced,approximately'
p46552
(F1
F0.00014334862385321102
I0
I1
I-1
tp46553
sS'ns,is'
p46554
(F1
F0.00014334862385321102
I1
I0
I1
tp46555
sS'and,requires'
p46556
(F1
F0.00028669724770642203
I2
I0
I2
tp46557
sS'of,hmg-coa'
p46558
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46559
sS'and,pancreatic'
p46560
(F1
F0.00014334862385321102
I1
I0
I1
tp46561
sS'rat,days'
p46562
(F1
F0.00014334862385321102
I0
I1
I-1
tp46563
sS'placebo-controlled,trial'
p46564
(F1
F0.00014334862385321102
I1
I0
I1
tp46565
sS'by,is'
p46566
(F0
F0
I1
I1
I0
tp46567
sS'at,bedtime'
p46568
(F1
F0.00014334862385321102
I0
I1
I-1
tp46569
sS'and,tenofovir'
p46570
(F1
F0.00014334862385321102
I0
I1
I-1
tp46571
sS'phospholine,iodide'
p46572
(F1
F0.00014334862385321102
I1
I0
I1
tp46573
sS'v,v'
p46574
(F1
F0.00014334862385321102
I0
I1
I-1
tp46575
sS'reduced,dosage'
p46576
(F1
F0.00014334862385321102
I1
I0
I1
tp46577
sS'l-arginine,may'
p46578
(F1
F0.00028669724770642203
I2
I0
I2
tp46579
sS'receiving,multiple'
p46580
(F1
F0.00014334862385321102
I1
I0
I1
tp46581
sS'unknown,slightly'
p46582
(F1
F0.00014334862385321102
I1
I0
I1
tp46583
sS'dysrhythmias,and'
p46584
(F1
F0.00014334862385321102
I1
I0
I1
tp46585
sS'on,clearance'
p46586
(F1
F0.00014334862385321102
I0
I1
I-1
tp46587
sS'arrhythmias,may'
p46588
(F0
F0
I1
I1
I0
tp46589
sS'in,subjects'
p46590
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp46591
sS'elevations,and'
p46592
(F1
F0.00014334862385321102
I1
I0
I1
tp46593
sS'both,crixivan'
p46594
(F1
F0.00014334862385321102
I0
I1
I-1
tp46595
sS'needed,the'
p46596
(F0
F0
I1
I1
I0
tp46597
sS'reduced,the'
p46598
(F1
F0.0012901376146788992
I9
I0
I9
tp46599
sS'effects,were'
p46600
(F0
F0
I2
I2
I0
tp46601
sS'concomitantly,physicians'
p46602
(F1
F0.00014334862385321102
I1
I0
I1
tp46603
sS'fasting,or'
p46604
(F1
F0.00014334862385321102
I0
I1
I-1
tp46605
sS'and,receptors'
p46606
(F1
F0.00014334862385321102
I1
I0
I1
tp46607
sS'to,various'
p46608
(F1
F0.00014334862385321102
I0
I1
I-1
tp46609
sS'prevented,by'
p46610
(F1
F0.00043004587155963305
I3
I0
I3
tp46611
sS'hypnotics,contraindicated'
p46612
(F1
F0.00014334862385321102
I0
I1
I-1
tp46613
sS'consistent,effects'
p46614
(F1
F0.00014334862385321102
I0
I1
I-1
tp46615
sS'a,inhaler'
p46616
(F1
F0.00014334862385321102
I1
I0
I1
tp46617
sS'pretreatment,period'
p46618
(F1
F0.00014334862385321102
I0
I1
I-1
tp46619
sS'acetaminophen,pharmacokinetic'
p46620
(F1
F0.00014334862385321102
I0
I1
I-1
tp46621
sS'cholinergic,reactions'
p46622
(F1
F0.00014334862385321102
I0
I1
I-1
tp46623
sS'was,increased'
p46624
(F1
F0.0008600917431192661
I6
I0
I6
tp46625
sS'other,therapies'
p46626
(F1
F0.00014334862385321102
I0
I1
I-1
tp46627
sS'induce,cyp3a'
p46628
(F1
F0.00014334862385321102
I0
I1
I-1
tp46629
sS'to,nonsteroidal'
p46630
(F1
F0.00014334862385321102
I1
I0
I1
tp46631
sS'alcoholic,beverages'
p46632
(F1
F0.00014334862385321102
I1
I0
I1
tp46633
sS'certain,compounds'
p46634
(F1
F0.00014334862385321102
I1
I0
I1
tp46635
sS'and,changes'
p46636
(F1
F0.00014334862385321102
I0
I1
I-1
tp46637
sS'rates,of'
p46638
(F0
F0
I1
I1
I0
tp46639
sS'ergotamine,or'
p46640
(F1
F0.00014334862385321102
I0
I1
I-1
tp46641
sS'gastrointestinal,lesions'
p46642
(F1
F0.00014334862385321102
I1
I0
I1
tp46643
sS'methoxycoronaridine,mc'
p46644
(F1
F0.00014334862385321102
I0
I1
I-1
tp46645
sS'requirement,i'
p46646
(F1
F0.00014334862385321102
I1
I0
I1
tp46647
sS'of,exogenous'
p46648
(F1
F0.00014334862385321102
I0
I1
I-1
tp46649
sS'day5,of'
p46650
(F1
F0.00014334862385321102
I1
I0
I1
tp46651
sS'avonex,and'
p46652
(F1
F0.00014334862385321102
I0
I1
I-1
tp46653
sS'drawn,if'
p46654
(F1
F0.00014334862385321102
I1
I0
I1
tp46655
sS'block,were'
p46656
(F1
F0.00014334862385321102
I0
I1
I-1
tp46657
sS'in,supporting'
p46658
(F1
F0.00014334862385321102
I0
I1
I-1
tp46659
sS'including,those'
p46660
(F1
F0.00028669724770642203
I2
I0
I2
tp46661
sS'meclofenamic,acid'
p46662
(F1
F0.00014334862385321102
I1
I0
I1
tp46663
sS'hour,blood'
p46664
(F1
F0.00014334862385321102
I1
I0
I1
tp46665
sS'inducer,of'
p46666
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp46667
sS'cognitive,dysfunction'
p46668
(F1
F0.00014334862385321102
I1
I0
I1
tp46669
sS'with,impaired'
p46670
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46671
sS'greater,therapeutic'
p46672
(F1
F0.00014334862385321102
I0
I1
I-1
tp46673
sS'important,for'
p46674
(F1
F0.00014334862385321102
I0
I1
I-1
tp46675
sS'inducer,or'
p46676
(F1
F0.00014334862385321102
I1
I0
I1
tp46677
sS'bid,on'
p46678
(F1
F0.00028669724770642203
I0
I2
I-2
tp46679
sS'wort,in'
p46680
(F1
F0.00014334862385321102
I0
I1
I-1
tp46681
sS'm,was'
p46682
(F1
F0.00014334862385321102
I0
I1
I-1
tp46683
sS'with,administration'
p46684
(F1
F0.00014334862385321102
I0
I1
I-1
tp46685
sS'with,agents'
p46686
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp46687
sS'clonidine,may'
p46688
(F1
F0.00014334862385321102
I1
I0
I1
tp46689
sS'by,as'
p46690
(F1
F0.00014334862385321102
I1
I0
I1
tp46691
sS'da,sh'
p46692
(F1
F0.00014334862385321102
I0
I1
I-1
tp46693
sS'by,at'
p46694
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46695
sS'ethyl,increases'
p46696
(F1
F0.00014334862385321102
I1
I0
I1
tp46697
sS'also,using'
p46698
(F1
F0.00014334862385321102
I1
I0
I1
tp46699
sS'showed,no'
p46700
(F1
F0.00043004587155963305
I0
I3
I-3
tp46701
sS'by,an'
p46702
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp46703
sS'significance,of'
p46704
(F1
F0.00028669724770642203
I2
I0
I2
tp46705
sS'with,each'
p46706
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46707
sS'proteins,may'
p46708
(F1
F0.00028669724770642203
I0
I2
I-2
tp46709
sS'failure,severe'
p46710
(F1
F0.00014334862385321102
I1
I0
I1
tp46711
sS'mg,intravenous'
p46712
(F1
F0.00014334862385321102
I0
I1
I-1
tp46713
sS'appropriate,package'
p46714
(F1
F0.00014334862385321102
I0
I1
I-1
tp46715
sS'diets,containing'
p46716
(F1
F0.00014334862385321102
I0
I1
I-1
tp46717
sS'further,these'
p46718
(F1
F0.00014334862385321102
I0
I1
I-1
tp46719
sS'trough,plasma'
p46720
(F0
F0
I2
I2
I0
tp46721
sS'significantly,p'
p46722
(F1
F0.00014334862385321102
I1
I0
I1
tp46723
sS'with,signs'
p46724
(F1
F0.00014334862385321102
I1
I0
I1
tp46725
sS'adjusting,and'
p46726
(F1
F0.00043004587155963305
I3
I0
I3
tp46727
sS'ranging,from'
p46728
(F0
F0
I2
I2
I0
tp46729
sS'profiles,comparable'
p46730
(F1
F0.00014334862385321102
I0
I1
I-1
tp46731
sS'epa,supplements'
p46732
(F1
F0.00014334862385321102
I1
I0
I1
tp46733
sS'to,fold'
p46734
(F1
F0.0008600917431192661
I6
I0
I6
tp46735
sS'nephrotoxicity,and'
p46736
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp46737
sS'with,regimens'
p46738
(F1
F0.00014334862385321102
I0
I1
I-1
tp46739
sS'the,initiate'
p46740
(F1
F0.00014334862385321102
I1
I0
I1
tp46741
sS'and,cardiac'
p46742
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp46743
sS'sinus,node'
p46744
(F1
F0.00014334862385321102
I1
I0
I1
tp46745
sS'and,lodine'
p46746
(F0
F0
I1
I1
I0
tp46747
sS'but,dose-dependently'
p46748
(F1
F0.00014334862385321102
I1
I0
I1
tp46749
sS'that,would'
p46750
(F1
F0.00028669724770642203
I0
I2
I-2
tp46751
sS'megakaryocytes,with'
p46752
(F0
F0
I1
I1
I0
tp46753
sS'tnf,antagonists'
p46754
(F1
F0.00014334862385321102
I1
I0
I1
tp46755
sS'carefully,about'
p46756
(F1
F0.00014334862385321102
I0
I1
I-1
tp46757
sS'is,started'
p46758
(F1
F0.00028669724770642203
I2
I0
I2
tp46759
sS'squirrel,monkeys'
p46760
(F1
F0.00014334862385321102
I0
I1
I-1
tp46761
sS'pyrocarbonate,could'
p46762
(F1
F0.00014334862385321102
I0
I1
I-1
tp46763
sS'absorption,site'
p46764
(F1
F0.00014334862385321102
I0
I1
I-1
tp46765
sS'following,nimbex'
p46766
(F1
F0.00014334862385321102
I1
I0
I1
tp46767
sS'modification,of'
p46768
(F0
F0
I1
I1
I0
tp46769
sS'data,indicate'
p46770
(F0.75
F0.0008600917431192661
I7
I1
I6
tp46771
sS'certain,types'
p46772
(F1
F0.00014334862385321102
I1
I0
I1
tp46773
sS'to,individuals'
p46774
(F1
F0.00014334862385321102
I0
I1
I-1
tp46775
sS'evaluated,in'
p46776
(F1
F0.0017201834862385322
I0
I12
I-12
tp46777
sS'does,affect'
p46778
(F1
F0.00014334862385321102
I0
I1
I-1
tp46779
sS'no,potential'
p46780
(F1
F0.00014334862385321102
I0
I1
I-1
tp46781
sS'experience,bleeding'
p46782
(F1
F0.00028669724770642203
I2
I0
I2
tp46783
sS'to,copaxone'
p46784
(F1
F0.00014334862385321102
I0
I1
I-1
tp46785
sS'of,human'
p46786
(F1
F0.00014334862385321102
I1
I0
I1
tp46787
sS'the,user'
p46788
(F1
F0.00014334862385321102
I0
I1
I-1
tp46789
sS'of,guinea-pig'
p46790
(F1
F0.00014334862385321102
I0
I1
I-1
tp46791
sS'suppressed,by'
p46792
(F1
F0.00014334862385321102
I0
I1
I-1
tp46793
sS'tykerb,is'
p46794
(F1
F0.00014334862385321102
I0
I1
I-1
tp46795
sS'cause,hypertension'
p46796
(F1
F0.00014334862385321102
I1
I0
I1
tp46797
sS'in,rabbit'
p46798
(F1
F0.00028669724770642203
I2
I0
I2
tp46799
sS'blockers,l-type'
p46800
(F1
F0.00014334862385321102
I0
I1
I-1
tp46801
sS'when,multiple'
p46802
(F1
F0.00028669724770642203
I2
I0
I2
tp46803
sS'for,increased'
p46804
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp46805
sS'of,intestinal'
p46806
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp46807
sS'hyperreflexia,and'
p46808
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp46809
sS'concomitant,medications'
p46810
(F0.77777777777777779
F0.0010034403669724771
I1
I8
I-7
tp46811
sS'for,increases'
p46812
(F1
F0.00014334862385321102
I1
I0
I1
tp46813
sS'indicating,no'
p46814
(F1
F0.00028669724770642203
I0
I2
I-2
tp46815
sS'videx,should'
p46816
(F0
F0
I1
I1
I0
tp46817
sS'frequently,thereafter'
p46818
(F1
F0.00014334862385321102
I1
I0
I1
tp46819
sS'after,introduction'
p46820
(F1
F0.00014334862385321102
I1
I0
I1
tp46821
sS'inconsistent,reports'
p46822
(F1
F0.00014334862385321102
I0
I1
I-1
tp46823
sS'antidepressant,eg'
p46824
(F1
F0.00014334862385321102
I1
I0
I1
tp46825
sS'increased,serum'
p46826
(F1
F0.0008600917431192661
I6
I0
I6
tp46827
sS'or,systemic'
p46828
(F1
F0.00014334862385321102
I1
I0
I1
tp46829
sS'and,extends'
p46830
(F1
F0.00014334862385321102
I1
I0
I1
tp46831
sS'to,for'
p46832
(F1
F0.00014334862385321102
I1
I0
I1
tp46833
sS'antacid,products'
p46834
(F1
F0.00014334862385321102
I0
I1
I-1
tp46835
sS'here,demonstrate'
p46836
(F1
F0.00014334862385321102
I0
I1
I-1
tp46837
sS'of,absorption'
p46838
(F0.16666666666666666
F0.00028669724770642203
I5
I7
I-2
tp46839
sS'that,intraventricular'
p46840
(F1
F0.00014334862385321102
I0
I1
I-1
tp46841
sS'metabolizers,after'
p46842
(F1
F0.00014334862385321102
I0
I1
I-1
tp46843
sS'enzyme,inducers'
p46844
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp46845
sS'many,people'
p46846
(F1
F0.00014334862385321102
I0
I1
I-1
tp46847
sS'with,anion-exchange'
p46848
(F1
F0.00014334862385321102
I1
I0
I1
tp46849
sS'cells,whereas'
p46850
(F1
F0.00028669724770642203
I0
I2
I-2
tp46851
sS'vitro,data'
p46852
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp46853
sS'on,resistance'
p46854
(F1
F0.00014334862385321102
I0
I1
I-1
tp46855
sS'evaluated,cyp1a2'
p46856
(F1
F0.00014334862385321102
I0
I1
I-1
tp46857
sS'after,clinical'
p46858
(F1
F0.00014334862385321102
I0
I1
I-1
tp46859
sS'unsteady,gait'
p46860
(F1
F0.00014334862385321102
I1
I0
I1
tp46861
sS'cyp1a2,inducers'
p46862
(F1
F0.00014334862385321102
I0
I1
I-1
tp46863
sS'classes,or'
p46864
(F1
F0.00014334862385321102
I1
I0
I1
tp46865
sS'concentrations,it'
p46866
(F1
F0.00014334862385321102
I0
I1
I-1
tp46867
sS'classes,of'
p46868
(F1
F0.00014334862385321102
I1
I0
I1
tp46869
sS'during,conversion'
p46870
(F1
F0.00014334862385321102
I0
I1
I-1
tp46871
sS'affect,bleeding'
p46872
(F1
F0.00014334862385321102
I1
I0
I1
tp46873
sS'cns-active,should'
p46874
(F1
F0.00014334862385321102
I1
I0
I1
tp46875
sS'weeks,and'
p46876
(F1
F0.00014334862385321102
I0
I1
I-1
tp46877
sS'local,like'
p46878
(F1
F0.00014334862385321102
I0
I1
I-1
tp46879
sS'kg,day'
p46880
(F0.25
F0.00028669724770642203
I5
I3
I2
tp46881
sS'the,disposition'
p46882
(F1
F0.00028669724770642203
I0
I2
I-2
tp46883
sS'negatively,coupled'
p46884
(F1
F0.00014334862385321102
I0
I1
I-1
tp46885
sS'and,proleukin'
p46886
(F1
F0.00014334862385321102
I1
I0
I1
tp46887
sS'aggravated,by'
p46888
(F1
F0.00014334862385321102
I1
I0
I1
tp46889
sS'inactivated,due'
p46890
(F1
F0.00014334862385321102
I1
I0
I1
tp46891
sS'and,levonorgestrel-treated'
p46892
(F1
F0.00014334862385321102
I0
I1
I-1
tp46893
sS'extends,its'
p46894
(F1
F0.00014334862385321102
I1
I0
I1
tp46895
sS'change,significantly'
p46896
(F1
F0.00014334862385321102
I0
I1
I-1
tp46897
sS'zyvox,or'
p46898
(F1
F0.00014334862385321102
I1
I0
I1
tp46899
sS'agents,seizures'
p46900
(F1
F0.00014334862385321102
I1
I0
I1
tp46901
sS'antagonists,because'
p46902
(F1
F0.00014334862385321102
I1
I0
I1
tp46903
sS'normal,when'
p46904
(F1
F0.00014334862385321102
I0
I1
I-1
tp46905
sS'enzyme,oxidation'
p46906
(F1
F0.00014334862385321102
I0
I1
I-1
tp46907
sS'to,warrant'
p46908
(F1
F0.00014334862385321102
I1
I0
I1
tp46909
sS'and,suboxone'
p46910
(F1
F0.00014334862385321102
I1
I0
I1
tp46911
sS'of,patients'
p46912
(F0.21212121212121213
F0.0010034403669724771
I13
I20
I-7
tp46913
sS'the,perioperative'
p46914
(F1
F0.00014334862385321102
I1
I0
I1
tp46915
sS'have,an'
p46916
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp46917
sS'similarly,to'
p46918
(F1
F0.00014334862385321102
I1
I0
I1
tp46919
sS'during,co-administration'
p46920
(F1
F0.00014334862385321102
I0
I1
I-1
tp46921
sS'kg,bwt'
p46922
(F1
F0.00014334862385321102
I0
I1
I-1
tp46923
sS'prothrom-bin,time'
p46924
(F1
F0.00028669724770642203
I2
I0
I2
tp46925
sS'the,ninds'
p46926
(F1
F0.00014334862385321102
I0
I1
I-1
tp46927
sS'reason,the'
p46928
(F0
F0
I1
I1
I0
tp46929
sS'the,diets'
p46930
(F1
F0.00014334862385321102
I0
I1
I-1
tp46931
sS'metabolite,after'
p46932
(F1
F0.00014334862385321102
I0
I1
I-1
tp46933
sS'administration,does'
p46934
(F1
F0.00014334862385321102
I0
I1
I-1
tp46935
sS'of,hivid'
p46936
(F0
F0
I1
I1
I0
tp46937
sS'zyvox,and'
p46938
(F1
F0.00028669724770642203
I2
I0
I2
tp46939
sS'is,sensitive'
p46940
(F1
F0.00014334862385321102
I0
I1
I-1
tp46941
sS'examples,include'
p46942
(F1
F0.00014334862385321102
I0
I1
I-1
tp46943
sS'the,solubility'
p46944
(F1
F0.00014334862385321102
I0
I1
I-1
tp46945
sS'of,gly-buride'
p46946
(F1
F0.00014334862385321102
I0
I1
I-1
tp46947
sS'of,amphotericin'
p46948
(F0
F0
I2
I2
I0
tp46949
sS'that,induce'
p46950
(F0.090909090909090912
F0.00014334862385321102
I5
I6
I-1
tp46951
sS'were,cardiac'
p46952
(F1
F0.00014334862385321102
I0
I1
I-1
tp46953
sS'mtc-mdp,as'
p46954
(F1
F0.00014334862385321102
I0
I1
I-1
tp46955
sS'therapeutic,effects'
p46956
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46957
sS'elimination,and'
p46958
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp46959
sS'of,theophylline'
p46960
(F1
F0.00014334862385321102
I0
I1
I-1
tp46961
sS'daypro,and'
p46962
(F1
F0.00014334862385321102
I0
I1
I-1
tp46963
sS'proteins,is'
p46964
(F0
F0
I1
I1
I0
tp46965
sS'reduced,while'
p46966
(F1
F0.00014334862385321102
I1
I0
I1
tp46967
sS'of,cyp2c9'
p46968
(F0
F0
I1
I1
I0
tp46969
sS'as,anorexia'
p46970
(F1
F0.00014334862385321102
I1
I0
I1
tp46971
sS'ketoconazole,erythromycin'
p46972
(F1
F0.00014334862385321102
I0
I1
I-1
tp46973
sS'of,beta'
p46974
(F1
F0.00028669724770642203
I2
I0
I2
tp46975
sS'can,prolong'
p46976
(F1
F0.00014334862385321102
I1
I0
I1
tp46977
sS'following,administration'
p46978
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp46979
sS'however,reports'
p46980
(F1
F0.00014334862385321102
I1
I0
I1
tp46981
sS'inhibitor,of'
p46982
(F0.22580645161290322
F0.0010034403669724771
I19
I12
I7
tp46983
sS'of,heparinized'
p46984
(F1
F0.00014334862385321102
I1
I0
I1
tp46985
sS'also,induces'
p46986
(F1
F0.00014334862385321102
I0
I1
I-1
tp46987
sS'therapy,the'
p46988
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46989
sS'inhibitor,or'
p46990
(F1
F0.00014334862385321102
I0
I1
I-1
tp46991
sS'pressor,agents'
p46992
(F1
F0.00014334862385321102
I0
I1
I-1
tp46993
sS'the,bleeding'
p46994
(F1
F0.00014334862385321102
I1
I0
I1
tp46995
sS'simply,normalizing'
p46996
(F1
F0.00014334862385321102
I0
I1
I-1
tp46997
sS'it,alter'
p46998
(F1
F0.00014334862385321102
I0
I1
I-1
tp46999
sS'and,medication'
p47000
(F1
F0.00014334862385321102
I1
I0
I1
tp47001
sS'this,time'
p47002
(F1
F0.00014334862385321102
I1
I0
I1
tp47003
sS'vaccine,inhalation'
p47004
(F1
F0.00014334862385321102
I1
I0
I1
tp47005
sS'levels,limit'
p47006
(F1
F0.00014334862385321102
I1
I0
I1
tp47007
sS'gas,chromatographic-mass'
p47008
(F1
F0.00014334862385321102
I0
I1
I-1
tp47009
sS'were,randomly'
p47010
(F1
F0.00028669724770642203
I0
I2
I-2
tp47011
sS'design,that'
p47012
(F1
F0.00014334862385321102
I1
I0
I1
tp47013
sS'volunteers,there'
p47014
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp47015
sS'of,increases'
p47016
(F1
F0.00028669724770642203
I2
I0
I2
tp47017
sS'sinus,rhythm'
p47018
(F1
F0.00014334862385321102
I1
I0
I1
tp47019
sS'effects,by'
p47020
(F1
F0.00014334862385321102
I1
I0
I1
tp47021
sS'antibiotics,pregnancy'
p47022
(F1
F0.00014334862385321102
I0
I1
I-1
tp47023
sS'of,increased'
p47024
(F0.45454545454545453
F0.0014334862385321102
I16
I6
I10
tp47025
sS'from,dietary-obese'
p47026
(F1
F0.00028669724770642203
I0
I2
I-2
tp47027
sS'using,acetate'
p47028
(F1
F0.00014334862385321102
I1
I0
I1
tp47029
sS'cecectomized,rats'
p47030
(F1
F0.00028669724770642203
I0
I2
I-2
tp47031
sS'three,duloxetine-treated'
p47032
(F1
F0.00014334862385321102
I0
I1
I-1
tp47033
sS'one,third'
p47034
(F1
F0.00014334862385321102
I1
I0
I1
tp47035
sS'digoxin,coadministration'
p47036
(F1
F0.00014334862385321102
I1
I0
I1
tp47037
sS'with,long-'
p47038
(F1
F0.00014334862385321102
I0
I1
I-1
tp47039
sS'endothelial,dysfunction'
p47040
(F1
F0.00014334862385321102
I0
I1
I-1
tp47041
sS'certain,microsomal'
p47042
(F1
F0.00014334862385321102
I1
I0
I1
tp47043
sS'coagulation,system'
p47044
(F1
F0.00014334862385321102
I0
I1
I-1
tp47045
sS'greater,in'
p47046
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp47047
sS'to,require'
p47048
(F1
F0.00014334862385321102
I1
I0
I1
tp47049
sS'rashes,with'
p47050
(F1
F0.00014334862385321102
I0
I1
I-1
tp47051
sS'than,of'
p47052
(F1
F0.00014334862385321102
I0
I1
I-1
tp47053
sS'mg,subcutaneous'
p47054
(F1
F0.00014334862385321102
I0
I1
I-1
tp47055
sS'warfarin-vitamin,k'
p47056
(F1
F0.00014334862385321102
I1
I0
I1
tp47057
sS'haldol,may'
p47058
(F1
F0.00014334862385321102
I1
I0
I1
tp47059
sS'tricyclic,tcas'
p47060
(F1
F0.00014334862385321102
I0
I1
I-1
tp47061
sS'would,warrant'
p47062
(F1
F0.00014334862385321102
I0
I1
I-1
tp47063
sS'with,vitamin'
p47064
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp47065
sS'to,several-'
p47066
(F1
F0.00014334862385321102
I0
I1
I-1
tp47067
sS'rapid,fluctuations'
p47068
(F1
F0.00014334862385321102
I1
I0
I1
tp47069
sS'polymer,p'
p47070
(F1
F0.00014334862385321102
I0
I1
I-1
tp47071
sS'rat,thoracic'
p47072
(F1
F0.00014334862385321102
I0
I1
I-1
tp47073
sS'tablets,are'
p47074
(F1
F0.00014334862385321102
I1
I0
I1
tp47075
sS'measured,in'
p47076
(F1
F0.00014334862385321102
I0
I1
I-1
tp47077
sS'acetaminophen,in'
p47078
(F1
F0.00014334862385321102
I1
I0
I1
tp47079
sS'isosorbide,mononitrate'
p47080
(F1
F0.00014334862385321102
I1
I0
I1
tp47081
sS'in,cyp2d6'
p47082
(F1
F0.00014334862385321102
I1
I0
I1
tp47083
sS'include,sufficient'
p47084
(F1
F0.00014334862385321102
I0
I1
I-1
tp47085
sS'cardiac,channel'
p47086
(F1
F0.00014334862385321102
I0
I1
I-1
tp47087
sS'also,occur'
p47088
(F1
F0.00014334862385321102
I0
I1
I-1
tp47089
sS'maximize,the'
p47090
(F1
F0.00014334862385321102
I0
I1
I-1
tp47091
sS'and,then'
p47092
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp47093
sS'antagonists,should'
p47094
(F1
F0.00028669724770642203
I2
I0
I2
tp47095
sS'overall,response'
p47096
(F0
F0
I1
I1
I0
tp47097
sS'for,cmax'
p47098
(F1
F0.00014334862385321102
I1
I0
I1
tp47099
sS'with,glycosides'
p47100
(F1
F0.00014334862385321102
I1
I0
I1
tp47101
sS'intravenous,injection'
p47102
(F1
F0.00028669724770642203
I2
I0
I2
tp47103
sS'is,associated'
p47104
(F1
F0.00014334862385321102
I0
I1
I-1
tp47105
sS'brovana,may'
p47106
(F1
F0.00028669724770642203
I2
I0
I2
tp47107
sS'accelerates,the'
p47108
(F1
F0.00014334862385321102
I1
I0
I1
tp47109
sS'nsaids,can'
p47110
(F1
F0.0008600917431192661
I6
I0
I6
tp47111
sS'common,transport'
p47112
(F1
F0.00014334862385321102
I0
I1
I-1
tp47113
sS'eliminated,or'
p47114
(F1
F0.00014334862385321102
I0
I1
I-1
tp47115
sS'cell,and'
p47116
(F1
F0.00014334862385321102
I0
I1
I-1
tp47117
sS'the,depth'
p47118
(F1
F0.00014334862385321102
I1
I0
I1
tp47119
sS'by,bretylium'
p47120
(F1
F0.00014334862385321102
I1
I0
I1
tp47121
sS'etc,that'
p47122
(F1
F0.00014334862385321102
I1
I0
I1
tp47123
sS'by,concurrent'
p47124
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47125
sS'either,and'
p47126
(F0
F0
I1
I1
I0
tp47127
sS'simultaneous,use'
p47128
(F0
F0
I2
I2
I0
tp47129
sS'in,neither'
p47130
(F1
F0.00014334862385321102
I0
I1
I-1
tp47131
sS'suppress,certain'
p47132
(F1
F0.00014334862385321102
I0
I1
I-1
tp47133
sS'alone,they'
p47134
(F1
F0.00014334862385321102
I1
I0
I1
tp47135
sS'lower,pulmonary'
p47136
(F1
F0.00014334862385321102
I1
I0
I1
tp47137
sS'noted,in'
p47138
(F1
F0.00014334862385321102
I1
I0
I1
tp47139
sS'to,plenaxis'
p47140
(F1
F0.00014334862385321102
I0
I1
I-1
tp47141
sS'vs,placebo'
p47142
(F1
F0.00014334862385321102
I0
I1
I-1
tp47143
sS'was,significantly'
p47144
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp47145
sS'and,agitation'
p47146
(F1
F0.00014334862385321102
I0
I1
I-1
tp47147
sS'undergoing,ptca'
p47148
(F1
F0.00014334862385321102
I1
I0
I1
tp47149
sS'or,delavirdine-based'
p47150
(F1
F0.00014334862385321102
I0
I1
I-1
tp47151
sS'pigeons,nanm'
p47152
(F1
F0.00014334862385321102
I0
I1
I-1
tp47153
sS'preliminary,data'
p47154
(F1
F0.00014334862385321102
I1
I0
I1
tp47155
sS'received,alone'
p47156
(F1
F0.00028669724770642203
I0
I2
I-2
tp47157
sS'in,glucose'
p47158
(F1
F0.00014334862385321102
I1
I0
I1
tp47159
sS'ergot-type,oxytocic'
p47160
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47161
sS'depressants,should'
p47162
(F1
F0.00014334862385321102
I1
I0
I1
tp47163
sS'that,m'
p47164
(F1
F0.00014334862385321102
I0
I1
I-1
tp47165
sS'usually,a'
p47166
(F1
F0.00014334862385321102
I1
I0
I1
tp47167
sS'protein,may'
p47168
(F1
F0.00014334862385321102
I1
I0
I1
tp47169
sS'of,dmpge2'
p47170
(F1
F0.00014334862385321102
I0
I1
I-1
tp47171
sS'of,enbrel'
p47172
(F1
F0.00014334862385321102
I0
I1
I-1
tp47173
sS'organophosphorous,compound'
p47174
(F1
F0.00014334862385321102
I0
I1
I-1
tp47175
sS'interpretation,glucose'
p47176
(F1
F0.00014334862385321102
I0
I1
I-1
tp47177
sS'with,hiv-nhl'
p47178
(F1
F0.00014334862385321102
I0
I1
I-1
tp47179
sS'bad,general'
p47180
(F1
F0.00014334862385321102
I1
I0
I1
tp47181
sS'decision,must'
p47182
(F1
F0.00014334862385321102
I0
I1
I-1
tp47183
sS'for,long'
p47184
(F1
F0.00014334862385321102
I0
I1
I-1
tp47185
sS'medications,including'
p47186
(F1
F0.00014334862385321102
I0
I1
I-1
tp47187
sS'safely,coadministered'
p47188
(F1
F0.00014334862385321102
I0
I1
I-1
tp47189
sS'blockers,requires'
p47190
(F1
F0.00014334862385321102
I1
I0
I1
tp47191
sS'of,cyp'
p47192
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47193
sS'an,interactive'
p47194
(F1
F0.00028669724770642203
I0
I2
I-2
tp47195
sS'tachycardia,in'
p47196
(F1
F0.00014334862385321102
I1
I0
I1
tp47197
sS'isoniazid,may'
p47198
(F1
F0.00014334862385321102
I1
I0
I1
tp47199
sS'certain,tricyclic'
p47200
(F1
F0.00014334862385321102
I1
I0
I1
tp47201
sS'prolongation,with'
p47202
(F1
F0.00014334862385321102
I0
I1
I-1
tp47203
sS'elemental,reduced'
p47204
(F1
F0.00014334862385321102
I1
I0
I1
tp47205
sS'pathway,that'
p47206
(F1
F0.00014334862385321102
I0
I1
I-1
tp47207
sS'a,preparation'
p47208
(F1
F0.00014334862385321102
I1
I0
I1
tp47209
sS'fold,higher'
p47210
(F1
F0.00014334862385321102
I1
I0
I1
tp47211
sS'platelet-aggregation,reactions'
p47212
(F1
F0.00014334862385321102
I1
I0
I1
tp47213
sS'to,transport-related'
p47214
(F1
F0.00014334862385321102
I1
I0
I1
tp47215
sS'cholesterol,levels'
p47216
(F1
F0.00014334862385321102
I1
I0
I1
tp47217
sS'excretion,but'
p47218
(F1
F0.00014334862385321102
I1
I0
I1
tp47219
sS'nalfon,and'
p47220
(F1
F0.00028669724770642203
I2
I0
I2
tp47221
sS'receiving,known'
p47222
(F1
F0.00014334862385321102
I1
I0
I1
tp47223
sS'state,on'
p47224
(F1
F0.00014334862385321102
I0
I1
I-1
tp47225
sS'response,was'
p47226
(F1
F0.00014334862385321102
I0
I1
I-1
tp47227
sS'any,unexpected'
p47228
(F1
F0.00014334862385321102
I0
I1
I-1
tp47229
sS'with,cgs'
p47230
(F1
F0.00014334862385321102
I1
I0
I1
tp47231
sS'a4,cyp3a4'
p47232
(F1
F0.00014334862385321102
I0
I1
I-1
tp47233
sS'after,intravenous'
p47234
(F1
F0.00014334862385321102
I0
I1
I-1
tp47235
sS'lapatinib,inhibits'
p47236
(F1
F0.00014334862385321102
I0
I1
I-1
tp47237
sS'the,maintenance'
p47238
(F0
F0
I1
I1
I0
tp47239
sS'various,pesticides'
p47240
(F1
F0.00014334862385321102
I0
I1
I-1
tp47241
sS'h,antagonists'
p47242
(F0
F0
I1
I1
I0
tp47243
sS'hmgcoa,reductase'
p47244
(F1
F0.00028669724770642203
I0
I2
I-2
tp47245
sS'can,attenuate'
p47246
(F1
F0.00028669724770642203
I2
I0
I2
tp47247
sS'high,maintenance'
p47248
(F1
F0.00014334862385321102
I1
I0
I1
tp47249
sS'anti-arrhythmic,agents'
p47250
(F1
F0.00014334862385321102
I0
I1
I-1
tp47251
sS'estradiol,and'
p47252
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp47253
sS'dl,dose'
p47254
(F1
F0.00014334862385321102
I1
I0
I1
tp47255
sS'inomax,on'
p47256
(F1
F0.00014334862385321102
I1
I0
I1
tp47257
sS'severe,rhabdomyolysis'
p47258
(F1
F0.00014334862385321102
I1
I0
I1
tp47259
sS'well,concurrent'
p47260
(F1
F0.00014334862385321102
I1
I0
I1
tp47261
sS'examine,the'
p47262
(F1
F0.00043004587155963305
I0
I3
I-3
tp47263
sS'ergocalcitriol,will'
p47264
(F1
F0.00043004587155963305
I0
I3
I-3
tp47265
sS'be,interrupted'
p47266
(F1
F0.00014334862385321102
I0
I1
I-1
tp47267
sS'increases,extracellular'
p47268
(F1
F0.00014334862385321102
I0
I1
I-1
tp47269
sS'withdrawn,several'
p47270
(F1
F0.00014334862385321102
I1
I0
I1
tp47271
sS'or,compete'
p47272
(F1
F0.00014334862385321102
I0
I1
I-1
tp47273
sS'of,beta-adrenergic'
p47274
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47275
sS'adl-8,is'
p47276
(F1
F0.00014334862385321102
I1
I0
I1
tp47277
sS'colazal,however'
p47278
(F1
F0.00014334862385321102
I0
I1
I-1
tp47279
sS'enhance,nutrient'
p47280
(F1
F0.00014334862385321102
I1
I0
I1
tp47281
sS'of,only'
p47282
(F1
F0.00028669724770642203
I2
I0
I2
tp47283
sS'times,day'
p47284
(F1
F0.00014334862385321102
I0
I1
I-1
tp47285
sS'document,no'
p47286
(F1
F0.00014334862385321102
I0
I1
I-1
tp47287
sS'as,channel-blockers'
p47288
(F1
F0.00014334862385321102
I0
I1
I-1
tp47289
sS'recommended,and'
p47290
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47291
sS'a,sulfa-based'
p47292
(F1
F0.00014334862385321102
I0
I1
I-1
tp47293
sS'n-acetyltransferase,may'
p47294
(F1
F0.00014334862385321102
I1
I0
I1
tp47295
sS'd,is'
p47296
(F1
F0.00014334862385321102
I0
I1
I-1
tp47297
sS'to,fivefold'
p47298
(F1
F0.00014334862385321102
I0
I1
I-1
tp47299
sS'this,activity'
p47300
(F1
F0.00014334862385321102
I0
I1
I-1
tp47301
sS'warfarin,eszopiclone'
p47302
(F1
F0.00014334862385321102
I0
I1
I-1
tp47303
sS'metabolizing,enzymes'
p47304
(F1
F0.00014334862385321102
I0
I1
I-1
tp47305
sS'rate-limiting,step'
p47306
(F1
F0.00014334862385321102
I0
I1
I-1
tp47307
sS'exposure,and'
p47308
(F1
F0.00014334862385321102
I1
I0
I1
tp47309
sS'to,survive'
p47310
(F1
F0.00014334862385321102
I0
I1
I-1
tp47311
sS'may,affect'
p47312
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp47313
sS'cause,severe'
p47314
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp47315
sS'related,metabolic'
p47316
(F1
F0.00014334862385321102
I0
I1
I-1
tp47317
sS'mtx,nsaids'
p47318
(F1
F0.00028669724770642203
I0
I2
I-2
tp47319
sS'both,invirase'
p47320
(F1
F0.00014334862385321102
I0
I1
I-1
tp47321
sS'containing,sequential'
p47322
(F1
F0.00014334862385321102
I1
I0
I1
tp47323
sS'include,optimal'
p47324
(F1
F0.00014334862385321102
I0
I1
I-1
tp47325
sS'false-positive,reaction'
p47326
(F1
F0.00071674311926605509
I0
I5
I-5
tp47327
sS'made,of'
p47328
(F0
F0
I1
I1
I0
tp47329
sS'from,intravenous'
p47330
(F1
F0.00014334862385321102
I0
I1
I-1
tp47331
sS'time,course'
p47332
(F1
F0.00014334862385321102
I0
I1
I-1
tp47333
sS'agents,dynamic'
p47334
(F1
F0.00014334862385321102
I0
I1
I-1
tp47335
sS'taking,this'
p47336
(F1
F0.00014334862385321102
I0
I1
I-1
tp47337
sS'acetate,l-histidine'
p47338
(F1
F0.00014334862385321102
I1
I0
I1
tp47339
sS'behavior,in'
p47340
(F1
F0.00028669724770642203
I0
I2
I-2
tp47341
sS'these,disturbances'
p47342
(F1
F0.00014334862385321102
I1
I0
I1
tp47343
sS'ptx,c129h223n3o54'
p47344
(F1
F0.00014334862385321102
I0
I1
I-1
tp47345
sS'of,many'
p47346
(F1
F0.00014334862385321102
I1
I0
I1
tp47347
sS'cholestyramine,has'
p47348
(F1
F0.00043004587155963305
I3
I0
I3
tp47349
sS'diet,high'
p47350
(F1
F0.00014334862385321102
I1
I0
I1
tp47351
sS'of,antimicrobial'
p47352
(F1
F0.00014334862385321102
I0
I1
I-1
tp47353
sS'high,temperature'
p47354
(F1
F0.00014334862385321102
I1
I0
I1
tp47355
sS'pronounced,though'
p47356
(F1
F0.00014334862385321102
I1
I0
I1
tp47357
sS'not,performed'
p47358
(F1
F0.00028669724770642203
I0
I2
I-2
tp47359
sS'concentrating,as'
p47360
(F1
F0.00014334862385321102
I0
I1
I-1
tp47361
sS'adjustments,considered'
p47362
(F1
F0.00014334862385321102
I1
I0
I1
tp47363
sS'using,more'
p47364
(F1
F0.00014334862385321102
I0
I1
I-1
tp47365
sS'symptoms,that'
p47366
(F1
F0.00014334862385321102
I1
I0
I1
tp47367
sS'together,with'
p47368
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp47369
sS'alternate-day,administration'
p47370
(F1
F0.00014334862385321102
I1
I0
I1
tp47371
sS'the,tca'
p47372
(F1
F0.00014334862385321102
I1
I0
I1
tp47373
sS'therefore,potential'
p47374
(F1
F0.00014334862385321102
I0
I1
I-1
tp47375
sS'professional,know'
p47376
(F1
F0.00014334862385321102
I1
I0
I1
tp47377
sS'such,medication'
p47378
(F1
F0.00014334862385321102
I0
I1
I-1
tp47379
sS'the,pharmacologically'
p47380
(F1
F0.00014334862385321102
I1
I0
I1
tp47381
sS'weather,prolonged'
p47382
(F1
F0.00014334862385321102
I1
I0
I1
tp47383
sS'added,to'
p47384
(F0.25
F0.00057339449541284407
I10
I6
I4
tp47385
sS'min,before'
p47386
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47387
sS'other,has'
p47388
(F1
F0.00014334862385321102
I1
I0
I1
tp47389
sS'amantadine,and'
p47390
(F1
F0.00014334862385321102
I1
I0
I1
tp47391
sS'mg,clo-4'
p47392
(F1
F0.00014334862385321102
I0
I1
I-1
tp47393
sS'similar,mechanism'
p47394
(F1
F0.00014334862385321102
I1
I0
I1
tp47395
sS'activity,effects'
p47396
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp47397
sS'cavity,or'
p47398
(F1
F0.00014334862385321102
I0
I1
I-1
tp47399
sS'total,bilirubin'
p47400
(F1
F0.00014334862385321102
I0
I1
I-1
tp47401
sS'csf,primarily'
p47402
(F1
F0.00014334862385321102
I0
I1
I-1
tp47403
sS'associated,dental'
p47404
(F1
F0.00014334862385321102
I1
I0
I1
tp47405
sS'a,substitute'
p47406
(F1
F0.00057339449541284407
I0
I4
I-4
tp47407
sS'bovine,lung'
p47408
(F1
F0.00014334862385321102
I0
I1
I-1
tp47409
sS'of,hormone'
p47410
(F1
F0.00028669724770642203
I0
I2
I-2
tp47411
sS'distinctive,effects'
p47412
(F1
F0.00014334862385321102
I0
I1
I-1
tp47413
sS'cause,weakness'
p47414
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47415
sS'max,is'
p47416
(F1
F0.00014334862385321102
I1
I0
I1
tp47417
sS'formal,clinical'
p47418
(F1
F0.00028669724770642203
I0
I2
I-2
tp47419
sS'or,without'
p47420
(F0.25
F0.00028669724770642203
I5
I3
I2
tp47421
sS'that,chronic'
p47422
(F1
F0.00014334862385321102
I1
I0
I1
tp47423
sS'no,influence'
p47424
(F1
F0.00043004587155963305
I0
I3
I-3
tp47425
sS'daily,before'
p47426
(F1
F0.00028669724770642203
I0
I2
I-2
tp47427
sS'requirements,in'
p47428
(F1
F0.00014334862385321102
I1
I0
I1
tp47429
sS'erythromycin,and'
p47430
(F0
F0
I1
I1
I0
tp47431
sS'the,bio-rad'
p47432
(F1
F0.00014334862385321102
I0
I1
I-1
tp47433
sS'on,respiration'
p47434
(F1
F0.00014334862385321102
I0
I1
I-1
tp47435
sS'other,hypotensive'
p47436
(F1
F0.00014334862385321102
I1
I0
I1
tp47437
sS'diagnostic,serum'
p47438
(F1
F0.00014334862385321102
I0
I1
I-1
tp47439
sS'be,inhibited'
p47440
(F1
F0.00057339449541284407
I4
I0
I4
tp47441
sS'any,changes'
p47442
(F1
F0.00043004587155963305
I0
I3
I-3
tp47443
sS'clearance,may'
p47444
(F1
F0.00014334862385321102
I0
I1
I-1
tp47445
sS'resemblance,of'
p47446
(F1
F0.00014334862385321102
I1
I0
I1
tp47447
sS'digitalis,toxicity'
p47448
(F1
F0.00014334862385321102
I1
I0
I1
tp47449
sS'activity,can'
p47450
(F1
F0.00014334862385321102
I1
I0
I1
tp47451
sS'the,possibility'
p47452
(F0.63636363636363635
F0.0020068807339449542
I18
I4
I14
tp47453
sS'since,interactions'
p47454
(F1
F0.00028669724770642203
I2
I0
I2
tp47455
sS'milk,on'
p47456
(F1
F0.00014334862385321102
I0
I1
I-1
tp47457
sS'reported,upon'
p47458
(F1
F0.00014334862385321102
I1
I0
I1
tp47459
sS'the,longterm'
p47460
(F1
F0.00014334862385321102
I0
I1
I-1
tp47461
sS'trials,currently'
p47462
(F1
F0.00014334862385321102
I0
I1
I-1
tp47463
sS'bradycardia,and'
p47464
(F0
F0
I1
I1
I0
tp47465
sS'enzymes,inducers'
p47466
(F1
F0.00014334862385321102
I0
I1
I-1
tp47467
sS'prinivil,is'
p47468
(F1
F0.00014334862385321102
I1
I0
I1
tp47469
sS'the,model'
p47470
(F1
F0.00014334862385321102
I0
I1
I-1
tp47471
sS'and,congestive'
p47472
(F1
F0.00014334862385321102
I1
I0
I1
tp47473
sS'or,effect'
p47474
(F1
F0.00014334862385321102
I1
I0
I1
tp47475
sS'reaction,of'
p47476
(F1
F0.00028669724770642203
I2
I0
I2
tp47477
sS'oral,including'
p47478
(F1
F0.00014334862385321102
I1
I0
I1
tp47479
sS'concentrations,decreases'
p47480
(F1
F0.00014334862385321102
I1
I0
I1
tp47481
sS'its,epoxide'
p47482
(F1
F0.00014334862385321102
I0
I1
I-1
tp47483
sS'frequently,in'
p47484
(F1
F0.00014334862385321102
I0
I1
I-1
tp47485
sS'volunteers,has'
p47486
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp47487
sS'eg,and'
p47488
(F1
F0.0012901376146788992
I9
I0
I9
tp47489
sS'volunteers,had'
p47490
(F1
F0.00014334862385321102
I1
I0
I1
tp47491
sS'evidence,to'
p47492
(F1
F0.00014334862385321102
I0
I1
I-1
tp47493
sS'or,metabolic'
p47494
(F1
F0.00014334862385321102
I0
I1
I-1
tp47495
sS'rate,compared'
p47496
(F1
F0.00014334862385321102
I1
I0
I1
tp47497
sS'crohns,disease'
p47498
(F1
F0.00014334862385321102
I1
I0
I1
tp47499
sS'simultaneous,administration'
p47500
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp47501
sS'because,increases'
p47502
(F1
F0.00014334862385321102
I1
I0
I1
tp47503
sS'than,seven'
p47504
(F1
F0.00014334862385321102
I0
I1
I-1
tp47505
sS'synkayvite,use'
p47506
(F1
F0.00014334862385321102
I0
I1
I-1
tp47507
sS'one,study'
p47508
(F0
F0
I2
I2
I0
tp47509
sS'humans,was'
p47510
(F1
F0.00014334862385321102
I0
I1
I-1
tp47511
sS'therapy,to'
p47512
(F1
F0.00028669724770642203
I2
I0
I2
tp47513
sS'extended,a'
p47514
(F1
F0.00014334862385321102
I1
I0
I1
tp47515
sS'volunteers,resulting'
p47516
(F1
F0.00014334862385321102
I0
I1
I-1
tp47517
sS'scale,were'
p47518
(F1
F0.00014334862385321102
I1
I0
I1
tp47519
sS'route,and'
p47520
(F1
F0.00014334862385321102
I1
I0
I1
tp47521
sS'taken,into'
p47522
(F1
F0.00028669724770642203
I2
I0
I2
tp47523
sS'humans,can'
p47524
(F1
F0.00014334862385321102
I1
I0
I1
tp47525
sS'approximately,a'
p47526
(F1
F0.00014334862385321102
I1
I0
I1
tp47527
sS'differences,in'
p47528
(F1
F0.00071674311926605509
I0
I5
I-5
tp47529
sS'period,after'
p47530
(F1
F0.00014334862385321102
I0
I1
I-1
tp47531
sS'with,hepatotoxicity'
p47532
(F1
F0.00014334862385321102
I1
I0
I1
tp47533
sS'and,were'
p47534
(F0.33333333333333331
F0.0011467889908256881
I8
I16
I-8
tp47535
sS'higher,occurrence'
p47536
(F1
F0.00028669724770642203
I2
I0
I2
tp47537
sS'the,recommended'
p47538
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp47539
sS'co,administration'
p47540
(F1
F0.00014334862385321102
I1
I0
I1
tp47541
sS'leucovorin,may'
p47542
(F1
F0.00014334862385321102
I1
I0
I1
tp47543
sS'their,selective'
p47544
(F1
F0.00014334862385321102
I0
I1
I-1
tp47545
sS'a,the'
p47546
(F1
F0.00028669724770642203
I0
I2
I-2
tp47547
sS'survanta,on'
p47548
(F1
F0.00014334862385321102
I0
I1
I-1
tp47549
sS'hypo-prothrombinemic,effect'
p47550
(F1
F0.00014334862385321102
I0
I1
I-1
tp47551
sS'initial,dosage'
p47552
(F1
F0.00014334862385321102
I1
I0
I1
tp47553
sS'theophylline,following'
p47554
(F1
F0.00014334862385321102
I0
I1
I-1
tp47555
sS'products,may'
p47556
(F1
F0.00014334862385321102
I1
I0
I1
tp47557
sS'hivid,and'
p47558
(F1
F0.00014334862385321102
I0
I1
I-1
tp47559
sS'with,b-blocking'
p47560
(F1
F0.00071674311926605509
I5
I0
I5
tp47561
sS'c,g'
p47562
(F1
F0.00014334862385321102
I1
I0
I1
tp47563
sS'triglycerides,sgot'
p47564
(F1
F0.00014334862385321102
I1
I0
I1
tp47565
sS'and,should'
p47566
(F0.8571428571428571
F0.0034403669724770644
I26
I2
I24
tp47567
sS'enablex,is'
p47568
(F1
F0.00014334862385321102
I1
I0
I1
tp47569
sS'a,agonist'
p47570
(F1
F0.00028669724770642203
I2
I0
I2
tp47571
sS'to,beta-lactam'
p47572
(F1
F0.00014334862385321102
I1
I0
I1
tp47573
sS'c,p'
p47574
(F0
F0
I1
I1
I0
tp47575
sS'patients,take'
p47576
(F0
F0
I1
I1
I0
tp47577
sS'when,either'
p47578
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp47579
sS'these,changes'
p47580
(F1
F0.00014334862385321102
I0
I1
I-1
tp47581
sS'on,activity'
p47582
(F1
F0.00014334862385321102
I1
I0
I1
tp47583
sS'recovery,following'
p47584
(F1
F0.00014334862385321102
I1
I0
I1
tp47585
sS'to,lead'
p47586
(F1
F0.00043004587155963305
I3
I0
I3
tp47587
sS'serious,ventricular'
p47588
(F0
F0
I1
I1
I0
tp47589
sS'inspra,to'
p47590
(F0
F0
I1
I1
I0
tp47591
sS'concentrations,appeared'
p47592
(F1
F0.00014334862385321102
I0
I1
I-1
tp47593
sS'anti-inflammatory,action'
p47594
(F1
F0.00014334862385321102
I1
I0
I1
tp47595
sS'displacement,studies'
p47596
(F1
F0.00014334862385321102
I0
I1
I-1
tp47597
sS'whether,has'
p47598
(F1
F0.00014334862385321102
I0
I1
I-1
tp47599
sS'antiminth,taking'
p47600
(F1
F0.00014334862385321102
I1
I0
I1
tp47601
sS'elemental,as'
p47602
(F1
F0.00014334862385321102
I1
I0
I1
tp47603
sS'receiving,azopt'
p47604
(F1
F0.00014334862385321102
I0
I1
I-1
tp47605
sS'solution,may'
p47606
(F1
F0.00057339449541284407
I4
I0
I4
tp47607
sS'in,interaction'
p47608
(F1
F0.00028669724770642203
I0
I2
I-2
tp47609
sS'unmodified,nacmc'
p47610
(F1
F0.00014334862385321102
I0
I1
I-1
tp47611
sS'before,a'
p47612
(F0
F0
I1
I1
I0
tp47613
sS'studies,are'
p47614
(F1
F0.00014334862385321102
I0
I1
I-1
tp47615
sS'regimen,plus'
p47616
(F1
F0.00014334862385321102
I0
I1
I-1
tp47617
sS'chop-like,regimen'
p47618
(F1
F0.00014334862385321102
I0
I1
I-1
tp47619
sS'with,monurol'
p47620
(F1
F0.00014334862385321102
I1
I0
I1
tp47621
sS'the,formation'
p47622
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47623
sS'therapeutic,value'
p47624
(F1
F0.00014334862385321102
I0
I1
I-1
tp47625
sS'anticholinesterase,poisoning'
p47626
(F1
F0.00014334862385321102
I1
I0
I1
tp47627
sS'circulating,metabolite'
p47628
(F1
F0.00014334862385321102
I0
I1
I-1
tp47629
sS'ph,h2-receptor'
p47630
(F1
F0.00014334862385321102
I1
I0
I1
tp47631
sS'administered,intravenously'
p47632
(F1
F0.00028669724770642203
I2
I0
I2
tp47633
sS'safely,used'
p47634
(F1
F0.00057339449541284407
I0
I4
I-4
tp47635
sS'with,another'
p47636
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp47637
sS'of,vistide'
p47638
(F1
F0.00014334862385321102
I1
I0
I1
tp47639
sS'of,or'
p47640
(F0.21951219512195122
F0.0012901376146788992
I16
I25
I-9
tp47641
sS'monitor,concentrations'
p47642
(F1
F0.00014334862385321102
I1
I0
I1
tp47643
sS'of,on'
p47644
(F0.50877192982456143
F0.0041571100917431195
I14
I43
I-29
tp47645
sS'some,attenuation'
p47646
(F1
F0.00014334862385321102
I0
I1
I-1
tp47647
sS'slightly,reduced'
p47648
(F1
F0.00014334862385321102
I1
I0
I1
tp47649
sS'of,of'
p47650
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47651
sS'concomitantly,given'
p47652
(F1
F0.00014334862385321102
I0
I1
I-1
tp47653
sS'minutes,before'
p47654
(F1
F0.00028669724770642203
I2
I0
I2
tp47655
sS'rare,reports'
p47656
(F1
F0.00071674311926605509
I5
I0
I5
tp47657
sS'reflex,tachycardia'
p47658
(F1
F0.00014334862385321102
I1
I0
I1
tp47659
sS'system,maybe'
p47660
(F1
F0.00014334862385321102
I0
I1
I-1
tp47661
sS'a,hmgcoa'
p47662
(F1
F0.00014334862385321102
I0
I1
I-1
tp47663
sS'both,species'
p47664
(F1
F0.00028669724770642203
I2
I0
I2
tp47665
sS'given,concurrently'
p47666
(F0.5
F0.00057339449541284407
I6
I2
I4
tp47667
sS'when,tracleer'
p47668
(F1
F0.00014334862385321102
I1
I0
I1
tp47669
sS'bleeding,tendency'
p47670
(F1
F0.00014334862385321102
I1
I0
I1
tp47671
sS'levels,was'
p47672
(F1
F0.00028669724770642203
I2
I0
I2
tp47673
sS'inducers,and'
p47674
(F0.5
F0.00028669724770642203
I3
I1
I2
tp47675
sS'm,of'
p47676
(F1
F0.00014334862385321102
I0
I1
I-1
tp47677
sS'equivalent,amount'
p47678
(F1
F0.00014334862385321102
I0
I1
I-1
tp47679
sS'dose,bioavailability'
p47680
(F1
F0.00014334862385321102
I0
I1
I-1
tp47681
sS'poor,metabolizers'
p47682
(F0.66666666666666663
F0.0011467889908256881
I2
I10
I-8
tp47683
sS'least,weeks'
p47684
(F1
F0.00043004587155963305
I3
I0
I3
tp47685
sS'm,or'
p47686
(F1
F0.00028669724770642203
I2
I0
I2
tp47687
sS'halogenated,hydrocarbon'
p47688
(F1
F0.00028669724770642203
I2
I0
I2
tp47689
sS'acetaminophen,diminished'
p47690
(F1
F0.00014334862385321102
I1
I0
I1
tp47691
sS'calcitriol,and'
p47692
(F1
F0.00043004587155963305
I3
I0
I3
tp47693
sS'is,however'
p47694
(F1
F0.00014334862385321102
I1
I0
I1
tp47695
sS'was,for'
p47696
(F1
F0.00014334862385321102
I1
I0
I1
tp47697
sS'zdv,and'
p47698
(F1
F0.00014334862385321102
I0
I1
I-1
tp47699
sS'and,dyspnea'
p47700
(F1
F0.00014334862385321102
I1
I0
I1
tp47701
sS'dosed,simultaneously'
p47702
(F1
F0.00014334862385321102
I1
I0
I1
tp47703
sS'an,additional'
p47704
(F1
F0.00014334862385321102
I1
I0
I1
tp47705
sS'enhanced,the'
p47706
(F0
F0
I1
I1
I0
tp47707
sS'receiving,hydrochloride'
p47708
(F1
F0.00014334862385321102
I1
I0
I1
tp47709
sS'dosage,may'
p47710
(F0
F0
I1
I1
I0
tp47711
sS'a,multicenter'
p47712
(F1
F0.00014334862385321102
I0
I1
I-1
tp47713
sS'bronchospasm,in'
p47714
(F1
F0.00014334862385321102
I1
I0
I1
tp47715
sS'expected,since'
p47716
(F1
F0.00014334862385321102
I0
I1
I-1
tp47717
sS'initiating,replacement'
p47718
(F1
F0.00014334862385321102
I0
I1
I-1
tp47719
sS'when,viracept'
p47720
(F1
F0.00014334862385321102
I0
I1
I-1
tp47721
sS'since,photic'
p47722
(F1
F0.00014334862385321102
I0
I1
I-1
tp47723
sS'theophylline,a'
p47724
(F1
F0.00014334862385321102
I0
I1
I-1
tp47725
sS'nonsteroidal,antiinflammatories'
p47726
(F1
F0.00014334862385321102
I0
I1
I-1
tp47727
sS'have,any'
p47728
(F1
F0.0008600917431192661
I0
I6
I-6
tp47729
sS'when,atromid-s'
p47730
(F1
F0.00014334862385321102
I1
I0
I1
tp47731
sS'abilify,to'
p47732
(F1
F0.00014334862385321102
I0
I1
I-1
tp47733
sS'true,interaction'
p47734
(F1
F0.00014334862385321102
I1
I0
I1
tp47735
sS'induction,potential'
p47736
(F1
F0.00014334862385321102
I0
I1
I-1
tp47737
sS'hyperkalemia,may'
p47738
(F1
F0.00014334862385321102
I1
I0
I1
tp47739
sS'and,titrated'
p47740
(F1
F0.00028669724770642203
I0
I2
I-2
tp47741
sS'the,nervous'
p47742
(F1
F0.00014334862385321102
I1
I0
I1
tp47743
sS'pk,properties'
p47744
(F1
F0.00014334862385321102
I0
I1
I-1
tp47745
sS'concentrations,should'
p47746
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp47747
sS'was,comparable'
p47748
(F1
F0.00014334862385321102
I0
I1
I-1
tp47749
sS'clo-4,simultaneously'
p47750
(F1
F0.00014334862385321102
I0
I1
I-1
tp47751
sS'mc,and'
p47752
(F1
F0.00043004587155963305
I0
I3
I-3
tp47753
sS'disease,congestive'
p47754
(F1
F0.00014334862385321102
I1
I0
I1
tp47755
sS'blockers,and'
p47756
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp47757
sS'digitalis,glycosides'
p47758
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47759
sS's,influence'
p47760
(F1
F0.00014334862385321102
I1
I0
I1
tp47761
sS'and,distribution'
p47762
(F1
F0.00014334862385321102
I0
I1
I-1
tp47763
sS'possessing,nephrotoxic'
p47764
(F1
F0.00014334862385321102
I1
I0
I1
tp47765
sS'benefits,against'
p47766
(F1
F0.00014334862385321102
I0
I1
I-1
tp47767
sS'level,has'
p47768
(F1
F0.00028669724770642203
I2
I0
I2
tp47769
sS'proscar,mg'
p47770
(F1
F0.00014334862385321102
I0
I1
I-1
tp47771
sS'fold,and'
p47772
(F1
F0.0010034403669724771
I7
I0
I7
tp47773
sS'alleles,cyp2c9'
p47774
(F1
F0.00014334862385321102
I0
I1
I-1
tp47775
sS'if,at'
p47776
(F0
F0
I1
I1
I0
tp47777
sS'n-methylthiotetrazole,or'
p47778
(F1
F0.00014334862385321102
I0
I1
I-1
tp47779
sS'been,collected'
p47780
(F1
F0.00014334862385321102
I0
I1
I-1
tp47781
sS'have,elevated'
p47782
(F1
F0.00014334862385321102
I1
I0
I1
tp47783
sS'if,an'
p47784
(F1
F0.00014334862385321102
I1
I0
I1
tp47785
sS'aeds,and'
p47786
(F1
F0.00028669724770642203
I0
I2
I-2
tp47787
sS'coadministration,were'
p47788
(F1
F0.00014334862385321102
I1
I0
I1
tp47789
sS'mean,auc'
p47790
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp47791
sS'slightly,about'
p47792
(F1
F0.00014334862385321102
I1
I0
I1
tp47793
sS'to,temporarily'
p47794
(F1
F0.00028669724770642203
I2
I0
I2
tp47795
sS'users,the'
p47796
(F1
F0.00014334862385321102
I0
I1
I-1
tp47797
sS'discussion,clarithromycin'
p47798
(F1
F0.00014334862385321102
I1
I0
I1
tp47799
sS'intravenous,in'
p47800
(F1
F0.00014334862385321102
I0
I1
I-1
tp47801
sS'clinically,warranted'
p47802
(F1
F0.00057339449541284407
I4
I0
I4
tp47803
sS'to,peak'
p47804
(F1
F0.00014334862385321102
I0
I1
I-1
tp47805
sS'studies,performed'
p47806
(F1
F0.00014334862385321102
I0
I1
I-1
tp47807
sS'levels,of'
p47808
(F0.43661971830985913
F0.0044438073394495415
I51
I20
I31
tp47809
sS'the,cellular'
p47810
(F1
F0.00028669724770642203
I0
I2
I-2
tp47811
sS'not,needed'
p47812
(F1
F0.00014334862385321102
I1
I0
I1
tp47813
sS'type,diabetes'
p47814
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47815
sS'levels,or'
p47816
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp47817
sS'causes,increase'
p47818
(F1
F0.00014334862385321102
I1
I0
I1
tp47819
sS'oral,nicotinic'
p47820
(F1
F0.00057339449541284407
I0
I4
I-4
tp47821
sS'corticosteroids,may'
p47822
(F1
F0.00028669724770642203
I2
I0
I2
tp47823
sS'a,level'
p47824
(F1
F0.00014334862385321102
I0
I1
I-1
tp47825
sS'to,premature'
p47826
(F1
F0.00014334862385321102
I0
I1
I-1
tp47827
sS'or,potent'
p47828
(F1
F0.00014334862385321102
I1
I0
I1
tp47829
sS'these,could'
p47830
(F1
F0.00014334862385321102
I1
I0
I1
tp47831
sS'arimidex,as'
p47832
(F1
F0.00014334862385321102
I1
I0
I1
tp47833
sS'a,result'
p47834
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47835
sS'mg,and'
p47836
(F0.037037037037037035
F0.00014334862385321102
I13
I14
I-1
tp47837
sS'this,regimen'
p47838
(F1
F0.00014334862385321102
I1
I0
I1
tp47839
sS'chronically,receiving'
p47840
(F1
F0.00028669724770642203
I0
I2
I-2
tp47841
sS'p-450,for'
p47842
(F1
F0.00014334862385321102
I1
I0
I1
tp47843
sS'tambocor,and'
p47844
(F0
F0
I2
I2
I0
tp47845
sS'curve,at'
p47846
(F1
F0.00014334862385321102
I1
I0
I1
tp47847
sS'a,pharmacological'
p47848
(F1
F0.00014334862385321102
I0
I1
I-1
tp47849
sS'aim,and'
p47850
(F1
F0.00014334862385321102
I0
I1
I-1
tp47851
sS'rapid,and'
p47852
(F1
F0.00028669724770642203
I2
I0
I2
tp47853
sS'to,health'
p47854
(F0
F0
I1
I1
I0
tp47855
sS'photic,evoked'
p47856
(F1
F0.00014334862385321102
I0
I1
I-1
tp47857
sS'infusion,to'
p47858
(F1
F0.00014334862385321102
I0
I1
I-1
tp47859
sS'increase,steadystate'
p47860
(F1
F0.00014334862385321102
I1
I0
I1
tp47861
sS'ze,patients'
p47862
(F1
F0.00014334862385321102
I0
I1
I-1
tp47863
sS'factrel,may'
p47864
(F1
F0.00014334862385321102
I1
I0
I1
tp47865
sS'c,min'
p47866
(F1
F0.00014334862385321102
I0
I1
I-1
tp47867
sS'use,especially'
p47868
(F1
F0.00014334862385321102
I0
I1
I-1
tp47869
sS'if,vioxx'
p47870
(F1
F0.00014334862385321102
I1
I0
I1
tp47871
sS'with,must'
p47872
(F1
F0.00014334862385321102
I1
I0
I1
tp47873
sS'to,mice'
p47874
(F1
F0.00014334862385321102
I0
I1
I-1
tp47875
sS'dissolving,dosage'
p47876
(F1
F0.00014334862385321102
I1
I0
I1
tp47877
sS'however,total'
p47878
(F1
F0.00014334862385321102
I0
I1
I-1
tp47879
sS'rat,stomach'
p47880
(F1
F0.00014334862385321102
I1
I0
I1
tp47881
sS'extent,with'
p47882
(F1
F0.00014334862385321102
I0
I1
I-1
tp47883
sS'these,patients'
p47884
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp47885
sS'time,lst'
p47886
(F1
F0.00014334862385321102
I0
I1
I-1
tp47887
sS'approximately,given'
p47888
(F1
F0.00014334862385321102
I1
I0
I1
tp47889
sS'the,sedative'
p47890
(F1
F0.00014334862385321102
I1
I0
I1
tp47891
sS'the,natriuresis'
p47892
(F1
F0.00014334862385321102
I1
I0
I1
tp47893
sS'concomitant,use'
p47894
(F0.32631578947368423
F0.0044438073394495415
I63
I32
I31
tp47895
sS'may,color'
p47896
(F1
F0.00014334862385321102
I0
I1
I-1
tp47897
sS'tablets,administered'
p47898
(F1
F0.00014334862385321102
I0
I1
I-1
tp47899
sS'induce,bleeding'
p47900
(F1
F0.00014334862385321102
I1
I0
I1
tp47901
sS'diphenhydramine,hydrochloride'
p47902
(F1
F0.00014334862385321102
I1
I0
I1
tp47903
sS'explain,the'
p47904
(F1
F0.00014334862385321102
I1
I0
I1
tp47905
sS'or,inhibitors'
p47906
(F0
F0
I2
I2
I0
tp47907
sS'potentially,hepatotoxic'
p47908
(F1
F0.00014334862385321102
I1
I0
I1
tp47909
sS'of,escherichia'
p47910
(F1
F0.00028669724770642203
I0
I2
I-2
tp47911
sS'more,possibly'
p47912
(F1
F0.00014334862385321102
I1
I0
I1
tp47913
sS'effects,can'
p47914
(F1
F0.00014334862385321102
I1
I0
I1
tp47915
sS'six,clinical'
p47916
(F1
F0.00014334862385321102
I0
I1
I-1
tp47917
sS'and,consequently'
p47918
(F1
F0.00014334862385321102
I0
I1
I-1
tp47919
sS'indeed,agents'
p47920
(F1
F0.00014334862385321102
I0
I1
I-1
tp47921
sS'may,prolong'
p47922
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp47923
sS'rat,bone'
p47924
(F1
F0.00014334862385321102
I0
I1
I-1
tp47925
sS'sulfate,and'
p47926
(F1
F0.00014334862385321102
I1
I0
I1
tp47927
sS'saline,g'
p47928
(F1
F0.00014334862385321102
I0
I1
I-1
tp47929
sS'eszopiclone,mg'
p47930
(F1
F0.00014334862385321102
I0
I1
I-1
tp47931
sS'for,ketones'
p47932
(F1
F0.00028669724770642203
I0
I2
I-2
tp47933
sS'availability,of'
p47934
(F1
F0.00014334862385321102
I0
I1
I-1
tp47935
sS'derivative,while'
p47936
(F1
F0.00014334862385321102
I0
I1
I-1
tp47937
sS'be,carried'
p47938
(F1
F0.00014334862385321102
I0
I1
I-1
tp47939
sS'cefizox,nephrotoxicity'
p47940
(F1
F0.00014334862385321102
I1
I0
I1
tp47941
sS'qt,interval'
p47942
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp47943
sS'marked,bradycardia'
p47944
(F0.5
F0.00028669724770642203
I3
I1
I2
tp47945
sS'of,phosphatases'
p47946
(F1
F0.00014334862385321102
I0
I1
I-1
tp47947
sS'any,from'
p47948
(F1
F0.00014334862385321102
I0
I1
I-1
tp47949
sS'pipracil,produces'
p47950
(F1
F0.00014334862385321102
I1
I0
I1
tp47951
sS'fold,which'
p47952
(F1
F0.00014334862385321102
I1
I0
I1
tp47953
sS'the,doses'
p47954
(F1
F0.00043004587155963305
I3
I0
I3
tp47955
sS'from,interaction'
p47956
(F1
F0.00014334862385321102
I0
I1
I-1
tp47957
sS'for,heart'
p47958
(F1
F0.00014334862385321102
I0
I1
I-1
tp47959
sS'pharmacokinetics,but'
p47960
(F1
F0.00014334862385321102
I1
I0
I1
tp47961
sS'metabolite,metabolite'
p47962
(F1
F0.00014334862385321102
I0
I1
I-1
tp47963
sS'immobilised,cmc-cys7'
p47964
(F1
F0.00014334862385321102
I0
I1
I-1
tp47965
sS'a,neutralizing'
p47966
(F1
F0.00014334862385321102
I1
I0
I1
tp47967
sS'a,cause'
p47968
(F1
F0.00014334862385321102
I1
I0
I1
tp47969
sS'a,min'
p47970
(F1
F0.00014334862385321102
I1
I0
I1
tp47971
sS'lean,animals'
p47972
(F1
F0.00014334862385321102
I0
I1
I-1
tp47973
sS'potential,risk'
p47974
(F1
F0.00014334862385321102
I1
I0
I1
tp47975
sS'cytokines,have'
p47976
(F1
F0.00014334862385321102
I0
I1
I-1
tp47977
sS'other,on'
p47978
(F1
F0.00028669724770642203
I0
I2
I-2
tp47979
sS'urinary,tract'
p47980
(F1
F0.00014334862385321102
I0
I1
I-1
tp47981
sS'other,or'
p47982
(F0
F0
I2
I2
I0
tp47983
sS'striatal,but'
p47984
(F1
F0.00014334862385321102
I1
I0
I1
tp47985
sS'of,potent'
p47986
(F0
F0
I1
I1
I0
tp47987
sS'degenerative,changes'
p47988
(F1
F0.00014334862385321102
I0
I1
I-1
tp47989
sS'metabolism,causing'
p47990
(F1
F0.00014334862385321102
I1
I0
I1
tp47991
sS'with,copegus'
p47992
(F1
F0.00043004587155963305
I0
I3
I-3
tp47993
sS'schizophrenic,patients'
p47994
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47995
sS'subjects,received'
p47996
(F1
F0.0008600917431192661
I0
I6
I-6
tp47997
sS'excretion,as'
p47998
(F1
F0.00014334862385321102
I0
I1
I-1
tp47999
sS'cardiovascular,safety'
p48000
(F1
F0.00014334862385321102
I0
I1
I-1
tp48001
sS'values,were'
p48002
(F1
F0.00028669724770642203
I0
I2
I-2
tp48003
sS'times,when'
p48004
(F1
F0.00014334862385321102
I1
I0
I1
tp48005
sS'p450,enzymes'
p48006
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp48007
sS'of,osteoarthritis'
p48008
(F1
F0.00014334862385321102
I0
I1
I-1
tp48009
sS'extrarenal,mechanisms'
p48010
(F1
F0.00014334862385321102
I0
I1
I-1
tp48011
sS'the,half-'
p48012
(F1
F0.00043004587155963305
I0
I3
I-3
tp48013
sS'low-dose,with'
p48014
(F1
F0.00014334862385321102
I1
I0
I1
tp48015
sS'when,taxol'
p48016
(F1
F0.00028669724770642203
I2
I0
I2
tp48017
sS'oral,anticoagulants'
p48018
(F0
F0
I2
I2
I0
tp48019
sS'transient,increases'
p48020
(F0
F0
I1
I1
I0
tp48021
sS'the,patient'
p48022
(F0.41666666666666669
F0.0014334862385321102
I17
I7
I10
tp48023
sS'live,or'
p48024
(F1
F0.00014334862385321102
I1
I0
I1
tp48025
sS'cardiotoxicity,associated'
p48026
(F1
F0.00014334862385321102
I0
I1
I-1
tp48027
sS'iodide,i'
p48028
(F1
F0.00014334862385321102
I0
I1
I-1
tp48029
sS'are,direct'
p48030
(F1
F0.00014334862385321102
I1
I0
I1
tp48031
sS'receive,mg'
p48032
(F1
F0.00014334862385321102
I1
I0
I1
tp48033
sS'daily,maintenance'
p48034
(F1
F0.00014334862385321102
I1
I0
I1
tp48035
sS'increase,to'
p48036
(F1
F0.00014334862385321102
I0
I1
I-1
tp48037
sS'in,psychiatric'
p48038
(F1
F0.00014334862385321102
I1
I0
I1
tp48039
sS'were,maintained'
p48040
(F1
F0.00014334862385321102
I0
I1
I-1
tp48041
sS'the-curve,after'
p48042
(F1
F0.00014334862385321102
I1
I0
I1
tp48043
sS'antagonists,and'
p48044
(F0
F0
I4
I4
I0
tp48045
sS'at,lower'
p48046
(F1
F0.00014334862385321102
I1
I0
I1
tp48047
sS'therefore,should'
p48048
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp48049
sS'of,rocaltrol'
p48050
(F1
F0.00043004587155963305
I0
I3
I-3
tp48051
sS'the,remainder'
p48052
(F1
F0.00014334862385321102
I0
I1
I-1
tp48053
sS'epidural,injection'
p48054
(F1
F0.00014334862385321102
I1
I0
I1
tp48055
sS'medications,such'
p48056
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp48057
sS'evaluation,of'
p48058
(F1
F0.00014334862385321102
I0
I1
I-1
tp48059
sS'with,for'
p48060
(F0.5
F0.00028669724770642203
I3
I1
I2
tp48061
sS'of,magnitude'
p48062
(F1
F0.00014334862385321102
I0
I1
I-1
tp48063
sS'hypoglycemics,diclofenac'
p48064
(F1
F0.00014334862385321102
I0
I1
I-1
tp48065
sS'the,tubular'
p48066
(F1
F0.00057339449541284407
I4
I0
I4
tp48067
sS'a,digitalized'
p48068
(F1
F0.00014334862385321102
I1
I0
I1
tp48069
sS'subutex,or'
p48070
(F1
F0.00014334862385321102
I0
I1
I-1
tp48071
sS'enzyme-inducing,such'
p48072
(F1
F0.00014334862385321102
I1
I0
I1
tp48073
sS'female,subjects'
p48074
(F1
F0.00028669724770642203
I0
I2
I-2
tp48075
sS'agents,co-administration'
p48076
(F1
F0.00014334862385321102
I0
I1
I-1
tp48077
sS'to,raise'
p48078
(F1
F0.00014334862385321102
I1
I0
I1
tp48079
sS'respectively,after'
p48080
(F0
F0
I1
I1
I0
tp48081
sS'administered,enter'
p48082
(F1
F0.00014334862385321102
I0
I1
I-1
tp48083
sS'task,it'
p48084
(F1
F0.00014334862385321102
I0
I1
I-1
tp48085
sS'isoenzymes,and'
p48086
(F1
F0.00014334862385321102
I0
I1
I-1
tp48087
sS'foscavir,should'
p48088
(F1
F0.00014334862385321102
I1
I0
I1
tp48089
sS'dependent,labelling'
p48090
(F1
F0.00014334862385321102
I0
I1
I-1
tp48091
sS'patients,by'
p48092
(F0
F0
I1
I1
I0
tp48093
sS'the,anorectic'
p48094
(F1
F0.00028669724770642203
I2
I0
I2
tp48095
sS'p450,a'
p48096
(F1
F0.00043004587155963305
I0
I3
I-3
tp48097
sS'celebrex,may'
p48098
(F1
F0.00014334862385321102
I1
I0
I1
tp48099
sS'and,overuse'
p48100
(F1
F0.00014334862385321102
I0
I1
I-1
tp48101
sS'profile,between'
p48102
(F1
F0.00014334862385321102
I0
I1
I-1
tp48103
sS'of,suggested'
p48104
(F1
F0.00014334862385321102
I0
I1
I-1
tp48105
sS'activity,patients'
p48106
(F1
F0.00028669724770642203
I2
I0
I2
tp48107
sS'concentrations,auc'
p48108
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp48109
sS'deficit,i'
p48110
(F1
F0.00014334862385321102
I0
I1
I-1
tp48111
sS'the,extremities'
p48112
(F1
F0.00014334862385321102
I0
I1
I-1
tp48113
sS'av,conduction'
p48114
(F0.5
F0.00028669724770642203
I3
I1
I2
tp48115
sS'inhibitor,class'
p48116
(F1
F0.00028669724770642203
I2
I0
I2
tp48117
sS'types,of'
p48118
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp48119
sS'present,study'
p48120
(F1
F0.00028669724770642203
I0
I2
I-2
tp48121
sS'single-dose,study'
p48122
(F1
F0.00014334862385321102
I0
I1
I-1
tp48123
sS'placebo,was'
p48124
(F1
F0.00014334862385321102
I0
I1
I-1
tp48125
sS'in,cyclosporine-induced'
p48126
(F1
F0.00028669724770642203
I2
I0
I2
tp48127
sS'macrolide,immunosuppressant'
p48128
(F1
F0.00014334862385321102
I0
I1
I-1
tp48129
sS'were,completely'
p48130
(F1
F0.00014334862385321102
I1
I0
I1
tp48131
sS'parameters,the'
p48132
(F1
F0.00014334862385321102
I0
I1
I-1
tp48133
sS'which,patients'
p48134
(F1
F0.00028669724770642203
I2
I0
I2
tp48135
sS'such,an'
p48136
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48137
sS'however,as'
p48138
(F1
F0.00014334862385321102
I1
I0
I1
tp48139
sS'travelers,receiving'
p48140
(F1
F0.00014334862385321102
I1
I0
I1
tp48141
sS'marked,and'
p48142
(F1
F0.00014334862385321102
I1
I0
I1
tp48143
sS'report,nine'
p48144
(F1
F0.00014334862385321102
I1
I0
I1
tp48145
sS'adl,prevents'
p48146
(F1
F0.00014334862385321102
I1
I0
I1
tp48147
sS'and,beta'
p48148
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp48149
sS'encouraged,to'
p48150
(F1
F0.00014334862385321102
I0
I1
I-1
tp48151
sS'in,fatal'
p48152
(F1
F0.00014334862385321102
I1
I0
I1
tp48153
sS'improved,the'
p48154
(F1
F0.00014334862385321102
I0
I1
I-1
tp48155
sS'if,prinivil'
p48156
(F1
F0.00014334862385321102
I1
I0
I1
tp48157
sS'hearing,impairment'
p48158
(F1
F0.00014334862385321102
I1
I0
I1
tp48159
sS'hormones,complex'
p48160
(F1
F0.00014334862385321102
I0
I1
I-1
tp48161
sS'in,heart'
p48162
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48163
sS'concentrations,considerably'
p48164
(F1
F0.00014334862385321102
I1
I0
I1
tp48165
sS'small,to'
p48166
(F1
F0.00014334862385321102
I0
I1
I-1
tp48167
sS'of,angina'
p48168
(F1
F0.00014334862385321102
I1
I0
I1
tp48169
sS'prescribed,foradil'
p48170
(F1
F0.00014334862385321102
I0
I1
I-1
tp48171
sS'rats,in'
p48172
(F0
F0
I1
I1
I0
tp48173
sS'apparent,pharmacokinetic'
p48174
(F1
F0.00057339449541284407
I0
I4
I-4
tp48175
sS'of,phenolic'
p48176
(F1
F0.00014334862385321102
I0
I1
I-1
tp48177
sS'effect,agents'
p48178
(F1
F0.00014334862385321102
I0
I1
I-1
tp48179
sS'was,generally'
p48180
(F0
F0
I1
I1
I0
tp48181
sS'and,mixed'
p48182
(F1
F0.00014334862385321102
I0
I1
I-1
tp48183
sS'however,when'
p48184
(F1
F0.00014334862385321102
I1
I0
I1
tp48185
sS'the,maximum'
p48186
(F1
F0.00071674311926605509
I5
I0
I5
tp48187
sS'sustained-release,calan'
p48188
(F1
F0.00014334862385321102
I1
I0
I1
tp48189
sS'warfarin,administration'
p48190
(F1
F0.00014334862385321102
I0
I1
I-1
tp48191
sS'since,hydrochloride'
p48192
(F1
F0.00014334862385321102
I0
I1
I-1
tp48193
sS'standard,monitoring'
p48194
(F0
F0
I1
I1
I0
tp48195
sS'like,may'
p48196
(F1
F0.00014334862385321102
I1
I0
I1
tp48197
sS'a,drugs'
p48198
(F1
F0.00014334862385321102
I0
I1
I-1
tp48199
sS'is,normal'
p48200
(F1
F0.00014334862385321102
I1
I0
I1
tp48201
sS'with,should'
p48202
(F0.5
F0.00057339449541284407
I6
I2
I4
tp48203
sS'vasodilator,effects'
p48204
(F1
F0.00014334862385321102
I0
I1
I-1
tp48205
sS'be,temporarily'
p48206
(F1
F0.00014334862385321102
I1
I0
I1
tp48207
sS'reduced,to'
p48208
(F1
F0.00071674311926605509
I5
I0
I5
tp48209
sS'overall,direct'
p48210
(F1
F0.00014334862385321102
I0
I1
I-1
tp48211
sS'of,prostatic'
p48212
(F1
F0.00014334862385321102
I1
I0
I1
tp48213
sS'dosage,is'
p48214
(F1
F0.00014334862385321102
I1
I0
I1
tp48215
sS'ranitidine,also'
p48216
(F1
F0.00014334862385321102
I0
I1
I-1
tp48217
sS'weak,inhibitor'
p48218
(F0
F0
I1
I1
I0
tp48219
sS'expect,that'
p48220
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48221
sS'and,by'
p48222
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp48223
sS'safely,without'
p48224
(F1
F0.00014334862385321102
I0
I1
I-1
tp48225
sS'most,cases'
p48226
(F1
F0.00014334862385321102
I0
I1
I-1
tp48227
sS'angiotensin,on'
p48228
(F1
F0.00014334862385321102
I0
I1
I-1
tp48229
sS'as,muscle'
p48230
(F1
F0.00014334862385321102
I0
I1
I-1
tp48231
sS'k,deficiency'
p48232
(F1
F0.00014334862385321102
I0
I1
I-1
tp48233
sS'acid,in'
p48234
(F0
F0
I1
I1
I0
tp48235
sS'for,response'
p48236
(F1
F0.00014334862385321102
I0
I1
I-1
tp48237
sS'multiple,enzyme'
p48238
(F1
F0.00014334862385321102
I0
I1
I-1
tp48239
sS'single,case'
p48240
(F1
F0.00014334862385321102
I1
I0
I1
tp48241
sS'well-controlled,patients'
p48242
(F1
F0.00028669724770642203
I2
I0
I2
tp48243
sS'the,synthesis'
p48244
(F1
F0.00028669724770642203
I0
I2
I-2
tp48245
sS'coadministration,up'
p48246
(F1
F0.00014334862385321102
I1
I0
I1
tp48247
sS'pharmacological,interaction'
p48248
(F1
F0.00014334862385321102
I1
I0
I1
tp48249
sS'prothrombin,response'
p48250
(F1
F0.00043004587155963305
I3
I0
I3
tp48251
sS'increases,the'
p48252
(F0.66666666666666663
F0.0017201834862385322
I15
I3
I12
tp48253
sS'nondepolarizing,relaxants'
p48254
(F1
F0.00014334862385321102
I0
I1
I-1
tp48255
sS'alfenta,is'
p48256
(F1
F0.00014334862385321102
I1
I0
I1
tp48257
sS'is,the'
p48258
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp48259
sS'exposure,auc'
p48260
(F1
F0.0008600917431192661
I6
I0
I6
tp48261
sS'significantly,when'
p48262
(F1
F0.00014334862385321102
I1
I0
I1
tp48263
sS'lower,than'
p48264
(F0
F0
I2
I2
I0
tp48265
sS'lactulose-induced,drop'
p48266
(F1
F0.00014334862385321102
I1
I0
I1
tp48267
sS'both,or'
p48268
(F1
F0.00014334862385321102
I0
I1
I-1
tp48269
sS'misuse,of'
p48270
(F1
F0.00014334862385321102
I1
I0
I1
tp48271
sS'both,of'
p48272
(F1
F0.00014334862385321102
I1
I0
I1
tp48273
sS'aluminum-,and'
p48274
(F1
F0.00014334862385321102
I0
I1
I-1
tp48275
sS'agents,protease'
p48276
(F1
F0.00014334862385321102
I1
I0
I1
tp48277
sS'day,before'
p48278
(F1
F0.00014334862385321102
I0
I1
I-1
tp48279
sS'there,is'
p48280
(F0.081081081081081086
F0.00043004587155963305
I17
I20
I-3
tp48281
sS'cancidas,may'
p48282
(F1
F0.00014334862385321102
I1
I0
I1
tp48283
sS'proprietary,cold'
p48284
(F1
F0.00014334862385321102
I1
I0
I1
tp48285
sS'level,however'
p48286
(F1
F0.00014334862385321102
I1
I0
I1
tp48287
sS'to,double'
p48288
(F1
F0.00014334862385321102
I1
I0
I1
tp48289
sS'concomitant,beta-1a'
p48290
(F1
F0.00014334862385321102
I0
I1
I-1
tp48291
sS'in,six'
p48292
(F0.5
F0.00028669724770642203
I3
I1
I2
tp48293
sS'orlistat-orlistat,may'
p48294
(F1
F0.00014334862385321102
I1
I0
I1
tp48295
sS'microdilution,method'
p48296
(F1
F0.00014334862385321102
I0
I1
I-1
tp48297
sS'infusion,reactions'
p48298
(F1
F0.00014334862385321102
I0
I1
I-1
tp48299
sS'doses,that'
p48300
(F1
F0.00014334862385321102
I0
I1
I-1
tp48301
sS'ordinarily,should'
p48302
(F1
F0.00014334862385321102
I0
I1
I-1
tp48303
sS'additive,negative'
p48304
(F1
F0.00014334862385321102
I1
I0
I1
tp48305
sS'an,increase'
p48306
(F0.73333333333333328
F0.0047305045871559636
I39
I6
I33
tp48307
sS'of,hydrochloride'
p48308
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp48309
sS'a,first-line'
p48310
(F1
F0.00014334862385321102
I0
I1
I-1
tp48311
sS'cytoprotective,properties'
p48312
(F1
F0.00014334862385321102
I0
I1
I-1
tp48313
sS'and,results'
p48314
(F1
F0.00014334862385321102
I1
I0
I1
tp48315
sS'potassium,kinetics'
p48316
(F1
F0.00014334862385321102
I1
I0
I1
tp48317
sS'state,following'
p48318
(F1
F0.00014334862385321102
I0
I1
I-1
tp48319
sS'implantable,insertable'
p48320
(F1
F0.00014334862385321102
I0
I1
I-1
tp48321
sS'cmin,decreased'
p48322
(F1
F0.00014334862385321102
I1
I0
I1
tp48323
sS'show,potential'
p48324
(F1
F0.00014334862385321102
I0
I1
I-1
tp48325
sS'with,particularly'
p48326
(F1
F0.00014334862385321102
I1
I0
I1
tp48327
sS'oral,who'
p48328
(F1
F0.00014334862385321102
I1
I0
I1
tp48329
sS'dosage,when'
p48330
(F1
F0.00014334862385321102
I1
I0
I1
tp48331
sS'interact,significantly'
p48332
(F1
F0.00014334862385321102
I0
I1
I-1
tp48333
sS'a,more'
p48334
(F1
F0.00014334862385321102
I0
I1
I-1
tp48335
sS'or,citrate'
p48336
(F1
F0.00014334862385321102
I0
I1
I-1
tp48337
sS'controlled,crossover'
p48338
(F1
F0.00014334862385321102
I0
I1
I-1
tp48339
sS'of,animal'
p48340
(F1
F0.00014334862385321102
I0
I1
I-1
tp48341
sS'slower,absorption'
p48342
(F1
F0.00014334862385321102
I1
I0
I1
tp48343
sS'concomitant,may'
p48344
(F1
F0.00014334862385321102
I1
I0
I1
tp48345
sS'of,whether'
p48346
(F1
F0.00014334862385321102
I1
I0
I1
tp48347
sS'plasma,maximum'
p48348
(F1
F0.00014334862385321102
I0
I1
I-1
tp48349
sS'hydroxide,and'
p48350
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48351
sS'chloride,in'
p48352
(F1
F0.00014334862385321102
I1
I0
I1
tp48353
sS'and,animal'
p48354
(F1
F0.00028669724770642203
I2
I0
I2
tp48355
sS'was,usually'
p48356
(F1
F0.00014334862385321102
I1
I0
I1
tp48357
sS'remedies,and'
p48358
(F1
F0.00014334862385321102
I1
I0
I1
tp48359
sS'methotrexate,concomitant'
p48360
(F1
F0.00014334862385321102
I1
I0
I1
tp48361
sS'a,dosing'
p48362
(F1
F0.00014334862385321102
I0
I1
I-1
tp48363
sS'pegasys,in'
p48364
(F1
F0.00028669724770642203
I0
I2
I-2
tp48365
sS'naflu,and'
p48366
(F1
F0.00028669724770642203
I0
I2
I-2
tp48367
sS'required,to'
p48368
(F1
F0.00043004587155963305
I3
I0
I3
tp48369
sS'it,increased'
p48370
(F1
F0.00014334862385321102
I0
I1
I-1
tp48371
sS'by,in'
p48372
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp48373
sS'after,or'
p48374
(F1
F0.00043004587155963305
I3
I0
I3
tp48375
sS'but,did'
p48376
(F1
F0.00043004587155963305
I3
I0
I3
tp48377
sS'of,body'
p48378
(F1
F0.00014334862385321102
I0
I1
I-1
tp48379
sS'as,amphotericin'
p48380
(F1
F0.00014334862385321102
I1
I0
I1
tp48381
sS'receiving,for'
p48382
(F1
F0.00014334862385321102
I0
I1
I-1
tp48383
sS'resolution,of'
p48384
(F1
F0.00014334862385321102
I1
I0
I1
tp48385
sS'by,dose'
p48386
(F1
F0.00014334862385321102
I1
I0
I1
tp48387
sS'its,efficacy'
p48388
(F1
F0.00014334862385321102
I0
I1
I-1
tp48389
sS'pi,over'
p48390
(F1
F0.00014334862385321102
I0
I1
I-1
tp48391
sS'drugs,possessing'
p48392
(F1
F0.00014334862385321102
I1
I0
I1
tp48393
sS'hormonal,causing'
p48394
(F1
F0.00014334862385321102
I1
I0
I1
tp48395
sS'screening,in'
p48396
(F1
F0.00014334862385321102
I0
I1
I-1
tp48397
sS'or,divalent'
p48398
(F1
F0.00014334862385321102
I0
I1
I-1
tp48399
sS'physicians,needing'
p48400
(F1
F0.00014334862385321102
I0
I1
I-1
tp48401
sS'decreased,core'
p48402
(F1
F0.00014334862385321102
I0
I1
I-1
tp48403
sS'those,achieved'
p48404
(F1
F0.00014334862385321102
I1
I0
I1
tp48405
sS'when,cime-tidine'
p48406
(F1
F0.00014334862385321102
I1
I0
I1
tp48407
sS'in,how'
p48408
(F1
F0.00014334862385321102
I0
I1
I-1
tp48409
sS'influence,in'
p48410
(F1
F0.00014334862385321102
I0
I1
I-1
tp48411
sS'responses,to'
p48412
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp48413
sS'stimulated,gastric'
p48414
(F1
F0.00014334862385321102
I0
I1
I-1
tp48415
sS'permeation,however'
p48416
(F1
F0.00014334862385321102
I0
I1
I-1
tp48417
sS'outweigh,the'
p48418
(F1
F0.00057339449541284407
I4
I0
I4
tp48419
sS'day,as'
p48420
(F1
F0.00014334862385321102
I1
I0
I1
tp48421
sS'inhibitors,in'
p48422
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp48423
sS'could,lead'
p48424
(F1
F0.00014334862385321102
I1
I0
I1
tp48425
sS'once,monthly'
p48426
(F1
F0.00014334862385321102
I0
I1
I-1
tp48427
sS'the,prescription'
p48428
(F1
F0.00014334862385321102
I1
I0
I1
tp48429
sS'on,pupil'
p48430
(F1
F0.00014334862385321102
I1
I0
I1
tp48431
sS'applied,to'
p48432
(F1
F0.00014334862385321102
I1
I0
I1
tp48433
sS'inhibitors,it'
p48434
(F1
F0.00014334862385321102
I0
I1
I-1
tp48435
sS'reduction,were'
p48436
(F1
F0.00014334862385321102
I0
I1
I-1
tp48437
sS'studied,two'
p48438
(F1
F0.00014334862385321102
I1
I0
I1
tp48439
sS'anticoagulation,test'
p48440
(F1
F0.00014334862385321102
I1
I0
I1
tp48441
sS'narrow,serum'
p48442
(F1
F0.00014334862385321102
I0
I1
I-1
tp48443
sS'hepatic,enzyme-inducing'
p48444
(F1
F0.00014334862385321102
I1
I0
I1
tp48445
sS'little,experience'
p48446
(F1
F0.00028669724770642203
I0
I2
I-2
tp48447
sS'concentrations,in'
p48448
(F0
F0
I5
I5
I0
tp48449
sS'plasma,m1'
p48450
(F1
F0.00014334862385321102
I1
I0
I1
tp48451
sS'dosing,was'
p48452
(F1
F0.00014334862385321102
I1
I0
I1
tp48453
sS'at,greater'
p48454
(F1
F0.00014334862385321102
I0
I1
I-1
tp48455
sS'misused,by'
p48456
(F1
F0.00014334862385321102
I0
I1
I-1
tp48457
sS'with,elspar'
p48458
(F1
F0.00014334862385321102
I1
I0
I1
tp48459
sS'however,pharmacokinetic'
p48460
(F1
F0.00014334862385321102
I0
I1
I-1
tp48461
sS'coagulation,parameters'
p48462
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48463
sS'reach,toxic'
p48464
(F1
F0.00014334862385321102
I0
I1
I-1
tp48465
sS'of,deoxy'
p48466
(F1
F0.00014334862385321102
I0
I1
I-1
tp48467
sS'although,has'
p48468
(F1
F0.00014334862385321102
I1
I0
I1
tp48469
sS'level,by'
p48470
(F1
F0.00014334862385321102
I0
I1
I-1
tp48471
sS'or,clinically'
p48472
(F1
F0.00028669724770642203
I0
I2
I-2
tp48473
sS'careful,adjustment'
p48474
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp48475
sS'cyclosporine,and'
p48476
(F1
F0.00014334862385321102
I1
I0
I1
tp48477
sS'and,fetal'
p48478
(F1
F0.00014334862385321102
I0
I1
I-1
tp48479
sS'potassium-sparing,or'
p48480
(F0
F0
I1
I1
I0
tp48481
sS'lead,tml'
p48482
(F1
F0.00014334862385321102
I0
I1
I-1
tp48483
sS'responding,under'
p48484
(F1
F0.00014334862385321102
I0
I1
I-1
tp48485
sS'from,protein'
p48486
(F1
F0.00028669724770642203
I2
I0
I2
tp48487
sS'and,coadministration'
p48488
(F1
F0.00043004587155963305
I3
I0
I3
tp48489
sS'the,peritoneal'
p48490
(F1
F0.00014334862385321102
I0
I1
I-1
tp48491
sS'have,occurred'
p48492
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp48493
sS'that,a'
p48494
(F0.076923076923076927
F0.00014334862385321102
I6
I7
I-1
tp48495
sS'and,possibly'
p48496
(F0.25
F0.00028669724770642203
I5
I3
I2
tp48497
sS'of,q12h'
p48498
(F1
F0.00014334862385321102
I1
I0
I1
tp48499
sS'and,possible'
p48500
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp48501
sS'for,vitamin'
p48502
(F1
F0.00057339449541284407
I4
I0
I4
tp48503
sS'may,alter'
p48504
(F0.5
F0.00057339449541284407
I6
I2
I4
tp48505
sS'n,n'
p48506
(F1
F0.00014334862385321102
I0
I1
I-1
tp48507
sS'mg,tid'
p48508
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp48509
sS'prolonged,or'
p48510
(F0
F0
I1
I1
I0
tp48511
sS'the,majority'
p48512
(F1
F0.00014334862385321102
I0
I1
I-1
tp48513
sS'of,fold'
p48514
(F1
F0.00014334862385321102
I1
I0
I1
tp48515
sS'concurrent,enbrel'
p48516
(F1
F0.00014334862385321102
I1
I0
I1
tp48517
sS'interactions,associated'
p48518
(F1
F0.00014334862385321102
I0
I1
I-1
tp48519
sS'class,i'
p48520
(F1
F0.00014334862385321102
I0
I1
I-1
tp48521
sS'conduction,observed'
p48522
(F1
F0.00014334862385321102
I1
I0
I1
tp48523
sS'escherichia,coli'
p48524
(F1
F0.00028669724770642203
I0
I2
I-2
tp48525
sS'of,hydroxytolbutamide'
p48526
(F1
F0.00014334862385321102
I0
I1
I-1
tp48527
sS'starting,daily'
p48528
(F1
F0.00014334862385321102
I0
I1
I-1
tp48529
sS'normal,renal'
p48530
(F1
F0.00014334862385321102
I0
I1
I-1
tp48531
sS'intrathecal,injection'
p48532
(F1
F0.00014334862385321102
I1
I0
I1
tp48533
sS'the,present'
p48534
(F1
F0.00043004587155963305
I0
I3
I-3
tp48535
sS'addition,fondaparinux'
p48536
(F1
F0.00014334862385321102
I0
I1
I-1
tp48537
sS'induce,a'
p48538
(F1
F0.00028669724770642203
I0
I2
I-2
tp48539
sS'monitoring,for'
p48540
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp48541
sS'vioxx,and'
p48542
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp48543
sS'study,there'
p48544
(F1
F0.00014334862385321102
I0
I1
I-1
tp48545
sS'digitalis,thyroid'
p48546
(F1
F0.00014334862385321102
I1
I0
I1
tp48547
sS'mean,elimination'
p48548
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48549
sS'be,useful'
p48550
(F1
F0.00014334862385321102
I1
I0
I1
tp48551
sS'with,hormonal'
p48552
(F0
F0
I1
I1
I0
tp48553
sS'i,without'
p48554
(F1
F0.00014334862385321102
I0
I1
I-1
tp48555
sS'non-steroidal,agent'
p48556
(F1
F0.00014334862385321102
I1
I0
I1
tp48557
sS'while,on'
p48558
(F1
F0.00028669724770642203
I2
I0
I2
tp48559
sS'cause,ventricular'
p48560
(F1
F0.00014334862385321102
I1
I0
I1
tp48561
sS'study,volunteers'
p48562
(F1
F0.00014334862385321102
I0
I1
I-1
tp48563
sS'in,psychopathology'
p48564
(F1
F0.00014334862385321102
I0
I1
I-1
tp48565
sS'depressants,and'
p48566
(F1
F0.00014334862385321102
I1
I0
I1
tp48567
sS'adolescent,with'
p48568
(F1
F0.00014334862385321102
I1
I0
I1
tp48569
sS'placebo,oral'
p48570
(F1
F0.00014334862385321102
I0
I1
I-1
tp48571
sS'these,medicines'
p48572
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp48573
sS'of,auc'
p48574
(F1
F0.00014334862385321102
I1
I0
I1
tp48575
sS'inhibitors,within'
p48576
(F1
F0.00014334862385321102
I1
I0
I1
tp48577
sS'intravenous,unless'
p48578
(F1
F0.00014334862385321102
I1
I0
I1
tp48579
sS'of,normal'
p48580
(F0
F0
I1
I1
I0
tp48581
sS'rats,responding'
p48582
(F1
F0.00014334862385321102
I1
I0
I1
tp48583
sS'be,decided'
p48584
(F1
F0.00014334862385321102
I1
I0
I1
tp48585
sS'each,would'
p48586
(F1
F0.00014334862385321102
I0
I1
I-1
tp48587
sS'doxorubicin,doxorubicin'
p48588
(F1
F0.00014334862385321102
I1
I0
I1
tp48589
sS'one-half,of'
p48590
(F1
F0.00028669724770642203
I2
I0
I2
tp48591
sS'with,difluoroacetone'
p48592
(F1
F0.00014334862385321102
I0
I1
I-1
tp48593
sS'ria,kit'
p48594
(F1
F0.00014334862385321102
I0
I1
I-1
tp48595
sS'oxidized,metabolites'
p48596
(F1
F0.00014334862385321102
I0
I1
I-1
tp48597
sS'by,aom'
p48598
(F1
F0.00014334862385321102
I0
I1
I-1
tp48599
sS'activity,may'
p48600
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp48601
sS'experience,indicates'
p48602
(F1
F0.00028669724770642203
I2
I0
I2
tp48603
sS'potent,inducers'
p48604
(F0
F0
I1
I1
I0
tp48605
sS'decreased,efficacy'
p48606
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48607
sS'allegra,should'
p48608
(F0
F0
I1
I1
I0
tp48609
sS'for,converting'
p48610
(F1
F0.00014334862385321102
I1
I0
I1
tp48611
sS'colitis,a'
p48612
(F1
F0.00014334862385321102
I1
I0
I1
tp48613
sS'probenecid,concomitant'
p48614
(F1
F0.00014334862385321102
I1
I0
I1
tp48615
sS'average,higher'
p48616
(F1
F0.00014334862385321102
I0
I1
I-1
tp48617
sS'may,help'
p48618
(F1
F0.00014334862385321102
I0
I1
I-1
tp48619
sS'target,added'
p48620
(F1
F0.00014334862385321102
I0
I1
I-1
tp48621
sS'of,doses'
p48622
(F1
F0.00028669724770642203
I0
I2
I-2
tp48623
sS'known,property'
p48624
(F1
F0.00014334862385321102
I1
I0
I1
tp48625
sS'studies,suggest'
p48626
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48627
sS'daily,the'
p48628
(F1
F0.00028669724770642203
I2
I0
I2
tp48629
sS'which,effectiveness'
p48630
(F1
F0.00014334862385321102
I0
I1
I-1
tp48631
sS'diminished,urinary'
p48632
(F1
F0.00014334862385321102
I1
I0
I1
tp48633
sS'time,measured'
p48634
(F1
F0.00028669724770642203
I2
I0
I2
tp48635
sS'are,required'
p48636
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp48637
sS'injection,lorazepam'
p48638
(F1
F0.00014334862385321102
I1
I0
I1
tp48639
sS'of,qtc'
p48640
(F1
F0.00014334862385321102
I0
I1
I-1
tp48641
sS'interact,altered'
p48642
(F1
F0.00014334862385321102
I0
I1
I-1
tp48643
sS'not,seem'
p48644
(F1
F0.00014334862385321102
I0
I1
I-1
tp48645
sS'cyp2d6,pathway'
p48646
(F1
F0.00014334862385321102
I0
I1
I-1
tp48647
sS'beta-naltrexol,were'
p48648
(F1
F0.00014334862385321102
I0
I1
I-1
tp48649
sS'or,daily'
p48650
(F1
F0.00014334862385321102
I0
I1
I-1
tp48651
sS'capsules,or'
p48652
(F1
F0.00014334862385321102
I1
I0
I1
tp48653
sS'necessitate,an'
p48654
(F1
F0.00014334862385321102
I0
I1
I-1
tp48655
sS'of,birth'
p48656
(F1
F0.00014334862385321102
I1
I0
I1
tp48657
sS'nimodipine,had'
p48658
(F1
F0.00014334862385321102
I0
I1
I-1
tp48659
sS'that,if'
p48660
(F1
F0.00014334862385321102
I1
I0
I1
tp48661
sS'with,those'
p48662
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp48663
sS'time,pt'
p48664
(F1
F0.00014334862385321102
I1
I0
I1
tp48665
sS'alcohol-related,deaths'
p48666
(F1
F0.00014334862385321102
I0
I1
I-1
tp48667
sS'increase,cardiac'
p48668
(F1
F0.00014334862385321102
I1
I0
I1
tp48669
sS'amprenavir,plus'
p48670
(F0
F0
I1
I1
I0
tp48671
sS'advil,nuprin'
p48672
(F1
F0.00014334862385321102
I0
I1
I-1
tp48673
sS'is,higher'
p48674
(F1
F0.00014334862385321102
I1
I0
I1
tp48675
sS'buprenorphine,is'
p48676
(F1
F0.00014334862385321102
I0
I1
I-1
tp48677
sS'gastrointestinal,alkalinizing'
p48678
(F1
F0.00014334862385321102
I1
I0
I1
tp48679
sS'is,only'
p48680
(F0
F0
I1
I1
I0
tp48681
sS'to,orders'
p48682
(F1
F0.00014334862385321102
I0
I1
I-1
tp48683
sS'recommended,doses'
p48684
(F1
F0.00014334862385321102
I1
I0
I1
tp48685
sS'used,clinically'
p48686
(F1
F0.00014334862385321102
I0
I1
I-1
tp48687
sS'lamivudine,in'
p48688
(F1
F0.00014334862385321102
I1
I0
I1
tp48689
sS'women,who'
p48690
(F1
F0.00014334862385321102
I0
I1
I-1
tp48691
sS'toradol,iv'
p48692
(F1
F0.00014334862385321102
I1
I0
I1
tp48693
sS'ht1,agonists'
p48694
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48695
sS'morphine-induced,increases'
p48696
(F1
F0.00014334862385321102
I1
I0
I1
tp48697
sS'symbol,substitution'
p48698
(F1
F0.00014334862385321102
I1
I0
I1
tp48699
sS'cyp2d6,metabolizers'
p48700
(F1
F0.00014334862385321102
I0
I1
I-1
tp48701
sS'following,immunosuppressives'
p48702
(F1
F0.00014334862385321102
I0
I1
I-1
tp48703
sS'responses,with'
p48704
(F1
F0.00014334862385321102
I0
I1
I-1
tp48705
sS'vasodilator,properties'
p48706
(F1
F0.00014334862385321102
I0
I1
I-1
tp48707
sS'vitro,glucuronidation'
p48708
(F1
F0.00014334862385321102
I0
I1
I-1
tp48709
sS'cyp2e1,cyp4a9'
p48710
(F1
F0.00014334862385321102
I0
I1
I-1
tp48711
sS'concomitantly,there'
p48712
(F1
F0.00014334862385321102
I1
I0
I1
tp48713
sS'effects,would'
p48714
(F1
F0.00014334862385321102
I0
I1
I-1
tp48715
sS'inhibitors,without'
p48716
(F1
F0.00014334862385321102
I0
I1
I-1
tp48717
sS'stadol,ns'
p48718
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp48719
sS'when,toradol'
p48720
(F1
F0.00014334862385321102
I1
I0
I1
tp48721
sS'seminiferous,tubules'
p48722
(F1
F0.00014334862385321102
I0
I1
I-1
tp48723
sS'h,following'
p48724
(F1
F0.00014334862385321102
I1
I0
I1
tp48725
sS'dose-dependently,inhibits'
p48726
(F1
F0.00014334862385321102
I1
I0
I1
tp48727
sS'release,and'
p48728
(F1
F0.00014334862385321102
I0
I1
I-1
tp48729
sS'primarily,as'
p48730
(F1
F0.00014334862385321102
I0
I1
I-1
tp48731
sS'encountered,during'
p48732
(F1
F0.00014334862385321102
I0
I1
I-1
tp48733
sS'were,similar'
p48734
(F1
F0.00043004587155963305
I0
I3
I-3
tp48735
sS'unaffected,following'
p48736
(F1
F0.00014334862385321102
I0
I1
I-1
tp48737
sS'obtain,serum'
p48738
(F1
F0.00014334862385321102
I1
I0
I1
tp48739
sS'platelet,activation'
p48740
(F1
F0.00014334862385321102
I0
I1
I-1
tp48741
s.